confidence_score,assay_strain,src_id,cell_id,assay_tax_id,assay_id,assay_category,assay_test_type,assay_type,tissue_id,src_assay_id,variant_id,assay_organism,assay_cell_type,relationship_type,chembl_id,bao_format,description,doc_id,assay_subcellular_fraction,assay_tissue,tid,curated_by
8,,1,,,1,,,B,,,,,,H,CHEMBL615117,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,11087,,,12052,Autocuration
0,,1,,,2,,,F,,,,,,U,CHEMBL615118,BAO_0000219,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,684,,,22226,Autocuration
0,,1,,,3,,,B,,,,,,U,CHEMBL615119,BAO_0000019,,15453,,,22226,Autocuration
4,,1,,9913.0,4,,,B,,,,Bos taurus,,H,CHEMBL615120,BAO_0000249,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,17841,,,104729,Autocuration
1,,1,163.0,9606.0,5,,,F,,,,Homo sapiens,143B,N,CHEMBL615121,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),17430,,,80001,Intermediate
1,,1,163.0,9606.0,6,,,F,,,,Homo sapiens,143B,N,CHEMBL615122,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),17430,,,80001,Intermediate
1,,1,163.0,10090.0,7,,,F,,,,Mus musculus,143B,N,CHEMBL615123,BAO_0000219,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,13799,,,80001,Intermediate
1,,1,163.0,9606.0,8,,,F,,,,Homo sapiens,143B,N,CHEMBL615124,BAO_0000219,In vitro cell cytotoxicity was determined against 143B cell line,17774,,,80001,Expert
1,,1,163.0,9606.0,9,,,F,,,,Homo sapiens,143B,N,CHEMBL615125,BAO_0000219,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,3801,,,80001,Intermediate
1,,1,163.0,9606.0,10,,,F,,,,Homo sapiens,143B,N,CHEMBL615126,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,17430,,,80001,Intermediate
1,,1,163.0,9606.0,11,,,F,,,,Homo sapiens,143B,N,CHEMBL615127,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,17430,,,80001,Intermediate
1,,1,163.0,9606.0,12,,,F,,,,Homo sapiens,143B,N,CHEMBL615128,BAO_0000219,In vitro cell cytotoxicity was determined against 143B-LTK cell line,17774,,,80001,Expert
1,,1,,1280.0,13,,,F,,,,Staphylococcus aureus,,N,CHEMBL857900,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,,,50185,Intermediate
1,,1,,1280.0,14,,,F,,,,Staphylococcus aureus,,N,CHEMBL615129,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,,,50185,Intermediate
1,,1,,1280.0,15,,,F,,,,Staphylococcus aureus,,N,CHEMBL615130,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,,,50185,Intermediate
1,,1,,1280.0,16,,,F,,,,Staphylococcus aureus,,N,CHEMBL615131,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,,,50185,Intermediate
9,,1,,10116.0,17,,,A,,,,Rattus norvegicus,,D,CHEMBL884521,BAO_0000357,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,11347,,,100122,Expert
8,,1,,,18,,,B,,,,,,H,CHEMBL615132,BAO_0000357,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),16474,,,12054,Autocuration
8,,1,,,19,,,B,,,,,,H,CHEMBL615133,BAO_0000019,Inhibition of partially purified 15-lipoxygenase from human leukocytes,10091,,,12054,Autocuration
8,,1,,,20,,,B,,,,,,H,CHEMBL615134,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),16474,,,12054,Autocuration
8,,1,,,21,,,B,,,,,,H,CHEMBL615135,BAO_0000357,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),16474,,,12054,Autocuration
8,,1,,,22,,,B,,,,,,H,CHEMBL615136,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),16474,,,12054,Autocuration
8,,1,,,23,,,B,,,,,,H,CHEMBL615137,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,16474,,,12054,Autocuration
8,,1,,,24,,,B,,,,,,H,CHEMBL615138,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,16474,,,12054,Autocuration
0,,1,,,25,,,B,,,,,,U,CHEMBL836324,BAO_0000219,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",14352,,,22226,Autocuration
8,,1,,9986.0,26,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL615139,BAO_0000357,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,5646,,,12054,Autocuration
8,,1,,9986.0,27,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL615140,BAO_0000357,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),5646,,,12054,Autocuration
8,,1,,,28,,,B,,,,,,H,CHEMBL615141,BAO_0000219,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,10997,,,12426,Autocuration
8,,1,,3847.0,29,,,B,,,,soya bean,,H,CHEMBL615142,BAO_0000357,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,6309,,,12054,Autocuration
8,,1,,3847.0,30,,,B,,,,Glycine max,,H,CHEMBL615143,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated,167,,,12054,Autocuration
8,,1,,3847.0,31,,,B,,,,Glycine max,,H,CHEMBL615144,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,167,,,12054,Autocuration
8,,1,,3847.0,32,,,B,,,,Glycine max,,H,CHEMBL872867,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,11087,,,12054,Autocuration
8,,1,,3847.0,33,,,B,,,,Glycine max,,H,CHEMBL615145,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,11087,,,12054,Autocuration
8,,1,,3847.0,34,,,B,,,,Glycine max,,H,CHEMBL615146,BAO_0000357,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,13622,,,12054,Autocuration
8,,1,,3847.0,35,,,B,,,,Glycine max,,H,CHEMBL615147,BAO_0000357,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,13622,,,12054,Autocuration
0,,1,,10116.0,36,,,A,,,,Rattus norvegicus,,U,CHEMBL615148,BAO_0000019,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,11347,,,22226,Autocuration
0,,1,,562.0,37,,,B,,,,Escherichia coli,,U,CHEMBL615149,BAO_0000019,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,5926,,,22226,Autocuration
0,,1,,,38,,,B,,,,,,U,CHEMBL615150,BAO_0000019,Dissociation constant with dimeric 16S rRNA RNA construct B,4567,,,22226,Autocuration
3,,1,,,39,,,B,,,,,,M,CHEMBL615151,BAO_0000225,Dissociation constant towards 16S rRNA construct A,3782,,,22222,Intermediate
3,,1,,,40,,,B,,,,,,M,CHEMBL615152,BAO_0000225,Dissociation constant towards 16S rRNA construct B,3782,,,22222,Intermediate
3,,1,,562.0,41,,,B,,,,Escherichia coli,,M,CHEMBL615153,BAO_0000225,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,4466,,,100263,Expert
3,,1,,562.0,42,,,B,,,,Escherichia coli,,M,CHEMBL615154,BAO_0000225,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,6592,,,100263,Expert
8,,1,,,43,,,B,,,,,,H,CHEMBL615155,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,,,13053,Autocuration
8,,1,,,44,,,B,,,,,,H,CHEMBL615156,BAO_0000019,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,,,13053,Autocuration
8,,1,,9606.0,45,,,B,,,,Homo sapiens,,H,CHEMBL615157,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,13163,,,20001,Autocuration
8,,1,,9606.0,46,,,B,,,,Homo sapiens,,H,CHEMBL615158,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,13163,,,20001,Autocuration
9,,1,,10116.0,47,,,B,,,,Rattus norvegicus,,D,CHEMBL615159,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10691,,,12971,Expert
9,,1,,10116.0,48,,,B,,,,Rattus norvegicus,,D,CHEMBL615172,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10691,,,12971,Expert
9,,1,,10116.0,49,,,B,,,,Rattus norvegicus,,D,CHEMBL615173,BAO_0000019,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10691,,,12971,Expert
9,,1,,10116.0,50,,,B,,,,Rattus norvegicus,,D,CHEMBL615174,BAO_0000019,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10691,,,12971,Expert
8,,1,,,51,,,B,,,,,,H,CHEMBL884518,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,,,13053,Autocuration
8,,1,,,52,,,B,,,,,,H,CHEMBL615175,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),912,,,11512,Autocuration
8,,1,,,53,,,B,,,,,,H,CHEMBL615176,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,912,,,11512,Autocuration
8,,1,,,54,,,B,,,,,,H,CHEMBL615177,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,912,,,11512,Autocuration
5,,1,,10116.0,55,,,B,,,,Rattus norvegicus,,D,CHEMBL615178,BAO_0000249,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,15103,Membranes,,104740,Autocuration
1,,1,506.0,9606.0,56,,,F,,,,Homo sapiens,1A9,N,CHEMBL615179,BAO_0000219,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,5116,,,80002,Intermediate
7,,1,,10116.0,57,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL615180,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,14578,,,104835,Autocuration
7,,1,,10116.0,58,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL615181,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,14578,,,104821,Autocuration
7,,1,,10116.0,59,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL615182,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,14578,,,104848,Autocuration
1,,1,506.0,9606.0,60,,,F,,,,Homo sapiens,1A9,N,CHEMBL615183,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,4787,,,80002,Expert
1,,1,506.0,9606.0,61,,,F,,,,Homo sapiens,1A9,N,CHEMBL615184,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,4787,,,80002,Intermediate
1,,1,506.0,9606.0,62,,,F,,,,Homo sapiens,1A9,N,CHEMBL615185,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line,3547,,,80002,Intermediate
1,,1,506.0,9606.0,63,,,F,,,,Homo sapiens,1A9,N,CHEMBL615186,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,3547,,,80002,Intermediate
1,,1,506.0,9606.0,64,,,F,,,,Homo sapiens,1A9,N,CHEMBL615187,BAO_0000219,Effective dose of compound against replication of 1A9 cell line was evaluated,6726,,,80002,Intermediate
1,,1,506.0,9606.0,65,,,F,,,,Homo sapiens,1A9,N,CHEMBL885343,BAO_0000219,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,3455,,,80002,Expert
1,,1,506.0,9606.0,66,,,F,,,,Homo sapiens,1A9,N,CHEMBL615188,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),5726,,,80002,Intermediate
1,,1,506.0,9606.0,67,,,F,,,,Homo sapiens,1A9,N,CHEMBL615189,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,5726,,,80002,Intermediate
1,,1,506.0,9606.0,68,,,F,,,,Homo sapiens,1A9,N,CHEMBL615190,BAO_0000219,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,5726,,,80002,Intermediate
1,,1,506.0,9606.0,69,,,F,,,,Homo sapiens,1A9,N,CHEMBL615191,BAO_0000219,Inhibitory activity against Taxol resistant 1A9 cell lines,3395,,,80002,Intermediate
1,,1,506.0,9606.0,70,,,F,,,,Homo sapiens,1A9,N,CHEMBL615192,BAO_0000219,Cytotoxicity against human ovarian cancer (1A9) cell lines.,3415,,,80002,Expert
1,,1,506.0,9606.0,71,,,F,,,,Homo sapiens,1A9,N,CHEMBL827083,BAO_0000219,Percentage inhibition of human ovarian cancer (1A9) cell lines.,3415,,,80002,Expert
1,,1,506.0,9606.0,72,,,F,,,,Homo sapiens,1A9,N,CHEMBL615193,BAO_0000219,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,17099,,,80002,Expert
1,,1,506.0,9606.0,73,,,F,,,,Homo sapiens,1A9,N,CHEMBL615194,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,17099,,,80002,Intermediate
1,,1,506.0,9606.0,74,,,F,,,,Homo sapiens,1A9,N,CHEMBL615195,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,17099,,,80002,Intermediate
1,,1,506.0,9606.0,75,,,F,,,,Homo sapiens,1A9,N,CHEMBL615196,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,17099,,,80002,Intermediate
1,,1,503.0,9606.0,76,,,F,,,,Homo sapiens,Jurkat,N,CHEMBL615197,BAO_0000219,Inhibitory concentration against Jurkat cells,17721,,,81072,Intermediate
0,,1,,,77,,,F,,,,,,U,CHEMBL615198,BAO_0000019,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1229,,,22226,Intermediate
9,,1,,10116.0,78,,,A,,,,Rattus norvegicus,,D,CHEMBL615199,BAO_0000357,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,11347,,,100121,Expert
8,,1,,,79,,,B,,,,,,H,CHEMBL615200,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",17117,,,11231,Expert
8,,1,,,80,,,B,,,,,,H,CHEMBL615201,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",17117,,,11231,Expert
8,,1,,,81,,,B,,,,,,H,CHEMBL615202,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",17117,,,11231,Expert
8,,1,,5476.0,82,,,B,,,,Candida albicans,,H,CHEMBL615203,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11375,Microsomes,,11231,Autocuration
8,,1,,5476.0,83,,,B,,,,Candida albicans,,H,CHEMBL615204,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11375,Microsomes,,11231,Autocuration
8,,1,,4932.0,84,,,B,,,,Saccharomyces cerevisiae,,H,CHEMBL615205,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11375,Microsomes,,11231,Autocuration
8,,1,,4932.0,85,,,B,,,,Saccharomyces cerevisiae,,H,CHEMBL615206,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11375,Microsomes,,11231,Autocuration
8,,1,,9823.0,86,,,B,2107.0,,,Sus scrofa,,H,CHEMBL615207,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",11375,Microsomes,Liver,12083,Autocuration
8,,1,,10116.0,87,,,B,,,,Rattus norvegicus,,H,CHEMBL827084,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",791,,,11231,Autocuration
8,,1,,10116.0,88,,,B,,,,Rattus norvegicus,,H,CHEMBL615208,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",791,,,11231,Autocuration
8,,1,,10116.0,89,,,B,,,,Rattus norvegicus,,H,CHEMBL615209,BAO_0000019,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",791,,,11231,Autocuration
9,,1,,10116.0,90,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615210,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",11375,Microsomes,Liver,12083,Autocuration
9,,1,,10116.0,91,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615211,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",11375,Microsomes,Liver,12083,Autocuration
9,,1,,10116.0,92,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615212,BAO_0000251,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",153,Microsomes,Liver,12083,Autocuration
8,,1,,,93,,,B,,,,,,H,CHEMBL615213,BAO_0000357,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),8269,,,11377,Expert
8,,1,,,94,,,B,,,,,,H,CHEMBL615273,BAO_0000357,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,8269,,,11377,Expert
1,,1,726.0,9606.0,95,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615274,BAO_0000219,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,17653,,,81020,Expert
1,,1,726.0,9606.0,96,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615275,BAO_0000219,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,14277,,,81020,Intermediate
1,,1,726.0,9606.0,97,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615276,BAO_0000219,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1717,,,81020,Intermediate
1,,1,726.0,9606.0,98,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615277,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,14091,,,81020,Intermediate
1,,1,726.0,9606.0,99,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615326,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,14091,,,81020,Intermediate
1,,1,,10407.0,100,,,F,,,,Hepatitis B virus,,N,CHEMBL883130,BAO_0000218,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,17653,,,50606,Expert
1,,1,726.0,9606.0,101,,,F,,,,Homo sapiens,HepG2,N,CHEMBL884519,BAO_0000219,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,13105,,,81020,Intermediate
1,,1,726.0,9606.0,102,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615327,BAO_0000219,Concentration required to inhibit 50% of 2.2.15 cell line,1717,,,81020,Intermediate
1,,1,726.0,9606.0,103,,,A,,,,Homo sapiens,HepG2,N,CHEMBL615328,BAO_0000219,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,13105,,,81020,Intermediate
1,,1,,9606.0,104,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615329,BAO_0000218,Cytotoxic activity of compound against uninfected 2.2.15 cells.,13600,,,50587,Intermediate
1,,1,,9606.0,105,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615330,BAO_0000218,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,13467,,,50587,Intermediate
1,,1,,10407.0,106,,,F,,,,Hepatitis B virus,2.2.15,N,CHEMBL615331,BAO_0000218,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",17477,,,50606,Expert
1,,1,,9606.0,107,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615332,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells,1593,,,50587,Intermediate
1,,1,,9606.0,108,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615333,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1593,,,50587,Intermediate
1,,1,,9606.0,109,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615334,BAO_0000218,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,15089,,,50587,Intermediate
1,,1,,9606.0,110,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615335,BAO_0000218,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,15089,,,50587,Intermediate
1,,1,,9606.0,111,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615336,BAO_0000218,Cytotoxicity in 2.2.15 cells,1593,,,50587,Intermediate
1,,1,,9606.0,112,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615337,BAO_0000218,Cytotoxicity in 2.2.15 cells; Not determined,1593,,,50587,Intermediate
1,,1,,9606.0,113,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615338,BAO_0000218,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,13600,,,50587,Intermediate
1,,1,,9606.0,114,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615339,BAO_0000218,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,13467,,,50587,Intermediate
1,,1,,9606.0,115,,,F,,,,Homo sapiens,2.2.15,N,CHEMBL615340,BAO_0000218,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,13467,,,50587,Intermediate
1,,1,726.0,9606.0,116,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615341,BAO_0000219,Antiviral activity against HBV was determined in 2.215 cell line,14764,,,81020,Intermediate
0,,1,,9606.0,117,,,B,,,,Homo sapiens,,U,CHEMBL615342,BAO_0000251,Inhibition of 20-HETE synthesis in human renal microsomes,6531,Microsomes,,22226,Autocuration
0,,1,,,118,,,B,,,,,,U,CHEMBL615343,BAO_0000019,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,17322,,,22226,Autocuration
1,,1,388.0,9606.0,119,,,F,,,,Homo sapiens,2008,N,CHEMBL615344,BAO_0000219,Inhibitory concentration against 2008 (ovarian) cells,17072,,,80612,Intermediate
1,,1,388.0,9606.0,120,,,F,,,,Homo sapiens,2008,N,CHEMBL615345,BAO_0000219,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,16936,,,80612,Intermediate
1,,1,388.0,9606.0,121,,,F,,,,Homo sapiens,2008,N,CHEMBL615346,BAO_0000219,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),16936,,,80612,Intermediate
1,,1,388.0,9606.0,122,,,F,,,,Homo sapiens,2008,N,CHEMBL615347,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,17146,,,80612,Intermediate
1,,1,388.0,9606.0,123,,,F,,,,Homo sapiens,2008,N,CHEMBL615348,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,17146,,,80612,Intermediate
1,,1,561.0,9606.0,124,,,F,,,,Homo sapiens,2008/R,N,CHEMBL827085,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line,10797,,,80613,Intermediate
1,,1,561.0,9606.0,125,,,F,,,,Homo sapiens,2008/R,N,CHEMBL615349,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,10797,,,80613,Intermediate
1,,1,389.0,9606.0,126,,,F,,,,Homo sapiens,2008/S,N,CHEMBL615350,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line,10797,,,80614,Intermediate
1,,1,389.0,9606.0,127,,,F,,,,Homo sapiens,2008/S,N,CHEMBL615351,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,10797,,,80614,Intermediate
2,,1,,9606.0,128,,,B,,,,Homo sapiens,,S,CHEMBL615352,BAO_0000220,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,4823,,,100256,Expert
2,,1,,9606.0,129,,,B,,,,Homo sapiens,,S,CHEMBL615353,BAO_0000220,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,12912,,,100256,Intermediate
2,,1,,,130,,,B,,,,,,S,CHEMBL615354,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome,2957,,,100256,Expert
2,,1,,,131,,,B,,,,,,S,CHEMBL615355,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,2957,,,100256,Expert
2,,1,,,132,,,B,,,,,,S,CHEMBL615356,BAO_0000220,Inhibitory activity against 20S proteosome,3260,,,100256,Intermediate
0,,1,,9606.0,133,,,B,,,,Homo sapiens,,U,CHEMBL615357,BAO_0000019,Compound was tested for inhibitory activity against tryptase,3451,,,22226,Autocuration
1,,1,726.0,9606.0,134,,,F,,,,Homo sapiens,HepG2,N,CHEMBL615358,BAO_0000219,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,13885,,,81020,Intermediate
1,,1,726.0,9606.0,135,,,F,,,,Homo sapiens,HepG2,N,CHEMBL827086,BAO_0000219,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,13885,,,81020,Intermediate
0,,1,,,136,,,B,,,,,,U,CHEMBL615359,BAO_0000019,Compound was tested for the inhibition of Alpha-glucosidase,3676,,,22226,Autocuration
8,,1,,,137,,,B,,,,,,H,CHEMBL615360,BAO_0000357,Inhibitory concentration against human neutrophil elastase (HNE),6043,,,235,Autocuration
0,,1,,10116.0,138,,,F,948.0,,,Rattus norvegicus,,U,CHEMBL615361,BAO_0000218,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,11140,,Heart,22226,Autocuration
8,,1,,,139,,,F,,,,,,H,CHEMBL615362,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,10543,,,19640,Autocuration
8,,1,,,140,,,F,,,,,,H,CHEMBL615363,BAO_0000019,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,10543,,,19640,Expert
8,,1,,,141,,,B,,,,,,H,CHEMBL615364,BAO_0000357,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,10543,,,19640,Autocuration
8,,1,,,142,,,F,,,,,,H,CHEMBL615365,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,10543,,,19640,Expert
1,,1,524.0,10090.0,143,,,F,,,,Mus musculus,P338,N,CHEMBL615366,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,11365,,,80360,Intermediate
1,,1,524.0,10090.0,144,,,F,,,,Mus musculus,P338,N,CHEMBL615367,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,11365,,,80360,Intermediate
1,,1,554.0,9606.0,145,,,F,,,,Homo sapiens,PBL,N,CHEMBL615368,BAO_0000219,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,11803,,,80384,Intermediate
0,,1,,9940.0,146,,,F,,,,Ovis aries,,U,CHEMBL615369,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,11803,,,22226,Autocuration
0,,1,,9940.0,147,,,F,,,,Ovis aries,,U,CHEMBL615370,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,11803,,,22226,Autocuration
8,,1,,,148,,,B,,,,,,H,CHEMBL615673,BAO_0000357,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),12278,,,191,Autocuration
0,,1,,9606.0,149,,,F,,,,Homo sapiens,,U,CHEMBL615674,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,8249,,,22226,Autocuration
0,,1,,9606.0,150,,,F,,,,Homo sapiens,,U,CHEMBL615675,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,8249,,,22226,Autocuration
0,,1,635.0,9606.0,151,,,F,,,,Homo sapiens,CCRF-CEM,U,CHEMBL615676,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,8249,,,22226,Autocuration
0,,1,635.0,9606.0,152,,,F,,,,Homo sapiens,CCRF-CEM,U,CHEMBL615677,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,8249,,,22226,Autocuration
0,,1,635.0,9606.0,153,,,F,,,,Homo sapiens,CCRF-CEM,U,CHEMBL615678,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,8249,,,22226,Autocuration
0,,1,635.0,9606.0,154,,,F,,,,Homo sapiens,CCRF-CEM,U,CHEMBL615679,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,8249,,,22226,Autocuration
0,,1,,9606.0,155,,,F,,,,Homo sapiens,,U,CHEMBL615680,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,8249,,,22226,Autocuration
0,,1,,9606.0,156,,,F,,,,Homo sapiens,,U,CHEMBL615681,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,8249,,,22226,Autocuration
6,,1,,,157,,,B,,,,,,H,CHEMBL857972,BAO_0000249,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,16992,,,104290,Autocuration
1,,1,,1314.0,158,,,F,,,,Streptococcus pyogenes,,N,CHEMBL857899,BAO_0000218,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,10543,,,50264,Intermediate
1,,1,,10335.0,159,,,F,,,,Human herpesvirus 3,,N,CHEMBL615371,BAO_0000218,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),17833,,,50527,Intermediate
1,,1,468.0,10335.0,160,,,F,,,,vericilla zoster virus,HEL,N,CHEMBL615372,BAO_0000218,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,17290,,,50527,Expert
1,,1,,10335.0,161,,,F,,,,vericilla zoster virus,,N,CHEMBL615373,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND: No data,17290,,,50527,Intermediate
1,,1,,10335.0,162,,,F,,,,vericilla zoster virus,,N,CHEMBL615374,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND=No data,17290,,,50527,Intermediate
1,,1,,561.0,163,,,F,,,,escherichia cloac,,N,CHEMBL615375,BAO_0000218,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",10932,,,50145,Intermediate
0,,1,,,164,,,B,,,,,,U,CHEMBL615376,BAO_0000019,Ratio of Ki at A2 to Ki at A1 receptors,9707,,,22226,Autocuration
8,,1,,5476.0,165,,,B,,,,Candida albicans,,H,CHEMBL615377,BAO_0000249,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",2346,,,11143,Expert
8,,1,,284593.0,166,,,B,,,,Candida glabrata CBS 138,,H,CHEMBL615378,BAO_0000357,"Inhibition of 1,3-beta-glucan synthase",2205,,,18077,Expert
1,,1,832.0,9606.0,167,,,F,,,,Homo sapiens,1-87 tumor cell line,N,CHEMBL615379,BAO_0000219,Inhibition of growth of 1-87 human tumor cell line,11900,,,80609,Intermediate
9,,1,,10116.0,168,,,B,,,,Rattus norvegicus,,D,CHEMBL615380,BAO_0000219,Inhibition of 1-lipoxygenase (LOX)in RBL cells,14864,,,12166,Expert
9,,1,,3847.0,169,,,B,,,,Glycine max,,D,CHEMBL615381,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO),16474,,,100171,Autocuration
9,,1,,3847.0,170,,,B,,,,Glycine max,,D,CHEMBL615382,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,16474,,,100171,Autocuration
9,,1,,3847.0,171,,,B,,,,Glycine max,,D,CHEMBL615383,BAO_0000357,% inhibition against soybean 1-lipoxygenase (SLO),16474,,,100171,Autocuration
9,,1,,3847.0,172,,,B,,,,Glycine max,,D,CHEMBL615384,BAO_0000357,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,16474,,,100171,Autocuration
9,,1,,3847.0,173,,,B,,,,Glycine max,,D,CHEMBL615385,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,3094,,,100171,Autocuration
9,,1,,3847.0,174,,,B,,,,Glycine max,,D,CHEMBL615386,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,3094,,,100171,Autocuration
9,,1,,3847.0,175,,,B,,,,Glycine max,,D,CHEMBL615387,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,3094,,,100171,Autocuration
9,,1,,3847.0,176,,,B,,,,Glycine max,,D,CHEMBL615388,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,3094,,,100171,Autocuration
9,,1,,3847.0,177,,,B,,,,Glycine max,,D,CHEMBL615214,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,3094,,,100171,Autocuration
9,,1,,3847.0,178,,,B,,,,Glycine max,,D,CHEMBL827087,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,3094,,,100171,Autocuration
9,,1,,3847.0,179,,,B,,,,Glycine max,,D,CHEMBL615215,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,3094,,,100171,Autocuration
9,,1,,3847.0,180,,,B,,,,Glycine max,,D,CHEMBL615216,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,3094,,,100171,Autocuration
9,,1,,3847.0,181,,,B,,,,Glycine max,,D,CHEMBL615217,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,3094,,,100171,Autocuration
9,,1,,3847.0,182,,,B,,,,Glycine max,,D,CHEMBL615218,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,3094,,,100171,Autocuration
9,,1,,3847.0,183,,,B,,,,Glycine max,,D,CHEMBL615219,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,3094,,,100171,Autocuration
0,,1,,10090.0,184,,,B,,,,Mus musculus,,U,CHEMBL615220,BAO_0000019,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,10413,,,22226,Autocuration
1,,1,294.0,10090.0,185,,,F,,,,Mus musculus,C3H 10T1/2,N,CHEMBL615221,BAO_0000219,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),16929,,,80049,Intermediate
0,,1,,,186,,,F,,,,,,U,CHEMBL615222,BAO_0000019,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1229,,,22226,Intermediate
8,,1,,,187,,,B,,,,,,H,CHEMBL615223,BAO_0000357,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),16587,,,11489,Autocuration
8,,1,,,188,,,B,,,,,,H,CHEMBL615224,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),16587,,,11862,Autocuration
8,,1,,,189,,,B,,,,,,H,CHEMBL615225,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,16587,,,11862,Autocuration
8,,1,,,190,,,B,,,,,,H,CHEMBL615226,BAO_0000357,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,16587,,,11489,Autocuration
8,,1,,,191,,,B,,,,,,H,CHEMBL615227,BAO_0000357,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,16587,,,11862,Autocuration
9,,1,,9913.0,192,,,F,,,,Bos taurus,,D,CHEMBL615228,BAO_0000019,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,8058,,,12347,Expert
9,,1,,10116.0,193,,,B,,,,Rattus norvegicus,,D,CHEMBL615229,BAO_0000357,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,9065,,,100120,Expert
9,,1,,10116.0,194,,,B,2369.0,,,Rattus norvegicus,,D,CHEMBL615230,BAO_0000357,Inhibition of 11 beta-hydroxylase from rat adrenal gland,8865,,Adrenal gland,100120,Expert
9,,1,,10116.0,195,,,B,,,,Rattus norvegicus,,D,CHEMBL615231,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,9066,,,100120,Expert
9,,1,,10116.0,196,,,B,,,,Rattus norvegicus,,D,CHEMBL884520,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,8394,,,100120,Expert
9,,1,,10116.0,197,,,B,,,,Rattus norvegicus,,D,CHEMBL615232,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,8394,,,100120,Expert
8,,1,,,198,,,B,,,,,,H,CHEMBL615233,BAO_0000019,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,6431,,,10328,Autocuration
8,,1,,,199,,,B,,,,,,H,CHEMBL827088,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,6431,,,11490,Autocuration
8,,1,,,200,,,B,,,,,,H,CHEMBL615234,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,6431,,,11490,Autocuration
8,,1,,,201,,,F,,,,,,H,CHEMBL615235,BAO_0000019,Compound was tested for the percent of inhibition against 12-LO at 10 uM,9295,,,11134,Autocuration
8,,1,,,202,,,B,,,,,,H,CHEMBL615236,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,,,12052,Autocuration
8,,1,,,203,,,B,,,,,,H,CHEMBL615237,BAO_0000019,Compound was tested in vitro for inhibition of 12-LO human platelet,13622,,,11134,Autocuration
8,,1,,,204,,,F,,,,,,H,CHEMBL615238,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,12079,,,11134,Autocuration
8,,1,,,205,,,B,,,,,,H,CHEMBL615239,BAO_0000019,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,13622,,,11134,Autocuration
9,,1,,9606.0,206,,,F,,,,Homo sapiens,,D,CHEMBL615240,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,12079,,,11134,Autocuration
8,,1,,,207,,,B,,,,,,H,CHEMBL615241,BAO_0000019,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,13500,,,11835,Expert
8,,1,,,208,,,B,,,,,,H,CHEMBL615242,BAO_0000357,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,13723,,,11601,Expert
8,,1,,,209,,,B,,,,,,H,CHEMBL615243,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),16474,,,11134,Autocuration
8,,1,,,210,,,B,,,,,,H,CHEMBL615244,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase,1630,,,11134,Autocuration
8,,1,,,211,,,B,,,,,,H,CHEMBL615245,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,167,,,11134,Autocuration
8,,1,,,212,,,B,,,,,,H,CHEMBL615246,BAO_0000019,% inhibition against human platelet 12-lipoxygenase (12-HLO),16474,,,11134,Autocuration
8,,1,,,213,,,B,,,,,,H,CHEMBL615247,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,167,,,11134,Autocuration
8,,1,,,214,,,B,,,,,,H,CHEMBL615248,BAO_0000019,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,16474,,,11134,Autocuration
8,,1,,,215,,,B,,,,,,H,CHEMBL615249,BAO_0000357,Inhibitory activity towards porcine 12-lipoxygenase,10091,,,11601,Autocuration
8,,1,,,216,,,B,,,,,,H,CHEMBL615250,BAO_0000357,Tested for inhibition against porcine 12-LO,11966,,,11601,Autocuration
8,,1,,,217,,,B,,,,,,H,CHEMBL615251,BAO_0000019,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,951,,,12052,Autocuration
8,,1,,,218,,,B,,,,,,H,CHEMBL615252,BAO_0000019,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,10997,,,12052,Autocuration
8,,1,,,219,,,B,,,,,,H,CHEMBL828340,BAO_0000019,In vitro inhibition of rat platelet 12-lipoxygenase,10193,,,12052,Expert
8,,1,,,220,,,B,,,,,,H,CHEMBL615253,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,,,12052,Autocuration
8,,1,,,221,,,B,,,,,,H,CHEMBL615254,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,10193,,,12052,Autocuration
8,,1,,,222,,,B,,,,,,H,CHEMBL615255,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,10193,,,12052,Autocuration
8,,1,,,223,,,B,,,,,,H,CHEMBL615256,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,,,12052,Autocuration
8,,1,,,224,,,B,,,,,,H,CHEMBL615257,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase,10193,,,12052,Autocuration
8,,1,,,225,,,B,,,,,,H,CHEMBL615258,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,11087,,,12052,Autocuration
1,,1,621.0,9606.0,226,,,F,,,,Homo sapiens,41M,N,CHEMBL615259,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,15569,,,80007,Intermediate
1,,1,621.0,9606.0,227,,,F,,,,Homo sapiens,41M,N,CHEMBL615260,BAO_0000219,In vitro antitumor activity against 41M cell line.,12989,,,80007,Expert
1,,1,621.0,9606.0,228,,,F,,,,Homo sapiens,41M,N,CHEMBL615261,BAO_0000219,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,16745,,,80007,Intermediate
1,,1,621.0,9606.0,229,,,F,,,,Homo sapiens,41M,N,CHEMBL615262,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,15569,,,80007,Intermediate
1,,1,621.0,9606.0,230,,,F,,,,Homo sapiens,41M,N,CHEMBL615263,BAO_0000219,In vitro antitumor activity against 41McisR cell line.,12989,,,80007,Expert
1,,1,621.0,9606.0,231,,,F,,,,Homo sapiens,41M,N,CHEMBL838393,BAO_0000219,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,12989,,,80007,Expert
1,,1,621.0,9606.0,232,,,F,,,,Homo sapiens,41M,N,CHEMBL615264,BAO_0000219,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,16745,,,80007,Intermediate
9,,1,,9606.0,233,,,B,,,,Homo sapiens,,D,CHEMBL615265,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),6210,,,84,Expert
9,,1,,9606.0,234,,,B,,,,Homo sapiens,,D,CHEMBL615266,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),6210,,,68,Expert
8,,1,,,235,,,B,,,,,,H,CHEMBL615267,BAO_0000357,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),6226,,,68,Expert
8,,1,,,236,,,B,,,,,,H,CHEMBL615268,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,17855,,,10201,Expert
8,,1,,,237,,,B,,,,,,H,CHEMBL615269,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,17855,,,10201,Expert
8,,1,,,238,,,B,,,,,,H,CHEMBL615270,BAO_0000357,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,17855,,,10201,Expert
8,,1,,,239,,,B,,,,,,H,CHEMBL615271,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",10413,,,12220,Autocuration
8,,1,,562.0,240,,,B,,,,Escherichia coli,,H,CHEMBL615272,BAO_0000357,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",10413,,,11303,Autocuration
8,,1,,562.0,241,,,B,,,,Escherichia coli,,H,CHEMBL615103,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",10413,,,11303,Autocuration
8,,1,,562.0,242,,,B,,,,Escherichia coli,,H,CHEMBL615104,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",10413,,,11303,Autocuration
8,,1,,,243,,,B,,,,,,H,CHEMBL615105,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",10413,,,12220,Autocuration
8,,1,,,244,,,B,,,,,,H,CHEMBL872866,BAO_0000357,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",10413,,,12220,Autocuration
8,,1,,9823.0,245,,,B,,,,Sus scrofa,,H,CHEMBL615106,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,246,,,B,,,,Sus scrofa,,H,CHEMBL615107,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",7587,,,11303,Autocuration
8,,1,,9823.0,247,,,B,,,,Sus scrofa,,H,CHEMBL615108,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,248,,,B,,,,Sus scrofa,,H,CHEMBL615109,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,249,,,B,,,,Sus scrofa,,H,CHEMBL615110,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,250,,,B,,,,Sus scrofa,,H,CHEMBL840105,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,251,,,B,,,,Sus scrofa,,H,CHEMBL615111,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,252,,,B,,,,Sus scrofa,,H,CHEMBL615112,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,253,,,B,,,,Sus scrofa,,H,CHEMBL615113,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,254,,,B,,,,Sus scrofa,,H,CHEMBL615114,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",7587,,,11303,Autocuration
8,,1,,9823.0,255,,,B,,,,Sus scrofa,,H,CHEMBL615115,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,9823.0,256,,,B,,,,Sus scrofa,,H,CHEMBL615116,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",7587,,,11303,Autocuration
8,,1,,,257,,,B,,,,,,H,CHEMBL615698,BAO_0000357,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",7323,,,11303,Autocuration
0,,1,,9823.0,258,,,B,,,,Sus scrofa,,U,CHEMBL615699,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",7587,,,22226,Autocuration
0,,1,,9823.0,259,,,B,,,,Sus scrofa,,U,CHEMBL615700,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",7587,,,22226,Autocuration
8,,1,,4932.0,260,,,B,,,,Saccharomyces cerevisiae,,H,CHEMBL615701,BAO_0000357,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,13750,,,100249,Expert
0,,1,,10116.0,261,,,B,,,,Rattus norvegicus,,U,CHEMBL615702,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,7662,,,22226,Autocuration
0,,1,,10116.0,262,,,B,,,,Rattus norvegicus,,U,CHEMBL615703,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,7662,,,22226,Autocuration
0,,1,,10116.0,263,,,B,,,,Rattus norvegicus,,U,CHEMBL615704,BAO_0000019,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",7662,,,22226,Autocuration
6,,1,,,264,,,F,,,,,,H,CHEMBL615705,BAO_0000019,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",12211,,,104698,Autocuration
6,,1,,,265,,,F,,,,,,H,CHEMBL615706,BAO_0000019,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",12211,,,104698,Autocuration
9,,1,,10141.0,266,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL615707,BAO_0000221,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,12211,,Ileum,20033,Intermediate
8,,1,,,267,,,F,,,,,,H,CHEMBL615708,BAO_0000019,Stimulatory activity of intragastric pressure was tested in the rat,12211,,,10623,Expert
8,,1,,,268,,,B,,,,,,H,CHEMBL615709,BAO_0000357,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,15453,,,121,Autocuration
0,,1,,10116.0,269,,,F,,,,Rattus norvegicus,,U,CHEMBL615710,BAO_0000218,Dose to reduce neuronal firing against 5-HT cells in rats (iv),11884,,,22226,Autocuration
8,,1,,,270,,,F,,,,,,H,CHEMBL615711,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,7185,,,12688,Autocuration
9,,1,,9606.0,271,,,B,,,,Homo sapiens,,D,CHEMBL615712,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,6876,,,121,Expert
9,,1,,9606.0,272,,,B,,,,Homo sapiens,,D,CHEMBL836325,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,6876,,,121,Expert
8,,1,,,273,,,F,,,,,,H,CHEMBL615713,BAO_0000019,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,11863,,,12198,Autocuration
8,,1,,,274,,,B,,,,,,H,CHEMBL615714,BAO_0000357,Inhibition constant of high-affinity 5-HT uptake,11863,,,12198,Autocuration
8,,1,,,275,,,F,,,,,,H,CHEMBL615715,BAO_0000019,Michaelis-Menten constant was reported for high affinity transport of 5-HT,11863,,,12198,Autocuration
8,,1,,,276,,,F,,,,,,H,CHEMBL615716,BAO_0000019,Maximum rate was determined for high affinity transport of 5-HT,11863,,,12198,Autocuration
4,,1,,,277,,,F,,,,,,H,CHEMBL615717,BAO_0000019,Compound was tested for agonistic activity against 5-HT uptake,4639,,,104714,Autocuration
8,,1,,,278,,,B,,,,,,H,CHEMBL881818,BAO_0000019,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,15796,,,10577,Expert
8,,1,,9913.0,279,,,B,,,,Bos taurus,,H,CHEMBL884540,BAO_0000357,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,15796,,,105,Expert
5,,1,,10116.0,280,,,B,,,,Rattus norvegicus,,D,CHEMBL615718,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,12801,,,104744,Autocuration
4,,1,,,281,,,B,,,,,,H,CHEMBL615719,BAO_0000224,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,12801,,,104744,Autocuration
4,,1,,,282,,,B,,,,,,H,CHEMBL615720,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,12120,Membranes,,104744,Autocuration
4,,1,,,283,,,B,,,,,,H,CHEMBL615721,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,12120,Membranes,,104744,Autocuration
4,,1,,,284,,,B,,,,,,H,CHEMBL615722,BAO_0000019,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,11963,,,104744,Autocuration
8,,1,,,285,,,F,,,,,,H,CHEMBL615723,BAO_0000019,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,11701,,,51,Autocuration
8,,1,,,286,,,B,10000000.0,,,,,H,CHEMBL615724,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,287,,,B,10000000.0,,,,,H,CHEMBL615725,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,288,,,B,10000000.0,,,,,H,CHEMBL615726,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,289,,In vivo,F,,,,,,H,CHEMBL615727,BAO_0000218,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),16394,,,10576,Autocuration
9,,1,,10141.0,290,,,F,,,,Cavia porcellus,,D,CHEMBL615728,BAO_0000019,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,11574,,,105570,Intermediate
8,,1,449.0,,291,,,B,,,,,CHO,H,CHEMBL857971,BAO_0000219,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,,,279,Autocuration
8,,1,,,292,,,B,,,,,,H,CHEMBL615729,BAO_0000357,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,15363,,,107,Autocuration
9,,1,,10116.0,293,,,F,,,,Rattus norvegicus,,D,CHEMBL615730,BAO_0000019,Efficacy against 5-hydroxytryptamine 2A receptor,15363,,,12687,Expert
8,,1,,,294,,,F,,,,,,H,CHEMBL615731,BAO_0000019,Intrinsic activity towards 5-HT2A receptor of rat tail artery,15329,,,12687,Expert
8,,1,,,295,,,F,,,,,,H,CHEMBL615732,BAO_0000019,Relative potency towards 5-HT2A receptor of rat tail artery,15329,,,12687,Expert
8,,1,,,296,,,F,,,,,,H,CHEMBL615733,BAO_0000019,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,15329,,,12687,Expert
8,,1,,,297,,,F,,,,,,H,CHEMBL615734,BAO_0000019,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,15329,,,12687,Expert
8,,1,,,298,,,F,,,,,,H,CHEMBL615735,BAO_0000019,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,15329,,,12687,Autocuration
8,,1,,,299,,,F,,,,,,H,CHEMBL615736,BAO_0000019,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,15329,,,12687,Expert
9,,1,,10141.0,300,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL615737,BAO_0000221,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,273,,Ileum,20033,Intermediate
9,,1,,10141.0,301,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL615738,BAO_0000221,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),273,,Ileum,20033,Intermediate
9,,1,,10141.0,302,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL615739,BAO_0000221,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,273,,Ileum,20033,Intermediate
8,,1,,,303,,,B,,,,,,H,CHEMBL615278,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,12092,,,10623,Autocuration
9,,1,,10116.0,304,,,F,,,,Rattus norvegicus,,D,CHEMBL615279,BAO_0000019,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1317,,,10623,Expert
8,,1,,,305,,,B,,,,,,H,CHEMBL615280,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,12409,,,168,Expert
0,,1,,9031.0,306,,,B,,,,Gallus gallus,,U,CHEMBL615281,BAO_0000019,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,11126,,,22226,Autocuration
0,,1,,9606.0,307,,,F,,,,Homo sapiens,,U,CHEMBL615282,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,11126,,,22226,Autocuration
0,,1,,9606.0,308,,,F,,,,Homo sapiens,,U,CHEMBL615283,BAO_0000019,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,11126,,,22226,Autocuration
1,,1,649.0,9606.0,309,,,B,,,,Homo sapiens,HL-60,N,CHEMBL615284,BAO_0000219,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,11126,,,80156,Autocuration
0,,1,,9606.0,310,,,B,,,,Homo sapiens,,U,CHEMBL615285,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,11126,,,22226,Autocuration
0,,1,,9606.0,311,,,B,,,,Homo sapiens,,U,CHEMBL615286,BAO_0000019,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,11126,,,22226,Autocuration
7,,1,,9606.0,312,,,B,,,,Homo sapiens,Oocytes,D,CHEMBL615287,BAO_0000219,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,17807,,,104703,Autocuration
2,,1,,,313,,,F,,,,,,S,CHEMBL615288,BAO_0000220,Chymotryptic inhibitory activity against 26S proteasome,16575,,,100256,Intermediate
2,,1,,,314,,,B,,,,,,S,CHEMBL615289,BAO_0000220,Inhibitory activity against 26S proteasome degradation of IkB,15407,,,100256,Intermediate
1,,1,478.0,9606.0,315,,,F,,,,Homo sapiens,A2780,N,CHEMBL615290,BAO_0000219,In vitro inhibition of 2780/DOX ovarian cancer cell line,10797,,,81034,Intermediate
1,,1,478.0,9606.0,316,,,F,,,,Homo sapiens,A2780,N,CHEMBL884522,BAO_0000219,In vitro inhibition of 2780/S ovarian cancer cell line,10797,,,81034,Intermediate
0,,1,,9606.0,317,,,F,,,,Homo sapiens,,U,CHEMBL615291,BAO_0000019,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,3469,,,22226,Autocuration
3,,1,,,318,,,B,,,,,,M,CHEMBL615292,BAO_0000225,Association constant for binding to AATT 28-mer AATT hairpin,16037,,,22222,Intermediate
3,,1,,,319,,,B,,,,,,M,CHEMBL615293,BAO_0000225,Kinetically Defined Association Constant for 28-mer AATT hairpin.,16037,,,22222,Intermediate
3,,1,,,320,,,B,,,,,,M,CHEMBL615294,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,16037,,,22222,Intermediate
3,,1,,,321,,,B,,,,,,M,CHEMBL615295,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,16037,,,22222,Intermediate
0,,1,,9606.0,322,,,F,,,,Homo sapiens,,U,CHEMBL825021,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),16524,,,22226,Autocuration
0,,1,,9606.0,323,,,F,,,,Homo sapiens,,U,CHEMBL615296,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),16524,,,22226,Autocuration
0,,1,,9606.0,324,,,F,,,,Homo sapiens,,U,CHEMBL615297,BAO_0000019,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,16524,,,22226,Autocuration
0,,1,,10029.0,325,,,F,,,,Cricetulus griseus,,U,CHEMBL615298,BAO_0000019,Cytotoxicity against cell line 2SC/20 determined by MTT test,16758,,,22226,Autocuration
0,,1,,10029.0,326,,,F,,,,Cricetulus griseus,,U,CHEMBL615299,BAO_0000019,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,16758,,,22226,Autocuration
0,,1,,10029.0,327,,,F,,,,Cricetulus griseus,,U,CHEMBL615300,BAO_0000019,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,16758,,,22226,Autocuration
8,,1,,,328,,,B,,,,,,H,CHEMBL615301,BAO_0000357,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,14360,,,241,Autocuration
9,,1,,9606.0,329,,,B,,,,Homo sapiens,,D,CHEMBL615302,BAO_0000357,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,14360,,,241,Expert
0,,1,,10116.0,330,,,B,,,,Rattus norvegicus,,U,CHEMBL615303,BAO_0000019,Selectivity ratio of ID50 in liver and heart,9964,,,22226,Autocuration
8,,1,,,331,,,B,,,,,,H,CHEMBL615304,BAO_0000019,"Selectivity, ratio of relative ID50 in liver and heart",9964,,,12132,Autocuration
8,,1,,,332,,,B,,,,,,H,CHEMBL615305,BAO_0000019,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,9964,,,12132,Autocuration
8,,1,,,333,,,B,,,,,,H,CHEMBL615306,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
8,,1,,,334,,,B,,,,,,H,CHEMBL615307,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
8,,1,,,335,,In vivo,B,,,,,,H,CHEMBL615308,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
8,,1,,,336,,In vivo,F,,,,,,H,CHEMBL615309,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
0,,1,,,337,,,B,,,,,,U,CHEMBL615310,BAO_0000019,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",9964,,,22226,Autocuration
8,,1,,,338,,,B,,,,,,H,CHEMBL615311,BAO_0000019,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,9964,,,12132,Autocuration
0,,1,,9606.0,339,,,B,,,,Homo sapiens,,U,CHEMBL615312,BAO_0000019,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",9964,,,22226,Autocuration
8,,1,,,340,,,B,,,,,,H,CHEMBL615313,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,9964,,,12132,Autocuration
8,,1,,,341,,,F,,,,,,H,CHEMBL615314,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,9964,,,12132,Autocuration
8,,1,,,342,,,B,,,,,,H,CHEMBL615315,BAO_0000019,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
0,,1,,10116.0,343,,,B,,,,Rattus norvegicus,,U,CHEMBL615316,BAO_0000218,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",9964,,,22226,Autocuration
8,,1,,,344,,In vivo,B,,,,,,H,CHEMBL615317,BAO_0000218,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,9964,,,12132,Autocuration
8,,1,,,345,,,B,,,,,,H,CHEMBL615318,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
0,,1,,10116.0,346,,,B,,,,Rattus norvegicus,,U,CHEMBL615319,BAO_0000218,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",9964,,,22226,Autocuration
8,,1,,,347,,,B,,,,,,H,CHEMBL615320,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
8,,1,,,348,,,F,,,,,,H,CHEMBL615321,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",9964,,,12132,Autocuration
0,,1,,10116.0,349,,,B,,,,Rattus norvegicus,,U,CHEMBL615322,BAO_0000019,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",3796,,,22226,Autocuration
8,,1,,562.0,350,,,B,,,,Escherichia coli,,H,CHEMBL615323,BAO_0000357,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,4251,,,19690,Autocuration
8,,1,,562.0,351,,,B,,,,Escherichia coli,,H,CHEMBL615407,BAO_0000357,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,4251,,,19690,Autocuration
8,,1,,562.0,352,,,B,,,,Escherichia coli,,H,CHEMBL857267,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,4251,,,19690,Autocuration
8,,1,,562.0,353,,,B,,,,Escherichia coli,,H,CHEMBL615408,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,4251,,,19690,Autocuration
8,,1,,,354,,,B,,,,,,H,CHEMBL615409,BAO_0000357,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,166,,,19690,Autocuration
8,,1,,,355,,,B,,,,,,H,CHEMBL615410,BAO_0000357,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,17861,,,19690,Autocuration
8,,1,,,356,,,B,,,,,,H,CHEMBL615411,BAO_0000357,Inhibition constant against 3-dehydroquinate synthase,166,,,19690,Autocuration
8,,1,,,357,,,B,,,,,,H,CHEMBL615412,BAO_0000357,Association rate constant against 3-dehydroquinate synthase,166,,,19690,Autocuration
8,,1,,,358,,,B,,,,,,H,CHEMBL615413,BAO_0000357,Rate constant against 3-dehydroquinate synthase,166,,,19690,Autocuration
0,,1,,,359,,,B,,,,,,U,CHEMBL615414,BAO_0000019,Inhibitory activity against fuc-TVII,3548,,,22226,Autocuration
9,,1,,10116.0,360,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615415,BAO_0000251,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,361,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615416,BAO_0000251,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,362,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615417,BAO_0000251,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,363,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615418,BAO_0000251,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,364,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615419,BAO_0000251,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,365,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615420,BAO_0000251,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,366,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615421,BAO_0000251,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,367,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615422,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,368,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615423,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,369,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL872868,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,9877,Microsomes,Liver,12236,Autocuration
9,,1,,10116.0,370,,,B,2107.0,,,Rattus norvegicus,,D,CHEMBL615424,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,9877,Microsomes,Liver,12236,Autocuration
4,,1,,,371,,,B,,,,,,H,CHEMBL825022,BAO_0000224,Inhibitory activity against 3-phosphoglycerate kinase.,3003,,,104832,Autocuration
4,,1,,,372,,,B,,,,,,H,CHEMBL615425,BAO_0000224,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,3003,,,104832,Autocuration
4,,1,,,373,,,B,,,,,,H,CHEMBL615426,BAO_0000224,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",3003,,,104832,Autocuration
9,,1,,9606.0,374,,,B,,,,Homo sapiens,,D,CHEMBL615427,BAO_0000357,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,17185,,,10612,Expert
1,,1,844.0,9606.0,375,,,F,,,,Homo sapiens,3677 melanoma cell line,N,CHEMBL615428,BAO_0000219,Cytotoxicity on 3677 melanoma cells,6072,,,80616,Intermediate
1,,1,844.0,9606.0,376,,,F,,,,Homo sapiens,3677 melanoma cell line,N,CHEMBL615429,BAO_0000219,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,6072,,,80616,Intermediate
1,,1,700.0,10090.0,377,,,F,,,,Mus musculus,MC-38,N,CHEMBL615430,BAO_0000219,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,5018,,,80617,Intermediate
0,,1,,9606.0,378,,,F,,,,Homo sapiens,,U,CHEMBL615431,BAO_0000019,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,2852,,,22226,Intermediate
0,,1,798.0,,379,,,F,,,,,B16,U,CHEMBL615432,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,8663,,,22226,Autocuration
0,,1,798.0,,380,,,F,,,,,B16,U,CHEMBL615433,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,8663,,,22226,Autocuration
9,,1,,12131.0,381,,,F,,,,Human rhinovirus 14,,D,CHEMBL615434,BAO_0000019,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,3245,,,12464,Expert
1,,1,,169066.0,382,,,F,,,,Human rhinovirus sp.,,N,CHEMBL615435,BAO_0000218,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,3245,,,50085,Intermediate
1,,1,,169066.0,383,,,F,,,,human rhinovirus type 14,,N,CHEMBL615436,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,3877,,,50679,Intermediate
1,,1,,169066.0,384,,,F,,,,human rhinovirus type 14,,N,CHEMBL615437,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,3877,,,50679,Intermediate
9,,1,,12131.0,385,,,F,,,,Human rhinovirus 14,,D,CHEMBL615438,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,,,12464,Expert
9,,1,,12131.0,386,,,F,,,,Human rhinovirus 14,,D,CHEMBL615439,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,,,12464,Expert
9,,1,,12131.0,387,,,F,,,,Human rhinovirus 14,,D,CHEMBL615440,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,,,12464,Expert
9,,1,,12131.0,388,,,F,,,,Human rhinovirus 14,,D,CHEMBL615441,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,5861,,,12464,Expert
1,,1,,12059.0,389,,,F,,,,Enterovirus,,N,CHEMBL615641,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,13748,,,50665,Intermediate
1,,1,,12059.0,390,,,F,,,,Enterovirus,,N,CHEMBL872065,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,13748,,,50665,Intermediate
1,,1,,12059.0,391,,,F,,,,Enterovirus,,N,CHEMBL825023,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,13748,,,50665,Intermediate
1,,1,,12059.0,392,,,F,,,,Enterovirus,,N,CHEMBL615642,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,13748,,,50665,Intermediate
8,,1,,147712.0,393,,,B,,,,Human rhinovirus B,,H,CHEMBL615643,BAO_0000357,Inhibition of human rhinovirus 3C protease,13748,,,12464,Expert
0,,1,,9606.0,394,,,B,,,,Homo sapiens,,U,CHEMBL615644,BAO_0000019,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,17699,,,22226,Autocuration
1,,1,833.0,10090.0,395,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615645,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),7145,,,80619,Intermediate
1,,1,833.0,10090.0,396,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615646,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),7145,,,80619,Intermediate
1,,1,833.0,10090.0,397,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615647,BAO_0000218,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),7145,,,80619,Intermediate
1,,1,833.0,10090.0,398,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615648,BAO_0000218,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),7145,,,80619,Intermediate
1,,1,833.0,10090.0,399,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615649,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,7145,,,80619,Intermediate
1,,1,833.0,10090.0,400,,,F,,,,Mus musculus,3EM 37,N,CHEMBL615650,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,7145,,,80619,Intermediate
1,,1,847.0,10090.0,401,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615651,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,5325,,,80620,Intermediate
1,,1,847.0,10090.0,402,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615652,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,5325,,,80620,Intermediate
1,,1,847.0,10090.0,403,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615653,BAO_0000218,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,5325,,,80620,Expert
1,,1,847.0,10090.0,404,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615654,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,405,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615655,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,406,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL825024,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,407,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615656,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,408,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615657,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,409,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615658,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,410,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615659,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,411,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615660,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,412,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615661,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,413,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615662,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,414,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615663,BAO_0000219,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,16169,,,80620,Intermediate
1,,1,847.0,10090.0,415,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615664,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,16169,,,80620,Intermediate
1,,1,847.0,10090.0,416,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615665,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,16169,,,80620,Intermediate
1,,1,847.0,10090.0,417,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615666,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,16169,,,80620,Intermediate
1,,1,847.0,10090.0,418,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615667,BAO_0000219,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,419,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615668,BAO_0000219,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,420,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615669,BAO_0000219,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,421,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615670,BAO_0000219,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,422,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL836739,BAO_0000219,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,423,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615671,BAO_0000219,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,424,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615672,BAO_0000219,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,425,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615791,BAO_0000219,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,426,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615792,BAO_0000219,spermine levels in 3LL cells after the treatment of 1 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,427,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615793,BAO_0000219,spermine levels in 3LL cells after the treatment of 10 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,428,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615794,BAO_0000219,spermine levels in 3LL cells after the treatment of 250 uM of Compound,16169,,,80620,Intermediate
1,,1,847.0,10090.0,429,,,F,,,,Mus musculus,3LL cell line,N,CHEMBL615795,BAO_0000219,spermine levels in 3LL cells after the treatment of 50 uM of Compound,16169,,,80620,Intermediate
1,,1,971.0,9606.0,430,,,F,,,,Homo sapiens,3LLD122,N,CHEMBL615590,BAO_0000219,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,15547,,,80621,Intermediate
0,,1,,,431,,,F,,,,,,U,CHEMBL615591,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,8663,,,22226,Autocuration
0,,1,,,432,,,F,,,,,,U,CHEMBL615592,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,8663,,,22226,Autocuration
0,,1,,,433,,,F,,,,,,U,CHEMBL615593,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,8663,,,22226,Autocuration
0,,1,,,434,,,F,,,,,,U,CHEMBL615594,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,8663,,,22226,Autocuration
1,,1,723.0,10090.0,435,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615595,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,4504,,,80951,Intermediate
1,,1,723.0,10090.0,436,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615596,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,4504,,,80951,Intermediate
8,,1,723.0,,437,,,F,,,,,NIH3T3,H,CHEMBL615597,BAO_0000219,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,12695,,,11169,Expert
1,,1,723.0,10090.0,438,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615598,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,12695,,,80951,Intermediate
1,,1,723.0,10090.0,439,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615599,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,12695,,,80951,Intermediate
1,,1,723.0,10090.0,440,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615600,BAO_0000219,Effective dose against murine 3T3 fibroblasts cells,17642,,,80951,Expert
1,,1,723.0,10090.0,441,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615601,BAO_0000219,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,17642,,,80951,Expert
1,,1,723.0,10090.0,442,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615602,BAO_0000219,Cytotoxic effect on 3T3 cells,12340,,,80951,Expert
1,,1,723.0,10090.0,443,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615603,BAO_0000219,Cytotoxic effect on 3T3 cells,12340,,,80951,Expert
1,,1,723.0,10090.0,444,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615604,BAO_0000219,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,12716,,,80951,Intermediate
1,,1,723.0,10090.0,445,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615605,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,6277,,,80951,Intermediate
1,,1,723.0,10090.0,446,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615606,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,6277,,,80951,Intermediate
1,,1,723.0,10090.0,447,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL884526,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,6277,,,80951,Expert
1,,1,723.0,10090.0,448,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615607,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,6277,,,80951,Expert
1,,1,723.0,10090.0,449,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615608,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,6277,,,80951,Intermediate
1,,1,723.0,10090.0,450,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615609,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,6277,,,80951,Expert
1,,1,723.0,10090.0,451,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615682,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,6277,,,80951,Expert
1,,1,723.0,10090.0,452,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615683,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,6277,,,80951,Intermediate
1,,1,723.0,10090.0,453,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615684,BAO_0000218,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,17780,,,80951,Expert
7,,1,,10090.0,454,,,F,,,,Mus musculus,,D,CHEMBL615685,BAO_0000219,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,12751,,,104860,Autocuration
1,,1,723.0,10090.0,455,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615686,BAO_0000219,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,12380,,,80951,Expert
1,,1,723.0,10090.0,456,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615687,BAO_0000219,Inhibitory activity against 3T3 cell line,14892,,,80951,Intermediate
1,,1,723.0,10090.0,457,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL884523,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,12695,,,80951,Intermediate
8,,1,,,458,,,F,,,,,,H,CHEMBL615688,BAO_0000019,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,12695,,,11169,Expert
1,,1,723.0,10090.0,459,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615689,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,12695,,,80951,Intermediate
1,,1,723.0,10090.0,460,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615690,BAO_0000219,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,12695,,,80951,Intermediate
8,,1,,,461,,,F,,,,,,H,CHEMBL615691,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,12695,,,11169,Expert
8,,1,,,462,,,F,,,,,,H,CHEMBL615692,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,12695,,,11169,Expert
1,,1,723.0,10090.0,463,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615693,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,6277,,,80951,Intermediate
1,,1,723.0,10090.0,464,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615324,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,6277,,,80951,Expert
9,,1,723.0,9606.0,465,,,F,,,,Homo sapiens,NIH3T3,D,CHEMBL615325,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,4959,,,9,Expert
9,,1,723.0,9606.0,466,,,F,,,,Homo sapiens,NIH3T3,D,CHEMBL615490,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),4959,,,9,Expert
9,,1,723.0,9606.0,467,,,F,,,,Homo sapiens,NIH3T3,D,CHEMBL615491,BAO_0000219,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,4959,,,188,Expert
9,,1,723.0,9606.0,468,,,F,,,,Homo sapiens,NIH3T3,D,CHEMBL615492,BAO_0000219,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),4959,,,188,Expert
1,,1,723.0,10090.0,469,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615493,BAO_0000219,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,12082,,,80951,Intermediate
1,,1,723.0,10090.0,470,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615494,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,12082,,,80951,Intermediate
1,,1,723.0,10090.0,471,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615495,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,12082,,,80951,Intermediate
1,,1,723.0,10090.0,472,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615496,BAO_0000219,Inhibitory concentration was calculated on 3T3 cells by using growth assay,12082,,,80951,Intermediate
1,,1,723.0,10090.0,473,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615497,BAO_0000219,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,2643,,,80951,Intermediate
1,,1,723.0,10090.0,474,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615498,BAO_0000219,Inhibition of Swiss 3T3 mouse fibroblast proliferation,11926,,,80951,Expert
1,,1,723.0,10090.0,475,,,A,,,,Mus musculus,NIH3T3,N,CHEMBL615499,BAO_0000219,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,15204,,,80951,Intermediate
1,,1,723.0,10090.0,476,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL835522,BAO_0000219,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,15992,,,80951,Expert
1,,1,723.0,10090.0,477,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615500,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,16279,,,80951,Intermediate
1,,1,723.0,10090.0,478,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615501,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,,,80951,Intermediate
1,,1,723.0,10090.0,479,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615502,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,,,80951,Intermediate
1,,1,723.0,10090.0,480,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615503,BAO_0000219,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,,,80951,Intermediate
1,,1,723.0,10090.0,481,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615504,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,,,80951,Intermediate
1,,1,723.0,10090.0,482,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615505,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,,,80951,Intermediate
1,,1,723.0,10090.0,483,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615506,BAO_0000219,Inhibition of swiss 3T3 mouse fibroblast proliferation,12831,,,80951,Expert
1,,1,723.0,10090.0,484,,,F,,,,Mus musculus,NIH3T3,N,CHEMBL615507,BAO_0000219,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,13497,,,80951,Intermediate
1,,1,620.0,,485,,,F,,,,,3T3-L1,N,CHEMBL615508,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,10090.0,486,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615509,BAO_0000219,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,13618,,,80006,Intermediate
1,,1,620.0,10090.0,487,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615510,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,11902,,,80006,Intermediate
1,,1,620.0,10090.0,488,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615511,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,11902,,,80006,Intermediate
1,,1,620.0,10090.0,489,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615512,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,11902,,,80006,Intermediate
1,,1,620.0,10090.0,490,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615513,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",14840,,,80006,Intermediate
1,,1,620.0,10090.0,491,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615514,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",14840,,,80006,Intermediate
1,,1,620.0,,492,,,F,,,,,3T3-L1,N,CHEMBL615515,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,13715,,,80006,Intermediate
1,,1,620.0,,493,,,F,,,,,3T3-L1,N,CHEMBL615516,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,13715,,,80006,Intermediate
1,,1,620.0,,494,,,F,,,,,3T3-L1,N,CHEMBL615517,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,,,80006,Intermediate
1,,1,620.0,,495,,,F,,,,,3T3-L1,N,CHEMBL615518,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,13715,,,80006,Intermediate
1,,1,620.0,,496,,,F,,,,,3T3-L1,N,CHEMBL615519,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,,,80006,Intermediate
1,,1,620.0,,497,,,F,,,,,3T3-L1,N,CHEMBL615520,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,498,,,F,,,,,3T3-L1,N,CHEMBL615521,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,499,,,F,,,,,3T3-L1,N,CHEMBL615522,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,500,,,F,,,,,3T3-L1,N,CHEMBL615523,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,501,,,F,,,,,3T3-L1,N,CHEMBL615524,BAO_0000218,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,13715,,,80006,Expert
1,,1,620.0,,502,,,F,,,,,3T3-L1,N,CHEMBL615525,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,,,80006,Expert
1,,1,620.0,,503,,,F,,,,,3T3-L1,N,CHEMBL615526,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,504,,,F,,,,,3T3-L1,N,CHEMBL615527,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,505,,,F,,,,,3T3-L1,N,CHEMBL615528,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,506,,,F,,,,,3T3-L1,N,CHEMBL615529,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,,,80006,Expert
1,,1,620.0,,507,,,F,,,,,3T3-L1,N,CHEMBL615530,BAO_0000218,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,,,80006,Expert
1,,1,620.0,,508,,,F,,,,,3T3-L1,N,CHEMBL615531,BAO_0000218,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,13715,,,80006,Expert
1,,1,620.0,,509,,,F,,,,,3T3-L1,N,CHEMBL615532,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,13715,,,80006,Intermediate
1,,1,620.0,,510,,,F,,,,,3T3-L1,N,CHEMBL615533,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,,,80006,Intermediate
1,,1,620.0,,511,,,F,,,,,3T3-L1,N,CHEMBL615534,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,13715,,,80006,Intermediate
1,,1,620.0,,512,,,F,,,,,3T3-L1,N,CHEMBL615535,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,513,,,F,,,,,3T3-L1,N,CHEMBL615536,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,514,,,F,,,,,3T3-L1,N,CHEMBL615537,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,515,,,F,,,,,3T3-L1,N,CHEMBL615538,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,,,80006,Intermediate
1,,1,620.0,,516,,,F,,,,,3T3-L1,N,CHEMBL836166,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,13715,,,80006,Intermediate
8,,1,620.0,,517,,,F,,,,,3T3-L1,H,CHEMBL615539,BAO_0000219,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,6411,,,11214,Expert
1,,1,620.0,10090.0,518,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615540,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,6411,,,80006,Intermediate
8,,1,620.0,,519,,,F,,,,,3T3-L1,H,CHEMBL615541,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,6411,,,11214,Expert
1,,1,620.0,10090.0,520,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615542,BAO_0000219,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,3966,,,80006,Expert
1,,1,620.0,10090.0,521,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615543,BAO_0000219,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,3966,,,80006,Intermediate
1,,1,620.0,10090.0,522,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615544,BAO_0000219,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,15556,,,80006,Expert
1,,1,620.0,10090.0,523,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615545,BAO_0000219,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,5845,,,80006,Expert
1,,1,620.0,10090.0,524,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615546,BAO_0000219,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,14422,,,80006,Expert
1,,1,620.0,10090.0,525,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615547,BAO_0000219,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,5845,,,80006,Expert
1,,1,620.0,10090.0,526,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615548,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,14508,,,80006,Expert
1,,1,620.0,10090.0,527,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615549,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,14508,,,80006,Expert
1,,1,620.0,10090.0,528,,,F,,,,Mus musculus,3T3-L1,N,CHEMBL615550,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,14508,,,80006,Expert
1,,1,1118.0,10116.0,529,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615551,BAO_0000219,Inhibitory activity against rat fibroblast (3Y1) cell line,6349,,,80622,Intermediate
1,,1,1118.0,10116.0,530,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615552,BAO_0000219,Mean concentration causing inhibition of cell growth in 3Y1 cells.,15899,,,80622,Expert
1,,1,1118.0,10116.0,531,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615553,BAO_0000219,Cytotoxicity in 3Y1 cells.,15899,,,80622,Expert
1,,1,1118.0,10116.0,532,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615554,BAO_0000219,Cytostatic effect in 3Y1 cells.,15899,,,80622,Expert
1,,1,1118.0,10116.0,533,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615555,BAO_0000219,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",15899,,,80622,Intermediate
1,,1,1118.0,10116.0,534,,,F,,,,Rattus norvegicus,3Y1 cell line,N,CHEMBL615556,BAO_0000219,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,17038,,,80622,Expert
0,,1,,,535,,,B,,,,,,U,CHEMBL615557,BAO_0000019,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,12421,,,22226,Autocuration
0,,1,,,536,,,B,,,,,,U,CHEMBL615558,BAO_0000019,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,12947,,,22226,Autocuration
0,,1,,,537,,,B,,,,,,U,CHEMBL872066,BAO_0000019,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,12947,,,22226,Autocuration
9,,1,,9823.0,538,,,B,,,,Sus scrofa,,D,CHEMBL615559,BAO_0000019,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,4896,,,11607,Expert
8,,1,,,539,,,B,,,,,,H,CHEMBL615560,BAO_0000019,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,6148,,,11607,Autocuration
8,,1,,,540,,,B,,,,,,H,CHEMBL615561,BAO_0000019,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,16432,,,11607,Autocuration
8,,1,,,541,,,B,,,,,,H,CHEMBL857062,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,4978,,,11607,Expert
8,,1,,,542,,,B,,,,,,H,CHEMBL615562,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),4978,,,11607,Expert
8,,1,,,543,,,B,,,,,,H,CHEMBL615563,BAO_0000019,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,3723,,,11607,Autocuration
8,,1,,,544,,,B,,,,,,H,CHEMBL615564,BAO_0000357,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),3518,,,11607,Autocuration
8,,1,,,545,,,B,,,,,,H,CHEMBL615565,BAO_0000019,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,4164,,,11607,Autocuration
8,,1,,,546,,,B,,,,,,H,CHEMBL615566,BAO_0000019,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,3518,,,11607,Autocuration
9,,1,,9823.0,547,,,B,,,,Sus scrofa,,D,CHEMBL615567,BAO_0000019,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,4164,,,11607,Expert
8,,1,,,548,,,B,,,,,,H,CHEMBL615568,BAO_0000019,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,3518,,,11607,Autocuration
8,,1,,,549,,,B,,,,,,H,CHEMBL615569,BAO_0000357,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),3518,,,11607,Autocuration
8,,1,,,550,,,B,,,,,,H,CHEMBL615570,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,4978,,,11607,Autocuration
8,,1,,,551,,,B,,,,,,H,CHEMBL615571,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),4978,,,11607,Autocuration
4,,1,,,552,,,B,,,,,,H,CHEMBL615572,BAO_0000224,Binding affinity against melatonin (MT1) receptor (pC1),6455,,,104733,Autocuration
0,,1,,,553,,,B,,,,,,U,CHEMBL615573,BAO_0000019,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,2222,,,22226,Autocuration
0,,1,,,554,,,B,,,,,,U,CHEMBL615574,BAO_0000019,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,13020,,,22226,Autocuration
0,,1,,,555,,,B,,,,,,U,CHEMBL615575,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,13021,,,22226,Autocuration
8,,1,,,556,,,B,,,,,,H,CHEMBL615576,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,14532,,,10619,Autocuration
8,,1,,,557,,,B,,,,,,H,CHEMBL615577,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,14118,,,10619,Autocuration
8,,1,,,558,,,B,10000000.0,,,,,H,CHEMBL615578,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,11884,,Hippocampus,51,Autocuration
8,,1,,,559,,,B,,,,,,H,CHEMBL615579,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,13969,,,51,Expert
8,,1,,,560,,,B,,,,,,H,CHEMBL615580,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,13392,,,51,Expert
8,,1,,,561,,,B,,,,,,H,CHEMBL615581,BAO_0000019,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,14430,,,51,Expert
8,,1,,,562,,,B,10000000.0,,,,,H,CHEMBL615582,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12248,,Hippocampus,51,Autocuration
8,,1,,,563,,,B,10000000.0,,,,,H,CHEMBL615583,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,,Hippocampus,51,Autocuration
8,,1,,,564,,,B,10000000.0,,,,,H,CHEMBL615584,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,565,,,B,10000000.0,,,,,H,CHEMBL833691,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,566,,,B,10000000.0,,,,,H,CHEMBL615585,BAO_0000221,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,567,,,B,10000000.0,,,,,H,CHEMBL615586,BAO_0000221,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,568,,,B,10000000.0,,,,,H,CHEMBL884524,BAO_0000221,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,569,,,B,10000000.0,,,,,H,CHEMBL615587,BAO_0000221,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,,Hippocampus,51,Autocuration
8,,1,,,570,,,B,10000000.0,,,,,H,CHEMBL615588,BAO_0000221,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",11799,,Hippocampus,51,Autocuration
9,,1,,10116.0,571,,,B,,,,Rattus norvegicus,,D,CHEMBL615589,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,14331,Membranes,,10576,Expert
8,,1,,9913.0,572,,,B,10000000.0,,,Bos taurus,,H,CHEMBL615442,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,11884,,Hippocampus,51,Expert
8,,1,,,573,,,B,10000000.0,,,,,H,CHEMBL615443,BAO_0000221,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,14331,,Hippocampus,51,Autocuration
8,,1,,,574,,,B,10000000.0,,,,,H,CHEMBL615444,BAO_0000221,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,11701,,Hippocampus,51,Autocuration
8,,1,,,575,,,B,10000000.0,,,,,H,CHEMBL615445,BAO_0000221,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,11701,,Hippocampus,51,Expert
8,,1,,,576,,,B,10000000.0,,,,,H,CHEMBL615446,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,12248,,Hippocampus,51,Autocuration
8,,1,449.0,,577,,,B,,,,,CHO,H,CHEMBL615447,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,12248,,,51,Autocuration
8,,1,,,578,,,B,10000000.0,,,,,H,CHEMBL615448,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12248,,Hippocampus,51,Expert
8,,1,,,579,,,B,10000000.0,,,,,H,CHEMBL615449,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,,Hippocampus,51,Expert
8,,1,449.0,,580,,,B,,,,,CHO,H,CHEMBL615450,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12248,,,51,Autocuration
8,,1,,,581,,,B,10000000.0,,,,,H,CHEMBL615451,BAO_0000221,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",11799,,Hippocampus,51,Expert
8,,1,,,582,,,B,,,,,,H,CHEMBL615452,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,634,,,51,Autocuration
8,,1,,,583,,,B,10000000.0,,,,,H,CHEMBL615453,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,584,,,B,10000000.0,,,,,H,CHEMBL615454,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,585,,,B,10000000.0,,,,,H,CHEMBL615455,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,586,,,B,10000000.0,,,,,H,CHEMBL615456,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,587,,,B,10000000.0,,,,,H,CHEMBL615457,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,,Hippocampus,51,Autocuration
8,,1,,,588,,,B,10000000.0,,,,,H,CHEMBL615458,BAO_0000218,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,12210,,Hippocampus,51,Expert
8,,1,,,589,,,B,10000000.0,,,,,H,CHEMBL615459,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,13311,,Hippocampus,51,Expert
9,,1,449.0,9606.0,590,,,B,,,,Homo sapiens,CHO,D,CHEMBL615460,BAO_0000219,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",2331,,,51,Expert
8,,1,,10141.0,591,,,F,,,,Cavia porcellus,,H,CHEMBL615461,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1375,,,51,Autocuration
8,,1,,10141.0,592,,,F,,,,Cavia porcellus,,H,CHEMBL615462,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1375,,,51,Autocuration
8,,1,,10141.0,593,,,F,10000000.0,,,Cavia porcellus,,H,CHEMBL615463,BAO_0000221,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,11574,,Hippocampus,51,Autocuration
8,,1,,10141.0,594,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615464,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,12867,,Ileum,51,Autocuration
8,,1,,10141.0,595,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615465,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,,Ileum,51,Autocuration
8,,1,,10141.0,596,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615466,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,12867,,Ileum,51,Autocuration
8,,1,,10141.0,597,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615467,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,,Ileum,51,Autocuration
8,,1,,10141.0,598,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615468,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,,Ileum,51,Autocuration
8,,1,,10141.0,599,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL615469,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,12867,,Ileum,51,Autocuration
8,,1,,10141.0,600,,,B,,,,Cavia porcellus,,H,CHEMBL615470,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,11574,,,51,Autocuration
8,,1,,10141.0,601,,,B,,,,Cavia porcellus,,H,CHEMBL615471,BAO_0000357,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,13114,,,51,Autocuration
8,,1,,10141.0,602,,,B,,,,Cavia porcellus,,H,CHEMBL615472,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,13181,,,51,Autocuration
8,,1,,10141.0,603,,,B,10000000.0,,,Cavia porcellus,,H,CHEMBL883242,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10639,,Hippocampus,106,Autocuration
8,,1,,10141.0,604,,,F,10000000.0,,,Cavia porcellus,,H,CHEMBL615473,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10639,,Hippocampus,106,Autocuration
8,,1,449.0,10029.0,605,,,B,,,,Cricetulus griseus,CHO,H,CHEMBL615474,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11883,,,11863,Autocuration
8,,1,,,606,,,B,,,,,,H,CHEMBL615475,BAO_0000357,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,17785,,,51,Autocuration
8,,1,308.0,,607,,,F,,,,,HeLa,H,CHEMBL615476,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1558,,,51,Autocuration
8,,1,308.0,,608,,,F,,,,,HeLa,H,CHEMBL615477,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1558,,,51,Autocuration
8,,1,,,609,,,F,,,,,,H,CHEMBL615478,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,15740,,,51,Autocuration
8,,1,449.0,,610,,,F,,,,,CHO,H,CHEMBL615160,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,17624,,,51,Autocuration
8,,1,449.0,,611,,,F,,,,,CHO,H,CHEMBL615161,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,17624,,,51,Expert
8,,1,449.0,,612,,,F,,,,,CHO,H,CHEMBL615162,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,17624,,,51,Autocuration
8,,1,449.0,,613,,,F,,,,,CHO,H,CHEMBL615163,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,17624,,,51,Autocuration
8,,1,449.0,,614,,,B,,,,,CHO,H,CHEMBL615164,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Expert
8,,1,449.0,,615,,,B,,,,,CHO,H,CHEMBL615165,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Expert
8,,1,449.0,,616,,,B,,,,,CHO,H,CHEMBL615166,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,17624,,,51,Autocuration
8,,1,,,617,,,F,,,,,,H,CHEMBL615167,BAO_0000219,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,14256,,,51,Autocuration
9,,1,308.0,9606.0,618,,,B,,,,Homo sapiens,HeLa,D,CHEMBL615168,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,3445,,,51,Expert
9,,1,308.0,9606.0,619,,,B,,,,Homo sapiens,HeLa,D,CHEMBL615169,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,3445,,,51,Expert
9,,1,449.0,9606.0,620,,,B,,,,Homo sapiens,CHO,D,CHEMBL615170,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,17200,,,51,Expert
9,,1,449.0,9606.0,621,,,B,,,,Homo sapiens,CHO,D,CHEMBL615171,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,17200,,,51,Expert
8,,1,,,622,,,F,,,,,,H,CHEMBL615694,BAO_0000019,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,15180,,,51,Autocuration
8,,1,,,623,,,F,,,,,,H,CHEMBL615695,BAO_0000019,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,15180,,,51,Autocuration
8,,1,,,624,,,F,,,,,,H,CHEMBL615696,BAO_0000019,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,,,51,Autocuration
8,,1,449.0,,625,,,F,,,,,CHO,H,CHEMBL615697,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,,,51,Autocuration
9,,1,449.0,9606.0,626,,,F,,,,Homo sapiens,CHO,D,CHEMBL859410,BAO_0000219,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),2759,,,51,Expert
8,,1,449.0,,627,,,F,,,,,CHO,H,CHEMBL615841,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),2759,,,51,Autocuration
9,,1,449.0,9606.0,628,,,F,,,,Homo sapiens,CHO,D,CHEMBL615842,BAO_0000219,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),2759,,,51,Expert
8,,1,449.0,,629,,,F,,,,,CHO,H,CHEMBL835003,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,,,51,Autocuration
8,,1,449.0,,630,,,F,,,,,CHO,H,CHEMBL615843,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),2759,,,51,Autocuration
9,,1,449.0,9606.0,631,,,F,,,,Homo sapiens,CHO,D,CHEMBL615979,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),2759,,,51,Expert
8,,1,449.0,,632,,,F,,,,,CHO,H,CHEMBL615980,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),2759,,,51,Autocuration
9,,1,449.0,9606.0,633,,,F,,,,Homo sapiens,CHO,D,CHEMBL615981,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),2759,,,51,Expert
9,,1,,9606.0,634,,,F,,,,Homo sapiens,,D,CHEMBL615982,BAO_0000019,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,3445,,,51,Expert
9,,1,,9606.0,635,,,F,,,,Homo sapiens,,D,CHEMBL615983,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,,,51,Expert
9,,1,,9606.0,636,,,F,,,,Homo sapiens,,D,CHEMBL615984,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",5272,,,51,Expert
9,,1,,9606.0,637,,,F,,,,Homo sapiens,,D,CHEMBL615985,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",5272,,,51,Expert
8,,1,449.0,,638,,,F,,,,,CHO,H,CHEMBL615986,BAO_0000219,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,,,51,Autocuration
8,,1,449.0,,639,,,F,,,,,CHO,H,CHEMBL615987,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,,,51,Autocuration
8,,1,449.0,,640,,,F,,,,,CHO,H,CHEMBL615988,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,17624,,,51,Autocuration
8,,1,449.0,,641,,,F,,,,,CHO,H,CHEMBL615989,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,,,51,Expert
8,,1,449.0,,642,,,F,,,,,CHO,H,CHEMBL615990,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,17624,,,51,Autocuration
8,,1,449.0,,643,,,F,,,,,CHO,H,CHEMBL615991,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,17624,,,51,Autocuration
8,,1,449.0,,644,,,F,,,,,CHO,H,CHEMBL615992,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,,,51,Autocuration
8,,1,449.0,,645,,,F,,,,,CHO,H,CHEMBL615993,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,17624,,,51,Autocuration
8,,1,449.0,,646,,,F,,,,,CHO,H,CHEMBL615994,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,,,51,Expert
8,,1,449.0,,647,,,F,,,,,CHO,H,CHEMBL615995,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,17624,,,51,Autocuration
8,,1,449.0,,648,,,F,,,,,CHO,H,CHEMBL615996,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,,,51,Autocuration
8,,1,449.0,,649,,,F,,,,,CHO,H,CHEMBL615997,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,17624,,,51,Autocuration
8,,1,,,650,,,F,,,,,,H,CHEMBL615998,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,,,51,Autocuration
8,,1,,,651,,,F,,,,,,H,CHEMBL615999,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,,,51,Autocuration
8,,1,,,652,,,F,,,,,,H,CHEMBL616000,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,6563,,,51,Autocuration
8,,1,722.0,,653,,,F,,,,,HEK293,H,CHEMBL616001,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,,,51,Autocuration
9,,1,,9606.0,654,,,F,,,,Homo sapiens,,D,CHEMBL616002,BAO_0000019,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",6876,,,51,Expert
8,,1,,,655,,,F,,,,,,H,CHEMBL616003,BAO_0000019,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",6876,,,51,Expert
9,,1,,9606.0,656,,,F,,,,Homo sapiens,,D,CHEMBL616004,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,5272,,,51,Expert
9,,1,,9606.0,657,,,F,,,,Homo sapiens,,D,CHEMBL616005,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,5272,,,51,Expert
8,,1,,,658,,,F,,,,,,H,CHEMBL616006,BAO_0000019,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,,,51,Autocuration
8,,1,,,659,,,F,,,,,,H,CHEMBL616007,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",5548,,,51,Expert
8,,1,,,660,,,F,,,,,,H,CHEMBL616008,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,,,51,Autocuration
8,,1,,,661,,,F,,,,,,H,CHEMBL616009,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,,,51,Autocuration
8,,1,,,662,,,F,,,,,,H,CHEMBL616010,BAO_0000019,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",5929,,,51,Expert
9,,1,,9606.0,663,,,F,,,,Homo sapiens,,D,CHEMBL616011,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",5929,,,51,Expert
9,,1,,9606.0,664,,,F,,,,Homo sapiens,,D,CHEMBL615740,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",5929,,,51,Expert
8,,1,,,665,,,F,,,,,,H,CHEMBL615741,BAO_0000019,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",16245,,,51,Autocuration
8,,1,,,666,,,F,,,,,,H,CHEMBL615742,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",5640,,,51,Expert
8,,1,,,667,,,F,,,,,,H,CHEMBL615743,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",5640,,,51,Autocuration
8,,1,449.0,,668,,,F,,,,,CHO,H,CHEMBL615744,BAO_0000219,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,14509,,,51,Autocuration
8,,1,449.0,,669,,,F,,,,,CHO,H,CHEMBL615745,BAO_0000219,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,14509,,,51,Expert
8,,1,,,670,,,B,,,,,,H,CHEMBL615746,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,,,51,Autocuration
8,,1,,,671,,,B,,,,,,H,CHEMBL615747,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,,,51,Autocuration
8,,1,,,672,,,F,,,,,,H,CHEMBL615748,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,,,51,Autocuration
8,,1,,,673,,,F,,,,,,H,CHEMBL615749,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",6563,,,51,Autocuration
8,,1,,,674,,,F,,,,,,H,CHEMBL615750,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,6563,,,51,Autocuration
9,,1,,9606.0,675,,,F,,,,Homo sapiens,,D,CHEMBL616259,BAO_0000019,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,6563,,,51,Expert
8,,1,,,676,,,F,,,,,,H,CHEMBL616260,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,,,51,Autocuration
9,,1,,9606.0,677,,,F,,,,Homo sapiens,,D,CHEMBL616261,BAO_0000019,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,5272,,,51,Expert
9,,1,,9606.0,678,,,F,,,,Homo sapiens,,D,CHEMBL616262,BAO_0000019,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,,,51,Expert
9,,1,,9606.0,679,,,F,,,,Homo sapiens,,D,CHEMBL616263,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",5272,,,51,Expert
9,,1,,9606.0,680,,,F,,,,Homo sapiens,,D,CHEMBL616264,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,5272,,,51,Expert
9,,1,,9606.0,681,,,F,,,,Homo sapiens,,D,CHEMBL616265,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,5272,,,51,Expert
9,,1,,9606.0,682,,,F,,,,Homo sapiens,,D,CHEMBL616266,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,,,51,Expert
9,,1,,9606.0,683,,,F,,,,Homo sapiens,,D,CHEMBL616267,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",5272,,,51,Expert
9,,1,,9606.0,684,,,F,,,,Homo sapiens,,D,CHEMBL616268,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,5272,,,51,Expert
9,,1,,9606.0,685,,,B,,,,Homo sapiens,,D,CHEMBL616269,BAO_0000357,Inhibition of human 5-hydroxytryptamine 1A receptor,16146,,,51,Expert
8,,1,449.0,,686,,,B,,,,,CHO,H,CHEMBL884528,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Autocuration
9,,1,722.0,,687,,,B,,,,,HEK293,D,CHEMBL616270,BAO_0000219,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,13706,,,105,Expert
8,,1,449.0,,688,,,B,,,,,CHO,H,CHEMBL616271,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,15250,,,51,Autocuration
8,,1,449.0,,689,,,F,,,,,CHO,H,CHEMBL616272,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,,,51,Autocuration
8,,1,,,690,,,B,,,,,,H,CHEMBL616273,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,6861,,,51,Expert
9,,1,,9606.0,691,,,B,,,,Homo sapiens,,D,CHEMBL616274,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,17200,,,51,Expert
8,,1,449.0,,692,,,B,,,,,CHO,H,CHEMBL616275,BAO_0000219,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Autocuration
8,,1,449.0,,693,,,B,,,,,CHO,H,CHEMBL616276,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Autocuration
0,,1,,10116.0,694,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616277,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,12058,,,22226,Autocuration
0,,1,,10116.0,695,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616278,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,696,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616279,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,12058,,,22226,Autocuration
0,,1,,10116.0,697,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616280,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,698,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616281,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,12058,,,22226,Autocuration
0,,1,,10116.0,699,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616282,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,700,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616283,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,12058,,,22226,Autocuration
0,,1,,10116.0,701,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616284,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,702,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616285,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,12058,,,22226,Autocuration
0,,1,,10116.0,703,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616286,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,704,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616287,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,12058,,,22226,Autocuration
0,,1,,10116.0,705,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616288,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,12058,,,22226,Autocuration
0,,1,,10116.0,706,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL616289,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,707,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615610,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,12058,,,22226,Autocuration
0,,1,,10116.0,708,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615611,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,12058,,,22226,Autocuration
0,,1,,10116.0,709,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615612,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,12058,,,22226,Autocuration
0,,1,,10116.0,710,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615613,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,12058,,,22226,Autocuration
0,,1,,10116.0,711,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615614,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,12058,,,22226,Autocuration
0,,1,,10116.0,712,,In vivo,F,,,,Rattus norvegicus,,U,CHEMBL615615,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,12058,,,22226,Autocuration
4,,1,,,713,,,B,,,,,,H,CHEMBL615616,BAO_0000019,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,11440,,,105093,Autocuration
8,,1,,,714,,,B,1898.0,,,,,H,CHEMBL615617,BAO_0000249,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,6238,,Hypothalamus,11923,Autocuration
8,,1,,,715,,,B,,,,,,H,CHEMBL615618,BAO_0000019,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10046,,,10577,Autocuration
8,,1,,,716,,,B,,,,,,H,CHEMBL615619,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10046,,,10577,Autocuration
8,,1,,,717,,,B,,,,,,H,CHEMBL615620,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10046,,,10577,Expert
8,,1,,,718,,,B,,,,,,H,CHEMBL615621,BAO_0000357,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",167,,,55,Autocuration
8,,1,,,719,,,B,,,,,,H,CHEMBL615622,BAO_0000357,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",167,,,55,Autocuration
8,,1,,,720,,,F,,,,,,H,CHEMBL615623,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),11520,,,12166,Autocuration
8,,1,,,721,,,F,,,,,,H,CHEMBL615624,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,,,12166,Autocuration
8,,1,,,722,,,F,,,,,,H,CHEMBL615625,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,,,12166,Autocuration
8,,1,,,723,,,F,,,,,,H,CHEMBL767045,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,,,12166,Autocuration
8,,1,,10141.0,724,,,F,,,,Cavia porcellus,,H,CHEMBL615626,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,135,,,55,Autocuration
8,,1,,10141.0,725,,,F,,,,Cavia porcellus,,H,CHEMBL615627,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,135,,,55,Autocuration
8,,1,,10141.0,726,,,B,,,,Cavia porcellus,,H,CHEMBL615628,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,11311,,,55,Autocuration
8,,1,,10141.0,727,,,B,,,,Cavia porcellus,,H,CHEMBL615629,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10193,,,55,Autocuration
9,,1,,9606.0,728,,,B,,,,Homo sapiens,,D,CHEMBL615630,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from human whole blood,12281,,,55,Expert
8,,1,,,729,,,B,,,,,,H,CHEMBL615631,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],11311,,,55,Autocuration
8,,1,,,730,,,F,,,,,,H,CHEMBL615632,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,12576,,,17087,Autocuration
8,,1,,,731,,,B,,,,,,H,CHEMBL615633,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,12281,,,17087,Autocuration
8,,1,,,732,,,F,,,,,,H,CHEMBL615634,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,12576,,,17087,Autocuration
8,,1,,9823.0,733,,,B,,,,Sus scrofa,,H,CHEMBL615635,BAO_0000019,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,11089,,,55,Expert
8,,1,,,734,,,B,,,,,,H,CHEMBL615636,BAO_0000357,In vitro inhibition of rat 5-Lipoxygenase,11006,,,12166,Expert
9,,1,,10116.0,735,,,B,,,,Rattus norvegicus,,D,CHEMBL615637,BAO_0000357,Inhibitory activity against 5-Lipoxygenase,11481,,,12166,Expert
8,,1,702.0,,736,,,B,,,,,RBL-1,H,CHEMBL615638,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,10864,,,12166,Expert
8,,1,702.0,,737,,,B,,,,,RBL-1,H,CHEMBL615639,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,,,12166,Autocuration
8,,1,702.0,,738,,,B,,,,,RBL-1,H,CHEMBL615640,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,11311,,,12166,Autocuration
8,,1,,,739,,,B,,,,,,H,CHEMBL615796,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,11311,,,12166,Autocuration
8,,1,,,740,,,B,,,,,,H,CHEMBL615845,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],11311,,,12166,Autocuration
8,,1,,,741,,,B,,,,,,H,CHEMBL615846,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,11006,,,12166,Autocuration
8,,1,702.0,,742,,,B,,,,,RBL-1,H,CHEMBL615847,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,3595,,,12166,Autocuration
8,,1,,,743,,,B,,,,,,H,CHEMBL615848,BAO_0000357,The compound was tested for inhibition of isolated 5-Lipoxygenase,11311,,,12166,Autocuration
0,,1,,10116.0,744,,,B,,,,Rattus norvegicus,,U,CHEMBL615849,BAO_0000019,Ratio of IC50 against 5-LO and COX,11481,,,22226,Autocuration
8,,1,,,745,,,B,,,,,,H,CHEMBL615850,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,11006,,,12166,Autocuration
8,,1,,,746,,,B,,,,,,H,CHEMBL615851,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,11006,,,12166,Autocuration
8,,1,,,747,,,B,,,,,,H,CHEMBL615852,BAO_0000219,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,11311,,,12166,Autocuration
8,,1,,,748,,,F,,,,,,H,CHEMBL615853,BAO_0000019,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,11006,,,12166,Autocuration
8,,1,,,749,,,B,2367.0,,,,,H,CHEMBL884527,BAO_0000357,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,4288,,Prostate gland,120,Autocuration
0,,1,,8932.0,750,,,B,,,,Columba livia,,U,CHEMBL872871,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,7587,,,22226,Autocuration
0,,1,,8932.0,751,,,B,,,,Columba livia,,U,CHEMBL615854,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,7587,,,22226,Autocuration
0,,1,,8932.0,752,,,B,,,,Columba livia,,U,CHEMBL767046,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,7587,,,22226,Autocuration
8,,1,,,753,,,B,,,,,,H,CHEMBL615855,BAO_0000357,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,11249,,,10732,Autocuration
9,,1,,10116.0,754,,,F,,,,Rattus norvegicus,,D,CHEMBL615856,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,8003,,,12198,Expert
9,,1,,10116.0,755,,,F,,,,Rattus norvegicus,,D,CHEMBL615857,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),8003,,,12198,Expert
9,,1,,10116.0,756,,,F,,,,Rattus norvegicus,,D,CHEMBL615858,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),8003,,,12198,Expert
8,,1,,,757,,,B,10000000.0,,,,,H,CHEMBL615859,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,12416,,Hippocampus,10576,Expert
8,,1,,,758,,,B,,,,,,H,CHEMBL615860,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1 receptor,16293,,,51,Autocuration
0,,1,,9986.0,759,,,B,,,,Oryctolagus cuniculus,,U,CHEMBL615861,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,,,22226,Autocuration
0,,1,,9986.0,760,,,B,,,,Oryctolagus cuniculus,,U,CHEMBL615862,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,,,22226,Autocuration
0,,1,,9986.0,761,,,B,,,,Oryctolagus cuniculus,,U,CHEMBL615863,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,13047,,,22226,Autocuration
0,,1,,9986.0,762,,,B,,,,Oryctolagus cuniculus,,U,CHEMBL615864,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,13047,,,22226,Autocuration
4,,1,,,763,,,B,10000000.0,,,,,H,CHEMBL615865,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,,Hippocampus,104744,Autocuration
4,,1,,,764,,,B,10000000.0,,,,,H,CHEMBL615866,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,,Hippocampus,104744,Autocuration
4,,1,,,765,,,B,10000000.0,,,,,H,CHEMBL615867,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,,Hippocampus,104744,Autocuration
4,,1,,,766,,,B,,,,,,H,CHEMBL615868,BAO_0000249,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,9841,Membranes,,104744,Autocuration
5,,1,,10116.0,767,,,B,,,,Rattus norvegicus,,D,CHEMBL615869,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,8822,,,104744,Autocuration
5,,1,,10116.0,768,,,B,,,,Rattus norvegicus,,D,CHEMBL615870,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,9806,,,104744,Autocuration
5,,1,,10116.0,769,,,B,,,,Rattus norvegicus,,D,CHEMBL615871,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,9806,,,104744,Autocuration
4,,1,,,770,,,B,,,,,,H,CHEMBL615872,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,8868,,,104744,Autocuration
4,,1,,,771,,,B,10000000.0,,,,,H,CHEMBL833492,BAO_0000221,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,9036,,Hippocampus,104744,Autocuration
4,,1,,,772,,,B,10000000.0,,,,,H,CHEMBL615873,BAO_0000221,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,11374,,Hippocampus,104744,Autocuration
4,,1,,,773,,,B,,,,,,H,CHEMBL615479,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,10881,,,104744,Autocuration
4,,1,,,774,,,B,,,,,,H,CHEMBL615480,BAO_0000019,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,8822,,,104744,Autocuration
5,,1,,10116.0,775,,,B,,,,Rattus norvegicus,,D,CHEMBL615481,BAO_0000249,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,9806,,,104744,Autocuration
4,,1,,,776,,,B,,,,,,H,CHEMBL872869,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,15463,,,104744,Autocuration
4,,1,,,777,,,B,,,,,,H,CHEMBL615482,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,15463,,,104744,Autocuration
4,,1,,,778,,,B,955.0,,,,,H,CHEMBL615483,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,,Brain,104744,Autocuration
4,,1,,,779,,,B,955.0,,,,,H,CHEMBL615484,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,,Brain,104744,Autocuration
4,,1,,,780,,,B,,,,,,H,CHEMBL615485,BAO_0000019,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,8569,,,104744,Autocuration
5,,1,,10116.0,781,,,B,,,,Rattus norvegicus,,D,CHEMBL615486,BAO_0000224,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,10062,,,104744,Autocuration
4,,1,,,782,,,B,,,,,,H,CHEMBL615487,BAO_0000224,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,4771,,,104744,Autocuration
4,,1,,,783,,,B,,,,,,H,CHEMBL615488,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,,,104744,Autocuration
4,,1,,,784,,,B,,,,,,H,CHEMBL615489,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,,,104744,Autocuration
4,,1,,,785,,,B,,,,,,H,CHEMBL615389,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,,,104744,Autocuration
4,,1,,,786,,,B,,,,,,H,CHEMBL615390,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,15463,,,104744,Autocuration
4,,1,,,787,,,B,,,,,,H,CHEMBL615391,BAO_0000019,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,15463,,,104744,Autocuration
4,,1,,,788,,,B,,,,,,H,CHEMBL615392,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,9098,,,104744,Autocuration
0,,1,,10116.0,789,,,B,,,,Rattus norvegicus,,U,CHEMBL615393,BAO_0000019,Affinity for 5-hydroxytryptamine 1 receptor,3070,,,22226,Autocuration
4,,1,,,790,,,B,955.0,,,,,H,CHEMBL615394,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,14542,,Brain,104744,Autocuration
4,,1,,,791,,,B,955.0,,,,,H,CHEMBL615395,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,,Brain,104744,Autocuration
4,,1,,,792,,,B,,,,,,H,CHEMBL615396,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,6398,,,104744,Autocuration
4,,1,,,793,,,B,955.0,,,,,H,CHEMBL615397,BAO_0000221,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1344,,Brain,104744,Autocuration
4,,1,,,794,,,B,,,,,,H,CHEMBL615398,BAO_0000019,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,11963,,,104744,Autocuration
0,,1,,10116.0,795,,,B,,,,Rattus norvegicus,,U,CHEMBL615399,BAO_0000019,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,8908,,,22226,Autocuration
4,,1,,,796,,,B,,,,,,H,CHEMBL615400,BAO_0000019,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,9098,,,104744,Autocuration
5,,1,,10116.0,797,,,B,,,,Rattus norvegicus,,D,CHEMBL615401,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,8841,,,104744,Autocuration
0,,1,,10116.0,798,,,B,,,,Rattus norvegicus,,U,CHEMBL615402,BAO_0000019,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,8814,,,22226,Autocuration
4,,1,,,799,,,B,,,,,,H,CHEMBL615403,BAO_0000019,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,11752,,,104744,Autocuration
4,,1,,,800,,,B,955.0,,,,,H,CHEMBL615404,BAO_0000221,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,11642,,Brain,104744,Autocuration
4,,1,,,801,,,B,,,,,,H,CHEMBL615781,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,11642,,,104744,Autocuration
4,,1,,,802,,,B,955.0,,,,,H,CHEMBL615782,BAO_0000220,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,9231,,Brain,104744,Autocuration
4,,1,,,803,,,B,955.0,,,,,H,CHEMBL615783,BAO_0000221,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,11351,,Brain,104744,Autocuration
0,,1,,,804,,,B,,,,,,U,CHEMBL873481,BAO_0000019,Compound was tested for binding affinity against 5-HT1 receptor,4639,,,22226,Autocuration
0,,1,,,805,,,B,,,,,,U,CHEMBL615784,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1205,,,22226,Autocuration
8,,1,,,806,,,B,,,,,,H,CHEMBL615785,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10025,,,10576,Expert
8,,1,,,807,,,F,,,,,,H,CHEMBL615786,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",13241,,,10576,Autocuration
8,,1,,,808,,In vivo,F,,,,,,H,CHEMBL615787,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,16245,,,10576,Autocuration
8,,1,,,809,,In vivo,F,,,,,,H,CHEMBL615788,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,16245,,,10576,Autocuration
8,,1,,,810,,,F,,,,,,H,CHEMBL767044,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,12438,,,10576,Autocuration
8,,1,,,811,,In vivo,F,,,,,,H,CHEMBL615789,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,16245,,,10576,Autocuration
8,,1,,,812,,In vivo,F,,,,,,H,CHEMBL615790,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,16245,,,10576,Autocuration
8,,1,,,813,,,F,,,,,,H,CHEMBL615813,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,15740,,,10576,Autocuration
8,,1,,,814,,,F,,,,,,H,CHEMBL615814,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,15535,,,10576,Autocuration
8,,1,,,815,,,F,,,,,,H,CHEMBL615815,BAO_0000219,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,15535,,,51,Expert
8,,1,,,816,,,F,,,,,,H,CHEMBL615816,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,15535,,,10576,Autocuration
8,,1,,,817,,,B,,,,,,H,CHEMBL615817,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,9888,,,10576,Expert
8,,1,,,818,,,B,10000000.0,,,,,H,CHEMBL615818,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10085,,Hippocampus,10576,Autocuration
8,,1,,,819,,,B,10000000.0,,,,,H,CHEMBL615819,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10085,,Hippocampus,10576,Autocuration
8,,1,,,820,,,B,,,,,,H,CHEMBL615820,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,17331,Membranes,,10576,Expert
9,,1,,10116.0,821,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615821,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10845,,Hippocampus,10576,Expert
9,,1,,10116.0,822,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615822,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10845,,Hippocampus,10576,Expert
8,,1,,,823,,,B,10000000.0,,,,,H,CHEMBL615823,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10845,,Hippocampus,10576,Expert
9,,1,,10116.0,824,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615824,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10845,,Hippocampus,10576,Expert
9,,1,,10116.0,825,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615825,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10845,,Hippocampus,10576,Expert
8,,1,,,826,,,B,,,,,,H,CHEMBL615826,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,13730,,,10576,Expert
8,,1,,,827,,,B,,,,,,H,CHEMBL615827,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,13508,,,10576,Expert
8,,1,,,828,,,B,10000000.0,,,,,H,CHEMBL615828,BAO_0000249,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,13508,,Hippocampus,10576,Expert
8,,1,,,829,,,B,10000000.0,,,,,H,CHEMBL615829,BAO_0000221,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,,Hippocampus,10576,Expert
8,,1,,,830,,,B,10000000.0,,,,,H,CHEMBL615830,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,4671,,Hippocampus,10576,Autocuration
8,,1,,,831,,,B,10000000.0,,,,,H,CHEMBL615831,BAO_0000221,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,13631,,Hippocampus,10576,Expert
8,,1,,,832,,,B,,,,,,H,CHEMBL615832,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,12438,,,10576,Autocuration
8,,1,,,833,,,B,,,,,,H,CHEMBL615833,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10483,,,10576,Autocuration
8,,1,,,834,,,B,10000000.0,,,,,H,CHEMBL615834,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10483,,Hippocampus,10576,Autocuration
8,,1,,,835,,,B,,,,,,H,CHEMBL615835,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,12352,,,10576,Intermediate
8,,1,,,836,,,B,10000000.0,,,,,H,CHEMBL615836,BAO_0000249,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,14732,,Hippocampus,10576,Autocuration
9,,1,,10116.0,837,,,B,,,,Rattus norvegicus,,D,CHEMBL615837,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,11049,,,10576,Expert
9,,1,,10116.0,838,,,B,,,,Rattus norvegicus,,D,CHEMBL615838,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,11049,,,10576,Expert
8,,1,,,839,,,B,,,,,,H,CHEMBL615839,BAO_0000249,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",13657,,,10576,Expert
8,,1,,,840,,,B,,,,,,H,CHEMBL884525,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,11473,,,10576,Autocuration
8,,1,,,841,,,B,,,,,,H,CHEMBL615840,BAO_0000249,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,2014,,,10576,Autocuration
8,,1,,,842,,,B,10000000.0,,,,,H,CHEMBL615405,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,3086,,Hippocampus,10576,Expert
8,,1,,,843,,,B,,,,,,H,CHEMBL615406,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,,,10576,Expert
8,,1,,,844,,,B,10000000.0,,,,,H,CHEMBL615900,BAO_0000221,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10922,,Hippocampus,10576,Expert
8,,1,,,845,,,B,10000000.0,,,,,H,CHEMBL615901,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,13346,,Hippocampus,10576,Expert
8,,1,,,846,,,B,,,,,,H,CHEMBL615902,BAO_0000357,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,15311,,,10576,Expert
8,,1,,,847,,,B,10000000.0,,,,,H,CHEMBL615903,BAO_0000221,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10922,,Hippocampus,10576,Autocuration
8,,1,,,848,,,B,,,,,,H,CHEMBL615904,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10025,,,10576,Autocuration
8,,1,,,849,,,B,,,,,,H,CHEMBL615905,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10025,,,10576,Expert
8,,1,,,850,,,B,,,,,,H,CHEMBL615906,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,9742,,,10576,Autocuration
8,,1,,,851,,,F,,,,,,H,CHEMBL615907,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,9742,,,10576,Autocuration
8,,1,,,852,,,B,,,,,,H,CHEMBL615908,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,12304,,,10576,Expert
8,,1,,,853,,,B,10000000.0,,,,,H,CHEMBL615909,BAO_0000221,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,15789,,Hippocampus,10576,Autocuration
8,,1,,,854,,,B,,,,,,H,CHEMBL615910,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",9912,,,10576,Autocuration
8,,1,,,855,,,B,,,,,,H,CHEMBL615911,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",9912,,,10576,Autocuration
8,,1,,,856,,,B,,,,,,H,CHEMBL615912,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",9912,,,10576,Autocuration
8,,1,,,857,,,B,,,,,,H,CHEMBL615913,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,16693,,,10576,Expert
8,,1,,,858,,,B,,,,,,H,CHEMBL615914,BAO_0000357,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,13276,,,10576,Expert
8,,1,,,859,,,B,10000000.0,,,,,H,CHEMBL615915,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,12678,,Hippocampus,10576,Autocuration
8,,1,,,860,,,B,,,,,,H,CHEMBL615916,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,11825,,,10576,Autocuration
8,,1,,,861,,,B,,,,,,H,CHEMBL615917,BAO_0000357,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,12443,,,10576,Expert
8,,1,,,862,,,B,,,,,,H,CHEMBL615918,BAO_0000357,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,13830,,,10576,Expert
8,,1,,,863,,,B,10000000.0,,,,,H,CHEMBL615919,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,14286,,Hippocampus,10576,Expert
9,,1,,10116.0,864,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615920,BAO_0000221,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,14356,,Hippocampus,10576,Expert
8,,1,,,865,,,B,,,,,,H,CHEMBL615921,BAO_0000357,Inhibition concentration against 5-hydroxytryptamine 1A receptor,15306,,,10576,Autocuration
8,,1,,,866,,,B,,,,,,H,CHEMBL615922,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),15306,,,10576,Expert
9,,1,,10116.0,867,,,F,,,,Rattus norvegicus,,D,CHEMBL881290,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",16616,,,10576,Expert
8,,1,,,868,,,B,10000000.0,,,,,H,CHEMBL615923,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",3651,,Hippocampus,10576,Autocuration
8,,1,,,869,,,F,10000000.0,,,,,H,CHEMBL615924,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,14331,,Hippocampus,10576,Autocuration
8,,1,,,870,,,F,10000000.0,,,,,H,CHEMBL615925,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,14331,,Hippocampus,10576,Autocuration
9,,1,,10116.0,871,,,B,,,,Rattus norvegicus,,D,CHEMBL615926,BAO_0000357,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,14178,,,10576,Expert
9,,1,,10116.0,872,,,B,,,,Rattus norvegicus,,D,CHEMBL615927,BAO_0000019,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10639,,,10576,Expert
8,,1,,,873,,,B,10000000.0,,,,,H,CHEMBL615928,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,,Hippocampus,10576,Autocuration
9,,1,,10116.0,874,,,B,,,,Rattus norvegicus,,D,CHEMBL615929,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1348,,,10576,Expert
8,,1,,,875,,,B,10000000.0,,,,,H,CHEMBL615930,BAO_0000221,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,13605,,Hippocampus,10576,Autocuration
8,,1,449.0,,876,,,B,,,,,CHO,H,CHEMBL615931,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,,,51,Autocuration
8,,1,449.0,,877,,,F,,,,,CHO,H,CHEMBL615932,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,,,51,Autocuration
8,,1,449.0,,878,,,F,,,,,CHO,H,CHEMBL615933,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,,,51,Autocuration
8,,1,,,879,,,B,,,,,,H,CHEMBL615934,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,15267,,,51,Autocuration
8,,1,,,880,,,B,,,,,,H,CHEMBL615935,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,16532,,,51,Autocuration
8,,1,,,881,,,F,,,,,,H,CHEMBL615936,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,,,51,Autocuration
8,,1,449.0,,882,,,B,,,,,CHO,H,CHEMBL615937,BAO_0000219,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,4751,,,51,Autocuration
8,,1,,,883,,,B,,,,,,H,CHEMBL615938,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,15463,,,51,Autocuration
8,,1,,,884,,,B,,,,,,H,CHEMBL615797,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),3805,,,51,Autocuration
8,,1,,,885,,,B,,,,,,H,CHEMBL615798,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5640,,,51,Autocuration
8,,1,,,886,,,B,,,,,,H,CHEMBL872870,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,6563,,,51,Autocuration
8,,1,,,887,,,B,,,,,,H,CHEMBL615799,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,5548,,,51,Autocuration
8,,1,,,888,,,B,,,,,,H,CHEMBL615800,BAO_0000357,Percent binding affinity against 5-hydroxytryptamine 1A receptor,6347,,,51,Autocuration
8,,1,722.0,,889,,,F,,,,,HEK293,H,CHEMBL615801,BAO_0000219,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,,,51,Autocuration
8,,1,,,890,,,B,,,,,,H,CHEMBL615802,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,13047,,,51,Autocuration
8,,1,,,891,,,B,,,,,,H,CHEMBL615803,BAO_0000357,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,15740,,,51,Autocuration
8,,1,,,892,,,F,,,,,,H,CHEMBL835002,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",5640,,,51,Expert
8,,1,,,893,,,F,,,,,,H,CHEMBL615804,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",5640,,,51,Autocuration
8,,1,308.0,,894,,,B,,,,,HeLa,H,CHEMBL615805,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,17211,,,51,Expert
8,,1,449.0,,895,,,B,,,,,CHO,H,CHEMBL615806,BAO_0000219,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,4751,,,51,Autocuration
9,,1,,9606.0,896,,,B,,,,Homo sapiens,,D,CHEMBL615807,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,6491,,,51,Expert
8,,1,,,897,,,B,,,,,,H,CHEMBL615808,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,4707,,,51,Autocuration
9,,1,,9606.0,898,,,B,,,,Homo sapiens,,D,CHEMBL615809,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,13910,,,51,Expert
8,,1,308.0,,899,,,B,,,,,HeLa,H,CHEMBL615810,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,16190,,,51,Autocuration
8,,1,,,900,,,B,,,,,,H,CHEMBL615811,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16633,,,51,Autocuration
8,,1,449.0,,901,,,B,,,,,CHO,H,CHEMBL615812,BAO_0000219,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,11898,,,51,Autocuration
8,,1,449.0,,902,,,B,,,,,CHO,H,CHEMBL615751,BAO_0000219,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11898,,,51,Autocuration
8,,1,,,903,,,B,,,,,,H,CHEMBL615752,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 1A receptor,14331,,,51,Autocuration
8,,1,449.0,,904,,,B,,,,,CHO,H,CHEMBL615753,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,17624,,,51,Expert
8,,1,449.0,,905,,,B,,,,,CHO,H,CHEMBL615754,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,17624,,,51,Autocuration
8,,1,,,906,,,B,,,,,,H,CHEMBL615755,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,3307,,,51,Autocuration
9,,1,449.0,9606.0,907,,,B,,,,Homo sapiens,CHO,D,CHEMBL615756,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,6563,,,51,Expert
8,,1,,,908,,,B,,,,,,H,CHEMBL615757,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,14165,,,51,Autocuration
8,,1,,,909,,,B,,,,,,H,CHEMBL615758,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,5732,,,51,Autocuration
8,,1,,,910,,,B,,,,,,H,CHEMBL615759,BAO_0000357,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,13366,,,51,Expert
8,,1,,,911,,,B,,,,,,H,CHEMBL615760,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor,17626,,,51,Autocuration
8,,1,308.0,,912,,,B,,,,,HeLa,H,CHEMBL615761,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,6588,,,51,Expert
8,,1,,,913,,,B,,,,,,H,CHEMBL872104,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,16209,,,51,Autocuration
8,,1,,,914,,,B,,,,,,H,CHEMBL615762,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,15463,,,51,Autocuration
8,,1,,,915,,,B,,,,,,H,CHEMBL615763,BAO_0000357,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,15463,,,51,Autocuration
8,,1,,,916,,,B,,,,,,H,CHEMBL615764,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,14770,,,51,Autocuration
8,,1,1167.0,,917,,,B,,,,,Cell line,H,CHEMBL615765,BAO_0000219,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),16245,,,51,Autocuration
8,,1,,,918,,,B,,,,,,H,CHEMBL615766,BAO_0000019,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),16245,,,51,Autocuration
8,,1,,,919,,,B,,,,,,H,CHEMBL615767,BAO_0000357,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,5548,,,51,Autocuration
8,,1,,,920,,,B,,,,,,H,CHEMBL615768,BAO_0000357,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5548,,,51,Expert
8,,1,,,921,,,B,,,,,,H,CHEMBL615769,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5548,,,51,Autocuration
8,,1,,,922,,,B,,,,,,H,CHEMBL615770,BAO_0000357,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,6876,,,51,Expert
8,,1,,,923,,,B,,,,,,H,CHEMBL615771,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,2598,,,51,Autocuration
8,,1,,,924,,,B,,,,,,H,CHEMBL615772,BAO_0000357,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,17785,,,51,Expert
8,,1,,,925,,,B,,,,,,H,CHEMBL615773,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,6013,,,51,Autocuration
8,,1,,,926,,,B,,,,,,H,CHEMBL615774,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,5929,,,51,Expert
8,,1,,,927,,,B,,,,,,H,CHEMBL615775,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16633,,,51,Autocuration
8,,1,,,928,,,B,,,,,,H,CHEMBL615776,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1558,,,51,Autocuration
8,,1,,,929,,,B,,,,,,H,CHEMBL615777,BAO_0000357,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16026,,,51,Expert
8,,1,,,930,,,B,,,,,,H,CHEMBL615778,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,12469,,,51,Autocuration
9,,1,,9606.0,931,,,B,,,,Homo sapiens,,D,CHEMBL615779,BAO_0000357,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,,,51,Expert
8,,1,,,932,,,B,,,,,,H,CHEMBL615780,BAO_0000357,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,,,51,Autocuration
8,,1,,,933,,,B,,,,,,H,CHEMBL616298,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,3935,,,51,Autocuration
8,,1,,,934,,,B,,,,,,H,CHEMBL616299,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,15818,,,51,Autocuration
8,,1,485.0,,935,,,B,,,,,CHO-K1,H,CHEMBL616300,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,13706,,,51,Autocuration
8,,1,485.0,,936,,,F,,,,,CHO-K1,H,CHEMBL616301,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,13729,,,51,Expert
8,,1,,,937,,,B,,,,,,H,CHEMBL616302,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,15413,,,51,Autocuration
8,,1,,,938,,,B,,,,,,H,CHEMBL616117,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),15413,,,51,Autocuration
8,,1,,,939,,,B,,,,,,H,CHEMBL616118,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),15413,,,51,Autocuration
8,,1,,,940,,,B,,,,,,H,CHEMBL616119,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,15413,,,51,Autocuration
9,,1,308.0,9606.0,941,,,B,,,,Homo sapiens,HeLa,D,CHEMBL616120,BAO_0000219,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,3445,,,51,Expert
8,,1,,,942,,,B,,,,,,H,CHEMBL616121,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,15740,,,51,Autocuration
8,,1,,,943,,,B,,,,,,H,CHEMBL616122,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,15740,,,51,Autocuration
8,,1,,,944,,,B,,,,,,H,CHEMBL616123,BAO_0000357,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,17626,,,51,Autocuration
9,,1,,9606.0,945,,,B,,,,Homo sapiens,,D,CHEMBL616124,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,4234,,,51,Expert
8,,1,,,946,,,B,,,,,,H,CHEMBL616125,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,5640,,,51,Expert
8,,1,,10116.0,947,,,B,,,,Rattus norvegicus,,H,CHEMBL616126,BAO_0000357,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,5272,,,51,Expert
8,,1,449.0,,948,,,B,,,,,CHO,H,CHEMBL616127,BAO_0000219,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,4622,,,51,Autocuration
8,,1,,,949,,,B,,,,,,H,CHEMBL616128,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,17085,,,51,Expert
8,,1,,,950,,,B,,,,,,H,CHEMBL616129,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,3025,,,51,Autocuration
8,,1,,,951,,,B,,,,,,H,CHEMBL616130,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,15315,,,51,Expert
8,,1,,,952,,,B,,,,,,H,CHEMBL616131,BAO_0000357,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,15267,,,51,Autocuration
8,,1,308.0,,953,,,B,,,,,HeLa,H,CHEMBL616132,BAO_0000219,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,17158,,,51,Autocuration
9,,1,308.0,9606.0,954,,,B,,,,Homo sapiens,HeLa,D,CHEMBL616133,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,14214,,,51,Expert
8,,1,,,955,,,B,,,,,,H,CHEMBL616134,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,17133,,,51,Autocuration
8,,1,,,956,,,B,,,,,,H,CHEMBL616135,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,16532,,,51,Autocuration
9,,1,,9606.0,957,,,B,,,,Homo sapiens,,D,CHEMBL616136,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor subtype,2391,,,51,Expert
8,,1,,,958,,,B,,,,,,H,CHEMBL616137,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,14447,,,51,Autocuration
8,,1,,,959,,,B,,,,,,H,CHEMBL872105,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,14447,,,51,Autocuration
8,,1,,,960,,,B,,,,,,H,CHEMBL616138,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,15086,,,51,Autocuration
9,,1,,9606.0,961,,,B,,,,Homo sapiens,,D,CHEMBL616139,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,13051,,,51,Expert
8,,1,,,962,,,F,,,,,,H,CHEMBL616140,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",16026,,,51,Autocuration
8,,1,,,963,,,B,,,,,,H,CHEMBL616141,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,17085,,,51,Expert
8,,1,,,964,,,B,,,,,,H,CHEMBL616142,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,17133,,,51,Autocuration
8,,1,,,965,,,B,,,,,,H,CHEMBL616143,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,17133,,,51,Autocuration
8,,1,308.0,,966,,,B,,,,,HeLa,H,CHEMBL616144,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,,,51,Autocuration
8,,1,308.0,,967,,,B,,,,,HeLa,H,CHEMBL616145,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,17211,,,51,Autocuration
8,,1,308.0,,968,,,B,,,,,HeLa,H,CHEMBL616012,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,,,51,Autocuration
8,,1,308.0,,969,,,B,,,,,HeLa,H,CHEMBL616013,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,,,51,Autocuration
8,,1,,,970,,,F,,,,,,H,CHEMBL616014,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,,,51,Autocuration
8,,1,,,971,,,F,,,,,,H,CHEMBL616015,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,,,51,Autocuration
8,,1,,,972,,,F,,,,,,H,CHEMBL616016,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,,,51,Autocuration
8,,1,,,973,,In vivo,F,,,,,,H,CHEMBL616017,BAO_0000218,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,16394,,,51,Autocuration
8,,1,,,974,,,B,,,,,,H,CHEMBL616018,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,16394,,,51,Autocuration
8,,1,,,975,,,F,,,,,,H,CHEMBL616019,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,15740,,,51,Autocuration
8,,1,,,976,,,F,,,,,,H,CHEMBL616020,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,15740,,,51,Autocuration
8,,1,,,977,,,B,,,,,,H,CHEMBL858018,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,15740,,,51,Autocuration
8,,1,722.0,,978,,,F,,,,,HEK293,H,CHEMBL616021,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,,,51,Autocuration
8,,1,,,979,,,F,,,,,,H,CHEMBL616022,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",5640,,,51,Expert
8,,1,,,980,,,F,,,,,,H,CHEMBL616023,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",5640,,,51,Autocuration
8,,1,,,981,,,F,,,,,,H,CHEMBL616024,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",5640,,,51,Autocuration
8,,1,,,982,,,F,,,,,,H,CHEMBL616025,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",5640,,,51,Autocuration
8,,1,449.0,,983,,,F,,,,,CHO,H,CHEMBL616026,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,,,51,Autocuration
8,,1,,,984,,,F,,,,,,H,CHEMBL616027,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",16394,,,51,Autocuration
9,,1,,9606.0,985,,,F,,,,Homo sapiens,,D,CHEMBL616028,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",16394,,,51,Expert
9,,1,,9606.0,986,,,F,,,,Homo sapiens,,D,CHEMBL616029,BAO_0000019,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,3445,,,51,Expert
8,,1,449.0,,987,,,B,,,,,CHO,H,CHEMBL616030,BAO_0000219,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,4316,,,51,Expert
8,,1,,,988,,,B,,,,,,H,CHEMBL616031,BAO_0000019,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,4316,,,51,Expert
9,,1,,9606.0,989,,,F,,,,Homo sapiens,,D,CHEMBL616032,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,15180,,,51,Expert
9,,1,,9606.0,990,,,F,,,,Homo sapiens,,D,CHEMBL616033,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,15180,,,51,Expert
8,,1,,,991,,,F,,,,,,H,CHEMBL616034,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,,,51,Autocuration
8,,1,,,992,,,F,,,,,,H,CHEMBL616035,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,,,51,Autocuration
8,,1,,,993,,,F,,,,,,H,CHEMBL616036,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,15042,,,51,Autocuration
8,,1,,,994,,,F,,,,,,H,CHEMBL616037,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,,,51,Autocuration
8,,1,,,995,,,F,,,,,,H,CHEMBL616038,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,,,51,Autocuration
8,,1,,,996,,,F,,,,,,H,CHEMBL616039,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,,,51,Autocuration
8,,1,,,997,,,F,,,,,,H,CHEMBL616040,BAO_0000019,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,15042,,,51,Autocuration
9,,1,308.0,9606.0,998,,,F,,,,Homo sapiens,HeLa,D,CHEMBL616041,BAO_0000219,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,,,51,Expert
9,,1,308.0,9606.0,999,,,F,,,,Homo sapiens,HeLa,D,CHEMBL616042,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,,,51,Expert
9,,1,308.0,9606.0,1000,,,F,,,,Homo sapiens,HeLa,D,CHEMBL616043,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,,,51,Expert
8,,1,,,1001,,,F,,,,,,H,CHEMBL616044,BAO_0000019,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",16245,,,51,Autocuration
8,,1,,,1002,,,F,,,,,,H,CHEMBL616045,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,,,51,Autocuration
8,,1,722.0,,1003,,,F,,,,,HEK293,H,CHEMBL616046,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,,,51,Autocuration
8,,1,449.0,,1004,,,F,,,,,CHO,H,CHEMBL616047,BAO_0000219,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),2759,,,51,Autocuration
8,,1,449.0,,1005,,,F,,,,,CHO,H,CHEMBL616048,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,2759,,,51,Autocuration
9,,1,449.0,9606.0,1006,,,F,,,,Homo sapiens,CHO,D,CHEMBL616049,BAO_0000219,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),2759,,,51,Expert
8,,1,449.0,,1007,,,F,,,,,CHO,H,CHEMBL616050,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),2759,,,51,Autocuration
8,,1,,,1008,,,F,,,,,,H,CHEMBL616051,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,15419,,,51,Expert
8,,1,,,1009,,,F,,,,,,H,CHEMBL616212,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,15419,,,51,Autocuration
8,,1,,,1010,,,F,,,,,,H,CHEMBL616213,BAO_0000019,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,,,51,Autocuration
8,,1,,,1011,,In vitro,B,,,,,,H,CHEMBL616214,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1414,,,51,Expert
8,,1,,,1012,,In vitro,B,,,,,,H,CHEMBL616215,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1414,,,51,Expert
8,,1,,,1013,,,B,,,,,,H,CHEMBL616216,BAO_0000357,Binding activity radioligand.,12861,,,51,Autocuration
8,,1,,,1014,,,B,,,,,,H,CHEMBL616217,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,,,51,Autocuration
8,,1,,,1015,,,B,,,,,,H,CHEMBL616218,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,5104,,,51,Autocuration
8,,1,,,1016,,,B,,,,,,H,CHEMBL616219,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,5105,,,51,Autocuration
8,,1,,,1017,,,B,,,,,,H,CHEMBL616220,BAO_0000357,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,16312,,,51,Autocuration
9,,1,,9606.0,1018,,,B,,,,Homo sapiens,,D,CHEMBL833493,BAO_0000357,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,15180,,,51,Expert
8,,1,,,1019,,,B,,,,,,H,CHEMBL616221,BAO_0000357,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,5033,,,51,Autocuration
9,,1,449.0,9606.0,1020,,,B,,,,Homo sapiens,CHO,D,CHEMBL616222,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,16909,,,51,Expert
8,,1,,,1021,,,F,,,,,,H,CHEMBL616223,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,2590,,,51,Autocuration
8,,1,,,1022,,,F,,,,,,H,CHEMBL616224,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,2590,,,51,Autocuration
8,,1,,,1023,,,B,,,,,,H,CHEMBL616225,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,16394,,,51,Expert
9,,1,722.0,9606.0,1024,,,B,,,,Homo sapiens,HEK293,D,CHEMBL616226,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,4540,,,51,Expert
8,,1,722.0,,1025,,,B,,,,,HEK293,H,CHEMBL616227,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,17296,,,51,Autocuration
8,,1,722.0,,1026,,,B,,,,,HEK293,H,CHEMBL616228,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,17296,,,51,Autocuration
8,,1,722.0,,1027,,,B,,,,,HEK293,H,CHEMBL616229,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,15779,,,51,Autocuration
8,,1,722.0,,1028,,,B,,,,,HEK293,H,CHEMBL616230,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,15779,,,51,Autocuration
8,,1,722.0,,1029,,,B,,,,,HEK293,H,CHEMBL616231,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,15779,,,51,Autocuration
8,,1,,,1030,,,B,,,,,,H,CHEMBL616232,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,6166,,,51,Autocuration
8,,1,722.0,,1031,,,B,,,,,HEK293,H,CHEMBL616233,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,15779,,,51,Autocuration
8,,1,722.0,,1032,,,B,,,,,HEK293,H,CHEMBL857973,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,4199,,,51,Autocuration
8,,1,,,1033,,,B,,,,,,H,CHEMBL616234,BAO_0000219,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,15316,,,51,Autocuration
8,,1,,,1034,,,B,,,,,,H,CHEMBL616235,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,14875,,,51,Autocuration
8,,1,308.0,,1035,,,B,,,,,HeLa,H,CHEMBL616236,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,14727,,,51,Expert
8,,1,,,1036,,,B,,,,,,H,CHEMBL616237,BAO_0000019,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,14727,,,51,Expert
8,,1,722.0,,1037,,,B,,,,,HEK293,H,CHEMBL616238,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,15146,,,51,Autocuration
8,,1,722.0,,1038,,,B,,,,,HEK293,H,CHEMBL616239,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,5213,,,51,Autocuration
8,,1,,,1039,,,B,,,,,,H,CHEMBL616240,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,16429,,,51,Autocuration
9,,1,308.0,9606.0,1040,,,B,,,,Homo sapiens,HeLa,D,CHEMBL616241,BAO_0000219,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,15042,,,51,Expert
8,,1,722.0,,1041,,,B,,,,,HEK293,H,CHEMBL616242,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,14818,,,51,Autocuration
8,,1,722.0,,1042,,,B,,,,,HEK293,H,CHEMBL616243,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",4829,,,51,Autocuration
9,,1,,,1043,,,B,,,,,,D,CHEMBL616244,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,17200,,,51,Expert
9,,1,,9606.0,1044,,,B,,,,Homo sapiens,,D,CHEMBL616245,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,13051,,,51,Autocuration
8,,1,,,1045,,,B,,,,,,H,CHEMBL616246,BAO_0000357,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,5486,,,106,Autocuration
8,,1,,,1046,,,B,,,,,,H,CHEMBL616247,BAO_0000357,Binding affinity against 5-HT1D receptor,5254,,,105,Autocuration
8,,1,,,1047,,,B,,,,,,H,CHEMBL616248,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,5254,,,105,Autocuration
8,,1,,,1048,,,B,,,,,,H,CHEMBL616249,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,,,107,Autocuration
8,,1,,9606.0,1049,,,B,,,,Homo sapiens,,H,CHEMBL616250,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,13506,,,10576,Autocuration
8,,1,,,1050,,,B,,,,,,H,CHEMBL616251,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,15267,,,51,Autocuration
8,,1,,,1051,,In vivo,F,,,,,,H,CHEMBL616252,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,16616,,,11863,Autocuration
8,,1,,,1052,,In vivo,F,,,,,,H,CHEMBL616253,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,16616,,,11863,Autocuration
8,,1,,,1053,,In vivo,F,,,,,,H,CHEMBL616254,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,16616,,,11863,Autocuration
9,,1,,10090.0,1054,,,F,,,,Mus musculus,,D,CHEMBL616255,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,16616,,,11863,Expert
9,,1,,10090.0,1055,,,F,,,,Mus musculus,,D,CHEMBL832872,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,16616,,,11863,Expert
9,,1,,10090.0,1056,,,F,,,,Mus musculus,,D,CHEMBL616256,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,16616,,,11863,Expert
9,,1,,10090.0,1057,,,F,,,,Mus musculus,,D,CHEMBL616257,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,16616,,,11863,Expert
9,,1,,10090.0,1058,,,F,,,,Mus musculus,,D,CHEMBL616258,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,16616,,,11863,Expert
9,,1,,10090.0,1059,,,F,,,,Mus musculus,,D,CHEMBL616384,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,16616,,,11863,Expert
8,,1,,,1060,,,B,10000000.0,,,,,H,CHEMBL616385,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10297,,Hippocampus,11863,Autocuration
8,,1,,,1061,,,B,,,,,,H,CHEMBL616386,BAO_0000357,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,13704,,,11863,Expert
9,,1,,10090.0,1062,,,B,10000000.0,,,Mus musculus,,D,CHEMBL616387,BAO_0000221,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10297,,Hippocampus,11863,Expert
8,,1,,,1063,,,B,10000000.0,,,,,H,CHEMBL616388,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10297,,Hippocampus,11863,Autocuration
9,,1,,10090.0,1064,,,B,10000000.0,,,Mus musculus,,D,CHEMBL616389,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10297,,Hippocampus,11863,Expert
8,,1,,,1065,,,B,10000000.0,,,,,H,CHEMBL616390,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10297,,Hippocampus,11863,Autocuration
8,,1,,,1066,,,B,,,,,,H,CHEMBL616391,BAO_0000357,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,217,,,11863,Autocuration
9,,1,,10090.0,1067,,,B,10000000.0,,,Mus musculus,,D,CHEMBL616392,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10297,,Hippocampus,11863,Expert
8,,1,,9823.0,1068,,,B,,,,Sus scrofa,,H,CHEMBL616393,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,4921,,,51,Autocuration
8,,1,,9823.0,1069,,,B,,,,Sus scrofa,,H,CHEMBL616394,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,4921,,,51,Autocuration
8,,1,,9823.0,1070,,,B,,,,Sus scrofa,,H,CHEMBL616395,BAO_0000019,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,4996,,,51,Autocuration
8,,1,,9823.0,1071,,,B,,,,Sus scrofa,,H,CHEMBL616396,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT1A receptor,12918,,,51,Autocuration
8,,1,,9823.0,1072,,,B,,,,Sus scrofa,,H,CHEMBL872907,BAO_0000019,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,5333,,,51,Autocuration
8,,1,,9823.0,1073,,,B,,,,Sus scrofa,,H,CHEMBL616397,BAO_0000019,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,4437,,,51,Autocuration
8,,1,,9823.0,1074,,,B,,,,Sus scrofa,,H,CHEMBL616398,BAO_0000019,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1742,,,51,Autocuration
8,,1,,9823.0,1075,,,B,,,,Sus scrofa,,H,CHEMBL616399,BAO_0000357,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,16688,,,51,Expert
8,,1,,9823.0,1076,,,B,,,,Sus scrofa,,H,CHEMBL857065,BAO_0000357,Binding activity radioligand.,12861,,,51,Autocuration
8,,1,,9823.0,1077,,,B,,,,Sus scrofa,,H,CHEMBL616400,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,12861,,,51,Expert
8,,1,,9823.0,1078,,,B,,,,Sus scrofa,,H,CHEMBL616401,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,12861,,,51,Autocuration
8,,1,,,1079,,,B,,,,,,H,CHEMBL616402,BAO_0000019,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,12490,,,10624,Expert
8,,1,,9823.0,1080,,,B,,,,Sus scrofa,,H,CHEMBL616403,BAO_0000019,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,11828,,,51,Expert
8,,1,,9823.0,1081,,,B,10000000.0,,,Sus scrofa,,H,CHEMBL616404,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,11866,,Hippocampus,51,Autocuration
8,,1,,9823.0,1082,,,B,,,,Sus scrofa,,H,CHEMBL616405,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,12827,,,51,Autocuration
8,,1,,9823.0,1083,,,B,,,,Sus scrofa,,H,CHEMBL616406,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,12918,,,51,Autocuration
8,,1,,9823.0,1084,,,F,,,,Sus scrofa,,H,CHEMBL616407,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,12919,,,51,Expert
8,,1,,9986.0,1085,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616408,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,13047,,,51,Autocuration
9,,1,,10116.0,1086,,,B,,,,Rattus norvegicus,,D,CHEMBL616409,BAO_0000249,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,15796,,,10576,Expert
9,,1,,10116.0,1087,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616410,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",3651,,Hippocampus,10576,Expert
8,,1,,,1088,,,B,,,,,,H,CHEMBL616411,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,188,,,10576,Autocuration
9,,1,,10116.0,1089,,,F,,,,Rattus norvegicus,,D,CHEMBL616412,BAO_0000249,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",16616,Membranes,,10576,Expert
9,,1,,10116.0,1090,,,F,10000000.0,,,Rattus norvegicus,,D,CHEMBL616413,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",16616,Membranes,Hippocampus,10576,Expert
8,,1,,,1091,,,B,10000000.0,,,,,H,CHEMBL616414,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1092,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616415,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,17167,,Hippocampus,10576,Expert
8,,1,,,1093,,,B,,,,,,H,CHEMBL616416,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,14776,,,10576,Autocuration
8,,1,,,1094,,,B,,,,,,H,CHEMBL616417,BAO_0000357,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,12158,,,10576,Expert
8,,1,,,1095,,,B,,,,,,H,CHEMBL616418,BAO_0000357,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,13481,,,10576,Autocuration
8,,1,,,1096,,In vitro,B,,,,,,H,CHEMBL616419,BAO_0000219,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,,,10576,Autocuration
8,,1,,,1097,,,B,,,,,,H,CHEMBL616420,BAO_0000357,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10210,,,10576,Autocuration
8,,1,,,1098,,,B,,,,,,H,CHEMBL616421,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10205,Membranes,,10576,Autocuration
8,,1,,,1099,,,B,,,,,,H,CHEMBL616422,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10205,Membranes,,10576,Autocuration
8,,1,,,1100,,,B,,,,,,H,CHEMBL616423,BAO_0000249,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10205,Membranes,,10576,Expert
9,,1,,10116.0,1101,,,B,,,,Rattus norvegicus,,D,CHEMBL616424,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,12280,,,10576,Expert
8,,1,,,1102,,,B,,,,,,H,CHEMBL616425,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,17386,,,10576,Expert
8,,1,,,1103,,,B,,,,,,H,CHEMBL616426,BAO_0000357,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,13654,,,10576,Expert
8,,1,,,1104,,,B,10000000.0,,,,,H,CHEMBL616427,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,14423,,Hippocampus,10576,Autocuration
8,,1,,,1105,,,B,10000000.0,,,,,H,CHEMBL616428,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,15412,,Hippocampus,10576,Autocuration
8,,1,,,1106,,,B,10000000.0,,,,,H,CHEMBL616290,BAO_0000221,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1107,,,B,,,,Rattus norvegicus,,D,CHEMBL616052,BAO_0000357,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,4101,,,10576,Expert
8,,1,,,1108,,,B,,,,,,H,CHEMBL616053,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10062,,,10576,Autocuration
8,,1,,,1109,,,B,,,,,,H,CHEMBL616054,BAO_0000249,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,6238,,,10576,Autocuration
8,,1,,,1110,,,B,,,,,,H,CHEMBL616055,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,16273,,,10576,Autocuration
8,,1,,,1111,,,B,,,,,,H,CHEMBL616056,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,11139,,,10576,Autocuration
8,,1,,,1112,,,B,,,,,,H,CHEMBL616057,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,16796,,,10576,Expert
9,,1,,10116.0,1113,,,B,955.0,,,Rattus norvegicus,,D,CHEMBL616058,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9548,,Brain,10576,Expert
8,,1,,,1114,,,B,955.0,,,,,H,CHEMBL616059,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10381,,Brain,10576,Autocuration
8,,1,,,1115,,,B,,,,,,H,CHEMBL616060,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,13408,,,10576,Autocuration
9,,1,,10116.0,1116,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616061,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,13825,,Hippocampus,10576,Expert
8,,1,,,1117,,,B,10000000.0,,,,,H,CHEMBL616062,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,11147,,Hippocampus,10576,Expert
8,,1,,,1118,,,B,,,,,,H,CHEMBL616063,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10552,,,10576,Autocuration
8,,1,,,1119,,,B,2435.0,,,,,H,CHEMBL616064,BAO_0000249,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10552,,Striatum,10576,Autocuration
9,,1,,10116.0,1120,,,B,,,,Rattus norvegicus,,D,CHEMBL616065,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,17136,Membranes,,10576,Expert
9,,1,,10116.0,1121,,,B,,,,Rattus norvegicus,,D,CHEMBL616066,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,5778,Membranes,,10576,Expert
8,,1,,,1122,,,B,10000000.0,,,,,H,CHEMBL616067,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,13481,,Hippocampus,10576,Autocuration
8,,1,,,1123,,,B,10000000.0,,,,,H,CHEMBL616068,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,13481,,Hippocampus,10576,Autocuration
8,,1,,,1124,,,B,10000000.0,,,,,H,CHEMBL616069,BAO_0000221,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,13630,,Hippocampus,10576,Intermediate
8,,1,,,1125,,,B,,,,,,H,CHEMBL616070,BAO_0000249,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,16245,,,10576,Expert
8,,1,,,1126,,,B,10000000.0,,,,,H,CHEMBL616071,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,14509,,Hippocampus,10576,Autocuration
8,,1,,,1127,,,B,10000000.0,,,,,H,CHEMBL616072,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,14509,,Hippocampus,10576,Expert
8,,1,,,1128,,,B,10000000.0,,,,,H,CHEMBL616073,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,14509,,Hippocampus,10576,Autocuration
8,,1,,,1129,,,B,10000000.0,,,,,H,CHEMBL616074,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,14509,,Hippocampus,10576,Autocuration
8,,1,,,1130,,,B,,,,,,H,CHEMBL616075,BAO_0000019,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,14256,,,10576,Expert
8,,1,,,1131,,,B,,,,,,H,CHEMBL616076,BAO_0000357,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,11139,,,10576,Autocuration
9,,1,,10116.0,1132,,,B,,,,Rattus norvegicus,,D,CHEMBL616077,BAO_0000019,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,11047,,,10576,Expert
9,,1,,10116.0,1133,,,B,,,,Rattus norvegicus,,D,CHEMBL616078,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,11047,,,10576,Expert
9,,1,,10116.0,1134,,,B,,,,Rattus norvegicus,,D,CHEMBL616079,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,11047,,,10576,Expert
9,,1,485.0,10116.0,1135,,,B,,,,Rattus norvegicus,CHO-K1,D,CHEMBL616080,BAO_0000219,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,2395,,,10576,Expert
8,,1,,,1136,,,B,,,,,,H,CHEMBL616081,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,9699,,,10576,Autocuration
9,,1,,10116.0,1137,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616082,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,12028,,Hippocampus,10576,Expert
8,,1,,,1138,,,B,10000000.0,,,,,H,CHEMBL616083,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,12028,,Hippocampus,10576,Autocuration
8,,1,,,1139,,,B,,,,,,H,CHEMBL616084,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,5815,,,10576,Autocuration
8,,1,,,1140,,,B,,,,,,H,CHEMBL616085,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,16616,,,10576,Expert
8,,1,,,1141,,,B,,,,,,H,CHEMBL616086,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,5815,,,10576,Autocuration
8,,1,,,1142,,,B,10000000.0,,,,,H,CHEMBL616087,BAO_0000221,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",2761,,Hippocampus,10576,Autocuration
8,,1,,,1143,,,B,,,,,,H,CHEMBL616088,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,13133,,,10576,Expert
8,,1,,,1144,,,B,,,,,,H,CHEMBL616089,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10444,,,10576,Autocuration
9,,1,,10116.0,1145,,,B,,,,Rattus norvegicus,,D,CHEMBL616090,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,13278,,,10576,Expert
8,,1,,,1146,,,B,,,,,,H,CHEMBL616091,BAO_0000357,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,,,10576,Autocuration
8,,1,,,1147,,,B,2435.0,,,,,H,CHEMBL616092,BAO_0000249,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10552,Membranes,Striatum,10576,Autocuration
8,,1,,,1148,,,B,,,,,,H,CHEMBL616093,BAO_0000357,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),11130,,,10576,Autocuration
8,,1,,,1149,,In vivo,B,,,,,,H,CHEMBL616094,BAO_0000218,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),11130,,,10576,Autocuration
8,,1,,,1150,,,B,955.0,,,,,H,CHEMBL616095,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,14542,,Brain,10576,Autocuration
9,,1,,10116.0,1151,,,B,,,,Rattus norvegicus,,D,CHEMBL616096,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,13670,,,10576,Expert
8,,1,,,1152,,,B,,,,,,H,CHEMBL616097,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,9888,,,10576,Expert
9,,1,,10116.0,1153,,,B,,,,Rattus norvegicus,,D,CHEMBL616098,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,3678,Membranes,,10576,Expert
8,,1,,,1154,,,B,10000000.0,,,,,H,CHEMBL616099,BAO_0000221,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,11332,,Hippocampus,10576,Autocuration
8,,1,,,1155,,,B,10000000.0,,,,,H,CHEMBL616100,BAO_0000221,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,11332,,Hippocampus,10576,Autocuration
8,,1,,,1156,,,B,,,,,,H,CHEMBL616101,BAO_0000357,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1185,,,10576,Expert
8,,1,,,1157,,,B,,,,,,H,CHEMBL616102,BAO_0000249,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,2014,,,10576,Expert
8,,1,,,1158,,,B,,,,,,H,CHEMBL616103,BAO_0000357,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1185,,,10576,Autocuration
8,,1,,,1159,,,B,,,,,,H,CHEMBL616104,BAO_0000019,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,14429,,,10576,Expert
8,,1,,,1160,,,B,,,,,,H,CHEMBL616105,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",16288,,,10576,Expert
9,,1,,10116.0,1161,,,B,,,,Rattus norvegicus,,D,CHEMBL616106,BAO_0000019,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,5432,,,10576,Expert
8,,1,,,1162,,,B,,,,,,H,CHEMBL616107,BAO_0000019,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,14429,,,10576,Autocuration
8,,1,,,1163,,,B,,,,,,H,CHEMBL616108,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,13672,,,10576,Expert
8,,1,,,1164,,,B,10000000.0,,,,,H,CHEMBL616109,BAO_0000221,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,,Hippocampus,10576,Expert
8,,1,,,1165,,,B,,,,,,H,CHEMBL616110,BAO_0000357,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,11296,,,10576,Autocuration
8,,1,449.0,,1166,,,B,,,,,CHO,H,CHEMBL616111,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,14749,,,10576,Expert
8,,1,,,1167,,,B,,,,,,H,CHEMBL616112,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,15086,,,10576,Expert
8,,1,,,1168,,,B,10000000.0,,,,,H,CHEMBL616113,BAO_0000221,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,13462,,Hippocampus,10576,Autocuration
8,,1,,,1169,,,B,,,,,,H,CHEMBL616114,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,15363,,,10576,Autocuration
8,,1,,,1170,,,B,,,,,,H,CHEMBL616115,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,15363,,,10576,Autocuration
8,,1,,,1171,,,B,,,,,,H,CHEMBL616116,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10796,,,10576,Autocuration
8,,1,,,1172,,,B,955.0,,,,,H,CHEMBL615844,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,12816,,Brain,10576,Expert
8,,1,,,1173,,,B,10000000.0,,,,,H,CHEMBL615939,BAO_0000221,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,13542,,Hippocampus,10576,Expert
8,,1,,,1174,,,B,,,,,,H,CHEMBL615940,BAO_0000019,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,13308,,,10576,Expert
8,,1,,,1175,,,B,10000000.0,,,,,H,CHEMBL615941,BAO_0000221,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,13541,,Hippocampus,10576,Expert
8,,1,,,1176,,,B,10000000.0,,,,,H,CHEMBL615942,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10058,,Hippocampus,10576,Autocuration
8,,1,,,1177,,,B,10000000.0,,,,,H,CHEMBL615943,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10058,,Hippocampus,10576,Autocuration
8,,1,,,1178,,,B,10000000.0,,,,,H,CHEMBL615944,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10058,,Hippocampus,10576,Autocuration
8,,1,,,1179,,,B,10000000.0,,,,,H,CHEMBL615945,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10058,,Hippocampus,10576,Autocuration
8,,1,,,1180,,,B,10000000.0,,,,,H,CHEMBL615946,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10058,,Hippocampus,10576,Autocuration
8,,1,,,1181,,,B,10000000.0,,,,,H,CHEMBL615947,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10058,,Hippocampus,10576,Autocuration
8,,1,,,1182,,,B,10000000.0,,,,,H,CHEMBL615948,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10058,,Hippocampus,10576,Autocuration
8,,1,,,1183,,,B,10000000.0,,,,,H,CHEMBL615949,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10058,,Hippocampus,10576,Autocuration
8,,1,,,1184,,,B,10000000.0,,,,,H,CHEMBL615950,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10058,,Hippocampus,10576,Autocuration
8,,1,,,1185,,,B,10000000.0,,,,,H,CHEMBL615951,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10058,,Hippocampus,10576,Autocuration
8,,1,,,1186,,,B,10000000.0,,,,,H,CHEMBL615952,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10058,,Hippocampus,10576,Autocuration
8,,1,,,1187,,,B,10000000.0,,,,,H,CHEMBL615953,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10058,,Hippocampus,10576,Autocuration
8,,1,,,1188,,,B,10000000.0,,,,,H,CHEMBL615954,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10058,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1189,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL615955,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10058,,Hippocampus,10576,Expert
8,,1,,,1190,,,B,10000000.0,,,,,H,CHEMBL615956,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10058,,Hippocampus,10576,Autocuration
8,,1,,,1191,,,B,10000000.0,,,,,H,CHEMBL615957,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10058,,Hippocampus,10576,Autocuration
8,,1,,,1192,,,B,,,,,,H,CHEMBL615958,BAO_0000019,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,12879,,,10576,Expert
8,,1,,,1193,,,B,,,,,,H,CHEMBL615959,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,11964,,,10576,Expert
8,,1,,,1194,,,B,,,,,,H,CHEMBL615960,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),11964,,,10576,Autocuration
8,,1,,,1195,,,B,,,,,,H,CHEMBL615961,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),11964,,,10576,Autocuration
8,,1,,,1196,,,B,955.0,,,,,H,CHEMBL615962,BAO_0000221,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9548,,Brain,10576,Expert
8,,1,,,1197,,,B,,,,,,H,CHEMBL615963,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,9098,,,10576,Expert
8,,1,,,1198,,,B,,,,,,H,CHEMBL615964,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,9098,,,10576,Autocuration
8,,1,,,1199,,,B,,,,,,H,CHEMBL615965,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,9098,,,10576,Autocuration
8,,1,449.0,,1200,,,B,,,,,CHO,H,CHEMBL615966,BAO_0000219,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,13248,,,10576,Expert
8,,1,,,1201,,,B,,,,,,H,CHEMBL615967,BAO_0000249,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,3147,,,10576,Expert
8,,1,,,1202,,,B,,,,,,H,CHEMBL615968,BAO_0000019,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,13949,,,10576,Expert
8,,1,449.0,,1203,,,B,,,,,CHO,H,CHEMBL615969,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11883,,,10576,Autocuration
8,,1,,,1204,,,B,,,,,,H,CHEMBL615970,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),11883,,,10576,Autocuration
9,,1,,10116.0,1205,,,B,,,,Rattus norvegicus,,D,CHEMBL615971,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,11883,,,10576,Expert
8,,1,,,1206,,,B,,,,,,H,CHEMBL615972,BAO_0000249,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,15535,Membranes,,10576,Expert
8,,1,,,1207,,,B,,,,,,H,CHEMBL615973,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,15535,,,10576,Autocuration
8,,1,,,1208,,,B,,,,,,H,CHEMBL615974,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,15535,,,10576,Autocuration
9,,1,449.0,9606.0,1209,,,B,,,,Homo sapiens,CHO,D,CHEMBL615975,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,16372,,,51,Expert
8,,1,,,1210,,,B,,,,,,H,CHEMBL615976,BAO_0000249,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,14608,,,10576,Expert
9,,1,,10116.0,1211,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL872106,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,4795,,Hippocampus,10576,Expert
8,,1,,,1212,,,B,,,,,,H,CHEMBL615977,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,13863,,,10576,Autocuration
8,,1,,,1213,,,B,,,,,,H,CHEMBL615978,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,13863,,,10576,Autocuration
8,,1,,,1214,,,B,,,,,,H,CHEMBL616166,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,13863,,,10576,Autocuration
8,,1,,,1215,,,B,,,,,,H,CHEMBL616167,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,13863,,,10576,Autocuration
8,,1,,,1216,,,B,,,,,,H,CHEMBL616168,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,13863,,,10576,Autocuration
8,,1,,,1217,,,B,,,,,,H,CHEMBL616169,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,13863,,,10576,Autocuration
8,,1,,,1218,,,B,,,,,,H,CHEMBL616170,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,13863,,,10576,Autocuration
8,,1,,,1219,,,B,,,,,,H,CHEMBL616171,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,13863,,,10576,Autocuration
8,,1,,,1220,,,B,,,,,,H,CHEMBL616172,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,13863,,,10576,Autocuration
8,,1,,,1221,,,B,,,,,,H,CHEMBL616173,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,13863,,,10576,Autocuration
8,,1,,,1222,,,B,,,,,,H,CHEMBL616174,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,13863,,,10576,Autocuration
8,,1,,,1223,,,B,,,,,,H,CHEMBL616175,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,13863,,,10576,Autocuration
8,,1,,,1224,,,B,,,,,,H,CHEMBL616176,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,13863,,,10576,Autocuration
8,,1,,,1225,,,B,,,,,,H,CHEMBL616177,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,13863,,,10576,Autocuration
8,,1,,,1226,,,B,,,,,,H,CHEMBL616178,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,13863,,,10576,Autocuration
8,,1,,,1227,,,B,,,,,,H,CHEMBL616179,BAO_0000019,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,9742,,,10576,Autocuration
8,,1,,,1228,,,B,,,,,,H,CHEMBL616180,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,12073,,,10576,Autocuration
8,,1,,,1229,,,B,,,,,,H,CHEMBL616181,BAO_0000357,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,4101,,,10576,Autocuration
8,,1,,,1230,,,B,,,,,,H,CHEMBL616182,BAO_0000019,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,15360,,,10576,Autocuration
8,,1,,,1231,,,B,10000000.0,,,,,H,CHEMBL616183,BAO_0000221,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,11576,,Hippocampus,10576,Autocuration
8,,1,,,1232,,,B,,,,,,H,CHEMBL615874,BAO_0000019,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,5834,,,10576,Expert
9,,1,485.0,10116.0,1233,,,B,,,,Rattus norvegicus,CHO-K1,D,CHEMBL615875,BAO_0000219,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,2395,,,10576,Expert
8,,1,,,1234,,,B,,,,,,H,CHEMBL615876,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1375,,,10576,Autocuration
8,,1,,,1235,,,B,,,,,,H,CHEMBL615877,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1375,,,10576,Autocuration
8,,1,,,1236,,,B,,,,,,H,CHEMBL615878,BAO_0000357,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),3967,,,10576,Autocuration
8,,1,,,1237,,,B,,,,,,H,CHEMBL615879,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,12884,,,10576,Expert
8,,1,,,1238,,,B,,,,,,H,CHEMBL615880,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,2343,,,10576,Expert
8,,1,,,1239,,,B,,,,,,H,CHEMBL615881,BAO_0000019,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",11511,,,10576,Autocuration
9,,1,,10116.0,1240,,,B,,,,Rattus norvegicus,,D,CHEMBL615882,BAO_0000019,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",11511,,,10576,Expert
8,,1,,,1241,,In vivo,F,,,,,,H,CHEMBL615883,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,16394,,,10576,Autocuration
8,,1,,,1242,,In vivo,F,,,,,,H,CHEMBL615884,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),16394,,,10576,Autocuration
8,,1,,,1243,,In vivo,F,,,,,,H,CHEMBL615885,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),16394,,,10576,Autocuration
8,,1,,,1244,,In vivo,F,,,,,,H,CHEMBL615886,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),16394,,,10576,Autocuration
8,,1,,,1245,,In vivo,F,,,,,,H,CHEMBL615887,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),16394,,,10576,Autocuration
8,,1,,,1246,,In vivo,F,,,,,,H,CHEMBL615888,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),16394,,,10576,Autocuration
8,,1,,,1247,,In vivo,F,,,,,,H,CHEMBL615889,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),16394,,,10576,Autocuration
8,,1,,,1248,,In vivo,F,,,,,,H,CHEMBL615890,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),16394,,,10576,Autocuration
8,,1,,,1249,,In vivo,F,,,,,,H,CHEMBL615891,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),16394,,,10576,Autocuration
8,,1,,,1250,,In vivo,F,,,,,,H,CHEMBL615892,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),16394,,,10576,Autocuration
8,,1,,,1251,,In vivo,F,,,,,,H,CHEMBL615893,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),16394,,,10576,Autocuration
8,,1,,,1252,,In vivo,F,,,,,,H,CHEMBL615894,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),16394,,,10576,Autocuration
8,,1,,,1253,,In vivo,F,,,,,,H,CHEMBL615895,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),16394,,,10576,Autocuration
8,,1,,,1254,,In vivo,F,,,,,,H,CHEMBL615896,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),16394,,,10576,Autocuration
8,,1,,,1255,,In vivo,F,,,,,,H,CHEMBL615897,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,16394,,,10576,Autocuration
9,,1,,10116.0,1256,,,F,,,,Rattus norvegicus,,D,CHEMBL615898,BAO_0000249,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",16616,Membranes,,10576,Expert
8,,1,,,1257,,,B,,,,,,H,CHEMBL615899,BAO_0000019,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,16796,,,10576,Autocuration
8,,1,,,1258,,,B,,,,,,H,CHEMBL616291,BAO_0000019,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,16796,,,10576,Autocuration
8,,1,,,1259,,,B,,,,,,H,CHEMBL616292,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,15629,,,10576,Autocuration
8,,1,,,1260,,,F,,,,,,H,CHEMBL616293,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",13241,,,10576,Autocuration
8,,1,,,1261,,,B,10000000.0,,,,,H,CHEMBL616294,BAO_0000221,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,,Hippocampus,10576,Expert
8,,1,,,1262,,,B,10000000.0,,,,,H,CHEMBL616295,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,14286,,Hippocampus,10576,Autocuration
8,,1,,,1263,,,B,955.0,,,,,H,CHEMBL616296,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,14542,,Brain,10576,Autocuration
8,,1,,,1264,,,F,,,,,,H,CHEMBL616297,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1265,,,F,,,,,,H,CHEMBL616605,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1266,,,F,,,,,,H,CHEMBL616606,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1267,,,F,,,,,,H,CHEMBL616607,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,13630,,,10576,Autocuration
8,,1,,,1268,,,F,,,,,,H,CHEMBL616608,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,13630,,,10576,Expert
8,,1,,,1269,,,F,,,,,,H,CHEMBL616609,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,13630,,,10576,Autocuration
9,,1,,10116.0,1270,,,F,,,,Rattus norvegicus,,D,CHEMBL616610,BAO_0000019,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,13630,,,10576,Expert
8,,1,,,1271,,,F,,,,,,H,CHEMBL616611,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1272,,,F,,,,,,H,CHEMBL616612,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,13630,,,10576,Expert
8,,1,,,1273,,,F,,,,,,H,CHEMBL616613,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1274,,,F,,,,,,H,CHEMBL616614,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,13630,,,10576,Expert
8,,1,,,1275,,,F,,,,,,H,CHEMBL616615,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1276,,,F,,,,,,H,CHEMBL616616,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,13630,,,10576,Expert
8,,1,,,1277,,,F,,,,,,H,CHEMBL616617,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1278,,,F,,,,,,H,CHEMBL616618,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1279,,,F,,,,,,H,CHEMBL616619,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1280,,,F,,,,,,H,CHEMBL616620,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,13630,,,10576,Expert
8,,1,,,1281,,,F,,,,,,H,CHEMBL616621,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,13630,,,10576,Expert
8,,1,,,1282,,,F,,,,,,H,CHEMBL616622,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,13630,,,10576,Autocuration
8,,1,,,1283,,,F,,,,,,H,CHEMBL616146,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,13630,,,10576,Expert
8,,1,,,1284,,,F,,,,,,H,CHEMBL832873,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1285,,,F,,,,,,H,CHEMBL616147,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,13630,,,10576,Autocuration
8,,1,,,1286,,,F,,,,,,H,CHEMBL872872,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1287,,,F,,,,,,H,CHEMBL616148,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,13630,,,10576,Autocuration
8,,1,,,1288,,,B,10000000.0,,,,,H,CHEMBL616149,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,9783,,Hippocampus,10576,Autocuration
8,,1,,,1289,,,B,10000000.0,,,,,H,CHEMBL616150,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,9783,,Hippocampus,10576,Expert
9,,1,,10116.0,1290,,,B,,,,Rattus norvegicus,,D,CHEMBL616151,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,14331,Membranes,,10576,Expert
8,,1,,,1291,,,B,10000000.0,,,,,H,CHEMBL872873,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,15260,,Hippocampus,10576,Expert
8,,1,,,1292,,,B,10000000.0,,,,,H,CHEMBL616670,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,15260,,Hippocampus,10576,Autocuration
8,,1,,,1293,,,B,10000000.0,,,,,H,CHEMBL616671,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,15260,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1294,,,F,,,,Rattus norvegicus,,D,CHEMBL884861,BAO_0000249,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",16616,,,10576,Expert
8,,1,,,1295,,,B,,,,,,H,CHEMBL616672,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,15629,,,10576,Autocuration
8,,1,,,1296,,,B,,,,,,H,CHEMBL616673,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,15086,,,10576,Autocuration
8,,1,,,1297,,,F,,,,,,H,CHEMBL616674,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,5717,,,10576,Expert
8,,1,,,1298,,,B,,,,,,H,CHEMBL616675,BAO_0000357,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,12652,,,10576,Autocuration
8,,1,,,1299,,,B,10000000.0,,,,,H,CHEMBL616676,BAO_0000221,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,14608,,Hippocampus,10576,Autocuration
8,,1,,,1300,,,B,10000000.0,,,,,H,CHEMBL616677,BAO_0000221,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,,Hippocampus,10576,Autocuration
8,,1,,,1301,,,B,10000000.0,,,,,H,CHEMBL616678,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1302,,,B,,,,Rattus norvegicus,,D,CHEMBL616679,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,15247,,,10576,Expert
8,,1,,,1303,,,B,10000000.0,,,,,H,CHEMBL616680,BAO_0000221,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,17529,,Hippocampus,10576,Expert
8,,1,,,1304,,,B,10000000.0,,,,,H,CHEMBL616681,BAO_0000221,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,14826,,Hippocampus,10576,Autocuration
8,,1,,,1305,,,B,10000000.0,,,,,H,CHEMBL616682,BAO_0000221,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,14826,,Hippocampus,10576,Autocuration
8,,1,,,1306,,,B,10000000.0,,,,,H,CHEMBL616683,BAO_0000221,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,13241,,Hippocampus,10576,Autocuration
8,,1,,,1307,,,B,10000000.0,,,,,H,CHEMBL616684,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,14093,,Hippocampus,10576,Autocuration
8,,1,,,1308,,,B,10000000.0,,,,,H,CHEMBL616685,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,14093,,Hippocampus,10576,Autocuration
8,,1,,,1309,,,B,955.0,,,,,H,CHEMBL616686,BAO_0000221,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,14442,,Brain,10576,Autocuration
8,,1,,,1310,,,B,,,,,,H,CHEMBL616687,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,9919,,,10576,Autocuration
8,,1,,,1311,,,B,,,,,,H,CHEMBL616688,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,9919,,,10576,Autocuration
8,,1,,,1312,,,B,10000000.0,,,,,H,CHEMBL616689,BAO_0000221,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,11440,,Hippocampus,10576,Autocuration
8,,1,,,1313,,,B,,,,,,H,CHEMBL616690,BAO_0000357,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,11257,,,10576,Autocuration
8,,1,,,1314,,,B,,,,,,H,CHEMBL616691,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10330,,,10576,Expert
9,,1,,10116.0,1315,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616692,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,17331,,Hippocampus,10576,Expert
8,,1,,,1316,,,B,,,,,,H,CHEMBL616693,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,16567,,,10576,Expert
9,,1,,10116.0,1317,,,B,,,,Rattus norvegicus,,D,CHEMBL616694,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",12058,,,10576,Expert
8,,1,,,1318,,,B,10000000.0,,,,,H,CHEMBL616695,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,9699,,Hippocampus,10576,Autocuration
8,,1,,,1319,,,B,,,,,,H,CHEMBL616696,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,9547,,,10576,Autocuration
8,,1,,,1320,,,B,,,,,,H,CHEMBL616697,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10330,,,10576,Autocuration
8,,1,,,1321,,,B,,,,,,H,CHEMBL616698,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,14331,,,10576,Autocuration
9,,1,,10116.0,1322,,,B,,,,Rattus norvegicus,,D,CHEMBL616949,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,14060,,,10576,Expert
8,,1,,,1323,,,B,10000000.0,,,,,H,CHEMBL616950,BAO_0000221,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,14744,,Hippocampus,10576,Autocuration
8,,1,,,1324,,,B,,,,,,H,CHEMBL832875,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,13506,,,10576,Autocuration
8,,1,,,1325,,,B,955.0,,,,,H,CHEMBL616951,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,,Brain,10576,Expert
8,,1,,,1326,,,B,955.0,,,,,H,CHEMBL616952,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,,Brain,10576,Expert
8,,1,,,1327,,,B,,,,,,H,CHEMBL616953,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10062,,,10576,Expert
8,,1,,,1328,,,B,,,,,,H,CHEMBL616954,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,12073,,,10576,Autocuration
8,,1,,,1329,,,B,,,,,,H,CHEMBL616955,BAO_0000357,GTPgammaS radioligand binding assay,14875,,,106,Autocuration
8,,1,,,1330,,,B,,,,,,H,CHEMBL616956,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,2391,,,106,Autocuration
8,,1,,,1331,,,F,,,,,,H,CHEMBL616957,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,2391,,,106,Autocuration
8,,1,,,1332,,,F,,,,,,H,CHEMBL616958,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,2391,,,106,Autocuration
8,,1,,,1333,,,B,,,,,,H,CHEMBL616959,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,2391,,,106,Autocuration
8,,1,,,1334,,,B,,,,,,H,CHEMBL616960,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,2391,,,106,Autocuration
8,,1,,,1335,,,F,,,,,,H,CHEMBL616961,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,2391,,,106,Autocuration
8,,1,308.0,,1336,,,B,,,,,HeLa,H,CHEMBL616962,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,17211,,,106,Expert
8,,1,308.0,,1337,,,B,,,,,HeLa,H,CHEMBL616963,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,17211,,,106,Autocuration
9,,1,,9606.0,1338,,,B,,,,Homo sapiens,,D,CHEMBL616524,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,6491,,,106,Expert
8,,1,449.0,,1339,,,B,,,,,CHO,H,CHEMBL616525,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,16190,,,106,Autocuration
8,,1,,,1340,,,B,,,,,,H,CHEMBL872908,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,14165,,,106,Autocuration
8,,1,,,1341,,,B,,,,,,H,CHEMBL616526,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,14165,,,106,Autocuration
9,,1,,9606.0,1342,,,B,,,,Homo sapiens,,D,CHEMBL616527,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,4234,,,106,Expert
8,,1,,,1343,,,B,,,,,,H,CHEMBL616528,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,6328,,,106,Expert
8,,1,,,1344,,,B,,,,,,H,CHEMBL616529,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,14770,,,106,Autocuration
8,,1,,,1345,,,B,,,,,,H,CHEMBL616530,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,2598,,,106,Autocuration
8,,1,,,1346,,,B,,,,,,H,CHEMBL616531,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,6897,,,106,Expert
8,,1,,,1347,,,B,,,,,,H,CHEMBL616532,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,6897,,,106,Autocuration
8,,1,,,1348,,,B,,,,,,H,CHEMBL616533,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,6013,,,106,Autocuration
8,,1,,,1349,,,B,,,,,,H,CHEMBL616534,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,5843,,,106,Expert
8,,1,,,1350,,,B,,,,,,H,CHEMBL616535,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,14454,,,106,Expert
8,,1,,,1351,,,B,,,,,,H,CHEMBL616536,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,16209,,,106,Autocuration
8,,1,,,1352,,,B,,,,,,H,CHEMBL616537,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,3935,,,106,Autocuration
8,,1,485.0,,1353,,,F,,,,,CHO-K1,H,CHEMBL616538,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,13729,,,106,Expert
8,,1,,,1354,,,F,,,,,,H,CHEMBL616539,BAO_0000019,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,14251,,,106,Expert
8,,1,,,1355,,,B,,,,,,H,CHEMBL616540,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,17085,,,106,Expert
8,,1,,,1356,,,B,,,,,,H,CHEMBL616429,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,3025,,,106,Autocuration
8,,1,,,1357,,,B,,,,,,H,CHEMBL616430,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,15315,,,106,Expert
9,,1,,9606.0,1358,,,B,,,,Homo sapiens,,D,CHEMBL616431,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,14214,,,106,Expert
9,,1,,9606.0,1359,,,B,,,,Homo sapiens,,D,CHEMBL616432,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,3804,,,106,Expert
9,,1,,9606.0,1360,,,B,,,,Homo sapiens,,D,CHEMBL616433,BAO_0000357,Affinity for 5-hydroxytryptamine 1B receptor subtype,2391,,,106,Expert
9,,1,,9606.0,1361,,,B,,,,Homo sapiens,,D,CHEMBL616434,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,4175,,,106,Expert
8,,1,449.0,,1362,,,B,,,,,CHO,H,CHEMBL616435,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,17296,,,106,Autocuration
8,,1,,,1363,,,B,,,,,,H,CHEMBL616436,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,17085,,,106,Expert
8,,1,308.0,,1364,,,B,,,,,HeLa,H,CHEMBL616437,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,17211,,,106,Autocuration
8,,1,308.0,,1365,,,B,,,,,HeLa,H,CHEMBL616438,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,17211,,,106,Autocuration
8,,1,308.0,,1366,,,B,,,,,HeLa,H,CHEMBL616439,BAO_0000219,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,17211,,,106,Autocuration
9,,1,,9606.0,1367,,,B,,,,Homo sapiens,,D,CHEMBL616440,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,15926,,,106,Expert
8,,1,485.0,,1368,,,B,,,,,CHO-K1,H,CHEMBL616441,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,16312,,,106,Autocuration
8,,1,,,1369,,,B,,,,,,H,CHEMBL616442,BAO_0000357,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,5843,,,106,Expert
8,,1,,,1370,,,B,,,,,,H,CHEMBL616443,BAO_0000357,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,5843,,,106,Autocuration
8,,1,485.0,,1371,,,B,,,,,CHO-K1,H,CHEMBL616444,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,16312,,,106,Expert
9,,1,,9606.0,1372,,,B,,,,Homo sapiens,,D,CHEMBL616445,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,15926,,,106,Expert
9,,1,,9606.0,1373,,,B,,,,Homo sapiens,,D,CHEMBL616446,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,15926,,,106,Expert
9,,1,449.0,9606.0,1374,,,B,,,,Homo sapiens,CHO,D,CHEMBL616447,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,4540,,,106,Expert
8,,1,,,1375,,,B,,,,,,H,CHEMBL616448,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,6166,,,106,Autocuration
8,,1,449.0,,1376,,,B,,,,,CHO,H,CHEMBL616449,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,17296,,,106,Autocuration
8,,1,449.0,,1377,,,B,,,,,CHO,H,CHEMBL616450,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,17296,,,106,Autocuration
8,,1,449.0,,1378,,,B,,,,,CHO,H,CHEMBL857974,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,17296,,,106,Autocuration
8,,1,449.0,,1379,,,B,,,,,CHO,H,CHEMBL616451,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,,,106,Autocuration
8,,1,449.0,,1380,,,B,,,,,CHO,H,CHEMBL616452,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,,,106,Autocuration
8,,1,449.0,,1381,,,B,,,,,CHO,H,CHEMBL616453,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,15779,,,106,Autocuration
8,,1,449.0,,1382,,,B,,,,,CHO,H,CHEMBL616454,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,4199,,,106,Autocuration
9,,1,,9606.0,1383,,,B,,,,Homo sapiens,,D,CHEMBL616455,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,14875,,,106,Expert
8,,1,449.0,,1384,,,B,,,,,CHO,H,CHEMBL616456,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,15146,,,106,Autocuration
8,,1,,,1385,,,B,,,,,,H,CHEMBL616457,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,5213,,,106,Autocuration
8,,1,449.0,,1386,,,B,,,,,CHO,H,CHEMBL616458,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,14818,,,106,Autocuration
8,,1,449.0,,1387,,,B,,,,,CHO,H,CHEMBL616459,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",4829,,,106,Autocuration
8,,1,,,1388,,,F,,,,,,H,CHEMBL616460,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,14454,,,106,Expert
8,,1,,,1389,,,F,,,,,,H,CHEMBL616461,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,14454,,,106,Expert
8,,1,449.0,,1390,,,F,,,,,CHO,H,CHEMBL616462,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",14875,,,106,Autocuration
8,,1,449.0,,1391,,,F,,,,,CHO,H,CHEMBL616463,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",14875,,,106,Autocuration
8,,1,,,1392,,,F,,,,,,H,CHEMBL616464,BAO_0000019,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",15250,,,105,Autocuration
8,,1,449.0,,1393,,,B,,,,,CHO,H,CHEMBL616465,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,15250,,,105,Autocuration
8,,1,,,1394,,,B,,,,,,H,CHEMBL832874,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,15086,,,17105,Autocuration
8,,1,,9986.0,1395,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL616184,BAO_0000019,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,3025,,,106,Autocuration
8,,1,,9986.0,1396,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616185,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,14998,,,106,Autocuration
8,,1,,9986.0,1397,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616186,BAO_0000019,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",14998,,,106,Intermediate
8,,1,,9986.0,1398,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616187,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,14998,,,106,Autocuration
8,,1,,,1399,,,B,,,,,,H,CHEMBL616188,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,13969,,,10577,Expert
9,,1,,,1400,,,B,,,,,,D,CHEMBL873475,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor,13392,,,10577,Intermediate
9,,1,,10116.0,1401,,,B,2435.0,,,Rattus norvegicus,,D,CHEMBL616189,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,3651,,Striatum,10577,Expert
8,,1,,,1402,,,B,,,,,,H,CHEMBL616190,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10025,,,10577,Expert
8,,1,,,1403,,,B,,,,,,H,CHEMBL616191,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,13863,,,10576,Autocuration
8,,1,,,1404,,,B,,,,,,H,CHEMBL616192,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,13863,,,10576,Autocuration
8,,1,,,1405,,,B,,,,,,H,CHEMBL616193,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,13863,,,10576,Autocuration
8,,1,,,1406,,,B,,,,,,H,CHEMBL616194,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,13863,,,10576,Autocuration
8,,1,,,1407,,,B,,,,,,H,CHEMBL616195,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,13863,,,10576,Autocuration
8,,1,,,1408,,,B,,,,,,H,CHEMBL616196,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,13863,,,10576,Autocuration
8,,1,,,1409,,,B,10000000.0,,,,,H,CHEMBL616197,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,4622,,Hippocampus,10576,Autocuration
8,,1,,,1410,,,B,,,,,,H,CHEMBL616198,BAO_0000019,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,14911,,,10576,Intermediate
8,,1,,,1411,,,B,10000000.0,,,,,H,CHEMBL616199,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,12678,,Hippocampus,10576,Autocuration
8,,1,,,1412,,,B,10000000.0,,,,,H,CHEMBL616200,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,12678,,Hippocampus,10576,Expert
8,,1,,,1413,,,B,10000000.0,,,,,H,CHEMBL616201,BAO_0000221,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,14235,,Hippocampus,10576,Expert
8,,1,,,1414,,,B,10000000.0,,,,,H,CHEMBL616202,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,14949,,Hippocampus,10576,Expert
8,,1,,,1415,,,B,10000000.0,,,,,H,CHEMBL616203,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,14949,,Hippocampus,10576,Expert
8,,1,,,1416,,,B,10000000.0,,,,,H,CHEMBL616204,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,14949,,Hippocampus,10576,Expert
8,,1,,,1417,,,B,10000000.0,,,,,H,CHEMBL616205,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,14949,,Hippocampus,10576,Expert
8,,1,,,1418,,,B,10000000.0,,,,,H,CHEMBL616206,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,14949,,Hippocampus,10576,Expert
8,,1,,,1419,,,B,,,,,,H,CHEMBL616207,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,16118,,,10576,Expert
8,,1,,,1420,,,B,,,,,,H,CHEMBL616208,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,3268,,,10576,Autocuration
8,,1,,,1421,,,B,,,,,,H,CHEMBL616209,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,3268,,,10576,Autocuration
8,,1,,,1422,,,B,,,,,,H,CHEMBL616210,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,16117,,,10576,Expert
8,,1,,,1423,,,B,10000000.0,,,,,H,CHEMBL616211,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,9783,,Hippocampus,10576,Expert
8,,1,,,1424,,,B,10000000.0,,,,,H,CHEMBL616504,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,9783,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1425,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616505,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,14356,,Hippocampus,10576,Expert
8,,1,,,1426,,,F,,,,,,H,CHEMBL616506,BAO_0000019,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,15740,,,10576,Autocuration
8,,1,,,1427,,,B,10000000.0,,,,,H,CHEMBL872107,BAO_0000221,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1428,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616507,BAO_0000221,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,13348,,Hippocampus,10576,Expert
8,,1,,,1429,,,B,,,,,,H,CHEMBL616303,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10394,,,10576,Autocuration
8,,1,,,1430,,,B,10000000.0,,,,,H,CHEMBL616304,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,15260,,Hippocampus,10576,Autocuration
8,,1,,,1431,,,B,10000000.0,,,,,H,CHEMBL616305,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,,Hippocampus,10576,Expert
8,,1,,,1432,,,F,10000000.0,,,,,H,CHEMBL616306,BAO_0000221,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,15260,,Hippocampus,10576,Intermediate
8,,1,,,1433,,,B,,,,,,H,CHEMBL616307,BAO_0000357,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,12851,,,10576,Autocuration
9,,1,,10116.0,1434,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL881829,BAO_0000221,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,2148,,Hippocampus,10576,Expert
8,,1,,,1435,,,B,,,,,,H,CHEMBL616308,BAO_0000357,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,13134,,,10576,Expert
8,,1,,,1436,,,B,,,,,,H,CHEMBL616309,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,12462,,,10576,Autocuration
8,,1,,,1437,,,B,,,,,,H,CHEMBL616310,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,12462,,,10576,Expert
8,,1,449.0,,1438,,,B,,,,,CHO,H,CHEMBL616311,BAO_0000219,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,12462,,,10576,Autocuration
8,,1,,,1439,,,B,,,,,,H,CHEMBL616312,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,11933,,,10576,Expert
8,,1,,,1440,,,B,,,,,,H,CHEMBL616313,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,11933,,,10576,Autocuration
9,,1,,10116.0,1441,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616314,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,403,,Hippocampus,10576,Expert
8,,1,,,1442,,,B,10000000.0,,,,,H,CHEMBL616315,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,15538,,Hippocampus,10576,Autocuration
8,,1,,,1443,,,B,10000000.0,,,,,H,CHEMBL616567,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,15538,,Hippocampus,10576,Autocuration
8,,1,,,1444,,,B,10000000.0,,,,,H,CHEMBL616568,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,15538,,Hippocampus,10576,Autocuration
8,,1,,,1445,,,B,,,,,,H,CHEMBL616569,BAO_0000019,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,12464,,,10576,Intermediate
8,,1,,,1446,,,B,,,,,,H,CHEMBL616570,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1455,,,10576,Expert
8,,1,,,1447,,,B,,,,,,H,CHEMBL616571,BAO_0000357,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,12652,,,10576,Autocuration
8,,1,,,1448,,,B,10000000.0,,,,,H,CHEMBL616572,BAO_0000221,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,12639,,Hippocampus,10576,Autocuration
8,,1,,,1449,,,B,,,,,,H,CHEMBL616573,BAO_0000249,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,13949,,,10576,Expert
9,,1,,10116.0,1450,,,B,,,,Rattus norvegicus,,D,CHEMBL616574,BAO_0000357,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,12463,,,10576,Expert
8,,1,,,1451,,,B,10000000.0,,,,,H,CHEMBL616575,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,14829,,Hippocampus,10576,Expert
8,,1,,,1452,,,B,10000000.0,,,,,H,CHEMBL872108,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,14829,,Hippocampus,10576,Autocuration
8,,1,,,1453,,,B,,,,,,H,CHEMBL616576,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,12092,,,10576,Autocuration
8,,1,,,1454,,,B,,,,,,H,CHEMBL616577,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,403,,,10576,Autocuration
8,,1,,,1455,,,B,,,,,,H,CHEMBL616578,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,403,,,10576,Autocuration
8,,1,,,1456,,,B,,,,,,H,CHEMBL616579,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,3967,,,10576,Expert
9,,1,,10116.0,1457,,,B,,,,Rattus norvegicus,,D,CHEMBL616580,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,12771,,,10576,Expert
8,,1,,,1458,,,B,,,,,,H,CHEMBL616581,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,15086,,,10576,Autocuration
8,,1,,,1459,,,B,10000000.0,,,,,H,CHEMBL616582,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,14909,,Hippocampus,10576,Autocuration
8,,1,,,1460,,,B,10000000.0,,,,,H,CHEMBL616583,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,14949,,Hippocampus,10576,Expert
9,,1,,10116.0,1461,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616584,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,2309,,Hippocampus,10576,Expert
8,,1,,,1462,,,B,,,,,,H,CHEMBL616585,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,4170,,,10576,Expert
9,,1,,10116.0,1463,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616586,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,11642,,Hippocampus,10576,Expert
8,,1,,,1464,,,B,10000000.0,,,,,H,CHEMBL616587,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,11642,,Hippocampus,10576,Autocuration
8,,1,,,1465,,,B,10000000.0,,,,,H,CHEMBL616588,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,12953,,Hippocampus,10576,Autocuration
8,,1,,,1466,,,B,10000000.0,,,,,H,CHEMBL616589,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,12953,,Hippocampus,10576,Autocuration
8,,1,,,1467,,,B,10000000.0,,,,,H,CHEMBL616590,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,12953,,Hippocampus,10576,Expert
8,,1,449.0,,1468,,,B,,,,,CHO,H,CHEMBL616591,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",12903,,,10576,Expert
8,,1,,,1469,,,B,,,,,,H,CHEMBL616592,BAO_0000357,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,12536,,,10576,Expert
8,,1,,,1470,,,B,,,,,,H,CHEMBL616593,BAO_0000357,The inhibition activity of 5-HT1A at 1 uM,10058,,,10576,Autocuration
8,,1,485.0,,1471,,,B,,,,,CHO-K1,H,CHEMBL616594,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",12902,,,10576,Expert
8,,1,,,1472,,,B,,,,,,H,CHEMBL616595,BAO_0000249,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,14057,,,10576,Expert
8,,1,,,1473,,,B,,,,,,H,CHEMBL616596,BAO_0000357,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,11296,,,10576,Autocuration
8,,1,,,1474,,,B,10000000.0,,,,,H,CHEMBL616597,BAO_0000221,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,,Hippocampus,10576,Autocuration
8,,1,,,1475,,,B,10000000.0,,,,,H,CHEMBL616598,BAO_0000221,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,,Hippocampus,10576,Expert
9,,1,,10116.0,1476,,,F,,,,Rattus norvegicus,,D,CHEMBL616599,BAO_0000249,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,16616,Membranes,,10576,Expert
9,,1,,10116.0,1477,,,F,10000000.0,,,Rattus norvegicus,,D,CHEMBL616600,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",16616,Membranes,Hippocampus,10576,Expert
8,,1,,,1478,,,B,,,,,,H,CHEMBL616601,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,16567,,,10576,Autocuration
8,,1,,,1479,,,B,,,,,,H,CHEMBL616602,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,16567,,,10576,Autocuration
8,,1,,,1480,,,B,,,,,,H,CHEMBL616603,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,16567,,,10576,Autocuration
8,,1,,,1481,,,B,,,,,,H,CHEMBL616604,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,16567,,,10576,Autocuration
8,,1,,,1482,,,B,,,,,,H,CHEMBL616316,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,17136,,,10576,Autocuration
8,,1,,,1483,,,B,,,,,,H,CHEMBL616317,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,17136,,,10576,Autocuration
9,,1,,10116.0,1484,,,B,,,,Rattus norvegicus,,D,CHEMBL616318,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,16616,,,10576,Expert
8,,1,,,1485,,,B,10000000.0,,,,,H,CHEMBL616319,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,17331,,Hippocampus,10576,Autocuration
8,,1,,,1486,,,B,10000000.0,,,,,H,CHEMBL616320,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,17331,,Hippocampus,10576,Autocuration
9,,1,,10116.0,1487,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616321,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,17167,,Hippocampus,10576,Expert
8,,1,,,1488,,,F,,,,,,H,CHEMBL616322,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,15740,,,10576,Autocuration
8,,1,,,1489,,,F,,,,,,H,CHEMBL616323,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,15740,,,10576,Autocuration
8,,1,,,1490,,,B,,,,,,H,CHEMBL616324,BAO_0000357,Ratio of binding affinity to 5-HT 1A and D2 receptor,4671,,,10576,Autocuration
8,,1,,,1491,,,B,10000000.0,,,,,H,CHEMBL616325,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10058,,Hippocampus,10576,Autocuration
8,,1,,,1492,,,B,10000000.0,,,,,H,CHEMBL616326,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10058,,Hippocampus,10576,Autocuration
8,,1,,,1493,,,B,10000000.0,,,,,H,CHEMBL616327,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10058,,Hippocampus,10576,Autocuration
8,,1,,,1494,,,B,,,,,,H,CHEMBL616328,BAO_0000357,Percentage inhibition against 5-hydroxytryptamine 1A receptor,12073,,,10576,Autocuration
8,,1,,,1495,,,B,,,,,,H,CHEMBL858110,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),2759,,,10576,Autocuration
8,,1,,,1496,,,F,,,,,,H,CHEMBL616329,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),2759,,,10576,Autocuration
8,,1,,,1497,,,B,,,,,,H,CHEMBL616330,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),2759,,,10576,Autocuration
8,,1,,,1498,,,F,,,,,,H,CHEMBL616331,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),2759,,,10576,Autocuration
8,,1,,,1499,,,F,,,,,,H,CHEMBL616332,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,2759,,,10576,Autocuration
8,,1,,,1500,,,B,955.0,,,,,H,CHEMBL857063,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,,Brain,10576,Autocuration
8,,1,,,1501,,,B,,,,,,H,CHEMBL616333,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,9737,,,10576,Autocuration
8,,1,,,1502,,,F,,,,,,H,CHEMBL616334,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,5717,,,10576,Expert
8,,1,,,1503,,,B,10000000.0,,,,,H,CHEMBL616335,BAO_0000221,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,12253,,Hippocampus,10576,Autocuration
8,,1,,,1504,,,B,,,,,,H,CHEMBL616336,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,14025,,,10576,Autocuration
8,,1,,,1505,,,B,,,,,,H,CHEMBL616337,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10425,,,10576,Expert
8,,1,,,1506,,,B,,,,,,H,CHEMBL616338,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,14998,,,10576,Autocuration
8,,1,,,1507,,,B,10000000.0,,,,,H,CHEMBL616339,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,13694,,Hippocampus,10576,Autocuration
8,,1,,,1508,,,B,10000000.0,,,,,H,CHEMBL616340,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,13694,,Hippocampus,10576,Autocuration
8,,1,,,1509,,,B,,,,,,H,CHEMBL616341,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,4342,,,10576,Autocuration
9,,1,,10116.0,1510,,,B,,,,Rattus norvegicus,,D,CHEMBL616342,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,12936,,,10576,Expert
9,,1,,10116.0,1511,,,B,,,,Rattus norvegicus,,D,CHEMBL616343,BAO_0000019,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,13144,,,10576,Expert
8,,1,,,1512,,,B,,,,,,H,CHEMBL616344,BAO_0000019,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,13343,,,10576,Expert
8,,1,,,1513,,,B,,,,,,H,CHEMBL616345,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,12132,,,10576,Expert
8,,1,,,1514,,,B,,,,,,H,CHEMBL616346,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,15419,,,10576,Expert
8,,1,,,1515,,,B,10000000.0,,,,,H,CHEMBL616347,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1479,,Hippocampus,10576,Autocuration
8,,1,,,1516,,,B,,,,,,H,CHEMBL616348,BAO_0000019,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,14287,,,10576,Expert
8,,1,,,1517,,,B,,,,,,H,CHEMBL616349,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,13116,,,10576,Expert
9,,1,,10116.0,1518,,,B,,,,Rattus norvegicus,,D,CHEMBL616152,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,2759,Membranes,,10576,Expert
8,,1,,,1519,,,B,,,,,,H,CHEMBL616153,BAO_0000249,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,2759,,,10576,Autocuration
8,,1,,,1520,,,B,,,,,,H,CHEMBL616154,BAO_0000019,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",14748,,,10576,Expert
8,,1,,,1521,,,B,,,,,,H,CHEMBL616155,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,12304,,,10576,Autocuration
9,,1,,10116.0,1522,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616156,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,12409,,Hippocampus,10576,Expert
9,,1,,10116.0,1523,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL616157,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,12409,,Hippocampus,10576,Expert
8,,1,,,1524,,,B,10000000.0,,,,,H,CHEMBL616158,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,13267,,Hippocampus,10576,Autocuration
8,,1,,,1525,,,B,,,,,,H,CHEMBL616159,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,15194,,,10576,Autocuration
8,,1,,,1526,,,B,,,,,,H,CHEMBL616160,BAO_0000357,pKi value against rat 5-hydroxytryptamine 1A receptor.,14256,,,10576,Expert
8,,1,,,1527,,,B,,,,,,H,CHEMBL616161,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,16567,,,10576,Autocuration
8,,1,,,1528,,,F,,,,,,H,CHEMBL616162,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,15740,,,10576,Autocuration
9,,1,,10116.0,1529,,,B,,,,Rattus norvegicus,,D,CHEMBL616163,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,13278,,,12687,Expert
8,,1,,,1530,,,B,,,,,,H,CHEMBL616164,BAO_0000249,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1970,Membranes,,10626,Expert
8,,1,,,1531,,,B,955.0,,,,,H,CHEMBL616165,BAO_0000221,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10034,,Brain,10576,Autocuration
8,,1,,10116.0,1532,,,B,,,,Rattus norvegicus,,H,CHEMBL616355,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,13348,,,51,Autocuration
8,,1,,,1533,,,F,,,,,,H,CHEMBL616356,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,13630,,,10576,Autocuration
8,,1,,,1534,,,B,955.0,,,,,H,CHEMBL616357,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,,Brain,10576,Autocuration
8,,1,,,1535,,,B,,,,,,H,CHEMBL616358,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",12058,,,10576,Autocuration
8,,1,,,1536,,,B,,,,,,H,CHEMBL616359,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,4639,,,51,Autocuration
8,,1,,,1537,,,B,,,,,,H,CHEMBL616360,BAO_0000357,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,15453,,,51,Expert
8,,1,,,1538,,,B,,,,,,H,CHEMBL616361,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,4820,,,51,Expert
8,,1,,,1539,,,B,,,,,,H,CHEMBL616362,BAO_0000357,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1089,,,51,Autocuration
8,,1,,,1540,,,B,,,,,,H,CHEMBL616363,BAO_0000249,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,386,Brain membranes,,51,Autocuration
8,,1,,,1541,,,B,,,,,,H,CHEMBL616364,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,6011,,,51,Autocuration
8,,1,,,1542,,,B,,,,,,H,CHEMBL616365,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,5014,,,51,Autocuration
8,,1,,,1543,,,B,,,,,,H,CHEMBL616366,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,4402,,,51,Expert
8,,1,,,1544,,,B,,,,,,H,CHEMBL872906,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,17066,,,51,Expert
8,,1,,,1545,,,B,,,,,,H,CHEMBL616367,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,17515,,,51,Autocuration
8,,1,,,1546,,,B,,,,,,H,CHEMBL616368,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,2474,,,51,Autocuration
8,,1,,,1547,,,B,,,,,,H,CHEMBL616369,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,4775,,,51,Autocuration
9,,1,,9606.0,1548,,,B,,,,Homo sapiens,,D,CHEMBL616370,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,14294,,,51,Expert
9,,1,,9606.0,1549,,,B,,,,Homo sapiens,,D,CHEMBL616371,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,14294,,,51,Expert
8,,1,449.0,,1550,,,B,,,,,CHO,H,CHEMBL616372,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12249,,,51,Autocuration
8,,1,,,1551,,,B,,,,,,H,CHEMBL616373,BAO_0000219,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,11376,,,51,Expert
8,,1,,,1552,,In vivo,B,,,,,,H,CHEMBL616374,BAO_0000218,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,2474,,,51,Autocuration
8,,1,,,1553,,,B,10000000.0,,,,,H,CHEMBL616375,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,13311,,Hippocampus,51,Autocuration
8,,1,,,1554,,,B,,,,,,H,CHEMBL616376,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,4373,,,51,Autocuration
8,,1,,,1555,,,B,,,,,,H,CHEMBL857064,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1633,,,51,Expert
8,,1,,,1556,,,B,,,,,,H,CHEMBL616377,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,11866,,,51,Autocuration
8,,1,,,1557,,,B,,,,,,H,CHEMBL616378,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,4373,,,51,Autocuration
8,,1,,,1558,,,B,,,,,,H,CHEMBL616379,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,4687,,,51,Autocuration
8,,1,,,1559,,,B,,,,,,H,CHEMBL616380,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,16946,,,11863,Autocuration
8,,1,,,1560,,,B,,,,,,H,CHEMBL616381,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,13291,,,11863,Autocuration
8,,1,,,1561,,,B,,,,,,H,CHEMBL616382,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,14159,,,11863,Autocuration
8,,1,,,1562,,,B,,,,,,H,CHEMBL616383,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,10812,,,11863,Autocuration
9,,1,449.0,10090.0,1563,,,B,,,,Mus musculus,CHO,D,CHEMBL616350,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,3032,,,11863,Expert
8,,1,,,1564,,,B,,,,,,H,CHEMBL616351,BAO_0000357,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,16655,,,11863,Autocuration
8,,1,,,1565,,,B,,,,,,H,CHEMBL616352,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,14532,,,11863,Autocuration
8,,1,,,1566,,,B,,,,,,H,CHEMBL616353,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,13944,,,11863,Autocuration
8,,1,,,1567,,,B,,,,,,H,CHEMBL616354,BAO_0000357,Binding affinity against serotonergic 5-HT1a receptor,13033,,,11863,Autocuration
8,,1,,,1568,,,B,,,,,,H,CHEMBL616508,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,10321,,,11863,Autocuration
9,,1,,10090.0,1569,,,B,,,,Mus musculus,,D,CHEMBL616559,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,2968,,,11863,Expert
8,,1,,,1570,,,B,,,,,,H,CHEMBL616560,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,13964,,,11863,Autocuration
8,,1,,,1571,,,B,,,,,,H,CHEMBL616561,BAO_0000357,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",15527,,,11863,Autocuration
8,,1,449.0,,1572,,,B,,,,,CHO,H,CHEMBL616562,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12248,,,11863,Autocuration
8,,1,449.0,,1573,,,B,,,,,CHO,H,CHEMBL616563,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12249,,,11863,Autocuration
8,,1,,,1574,,,B,,,,,,H,CHEMBL616564,BAO_0000357,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,15120,,,11863,Autocuration
8,,1,,,1575,,,B,,,,,,H,CHEMBL616565,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,13313,,,11863,Autocuration
8,,1,,,1576,,,B,,,,,,H,CHEMBL616566,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,2613,,,11863,Autocuration
8,,1,,,1577,,,B,,,,,,H,CHEMBL616989,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,16700,,,11863,Autocuration
8,,1,,,1578,,,B,,,,,,H,CHEMBL857975,BAO_0000357,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,2201,,,11863,Autocuration
9,,1,,10090.0,1579,,,B,,,,Mus musculus,,D,CHEMBL616990,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,1274,,,11863,Expert
8,,1,,,1580,,,B,,,,,,H,CHEMBL616991,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1317,,,11863,Autocuration
8,,1,,,1581,,,B,,,,,,H,CHEMBL616992,BAO_0000357,Tested against 5-hydroxytryptamine 1A receptor,12146,,,11863,Autocuration
8,,1,,,1582,,,B,,,,,,H,CHEMBL616993,BAO_0000357,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,14059,,,11863,Autocuration
8,,1,,9986.0,1583,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616994,BAO_0000019,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,14025,,,106,Expert
8,,1,,9986.0,1584,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616995,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,14025,,,106,Autocuration
9,,1,722.0,9593.0,1585,,,B,,,,Gorilla gorilla,HEK293,D,CHEMBL616996,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,14447,,,105571,Intermediate
8,,1,,10141.0,1586,,In vivo,F,,,,Cavia porcellus,,H,CHEMBL616997,BAO_0000218,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,3025,,,106,Autocuration
8,,1,,10141.0,1587,,In vivo,F,,,,Cavia porcellus,,H,CHEMBL616998,BAO_0000218,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,3025,,,106,Autocuration
8,,1,,10141.0,1588,,,F,,,,Cavia porcellus,,H,CHEMBL616999,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,15329,,,106,Autocuration
8,,1,,10141.0,1589,,,F,,,,Cavia porcellus,,H,CHEMBL617000,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,15329,,,106,Autocuration
8,,1,,10141.0,1590,,,F,,,,Cavia porcellus,,H,CHEMBL617001,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,15847,,,106,Autocuration
8,,1,,10141.0,1591,,,F,,,,Cavia porcellus,,H,CHEMBL858111,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,15847,,,106,Autocuration
8,,1,,,1592,,,F,,,,,,H,CHEMBL617002,BAO_0000019,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,14165,,,106,Autocuration
8,,1,,,1593,,,F,,,,,,H,CHEMBL617003,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),14214,,,106,Autocuration
8,,1,,,1594,,,F,,,,,,H,CHEMBL617004,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),14214,,,106,Autocuration
9,,1,,9606.0,1595,,,F,,,,Homo sapiens,,D,CHEMBL617005,BAO_0000019,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,14214,,,106,Expert
9,,1,485.0,9606.0,1596,,,F,,,,Homo sapiens,CHO-K1,D,CHEMBL616623,BAO_0000219,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,13729,,,106,Expert
8,,1,449.0,,1597,,,F,,,,,CHO,H,CHEMBL616624,BAO_0000219,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,3025,,,106,Autocuration
8,,1,,,1598,,,B,,,,,,H,CHEMBL883243,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,2391,,,106,Autocuration
8,,1,,,1599,,,F,,,,,,H,CHEMBL616625,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,2391,,,106,Autocuration
8,,1,449.0,,1600,,,F,,,,,CHO,H,CHEMBL616626,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",14956,,,106,Expert
8,,1,449.0,,1601,,,F,,,,,CHO,H,CHEMBL616627,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,2598,,,106,Autocuration
8,,1,449.0,,1602,,,F,,,,,CHO,H,CHEMBL616628,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,2598,,,106,Autocuration
8,,1,449.0,,1603,,,F,,,,,CHO,H,CHEMBL616629,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,2598,,,106,Autocuration
8,,1,449.0,,1604,,,F,,,,,CHO,H,CHEMBL616630,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,2598,,,106,Autocuration
8,,1,,,1605,,,F,,,,,,H,CHEMBL616631,BAO_0000019,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",14956,,,106,Expert
8,,1,,,1606,,,F,,,,,,H,CHEMBL616632,BAO_0000019,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",14956,,,106,Autocuration
9,,1,,9606.0,1607,,,B,,,,Homo sapiens,,D,CHEMBL616633,BAO_0000357,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,14214,,,106,Expert
8,,1,449.0,,1608,,,B,,,,,CHO,H,CHEMBL616634,BAO_0000219,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,3463,,,106,Expert
8,,1,,,1609,,,B,,,,,,H,CHEMBL616635,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,15331,,,106,Autocuration
9,,1,,9606.0,1610,,,B,,,,Homo sapiens,,D,CHEMBL885358,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,16146,,,106,Expert
9,,1,449.0,9606.0,1611,,,B,,,,Homo sapiens,CHO,D,CHEMBL616636,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,14159,,,106,Expert
8,,1,449.0,,1612,,,B,,,,,CHO,H,CHEMBL616637,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,14158,,,106,Expert
8,,1,,,1613,,,B,,,,,,H,CHEMBL616638,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,14159,,,106,Autocuration
8,,1,449.0,,1614,,,B,,,,,CHO,H,CHEMBL616639,BAO_0000219,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,15250,,,106,Expert
8,,1,449.0,,1615,,,B,,,,,CHO,H,CHEMBL616640,BAO_0000219,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,15250,,,106,Expert
8,,1,449.0,,1616,,,B,,,,,CHO,H,CHEMBL616641,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,15331,,,106,Expert
8,,1,449.0,,1617,,,B,,,,,CHO,H,CHEMBL616642,BAO_0000219,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,15332,,,106,Expert
8,,1,449.0,,1618,,,B,,,,,CHO,H,CHEMBL616643,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,14956,,,106,Expert
8,,1,,,1619,,,B,,,,,,H,CHEMBL616644,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),3805,,,106,Autocuration
8,,1,,,1620,,,B,,,,,,H,CHEMBL616645,BAO_0000357,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,14875,,,106,Autocuration
8,,1,,9986.0,1621,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL616646,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,,,105,Autocuration
8,,1,,9986.0,1622,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL616647,BAO_0000019,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,,,105,Expert
8,,1,,,1623,,,B,,,,,,H,CHEMBL616509,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),16288,,,105,Autocuration
8,,1,,,1624,,,B,,,,,,H,CHEMBL616510,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),16288,,,105,Autocuration
8,,1,,,1625,,,B,,,,,,H,CHEMBL616511,BAO_0000357,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,16312,,,105,Autocuration
8,,1,,9913.0,1626,,,B,,,,Bos taurus,,H,CHEMBL616512,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1348,,,105,Expert
8,,1,,9913.0,1627,,,B,,,,Bos taurus,,H,CHEMBL616513,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,5834,,,105,Autocuration
8,,1,,9913.0,1628,,,B,2435.0,,,Bos taurus,,H,CHEMBL616514,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,13366,,Striatum,105,Autocuration
8,,1,,9913.0,1629,,,B,,,,Bos taurus,,H,CHEMBL616515,BAO_0000357,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1414,,,105,Expert
8,,1,,9913.0,1630,,,B,,,,Bos taurus,,H,CHEMBL616516,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,14998,,,105,Autocuration
8,,1,,9913.0,1631,,,B,,,,Bos taurus,,H,CHEMBL616517,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,11473,,,105,Autocuration
8,,1,,9913.0,1632,,,B,,,,Bos taurus,,H,CHEMBL616518,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,11473,,,105,Autocuration
8,,1,,9913.0,1633,,,B,,,,Bos taurus,,H,CHEMBL616519,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,10639,,,105,Autocuration
8,,1,,9913.0,1634,,,B,,,,Bos taurus,,H,CHEMBL616520,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,10639,,,105,Autocuration
8,,1,,9913.0,1635,,,B,,,,Bos taurus,,H,CHEMBL616521,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1375,,,105,Autocuration
8,,1,,9913.0,1636,,,B,,,,Bos taurus,,H,CHEMBL616522,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1375,,,105,Autocuration
8,,1,,9913.0,1637,,,B,,,,Bos taurus,,H,CHEMBL884531,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,16532,,,105,Autocuration
8,,1,,9913.0,1638,,,B,,,,Bos taurus,,H,CHEMBL616523,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,11147,,,105,Autocuration
8,,1,,9913.0,1639,,,B,2435.0,,,Bos taurus,,H,CHEMBL616731,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,13366,,Striatum,105,Autocuration
8,,1,,9913.0,1640,,,B,,,,Bos taurus,,H,CHEMBL616732,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,10444,,,105,Autocuration
8,,1,,9913.0,1641,,,B,,,,Bos taurus,,H,CHEMBL616733,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,16532,,,105,Autocuration
8,,1,,9913.0,1642,,,B,,,,Bos taurus,,H,CHEMBL616734,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,16532,,,105,Autocuration
8,,1,,9913.0,1643,,,B,,,,Bos taurus,,H,CHEMBL616735,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,12827,,,105,Autocuration
8,,1,,9913.0,1644,,,B,,,,Bos taurus,,H,CHEMBL616736,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,12827,,,105,Autocuration
8,,1,,9913.0,1645,,,F,,,,Bos taurus,,H,CHEMBL616737,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,,,105,Expert
8,,1,,9913.0,1646,,,B,,,,Bos taurus,,H,CHEMBL616738,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,14025,,,105,Autocuration
8,,1,,9913.0,1647,,,F,,,,Bos taurus,,H,CHEMBL616739,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,,,105,Expert
8,,1,,9913.0,1648,,,F,,,,Bos taurus,,H,CHEMBL616740,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,,,105,Expert
8,,1,,9913.0,1649,,,F,,,,Bos taurus,,H,CHEMBL616741,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,,,105,Expert
8,,1,722.0,9593.0,1650,,,B,,,,Gorilla gorilla,HEK293,H,CHEMBL616742,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,14447,,,105,Autocuration
9,,1,,10141.0,1651,,,B,,,,Cavia porcellus,,D,CHEMBL616743,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1375,,,105570,Intermediate
9,,1,,10141.0,1652,,,B,,,,Cavia porcellus,,D,CHEMBL616744,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1375,,,105570,Intermediate
9,,1,,10141.0,1653,,,F,,,,Cavia porcellus,,D,CHEMBL616745,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,12409,,,105570,Intermediate
9,,1,,10141.0,1654,,,F,,,,Cavia porcellus,,D,CHEMBL616746,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,,,105570,Intermediate
9,,1,,10141.0,1655,,,F,,,,Cavia porcellus,,D,CHEMBL616747,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,12409,,,105570,Intermediate
9,,1,,10141.0,1656,,,F,,,,Cavia porcellus,,D,CHEMBL616748,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,12409,,,105570,Intermediate
9,,1,,10141.0,1657,,,F,,,,Cavia porcellus,,D,CHEMBL616648,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,12409,,,105570,Intermediate
9,,1,,10141.0,1658,,,B,,,,Cavia porcellus,,D,CHEMBL616649,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,11574,,,105570,Intermediate
9,,1,,10141.0,1659,,,B,,,,Cavia porcellus,,D,CHEMBL616650,BAO_0000357,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1558,,,105570,Intermediate
9,,1,,10141.0,1660,,,F,,,,Cavia porcellus,,D,CHEMBL616651,BAO_0000218,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,,,105570,Intermediate
9,,1,,10141.0,1661,,,F,,,,Cavia porcellus,,D,CHEMBL616652,BAO_0000218,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,,,105570,Intermediate
9,,1,,10141.0,1662,,,F,,,,Cavia porcellus,,D,CHEMBL616653,BAO_0000218,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,,,105570,Intermediate
9,,1,,10141.0,1663,,,F,,,,Cavia porcellus,,D,CHEMBL616654,BAO_0000218,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,12409,,,105570,Intermediate
9,,1,,10141.0,1664,,,B,,,,Cavia porcellus,,D,CHEMBL616655,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,12253,,,105570,Intermediate
9,,1,,10141.0,1665,,,B,,,,Cavia porcellus,,D,CHEMBL616656,BAO_0000357,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,12936,,,105570,Intermediate
8,,1,,10141.0,1666,,,B,,,,Cavia porcellus,,H,CHEMBL616657,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,13181,,,105,Autocuration
9,,1,,10141.0,1667,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL616658,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,12409,,Striatum,105570,Intermediate
9,,1,,10141.0,1668,,,B,,,,Cavia porcellus,,D,CHEMBL616659,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,10639,,,105570,Intermediate
8,,1,,,1669,,,B,,,,,,H,CHEMBL616660,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,5254,,,51,Autocuration
8,,1,,,1670,,,B,,,,,,H,CHEMBL616661,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,13051,,,106,Autocuration
8,,1,,,1671,,,F,,,,,,H,CHEMBL616662,BAO_0000019,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,3463,,,105,Expert
8,,1,,,1672,,,F,,,,,,H,CHEMBL616663,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,15315,,,105,Autocuration
8,,1,,,1673,,,F,,,,,,H,CHEMBL616664,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,6011,,,105,Autocuration
9,,1,449.0,9606.0,1674,,,F,,,,Homo sapiens,CHO,D,CHEMBL881820,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",14159,,,105,Expert
8,,1,449.0,,1675,,,F,,,,,CHO,H,CHEMBL616665,BAO_0000219,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",14159,,,105,Autocuration
8,,1,449.0,,1676,,,B,,,,,CHO,H,CHEMBL616666,BAO_0000219,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,15250,,,105,Expert
8,,1,449.0,,1677,,,B,,,,,CHO,H,CHEMBL616667,BAO_0000219,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,15250,,,105,Autocuration
8,,1,449.0,,1678,,,F,,,,,CHO,H,CHEMBL616668,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",15331,,,105,Expert
9,,1,449.0,9606.0,1679,,,F,,,,Homo sapiens,CHO,D,CHEMBL616669,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",15332,,,105,Expert
8,,1,449.0,,1680,,,F,,,,,CHO,H,CHEMBL617040,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",15332,,,105,Expert
8,,1,449.0,,1681,,,F,,,,,CHO,H,CHEMBL617041,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",3294,,,105,Autocuration
8,,1,449.0,,1682,,,F,,,,,CHO,H,CHEMBL617042,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",14158,,,105,Expert
8,,1,449.0,,1683,,,F,,,,,CHO,H,CHEMBL617043,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",14956,,,105,Expert
8,,1,,,1684,,,F,,,,,,H,CHEMBL617044,BAO_0000019,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,12469,,,105,Autocuration
8,,1,449.0,,1685,,,F,,,,,CHO,H,CHEMBL617045,BAO_0000219,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,3463,,,105,Expert
9,,1,449.0,9606.0,1686,,,F,,,,Homo sapiens,CHO,D,CHEMBL617046,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",15250,,,105,Expert
9,,1,449.0,9606.0,1687,,,F,,,,Homo sapiens,CHO,D,CHEMBL617047,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",15250,,,105,Expert
8,,1,,,1688,,,F,,,,,,H,CHEMBL617048,BAO_0000019,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",14956,,,105,Expert
8,,1,,,1689,,,F,,,,,,H,CHEMBL616897,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",14159,,,105,Autocuration
9,,1,,9606.0,1690,,,F,,,,Homo sapiens,,D,CHEMBL616898,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",14159,,,105,Expert
9,,1,449.0,9606.0,1691,,,F,,,,Homo sapiens,CHO,D,CHEMBL858201,BAO_0000219,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,14499,,,105,Expert
8,,1,,,1692,,,F,,,,,,H,CHEMBL616899,BAO_0000019,Intrinsic activity for 5-hydroxytryptamine 1D receptor,15315,,,105,Autocuration
8,,1,,,1693,,In vitro,B,,,,,,H,CHEMBL616900,BAO_0000219,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),3294,,,105,Autocuration
8,,1,449.0,,1694,,,B,,,,,CHO,H,CHEMBL616901,BAO_0000219,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,3463,,,105,Expert
8,,1,,,1695,,,B,,,,,,H,CHEMBL616902,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,15331,,,105,Autocuration
9,,1,449.0,9606.0,1696,,,B,,,,Homo sapiens,CHO,D,CHEMBL616903,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14159,,,105,Expert
8,,1,449.0,,1697,,,B,,,,,CHO,H,CHEMBL616904,BAO_0000219,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,14158,,,105,Expert
8,,1,,,1698,,,B,,,,,,H,CHEMBL616905,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,14159,,,105,Autocuration
8,,1,449.0,,1699,,,B,,,,,CHO,H,CHEMBL616906,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,15250,,,105,Expert
8,,1,449.0,,1700,,,B,,,,,CHO,H,CHEMBL616907,BAO_0000219,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15250,,,105,Expert
8,,1,449.0,,1701,,,B,,,,,CHO,H,CHEMBL616908,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15331,,,105,Expert
9,,1,449.0,9606.0,1702,,,B,,,,Homo sapiens,CHO,D,CHEMBL616909,BAO_0000219,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,15332,,,105,Expert
9,,1,449.0,9606.0,1703,,,B,,,,Homo sapiens,CHO,D,CHEMBL616910,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14499,,,105,Expert
8,,1,449.0,,1704,,,B,,,,,CHO,H,CHEMBL616911,BAO_0000219,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15332,,,105,Expert
8,,1,449.0,,1705,,,B,,,,,CHO,H,CHEMBL616912,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14956,,,105,Expert
8,,1,,,1706,,,B,,,,,,H,CHEMBL616913,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),3805,,,105,Autocuration
9,,1,449.0,9606.0,1707,,,B,,,,Homo sapiens,CHO,D,CHEMBL616914,BAO_0000219,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,6011,,,105,Expert
8,,1,449.0,,1708,,,B,,,,,CHO,H,CHEMBL616915,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,16190,,,105,Autocuration
8,,1,,,1709,,,B,,,,,,H,CHEMBL616916,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,14165,,,105,Autocuration
9,,1,,9606.0,1710,,,B,,,,Homo sapiens,,D,CHEMBL616917,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,4234,,,105,Expert
8,,1,,,1711,,,B,,,,,,H,CHEMBL616918,BAO_0000357,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",15527,,,105,Autocuration
8,,1,,,1712,,,B,,,,,,H,CHEMBL616919,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,6328,,,105,Expert
8,,1,,,1713,,,B,,,,,,H,CHEMBL616920,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,16209,,,105,Autocuration
8,,1,,,1714,,,B,,,,,,H,CHEMBL872914,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,14770,,,105,Autocuration
8,,1,,,1715,,,B,,,,,,H,CHEMBL616921,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,2598,,,105,Autocuration
8,,1,,,1716,,,B,,,,,,H,CHEMBL616922,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,6897,,,105,Expert
8,,1,,,1717,,,B,,,,,,H,CHEMBL616923,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor,6013,,,105,Autocuration
8,,1,,,1718,,,B,,,,,,H,CHEMBL616924,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,5843,,,105,Expert
8,,1,,,1719,,,B,,,,,,H,CHEMBL875909,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,14454,,,105,Expert
8,,1,,,1720,,,B,,,,,,H,CHEMBL616925,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,14454,,,105,Autocuration
8,,1,,,1721,,,B,,,,,,H,CHEMBL616926,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,14454,,,105,Autocuration
8,,1,,,1722,,,B,,,,,,H,CHEMBL616927,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,15818,,,105,Autocuration
8,,1,485.0,,1723,,,F,,,,,CHO-K1,H,CHEMBL616928,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,13729,,,105,Expert
9,,1,,9606.0,1724,,In vitro,B,,,,Homo sapiens,,D,CHEMBL616929,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),6011,,,105,Expert
9,,1,,9606.0,1725,,,B,,,,Homo sapiens,,D,CHEMBL616930,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,4234,,,105,Expert
8,,1,,,1726,,,B,,,,,,H,CHEMBL616931,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,17085,,,105,Expert
8,,1,,,1727,,,B,,,,,,H,CHEMBL616932,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,3025,,,105,Autocuration
8,,1,,,1728,,,B,,,,,,H,CHEMBL616933,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,15315,,,105,Expert
9,,1,,9606.0,1729,,,B,,,,Homo sapiens,,D,CHEMBL616934,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,14214,,,105,Expert
9,,1,,9606.0,1730,,,B,,,,Homo sapiens,,D,CHEMBL616935,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,3804,,,105,Expert
8,,1,,,1731,,,B,,,,,,H,CHEMBL616936,BAO_0000357,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,16700,,,105,Autocuration
9,,1,,9606.0,1732,,,B,,,,Homo sapiens,,D,CHEMBL616937,BAO_0000357,Affinity for 5-hydroxytryptamine 1D receptor subtype,2391,,,105,Expert
9,,1,,9606.0,1733,,,B,,,,Homo sapiens,,D,CHEMBL616938,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,4175,,,105,Expert
8,,1,,,1734,,,B,,,,,,H,CHEMBL616939,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,17085,,,105,Autocuration
8,,1,,,1735,,,B,,,,,,H,CHEMBL616940,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,17085,,,105,Expert
9,,1,,9606.0,1736,,,B,,,,Homo sapiens,,D,CHEMBL616941,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,15926,,,105,Expert
8,,1,485.0,,1737,,,B,,,,,CHO-K1,H,CHEMBL616942,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,16312,,,105,Autocuration
8,,1,485.0,,1738,,,B,,,,,CHO-K1,H,CHEMBL616943,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,16312,,,105,Autocuration
4,,1,449.0,,1739,,,B,,,,,CHO,H,CHEMBL616944,BAO_0000219,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,14956,,,104802,Autocuration
8,,1,,,1740,,,F,,,,,,H,CHEMBL616945,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",3294,,,105,Autocuration
8,,1,,,1741,,,B,,,,,,H,CHEMBL616946,BAO_0000357,Binding activity radioligand.,12861,,,105,Autocuration
8,,1,,,1742,,,B,,,,,,H,CHEMBL616947,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,,,105,Autocuration
8,,1,485.0,,1743,,,B,,,,,CHO-K1,H,CHEMBL616948,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,16312,,,105,Expert
8,,1,,,1744,,,B,,,,,,H,CHEMBL616851,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,5104,,,105,Autocuration
8,,1,,,1745,,,B,,,,,,H,CHEMBL616852,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,5105,,,105,Autocuration
8,,1,,,1746,,,B,,,,,,H,CHEMBL616853,BAO_0000357,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,14499,,,105,Autocuration
9,,1,,9606.0,1747,,,B,,,,Homo sapiens,,D,CHEMBL616854,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor,15926,,,105,Expert
9,,1,449.0,9606.0,1748,,,B,,,,Homo sapiens,CHO,D,CHEMBL616855,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,4540,,,105,Expert
8,,1,449.0,,1749,,,B,,,,,CHO,H,CHEMBL616856,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,15779,,,105,Autocuration
8,,1,449.0,,1750,,,B,,,,,CHO,H,CHEMBL616857,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,,,105,Autocuration
8,,1,,,1751,,,B,,,,,,H,CHEMBL616858,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,6166,,,105,Autocuration
8,,1,449.0,,1752,,,B,,,,,CHO,H,CHEMBL616859,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,15779,,,105,Autocuration
8,,1,449.0,,1753,,,B,,,,,CHO,H,CHEMBL616860,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,15779,,,105,Autocuration
8,,1,722.0,,1754,,,B,,,,,HEK293,H,CHEMBL616861,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,17451,,,105,Autocuration
8,,1,722.0,,1755,,,B,,,,,HEK293,H,CHEMBL616541,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,17451,,,105,Autocuration
8,,1,722.0,,1756,,,B,,,,,HEK293,H,CHEMBL616542,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,17451,,,105,Autocuration
8,,1,449.0,,1757,,,B,,,,,CHO,H,CHEMBL616543,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,4199,,,105,Autocuration
9,,1,,9606.0,1758,,,B,,,,Homo sapiens,,D,CHEMBL616544,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,14875,,,105,Expert
8,,1,449.0,,1759,,,B,,,,,CHO,H,CHEMBL616545,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,15146,,,105,Autocuration
8,,1,,,1760,,,B,,,,,,H,CHEMBL616546,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,5213,,,105,Autocuration
8,,1,449.0,,1761,,,B,,,,,CHO,H,CHEMBL616547,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,14818,,,105,Autocuration
8,,1,449.0,,1762,,,B,,,,,CHO,H,CHEMBL616548,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",4829,,,105,Autocuration
8,,1,,,1763,,,F,,,,,,H,CHEMBL616549,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,14454,,,105,Expert
8,,1,,,1764,,,F,,,,,,H,CHEMBL616550,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,14454,,,105,Expert
8,,1,,,1765,,,B,,,,,,H,CHEMBL857066,BAO_0000357,Binding affinity against 5-HT2C receptor,5254,,,108,Autocuration
8,,1,,,1766,,,B,,,,,,H,CHEMBL616551,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,5254,,,108,Autocuration
8,,1,,,1767,,,B,,,,,,H,CHEMBL616552,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10639,,,10577,Autocuration
8,,1,,,1768,,,F,,,,,,H,CHEMBL832876,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10639,,,10577,Autocuration
8,,1,,,1769,,,B,,,,,,H,CHEMBL616553,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",12352,,,10577,Expert
8,,1,,,1770,,,B,,,,,,H,CHEMBL616554,BAO_0000357,Binding affinity towards 5-HT1B was determined,9098,,,10577,Autocuration
8,,1,,,1771,,,B,,,,,,H,CHEMBL616555,BAO_0000019,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,14430,,,10577,Expert
8,,1,,,1772,,,B,,,,,,H,CHEMBL616556,BAO_0000019,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",13657,,,10577,Expert
8,,1,,,1773,,,B,,,,,,H,CHEMBL616557,BAO_0000019,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",13657,,,10577,Autocuration
8,,1,,,1774,,,B,,,,,,H,CHEMBL616558,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,,,10577,Expert
9,,1,,10116.0,1775,,,B,,,,Rattus norvegicus,,D,CHEMBL616749,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10639,,,10577,Expert
8,,1,,,1776,,,B,,,,,,H,CHEMBL616750,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10025,,,10577,Autocuration
8,,1,,,1777,,,B,,,,,,H,CHEMBL616751,BAO_0000357,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10025,,,10577,Autocuration
8,,1,,,1778,,,B,,,,,,H,CHEMBL616752,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,14286,,,10577,Autocuration
8,,1,,,1779,,,B,2435.0,,,,,H,CHEMBL616753,BAO_0000019,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,3651,,Striatum,10577,Autocuration
9,,1,,10116.0,1780,,,B,,,,Rattus norvegicus,,D,CHEMBL616754,BAO_0000357,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,14178,,,10577,Expert
8,,1,,,1781,,,B,,,,,,H,CHEMBL616755,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10639,,,10577,Autocuration
8,,1,,,1782,,,B,2435.0,,,,,H,CHEMBL616756,BAO_0000019,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,13605,,Striatum,10577,Autocuration
8,,1,,,1783,,,B,2435.0,,,,,H,CHEMBL616757,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,5834,,Striatum,10577,Autocuration
8,,1,,,1784,,,B,2435.0,,,,,H,CHEMBL616758,BAO_0000357,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10922,,Striatum,10577,Autocuration
8,,1,,,1785,,,B,,,,,,H,CHEMBL616759,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,14286,,,10577,Autocuration
8,,1,,,1786,,,B,,,,,,H,CHEMBL616760,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,11825,,,10577,Autocuration
8,,1,,,1787,,,B,2435.0,,,,,H,CHEMBL616761,BAO_0000019,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,14826,,Striatum,10577,Autocuration
8,,1,,,1788,,,B,2435.0,,,,,H,CHEMBL616762,BAO_0000019,Binding affinity against 5-HT1B serotonin receptor in rat striatum,9699,,Striatum,10577,Autocuration
8,,1,,,1789,,,B,,,,,,H,CHEMBL616763,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,14423,,,10577,Autocuration
8,,1,,,1790,,,B,,,,,,H,CHEMBL872909,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10062,,,10577,Expert
8,,1,,,1791,,,B,,,,,,H,CHEMBL616764,BAO_0000357,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10062,,,10577,Autocuration
9,,1,,10116.0,1792,,,B,,,,Rattus norvegicus,,D,CHEMBL616765,BAO_0000357,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,12280,,,10577,Expert
8,,1,,,1793,,,B,2435.0,,,,,H,CHEMBL616766,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,15412,,Striatum,10577,Autocuration
8,,1,,,1794,,,B,2435.0,,,,,H,CHEMBL616767,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,15412,,Striatum,10577,Autocuration
8,,1,,,1795,,,B,,,,,,H,CHEMBL616768,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10062,,,10577,Autocuration
8,,1,,,1796,,,B,,,,,,H,CHEMBL616769,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,11147,,,10577,Autocuration
8,,1,,,1797,,,B,,,,,,H,CHEMBL616770,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,9547,,,10577,Autocuration
8,,1,,,1798,,,B,,,,,,H,CHEMBL616771,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10444,,,10577,Autocuration
8,,1,,,1799,,,B,2435.0,,,,,H,CHEMBL616772,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,12469,,Striatum,10577,Autocuration
8,,1,,,1800,,,B,,,,,,H,CHEMBL616773,BAO_0000019,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,9098,,,10577,Expert
8,,1,,,1801,,,B,,,,,,H,CHEMBL616774,BAO_0000019,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,9098,,,10577,Autocuration
8,,1,,,1802,,,B,,,,,,H,CHEMBL616775,BAO_0000357,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,9699,,,10577,Autocuration
8,,1,,,1803,,,B,,,,,,H,CHEMBL616776,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10394,,,10577,Autocuration
8,,1,,,1804,,,B,,,,,,H,CHEMBL616777,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,12092,,,10577,Autocuration
8,,1,,,1805,,,B,,,,,,H,CHEMBL616778,BAO_0000357,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,16700,,,10577,Autocuration
9,,1,,10116.0,1806,,,B,,,,Rattus norvegicus,,D,CHEMBL616779,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,403,,,10577,Expert
9,,1,,10116.0,1807,,,B,,,,Rattus norvegicus,,D,CHEMBL616780,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,12771,,,10577,Expert
8,,1,,,1808,,,B,,,,,,H,CHEMBL616781,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,11642,,,10577,Autocuration
8,,1,,,1809,,,B,,,,,,H,CHEMBL616782,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,12953,,,10577,Autocuration
8,,1,,,1810,,,B,,,,,,H,CHEMBL616783,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,12953,,,10577,Autocuration
8,,1,,,1811,,,B,2435.0,,,,,H,CHEMBL616784,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,12953,,Striatum,10577,Expert
8,,1,,,1812,,,B,,,,,,H,CHEMBL616785,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,12953,,,10577,Autocuration
8,,1,,,1813,,,B,955.0,,,,,H,CHEMBL857067,BAO_0000249,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,,Brain,10577,Autocuration
8,,1,,,1814,,,B,,,,,,H,CHEMBL616786,BAO_0000019,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,9737,,,10577,Autocuration
8,,1,,,1815,,,B,955.0,,,,,H,CHEMBL616787,BAO_0000249,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,,Brain,10577,Autocuration
8,,1,,,1816,,,B,,,,,,H,CHEMBL616788,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,12827,,,10577,Autocuration
8,,1,,,1817,,,B,,,,,,H,CHEMBL616789,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,5033,,,10577,Autocuration
9,,1,,10116.0,1818,,,B,,,,Rattus norvegicus,,D,CHEMBL616790,BAO_0000019,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,9786,,,10577,Expert
8,,1,,,1819,,,B,,,,,,H,CHEMBL616791,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1B receptor,13116,,,10577,Expert
8,,1,,,1820,,,B,,,,,,H,CHEMBL616792,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,16429,,,10577,Autocuration
9,,1,,10116.0,1821,,,B,,,,Rattus norvegicus,,D,CHEMBL616793,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,12409,,,10577,Expert
8,,1,,,1822,,,B,,,,,,H,CHEMBL616794,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,15194,,,10577,Autocuration
8,,1,,,1823,,,B,,,,,,H,CHEMBL616795,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,15194,,,10577,Autocuration
4,,1,,,1824,,,B,,,,,,H,CHEMBL616796,BAO_0000019,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,5486,,,104686,Autocuration
8,,1,,,1825,,,B,,,,,,H,CHEMBL616797,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,4639,,,106,Autocuration
8,,1,,,1826,,,B,,,,,,H,CHEMBL616798,BAO_0000249,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,386,Brain membranes,,106,Autocuration
8,,1,,,1827,,,B,,,,,,H,CHEMBL616799,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,2474,,,106,Autocuration
8,,1,,,1828,,,B,,,,,,H,CHEMBL616800,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,6011,,,106,Autocuration
8,,1,,,1829,,,B,,,,,,H,CHEMBL616801,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,5014,,,106,Autocuration
8,,1,,,1830,,,B,,,,,,H,CHEMBL616802,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,17515,,,106,Autocuration
8,,1,,,1831,,,B,,,,,,H,CHEMBL616803,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,4373,,,106,Autocuration
8,,1,,,1832,,,B,,,,,,H,CHEMBL857068,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1633,,,106,Expert
8,,1,,,1833,,,B,,,,,,H,CHEMBL616804,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1633,,,106,Autocuration
8,,1,,,1834,,,B,,,,,,H,CHEMBL616805,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,4373,,,106,Autocuration
8,,1,,,1835,,,B,,,,,,H,CHEMBL616806,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,4687,,,106,Autocuration
8,,1,,,1836,,,B,,,,,,H,CHEMBL616807,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,11574,,,106,Autocuration
8,,1,,,1837,,,B,,,,,,H,CHEMBL616808,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,10321,,,106,Autocuration
8,,1,,,1838,,,B,,,,,,H,CHEMBL616809,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,15527,,,106,Autocuration
8,,1,,,1839,,,B,,,,,,H,CHEMBL616810,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,17200,,,106,Autocuration
4,,1,,,1840,,,B,,,,,,H,CHEMBL616811,BAO_0000224,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,14423,,,104802,Autocuration
8,,1,,9913.0,1841,,,B,,,,Bos taurus,,H,CHEMBL616812,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,5834,,,108,Autocuration
8,,1,,9823.0,1842,,,B,,,,Sus scrofa,,H,CHEMBL616813,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,11473,,,108,Autocuration
8,,1,,9823.0,1843,,,B,,,,Sus scrofa,,H,CHEMBL616814,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,11473,,,108,Autocuration
8,,1,,9823.0,1844,,,B,,,,Sus scrofa,,H,CHEMBL616815,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,10639,,,108,Autocuration
8,,1,,9823.0,1845,,,B,,,,Sus scrofa,,H,CHEMBL616816,BAO_0000357,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,10639,,,108,Autocuration
8,,1,,9823.0,1846,,,B,,,,Sus scrofa,,H,CHEMBL616817,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,14331,,,108,Autocuration
8,,1,,9823.0,1847,,,B,,,,Sus scrofa,,H,CHEMBL616818,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,10796,,,108,Autocuration
8,,1,,9823.0,1848,,,B,,,,Sus scrofa,,H,CHEMBL616819,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,9098,,,108,Expert
8,,1,,9823.0,1849,,,B,,,,Sus scrofa,,H,CHEMBL616820,BAO_0000357,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,14331,,,108,Expert
8,,1,,9823.0,1850,,,B,,,,Sus scrofa,,H,CHEMBL616821,BAO_0000019,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,11828,,,108,Expert
8,,1,,9823.0,1851,,,B,,,,Sus scrofa,,H,CHEMBL616822,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,11866,,,108,Autocuration
8,,1,,9986.0,1852,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616823,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,13047,,,108,Autocuration
9,,1,,10116.0,1853,,,B,,,,Rattus norvegicus,,D,CHEMBL616824,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,188,,,12689,Autocuration
9,,1,,10116.0,1854,,,B,,,,Rattus norvegicus,,D,CHEMBL616825,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,11825,,,12689,Autocuration
9,,1,,10116.0,1855,,,B,,,,Rattus norvegicus,,D,CHEMBL616826,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,11825,,,12689,Autocuration
9,,1,,10116.0,1856,,,B,,,,Rattus norvegicus,,D,CHEMBL616827,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,11624,,,12689,Expert
9,,1,,10116.0,1857,,,B,,,,Rattus norvegicus,,D,CHEMBL616828,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,11139,,,12689,Autocuration
9,,1,,10116.0,1858,,,B,,,,Rattus norvegicus,,D,CHEMBL616829,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,11147,,,12689,Autocuration
9,,1,,10116.0,1859,,,B,,,,Rattus norvegicus,,D,CHEMBL616830,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,10444,,,12689,Autocuration
9,,1,,10116.0,1860,,,B,,,,Rattus norvegicus,,D,CHEMBL616831,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,11624,,,12689,Expert
9,,1,,10116.0,1861,,,B,,,,Rattus norvegicus,,D,CHEMBL616832,BAO_0000019,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,,,12689,Autocuration
9,,1,,10116.0,1862,,,B,,,,Rattus norvegicus,,D,CHEMBL616833,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,,,12689,Autocuration
9,,1,,10116.0,1863,,,B,,,,Rattus norvegicus,,D,CHEMBL616834,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,,,12689,Expert
9,,1,,10116.0,1864,,,B,,,,Rattus norvegicus,,D,CHEMBL829595,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,,,12689,Autocuration
9,,1,,10116.0,1865,,,B,,,,Rattus norvegicus,,D,CHEMBL616835,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,9098,,,12689,Autocuration
9,,1,,10116.0,1866,,,B,,,,Rattus norvegicus,,D,CHEMBL872910,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,10394,,,12689,Autocuration
8,,1,,,1867,,,B,,,,,,H,CHEMBL616836,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,11933,,,12689,Expert
9,,1,,10116.0,1868,,,B,,,,Rattus norvegicus,,D,CHEMBL616837,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12092,,,12689,Autocuration
9,,1,,10116.0,1869,,,B,,,,Rattus norvegicus,,D,CHEMBL616466,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12253,,,12689,Autocuration
9,,1,722.0,10116.0,1870,,,B,,,,Rattus norvegicus,HEK293,D,CHEMBL616467,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12253,,,12689,Autocuration
8,,1,,,1871,,,B,,,,,,H,CHEMBL616468,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1558,,,108,Autocuration
8,,1,,,1872,,,B,,,,,,H,CHEMBL616469,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,2474,,,108,Autocuration
8,,1,,,1873,,,B,,,,,,H,CHEMBL616470,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,2474,,,108,Autocuration
8,,1,,,1874,,,B,,,,,,H,CHEMBL616471,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,11574,,,12689,Autocuration
8,,1,,,1875,,,B,,,,,,H,CHEMBL616472,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1558,,,12689,Autocuration
8,,1,,,1876,,,B,,,,,,H,CHEMBL616473,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,13944,,,12689,Autocuration
8,,1,,,1877,,,B,,,,,,H,CHEMBL616474,BAO_0000357,Binding affinity against serotonergic 5-HT1c receptor,13033,,,12689,Autocuration
8,,1,,,1878,,,B,,,,,,H,CHEMBL616475,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,10321,,,12689,Autocuration
8,,1,,,1879,,,B,,,,,,H,CHEMBL616476,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,11866,,,12689,Autocuration
8,,1,,9986.0,1880,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616477,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,,,105,Autocuration
4,,1,,,1881,,,B,,,,,,H,CHEMBL616478,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,11574,,,104686,Autocuration
4,,1,,,1882,,,B,,,,,,H,CHEMBL616479,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,11574,,,104686,Autocuration
4,,1,,,1883,,,B,,,,,,H,CHEMBL616480,BAO_0000019,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,13631,,,104686,Autocuration
5,,1,,10116.0,1884,,,B,,,,Rattus norvegicus,,D,CHEMBL616481,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,9630,,,104686,Autocuration
5,,1,,10116.0,1885,,,B,,,,Rattus norvegicus,,D,CHEMBL616482,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,8822,,,104686,Autocuration
5,,1,,10116.0,1886,,,B,955.0,,,Rattus norvegicus,,D,CHEMBL884713,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,9064,,Brain,104686,Autocuration
4,,1,,,1887,,,B,,,,,,H,CHEMBL616483,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,8868,,,104686,Autocuration
4,,1,,,1888,,,B,,,,,,H,CHEMBL616484,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,9064,,,104686,Autocuration
4,,1,,,1889,,,B,,,,,,H,CHEMBL616485,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,9806,,,104686,Autocuration
4,,1,,,1890,,,B,,,,,,H,CHEMBL616486,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,9098,,,104686,Autocuration
4,,1,,,1891,,,B,,,,,,H,CHEMBL616487,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,8868,,,104686,Autocuration
4,,1,,,1892,,,B,,,,,,H,CHEMBL616488,BAO_0000224,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,12765,,,104686,Autocuration
4,,1,,,1893,,,B,,,,,,H,CHEMBL616489,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,,,104686,Autocuration
4,,1,,,1894,,,B,,,,,,H,CHEMBL616490,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,,,104686,Autocuration
4,,1,,,1895,,,B,,,,,,H,CHEMBL616491,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,11049,,,104686,Autocuration
4,,1,,,1896,,,B,,,,,,H,CHEMBL616492,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,11049,,,104686,Autocuration
4,,1,,,1897,,,B,,,,,,H,CHEMBL616493,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,,,104686,Autocuration
4,,1,,,1898,,,B,,,,,,H,CHEMBL616494,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,11473,,,104686,Autocuration
4,,1,,,1899,,,B,,,,,,H,CHEMBL616495,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,11473,,,104686,Autocuration
4,,1,,,1900,,,B,,,,,,H,CHEMBL616496,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,3086,,,104686,Autocuration
4,,1,,,1901,,,B,,,,,,H,CHEMBL616497,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,,,104686,Autocuration
4,,1,,,1902,,,B,,,,,,H,CHEMBL616498,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,,,104686,Autocuration
4,,1,,,1903,,,B,,,,,,H,CHEMBL616499,BAO_0000019,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,10639,,,104686,Autocuration
4,,1,,,1904,,,B,,,,,,H,CHEMBL616500,BAO_0000019,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,10922,,,104686,Autocuration
5,,1,,10116.0,1905,,,B,955.0,,,Rattus norvegicus,,D,CHEMBL616501,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,9064,,Brain,104686,Autocuration
4,,1,,,1906,,,B,955.0,,,,,H,CHEMBL616502,BAO_0000221,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,10748,,Brain,104686,Autocuration
4,,1,,,1907,,,B,,,,,,H,CHEMBL884529,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,11614,Membranes,,104686,Autocuration
4,,1,,,1908,,,B,,,,,,H,CHEMBL616503,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,11615,Membranes,,104686,Autocuration
4,,1,,,1909,,,B,,,,,,H,CHEMBL616964,BAO_0000224,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,11615,,,104686,Autocuration
4,,1,,,1910,,,B,,,,,,H,CHEMBL616965,BAO_0000249,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,11614,Membranes,,104686,Autocuration
4,,1,,,1911,,,B,,,,,,H,CHEMBL616966,BAO_0000224,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,11702,,,104686,Autocuration
4,,1,,,1912,,,B,,,,,,H,CHEMBL616967,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,,,104686,Autocuration
5,,1,,10116.0,1913,,,B,,,,Rattus norvegicus,,D,CHEMBL616968,BAO_0000224,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,11702,,,104686,Autocuration
4,,1,,,1914,,,B,,,,,,H,CHEMBL616969,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,,,104686,Autocuration
4,,1,,,1915,,,B,,,,,,H,CHEMBL884530,BAO_0000019,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,13346,,,104686,Autocuration
4,,1,,,1916,,,B,,,,,,H,CHEMBL616970,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,10025,,,104686,Autocuration
4,,1,,,1917,,,B,,,,,,H,CHEMBL616971,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,10025,,,104686,Autocuration
4,,1,,,1918,,,B,,,,,,H,CHEMBL616972,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",10025,,,104686,Autocuration
4,,1,,,1919,,,B,,,,,,H,CHEMBL616973,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,9036,,,104686,Autocuration
4,,1,,,1920,,,B,,,,,,H,CHEMBL616974,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,9036,,,104686,Autocuration
4,,1,,,1921,,,B,,,,,,H,CHEMBL616975,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,9161,,,104686,Autocuration
4,,1,,,1922,,,B,,,,,,H,CHEMBL616976,BAO_0000019,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,12304,,,104686,Autocuration
4,,1,,,1923,,,B,,,,,,H,CHEMBL616977,BAO_0000224,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,13276,,,104686,Autocuration
4,,1,,,1924,,,B,,,,,,H,CHEMBL616978,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,11825,,,104686,Autocuration
4,,1,,,1925,,,B,,,,,,H,CHEMBL616979,BAO_0000224,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,12443,,,104686,Autocuration
4,,1,,,1926,,,B,,,,,,H,CHEMBL616980,BAO_0000224,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,13830,,,104686,Autocuration
4,,1,,,1927,,,B,,,,,,H,CHEMBL616981,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,9592,Membranes,,104686,Autocuration
4,,1,,,1928,,,B,,,,,,H,CHEMBL616982,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,9592,Membranes,,104686,Autocuration
4,,1,,,1929,,,B,,,,,,H,CHEMBL616983,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,10881,,,104686,Autocuration
4,,1,,,1930,,,B,,,,,,H,CHEMBL616984,BAO_0000019,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,13605,,,104686,Autocuration
5,,1,,10116.0,1931,,,B,,,,Rattus norvegicus,,D,CHEMBL616985,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor,11624,,,104686,Autocuration
4,,1,,,1932,,,B,,,,,,H,CHEMBL616986,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4101,,,104686,Autocuration
4,,1,,,1933,,,B,,,,,,H,CHEMBL616987,BAO_0000224,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4101,,,104686,Autocuration
4,,1,,,1934,,,B,,,,,,H,CHEMBL616988,BAO_0000019,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,15360,,,104686,Autocuration
4,,1,,,1935,,,B,,,,,,H,CHEMBL617243,BAO_0000019,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,11576,,,104686,Autocuration
4,,1,,,1936,,,B,,,,,,H,CHEMBL617244,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,5834,,,104686,Autocuration
5,,1,485.0,10116.0,1937,,,B,,,,Rattus norvegicus,CHO-K1,D,CHEMBL617245,BAO_0000219,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,,,104686,Autocuration
4,,1,,,1938,,,B,,,,,,H,CHEMBL617246,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,11965,Membranes,,104686,Autocuration
4,,1,,,1939,,,B,,,,,,H,CHEMBL617546,BAO_0000224,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),3967,,,104686,Autocuration
4,,1,,,1940,,,B,,,,,,H,CHEMBL617547,BAO_0000249,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),11130,Brain membranes,,104686,Autocuration
4,,1,,,1941,,In vitro,B,,,,,,H,CHEMBL617548,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,,,104686,Autocuration
4,,1,,,1942,,,B,,,,,,H,CHEMBL617549,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,9443,,,104686,Autocuration
4,,1,,,1943,,,B,,,,,,H,CHEMBL617550,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,9443,,,104686,Autocuration
4,,1,,,1944,,,B,,,,,,H,CHEMBL617551,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,11825,,,104686,Autocuration
4,,1,,,1945,,,B,,,,,,H,CHEMBL617552,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,12120,Membranes,,104686,Autocuration
4,,1,,,1946,,,B,,,,,,H,CHEMBL617553,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,12120,Membranes,,104686,Autocuration
4,,1,,,1947,,,F,1515.0,,,,,H,CHEMBL617554,BAO_0000019,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,11963,,Thoracic aorta,104686,Autocuration
4,,1,,,1948,,,B,,,,,,H,CHEMBL617555,BAO_0000019,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,9069,,,104686,Autocuration
4,,1,,,1949,,,B,,,,,,H,CHEMBL617556,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,8868,,,104686,Autocuration
8,,1,,,1950,,,B,,,,,,H,CHEMBL617557,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,17200,,,10624,Autocuration
8,,1,,,1951,,,B,,,,,,H,CHEMBL617558,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,17200,,,10624,Autocuration
8,,1,,,1952,,,B,,,,,,H,CHEMBL617559,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,13969,,,17106,Expert
9,,1,,,1953,,,B,,,,,,D,CHEMBL617560,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor,13392,,,17106,Expert
8,,1,,,1954,,,B,,,,,,H,CHEMBL617561,BAO_0000249,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1742,,,17106,Autocuration
8,,1,,,1955,,,B,,,,,,H,CHEMBL617562,BAO_0000249,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1742,,,17106,Autocuration
8,,1,,,1956,,,B,2435.0,,,,,H,CHEMBL617563,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,14331,,Striatum,17106,Autocuration
8,,1,,,1957,,,F,,,,,,H,CHEMBL617564,BAO_0000019,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,12861,,,17106,Autocuration
8,,1,,,1958,,,B,,,,,,H,CHEMBL617565,BAO_0000019,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,12861,,,17106,Expert
8,,1,,,1959,,,B,,,,,,H,CHEMBL856076,BAO_0000357,Binding activity radioligand.,12861,,,17106,Autocuration
8,,1,,,1960,,,B,,,,,,H,CHEMBL617566,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,,,17106,Autocuration
8,,1,,,1961,,,B,,,,,,H,CHEMBL875911,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,,,17106,Expert
8,,1,,,1962,,,B,,,,,,H,CHEMBL617567,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,12861,,,17106,Autocuration
8,,1,,,1963,,,B,,,,,,H,CHEMBL617568,BAO_0000249,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,675,,,17106,Autocuration
8,,1,,,1964,,,B,,,,,,H,CHEMBL617569,BAO_0000019,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,12490,,,17106,Expert
8,,1,,,1965,,,B,,,,,,H,CHEMBL617570,BAO_0000249,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,11828,,,17106,Expert
8,,1,,,1966,,,B,,,,,,H,CHEMBL617571,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,11866,,,17106,Autocuration
8,,1,,9823.0,1967,,,B,,,,Sus scrofa,,H,CHEMBL617572,BAO_0000357,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,773,,,105,Autocuration
8,,1,,9986.0,1968,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617573,BAO_0000357,The compound was tested for intrinsic activity against 5-HT1D receptor,13047,,,105,Expert
8,,1,,9986.0,1969,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617574,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,,,105,Autocuration
8,,1,,9986.0,1970,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617575,BAO_0000357,The compound was tested for binding affinity against 5-HT1D receptor,13047,,,105,Expert
8,,1,,,1971,,,B,,,,,,H,CHEMBL617576,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,188,,,10578,Autocuration
8,,1,,,1972,,,F,,,,,,H,CHEMBL617577,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10639,,,10578,Autocuration
8,,1,,,1973,,,F,,,,,,H,CHEMBL617578,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,12438,,,10578,Autocuration
8,,1,,,1974,,,B,,,,,,H,CHEMBL617579,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,12438,,,10578,Autocuration
8,,1,,,1975,,,B,,,,,,H,CHEMBL617580,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,,,10578,Expert
8,,1,,,1976,,,B,,,,,,H,CHEMBL617581,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10394,,,10578,Autocuration
8,,1,,,1977,,,B,,,,,,H,CHEMBL617582,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,12092,,,10578,Autocuration
8,,1,,,1978,,,B,,,,,,H,CHEMBL617583,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,3389,,,10578,Expert
8,,1,,,1979,,,B,,,,,,H,CHEMBL617584,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,6011,,,105,Autocuration
8,,1,,,1980,,,B,,,,,,H,CHEMBL617585,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,4639,,,105,Autocuration
8,,1,,,1981,,,B,,,,,,H,CHEMBL875912,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,2474,,,105,Autocuration
8,,1,,,1982,,,B,,,,,,H,CHEMBL617586,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,5014,,,105,Autocuration
8,,1,,,1983,,,B,,,,,,H,CHEMBL617587,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,17515,,,105,Autocuration
8,,1,,,1984,,,B,,,,,,H,CHEMBL617588,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,11866,,,105,Autocuration
8,,1,,,1985,,,B,,,,,,H,CHEMBL857980,BAO_0000357,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,4687,,,105,Autocuration
8,,1,,,1986,,,B,,,,,,H,CHEMBL617589,BAO_0000357,Tested against 5-hydroxytryptamine 1D receptor,12146,,,105,Autocuration
8,,1,,,1987,,,B,,,,,,H,CHEMBL617590,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,10321,,,105,Autocuration
8,,1,722.0,,1988,,,B,,,,,HEK293,H,CHEMBL617591,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,13267,,,105,Autocuration
9,,1,,9606.0,1989,,,B,,,,Homo sapiens,,D,CHEMBL617592,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 1D receptor,1274,,,105,Expert
8,,1,,,1990,,,B,,,,,,H,CHEMBL617593,BAO_0000357,,15250,,,105,Autocuration
8,,1,485.0,,1991,,,B,,,,,CHO-K1,H,CHEMBL617594,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,,,106,Autocuration
8,,1,485.0,,1992,,,B,,,,,CHO-K1,H,CHEMBL617595,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,,,105,Autocuration
8,,1,722.0,,1993,,,B,,,,,HEK293,H,CHEMBL617596,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,13706,,,105,Autocuration
8,,1,722.0,,1994,,,B,,,,,HEK293,H,CHEMBL617597,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,13706,,,105,Autocuration
8,,1,,,1995,,,B,,,,,,H,CHEMBL617598,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,13047,,,105,Autocuration
8,,1,,,1996,,,B,,,,,,H,CHEMBL872916,BAO_0000357,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,13366,,,105,Autocuration
8,,1,,,1997,,,B,,,,,,H,CHEMBL617599,BAO_0000357,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,13366,,,105,Expert
8,,1,,,1998,,,B,,,,,,H,CHEMBL617091,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1558,,,105,Autocuration
8,,1,485.0,,1999,,,B,,,,,CHO-K1,H,CHEMBL617092,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",12902,,,105,Expert
8,,1,485.0,,2000,,,B,,,,,CHO-K1,H,CHEMBL617093,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,,,105,Autocuration
8,,1,,,2001,,,F,,,,,,H,CHEMBL617094,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,13706,,,105,Autocuration
8,,1,,,2002,,,F,,,,,,H,CHEMBL617095,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,,,105,Autocuration
8,,1,,,2003,,,F,,,,,,H,CHEMBL617096,BAO_0000019,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,,,105,Autocuration
8,,1,,,2004,,,F,,,,,,H,CHEMBL617097,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,,,105,Autocuration
8,,1,,,2005,,,F,,,,,,H,CHEMBL617098,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,,,105,Autocuration
8,,1,,,2006,,,B,,,,,,H,CHEMBL617301,BAO_0000357,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,13313,,,105,Autocuration
8,,1,,,2007,,,B,,,,,,H,CHEMBL617302,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,13313,,,105,Autocuration
8,,1,,,2008,,,B,,,,,,H,CHEMBL617303,BAO_0000357,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,13366,,,105,Autocuration
8,,1,,,2009,,,B,,,,,,H,CHEMBL617304,BAO_0000357,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,13051,,,105,Expert
8,,1,449.0,,2010,,,B,,,,,CHO,H,CHEMBL617305,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",12903,,,105,Expert
9,,1,,9606.0,2011,,,B,,,,Homo sapiens,,D,CHEMBL617306,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,12469,,,105,Autocuration
8,,1,,,2012,,,B,,,,,,H,CHEMBL617307,BAO_0000357,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,5619,,,17106,Autocuration
8,,1,,9986.0,2013,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617308,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,13047,,,105,Autocuration
8,,1,,,2014,,,B,,,,,,H,CHEMBL617309,BAO_0000357,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,16633,,,105,Autocuration
8,,1,,,2015,,,B,,,,,,H,CHEMBL617310,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,16633,,,105,Autocuration
8,,1,,,2016,,,B,,,,,,H,CHEMBL617311,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,16633,,,105,Autocuration
8,,1,,,2017,,,B,,,,,,H,CHEMBL617312,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,16633,,,105,Autocuration
8,,1,,,2018,,,B,,,,,,H,CHEMBL617313,BAO_0000357,Affinity against 5-hydroxytryptamine 1D receptor alpha,3269,,,105,Autocuration
8,,1,,,2019,,,B,,,,,,H,CHEMBL617314,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,12409,,,105,Expert
8,,1,,,2020,,,F,,,,,,H,CHEMBL617315,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,,,106,Autocuration
8,,1,722.0,,2021,,,B,,,,,HEK293,H,CHEMBL617316,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,13706,,,106,Autocuration
8,,1,722.0,,2022,,,B,,,,,HEK293,H,CHEMBL617317,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,13706,,,106,Autocuration
8,,1,449.0,,2023,,,B,,,,,CHO,H,CHEMBL617318,BAO_0000219,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",12903,,,106,Autocuration
8,,1,,,2024,,,B,,,,,,H,CHEMBL617319,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,13047,,,106,Autocuration
9,,1,,,2025,,,B,,,,,,D,CHEMBL617320,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,,,106,Expert
9,,1,,,2026,,,B,,,,,,D,CHEMBL617321,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,,,106,Expert
9,,1,,,2027,,,B,,,,,,D,CHEMBL617322,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,,,106,Expert
8,,1,,,2028,,,B,,,,,,H,CHEMBL616862,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,13366,,,106,Autocuration
8,,1,,,2029,,,B,,,,,,H,CHEMBL616863,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,13366,,,106,Autocuration
8,,1,449.0,,2030,,,B,,,,,CHO,H,CHEMBL616864,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,12469,,,106,Autocuration
8,,1,485.0,,2031,,,B,,,,,CHO-K1,H,CHEMBL616865,BAO_0000219,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,13706,,,106,Autocuration
8,,1,485.0,,2032,,,B,,,,,CHO-K1,H,CHEMBL616866,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,13706,,,106,Autocuration
8,,1,,,2033,,,F,,,,,,H,CHEMBL616867,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,,,106,Autocuration
8,,1,485.0,,2034,,,B,,,,,CHO-K1,H,CHEMBL616868,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",12902,,,106,Expert
8,,1,,,2035,,,B,,,,,,H,CHEMBL616869,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,13051,,,105,Expert
8,,1,449.0,,2036,,,B,,,,,CHO,H,CHEMBL616870,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",12903,,,106,Expert
8,,1,485.0,,2037,,,F,,,,,CHO-K1,H,CHEMBL616871,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1558,,,105,Autocuration
8,,1,485.0,,2038,,,F,,,,,CHO-K1,H,CHEMBL616872,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1558,,,105,Autocuration
8,,1,485.0,,2039,,,F,,,,,CHO-K1,H,CHEMBL616873,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1558,,,105,Autocuration
8,,1,485.0,,2040,,,F,,,,,CHO-K1,H,CHEMBL616838,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1558,,,105,Autocuration
8,,1,,,2041,,,B,,,,,,H,CHEMBL616839,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1558,,,105,Autocuration
8,,1,,9986.0,2042,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL616840,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,13047,,,106,Autocuration
8,,1,,,2043,,,B,,,,,,H,CHEMBL616841,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,13313,,,105,Autocuration
8,,1,,,2044,,,B,,,,,,H,CHEMBL616842,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,13313,,,105,Autocuration
8,,1,,,2045,,,B,,,,,,H,CHEMBL857976,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor beta,12409,,,105,Expert
8,,1,449.0,,2046,,,B,,,,,CHO,H,CHEMBL616843,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,15250,,,10618,Autocuration
9,,1,,9606.0,2047,,,B,,,,Homo sapiens,,D,CHEMBL616844,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1348,,,10618,Expert
8,,1,,,2048,,,B,,,,,,H,CHEMBL616845,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1348,,,10618,Autocuration
9,,1,,9606.0,2049,,,B,,,,Homo sapiens,,D,CHEMBL616846,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,4234,,,10618,Expert
8,,1,,,2050,,,B,,,,,,H,CHEMBL616847,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,16209,,,10618,Autocuration
8,,1,,,2051,,,B,,,,,,H,CHEMBL616848,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10444,,,10618,Autocuration
8,,1,,,2052,,,B,,,,,,H,CHEMBL616849,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,3935,,,10618,Autocuration
8,,1,,,2053,,,B,,,,,,H,CHEMBL872911,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,15818,,,10618,Autocuration
8,,1,,,2054,,,B,,,,,,H,CHEMBL616850,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,17085,,,10618,Autocuration
9,,1,449.0,9606.0,2055,,,B,,,,Homo sapiens,CHO,D,CHEMBL616699,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,12936,,,10618,Expert
8,,1,,,2056,,,B,,,,,,H,CHEMBL616700,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,6166,,,10618,Autocuration
8,,1,449.0,,2057,,,B,,,,,CHO,H,CHEMBL616701,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,,,10618,Autocuration
8,,1,449.0,,2058,,,B,,,,,CHO,H,CHEMBL616702,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,15779,,,10618,Autocuration
8,,1,449.0,,2059,,,B,,,,,CHO,H,CHEMBL616703,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,15779,,,10618,Autocuration
8,,1,,,2060,,,B,,,,,,H,CHEMBL616704,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,13181,,,10618,Autocuration
8,,1,449.0,,2061,,,B,,,,,CHO,H,CHEMBL616705,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,4199,,,10618,Autocuration
8,,1,,,2062,,,B,,,,,,H,CHEMBL616706,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,14875,,,10618,Autocuration
8,,1,449.0,,2063,,,B,,,,,CHO,H,CHEMBL616707,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,15146,,,10618,Autocuration
8,,1,,,2064,,,B,,,,,,H,CHEMBL616708,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,5213,,,10618,Autocuration
8,,1,,,2065,,,B,,,,,,H,CHEMBL616709,BAO_0000357,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,12146,,,10618,Autocuration
8,,1,449.0,,2066,,,B,,,,,CHO,H,CHEMBL616710,BAO_0000219,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,13267,,,10618,Autocuration
8,,1,449.0,,2067,,,B,,,,,CHO,H,CHEMBL616711,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,14818,,,10618,Autocuration
8,,1,449.0,,2068,,,B,,,,,CHO,H,CHEMBL616712,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",4829,,,10618,Autocuration
8,,1,,,2069,,,B,,,,,,H,CHEMBL616713,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,4373,,,10618,Autocuration
8,,1,,,2070,,,B,,,,,,H,CHEMBL616714,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,4373,,,10618,Autocuration
8,,1,,,2071,,,B,,,,,,H,CHEMBL616715,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,14159,,,10618,Autocuration
8,,1,,,2072,,,B,,,,,,H,CHEMBL616716,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1E receptor,16633,,,10618,Autocuration
8,,1,,,2073,,,F,,,,,,H,CHEMBL616717,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",17085,,,279,Autocuration
8,,1,,,2074,,,F,,,,,,H,CHEMBL616718,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",17085,,,279,Expert
8,,1,,,2075,,,F,,,,,,H,CHEMBL875905,BAO_0000019,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,16209,,,279,Autocuration
8,,1,,,2076,,,F,,,,,,H,CHEMBL616719,BAO_0000019,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,16209,,,279,Autocuration
8,,1,,,2077,,,F,,,,,,H,CHEMBL616720,BAO_0000019,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",17085,,,279,Expert
8,,1,,,2078,,,B,,,,,,H,CHEMBL616721,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,14159,,,279,Autocuration
8,,1,449.0,,2079,,,B,,,,,CHO,H,CHEMBL616722,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,15250,,,279,Autocuration
8,,1,,,2080,,,B,,,,,,H,CHEMBL616723,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),3805,,,279,Autocuration
8,,1,449.0,,2081,,,B,,,,,CHO,H,CHEMBL616724,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,16190,,,279,Autocuration
8,,1,,,2082,,,B,,,,,,H,CHEMBL616725,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,16190,,,279,Autocuration
8,,1,,,2083,,,B,,,,,,H,CHEMBL616726,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor,16209,,,279,Autocuration
8,,1,,,2084,,,B,,,,,,H,CHEMBL616727,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,16209,,,279,Autocuration
8,,1,,,2085,,,B,,,,,,H,CHEMBL616728,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,16209,,,279,Autocuration
8,,1,,,2086,,,B,,,,,,H,CHEMBL616729,BAO_0000357,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,6866,,,279,Autocuration
8,,1,,,2087,,,B,,,,,,H,CHEMBL616730,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,17085,,,279,Expert
8,,1,,,2088,,,B,,,,,,H,CHEMBL617125,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,16312,,,279,Autocuration
8,,1,,,2089,,,B,,,,,,H,CHEMBL857977,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,6166,,,279,Autocuration
8,,1,449.0,,2090,,,B,,,,,CHO,H,CHEMBL617126,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,,,279,Autocuration
8,,1,449.0,,2091,,,B,,,,,CHO,H,CHEMBL617127,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,4199,,,279,Autocuration
8,,1,,,2092,,,B,,,,,,H,CHEMBL617128,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,14875,,,279,Autocuration
8,,1,449.0,,2093,,,B,,,,,CHO,H,CHEMBL617129,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,15146,,,279,Autocuration
8,,1,,,2094,,,B,,,,,,H,CHEMBL617130,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,5213,,,279,Autocuration
8,,1,449.0,,2095,,,B,,,,,CHO,H,CHEMBL617131,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,14818,,,279,Autocuration
8,,1,449.0,,2096,,,B,,,,,CHO,H,CHEMBL617132,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",4829,,,279,Autocuration
8,,1,449.0,,2097,,,B,,,,,CHO,H,CHEMBL617133,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",4829,,,279,Autocuration
8,,1,,,2098,,,B,,,,,,H,CHEMBL617134,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,4373,,,279,Autocuration
8,,1,,,2099,,,B,,,,,,H,CHEMBL617135,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,4373,,,279,Autocuration
8,,1,,,2100,,,B,,,,,,H,CHEMBL617136,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,5014,,,279,Autocuration
4,,1,,,2101,,,B,,,,,,H,CHEMBL617137,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",11662,,,104686,Autocuration
4,,1,,,2102,,,B,,,,,,H,CHEMBL617138,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",11662,,,104686,Autocuration
4,,1,,,2103,,,B,,,,,,H,CHEMBL617139,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,,,104686,Autocuration
8,,1,,,2104,,,B,,,,,,H,CHEMBL617140,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,14093,,,12687,Autocuration
4,,1,,,2105,,In vivo,F,,,,,,H,CHEMBL617141,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",11200,,,104686,Autocuration
4,,1,,,2106,,,F,,,,,,H,CHEMBL858112,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
8,,1,,,2107,,,B,,,,,,H,CHEMBL617142,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,12352,,,17005,Intermediate
0,,1,,9913.0,2108,,,B,,,,Bos taurus,,U,CHEMBL617143,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",13657,,,22226,Autocuration
0,,1,,9913.0,2109,,,B,,,,Bos taurus,,U,CHEMBL617144,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,14331,,,22226,Autocuration
0,,1,,9913.0,2110,,,B,,,,Bos taurus,,U,CHEMBL617145,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,14331,,,22226,Autocuration
0,,1,,,2111,,,B,,,,,,U,CHEMBL617146,BAO_0000019,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,14331,,,22226,Autocuration
4,,1,,10141.0,2112,,,B,,,,Cavia porcellus,,H,CHEMBL617147,BAO_0000019,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,12685,,,104784,Autocuration
4,,1,,10141.0,2113,,,B,,,,Cavia porcellus,,H,CHEMBL617148,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,14389,,,104784,Autocuration
4,,1,,10141.0,2114,,,B,,,,Cavia porcellus,,H,CHEMBL617149,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,14386,,,104784,Autocuration
4,,1,,,2115,,,B,,,,,,H,CHEMBL617150,BAO_0000224,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,5732,,,104784,Autocuration
4,,1,,,2116,,,B,,,,,,H,CHEMBL617151,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,16293,,,104784,Autocuration
4,,1,,,2117,,,B,,,,,,H,CHEMBL617201,BAO_0000224,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,2078,,,104784,Autocuration
8,,1,,,2118,,,B,,,,,,H,CHEMBL617202,BAO_0000357,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,5486,,,10209,Autocuration
4,,1,,,2119,,In vivo,B,,,,,,H,CHEMBL617203,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,11820,,,104826,Autocuration
4,,1,,,2120,,,B,,,,,,H,CHEMBL617204,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10297,,,104826,Autocuration
4,,1,,,2121,,,B,,,,,,H,CHEMBL617205,BAO_0000224,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,13704,,,104826,Autocuration
5,,1,,10090.0,2122,,,B,,,,Mus musculus,,D,CHEMBL617206,BAO_0000019,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,10297,,,104826,Autocuration
4,,1,,,2123,,In vivo,B,,,,,,H,CHEMBL617207,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,11820,,,104826,Autocuration
5,,1,,10090.0,2124,,,B,,,,Mus musculus,,D,CHEMBL617208,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,10297,,,104826,Autocuration
4,,1,,,2125,,,B,,,,,,H,CHEMBL617209,BAO_0000224,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,11555,,,104826,Autocuration
4,,1,,,2126,,,B,,,,,,H,CHEMBL617210,BAO_0000224,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,11555,,,104826,Autocuration
4,,1,,,2127,,,B,,,,,,H,CHEMBL617211,BAO_0000224,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,11555,,,104826,Autocuration
5,,1,,10090.0,2128,,,B,,,,Mus musculus,,D,CHEMBL617212,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10297,,,104826,Autocuration
4,,1,,9823.0,2129,,,B,,,,Sus scrofa,,H,CHEMBL617213,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,16688,,,104784,Autocuration
4,,1,,9823.0,2130,,,B,,,,Sus scrofa,,H,CHEMBL617214,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,16688,,,104784,Autocuration
0,,1,,,2131,,,B,,,,,,U,CHEMBL617215,BAO_0000221,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,5333,,,22226,Autocuration
0,,1,,,2132,,,B,,,,,,U,CHEMBL617216,BAO_0000221,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,4437,,,22226,Autocuration
8,,1,,9823.0,2133,,,B,,,,Sus scrofa,,H,CHEMBL617217,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,5033,,,17005,Autocuration
4,,1,,,2134,,,B,,,,,,H,CHEMBL617218,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,15267,,,104686,Autocuration
4,,1,,,2135,,,B,,,,,,H,CHEMBL872913,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,15267,,,104686,Autocuration
4,,1,,,2136,,,B,,,,,,H,CHEMBL617219,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,11820,,,104826,Autocuration
4,,1,,,2137,,,B,,,,,,H,CHEMBL873482,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,9069,,,104686,Autocuration
5,,1,,10116.0,2138,,,B,,,,Rattus norvegicus,,D,CHEMBL617220,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,9162,,,104686,Autocuration
4,,1,,,2139,,,B,,,,,,H,CHEMBL617221,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,9162,,,104686,Autocuration
4,,1,,,2140,,,B,,,,,,H,CHEMBL617222,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,9162,,,104686,Autocuration
4,,1,,,2141,,,F,,,,,,H,CHEMBL875906,BAO_0000019,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,10428,,,104686,Autocuration
4,,1,,,2142,,,B,,,,,,H,CHEMBL617223,BAO_0000019,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,9628,,,104686,Autocuration
4,,1,,,2143,,,B,,,,,,H,CHEMBL617224,BAO_0000224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,12704,,,104686,Autocuration
5,,1,,10116.0,2144,,,B,,,,Rattus norvegicus,,D,CHEMBL617225,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,15453,,,104686,Autocuration
4,,1,,,2145,,,B,,,,,,H,CHEMBL617226,BAO_0000224,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,188,,,104686,Autocuration
4,,1,,,2146,,,B,,,,,,H,CHEMBL617227,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,10349,,,104686,Autocuration
4,,1,,,2147,,,B,,,,,,H,CHEMBL617228,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,10349,,,104686,Autocuration
4,,1,,,2148,,,B,,,,,,H,CHEMBL617229,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,8868,,,104686,Autocuration
4,,1,,,2149,,,B,,,,,,H,CHEMBL617230,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,10025,,,104686,Autocuration
4,,1,,,2150,,,B,,,,,,H,CHEMBL617231,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",10025,,,104686,Autocuration
4,,1,,,2151,,,B,,,,,,H,CHEMBL617232,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,11702,,,104686,Autocuration
4,,1,,,2152,,,B,,,,,,H,CHEMBL617233,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,11702,,,104686,Autocuration
4,,1,,,2153,,,B,,,,,,H,CHEMBL617234,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,,,104686,Autocuration
4,,1,,,2154,,,F,,,,,,H,CHEMBL617235,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats,11702,,,104686,Autocuration
4,,1,,,2155,,,F,,,,,,H,CHEMBL617236,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,11702,,,104686,Autocuration
4,,1,,,2156,,,B,10000000.0,,,,,H,CHEMBL617237,BAO_0000221,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,10085,,Hippocampus,104686,Autocuration
4,,1,,,2157,,,B,10000000.0,,,,,H,CHEMBL617238,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,10085,,Hippocampus,104686,Autocuration
5,,1,,10116.0,2158,,,B,955.0,,,Rattus norvegicus,,D,CHEMBL617239,BAO_0000221,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,9630,,Brain,104686,Autocuration
4,,1,,,2159,,,B,,,,,,H,CHEMBL617240,BAO_0000019,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,11070,,,104686,Autocuration
4,,1,,,2160,,,B,,,,,,H,CHEMBL617241,BAO_0000249,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,9841,Membranes,,104686,Autocuration
4,,1,,,2161,,,B,,,,,,H,CHEMBL875907,BAO_0000249,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,9841,Membranes,,104686,Autocuration
4,,1,,,2162,,,B,,,,,,H,CHEMBL617242,BAO_0000019,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,13291,,,104686,Autocuration
4,,1,,,2163,,,F,,,,,,H,CHEMBL617152,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,10590,,,104686,Autocuration
5,,1,,10116.0,2164,,,B,955.0,,,Rattus norvegicus,,D,CHEMBL617153,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,9064,,Brain,104686,Autocuration
5,,1,,10116.0,2165,,,B,,,,Rattus norvegicus,,D,CHEMBL617154,BAO_0000249,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,12268,Membranes,,104686,Autocuration
4,,1,,,2166,,,B,955.0,,,,,H,CHEMBL617155,BAO_0000221,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,13508,,Brain,104686,Autocuration
4,,1,,,2167,,,F,,,,,,H,CHEMBL617156,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,11279,,,104686,Autocuration
4,,1,,,2168,,,F,,,,,,H,CHEMBL617157,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
4,,1,,,2169,,,F,,,,,,H,CHEMBL617158,BAO_0000019,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
4,,1,,,2170,,,F,,,,,,H,CHEMBL617159,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,11200,,,104686,Autocuration
4,,1,,,2171,,,F,,,,,,H,CHEMBL617160,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,11200,,,104686,Autocuration
4,,1,,,2172,,,F,,,,,,H,CHEMBL858113,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
4,,1,,,2173,,,B,955.0,,,,,H,CHEMBL617247,BAO_0000220,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,9231,,Brain,104686,Autocuration
4,,1,,,2174,,,B,,,,,,H,CHEMBL617248,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,9737,,,104686,Autocuration
4,,1,,,2175,,,B,955.0,,,,,H,CHEMBL617249,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,,Brain,104686,Autocuration
4,,1,,,2176,,,B,,,,,,H,CHEMBL617250,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,9737,,,104686,Autocuration
4,,1,,,2177,,,B,,,,,,H,CHEMBL617251,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,9737,,,104686,Autocuration
5,,1,,10116.0,2178,,,B,,,,Rattus norvegicus,,D,CHEMBL617252,BAO_0000019,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,11828,,,104686,Autocuration
4,,1,,,2179,,,B,,,,,,H,CHEMBL617006,BAO_0000019,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,12253,,,104686,Autocuration
4,,1,,,2180,,,B,,,,,,H,CHEMBL617007,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,12253,,,104686,Autocuration
4,,1,,,2181,,,F,,,,,,H,CHEMBL617008,BAO_0000019,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",11279,,,104686,Autocuration
4,,1,,,2182,,,B,,,,,,H,CHEMBL617009,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,11866,,,104686,Autocuration
5,,1,,10116.0,2183,,,B,,,,Rattus norvegicus,,D,CHEMBL617010,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,14424,,,104686,Autocuration
5,,1,,10116.0,2184,,,B,,,,Rattus norvegicus,,D,CHEMBL857978,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,15180,,,104686,Autocuration
5,,1,,10116.0,2185,,,B,,,,Rattus norvegicus,,D,CHEMBL617011,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,15180,,,104686,Autocuration
5,,1,,10116.0,2186,,,B,,,,Rattus norvegicus,,D,CHEMBL617012,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,9786,,,104686,Autocuration
4,,1,,,2187,,,B,,,,,,H,CHEMBL617013,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,12132,,,104686,Autocuration
4,,1,,,2188,,,B,,,,,,H,CHEMBL617014,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,5486,,,104686,Autocuration
4,,1,,,2189,,,B,,,,,,H,CHEMBL617015,BAO_0000019,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,15316,,,104686,Autocuration
4,,1,,,2190,,,B,,,,,,H,CHEMBL617016,BAO_0000019,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,16429,,,104686,Autocuration
4,,1,,,2191,,,B,,,,,,H,CHEMBL617017,BAO_0000224,pKi value for 5-hydroxytryptamine 2 receptor binding site,14617,,,104686,Autocuration
4,,1,,,2192,,,B,955.0,,,,,H,CHEMBL617018,BAO_0000221,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,11351,,Brain,104686,Autocuration
4,,1,,,2193,,,F,,,,,,H,CHEMBL617019,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,11279,,,104686,Autocuration
4,,1,,,2194,,,B,,,,,,H,CHEMBL617020,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2195,,,B,,,,,,H,CHEMBL617021,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2196,,,B,,,,,,H,CHEMBL617022,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2197,,,B,,,,,,H,CHEMBL617023,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2198,,,B,,,,,,H,CHEMBL617024,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2199,,,B,,,,,,H,CHEMBL617025,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,,,105075,Autocuration
4,,1,,,2200,,,B,,,,,,H,CHEMBL617026,BAO_0000224,Hill coefficient of compound was determined,9523,,,105075,Autocuration
0,,1,,,2201,,,B,,,,,,U,CHEMBL617027,BAO_0000019,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,4771,,,22226,Autocuration
5,,1,,10116.0,2202,,,B,,,,Rattus norvegicus,,D,CHEMBL617028,BAO_0000019,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,5033,,,104686,Autocuration
8,,1,,,2203,,,B,,,,,,H,CHEMBL617029,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,10845,,,12687,Expert
8,,1,,,2204,,,B,,,,,,H,CHEMBL875908,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,10845,,,12687,Expert
8,,1,,,2205,,,B,,,,,,H,CHEMBL617030,BAO_0000357,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),16288,,,12687,Autocuration
8,,1,,,2206,,,B,,,,,,H,CHEMBL617031,BAO_0000019,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),16288,,,12687,Autocuration
8,,1,,,2207,,,B,,,,,,H,CHEMBL617032,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,16190,,,12687,Autocuration
5,,1,,10116.0,2208,,,B,,,,Rattus norvegicus,,D,CHEMBL617033,BAO_0000224,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,12463,,,104686,Autocuration
4,,1,,,2209,,,B,,,,,,H,CHEMBL617034,BAO_0000224,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",9699,,,104686,Autocuration
4,,1,,,2210,,,B,,,,,,H,CHEMBL617035,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,9699,,,104686,Autocuration
4,,1,,,2211,,,B,,,,,,H,CHEMBL617036,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,,,104686,Autocuration
4,,1,,,2212,,,B,,,,,,H,CHEMBL617037,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1205,,,104784,Autocuration
0,,1,,,2213,,,B,,,,,,U,CHEMBL617038,BAO_0000219,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,11376,,,22226,Autocuration
4,,1,,,2214,,,B,,,,,,H,CHEMBL617039,BAO_0000219,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",11376,,,104784,Autocuration
4,,1,,,2215,,,B,,,,,,H,CHEMBL617161,BAO_0000224,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,4639,,,104784,Autocuration
4,,1,,,2216,,,B,,,,,,H,CHEMBL617162,BAO_0000224,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,2222,,,104784,Autocuration
4,,1,,,2217,,,B,,,,,,H,CHEMBL617163,BAO_0000224,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1558,,,104784,Autocuration
4,,1,,,2218,,,B,,,,,,H,CHEMBL617164,BAO_0000224,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1089,,,104784,Autocuration
4,,1,,,2219,,,B,,,,,,H,CHEMBL617165,BAO_0000249,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,386,Brain membranes,,104784,Autocuration
4,,1,,,2220,,,B,,,,,,H,CHEMBL617166,BAO_0000224,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,2474,,,104784,Autocuration
4,,1,,,2221,,,B,,,,,,H,CHEMBL617167,BAO_0000224,Binding affinity towards 5-HT2 receptor,17066,,,104784,Autocuration
4,,1,,,2222,,,B,,,,,,H,CHEMBL872912,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,959,,,104784,Autocuration
4,,1,,,2223,,,B,,,,,,H,CHEMBL617168,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,6398,,,104784,Autocuration
4,,1,,,2224,,,B,,,,,,H,CHEMBL617169,BAO_0000224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,11889,,,104686,Autocuration
4,,1,,,2225,,,B,,,,,,H,CHEMBL617170,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4221,,,104784,Autocuration
4,,1,,,2226,,,B,,,,,,H,CHEMBL617171,BAO_0000224,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,11026,,,104784,Autocuration
4,,1,,,2227,,,B,,,,,,H,CHEMBL617172,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,11866,,,104784,Autocuration
4,,1,,,2228,,,B,,,,,,H,CHEMBL617173,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4221,,,104784,Autocuration
0,,1,,,2229,,,B,,,,,,U,CHEMBL617174,BAO_0000019,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,13950,,,22226,Autocuration
4,,1,,,2230,,,B,,,,,,H,CHEMBL617175,BAO_0000224,5-hydroxytryptamine 2 receptor binding affinity,1263,,,104784,Autocuration
8,,1,,,2231,,,B,,,,,,H,CHEMBL617176,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,13291,,,17005,Autocuration
8,,1,,,2232,,,B,,,,,,H,CHEMBL617177,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,10812,,,17005,Autocuration
4,,1,,,2233,,,B,,,,,,H,CHEMBL617178,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,13020,,,104784,Autocuration
4,,1,,,2234,,,B,,,,,,H,CHEMBL617179,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,13021,,,104784,Autocuration
4,,1,,,2235,,,B,,,,,,H,CHEMBL617180,BAO_0000224,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,13020,,,104784,Autocuration
8,,1,,,2236,,,B,,,,,,H,CHEMBL617181,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,14532,,,17005,Autocuration
8,,1,,,2237,,,B,,,,,,H,CHEMBL617182,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,13944,,,17005,Autocuration
8,,1,,,2238,,,B,,,,,,H,CHEMBL617183,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,14331,,,17005,Autocuration
8,,1,,,2239,,,B,,,,,,H,CHEMBL617184,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,14118,,,17005,Autocuration
8,,1,,,2240,,,B,,,,,,H,CHEMBL617185,BAO_0000357,Binding affinity against serotonergic 5-HT2 receptor,13033,,,17005,Autocuration
8,,1,,,2241,,,B,,,,,,H,CHEMBL617186,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,10321,,,17005,Autocuration
8,,1,,,2242,,,B,,,,,,H,CHEMBL617187,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT2 receptor,12918,,,17005,Autocuration
8,,1,,,2243,,,B,,,,,,H,CHEMBL617188,BAO_0000357,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,15120,,,17005,Autocuration
8,,1,,,2244,,,B,,,,,,H,CHEMBL617189,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,2613,,,17005,Autocuration
5,,1,,9606.0,2245,,,B,,,,Homo sapiens,,D,CHEMBL617190,BAO_0000224,Inhibitory activity against cloned human 5-HT2 receptor,13378,,,104784,Autocuration
5,,1,449.0,9606.0,2246,,,B,,,,Homo sapiens,CHO,D,CHEMBL617191,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",2331,,,104784,Autocuration
5,,1,449.0,9606.0,2247,,,B,,,,Homo sapiens,CHO,D,CHEMBL617192,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",2331,,,104784,Autocuration
5,,1,449.0,9606.0,2248,,,B,,,,Homo sapiens,CHO,D,CHEMBL617193,BAO_0000219,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",2331,,,104784,Autocuration
5,,1,449.0,9606.0,2249,,,B,,,,Homo sapiens,CHO,D,CHEMBL617194,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",2331,,,104784,Autocuration
4,,1,,,2250,,,B,,,,,,H,CHEMBL617195,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,4170,,,104784,Autocuration
4,,1,,,2251,,,B,,,,,,H,CHEMBL881830,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,15453,,,104784,Autocuration
8,,1,,,2252,,,B,,,,,,H,CHEMBL617196,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2 receptor,1479,,,17005,Autocuration
4,,1,,,2253,,,B,,,,,,H,CHEMBL617197,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,11139,,,104686,Autocuration
8,,1,,,2254,,,B,,,,,,H,CHEMBL617198,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,13969,,,17005,Expert
8,,1,,,2255,,,B,,,,,,H,CHEMBL873476,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,13392,,,17005,Expert
8,,1,,,2256,,,B,,,,,,H,CHEMBL617199,BAO_0000019,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,14430,,,17005,Expert
8,,1,,10141.0,2257,,,B,,,,Cavia porcellus,,H,CHEMBL617200,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,13181,,,107,Autocuration
8,,1,,,2258,,,B,,,,,,H,CHEMBL617484,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,,,51,Autocuration
8,,1,,,2259,,,B,,,,,,H,CHEMBL617485,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,,,107,Autocuration
8,,1,,,2260,,,B,,,,,,H,CHEMBL617486,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,,,51,Autocuration
8,,1,,,2261,,,B,,,,,,H,CHEMBL858022,BAO_0000357,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,13463,,,107,Autocuration
8,,1,449.0,,2262,,,B,,,,,CHO,H,CHEMBL617049,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,6347,,,107,Autocuration
9,,1,449.0,9606.0,2263,,,F,,,,Homo sapiens,CHO,D,CHEMBL617050,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,6857,,,107,Expert
8,,1,,,2264,,,F,,,,,,H,CHEMBL617051,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,4176,,,107,Autocuration
8,,1,,,2265,,,F,,,,,,H,CHEMBL617052,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,4176,,,107,Autocuration
8,,1,,,2266,,,F,,,,,,H,CHEMBL617053,BAO_0000219,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,4176,,,107,Autocuration
8,,1,449.0,,2267,,,B,,,,,CHO,H,CHEMBL617054,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",6347,,,107,Autocuration
8,,1,449.0,,2268,,,B,,,,,CHO,H,CHEMBL617055,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",6347,,,107,Autocuration
8,,1,,,2269,,,B,,,,,,H,CHEMBL882924,BAO_0000357,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,15331,,,107,Autocuration
9,,1,,9606.0,2270,,,B,,,,Homo sapiens,,D,CHEMBL617056,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2A receptor,16146,,,107,Expert
8,,1,449.0,,2271,,,B,,,,,CHO,H,CHEMBL617057,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,15250,,,107,Autocuration
8,,1,,,2272,,,B,,,,,,H,CHEMBL617058,BAO_0000219,Inhibitory concentration against human 5-HT2A receptor in BEK cells,13631,,,107,Expert
8,,1,,,2273,,,B,,,,,,H,CHEMBL617059,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),3805,,,107,Autocuration
8,,1,449.0,,2274,,,B,,,,,CHO,H,CHEMBL617060,BAO_0000219,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,4011,,,107,Autocuration
8,,1,449.0,,2275,,,B,,,,,CHO,H,CHEMBL617061,BAO_0000219,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,4012,,,107,Expert
8,,1,307.0,,2276,,,B,,,,,L929,H,CHEMBL617062,BAO_0000219,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,6366,,,107,Expert
8,,1,449.0,,2277,,,B,,,,,CHO,H,CHEMBL617063,BAO_0000219,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,15949,,,107,Expert
8,,1,,,2278,,,F,,,,,,H,CHEMBL617064,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,14093,,,107,Autocuration
8,,1,,,2279,,,F,,,,,,H,CHEMBL617065,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,13481,,,107,Autocuration
8,,1,449.0,,2280,,,B,,,,,CHO,H,CHEMBL617066,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,6347,,,107,Autocuration
8,,1,449.0,,2281,,,B,,,,,CHO,H,CHEMBL617067,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,6347,,,107,Autocuration
8,,1,,,2282,,,F,,,,,,H,CHEMBL617068,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,14093,,,107,Autocuration
8,,1,,,2283,,,F,,,,,,H,CHEMBL617069,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,14093,,,107,Autocuration
8,,1,,,2284,,,F,,,,,,H,CHEMBL617070,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,13481,,,107,Autocuration
8,,1,,,2285,,,B,,,,,,H,CHEMBL617071,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,14442,,,107,Autocuration
8,,1,,,2286,,,B,,,,,,H,CHEMBL872915,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,14442,,,107,Autocuration
8,,1,,,2287,,,B,,,,,,H,CHEMBL617072,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,14755,,,107,Autocuration
8,,1,,,2288,,,B,,,,,,H,CHEMBL617073,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,16441,,,107,Autocuration
8,,1,,,2289,,,B,,,,,,H,CHEMBL617074,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,14744,,,107,Autocuration
8,,1,449.0,,2290,,,B,,,,,CHO,H,CHEMBL617075,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,16659,,,107,Expert
8,,1,,,2291,,,B,,,,,,H,CHEMBL617076,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,3307,,,107,Autocuration
9,,1,,9606.0,2292,,,B,,,,Homo sapiens,,D,CHEMBL617077,BAO_0000019,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,6857,,,107,Expert
8,,1,,,2293,,,B,,,,,,H,CHEMBL617078,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,5635,,,107,Expert
9,,1,,9606.0,2294,,,B,,,,Homo sapiens,,D,CHEMBL617079,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,4234,,,107,Expert
8,,1,,,2295,,,B,,,,,,H,CHEMBL617080,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,15527,,,107,Autocuration
8,,1,449.0,,2296,,,B,,,,,CHO,H,CHEMBL617081,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,6588,,,107,Expert
8,,1,,,2297,,,B,,,,,,H,CHEMBL617082,BAO_0000219,Binding affinity towards human 5-HT2A receptor in BEK cells,13631,,,107,Expert
8,,1,,,2298,,,B,,,,,,H,CHEMBL617083,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,17723,,,107,Autocuration
8,,1,,,2299,,,B,,,,,,H,CHEMBL617084,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,14770,,,107,Autocuration
9,,1,,9606.0,2300,,,B,,,,Homo sapiens,,D,CHEMBL617085,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,16293,,,107,Expert
8,,1,,,2301,,,B,,,,,,H,CHEMBL617086,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16209,,,107,Autocuration
8,,1,,,2302,,,B,,,,,,H,CHEMBL617087,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,12469,,,107,Autocuration
8,,1,,,2303,,,B,,,,,,H,CHEMBL617088,BAO_0000357,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,15363,,,107,Autocuration
8,,1,,,2304,,,B,,,,,,H,CHEMBL617089,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,15363,,,107,Autocuration
8,,1,,,2305,,,B,,,,,,H,CHEMBL617090,BAO_0000019,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",16441,,,107,Expert
8,,1,,,2306,,,B,,,,,,H,CHEMBL617513,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,8,,,107,Autocuration
8,,1,722.0,,2307,,,B,,,,,HEK293,H,CHEMBL617514,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,4176,,,107,Autocuration
8,,1,,,2308,,,B,,,,,,H,CHEMBL617515,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,17085,,,107,Autocuration
8,,1,,,2309,,,B,,,,,,H,CHEMBL617516,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,,,107,Autocuration
9,,1,,9606.0,2310,,,B,,,,Homo sapiens,,D,CHEMBL617517,BAO_0000357,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,,,107,Expert
9,,1,449.0,9606.0,2311,,,B,,,,Homo sapiens,CHO,D,CHEMBL617518,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,4013,,,107,Expert
8,,1,,,2312,,,B,,,,,,H,CHEMBL617519,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,5088,,,107,Autocuration
9,,1,,9606.0,2313,,,B,,,,Homo sapiens,,D,CHEMBL617520,BAO_0000357,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,5088,,,107,Expert
8,,1,,,2314,,,B,,,,,,H,CHEMBL617521,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,5088,,,107,Autocuration
9,,1,,9606.0,2315,,,B,,,,Homo sapiens,,D,CHEMBL617522,BAO_0000357,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,5088,,,107,Expert
8,,1,,,2316,,,B,,,,,,H,CHEMBL617523,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,5088,,,107,Autocuration
8,,1,,,2317,,,B,,,,,,H,CHEMBL617524,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,5088,,,107,Autocuration
4,,1,,,2318,,,B,,,,,,H,CHEMBL617525,BAO_0000019,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,9786,,,104686,Autocuration
5,,1,,10116.0,2319,,,B,,,,Rattus norvegicus,,D,CHEMBL617526,BAO_0000019,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,9205,,,104686,Autocuration
4,,1,,,2320,,,B,,,,,,H,CHEMBL617527,BAO_0000224,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,11257,,,104686,Autocuration
4,,1,,,2321,,,B,,,,,,H,CHEMBL617528,BAO_0000019,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,9362,,,104686,Autocuration
4,,1,,,2322,,,B,,,,,,H,CHEMBL617529,BAO_0000019,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,9362,,,104686,Autocuration
4,,1,,,2323,,,B,,,,,,H,CHEMBL617530,BAO_0000224,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,10590,,,104686,Autocuration
4,,1,,,2324,,,B,,,,,,H,CHEMBL617531,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,10468,,,104686,Autocuration
4,,1,,,2325,,,B,,,,,,H,CHEMBL617532,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,13050,,,104686,Autocuration
4,,1,,,2326,,,B,,,,,,H,CHEMBL617533,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,11624,,,104686,Autocuration
4,,1,,,2327,,,B,,,,,,H,CHEMBL617534,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,10468,,,104686,Autocuration
4,,1,,,2328,,,B,,,,,,H,CHEMBL617535,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,10330,,,104686,Autocuration
4,,1,,,2329,,,B,,,,,,H,CHEMBL617536,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,10062,,,104686,Autocuration
4,,1,,,2330,,,B,,,,,,H,CHEMBL617537,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,11642,,,104686,Autocuration
4,,1,,,2331,,,B,,,,,,H,CHEMBL617538,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,10062,,,104686,Autocuration
4,,1,,,2332,,In vitro,B,,,,,,H,CHEMBL617539,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,,,104686,Autocuration
5,,1,,10116.0,2333,,,B,,,,Rattus norvegicus,,D,CHEMBL617540,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,12280,,,104686,Autocuration
5,,1,,10116.0,2334,,,B,,,,Rattus norvegicus,,D,CHEMBL617541,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,4101,,,104686,Autocuration
4,,1,,,2335,,,B,,,,,,H,CHEMBL617542,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,10062,,,104686,Autocuration
4,,1,,,2336,,,B,,,,,,H,CHEMBL617543,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,11147,,,104686,Autocuration
5,,1,485.0,10116.0,2337,,,B,,,,Rattus norvegicus,CHO-K1,D,CHEMBL617544,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,,,104686,Autocuration
5,,1,485.0,10116.0,2338,,,B,,,,Rattus norvegicus,CHO-K1,D,CHEMBL617545,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,,,104686,Autocuration
5,,1,,10116.0,2339,,,B,,,,Rattus norvegicus,,D,CHEMBL617413,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,9098,,,104686,Autocuration
4,,1,,,2340,,,B,,,,,,H,CHEMBL617414,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,9098,,,104686,Autocuration
5,,1,,10116.0,2341,,,B,,,,Rattus norvegicus,,D,CHEMBL617415,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,9098,,,104686,Autocuration
4,,1,,,2342,,,B,,,,,,H,CHEMBL617416,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,9443,,,104686,Autocuration
4,,1,,,2343,,,B,,,,,,H,CHEMBL617417,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,9443,,,104686,Autocuration
4,,1,,,2344,,,B,,,,,,H,CHEMBL617418,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",9699,,,104686,Autocuration
4,,1,,,2345,,,B,,,,,,H,CHEMBL617419,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,9699,,,104686,Autocuration
4,,1,,,2346,,,B,,,,,,H,CHEMBL617420,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,9098,,,104686,Autocuration
5,,1,,10116.0,2347,,,B,,,,Rattus norvegicus,,D,CHEMBL617421,BAO_0000224,Affinity for 5-hydroxytryptamine 2 receptor,3070,,,104686,Autocuration
4,,1,,,2348,,,B,,,,,,H,CHEMBL617422,BAO_0000224,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,9547,,,104686,Autocuration
4,,1,,,2349,,,B,,,,,,H,CHEMBL617423,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,10444,,,104686,Autocuration
4,,1,,,2350,,,B,,,,,,H,CHEMBL617424,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,14617,,,104686,Autocuration
4,,1,,,2351,,,B,,,,,,H,CHEMBL617425,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,14617,,,104686,Autocuration
4,,1,,,2352,,,B,,,,,,H,CHEMBL617426,BAO_0000224,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),11130,,,104686,Autocuration
4,,1,,,2353,,In vivo,B,,,,,,H,CHEMBL617427,BAO_0000218,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),11130,,,104686,Autocuration
4,,1,,,2354,,,B,955.0,,,,,H,CHEMBL617428,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,14542,,Brain,104686,Autocuration
4,,1,,,2355,,,B,,,,,,H,CHEMBL617429,BAO_0000224,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,2797,,,104686,Autocuration
4,,1,,,2356,,,B,,,,,,H,CHEMBL617430,BAO_0000019,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,11332,,,104686,Autocuration
4,,1,,,2357,,,B,,,,,,H,CHEMBL617431,BAO_0000019,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,11332,,,104686,Autocuration
4,,1,,,2358,,,B,1870.0,,,,,H,CHEMBL617432,BAO_0000019,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,10752,,Frontal cortex,104686,Autocuration
4,,1,,,2359,,,B,,,,,,H,CHEMBL617433,BAO_0000224,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1185,,,104686,Autocuration
4,,1,,,2360,,,B,,,,,,H,CHEMBL617434,BAO_0000224,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1185,,,104686,Autocuration
5,,1,,10116.0,2361,,,B,,,,Rattus norvegicus,,D,CHEMBL617435,BAO_0000224,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,11624,,,104686,Autocuration
4,,1,,,2362,,,B,,,,,,H,CHEMBL617436,BAO_0000019,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1344,,,104686,Autocuration
5,,1,,10116.0,2363,,,B,2435.0,,,Rattus norvegicus,,D,CHEMBL617437,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,15453,,Striatum,104686,Autocuration
4,,1,,,2364,,,B,,,,,,H,CHEMBL617438,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",11662,,,104686,Autocuration
4,,1,,,2365,,,B,,,,,,H,CHEMBL617439,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,,,104686,Autocuration
4,,1,,,2366,,,B,,,,,,H,CHEMBL617440,BAO_0000224,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,10796,,,104686,Autocuration
4,,1,,,2367,,,B,,,,,,H,CHEMBL617441,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,9069,,,104686,Autocuration
5,,1,,10116.0,2368,,,B,,,,Rattus norvegicus,,D,CHEMBL872918,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,8814,,,104686,Autocuration
5,,1,,10116.0,2369,,,B,,,,Rattus norvegicus,,D,CHEMBL617442,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,8908,,,104686,Autocuration
4,,1,,,2370,,,B,,,,,,H,CHEMBL617443,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,9098,,,104686,Autocuration
4,,1,,,2371,,,B,,,,,,H,CHEMBL617444,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,9098,,,104686,Autocuration
4,,1,,,2372,,,B,,,,,,H,CHEMBL617445,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,9098,,,104686,Autocuration
4,,1,,,2373,,,B,,,,,,H,CHEMBL617446,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,9098,,,104686,Autocuration
4,,1,,,2374,,,B,,,,,,H,CHEMBL617447,BAO_0000249,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,9098,,,104686,Autocuration
4,,1,,,2375,,,B,,,,,,H,CHEMBL617448,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,9098,,,104686,Autocuration
4,,1,,,2376,,,B,,,,,,H,CHEMBL617449,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,9098,,,104686,Autocuration
4,,1,,,2377,,,B,,,,,,H,CHEMBL617450,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,9161,,,104686,Autocuration
4,,1,,,2378,,,B,,,,,,H,CHEMBL617451,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,9161,,,104686,Autocuration
4,,1,,,2379,,,B,,,,,,H,CHEMBL617452,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,9161,,,104686,Autocuration
4,,1,,,2380,,,B,,,,,,H,CHEMBL617453,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,9161,,,104686,Autocuration
4,,1,,,2381,,,B,,,,,,H,CHEMBL617660,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,9161,,,104686,Autocuration
4,,1,,,2382,,,B,,,,,,H,CHEMBL617661,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,9161,,,104686,Autocuration
4,,1,,,2383,,,B,,,,,,H,CHEMBL617662,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,9161,,,104686,Autocuration
4,,1,,,2384,,,B,,,,,,H,CHEMBL872919,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,9161,,,104686,Autocuration
4,,1,,,2385,,,B,,,,,,H,CHEMBL617663,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,9161,,,104686,Autocuration
4,,1,,,2386,,,B,,,,,,H,CHEMBL617664,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,9161,,,104686,Autocuration
4,,1,,,2387,,,B,,,,,,H,CHEMBL617665,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,9161,,,104686,Autocuration
4,,1,,,2388,,,B,,,,,,H,CHEMBL617666,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,9161,,,104686,Autocuration
4,,1,,,2389,,,B,,,,,,H,CHEMBL617667,BAO_0000019,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,12094,,,104686,Autocuration
4,,1,,,2390,,,B,,,,,,H,CHEMBL617668,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,12018,,,104686,Autocuration
4,,1,,,2391,,,B,,,,,,H,CHEMBL617669,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,10394,,,104686,Autocuration
4,,1,,,2392,,,B,,,,,,H,CHEMBL617670,BAO_0000224,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,15260,,,104686,Autocuration
5,,1,,10116.0,2393,,,B,,,,Rattus norvegicus,,D,CHEMBL617671,BAO_0000224,Inhibitory constant against 5-hydroxytryptamine 2 receptor,11624,,,104686,Autocuration
4,,1,,,2394,,,B,,,,,,H,CHEMBL617672,BAO_0000224,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,13654,,,104686,Autocuration
4,,1,,,2395,,,B,,,,,,H,CHEMBL617673,BAO_0000019,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,9541,,,104686,Autocuration
4,,1,,,2396,,,B,,,,,,H,CHEMBL617674,BAO_0000224,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,11933,,,104686,Autocuration
4,,1,,,2397,,,B,,,,,,H,CHEMBL617675,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,15538,,,104686,Autocuration
4,,1,,,2398,,,B,,,,,,H,CHEMBL617676,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,15538,,,104686,Autocuration
4,,1,,,2399,,,B,,,,,,H,CHEMBL617677,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,15538,,,104686,Autocuration
5,,1,,,2400,,,B,,,,,,D,CHEMBL617678,BAO_0000019,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,8841,,,104686,Autocuration
4,,1,,,2401,,,B,,,,,,H,CHEMBL617679,BAO_0000224,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1455,,,104686,Autocuration
4,,1,,,2402,,,B,,,,,,H,CHEMBL617680,BAO_0000224,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1455,,,104686,Autocuration
4,,1,,,2403,,,B,,,,,,H,CHEMBL617681,BAO_0000019,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,11752,,,104686,Autocuration
4,,1,,,2404,,,B,955.0,,,,,H,CHEMBL617682,BAO_0000221,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,11642,,Brain,104686,Autocuration
4,,1,,,2405,,,B,,,,,,H,CHEMBL617683,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,12092,,,104686,Autocuration
4,,1,,,2406,,,B,,,,,,H,CHEMBL617684,BAO_0000224,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,3967,,,104686,Autocuration
5,,1,,10116.0,2407,,,B,,,,Rattus norvegicus,,D,CHEMBL617685,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,12771,,,104686,Autocuration
4,,1,,,2408,,,B,,,,,,H,CHEMBL617686,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,11642,,,104686,Autocuration
4,,1,,,2409,,,B,,,,,,H,CHEMBL617687,BAO_0000224,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,11628,,,104686,Autocuration
4,,1,,,2410,,,B,,,,,,H,CHEMBL617688,BAO_0000224,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,13654,,,104686,Autocuration
4,,1,,,2411,,,F,,,,,,H,CHEMBL617689,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
4,,1,,,2412,,,F,,,,,,H,CHEMBL617690,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,,,104686,Autocuration
4,,1,,,2413,,In vivo,F,,,,,,H,CHEMBL617691,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",11200,,,104686,Autocuration
4,,1,,,2414,,In vivo,F,,,,,,H,CHEMBL617692,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",11200,,,104686,Autocuration
4,,1,,,2415,,In vivo,F,,,,,,H,CHEMBL617693,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",11200,,,104686,Autocuration
4,,1,,,2416,,In vivo,F,,,,,,H,CHEMBL617694,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",11200,,,104686,Autocuration
8,,1,,,2417,,,B,955.0,,,,,H,CHEMBL857985,BAO_0000221,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,15436,,Brain,12687,Expert
9,,1,,10116.0,2418,,,B,,,,Rattus norvegicus,,D,CHEMBL617695,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,,,12687,Expert
8,,1,,,2419,,,B,,,,,,H,CHEMBL617696,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,14025,,,12687,Autocuration
8,,1,,,2420,,,B,,,,,,H,CHEMBL617697,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,4342,,,12687,Autocuration
9,,1,,10116.0,2421,,,B,,,,Rattus norvegicus,,D,CHEMBL617257,BAO_0000019,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,13735,,,12687,Expert
9,,1,,10116.0,2422,,,B,,,,Rattus norvegicus,,D,CHEMBL617258,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,5816,,,12687,Expert
8,,1,,,2423,,,B,,,,,,H,CHEMBL617259,BAO_0000019,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,14287,,,12687,Expert
8,,1,,,2424,,,B,,,,,,H,CHEMBL617260,BAO_0000357,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,15738,,,12687,Autocuration
9,,1,,10116.0,2425,,,B,,,,Rattus norvegicus,,D,CHEMBL617261,BAO_0000357,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,15738,,,12687,Expert
8,,1,,,2426,,,B,,,,,,H,CHEMBL617262,BAO_0000019,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,15026,,,12687,Autocuration
8,,1,,,2427,,,B,,,,,,H,CHEMBL617263,BAO_0000019,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,16647,,,12687,Expert
8,,1,,,2428,,,B,,,,,,H,CHEMBL617264,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,16647,,,12687,Autocuration
9,,1,,10116.0,2429,,,B,,,,Rattus norvegicus,,D,CHEMBL617265,BAO_0000019,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,13345,,,12687,Expert
8,,1,,,2430,,,B,,,,,,H,CHEMBL617266,BAO_0000249,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1543,Membranes,,12687,Autocuration
8,,1,,,2431,,,B,,,,,,H,CHEMBL617267,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12444,,,12687,Autocuration
8,,1,,,2432,,,B,,,,,,H,CHEMBL617268,BAO_0000019,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,16404,,,12687,Expert
8,,1,449.0,,2433,,,B,,,,,CHO,H,CHEMBL617269,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,16404,,,12687,Autocuration
8,,1,,,2434,,,B,,,,,,H,CHEMBL617323,BAO_0000357,Kinetic inhibition constant evaluated by measuring serotonergic activity,15577,,,12687,Expert
8,,1,,,2435,,,B,,,,,,H,CHEMBL617324,BAO_0000357,Serotonergic activity of the compound.,15577,,,12687,Autocuration
8,,1,,,2436,,,B,,,,,,H,CHEMBL617325,BAO_0000249,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,2495,,,12687,Autocuration
9,,1,,10116.0,2437,,,B,,,,Rattus norvegicus,,D,CHEMBL617326,BAO_0000019,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,15042,,,12687,Expert
8,,1,,,2438,,,B,,,,,,H,CHEMBL617327,BAO_0000249,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,15026,,,12687,Expert
9,,1,,10116.0,2439,,,F,,,,Rattus norvegicus,,D,CHEMBL617328,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,,,12687,Expert
9,,1,,10116.0,2440,,,F,,,,Rattus norvegicus,,D,CHEMBL617329,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,,,12687,Expert
9,,1,,10116.0,2441,,,F,,,,Rattus norvegicus,,D,CHEMBL617330,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,,,12687,Expert
8,,1,,,2442,,,B,,,,,,H,CHEMBL617331,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,15194,,,12687,Autocuration
8,,1,,,2443,,,B,,,,,,H,CHEMBL617332,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,15194,,,12687,Autocuration
8,,1,,,2444,,,B,,,,,,H,CHEMBL617333,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,4820,,,107,Expert
8,,1,,,2445,,,B,,,,,,H,CHEMBL617334,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,6736,,,107,Autocuration
8,,1,,,2446,,,B,,,,,,H,CHEMBL617335,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,5163,,,107,Autocuration
8,,1,,,2447,,,B,,,,,,H,CHEMBL617336,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,5163,,,107,Autocuration
8,,1,,,2448,,,B,,,,,,H,CHEMBL617337,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,6011,,,107,Autocuration
9,,1,,9606.0,2449,,,B,,,,Homo sapiens,,D,CHEMBL617338,BAO_0000357,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,14294,,,107,Expert
8,,1,,,2450,,,B,,,,,,H,CHEMBL617339,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,5014,,,107,Autocuration
8,,1,,,2451,,,B,,,,,,H,CHEMBL617340,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,17066,,,107,Expert
8,,1,,,2452,,,B,,,,,,H,CHEMBL617341,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,17515,,,107,Autocuration
8,,1,,,2453,,,B,,,,,,H,CHEMBL617342,BAO_0000357,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,6736,,,107,Expert
8,,1,,,2454,,,B,,,,,,H,CHEMBL617343,BAO_0000357,Affinity for 5-hydroxytryptamine 2A receptor,5163,,,107,Expert
8,,1,723.0,,2455,,,B,,,,,NIH3T3,H,CHEMBL617344,BAO_0000219,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,16911,,,107,Expert
8,,1,,,2456,,,B,,,,,,H,CHEMBL617345,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,6841,,,107,Expert
8,,1,,,2457,,,B,,,,,,H,CHEMBL617346,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,6119,,,107,Expert
8,,1,,,2458,,,B,,,,,,H,CHEMBL617347,BAO_0000357,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,3962,,,107,Autocuration
8,,1,,,2459,,,B,,,,,,H,CHEMBL617348,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,4373,,,107,Autocuration
8,,1,,,2460,,,B,,,,,,H,CHEMBL617349,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,4373,,,107,Autocuration
8,,1,,,2461,,,F,,,,,,H,CHEMBL617350,BAO_0000019,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,3962,,,107,Autocuration
8,,1,,,2462,,,B,,,,,,H,CHEMBL872339,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1633,,,107,Expert
8,,1,,,2463,,,B,,,,,,H,CHEMBL617351,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,4373,,,107,Autocuration
8,,1,,,2464,,,B,,,,,,H,CHEMBL617352,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,6576,,,107,Expert
8,,1,,,2465,,,B,,,,,,H,CHEMBL617353,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,4687,,,107,Autocuration
8,,1,,,2466,,,B,,,,,,H,CHEMBL617354,BAO_0000357,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,16946,,,107,Autocuration
8,,1,,,2467,,,B,,,,,,H,CHEMBL617355,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,14159,,,107,Autocuration
8,,1,449.0,10090.0,2468,,,B,,,,Mus musculus,CHO,H,CHEMBL617356,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,3032,,,107,Expert
8,,1,,,2469,,,B,,,,,,H,CHEMBL617357,BAO_0000357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,16655,,,107,Autocuration
8,,1,,,2470,,,B,,,,,,H,CHEMBL617358,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor,13964,,,107,Autocuration
8,,1,,,2471,,,B,,,,,,H,CHEMBL617359,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,16989,,,107,Expert
8,,1,,,2472,,,B,,,,,,H,CHEMBL617360,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,16117,,,107,Autocuration
8,,1,,,2473,,,B,,,,,,H,CHEMBL875913,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,16700,,,107,Autocuration
8,,1,,,2474,,,B,,,,,,H,CHEMBL617361,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor,3269,,,107,Autocuration
9,,1,,9606.0,2475,,,B,,,,Homo sapiens,,D,CHEMBL617362,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2A receptor,1274,,,107,Expert
8,,1,,,2476,,,B,,,,,,H,CHEMBL617363,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1317,,,107,Autocuration
8,,1,,,2477,,,B,,,,,,H,CHEMBL617364,BAO_0000357,Tested against 5-hydroxytryptamine 2A receptor,12146,,,107,Autocuration
4,,1,,,2478,,,B,,,,,,H,CHEMBL617365,BAO_0000224,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,12652,,,105075,Autocuration
4,,1,,,2479,,,B,,,,,,H,CHEMBL617366,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,12652,,,105075,Autocuration
4,,1,,,2480,,,B,,,,,,H,CHEMBL617367,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,12652,,,105075,Autocuration
4,,1,,,2481,,,B,,,,,,H,CHEMBL617368,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,12652,,,105075,Autocuration
8,,1,,,2482,,,B,,,,,,H,CHEMBL617369,BAO_0000357,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),16647,,,107,Autocuration
9,,1,722.0,9606.0,2483,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617370,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,15851,,,227,Expert
9,,1,449.0,9606.0,2484,,,F,,,,Homo sapiens,CHO,D,CHEMBL617371,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,6857,,,227,Expert
8,,1,,,2485,,,B,,,,,,H,CHEMBL617372,BAO_0000357,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),3805,,,227,Autocuration
9,,1,,9606.0,2486,,,B,,,,Homo sapiens,,D,CHEMBL617373,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,6491,,,227,Expert
8,,1,,,2487,,,F,,,,,,H,CHEMBL617374,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,14093,,,227,Autocuration
8,,1,,,2488,,,F,,,,,,H,CHEMBL617375,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,13481,,,227,Autocuration
8,,1,,,2489,,,F,,,,,,H,CHEMBL617376,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,14093,,,227,Autocuration
8,,1,,,2490,,,F,,,,,,H,CHEMBL617377,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,14093,,,227,Autocuration
8,,1,,,2491,,,F,,,,,,H,CHEMBL617378,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,14093,,,227,Autocuration
8,,1,,,2492,,,F,,,,,,H,CHEMBL617379,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,13481,,,227,Autocuration
8,,1,,,2493,,,B,,,,,,H,CHEMBL617380,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,14442,,,227,Autocuration
8,,1,,,2494,,,B,,,,,,H,CHEMBL617381,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,14442,,,227,Autocuration
8,,1,,,2495,,,B,,,,,,H,CHEMBL617382,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,14442,,,227,Autocuration
8,,1,,,2496,,,B,,,,,,H,CHEMBL617383,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,12369,,,107,Autocuration
8,,1,,,2497,,,B,,,,,,H,CHEMBL617384,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,12369,,,107,Expert
8,,1,,,2498,,,B,,,,,,H,CHEMBL617385,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,12369,,,107,Expert
8,,1,,,2499,,,B,,,,,,H,CHEMBL617386,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,14447,,,107,Autocuration
8,,1,,,2500,,,B,,,,,,H,CHEMBL617387,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,14447,,,107,Autocuration
8,,1,723.0,,2501,,,B,,,,,NIH3T3,H,CHEMBL617388,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,,,107,Autocuration
8,,1,449.0,,2502,,,F,,,,,CHO,H,CHEMBL617389,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,,,107,Autocuration
9,,1,449.0,9606.0,2503,,,F,,,,Homo sapiens,CHO,D,CHEMBL617390,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,,,107,Expert
4,,1,,,2504,,,B,,,,,,H,CHEMBL617391,BAO_0000224,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,5635,,,104817,Autocuration
8,,1,,,2505,,,B,,,,,,H,CHEMBL617392,BAO_0000357,Binding activity radioligand.,12861,,,107,Autocuration
8,,1,,,2506,,,B,,,,,,H,CHEMBL617393,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,,,107,Autocuration
8,,1,307.0,,2507,,,B,,,,,L929,H,CHEMBL617394,BAO_0000219,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,5105,,,107,Autocuration
8,,1,307.0,,2508,,,B,,,,,L929,H,CHEMBL617395,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,5104,,,107,Expert
8,,1,307.0,,2509,,,B,,,,,L929,H,CHEMBL617396,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,5105,,,107,Expert
8,,1,307.0,,2510,,,B,,,,,L929,H,CHEMBL617397,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,5105,,,107,Autocuration
8,,1,,,2511,,,B,,,,,,H,CHEMBL617398,BAO_0000357,Binding affinity against 5-HT2A receptor,5254,,,107,Autocuration
8,,1,,,2512,,,B,,,,,,H,CHEMBL617399,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,5254,,,107,Autocuration
8,,1,722.0,,2513,,,B,,,,,HEK293,H,CHEMBL617400,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,13267,,,107,Autocuration
8,,1,722.0,,2514,,,B,,,,,HEK293,H,CHEMBL617401,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,13267,,,107,Autocuration
9,,1,722.0,9606.0,2515,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617402,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,14157,,,107,Expert
9,,1,722.0,9606.0,2516,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617403,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,,,107,Expert
8,,1,,,2517,,,B,,,,,,H,CHEMBL617404,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,14068,,,107,Expert
9,,1,722.0,9606.0,2518,,,B,,,,Homo sapiens,HEK293,D,CHEMBL857981,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,,,107,Expert
9,,1,722.0,9606.0,2519,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617405,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,,,107,Expert
9,,1,722.0,9606.0,2520,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617253,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,4540,,,107,Expert
8,,1,,,2521,,,B,,,,,,H,CHEMBL617254,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,6166,,,107,Expert
8,,1,722.0,,2522,,,B,,,,,HEK293,H,CHEMBL617255,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,17296,,,107,Autocuration
8,,1,722.0,,2523,,,B,,,,,HEK293,H,CHEMBL617256,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,17296,,,107,Autocuration
8,,1,722.0,,2524,,,B,,,,,HEK293,H,CHEMBL616874,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,17296,,,107,Autocuration
9,,1,722.0,9606.0,2525,,,B,,,,Homo sapiens,HEK293,D,CHEMBL616875,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,15779,,,107,Expert
8,,1,722.0,,2526,,,B,,,,,HEK293,H,CHEMBL616876,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,14391,,,107,Expert
8,,1,722.0,,2527,,,B,,,,,HEK293,H,CHEMBL616877,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",15851,,,107,Expert
9,,1,722.0,9606.0,2528,,,B,,,,Homo sapiens,HEK293,D,CHEMBL616878,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,15851,,,107,Expert
8,,1,722.0,,2529,,,B,,,,,HEK293,H,CHEMBL616879,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,3832,,,107,Expert
8,,1,722.0,,2530,,,B,,,,,HEK293,H,CHEMBL616880,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,3833,,,107,Expert
9,,1,722.0,9606.0,2531,,,B,,,,Homo sapiens,HEK293,D,CHEMBL616881,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,,,107,Expert
8,,1,723.0,,2532,,,B,,,,,NIH3T3,H,CHEMBL616882,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,17451,,,107,Autocuration
8,,1,723.0,,2533,,,B,,,,,NIH3T3,H,CHEMBL616883,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,,,107,Autocuration
8,,1,723.0,,2534,,,B,,,,,NIH3T3,H,CHEMBL616884,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,,,107,Autocuration
8,,1,722.0,,2535,,,B,,,,,HEK293,H,CHEMBL616885,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,4199,,,107,Autocuration
8,,1,485.0,,2536,,,B,,,,,CHO-K1,H,CHEMBL616886,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1883,,,107,Autocuration
8,,1,485.0,,2537,,,B,,,,,CHO-K1,H,CHEMBL616887,BAO_0000219,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1883,,,107,Expert
9,,1,,9606.0,2538,,,B,,,,Homo sapiens,,D,CHEMBL616888,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,14875,,,107,Expert
8,,1,722.0,,2539,,,B,,,,,HEK293,H,CHEMBL616889,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,15146,,,107,Autocuration
8,,1,722.0,,2540,,,B,,,,,HEK293,H,CHEMBL616890,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,5213,,,107,Autocuration
9,,1,449.0,9606.0,2541,,,B,,,,Homo sapiens,CHO,D,CHEMBL616891,BAO_0000219,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,16404,,,107,Expert
8,,1,722.0,,2542,,,B,,,,,HEK293,H,CHEMBL616892,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,14818,,,107,Autocuration
8,,1,722.0,,2543,,,B,,,,,HEK293,H,CHEMBL616893,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",4829,,,107,Autocuration
8,,1,723.0,,2544,,,F,,,,,NIH3T3,H,CHEMBL616894,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,12652,,,10620,Autocuration
8,,1,723.0,,2545,,,B,,,,,NIH3T3,H,CHEMBL616895,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,4682,,,107,Expert
8,,1,,,2546,,,F,,,,,,H,CHEMBL616896,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,12652,,,10620,Autocuration
8,,1,,,2547,,,B,,,,,,H,CHEMBL617099,BAO_0000357,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,4921,,,10621,Autocuration
8,,1,,,2548,,,B,,,,,,H,CHEMBL617100,BAO_0000357,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,4921,,,10621,Autocuration
8,,1,,9986.0,2549,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL884532,BAO_0000357,Binding affinity against rabbit aorta 5-HT2A receptor,16312,,,107,Autocuration
8,,1,,9986.0,2550,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617101,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,14998,,,107,Expert
8,,1,,9986.0,2551,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617102,BAO_0000357,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,14025,,,107,Expert
8,,1,,9986.0,2552,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617103,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,13047,,,107,Autocuration
8,,1,,9986.0,2553,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617104,BAO_0000357,The compound was tested for binding affinity against 5-HT2A receptor,13047,,,107,Expert
8,,1,485.0,,2554,,,B,,,,,CHO-K1,H,CHEMBL857979,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1883,,,10576,Autocuration
8,,1,,,2555,,,B,,,,,,H,CHEMBL857502,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein,13463,,,12687,Autocuration
8,,1,,,2556,,,B,,,,,,H,CHEMBL617105,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,13463,,,12687,Autocuration
8,,1,,,2557,,,B,945.0,,,,,H,CHEMBL858021,BAO_0000019,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,13463,,Stomach,12687,Autocuration
9,,1,,10116.0,2558,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL875910,BAO_0000019,Binding affinity for 5-HT 2A in rat stomach fundus,13463,,Stomach,12687,Expert
8,,1,,,2559,,,B,,,,,,H,CHEMBL617106,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,13463,,,12687,Autocuration
8,,1,723.0,,2560,,,B,,,,,NIH3T3,H,CHEMBL617107,BAO_0000219,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,16326,,,12687,Expert
8,,1,,,2561,,,F,,,,,,H,CHEMBL617108,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,14093,,,12687,Autocuration
8,,1,,,2562,,,F,,,,,,H,CHEMBL617109,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,14093,,,12687,Autocuration
8,,1,,,2563,,,B,,,,,,H,CHEMBL617110,BAO_0000357,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,15740,,,12687,Autocuration
8,,1,,,2564,,,B,,,,,,H,CHEMBL617111,BAO_0000357,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,16633,,,12687,Autocuration
9,,1,,10116.0,2565,,,F,,,,Rattus norvegicus,,D,CHEMBL617112,BAO_0000019,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,17200,,,12687,Expert
8,,1,,,2566,,,B,,,,,,H,CHEMBL617113,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,,,12687,Autocuration
8,,1,,,2567,,,B,,,,,,H,CHEMBL617114,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,,,12687,Autocuration
8,,1,,,2568,,,B,,,,,,H,CHEMBL617115,BAO_0000357,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,,,12687,Autocuration
8,,1,,,2569,,,F,,,,,,H,CHEMBL617116,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,,,12687,Autocuration
8,,1,,,2570,,,F,,,,,,H,CHEMBL617117,BAO_0000019,Efficacy at 5-hydroxytryptamine 2A receptor,15363,,,12687,Autocuration
8,,1,,,2571,,,B,,,,,,H,CHEMBL617118,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),17200,,,12687,Autocuration
9,,1,,10116.0,2572,,,B,,,,Rattus norvegicus,,D,CHEMBL617119,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),17200,,,12687,Expert
9,,1,,10116.0,2573,,,B,,,,Rattus norvegicus,,D,CHEMBL617120,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),17200,,,12687,Expert
9,,1,,10116.0,2574,,,F,,,,Rattus norvegicus,,D,CHEMBL617121,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,,,12687,Expert
8,,1,,,2575,,,F,,,,,,H,CHEMBL617122,BAO_0000219,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,,,12687,Autocuration
8,,1,,,2576,,,B,,,,,,H,CHEMBL617123,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,17211,,,12687,Autocuration
8,,1,,,2577,,,B,,,,,,H,CHEMBL617124,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,17331,,,12687,Expert
8,,1,,,2578,,,B,,,,,,H,CHEMBL617600,BAO_0000249,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,13565,,,12687,Expert
8,,1,,,2579,,,B,,,,,,H,CHEMBL617601,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,13730,,,12687,Expert
8,,1,,,2580,,,B,,,,,,H,CHEMBL882923,BAO_0000019,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12416,,,12687,Expert
8,,1,,,2581,,,B,,,,,,H,CHEMBL617602,BAO_0000357,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,15295,,,12687,Autocuration
8,,1,,,2582,,,B,,,,,,H,CHEMBL617603,BAO_0000019,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1742,,,12687,Autocuration
8,,1,,,2583,,,B,,,,,,H,CHEMBL617604,BAO_0000357,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,15295,,,12687,Autocuration
8,,1,,,2584,,,B,,,,,,H,CHEMBL617605,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,14970,,,12687,Expert
8,,1,,,2585,,,B,,,,,,H,CHEMBL617606,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,16693,,,12687,Expert
9,,1,,10116.0,2586,,,B,,,,Rattus norvegicus,,D,CHEMBL617607,BAO_0000019,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,14776,,,12687,Expert
8,,1,,,2587,,,B,,,,,,H,CHEMBL617455,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,14286,,,12687,Autocuration
9,,1,,10116.0,2588,,,B,,,,Rattus norvegicus,,D,CHEMBL617456,BAO_0000019,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,17200,,,12687,Expert
8,,1,,,2589,,,B,,,,,,H,CHEMBL617457,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),15306,,,12687,Expert
9,,1,,10116.0,2590,,,B,,,,Rattus norvegicus,,D,CHEMBL617458,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,14178,,,12687,Expert
9,,1,,10116.0,2591,,,B,,,,Rattus norvegicus,,D,CHEMBL617459,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,14229,,,12687,Expert
8,,1,,,2592,,,B,,,,,,H,CHEMBL617460,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12884,,,12687,Expert
8,,1,,,2593,,,B,,,,,,H,CHEMBL617461,BAO_0000357,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",13149,,,12687,Expert
9,,1,,10116.0,2594,,,B,,,,Rattus norvegicus,,D,CHEMBL617462,BAO_0000019,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,15295,,,12687,Expert
8,,1,,,2595,,,B,,,,,,H,CHEMBL617463,BAO_0000357,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,15740,,,12687,Autocuration
8,,1,,,2596,,,B,,,,,,H,CHEMBL617464,BAO_0000019,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",15185,,,12687,Autocuration
8,,1,,,2597,,,B,,,,,,H,CHEMBL617465,BAO_0000019,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",15185,,,12687,Autocuration
8,,1,,,2598,,,B,,,,,,H,CHEMBL617466,BAO_0000019,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,17529,,,12687,Expert
8,,1,,,2599,,,B,,,,,,H,CHEMBL617467,BAO_0000019,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,14826,,,12687,Autocuration
8,,1,,,2600,,,B,,,,,,H,CHEMBL617468,BAO_0000019,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,17211,,,12687,Expert
8,,1,,,2601,,,B,,,,,,H,CHEMBL617469,BAO_0000019,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,14826,,,12687,Autocuration
8,,1,,,2602,,,B,,,,,,H,CHEMBL617470,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,14093,,,12687,Autocuration
8,,1,,,2603,,,B,,,,,,H,CHEMBL617471,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,14093,,,12687,Autocuration
8,,1,723.0,,2604,,,B,,,,,NIH3T3,H,CHEMBL617472,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,13246,,,12687,Expert
8,,1,,,2605,,,B,,,,,,H,CHEMBL617473,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,13246,,,12687,Expert
9,,1,,10116.0,2606,,,B,,,,Rattus norvegicus,,D,CHEMBL617474,BAO_0000019,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,,,12687,Expert
9,,1,,10116.0,2607,,,B,,,,Rattus norvegicus,,D,CHEMBL617475,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,,,12687,Expert
8,,1,,,2608,,,B,955.0,,,,,H,CHEMBL617476,BAO_0000221,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,14442,,Brain,12687,Autocuration
8,,1,,,2609,,,B,,,,,,H,CHEMBL617477,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12457,,,12687,Expert
8,,1,723.0,,2610,,,B,,,,,NIH3T3,H,CHEMBL617478,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12457,,,12687,Expert
8,,1,,,2611,,,F,,,,,,H,CHEMBL617479,BAO_0000221,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",14755,,,12687,Autocuration
8,,1,,,2612,,,B,,,,,,H,CHEMBL617480,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,4707,,,12687,Autocuration
8,,1,,,2613,,,B,,,,,,H,CHEMBL617481,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,13297,,,12687,Expert
8,,1,,,2614,,,B,,,,,,H,CHEMBL617482,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,17331,,,12687,Expert
8,,1,,,2615,,,B,,,,,,H,CHEMBL617483,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,4664,,,12687,Autocuration
8,,1,,,2616,,,B,,,,,,H,CHEMBL621528,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16633,,,12687,Autocuration
9,,1,723.0,10116.0,2617,,,B,,,,Rattus norvegicus,NIH3T3,D,CHEMBL621529,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,4664,,,12687,Expert
8,,1,,,2618,,,B,,,,,,H,CHEMBL621530,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,16133,,,12687,Expert
8,,1,,,2619,,,B,,,,,,H,CHEMBL621531,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,16133,,,12687,Expert
9,,1,,10116.0,2620,,,B,,,,Rattus norvegicus,,D,CHEMBL621532,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,14060,,,12687,Expert
8,,1,,,2621,,,B,,,,,,H,CHEMBL621533,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,16326,,,12687,Expert
8,,1,449.0,,2622,,,B,,,,,CHO,H,CHEMBL621534,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,16659,,,12687,Expert
8,,1,,,2623,,,B,,,,,,H,CHEMBL621535,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,14776,,,12687,Autocuration
8,,1,,,2624,,,B,,,,,,H,CHEMBL621536,BAO_0000357,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,13481,,,12687,Autocuration
8,,1,,,2625,,,B,,,,,,H,CHEMBL621537,BAO_0000357,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,17386,,,12687,Autocuration
9,,1,,10116.0,2626,,,B,,,,Rattus norvegicus,,D,CHEMBL621538,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor,6611,,,12687,Expert
8,,1,,,2627,,,B,,,,,,H,CHEMBL621539,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,14423,,,12687,Autocuration
8,,1,,,2628,,,B,,,,,,H,CHEMBL621540,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,15412,,,12687,Autocuration
8,,1,,,2629,,,B,,,,,,H,CHEMBL621541,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,15412,,,12687,Autocuration
8,,1,,,2630,,,B,,,,,,H,CHEMBL621542,BAO_0000019,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,6238,,,12687,Autocuration
8,,1,,,2631,,,B,,,,,,H,CHEMBL621543,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,6648,,,12687,Expert
8,,1,,,2632,,,B,,,,,,H,CHEMBL621544,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,5667,,,12687,Expert
9,,1,,10116.0,2633,,,B,,,,Rattus norvegicus,,D,CHEMBL621545,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,6611,,,12687,Expert
8,,1,,,2634,,,B,,,,,,H,CHEMBL621546,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,13481,,,12687,Autocuration
8,,1,,,2635,,,B,,,,,,H,CHEMBL621547,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,13481,,,12687,Autocuration
8,,1,723.0,,2636,,,B,,,,,NIH3T3,H,CHEMBL618692,BAO_0000219,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,15558,,,12687,Expert
8,,1,,,2637,,,B,,,,,,H,CHEMBL618693,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,6013,,,12687,Autocuration
8,,1,,,2638,,,B,,,,,,H,CHEMBL872922,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16633,,,12687,Autocuration
8,,1,,,2639,,,B,,,,,,H,CHEMBL618694,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,6013,,,12687,Autocuration
9,,1,,10116.0,2640,,,B,,,,Rattus norvegicus,,D,CHEMBL618695,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,6013,,,12687,Expert
8,,1,,,2641,,,B,,,,,,H,CHEMBL618696,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,6013,,,12687,Autocuration
8,,1,,,2642,,,B,,,,,,H,CHEMBL618697,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,6013,,,12687,Expert
8,,1,,,2643,,,B,,,,,,H,CHEMBL618892,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,6013,,,12687,Autocuration
8,,1,,,2644,,,B,,,,,,H,CHEMBL618893,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,6013,,,12687,Autocuration
8,,1,,,2645,,,B,,,,,,H,CHEMBL618894,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,16293,,,12687,Autocuration
8,,1,723.0,,2646,,,B,,,,,NIH3T3,H,CHEMBL618895,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,17175,,,12687,Expert
9,,1,,10116.0,2647,,,B,,,,Rattus norvegicus,,D,CHEMBL618896,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,13278,,,12687,Expert
8,,1,,,2648,,,B,5383.0,,,,,H,CHEMBL618897,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,3682,,Caudate-putamen,12687,Autocuration
8,,1,,,2649,,,B,,,,,,H,CHEMBL618898,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,2014,,,12687,Autocuration
8,,1,,,2650,,,B,,,,,,H,CHEMBL618899,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,2014,,,12687,Autocuration
8,,1,,,2651,,,B,,,,,,H,CHEMBL618900,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,4932,,,12687,Autocuration
8,,1,,,2652,,,B,,,,,,H,CHEMBL618901,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,4932,,,12687,Autocuration
8,,1,,,2653,,,B,,,,,,H,CHEMBL618902,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,3935,,,12687,Autocuration
9,,1,,10116.0,2654,,,B,10000000.0,,,Rattus norvegicus,,D,CHEMBL618903,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,5432,,Hippocampus,12687,Expert
8,,1,,,2655,,,B,,,,,,H,CHEMBL618904,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,15818,,,12687,Autocuration
8,,1,,,2656,,,B,,,,,,H,CHEMBL618905,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,13672,,,12687,Autocuration
8,,1,,,2657,,,B,,,,,,H,CHEMBL618906,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,13672,,,12687,Autocuration
8,,1,723.0,,2658,,,B,,,,,NIH3T3,H,CHEMBL618907,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,14749,,,12687,Expert
8,,1,,,2659,,,B,,,,,,H,CHEMBL618908,BAO_0000019,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,13462,,,12687,Autocuration
8,,1,,,2660,,,B,,,,,,H,CHEMBL617909,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,15740,,,12687,Autocuration
8,,1,,,2661,,,B,,,,,,H,CHEMBL617910,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,16647,,,12687,Expert
8,,1,,,2662,,,B,955.0,,,,,H,CHEMBL617911,BAO_0000221,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,13345,,Brain,12687,Autocuration
8,,1,,,2663,,,B,,,,,,H,CHEMBL872923,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,,,12687,Autocuration
8,,1,,,2664,,,B,,,,,,H,CHEMBL617912,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,,,12687,Autocuration
9,,1,,10116.0,2665,,,B,,,,Rattus norvegicus,,D,CHEMBL617913,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,15535,,,12687,Expert
8,,1,,,2666,,,B,,,,,,H,CHEMBL617914,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,,,12687,Expert
8,,1,,,2667,,,B,,,,,,H,CHEMBL617915,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,,,12687,Autocuration
8,,1,,,2668,,,B,,,,,,H,CHEMBL617916,BAO_0000249,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,,,12687,Autocuration
9,,1,,10116.0,2669,,,B,,,,Rattus norvegicus,,D,CHEMBL617917,BAO_0000019,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,4795,,,12687,Expert
8,,1,,,2670,,,B,,,,,,H,CHEMBL617918,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,8,,,12687,Expert
8,,1,,,2671,,,B,,,,,,H,CHEMBL617919,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,8,,,12687,Autocuration
9,,1,,10116.0,2672,,,B,,,,Rattus norvegicus,,D,CHEMBL617920,BAO_0000019,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,17200,,,12687,Expert
9,,1,,10116.0,2673,,,B,,,,Rattus norvegicus,,D,CHEMBL617921,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,2148,,,12687,Expert
5,,1,,10116.0,2674,,,B,,,,Rattus norvegicus,,D,CHEMBL617922,BAO_0000224,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",13345,,,105102,Expert
8,,1,,,2675,,,B,,,,,,H,CHEMBL617923,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,5088,,,12687,Autocuration
8,,1,,,2676,,,B,,,,,,H,CHEMBL617924,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,5088,,,12687,Autocuration
8,,1,,,2677,,,B,,,,,,H,CHEMBL617925,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,17133,,,12687,Autocuration
9,,1,,10116.0,2678,,,B,,,,Rattus norvegicus,,D,CHEMBL617926,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,17133,,,12687,Expert
8,,1,,,2679,,,B,,,,,,H,CHEMBL617927,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,16532,,,12687,Autocuration
8,,1,,,2680,,,B,,,,,,H,CHEMBL617928,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,15086,,,12687,Autocuration
9,,1,,10116.0,2681,,,B,,,,Rattus norvegicus,,D,CHEMBL617929,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,2309,,,12687,Expert
8,,1,,,2682,,,B,,,,,,H,CHEMBL617930,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12953,,,12687,Expert
8,,1,,,2683,,,B,,,,,,H,CHEMBL617931,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12953,,,12687,Autocuration
8,,1,,,2684,,,B,,,,,,H,CHEMBL617932,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12953,,,12687,Autocuration
8,,1,449.0,,2685,,,B,,,,,CHO,H,CHEMBL617933,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,16659,,,12687,Autocuration
8,,1,,,2686,,,B,,,,,,H,CHEMBL617934,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,16740,,,12687,Autocuration
8,,1,,,2687,,,B,,,,,,H,CHEMBL617935,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,16740,,,12687,Autocuration
8,,1,,,2688,,,B,,,,,,H,CHEMBL617936,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,17133,,,12687,Autocuration
8,,1,,,2689,,,B,,,,,,H,CHEMBL617937,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,17211,,,12687,Autocuration
8,,1,,,2690,,,B,,,,,,H,CHEMBL617938,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,17331,,,12687,Autocuration
8,,1,,,2691,,,B,,,,,,H,CHEMBL617939,BAO_0000218,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,16633,,,12687,Autocuration
8,,1,,,2692,,,B,,,,,,H,CHEMBL617940,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,16633,,,12687,Autocuration
8,,1,,,2693,,,B,,,,,,H,CHEMBL617941,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,16633,,,12687,Autocuration
8,,1,,,2694,,,B,,,,,,H,CHEMBL617942,BAO_0000357,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,15026,,,12687,Expert
8,,1,,,2695,,,B,,,,,,H,CHEMBL617943,BAO_0000357,Ratio of pKi of 5-HT2A to that of D2 receptor,15026,,,12687,Expert
4,,1,,,2696,,,B,,,,,,H,CHEMBL617944,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,16404,,,105093,Expert
4,,1,,,2697,,,B,,,,,,H,CHEMBL617945,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,16404,,,105093,Expert
4,,1,,,2698,,,B,,,,,,H,CHEMBL617946,BAO_0000224,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,16404,,,105075,Expert
8,,1,,,2699,,,B,,,,,,H,CHEMBL617947,BAO_0000357,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,16404,,,12687,Autocuration
8,,1,,,2700,,,B,,,,,,H,CHEMBL617948,BAO_0000357,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,16326,,,12687,Expert
8,,1,,,2701,,,F,,,,,,H,CHEMBL858116,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,15847,,,12687,Autocuration
8,,1,,,2702,,,F,,,,,,H,CHEMBL617949,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,15847,,,12687,Autocuration
8,,1,,,2703,,,F,,,,,,H,CHEMBL617950,BAO_0000019,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,15329,,,12687,Autocuration
8,,1,,,2704,,,F,1515.0,,,,,H,CHEMBL617951,BAO_0000019,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,16404,,Thoracic aorta,12687,Expert
8,,1,,,2705,,,F,1515.0,,,,,H,CHEMBL617952,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,16404,,Thoracic aorta,12687,Expert
8,,1,,,2706,,,F,1515.0,,,,,H,CHEMBL617953,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,16404,,Thoracic aorta,12687,Autocuration
8,,1,,,2707,,,B,,,,,,H,CHEMBL617954,BAO_0000357,Binding activity radioligand.,12861,,,12687,Autocuration
8,,1,,,2708,,,B,,,,,,H,CHEMBL617955,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,,,12687,Expert
8,,1,,,2709,,,B,,,,,,H,CHEMBL857071,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12861,,,12687,Autocuration
8,,1,,,2710,,,B,,,,,,H,CHEMBL617270,BAO_0000019,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12490,,,12687,Expert
8,,1,339.0,,2711,,,B,,,,,N1E-115,H,CHEMBL617271,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12827,,,12687,Autocuration
8,,1,339.0,,2712,,,B,,,,,N1E-115,H,CHEMBL617272,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12827,,,12687,Autocuration
8,,1,,,2713,,,B,,,,,,H,CHEMBL617273,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12918,,,12687,Autocuration
9,,1,,10116.0,2714,,,F,,,,Rattus norvegicus,,D,CHEMBL617274,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12919,,,12687,Expert
8,,1,,,2715,,,B,,,,,,H,CHEMBL617275,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,17723,,,108,Autocuration
8,,1,,,2716,,,B,,,,,,H,CHEMBL617276,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,6013,,,108,Autocuration
8,,1,,,2717,,,B,,,,,,H,CHEMBL617277,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor,16293,,,108,Autocuration
8,,1,,,2718,,,B,,,,,,H,CHEMBL617278,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,3857,,,108,Expert
8,,1,,,2719,,,B,,,,,,H,CHEMBL617279,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,3857,,,108,Expert
8,,1,,,2720,,,B,,,,,,H,CHEMBL617280,BAO_0000019,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,3857,,,108,Expert
8,,1,,,2721,,,B,,,,,,H,CHEMBL617281,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,15363,,,108,Autocuration
8,,1,,,2722,,,B,,,,,,H,CHEMBL617282,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,15363,,,108,Autocuration
8,,1,,,2723,,,B,,,,,,H,CHEMBL617283,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,16441,,,108,Expert
8,,1,,,2724,,,B,,,,,,H,CHEMBL617284,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,16441,,,108,Expert
8,,1,722.0,,2725,,,B,,,,,HEK293,H,CHEMBL617285,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,4176,,,108,Autocuration
8,,1,,,2726,,,B,,,,,,H,CHEMBL617286,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,17085,,,108,Autocuration
9,,1,,9606.0,2727,,,B,,,,Homo sapiens,,D,CHEMBL617287,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,17200,,,108,Expert
8,,1,,,2728,,,B,,,,,,H,CHEMBL617288,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,5088,,,108,Expert
8,,1,,,2729,,,B,,,,,,H,CHEMBL617289,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,5088,,,108,Autocuration
8,,1,,,2730,,,B,,,,,,H,CHEMBL872917,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,5088,,,108,Autocuration
8,,1,,,2731,,,B,,,,,,H,CHEMBL617290,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,5088,,,108,Autocuration
8,,1,449.0,,2732,,,B,,,,,CHO,H,CHEMBL617291,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,16659,,,108,Autocuration
8,,1,449.0,,2733,,,B,,,,,CHO,H,CHEMBL617292,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,16659,,,108,Autocuration
8,,1,723.0,,2734,,,B,,,,,NIH3T3,H,CHEMBL617293,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,,,108,Autocuration
9,,1,449.0,9606.0,2735,,,F,,,,Homo sapiens,CHO,D,CHEMBL617294,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,,,108,Expert
8,,1,,,2736,,,B,,,,,,H,CHEMBL617295,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,3857,,,108,Expert
8,,1,,,2737,,,B,,,,,,H,CHEMBL617296,BAO_0000357,Binding activity radioligand.,12861,,,108,Autocuration
8,,1,,,2738,,,B,,,,,,H,CHEMBL617297,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,,,108,Autocuration
8,,1,449.0,,2739,,,B,,,,,CHO,H,CHEMBL617298,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,5104,,,108,Expert
8,,1,449.0,,2740,,,B,,,,,CHO,H,CHEMBL617299,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,5105,,,108,Expert
8,,1,449.0,,2741,,,B,,,,,CHO,H,CHEMBL617300,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,5105,,,108,Autocuration
8,,1,,,2742,,,B,,,,,,H,CHEMBL617454,BAO_0000357,Binding affinity against 5-HT2C receptor,5254,,,108,Autocuration
8,,1,722.0,,2743,,,B,,,,,HEK293,H,CHEMBL617505,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,13267,,,108,Autocuration
9,,1,722.0,9606.0,2744,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617506,BAO_0000219,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,14157,,,108,Expert
9,,1,722.0,9606.0,2745,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617507,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,12936,,,108,Expert
8,,1,,,2746,,,B,,,,,,H,CHEMBL617508,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,14068,,,108,Expert
9,,1,722.0,9606.0,2747,,,B,,,,Homo sapiens,HEK293,D,CHEMBL857982,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,12936,,,108,Expert
9,,1,722.0,9606.0,2748,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617509,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,4540,,,108,Expert
9,,1,722.0,9606.0,2749,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617510,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,4540,,,108,Expert
8,,1,,,2750,,,B,,,,,,H,CHEMBL617511,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,6166,,,108,Autocuration
8,,1,722.0,,2751,,,B,,,,,HEK293,H,CHEMBL617512,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,17296,,,108,Autocuration
8,,1,722.0,,2752,,,B,,,,,HEK293,H,CHEMBL617749,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,17296,,,108,Autocuration
8,,1,722.0,,2753,,,B,,,,,HEK293,H,CHEMBL617750,BAO_0000219,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,,,108,Autocuration
8,,1,722.0,,2754,,,B,,,,,HEK293,H,CHEMBL617751,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,,,108,Autocuration
8,,1,722.0,,2755,,,B,,,,,HEK293,H,CHEMBL617752,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,14391,,,108,Expert
8,,1,722.0,,2756,,,B,,,,,HEK293,H,CHEMBL617753,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",15779,,,108,Autocuration
8,,1,722.0,,2757,,,B,,,,,HEK293,H,CHEMBL617754,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",15851,,,108,Expert
9,,1,722.0,9606.0,2758,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617755,BAO_0000219,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,15851,,,108,Expert
8,,1,722.0,,2759,,,B,,,,,HEK293,H,CHEMBL617756,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",15779,,,108,Autocuration
8,,1,722.0,,2760,,,B,,,,,HEK293,H,CHEMBL617757,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,3832,,,108,Expert
8,,1,722.0,,2761,,,B,,,,,HEK293,H,CHEMBL617758,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,3833,,,108,Expert
8,,1,723.0,,2762,,,B,,,,,NIH3T3,H,CHEMBL617759,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,17451,,,108,Autocuration
8,,1,722.0,,2763,,,B,,,,,HEK293,H,CHEMBL617760,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,4199,,,108,Autocuration
8,,1,485.0,,2764,,,B,,,,,CHO-K1,H,CHEMBL617761,BAO_0000219,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1883,,,108,Expert
9,,1,,9606.0,2765,,,B,,,,Homo sapiens,,D,CHEMBL617762,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,4321,,,108,Expert
8,,1,,,2766,,,B,,,,,,H,CHEMBL617763,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,14875,,,108,Autocuration
8,,1,722.0,,2767,,,B,,,,,HEK293,H,CHEMBL857983,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,15146,,,108,Autocuration
8,,1,722.0,,2768,,,B,,,,,HEK293,H,CHEMBL617764,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,5213,,,108,Autocuration
8,,1,308.0,,2769,,,B,,,,,HeLa,H,CHEMBL617765,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,16404,,,108,Autocuration
8,,1,,,2770,,,F,,,,,,H,CHEMBL617766,BAO_0000019,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,13267,,,108,Autocuration
8,,1,,,2771,,,F,10000000.0,,,,,H,CHEMBL617767,BAO_0000221,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,13267,,Hippocampus,108,Autocuration
8,,1,722.0,,2772,,,B,,,,,HEK293,H,CHEMBL617768,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,14818,,,108,Autocuration
8,,1,722.0,,2773,,,B,,,,,HEK293,H,CHEMBL617769,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",4829,,,108,Autocuration
8,,1,,,2774,,,B,,,,,,H,CHEMBL858023,BAO_0000357,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,13463,,,11864,Autocuration
8,,1,,,2775,,,B,945.0,,,,,H,CHEMBL617770,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus,13463,,Stomach,11864,Autocuration
8,,1,,,2776,,,B,945.0,,,,,H,CHEMBL617771,BAO_0000019,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,13463,,Stomach,11864,Autocuration
8,,1,625.0,,2777,,,F,,,,,A9,H,CHEMBL617772,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,12652,,,11864,Autocuration
8,,1,723.0,,2778,,,B,,,,,NIH3T3,H,CHEMBL617773,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,4682,,,11864,Autocuration
8,,1,723.0,,2779,,,B,,,,,NIH3T3,H,CHEMBL617850,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,4682,,,11864,Autocuration
8,,1,723.0,,2780,,,B,,,,,NIH3T3,H,CHEMBL617851,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,4682,,,11864,Autocuration
8,,1,,,2781,,,F,,,,,,H,CHEMBL617852,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,12652,,,11864,Autocuration
8,,1,,10090.0,2782,,,B,945.0,,,Mus musculus,,H,CHEMBL858024,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,13463,,Stomach,12689,Autocuration
9,,1,,10116.0,2783,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617853,BAO_0000019,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,13463,,Stomach,12689,Expert
8,,1,,,2784,,,B,,,,,,H,CHEMBL617854,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,13969,,,108,Expert
8,,1,,9823.0,2785,,,B,,,,Sus scrofa,,H,CHEMBL873477,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,13392,,,108,Expert
8,,1,,,2786,,,B,,,,,,H,CHEMBL617855,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,13392,,,108,Expert
8,,1,,,2787,,,B,,,,,,H,CHEMBL617856,BAO_0000019,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,14430,,,108,Expert
8,,1,,,2788,,,B,,,,,,H,CHEMBL617857,BAO_0000019,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1742,,,108,Autocuration
8,,1,,,2789,,,B,,,,,,H,CHEMBL617858,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,14286,,,108,Autocuration
8,,1,,,2790,,,B,,,,,,H,CHEMBL617859,BAO_0000357,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,5619,,,108,Autocuration
8,,1,,,2791,,,B,,,,,,H,CHEMBL617860,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,15086,,,108,Autocuration
8,,1,,,2792,,,B,,,,,,H,CHEMBL617861,BAO_0000357,Binding activity radioligand.,12861,,,108,Autocuration
8,,1,,,2793,,,B,,,,,,H,CHEMBL617862,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,,,108,Expert
8,,1,,,2794,,,B,,,,,,H,CHEMBL617863,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12861,,,108,Autocuration
8,,1,,,2795,,,B,,,,,,H,CHEMBL617864,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,12827,,,108,Autocuration
8,,1,,,2796,,,B,,,,,,H,CHEMBL617649,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,12827,,,108,Autocuration
8,,1,,9823.0,2797,,,F,,,,Sus scrofa,,H,CHEMBL617650,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,12919,,,108,Expert
8,,1,,9823.0,2798,,,F,,,,Sus scrofa,,H,CHEMBL617651,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,12919,,,108,Expert
8,,1,,9823.0,2799,,,B,,,,Sus scrofa,,H,CHEMBL617652,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,16429,,,108,Autocuration
8,,1,,9823.0,2800,,,B,,,,Sus scrofa,,H,CHEMBL857072,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,773,,,108,Autocuration
8,,1,,9823.0,2801,,,B,,,,Sus scrofa,,H,CHEMBL617653,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,5033,,,108,Autocuration
8,,1,,,2802,,,B,,,,,,H,CHEMBL617654,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,,,12687,Autocuration
8,,1,,,2803,,,F,,,,,,H,CHEMBL617655,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,14093,,,12689,Autocuration
8,,1,,,2804,,,B,,,,,,H,CHEMBL617656,BAO_0000357,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,14970,,,12689,Expert
8,,1,,,2805,,,B,,,,,,H,CHEMBL617657,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,14970,,,12689,Autocuration
8,,1,,,2806,,,B,,,,,,H,CHEMBL617658,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,14970,,,12689,Autocuration
9,,1,,10116.0,2807,,,B,,,,Rattus norvegicus,,D,CHEMBL617659,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,14178,,,12689,Expert
9,,1,,10116.0,2808,,,B,,,,Rattus norvegicus,,D,CHEMBL617838,BAO_0000357,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,14178,,,12689,Expert
9,,1,,10116.0,2809,,,B,,,,Rattus norvegicus,,D,CHEMBL617839,BAO_0000249,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,14229,Brain membranes,,12689,Expert
8,,1,,,2810,,,B,,,,,,H,CHEMBL617840,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,16532,,,12689,Autocuration
8,,1,,,2811,,,B,,,,,,H,CHEMBL617841,BAO_0000019,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,14826,,,12689,Autocuration
8,,1,,,2812,,,B,,,,,,H,CHEMBL875915,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,17211,,,12689,Autocuration
8,,1,,,2813,,In vitro,B,,,,,,H,CHEMBL617842,BAO_0000219,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,17211,,,12689,Expert
8,,1,723.0,,2814,,,B,,,,,NIH3T3,H,CHEMBL617843,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,13246,,,12689,Expert
8,,1,,,2815,,,B,,,,,,H,CHEMBL617844,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,13246,,,12689,Expert
8,,1,,,2816,,,B,,,,,,H,CHEMBL617845,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12457,,,12689,Expert
8,,1,723.0,,2817,,,B,,,,,NIH3T3,H,CHEMBL617846,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12457,,,12689,Expert
8,,1,,,2818,,,B,,,,,,H,CHEMBL617847,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,4707,,,12689,Autocuration
8,,1,,,2819,,,B,,,,,,H,CHEMBL617848,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,13297,,,12689,Expert
8,,1,,,2820,,,B,,,,,,H,CHEMBL617849,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,16633,,,12689,Autocuration
8,,1,,,2821,,,B,,,,,,H,CHEMBL621507,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,16133,,,12689,Expert
8,,1,,,2822,,,B,,,,,,H,CHEMBL621508,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,16326,,,12689,Expert
8,,1,,,2823,,,B,,,,,,H,CHEMBL621509,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,14423,,,12689,Autocuration
8,,1,,,2824,,,B,,,,,,H,CHEMBL621510,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,15412,,,12689,Autocuration
8,,1,,,2825,,,B,,,,,,H,CHEMBL621511,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,15412,,,12689,Autocuration
8,,1,625.0,,2826,,,B,,,,,A9,H,CHEMBL621512,BAO_0000219,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,15558,,,12689,Expert
8,,1,,,2827,,,B,,,,,,H,CHEMBL621513,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,16633,,,12689,Autocuration
8,,1,,,2828,,,B,,,,,,H,CHEMBL621514,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,6013,,,12689,Expert
8,,1,,,2829,,In vitro,B,,,,,,H,CHEMBL621515,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,17175,,,12689,Expert
8,,1,,,2830,,,B,,,,,,H,CHEMBL621516,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12469,,,12689,Autocuration
8,,1,,,2831,,,B,5383.0,,,,,H,CHEMBL621517,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,3682,,Caudate-putamen,12689,Autocuration
8,,1,,,2832,,,B,,,,,,H,CHEMBL621518,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,4932,,,12689,Autocuration
8,,1,,,2833,,,B,,,,,,H,CHEMBL621519,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,4932,,,12689,Autocuration
8,,1,,,2834,,,B,,,,,,H,CHEMBL621520,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,3935,,,12689,Autocuration
8,,1,,,2835,,,B,,,,,,H,CHEMBL621521,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,15818,,,12689,Autocuration
8,,1,,,2836,,,B,,,,,,H,CHEMBL621522,BAO_0000357,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,15818,,,12689,Autocuration
8,,1,,,2837,,,B,,,,,,H,CHEMBL621523,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,14749,,,12689,Expert
8,,1,,,2838,,,B,,,,,,H,CHEMBL621524,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,15740,,,12689,Autocuration
9,,1,,10116.0,2839,,,B,,,,Rattus norvegicus,,D,CHEMBL621525,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,17133,,,12689,Expert
8,,1,,,2840,,,B,,,,,,H,CHEMBL872921,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,16532,,,12689,Autocuration
8,,1,,,2841,,,B,,,,,,H,CHEMBL621526,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12369,,,12689,Autocuration
8,,1,,,2842,,,B,,,,,,H,CHEMBL621527,BAO_0000219,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12369,,,12689,Expert
9,,1,,10116.0,2843,,,B,,,,Rattus norvegicus,,D,CHEMBL617865,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,2309,,,12689,Expert
8,,1,,,2844,,,B,,,,,,H,CHEMBL617866,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12953,,,12689,Autocuration
8,,1,,,2845,,,B,,,,,,H,CHEMBL617867,BAO_0000019,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12953,,,12689,Autocuration
8,,1,,,2846,,,B,,,,,,H,CHEMBL617487,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12953,,,12689,Autocuration
8,,1,,,2847,,,B,,,,,,H,CHEMBL617488,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,12953,,,12689,Expert
8,,1,,,2848,,,B,,,,,,H,CHEMBL617489,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,17133,,,12689,Autocuration
8,,1,,,2849,,,B,,,,,,H,CHEMBL617490,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,17211,,,12689,Autocuration
8,,1,,,2850,,,B,,,,,,H,CHEMBL617491,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,17211,,,12689,Autocuration
8,,1,,,2851,,,B,,,,,,H,CHEMBL617492,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,14025,,,12689,Autocuration
8,,1,,,2852,,,B,,,,,,H,CHEMBL617493,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,14998,,,12689,Autocuration
8,,1,,,2853,,,B,,,,,,H,CHEMBL617494,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,4342,,,12689,Autocuration
9,,1,,10116.0,2854,,,B,,,,Rattus norvegicus,,D,CHEMBL617495,BAO_0000019,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,13735,,,12689,Expert
8,,1,,,2855,,,B,,,,,,H,CHEMBL617496,BAO_0000357,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,13181,,,12689,Autocuration
8,,1,485.0,,2856,,,B,,,,,CHO-K1,H,CHEMBL617497,BAO_0000219,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1883,,,12689,Autocuration
8,,1,,,2857,,,B,,,,,,H,CHEMBL617498,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,15194,,,12689,Autocuration
8,,1,,,2858,,,B,,,,,,H,CHEMBL617499,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,15194,,,12689,Autocuration
8,,1,,,2859,,,F,,,,,,H,CHEMBL617500,BAO_0000019,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,14579,,,12689,Autocuration
8,,1,,,2860,,,B,,,,,,H,CHEMBL617501,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,4639,,,108,Autocuration
8,,1,,,2861,,,B,,,,,,H,CHEMBL617502,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,4820,,,108,Expert
8,,1,,,2862,,,B,,,,,,H,CHEMBL617503,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,14442,,,227,Autocuration
8,,1,,,2863,,,B,,,,,,H,CHEMBL617504,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,14755,,,227,Autocuration
8,,1,,,2864,,,B,,,,,,H,CHEMBL617406,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,14744,,,227,Autocuration
9,,1,,9606.0,2865,,,B,,,,Homo sapiens,,D,CHEMBL617407,BAO_0000019,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,6857,,,227,Expert
8,,1,,,2866,,,B,,,,,,H,CHEMBL617408,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,16209,,,227,Autocuration
8,,1,,,2867,,,B,,,,,,H,CHEMBL617409,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,15363,,,227,Autocuration
8,,1,,,2868,,,B,,,,,,H,CHEMBL617410,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,15363,,,227,Autocuration
8,,1,,,2869,,,B,,,,,,H,CHEMBL617411,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,15363,,,227,Autocuration
8,,1,,,2870,,,B,,,,,,H,CHEMBL617412,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,17085,,,227,Autocuration
9,,1,,9606.0,2871,,,B,,,,Homo sapiens,,D,CHEMBL617774,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,17200,,,227,Expert
9,,1,722.0,9606.0,2872,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617775,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,15851,,,227,Expert
9,,1,722.0,9606.0,2873,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617776,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,15851,,,227,Expert
9,,1,449.0,9606.0,2874,,,F,,,,Homo sapiens,CHO,D,CHEMBL617777,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,,,227,Expert
9,,1,449.0,9606.0,2875,,,F,,,,Homo sapiens,CHO,D,CHEMBL617778,BAO_0000219,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,,,227,Expert
8,,1,722.0,,2876,,,B,,,,,HEK293,H,CHEMBL617779,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",15779,,,227,Autocuration
8,,1,722.0,,2877,,,B,,,,,HEK293,H,CHEMBL617780,BAO_0000219,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,15851,,,227,Expert
8,,1,722.0,,2878,,,B,,,,,HEK293,H,CHEMBL617781,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",15779,,,227,Autocuration
9,,1,722.0,9606.0,2879,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617782,BAO_0000219,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,14157,,,227,Expert
9,,1,722.0,9606.0,2880,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617783,BAO_0000219,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,4540,,,227,Expert
8,,1,,,2881,,,B,,,,,,H,CHEMBL617784,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,6166,,,227,Autocuration
8,,1,722.0,,2882,,,B,,,,,HEK293,H,CHEMBL617785,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,15779,,,227,Autocuration
8,,1,722.0,,2883,,,B,,,,,HEK293,H,CHEMBL857984,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,14391,,,227,Expert
8,,1,722.0,,2884,,,B,,,,,HEK293,H,CHEMBL617786,BAO_0000219,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,3832,,,227,Expert
8,,1,722.0,,2885,,,B,,,,,HEK293,H,CHEMBL617787,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,3833,,,227,Expert
9,,1,722.0,9606.0,2886,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617788,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,15851,,,227,Expert
9,,1,722.0,9606.0,2887,,,B,,,,Homo sapiens,HEK293,D,CHEMBL617789,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,15851,,,227,Expert
8,,1,722.0,,2888,,,B,,,,,HEK293,H,CHEMBL617790,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,4199,,,227,Autocuration
8,,1,485.0,,2889,,,B,,,,,CHO-K1,H,CHEMBL617791,BAO_0000219,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1883,,,227,Expert
8,,1,,,2890,,,B,,,,,,H,CHEMBL617608,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2B receptor,4321,,,227,Expert
8,,1,722.0,,2891,,,B,,,,,HEK293,H,CHEMBL617609,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,15146,,,227,Autocuration
8,,1,722.0,,2892,,,B,,,,,HEK293,H,CHEMBL617610,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,5213,,,227,Autocuration
8,,1,722.0,,2893,,,B,,,,,HEK293,H,CHEMBL617611,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,14818,,,227,Autocuration
8,,1,722.0,,2894,,,B,,,,,HEK293,H,CHEMBL617612,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",4829,,,227,Autocuration
8,,1,722.0,,2895,,,B,,,,,HEK293,H,CHEMBL617613,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",4829,,,227,Autocuration
8,,1,,9986.0,2896,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617614,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,14025,,,227,Autocuration
8,,1,,,2897,,,B,945.0,,,,,H,CHEMBL617615,BAO_0000019,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,13463,,Stomach,12688,Expert
8,,1,,,2898,,,B,945.0,,,,,H,CHEMBL858114,BAO_0000357,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,7259,,Stomach,12688,Expert
8,,1,,,2899,,,B,945.0,,,,,H,CHEMBL617616,BAO_0000357,Affinity against serotonergic receptor in the isolated rat stomach fundus,7259,,Stomach,12688,Autocuration
9,,1,,10116.0,2900,,,F,945.0,,,Rattus norvegicus,,D,CHEMBL617617,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,7185,,Stomach,12688,Expert
9,,1,,10116.0,2901,,,F,,,,Rattus norvegicus,,D,CHEMBL875914,BAO_0000019,Antagonistic against 5-hydroxytryptamine 2B receptor,7185,,,12688,Expert
8,,1,,,2902,,,F,945.0,,,,,H,CHEMBL617618,BAO_0000019,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,13267,,Stomach,12688,Autocuration
9,,1,,10116.0,2903,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617619,BAO_0000357,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,13735,,Stomach,12688,Expert
8,,1,,,2904,,,F,,,,,,H,CHEMBL617620,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,15738,,,12688,Autocuration
8,,1,,,2905,,,F,,,,,,H,CHEMBL617621,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,15738,,,12688,Autocuration
8,,1,,,2906,,,F,,,,,,H,CHEMBL617622,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,15738,,,12688,Autocuration
9,,1,,10116.0,2907,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617623,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,,Stomach,12688,Expert
9,,1,,10116.0,2908,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617624,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,,Stomach,12688,Expert
9,,1,,10116.0,2909,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617625,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,,Stomach,12688,Expert
9,,1,,10116.0,2910,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL617626,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,,Stomach,12688,Expert
8,,1,,,2911,,,F,945.0,,,,,H,CHEMBL617627,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,,Stomach,12688,Autocuration
8,,1,,,2912,,,F,945.0,,,,,H,CHEMBL617628,BAO_0000019,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,,Stomach,12688,Expert
8,,1,,,2913,,,F,945.0,,,,,H,CHEMBL617629,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,16404,,Stomach,12688,Autocuration
8,,1,,,2914,,,F,945.0,,,,,H,CHEMBL858115,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,16404,,Stomach,12688,Autocuration
9,,1,,10116.0,2915,,,F,945.0,,,Rattus norvegicus,,D,CHEMBL617630,BAO_0000019,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,16404,,Stomach,12688,Expert
8,,1,,,2916,,,F,1515.0,,,,,H,CHEMBL617631,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,16404,,Thoracic aorta,12688,Autocuration
8,,1,,,2917,,,B,,,,,,H,CHEMBL617632,BAO_0000357,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,7483,,,12688,Autocuration
8,,1,,,2918,,,B,,,,,,H,CHEMBL617633,BAO_0000357,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,7483,,,12688,Expert
8,,1,,,2919,,,B,,,,,,H,CHEMBL617634,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,7483,,,12688,Autocuration
8,,1,,,2920,,,B,,,,,,H,CHEMBL617635,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,7483,,,12688,Autocuration
9,,1,,10116.0,2922,,,F,945.0,,,Rattus norvegicus,,D,CHEMBL617637,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,,Stomach,12688,Autocuration
8,,1,,,2923,,,B,,,,,,H,CHEMBL617638,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,6347,,,227,Autocuration
8,,1,,,2924,,,B,,,,,,H,CHEMBL617639,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,4373,,,227,Autocuration
8,,1,,,2925,,,B,,,,,,H,CHEMBL617640,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,4373,,,227,Autocuration
8,,1,,,2926,,,B,,,,,,H,CHEMBL617641,BAO_0000357,Evaluated for the binding affinity to 5-HT 2B receptor,4687,,,227,Autocuration
8,,1,,,2927,,,B,,,,,,H,CHEMBL617642,BAO_0000357,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,16946,,,227,Autocuration
8,,1,,,2928,,,B,,,,,,H,CHEMBL617643,BAO_0000357,Binding affinities against 5-hydroxytryptamine 2B receptor,16633,,,227,Autocuration
8,,1,,,2929,,,B,,,,,,H,CHEMBL617644,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 2B receptor,16633,,,227,Autocuration
8,,1,,,2930,,,B,,,,,,H,CHEMBL617645,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,16633,,,227,Autocuration
8,,1,,,2931,,,B,,,,,,H,CHEMBL617646,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,15026,,,108,Expert
8,,1,,9913.0,2932,,,B,,,,Bos taurus,,H,CHEMBL617647,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,15738,,,108,Autocuration
8,,1,,9913.0,2933,,,B,,,,Bos taurus,,H,CHEMBL617648,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,15738,,,108,Autocuration
8,,1,,9913.0,2934,,,B,,,,Bos taurus,,H,CHEMBL617875,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,15738,,,108,Autocuration
8,,1,,9913.0,2935,,,B,,,,Bos taurus,,H,CHEMBL617876,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,15738,,,108,Autocuration
8,,1,,9913.0,2936,,,B,,,,Bos taurus,,H,CHEMBL617877,BAO_0000357,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,16404,,,108,Expert
8,,1,,9913.0,2937,,,B,,,,Bos taurus,,H,CHEMBL617878,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,15026,,,108,Expert
8,,1,,9913.0,2938,,,B,,,,Bos taurus,,H,CHEMBL617879,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,15738,,,108,Autocuration
8,,1,,10141.0,2939,,,B,,,,Cavia porcellus,,H,CHEMBL617880,BAO_0000019,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,16312,,,108,Autocuration
9,,1,,10141.0,2940,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617881,BAO_0000357,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,5486,,Striatum,20033,Intermediate
8,,1,,,2941,,,B,,,,,,H,CHEMBL857073,BAO_0000357,Binding affinity against 5-HT1A receptor,5254,,,51,Autocuration
8,,1,449.0,,2942,,,F,,,,,CHO,H,CHEMBL617882,BAO_0000219,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,3857,,,108,Expert
9,,1,449.0,9606.0,2943,,,F,,,,Homo sapiens,CHO,D,CHEMBL617883,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,6857,,,108,Expert
8,,1,,,2944,,,F,,,,,,H,CHEMBL617884,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,4176,,,108,Autocuration
8,,1,449.0,,2945,,,B,,,,,CHO,H,CHEMBL617885,BAO_0000219,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,6347,,,108,Autocuration
8,,1,449.0,,2946,,,B,,,,,CHO,H,CHEMBL617886,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",6347,,,108,Autocuration
9,,1,,9606.0,2947,,,B,,,,Homo sapiens,,D,CHEMBL617887,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2C receptor,16146,,,108,Expert
8,,1,,,2948,,,B,,,,,,H,CHEMBL617888,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),3805,,,108,Autocuration
8,,1,,,2949,,,B,,,,,,H,CHEMBL617889,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,3857,,,108,Autocuration
8,,1,,,2950,,,B,,,,,,H,CHEMBL617890,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,5635,,,108,Autocuration
8,,1,,,2951,,,B,,,,,,H,CHEMBL617891,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,5635,,,108,Autocuration
8,,1,,,2952,,,B,,,,,,H,CHEMBL617892,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,5635,,,108,Autocuration
8,,1,449.0,,2953,,,B,,,,,CHO,H,CHEMBL617893,BAO_0000219,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,4012,,,108,Expert
8,,1,449.0,,2954,,,B,,,,,CHO,H,CHEMBL617894,BAO_0000219,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,6366,,,108,Expert
8,,1,449.0,,2955,,,B,,,,,CHO,H,CHEMBL617895,BAO_0000219,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,15949,,,108,Expert
8,,1,449.0,,2956,,,B,,,,,CHO,H,CHEMBL617896,BAO_0000219,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,17211,,,108,Autocuration
9,,1,,9606.0,2957,,,B,,,,Homo sapiens,,D,CHEMBL617897,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,6491,,,108,Expert
8,,1,,,2958,,,F,,,,,,H,CHEMBL617898,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,14093,,,108,Autocuration
8,,1,,,2959,,,F,,,,,,H,CHEMBL617899,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,13481,,,108,Autocuration
8,,1,449.0,10116.0,2960,,,B,,,,Rattus norvegicus,CHO,H,CHEMBL617900,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,6347,,,108,Expert
8,,1,,,2961,,,F,,,,,,H,CHEMBL617901,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,14093,,,108,Autocuration
8,,1,,,2962,,,F,,,,,,H,CHEMBL617902,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,14093,,,108,Autocuration
8,,1,,,2963,,,F,,,,,,H,CHEMBL617903,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,13481,,,108,Autocuration
8,,1,,,2964,,,B,,,,,,H,CHEMBL617904,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,14442,,,108,Autocuration
8,,1,,,2965,,,B,,,,,,H,CHEMBL617905,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,14442,,,108,Autocuration
8,,1,,,2966,,,B,,,,,,H,CHEMBL617906,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,14442,,,108,Autocuration
8,,1,,,2967,,,B,,,,,,H,CHEMBL617907,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,14755,,,108,Autocuration
8,,1,,,2968,,,B,,,,,,H,CHEMBL617908,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,14744,,,108,Autocuration
8,,1,449.0,,2969,,,B,,,,,CHO,H,CHEMBL620617,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,16659,,,108,Expert
9,,1,,9606.0,2970,,,B,,,,Homo sapiens,,D,CHEMBL620618,BAO_0000019,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,6857,,,108,Expert
8,,1,,,2971,,,B,,,,,,H,CHEMBL620619,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,5635,,,108,Expert
9,,1,,9606.0,2972,,,B,,,,Homo sapiens,,D,CHEMBL620620,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,4234,,,108,Expert
8,,1,,,2973,,,B,,,,,,H,CHEMBL620621,BAO_0000357,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,16209,,,108,Autocuration
7,,1,,10116.0,2974,,,B,,,,Rattus norvegicus,,D,CHEMBL872920,BAO_0000249,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,5778,Membranes,,104698,Autocuration
6,,1,,,2975,,,B,,,,,,H,CHEMBL620622,BAO_0000223,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,5094,,,104698,Autocuration
7,,1,,10116.0,2976,,,B,,,,Rattus norvegicus,,D,CHEMBL620623,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,809,,,104698,Autocuration
6,,1,,,2977,,,B,,,,,,H,CHEMBL620624,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1578,,,104698,Autocuration
6,,1,,,2978,,,B,,,,,,H,CHEMBL620625,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,809,,,104698,Autocuration
6,,1,,,2979,,,B,,,,,,H,CHEMBL620626,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,12469,,,104698,Autocuration
6,,1,,,2980,,,B,,,,,,H,CHEMBL621307,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,14290,,,104698,Autocuration
6,,1,,,2981,,,B,,,,,,H,CHEMBL621308,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,14290,,,104698,Autocuration
6,,1,,,2982,,,B,,,,,,H,CHEMBL621309,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,10609,,,104698,Autocuration
6,,1,,,2983,,,B,,,,,,H,CHEMBL621310,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,10609,,,104698,Autocuration
6,,1,,,2984,,,B,,,,,,H,CHEMBL621311,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,10609,,,104698,Autocuration
6,,1,,,2985,,,B,,,,,,H,CHEMBL621502,BAO_0000249,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",15253,,,104698,Autocuration
6,,1,,,2986,,,B,,,,,,H,CHEMBL621503,BAO_0000249,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",15253,,,104698,Autocuration
6,,1,,,2987,,,B,,,,,,H,CHEMBL621504,BAO_0000249,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,11683,Membranes,,104698,Autocuration
6,,1,,,2988,,,B,,,,,,H,CHEMBL621505,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,12092,,,104698,Autocuration
6,,1,,,2989,,,B,,,,,,H,CHEMBL621506,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1946,,,104698,Autocuration
6,,1,,,2990,,,B,,,,,,H,CHEMBL619781,BAO_0000223,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,11623,,,104698,Autocuration
6,,1,,,2991,,,B,,,,,,H,CHEMBL619782,BAO_0000223,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,11623,,,104698,Autocuration
6,,1,,,2992,,,B,,,,,,H,CHEMBL619783,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,14788,,,104698,Autocuration
7,,1,,10116.0,2993,,,B,,,,Rattus norvegicus,,D,CHEMBL619784,BAO_0000019,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,5432,,,104698,Autocuration
6,,1,,,2994,,,B,,,,,,H,CHEMBL619785,BAO_0000249,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,14826,,,104698,Autocuration
6,,1,,,2995,,,B,,,,,,H,CHEMBL619786,BAO_0000223,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,2222,,,104698,Autocuration
6,,1,,,2996,,,B,,,,,,H,CHEMBL619787,BAO_0000019,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,11963,,,104698,Autocuration
6,,1,,,2997,,,B,,,,,,H,CHEMBL872925,BAO_0000019,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,14145,,,104698,Autocuration
6,,1,,,2998,,,B,,,,,,H,CHEMBL619788,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,17819,,,104698,Autocuration
6,,1,,,2999,,,B,,,,,,H,CHEMBL619789,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,10394,,,104698,Autocuration
6,,1,,,3000,,,B,,,,,,H,CHEMBL619790,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,10394,,,104698,Autocuration
6,,1,,,3001,,,B,,,,,,H,CHEMBL619791,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,15034,,,104698,Autocuration
6,,1,,,3002,,,B,,,,,,H,CHEMBL619792,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,691,,,104698,Autocuration
6,,1,,,3003,,,B,,,,,,H,CHEMBL619793,BAO_0000249,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,12092,Membranes,,104698,Autocuration
7,,1,,10116.0,3004,,,B,,,,Rattus norvegicus,,D,CHEMBL619794,BAO_0000223,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,11752,,,104698,Autocuration
6,,1,,,3005,,,B,955.0,,,,,H,CHEMBL619795,BAO_0000221,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,11752,,Brain,104698,Autocuration
6,,1,,,3006,,,B,,,,,,H,CHEMBL619796,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,301,,,104698,Autocuration
6,,1,,,3007,,,B,,,,,,H,CHEMBL620448,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,16532,,,104698,Autocuration
6,,1,,,3008,,,B,,,,,,H,CHEMBL620449,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,16532,,,104698,Autocuration
6,,1,,,3009,,,B,,,,,,H,CHEMBL620450,BAO_0000223,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,12092,,,104698,Autocuration
6,,1,,,3010,,,B,,,,,,H,CHEMBL620451,BAO_0000223,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,11684,,,104698,Autocuration
6,,1,,,3011,,,B,,,,,,H,CHEMBL620631,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,11684,,,104698,Autocuration
6,,1,,,3012,,,B,,,,,,H,CHEMBL620632,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,12953,,,104698,Autocuration
6,,1,,,3013,,,B,,,,,,H,CHEMBL620633,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,12953,,,104698,Autocuration
6,,1,,,3014,,,B,,,,,,H,CHEMBL620634,BAO_0000223,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,12953,,,104698,Autocuration
6,,1,,,3015,,,B,,,,,,H,CHEMBL620635,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,12861,,,104698,Autocuration
6,,1,,,3016,,In vivo,F,,,,,,H,CHEMBL620636,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3017,,In vivo,F,,,,,,H,CHEMBL620637,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3018,,In vivo,F,,,,,,H,CHEMBL620638,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3019,,In vivo,F,,,,,,H,CHEMBL620639,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3020,,In vivo,F,,,,,,H,CHEMBL620640,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3021,,In vivo,F,,,,,,H,CHEMBL620641,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3022,,In vivo,F,,,,,,H,CHEMBL620642,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3023,,In vivo,F,,,,,,H,CHEMBL620643,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3024,,In vivo,F,,,,,,H,CHEMBL620644,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3025,,In vivo,F,,,,,,H,CHEMBL620645,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3026,,In vivo,F,,,,,,H,CHEMBL620646,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3027,,In vivo,F,,,,,,H,CHEMBL620647,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3028,,In vivo,F,,,,,,H,CHEMBL620648,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3029,,In vivo,F,,,,,,H,CHEMBL620649,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3030,,In vivo,F,,,,,,H,CHEMBL620650,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3031,,In vivo,F,,,,,,H,CHEMBL620651,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3032,,In vivo,F,,,,,,H,CHEMBL872875,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3033,,In vivo,F,,,,,,H,CHEMBL620652,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3034,,,F,,,,,,H,CHEMBL620653,BAO_0000019,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,10609,,,104698,Autocuration
6,,1,,,3035,,,B,,,,,,H,CHEMBL857076,BAO_0000019,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,12861,,,104698,Autocuration
7,,1,,10116.0,3036,,,B,,,,Rattus norvegicus,,D,CHEMBL620654,BAO_0000019,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,12861,,,104698,Autocuration
6,,1,,,3037,,,B,,,,,,H,CHEMBL620655,BAO_0000223,Binding activity radioligand.,12861,,,104698,Autocuration
6,,1,,,3038,,,B,,,,,,H,CHEMBL620656,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,10728,Brain membranes,,104698,Autocuration
6,,1,,,3039,,,B,,,,,,H,CHEMBL620657,BAO_0000249,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,10728,Brain membranes,,104698,Autocuration
8,,1,,,3040,,,B,,,,,,H,CHEMBL620658,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,5163,,,108,Autocuration
8,,1,,,3041,,,B,,,,,,H,CHEMBL620659,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,5163,,,108,Autocuration
8,,1,,,3042,,,B,,,,,,H,CHEMBL620660,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,6011,,,108,Autocuration
8,,1,,,3043,,,B,,,,,,H,CHEMBL620661,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,5014,,,108,Autocuration
8,,1,,,3044,,,B,,,,,,H,CHEMBL620662,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,5635,,,108,Autocuration
8,,1,,,3045,,,B,,,,,,H,CHEMBL620663,BAO_0000357,Affinity for 5-hydroxytryptamine 2C receptor,5163,,,108,Expert
8,,1,,,3046,,,B,,,,,,H,CHEMBL620664,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,6841,,,108,Autocuration
8,,1,,,3047,,,B,,,,,,H,CHEMBL620665,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,6119,,,108,Expert
8,,1,,,3048,,,B,,,,,,H,CHEMBL620666,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,4373,,,108,Autocuration
8,,1,,,3049,,,B,,,,,,H,CHEMBL620667,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1633,,,108,Autocuration
8,,1,,,3050,,,B,,,,,,H,CHEMBL620668,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1633,,,108,Expert
8,,1,,,3051,,,B,,,,,,H,CHEMBL620669,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,4373,,,108,Autocuration
8,,1,,,3052,,,B,,,,,,H,CHEMBL620670,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,6576,,,108,Expert
8,,1,,,3053,,,B,,,,,,H,CHEMBL620671,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,4687,,,108,Autocuration
8,,1,,,3054,,,B,,,,,,H,CHEMBL620672,BAO_0000357,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,12146,,,108,Autocuration
8,,1,,,3055,,,B,,,,,,H,CHEMBL620673,BAO_0000357,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,12146,,,108,Autocuration
8,,1,,,3056,,,B,,,,,,H,CHEMBL620674,BAO_0000357,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,16946,,,108,Autocuration
8,,1,,,3057,,,B,,,,,,H,CHEMBL620675,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,14159,,,108,Autocuration
8,,1,,,3058,,,B,,,,,,H,CHEMBL620676,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,16700,,,108,Autocuration
8,,1,,,3059,,,B,,,,,,H,CHEMBL621382,BAO_0000357,Affinity against 5-hydroxytryptamine 2C receptor,3269,,,108,Autocuration
9,,1,,9606.0,3060,,,B,,,,Homo sapiens,,D,CHEMBL621383,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,1274,,,108,Expert
8,,1,,,3061,,,B,,,,,,H,CHEMBL621384,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1317,,,108,Autocuration
8,,1,,9913.0,3062,,,B,,,,Bos taurus,,H,CHEMBL621385,BAO_0000357,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,5834,,,144,Autocuration
8,,1,,9913.0,3063,,,B,,,,Bos taurus,,H,CHEMBL617989,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,11147,,,144,Autocuration
4,,1,,10141.0,3064,,,F,,,,Cavia porcellus,,H,CHEMBL617990,BAO_0000019,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,14145,,,104714,Expert
4,,1,,10141.0,3065,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL875085,BAO_0000221,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10561,,Ileum,104714,Autocuration
4,,1,,10141.0,3066,,,F,,,,Cavia porcellus,,H,CHEMBL617991,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,15847,,,104714,Autocuration
4,,1,,10141.0,3067,,,F,,,,Cavia porcellus,,H,CHEMBL617992,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,15847,,,104714,Autocuration
4,,1,,10141.0,3068,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617993,BAO_0000221,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10561,,Ileum,104714,Autocuration
4,,1,,10141.0,3069,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617994,BAO_0000221,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,11454,,Ileum,104714,Autocuration
4,,1,,10141.0,3070,,,F,,,,Cavia porcellus,,H,CHEMBL617995,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3071,,,F,,,,Cavia porcellus,,H,CHEMBL617996,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3072,,,F,,,,Cavia porcellus,,H,CHEMBL617997,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3073,,,F,,,,Cavia porcellus,,H,CHEMBL617998,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,4639,,,104714,Autocuration
4,,1,,10141.0,3074,,,F,,,,Cavia porcellus,,H,CHEMBL617999,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3075,,,F,,,,Cavia porcellus,,H,CHEMBL618000,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3076,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617815,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",15253,,Ileum,104714,Autocuration
4,,1,,10141.0,3077,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617816,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",15253,,Ileum,104714,Autocuration
4,,1,,10141.0,3078,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617817,BAO_0000221,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,11963,,Ileum,104714,Autocuration
4,,1,,10141.0,3079,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617818,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1946,,Ileum,104714,Autocuration
4,,1,,10141.0,3080,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617819,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1946,,Ileum,104714,Autocuration
4,,1,,10141.0,3081,,,B,,,,Cavia porcellus,,H,CHEMBL617820,BAO_0000223,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,12045,,,104714,Autocuration
4,,1,,10141.0,3082,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617821,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,,Ileum,104714,Autocuration
4,,1,,10141.0,3083,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617822,BAO_0000221,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,,Ileum,104714,Autocuration
4,,1,,10141.0,3084,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617823,BAO_0000221,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),273,,Ileum,104714,Autocuration
4,,1,,10141.0,3085,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617824,BAO_0000221,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,188,,Ileum,104714,Autocuration
4,,1,,10141.0,3086,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617825,BAO_0000221,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,12919,,Ileum,104714,Autocuration
4,,1,,10141.0,3087,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617826,BAO_0000221,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,12918,,Ileum,104714,Autocuration
4,,1,,10141.0,3088,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617827,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,,Ileum,104714,Autocuration
4,,1,,10141.0,3089,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL617828,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,,Ileum,104714,Autocuration
4,,1,,10141.0,3090,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617829,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,,Ileum,104714,Autocuration
4,,1,,10141.0,3091,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617830,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1559,,Ileum,104714,Autocuration
4,,1,,10141.0,3092,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617831,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1559,,Ileum,104714,Autocuration
4,,1,,10141.0,3093,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL617832,BAO_0000221,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,14424,,Ileum,104714,Autocuration
0,,1,,10141.0,3094,,,B,,,,Cavia porcellus,,U,CHEMBL617833,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,13181,,,22226,Autocuration
8,,1,,,3095,,,B,,,,,,H,CHEMBL617834,BAO_0000357,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,5486,,,51,Autocuration
5,,1,,9606.0,3096,,,B,,,,Homo sapiens,,D,CHEMBL617835,BAO_0000223,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,6491,,,104714,Expert
4,,1,,,3097,,,B,,,,,,H,CHEMBL617836,BAO_0000223,Binding affinity towards 5-HT3 receptor,6013,,,104714,Autocuration
4,,1,,,3098,,,B,,,,,,H,CHEMBL617837,BAO_0000223,Binding activity radioligand.,12861,,,104714,Autocuration
4,,1,,,3099,,,B,,,,,,H,CHEMBL620392,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,12861,,,104714,Autocuration
4,,1,,,3100,,,B,,,,,,H,CHEMBL620393,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,5104,,,104714,Autocuration
4,,1,,,3101,,,B,,,,,,H,CHEMBL620394,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,5105,,,104714,Autocuration
4,,1,,,3102,,,B,,,,,,H,CHEMBL620395,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,5104,,,104714,Autocuration
0,,1,,,3103,,,B,,,,,,U,CHEMBL620396,BAO_0000019,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,3935,,,22226,Autocuration
4,,1,433.0,,3104,,,B,,,,,NG108-15,H,CHEMBL620582,BAO_0000219,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,13657,,,105030,Expert
4,,1,,,3105,,In vivo,B,,,,,,H,CHEMBL620583,BAO_0000218,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",10369,,,105030,Autocuration
4,,1,,,3106,,,B,,,,,,H,CHEMBL620584,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),10369,,,105030,Autocuration
4,,1,,,3107,,,B,,,,,,H,CHEMBL620585,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,12918,,,105030,Autocuration
4,,1,,,3108,,,B,,,,,,H,CHEMBL620586,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor,12918,,,105030,Autocuration
4,,1,,,3109,,,B,,,,,,H,CHEMBL620587,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),10369,,,105030,Autocuration
4,,1,,,3110,,,B,,,,,,H,CHEMBL620588,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,773,,,105030,Autocuration
4,,1,,,3111,,,F,,,,,,H,CHEMBL620589,BAO_0000218,5-hydroxytryptamine 3 receptor agonism in mouse,12918,,,105030,Autocuration
4,,1,,,3112,,,B,,,,,,H,CHEMBL620590,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,10561,,,105030,Autocuration
4,,1,,,3113,,,B,,,,,,H,CHEMBL617956,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,12827,,,105030,Autocuration
4,,1,,,3114,,,B,,,,,,H,CHEMBL617957,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,12827,,,105030,Autocuration
4,,1,,,3115,,,B,,,,,,H,CHEMBL617958,BAO_0000224,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,12918,,,105030,Autocuration
4,,1,,,3116,,,B,,,,,,H,CHEMBL617959,BAO_0000219,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,273,,,105030,Autocuration
4,,1,,,3117,,,B,,,,,,H,CHEMBL617960,BAO_0000219,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,273,,,105030,Autocuration
4,,1,,,3118,,,B,,,,,,H,CHEMBL617961,BAO_0000224,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,10561,,,105030,Autocuration
4,,1,,,3119,,In vitro,B,,,,,,H,CHEMBL617962,BAO_0000219,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,5033,,,105030,Autocuration
4,,1,339.0,,3120,,,B,,,,,N1E-115,H,CHEMBL617963,BAO_0000219,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,16429,,,105030,Autocuration
8,,1,,,3121,,,B,,,,,,H,CHEMBL617964,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,10322,,,11765,Autocuration
8,,1,,,3122,,,B,,,,,,H,CHEMBL617965,BAO_0000219,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,14331,,,11765,Autocuration
9,,1,,10090.0,3123,,,B,,,,Mus musculus,,D,CHEMBL617966,BAO_0000357,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,13462,,,10630,Autocuration
8,,1,,,3124,,,B,,,,,,H,CHEMBL857074,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,,,17106,Autocuration
8,,1,,9823.0,3125,,,B,,,,Sus scrofa,,H,CHEMBL617967,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,15086,,,144,Autocuration
8,,1,,9823.0,3126,,,B,,,,Sus scrofa,,H,CHEMBL617968,BAO_0000357,Binding activity radioligand.,12861,,,144,Autocuration
4,,1,,9986.0,3127,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617969,BAO_0000223,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,10561,,,104714,Autocuration
4,,1,,9986.0,3128,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617970,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,10561,,,104714,Autocuration
4,,1,,9986.0,3129,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617971,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,10561,,,104714,Autocuration
4,,1,,9986.0,3130,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL617972,BAO_0000019,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,10561,,,104714,Autocuration
4,,1,,9986.0,3131,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617973,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,,,104714,Autocuration
4,,1,,9986.0,3132,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617974,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,,,104714,Autocuration
4,,1,,9986.0,3133,,,F,2116.0,,,Oryctolagus cuniculus,,H,CHEMBL617975,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,,Ileum,104714,Autocuration
4,,1,,9986.0,3134,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617976,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,,,104714,Autocuration
4,,1,,9986.0,3135,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617977,BAO_0000019,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,,,104714,Autocuration
4,,1,,9986.0,3136,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617978,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,,,104714,Autocuration
4,,1,,9986.0,3137,,,F,,,,Oryctolagus cuniculus,,H,CHEMBL617979,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,,,104714,Autocuration
4,,1,449.0,9986.0,3138,,,B,,,,Oryctolagus cuniculus,CHO,H,CHEMBL617980,BAO_0000219,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,13047,,,104714,Autocuration
7,,1,,10116.0,3139,,,B,,,,Rattus norvegicus,,D,CHEMBL617981,BAO_0000019,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1650,,,104698,Autocuration
8,,1,,,3140,,,B,,,,,,H,CHEMBL617982,BAO_0000019,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),16288,,,12020,Autocuration
8,,1,,,3141,,,B,,,,,,H,CHEMBL617983,BAO_0000357,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),16288,,,12020,Autocuration
7,,1,,10116.0,3142,,,B,,,,Rattus norvegicus,,D,CHEMBL617984,BAO_0000019,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,10254,,,104698,Autocuration
6,,1,,,3143,,,B,,,,,,H,CHEMBL617985,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",14532,,,104698,Autocuration
6,,1,,,3144,,In vivo,F,948.0,,,,,H,CHEMBL617986,BAO_0000218,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",13392,,Heart,104698,Autocuration
6,,1,,,3145,,,F,948.0,,,,,H,CHEMBL617987,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",13392,,Heart,104698,Autocuration
6,,1,,,3146,,,F,948.0,,,,,H,CHEMBL617988,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",13392,,Heart,104698,Autocuration
6,,1,,,3147,,,F,948.0,,,,,H,CHEMBL617792,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",13392,,Heart,104698,Autocuration
6,,1,,,3148,,,F,948.0,,,,,H,CHEMBL617793,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",13392,,Heart,104698,Autocuration
6,,1,,,3149,,,F,,,,,,H,CHEMBL617794,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",13392,,,104698,Autocuration
6,,1,,,3150,,,F,,,,,,H,CHEMBL617795,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",13392,,,104698,Autocuration
6,,1,,,3151,,,F,,,,,,H,CHEMBL617796,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",13392,,,104698,Autocuration
6,,1,,,3152,,,F,,,,,,H,CHEMBL617797,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",13392,,,104698,Autocuration
7,,1,,10116.0,3153,,In vivo,F,,,,Rattus norvegicus,,D,CHEMBL617798,BAO_0000218,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1089,,,104698,Autocuration
6,,1,,,3154,,In vivo,F,,,,,,H,CHEMBL617799,BAO_0000218,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1089,,,104698,Autocuration
7,,1,,10116.0,3155,,In vivo,F,,,,Rattus norvegicus,,D,CHEMBL617800,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
7,,1,,10116.0,3156,,,F,,,,Rattus norvegicus,,D,CHEMBL617801,BAO_0000019,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,11454,,,104698,Autocuration
7,,1,,10116.0,3157,,In vivo,F,,,,Rattus norvegicus,,D,CHEMBL617802,BAO_0000218,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,12205,,,104698,Autocuration
7,,1,,10116.0,3158,,,F,,,,Rattus norvegicus,,D,CHEMBL617803,BAO_0000019,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1089,,,104698,Autocuration
6,,1,,,3159,,,B,,,,,,H,CHEMBL617804,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,5094,,,104698,Autocuration
7,,1,,10116.0,3160,,,B,,,,Rattus norvegicus,,D,CHEMBL617805,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,2622,,,104698,Autocuration
6,,1,,,3161,,,B,,,,,,H,CHEMBL617806,BAO_0000223,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,245,,,104698,Autocuration
6,,1,,,3162,,,B,,,,,,H,CHEMBL617807,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,14788,,,104698,Autocuration
6,,1,,,3163,,,B,,,,,,H,CHEMBL617808,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,14788,,,104698,Autocuration
6,,1,,,3164,,,B,,,,,,H,CHEMBL617809,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,3020,,,104698,Autocuration
6,,1,,,3165,,,B,,,,,,H,CHEMBL617810,BAO_0000019,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1742,,,104698,Autocuration
6,,1,,,3166,,,B,955.0,,,,,H,CHEMBL617811,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,17394,,Brain,104698,Autocuration
6,,1,,,3167,,,B,955.0,,,,,H,CHEMBL617812,BAO_0000221,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,17394,,Brain,104698,Autocuration
6,,1,,,3168,,,B,,,,,,H,CHEMBL617813,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,17394,,,104698,Autocuration
6,,1,,,3169,,,B,,,,,,H,CHEMBL617814,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,14286,,,104698,Autocuration
6,,1,,,3170,,,B,,,,,,H,CHEMBL617698,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,14178,,,104698,Autocuration
7,,1,,10116.0,3171,,,B,,,,Rattus norvegicus,,D,CHEMBL617699,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,14178,,,104698,Autocuration
7,,1,,10116.0,3172,,,B,,,,Rattus norvegicus,,D,CHEMBL617700,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,14178,,,104698,Autocuration
7,,1,,10116.0,3173,,,B,,,,Rattus norvegicus,,D,CHEMBL617701,BAO_0000223,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,14178,,,104698,Autocuration
6,,1,,,3174,,,B,,,,,,H,CHEMBL617702,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,15034,,,104698,Autocuration
6,,1,,,3175,,,B,,,,,,H,CHEMBL617703,BAO_0000249,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1089,Membranes,,104698,Autocuration
7,,1,,10116.0,3176,,,B,,,,Rattus norvegicus,,D,CHEMBL617704,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1089,,,104698,Autocuration
6,,1,,,3177,,,B,,,,,,H,CHEMBL617705,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,16532,,,104698,Autocuration
7,,1,,10116.0,3178,,,B,,,,Rattus norvegicus,,D,CHEMBL617706,BAO_0000223,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,12801,,,104698,Autocuration
6,,1,433.0,,3179,,,B,,,,,NG108-15,H,CHEMBL617707,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),15194,,,104698,Autocuration
6,,1,433.0,,3180,,,B,,,,,NG108-15,H,CHEMBL617708,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,15194,,,104698,Autocuration
6,,1,,,3181,,,B,,,,,,H,CHEMBL617709,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,15194,,,104698,Autocuration
6,,1,,,3182,,,B,,,,,,H,CHEMBL617710,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,15194,,,104698,Autocuration
6,,1,,,3183,,,B,,,,,,H,CHEMBL882925,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,15194,,,104698,Autocuration
6,,1,,,3184,,,B,,,,,,H,CHEMBL617711,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,15194,,,104698,Autocuration
6,,1,,,3185,,,F,,,,,,H,CHEMBL617712,BAO_0000019,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,10610,,,104698,Autocuration
7,,1,,10116.0,3186,,,F,,,,Rattus norvegicus,,D,CHEMBL617713,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,10355,,,104698,Autocuration
6,,1,,,3187,,,F,,,,,,H,CHEMBL617714,BAO_0000019,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",691,,,104698,Autocuration
6,,1,,,3188,,,F,,,,,,H,CHEMBL617715,BAO_0000218,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,10611,,,104698,Autocuration
6,,1,,,3189,,In vivo,F,,,,,,H,CHEMBL617716,BAO_0000218,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,12801,,,104698,Autocuration
6,,1,,,3190,,,F,,,,,,H,CHEMBL617717,BAO_0000218,Inhibition of 5-HT evoked reflex bradycardia in rat.,10609,,,104698,Autocuration
6,,1,,,3191,,In vivo,F,,,,,,H,CHEMBL617718,BAO_0000218,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3192,,In vivo,F,,,,,,H,CHEMBL617719,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3193,,In vivo,F,,,,,,H,CHEMBL617720,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),11454,,,104698,Autocuration
7,,1,,10116.0,3194,,In vivo,F,,,,Rattus norvegicus,,D,CHEMBL617721,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3195,,In vivo,F,,,,,,H,CHEMBL617722,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3196,,In vivo,F,,,,,,H,CHEMBL617723,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,11454,,,104698,Autocuration
6,,1,,,3197,,In vivo,F,,,,,,H,CHEMBL617724,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3198,,In vivo,F,,,,,,H,CHEMBL617725,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3199,,In vivo,F,,,,,,H,CHEMBL617726,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3200,,In vivo,F,,,,,,H,CHEMBL617727,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3201,,In vivo,F,,,,,,H,CHEMBL617728,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3202,,In vivo,F,,,,,,H,CHEMBL617729,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3203,,In vivo,F,,,,,,H,CHEMBL617730,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3204,,In vivo,F,,,,,,H,CHEMBL617731,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3205,,In vivo,F,,,,,,H,CHEMBL617732,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3206,,In vivo,F,,,,,,H,CHEMBL617733,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3207,,In vivo,F,,,,,,H,CHEMBL617734,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3208,,In vivo,F,,,,,,H,CHEMBL872874,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,11454,,,104698,Autocuration
6,,1,,,3209,,In vivo,F,,,,,,H,CHEMBL617735,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,11454,,,104698,Autocuration
6,,1,,,3210,,In vivo,F,,,,,,H,CHEMBL617736,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,11454,,,104698,Autocuration
6,,1,,,3211,,In vivo,F,,,,,,H,CHEMBL617737,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,11454,,,104698,Autocuration
6,,1,,,3212,,In vivo,F,,,,,,H,CHEMBL617738,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,11454,,,104698,Autocuration
6,,1,,,3213,,In vivo,F,,,,,,H,CHEMBL617739,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3214,,In vivo,F,,,,,,H,CHEMBL617740,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3215,,In vivo,F,,,,,,H,CHEMBL617741,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3216,,In vivo,F,,,,,,H,CHEMBL617742,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3217,,In vivo,F,,,,,,H,CHEMBL617743,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3218,,In vivo,F,,,,,,H,CHEMBL617744,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3219,,In vivo,F,,,,,,H,CHEMBL617745,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,11454,,,104698,Autocuration
6,,1,,,3220,,,F,,,,,,H,CHEMBL617746,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",670,,,104698,Autocuration
6,,1,,,3221,,,F,,,,,,H,CHEMBL617747,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",670,,,104698,Autocuration
6,,1,,,3222,,In vivo,F,,,,,,H,CHEMBL617748,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,10321,,,104698,Autocuration
6,,1,,,3223,,In vivo,F,,,,,,H,CHEMBL618909,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,10321,,,104698,Autocuration
6,,1,,,3224,,In vivo,F,,,,,,H,CHEMBL618910,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,10321,,,104698,Autocuration
6,,1,,,3225,,In vivo,F,,,,,,H,CHEMBL618911,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,10321,,,104698,Autocuration
6,,1,,,3226,,In vivo,F,,,,,,H,CHEMBL618912,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,10321,,,104698,Autocuration
6,,1,,,3227,,In vivo,F,,,,,,H,CHEMBL618913,BAO_0000218,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),10322,,,104698,Autocuration
6,,1,,,3228,,,F,,,,,,H,CHEMBL618914,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,15412,,,104698,Autocuration
6,,1,,,3229,,,F,,,,,,H,CHEMBL618915,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,15412,,,104698,Autocuration
7,,1,,10116.0,3230,,,B,,,,Rattus norvegicus,,D,CHEMBL618916,BAO_0000223,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,15412,,,104698,Autocuration
6,,1,,,3231,,,F,,,,,,H,CHEMBL618917,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,15412,,,104698,Autocuration
7,,1,,,3232,,,B,10000000.0,,,,,D,CHEMBL618918,BAO_0000221,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,15412,,Hippocampus,104698,Intermediate
7,,1,,10116.0,3233,,,B,,,,Rattus norvegicus,,D,CHEMBL618919,BAO_0000019,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,15412,,,104698,Autocuration
7,,1,,10116.0,3234,,,B,,,,Rattus norvegicus,,D,CHEMBL618920,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,17394,,,104698,Autocuration
6,,1,,,3235,,,B,,,,,,H,CHEMBL618921,BAO_0000223,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,12457,,,104698,Autocuration
6,,1,,,3236,,,B,,,,,,H,CHEMBL618922,BAO_0000019,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,12457,,,104698,Autocuration
6,,1,,,3237,,,B,,,,,,H,CHEMBL618923,BAO_0000019,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,12205,,,104698,Autocuration
6,,1,,,3238,,,B,,,,,,H,CHEMBL618924,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,14532,,,104698,Autocuration
6,,1,,,3239,,,B,,,,,,H,CHEMBL618925,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1122,,,104698,Autocuration
6,,1,,,3240,,,B,,,,,,H,CHEMBL618926,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,5094,,,104698,Autocuration
9,,1,,10141.0,3241,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL618927,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3242,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL618928,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3243,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL618929,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3244,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL618930,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3245,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL618931,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3246,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619594,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3247,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619595,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3248,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619596,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,13961,,Ileum,20033,Intermediate
9,,1,,10141.0,3249,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619755,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,13961,,Ileum,20033,Intermediate
9,,1,,10141.0,3250,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619756,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3251,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619757,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3252,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619758,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3253,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619759,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3254,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619760,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3255,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619761,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3256,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619762,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3257,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619763,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3258,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL617868,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",14290,,Ileum,20033,Intermediate
9,,1,,10141.0,3259,,,B,,,,Cavia porcellus,,D,CHEMBL617869,BAO_0000357,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,15034,,,20033,Intermediate
9,,1,,10141.0,3260,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL882926,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,,Striatum,20033,Intermediate
9,,1,,10141.0,3261,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617870,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,,Striatum,20033,Intermediate
9,,1,,10141.0,3262,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617871,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,5399,,Striatum,20033,Intermediate
9,,1,,10141.0,3263,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617872,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,17394,,Striatum,20033,Intermediate
9,,1,,10141.0,3264,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617873,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,17394,,Striatum,20033,Intermediate
9,,1,,10141.0,3265,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL617874,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,17394,,Striatum,20033,Intermediate
9,,1,,10141.0,3266,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619067,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,13961,,Ileum,20033,Intermediate
9,,1,,10141.0,3267,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619068,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,13961,,Ileum,20033,Intermediate
9,,1,,10141.0,3268,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619069,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,13961,,Ileum,20033,Intermediate
9,,1,,10141.0,3269,,,B,,,,Cavia porcellus,,D,CHEMBL619070,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,16946,,,20033,Intermediate
9,,1,,10141.0,3270,,,B,,,,Cavia porcellus,,D,CHEMBL619071,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,16946,,,20033,Intermediate
9,,1,,10141.0,3271,,,F,,,,Cavia porcellus,,D,CHEMBL619072,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor,15034,,,20033,Intermediate
9,,1,,10141.0,3272,,,F,,,,Cavia porcellus,,D,CHEMBL619073,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,15034,,,20033,Intermediate
9,,1,,10141.0,3273,,,F,,,,Cavia porcellus,,D,CHEMBL619074,BAO_0000019,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,12918,,,20033,Intermediate
9,,1,,10141.0,3274,,,B,,,,Cavia porcellus,,D,CHEMBL619075,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,16946,,,20033,Intermediate
9,,1,,10141.0,3275,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL619076,BAO_0000357,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,17394,,Striatum,20033,Intermediate
9,,1,,10141.0,3276,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL619077,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,15034,,Striatum,20033,Intermediate
9,,1,,10141.0,3277,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL619078,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,,Striatum,20033,Intermediate
9,,1,,10141.0,3278,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL619079,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,,Striatum,20033,Intermediate
9,,1,,10141.0,3279,,,B,2116.0,,,Cavia porcellus,,D,CHEMBL619080,BAO_0000221,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,17358,,Ileum,20033,Intermediate
9,,1,,10141.0,3280,,,B,,,,Cavia porcellus,,D,CHEMBL619081,BAO_0000357,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,12953,,,20033,Expert
9,,1,,10141.0,3281,,,B,,,,Cavia porcellus,,D,CHEMBL619082,BAO_0000357,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,12953,,,20033,Intermediate
9,,1,,10141.0,3282,,,B,,,,Cavia porcellus,,D,CHEMBL619083,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,12953,,,20033,Intermediate
9,,1,,10141.0,3283,,,B,,,,Cavia porcellus,,D,CHEMBL619084,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,12953,,,20033,Intermediate
9,,1,,10141.0,3284,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL859397,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,273,,Ileum,20033,Intermediate
9,,1,,10141.0,3285,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619085,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,12918,,Ileum,20033,Intermediate
9,,1,,10141.0,3286,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619086,BAO_0000221,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,12919,,Ileum,20033,Intermediate
9,,1,,10141.0,3287,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619087,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,273,,Ileum,20033,Intermediate
9,,1,,10141.0,3288,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619088,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,273,,Ileum,20033,Intermediate
9,,1,,10141.0,3289,,,B,,,,Cavia porcellus,,D,CHEMBL619089,BAO_0000357,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,13181,,,20033,Intermediate
8,,1,,10141.0,3290,,,B,,,,Cavia porcellus,,H,CHEMBL619090,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,13181,,,168,Autocuration
9,,1,,10141.0,3291,,,F,,,,Cavia porcellus,,D,CHEMBL619091,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 4 receptor,15034,,,20033,Intermediate
9,,1,,10141.0,3292,,,B,,,,Cavia porcellus,,D,CHEMBL619092,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,5033,,,20033,Intermediate
9,,1,,10141.0,3293,,,B,,,,Cavia porcellus,,D,CHEMBL619093,BAO_0000019,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1980,,,20033,Intermediate
8,,1,722.0,10141.0,3294,,,B,,,,Cavia porcellus,HEK293,H,CHEMBL619094,BAO_0000219,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,13181,,,168,Autocuration
9,,1,,10141.0,3295,,,B,,,,Cavia porcellus,,D,CHEMBL619095,BAO_0000019,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,14287,,,20033,Intermediate
9,,1,,10141.0,3296,,,B,,,,Cavia porcellus,,D,CHEMBL857988,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1317,,,20033,Intermediate
9,,1,,10141.0,3297,,,B,,,,Cavia porcellus,,D,CHEMBL619096,BAO_0000357,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,15316,,,20033,Intermediate
9,,1,,10141.0,3298,,,B,2435.0,,,Cavia porcellus,,D,CHEMBL619097,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,16429,,Striatum,20033,Intermediate
9,,1,,10141.0,3299,,,B,10000000.0,,,Cavia porcellus,,D,CHEMBL619098,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,14818,,Hippocampus,20033,Intermediate
9,,1,,10141.0,3300,,,B,,,,Cavia porcellus,,D,CHEMBL619751,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,15194,,,20033,Intermediate
9,,1,,10141.0,3301,,,B,,,,Cavia porcellus,,D,CHEMBL619752,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,15194,,,20033,Intermediate
9,,1,,10141.0,3302,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL875096,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,13961,,Ileum,20033,Intermediate
8,,1,,,3303,,,B,,,,,,H,CHEMBL619004,BAO_0000357,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,5486,,,108,Autocuration
8,,1,,,3304,,,B,,,,,,H,CHEMBL619005,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,16209,,,168,Autocuration
8,,1,,,3305,,,B,,,,,,H,CHEMBL619006,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,17085,,,168,Autocuration
8,,1,308.0,,3306,,,B,,,,,HeLa,H,CHEMBL619007,BAO_0000219,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,4199,,,168,Autocuration
8,,1,,,3307,,,B,,,,,,H,CHEMBL619008,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,15146,,,168,Autocuration
8,,1,,,3308,,,B,,,,,,H,CHEMBL619009,BAO_0000357,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,5213,,,168,Autocuration
8,,1,308.0,,3309,,,B,,,,,HeLa,H,CHEMBL619010,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",4829,,,168,Autocuration
8,,1,,,3310,,,B,,,,,,H,CHEMBL619011,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,17358,,,10622,Autocuration
8,,1,,,3311,,,B,,,,,,H,CHEMBL619012,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,17358,,,10622,Autocuration
8,,1,,,3312,,,B,,,,,,H,CHEMBL619013,BAO_0000219,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,16946,,,10622,Autocuration
8,,1,,,3313,,,B,,,,,,H,CHEMBL619014,BAO_0000357,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,17358,,,10622,Autocuration
8,,1,,,3314,,,F,2081.0,,,,,H,CHEMBL857503,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,268,,Cardiac atrium,11249,Autocuration
8,,1,,,3315,,,F,2081.0,,,,,H,CHEMBL619015,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,268,,Cardiac atrium,11249,Autocuration
8,,1,,,3316,,,B,,,,,,H,CHEMBL619016,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,15086,,,11249,Autocuration
8,,1,,,3317,,,B,10000000.0,,,,,H,CHEMBL619017,BAO_0000221,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,14875,,Hippocampus,11249,Autocuration
8,,1,,9823.0,3318,,,B,10000000.0,,,Sus scrofa,,H,CHEMBL619018,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,13267,,Hippocampus,168,Autocuration
8,,1,,9986.0,3319,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL619019,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,13047,,,168,Autocuration
9,,1,,10116.0,3320,,,B,,,,Rattus norvegicus,,D,CHEMBL619020,BAO_0000357,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1650,,,10623,Expert
8,,1,,,3321,,,F,,,,,,H,CHEMBL619021,BAO_0000019,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,567,,,10623,Autocuration
8,,1,,,3322,,,B,,,,,,H,CHEMBL619022,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,17358,,,10623,Autocuration
8,,1,,,3323,,,B,,,,,,H,CHEMBL619023,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,188,,,10623,Autocuration
8,,1,,,3324,,,F,,,,,,H,CHEMBL619024,BAO_0000019,lntrinsic activity relative to 5-HT receptor,670,,,10623,Autocuration
8,,1,,,3325,,,F,,,,,,H,CHEMBL619025,BAO_0000019,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,204,,,10623,Autocuration
8,,1,,,3326,,,F,,,,,,H,CHEMBL619026,BAO_0000019,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1946,,,10623,Expert
8,,1,,,3327,,,F,,,,,,H,CHEMBL619027,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,6398,,,10623,Autocuration
8,,1,,,3328,,,F,,,,,,H,CHEMBL619028,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,6398,,,10623,Autocuration
8,,1,,,3329,,,F,,,,,,H,CHEMBL619029,BAO_0000019,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,17358,,,10623,Autocuration
8,,1,,,3330,,,F,,,,,,H,CHEMBL619030,BAO_0000019,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,6398,,,10623,Autocuration
8,,1,,,3331,,,B,,,,,,H,CHEMBL619031,BAO_0000357,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,11752,,,10623,Expert
8,,1,,,3332,,,F,,,,,,H,CHEMBL619032,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,809,,,10623,Autocuration
9,,1,,10116.0,3333,,,B,,,,Rattus norvegicus,,D,CHEMBL619033,BAO_0000357,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,14178,,,10623,Expert
8,,1,,,3334,,,B,,,,,,H,CHEMBL619034,BAO_0000357,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,567,,,10623,Autocuration
8,,1,,,3335,,,B,,,,,,H,CHEMBL619035,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1946,,,10623,Autocuration
8,,1,,,3336,,,B,,,,,,H,CHEMBL619036,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1946,,,10623,Autocuration
9,,1,,10116.0,3337,,,B,,,,Rattus norvegicus,,D,CHEMBL619037,BAO_0000019,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,13961,,,10623,Expert
8,,1,,,3338,,,B,2435.0,,,,,H,CHEMBL619038,BAO_0000249,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,6238,,Striatum,10623,Autocuration
8,,1,,,3339,,,B,,,,,,H,CHEMBL619039,BAO_0000249,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,14290,,,10623,Autocuration
8,,1,,,3340,,,B,,,,,,H,CHEMBL619040,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,14290,,,10623,Expert
9,,1,,10116.0,3341,,,B,2435.0,,,Rattus norvegicus,,D,CHEMBL619041,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,809,,Striatum,10623,Expert
8,,1,,,3342,,,B,2435.0,,,,,H,CHEMBL619042,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1578,,Striatum,10623,Autocuration
8,,1,,,3343,,,B,2435.0,,,,,H,CHEMBL619043,BAO_0000249,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,16709,,Striatum,10623,Expert
8,,1,,,3344,,,B,2435.0,,,,,H,CHEMBL619044,BAO_0000019,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1946,,Striatum,10623,Expert
8,,1,,,3345,,,B,2435.0,,,,,H,CHEMBL619045,BAO_0000249,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,15253,,Striatum,10623,Expert
8,,1,,,3346,,,B,2435.0,,,,,H,CHEMBL619046,BAO_0000249,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,4535,,Striatum,10623,Expert
8,,1,,,3347,,,B,,,,,,H,CHEMBL619047,BAO_0000249,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,13961,,,10623,Expert
8,,1,,,3348,,,F,955.0,,,,,H,CHEMBL619048,BAO_0000221,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,17358,,Brain,10623,Autocuration
8,,1,,,3349,,,F,,,,,,H,CHEMBL859398,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,15847,,,10623,Autocuration
8,,1,,,3350,,,F,,,,,,H,CHEMBL619049,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,15847,,,10623,Autocuration
8,,1,,,3351,,,F,,,,,,H,CHEMBL857886,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,670,,,10623,Autocuration
8,,1,,,3352,,,F,,,,,,H,CHEMBL619050,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,670,,,10623,Autocuration
8,,1,,,3353,,,F,,,,,,H,CHEMBL620591,BAO_0000019,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1317,,,10623,Autocuration
9,,1,,10116.0,3354,,,B,,,,Rattus norvegicus,,D,CHEMBL620592,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 4 receptor,12936,,,10623,Expert
8,,1,,,3355,,,B,2435.0,,,,,H,CHEMBL620593,BAO_0000249,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,4535,,Striatum,10623,Expert
9,,1,,10116.0,3356,,,F,,,,Rattus norvegicus,,D,CHEMBL620594,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,14424,,,10623,Expert
8,,1,,,3357,,,F,,,,,,H,CHEMBL875079,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,14424,,,10623,Expert
8,,1,,,3358,,,F,,,,,,H,CHEMBL620595,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,14424,,,10623,Expert
9,,1,,10116.0,3359,,,F,,,,Rattus norvegicus,,D,CHEMBL620596,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,14424,,,10623,Expert
8,,1,,,3360,,,F,,,,,,H,CHEMBL620597,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,14424,,,10623,Autocuration
8,,1,,,3361,,,F,,,,,,H,CHEMBL620598,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,14424,,,10623,Expert
8,,1,,,3362,,,F,,,,,,H,CHEMBL620599,BAO_0000218,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),14424,,,10623,Expert
8,,1,,,3363,,,F,,,,,,H,CHEMBL620600,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,14424,,,10623,Autocuration
8,,1,,10116.0,3364,,,F,,,,Rattus norvegicus,,H,CHEMBL620601,BAO_0000019,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1980,,,168,Autocuration
8,,1,,,3365,,,F,,,,,,H,CHEMBL620602,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,4639,,,168,Autocuration
8,,1,,,3366,,,B,,,,,,H,CHEMBL620603,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor,17358,,,168,Autocuration
8,,1,,,3367,,,B,,,,,,H,CHEMBL620604,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,17358,,,168,Autocuration
8,,1,,,3368,,,B,,,,,,H,CHEMBL620605,BAO_0000357,Compound was tested for 5-hydroxytryptamine 4 binding affinity,17358,,,168,Autocuration
8,,1,,,3369,,,B,,,,,,H,CHEMBL620606,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1558,,,168,Autocuration
8,,1,,,3370,,,F,,,,,,H,CHEMBL620607,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,,,168,Autocuration
8,,1,,,3371,,,B,,,,,,H,CHEMBL620608,BAO_0000357,In vitro binding affinity towards 5-HT4 receptor was determined,16117,,,168,Autocuration
8,,1,,,3372,,,F,,,,,,H,CHEMBL620609,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,,,168,Autocuration
8,,1,,,3373,,,F,,,,,,H,CHEMBL620610,BAO_0000019,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,17358,,,168,Autocuration
8,,1,,,3374,,,B,,,,,,H,CHEMBL620611,BAO_0000357,Tested for selectivity for 5-hydroxytryptamine 4 receptor,17358,,,168,Autocuration
8,,1,,,3375,,,B,,,,,,H,CHEMBL620612,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,17358,,,168,Autocuration
8,,1,,,3376,,,B,,,,,,H,CHEMBL620613,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,17358,,,168,Autocuration
8,,1,,,3377,,,B,,,,,,H,CHEMBL620614,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,17358,,,168,Autocuration
8,,1,,,3378,,,B,,,,,,H,CHEMBL620615,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 4 receptor,1274,,,168,Expert
6,,1,,,3379,,,B,,,,,,H,CHEMBL857075,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,10728,Brain membranes,,104698,Autocuration
6,,1,,,3380,,,B,,,,,,H,CHEMBL620616,BAO_0000249,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,11695,Brain membranes,,104698,Autocuration
6,,1,,,3381,,,B,,,,,,H,CHEMBL619411,BAO_0000249,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,11695,Brain membranes,,104698,Autocuration
6,,1,,,3382,,,B,,,,,,H,CHEMBL619412,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,12490,,,104698,Autocuration
7,,1,,10116.0,3383,,,B,,,,Rattus norvegicus,,D,CHEMBL619413,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,11828,,,104698,Autocuration
6,,1,,,3384,,,B,10000000.0,,,,,H,CHEMBL619414,BAO_0000221,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,12253,,Hippocampus,104698,Autocuration
6,,1,,,3385,,,B,,,,,,H,CHEMBL619415,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,10561,,,104698,Autocuration
6,,1,,,3386,,,B,,,,,,H,CHEMBL619416,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,10561,,,104698,Autocuration
6,,1,,,3387,,,F,,,,,,H,CHEMBL619417,BAO_0000019,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,14432,,,104698,Autocuration
7,,1,,10116.0,3388,,,B,,,,Rattus norvegicus,,D,CHEMBL619418,BAO_0000223,Binding affinity against rat 5-hydroxytryptamine 3 receptor,12936,,,104698,Autocuration
7,,1,,10116.0,3389,,,B,,,,Rattus norvegicus,,D,CHEMBL619419,BAO_0000223,Binding affinity against 5-Hydroxytryptamine 3 receptor,1274,,,104698,Autocuration
6,,1,,,3390,,,B,,,,,,H,CHEMBL619420,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1980,,,104698,Autocuration
6,,1,,,3391,,,B,,,,,,H,CHEMBL619421,BAO_0000249,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,670,,,104698,Autocuration
7,,1,,10116.0,3392,,,B,,,,Rattus norvegicus,,D,CHEMBL619422,BAO_0000019,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,968,,,104698,Autocuration
6,,1,,,3393,,,B,,,,,,H,CHEMBL619423,BAO_0000019,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,14287,,,104698,Autocuration
6,,1,,,3394,,,B,,,,,,H,CHEMBL875080,BAO_0000019,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,567,,,104698,Autocuration
6,,1,,,3395,,,B,,,,,,H,CHEMBL619424,BAO_0000019,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,13267,,,104698,Autocuration
6,,1,,,3396,,,B,,,,,,H,CHEMBL619425,BAO_0000249,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,14826,,,104698,Autocuration
6,,1,,,3397,,,B,,,,,,H,CHEMBL619426,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,15194,,,104698,Autocuration
6,,1,,,3398,,,B,,,,,,H,CHEMBL619427,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,15194,,,104698,Autocuration
7,,1,,10116.0,3399,,,B,,,,Rattus norvegicus,,D,CHEMBL619645,BAO_0000223,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,10394,,,104698,Autocuration
9,,1,,,3400,,,B,,,,,,D,CHEMBL619646,BAO_0000249,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",13657,,,10576,Expert
8,,1,,,3401,,,F,955.0,,,,,H,CHEMBL619647,BAO_0000221,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1879,,Brain,12020,Autocuration
8,,1,,,3402,,,F,,,,,,H,CHEMBL619648,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1879,,,12020,Autocuration
8,,1,,,3403,,,F,,,,,,H,CHEMBL619165,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1879,,,12020,Autocuration
8,,1,,,3404,,In vivo,F,,,,,,H,CHEMBL620719,BAO_0000218,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,204,,,12020,Autocuration
8,,1,,,3405,,,B,,,,,,H,CHEMBL872924,BAO_0000019,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1879,,,12020,Autocuration
8,,1,,,3406,,,B,,,,,,H,CHEMBL620720,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1879,,,12020,Autocuration
8,,1,,,3407,,,B,,,,,,H,CHEMBL620721,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1879,,,12020,Autocuration
8,,1,,,3408,,,B,,,,,,H,CHEMBL620722,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1879,,,12020,Autocuration
6,,1,,,3409,,,B,,,,,,H,CHEMBL620723,BAO_0000019,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",10641,,,104698,Autocuration
8,,1,,,3410,,,B,,,,,,H,CHEMBL620724,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,773,,,12020,Autocuration
6,,1,,,3411,,,B,,,,,,H,CHEMBL620725,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,11952,,,104698,Autocuration
9,,1,,10116.0,3412,,,F,,,,Rattus norvegicus,,D,CHEMBL620726,BAO_0000019,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,14145,,,12020,Autocuration
8,,1,,,3413,,,B,,,,,,H,CHEMBL620727,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor,17066,,,144,Expert
4,,1,,,3414,,,B,,,,,,H,CHEMBL620728,BAO_0000223,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,6398,,,104714,Autocuration
0,,1,,,3415,,,B,,,,,,U,CHEMBL620729,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,10321,,,22226,Autocuration
4,,1,,,3416,,,F,,,,,,H,CHEMBL858288,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,511,,,104714,Autocuration
4,,1,,,3417,,,B,,,,,,H,CHEMBL620730,BAO_0000223,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,4639,,,104714,Autocuration
4,,1,,,3418,,,B,,,,,,H,CHEMBL620731,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,4639,,,104714,Autocuration
4,,1,,10141.0,3419,,,F,,,,Cavia porcellus,,H,CHEMBL620732,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3420,,,F,,,,Cavia porcellus,,H,CHEMBL618042,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3421,,,F,,,,Cavia porcellus,,H,CHEMBL618043,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,4639,,,104714,Autocuration
4,,1,,,3422,,,B,,,,,,H,CHEMBL618044,BAO_0000223,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1558,,,104714,Autocuration
4,,1,,,3423,,,F,,,,,,H,CHEMBL618045,BAO_0000019,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,268,,,104714,Autocuration
4,,1,,,3424,,,B,,,,,,H,CHEMBL618046,BAO_0000223,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,2474,,,104714,Autocuration
4,,1,,,3425,,,F,,,,,,H,CHEMBL618047,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,5067,,,104714,Autocuration
4,,1,,,3426,,,F,,,,,,H,CHEMBL875084,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,5067,,,104714,Autocuration
4,,1,,,3427,,,F,,,,,,H,CHEMBL618048,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,5067,,,104714,Autocuration
4,,1,,,3428,,,B,,,,,,H,CHEMBL618049,BAO_0000223,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,5067,,,104714,Autocuration
4,,1,,,3429,,,F,,,,,,H,CHEMBL619764,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,5067,,,104714,Autocuration
4,,1,,,3430,,,F,,,,,,H,CHEMBL619765,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,5067,,,104714,Autocuration
4,,1,,,3431,,,F,,,,,,H,CHEMBL619766,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,5067,,,104714,Autocuration
4,,1,,,3432,,,B,,,,,,H,CHEMBL619767,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,5067,,,104714,Autocuration
4,,1,,,3433,,,B,,,,,,H,CHEMBL619768,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,5067,,,104714,Autocuration
4,,1,,,3434,,,F,,,,,,H,CHEMBL619769,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,5067,,,104714,Autocuration
4,,1,,,3435,,,B,,,,,,H,CHEMBL619770,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,5067,,,104714,Autocuration
4,,1,,,3436,,,B,,,,,,H,CHEMBL619771,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,5067,,,104714,Autocuration
4,,1,,,3437,,,B,,,,,,H,CHEMBL619772,BAO_0000219,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,14331,,,104714,Autocuration
4,,1,,,3438,,,B,,,,,,H,CHEMBL619773,BAO_0000223,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,5067,,,104714,Autocuration
4,,1,433.0,,3439,,,B,,,,,NG108-15,H,CHEMBL619774,BAO_0000219,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,6179,,,104714,Autocuration
4,,1,,,3440,,,B,,,,,,H,CHEMBL875083,BAO_0000019,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,4265,,,104714,Autocuration
4,,1,433.0,,3441,,,B,,,,,NG108-15,H,CHEMBL620718,BAO_0000219,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,4265,,,104714,Autocuration
4,,1,,,3442,,,B,,,,,,H,CHEMBL618127,BAO_0000223,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,17358,,,104714,Autocuration
4,,1,,,3443,,,B,,,,,,H,CHEMBL618128,BAO_0000223,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,17358,,,104714,Autocuration
4,,1,,,3444,,In vitro,B,,,,,,H,CHEMBL618129,BAO_0000219,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,13628,,,104714,Autocuration
4,,1,,,3445,,,B,,,,,,H,CHEMBL618130,BAO_0000223,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,4612,,,104714,Autocuration
4,,1,,,3446,,,F,,,,,,H,CHEMBL618131,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,17358,,,104714,Autocuration
4,,1,,10141.0,3447,,,F,,,,Cavia porcellus,,H,CHEMBL618132,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3448,,,F,,,,Cavia porcellus,,H,CHEMBL618133,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,4639,,,104714,Autocuration
4,,1,,10141.0,3449,,,F,,,,Cavia porcellus,,H,CHEMBL618134,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,4639,,,104714,Autocuration
4,,1,,10141.0,3450,,,F,,,,Cavia porcellus,,H,CHEMBL618135,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4639,,,104714,Autocuration
4,,1,,,3451,,,B,,,,,,H,CHEMBL618136,BAO_0000223,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,511,,,104714,Autocuration
4,,1,,,3452,,,B,,,,,,H,CHEMBL618137,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,1479,,,104714,Autocuration
4,,1,,,3453,,,B,,,,,,H,CHEMBL618138,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1317,,,104714,Autocuration
4,,1,,,3454,,,B,,,,,,H,CHEMBL618139,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,12146,,,104714,Autocuration
4,,1,,,3455,,,B,,,,,,H,CHEMBL618140,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,12146,,,104714,Autocuration
4,,1,,,3456,,,B,,,,,,H,CHEMBL618141,BAO_0000223,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,13969,,,104714,Autocuration
8,,1,,,3457,,,B,,,,,,H,CHEMBL873478,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,13392,,,108,Expert
6,,1,,,3458,,,B,,,,,,H,CHEMBL618142,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,13392,,,104698,Autocuration
8,,1,,,3459,,,B,,,,,,H,CHEMBL618143,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,14159,,,144,Autocuration
8,,1,,,3460,,,B,,,,,,H,CHEMBL618144,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1558,,,144,Autocuration
8,,1,,,3461,,,B,,,,,,H,CHEMBL618145,BAO_0000357,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,16655,,,144,Autocuration
4,,1,,,3462,,,B,,,,,,H,CHEMBL618146,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,13020,,,104714,Autocuration
4,,1,,,3463,,,B,,,,,,H,CHEMBL618147,BAO_0000223,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,13021,,,104714,Autocuration
4,,1,,,3464,,,B,,,,,,H,CHEMBL618148,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,13020,,,104714,Autocuration
8,,1,,,3465,,,B,,,,,,H,CHEMBL618149,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,10321,,,144,Autocuration
8,,1,,,3466,,,B,,,,,,H,CHEMBL872927,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,15818,,,144,Autocuration
8,,1,,,3467,,,B,,,,,,H,CHEMBL618150,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,15818,,,144,Autocuration
8,,1,,,3468,,,B,,,,,,H,CHEMBL618151,BAO_0000357,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,17358,,,144,Autocuration
8,,1,,,3469,,,B,,,,,,H,CHEMBL875094,BAO_0000357,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,2222,,,144,Autocuration
8,,1,,,3470,,,B,,,,,,H,CHEMBL618152,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,10322,,,144,Autocuration
8,,1,,,3471,,,B,,,,,,H,CHEMBL618153,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,16117,,,144,Autocuration
8,,1,,,3472,,,B,,,,,,H,CHEMBL618888,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,17200,,,144,Autocuration
8,,1,,,3473,,,F,,,,,,H,CHEMBL618889,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor agonist activity,17358,,,144,Autocuration
8,,1,,,3474,,,B,,,,,,H,CHEMBL618890,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,16700,,,144,Autocuration
8,,1,,,3475,,,B,,,,,,H,CHEMBL618891,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1980,,,144,Autocuration
8,,1,,,3476,,,B,,,,,,H,CHEMBL619054,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1980,,,144,Autocuration
4,,1,,,3477,,,B,,,,,,H,CHEMBL619055,BAO_0000223,Binding affinity against the 5-hydroxytryptamine 3 receptor,12409,,,104714,Autocuration
8,,1,,,3478,,,B,,,,,,H,CHEMBL619056,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,4365,,,144,Autocuration
8,,1,,,3479,,,F,,,,,,H,CHEMBL619057,BAO_0000019,Percent efficacy against 5-hydroxytryptamine 3A receptor,4365,,,144,Autocuration
8,,1,,,3480,,,B,,,,,,H,CHEMBL619058,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,4365,,,144,Autocuration
9,,1,,10116.0,3481,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL619059,BAO_0000219,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,6769,,,12020,Expert
9,,1,,10116.0,3482,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL619060,BAO_0000219,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,6769,,,12020,Expert
9,,1,,10116.0,3483,,,F,,,,Rattus norvegicus,Oocytes,D,CHEMBL875095,BAO_0000219,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,6769,,,12020,Expert
9,,1,,10141.0,3484,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619061,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3485,,,F,2116.0,,,Cavia porcellus,,D,CHEMBL619062,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,809,,Ileum,20033,Intermediate
9,,1,,10141.0,3486,,,F,,,,Cavia porcellus,,D,CHEMBL619063,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,14290,,,20033,Intermediate
9,,1,,10141.0,3487,,,B,2116.0,,,Cavia porcellus,,D,CHEMBL619064,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,17358,,Ileum,20033,Intermediate
9,,1,,10141.0,3488,,,B,,,,Cavia porcellus,,D,CHEMBL619065,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,17358,,,20033,Intermediate
9,,1,,10141.0,3489,,,B,2116.0,,,Cavia porcellus,,D,CHEMBL619066,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,17358,,Ileum,20033,Intermediate
8,,1,,,3490,,,B,2116.0,,,,,H,CHEMBL619775,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,17386,,Ileum,10209,Autocuration
8,,1,,,3491,,,B,,,,,,H,CHEMBL619776,BAO_0000357,Affinity against 5-hydroxytryptamine 7 receptor,3269,,,10209,Autocuration
4,,1,,10141.0,3492,,,B,,,,Cavia porcellus,,H,CHEMBL619777,BAO_0000224,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,7721,,,104841,Autocuration
4,,1,,10141.0,3493,,,B,,,,Cavia porcellus,,H,CHEMBL619778,BAO_0000224,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,7721,,,104841,Autocuration
4,,1,,10141.0,3494,,,B,2116.0,,,Cavia porcellus,,H,CHEMBL619779,BAO_0000221,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,9117,,Ileum,104841,Autocuration
4,,1,,10141.0,3495,,,B,,,,Cavia porcellus,,H,CHEMBL619780,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",7721,,,104841,Autocuration
4,,1,,10141.0,3496,,,B,,,,Cavia porcellus,,H,CHEMBL619166,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",7721,,,104841,Autocuration
4,,1,,10141.0,3497,,,F,,,,Cavia porcellus,,H,CHEMBL619167,BAO_0000019,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,15796,,,104841,Autocuration
4,,1,,10141.0,3498,,,F,,,,Cavia porcellus,,H,CHEMBL619168,BAO_0000019,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,15796,,,104841,Autocuration
9,,1,,9606.0,3499,,,B,2081.0,,,Homo sapiens,,D,CHEMBL619169,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,15650,,Cardiac atrium,168,Expert
9,,1,,9606.0,3500,,,B,2081.0,,,Homo sapiens,,D,CHEMBL619170,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,15650,,Cardiac atrium,168,Expert
5,,1,,9606.0,3501,,,F,,,,Homo sapiens,,D,CHEMBL619171,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",6866,,,104841,Autocuration
9,,1,,9606.0,3502,,,F,2081.0,,,Homo sapiens,,D,CHEMBL619172,BAO_0000219,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",15650,,Cardiac atrium,168,Expert
0,,1,,10090.0,3503,,,B,,,,Mus musculus,,U,CHEMBL619173,BAO_0000019,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,10063,,,22226,Autocuration
0,,1,,10090.0,3504,,,B,,,,Mus musculus,,U,CHEMBL619174,BAO_0000019,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,12665,,,22226,Autocuration
4,,1,,,3505,,,B,,,,,,H,CHEMBL619175,BAO_0000019,5-hydroxytryptamine receptor binding affinity was determined in rats,7504,,,104705,Autocuration
4,,1,,,3506,,,B,,,,,,H,CHEMBL619176,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine receptor.,7504,,,104705,Autocuration
4,,1,,,3507,,,B,,,,,,H,CHEMBL619177,BAO_0000019,Affinity against 5-hydroxytryptamine receptors in rat fundus model,7038,,,104705,Autocuration
4,,1,,,3508,,,B,,,,,,H,CHEMBL619178,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,7626,,,104705,Autocuration
4,,1,,,3509,,,B,,,,,,H,CHEMBL619179,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,7626,,,104705,Autocuration
4,,1,,,3510,,,F,945.0,,,,,H,CHEMBL619180,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,7185,,Stomach,104705,Autocuration
4,,1,,,3511,,,F,945.0,,,,,H,CHEMBL619181,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,7185,,Stomach,104705,Autocuration
4,,1,,,3512,,,F,,,,,,H,CHEMBL619182,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,7185,,,104705,Autocuration
4,,1,,,3513,,,B,,,,,,H,CHEMBL619183,BAO_0000224,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,6960,,,104705,Autocuration
4,,1,,,3514,,,B,,,,,,H,CHEMBL619184,BAO_0000224,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",6960,,,104705,Autocuration
8,,1,,,3515,,,B,10000000.0,,,,,H,CHEMBL619185,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,12416,,Hippocampus,10576,Autocuration
8,,1,,,3516,,,B,,,,,,H,CHEMBL619186,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine transporter.,15753,,,12198,Expert
4,,1,,,3517,,,B,,,,,,H,CHEMBL619187,BAO_0000019,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,8062,,,104705,Autocuration
5,,1,,10116.0,3518,,,B,,,,Rattus norvegicus,,D,CHEMBL619188,BAO_0000019,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,9036,,,104705,Autocuration
5,,1,,10116.0,3519,,,B,,,,Rattus norvegicus,,D,CHEMBL619189,BAO_0000224,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,15067,,,104705,Autocuration
9,,1,,10116.0,3520,,,F,955.0,,,Rattus norvegicus,,D,CHEMBL619190,BAO_0000019,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,15753,,Brain,12198,Expert
9,,1,,10116.0,3521,,,F,2037.0,,,Rattus norvegicus,,D,CHEMBL619191,BAO_0000221,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,15753,,Cerebellum,12198,Expert
5,,1,,10116.0,3522,,,B,,,,Rattus norvegicus,,D,CHEMBL619192,BAO_0000019,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,15295,,,104705,Autocuration
5,,1,,10116.0,3523,,,B,,,,Rattus norvegicus,,D,CHEMBL619193,BAO_0000224,Percent binding affinity against 5-hydroxytryptamine receptor,6347,,,104705,Autocuration
0,,1,,,3524,,,B,,,,,,U,CHEMBL619194,BAO_0000019,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,6763,,,22226,Autocuration
5,,1,,10116.0,3525,,,B,,,,Rattus norvegicus,,D,CHEMBL619195,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,12092,,,104705,Autocuration
5,,1,,10116.0,3526,,,B,,,,Rattus norvegicus,,D,CHEMBL619196,BAO_0000224,Affinity against 5-hydroxytryptamine receptor was determined,1579,,,104705,Autocuration
5,,1,,10116.0,3527,,,B,945.0,,,Rattus norvegicus,,D,CHEMBL619197,BAO_0000019,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1579,,Stomach,104705,Autocuration
9,,1,,9606.0,3528,,In vitro,B,,,,Homo sapiens,,D,CHEMBL619198,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,5963,,,121,Expert
9,,1,,9606.0,3529,,In vitro,B,,,,Homo sapiens,,D,CHEMBL875081,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,5963,,,121,Expert
8,,1,,,3530,,,B,,,,,,H,CHEMBL884712,BAO_0000357,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,5030,,,18065,Autocuration
8,,1,,,3531,,,B,,,,,,H,CHEMBL884710,BAO_0000357,Inhibition of 5-hydroxytryptamine reuptake,15796,,,121,Expert
8,,1,,,3532,,,F,,,,,,H,CHEMBL619199,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",15413,,,18065,Autocuration
8,,1,,,3533,,,F,,,,,,H,CHEMBL619200,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",15413,,,18065,Autocuration
8,,1,,,3534,,,F,,,,,,H,CHEMBL619201,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",15413,,,18065,Autocuration
8,,1,,,3535,,,F,,,,,,H,CHEMBL619202,BAO_0000019,Tested for 5-hydroxytryptamine receptor uptake,12409,,,18065,Autocuration
9,,1,449.0,9606.0,3536,,,B,,,,Homo sapiens,CHO,D,CHEMBL619203,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,16909,,,51,Expert
9,,1,,9606.0,3537,,,F,,,,Homo sapiens,,D,CHEMBL619204,BAO_0000019,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,16909,,,51,Expert
8,,1,,9606.0,3538,,,B,,,,Homo sapiens,,H,CHEMBL619205,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,15629,,,10576,Autocuration
8,,1,,,3539,,,B,,,,,,H,CHEMBL619206,BAO_0000357,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,15629,,,10576,Autocuration
8,,1,,,3540,,,B,,,,,,H,CHEMBL619207,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,15629,,,10576,Expert
8,,1,,,3541,,,F,2435.0,,,,,H,CHEMBL619208,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3542,,,F,2435.0,,,,,H,CHEMBL619209,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3543,,,F,2435.0,,,,,H,CHEMBL619210,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3544,,,F,2435.0,,,,,H,CHEMBL619211,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3545,,,F,2435.0,,,,,H,CHEMBL619212,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3546,,,F,2435.0,,,,,H,CHEMBL620681,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3547,,,F,2435.0,,,,,H,CHEMBL620682,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3548,,,F,2435.0,,,,,H,CHEMBL620683,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3549,,,F,2435.0,,,,,H,CHEMBL620684,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3550,,,F,2435.0,,,,,H,CHEMBL620685,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3551,,,F,2435.0,,,,,H,CHEMBL620686,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10034,,Striatum,10825,Autocuration
8,,1,,,3552,,,F,349.0,,,,,H,CHEMBL620687,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3553,,,F,349.0,,,,,H,CHEMBL620688,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3554,,,F,349.0,,,,,H,CHEMBL620689,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3555,,,F,349.0,,,,,H,CHEMBL620690,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3556,,,F,349.0,,,,,H,CHEMBL620691,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3557,,,F,349.0,,,,,H,CHEMBL620692,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3558,,,F,349.0,,,,,H,CHEMBL620693,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3559,,,B,,,,,,H,CHEMBL620694,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,1274,,,168,Expert
8,,1,,,3560,,,F,,,,,,H,CHEMBL857986,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,,,168,Autocuration
8,,1,,,3561,,,B,,,,,,H,CHEMBL620695,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,14532,,,168,Autocuration
8,,1,,,3562,,,B,,,,,,H,CHEMBL620696,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,16989,,,168,Expert
8,,1,,,3563,,,B,,,,,,H,CHEMBL620697,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,17200,,,168,Autocuration
8,,1,,,3564,,,B,,,,,,H,CHEMBL620698,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor,15779,,,168,Autocuration
8,,1,,,3565,,,B,,,,,,H,CHEMBL620699,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,15779,,,168,Autocuration
8,,1,,,3566,,,B,,,,,,H,CHEMBL620700,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,15779,,,168,Autocuration
8,,1,643.0,,3567,,,B,,,,,COS-7,H,CHEMBL620701,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,15650,,,168,Autocuration
8,,1,643.0,,3568,,,B,,,,,COS-7,H,CHEMBL875082,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,15650,,,168,Autocuration
8,,1,643.0,,3569,,,B,,,,,COS-7,H,CHEMBL620702,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,15650,,,168,Autocuration
8,,1,643.0,,3570,,,B,,,,,COS-7,H,CHEMBL620703,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,15650,,,168,Autocuration
8,,1,673.0,,3571,,,B,,,,,C6,H,CHEMBL620704,BAO_0000219,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,17046,,,168,Autocuration
8,,1,673.0,,3572,,,B,,,,,C6,H,CHEMBL620705,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,17046,,,168,Expert
8,,1,673.0,,3573,,,B,,,,,C6,H,CHEMBL620706,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,15650,,,168,Expert
8,,1,673.0,,3574,,,B,,,,,C6,H,CHEMBL620707,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,17046,,,168,Expert
8,,1,,,3575,,,B,,,,,,H,CHEMBL620708,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5 receptor,17066,,,10624,Expert
8,,1,,,3576,,,B,,,,,,H,CHEMBL620709,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,17200,,,105,Autocuration
9,,1,,9606.0,3577,,,B,,,,Homo sapiens,,D,CHEMBL620710,BAO_0000357,Binding affinity against 5-hydroxytryptamine 5A receptor,16146,,,10624,Expert
8,,1,449.0,,3578,,,B,,,,,CHO,H,CHEMBL620711,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,15250,,,10624,Autocuration
9,,1,,9606.0,3579,,,B,,,,Homo sapiens,,D,CHEMBL620712,BAO_0000357,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,6491,,,10624,Expert
9,,1,,9606.0,3580,,,B,,,,Homo sapiens,,D,CHEMBL620713,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor,17066,,,10624,Expert
9,,1,,9606.0,3581,,,B,,,,Homo sapiens,,D,CHEMBL620714,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,17066,,,10624,Expert
9,,1,,9606.0,3582,,,B,,,,Homo sapiens,,D,CHEMBL620715,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,4234,,,10624,Expert
8,,1,,,3583,,,B,,,,,,H,CHEMBL620716,BAO_0000357,Binding affinity towards 5-HT5A receptor,6013,,,10624,Autocuration
8,,1,,,3584,,,B,,,,,,H,CHEMBL620717,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,17175,,,10624,Expert
8,,1,,,3585,,,B,,,,,,H,CHEMBL618072,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,15818,,,10624,Autocuration
8,,1,,,3586,,,B,,,,,,H,CHEMBL857987,BAO_0000357,Binding affinity towards cloned human 5-HT5A receptor was determined,6166,,,10624,Autocuration
8,,1,722.0,,3587,,,B,,,,,HEK293,H,CHEMBL618073,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,,,10624,Autocuration
8,,1,722.0,,3588,,,B,,,,,HEK293,H,CHEMBL618074,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,15779,,,10624,Autocuration
8,,1,722.0,,3589,,,B,,,,,HEK293,H,CHEMBL618075,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),5213,,,10624,Autocuration
9,,1,,10090.0,3590,,,B,,,,Mus musculus,,D,CHEMBL618076,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,17066,,,10625,Expert
9,,1,,10090.0,3591,,,B,,,,Mus musculus,,D,CHEMBL618077,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,17066,,,10625,Expert
9,,1,,10090.0,3592,,,B,,,,Mus musculus,,D,CHEMBL618078,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,17066,,,10625,Expert
9,,1,,10090.0,3593,,,B,,,,Mus musculus,,D,CHEMBL881821,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,17066,,,10625,Expert
9,,1,,10090.0,3594,,,B,,,,Mus musculus,,D,CHEMBL618079,BAO_0000357,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,17066,,,10625,Expert
8,,1,,,3595,,,B,,,,,,H,CHEMBL618080,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,17175,,,10625,Expert
8,,1,722.0,,3596,,,B,,,,,HEK293,H,CHEMBL618081,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,16190,,,10576,Autocuration
8,,1,722.0,,3597,,,B,,,,,HEK293,H,CHEMBL618082,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,16190,,,10626,Autocuration
8,,1,,,3598,,,B,,,,,,H,CHEMBL618083,BAO_0000357,Binding affinity towards 5-HT5a receptor,4820,,,10624,Expert
9,,1,,9606.0,3599,,,B,,,,Homo sapiens,,D,CHEMBL618084,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor,17066,,,10624,Expert
8,,1,,,3600,,,B,,,,,,H,CHEMBL618085,BAO_0000357,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,17066,,,10624,Expert
8,,1,,,3601,,,B,,,,,,H,CHEMBL618086,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,17175,,,10624,Expert
8,,1,,,3602,,,B,,,,,,H,CHEMBL875092,BAO_0000357,Binding affinities against 5-hydroxytryptamine 5A receptor,16633,,,10624,Autocuration
8,,1,,,3603,,,B,,,,,,H,CHEMBL618087,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 5A receptor,16633,,,10624,Autocuration
8,,1,,,3604,,,B,,,,,,H,CHEMBL872926,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,16700,,,10624,Autocuration
4,,1,,10141.0,3605,,,F,,,,Cavia porcellus,,H,CHEMBL618088,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,4639,,,104714,Autocuration
4,,1,,,3606,,,B,,,,,,H,CHEMBL618089,BAO_0000223,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,5486,,,104714,Autocuration
9,,1,,9606.0,3607,,,B,,,,Homo sapiens,,D,CHEMBL618090,BAO_0000357,Inhibition of human 5-hydroxytryptamine 6 receptor,16146,,,10627,Expert
9,,1,,9606.0,3608,,,B,,,,Homo sapiens,,D,CHEMBL618091,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,17273,,,10627,Expert
8,,1,,,3609,,,B,,,,,,H,CHEMBL618092,BAO_0000357,Inhibition against human 5-hydroxytryptamine 6 receptor,17687,,,10627,Autocuration
9,,1,,9606.0,3610,,,B,,,,Homo sapiens,,D,CHEMBL618093,BAO_0000357,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,6491,,,10627,Expert
8,,1,308.0,,3611,,,B,,,,,HeLa,H,CHEMBL618094,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,16190,,,10627,Expert
9,,1,,9606.0,3612,,,B,,,,Homo sapiens,,D,CHEMBL618095,BAO_0000357,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,17066,,,10627,Expert
9,,1,,9606.0,3613,,,B,,,,Homo sapiens,,D,CHEMBL875093,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,17066,,,10627,Expert
9,,1,,9606.0,3614,,,B,,,,Homo sapiens,,D,CHEMBL618096,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,17066,,,10627,Expert
9,,1,,9606.0,3615,,,B,,,,Homo sapiens,,D,CHEMBL618118,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,17066,,,10627,Expert
9,,1,,9606.0,3616,,,B,,,,Homo sapiens,,D,CHEMBL618119,BAO_0000357,Binding affinity against 5-hydroxytryptamine 6 receptor,3555,,,10627,Expert
8,,1,,,3617,,,B,,,,,,H,CHEMBL618120,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,5808,,,10627,Expert
8,,1,,,3618,,,B,,,,,,H,CHEMBL618121,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,6013,,,10627,Autocuration
8,,1,722.0,,3619,,,B,,,,,HEK293,H,CHEMBL618122,BAO_0000219,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",15818,,,10627,Expert
8,,1,,,3620,,,B,,,,,,H,CHEMBL618123,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,16209,,,10627,Autocuration
8,,1,722.0,,3621,,,B,,,,,HEK293,H,CHEMBL618124,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,3935,,,10627,Expert
8,,1,,,3622,,,B,,,,,,H,CHEMBL618125,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,15818,,,10627,Autocuration
9,,1,722.0,9606.0,3623,,,B,,,,Homo sapiens,HEK293,D,CHEMBL618126,BAO_0000219,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,3805,,,10627,Expert
8,,1,,,3624,,,B,,,,,,H,CHEMBL618236,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,16441,,,10627,Expert
8,,1,,,3625,,,B,,,,,,H,CHEMBL618237,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,16441,,,10627,Expert
8,,1,643.0,,3626,,,B,,,,,COS-7,H,CHEMBL618238,BAO_0000219,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,6786,,,10627,Expert
9,,1,,9606.0,3627,,,B,,,,Homo sapiens,,D,CHEMBL618239,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,4234,,,10627,Expert
8,,1,,,3628,,,B,,,,,,H,CHEMBL618240,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,17085,,,10627,Autocuration
8,,1,,,3629,,,B,,,,,,H,CHEMBL618241,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,17200,,,10627,Autocuration
8,,1,722.0,,3630,,,B,,,,,HEK293,H,CHEMBL859399,BAO_0000219,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,17451,,,10627,Autocuration
8,,1,,,3631,,,F,,,,,,H,CHEMBL618242,BAO_0000019,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,3935,,,10627,Autocuration
8,,1,,,3632,,,B,,,,,,H,CHEMBL857991,BAO_0000357,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,5033,,,10627,Autocuration
8,,1,,,3633,,,B,,,,,,H,CHEMBL619951,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,4540,,,10627,Expert
9,,1,308.0,9606.0,3634,,,B,,,,Homo sapiens,HeLa,D,CHEMBL619952,BAO_0000219,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,4540,,,10627,Expert
9,,1,308.0,9606.0,3635,,,B,,,,Homo sapiens,HeLa,D,CHEMBL619953,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,4540,,,10627,Expert
8,,1,308.0,,3636,,,B,,,,,HeLa,H,CHEMBL619954,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,17296,,,10627,Autocuration
8,,1,308.0,,3637,,,B,,,,,HeLa,H,CHEMBL619955,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,17296,,,10627,Autocuration
8,,1,308.0,,3638,,,B,,,,,HeLa,H,CHEMBL619956,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,17296,,,10627,Autocuration
8,,1,449.0,,3639,,,B,,,,,CHO,H,CHEMBL619957,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,,,10627,Autocuration
8,,1,722.0,,3640,,,B,,,,,HEK293,H,CHEMBL619958,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,,,10627,Autocuration
8,,1,722.0,,3641,,,B,,,,,HEK293,H,CHEMBL620627,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,15779,,,10627,Autocuration
8,,1,722.0,,3642,,,B,,,,,HEK293,H,CHEMBL620628,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,15779,,,10627,Autocuration
8,,1,308.0,,3643,,,B,,,,,HeLa,H,CHEMBL620629,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,15779,,,10627,Autocuration
8,,1,,,3644,,,B,,,,,,H,CHEMBL620630,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,6166,,,10627,Autocuration
8,,1,308.0,,3645,,,B,,,,,HeLa,H,CHEMBL620782,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,17451,,,10627,Autocuration
8,,1,,,3646,,,B,,,,,,H,CHEMBL620783,BAO_0000357,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,15316,,,10627,Autocuration
8,,1,,,3647,,,B,,,,,,H,CHEMBL620784,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,4199,,,10627,Expert
8,,1,308.0,,3648,,,B,,,,,HeLa,H,CHEMBL620785,BAO_0000219,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,15146,,,10627,Expert
8,,1,,,3649,,,B,,,,,,H,CHEMBL857992,BAO_0000357,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),5213,,,10627,Autocuration
8,,1,,,3650,,,B,,,,,,H,CHEMBL620786,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,16429,,,10627,Autocuration
8,,1,308.0,,3651,,,B,,,,,HeLa,H,CHEMBL620787,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,14818,,,10627,Autocuration
8,,1,308.0,,3652,,,B,,,,,HeLa,H,CHEMBL620788,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",4829,,,10627,Autocuration
8,,1,308.0,,3653,,,B,,,,,HeLa,H,CHEMBL620789,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",4829,,,10627,Autocuration
8,,1,308.0,,3654,,,B,,,,,HeLa,H,CHEMBL620790,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",4829,,,10627,Autocuration
8,,1,449.0,,3655,,,B,,,,,CHO,H,CHEMBL620791,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,15250,,,10628,Autocuration
8,,1,,,3656,,,B,,,,,,H,CHEMBL620792,BAO_0000019,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,14423,,,10628,Autocuration
8,,1,,,3657,,,B,,,,,,H,CHEMBL620793,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,15086,,,10628,Autocuration
8,,1,,,3658,,,B,,,,,,H,CHEMBL620794,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,4342,,,10628,Autocuration
9,,1,308.0,9606.0,3659,,,B,,,,Homo sapiens,HeLa,D,CHEMBL620795,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,16190,,,10627,Autocuration
8,,1,,,3660,,,B,,,,,,H,CHEMBL620796,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,4820,,,10627,Expert
8,,1,,,3661,,,B,,,,,,H,CHEMBL620797,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,4639,,,10627,Autocuration
9,,1,,9606.0,3662,,,F,,,,Homo sapiens,,D,CHEMBL620798,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,17066,,,10627,Expert
8,,1,,,3663,,,B,,,,,,H,CHEMBL620799,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,6011,,,10627,Autocuration
8,,1,,,3664,,,B,,,,,,H,CHEMBL620800,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,17066,,,10627,Expert
8,,1,,,3665,,,B,,,,,,H,CHEMBL620801,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,17515,,,10627,Autocuration
8,,1,,,3666,,,B,,,,,,H,CHEMBL875100,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,5014,,,10627,Autocuration
8,,1,,,3667,,,B,,,,,,H,CHEMBL620802,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,4373,,,10627,Autocuration
8,,1,,,3668,,,F,,,,,,H,CHEMBL620803,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,17066,,,10627,Expert
8,,1,,,3669,,,F,,,,,,H,CHEMBL620804,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,17066,,,10627,Expert
8,,1,,,3670,,,B,,,,,,H,CHEMBL620805,BAO_0000357,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,4373,,,10627,Autocuration
8,,1,,,3671,,,B,,,,,,H,CHEMBL620806,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,4687,,,10627,Autocuration
8,,1,,,3672,,,B,,,,,,H,CHEMBL620807,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,16946,,,10627,Autocuration
8,,1,,,3673,,,B,,,,,,H,CHEMBL620808,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,16946,,,10627,Autocuration
8,,1,,,3674,,,B,,,,,,H,CHEMBL620809,BAO_0000357,Binding affinities against 5-hydroxytryptamine 6 receptor,16633,,,10627,Autocuration
8,,1,,,3675,,,B,,,,,,H,CHEMBL620810,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 6 receptor,16633,,,10627,Autocuration
9,,1,,9606.0,3676,,,B,,,,Homo sapiens,,D,CHEMBL620811,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor,17066,,,10627,Expert
8,,1,,,3677,,,B,,,,,,H,CHEMBL620812,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,16700,,,10627,Autocuration
8,,1,,,3678,,,B,,,,,,H,CHEMBL620813,BAO_0000357,Affinity against 5-hydroxytryptamine 6 receptor,3269,,,10627,Autocuration
8,,1,,,3679,,,B,,,,,,H,CHEMBL620814,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],5486,,,10627,Autocuration
9,,1,,9606.0,3680,,,B,,,,Homo sapiens,,D,CHEMBL620815,BAO_0000357,Inhibition of human 5-hydroxytryptamine 7 receptor,16146,,,10209,Expert
8,,1,722.0,,3681,,,B,,,,,HEK293,H,CHEMBL620816,BAO_0000219,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,5014,,,10209,Autocuration
8,,1,,,3682,,,B,,,,,,H,CHEMBL620817,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,15463,,,10209,Autocuration
8,,1,,,3683,,,B,,,,,,H,CHEMBL620818,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),3805,,,10209,Autocuration
8,,1,722.0,,3684,,,B,,,,,HEK293,H,CHEMBL620819,BAO_0000219,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,5014,,,10209,Expert
9,,1,,9606.0,3685,,,B,,,,Homo sapiens,,D,CHEMBL620820,BAO_0000357,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,6491,,,10209,Expert
8,,1,449.0,,3686,,,B,,,,,CHO,H,CHEMBL620821,BAO_0000219,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,16190,,,10209,Autocuration
9,,1,,9606.0,3687,,,B,,,,Homo sapiens,,D,CHEMBL620822,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,17066,,,10209,Expert
9,,1,,9606.0,3688,,,B,,,,Homo sapiens,,D,CHEMBL620823,BAO_0000357,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,17066,,,10209,Expert
9,,1,,9606.0,3689,,,B,,,,Homo sapiens,,D,CHEMBL620824,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 receptor,3555,,,10209,Expert
8,,1,449.0,,3690,,,B,,,,,CHO,H,CHEMBL620825,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,6588,,,10209,Expert
8,,1,,,3691,,,B,,,,,,H,CHEMBL872930,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,15463,,,10209,Autocuration
8,,1,,,3692,,,B,,,,,,H,CHEMBL620826,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,6013,,,10209,Autocuration
8,,1,,,3693,,,B,,,,,,H,CHEMBL620827,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,16209,,,10209,Autocuration
8,,1,,,3694,,,B,,,,,,H,CHEMBL620828,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,3935,,,10209,Autocuration
8,,1,,,3695,,,B,,,,,,H,CHEMBL620829,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,15818,,,10209,Autocuration
8,,1,722.0,,3696,,,B,,,,,HEK293,H,CHEMBL620830,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,5014,,,10209,Expert
8,,1,,,3697,,,B,,,,,,H,CHEMBL620831,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,16441,,,10209,Expert
8,,1,,,3698,,,B,,,,,,H,CHEMBL620832,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,16441,,,10209,Expert
9,,1,,9606.0,3699,,,B,,,,Homo sapiens,,D,CHEMBL621548,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,4234,,,10209,Expert
8,,1,,,3700,,,B,,,,,,H,CHEMBL621549,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,17085,,,10209,Autocuration
8,,1,,,3701,,,B,,,,,,H,CHEMBL621550,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,17200,,,10209,Autocuration
8,,1,449.0,,3702,,,B,,,,,CHO,H,CHEMBL621551,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,17451,,,10209,Autocuration
8,,1,,,3703,,,B,,,,,,H,CHEMBL621552,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,17085,,,10209,Autocuration
8,,1,,,3704,,,B,,,,,,H,CHEMBL857077,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,5104,,,10209,Autocuration
8,,1,,,3705,,,B,,,,,,H,CHEMBL618158,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,5104,,,10209,Autocuration
9,,1,643.0,9606.0,3706,,,B,,,,Homo sapiens,COS-7,D,CHEMBL618159,BAO_0000219,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,5033,,,10209,Expert
8,,1,643.0,,3707,,,B,,,,,COS-7,H,CHEMBL875101,BAO_0000219,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,5486,,,10209,Autocuration
9,,1,722.0,9606.0,3708,,,B,,,,Homo sapiens,HEK293,D,CHEMBL618160,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,4540,,,10209,Expert
8,,1,,,3709,,,B,,,,,,H,CHEMBL618161,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,6166,,,10209,Expert
8,,1,722.0,,3710,,,B,,,,,HEK293,H,CHEMBL618162,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,17342,,,10209,Expert
8,,1,,,3711,,,B,,,,,,H,CHEMBL618163,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,17342,,,10209,Expert
8,,1,,,3712,,,B,,,,,,H,CHEMBL618164,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 human receptors,17296,,,10209,Autocuration
8,,1,,,3713,,,B,,,,,,H,CHEMBL618165,BAO_0000219,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,16429,,,10209,Expert
8,,1,722.0,,3714,,,B,,,,,HEK293,H,CHEMBL618166,BAO_0000219,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,15779,,,10209,Autocuration
8,,1,722.0,,3715,,,B,,,,,HEK293,H,CHEMBL857989,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,,,10209,Autocuration
8,,1,722.0,,3716,,,B,,,,,HEK293,H,CHEMBL619888,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,,,10209,Autocuration
8,,1,722.0,,3717,,,B,,,,,HEK293,H,CHEMBL619889,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,,,10209,Autocuration
8,,1,722.0,,3718,,,B,,,,,HEK293,H,CHEMBL619890,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,15779,,,10209,Autocuration
8,,1,449.0,,3719,,,B,,,,,CHO,H,CHEMBL619891,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,17451,,,10209,Autocuration
8,,1,722.0,,3720,,,B,,,,,HEK293,H,CHEMBL619892,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),4199,,,10209,Autocuration
9,,1,722.0,,3721,,,B,,,,,HEK293,D,CHEMBL619893,BAO_0000219,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,4199,,,10209,Expert
8,,1,722.0,,3722,,,B,,,,,HEK293,H,CHEMBL619894,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),4199,,,10209,Autocuration
9,,1,722.0,,3723,,,B,,,,,HEK293,D,CHEMBL619895,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,3680,,,10209,Intermediate
9,,1,,,3724,,,B,,,,,,D,CHEMBL619896,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,3680,,,10209,Intermediate
8,,1,643.0,,3725,,,B,,,,,COS-7,H,CHEMBL619897,BAO_0000219,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,15316,,,10209,Autocuration
8,,1,722.0,,3726,,,B,,,,,HEK293,H,CHEMBL619898,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,15146,,,10209,Autocuration
8,,1,722.0,,3727,,,B,,,,,HEK293,H,CHEMBL619899,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,5213,,,10209,Expert
8,,1,722.0,,3728,,,B,,,,,HEK293,H,CHEMBL619900,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),5213,,,10209,Autocuration
9,,1,722.0,9606.0,3729,,,B,,,,Homo sapiens,HEK293,D,CHEMBL619901,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,14818,,,10209,Expert
8,,1,722.0,,3730,,,B,,,,,HEK293,H,CHEMBL620580,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,14818,,,10209,Autocuration
8,,1,722.0,,3731,,,B,,,,,HEK293,H,CHEMBL620581,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,14818,,,10209,Autocuration
8,,1,722.0,,3732,,,B,,,,,HEK293,H,CHEMBL620733,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",4829,,,10209,Autocuration
9,,1,,9606.0,3733,,,B,,,,Homo sapiens,,D,CHEMBL620734,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,17200,,,10209,Autocuration
9,,1,,10090.0,3734,,,B,,,,Mus musculus,,D,CHEMBL620735,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,17066,,,10022,Expert
8,,1,,9986.0,3735,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL620736,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,14025,,,10209,Autocuration
8,,1,449.0,,3736,,,B,,,,,CHO,H,CHEMBL620737,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,15250,,,11923,Autocuration
8,,1,449.0,,3737,,,B,,,,,CHO,H,CHEMBL620738,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,16372,,,11923,Autocuration
8,,1,449.0,,3738,,,B,,,,,CHO,H,CHEMBL620739,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,16372,,,11923,Autocuration
8,,1,449.0,,3739,,,B,,,,,CHO,H,CHEMBL620740,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,16372,,,11923,Autocuration
8,,1,449.0,,3740,,,B,,,,,CHO,H,CHEMBL620741,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,16372,,,11923,Autocuration
8,,1,449.0,,3741,,,B,,,,,CHO,H,CHEMBL620742,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,16372,,,11923,Autocuration
8,,1,449.0,,3742,,,B,,,,,CHO,H,CHEMBL620743,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,16372,,,11923,Autocuration
8,,1,449.0,,3743,,,B,,,,,CHO,H,CHEMBL620744,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,16372,,,11923,Autocuration
8,,1,449.0,,3744,,,B,,,,,CHO,H,CHEMBL620745,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,16372,,,11923,Autocuration
8,,1,449.0,,3745,,,B,,,,,CHO,H,CHEMBL620746,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,16372,,,11923,Autocuration
8,,1,449.0,,3746,,,B,,,,,CHO,H,CHEMBL620747,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,16372,,,11923,Autocuration
8,,1,449.0,,3747,,,B,,,,,CHO,H,CHEMBL620748,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,16372,,,11923,Autocuration
8,,1,449.0,,3748,,,B,,,,,CHO,H,CHEMBL620749,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,16372,,,11923,Autocuration
8,,1,,,3749,,,B,,,,,,H,CHEMBL620750,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,17066,,,11923,Expert
9,,1,,10116.0,3750,,,B,,,,Rattus norvegicus,,D,CHEMBL620751,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,17066,,,11923,Expert
8,,1,,,3751,,,B,,,,,,H,CHEMBL620752,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,17386,,,11923,Expert
8,,1,,,3752,,,B,,,,,,H,CHEMBL872929,BAO_0000019,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,14423,,,11923,Autocuration
9,,1,,10116.0,3753,,,B,,,,Rattus norvegicus,,D,CHEMBL620753,BAO_0000357,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,15874,,,11923,Expert
9,,1,,10116.0,3754,,,B,,,,Rattus norvegicus,,D,CHEMBL620754,BAO_0000357,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,15874,,,11923,Expert
9,,1,449.0,10116.0,3755,,,B,,,,Rattus norvegicus,CHO,D,CHEMBL620755,BAO_0000219,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,16372,,,11923,Expert
8,,1,,,3756,,,B,,,,,,H,CHEMBL620756,BAO_0000357,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,4622,,,11923,Autocuration
8,,1,,,3757,,,B,,,,,,H,CHEMBL620757,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,15086,,,11923,Autocuration
8,,1,449.0,,3758,,,B,,,,,CHO,H,CHEMBL620758,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",16372,,,11923,Autocuration
8,,1,449.0,,3759,,,B,,,,,CHO,H,CHEMBL620759,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",16372,,,11923,Autocuration
8,,1,449.0,,3760,,,B,,,,,CHO,H,CHEMBL620760,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,16372,,,11923,Autocuration
8,,1,449.0,,3761,,,B,,,,,CHO,H,CHEMBL620761,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,16372,,,11923,Autocuration
8,,1,,,3762,,,F,2116.0,,,,,H,CHEMBL620762,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,17386,,Ileum,11923,Autocuration
8,,1,,,3763,,,F,2116.0,,,,,H,CHEMBL620763,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,17386,,Ileum,11923,Autocuration
8,,1,,,3764,,,F,2116.0,,,,,H,CHEMBL620764,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,17386,,Ileum,11923,Autocuration
9,,1,,10116.0,3765,,,B,,,,Rattus norvegicus,,D,CHEMBL857990,BAO_0000249,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,5831,Membranes,,11923,Expert
8,,1,,,3766,,,B,,,,,,H,CHEMBL620765,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,4342,,,11923,Autocuration
8,,1,,,3767,,,B,,,,,,H,CHEMBL620766,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,17319,,,11923,Expert
8,,1,,,3768,,,B,1898.0,,,,,H,CHEMBL620767,BAO_0000019,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,17342,,Hypothalamus,11923,Expert
8,,1,,,3769,,,B,,,,,,H,CHEMBL620768,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,17342,,,11923,Autocuration
8,,1,,,3770,,,B,1898.0,,,,,H,CHEMBL619051,BAO_0000249,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,3680,,Hypothalamus,11923,Expert
8,,1,,,3771,,,B,,,,,,H,CHEMBL619052,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,3680,,,11923,Expert
9,,1,722.0,10116.0,3772,,,F,,,,Rattus norvegicus,HEK293,D,CHEMBL619053,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,17319,,,11923,Expert
9,,1,722.0,10116.0,3773,,,F,,,,Rattus norvegicus,HEK293,D,CHEMBL619703,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,17319,,,11923,Expert
9,,1,722.0,10116.0,3774,,,F,,,,Rattus norvegicus,HEK293,D,CHEMBL619704,BAO_0000219,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,17319,,,11923,Autocuration
8,,1,,,3775,,,B,,,,,,H,CHEMBL619851,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,4820,,,10209,Expert
8,,1,,,3776,,,B,,,,,,H,CHEMBL619852,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,4639,,,10209,Autocuration
8,,1,,,3777,,,B,,,,,,H,CHEMBL619853,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,6011,,,10209,Autocuration
9,,1,,9606.0,3778,,,B,,,,Homo sapiens,,D,CHEMBL619854,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,17066,,,10209,Expert
8,,1,,,3779,,,B,,,,,,H,CHEMBL619855,BAO_0000357,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,17066,,,10209,Expert
8,,1,,,3780,,,B,,,,,,H,CHEMBL619856,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,17515,,,10209,Autocuration
8,,1,,,3781,,,B,,,,,,H,CHEMBL619857,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,4373,,,10209,Autocuration
8,,1,,,3782,,,F,,,,,,H,CHEMBL619858,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,17066,,,10209,Expert
8,,1,,,3783,,,B,,,,,,H,CHEMBL619859,BAO_0000357,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,4373,,,10209,Autocuration
8,,1,,,3784,,,B,,,,,,H,CHEMBL619860,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,4373,,,10209,Autocuration
8,,1,,,3785,,,B,,,,,,H,CHEMBL619861,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,4687,,,10209,Autocuration
8,,1,,,3786,,,B,,,,,,H,CHEMBL619862,BAO_0000357,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,17342,,,10209,Expert
8,,1,,,3787,,,B,,,,,,H,CHEMBL619863,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,16946,,,10209,Autocuration
8,,1,,,3788,,,B,,,,,,H,CHEMBL619864,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,16946,,,10209,Autocuration
8,,1,,,3789,,,B,,,,,,H,CHEMBL872928,BAO_0000357,Binding affinities against 5-hydroxytryptamine 7 receptor,16633,,,10209,Autocuration
8,,1,,,3790,,,B,,,,,,H,CHEMBL619865,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 7 receptor,16633,,,10209,Autocuration
8,,1,,,3791,,,B,,,,,,H,CHEMBL619866,BAO_0000357,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,17066,,,10209,Expert
8,,1,,,3792,,,B,,,,,,H,CHEMBL619867,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,16700,,,10209,Autocuration
8,,1,,,3793,,,B,2116.0,,,,,H,CHEMBL619868,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,17386,,Ileum,10209,Autocuration
8,,1,,,3794,,,F,,,,,,H,CHEMBL619869,BAO_0000019,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,14080,,,55,Autocuration
9,,1,,9606.0,3795,,,F,,,,Homo sapiens,,D,CHEMBL619870,BAO_0000019,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,14080,,,55,Expert
8,,1,,,3796,,,B,,,,,,H,CHEMBL619871,BAO_0000357,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,409,,,55,Autocuration
8,,1,,,3797,,,B,,,,,,H,CHEMBL619872,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme,409,,,55,Autocuration
8,,1,,,3798,,,B,,,,,,H,CHEMBL619873,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,409,,,55,Autocuration
8,,1,,,3799,,,B,178.0,,,,,H,CHEMBL619874,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,11090,,Blood,55,Expert
8,,1,,,3800,,,B,178.0,,,,,H,CHEMBL619875,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,11090,,Blood,55,Expert
8,,1,,,3801,,,B,,,,,,H,CHEMBL619876,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,948,,,55,Autocuration
8,,1,,,3802,,,B,,,,,,H,CHEMBL619877,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),948,,,55,Autocuration
8,,1,,,3803,,,F,,,,,,H,CHEMBL619878,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,13622,,,55,Expert
8,,1,,,3804,,,F,178.0,,,,,H,CHEMBL619879,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,13622,,Blood,55,Autocuration
8,,1,,,3805,,,B,,,,,,H,CHEMBL619880,BAO_0000357,In vitro inhibition of 5-lipoxygenase from human polymorphs,9637,,,55,Autocuration
8,,1,,,3806,,,B,,,,,,H,CHEMBL619881,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),11320,,,55,Autocuration
8,,1,,,3807,,,B,,,,,,H,CHEMBL619882,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,11320,,,55,Expert
8,,1,,,3808,,,B,,,,,,H,CHEMBL619883,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,6838,,,55,Autocuration
9,,1,,9606.0,3809,,,B,178.0,,,Homo sapiens,,D,CHEMBL619884,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),17667,,Blood,55,Expert
8,,1,,,3810,,,B,,,,,,H,CHEMBL619885,BAO_0000357,In vitro potency against human 5-Lipoxygenase,12703,,,55,Autocuration
9,,1,,9606.0,3811,,,F,,,,Homo sapiens,,D,CHEMBL619886,BAO_0000019,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,14312,,,55,Expert
8,,1,,,3812,,,F,178.0,,,,,H,CHEMBL619887,BAO_0000019,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,14312,,Blood,55,Autocuration
8,,1,,,3813,,,F,,,,,,H,CHEMBL875097,BAO_0000019,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,5364,,,55,Autocuration
8,,1,,,3814,,,B,,,,,,H,CHEMBL618001,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,951,,,55,Autocuration
8,,1,,,3815,,,B,,,,,,H,CHEMBL618002,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,951,,,55,Autocuration
8,,1,,,3816,,,B,,,,,,H,CHEMBL618003,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,951,,,55,Autocuration
8,,1,,,3817,,,B,,,,,,H,CHEMBL618004,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,951,,,55,Autocuration
8,,1,,,3818,,,B,,,,,,H,CHEMBL618005,BAO_0000219,Inhibition of human 5-lipoxygenase in human cells,12365,,,55,Autocuration
8,,1,,,3819,,,B,,,,,,H,CHEMBL618006,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase,10603,,,55,Expert
8,,1,,,3820,,,B,,,,,,H,CHEMBL875086,BAO_0000019,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,10501,,,55,Autocuration
8,,1,,,3821,,,B,178.0,,,,,H,CHEMBL618007,BAO_0000357,Inhibition of 5-lipoxygenase from human whole blood,12281,,Blood,55,Expert
8,,1,,,3822,,,B,,,,,,H,CHEMBL618008,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,2567,,,55,Autocuration
8,,1,,,3823,,,B,,,,,,H,CHEMBL618009,BAO_0000219,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,2567,,,55,Autocuration
8,,1,,,3824,,,B,,,,,,H,CHEMBL618010,BAO_0000357,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,10193,,,55,Expert
8,,1,,,3825,,,B,,,,,,H,CHEMBL618011,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,,,55,Autocuration
8,,1,,,3826,,,B,,,,,,H,CHEMBL618012,BAO_0000357,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,13623,,,55,Expert
8,,1,,,3827,,,B,,,,,,H,CHEMBL882927,BAO_0000357,Tested against 5-lipoxygenase,12780,,,55,Autocuration
8,,1,,,3828,,,B,,,,,,H,CHEMBL618013,BAO_0000357,Tested for activity against 5-Lipoxygenase (5-LO),12780,,,55,Autocuration
8,,1,,,3829,,,B,,,,,,H,CHEMBL618014,BAO_0000357,Tested for activity against 5-lipoxygenase,12780,,,55,Autocuration
8,,1,,,3830,,,B,,,,,,H,CHEMBL618015,BAO_0000357,Tested for inhibition of 5-HPETE production by human 5-LO,11966,,,55,Autocuration
8,,1,,,3831,,,F,,,,,,H,CHEMBL618016,BAO_0000019,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,5364,,,55,Autocuration
8,,1,,,3832,,,B,,,,,,H,CHEMBL618017,BAO_0000357,Inhibition of Human 5-lipoxygenase,13165,,,55,Expert
8,,1,,,3833,,,B,,,,,,H,CHEMBL618018,BAO_0000019,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,5364,,,55,Autocuration
8,,1,,,3834,,,B,,,,,,H,CHEMBL875087,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],11311,,,55,Autocuration
8,,1,,,3835,,,B,,,,,,H,CHEMBL618019,BAO_0000219,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],11311,,,55,Autocuration
8,,1,,,3836,,,B,,,,,,H,CHEMBL618020,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,14863,,,55,Autocuration
8,,1,,,3837,,,B,,,,,,H,CHEMBL618021,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,14863,,,55,Autocuration
8,,1,,,3838,,,B,178.0,,,,,H,CHEMBL618022,BAO_0000357,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),11087,,Blood,55,Autocuration
8,,1,,,3839,,,B,,,,,,H,CHEMBL618023,BAO_0000357,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,455,,,55,Autocuration
8,,1,,,3840,,,B,,,,,,H,CHEMBL618024,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,,,55,Autocuration
8,,1,,,3841,,,B,,,,,,H,CHEMBL873950,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,10319,,,55,Expert
8,,1,,,3842,,,B,,,,,,H,CHEMBL618025,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,,,55,Autocuration
8,,1,,,3843,,,B,,,,,,H,CHEMBL618026,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,951,,,55,Autocuration
8,,1,,,3844,,,B,,,,,,H,CHEMBL618027,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,951,,,55,Autocuration
8,,1,,,3845,,,B,,,,,,H,CHEMBL618028,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,951,,,55,Autocuration
8,,1,,,3846,,,B,,,,,,H,CHEMBL618029,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,951,,,55,Autocuration
8,,1,,,3847,,,B,,,,,,H,CHEMBL618030,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,9859,,,55,Expert
8,,1,,,3848,,,B,,,,,,H,CHEMBL618031,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,9859,,,55,Expert
8,,1,,,3849,,,B,,,,,,H,CHEMBL618032,BAO_0000357,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,9859,,,55,Autocuration
8,,1,,,3850,,,B,,,,,,H,CHEMBL618033,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,2567,,,55,Autocuration
8,,1,,,3851,,,B,,,,,,H,CHEMBL618034,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,10193,,,55,Autocuration
8,,1,,,3852,,,B,,,,,,H,CHEMBL875088,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,,,55,Autocuration
8,,1,,,3853,,,B,,,,,,H,CHEMBL618035,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,949,,,55,Autocuration
8,,1,,,3854,,,B,,,,,,H,CHEMBL618036,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,949,,,55,Autocuration
8,,1,,,3855,,,B,,,,,,H,CHEMBL618037,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,10603,,,55,Expert
8,,1,,,3856,,,B,,,,,,H,CHEMBL618038,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,10603,,,55,Expert
8,,1,,,3857,,,F,,,,,,H,CHEMBL618761,BAO_0000019,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,10603,,,55,Autocuration
8,,1,,,3858,,,B,,,,,,H,CHEMBL618762,BAO_0000357,Inhibition of lipoxygenase at the concentration of 0.1 uM,10603,,,55,Expert
8,,1,,,3859,,,B,,,,,,H,CHEMBL618763,BAO_0000357,Inhibition of lipoxygenase at the concentration of 1 uM,10603,,,55,Expert
8,,1,,,3860,,,B,,,,,,H,CHEMBL618764,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,10193,,,55,Autocuration
9,,1,,9606.0,3861,,,B,,,,Homo sapiens,,D,CHEMBL618765,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LOX),14580,,,55,Expert
8,,1,,,3862,,,B,,,,,,H,CHEMBL618766,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,11090,,,17087,Expert
8,,1,,,3863,,,B,,,,,,H,CHEMBL618767,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,11090,,,17087,Expert
8,,1,,,3864,,,B,,,,,,H,CHEMBL619380,BAO_0000357,Inhibitory activity against lipoxygenase-2 in mice,6339,,,17087,Autocuration
8,,1,,,3865,,,B,,,,,,H,CHEMBL619381,BAO_0000357,Inhibitory activity against murine lipoxygenase-2.,6339,,,17087,Expert
9,,1,,10090.0,3866,,,B,,,,Mus musculus,,D,CHEMBL619382,BAO_0000357,Inhibition of 5-lipoxygenase from mouse macrophage,12281,,,17087,Expert
8,,1,,,3867,,,B,,,,,,H,CHEMBL619383,BAO_0000357,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,11311,,,17087,Autocuration
8,,1,,9823.0,3868,,,B,,,,Sus scrofa,,H,CHEMBL619384,BAO_0000019,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,11089,,,55,Autocuration
8,,1,,9823.0,3869,,,B,,,,Sus scrofa,,H,CHEMBL619385,BAO_0000019,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,10091,,,55,Autocuration
8,,1,,9986.0,3870,,,B,,,,Oryctolagus cuniculus,,H,CHEMBL882928,BAO_0000019,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,14352,,,55,Autocuration
9,,1,,10116.0,3871,,,B,,,,Rattus norvegicus,,D,CHEMBL619386,BAO_0000019,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,13329,,,12166,Expert
8,,1,,,3872,,,B,,,,,,H,CHEMBL619387,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",13329,,,12166,Autocuration
8,,1,,,3873,,,B,,,,,,H,CHEMBL619388,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",13329,,,12166,Autocuration
8,,1,,,3874,,,B,,,,,,H,CHEMBL619389,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",13329,,,12166,Autocuration
8,,1,,,3875,,,B,,,,,,H,CHEMBL619390,BAO_0000019,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),13329,,,12166,Expert
8,,1,,,3876,,,B,,,,,,H,CHEMBL619391,BAO_0000019,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",13329,,,12166,Expert
8,,1,,,3877,,,B,,,,,,H,CHEMBL619392,BAO_0000019,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,13329,,,12166,Autocuration
8,,1,,,3878,,,B,,,,,,H,CHEMBL619393,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),11311,,,12166,Autocuration
8,,1,,,3879,,,B,,,,,,H,CHEMBL619394,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,11311,,,12166,Autocuration
8,,1,702.0,,3880,,,B,,,,,RBL-1,H,CHEMBL619395,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",105,,,12166,Autocuration
8,,1,702.0,,3881,,,B,,,,,RBL-1,H,CHEMBL619396,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",105,,,12166,Autocuration
8,,1,,,3882,,,B,,,,,,H,CHEMBL619397,BAO_0000357,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),9138,,,12166,Autocuration
8,,1,,,3883,,,B,,,,,,H,CHEMBL619398,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",9138,,,12166,Autocuration
8,,1,,,3884,,,B,,,,,,H,CHEMBL619399,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",9138,,,12166,Autocuration
8,,1,,,3885,,,B,,,,,,H,CHEMBL619400,BAO_0000357,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,14427,,,12166,Autocuration
8,,1,,,3886,,,B,,,,,,H,CHEMBL619401,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",13329,,,12166,Autocuration
8,,1,,,3887,,,B,,,,,,H,CHEMBL619402,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",13329,,,12166,Autocuration
9,,1,663.0,10116.0,3888,,,B,,,,Rattus norvegicus,RBL-2H3,D,CHEMBL619403,BAO_0000219,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,14427,,,12166,Expert
8,,1,,,3889,,,B,,,,,,H,CHEMBL619404,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,14427,,,12166,Autocuration
8,,1,,,3890,,,B,,,,,,H,CHEMBL619405,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,14427,,,12166,Autocuration
8,,1,702.0,,3891,,,B,,,,,RBL-1,H,CHEMBL619406,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,10293,,,12166,Expert
9,,1,702.0,10116.0,3892,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL619407,BAO_0000219,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,338,,,12166,Expert
8,,1,,,3893,,,B,,,,,,H,CHEMBL619408,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),303,,,12166,Autocuration
8,,1,702.0,,3894,,,B,,,,,RBL-1,H,CHEMBL619409,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,303,,,12166,Autocuration
8,,1,702.0,,3895,,,B,,,,,RBL-1,H,CHEMBL619410,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,9247,,,12166,Expert
8,,1,702.0,,3896,,,B,,,,,RBL-1,H,CHEMBL619753,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,9247,,,12166,Autocuration
8,,1,702.0,,3897,,,B,,,,,RBL-1,H,CHEMBL619754,BAO_0000219,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,137,,,12166,Autocuration
8,,1,,,3898,,,B,,,,,,H,CHEMBL619903,BAO_0000357,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,11481,,,12166,Expert
8,,1,,,3899,,,B,,,,,,H,CHEMBL619904,BAO_0000357,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",11481,,,12166,Expert
8,,1,,,3900,,,B,,,,,,H,CHEMBL619905,BAO_0000357,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,9029,,,12166,Expert
8,,1,,,3901,,,B,,,,,,H,CHEMBL619906,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1701,,,12166,Autocuration
8,,1,,,3902,,,B,,,,,,H,CHEMBL619907,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1701,,,12166,Autocuration
8,,1,,,3903,,,B,,,,,,H,CHEMBL619908,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1701,,,12166,Autocuration
8,,1,,,3904,,,B,,,,,,H,CHEMBL619909,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1701,,,12166,Autocuration
8,,1,702.0,,3905,,,F,,,,,RBL-1,H,CHEMBL619910,BAO_0000219,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,13358,,,12166,Expert
8,,1,702.0,,3906,,,B,,,,,RBL-1,H,CHEMBL882929,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1175,,,12166,Expert
8,,1,702.0,,3907,,,B,,,,,RBL-1,H,CHEMBL619911,BAO_0000219,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,8797,,,12166,Expert
8,,1,,,3908,,,B,,,,,,H,CHEMBL619912,BAO_0000019,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,8797,,,12166,Autocuration
9,,1,,10116.0,3909,,,B,,,,Rattus norvegicus,,D,CHEMBL619913,BAO_0000357,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,577,,,12166,Expert
8,,1,702.0,,3910,,,B,,,,,RBL-1,H,CHEMBL619914,BAO_0000219,In vitro inhibitory activity against RBL-1 5-LO,9295,,,12166,Expert
8,,1,702.0,,3911,,,B,,,,,RBL-1,H,CHEMBL619915,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),9295,,,12166,Autocuration
8,,1,702.0,,3912,,,B,,,,,RBL-1,H,CHEMBL619916,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),9295,,,12166,Autocuration
8,,1,,,3913,,,B,,,,,,H,CHEMBL619917,BAO_0000218,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,9295,,,12166,Autocuration
8,,1,,,3914,,,B,,,,,,H,CHEMBL619918,BAO_0000357,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,9295,,,12166,Autocuration
8,,1,,,3915,,,B,,,,,,H,CHEMBL619919,BAO_0000218,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,216,,,12166,Autocuration
8,,1,702.0,,3916,,,B,,,,,RBL-1,H,CHEMBL883710,BAO_0000219,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,11090,,,12166,Autocuration
8,,1,,,3917,,,B,178.0,,,,,H,CHEMBL619920,BAO_0000019,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,11090,,Blood,12166,Autocuration
8,,1,,,3918,,,B,,,,,,H,CHEMBL619921,BAO_0000357,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,10091,,,12166,Expert
8,,1,,,3919,,,F,,,,,,H,CHEMBL619922,BAO_0000019,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,10274,,,12166,Autocuration
8,,1,,,3920,,,F,,,,,,H,CHEMBL619923,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,13622,,,12166,Autocuration
8,,1,702.0,,3921,,,B,,,,,RBL-1,H,CHEMBL619924,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12118,,,12166,Expert
8,,1,,,3922,,,B,,,,,,H,CHEMBL619925,BAO_0000357,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12576,,,12166,Expert
8,,1,702.0,,3923,,,B,,,,,RBL-1,H,CHEMBL619926,BAO_0000219,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,9546,,,12166,Expert
8,,1,702.0,,3924,,,B,,,,,RBL-1,H,CHEMBL619927,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,9521,,,12166,Autocuration
8,,1,702.0,,3925,,,B,,,,,RBL-1,H,CHEMBL619928,BAO_0000219,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,10626,,,12166,Expert
8,,1,702.0,,3926,,,B,,,,,RBL-1,H,CHEMBL619929,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase,9225,,,12166,Autocuration
8,,1,702.0,,3927,,,B,,,,,RBL-1,H,CHEMBL875089,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,9225,,,12166,Autocuration
8,,1,702.0,,3928,,,B,,,,,RBL-1,H,CHEMBL619930,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,9225,,,12166,Autocuration
8,,1,702.0,,3929,,,B,,,,,RBL-1,H,CHEMBL619931,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,9225,,,12166,Autocuration
8,,1,702.0,,3930,,,B,,,,,RBL-1,H,CHEMBL619932,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,9225,,,12166,Autocuration
8,,1,702.0,,3931,,,B,,,,,RBL-1,H,CHEMBL619933,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,9225,,,12166,Autocuration
8,,1,702.0,,3932,,,B,,,,,RBL-1,H,CHEMBL619934,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,9225,,,12166,Autocuration
8,,1,702.0,,3933,,,B,,,,,RBL-1,H,CHEMBL619935,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,9225,,,12166,Autocuration
8,,1,702.0,,3934,,,B,,,,,RBL-1,H,CHEMBL619936,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,9225,,,12166,Autocuration
8,,1,702.0,,3935,,,B,,,,,RBL-1,H,CHEMBL619937,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,9225,,,12166,Autocuration
8,,1,702.0,,3936,,,B,,,,,RBL-1,H,CHEMBL619938,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,9225,,,12166,Autocuration
8,,1,702.0,,3937,,,B,,,,,RBL-1,H,CHEMBL619939,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,9225,,,12166,Autocuration
8,,1,702.0,,3938,,,B,,,,,RBL-1,H,CHEMBL619940,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,9225,,,12166,Autocuration
8,,1,702.0,,3939,,,B,,,,,RBL-1,H,CHEMBL875090,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,9225,,,12166,Autocuration
8,,1,702.0,,3940,,,B,,,,,RBL-1,H,CHEMBL619941,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,9225,,,12166,Autocuration
8,,1,702.0,,3941,,,B,,,,,RBL-1,H,CHEMBL619942,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,9225,,,12166,Autocuration
8,,1,702.0,,3942,,,B,,,,,RBL-1,H,CHEMBL883711,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,9225,,,12166,Autocuration
8,,1,702.0,,3943,,,B,,,,,RBL-1,H,CHEMBL619943,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,9225,,,12166,Autocuration
8,,1,702.0,,3944,,,B,,,,,RBL-1,H,CHEMBL619944,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,9225,,,12166,Autocuration
8,,1,702.0,,3945,,,B,,,,,RBL-1,H,CHEMBL619945,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,9225,,,12166,Autocuration
8,,1,702.0,,3946,,,B,,,,,RBL-1,H,CHEMBL619946,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,9225,,,12166,Autocuration
8,,1,702.0,,3947,,,B,,,,,RBL-1,H,CHEMBL619947,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,9225,,,12166,Autocuration
8,,1,702.0,,3948,,,B,,,,,RBL-1,H,CHEMBL619948,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,9225,,,12166,Autocuration
8,,1,702.0,,3949,,,B,,,,,RBL-1,H,CHEMBL619949,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,9225,,,12166,Autocuration
8,,1,,,3950,,,B,,,,,,H,CHEMBL619950,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,9401,,,12166,Expert
8,,1,,,3951,,,B,,,,,,H,CHEMBL618050,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,10325,,,12166,Autocuration
8,,1,663.0,,3952,,,F,,,,,RBL-2H3,H,CHEMBL875091,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1556,,,12166,Expert
8,,1,663.0,,3953,,,F,,,,,RBL-2H3,H,CHEMBL618051,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1556,,,12166,Expert
9,,1,702.0,10116.0,3954,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618052,BAO_0000219,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,961,,,12166,Expert
8,,1,,,3955,,,B,,,,,,H,CHEMBL618053,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,6838,,,12166,Autocuration
8,,1,,,3956,,,B,,,,,,H,CHEMBL618054,BAO_0000019,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),10325,,,12166,Expert
9,,1,702.0,10116.0,3957,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618055,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,9209,,,12166,Expert
8,,1,702.0,,3958,,,B,,,,,RBL-1,H,CHEMBL618056,BAO_0000219,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,11520,,,12166,Expert
8,,1,,,3959,,,B,,,,,,H,CHEMBL618057,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined,137,,,12166,Autocuration
8,,1,702.0,,3960,,,B,,,,,RBL-1,H,CHEMBL618058,BAO_0000219,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,4717,,,12166,Autocuration
8,,1,702.0,,3961,,,B,,,,,RBL-1,H,CHEMBL618059,BAO_0000219,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,10636,,,12166,Expert
9,,1,,10116.0,3962,,,F,,,,Rattus norvegicus,,D,CHEMBL618060,BAO_0000019,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,14312,,,12166,Expert
8,,1,702.0,,3963,,,B,,,,,RBL-1,H,CHEMBL618061,BAO_0000219,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1203,,,12166,Autocuration
8,,1,,,3964,,,B,,,,,,H,CHEMBL618062,BAO_0000019,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1203,,,12166,Autocuration
8,,1,702.0,,3965,,,B,,,,,RBL-1,H,CHEMBL618063,BAO_0000219,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,13622,,,12166,Expert
8,,1,,,3966,,,B,,,,,,H,CHEMBL618064,BAO_0000357,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,9793,,,12166,Autocuration
9,,1,702.0,10116.0,3967,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618065,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1143,,,12166,Expert
9,,1,702.0,10116.0,3968,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618066,BAO_0000219,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,11854,,,12166,Expert
8,,1,702.0,,3969,,,B,,,,,RBL-1,H,CHEMBL618067,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,,,12166,Autocuration
8,,1,702.0,,3970,,,B,,,,,RBL-1,H,CHEMBL618068,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),3595,,,12166,Autocuration
9,,1,702.0,10116.0,3971,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618069,BAO_0000219,Inhibition of 5-lipoxygenase in rat RBL-1 cells,10501,,,12166,Expert
8,,1,702.0,,3972,,,B,,,,,RBL-1,H,CHEMBL618070,BAO_0000219,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,,,12166,Expert
8,,1,,,3973,,,F,349.0,,,,,H,CHEMBL618071,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3974,,,F,349.0,,,,,H,CHEMBL619247,BAO_0000019,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10034,,Limbic system,10825,Autocuration
8,,1,,,3975,,,F,,,,,,H,CHEMBL619248,BAO_0000019,Approximate dose levels for a half maximal reduction of 5-HTP levels,10034,,,10825,Autocuration
8,,1,,,3976,,,B,10000000.0,,,,,H,CHEMBL619249,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,,Hippocampus,10576,Autocuration
8,,1,,,3977,,,B,10000000.0,,,,,H,CHEMBL619250,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,,Hippocampus,10576,Autocuration
8,,1,,,3978,,,B,,,,,,H,CHEMBL619251,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10046,,,10577,Autocuration
8,,1,,9615.0,3979,,,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619252,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,12079,,Blood,55,Autocuration
8,,1,,,3980,,,F,178.0,,,,,H,CHEMBL619253,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,12079,,Blood,55,Autocuration
8,,1,,,3981,,,B,,,,,,H,CHEMBL619254,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],11311,,,12166,Autocuration
8,,1,,,3982,,,B,,,,,,H,CHEMBL619255,BAO_0000219,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,12338,,,17140,Expert
8,,1,,,3983,,,B,,,,,,H,CHEMBL619256,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,12143,,,17140,Expert
8,,1,,,3984,,,B,,,,,,H,CHEMBL875418,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),12143,,,17140,Autocuration
8,,1,,,3985,,,B,,,,,,H,CHEMBL619257,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,12143,,,17140,Expert
8,,1,,,3986,,,B,,,,,,H,CHEMBL619258,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,12143,,,17140,Autocuration
8,,1,,,3987,,,B,,,,,,H,CHEMBL619259,BAO_0000357,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,12365,,,17140,Expert
8,,1,,,3988,,,B,,,,,,H,CHEMBL619260,BAO_0000357,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,13500,,,17140,Expert
8,,1,,9615.0,3989,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619261,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3990,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619263,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3991,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619264,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3992,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619265,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3993,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619266,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3994,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619902,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3995,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620058,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3996,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620059,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3997,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620060,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3998,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620061,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,3999,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620062,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4000,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620063,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4001,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620064,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4002,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620065,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4003,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620066,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4004,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620067,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4005,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620068,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4006,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620069,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4007,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620070,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4008,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620071,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4009,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620072,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4010,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620036,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4011,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL857702,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4012,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620037,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4013,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620038,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4014,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620039,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4015,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620040,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4016,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620041,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4017,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620042,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4018,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620043,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4019,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620044,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4020,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620045,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4021,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620046,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4022,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620047,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4023,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620048,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4024,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL857703,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4025,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620049,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4026,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620050,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4027,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL620051,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4028,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619213,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4029,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619214,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4030,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619804,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4031,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619805,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4032,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619806,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4033,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619807,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4034,,In vivo,F,178.0,,,Canis lupus familiaris,,H,CHEMBL619808,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,9615.0,4035,,,B,,,,Canis lupus familiaris,,H,CHEMBL619809,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,3595,,,55,Autocuration
8,,1,,9615.0,4036,,,B,,,,Canis lupus familiaris,,H,CHEMBL619810,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,3595,,,55,Autocuration
8,,1,,9615.0,4037,,,B,,,,Canis lupus familiaris,,H,CHEMBL619811,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,3595,,,55,Autocuration
8,,1,,9615.0,4038,,,B,,,,Canis lupus familiaris,,H,CHEMBL620769,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,3595,,,55,Autocuration
8,,1,,9615.0,4039,,,B,,,,Canis lupus familiaris,,H,CHEMBL620770,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,3595,,,55,Autocuration
8,,1,,9615.0,4040,,,B,,,,Canis lupus familiaris,,H,CHEMBL620771,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,3595,,,55,Autocuration
8,,1,,9615.0,4041,,,B,,,,Canis lupus familiaris,,H,CHEMBL620772,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,3595,,,55,Autocuration
8,,1,,9615.0,4042,,,B,,,,Canis lupus familiaris,,H,CHEMBL620773,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,3595,,,55,Autocuration
8,,1,,10141.0,4043,,,B,,,,Cavia porcellus,,H,CHEMBL620774,BAO_0000357,Ability to inhibit 5-lipoxygenase in guinea pig,9203,,,55,Autocuration
8,,1,,10141.0,4044,,,B,,,,Cavia porcellus,,H,CHEMBL620775,BAO_0000357,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),82,,,55,Expert
8,,1,,10141.0,4045,,,B,,,,Cavia porcellus,,H,CHEMBL620776,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,11090,,,55,Autocuration
8,,1,,10141.0,4046,,,B,178.0,,,Cavia porcellus,,H,CHEMBL620777,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",12832,,Blood,55,Autocuration
8,,1,,10141.0,4047,,,B,,,,Cavia porcellus,,H,CHEMBL620778,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1065,,,55,Autocuration
8,,1,,10141.0,4048,,,B,,,,Cavia porcellus,,H,CHEMBL620779,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1065,,,55,Autocuration
8,,1,,10141.0,4049,,,B,,,,Cavia porcellus,,H,CHEMBL621500,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,12832,,,55,Expert
8,,1,,10141.0,4050,,,B,,,,Cavia porcellus,,H,CHEMBL621501,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,12832,,,55,Expert
8,,1,,10141.0,4051,,,B,,,,Cavia porcellus,,H,CHEMBL618098,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,12832,,,55,Autocuration
8,,1,,10141.0,4052,,,B,,,,Cavia porcellus,,H,CHEMBL618099,BAO_0000019,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10504,,,55,Autocuration
8,,1,,10141.0,4053,,,B,,,,Cavia porcellus,,H,CHEMBL618100,BAO_0000357,Inhibitory activity against 5-lipoxygenase,7788,,,55,Autocuration
8,,1,,10141.0,4054,,,B,,,,Cavia porcellus,,H,CHEMBL618101,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,10001,,,55,Autocuration
8,,1,,10141.0,4055,,,B,,,,Cavia porcellus,,H,CHEMBL618102,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,10193,,,55,Autocuration
8,,1,,10141.0,4056,,,B,,,,Cavia porcellus,,H,CHEMBL618103,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,13243,,,55,Autocuration
8,,1,,10141.0,4057,,,B,,,,Cavia porcellus,,H,CHEMBL618104,BAO_0000357,Inhibitory activity uM,13243,,,55,Autocuration
8,,1,,10141.0,4058,,,B,,,,Cavia porcellus,,H,CHEMBL883712,BAO_0000219,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,969,,,55,Autocuration
8,,1,,10141.0,4059,,,B,,,,Cavia porcellus,,H,CHEMBL618105,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,10001,,,55,Autocuration
8,,1,,10141.0,4060,,,B,,,,Cavia porcellus,,H,CHEMBL618106,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,7788,,,55,Autocuration
8,,1,,10141.0,4061,,,B,,,,Cavia porcellus,,H,CHEMBL618107,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,10001,,,55,Autocuration
8,,1,,10141.0,4062,,,B,,,,Cavia porcellus,,H,CHEMBL618108,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10193,,,55,Autocuration
8,,1,,10141.0,4063,,,B,,,,Cavia porcellus,,H,CHEMBL618109,BAO_0000357,Inhibitory activity uM,13243,,,55,Autocuration
8,,1,,10141.0,4064,,,B,,,,Cavia porcellus,,H,CHEMBL618110,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,13243,,,55,Autocuration
8,,1,,10141.0,4065,,,B,,,,Cavia porcellus,,H,CHEMBL618111,BAO_0000357,Inhibitory activity uM,13243,,,55,Expert
8,,1,,10141.0,4066,,,F,,,,Cavia porcellus,,H,CHEMBL618112,BAO_0000019,Inhibitory activity uM,13243,,,55,Autocuration
8,,1,,10141.0,4067,,,B,,,,Cavia porcellus,,H,CHEMBL618113,BAO_0000019,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10504,,,55,Autocuration
8,,1,,10141.0,4068,,,B,,,,Cavia porcellus,,H,CHEMBL618114,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,7788,,,55,Autocuration
8,,1,,10141.0,4069,,,F,2116.0,,,Cavia porcellus,,H,CHEMBL620871,BAO_0000221,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,10546,,Ileum,55,Expert
8,,1,,,4070,,,B,,,,,,H,CHEMBL620872,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,,,55,Autocuration
8,,1,,,4071,,,B,,,,,,H,CHEMBL620873,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,,,55,Autocuration
8,,1,,,4072,,,B,,,,,,H,CHEMBL620874,BAO_0000357,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),2578,,,55,Autocuration
8,,1,,,4073,,,B,,,,,,H,CHEMBL620875,BAO_0000357,In vitro inhibition of human 5-Lipoxygenase.,12780,,,55,Expert
0,,1,,10116.0,4074,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620876,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4075,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620877,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4076,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL857854,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4077,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620878,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4078,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620879,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4079,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620880,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4080,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620881,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4081,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620882,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4082,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620883,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4083,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620884,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4084,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620885,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4085,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620886,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4086,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620887,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4087,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618039,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4088,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618040,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4089,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618041,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4090,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618216,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4091,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618217,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4092,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618218,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4093,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618219,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4094,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618220,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4095,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618221,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4096,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618222,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4097,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618223,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4098,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618224,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4099,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618225,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4100,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618226,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4101,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618227,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4102,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618228,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4103,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618229,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4104,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618230,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4105,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618231,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4106,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618232,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4107,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618233,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4108,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618234,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4109,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618235,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4110,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618115,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4111,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618116,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4112,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL618117,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4113,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619968,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4114,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619969,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4115,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619970,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4116,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619971,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4117,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619972,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4118,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619973,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4119,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619974,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4120,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619975,BAO_0000251,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4121,,,B,,,,Rattus norvegicus,,U,CHEMBL619976,BAO_0000251,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,7411,Microsomes,,22226,Autocuration
0,,1,,10116.0,4122,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619977,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4123,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619978,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4124,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619979,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4125,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619980,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4126,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619981,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,Microsomes,Liver,22226,Autocuration
1,,1,741.0,9606.0,4127,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619982,BAO_0000219,In vitro inhibition of 7226/S myeloma cancer cell line,10797,,,80433,Intermediate
1,,1,993.0,9606.0,4128,,,F,,,,Homo sapiens,BEL-7404 tumor cell line,N,CHEMBL619983,BAO_0000219,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),6881,,,80698,Intermediate
1,,1,391.0,9606.0,4129,,,F,,,,Homo sapiens,786-0,N,CHEMBL620031,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,3838,,,80640,Intermediate
1,,1,391.0,9606.0,4130,,,F,,,,Homo sapiens,786-0,N,CHEMBL620032,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,3838,,,80640,Intermediate
1,,1,505.0,10029.0,4131,,,F,,,,Cricetulus griseus,V79,N,CHEMBL620033,BAO_0000219,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,12981,,,81264,Expert
1,,1,505.0,10029.0,4132,,,F,,,,Cricetulus griseus,V79,N,CHEMBL620034,BAO_0000219,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,12981,,,81264,Expert
1,,1,1119.0,10116.0,4133,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL620035,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,7653,,,80635,Intermediate
1,,1,1119.0,10116.0,4134,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL618318,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,7653,,,80635,Intermediate
1,,1,1119.0,10116.0,4135,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL618319,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,7653,,,80635,Intermediate
1,,1,1119.0,10116.0,4136,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL618320,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,7653,,,80635,Intermediate
1,,1,1119.0,10116.0,4137,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL618321,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,7653,,,80635,Intermediate
1,,1,1119.0,10116.0,4138,,,F,,,,Rattus norvegicus,7800C1 cell line,N,CHEMBL883118,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,7653,,,80635,Intermediate
1,,1,391.0,9606.0,4139,,,F,,,,Homo sapiens,786-0,N,CHEMBL883795,BAO_0000219,In vitro antitumor activity against renal 786-0 tumor cell lines,17229,,,80640,Intermediate
1,,1,391.0,9606.0,4140,,,F,,,,Homo sapiens,786-0,N,CHEMBL618322,BAO_0000219,Cytotoxic activity against 786-0 Renal cancer cell line,12858,,,80640,Intermediate
1,,1,391.0,9606.0,4141,,,F,,,,Homo sapiens,786-0,N,CHEMBL618323,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,16325,,,80640,Intermediate
1,,1,391.0,9606.0,4142,,,F,,,,Homo sapiens,786-0,N,CHEMBL618324,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,16325,,,80640,Intermediate
1,,1,391.0,9606.0,4143,,,F,,,,Homo sapiens,786-0,N,CHEMBL618325,BAO_0000219,In vitro antitumor activity against human renal 786-0 cell line,5858,,,80640,Intermediate
1,,1,391.0,9606.0,4144,,,F,,,,Homo sapiens,786-0,N,CHEMBL875416,BAO_0000219,Inhibition of Renal cancer in 786-0 cancer cell lines,16325,,,80640,Intermediate
1,,1,391.0,9606.0,4145,,,F,,,,Homo sapiens,786-0,N,CHEMBL618326,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,14696,,,80640,Intermediate
1,,1,391.0,9606.0,4146,,,F,,,,Homo sapiens,786-0,N,CHEMBL618327,BAO_0000219,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,3786,,,80640,Intermediate
1,,1,391.0,9606.0,4147,,,F,,,,Homo sapiens,786-0,N,CHEMBL619215,BAO_0000219,inhibition of the growth of renal cancer(786-0) cell line,14696,,,80640,Intermediate
1,,1,391.0,9606.0,4148,,,F,,,,Homo sapiens,786-0,N,CHEMBL619216,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),14769,,,80640,Intermediate
1,,1,391.0,9606.0,4149,,,F,,,,Homo sapiens,786-0,N,CHEMBL619217,BAO_0000219,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,15354,,,80640,Intermediate
1,,1,391.0,9606.0,4150,,,F,,,,Homo sapiens,786-0,N,CHEMBL619218,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor,14255,,,80640,Intermediate
1,,1,391.0,9606.0,4151,,,F,,,,Homo sapiens,786-0,N,CHEMBL619219,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,14255,,,80640,Intermediate
1,,1,391.0,9606.0,4152,,,F,,,,Homo sapiens,786-0,N,CHEMBL619220,BAO_0000219,The IC50 value was measured on 786-0 cell line in renal tumor type.,14255,,,80640,Intermediate
1,,1,391.0,9606.0,4153,,,F,,,,Homo sapiens,786-0,N,CHEMBL619221,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,14696,,,80640,Intermediate
1,,1,391.0,9606.0,4154,,,F,,,,Homo sapiens,786-0,N,CHEMBL619222,BAO_0000219,Tested for cytotoxic activity against renal cancer 786-0 cell line,12016,,,80640,Intermediate
1,,1,391.0,9606.0,4155,,,F,,,,Homo sapiens,786-0,N,CHEMBL857454,BAO_0000219,Compound was tested for growth inhibitory activity against 786-0 cell line,2597,,,80640,Intermediate
8,,1,702.0,,4156,,,B,,,,,RBL-1,H,CHEMBL619223,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12526,,,12166,Autocuration
8,,1,702.0,,4157,,,B,,,,,RBL-1,H,CHEMBL619224,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12526,,,12166,Autocuration
8,,1,,,4158,,,B,,,,,,H,CHEMBL619225,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,14799,,,12166,Autocuration
8,,1,702.0,,4159,,,B,,,,,RBL-1,H,CHEMBL619226,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,,,12166,Expert
8,,1,702.0,,4160,,,B,,,,,RBL-1,H,CHEMBL619227,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),3595,,,12166,Expert
8,,1,,,4161,,,B,,,,,,H,CHEMBL619228,BAO_0000357,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12767,,,12166,Autocuration
8,,1,,,4162,,,B,,,,,,H,CHEMBL619229,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,10997,,,12166,Autocuration
8,,1,702.0,,4163,,,B,,,,,RBL-1,H,CHEMBL619230,BAO_0000219,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,11388,,,12166,Autocuration
8,,1,,,4164,,,B,,,,,,H,CHEMBL619231,BAO_0000357,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,167,,,12166,Autocuration
8,,1,,,4165,,,B,,,,,,H,CHEMBL619232,BAO_0000357,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",167,,,12166,Autocuration
8,,1,,,4166,,,B,,,,,,H,CHEMBL619233,BAO_0000357,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,13744,,,12166,Expert
8,,1,,,4167,,,B,,,,,,H,CHEMBL619234,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1630,,,12166,Autocuration
8,,1,,,4168,,,B,,,,,,H,CHEMBL619235,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1630,,,12166,Autocuration
9,,1,,10116.0,4169,,,B,,,,Rattus norvegicus,,D,CHEMBL619236,BAO_0000019,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",969,,,12166,Expert
8,,1,702.0,,4170,,,B,,,,,RBL-1,H,CHEMBL619237,BAO_0000219,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,13621,,,12166,Autocuration
8,,1,,,4171,,,B,,,,,,H,CHEMBL619238,BAO_0000357,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,10089,,,12166,Autocuration
8,,1,,,4172,,,B,,,,,,H,CHEMBL619239,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,10193,,,12166,Expert
8,,1,,,4173,,,B,,,,,,H,CHEMBL619240,BAO_0000357,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,11966,,,12166,Autocuration
8,,1,,,4174,,,B,,,,,,H,CHEMBL875417,BAO_0000019,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12251,,,12166,Autocuration
8,,1,702.0,,4175,,,B,,,,,RBL-1,H,CHEMBL619241,BAO_0000219,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),211,,,12166,Autocuration
8,,1,,,4176,,,F,,,,,,H,CHEMBL619242,BAO_0000019,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12251,,,12166,Expert
8,,1,702.0,,4177,,,B,,,,,RBL-1,H,CHEMBL883796,BAO_0000219,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12495,,,12166,Autocuration
8,,1,,,4178,,,B,,,,,,H,CHEMBL619243,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase,414,,,12166,Autocuration
8,,1,,,4179,,,B,,,,,,H,CHEMBL619244,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,414,,,12166,Autocuration
8,,1,,,4180,,,B,,,,,,H,CHEMBL619245,BAO_0000019,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",10325,,,12166,Expert
8,,1,,,4181,,,B,,,,,,H,CHEMBL619246,BAO_0000019,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,11966,,,12166,Expert
8,,1,702.0,,4182,,,B,,,,,RBL-1,H,CHEMBL619984,BAO_0000219,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,,,12166,Expert
8,,1,702.0,,4183,,,B,,,,,RBL-1,H,CHEMBL619985,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,165,,,12166,Autocuration
8,,1,702.0,,4184,,,B,,,,,RBL-1,H,CHEMBL619986,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,,,12166,Autocuration
8,,1,702.0,,4185,,,B,,,,,RBL-1,H,CHEMBL619987,BAO_0000219,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,,,12166,Expert
8,,1,,,4186,,,B,,,,,,H,CHEMBL619988,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,11311,,,12166,Autocuration
8,,1,702.0,,4187,,,B,,,,,RBL-1,H,CHEMBL619989,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,11311,,,12166,Autocuration
8,,1,702.0,,4188,,,B,,,,,RBL-1,H,CHEMBL619990,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,11311,,,12166,Autocuration
8,,1,,,4189,,,B,,,,,,H,CHEMBL619991,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],11311,,,12166,Autocuration
8,,1,,,4190,,,B,,,,,,H,CHEMBL619992,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),11311,,,12166,Autocuration
8,,1,,,4191,,In vivo,B,,,,,,H,CHEMBL619993,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),11311,,,12166,Autocuration
8,,1,663.0,,4192,,,F,,,,,RBL-2H3,H,CHEMBL619994,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,663.0,,4193,,,F,,,,,RBL-2H3,H,CHEMBL619995,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,,,4194,,,B,,,,,,H,CHEMBL619996,BAO_0000019,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],11311,,,12166,Autocuration
8,,1,,,4195,,,B,,,,,,H,CHEMBL619997,BAO_0000019,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,11732,,,12166,Autocuration
8,,1,,,4196,,,B,,,,,,H,CHEMBL619998,BAO_0000019,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,11732,,,12166,Expert
8,,1,,,4197,,,B,,,,,,H,CHEMBL619999,BAO_0000019,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,11087,,,12166,Expert
8,,1,,,4198,,,B,,,,,,H,CHEMBL620000,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,11087,,,12166,Autocuration
8,,1,702.0,,4199,,,B,,,,,RBL-1,H,CHEMBL620001,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,11087,,,12166,Autocuration
9,,1,,10116.0,4200,,,B,,,,Rattus norvegicus,,D,CHEMBL620002,BAO_0000357,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,11087,,,12166,Expert
8,,1,702.0,,4201,,,B,,,,,RBL-1,H,CHEMBL620003,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,496,,,12166,Autocuration
8,,1,702.0,,4202,,,F,,,,,RBL-1,H,CHEMBL620004,BAO_0000219,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,13986,,,12166,Expert
8,,1,,,4203,,,B,,,,,,H,CHEMBL874063,BAO_0000357,Compound was evaluated for the inhibition of 5-lipoxygenase,11520,,,12166,Autocuration
8,,1,702.0,,4204,,,B,,,,,RBL-1,H,CHEMBL620005,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,10293,,,12166,Autocuration
8,,1,702.0,,4205,,,B,,,,,RBL-1,H,CHEMBL620006,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,303,,,12166,Autocuration
8,,1,702.0,,4206,,,B,,,,,RBL-1,H,CHEMBL620007,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,303,,,12166,Autocuration
8,,1,702.0,,4207,,,B,,,,,RBL-1,H,CHEMBL620008,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,9247,,,12166,Autocuration
9,,1,702.0,10116.0,4208,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL620009,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,9247,,,12166,Expert
8,,1,702.0,,4209,,,B,,,,,RBL-1,H,CHEMBL620010,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,9247,,,12166,Autocuration
8,,1,702.0,,4210,,,B,,,,,RBL-1,H,CHEMBL620011,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,9247,,,12166,Autocuration
8,,1,702.0,,4211,,,B,,,,,RBL-1,H,CHEMBL620677,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,9247,,,12166,Autocuration
8,,1,702.0,,4212,,,B,,,,,RBL-1,H,CHEMBL620678,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,9247,,,12166,Autocuration
8,,1,702.0,,4213,,,B,,,,,RBL-1,H,CHEMBL620679,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,9247,,,12166,Autocuration
8,,1,702.0,,4214,,,B,,,,,RBL-1,H,CHEMBL620680,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,9247,,,12166,Autocuration
9,,1,,10116.0,4215,,,B,,,,Rattus norvegicus,,D,CHEMBL620838,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,11481,,,12166,Expert
8,,1,,,4216,,,B,,,,,,H,CHEMBL620839,BAO_0000357,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,105,,,12166,Autocuration
8,,1,,,4217,,,B,,,,,,H,CHEMBL620840,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,9029,,,12166,Expert
8,,1,702.0,,4218,,,B,,,,,RBL-1,H,CHEMBL620841,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1175,,,12166,Expert
8,,1,702.0,,4219,,,B,,,,,RBL-1,H,CHEMBL620842,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12118,,,12166,Autocuration
8,,1,702.0,,4220,,,B,,,,,RBL-1,H,CHEMBL620843,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12118,,,12166,Autocuration
8,,1,702.0,,4221,,,B,,,,,RBL-1,H,CHEMBL620844,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12118,,,12166,Autocuration
8,,1,702.0,,4222,,,B,,,,,RBL-1,H,CHEMBL620845,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,9225,,,12166,Autocuration
8,,1,,,4223,,,B,,,,,,H,CHEMBL620846,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,9401,,,12166,Autocuration
8,,1,,,4224,,,B,,,,,,H,CHEMBL873951,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,137,,,12166,Autocuration
8,,1,,,4225,,,B,,,,,,H,CHEMBL620847,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,137,,,12166,Autocuration
8,,1,702.0,,4226,,,B,,,,,RBL-1,H,CHEMBL620848,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,4717,,,12166,Autocuration
8,,1,702.0,,4227,,,B,,,,,RBL-1,H,CHEMBL620849,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,3595,,,12166,Autocuration
8,,1,702.0,,4228,,,B,,,,,RBL-1,H,CHEMBL620850,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,10501,,,12166,Autocuration
8,,1,702.0,,4229,,,B,,,,,RBL-1,H,CHEMBL620851,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,10501,,,12166,Autocuration
8,,1,702.0,,4230,,,B,,,,,RBL-1,H,CHEMBL620852,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,10501,,,12166,Autocuration
8,,1,702.0,,4231,,,B,,,,,RBL-1,H,CHEMBL875098,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,,,12166,Autocuration
9,,1,702.0,10116.0,4232,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL620853,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,14799,,,12166,Expert
8,,1,,,4233,,,B,,,,,,H,CHEMBL620854,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,14799,,,12166,Autocuration
8,,1,702.0,,4234,,,B,,,,,RBL-1,H,CHEMBL620855,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,3595,,,12166,Autocuration
8,,1,702.0,,4235,,,B,,,,,RBL-1,H,CHEMBL839884,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,3595,,,12166,Expert
8,,1,702.0,,4236,,,B,,,,,RBL-1,H,CHEMBL620856,BAO_0000219,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,,,12166,Autocuration
8,,1,702.0,,4237,,,B,,,,,RBL-1,H,CHEMBL620857,BAO_0000219,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,,,12166,Autocuration
8,,1,,,4238,,,B,,,,,,H,CHEMBL620858,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,10193,,,12166,Autocuration
8,,1,,,4239,,,B,,,,,,H,CHEMBL620859,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,10193,,,12166,Autocuration
8,,1,,,4240,,,B,,,,,,H,CHEMBL620860,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,10193,,,12166,Autocuration
8,,1,,,4241,,,B,,,,,,H,CHEMBL620861,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,10193,,,12166,Autocuration
8,,1,,,4242,,,B,,,,,,H,CHEMBL620862,BAO_0000357,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),9138,,,12166,Expert
8,,1,,,4243,,,B,,,,,,H,CHEMBL620863,BAO_0000357,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,9138,,,12166,Autocuration
8,,1,,,4244,,,B,,,,,,H,CHEMBL620864,BAO_0000019,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,11966,,,12166,Autocuration
8,,1,702.0,,4245,,,B,,,,,RBL-1,H,CHEMBL620865,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,165,,,12166,Autocuration
8,,1,702.0,,4246,,,B,,,,,RBL-1,H,CHEMBL620866,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,165,,,12166,Autocuration
8,,1,663.0,,4247,,,B,,,,,RBL-2H3,H,CHEMBL620867,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,663.0,,4248,,,B,,,,,RBL-2H3,H,CHEMBL620868,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,663.0,,4249,,,F,,,,,RBL-2H3,H,CHEMBL620869,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,,,4250,,,F,,,,,,H,CHEMBL873952,BAO_0000019,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,11311,,,12166,Autocuration
8,,1,,,4251,,,B,,,,,,H,CHEMBL875099,BAO_0000357,The compound was tested for inhibition of isolated 5-lipoxygenase,11311,,,12166,Autocuration
8,,1,663.0,,4252,,,F,,,,,RBL-2H3,H,CHEMBL620870,BAO_0000219,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,11311,,,12166,Autocuration
8,,1,,,4253,,,B,,,,,,H,CHEMBL618261,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,11087,,,12166,Autocuration
8,,1,,,4254,,,B,,,,,,H,CHEMBL618262,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,11087,,,12166,Autocuration
8,,1,,,4255,,,B,,,,,,H,CHEMBL619428,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,11087,,,12166,Autocuration
8,,1,,,4256,,,B,,,,,,H,CHEMBL619429,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,11087,,,12166,Autocuration
8,,1,,,4257,,,B,,,,,,H,CHEMBL619430,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,11087,,,12166,Autocuration
8,,1,702.0,,4258,,,B,,,,,RBL-1,H,CHEMBL620017,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,496,,,12166,Autocuration
8,,1,702.0,,4259,,,B,,,,,RBL-1,H,CHEMBL620018,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,496,,,12166,Autocuration
8,,1,702.0,,4260,,,F,,,,,RBL-1,H,CHEMBL620019,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,13986,,,12166,Autocuration
8,,1,702.0,,4261,,,F,,,,,RBL-1,H,CHEMBL620020,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,13986,,,12166,Autocuration
8,,1,702.0,,4262,,,F,,,,,RBL-1,H,CHEMBL620021,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,13986,,,12166,Autocuration
8,,1,702.0,,4263,,,F,,,,,RBL-1,H,CHEMBL620022,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,13986,,,12166,Autocuration
8,,1,702.0,,4264,,,F,,,,,RBL-1,H,CHEMBL620023,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,13986,,,12166,Autocuration
8,,1,702.0,,4265,,,F,,,,,RBL-1,H,CHEMBL620024,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,13986,,,12166,Autocuration
8,,1,702.0,,4266,,,F,,,,,RBL-1,H,CHEMBL620025,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,13986,,,12166,Autocuration
8,,1,702.0,,4267,,,F,,,,,RBL-1,H,CHEMBL620026,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,13986,,,12166,Autocuration
8,,1,702.0,,4268,,,F,,,,,RBL-1,H,CHEMBL620027,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,13986,,,12166,Autocuration
9,,1,,10116.0,4269,,,F,,,,Rattus norvegicus,,D,CHEMBL620028,BAO_0000019,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,13986,,,12166,Expert
8,,1,,,4270,,,B,,,,,,H,CHEMBL620029,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,10193,,,12166,Autocuration
8,,1,,,4271,,,B,,,,,,H,CHEMBL620030,BAO_0000357,Compound was tested for the percent of inhibition against 5-LO at 10 uM,9295,,,12166,Autocuration
8,,1,702.0,,4272,,,B,,,,,RBL-1,H,CHEMBL875415,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,4717,,,12166,Autocuration
8,,1,702.0,,4273,,,B,,,,,RBL-1,H,CHEMBL618256,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,4717,,,12166,Autocuration
8,,1,702.0,,4274,,,B,,,,,RBL-1,H,CHEMBL618257,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,11854,,,12166,Autocuration
8,,1,702.0,,4275,,,B,,,,,RBL-1,H,CHEMBL618258,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,11854,,,12166,Autocuration
8,,1,702.0,,4276,,,B,,,,,RBL-1,H,CHEMBL618259,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,11854,,,12166,Autocuration
8,,1,,,4277,,,B,,,,,,H,CHEMBL618260,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,10193,,,12166,Autocuration
8,,1,702.0,,4278,,,B,,,,,RBL-1,H,CHEMBL618215,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,9295,,,12166,Autocuration
8,,1,702.0,,4279,,,B,,,,,RBL-1,H,CHEMBL618390,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,9295,,,12166,Autocuration
8,,1,702.0,,4280,,,B,,,,,RBL-1,H,CHEMBL618391,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,9295,,,12166,Autocuration
8,,1,702.0,,4281,,,B,,,,,RBL-1,H,CHEMBL618392,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,9295,,,12166,Autocuration
8,,1,702.0,,4282,,,B,,,,,RBL-1,H,CHEMBL618393,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,165,,,12166,Autocuration
8,,1,,,4283,,,B,,,,,,H,CHEMBL618394,BAO_0000219,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,11311,,,12166,Autocuration
8,,1,702.0,9606.0,4284,,,B,,,,Homo sapiens,RBL-1,H,CHEMBL618395,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10489,,,12166,Expert
9,,1,702.0,10116.0,4285,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL618396,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10489,,,12166,Expert
9,,1,702.0,10116.0,4286,,,B,,,,Rattus norvegicus,RBL-1,D,CHEMBL858253,BAO_0000219,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),10489,,,12166,Expert
9,,1,,10116.0,4287,,,B,,,,Rattus norvegicus,,D,CHEMBL618397,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,14799,,,12166,Autocuration
8,,1,,3847.0,4288,,,B,,,,Glycine max,,H,CHEMBL618398,BAO_0000357,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),9295,,,12054,Autocuration
0,,1,,,4289,,,B,,,,,,U,CHEMBL618399,BAO_0000019,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",16811,,,22226,Autocuration
8,,1,,,4290,,,B,,,,,,H,CHEMBL618400,BAO_0000357,In vitro inhibition of 5-Lipoxygenase; Inactive.,168,,,55,Expert
8,,1,,,4291,,,B,,,,,,H,CHEMBL618401,BAO_0000357,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,6309,,,55,Autocuration
8,,1,,,4292,,,B,,,,,,H,CHEMBL618402,BAO_0000357,Inhibitory concentration against 5-lipoxygenase; No inhibition,6309,,,55,Autocuration
8,,1,702.0,,4293,,,B,,,,,RBL-1,H,CHEMBL876400,BAO_0000219,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,3092,,,55,Autocuration
8,,1,,,4294,,,B,,,,,,H,CHEMBL618403,BAO_0000357,Inhibitory activity against 5-lipoxygenase.,168,,,55,Expert
8,,1,,,4295,,,B,,,,,,H,CHEMBL618404,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,168,,,55,Autocuration
8,,1,,,4296,,,B,,,,,,H,CHEMBL618405,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,168,,,55,Autocuration
8,,1,,,4297,,,B,,,,,,H,CHEMBL618406,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,168,,,55,Autocuration
8,,1,,,4298,,,F,,,,,,H,CHEMBL618407,BAO_0000019,Inhibitory concentration against arachidonic acid 5-lipoxygenation,12338,,,55,Expert
8,,1,,,4299,,,B,,,,,,H,CHEMBL618408,BAO_0000357,Tested for the inhibitory activity against 5-lipoxygenase,4501,,,55,Autocuration
8,,1,,,4300,,,B,,,,,,H,CHEMBL618409,BAO_0000357,Compound was tested for its inhibitory activity against 5-lipoxygenase,1132,,,55,Autocuration
8,,1,,,4301,,,B,,,,,,H,CHEMBL618410,BAO_0000357,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,2117,,,55,Autocuration
8,,1,,,4302,,,B,,,,,,H,CHEMBL618411,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,168,,,55,Autocuration
8,,1,,,4303,,,B,,,,,,H,CHEMBL618412,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,168,,,55,Autocuration
8,,1,702.0,,4304,,,B,,,,,RBL-1,H,CHEMBL618413,BAO_0000219,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,13575,,,12166,Autocuration
8,,1,,,4305,,,B,,,,,,H,CHEMBL618414,BAO_0000357,,11089,,,12166,Autocuration
8,,1,,,4306,,,B,,,,,,H,CHEMBL618415,BAO_0000357,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),216,,,10102,Autocuration
8,,1,,,4307,,,B,,,,,,H,CHEMBL618416,BAO_0000019,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,13165,,,10102,Autocuration
8,,1,,,4308,,,B,,,,,,H,CHEMBL876401,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,3278,,,10102,Autocuration
8,,1,,,4309,,,B,,,,,,H,CHEMBL618417,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,3278,,,10102,Expert
8,,1,,,4310,,,B,,,,,,H,CHEMBL618418,BAO_0000357,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,11966,,,10102,Autocuration
8,,1,,,4311,,,B,,,,,,H,CHEMBL618419,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",175,,,10102,Autocuration
8,,1,,,4312,,,B,,,,,,H,CHEMBL618420,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",175,,,10102,Autocuration
8,,1,,,4313,,,B,,,,,,H,CHEMBL618421,BAO_0000357,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,13449,,,10102,Autocuration
8,,1,,,4314,,,B,,,,,,H,CHEMBL618422,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,12014,,,11238,Autocuration
8,,1,,,4315,,,B,,,,,,H,CHEMBL618423,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),12014,,,11238,Autocuration
8,,1,,,4316,,,B,,,,,,H,CHEMBL618424,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),12014,,,11238,Autocuration
2,,1,,,4317,,,B,,,,,,S,CHEMBL618425,BAO_0000220,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,99,,,100284,Intermediate
0,,1,,9606.0,4318,,,F,,,,Homo sapiens,,U,CHEMBL618426,BAO_0000019,The dark toxicity against 543 human galactophore carcinoma cells,4349,,,22226,Autocuration
1,,1,390.0,9606.0,4319,,,F,,,,Homo sapiens,Panel (56 tumour cell lines),N,CHEMBL618427,BAO_0000219,Tested in vitro for cytotoxicity against 56 human tumor cell lines,4071,,,80623,Expert
1,,1,345.0,9606.0,4320,,,F,,,,Homo sapiens,5637,N,CHEMBL618428,BAO_0000219,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,17589,,,80008,Expert
1,,1,345.0,9606.0,4321,,,F,,,,Homo sapiens,5637,N,CHEMBL618429,BAO_0000219,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,15002,,,80008,Intermediate
1,,1,345.0,9606.0,4322,,,F,,,,Homo sapiens,5637,N,CHEMBL618430,BAO_0000219,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",13958,,,80008,Intermediate
1,,1,345.0,9606.0,4323,,,F,,,,Homo sapiens,5637,N,CHEMBL618431,BAO_0000219,Growth inhibition against human 5637 cell lines,17589,,,80008,Expert
1,,1,345.0,9606.0,4324,,,F,,,,Homo sapiens,5637,N,CHEMBL883799,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells.,16748,,,80008,Expert
1,,1,345.0,9606.0,4325,,,F,,,,Homo sapiens,5637,N,CHEMBL618432,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,16747,,,80008,Intermediate
1,,1,345.0,9606.0,4326,,,F,,,,Homo sapiens,5637,N,CHEMBL618433,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,16747,,,80008,Intermediate
9,,1,,9913.0,4327,,,B,,,,Bos taurus,,D,CHEMBL618434,BAO_0000357,In vitro inhibition of bovine trypsin(Trp).,15285,,,10443,Expert
8,,1,407.0,9527.0,4328,,,B,,,,Cercopithecidae,CV-1,H,CHEMBL618435,BAO_0000219,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,3726,,,240,Expert
8,,1,,,4329,,,B,,,,,,H,CHEMBL876402,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,5033,,,10577,Autocuration
6,,1,,,4330,,,F,,,,,,H,CHEMBL618436,BAO_0000019,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,11756,,,104698,Autocuration
0,,1,,,4331,,In vivo,F,,,,,,U,CHEMBL618437,BAO_0000218,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,11953,,,22226,Autocuration
9,,1,,10141.0,4332,,,B,,,,Cavia porcellus,,D,CHEMBL618438,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,5033,,,20033,Intermediate
8,,1,,10116.0,4333,,,A,,,,Rattus norvegicus,,H,CHEMBL883800,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,11347,Microsomes,,17045,Expert
8,,1,,10116.0,4334,,,A,,,,Rattus norvegicus,,H,CHEMBL618439,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,11347,Microsomes,,17045,Expert
0,,1,,,4335,,,F,,,,,,U,CHEMBL618440,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1229,,,22226,Intermediate
0,,1,,,4336,,,F,,,,,,U,CHEMBL618441,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1229,,,22226,Intermediate
8,,1,,5691.0,4337,,,B,,,,Trypanosoma brucei,,H,CHEMBL618442,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,17588,,,11938,Expert
8,,1,,5691.0,4338,,,B,,,,Trypanosoma brucei,,H,CHEMBL618443,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,17588,,,11938,Autocuration
8,,1,,9940.0,4339,,,B,,,,Ovis aries,,H,CHEMBL619158,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,17588,,,11938,Expert
8,,1,,9940.0,4340,,,B,,,,Ovis aries,,H,CHEMBL620974,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,17588,,,11938,Autocuration
8,,1,,,4341,,,B,,,,,,H,CHEMBL620975,BAO_0000357,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,16485,,,11938,Autocuration
0,,1,,9606.0,4342,,,F,,,,Homo sapiens,,U,CHEMBL620976,BAO_0000019,Average inhibitory concentration against 60 human cell lines was reported,4337,,,22226,Intermediate
0,,1,,9606.0,4343,,,F,,,,Homo sapiens,,U,CHEMBL620977,BAO_0000019,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,4112,,,22226,Expert
1,,1,542.0,9606.0,4344,,,F,,,,Homo sapiens,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620978,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,16160,,,80315,Intermediate
1,,1,542.0,9606.0,4345,,,F,,,,Homo sapiens,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620979,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,16160,,,80315,Intermediate
1,,1,542.0,,4346,,,F,,,,,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620980,BAO_0000219,In vitro mean growth inhibitory activity against 60-cell panel,17376,,,80315,Expert
1,,1,542.0,,4347,,,F,,,,,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620981,BAO_0000219,In vitro mean growth lethal concentration against 60-cell panel,17376,,,80315,Expert
1,,1,542.0,,4348,,,F,,,,,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620982,BAO_0000219,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,17376,,,80315,Expert
1,,1,542.0,,4349,,,F,,,,,Panel NCI-60 (60 carcinoma cell lines),N,CHEMBL620983,BAO_0000219,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,17376,,,80315,Expert
4,,1,,,4350,,,F,,,,,,H,CHEMBL620984,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,3241,,,104775,Autocuration
4,,1,,,4351,,,F,,,,,,H,CHEMBL620985,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,3241,,,104775,Autocuration
8,,1,,,4352,,,B,,,,,,H,CHEMBL620986,BAO_0000357,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,3725,,,275,Expert
1,,1,,5833.0,4353,,,F,,,,Plasmodium falciparum,,N,CHEMBL620987,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,10805,,,50425,Expert
1,,1,,5833.0,4354,,,F,,,,Plasmodium falciparum,,N,CHEMBL620988,BAO_0000218,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,10805,,,50425,Expert
1,,1,,5833.0,4355,,,F,,,,Plasmodium falciparum,,N,CHEMBL620989,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,10805,,,50425,Expert
1,,1,,5833.0,4356,,,F,,,,Plasmodium falciparum,,N,CHEMBL620990,BAO_0000218,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,10805,,,50425,Expert
1,,1,,5833.0,4357,,,F,,,,Plasmodium falciparum,,N,CHEMBL620991,BAO_0000218,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,10805,,,50425,Intermediate
1,,1,850.0,10090.0,4358,,,F,,,,Mus musculus,6C3HED,N,CHEMBL620992,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10144,,,80628,Intermediate
1,,1,850.0,10090.0,4359,,,F,,,,Mus musculus,6C3HED,N,CHEMBL620993,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10144,,,80628,Intermediate
1,,1,850.0,10090.0,4360,,,F,,,,Mus musculus,6C3HED,N,CHEMBL620994,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,10144,,,80628,Intermediate
1,,1,850.0,10090.0,4361,,,F,,,,Mus musculus,6C3HED,N,CHEMBL620995,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10144,,,80628,Intermediate
1,,1,850.0,10090.0,4362,,,F,,,,Mus musculus,6C3HED,N,CHEMBL620996,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10144,,,80628,Intermediate
1,,1,850.0,10090.0,4363,,,F,,,,Mus musculus,6C3HED,N,CHEMBL875581,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,10144,,,80628,Intermediate
0,,1,,10090.0,4364,,In vivo,F,,,,Mus musculus,,U,CHEMBL620997,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4365,,In vivo,F,,,,Mus musculus,,U,CHEMBL620998,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4366,,In vivo,F,,,,Mus musculus,,U,CHEMBL620999,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),10685,,,22224,Autocuration
0,,1,,10090.0,4367,,In vivo,F,,,,Mus musculus,,U,CHEMBL621000,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4368,,In vivo,F,,,,Mus musculus,,U,CHEMBL621001,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4369,,In vivo,F,,,,Mus musculus,,U,CHEMBL621002,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4370,,In vivo,F,,,,Mus musculus,,U,CHEMBL621003,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4371,,In vivo,F,,,,Mus musculus,,U,CHEMBL621004,BAO_0000218,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",10685,,,22224,Autocuration
0,,1,,10090.0,4372,,In vivo,F,,,,Mus musculus,,U,CHEMBL621005,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),10685,,,22224,Autocuration
0,,1,,10090.0,4373,,In vivo,F,,,,Mus musculus,,U,CHEMBL621006,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),10685,,,22224,Autocuration
0,,1,,10090.0,4374,,In vivo,F,,,,Mus musculus,,U,CHEMBL621007,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,10685,,,22224,Autocuration
0,,1,,10090.0,4375,,,F,,,,Mus musculus,,U,CHEMBL621008,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10144,,,22224,Autocuration
0,,1,,10090.0,4376,,,F,,,,Mus musculus,,U,CHEMBL621009,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10144,,,22224,Autocuration
0,,1,,10090.0,4377,,,F,,,,Mus musculus,,U,CHEMBL857705,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10144,,,22224,Autocuration
0,,1,,10090.0,4378,,,F,,,,Mus musculus,,U,CHEMBL619828,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10144,,,22224,Autocuration
0,,1,,10090.0,4379,,,F,,,,Mus musculus,,U,CHEMBL619829,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,10685,,,22224,Autocuration
0,,1,,10090.0,4380,,,F,,,,Mus musculus,,U,CHEMBL619830,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,10685,,,22224,Autocuration
0,,1,,10090.0,4381,,,F,,,,Mus musculus,,U,CHEMBL619831,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,10685,,,22224,Autocuration
0,,1,,10090.0,4382,,,F,,,,Mus musculus,,U,CHEMBL619832,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,10685,,,22224,Autocuration
0,,1,,10090.0,4383,,,A,,,,Mus musculus,,U,CHEMBL619833,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,10685,,,22224,Autocuration
0,,1,,10090.0,4384,,,A,,,,Mus musculus,,U,CHEMBL619834,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,10685,,,22224,Autocuration
0,,1,,10090.0,4385,,,A,,,,Mus musculus,,U,CHEMBL619835,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,10685,,,22224,Autocuration
0,,1,,10090.0,4386,,,A,,,,Mus musculus,,U,CHEMBL619836,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,10685,,,22224,Autocuration
1,,1,850.0,10090.0,4387,,,F,,,,Mus musculus,6C3HED,N,CHEMBL619837,BAO_0000218,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",8831,,,80628,Intermediate
0,,1,,,4388,,In vivo,F,,,,,,U,CHEMBL619838,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,11704,,,22224,Autocuration
1,,1,,10090.0,4389,,,A,,,,Mus musculus,,N,CHEMBL619839,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,11704,,,50594,Intermediate
1,,1,850.0,10090.0,4390,,In vivo,F,,,,Mus musculus,6C3HED,N,CHEMBL619840,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,10685,,,80628,Intermediate
1,,1,850.0,10090.0,4391,,In vivo,F,,,,Mus musculus,6C3HED,N,CHEMBL619841,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,10685,,,80628,Intermediate
1,,1,850.0,10090.0,4392,,,F,,,,Mus musculus,6C3HED,N,CHEMBL857704,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),11368,,,80628,Expert
1,,1,850.0,10090.0,4393,,,F,,,,Mus musculus,6C3HED,N,CHEMBL619842,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),11368,,,80628,Intermediate
1,,1,850.0,10090.0,4394,,,F,,,,Mus musculus,6C3HED,N,CHEMBL619843,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),11368,,,80628,Expert
0,,1,,1280.0,4395,,,B,,,,Staphylococcus aureus,,U,CHEMBL619844,BAO_0000019,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",17763,,,22226,Autocuration
0,,1,,10116.0,4396,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL857855,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4397,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619845,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4398,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619846,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4399,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619847,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4400,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL619848,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4401,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620893,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4402,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620894,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4403,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620895,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4404,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620896,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4405,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620897,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4406,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620898,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,10116.0,4407,,,B,2107.0,,,Rattus norvegicus,,U,CHEMBL620899,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,7411,Microsomes,Liver,22226,Autocuration
0,,1,,9527.0,4408,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620900,BAO_0000218,The apparent total plasma clearance in monkey,347,,Plasma,22224,Autocuration
0,,1,,9527.0,4409,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620901,BAO_0000218,Compound was evaluated for Hepatic clearance in monkey,3341,,,22224,Autocuration
0,,1,,9527.0,4410,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620902,BAO_0000218,Lower clearance in monkey (i.v.) at 0.5 mpk,17853,,,22224,Autocuration
0,,1,,9527.0,4411,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620903,BAO_0000218,Plasma clearance in rhesus monkey,4514,,,22224,Autocuration
0,,1,,9527.0,4412,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620904,BAO_0000218,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,6062,,,22224,Autocuration
0,,1,,9527.0,4413,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620905,BAO_0000218,Plasma clearance of compound was determined in monkey,6821,,,22224,Autocuration
0,,1,,9527.0,4414,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620906,BAO_0000218,Plasma clearance was calculated in rhesus monkey,6057,,,22224,Autocuration
0,,1,,9527.0,4415,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL875420,BAO_0000218,Plasma clearance in rhesus monkey,5145,,,22224,Autocuration
0,,1,,9527.0,4416,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620907,BAO_0000218,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,22224,Autocuration
0,,1,,9527.0,4417,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620908,BAO_0000218,Plasma clearance was evaluated in rhesus,5472,,,22224,Autocuration
0,,1,,9527.0,4418,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620909,BAO_0000218,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,4257,,,22224,Autocuration
0,,1,,9527.0,4419,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620910,BAO_0000218,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,,,22224,Autocuration
0,,1,,9527.0,4420,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620911,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9527.0,4421,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620912,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9527.0,4422,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620913,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in monkeys,17509,,,22224,Autocuration
0,,1,,9527.0,4423,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620914,BAO_0000218,Cmax in monkey after administration of 1 mg/kg iv,6535,,,22224,Autocuration
0,,1,,9527.0,4424,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620915,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,5668,,,22224,Autocuration
0,,1,,9527.0,4425,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620916,BAO_0000218,Cmax in cynomolgus monkey by iv administration,5922,,,22224,Autocuration
0,,1,,9527.0,4426,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620917,BAO_0000218,Cmax in cynomolgus monkey by po administration,5922,,,22224,Autocuration
0,,1,,9527.0,4427,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620918,BAO_0000218,Cmax value evaluated in monkey,6078,,,22224,Autocuration
0,,1,,9527.0,4428,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620919,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,4429,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620920,BAO_0000218,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,3249,,Plasma,22224,Autocuration
0,,1,,9527.0,4430,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620921,BAO_0000218,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,3249,,Plasma,22224,Autocuration
0,,1,,9527.0,4431,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620922,BAO_0000218,Maximal plasma concentration in squirrel monkeys,5553,,Plasma,22224,Autocuration
0,,1,,9527.0,4432,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620923,BAO_0000218,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9527.0,4433,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620924,BAO_0000218,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,6227,,Plasma,22224,Autocuration
0,,1,,9527.0,4434,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620925,BAO_0000218,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4435,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620926,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4436,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620927,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4437,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620928,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4438,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620929,BAO_0000218,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,4439,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL620930,BAO_0000218,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,6221,,Plasma,22224,Autocuration
0,,1,,9527.0,4440,,,A,,,,Cercopithecidae,,U,CHEMBL620931,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,167,,,22224,Autocuration
0,,1,,9527.0,4441,,,A,,,,Cercopithecidae,,U,CHEMBL620932,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,167,,,22224,Autocuration
0,,1,,9443.0,4442,,In vivo,A,,,,monkey,,U,CHEMBL620933,BAO_0000218,Absolute bioavailability was evaluated in monkey,4257,,,22224,Autocuration
0,,1,,9443.0,4443,,In vivo,A,,,,monkey,,U,CHEMBL620934,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,6221,,,22224,Autocuration
0,,1,,9443.0,4444,,In vivo,A,,,,monkey,,U,CHEMBL620935,BAO_0000218,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,17667,,,22224,Autocuration
0,,1,,9544.0,4445,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620936,BAO_0000218,Bioavailability of compound was determined in rhesus monkey,17267,,,22224,Autocuration
0,,1,,38020.0,4446,,In vivo,A,,,,marmosets,,U,CHEMBL620937,BAO_0000218,Bioavailability determined after oral administration in marmoset,4256,,,22224,Autocuration
0,,1,,9541.0,4447,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL620938,BAO_0000218,Oral bioavailability in cynomolgus monkey,4256,,,22224,Autocuration
0,,1,,9443.0,4448,,In vivo,A,,,,monkey,,U,CHEMBL620939,BAO_0000218,Bioavailability in monkey (p.o.) at 2.0 mpk,17853,,,22224,Autocuration
0,,1,,9443.0,4449,,In vivo,A,,,,monkey,,U,CHEMBL620940,BAO_0000218,Bioavailability was evaluated after oral administration in monkey,16365,,,22224,Autocuration
0,,1,,9541.0,4450,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL620941,BAO_0000218,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9544.0,4451,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620942,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9544.0,4452,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620943,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9443.0,4453,,In vivo,A,,,,monkey,,U,CHEMBL620944,BAO_0000218,Bioavailability of the compound was determined in monkey,17592,,,22224,Autocuration
0,,1,,9521.0,4454,,In vivo,A,,,,Saimiri sciureus,,U,CHEMBL620945,BAO_0000218,Bioavailability in squirrel monkey (dose 5 mg/kg),1399,,,22224,Autocuration
0,,1,,9443.0,4455,,In vivo,A,,,,monkey,,U,CHEMBL620946,BAO_0000218,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,,,22224,Autocuration
0,,1,,9443.0,4456,,In vivo,A,,,,monkey,,U,CHEMBL620947,BAO_0000218,Oral bioavailability in monkey,3341,,,22224,Autocuration
0,,1,,9521.0,4457,,In vivo,A,,,,Saimiri sciureus,,U,CHEMBL620948,BAO_0000218,Compound was tested for bioavailability in squirrel monkey,64,,,22224,Autocuration
0,,1,,9544.0,4458,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620949,BAO_0000218,Oral bioavailability in Rhesus monkey,5005,,,22224,Autocuration
0,,1,,9544.0,4459,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620950,BAO_0000218,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),5005,,,22224,Autocuration
0,,1,,9541.0,4460,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL620951,BAO_0000218,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,5237,,,22224,Autocuration
0,,1,,9541.0,4461,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL620952,BAO_0000218,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,5237,,,22224,Autocuration
0,,1,,9443.0,4462,,In vivo,A,,,,monkey,,U,CHEMBL875421,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),5302,,,22224,Autocuration
0,,1,,9443.0,4463,,In vivo,A,,,,monkey,,U,CHEMBL620953,BAO_0000218,Oral bioavailability of compound at 5 mg/kg in monkey,17667,,,22224,Autocuration
1,,1,,9615.0,4464,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873491,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,6161,,,50588,Intermediate
1,,1,,9615.0,4465,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL620954,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,6161,,,50588,Intermediate
1,,1,,9615.0,4466,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620955,BAO_0000218,Plasma half life determined,3854,,Plasma,50588,Intermediate
1,,1,,9615.0,4467,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618097,BAO_0000218,Plasma half life in dog,993,,Plasma,50588,Intermediate
1,,1,,9615.0,4468,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618268,BAO_0000218,Plasma half-life in Beagle dogs,4514,,Plasma,50588,Intermediate
1,,1,,9615.0,4469,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618269,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,,Plasma,50588,Intermediate
1,,1,,9615.0,4470,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618270,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),5334,,Plasma,50588,Intermediate
1,,1,,9615.0,4471,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618271,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1466,,,50588,Intermediate
1,,1,,9615.0,4472,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873493,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1466,,,50588,Intermediate
1,,1,,9615.0,4473,,,A,,,,Canis lupus familiaris,,N,CHEMBL621031,BAO_0000218,Tested for the half life period in dog,5313,,,50588,Intermediate
1,,1,,9615.0,4474,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621032,BAO_0000218,Tested for the half life period in dog at dosage of 10 mpk,5313,,,50588,Intermediate
1,,1,,9615.0,4475,,,A,,,,Canis lupus familiaris,,N,CHEMBL621033,BAO_0000218,The compound was tested for half life in dog,3880,,,50588,Intermediate
1,,1,,9615.0,4476,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621034,BAO_0000218,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",3639,,Plasma,50588,Intermediate
1,,1,,9615.0,4477,,,A,,,,Canis lupus familiaris,,N,CHEMBL621035,BAO_0000218,The half life was determined,3880,,,50588,Intermediate
1,,1,,9615.0,4478,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621036,BAO_0000218,The plasma half-life in dogs,3918,,Plasma,50588,Intermediate
1,,1,,9615.0,4479,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621037,BAO_0000218,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,16452,,Plasma,50588,Intermediate
1,,1,,9615.0,4480,,,A,,,,Canis lupus familiaris,,N,CHEMBL619812,BAO_0000218,Half life in dog,17796,,,50588,Intermediate
1,,1,,9615.0,4481,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619813,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,5983,,,50588,Intermediate
1,,1,,9615.0,4482,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873335,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1466,,,50588,Intermediate
1,,1,,9615.0,4483,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619814,BAO_0000218,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,,,50588,Intermediate
1,,1,,9669.0,4484,,In vivo,A,,,,Mustela putorius furo,,N,CHEMBL619815,BAO_0000218,Cmax in ferrets after 30 mg/kg oral dose,6113,,,50506,Expert
1,,1,,9669.0,4485,,In vivo,F,,,,Mustela putorius furo,,N,CHEMBL619816,BAO_0000218,Emesis in ferrets at 30 mg/kg oral dose,6113,,,50506,Expert
0,,1,,9541.0,4486,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL619817,BAO_0000218,Bioavailability in cynomolgus monkey,17796,,,22224,Autocuration
1,,1,,9541.0,4487,,In vivo,A,,,,Macaca fascicularis,,N,CHEMBL619818,BAO_0000218,Volume of distribution in cynomolgus,17796,,,100710,Intermediate
0,,1,,10141.0,4488,,,A,1969.0,,,Cavia porcellus,,U,CHEMBL619819,BAO_0000218,AUC tested in guinea pig when 3 mg/kg dose was given perorally,5308,,Plasma,22224,Autocuration
0,,1,,10141.0,4489,,,A,,,,Cavia porcellus,,U,CHEMBL619820,BAO_0000218,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,4877,,,22224,Autocuration
0,,1,,10141.0,4490,,,A,,,,Cavia porcellus,,U,CHEMBL875419,BAO_0000218,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",4876,,,22224,Autocuration
0,,1,,10141.0,4491,,In vivo,A,1969.0,,,Cavia porcellus,,U,CHEMBL619821,BAO_0000218,AUC in guinea pig after 3mg/kg oral dose,4878,,Plasma,22224,Autocuration
0,,1,,10141.0,4492,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL619822,BAO_0000218,Bioavailability in guinea pig was tested,5308,,,22224,Autocuration
0,,1,,10141.0,4493,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL619823,BAO_0000218,Tested for oral bioavailability in guinea pig at 5 mg/kg,4877,,,22224,Autocuration
0,,1,,10141.0,4494,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL619824,BAO_0000218,Tested for the oral bioavailability of the compound,4876,,,22224,Autocuration
0,,1,,10141.0,4495,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL619825,BAO_0000218,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,4876,,,22224,Autocuration
0,,1,,10141.0,4496,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL619826,BAO_0000218,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,5308,,,22224,Autocuration
0,,1,,10141.0,4497,,In vivo,A,2048.0,,,Cavia porcellus,,U,CHEMBL619827,BAO_0000218,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,4877,,Lung,22224,Autocuration
0,,1,,10141.0,4498,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618167,BAO_0000218,Cmax in guinea pig after 3mg/kg oral dose,4878,,,22224,Autocuration
0,,1,,10141.0,4499,,,A,178.0,,,Cavia porcellus,,U,CHEMBL618168,BAO_0000019,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Blood,22224,Autocuration
0,,1,,10141.0,4500,,,A,955.0,,,Cavia porcellus,,U,CHEMBL618169,BAO_0000019,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Brain,22224,Autocuration
0,,1,,10141.0,4501,,,A,,,,Cavia porcellus,,U,CHEMBL618170,BAO_0000019,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,5689,,,22224,Autocuration
0,,1,,10141.0,4502,,,A,160.0,,,Cavia porcellus,,U,CHEMBL618171,BAO_0000019,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Intestine,22224,Autocuration
0,,1,,10141.0,4503,,,A,2113.0,,,Cavia porcellus,,U,CHEMBL618172,BAO_0000019,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Kidney,22224,Autocuration
0,,1,,10141.0,4504,,,A,2107.0,,,Cavia porcellus,,U,CHEMBL618173,BAO_0000019,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Liver,22224,Autocuration
0,,1,,10141.0,4505,,,A,,,,Cavia porcellus,,U,CHEMBL618174,BAO_0000019,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,5689,,,22224,Autocuration
0,,1,,10141.0,4506,,,A,2106.0,,,Cavia porcellus,,U,CHEMBL875408,BAO_0000019,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,5689,,Spleen,22224,Autocuration
0,,1,,10141.0,4507,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL839827,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),14465,,,22224,Autocuration
0,,1,,10141.0,4508,,,A,,,,Cavia porcellus,,U,CHEMBL618175,BAO_0000019,Partition coefficient was measured as -log (counts per min ),5689,,,22224,Autocuration
0,,1,,10141.0,4509,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618176,BAO_0000218,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,611,,,22224,Autocuration
0,,1,,10141.0,4510,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618177,BAO_0000218,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,611,,,22224,Autocuration
0,,1,,10141.0,4511,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618178,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),14465,,,22224,Autocuration
0,,1,,10141.0,4512,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618179,BAO_0000218,"Tested for the half life period of the compound, intravenously",4876,,,22224,Autocuration
0,,1,,10141.0,4513,,,A,,,,Cavia porcellus,,U,CHEMBL873489,BAO_0000019,Half-life was measured,5689,,,22224,Autocuration
0,,1,,10141.0,4514,,,A,,,,Cavia porcellus,,U,CHEMBL618180,BAO_0000019,The time required for onset of inotropy after addition of a single dose of delta F75,7515,,,22224,Autocuration
0,,1,,10141.0,4515,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618181,BAO_0000218,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,17667,,,22224,Autocuration
0,,1,,10141.0,4516,,In vivo,A,,,,Cavia porcellus,,U,CHEMBL618182,BAO_0000218,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,17667,,,22224,Autocuration
0,,1,,10029.0,4517,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL618183,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,4727,,,22224,Autocuration
1,,1,,10090.0,4518,,In vivo,A,,,,Mus musculus,,N,CHEMBL618184,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4519,,In vivo,A,,,,Mus musculus,,N,CHEMBL618185,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4520,,In vivo,A,,,,Mus musculus,,N,CHEMBL618186,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4521,,In vivo,A,,,,Mus musculus,,N,CHEMBL618187,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4522,,In vivo,A,,,,Mus musculus,,N,CHEMBL618188,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,10107,,,50594,Intermediate
1,,1,,10090.0,4523,,In vivo,A,,,,Mus musculus,,N,CHEMBL875409,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4524,,In vivo,A,,,,Mus musculus,,N,CHEMBL618189,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,,50594,Intermediate
1,,1,,10090.0,4525,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL618190,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,3655,,Blood,50594,Intermediate
1,,1,,10090.0,4526,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL618191,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,3655,,Blood,50594,Intermediate
1,,1,,10090.0,4527,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL618192,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,3655,,Blood,50594,Intermediate
1,,1,,10090.0,4528,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL618193,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,3655,,Bone,50594,Intermediate
1,,1,,10090.0,4529,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL618194,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,3655,,Bone,50594,Intermediate
1,,1,,10090.0,4530,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL618195,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,3655,,Bone,50594,Intermediate
1,,1,,10090.0,4531,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL618196,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,3655,,Brain,50594,Intermediate
1,,1,,10090.0,4532,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL618197,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,3655,,Brain,50594,Intermediate
1,,1,,10090.0,4533,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL618198,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,3655,,Brain,50594,Intermediate
1,,1,,10090.0,4534,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL618199,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,3655,,Heart,50594,Intermediate
1,,1,,10090.0,4535,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL618200,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,3655,,Heart,50594,Intermediate
1,,1,,10090.0,4536,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL618201,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,3655,,Heart,50594,Intermediate
1,,1,,10090.0,4537,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL618202,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,3655,,Intestine,50594,Intermediate
1,,1,,10090.0,4538,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL618203,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,3655,,Intestine,50594,Intermediate
1,,1,,10090.0,4539,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL618204,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,3655,,Intestine,50594,Intermediate
1,,1,,10090.0,4540,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL618205,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,3655,,Kidney,50594,Intermediate
1,,1,,10090.0,4541,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL618206,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,3655,,Kidney,50594,Intermediate
1,,1,,10090.0,4542,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL618207,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,3655,,Kidney,50594,Intermediate
1,,1,,10090.0,4543,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL618208,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,3655,,Liver,50594,Intermediate
1,,1,,10090.0,4544,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL618932,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,3655,,Liver,50594,Intermediate
1,,1,,10090.0,4545,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL618933,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,3655,,Liver,50594,Intermediate
1,,1,,10090.0,4546,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL618934,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,3655,,Lung,50594,Intermediate
1,,1,,10090.0,4547,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL618935,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,3655,,Lung,50594,Intermediate
1,,1,,10090.0,4548,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL618936,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,3655,,Lung,50594,Intermediate
1,,1,,10090.0,4549,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL618937,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,3655,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,4550,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL618938,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,3655,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,4551,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL619104,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,3655,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,4552,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL619105,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,3655,,Spleen,50594,Intermediate
1,,1,,10090.0,4553,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL619106,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,3655,,Spleen,50594,Intermediate
1,,1,,10090.0,4554,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL619107,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,3655,,Spleen,50594,Intermediate
1,,1,,10090.0,4555,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL875410,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,3655,,Stomach,50594,Intermediate
1,,1,,10090.0,4556,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL619108,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,3655,,Stomach,50594,Intermediate
1,,1,,10090.0,4557,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL619109,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,3655,,Stomach,50594,Intermediate
1,,1,,10090.0,4558,,In vivo,A,,,,Mus musculus,,N,CHEMBL619110,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,16597,,,50594,Intermediate
1,,1,,10090.0,4559,,In vivo,F,,,,Mus musculus,,N,CHEMBL619111,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,16597,,,50594,Intermediate
1,,1,,10090.0,4560,,In vivo,A,,,,Mus musculus,,N,CHEMBL619112,BAO_0000218,MRT value at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4561,,In vivo,A,,,,Mus musculus,,N,CHEMBL619113,BAO_0000218,MRT value at a dose of 10 mg/kg peroral administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4562,,In vivo,A,,,,Mus musculus,,N,CHEMBL619114,BAO_0000218,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4563,,In vivo,F,,,,Mus musculus,,N,CHEMBL619115,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,17764,,,50594,Intermediate
1,,1,478.0,9606.0,4564,,,F,,,,Homo sapiens,A2780,N,CHEMBL619116,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,3830,,,81034,Intermediate
1,,1,478.0,9606.0,4565,,,F,,,,Homo sapiens,A2780,N,CHEMBL619117,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,3829,,,81034,Intermediate
1,,1,478.0,9606.0,4566,,,F,,,,Homo sapiens,A2780,N,CHEMBL619118,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell lines.,2040,,,81034,Intermediate
1,,1,478.0,9606.0,4567,,,F,,,,Homo sapiens,A2780,N,CHEMBL619119,BAO_0000219,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4568,,,F,,,,Homo sapiens,A2780,N,CHEMBL619120,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4569,,,F,,,,Homo sapiens,A2780,N,CHEMBL619121,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4570,,,F,,,,Homo sapiens,A2780,N,CHEMBL619122,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4571,,,F,,,,Homo sapiens,A2780,N,CHEMBL619123,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4572,,,F,,,,Homo sapiens,A2780,N,CHEMBL619124,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4573,,,F,,,,Homo sapiens,A2780,N,CHEMBL619125,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,2859,,,81034,Intermediate
1,,1,478.0,9606.0,4574,,,F,,,,Homo sapiens,A2780,N,CHEMBL875411,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780,5618,,,81034,Intermediate
1,,1,478.0,9606.0,4575,,,F,,,,Homo sapiens,A2780,N,CHEMBL619126,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4576,,,F,,,,Homo sapiens,A2780,N,CHEMBL619127,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4577,,,F,,,,Homo sapiens,A2780,N,CHEMBL619128,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4578,,,F,,,,Homo sapiens,A2780,N,CHEMBL619129,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4579,,,F,,,,Homo sapiens,A2780,N,CHEMBL619130,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,2113,,,81034,Intermediate
1,,1,478.0,9606.0,4580,,,F,,,,Homo sapiens,A2780,N,CHEMBL619131,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,2113,,,81034,Intermediate
1,,1,478.0,9606.0,4581,,,F,,,,Homo sapiens,A2780,N,CHEMBL619132,BAO_0000219,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,16745,,,81034,Intermediate
1,,1,478.0,9606.0,4582,,,F,,,,Homo sapiens,A2780,N,CHEMBL619133,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,,,81034,Expert
1,,1,478.0,9606.0,4583,,,F,,,,Homo sapiens,A2780,N,CHEMBL619134,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4584,,,F,,,,Homo sapiens,A2780,N,CHEMBL619135,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,15684,,,81034,Intermediate
1,,1,478.0,9606.0,4585,,,F,,,,Homo sapiens,A2780,N,CHEMBL619136,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,2040,,,81034,Intermediate
1,,1,478.0,9606.0,4586,,,F,,,,Homo sapiens,A2780,N,CHEMBL619137,BAO_0000219,Relative resistance factor in A2780 cisplatin-resistant line,2040,,,81034,Intermediate
1,,1,478.0,9606.0,4587,,,F,,,,Homo sapiens,A2780,N,CHEMBL883713,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,16165,,,81034,Intermediate
1,,1,478.0,9606.0,4588,,,F,,,,Homo sapiens,A2780,N,CHEMBL875412,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,16165,,,81034,Intermediate
1,,1,478.0,9606.0,4589,,,F,,,,Homo sapiens,A2780,N,CHEMBL619138,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,,,81034,Expert
1,,1,478.0,9606.0,4590,,,F,,,,Homo sapiens,A2780,N,CHEMBL619262,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,,,81034,Expert
1,,1,478.0,9606.0,4591,,,F,,,,Homo sapiens,A2780,N,CHEMBL619139,BAO_0000219,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,3992,,,81034,Intermediate
1,,1,478.0,9606.0,4592,,,F,,,,Homo sapiens,A2780,N,CHEMBL619140,BAO_0000219,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,10553,,,81034,Intermediate
1,,1,478.0,9606.0,4593,,,F,,,,Homo sapiens,A2780,N,CHEMBL619141,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4594,,,F,,,,Homo sapiens,A2780,N,CHEMBL619142,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4595,,,F,,,,Homo sapiens,A2780,N,CHEMBL619143,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4596,,,F,,,,Homo sapiens,A2780,N,CHEMBL619144,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4597,,,F,,,,Homo sapiens,A2780,N,CHEMBL619145,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4598,,,F,,,,Homo sapiens,A2780,N,CHEMBL619146,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,15608,,,81034,Intermediate
1,,1,478.0,9606.0,4599,,,F,,,,Homo sapiens,A2780,N,CHEMBL619147,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,15569,,,81034,Intermediate
1,,1,478.0,9606.0,4600,,,F,,,,Homo sapiens,A2780,N,CHEMBL619148,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line,17420,,,81034,Intermediate
1,,1,478.0,9606.0,4601,,,F,,,,Homo sapiens,A2780,N,CHEMBL619149,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,17420,,,81034,Intermediate
1,,1,478.0,9606.0,4602,,,F,,,,Homo sapiens,A2780,N,CHEMBL619150,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),15099,,,81034,Intermediate
1,,1,478.0,9606.0,4603,,,F,,,,Homo sapiens,A2780,N,CHEMBL619151,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),15099,,,81034,Intermediate
1,,1,478.0,9606.0,4604,,,F,,,,Homo sapiens,A2780,N,CHEMBL883794,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,17672,,,81034,Intermediate
1,,1,478.0,9606.0,4605,,,F,,,,Homo sapiens,A2780,N,CHEMBL619152,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,17672,,,81034,Intermediate
1,,1,478.0,9606.0,4606,,,F,,,,Homo sapiens,A2780,N,CHEMBL619153,BAO_0000219,In vitro cytotoxicity against A2780ADR cell line,17270,,,81034,Intermediate
1,,1,478.0,9606.0,4607,,,F,,,,Homo sapiens,A2780,N,CHEMBL619154,BAO_0000219,In vitro cytotoxicity against A2780CIS cell line,17270,,,81034,Intermediate
1,,1,478.0,9606.0,4608,,,F,,,,Homo sapiens,A2780,N,CHEMBL619155,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,5574,,,81034,Intermediate
1,,1,478.0,9606.0,4609,,,F,,,,Homo sapiens,A2780,N,CHEMBL619156,BAO_0000219,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,2113,,,81034,Intermediate
1,,1,478.0,9606.0,4610,,,F,,,,Homo sapiens,A2780,N,CHEMBL619157,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4611,,,F,,,,Homo sapiens,A2780,N,CHEMBL619797,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,,,81034,Intermediate
0,,1,,9544.0,4612,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL619798,BAO_0000218,Oral bioavailability of compound in rhesus macaques,17839,,,22224,Autocuration
0,,1,,9443.0,4613,,In vivo,A,,,,monkey,,U,CHEMBL619799,BAO_0000218,Oral bioavailability in monkey,6821,,,22224,Autocuration
0,,1,,9443.0,4614,,In vivo,A,,,,monkey,,U,CHEMBL619800,BAO_0000218,Oral bioavailability evaluated in monkey,6078,,,22224,Autocuration
0,,1,,9443.0,4615,,In vivo,A,,,,monkey,,U,CHEMBL619801,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg p.o.),6535,,,22224,Autocuration
0,,1,,9544.0,4616,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL619802,BAO_0000218,Oral bioavailability in Rhesus monkey,4449,,,22224,Autocuration
0,,1,,9544.0,4617,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL619803,BAO_0000218,Oral bioavailability was calculated in rhesus monkey,6057,,,22224,Autocuration
0,,1,,9541.0,4618,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL619965,BAO_0000218,Oral bioavailability in cynomolgus monkey,5922,,,22224,Autocuration
0,,1,,9443.0,4619,,In vivo,A,,,,monkey,,U,CHEMBL619966,BAO_0000218,Oral bioavailability in monkey,5940,,,22224,Autocuration
0,,1,,9443.0,4620,,In vivo,A,,,,monkey,,U,CHEMBL619967,BAO_0000218,Oral bioavailability in monkey,6265,,,22224,Autocuration
0,,1,,9443.0,4621,,In vivo,A,,,,monkey,,U,CHEMBL620073,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg),6265,,,22224,Autocuration
0,,1,,9443.0,4622,,In vivo,A,,,,monkey,,U,CHEMBL620074,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),6265,,,22224,Autocuration
0,,1,,9443.0,4623,,In vivo,A,,,,monkey,,U,CHEMBL620075,BAO_0000218,Oral bioavailability in monkey,5940,,,22224,Autocuration
0,,1,,9443.0,4624,,In vivo,A,,,,monkey,,U,CHEMBL620076,BAO_0000218,Oral bioavailability in monkey,5940,,,22224,Autocuration
0,,1,,9544.0,4625,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620077,BAO_0000218,Oral bioavailability in rhesus monkey,4514,,,22224,Autocuration
0,,1,,9544.0,4626,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620078,BAO_0000218,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,5546,,,22224,Autocuration
0,,1,,9521.0,4627,,In vivo,A,,,,Saimiri sciureus,,U,CHEMBL620079,BAO_0000218,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,5553,,,22224,Autocuration
0,,1,,9443.0,4628,,In vivo,A,,,,monkey,,U,CHEMBL620080,BAO_0000218,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,22224,Autocuration
0,,1,,9544.0,4629,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620081,BAO_0000218,Oral bioavailability in Rhesus monkey,5472,,,22224,Autocuration
0,,1,,9544.0,4630,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620082,BAO_0000218,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),5668,,,22224,Autocuration
0,,1,,9443.0,4631,,In vivo,A,,,,monkey,,U,CHEMBL620083,BAO_0000218,Oral bioavailability in monkey at 10 mg/kg of the compound,5711,,,22224,Autocuration
0,,1,,9544.0,4632,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL620084,BAO_0000218,Bioavailability in Rhesus monkey,5145,,,22224,Autocuration
0,,1,,9527.0,4633,,,A,,,,Cercopithecidae,,U,CHEMBL620085,BAO_0000218,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4634,,,A,,,,Cercopithecidae,,U,CHEMBL874595,BAO_0000218,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4635,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL873352,BAO_0000218,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,3249,,,22224,Autocuration
0,,1,,9527.0,4636,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620086,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,3249,,,22224,Autocuration
0,,1,,9527.0,4637,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620087,BAO_0000218,Mean residence time was determined after intravenous administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,4638,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620088,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4639,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620089,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4640,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620090,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4641,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620091,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4642,,,A,,,,Cercopithecidae,,U,CHEMBL620092,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9527.0,4643,,,A,,,,Cercopithecidae,,U,CHEMBL620093,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9527.0,4644,,,A,,,,Cercopithecidae,,U,CHEMBL620094,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9527.0,4645,,,A,,,,Cercopithecidae,,U,CHEMBL620095,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9527.0,4646,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620096,BAO_0000218,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4647,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620097,BAO_0000218,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4648,,,A,,,,Cercopithecidae,,U,CHEMBL620098,BAO_0000019,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,11271,,,22224,Autocuration
0,,1,,9527.0,4649,,,A,,,,Cercopithecidae,,U,CHEMBL620099,BAO_0000218,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4650,,,A,,,,Cercopithecidae,,U,CHEMBL620100,BAO_0000218,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4651,,,A,,,,Cercopithecidae,,U,CHEMBL620101,BAO_0000019,Elimination Half-life of compound was determined in monkey,6821,,,22224,Autocuration
0,,1,,9527.0,4652,,,A,,,,Cercopithecidae,,U,CHEMBL620102,BAO_0000019,Half life of compound was determined in rhesus monkey,17267,,,22224,Autocuration
0,,1,,9527.0,4653,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL620103,BAO_0000366,Half life in monkey plasma,5819,,Plasma,22224,Autocuration
0,,1,,9527.0,4654,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL620104,BAO_0000366,Half life in monkey plasma; Not detected,5819,,Plasma,22224,Autocuration
0,,1,,9527.0,4655,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL874596,BAO_0000218,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9527.0,4656,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL873490,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in monkeys,17509,,,22224,Autocuration
0,,1,,9527.0,4657,,,A,,,,Cercopithecidae,,U,CHEMBL620105,BAO_0000019,Terminal half life of the compound.,1399,,,22224,Autocuration
0,,1,,9527.0,4658,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620780,BAO_0000218,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9527.0,4659,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620781,BAO_0000218,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4660,,,A,,,,Cercopithecidae,,U,CHEMBL620956,BAO_0000218,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,,,22224,Autocuration
0,,1,,9527.0,4661,,,A,1088.0,,,Cercopithecidae,,U,CHEMBL620957,BAO_0000218,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,Urine,22224,Autocuration
0,,1,,9527.0,4662,,,A,1088.0,,,Cercopithecidae,,U,CHEMBL620958,BAO_0000218,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,Urine,22224,Autocuration
0,,1,,9527.0,4663,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620959,BAO_0000218,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,4257,,,22224,Autocuration
0,,1,,9527.0,4664,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620960,BAO_0000218,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,6221,,,22224,Autocuration
0,,1,,9527.0,4665,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL620961,BAO_0000218,Volume of distribution was evaluated in rhesus,5472,,,22224,Autocuration
0,,1,,10029.0,4666,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL620962,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,4727,,,22224,Autocuration
0,,1,,10029.0,4667,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL620963,BAO_0000218,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,4727,,,22224,Autocuration
0,,1,,10029.0,4668,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL620964,BAO_0000218,Bioavailability in hamster was determined,4727,,,22224,Autocuration
0,,1,,10029.0,4669,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL620965,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,4727,,,22224,Autocuration
0,,1,,10029.0,4670,,In vivo,A,,,,Cricetulus griseus,,U,CHEMBL620966,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,4727,,,22224,Autocuration
0,,1,,10029.0,4671,,,A,178.0,,,Cricetulus griseus,,U,CHEMBL620967,BAO_0000221,Half life of compound was determined in hamster blood,4727,,Blood,22224,Autocuration
0,,1,,9823.0,4672,,,A,,,,Sus scrofa,,U,CHEMBL620968,BAO_0000019,Michaelis-Menten constant of the compound.,1452,,,22224,Autocuration
0,,1,,9823.0,4673,,,A,,,,Sus scrofa,,U,CHEMBL874597,BAO_0000019,Vmax value was measured at 0 uM concentration of silyl ether.,1452,,,22224,Autocuration
0,,1,,9823.0,4674,,,A,,,,Sus scrofa,,U,CHEMBL620969,BAO_0000019,Vmax value was measured at 10 uM concentration of silyl ether.,1452,,,22224,Autocuration
0,,1,,9823.0,4675,,,A,,,,Sus scrofa,,U,CHEMBL620970,BAO_0000019,Vmax value was measured at 5 uM concentration of silyl ether.,1452,,,22224,Autocuration
9,,1,,9606.0,4676,,,B,,,,Homo sapiens,,D,CHEMBL620971,BAO_0000357,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,11706,,,235,Expert
0,,1,,9606.0,4677,,,A,,,,Homo sapiens,,U,CHEMBL620972,BAO_0000218,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9606.0,4678,,,A,,,,Homo sapiens,,U,CHEMBL620973,BAO_0000019,Compound was evaluated for area under the curve expressed as (h*ug/ml),17791,,,22224,Autocuration
0,,1,,9606.0,4679,,,A,,,,Homo sapiens,,U,CHEMBL618243,BAO_0000019,Active metabolite of ifosfamide determined in humans; A-Active,7766,,,22224,Autocuration
0,,1,,9606.0,4680,,,A,,,,Homo sapiens,,U,CHEMBL618244,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,6567,,,22224,Autocuration
0,,1,,9606.0,4681,,,A,,,,Homo sapiens,,U,CHEMBL618245,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,6567,,,22224,Autocuration
0,,1,,9606.0,4682,,,A,,,,Homo sapiens,,U,CHEMBL618246,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,6567,,,22224,Autocuration
0,,1,,9606.0,4683,,,A,,,,Homo sapiens,,U,CHEMBL618247,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,6567,,,22224,Autocuration
0,,1,,9606.0,4684,,,A,,,,Homo sapiens,,U,CHEMBL618248,BAO_0000218,Compound was evaluated for oral bioavailability in human,17791,,,22224,Autocuration
0,,1,,9606.0,4685,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618249,BAO_0000019,Metabolite of ifosfamide determined in urine; NF-Not found,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4686,,,A,,,,Homo sapiens,,U,CHEMBL618250,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),6852,,,22224,Autocuration
0,,1,,9606.0,4687,,,A,,,,Homo sapiens,,U,CHEMBL874598,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,6852,,,22224,Autocuration
0,,1,,9606.0,4688,,,A,,,,Homo sapiens,,U,CHEMBL618251,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,6852,,,22224,Autocuration
0,,1,,9606.0,4689,,,A,,,,Homo sapiens,,U,CHEMBL618252,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,6852,,,22224,Autocuration
0,,1,,9606.0,4690,,,A,,,,Homo sapiens,,U,CHEMBL618253,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,6852,,,22224,Autocuration
0,,1,,9606.0,4691,,,A,,,,Homo sapiens,,U,CHEMBL618254,BAO_0000019,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),6852,,,22224,Autocuration
0,,1,,9606.0,4692,,,A,,,,Homo sapiens,,U,CHEMBL618255,BAO_0000019,Percent of compound in healthy individuals (Group D),6852,,,22224,Autocuration
0,,1,,9606.0,4693,,,A,2107.0,,,Homo sapiens,,U,CHEMBL618983,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,4397,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4694,,,A,,,,Homo sapiens,,U,CHEMBL618984,BAO_0000019,Binding towards human plasma protein at 10 uM,17409,,,22224,Autocuration
0,,1,,9606.0,4695,,,A,,,,Homo sapiens,,U,CHEMBL618985,BAO_0000019,Binding towards human plasma protein at 100 uM,17409,,,22224,Autocuration
0,,1,,9606.0,4696,,,A,,,,Homo sapiens,,U,CHEMBL618986,BAO_0000019,Human plasma protein binding activity was determined,17176,,,22224,Autocuration
0,,1,,9606.0,4697,,,A,,,,Homo sapiens,,U,CHEMBL618987,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),15444,,,22224,Autocuration
0,,1,,9606.0,4698,,,A,,,,Homo sapiens,,U,CHEMBL618988,BAO_0000019,Percent binding of compound towards human plasma protein was determined,17267,,,22224,Autocuration
0,,1,,9606.0,4699,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618989,BAO_0000251,Plasma clearance in human liver microsomes,5944,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4700,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618990,BAO_0000251,In vitro intrinsic clearance in human liver microsome,5668,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4701,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618991,BAO_0000251,In vitro intrinsic clearance in human liver microsome,5669,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4702,,In vitro,A,,,,Homo sapiens,,U,CHEMBL876725,BAO_0000251,In vitro microsome metabolism clearance in human was determined,5041,Microsomes,,22224,Autocuration
0,,1,,9606.0,4703,,In vitro,A,,,,Homo sapiens,,U,CHEMBL618992,BAO_0000251,In vitro microsome metabolism clearance in human was determined; High,5041,Microsomes,,22224,Autocuration
0,,1,,9606.0,4704,,In vitro,A,,,,Homo sapiens,,U,CHEMBL618993,BAO_0000251,In vitro microsome metabolism clearance in human was determined; ND denotes no data,5041,Microsomes,,22224,Autocuration
0,,1,,9606.0,4705,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618994,BAO_0000251,Pharmacokinetic property (clearance) in human liver microsome,5676,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4706,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618995,BAO_0000251,Plasma clearance in human liver microsomes,5944,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4707,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618996,BAO_0000251,In vitro clearance in human liver microsomes,17538,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4708,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618997,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,6331,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4709,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618998,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,5948,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4710,,In vivo,A,,,,Homo sapiens,,U,CHEMBL618999,BAO_0000218,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,5965,,,22224,Autocuration
0,,1,,9606.0,4711,,In vivo,A,,,,Homo sapiens,,U,CHEMBL620223,BAO_0000218,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9606.0,4712,,,A,,,,Homo sapiens,,U,CHEMBL620224,BAO_0000218,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,5965,,,22224,Autocuration
0,,1,,9606.0,4713,,,A,,,,Homo sapiens,,U,CHEMBL620225,BAO_0000019,Stability in human plasma 2 hr after incubation expressed as percent concentration,1299,,,22224,Autocuration
0,,1,,9606.0,4714,,,A,,,,Homo sapiens,,U,CHEMBL620226,BAO_0000019,Stability in human plasma 4 hr after incubation expressed as percent concentration,1299,,,22224,Autocuration
0,,1,,9606.0,4715,,,A,1088.0,,,Homo sapiens,,U,CHEMBL620227,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4716,,,A,1088.0,,,Homo sapiens,,U,CHEMBL876726,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4717,,,A,1088.0,,,Homo sapiens,,U,CHEMBL620228,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4718,,,A,1088.0,,,Homo sapiens,,U,CHEMBL620229,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
1,,1,,10090.0,4719,,In vivo,F,,,,Mus musculus,,N,CHEMBL620230,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4720,,In vivo,F,,,,Mus musculus,,N,CHEMBL620231,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4721,,In vivo,F,,,,Mus musculus,,N,CHEMBL620232,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4722,,In vivo,F,,,,Mus musculus,,N,CHEMBL620233,BAO_0000218,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4723,,,A,,,,Mus musculus,,N,CHEMBL620234,BAO_0000218,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),14294,,,50594,Intermediate
1,,1,,10090.0,4724,,,A,,,,Mus musculus,,N,CHEMBL620235,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),14294,,,50594,Intermediate
1,,1,,10090.0,4725,,,A,,,,Mus musculus,,N,CHEMBL620236,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),14294,,,50594,Intermediate
1,,1,,10090.0,4726,,,A,2107.0,,,Mus musculus,,N,CHEMBL620237,BAO_0000218,In vitro metabolic potential in mouse liver microsomes,6251,,Liver,50594,Intermediate
1,,1,,10090.0,4727,,,A,,,,Mus musculus,,N,CHEMBL620238,BAO_0000218,Ability of compound to bind to plasma protein was evaluated in HSA cells,17582,,,50594,Intermediate
1,,1,,10090.0,4728,,,A,2369.0,,,Mus musculus,,N,CHEMBL620239,BAO_0000218,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),17811,,Adrenal gland,50594,Intermediate
1,,1,,10090.0,4729,,,A,955.0,,,Mus musculus,,N,CHEMBL620240,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,17811,,Brain,50594,Intermediate
1,,1,,10090.0,4730,,,A,955.0,,,Mus musculus,,N,CHEMBL620241,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,17811,,Brain,50594,Intermediate
1,,1,,10090.0,4731,,,A,,,,Mus musculus,,N,CHEMBL876727,BAO_0000218,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),17811,,,50594,Intermediate
1,,1,,10090.0,4732,,,A,2113.0,,,Mus musculus,,N,CHEMBL620242,BAO_0000218,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),17811,,Kidney,50594,Intermediate
1,,1,,10090.0,4733,,,A,,,,Mus musculus,,N,CHEMBL620243,BAO_0000218,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),17811,,,50594,Intermediate
1,,1,,10090.0,4734,,,A,,,,Mus musculus,,N,CHEMBL620244,BAO_0000218,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,5288,,,50594,Intermediate
1,,1,,10090.0,4735,,,A,1977.0,,,Mus musculus,,N,CHEMBL620245,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,2717,,Serum,50594,Intermediate
1,,1,,10090.0,4736,,,A,1977.0,,,Mus musculus,,N,CHEMBL620246,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,2717,,Serum,50594,Intermediate
1,,1,,10090.0,4737,,,A,1977.0,,,Mus musculus,,N,CHEMBL620247,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,2717,,Serum,50594,Intermediate
1,,1,,10090.0,4738,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL620248,BAO_0000218,Half life of compound was determined in plasma of mice at 24 mg/Kg,17753,,Plasma,50594,Intermediate
1,,1,,10090.0,4739,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL873497,BAO_0000218,Half life of compound was determined in plasma of mice at 40 mg/Kg,17753,,Plasma,50594,Intermediate
1,,1,,10090.0,4740,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL620249,BAO_0000218,Half life of compound was determined in plasma of mice at 5 mg/Kg,17753,,Plasma,50594,Intermediate
1,,1,,10090.0,4741,,In vivo,F,,,,Mus musculus,,N,CHEMBL620250,BAO_0000218,Half life after intraperitoneal administration in mice at 18 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4742,,In vivo,F,,,,Mus musculus,,N,CHEMBL620251,BAO_0000218,Half life after intraperitoneal administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4743,,In vivo,F,,,,Mus musculus,,N,CHEMBL620252,BAO_0000218,Half life after intraperitoneal administration in mice at 25 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4744,,In vivo,F,,,,Mus musculus,,N,CHEMBL620253,BAO_0000218,Half life after intraperitoneal administration in mice at 26 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4745,,In vivo,F,,,,Mus musculus,,N,CHEMBL620254,BAO_0000218,Half life after intravenous administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4746,,In vivo,A,,,,Mus musculus,,N,CHEMBL620255,BAO_0000218,Half life after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4747,,In vivo,A,,,,Mus musculus,,N,CHEMBL620256,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,16597,,,50594,Intermediate
1,,1,,10090.0,4748,,In vivo,A,,,,Mus musculus,,N,CHEMBL876728,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,2675,,,50594,Intermediate
1,,1,,10090.0,4749,,In vivo,A,,,,Mus musculus,,N,CHEMBL620257,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after oral administration,2675,,,50594,Intermediate
1,,1,,10090.0,4750,,In vivo,A,,,,Mus musculus,,N,CHEMBL620258,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),16597,,,50594,Intermediate
1,,1,,10090.0,4751,,In vivo,A,,,,Mus musculus,,N,CHEMBL620259,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",4890,,,50594,Intermediate
1,,1,,10090.0,4752,,In vivo,A,,,,Mus musculus,,N,CHEMBL620260,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,429,,,50594,Intermediate
1,,1,,10090.0,4753,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL620261,BAO_0000218,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,17837,,Blood,50594,Intermediate
1,,1,,10090.0,4754,,In vivo,A,,,,Mus musculus,,N,CHEMBL620262,BAO_0000218,Half life at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4755,,In vivo,A,,,,Mus musculus,,N,CHEMBL620263,BAO_0000218,Half life at a dose of 10 mg/kg peroral administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4756,,,A,,,,Mus musculus,,N,CHEMBL620264,BAO_0000218,Half life in ob/ob mice,6619,,,50594,Intermediate
1,,1,,10090.0,4757,,In vivo,A,,,,Mus musculus,,N,CHEMBL620265,BAO_0000218,Half-life at a single subcutaneous administration of 40 mg/kg in mice,4066,,,50594,Intermediate
1,,1,,10090.0,4758,,,A,,,,Mus musculus,,N,CHEMBL620266,BAO_0000218,Half-life was measured in mouse,4239,,,50594,Intermediate
1,,1,,10090.0,4759,,In vivo,A,,,,Mus musculus,,N,CHEMBL620267,BAO_0000218,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,4760,,,A,,,,Mus musculus,,N,CHEMBL619364,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,8999,,,50594,Intermediate
1,,1,,10090.0,4761,,,A,,,,Mus musculus,,N,CHEMBL619365,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,8999,,,50594,Intermediate
1,,1,,10090.0,4762,,,A,955.0,,,Mus musculus,,N,CHEMBL619366,BAO_0000218,T2 in brain of mice at the oral dose of 50 mg/kg,17641,,Brain,50594,Intermediate
1,,1,,10090.0,4763,,,A,2113.0,,,Mus musculus,,N,CHEMBL619367,BAO_0000218,T2 in kidney of mice at the oral dose of 50 mg/kg,17641,,Kidney,50594,Intermediate
1,,1,,10090.0,4764,,,A,2107.0,,,Mus musculus,,N,CHEMBL619368,BAO_0000218,T2 in liver of mice at the oral dose of 50 mg/kg,17641,,Liver,50594,Intermediate
1,,1,,10090.0,4765,,,A,2048.0,,,Mus musculus,,N,CHEMBL619369,BAO_0000218,T2 in lungs of mice at the oral dose of 50 mg/kg,17641,,Lung,50594,Intermediate
1,,1,,10090.0,4766,,,A,2106.0,,,Mus musculus,,N,CHEMBL876729,BAO_0000218,T2 in spleen of mice at the oral dose of 50 mg/kg,17641,,Spleen,50594,Intermediate
1,,1,,10090.0,4767,,In vivo,A,,,,Mus musculus,,N,CHEMBL619370,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,16597,,,50594,Intermediate
1,,1,,10090.0,4768,,In vivo,A,,,,Mus musculus,,N,CHEMBL619371,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",4890,,,50594,Intermediate
1,,1,,10090.0,4769,,In vivo,A,,,,Mus musculus,,N,CHEMBL619372,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,429,,,50594,Intermediate
1,,1,,10090.0,4770,,In vivo,A,,,,Mus musculus,,N,CHEMBL620012,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,429,,,50594,Intermediate
1,,1,,10090.0,4771,,In vivo,A,,,,Mus musculus,,N,CHEMBL620013,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,5969,,,50594,Intermediate
1,,1,478.0,9606.0,4772,,,F,,,,Homo sapiens,A2780,N,CHEMBL620014,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4773,,,F,,,,Homo sapiens,A2780,N,CHEMBL620015,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4774,,,F,,,,Homo sapiens,A2780,N,CHEMBL621010,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4775,,,F,,,,Homo sapiens,A2780,N,CHEMBL621011,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4776,,,F,,,,Homo sapiens,A2780,N,CHEMBL621012,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4777,,,F,,,,Homo sapiens,A2780,N,CHEMBL621013,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,,,81034,Intermediate
1,,1,478.0,9606.0,4778,,,F,,,,Homo sapiens,A2780,N,CHEMBL621014,BAO_0000219,In vitro cytotoxicity against A2780TAX cell line,17270,,,81034,Intermediate
1,,1,481.0,9606.0,4779,,,F,,,,Homo sapiens,A2780cisR,N,CHEMBL618154,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780cis,5618,,,80017,Intermediate
1,,1,478.0,9606.0,4780,,,F,,,,Homo sapiens,A2780,N,CHEMBL618155,BAO_0000219,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,17777,,,81034,Expert
1,,1,481.0,9606.0,4781,,,F,,,,Homo sapiens,A2780cisR,N,CHEMBL618156,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,16112,,,80017,Intermediate
1,,1,481.0,9606.0,4782,,,F,,,,Homo sapiens,A2780cisR,N,CHEMBL618157,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),15748,,,80017,Intermediate
1,,1,478.0,9606.0,4783,,,F,,,,Homo sapiens,A2780,N,CHEMBL618328,BAO_0000219,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,6633,,,81034,Intermediate
1,,1,478.0,9606.0,4784,,,F,,,,Homo sapiens,A2780,N,CHEMBL618329,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,16930,,,81034,Intermediate
1,,1,478.0,9606.0,4785,,,F,,,,Homo sapiens,A2780,N,CHEMBL618330,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,17496,,,81034,Intermediate
1,,1,478.0,9606.0,4786,,,F,,,,Homo sapiens,A2780,N,CHEMBL618331,BAO_0000219,In vitro antitumor activity against A2780cisR cell line.,12989,,,81034,Expert
1,,1,478.0,9606.0,4787,,,F,,,,Homo sapiens,A2780,N,CHEMBL618332,BAO_0000219,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),4840,,,81034,Intermediate
1,,1,478.0,9606.0,4788,,,F,,,,Homo sapiens,A2780,N,CHEMBL618333,BAO_0000219,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,12989,,,81034,Expert
1,,1,481.0,9606.0,4789,,,F,,,,Homo sapiens,A2780cisR,N,CHEMBL618334,BAO_0000219,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,16745,,,80017,Intermediate
1,,1,478.0,9606.0,4790,,,F,,,,Homo sapiens,A2780,N,CHEMBL618335,BAO_0000219,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,16597,,,81034,Expert
9,,1,,10116.0,4791,,,B,,,,Rattus norvegicus,,D,CHEMBL618336,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,16547,,,11736,Expert
8,,1,,,4792,,,F,,,,,,H,CHEMBL618337,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),16547,,,11736,Expert
9,,1,,10116.0,4793,,,F,,,,Rattus norvegicus,,D,CHEMBL618338,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),16547,,,11736,Expert
9,,1,722.0,9606.0,4794,,,F,,,,Homo sapiens,HEK293,D,CHEMBL618339,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,15856,,,278,Expert
9,,1,722.0,9606.0,4795,,,F,,,,Homo sapiens,HEK293,D,CHEMBL618340,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,15856,,,278,Expert
9,,1,,10090.0,4796,,,B,,,,Mus musculus,,D,CHEMBL618341,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,16547,,,11831,Expert
8,,1,,,4797,,,F,,,,,,H,CHEMBL618342,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),16547,,,11831,Expert
9,,1,,10090.0,4798,,,F,,,,Mus musculus,,D,CHEMBL618343,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),16547,,,11831,Expert
8,,1,,,4799,,,B,,,,,,H,CHEMBL621038,BAO_0000357,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,17402,,,280,Expert
0,,1,574.0,9606.0,4800,,,F,,,,Homo sapiens,T-cells,U,CHEMBL621039,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),11746,,,22226,Autocuration
0,,1,574.0,9606.0,4801,,,F,,,,Homo sapiens,T-cells,U,CHEMBL621040,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,11746,,,22226,Autocuration
1,,1,455.0,9606.0,4802,,,F,,,,Homo sapiens,A-375,N,CHEMBL621041,BAO_0000219,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,5455,,,80018,Intermediate
1,,1,455.0,9606.0,4803,,,F,,,,Homo sapiens,A-375,N,CHEMBL621042,BAO_0000219,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,2068,,,80018,Intermediate
1,,1,455.0,9606.0,4804,,,F,,,,Homo sapiens,A-375,N,CHEMBL621043,BAO_0000219,In vitro antitumor activity against A375cell line extracted form melanoma,2683,,,80018,Intermediate
1,,1,455.0,9606.0,4805,,,F,,,,Homo sapiens,A-375,N,CHEMBL621044,BAO_0000219,Inhibition of cell growth in (A375) melan cell line,15313,,,80018,Expert
1,,1,455.0,9606.0,4806,,,F,,,,Homo sapiens,A-375,N,CHEMBL621045,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,13739,,,80018,Intermediate
1,,1,455.0,9606.0,4807,,,F,,,,Homo sapiens,A-375,N,CHEMBL621046,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,13739,,,80018,Intermediate
1,,1,455.0,9606.0,4808,,,F,,,,Homo sapiens,A-375,N,CHEMBL621047,BAO_0000219,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,14750,,,80018,Intermediate
1,,1,797.0,9606.0,4809,,,F,,,,Homo sapiens,A-427,N,CHEMBL621048,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,14777,,,80019,Intermediate
1,,1,797.0,9606.0,4810,,,F,,,,Homo sapiens,A-427,N,CHEMBL883798,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,14777,,,80019,Intermediate
1,,1,797.0,9606.0,4811,,,F,,,,Homo sapiens,A-427,N,CHEMBL621049,BAO_0000219,Cytotoxicity against lung carcinoma A427 tumor cell lines,17672,,,80019,Intermediate
1,,1,797.0,9606.0,4812,,,F,,,,Homo sapiens,A-427,N,CHEMBL621050,BAO_0000219,Inhibition of large cell lung carcinoma (A427),14368,,,80019,Intermediate
1,,1,797.0,9606.0,4813,,,F,,,,Homo sapiens,A-427,N,CHEMBL621051,BAO_0000219,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,14368,,,80019,Intermediate
1,,1,797.0,9606.0,4814,,,F,,,,Homo sapiens,A-427,N,CHEMBL621052,BAO_0000219,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,13866,,,80019,Intermediate
1,,1,797.0,9606.0,4815,,,F,,,,Homo sapiens,A-427,N,CHEMBL621053,BAO_0000219,Inhibitory concentration in human lung carcinoma A427 cell line,2545,,,80019,Intermediate
1,,1,797.0,9606.0,4816,,,F,,,,Homo sapiens,A-427,N,CHEMBL621054,BAO_0000219,Inhibitory concentration in human lung carcinoma A427/VCR cell line,2545,,,80019,Intermediate
0,,1,,9527.0,4817,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621055,BAO_0000218,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,6062,,,22224,Autocuration
0,,1,,9527.0,4818,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL876398,BAO_0000218,Tested for volume of distribution upon iv administration to african green monkey,4578,,,22224,Autocuration
0,,1,,9527.0,4819,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621056,BAO_0000218,Volume of distribution in monkey,17592,,,22224,Autocuration
0,,1,,9544.0,4820,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL621057,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,,,22224,Autocuration
0,,1,,9544.0,4821,,In vivo,A,,,,Macaca mulatta,,U,CHEMBL621058,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,5005,,,22224,Autocuration
0,,1,,9527.0,4822,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621059,BAO_0000218,Pharmacokinetic property(Vdss) in cynomolgus monkey,5922,,,22224,Autocuration
0,,1,,9527.0,4823,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621060,BAO_0000218,The distribution volume after intravenous administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,4824,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621061,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4825,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621062,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,4826,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621063,BAO_0000218,Volume displacement was calculated in rhesus monkey,6057,,,22224,Autocuration
0,,1,,9527.0,4827,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621064,BAO_0000218,Volume of distribution in steady state was determined in rhesus monkey,5145,,,22224,Autocuration
0,,1,,9527.0,4828,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621065,BAO_0000218,Volume of distribution of compound was determined in monkey,6821,,,22224,Autocuration
0,,1,,9527.0,4829,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621066,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9527.0,4830,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621067,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,,,22224,Autocuration
0,,1,,9527.0,4831,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621068,BAO_0000218,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,22224,Autocuration
0,,1,,9527.0,4832,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL876399,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,4833,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621069,BAO_0000218,Volume distribution in monkey after administration of 1 mg/kg iv,6535,,,22224,Autocuration
0,,1,,9527.0,4834,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621070,BAO_0000218,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4835,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621071,BAO_0000218,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,6062,,,22224,Autocuration
0,,1,,9527.0,4836,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621072,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,4837,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618209,BAO_0000218,Oral systemic bioavailability upon iv administration to african green monkey,4578,,,22224,Autocuration
0,,1,,9527.0,4838,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618210,BAO_0000218,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4839,,,A,,,,Cercopithecidae,,U,CHEMBL618211,BAO_0000019,Baboon plasma free fraction. ,11271,,,22224,Autocuration
0,,1,,9527.0,4840,,,A,,,,Cercopithecidae,,U,CHEMBL618212,BAO_0000218,Area under the curve was calculated in rhesus monkey after iv administration,6057,,,22224,Autocuration
0,,1,,9527.0,4841,,,A,,,,Cercopithecidae,,U,CHEMBL618213,BAO_0000019,Area under the curve was calculated in rhesus monkey after peroral administration,6057,,,22224,Autocuration
0,,1,,9527.0,4842,,,A,,,,Cercopithecidae,,U,CHEMBL618214,BAO_0000019,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,17853,,,22224,Autocuration
0,,1,,9527.0,4843,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL873492,BAO_0000218,Half life period in monkey after 5 mg/kg dose,5302,,,22224,Autocuration
0,,1,,9527.0,4844,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618272,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose,4257,,,22224,Autocuration
0,,1,,9527.0,4845,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618273,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,4257,,,22224,Autocuration
0,,1,,9527.0,4846,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL618274,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,13501,,Plasma,22224,Autocuration
0,,1,,9527.0,4847,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618275,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,5394,,,22224,Autocuration
0,,1,,9527.0,4848,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618276,BAO_0000218,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,4849,,,A,,,,Cercopithecidae,,U,CHEMBL618277,BAO_0000019,Compound was evaluated for terminal half life in monkey,3341,,,22224,Autocuration
0,,1,,9527.0,4850,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618278,BAO_0000218,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,3045,,,22224,Autocuration
0,,1,,9544.0,4851,,In vivo,A,1969.0,,,Macaca mulatta,,U,CHEMBL618279,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,,Plasma,22224,Autocuration
0,,1,,9527.0,4852,,,A,,,,Cercopithecidae,,U,CHEMBL618280,BAO_0000019,Half life of compound was determined in squirrel monkey,4847,,,22224,Autocuration
0,,1,,9541.0,4853,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL618281,BAO_0000218,Half life after iv administration in cynomolgus monkey,4256,,,22224,Autocuration
0,,1,,9527.0,4854,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL618282,BAO_0000218,Half life in monkey plasma after administration of 1 mg/kg iv,6535,,Plasma,22224,Autocuration
0,,1,,9527.0,4855,,,A,,,,Cercopithecidae,,U,CHEMBL618283,BAO_0000019,Half life was calculated in rhesus monkey,6057,,,22224,Autocuration
0,,1,,9527.0,4856,,,A,,,,Cercopithecidae,,U,CHEMBL618284,BAO_0000019,Half life in monkey,17592,,,22224,Autocuration
0,,1,,9527.0,4857,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618285,BAO_0000218,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,22224,Autocuration
0,,1,,9527.0,4858,,,A,,,,Cercopithecidae,,U,CHEMBL618286,BAO_0000019,Half life was evaluated in rhesus,5472,,,22224,Autocuration
0,,1,,9527.0,4859,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618287,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in monkey was determined,6221,,,22224,Autocuration
0,,1,,9527.0,4860,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618288,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in Rhesus,5668,,,22224,Autocuration
0,,1,,9527.0,4861,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL876393,BAO_0000218,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,,,22224,Autocuration
0,,1,,9527.0,4862,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618289,BAO_0000218,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,,,22224,Autocuration
0,,1,,9527.0,4863,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618290,BAO_0000218,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,5553,,,22224,Autocuration
0,,1,,9527.0,4864,,,A,,,,Cercopithecidae,,U,CHEMBL618291,BAO_0000019,Half-life was calculated in monkey,6078,,,22224,Autocuration
0,,1,,9527.0,4865,,,A,,,,Cercopithecidae,,U,CHEMBL618292,BAO_0000019,Half-life in Squirrel monkey,5147,,,22224,Autocuration
0,,1,,9527.0,4866,,,A,,,,Cercopithecidae,,U,CHEMBL618293,BAO_0000019,Half-life in rhesus monkey,5145,,,22224,Autocuration
0,,1,,9527.0,4867,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618294,BAO_0000218,Half-life was measured in monkey after an iv dose of 1 mg/kg,6062,,,22224,Autocuration
0,,1,,9527.0,4868,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618295,BAO_0000218,Half-life period after intravenous administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,4869,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618296,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,4870,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618297,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,5355,,,22224,Autocuration
0,,1,,9606.0,4871,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618298,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4872,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618299,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4873,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618300,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4874,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618301,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4875,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618302,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4876,,,A,1088.0,,,Homo sapiens,,U,CHEMBL876394,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4877,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618303,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4878,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618304,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,7766,,Urine,22224,Autocuration
0,,1,,9606.0,4879,,In vivo,A,,,,Homo sapiens,,U,CHEMBL618305,BAO_0000218,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1916,,,22224,Autocuration
0,,1,,9606.0,4880,,In vivo,A,,,,Homo sapiens,,U,CHEMBL618306,BAO_0000218,Oral bioavailability in human,16643,,,22224,Autocuration
0,,1,,9606.0,4881,,,A,,,,Homo sapiens,,U,CHEMBL618307,BAO_0000019,Compound was tested for human plasma protein binding,17248,,,22224,Autocuration
0,,1,,9606.0,4882,,,A,,,,Homo sapiens,,U,CHEMBL618308,BAO_0000019,Compound was tested for human plasma protein binding; Not determined,17248,,,22224,Autocuration
0,,1,,9606.0,4883,,,A,,,,Homo sapiens,,U,CHEMBL618309,BAO_0000019,Protein binding activity of compound in human plasma; % Free,6241,,,22224,Autocuration
0,,1,,9606.0,4884,,,A,,,,Homo sapiens,,U,CHEMBL618310,BAO_0000019,Unbound fraction (plasma),17716,,,22224,Autocuration
0,,1,,9606.0,4885,,,A,1969.0,,,Homo sapiens,,U,CHEMBL873353,BAO_0000366,Half life for the hydrolysis of compound in human blood serum,17605,,Plasma,22224,Autocuration
0,,1,,9606.0,4886,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618311,BAO_0000366,Half life period in human plasma using phosphate buffer (0.08 M),17625,,Plasma,22224,Autocuration
0,,1,,9606.0,4887,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618312,BAO_0000366,Half life period in human plasma using phosphate buffer (0.1 M),17625,,Plasma,22224,Autocuration
0,,1,,9606.0,4888,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618313,BAO_0000366,Half-life in human plasma was determined,17747,,Plasma,22224,Autocuration
0,,1,,9606.0,4889,,,A,,,,Homo sapiens,,U,CHEMBL618314,BAO_0000019,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,15613,,,22224,Autocuration
0,,1,,9606.0,4890,,,A,,,,Homo sapiens,,U,CHEMBL618315,BAO_0000019,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),354,,,22224,Autocuration
0,,1,,9606.0,4891,,,A,,,,Homo sapiens,,U,CHEMBL618316,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",3741,,,22224,Autocuration
0,,1,,9606.0,4892,,,A,,,,Homo sapiens,,U,CHEMBL618317,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",3741,,,22224,Autocuration
0,,1,,9606.0,4893,,,A,,,,Homo sapiens,,U,CHEMBL620138,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",3741,,,22224,Autocuration
0,,1,,9606.0,4894,,,A,,,,Homo sapiens,,U,CHEMBL858280,BAO_0000019,Partition coefficient (logP),17599,,,22224,Autocuration
0,,1,,9606.0,4895,,,A,,,,Homo sapiens,,U,CHEMBL620139,BAO_0000019,In vitro metabolic stability in human was measured as pmol/min/mg/protein,5486,,,22224,Autocuration
0,,1,,9606.0,4896,,,A,,,,Homo sapiens,,U,CHEMBL620140,BAO_0000251,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,5600,Microsomes,,22224,Autocuration
0,,1,,9606.0,4897,,,A,,,,Homo sapiens,,U,CHEMBL620141,BAO_0000019,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),14294,,,22224,Autocuration
0,,1,,9606.0,4898,,,A,,,,Homo sapiens,,U,CHEMBL620142,BAO_0000019,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),14294,,,22224,Autocuration
0,,1,,9606.0,4899,,,A,,,,Homo sapiens,,U,CHEMBL620143,BAO_0000019,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),14294,,,22224,Autocuration
0,,1,,9606.0,4900,,,A,,,,Homo sapiens,,U,CHEMBL620144,BAO_0000251,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9606.0,4901,,,A,,,,Homo sapiens,,U,CHEMBL620145,BAO_0000251,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),14294,Microsomes,,22224,Autocuration
0,,1,,9606.0,4902,,,A,,,,Homo sapiens,,U,CHEMBL620146,BAO_0000251,Metabolism of compound in human microsomes; Trace,14294,Microsomes,,22224,Autocuration
0,,1,,9606.0,4903,,,A,2107.0,,,Homo sapiens,,U,CHEMBL620147,BAO_0000251,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,6260,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4904,,,A,,,,Homo sapiens,,U,CHEMBL620148,BAO_0000251,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,6187,Microsomes,,22224,Autocuration
0,,1,,9606.0,4905,,,A,2107.0,,,Homo sapiens,,U,CHEMBL620149,BAO_0000251,In vitro metabolic potential in human liver microsomes,6251,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,4906,,,A,,,,Homo sapiens,,U,CHEMBL876412,BAO_0000019,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,3246,,,22224,Autocuration
0,,1,,9606.0,4907,,,A,,,,Homo sapiens,,U,CHEMBL619352,BAO_0000019,Tested for human plasma protein binding of the compound; Not tested,17313,,,22224,Autocuration
0,,1,,9606.0,4908,,,A,,,,Homo sapiens,,U,CHEMBL619353,BAO_0000019,Compound was tested for percent protein binding (PB) in human,6227,,,22224,Autocuration
0,,1,,9606.0,4909,,,A,1969.0,,,Homo sapiens,,U,CHEMBL619354,BAO_0000019,Protein binding in human plasma,5530,,Plasma,22224,Autocuration
0,,1,,9606.0,4910,,,A,,,,Homo sapiens,,U,CHEMBL619355,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,6108,,,22224,Autocuration
0,,1,,9606.0,4911,,,A,,,,Homo sapiens,,U,CHEMBL619356,BAO_0000019,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,6108,,,22224,Autocuration
0,,1,,9606.0,4912,,,A,,,,Homo sapiens,,U,CHEMBL619357,BAO_0000019,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),2774,,,22224,Autocuration
0,,1,,9606.0,4913,,,A,,,,Homo sapiens,,U,CHEMBL619358,BAO_0000019,In vitro rate of absorption observed as Caco-2 permeability in humans,16643,,,22224,Autocuration
0,,1,495.0,9606.0,4914,,,A,,,,Homo sapiens,Caco-2,U,CHEMBL619359,BAO_0000219,Cellular permeability of compound was determined in Caco-2 cells; High,17582,,,22224,Autocuration
0,,1,495.0,9606.0,4915,,,A,,,,Homo sapiens,Caco-2,U,CHEMBL619360,BAO_0000219,Permeability in Caco-2 cells of compound,6838,,,22224,Autocuration
0,,1,,9606.0,4916,,,A,,,,Homo sapiens,,U,CHEMBL619361,BAO_0000019,Permeability coefficient (A to B) in Caco-2 cell,6108,,,22224,Autocuration
0,,1,,9606.0,4917,,,A,,,,Homo sapiens,,U,CHEMBL619362,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,6108,,,22224,Autocuration
0,,1,,9606.0,4918,,,A,,,,Homo sapiens,,U,CHEMBL619363,BAO_0000019,Permeability coefficient (Papp) (Caco-2 cell monolayer),6108,,,22224,Autocuration
0,,1,,9606.0,4919,,,A,,,,Homo sapiens,,U,CHEMBL618942,BAO_0000019,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,2146,,,22224,Autocuration
0,,1,,9606.0,4920,,,A,,,,Homo sapiens,,U,CHEMBL618943,BAO_0000019,Compound was tested for protein binding in human plasma,4514,,,22224,Autocuration
0,,1,,9606.0,4921,,,A,,,,Homo sapiens,,U,CHEMBL618944,BAO_0000019,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,6108,,,22224,Autocuration
0,,1,,9606.0,4922,,,A,1088.0,,,Homo sapiens,,U,CHEMBL618945,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,7766,,Urine,22224,Autocuration
1,,1,,10090.0,4923,,In vivo,A,,,,Mus musculus,,N,CHEMBL618946,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,4924,,In vivo,A,,,,Mus musculus,,N,CHEMBL876413,BAO_0000218,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,,,50594,Intermediate
1,,1,,10090.0,4925,,In vivo,A,,,,Mus musculus,,N,CHEMBL618947,BAO_0000218,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,3802,,,50594,Intermediate
1,,1,,10090.0,4926,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL618948,BAO_0000218,Time taken to reach maximum concentration in plasma upon oral administration in mouse,2862,,Plasma,50594,Intermediate
1,,1,,10090.0,4927,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL618949,BAO_0000218,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,,Plasma,50594,Intermediate
1,,1,,10090.0,4928,,In vivo,F,,,,Mus musculus,,N,CHEMBL618950,BAO_0000218,Tmax after intraperitoneal administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4929,,In vivo,A,,,,Mus musculus,,N,CHEMBL618951,BAO_0000218,Tmax after oral administration at 30 mg/kg in ICR mouse,5781,,,50594,Intermediate
1,,1,,10090.0,4930,,In vivo,A,,,,Mus musculus,,N,CHEMBL618952,BAO_0000218,Tmax after peroral administration in mice at 2.4 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4931,,In vivo,A,,,,Mus musculus,,N,CHEMBL618953,BAO_0000218,Tmax at a single subcutaneous administration of 40 mg/kg in mice,4066,,,50594,Intermediate
1,,1,,10090.0,4932,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL618954,BAO_0000218,Tmax in brain of mice at the oral dose of 50 mg/kg,17641,,Brain,50594,Intermediate
1,,1,,10090.0,4933,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL618955,BAO_0000218,Tmax in kidney of mice at the oral dose of 50 mg/kg,17641,,Kidney,50594,Intermediate
1,,1,,10090.0,4934,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL618956,BAO_0000218,Tmax in liver of mice at the oral dose of 50 mg/kg,17641,,Liver,50594,Intermediate
1,,1,,10090.0,4935,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL618957,BAO_0000218,Tmax in lungs of mice at the oral dose of 50 mg/kg,17641,,Lung,50594,Intermediate
1,,1,,10090.0,4936,,In vivo,F,,,,Mus musculus,,N,CHEMBL618958,BAO_0000218,Tmax in mice at 18 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,4937,,In vivo,F,,,,Mus musculus,,N,CHEMBL618959,BAO_0000218,Tmax in mice at 23 uM/kg i.v. administration,17764,,,50594,Intermediate
1,,1,,10090.0,4938,,In vivo,F,,,,Mus musculus,,N,CHEMBL618960,BAO_0000218,Tmax in mice at 25 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,4939,,In vivo,F,,,,Mus musculus,,N,CHEMBL876723,BAO_0000218,Tmax in mice at 26 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,4940,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618961,BAO_0000218,Tmax in spleen of mice at the oral dose of 50 mg/kg,17641,,Spleen,50594,Intermediate
1,,1,,10090.0,4941,,In vivo,A,,,,Mus musculus,,N,CHEMBL618962,BAO_0000218,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4942,,In vivo,A,,,,Mus musculus,,N,CHEMBL618963,BAO_0000218,Tmax value at a dose of 10 mg/kg peroral administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4943,,,A,,,,Mus musculus,,N,CHEMBL618964,BAO_0000218,Tmax value in IRC mice,5951,,,50594,Intermediate
1,,1,,10090.0,4944,,In vivo,A,,,,Mus musculus,,N,CHEMBL618965,BAO_0000218,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,4945,,In vivo,A,,,,Mus musculus,,N,CHEMBL618966,BAO_0000218,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,4946,,,A,1088.0,,,Mus musculus,,N,CHEMBL618967,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),429,,Urine,50594,Intermediate
1,,1,,10090.0,4947,,,A,1088.0,,,Mus musculus,,N,CHEMBL618968,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),429,,Urine,50594,Intermediate
1,,1,,10090.0,4948,,,A,1088.0,,,Mus musculus,,N,CHEMBL618969,BAO_0000218,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),4066,,Urine,50594,Intermediate
1,,1,,10090.0,4949,,,A,,,,Mus musculus,,N,CHEMBL618970,BAO_0000218,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,,,50594,Intermediate
1,,1,,10090.0,4950,,,A,,,,Mus musculus,,N,CHEMBL618971,BAO_0000218,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,,,50594,Intermediate
1,,1,,10090.0,4951,,In vivo,A,,,,Mus musculus,,N,CHEMBL618972,BAO_0000218,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,6062,,,50594,Intermediate
1,,1,,10090.0,4952,,In vivo,A,,,,Mus musculus,,N,CHEMBL618973,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,4953,,In vivo,A,,,,Mus musculus,,N,CHEMBL618974,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,4954,,In vivo,A,,,,Mus musculus,,N,CHEMBL618975,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,,,50594,Intermediate
1,,1,,10090.0,4955,,In vivo,A,,,,Mus musculus,,N,CHEMBL618976,BAO_0000218,Vd in mice,5980,,,50594,Intermediate
1,,1,,10090.0,4956,,In vivo,A,,,,Mus musculus,,N,CHEMBL618977,BAO_0000218,Volume of distribution in mouse,17592,,,50594,Intermediate
1,,1,,10090.0,4957,,In vivo,A,,,,Mus musculus,,N,CHEMBL876724,BAO_0000218,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,,,50594,Intermediate
1,,1,,10090.0,4958,,In vivo,A,,,,Mus musculus,,N,CHEMBL618978,BAO_0000218,Volume of distribution of compound in plasma was determined at 24 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,4959,,In vivo,A,,,,Mus musculus,,N,CHEMBL618979,BAO_0000218,Volume of distribution of compound in plasma was determined at 40 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,4960,,In vivo,A,,,,Mus musculus,,N,CHEMBL618980,BAO_0000218,Volume of distribution of compound in plasma was determined at 5 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,4961,,In vivo,A,,,,Mus musculus,,N,CHEMBL618981,BAO_0000218,Pharmacokinetic property (vdss) was measured in mouse,4239,,,50594,Intermediate
1,,1,,10090.0,4962,,In vivo,A,,,,Mus musculus,,N,CHEMBL618982,BAO_0000218,Value distribution upon iv administration in mouse,2862,,,50594,Intermediate
1,,1,,10090.0,4963,,In vivo,A,,,,Mus musculus,,N,CHEMBL620150,BAO_0000218,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,,,50594,Intermediate
1,,1,,10090.0,4964,,In vivo,A,,,,Mus musculus,,N,CHEMBL620151,BAO_0000218,Volume of distribution was evaluated in mice after intravenous administration,2675,,,50594,Intermediate
1,,1,,10090.0,4965,,In vivo,A,,,,Mus musculus,,N,CHEMBL620152,BAO_0000218,Volume of distribution was evaluated in mice after oral administration,2675,,,50594,Intermediate
1,,1,,10090.0,4966,,In vivo,A,,,,Mus musculus,,N,CHEMBL620153,BAO_0000218,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,17837,,,50594,Intermediate
1,,1,,10090.0,4967,,In vivo,A,,,,Mus musculus,,N,CHEMBL876395,BAO_0000218,Steady state volume of distribution was determined in mice,5727,,,50594,Intermediate
1,,1,,10090.0,4968,,In vivo,A,,,,Mus musculus,,N,CHEMBL620154,BAO_0000218,Volume distribution (steady state) of compound was determined in mouse,17852,,,50594,Intermediate
1,,1,,10090.0,4969,,In vivo,A,,,,Mus musculus,,N,CHEMBL620155,BAO_0000218,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,4970,,In vivo,A,,,,Mus musculus,,N,CHEMBL620156,BAO_0000218,Vss value at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,4971,,In vivo,A,,,,Mus musculus,,N,CHEMBL620157,BAO_0000218,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,6062,,,50594,Intermediate
1,,1,,10090.0,4972,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL620158,BAO_0000218,Biodistribution of compound (oxidized form) in in kidney tissue,16438,,Kidney,50594,Intermediate
1,,1,,10090.0,4973,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL620159,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,,Blood,50594,Intermediate
1,,1,,10090.0,4974,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL620160,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,,Blood,50594,Intermediate
1,,1,,10090.0,4975,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL620161,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Blood,50594,Intermediate
1,,1,797.0,9606.0,4976,,,F,,,,Homo sapiens,A-427,N,CHEMBL620162,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,10708,,,80019,Intermediate
1,,1,500.0,9606.0,4977,,,F,,,,Homo sapiens,A-431,N,CHEMBL620163,BAO_0000219,Inhibition of A431 human squamous cell carcinoma cell proliferation,16597,,,80852,Expert
1,,1,500.0,9606.0,4978,,,F,,,,Homo sapiens,A-431,N,CHEMBL620833,BAO_0000219,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,16062,,,80852,Expert
1,,1,500.0,9606.0,4979,,,F,,,,Homo sapiens,A-431,N,CHEMBL876396,BAO_0000219,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,16062,,,80852,Expert
1,,1,500.0,9606.0,4980,,,F,,,,Homo sapiens,A-431,N,CHEMBL620834,BAO_0000219,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,16958,,,80852,Expert
1,,1,500.0,9606.0,4981,,,F,,,,Homo sapiens,A-431,N,CHEMBL620835,BAO_0000219,Inhibition of A431 human carcinoma cell proliferation,6700,,,80852,Expert
1,,1,500.0,9606.0,4982,,,F,,,,Homo sapiens,A-431,N,CHEMBL620836,BAO_0000219,In vitro inhibition of A431 (human carcinoma) cell basal growth.,17226,,,80852,Expert
1,,1,500.0,9606.0,4983,,,F,,,,Homo sapiens,A-431,N,CHEMBL620837,BAO_0000219,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,6828,,,80852,Intermediate
1,,1,500.0,9606.0,4984,,,F,,,,Homo sapiens,A-431,N,CHEMBL621017,BAO_0000219,In vitro cytotoxicity against epidermoid carcinoma cell line,12314,,,80852,Intermediate
9,,1,500.0,9606.0,4985,,,F,,,,Homo sapiens,A-431,D,CHEMBL621018,BAO_0000218,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",13412,,,9,Expert
1,,1,500.0,9606.0,4986,,,F,,,,Homo sapiens,A-431,N,CHEMBL621019,BAO_0000219,Antiproliferative activity of compound was measured on human tumor cell line A431.,13299,,,80852,Intermediate
1,,1,500.0,9606.0,4987,,,F,,,,Homo sapiens,A-431,N,CHEMBL621020,BAO_0000219,Antiproliferative effect of compound on A431 cell line expressing mutant p53,17420,,,80852,Intermediate
1,,1,500.0,9606.0,4988,,,F,,,,Homo sapiens,A-431,N,CHEMBL621021,BAO_0000219,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,13678,,,80852,Intermediate
8,,1,500.0,,4989,,,F,,,,,A-431,H,CHEMBL621022,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,14171,,,9,Expert
1,,1,500.0,9606.0,4990,,,F,,,,Homo sapiens,A-431,N,CHEMBL621023,BAO_0000219,Tested for antiproliferative activity against human A431 cells,6333,,,80852,Expert
9,,1,500.0,9606.0,4991,,,F,,,,Homo sapiens,A-431,D,CHEMBL621024,BAO_0000219,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,2356,,,9,Expert
1,,1,500.0,9606.0,4992,,,F,,,,Homo sapiens,A-431,N,CHEMBL621025,BAO_0000219,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,15578,,,80852,Expert
1,,1,500.0,9606.0,4993,,,F,,,,Homo sapiens,A-431,N,CHEMBL621026,BAO_0000219,Inhibition of A431 cell proliferation,5126,,,80852,Expert
1,,1,500.0,9606.0,4994,,,F,,,,Homo sapiens,A-431,N,CHEMBL621027,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells,6844,,,80852,Expert
1,,1,500.0,9606.0,4995,,,F,,,,Homo sapiens,A-431,N,CHEMBL876397,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),6844,,,80852,Expert
1,,1,500.0,9606.0,4996,,,F,,,,Homo sapiens,A-431,N,CHEMBL883797,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,4925,,,80852,Intermediate
1,,1,500.0,9606.0,4997,,,F,,,,Homo sapiens,A-431,N,CHEMBL621028,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,4925,,,80852,Intermediate
1,,1,500.0,9606.0,4998,,,F,,,,Homo sapiens,A-431,N,CHEMBL621029,BAO_0000219,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,13978,,,80852,Intermediate
1,,1,500.0,9606.0,4999,,,F,,,,Homo sapiens,A-431,N,CHEMBL621030,BAO_0000219,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,16786,,,80852,Intermediate
8,,1,500.0,,5000,,,F,,,,,A-431,H,CHEMBL621147,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,13412,,,9,Expert
1,,1,500.0,9606.0,5001,,,F,,,,Homo sapiens,A-431,N,CHEMBL621148,BAO_0000218,In vivo antiproliferative activity against A431 cell line,17824,,,80852,Intermediate
9,,1,500.0,9606.0,5002,,,F,,,,Homo sapiens,A-431,D,CHEMBL621149,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,12751,,,9,Expert
1,,1,500.0,9606.0,5003,,,F,,,,Homo sapiens,A-431,N,CHEMBL621150,BAO_0000219,Inhibition of A431 human epidermoid carcinoma cell proliferation,12380,,,80852,Expert
9,,1,500.0,9606.0,5004,,,F,,,,Homo sapiens,A-431,D,CHEMBL621151,BAO_0000219,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,4959,,,9,Expert
1,,1,500.0,9606.0,5005,,,F,,,,Homo sapiens,A-431,N,CHEMBL621152,BAO_0000219,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),6333,,,80852,Intermediate
1,,1,500.0,9606.0,5006,,,F,,,,Homo sapiens,A-431,N,CHEMBL621153,BAO_0000219,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),6333,,,80852,Intermediate
1,,1,500.0,9606.0,5007,,,F,,,,Homo sapiens,A-431,N,CHEMBL884000,BAO_0000219,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),6333,,,80852,Intermediate
9,,1,,9606.0,5008,,,F,,,,Homo sapiens,,D,CHEMBL621154,BAO_0000019,Inhibition of EGFR overexpressing A431 cell proliferation,5296,,,9,Expert
1,,1,500.0,9606.0,5009,,,F,,,,Homo sapiens,A-431,N,CHEMBL621155,BAO_0000219,Inhibition of A431 cell proliferation,12624,,,80852,Expert
9,,1,500.0,9606.0,5010,,,F,,,,Homo sapiens,A-431,D,CHEMBL621156,BAO_0000219,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,14926,,,9,Expert
9,,1,500.0,9606.0,5011,,,F,,,,Homo sapiens,A-431,D,CHEMBL621157,BAO_0000219,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",14926,,,9,Expert
8,,1,500.0,,5012,,,F,,,,,A-431,H,CHEMBL621158,BAO_0000219,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),14926,,,9,Expert
1,,1,500.0,9606.0,5013,,,F,,,,Homo sapiens,A-431,N,CHEMBL621159,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,15144,,,80852,Intermediate
1,,1,500.0,9606.0,5014,,,F,,,,Homo sapiens,A-431,N,CHEMBL621160,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,15144,,,80852,Intermediate
1,,1,500.0,9606.0,5015,,,F,,,,Homo sapiens,A-431,N,CHEMBL621161,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,5245,,,80852,Intermediate
1,,1,500.0,9606.0,5016,,,F,,,,Homo sapiens,A-431,N,CHEMBL621162,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,5245,,,80852,Intermediate
1,,1,500.0,9606.0,5017,,,F,,,,Homo sapiens,A-431,N,CHEMBL621163,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,5245,,,80852,Intermediate
1,,1,500.0,9606.0,5018,,,F,,,,Homo sapiens,A-431,N,CHEMBL621164,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,5245,,,80852,Intermediate
1,,1,500.0,9606.0,5019,,,F,,,,Homo sapiens,A-431,N,CHEMBL621165,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,5245,,,80852,Intermediate
0,,1,,9527.0,5020,,,A,,,,Cercopithecidae,,U,CHEMBL619159,BAO_0000019,Half-life period in cynomolgus monkey,5922,,,22224,Autocuration
0,,1,,9527.0,5021,,In vitro,A,1969.0,,,Cercopithecidae,,U,CHEMBL619160,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1116,,Plasma,22224,Autocuration
0,,1,,9527.0,5022,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL619161,BAO_0000218,Longer half-life in monkey (i.v.) at 0.5 mpk,17853,,,22224,Autocuration
0,,1,,9527.0,5023,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL619162,BAO_0000366,Plasma half life in monkey,993,,Plasma,22224,Autocuration
0,,1,,9527.0,5024,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL619163,BAO_0000366,Plasma half-life in rhesus monkey,4514,,Plasma,22224,Autocuration
0,,1,,9527.0,5025,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL619164,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,,Plasma,22224,Autocuration
0,,1,,9527.0,5026,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL619320,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,,Plasma,22224,Autocuration
0,,1,,9527.0,5027,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL619321,BAO_0000218,Tested for half life upon iv administration to african green monkey,4578,,,22224,Autocuration
0,,1,,9527.0,5028,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL873336,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,5029,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL619322,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,5030,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL619323,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,5031,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL619324,BAO_0000218,The time for peak concentration value after oral administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,5032,,,A,,,,Cercopithecidae,,U,CHEMBL619325,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5033,,,A,,,,Cercopithecidae,,U,CHEMBL876411,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5034,,,A,,,,Cercopithecidae,,U,CHEMBL619326,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5035,,,A,,,,Cercopithecidae,,U,CHEMBL619327,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5036,,,A,,,,Cercopithecidae,,U,CHEMBL619328,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5037,,,A,,,,Cercopithecidae,,U,CHEMBL619329,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5038,,,A,,,,Cercopithecidae,,U,CHEMBL619330,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5039,,,A,,,,Cercopithecidae,,U,CHEMBL619331,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5040,,,A,,,,Cercopithecidae,,U,CHEMBL619332,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5041,,,A,,,,Cercopithecidae,,U,CHEMBL619333,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5042,,,A,,,,Cercopithecidae,,U,CHEMBL619334,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5043,,,A,,,,Cercopithecidae,,U,CHEMBL619335,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5044,,,A,,,,Cercopithecidae,,U,CHEMBL619336,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5045,,,A,,,,Cercopithecidae,,U,CHEMBL619337,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5046,,,A,,,,Cercopithecidae,,U,CHEMBL619338,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,11271,,,22224,Autocuration
0,,1,,9527.0,5047,,,A,,,,Cercopithecidae,,U,CHEMBL619339,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,11271,,,22224,Autocuration
1,,1,,10116.0,5048,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL619340,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),5809,,,50597,Intermediate
1,,1,,10116.0,5049,,In vivo,A,1969.0,,,Rattus norvegicus,,N,CHEMBL873496,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,,Plasma,50597,Intermediate
1,,1,,10116.0,5050,,,A,1969.0,,,Rattus norvegicus,,N,CHEMBL619341,BAO_0000218,AUC value in rat after IV administration at a dose of 10 mg/kg,3546,,Plasma,50597,Intermediate
1,,1,,10116.0,5051,,,A,1969.0,,,Rattus norvegicus,,N,CHEMBL619342,BAO_0000218,AUC value in rat after oral administration at a dose of 10 mg/kg,3546,,Plasma,50597,Intermediate
1,,1,,10116.0,5052,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL619343,BAO_0000218,Cmax value in rat after oral administration at a dose of 10 mg/kg,3546,,,50597,Intermediate
1,,1,,10116.0,5053,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL619344,BAO_0000218,Bioavailability in rat after oral administration at a dose of 10 mg/kg,3546,,,50597,Intermediate
1,,1,,10116.0,5054,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL619345,BAO_0000218,Tmax value in rat after oral administration at a dose of 10 mg/kg,3546,,,50597,Intermediate
1,,1,,10116.0,5055,,,A,,,,Rattus norvegicus,,N,CHEMBL619346,BAO_0000218,Vc value in rat after IV administration at a dose of 10 mg/kg,3546,,,50597,Intermediate
1,,1,,10116.0,5056,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL619347,BAO_0000218,Half life period in rat after IV administration at a dose of 10 mg/kg,3546,,,50597,Intermediate
0,,1,,9557.0,5057,,,A,,,,Papio hamadryas,,U,CHEMBL619348,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,10625,,,22224,Autocuration
0,,1,,9557.0,5058,,,A,,,,Papio hamadryas,,U,CHEMBL619349,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),10625,,,22224,Autocuration
0,,1,,9557.0,5059,,,A,,,,Papio hamadryas,,U,CHEMBL619350,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),10625,,,22224,Autocuration
0,,1,,9557.0,5060,,,A,,,,Papio hamadryas,,U,CHEMBL619351,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,10625,,,22224,Autocuration
0,,1,,9557.0,5061,,,A,,,,Papio hamadryas,,U,CHEMBL875953,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,10625,,,22224,Autocuration
0,,1,,9557.0,5062,,,A,,,,Papio hamadryas,,U,CHEMBL621716,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,10625,,,22224,Autocuration
0,,1,,9557.0,5063,,,A,,,,Papio hamadryas,,U,CHEMBL621717,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,10625,,,22224,Autocuration
0,,1,,9557.0,5064,,,A,,,,Papio hamadryas,,U,CHEMBL621718,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,10625,,,22224,Autocuration
0,,1,,9615.0,5065,,,A,,,,beagle,,U,CHEMBL621719,BAO_0000019,Area under curve after 1 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,,1,,9615.0,5066,,,A,,,,beagle,,U,CHEMBL621720,BAO_0000019,Area under curve after 2 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,,1,,9615.0,5067,,In vivo,A,,,,beagle,,U,CHEMBL621721,BAO_0000218,Cmax value after 1 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,,1,,9606.0,5068,,,A,1088.0,,,Homo sapiens,,U,CHEMBL621722,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5069,,,A,1088.0,,,Homo sapiens,,U,CHEMBL621723,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5070,,,A,1088.0,,,Homo sapiens,,U,CHEMBL621724,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5071,,,A,1088.0,,,Homo sapiens,,U,CHEMBL623443,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5072,,,A,1088.0,,,Homo sapiens,,U,CHEMBL623444,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5073,,,A,1088.0,,,Homo sapiens,,U,CHEMBL623445,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5074,,,A,1088.0,,,Homo sapiens,,U,CHEMBL623446,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,7766,,Urine,22224,Autocuration
0,,1,,9606.0,5075,,,A,2107.0,,,Homo sapiens,,U,CHEMBL623447,BAO_0000251,Metabolic stability observed at 30 min after administration in human liver microsomes,16643,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5076,,,A,,,,Homo sapiens,,U,CHEMBL623448,BAO_0000019,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,6852,,,22224,Autocuration
0,,1,,9606.0,5077,,,A,,,,Homo sapiens,,U,CHEMBL623449,BAO_0000019,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,6852,,,22224,Autocuration
0,,1,,9606.0,5078,,,A,,,,Homo sapiens,,U,CHEMBL623450,BAO_0000019,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,6852,,,22224,Autocuration
0,,1,,9606.0,5079,,,A,2107.0,,,Homo sapiens,,U,CHEMBL623451,BAO_0000251,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",6567,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5080,,,A,,,,Homo sapiens,,U,CHEMBL623452,BAO_0000019,Metabolic stability (% remaining at 30 mins) in human S9.,6570,,,22224,Autocuration
0,,1,,9606.0,5081,,,A,,,,Homo sapiens,,U,CHEMBL623453,BAO_0000019,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,6570,,,22224,Autocuration
0,,1,,9606.0,5082,,,A,2107.0,,,Homo sapiens,,U,CHEMBL623454,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes,5237,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5083,,,A,2107.0,,,Homo sapiens,,U,CHEMBL623455,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,5237,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5084,,,A,2107.0,,,Homo sapiens,,U,CHEMBL624371,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,5237,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5085,,,A,,,,Homo sapiens,,U,CHEMBL624372,BAO_0000218,First pass metabolism and metabolic bioavailability using human hepatic microsomes,5202,,,22224,Autocuration
0,,1,,9606.0,5086,,,A,,,,Homo sapiens,,U,CHEMBL624373,BAO_0000019,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,5481,,,22224,Autocuration
0,,1,,9606.0,5087,,,A,,,,Homo sapiens,,U,CHEMBL624374,BAO_0000019,Percent remaining in human plasma after incubation for 60 min at 37 C.,5481,,,22224,Autocuration
0,,1,,9606.0,5088,,,A,,,,Homo sapiens,,U,CHEMBL624556,BAO_0000019,The percent remaining in human plasma after 30 min was determined,3956,,,22224,Autocuration
0,,1,,9606.0,5089,,,A,1969.0,,,Homo sapiens,,U,CHEMBL624557,BAO_0000366,Conversion rate of the prodrug in human plasma,5074,,Plasma,22224,Autocuration
0,,1,,9606.0,5090,,,A,1969.0,,,Homo sapiens,,U,CHEMBL624558,BAO_0000366,Conversion rate of the prodrug in human plasma; ND means no data,5074,,Plasma,22224,Autocuration
0,,1,,9606.0,5091,,,A,178.0,,,Homo sapiens,,U,CHEMBL624559,BAO_0000221,Half life of compound was determined in human blood,4727,,Blood,22224,Autocuration
0,,1,,9606.0,5092,,,A,,,,Homo sapiens,,U,CHEMBL624560,BAO_0000019,Half life of compound was determined in man with once daily dosing,5965,,,22224,Autocuration
0,,1,,9606.0,5093,,In vitro,A,,,,Homo sapiens,,U,CHEMBL624561,BAO_0000251,Half life in human microsomes,5732,Microsomes,,22224,Autocuration
0,,1,,9606.0,5094,,,A,1969.0,,,Homo sapiens,,U,CHEMBL624562,BAO_0000366,Half life in human plasma,5819,,Plasma,22224,Autocuration
0,,1,,9606.0,5095,,,A,1969.0,,,Homo sapiens,,U,CHEMBL624563,BAO_0000366,Half life in human plasma; Not detected,5819,,Plasma,22224,Autocuration
0,,1,,9606.0,5096,,In vivo,A,,,,Homo sapiens,,U,CHEMBL624564,BAO_0000218,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9606.0,5097,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL624565,BAO_0000251,Half-life for oxidative metabolic stability was determined using rat liver microsomes,6597,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5098,,,A,1969.0,,,Homo sapiens,,U,CHEMBL875152,BAO_0000366,Half-life in human plasma,5229,,Plasma,22224,Autocuration
0,,1,,9606.0,5099,,,A,1969.0,,,Homo sapiens,,U,CHEMBL624566,BAO_0000366,Half-life of the parent prodrug in plasma,5229,,Plasma,22224,Autocuration
0,,1,,9606.0,5100,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL873805,BAO_0000366,In vitro half life in human plasma was determined,2192,,Plasma,22224,Autocuration
0,,1,,9606.0,5101,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL624567,BAO_0000251,The compound was tested In Vitro for half life in human liver microsomes.,3032,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5102,,In vivo,A,,,,Homo sapiens,,U,CHEMBL624568,BAO_0000218,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9606.0,5103,,In vivo,A,,,,Homo sapiens,,U,CHEMBL624569,BAO_0000218,Observed volume of distribution,17716,,,22224,Autocuration
0,,1,,9606.0,5104,,In vivo,A,,,,Homo sapiens,,U,CHEMBL624570,BAO_0000218,Oral bioavailability in human,15778,,,22224,Autocuration
0,,1,,9606.0,5105,,,A,,,,Homo sapiens,,U,CHEMBL624571,BAO_0000019,Tested for human plasma protein binding of the compound,17313,,,22224,Autocuration
0,,1,,9606.0,5106,,,A,,,,Homo sapiens,,U,CHEMBL624572,BAO_0000019,"First order rate constant, k was determined in human plasma",4231,,,22224,Autocuration
0,,1,,9606.0,5107,,,A,,,,Homo sapiens,,U,CHEMBL624573,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,4755,,,22224,Autocuration
0,,1,,9606.0,5108,,,A,,,,Homo sapiens,,U,CHEMBL875153,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,4755,,,22224,Autocuration
0,,1,,9606.0,5109,,,A,2107.0,,,Homo sapiens,,U,CHEMBL624574,BAO_0000251,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,16907,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5110,,,A,,,,Homo sapiens,,U,CHEMBL624575,BAO_0000019,The compound was tested for the plasma binding in human,10839,,,22224,Autocuration
0,,1,,9606.0,5111,,,A,,,,Homo sapiens,,U,CHEMBL624576,BAO_0000019,Plasma protein binding (human),10839,,,22224,Autocuration
0,,1,,9606.0,5112,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL624577,BAO_0000251,Compound was evaluated for half-life in human liver microsomes,3199,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5113,,In vitro,A,178.0,,,Homo sapiens,,U,CHEMBL624578,BAO_0000221,Half life measured in vitro for its stability in human blood,1345,,Blood,22224,Autocuration
0,,1,,9606.0,5114,,,A,1977.0,,,Homo sapiens,,U,CHEMBL622796,BAO_0000019,Half life in human serum,4297,,Serum,22224,Autocuration
0,,1,,9606.0,5115,,,A,1977.0,,,Homo sapiens,,U,CHEMBL622797,BAO_0000019,Half life in human serum; ND=not determined,4297,,Serum,22224,Autocuration
0,,1,,9606.0,5116,,,A,,,,Homo sapiens,,U,CHEMBL622798,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 1,4297,,,22224,Autocuration
0,,1,,9606.0,5117,,,A,,,,Homo sapiens,,U,CHEMBL622799,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 2,4297,,,22224,Autocuration
0,,1,,9606.0,5118,,,A,1969.0,,,Homo sapiens,,U,CHEMBL622800,BAO_0000366,Half life of the in human plasma,4231,,Plasma,22224,Autocuration
0,,1,,9606.0,5119,,In vitro,A,,,,Homo sapiens,,U,CHEMBL622801,BAO_0000220,Half life period in human hepatic S9 fraction was determined,5633,S9,,22224,Autocuration
0,,1,,9606.0,5120,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL622802,BAO_0000251,Half life period in human liver microsome was determined,5633,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5121,,,A,,,,Homo sapiens,,U,CHEMBL622803,BAO_0000019,Half life period was determined; 6-7,17791,,,22224,Autocuration
0,,1,,9606.0,5122,,,A,,,,Homo sapiens,,U,CHEMBL875154,BAO_0000019,Half life period was evaluated in human,17791,,,22224,Autocuration
0,,1,,9606.0,5123,,,A,1969.0,,,Homo sapiens,,U,CHEMBL622804,BAO_0000366,Half life time in human plasma,3160,,Plasma,22224,Autocuration
1,,1,,10090.0,5124,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622805,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5125,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL622611,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5126,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL622612,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5127,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL875160,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5128,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL622613,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5129,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL622614,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5130,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL622615,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Liver,50594,Intermediate
1,,1,,10090.0,5131,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL622616,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,,Liver,50594,Intermediate
1,,1,,10090.0,5132,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL622617,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Liver,50594,Intermediate
1,,1,,10090.0,5133,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL622618,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,,Spleen,50594,Intermediate
1,,1,,10090.0,5134,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL622619,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,,Spleen,50594,Intermediate
1,,1,,10090.0,5135,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL622620,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Spleen,50594,Intermediate
1,,1,,10090.0,5136,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622621,BAO_0000218,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5137,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622622,BAO_0000218,Biodistribution of compound (oxidized form) in blood tissue,16438,,Blood,50594,Intermediate
1,,1,,10090.0,5138,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622623,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Blood,50594,Intermediate
1,,1,,10090.0,5139,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622624,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,,Blood,50594,Intermediate
1,,1,,10090.0,5140,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622625,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Blood,50594,Intermediate
1,,1,,10090.0,5141,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622626,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Blood,50594,Intermediate
1,,1,,10090.0,5142,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622627,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,,Blood,50594,Intermediate
1,,1,,10090.0,5143,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622628,BAO_0000218,Biodistribution of compound (oxidized form) in brain tissue of mice,16438,,Brain,50594,Intermediate
1,,1,,10090.0,5144,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622629,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5145,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622630,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5146,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622631,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5147,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622632,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5148,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL622633,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,,Brain,50594,Intermediate
1,,1,,10090.0,5149,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL622634,BAO_0000218,Biodistribution of compound (oxidized form) in heart tissue of mice,16438,,Heart,50594,Intermediate
1,,1,,10090.0,5150,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL622635,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5151,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL875161,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5152,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL622636,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5153,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL623335,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5154,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL623336,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,,Heart,50594,Intermediate
1,,1,,10090.0,5155,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623337,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5156,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623338,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5157,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623339,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5158,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623524,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5159,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623525,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,,Kidney,50594,Intermediate
1,,1,,10090.0,5160,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623526,BAO_0000218,Biodistribution of compound (oxidized form) in liver tissue,16438,,Liver,50594,Intermediate
1,,1,,10090.0,5161,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623527,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,,Liver,50594,Intermediate
1,,1,,10090.0,5162,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623528,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,,Liver,50594,Intermediate
1,,1,500.0,9606.0,5163,,,F,,,,Homo sapiens,A-431,N,CHEMBL624615,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,5245,,,80852,Intermediate
1,,1,500.0,9606.0,5164,,,F,,,,Homo sapiens,A-431,N,CHEMBL621672,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,5245,,,80852,Intermediate
1,,1,500.0,,5165,,,F,,,,,A-431,N,CHEMBL621673,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",16289,,,80852,Expert
1,,1,500.0,,5166,,,F,,,,,A-431,N,CHEMBL621674,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",16289,,,80852,Expert
9,,1,500.0,9606.0,5167,,,F,,,,Homo sapiens,A-431,D,CHEMBL884002,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,16093,,,9,Expert
1,,1,500.0,9606.0,5168,,,F,,,,Homo sapiens,A-431,N,CHEMBL621850,BAO_0000219,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",16825,,,80852,Intermediate
1,,1,500.0,9606.0,5169,,,F,,,,Homo sapiens,A-431,N,CHEMBL621851,BAO_0000219,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,4848,,,80852,Intermediate
9,,1,500.0,9606.0,5170,,,F,,,,Homo sapiens,A-431,D,CHEMBL621852,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,14827,,,9,Expert
9,,1,500.0,9606.0,5171,,,F,,,,Homo sapiens,A-431,D,CHEMBL621853,BAO_0000219,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,14827,,,9,Expert
1,,1,500.0,,5172,,,F,,,,,A-431,N,CHEMBL621854,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",16289,,,80852,Expert
1,,1,500.0,,5173,,,F,,,,,A-431,N,CHEMBL621855,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",16289,,,80852,Expert
1,,1,500.0,,5174,,,F,,,,,A-431,N,CHEMBL623724,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",16289,,,80852,Expert
1,,1,500.0,,5175,,,F,,,,,A-431,N,CHEMBL623725,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",16289,,,80852,Expert
1,,1,500.0,,5176,,,F,,,,,A-431,N,CHEMBL623726,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",16289,,,80852,Expert
9,,1,500.0,9606.0,5177,,,F,,,,Homo sapiens,A-431,D,CHEMBL623727,BAO_0000219,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",16289,,,9,Expert
8,,1,500.0,,5178,,,F,,,,,A-431,H,CHEMBL623728,BAO_0000219,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,16289,,,9,Expert
1,,1,500.0,,5179,,,F,,,,,A-431,N,CHEMBL623729,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",16289,,,80852,Expert
1,,1,500.0,,5180,,,F,,,,,A-431,N,CHEMBL623730,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",16289,,,80852,Expert
1,,1,500.0,,5181,,,F,,,,,A-431,N,CHEMBL623731,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",16289,,,80852,Expert
1,,1,500.0,10090.0,5182,,,F,,,,Mus musculus,A-431,N,CHEMBL623732,BAO_0000218,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,,,80852,Expert
1,,1,500.0,10090.0,5183,,,F,,,,Mus musculus,A-431,N,CHEMBL623733,BAO_0000218,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,,,80852,Expert
1,,1,500.0,10090.0,5184,,,F,,,,Mus musculus,A-431,N,CHEMBL623734,BAO_0000218,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,,,80852,Expert
1,,1,500.0,10090.0,5185,,,F,,,,Mus musculus,A-431,N,CHEMBL623735,BAO_0000218,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,,,80852,Expert
1,,1,500.0,9606.0,5186,,,F,,,,Homo sapiens,A-431,N,CHEMBL623736,BAO_0000219,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1937,,,80852,Expert
1,,1,500.0,9606.0,5187,,,F,,,,Homo sapiens,A-431,N,CHEMBL623737,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,13739,,,80852,Intermediate
1,,1,500.0,9606.0,5188,,,F,,,,Homo sapiens,A-431,N,CHEMBL623738,BAO_0000219,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,3558,,,80852,Intermediate
1,,1,500.0,9606.0,5189,,,F,,,,Homo sapiens,A-431,N,CHEMBL875168,BAO_0000219,Dose giving a 50% decrease in the living cell number (A437 cells),3558,,,80852,Intermediate
1,,1,646.0,9606.0,5190,,,F,,,,Homo sapiens,A549,N,CHEMBL623739,BAO_0000219,In vitro inhibitory concentration against proliferation of A459 cell line.,17686,,,80682,Expert
1,,1,646.0,9606.0,5191,,,F,,,,Homo sapiens,A549,N,CHEMBL623740,BAO_0000219,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,5305,,,80682,Intermediate
1,,1,646.0,9606.0,5192,,,F,,,,Homo sapiens,A549,N,CHEMBL624424,BAO_0000219,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,3614,,,80682,Intermediate
1,,1,624.0,9606.0,5193,,,F,,,,Homo sapiens,A498,N,CHEMBL624425,BAO_0000219,In vitro antitumor activity against renal A498 tumor cell lines,17229,,,80021,Intermediate
1,,1,624.0,9606.0,5194,,,F,,,,Homo sapiens,A498,N,CHEMBL624426,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",15935,,,80021,Intermediate
1,,1,624.0,9606.0,5195,,,F,,,,Homo sapiens,A498,N,CHEMBL624427,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",15935,,,80021,Intermediate
1,,1,624.0,9606.0,5196,,,F,,,,Homo sapiens,A498,N,CHEMBL624428,BAO_0000219,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,15560,,,80021,Intermediate
1,,1,624.0,9606.0,5197,,,F,,,,Homo sapiens,A498,N,CHEMBL624429,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,13891,,,80021,Intermediate
1,,1,624.0,9606.0,5198,,,F,,,,Homo sapiens,A498,N,CHEMBL624620,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,13891,,,80021,Intermediate
1,,1,624.0,9606.0,5199,,,F,,,,Homo sapiens,A498,N,CHEMBL624621,BAO_0000219,Cytotoxicity on kidney carcinoma (A-498) cell line,13788,,,80021,Intermediate
1,,1,624.0,9606.0,5200,,,F,,,,Homo sapiens,A498,N,CHEMBL624622,BAO_0000219,Compound was evaluated against Human cell line renal A498,15403,,,80021,Intermediate
1,,1,624.0,9606.0,5201,,,F,,,,Homo sapiens,A498,N,CHEMBL624623,BAO_0000219,Compound was tested for inhibition of A498 human renal cancer cell line,1009,,,80021,Intermediate
1,,1,624.0,9606.0,5202,,,F,,,,Homo sapiens,A498,N,CHEMBL874365,BAO_0000219,Growth inhibitory activity against A498 human cancer cell line,1043,,,80021,Intermediate
1,,1,624.0,9606.0,5203,,,F,,,,Homo sapiens,A498,N,CHEMBL624624,BAO_0000219,In vitro antitumor activity against human renal A498 cell line,5858,,,80021,Intermediate
1,,1,624.0,9606.0,5204,,,F,,,,Homo sapiens,A498,N,CHEMBL624625,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line,5958,,,80021,Intermediate
1,,1,624.0,9606.0,5205,,,F,,,,Homo sapiens,A498,N,CHEMBL624626,BAO_0000219,In vitro cytotoxic activity against human renal cancer (A498) cell line,5506,,,80021,Intermediate
1,,1,624.0,9606.0,5206,,,F,,,,Homo sapiens,A498,N,CHEMBL624627,BAO_0000219,Tested for cytostatic activity against renal A498 cell line,12781,,,80021,Intermediate
1,,1,624.0,9606.0,5207,,,F,,,,Homo sapiens,A498,N,CHEMBL883157,BAO_0000219,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,14399,,,80021,Intermediate
1,,1,624.0,9606.0,5208,,,F,,,,Homo sapiens,A498,N,CHEMBL624628,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,5958,,,80021,Expert
0,,1,,9615.0,5209,,In vivo,A,,,,beagle,,U,CHEMBL624629,BAO_0000218,Cmax value after 2 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,beagle,1,,9615.0,5210,,In vivo,A,,,,Canis lupus familiaris,,U,CHEMBL623551,BAO_0000218,Bioavailability,3510,,,22224,Autocuration
0,beagle,1,,9615.0,5211,,In vivo,A,,,,Canis lupus familiaris,,U,CHEMBL623552,BAO_0000218,Bioavailability after 1 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,beagle,1,,9615.0,5212,,In vivo,A,,,,Canis lupus familiaris,,U,CHEMBL623553,BAO_0000218,Bioavailability after 2 mpk peroral administration to beagles,3510,,,22224,Autocuration
0,,1,,9913.0,5213,,,A,,,,Bos taurus,,U,CHEMBL623554,BAO_0000019,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,3085,,,22224,Autocuration
0,,1,,9913.0,5214,,,A,,,,Bos taurus,,U,CHEMBL623555,BAO_0000019,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,3085,,,22224,Autocuration
0,,1,,9913.0,5215,,,A,,,,Bos taurus,,U,CHEMBL623556,BAO_0000019,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,3085,,,22224,Autocuration
0,,1,,9913.0,5216,,,A,,,,Bos taurus,,U,CHEMBL623557,BAO_0000019,Solubility against bovine alpha-chymotrypsin,9372,,,22224,Autocuration
0,,1,,9913.0,5217,,,A,,,,Bos taurus,,U,CHEMBL623558,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,3085,,,22224,Autocuration
0,,1,,9913.0,5218,,,A,,,,Bos taurus,,U,CHEMBL623559,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,3085,,,22224,Autocuration
0,,1,,9913.0,5219,,,A,2106.0,,,Bos taurus,,U,CHEMBL623560,BAO_0000221,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1469,,Spleen,22224,Autocuration
0,,1,,9913.0,5220,,,A,,,,Bos taurus,,U,CHEMBL623561,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum,4297,,,22224,Autocuration
0,,1,,9913.0,5221,,,A,,,,Bos taurus,,U,CHEMBL623562,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,4297,,,22224,Autocuration
0,,1,,9913.0,5222,,,A,,,,Bos taurus,,U,CHEMBL623563,BAO_0000019,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,17585,,,22224,Autocuration
0,,1,,9913.0,5223,,,A,2106.0,,,Bos taurus,,U,CHEMBL623564,BAO_0000221,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1336,,Spleen,22224,Autocuration
0,,1,,9913.0,5224,,,A,,,,Bos taurus,,U,CHEMBL873806,BAO_0000019,Half life in presence of 2 mg/mL BSA at pH 8.8,3085,,,22224,Autocuration
0,,1,,9913.0,5225,,,A,,,,Bos taurus,,U,CHEMBL623565,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,2857,,,22224,Autocuration
0,,1,,9913.0,5226,,,A,,,,Bos taurus,,U,CHEMBL623566,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,2857,,,22224,Autocuration
0,,1,,9913.0,5227,,,A,,,,Bos taurus,,U,CHEMBL623567,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,2857,,,22224,Autocuration
0,,1,,9913.0,5228,,,A,,,,Bos taurus,,U,CHEMBL623568,BAO_0000019,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1540,,,22224,Autocuration
1,,1,,9615.0,5229,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623569,BAO_0000218,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,6316,,Plasma,50588,Intermediate
1,,1,,9615.0,5230,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623570,BAO_0000218,AUC after administration at 100 mg/kg/day in dogs,17594,,Plasma,50588,Intermediate
1,,1,,9615.0,5231,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624254,BAO_0000218,AUC in dog at 0-24 hr by peroral administration at 3 mpk,4953,,Plasma,50588,Intermediate
1,,1,,9615.0,5232,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624255,BAO_0000218,AUC value after 15 mg/kg iv dose in Dogs,16907,,Plasma,50588,Intermediate
1,,1,,9615.0,5233,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624256,BAO_0000218,AUC value after 30 mg/kg po dose in Dogs,16907,,Plasma,50588,Intermediate
1,,1,,9615.0,5234,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624257,BAO_0000218,AUC value after administration of 4 mg/Kg oral dose in dog,2959,,Plasma,50588,Intermediate
1,,1,,9615.0,5235,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624258,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,17594,,Plasma,50588,Intermediate
1,,1,,9615.0,5236,,,A,,,,Canis lupus familiaris,,N,CHEMBL875277,BAO_0000218,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,5356,,,50588,Intermediate
1,,1,,9615.0,5237,,,A,,,,Canis lupus familiaris,,N,CHEMBL622667,BAO_0000218,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,16807,,,50588,Intermediate
1,,1,,9615.0,5238,,,A,,,,Canis lupus familiaris,,N,CHEMBL622668,BAO_0000218,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,5239,,,A,,,,Canis lupus familiaris,,N,CHEMBL622669,BAO_0000218,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,5240,,,A,,,,Canis lupus familiaris,,N,CHEMBL622670,BAO_0000218,Area under curve determined in dogs after intravenous administration of 3 mg/kg,15660,,,50588,Intermediate
1,,1,,9615.0,5241,,,A,,,,Canis lupus familiaris,,N,CHEMBL622671,BAO_0000218,Area under curve determined in dogs after oral administration of 10 mg/kg,15660,,,50588,Intermediate
1,,1,,9615.0,5242,,,A,,,,Canis lupus familiaris,,N,CHEMBL622672,BAO_0000218,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,,,50588,Intermediate
1,,1,,9615.0,5243,,,A,,,,Canis lupus familiaris,,N,CHEMBL622673,BAO_0000218,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,,,50588,Expert
1,,1,,9615.0,5244,,,A,,,,Canis lupus familiaris,,N,CHEMBL622674,BAO_0000218,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,3598,,,50588,Expert
1,,1,,9615.0,5245,,,A,,,,Canis lupus familiaris,,N,CHEMBL622675,BAO_0000218,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),5944,,,50588,Intermediate
1,,1,,9615.0,5246,,,A,,,,Canis lupus familiaris,,N,CHEMBL622676,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,5944,,,50588,Intermediate
1,,1,,9615.0,5247,,,A,,,,Canis lupus familiaris,,N,CHEMBL622677,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),5944,,,50588,Intermediate
1,,1,,9615.0,5248,,,A,,,,Canis lupus familiaris,,N,CHEMBL622678,BAO_0000218,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,5944,,,50588,Intermediate
1,,1,,9615.0,5249,,,A,,,,Canis lupus familiaris,,N,CHEMBL622679,BAO_0000218,Area under curve in dog after administration of 20 mg/kg dose through peroral route,4186,,,50588,Intermediate
1,,1,,9615.0,5250,,,A,,,,Canis lupus familiaris,,N,CHEMBL622680,BAO_0000218,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,,,50588,Intermediate
1,,1,,9615.0,5251,,,A,,,,Canis lupus familiaris,,N,CHEMBL622681,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5252,,,A,,,,Canis lupus familiaris,,N,CHEMBL875278,BAO_0000218,Area under curve was determine after peroral administration at 5 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5253,,,A,,,,Canis lupus familiaris,,N,CHEMBL622682,BAO_0000218,Area under curve was determined,5006,,,50588,Intermediate
1,,1,,9615.0,5254,,,A,,,,Canis lupus familiaris,,N,CHEMBL622683,BAO_0000218,Area under curve in dogs,5006,,,50588,Intermediate
1,,1,,9615.0,5255,,,A,,,,Canis lupus familiaris,,N,CHEMBL622684,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration,3771,,,50588,Intermediate
1,,1,,9615.0,5256,,,A,,,,Canis lupus familiaris,,N,CHEMBL622685,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),3771,,,50588,Intermediate
1,,1,,9615.0,5257,,,A,,,,Canis lupus familiaris,,N,CHEMBL622686,BAO_0000218,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,3771,,,50588,Intermediate
1,,1,,9615.0,5258,,,A,,,,Canis lupus familiaris,,N,CHEMBL618344,BAO_0000218,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,,,50588,Intermediate
1,,1,,9615.0,5259,,,A,,,,Canis lupus familiaris,,N,CHEMBL875582,BAO_0000218,Area under curve value in dog at a dose of 5 mg/kg,5302,,,50588,Intermediate
1,,1,,9615.0,5260,,,A,,,,Canis lupus familiaris,,N,CHEMBL618345,BAO_0000218,Area under curve was determined after 0.1 mg/kg iv administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,5261,,,A,,,,Canis lupus familiaris,,N,CHEMBL618346,BAO_0000218,Area under curve was determined after 0.3 mg/kg po administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,5262,,,A,,,,Canis lupus familiaris,,N,CHEMBL618347,BAO_0000218,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,5263,,,A,,,,Canis lupus familiaris,,N,CHEMBL618348,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,4368,,,50588,Intermediate
0,,1,,9606.0,5264,,,A,,,,Homo sapiens,,U,CHEMBL618349,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,5318,,,22224,Autocuration
0,,1,,9606.0,5265,,,A,,,,Homo sapiens,,U,CHEMBL618350,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,5318,,,22224,Autocuration
0,,1,,9606.0,5266,,,A,,,,Homo sapiens,,U,CHEMBL618351,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,5318,,,22224,Autocuration
0,,1,,9606.0,5267,,,A,,,,Homo sapiens,,U,CHEMBL618352,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,5318,,,22224,Autocuration
0,,1,,9606.0,5268,,,A,178.0,,,Homo sapiens,,U,CHEMBL873494,BAO_0000221,Time taken to reduce 50% of the concentration of compound in blood plasma,14518,,Blood,22224,Autocuration
0,,1,,9606.0,5269,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618353,BAO_0000366,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",2209,,Plasma,22224,Autocuration
0,,1,,9606.0,5270,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618354,BAO_0000366,Half life in human plasma,6787,,Plasma,22224,Autocuration
0,,1,,9606.0,5271,,,A,1969.0,,,Homo sapiens,,U,CHEMBL875583,BAO_0000366,Half life in human plasma was reported,4898,,Plasma,22224,Autocuration
0,,1,,9606.0,5272,,,A,1977.0,,,Homo sapiens,,U,CHEMBL618355,BAO_0000019,Half life in human serum,6072,,Serum,22224,Autocuration
0,,1,,9606.0,5273,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618356,BAO_0000366,Half life upon exposure to human plasma,16907,,Plasma,22224,Autocuration
0,,1,,9606.0,5274,,In vitro,A,,,,Homo sapiens,,U,CHEMBL618357,BAO_0000251,t1/2 in human microsomes,5656,Microsomes,,22224,Autocuration
0,,1,,9606.0,5275,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618358,BAO_0000366,Half life period in 80% human plasma at 37 degree Centigrade,4755,,Plasma,22224,Autocuration
0,,1,,9606.0,5276,,,A,14.0,,,Homo sapiens,,U,CHEMBL618359,BAO_0000221,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),17503,,Zone of skin,22224,Autocuration
0,,1,,9606.0,5277,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL618360,BAO_0000366,Half-life measured in in vitro Cathepsin B assay in human plasma,12357,,Plasma,22224,Autocuration
0,,1,,9606.0,5278,,,A,,,,Homo sapiens,,U,CHEMBL618361,BAO_0000019,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,3076,,,22224,Autocuration
0,,1,,9606.0,5279,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618362,BAO_0000251,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,6410,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5280,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618363,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",3741,,Plasma,22224,Autocuration
0,,1,,9606.0,5281,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618364,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",3741,,Plasma,22224,Autocuration
0,,1,,9606.0,5282,,,A,1969.0,,,Homo sapiens,,U,CHEMBL875584,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",3741,,Plasma,22224,Autocuration
0,,1,,9606.0,5283,,,A,,,,Homo sapiens,,U,CHEMBL618365,BAO_0000019,Half-life in the CEM cell extracts,1540,,,22224,Autocuration
0,,1,,9606.0,5284,,,A,1969.0,,,Homo sapiens,,U,CHEMBL873495,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,2905,,Plasma,22224,Autocuration
0,,1,,9606.0,5285,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618366,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,2905,,Plasma,22224,Autocuration
0,,1,,9606.0,5286,,,A,,,,Homo sapiens,,U,CHEMBL618367,BAO_0000019,Half-life was determined,5523,,,22224,Autocuration
0,,1,,9606.0,5287,,,A,178.0,,,Homo sapiens,,U,CHEMBL618368,BAO_0000221,Half-life (human blood stability),1499,,Blood,22224,Autocuration
0,,1,,9606.0,5288,,,A,178.0,,,Homo sapiens,,U,CHEMBL618369,BAO_0000221,Half-life (human blood stability); no data,1499,,Blood,22224,Autocuration
0,,1,,9606.0,5289,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618370,BAO_0000366,Half-life in human plasma,17065,,Plasma,22224,Autocuration
0,,1,,9606.0,5290,,,A,,,,Homo sapiens,,U,CHEMBL618371,BAO_0000019,CYP3A4 metabolism half-life (t1/2),6861,,,22224,Autocuration
0,,1,,9606.0,5291,,,A,178.0,,,Homo sapiens,,U,CHEMBL618372,BAO_0000221,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1499,,Blood,22224,Autocuration
0,,1,,9606.0,5292,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL618373,BAO_0000366,In vitro half life in human plasma,530,,Plasma,22224,Autocuration
0,,1,,9606.0,5293,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL618374,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1116,,Plasma,22224,Autocuration
0,,1,,9606.0,5294,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL618375,BAO_0000366,In vitro hydrolysis in human plasma,6695,,Plasma,22224,Autocuration
0,,1,,9606.0,5295,,In vitro,A,1969.0,,,Homo sapiens,,U,CHEMBL618376,BAO_0000366,In vitro hydrolysis in human plasma; no data,6695,,Plasma,22224,Autocuration
0,,1,,9606.0,5296,,In vitro,A,2107.0,,,Homo sapiens,,U,CHEMBL618377,BAO_0000251,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,10,Microsomes,Liver,22224,Autocuration
0,,1,,9606.0,5297,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618378,BAO_0000366,Plasma half life in human,993,,Plasma,22224,Autocuration
0,,1,,9606.0,5298,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618379,BAO_0000366,Stability after incubation with human plasma (at 37 degree C),15429,,Plasma,22224,Autocuration
0,,1,,9606.0,5299,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618380,BAO_0000366,T1/2 was evaluated in human plasma,1675,,Plasma,22224,Autocuration
0,,1,,9606.0,5300,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618381,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",2209,,Plasma,22224,Autocuration
0,,1,,9606.0,5301,,,A,1969.0,,,Homo sapiens,,U,CHEMBL618382,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",2209,,Plasma,22224,Autocuration
0,,1,,9606.0,5302,,,A,,,,Homo sapiens,,U,CHEMBL618383,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,5318,,,22224,Autocuration
0,,1,,9606.0,5303,,In vitro,A,,,,Homo sapiens,,U,CHEMBL618384,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,2412,,,22224,Autocuration
0,,1,,9606.0,5304,,In vitro,A,,,,Homo sapiens,,U,CHEMBL618385,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,2412,,,22224,Autocuration
0,,1,,9606.0,5305,,,A,1969.0,,,Homo sapiens,,U,CHEMBL619099,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,2906,,Plasma,22224,Autocuration
0,,1,,9606.0,5306,,,A,1969.0,,,Homo sapiens,,U,CHEMBL619100,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,2906,,Plasma,22224,Autocuration
0,,1,,9606.0,5307,,,A,,,,Homo sapiens,,U,CHEMBL619101,BAO_0000019,Time taken for 50% to be consumed by serum PON1 was determined,5495,,,22224,Autocuration
0,,1,,9606.0,5308,,,A,,,,Homo sapiens,,U,CHEMBL619102,BAO_0000019,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,5495,,,22224,Autocuration
0,,1,,9606.0,5309,,,A,2107.0,,,Homo sapiens,,U,CHEMBL619103,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,4397,Microsomes,Liver,22224,Autocuration
0,,1,,10095.0,5310,,,A,,,,Mus sp.,,U,CHEMBL619268,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5311,,,A,,,,Mus sp.,,U,CHEMBL619269,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5312,,,A,,,,Mus sp.,,U,CHEMBL619270,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5313,,,A,,,,Mus sp.,,U,CHEMBL619271,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5314,,,A,,,,Mus sp.,,U,CHEMBL875585,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5315,,,A,,,,Mus sp.,,U,CHEMBL619272,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,,,22224,Autocuration
1,,1,391.0,9606.0,5316,,,F,,,,Homo sapiens,786-0,N,CHEMBL619273,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line 786-0,6058,,,80640,Intermediate
1,,1,391.0,9606.0,5317,,,F,,,,Homo sapiens,786-0,N,CHEMBL619274,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,17708,,,80640,Intermediate
1,,1,391.0,9606.0,5318,,,F,,,,Homo sapiens,786-0,N,CHEMBL619275,BAO_0000219,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,14017,,,80640,Expert
1,,1,391.0,9606.0,5319,,,F,,,,Homo sapiens,786-0,N,CHEMBL619276,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",16818,,,80640,Intermediate
1,,1,391.0,9606.0,5320,,,F,,,,Homo sapiens,786-0,N,CHEMBL619277,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",16818,,,80640,Intermediate
1,,1,391.0,9606.0,5321,,,F,,,,Homo sapiens,786-0,N,CHEMBL619278,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",16818,,,80640,Intermediate
1,,1,391.0,9606.0,5322,,,F,,,,Homo sapiens,786-0,N,CHEMBL619279,BAO_0000219,Tested for cytotoxicity against 786-0 cell lines in renal cancer,11970,,,80640,Intermediate
1,,1,391.0,9606.0,5323,,,F,,,,Homo sapiens,786-0,N,CHEMBL858458,BAO_0000219,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,12400,,,80640,Intermediate
1,,1,391.0,9606.0,5324,,,F,,,,Homo sapiens,786-0,N,CHEMBL619280,BAO_0000219,Cytotoxic effect on renal cancer line 786-0,12888,,,80640,Expert
1,,1,391.0,9606.0,5325,,,F,,,,Homo sapiens,786-0,N,CHEMBL619281,BAO_0000219,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,15300,,,80640,Intermediate
1,,1,391.0,9606.0,5326,,,F,,,,Homo sapiens,786-0,N,CHEMBL619282,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),14769,,,80640,Intermediate
1,,1,391.0,9606.0,5327,,,F,,,,Homo sapiens,786-0,N,CHEMBL619283,BAO_0000219,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",15895,,,80640,Intermediate
1,,1,391.0,9606.0,5328,,,F,,,,Homo sapiens,786-0,N,CHEMBL619284,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,17376,,,80640,Intermediate
1,,1,391.0,9606.0,5329,,,F,,,,Homo sapiens,786-0,N,CHEMBL619285,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,14882,,,80640,Intermediate
1,,1,391.0,9606.0,5330,,,F,,,,Homo sapiens,786-0,N,CHEMBL619286,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),14882,,,80640,Intermediate
1,,1,391.0,9606.0,5331,,,F,,,,Homo sapiens,786-0,N,CHEMBL619287,BAO_0000219,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,15176,,,80640,Intermediate
1,,1,391.0,9606.0,5332,,,F,,,,Homo sapiens,786-0,N,CHEMBL857455,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,12696,,,80640,Intermediate
1,,1,391.0,9606.0,5333,,,F,,,,Homo sapiens,786-0,N,CHEMBL883801,BAO_0000219,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),2496,,,80640,Intermediate
1,,1,972.0,9606.0,5334,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619288,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,11831,,,80641,Intermediate
1,,1,972.0,9606.0,5335,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619289,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5336,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619290,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,11831,,,80641,Intermediate
1,,1,972.0,9606.0,5337,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619291,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5338,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619292,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5339,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619293,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,11831,,,80641,Intermediate
1,,1,972.0,9606.0,5340,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619294,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5341,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619295,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5342,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619296,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),11831,,,80641,Intermediate
1,,1,972.0,9606.0,5343,,,F,,,,Homo sapiens,791T cell line,N,CHEMBL619297,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,11831,,,80641,Intermediate
1,,1,391.0,9606.0,5344,,,F,,,,Homo sapiens,786-0,N,CHEMBL619298,BAO_0000219,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,12782,,,80640,Intermediate
0,,1,,,5345,,,F,,,,,,U,CHEMBL619299,BAO_0000019,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1229,,,22226,Intermediate
1,,1,741.0,9606.0,5346,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619300,BAO_0000219,Inhibition of cell growth in drug resistant 8226 myeloma cell line,15313,,,80433,Expert
1,,1,741.0,9606.0,5347,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619301,BAO_0000219,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,15313,,,80433,Expert
1,,1,741.0,9606.0,5348,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619302,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,11544,,,80433,Intermediate
1,,1,741.0,9606.0,5349,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619303,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5350,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619304,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5351,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL857706,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5352,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619305,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5353,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619306,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5354,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619307,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5355,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619308,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5356,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619309,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5357,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL619310,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,624.0,9606.0,5358,,,F,,,,Homo sapiens,A498,N,CHEMBL619311,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),14769,,,80021,Intermediate
1,,1,624.0,9606.0,5359,,,F,,,,Homo sapiens,A498,N,CHEMBL619312,BAO_0000219,Compound was tested for the growth inhibition of A498 renal tumor cell line,15354,,,80021,Intermediate
1,,1,624.0,9606.0,5360,,,F,,,,Homo sapiens,A498,N,CHEMBL619313,BAO_0000219,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),17445,,,80021,Intermediate
1,,1,624.0,9606.0,5361,,,F,,,,Homo sapiens,A498,N,CHEMBL619314,BAO_0000219,In vitro inhibitory concentration against renal cancer cell line A498,4337,,,80021,Intermediate
1,,1,624.0,9606.0,5362,,,F,,,,Homo sapiens,A498,N,CHEMBL619959,BAO_0000219,Cytotoxicity against A 498 tumor cell line,15277,,,80021,Intermediate
1,,1,624.0,9606.0,5363,,,F,,,,Homo sapiens,A498,N,CHEMBL619960,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line,4812,,,80021,Intermediate
1,,1,624.0,9606.0,5364,,,F,,,,Homo sapiens,A498,N,CHEMBL619961,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),4812,,,80021,Intermediate
1,,1,624.0,9606.0,5365,,,F,,,,Homo sapiens,A498,N,CHEMBL619962,BAO_0000219,Inhibitory dose required against A498 human tumor cell lines,4995,,,80021,Intermediate
1,,1,624.0,9606.0,5366,,,F,,,,Homo sapiens,A498,N,CHEMBL875586,BAO_0000219,Anticancer activity against one renal cancer (A498 cell line),5847,,,80021,Intermediate
1,,1,624.0,9606.0,5367,,,F,,,,Homo sapiens,A498,N,CHEMBL619963,BAO_0000219,In vitro cytotoxicity against melanoma A498 cell line,6557,,,80021,Intermediate
1,,1,624.0,9606.0,5368,,,F,,,,Homo sapiens,A498,N,CHEMBL619964,BAO_0000219,Compound was tested for growth inhibitory activity against A498 cell line,2597,,,80021,Intermediate
1,,1,624.0,9606.0,5369,,,F,,,,Homo sapiens,A498,N,CHEMBL620108,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line A498,6058,,,80021,Intermediate
1,,1,624.0,9606.0,5370,,,F,,,,Homo sapiens,A498,N,CHEMBL620109,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,17708,,,80021,Intermediate
1,,1,624.0,9606.0,5371,,,F,,,,Homo sapiens,A498,N,CHEMBL620110,BAO_0000219,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,15176,,,80021,Intermediate
1,,1,624.0,9606.0,5372,,,F,,,,Homo sapiens,A498,N,CHEMBL620111,BAO_0000219,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,15300,,,80021,Intermediate
1,,1,624.0,9606.0,5373,,,F,,,,Homo sapiens,A498,N,CHEMBL620112,BAO_0000219,Tested for cytotoxicity against A498 cell lines in renal cancer,11970,,,80021,Intermediate
1,,1,624.0,9606.0,5374,,,F,,,,Homo sapiens,A498,N,CHEMBL620113,BAO_0000219,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,12400,,,80021,Intermediate
1,,1,624.0,9606.0,5375,,,F,,,,Homo sapiens,A498,N,CHEMBL620114,BAO_0000219,Cytotoxic effect on renal cancer lines A498,12888,,,80021,Expert
1,,1,624.0,9606.0,5376,,,F,,,,Homo sapiens,A498,N,CHEMBL620115,BAO_0000219,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,3030,,,80021,Intermediate
1,,1,624.0,9606.0,5377,,,F,,,,Homo sapiens,A498,N,CHEMBL620116,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),14769,,,80021,Intermediate
1,,1,624.0,9606.0,5378,,,F,,,,Homo sapiens,A498,N,CHEMBL620117,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,17376,,,80021,Intermediate
1,,1,624.0,9606.0,5379,,,F,,,,Homo sapiens,A498,N,CHEMBL620118,BAO_0000219,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,16558,,,80021,Intermediate
1,,1,624.0,9606.0,5380,,,F,,,,Homo sapiens,A498,N,CHEMBL620119,BAO_0000219,Cytotoxicity against human kidney carcinoma cell lines A4982LM,5194,,,80021,Intermediate
1,,1,624.0,9606.0,5381,,,F,,,,Homo sapiens,A498,N,CHEMBL620120,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,10708,,,80021,Intermediate
1,,1,646.0,9606.0,5382,,,F,,,,Homo sapiens,A549,N,CHEMBL620121,BAO_0000219,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,16880,,,80682,Expert
1,,1,646.0,9606.0,5383,,,F,,,,Homo sapiens,A549,N,CHEMBL620122,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line,10196,,,80682,Intermediate
1,,1,646.0,9606.0,5384,,,F,,,,Homo sapiens,A549,N,CHEMBL620123,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,10196,,,80682,Intermediate
1,,1,646.0,9606.0,5385,,,F,,,,Homo sapiens,A549,N,CHEMBL620124,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,10196,,,80682,Intermediate
1,,1,646.0,9606.0,5386,,,F,,,,Homo sapiens,A549,N,CHEMBL620125,BAO_0000219,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",12083,,,80682,Intermediate
1,,1,646.0,9606.0,5387,,,F,,,,Homo sapiens,A549,N,CHEMBL620126,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,16464,,,80682,Expert
1,,1,646.0,9606.0,5388,,,F,,,,Homo sapiens,A549,N,CHEMBL883027,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80682,Intermediate
1,,1,646.0,9606.0,5389,,,F,,,,Homo sapiens,A549,N,CHEMBL620127,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line,16470,,,80682,Expert
1,,1,646.0,9606.0,5390,,,F,,,,Homo sapiens,A549,N,CHEMBL620128,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),16470,,,80682,Intermediate
1,,1,646.0,9606.0,5391,,,F,,,,Homo sapiens,A549,N,CHEMBL620129,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line),16470,,,80682,Intermediate
1,,1,646.0,9606.0,5392,,,F,,,,Homo sapiens,A549,N,CHEMBL620130,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,16470,,,80682,Intermediate
1,,1,646.0,9606.0,5393,,,F,,,,Homo sapiens,A549,N,CHEMBL620131,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A549.,16582,,,80682,Expert
1,,1,646.0,9606.0,5394,,,F,,,,Homo sapiens,A549,N,CHEMBL620132,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",15935,,,80682,Intermediate
1,,1,646.0,9606.0,5395,,,F,,,,Homo sapiens,A549,N,CHEMBL620133,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",15935,,,80682,Intermediate
1,,1,646.0,9606.0,5396,,,F,,,,Homo sapiens,A549,N,CHEMBL620134,BAO_0000219,Inhibition of A549 human lung carcinoma cell proliferation,16597,,,80682,Expert
1,,1,646.0,9606.0,5397,,,F,,,,Homo sapiens,A549,N,CHEMBL620135,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,17376,,,80682,Intermediate
1,,1,646.0,9606.0,5398,,,F,,,,Homo sapiens,A549,N,CHEMBL620136,BAO_0000219,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,16496,,,80682,Intermediate
1,,1,646.0,9606.0,5399,,,F,,,,Homo sapiens,A549,N,CHEMBL620137,BAO_0000219,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,16152,,,80682,Intermediate
1,,1,646.0,9606.0,5400,,,F,,,,Homo sapiens,A549,N,CHEMBL620268,BAO_0000219,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,16152,,,80682,Intermediate
1,,1,646.0,9606.0,5401,,,F,,,,Homo sapiens,A549,N,CHEMBL620269,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80682,Intermediate
1,,1,646.0,9606.0,5402,,,F,,,,Homo sapiens,A549,N,CHEMBL620270,BAO_0000219,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,2288,,,80682,Intermediate
1,,1,646.0,9606.0,5403,,,F,,,,Homo sapiens,A549,N,CHEMBL620271,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,17350,,,80682,Intermediate
1,,1,646.0,9606.0,5404,,,F,,,,Homo sapiens,A549,N,CHEMBL620272,BAO_0000219,Inhibition of A549 cancer cell proliferation,4090,,,80682,Expert
1,,1,646.0,9606.0,5405,,,F,,,,Homo sapiens,A549,N,CHEMBL620273,BAO_0000219,Inhibition of A549 cancer cell proliferation (Not tested),4090,,,80682,Expert
1,,1,646.0,9606.0,5406,,,F,,,,Homo sapiens,A549,N,CHEMBL620274,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,17350,,,80682,Intermediate
1,,1,646.0,9606.0,5407,,,F,,,,Homo sapiens,A549,N,CHEMBL620275,BAO_0000219,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,4197,,,80682,Intermediate
1,,1,646.0,9606.0,5408,,,F,,,,Homo sapiens,A549,N,CHEMBL620276,BAO_0000219,Antiproliferative potency determined as inhibitory concentration against A549 cells,17072,,,80682,Intermediate
1,,1,646.0,9606.0,5409,,,F,,,,Homo sapiens,A549,N,CHEMBL620277,BAO_0000219,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,17072,,,80682,Intermediate
1,,1,646.0,9606.0,5410,,,F,,,,Homo sapiens,A549,N,CHEMBL620278,BAO_0000219,Cytotoxicity against Renal cell lines A549 was determined,5194,,,80682,Intermediate
1,,1,,9615.0,5411,,,A,,,,Canis lupus familiaris,,N,CHEMBL620279,BAO_0000218,Area under curve was determined in dog after a 3 mg/kg of oral dose,4257,,,50588,Intermediate
1,,1,,9615.0,5412,,,A,,,,Canis lupus familiaris,,N,CHEMBL620280,BAO_0000218,Area under curve was determined in dog after oral administration at 1 mg/kg,6123,,,50588,Intermediate
1,,1,,9615.0,5413,,,A,,,,Canis lupus familiaris,,N,CHEMBL620281,BAO_0000218,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,,,50588,Intermediate
1,,1,,9615.0,5414,,,A,,,,Canis lupus familiaris,,N,CHEMBL620282,BAO_0000218,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,,,50588,Intermediate
1,,1,,9615.0,5415,,,A,,,,Canis lupus familiaris,,N,CHEMBL621134,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),8833,,,50588,Intermediate
1,,1,,9615.0,5416,,,A,,,,Canis lupus familiaris,,N,CHEMBL621135,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),8833,,,50588,Intermediate
1,,1,,9615.0,5417,,,A,,,,Canis lupus familiaris,,N,CHEMBL621136,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),8833,,,50588,Intermediate
1,,1,,9615.0,5418,,,A,,,,Canis lupus familiaris,,N,CHEMBL621137,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),8833,,,50588,Intermediate
1,,1,,9615.0,5419,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621138,BAO_0000218,Area under plasma concentration time curve in dog upon oral administration,17657,,Plasma,50588,Intermediate
1,,1,,9615.0,5420,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL875587,BAO_0000218,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,17650,,Plasma,50588,Intermediate
1,,1,,9615.0,5421,,,A,,,,Canis lupus familiaris,,N,CHEMBL621139,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1977,,,50588,Intermediate
1,,1,,9615.0,5422,,,A,,,,Canis lupus familiaris,,N,CHEMBL621140,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1977,,,50588,Intermediate
1,,1,,9615.0,5423,,,A,,,,Canis lupus familiaris,,N,CHEMBL621141,BAO_0000218,Area under the curve for the compound was obtained when tested in dog,3132,,,50588,Intermediate
1,,1,,9615.0,5424,,,A,,,,Canis lupus familiaris,,N,CHEMBL621142,BAO_0000218,Area under the curve at a dose of 1 mg/kg,5473,,,50588,Intermediate
1,,1,,9615.0,5425,,,A,,,,Canis lupus familiaris,,N,CHEMBL621143,BAO_0000218,Area under the curve at a dose of 1 mg/kg (oral),5474,,,50588,Intermediate
1,,1,,9615.0,5426,,,A,,,,Canis lupus familiaris,,N,CHEMBL621144,BAO_0000218,Area under the curve at i.v. dose of 0.2 mg/kg,5474,,,50588,Intermediate
1,,1,,9615.0,5427,,,A,,,,Canis lupus familiaris,,N,CHEMBL621145,BAO_0000218,Area under the curve was measured in dog after an iv dose of 1 mg/kg,6062,,,50588,Intermediate
1,,1,,9615.0,5428,,,A,,,,Canis lupus familiaris,,N,CHEMBL621146,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,5429,,,A,,,,Canis lupus familiaris,,N,CHEMBL622567,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,2652,,,50588,Intermediate
1,,1,,9615.0,5430,,,A,,,,Canis lupus familiaris,,N,CHEMBL622568,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,2652,,,50588,Intermediate
1,,1,,9615.0,5431,,,A,,,,Canis lupus familiaris,,N,CHEMBL622569,BAO_0000218,Compound was evaluated for area under the curve in dog blood.,2877,,,50588,Intermediate
1,,1,,9615.0,5432,,,A,,,,Canis lupus familiaris,,N,CHEMBL622570,BAO_0000218,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,5444,,,50588,Intermediate
1,,1,,9615.0,5433,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622571,BAO_0000218,AUC in dog after oral dose (1 mg/kg),5130,,Plasma,50588,Intermediate
1,,1,,9615.0,5434,,,A,,,,Canis lupus familiaris,,N,CHEMBL622572,BAO_0000218,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,6265,,,50588,Intermediate
1,,1,,9615.0,5435,,,A,,,,Canis lupus familiaris,,N,CHEMBL622573,BAO_0000218,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",4657,,,50588,Intermediate
1,,1,,9615.0,5436,,,A,,,,Canis lupus familiaris,,N,CHEMBL622574,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,5437,,,A,,,,Canis lupus familiaris,,N,CHEMBL622575,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,5438,,,A,,,,Canis lupus familiaris,,N,CHEMBL622576,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,9579,,,50588,Intermediate
1,,1,,9615.0,5439,,,A,,,,Canis lupus familiaris,,N,CHEMBL622577,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,9579,,,50588,Intermediate
1,,1,,9615.0,5440,,,A,,,,Canis lupus familiaris,,N,CHEMBL622578,BAO_0000218,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,5983,,,50588,Intermediate
1,,1,,9615.0,5441,,,A,,,,Canis lupus familiaris,,N,CHEMBL622579,BAO_0000218,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,6241,,,50588,Intermediate
1,,1,,9615.0,5442,,,A,,,,Canis lupus familiaris,,N,CHEMBL622580,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",5313,,,50588,Intermediate
1,,1,,9615.0,5443,,,A,,,,Canis lupus familiaris,,N,CHEMBL622581,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",5313,,,50588,Intermediate
1,,1,,9615.0,5444,,,A,,,,Canis lupus familiaris,,N,CHEMBL622582,BAO_0000218,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,,,50588,Intermediate
1,,1,,9615.0,5445,,,A,,,,Canis lupus familiaris,,N,CHEMBL622583,BAO_0000218,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,,,50588,Intermediate
1,,1,,9615.0,5446,,,A,,,,Canis lupus familiaris,,N,CHEMBL622584,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),6641,,,50588,Intermediate
1,,1,,9615.0,5447,,,A,,,,Canis lupus familiaris,,N,CHEMBL622585,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),6642,,,50588,Intermediate
1,,1,,9615.0,5448,,,A,,,,Canis lupus familiaris,,N,CHEMBL622586,BAO_0000218,Compound was evaluated for oral bioavailability in dog; 90-100,17791,,,50588,Intermediate
1,,1,,9615.0,5449,,,A,,,,Canis lupus familiaris,,N,CHEMBL623281,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,17655,,,50588,Intermediate
1,,1,,9615.0,5450,,,A,,,,Canis lupus familiaris,,N,CHEMBL623282,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,17655,,,50588,Intermediate
1,,1,,9615.0,5451,,,A,,,,Canis lupus familiaris,,N,CHEMBL623283,BAO_0000218,PAPP (membrane permeability) in dog kidney cell monolayer assay,6596,,,50588,Intermediate
1,,1,,9615.0,5452,,,A,,,,Canis lupus familiaris,,N,CHEMBL623284,BAO_0000218,Oral bioavailability in dog,3880,,,50588,Intermediate
1,,1,,9615.0,5453,,,A,,,,Canis lupus familiaris,,N,CHEMBL623285,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,5454,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623463,BAO_0000218,Plasma protein binding towards dog plasma at 10 uM,17409,,Plasma,50588,Intermediate
1,,1,,9615.0,5455,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL875952,BAO_0000218,Plasma protein binding towards dog plasma at 100 uM,17409,,Plasma,50588,Intermediate
1,,1,,9615.0,5456,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621705,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),2959,,,50588,Intermediate
1,,1,,9615.0,5457,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621706,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,13501,,,50588,Intermediate
1,,1,,9615.0,5458,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621707,BAO_0000218,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,5459,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621708,BAO_0000218,Bioavailability in dogs,15145,,,50588,Intermediate
1,,1,,9615.0,5460,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621709,BAO_0000218,Bioavailability,4219,,,50588,Intermediate
1,,1,,9615.0,5461,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621710,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),17538,,,50588,Intermediate
1,,1,,9615.0,5462,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621711,BAO_0000218,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,17538,,,50588,Intermediate
1,,1,,9615.0,5463,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621712,BAO_0000218,Bioavailability in dog (dose 10.0 mg/kg p.o.),1466,,,50588,Intermediate
1,,1,,9615.0,5464,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621713,BAO_0000218,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,17650,,,50588,Intermediate
1,,1,,9615.0,5465,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621714,BAO_0000218,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,3132,,,50588,Intermediate
0,,1,,10095.0,5466,,,A,,,,Mus sp.,,U,CHEMBL621715,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5467,,,A,2107.0,,,Mus sp.,,U,CHEMBL623717,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,Liver,22224,Autocuration
0,,1,,10095.0,5468,,,A,2107.0,,,Mus sp.,,U,CHEMBL623718,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,,Liver,22224,Autocuration
0,,1,,10095.0,5469,,,A,2107.0,,,Mus sp.,,U,CHEMBL623719,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,Liver,22224,Autocuration
0,,1,,10095.0,5470,,,A,,,,Mus sp.,,U,CHEMBL623720,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5471,,,A,,,,Mus sp.,,U,CHEMBL623721,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5472,,,A,2385.0,,,Mus sp.,,U,CHEMBL623722,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,Muscle tissue,22224,Autocuration
0,,1,,10095.0,5473,,,A,2385.0,,,Mus sp.,,U,CHEMBL623723,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,,Muscle tissue,22224,Autocuration
0,,1,,10095.0,5474,,,A,2385.0,,,Mus sp.,,U,CHEMBL618543,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,Muscle tissue,22224,Autocuration
0,,1,,10095.0,5475,,,A,2106.0,,,Mus sp.,,U,CHEMBL618544,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,Spleen,22224,Autocuration
0,,1,,10095.0,5476,,,A,2106.0,,,Mus sp.,,U,CHEMBL875155,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,Spleen,22224,Autocuration
0,,1,,10095.0,5477,,,A,,,,Mus sp.,,U,CHEMBL618545,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5478,,,A,,,,Mus sp.,,U,CHEMBL618546,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5479,,,A,,,,Mus sp.,,U,CHEMBL623529,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5480,,,A,,,,Mus sp.,,U,CHEMBL623530,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,,,22224,Autocuration
0,,1,,10095.0,5481,,,A,,,,Mus sp.,,U,CHEMBL621764,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,,,22224,Autocuration
0,,1,,9527.0,5482,,,A,,,,Cercopithecidae,,U,CHEMBL621765,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),17827,,,22224,Autocuration
0,,1,,9527.0,5483,,,A,2037.0,,,Cercopithecidae,,U,CHEMBL621766,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),17827,,Cerebellum,22224,Autocuration
0,,1,,9527.0,5484,,,A,1870.0,,,Cercopithecidae,,U,CHEMBL621767,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),17827,,Frontal cortex,22224,Autocuration
0,,1,,9527.0,5485,,,A,,,,Cercopithecidae,,U,CHEMBL621768,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),17827,,,22224,Autocuration
0,,1,,9527.0,5486,,,A,2435.0,,,Cercopithecidae,,U,CHEMBL621769,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),17827,,Striatum,22224,Autocuration
0,,1,,9527.0,5487,,,A,,,,Cercopithecidae,,U,CHEMBL621770,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),17827,,,22224,Autocuration
0,,1,,9527.0,5488,,,A,2037.0,,,Cercopithecidae,,U,CHEMBL621771,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),17827,,Cerebellum,22224,Autocuration
0,,1,,9527.0,5489,,,A,1870.0,,,Cercopithecidae,,U,CHEMBL621772,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),17827,,Frontal cortex,22224,Autocuration
0,,1,,9527.0,5490,,,A,,,,Cercopithecidae,,U,CHEMBL621773,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),17827,,,22224,Autocuration
0,,1,,9527.0,5491,,,A,2435.0,,,Cercopithecidae,,U,CHEMBL621774,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),17827,,Striatum,22224,Autocuration
0,,1,,9527.0,5492,,,A,,,,Cercopithecidae,,U,CHEMBL621775,BAO_0000218,Compound was evaluated for oral bioavailability in rats,17791,,,22224,Autocuration
0,,1,,9527.0,5493,,In vivo,A,1969.0,,,Cercopithecidae,,U,CHEMBL621776,BAO_0000218,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,17667,,Plasma,22224,Autocuration
0,,1,,9527.0,5494,,,A,,,,Cercopithecidae,,U,CHEMBL621777,BAO_0000019,Half life period was evaluated in monkey,17791,,,22224,Autocuration
0,,1,,9527.0,5495,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL875162,BAO_0000218,Half-life in rhesus monkeys by intravenous administration of dose,110,,,22224,Autocuration
1,,1,,10090.0,5496,,,A,1969.0,,,Mus musculus,,N,CHEMBL621778,BAO_0000218,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,5781,,Plasma,50594,Intermediate
1,,1,,10090.0,5497,,,A,1969.0,,,Mus musculus,,N,CHEMBL621779,BAO_0000218,AUC after intraperitoneal administration of 100 mg/kg in mice,17734,,Plasma,50594,Intermediate
1,,1,,10090.0,5498,,,A,1969.0,,,Mus musculus,,N,CHEMBL622479,BAO_0000218,AUC value was determined after oral administration,17718,,Plasma,50594,Intermediate
1,,1,,10090.0,5499,,,A,,,,Mus musculus,,N,CHEMBL622480,BAO_0000218,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,4573,,,50594,Intermediate
1,,1,,10090.0,5500,,,A,,,,Mus musculus,,N,CHEMBL622481,BAO_0000218,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,,,50594,Intermediate
1,,1,,10090.0,5501,,,A,,,,Mus musculus,,N,CHEMBL622482,BAO_0000218,Area under curve by ioral administration in mouse,2862,,,50594,Intermediate
1,,1,,10090.0,5502,,,A,,,,Mus musculus,,N,CHEMBL622483,BAO_0000218,Area under curve by iv administration in mouse,2862,,,50594,Intermediate
1,,1,,10090.0,5503,,,A,,,,Mus musculus,,N,CHEMBL622484,BAO_0000218,Area under curve at 0-8 hr in IRC mice after peroral administration,5951,,,50594,Intermediate
1,,1,,10090.0,5504,,,A,,,,Mus musculus,,N,CHEMBL622641,BAO_0000218,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,17729,,,50594,Intermediate
1,,1,,10090.0,5505,,,A,,,,Mus musculus,,N,CHEMBL622642,BAO_0000218,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,17728,,,50594,Intermediate
1,,1,,10090.0,5506,,,A,,,,Mus musculus,,N,CHEMBL622643,BAO_0000218,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,17728,,,50594,Intermediate
1,,1,,10090.0,5507,,,A,,,,Mus musculus,,N,CHEMBL622644,BAO_0000218,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,17729,,,50594,Intermediate
1,,1,741.0,9606.0,5508,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL622645,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5509,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL622646,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5510,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL621238,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5511,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL621239,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5512,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL621240,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5513,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL621241,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5514,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL621242,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5515,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620350,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5516,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620351,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5517,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620352,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,,,80433,Intermediate
1,,1,741.0,9606.0,5518,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620353,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5519,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620354,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5520,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620355,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5521,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620356,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5522,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620357,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5523,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620358,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,,,80433,Intermediate
1,,1,741.0,9606.0,5524,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620359,BAO_0000219,In vitro inhibition of human 8226 myeloma tumor cell line growth.,9424,,,80433,Expert
1,,1,741.0,9606.0,5525,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620360,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,11544,,,80433,Intermediate
1,,1,741.0,9606.0,5526,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620361,BAO_0000219,Cytotoxicity of compound against 8226/DOX1V cells,17378,,,80433,Intermediate
1,,1,741.0,9606.0,5527,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620362,BAO_0000219,Cytotoxicity of compound against 8226/S cells,17378,,,80433,Intermediate
1,,1,741.0,9606.0,5528,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620363,BAO_0000219,Inhibitory concentration against 8226 myeloma cancer cell line,17079,,,80433,Intermediate
1,,1,741.0,9606.0,5529,,,F,,,,Homo sapiens,RPMI-8226,N,CHEMBL620364,BAO_0000219,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,17079,,,80433,Intermediate
1,,1,854.0,9606.0,5530,,,F,,,,Homo sapiens,833K,N,CHEMBL620365,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K).,13466,,,80647,Intermediate
1,,1,854.0,9606.0,5531,,,F,,,,Homo sapiens,833K,N,CHEMBL620366,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',13466,,,80647,Intermediate
1,,1,854.0,9606.0,5532,,,F,,,,Homo sapiens,833K,N,CHEMBL620367,BAO_0000219,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,2392,,,80647,Expert
1,,1,854.0,9606.0,5533,,,F,,,,Homo sapiens,833K,N,CHEMBL620368,BAO_0000219,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,2392,,,80647,Intermediate
0,,1,,,5534,,,B,,,,,,U,CHEMBL620369,BAO_0000019,Inhibitory activity against caspase-1,6608,,,22226,Autocuration
8,,1,,1351.0,5535,,,B,,,,Enterococcus faecalis,,H,CHEMBL620370,BAO_0000357,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,10199,,,45,Autocuration
1,,1,705.0,9606.0,5536,,,F,,,,Homo sapiens,8701-BC,N,CHEMBL620371,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,17749,,,80648,Intermediate
1,,1,705.0,9606.0,5537,,,F,,,,Homo sapiens,8701-BC,N,CHEMBL620372,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,17749,,,80648,Intermediate
0,,1,,,5538,,,F,,,,,,U,CHEMBL876492,BAO_0000019,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1229,,,22226,Intermediate
0,,1,,,5539,,,F,,,,,,U,CHEMBL620373,BAO_0000019,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1229,,,22226,Intermediate
0,,1,,,5540,,,F,,,,,,U,CHEMBL620374,BAO_0000019,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1229,,,22226,Intermediate
0,,1,,,5541,,,B,,,,,,U,CHEMBL620375,BAO_0000019,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,6390,,,22226,Autocuration
0,,1,,1314.0,5542,,,F,,,,Streptococcus pyogenes,,U,CHEMBL857902,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,16219,,,22226,Autocuration
0,,1,,1314.0,5543,,,F,,,,Streptococcus pyogenes,,U,CHEMBL620376,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,16219,,,22226,Autocuration
8,,1,,,5544,,,B,,,,,,H,CHEMBL620377,BAO_0000357,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,17043,,,11922,Autocuration
1,,1,324.0,9606.0,5545,,,F,,,,Homo sapiens,KB ,N,CHEMBL620378,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,6929,,,81115,Intermediate
1,,1,324.0,9606.0,5546,,,A,,,,Homo sapiens,KB ,N,CHEMBL620379,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,6929,,,81115,Intermediate
0,,1,,9606.0,5547,,,F,,,,Homo sapiens,,U,CHEMBL620380,BAO_0000219,In vitro cytotoxicity of compound was tested against 9KB cells.,7083,,,22226,Autocuration
1,,1,392.0,10116.0,5548,,,F,,,,Rattus norvegicus,9L,N,CHEMBL884006,BAO_0000219,Cytotoxic concentration against 9L cells was determined on day 3,12446,,,80653,Intermediate
1,,1,392.0,10116.0,5549,,,F,,,,Rattus norvegicus,9L,N,CHEMBL620381,BAO_0000219,Tested in vitro for anticancer activity against 9L cells,15345,,,80653,Expert
1,,1,392.0,10116.0,5550,,,F,,,,Rattus norvegicus,9L,N,CHEMBL620382,BAO_0000219,Tested in vitro for anticancer activity against 9L cells; Not determined,15345,,,80653,Expert
1,,1,646.0,9606.0,5551,,,F,,,,Homo sapiens,A549,N,CHEMBL620383,BAO_0000219,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,6301,,,80682,Intermediate
1,,1,646.0,9606.0,5552,,,F,,,,Homo sapiens,A549,N,CHEMBL876493,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,4833,,,80682,Intermediate
1,,1,646.0,9606.0,5553,,,F,,,,Homo sapiens,A549,N,CHEMBL620384,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,4833,,,80682,Intermediate
1,,1,646.0,9606.0,5554,,,F,,,,Homo sapiens,A549,N,CHEMBL620385,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,4833,,,80682,Intermediate
1,,1,646.0,9606.0,5555,,,F,,,,Homo sapiens,A549,N,CHEMBL620386,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line,13330,,,80682,Expert
9,,1,646.0,9606.0,5556,,,F,,,,Homo sapiens,A549,D,CHEMBL620387,BAO_0000219,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,17517,,,25,Expert
9,,1,646.0,9606.0,5557,,,F,,,,Homo sapiens,A549,D,CHEMBL621404,BAO_0000219,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",17517,,,25,Expert
1,,1,646.0,9606.0,5558,,,F,,,,Homo sapiens,A549,N,CHEMBL621405,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5559,,,F,,,,Homo sapiens,A549,N,CHEMBL621406,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma.",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5560,,,F,,,,Homo sapiens,A549,N,CHEMBL621407,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,5228,,,80682,Expert
1,,1,646.0,9606.0,5561,,,F,,,,Homo sapiens,A549,N,CHEMBL621408,BAO_0000219,Cytotoxic activity against human lung cancer A549 cell line was determined,5351,,,80682,Intermediate
1,,1,646.0,9606.0,5562,,,F,,,,Homo sapiens,A549,N,CHEMBL885345,BAO_0000219,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,12198,,,80682,Expert
1,,1,646.0,9606.0,5563,,,F,,,,Homo sapiens,A549,N,CHEMBL621409,BAO_0000219,Cytotoxicity concentration against human lung carcinoma A-549 cell line,13891,,,80682,Intermediate
1,,1,646.0,9606.0,5564,,,F,,,,Homo sapiens,A549,N,CHEMBL876034,BAO_0000219,Cytotoxicity in A549 (human carcinoma) cell line.,5677,,,80682,Expert
1,,1,646.0,9606.0,5565,,,F,,,,Homo sapiens,A549,N,CHEMBL621410,BAO_0000219,Cytotoxicity on lung carcinoma (A-549) cell line,13788,,,80682,Intermediate
1,,1,646.0,9606.0,5566,,,F,,,,Homo sapiens,A549,N,CHEMBL621411,BAO_0000219,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,13384,,,80682,Expert
1,,1,646.0,9606.0,5567,,,F,,,,Homo sapiens,A549,N,CHEMBL621412,BAO_0000219,Effective dose of compound against replication of A549 cell line was evaluated,6726,,,80682,Intermediate
1,,1,646.0,9606.0,5568,,,F,,,,Homo sapiens,A549,N,CHEMBL621413,BAO_0000219,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,3455,,,80682,Expert
1,,1,646.0,9606.0,5569,,,F,,,,Homo sapiens,A549,N,CHEMBL621414,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),5726,,,80682,Intermediate
1,,1,646.0,9606.0,5570,,,F,,,,Homo sapiens,A549,N,CHEMBL621415,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,5726,,,80682,Intermediate
1,,1,646.0,9606.0,5571,,,F,,,,Homo sapiens,A549,N,CHEMBL621416,BAO_0000219,The compound was evaluated for antiproliferative activity against A549 cell line,3936,,,80682,Intermediate
1,,1,646.0,9606.0,5572,,,F,,,,Homo sapiens,A549,N,CHEMBL621417,BAO_0000219,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,14991,,,80682,Intermediate
1,,1,646.0,9606.0,5573,,,F,,,,Homo sapiens,A549,N,CHEMBL621418,BAO_0000219,Concentration required for growth inhibition of human lung carcinoma cell line A549,5243,,,80682,Intermediate
1,,1,646.0,9606.0,5574,,,F,,,,Homo sapiens,A549,N,CHEMBL621419,BAO_0000219,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,12858,,,80682,Intermediate
1,,1,646.0,9606.0,5575,,,F,,,,Homo sapiens,A549,N,CHEMBL621420,BAO_0000219,Growth inhibition against A549 cell line was evaluated,6776,,,80682,Intermediate
1,,1,646.0,9606.0,5576,,,F,,,,Homo sapiens,A549,N,CHEMBL875823,BAO_0000219,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,16558,,,80682,Intermediate
1,,1,646.0,9606.0,5577,,,F,,,,Homo sapiens,A549,N,CHEMBL621421,BAO_0000219,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,4583,,,80682,Expert
1,,1,646.0,9606.0,5578,,,F,,,,Homo sapiens,A549,N,CHEMBL621422,BAO_0000219,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,13514,,,80682,Intermediate
1,,1,646.0,9606.0,5579,,,F,,,,Homo sapiens,A549,N,CHEMBL884014,BAO_0000219,Chemosensitivity against DT-diaphorase rich A549 cell lines,15166,,,80682,Expert
1,,1,646.0,9606.0,5580,,,F,,,,Homo sapiens,A549,N,CHEMBL621423,BAO_0000219,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,13873,,,80682,Intermediate
1,,1,646.0,9606.0,5581,,,F,,,,Homo sapiens,A549,N,CHEMBL621424,BAO_0000219,In vitro cytotoxicity against human A549 (lung cancer) cell line.,6447,,,80682,Expert
1,,1,646.0,9606.0,5582,,,F,,,,Homo sapiens,A549,N,CHEMBL621425,BAO_0000219,In vitro antitumor activity against A549 (lung) human tumor cell lines.,2068,,,80682,Intermediate
1,,1,646.0,9606.0,5583,,,F,,,,Homo sapiens,A549,N,CHEMBL621426,BAO_0000219,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1863,,,80682,Expert
1,,1,646.0,9606.0,5584,,,F,,,,Homo sapiens,A549,N,CHEMBL621427,BAO_0000219,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,13873,,,80682,Intermediate
1,,1,646.0,9606.0,5585,,,F,,,,Homo sapiens,A549,N,CHEMBL621428,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,13873,,,80682,Intermediate
1,,1,646.0,9606.0,5586,,,F,,,,Homo sapiens,A549,N,CHEMBL621429,BAO_0000219,Tested against A549 lung carcinoma in the sulforhodamine B assay.,13873,,,80682,Expert
1,,1,646.0,9606.0,5587,,,F,,,,Homo sapiens,A549,N,CHEMBL621430,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),579,,,80682,Intermediate
1,,1,646.0,9606.0,5588,,,F,,,,Homo sapiens,A549,N,CHEMBL621431,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,579,,,80682,Intermediate
1,,1,646.0,9606.0,5589,,,F,,,,Homo sapiens,A549,N,CHEMBL621432,BAO_0000219,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,4584,,,80682,Intermediate
1,,1,646.0,9606.0,5590,,,F,,,,Homo sapiens,A549,N,CHEMBL621433,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,5421,,,80682,Expert
1,,1,646.0,9606.0,5591,,,F,,,,Homo sapiens,A549,N,CHEMBL875824,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5592,,,F,,,,Homo sapiens,A549,N,CHEMBL621434,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5593,,,F,,,,Homo sapiens,A549,N,CHEMBL621435,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5594,,,F,,,,Homo sapiens,A549,N,CHEMBL621436,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,14188,,,80682,Intermediate
1,,1,646.0,9606.0,5595,,,F,,,,Homo sapiens,A549,N,CHEMBL621437,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,14188,,,80682,Intermediate
1,,1,646.0,9606.0,5596,,,F,,,,Homo sapiens,A549,N,CHEMBL621438,BAO_0000219,Compound was tested for the growth inhibition of A549 lung tumor cell line,15354,,,80682,Intermediate
1,,1,646.0,9606.0,5597,,,F,,,,Homo sapiens,A549,N,CHEMBL621439,BAO_0000219,Growth inhibition of human non-small-lung carcinoma (A549) cell line,14253,,,80682,Expert
1,,1,646.0,9606.0,5598,,,F,,,,Homo sapiens,A549,N,CHEMBL621440,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,13873,,,80682,Intermediate
1,,1,,9615.0,5599,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621441,BAO_0000218,Oral bioavailability in dog (conscious),3043,,,50588,Intermediate
1,,1,,9615.0,5600,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621442,BAO_0000218,Compound was evaluated for the oral bioavailability after oral administration in dog.,3045,,,50588,Intermediate
1,,1,,9615.0,5601,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621443,BAO_0000218,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,3022,,,50588,Intermediate
1,,1,,9615.0,5602,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621444,BAO_0000218,Oral bioavailability in dog,4453,,,50588,Intermediate
1,,1,,9615.0,5603,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625133,BAO_0000218,Oral bioavailability in dog,1696,,,50588,Intermediate
1,,1,,9615.0,5604,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625134,BAO_0000218,Oral bioavailability in dog,5045,,,50588,Intermediate
1,,1,,9615.0,5605,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625135,BAO_0000218,Oral bioavailability in dog (fasted),5356,,,50588,Intermediate
1,,1,,9615.0,5606,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625136,BAO_0000218,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,5607,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625137,BAO_0000218,Oral bioavailability in dog,6448,,,50588,Intermediate
1,,1,,9615.0,5608,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625138,BAO_0000218,Oral bioavailability in dog,1475,,,50588,Intermediate
1,,1,,9615.0,5609,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625139,BAO_0000218,Percent bioavailability in dog,3788,,,50588,Intermediate
1,,1,,9615.0,5610,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL872264,BAO_0000218,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,3639,,,50588,Intermediate
1,,1,,9615.0,5611,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625140,BAO_0000218,Oral bioavailability in dog,13397,,,50588,Intermediate
1,,1,,9615.0,5612,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624436,BAO_0000218,The compound was evaluated for bioavailability in dogs; 34-44,2137,,,50588,Intermediate
1,,1,,9615.0,5613,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624437,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),2959,,,50588,Intermediate
1,,1,,9615.0,5614,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL872261,BAO_0000218,Oral bioavailability in dog,6448,,,50588,Intermediate
1,,1,,9615.0,5615,,,A,,,,Canis lupus familiaris,,N,CHEMBL624438,BAO_0000218,8 hour trough Blood level in dog was measured after administration of compound,6084,,,50588,Intermediate
1,,1,,9615.0,5616,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624439,BAO_0000218,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,3639,,Plasma,50588,Intermediate
1,,1,,9615.0,5617,,,A,,,,Canis lupus familiaris,,N,CHEMBL624440,BAO_0000218,C24 after oral administration at 5 mg/kg,6316,,,50588,Intermediate
1,,1,,9615.0,5618,,,A,,,,Canis lupus familiaris,,N,CHEMBL624441,BAO_0000218,Clearance after oral and iv dosing in dogs,5238,,,50588,Intermediate
1,,1,,9615.0,5619,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624442,BAO_0000218,Clearance of the drug was measured in the plasma of dog,17796,,Plasma,50588,Intermediate
1,,1,,9615.0,5620,,,A,,,,Canis lupus familiaris,,N,CHEMBL624443,BAO_0000218,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,2652,,,50588,Intermediate
1,,1,,9615.0,5621,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624444,BAO_0000218,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,,,50588,Intermediate
1,,1,,9615.0,5622,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624445,BAO_0000218,Clearance of compound was determined in dogs,6621,,,50588,Intermediate
1,,1,,9615.0,5623,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624446,BAO_0000218,Clearance on i.v. administration of 2 mg/kg was measured in dog,6505,,,50588,Intermediate
1,,1,,9615.0,5624,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624447,BAO_0000218,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,,,50588,Intermediate
1,,1,,9615.0,5625,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624448,BAO_0000218,Plasma clearance in dog was determined,17267,,,50588,Intermediate
1,,1,,9615.0,5626,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624449,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,,,50588,Intermediate
1,,1,,9615.0,5627,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624450,BAO_0000218,Plasma clearance in dog after administration of 0.25 mg/kg iv,6535,,,50588,Intermediate
1,,1,,9615.0,5628,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875942,BAO_0000218,Plasma clearance in dog after administration of 1 mg/kg iv,6535,,,50588,Intermediate
1,,1,,9615.0,5629,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624451,BAO_0000218,Plasma clearance in dogs,6535,,,50588,Intermediate
1,,1,,9615.0,5630,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624452,BAO_0000218,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,5542,,,50588,Intermediate
1,,1,,9615.0,5631,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624453,BAO_0000218,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,5199,,,50588,Intermediate
1,,1,,9615.0,5632,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624454,BAO_0000218,Plasma clearance after 15 mg/kg iv dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,5633,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624455,BAO_0000218,Plasma clearance after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,5634,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624456,BAO_0000218,Plasma administration to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,5635,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624457,BAO_0000218,Plasma clearance was determined,5505,,,50588,Intermediate
1,,1,,9615.0,5636,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624458,BAO_0000218,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,6215,,,50588,Intermediate
1,,1,,9615.0,5637,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624459,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1466,,,50588,Intermediate
2,,1,,9606.0,5638,,In vitro,A,2107.0,,,Homo sapiens,,S,CHEMBL624460,BAO_0000251,Intrinsic clearance in human liver microsomes,5007,Microsomes,Liver,102164,Intermediate
2,,1,,9606.0,5639,,In vitro,A,2107.0,,,Homo sapiens,,S,CHEMBL624461,BAO_0000251,Intrinsic clearance in human liver microsomes,5007,Microsomes,Liver,102164,Intermediate
1,,1,,9615.0,5640,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875943,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,,,50588,Intermediate
1,,1,,9615.0,5641,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624462,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,,,50588,Intermediate
1,,1,,9615.0,5642,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624463,BAO_0000218,Clearance in dog (dose 1 mg/kg i.v.),16452,,,50588,Intermediate
1,,1,,9615.0,5643,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624464,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,6221,,,50588,Intermediate
1,,1,,9615.0,5644,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624465,BAO_0000218,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,,,50588,Intermediate
1,,1,,9615.0,5645,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624466,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5646,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624467,BAO_0000218,Plasma clearance after peroral administration at 5 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5647,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624468,BAO_0000218,Plasma clearance after peroral administration at 5 mg/kg in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5648,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624469,BAO_0000218,Plasma clearance was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,5649,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624470,BAO_0000218,Plasma clearance was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,5650,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624471,BAO_0000218,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,5983,,,50588,Intermediate
1,,1,,9615.0,5651,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624472,BAO_0000218,Total clearance was determined after 0.1 mg/kg iv administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,5652,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622775,BAO_0000218,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,5653,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622776,BAO_0000218,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,5654,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622777,BAO_0000218,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,5655,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622778,BAO_0000218,Clearance after peroral administration of 0.2 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,5656,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622779,BAO_0000218,Clearance by intravenous administration of 1.2 mg/kg in dog,4368,,,50588,Intermediate
1,,1,,9615.0,5657,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622780,BAO_0000218,Clearance by iv administration in dogs at a dose of 1 mg/kg,4305,,,50588,Intermediate
1,,1,,9615.0,5658,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622781,BAO_0000218,Clearance value was evaluated in dog plasma,1918,,Plasma,50588,Intermediate
1,,1,,9615.0,5659,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622782,BAO_0000218,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,6005,,,50588,Intermediate
1,,1,,9615.0,5660,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622783,BAO_0000218,Compound was tested for plasma clearance in dog,4839,,Plasma,50588,Intermediate
1,,1,,9615.0,5661,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622784,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in dog,4239,,,50588,Intermediate
1,,1,,10090.0,5662,,,A,,,,Mus musculus,,N,CHEMBL622785,BAO_0000218,Area under curve when injected perorally in mice at a dose of 50 mg/kg,17729,,,50594,Intermediate
1,,1,,10090.0,5663,,,A,,,,Mus musculus,,N,CHEMBL622786,BAO_0000218,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,17728,,,50594,Intermediate
1,,1,,10090.0,5664,,,A,,,,Mus musculus,,N,CHEMBL622787,BAO_0000218,Area under curve value in mouse at a dose of 10 mg/kg,5302,,,50594,Intermediate
1,,1,,10090.0,5665,,,A,,,,Mus musculus,,N,CHEMBL875949,BAO_0000218,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,5666,,,A,,,,Mus musculus,,N,CHEMBL622788,BAO_0000218,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,5667,,,F,,,,Mus musculus,,N,CHEMBL622789,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,5668,,,F,,,,Mus musculus,,N,CHEMBL622790,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,5669,,,F,,,,Mus musculus,,N,CHEMBL622791,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,5670,,,F,,,,Mus musculus,,N,CHEMBL622792,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,5671,,,A,,,,Mus musculus,,N,CHEMBL622793,BAO_0000218,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,5672,,,A,,,,Mus musculus,,N,CHEMBL622794,BAO_0000218,Area under curve was determined for the compound at 24 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,5673,,,A,,,,Mus musculus,,N,CHEMBL622795,BAO_0000218,Area under curve was determined for the compound at 40 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,5674,,,A,,,,Mus musculus,,N,CHEMBL621803,BAO_0000218,Area under curve was determined for the compound at 5 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,5675,,,A,,,,Mus musculus,,N,CHEMBL621804,BAO_0000218,Area under the curve for the compound is obtained at dose 25 mg/kg,3132,,,50594,Intermediate
1,,1,,10090.0,5676,,,A,,,,Mus musculus,,N,CHEMBL621805,BAO_0000218,Area under the curve for the compound was obtained when tested in mouse,3132,,,50594,Intermediate
1,,1,,10090.0,5677,,,A,,,,Mus musculus,,N,CHEMBL621806,BAO_0000218,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,17837,,,50594,Intermediate
1,,1,,10090.0,5678,,,A,,,,Mus musculus,,N,CHEMBL621807,BAO_0000218,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,17837,,,50594,Intermediate
1,,1,,10090.0,5679,,,A,,,,Mus musculus,,N,CHEMBL621808,BAO_0000218,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,6062,,,50594,Intermediate
1,,1,,10090.0,5680,,,A,,,,Mus musculus,,N,CHEMBL621809,BAO_0000218,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,4066,,,50594,Intermediate
1,,1,,10090.0,5681,,,A,,,,Mus musculus,,N,CHEMBL621810,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),16597,,,50594,Intermediate
1,,1,,10090.0,5682,,,A,,,,Mus musculus,,N,CHEMBL875164,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,14239,,,50594,Intermediate
1,,1,,10090.0,5683,,,A,,,,Mus musculus,,N,CHEMBL621811,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,14239,,,50594,Intermediate
1,,1,,10090.0,5684,,,A,,,,Mus musculus,,N,CHEMBL621812,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, area under curve",4890,,,50594,Intermediate
1,,1,,10090.0,5685,,,A,,,,Mus musculus,,N,CHEMBL621813,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),429,,,50594,Intermediate
1,,1,,10090.0,5686,,,A,,,,Mus musculus,,N,CHEMBL621814,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),429,,,50594,Intermediate
1,,1,,10090.0,5687,,,A,,,,Mus musculus,,N,CHEMBL621815,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,5688,,,A,,,,Mus musculus,,N,CHEMBL621816,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,5689,,,A,,,,Mus musculus,,N,CHEMBL621817,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,,,50594,Intermediate
1,,1,,10090.0,5690,,,A,,,,Mus musculus,,N,CHEMBL621818,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,6091,,,50594,Intermediate
1,,1,,10090.0,5691,,,A,,,,Mus musculus,,N,CHEMBL621819,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,6091,,,50594,Intermediate
1,,1,,10090.0,5692,,,A,,,,Mus musculus,,N,CHEMBL621820,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,6091,,,50594,Intermediate
1,,1,,10090.0,5693,,,A,,,,Mus musculus,,N,CHEMBL621821,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,6091,,,50594,Intermediate
1,,1,,10090.0,5694,,,A,,,,Mus musculus,,N,CHEMBL621822,BAO_0000218,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,6178,,,50594,Intermediate
1,,1,,10090.0,5695,,,A,,,,Mus musculus,,N,CHEMBL619474,BAO_0000218,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,6178,,,50594,Intermediate
1,,1,,10090.0,5696,,,A,,,,Mus musculus,,N,CHEMBL619475,BAO_0000218,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",6619,,,50594,Intermediate
1,,1,,10090.0,5697,,,A,,,,Mus musculus,,N,CHEMBL619476,BAO_0000218,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",6619,,,50594,Intermediate
1,,1,,10090.0,5698,,,A,,,,Mus musculus,,N,CHEMBL619477,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",3760,,,50594,Intermediate
1,,1,,10090.0,5699,,,A,,,,Mus musculus,,N,CHEMBL619478,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",3760,,,50594,Intermediate
1,,1,,10090.0,5700,,,A,,,,Mus musculus,,N,CHEMBL619479,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",3760,,,50594,Intermediate
1,,1,,10090.0,5701,,,A,,,,Mus musculus,,N,CHEMBL619480,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",3760,,,50594,Intermediate
1,,1,,10090.0,5702,,,A,,,,Mus musculus,,N,CHEMBL619481,BAO_0000218,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,3192,,,50594,Intermediate
1,,1,,10090.0,5703,,,A,,,,Mus musculus,,N,CHEMBL619482,BAO_0000218,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,3192,,,50594,Intermediate
1,,1,,10090.0,5704,,,A,,,,Mus musculus,,N,CHEMBL619483,BAO_0000218,Area under the curve was evaluated in mice after intravenous administration,2675,,,50594,Intermediate
1,,1,,10090.0,5705,,,A,,,,Mus musculus,,N,CHEMBL619484,BAO_0000218,Area under the curve was evaluated in mice after oral administration,2675,,,50594,Intermediate
1,,1,,10090.0,5706,,,A,1969.0,,,Mus musculus,,N,CHEMBL619485,BAO_0000218,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,16597,,Plasma,50594,Intermediate
1,,1,,10090.0,5707,,,A,1969.0,,,Mus musculus,,N,CHEMBL619486,BAO_0000218,AUC total value at a dose of 10 mg/kg peroral administration in mice.,16597,,Plasma,50594,Intermediate
1,,1,,10090.0,5708,,,A,,,,Mus musculus,,N,CHEMBL619487,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),16597,,,50594,Intermediate
1,,1,,10090.0,5709,,,A,,,,Mus musculus,,N,CHEMBL619488,BAO_0000218,AUMC after intraperitoneal administration of 100 mg/kg in mice,17734,,,50594,Intermediate
1,,1,,10090.0,5710,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL620106,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,7767,,Blood,50594,Intermediate
1,,1,392.0,,5711,,,F,,,,,9L,N,CHEMBL620107,BAO_0000219,The compound was tested in vitro for anticancer activity against 9L cells,15345,,,80653,Intermediate
0,,1,,10116.0,5712,,,F,,,,Rattus norvegicus,,U,CHEMBL620283,BAO_0000019,Anti proliferation activity determined; Weak effect,2181,,,22226,Autocuration
0,,1,,10116.0,5713,,,F,,,,Rattus norvegicus,,U,CHEMBL875176,BAO_0000219,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,2181,,,22226,Autocuration
0,,1,,10116.0,5714,,,F,,,,Rattus norvegicus,,U,CHEMBL620284,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,2181,,,22226,Autocuration
0,,1,,10116.0,5715,,,F,,,,Rattus norvegicus,,U,CHEMBL623515,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,2181,,,22226,Autocuration
0,,1,,10090.0,5716,,,F,,,,Mus musculus,,U,CHEMBL623516,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method,10486,,,22226,Autocuration
0,,1,,10090.0,5717,,,F,,,,Mus musculus,,U,CHEMBL623517,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method.,10486,,,22226,Autocuration
0,,1,,,5718,,,A,,,,,,U,CHEMBL857878,BAO_0000019,Partition coefficient (logD6.5),15508,,,22224,Autocuration
1,,1,478.0,9606.0,5719,,,F,,,,Homo sapiens,A2780,N,CHEMBL623518,BAO_0000219,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,5242,,,81034,Expert
1,,1,455.0,9606.0,5720,,,F,,,,Homo sapiens,A-375,N,CHEMBL624195,BAO_0000219,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),16167,,,80018,Intermediate
1,,1,500.0,9606.0,5721,,,F,,,,Homo sapiens,A-431,N,CHEMBL624196,BAO_0000219,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,4782,,,80852,Expert
9,,1,500.0,9606.0,5722,,,F,,,,Homo sapiens,A-431,D,CHEMBL624197,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,16093,,,9,Expert
1,,1,624.0,9606.0,5723,,,F,,,,Homo sapiens,A498,N,CHEMBL624198,BAO_0000219,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,2596,,,80021,Intermediate
1,,1,624.0,9606.0,5724,,,F,,,,Homo sapiens,A498,N,CHEMBL621287,BAO_0000219,in vitro cytotoxicity against A 498 cancer cell line,2596,,,80021,Intermediate
1,,1,624.0,9606.0,5725,,,F,,,,Homo sapiens,A498,N,CHEMBL621288,BAO_0000219,In vitro cytotoxic activity against renal (A 498) cancer cell line.,3239,,,80021,Intermediate
1,,1,624.0,9606.0,5726,,,F,,,,Homo sapiens,A498,N,CHEMBL876496,BAO_0000219,Cytotoxic activity against A 498 renal cancer cell lines.,1847,,,80021,Intermediate
1,,1,624.0,9606.0,5727,,,F,,,,Homo sapiens,A498,N,CHEMBL621289,BAO_0000219,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,10553,,,80021,Intermediate
0,,1,,1280.0,5728,,,F,,,,Staphylococcus aureus,,U,CHEMBL621290,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,16219,,,22226,Autocuration
0,,1,,1280.0,5729,,,F,,,,Staphylococcus aureus,,U,CHEMBL621291,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,16219,,,22226,Autocuration
0,,1,,1280.0,5730,,,F,,,,Staphylococcus aureus,,U,CHEMBL621292,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,16219,,,22226,Autocuration
0,,1,,1280.0,5731,,,F,,,,Staphylococcus aureus,,U,CHEMBL621293,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,16219,,,22226,Autocuration
1,,1,646.0,9606.0,5732,,,F,,,,Homo sapiens,A549,N,CHEMBL621294,BAO_0000219,Inhibitory concentration required against A 549 lung cancer cell line,4782,,,80682,Intermediate
1,,1,646.0,9606.0,5733,,,F,,,,Homo sapiens,A549,N,CHEMBL621295,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,11805,,,80682,Intermediate
1,,1,646.0,9606.0,5734,,,F,,,,Homo sapiens,A549,N,CHEMBL884007,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,11805,,,80682,Intermediate
1,,1,646.0,9606.0,5735,,,F,,,,Homo sapiens,A549,N,CHEMBL621296,BAO_0000219,In vitro cytotoxicity against lung cancer A 549 cell lines,2007,,,80682,Intermediate
1,,1,646.0,9606.0,5736,,,F,,,,Homo sapiens,A549,N,CHEMBL621297,BAO_0000219,Compound was tested for its cytotoxicity against A 549 cell line,4594,,,80682,Intermediate
1,,1,646.0,9606.0,5737,,,F,,,,Homo sapiens,A549,N,CHEMBL839828,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",6018,,,80682,Expert
1,,1,646.0,9606.0,5738,,,F,,,,Homo sapiens,A549,N,CHEMBL620397,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",6018,,,80682,Intermediate
1,,1,646.0,9606.0,5739,,,F,,,,Homo sapiens,A549,N,CHEMBL620398,BAO_0000219,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,3599,,,80682,Expert
1,,1,646.0,9606.0,5740,,,F,,,,Homo sapiens,A549,N,CHEMBL620399,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,2551,,,80682,Intermediate
1,,1,646.0,9606.0,5741,,,F,,,,Homo sapiens,A549,N,CHEMBL620400,BAO_0000219,In vitro inhibition of A549 (human lung cancer) cell growth.,16132,,,80682,Expert
1,,1,646.0,9606.0,5742,,,F,,,,Homo sapiens,A549,N,CHEMBL620401,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,16132,,,80682,Intermediate
1,,1,646.0,9606.0,5743,,,F,,,,Homo sapiens,A549,N,CHEMBL620402,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,2551,,,80682,Expert
1,,1,646.0,9606.0,5744,,,F,,,,Homo sapiens,A549,N,CHEMBL620403,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),2551,,,80682,Expert
0,,1,,,5745,,,F,,,,,,U,CHEMBL620404,BAO_0000218,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,11913,,,22226,Autocuration
4,,1,,,5746,,In vivo,F,,,,,,H,CHEMBL620405,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,12621,,,104694,Autocuration
4,,1,,,5747,,In vivo,F,,,,,,H,CHEMBL620406,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,12621,,,104694,Autocuration
4,,1,,,5748,,In vivo,F,,,,,,H,CHEMBL620407,BAO_0000218,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,12621,,,104694,Autocuration
4,,1,,,5749,,In vivo,F,,,,,,H,CHEMBL620408,BAO_0000218,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,12621,,,104694,Autocuration
4,,1,,,5750,,In vivo,F,,,,,,H,CHEMBL620409,BAO_0000218,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,12621,,,104694,Autocuration
1,,1,624.0,9606.0,5751,,,F,,,,Homo sapiens,A498,N,CHEMBL620410,BAO_0000219,Inhibition of A-498 human Renal cell proliferation,3600,,,80021,Expert
0,,1,,10116.0,5752,,,F,,,,Rattus norvegicus,,U,CHEMBL620411,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1796,,,22226,Autocuration
0,,1,,10116.0,5753,,,F,,,,Rattus norvegicus,,U,CHEMBL620412,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1796,,,22226,Autocuration
0,,1,,10116.0,5754,,,F,,,,Rattus norvegicus,,U,CHEMBL876596,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1796,,,22226,Autocuration
1,,1,622.0,9606.0,5755,,,F,,,,Homo sapiens,A 172,N,CHEMBL620413,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,16464,,,80012,Expert
1,,1,622.0,9606.0,5756,,,F,,,,Homo sapiens,A 172,N,CHEMBL620414,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80012,Intermediate
1,,1,622.0,9606.0,5757,,,F,,,,Homo sapiens,A 172,N,CHEMBL620415,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80012,Intermediate
1,,1,646.0,9606.0,5758,,,F,,,,Homo sapiens,A549,N,CHEMBL620416,BAO_0000219,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,13617,,,80682,Expert
1,,1,646.0,9606.0,5759,,,F,,,,Homo sapiens,A549,N,CHEMBL620417,BAO_0000219,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,4584,,,80682,Intermediate
1,,1,646.0,9606.0,5760,,,F,,,,Homo sapiens,A549,N,CHEMBL620418,BAO_0000219,Cytotoxic activity evaluated against A549 tumor cells,13799,,,80682,Expert
1,,1,646.0,9606.0,5761,,,F,,,,Homo sapiens,A549,N,CHEMBL620419,BAO_0000219,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,16726,,,80682,Intermediate
1,,1,646.0,9606.0,5762,,,F,,,,Homo sapiens,A549,N,CHEMBL620420,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,16109,,,80682,Intermediate
1,,1,646.0,9606.0,5763,,,F,,,,Homo sapiens,A549,N,CHEMBL620421,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,16109,,,80682,Intermediate
1,,1,646.0,9606.0,5764,,,F,,,,Homo sapiens,A549,N,CHEMBL620422,BAO_0000219,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,15474,,,80682,Intermediate
1,,1,646.0,9606.0,5765,,,F,,,,Homo sapiens,A549,N,CHEMBL620423,BAO_0000219,Cytotoxicity of compound against A549 cell line,6851,,,80682,Intermediate
1,,1,646.0,9606.0,5766,,,F,,,,Homo sapiens,A549,N,CHEMBL620424,BAO_0000219,Cytotoxicity against human lung cell carcinoma A549 cell line,17534,,,80682,Expert
1,,1,646.0,9606.0,5767,,,F,,,,Homo sapiens,A549,N,CHEMBL620425,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,2621,,,80682,Intermediate
1,,1,646.0,9606.0,5768,,,F,,,,Homo sapiens,A549,N,CHEMBL620426,BAO_0000219,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,830,,,80682,Intermediate
1,,1,646.0,9606.0,5769,,,F,,,,Homo sapiens,A549,N,CHEMBL620427,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,14255,,,80682,Intermediate
1,,1,646.0,9606.0,5770,,,F,,,,Homo sapiens,A549,N,CHEMBL620428,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,14255,,,80682,Intermediate
1,,1,646.0,9606.0,5771,,,F,,,,Homo sapiens,A549,N,CHEMBL620429,BAO_0000219,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1590,,,80682,Intermediate
1,,1,646.0,9606.0,5772,,,F,,,,Homo sapiens,A549,N,CHEMBL620430,BAO_0000219,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,6146,,,80682,Expert
1,,1,646.0,9606.0,5773,,,F,,,,Homo sapiens,A549,N,CHEMBL839887,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,17427,,,80682,Expert
1,,1,646.0,9606.0,5774,,,F,,,,Homo sapiens,A549,N,CHEMBL620431,BAO_0000219,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,5280,,,80682,Intermediate
1,,1,646.0,9606.0,5775,,,F,,,,Homo sapiens,A549,N,CHEMBL884010,BAO_0000219,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,16786,,,80682,Intermediate
1,,1,646.0,9606.0,5776,,,F,,,,Homo sapiens,A549,N,CHEMBL620538,BAO_0000219,In vitro cytotoxicity against A549 (human lung cancer),5895,,,80682,Intermediate
1,,1,646.0,9606.0,5777,,,F,,,,Homo sapiens,A549,N,CHEMBL620539,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,14297,,,80682,Expert
1,,1,646.0,9606.0,5778,,,F,,,,Homo sapiens,A549,N,CHEMBL623373,BAO_0000218,In vivo antiproliferative activity against A549 cell line,17824,,,80682,Intermediate
1,,1,646.0,9606.0,5779,,,F,,,,Homo sapiens,A549,N,CHEMBL623374,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549),14368,,,80682,Intermediate
1,,1,646.0,9606.0,5780,,,F,,,,Homo sapiens,A549,N,CHEMBL623375,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,14368,,,80682,Intermediate
1,,1,646.0,9606.0,5781,,,F,,,,Homo sapiens,A549,N,CHEMBL623376,BAO_0000219,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,14254,,,80682,Intermediate
1,,1,646.0,9606.0,5782,,,F,,,,Homo sapiens,A549,N,CHEMBL623377,BAO_0000219,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),15897,,,80682,Intermediate
1,,1,646.0,9606.0,5783,,,F,,,,Homo sapiens,A549,N,CHEMBL623378,BAO_0000219,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,13866,,,80682,Intermediate
1,,1,646.0,9606.0,5784,,,F,,,,Homo sapiens,A549,N,CHEMBL623379,BAO_0000219,Inhibitory activity of compound against human A549 lung carcinoma cell line.,13370,,,80682,Intermediate
1,,1,646.0,9606.0,5785,,,F,,,,Homo sapiens,A549,N,CHEMBL623380,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,4862,,,80682,Intermediate
1,,1,646.0,9606.0,5786,,,F,,,,Homo sapiens,A549,N,CHEMBL623381,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,4862,,,80682,Intermediate
1,,1,646.0,9606.0,5787,,,F,,,,Homo sapiens,A549,N,CHEMBL623382,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,4862,,,80682,Intermediate
1,,1,646.0,9606.0,5788,,,F,,,,Homo sapiens,A549,N,CHEMBL623383,BAO_0000219,Inhibitory concentration against A549 (lung cancer) cell line,15970,,,80682,Intermediate
1,,1,646.0,9606.0,5789,,,F,,,,Homo sapiens,A549,N,CHEMBL623384,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,17713,,,80682,Expert
1,,1,646.0,9606.0,5790,,,F,,,,Homo sapiens,A549,N,CHEMBL623385,BAO_0000219,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,4833,,,80682,Intermediate
1,,1,646.0,9606.0,5791,,,F,,,,Homo sapiens,A549,N,CHEMBL623386,BAO_0000219,Activity against A549 cancer cell line.,13736,,,80682,Expert
1,,1,646.0,9606.0,5792,,,F,,,,Homo sapiens,A549,N,CHEMBL884105,BAO_0000219,The compound was evaluated for cytotoxicity against A549 cell line,4312,,,80682,Intermediate
1,,1,646.0,9606.0,5793,,,F,,,,Homo sapiens,A549,N,CHEMBL623387,BAO_0000219,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5794,,,F,,,,Homo sapiens,A549,N,CHEMBL621568,BAO_0000219,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5795,,,F,,,,Homo sapiens,A549,N,CHEMBL621569,BAO_0000219,Growth inhibitory activity was measured for human A549 tumor cell line.,14717,,,80682,Intermediate
1,,1,646.0,9606.0,5796,,,F,,,,Homo sapiens,A549,N,CHEMBL621570,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,4634,,,80682,Intermediate
1,,1,646.0,9606.0,5797,,,F,,,,Homo sapiens,A549,N,CHEMBL621571,BAO_0000219,Inhibitory activity against A549 cell line; inactive,1149,,,80682,Intermediate
1,,1,646.0,9606.0,5798,,,F,,,,Homo sapiens,A549,N,CHEMBL621572,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,5421,,,80682,Expert
1,,1,646.0,9606.0,5799,,,F,,,,Homo sapiens,A549,N,CHEMBL621573,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,5421,,,80682,Expert
1,,1,646.0,9606.0,5800,,,F,,,,Homo sapiens,A549,N,CHEMBL621574,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,5421,,,80682,Intermediate
1,,1,646.0,9606.0,5801,,,F,,,,Homo sapiens,A549,N,CHEMBL621575,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),3320,,,80682,Intermediate
1,,1,646.0,9606.0,5802,,,F,,,,Homo sapiens,A549,N,CHEMBL621576,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),3320,,,80682,Intermediate
1,,1,646.0,9606.0,5803,,,F,,,,Homo sapiens,A549,N,CHEMBL621577,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),3320,,,80682,Intermediate
1,,1,646.0,9606.0,5804,,,F,,,,Homo sapiens,A549,N,CHEMBL621578,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),3320,,,80682,Intermediate
1,,1,646.0,9606.0,5805,,,F,,,,Homo sapiens,A549,N,CHEMBL621579,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),3320,,,80682,Intermediate
1,,1,646.0,9606.0,5806,,,F,,,,Homo sapiens,A549,N,CHEMBL621580,BAO_0000219,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,5726,,,80682,Intermediate
1,,1,,9615.0,5807,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621581,BAO_0000218,Plasma clearance (in vivo) in mongrel dogs was determined,17800,,,50588,Intermediate
1,,1,,9615.0,5808,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621582,BAO_0000218,Plasma clearance was measured in dog,5985,,,50588,Intermediate
1,,1,,9615.0,5809,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621583,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,5530,,,50588,Intermediate
1,,1,,9615.0,5810,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621584,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,5530,,,50588,Intermediate
1,,1,,9615.0,5811,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621585,BAO_0000218,Tested for plasma clearance in dog,4839,,Plasma,50588,Intermediate
1,,1,,9615.0,5812,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621586,BAO_0000218,The compound was tested for clearance in dog plasma.,3639,,,50588,Intermediate
1,,1,,9615.0,5813,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875835,BAO_0000218,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",4838,,,50588,Intermediate
1,,1,,9615.0,5814,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621587,BAO_0000218,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,4137,,,50588,Intermediate
1,,1,,9615.0,5815,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621588,BAO_0000218,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),5017,,Plasma,50588,Intermediate
1,,1,,9615.0,5816,,In vitro,A,2107.0,,,Canis lupus familiaris,,N,CHEMBL621589,BAO_0000218,In vitro clearance in dog liver microsomes,17538,Microsomes,Liver,50588,Intermediate
1,,1,,9615.0,5817,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621590,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,6161,,,50588,Intermediate
1,,1,,9615.0,5818,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621591,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,6161,,,50588,Intermediate
1,,1,,9615.0,5819,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621592,BAO_0000218,Plasma clearance in dog,1696,,,50588,Intermediate
1,,1,,9615.0,5820,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621593,BAO_0000218,Clearance rate in dog,6762,,,50588,Intermediate
1,,1,,9615.0,5821,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621594,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,5932,,Plasma,50588,Intermediate
1,,1,,9615.0,5822,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621595,BAO_0000218,Clearance in dogs,6305,,,50588,Intermediate
1,,1,,9615.0,5823,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621596,BAO_0000218,Plasma clearance in dogs,4942,,,50588,Intermediate
1,,1,,9615.0,5824,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621597,BAO_0000218,Plasma clearance was determined,4219,,,50588,Intermediate
1,,1,,9615.0,5825,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621598,BAO_0000218,Lower clearance in dog (i.v.) at 0.5 mpk,17853,,,50588,Intermediate
1,,1,,9615.0,5826,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621599,BAO_0000218,Plasma clearance in Beagle dogs,4514,,,50588,Intermediate
1,,1,,9615.0,5827,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875836,BAO_0000218,Plasma clearance (Clp) in dog,6448,,,50588,Intermediate
1,,1,,9615.0,5828,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621600,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,6227,,,50588,Intermediate
1,,1,,9615.0,5829,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621601,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog was determined,6227,,,50588,Intermediate
1,,1,,9615.0,5830,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618474,BAO_0000218,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,6062,,,50588,Intermediate
1,,1,,9615.0,5831,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618475,BAO_0000218,Plasma clearance of compound was determined in dog,6821,,,50588,Intermediate
1,,1,,9615.0,5832,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624524,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,5833,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624525,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,,,50588,Intermediate
1,,1,,9615.0,5834,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624526,BAO_0000218,Plasma clearance in dog was determined,5374,,,50588,Intermediate
1,,1,,9615.0,5835,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624527,BAO_0000218,Plasma clearance was calculated in dog,6057,,,50588,Intermediate
1,,1,,9615.0,5836,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624528,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in dog,4727,,,50588,Intermediate
1,,1,,9615.0,5837,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624529,BAO_0000218,Plasma clearance in dog,5145,,,50588,Intermediate
1,,1,,9615.0,5838,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624530,BAO_0000218,Plasma clearance in dog,17657,,,50588,Intermediate
1,,1,,9615.0,5839,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624531,BAO_0000218,Plasma clearance in dog; Unable to calculate,17657,,,50588,Intermediate
1,,1,,9615.0,5840,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624532,BAO_0000218,Plasma clearance in rhesus monkey,5145,,,50588,Intermediate
1,,1,,9615.0,5841,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624533,BAO_0000218,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,,,50588,Intermediate
1,,1,,9615.0,5842,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624534,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,50588,Intermediate
1,,1,,9615.0,5843,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624535,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,,,50588,Intermediate
1,,1,,9615.0,5844,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624536,BAO_0000218,Plasma clearance was evaluated in dog,5472,,,50588,Intermediate
1,,1,,9615.0,5845,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624537,BAO_0000218,Plasma clearance was evaluated in dog; Not tested,5472,,,50588,Intermediate
1,,1,,9615.0,5846,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624538,BAO_0000218,Plasma clearance was evaluated in rhesus,5472,,,50588,Intermediate
1,,1,,9615.0,5847,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624539,BAO_0000218,Plasma clearance was evaluated in rhesus; Not tested,5472,,,50588,Intermediate
1,,1,,9615.0,5848,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624540,BAO_0000218,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,4257,,,50588,Intermediate
1,,1,,9615.0,5849,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624541,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,,,50588,Intermediate
1,,1,,9615.0,5850,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624542,BAO_0000218,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,,,50588,Intermediate
1,,1,,9615.0,5851,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624543,BAO_0000218,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,,50588,Intermediate
1,,1,,9615.0,5852,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624544,BAO_0000218,Clearance value at a dose of 0.2 mg/kg i.v.,5474,,,50588,Intermediate
1,,1,,9615.0,5853,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624545,BAO_0000218,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,6316,,Plasma,50588,Intermediate
1,,1,,9615.0,5854,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624546,BAO_0000218,Cmax after oral dose of compound at 3 mg/kg in dogs,17594,,,50588,Intermediate
1,,1,,9615.0,5855,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875957,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in dogs,17594,,,50588,Intermediate
1,,1,,9615.0,5856,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624547,BAO_0000218,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,,,50588,Intermediate
1,,1,,9615.0,5857,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624548,BAO_0000218,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,6535,,,50588,Intermediate
1,,1,,9615.0,5858,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624549,BAO_0000218,Cmax in dog after administration of 1 mg/kg iv,6535,,,50588,Intermediate
1,,1,,9615.0,5859,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624550,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1466,,Plasma,50588,Intermediate
1,,1,,9615.0,5860,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621613,BAO_0000218,Cmax on p.o. administration of 10 mg/kg was measured in dog,6505,,,50588,Intermediate
1,,1,,9615.0,5861,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621614,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5862,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623431,BAO_0000218,Cmax was determine after peroral administration at 5 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5863,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623432,BAO_0000218,Cmax was determine after peroral administration at 5 mg/kg in dog,5668,,,50588,Intermediate
1,,1,,9615.0,5864,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623433,BAO_0000218,Cmax after 0.3 mg/kg po administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,5865,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623434,BAO_0000218,Cmax after peroral administration in dogs at 2.4 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,5866,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623435,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg,6123,,,50588,Intermediate
1,,1,,9615.0,5867,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623436,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,6123,,,50588,Intermediate
1,,1,,9615.0,5868,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875958,BAO_0000218,Cmax upon oral administration in male Beagle dog at 10 mg/kg,6757,,,50588,Intermediate
1,,1,,9615.0,5869,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623437,BAO_0000218,Cmax value after 15 mg/kg iv dose in Dogs,16907,,,50588,Intermediate
1,,1,,10090.0,5870,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL623438,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Blood,50594,Intermediate
1,,1,,10090.0,5871,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL623439,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Blood,50594,Intermediate
1,,1,,10090.0,5872,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL623440,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Bone,50594,Intermediate
1,,1,,10090.0,5873,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL623441,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Bone,50594,Intermediate
1,,1,,10090.0,5874,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL623442,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Bone,50594,Intermediate
1,,1,,10090.0,5875,,In vivo,A,,,,Mus musculus,,N,CHEMBL623469,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5876,,In vivo,A,,,,Mus musculus,,N,CHEMBL623470,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5877,,In vivo,A,,,,Mus musculus,,N,CHEMBL623471,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5878,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL623472,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Heart,50594,Intermediate
1,,1,,10090.0,5879,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL623473,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Heart,50594,Intermediate
1,,1,,10090.0,5880,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL623474,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Heart,50594,Intermediate
1,,1,,10090.0,5881,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623475,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Kidney,50594,Intermediate
1,,1,,10090.0,5882,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623476,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Kidney,50594,Intermediate
1,,1,,10090.0,5883,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623477,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Kidney,50594,Intermediate
1,,1,,10090.0,5884,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL621896,BAO_0000218,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5885,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL621897,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5886,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL621898,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5887,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621899,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Liver,50594,Intermediate
1,,1,,10090.0,5888,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621900,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Liver,50594,Intermediate
1,,1,,10090.0,5889,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621901,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Liver,50594,Intermediate
1,,1,,10090.0,5890,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL621902,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Lung,50594,Intermediate
1,,1,,10090.0,5891,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL621903,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Lung,50594,Intermediate
1,,1,,10090.0,5892,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL622587,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Lung,50594,Intermediate
1,,1,,10090.0,5893,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL620285,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,5894,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL875285,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,5895,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL620286,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,5896,,In vivo,A,,,,Mus musculus,,N,CHEMBL620287,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5897,,In vivo,A,,,,Mus musculus,,N,CHEMBL620288,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5898,,In vivo,A,,,,Mus musculus,,N,CHEMBL620289,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,,50594,Intermediate
1,,1,,10090.0,5899,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL620290,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5900,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL620291,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5901,,In vivo,A,160.0,,,Mus musculus,,N,CHEMBL620292,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Intestine,50594,Intermediate
1,,1,,10090.0,5902,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL620293,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Spleen,50594,Intermediate
1,,1,,10090.0,5903,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL620294,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Spleen,50594,Intermediate
1,,1,,10090.0,5904,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618614,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Spleen,50594,Intermediate
1,,1,,10090.0,5905,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL618615,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Stomach,50594,Intermediate
1,,1,,10090.0,5906,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL618616,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,,Stomach,50594,Intermediate
1,,1,622.0,9606.0,5907,,,F,,,,Homo sapiens,A 172,N,CHEMBL618617,BAO_0000219,Cytotoxicity against A-172 human tumor cell lines,2036,,,80012,Expert
1,,1,622.0,9606.0,5908,,,F,,,,Homo sapiens,A 172,N,CHEMBL618618,BAO_0000219,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,2357,,,80012,Intermediate
1,,1,623.0,9606.0,5909,,,F,,,,Homo sapiens,A204,N,CHEMBL618619,BAO_0000219,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1457,,,80014,Intermediate
1,,1,478.0,9606.0,5910,,,F,,,,Homo sapiens,A2780,N,CHEMBL618620,BAO_0000219,Tested for antiproliferative activity against A-2780 tumoral cell line,4379,,,81034,Intermediate
1,,1,455.0,9606.0,5911,,,F,,,,Homo sapiens,A-375,N,CHEMBL618621,BAO_0000219,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1093,,,80018,Intermediate
1,,1,455.0,9606.0,5912,,,F,,,,Homo sapiens,A-375,N,CHEMBL618622,BAO_0000219,Tested in vitro against A-375 cell line human melanoma,12152,,,80018,Intermediate
1,,1,797.0,9606.0,5913,,,F,,,,Homo sapiens,A-427,N,CHEMBL618623,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,16464,,,80019,Expert
1,,1,797.0,9606.0,5914,,,F,,,,Homo sapiens,A-427,N,CHEMBL618624,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80019,Intermediate
1,,1,797.0,9606.0,5915,,,F,,,,Homo sapiens,A-427,N,CHEMBL618625,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,16582,,,80019,Expert
1,,1,797.0,9606.0,5916,,,F,,,,Homo sapiens,A-427,N,CHEMBL618626,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,,,80019,Intermediate
1,,1,797.0,9606.0,5917,,,F,,,,Homo sapiens,A-427,N,CHEMBL618627,BAO_0000219,Antitumor activity on A-427 lung carcinoma cell lines,10413,,,80019,Intermediate
1,,1,797.0,9606.0,5918,,,F,,,,Homo sapiens,A-427,N,CHEMBL618628,BAO_0000219,Cytotoxic activity against human A-427 lung tumor cell line,6418,,,80019,Intermediate
1,,1,797.0,9606.0,5919,,,F,,,,Homo sapiens,A-427,N,CHEMBL618629,BAO_0000219,In vitro antitumor effects against human A-427 cell lines.,17134,,,80019,Expert
1,,1,797.0,9606.0,5920,,,F,,,,Homo sapiens,A-427,N,CHEMBL618630,BAO_0000219,In vitro inhibition of A-427 (human lung cancer) cell growth.,16132,,,80019,Expert
1,,1,797.0,9606.0,5921,,,F,,,,Homo sapiens,A-427,N,CHEMBL618631,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,16132,,,80019,Intermediate
1,,1,797.0,9606.0,5922,,,F,,,,Homo sapiens,A-427,N,CHEMBL618632,BAO_0000219,Cytotoxic activity of compound against A-427 lung human tumor cell line,16780,,,80019,Intermediate
1,,1,500.0,9606.0,5923,,,F,,,,Homo sapiens,A-431,N,CHEMBL618633,BAO_0000219,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,4085,,,80852,Expert
1,,1,624.0,9606.0,5924,,,F,,,,Homo sapiens,A498,N,CHEMBL619315,BAO_0000219,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1276,,,80021,Intermediate
1,,1,624.0,9606.0,5925,,,F,,,,Homo sapiens,A498,N,CHEMBL619316,BAO_0000219,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,3498,,,80021,Expert
1,,1,624.0,9606.0,5926,,,F,,,,Homo sapiens,A498,N,CHEMBL619317,BAO_0000219,Cytotoxicity against human kidney carcinoma A-498cell lines,1169,,,80021,Intermediate
1,,1,624.0,9606.0,5927,,,F,,,,Homo sapiens,A498,N,CHEMBL619318,BAO_0000219,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,4450,,,80021,Intermediate
1,,1,624.0,9606.0,5928,,,F,,,,Homo sapiens,A498,N,CHEMBL619319,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,3311,,,80021,Intermediate
1,,1,624.0,9606.0,5929,,,F,,,,Homo sapiens,A498,N,CHEMBL619739,BAO_0000219,Antitumor cytotoxic activity against A-498 cell line was determined,4461,,,80021,Intermediate
1,,1,624.0,9606.0,5930,,,F,,,,Homo sapiens,A498,N,CHEMBL619740,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,3311,,,80021,Intermediate
1,,1,624.0,9606.0,5931,,,F,,,,Homo sapiens,A498,N,CHEMBL883158,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,3311,,,80021,Intermediate
1,,1,624.0,9606.0,5932,,,F,,,,Homo sapiens,A498,N,CHEMBL884012,BAO_0000219,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1457,,,80021,Intermediate
1,,1,624.0,9606.0,5933,,,F,,,,Homo sapiens,A498,N,CHEMBL619741,BAO_0000219,In vitro inhibitory activity against A-498 ovarian cancer cell lines,3664,,,80021,Intermediate
1,,1,624.0,9606.0,5934,,,F,,,,Homo sapiens,A498,N,CHEMBL619742,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",15895,,,80021,Intermediate
1,,1,646.0,9606.0,5935,,,F,,,,Homo sapiens,A549,N,CHEMBL876610,BAO_0000219,Inhibition of growth lung non-small cell carcinoma A-549 cell line,11843,,,80682,Intermediate
1,,1,646.0,9606.0,5936,,,F,,,,Homo sapiens,A549,N,CHEMBL619743,BAO_0000219,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,11843,,,80682,Intermediate
1,,1,646.0,9606.0,5937,,,F,,,,Homo sapiens,A549,N,CHEMBL619744,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line,17705,,,80682,Intermediate
1,,1,646.0,9606.0,5938,,,F,,,,Homo sapiens,A549,N,CHEMBL619745,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,17705,,,80682,Intermediate
1,,1,646.0,9606.0,5939,,,F,,,,Homo sapiens,A549,N,CHEMBL619746,BAO_0000219,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5940,,,F,,,,Homo sapiens,A549,N,CHEMBL619747,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5941,,,F,,,,Homo sapiens,A549,N,CHEMBL619748,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5942,,,F,,,,Homo sapiens,A549,N,CHEMBL619749,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5943,,,F,,,,Homo sapiens,A549,N,CHEMBL619750,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5944,,,F,,,,Homo sapiens,A549,N,CHEMBL624014,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5945,,,F,,,,Homo sapiens,A549,N,CHEMBL624015,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,4369,,,80682,Intermediate
1,,1,646.0,9606.0,5946,,,F,,,,Homo sapiens,A549,N,CHEMBL885344,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,4787,,,80682,Expert
1,,1,646.0,9606.0,5947,,,F,,,,Homo sapiens,A549,N,CHEMBL623224,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,4787,,,80682,Intermediate
1,,1,646.0,9606.0,5948,,,F,,,,Homo sapiens,A549,N,CHEMBL623225,BAO_0000219,Cytotoxic activity against A-549 cell line,6513,,,80682,Intermediate
1,,1,646.0,9606.0,5949,,,F,,,,Homo sapiens,A549,N,CHEMBL622698,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,6690,,,80682,Intermediate
1,,1,646.0,9606.0,5950,,,F,,,,Homo sapiens,A549,N,CHEMBL622699,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,6690,,,80682,Intermediate
1,,1,646.0,9606.0,5951,,,F,,,,Homo sapiens,A549,N,CHEMBL622700,BAO_0000219,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",12263,,,80682,Expert
1,,1,646.0,9606.0,5952,,,F,,,,Homo sapiens,A549,N,CHEMBL622701,BAO_0000219,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1054,,,80682,Intermediate
1,,1,646.0,9606.0,5953,,,F,,,,Homo sapiens,A549,N,CHEMBL622702,BAO_0000219,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1359,,,80682,Intermediate
1,,1,646.0,9606.0,5954,,,F,,,,Homo sapiens,A549,N,CHEMBL622703,BAO_0000219,Cytotoxic activity against human lung carcinoma (A-549) cell line,3547,,,80682,Intermediate
1,,1,646.0,9606.0,5955,,,F,,,,Homo sapiens,A549,N,CHEMBL622704,BAO_0000219,Cytotoxic activity towards A-549 cells,5771,,,80682,Expert
1,,1,646.0,9606.0,5956,,,F,,,,Homo sapiens,A549,N,CHEMBL622705,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5957,,,F,,,,Homo sapiens,A549,N,CHEMBL622706,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5958,,,F,,,,Homo sapiens,A549,N,CHEMBL622707,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5959,,,F,,,,Homo sapiens,A549,N,CHEMBL622708,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",14425,,,80682,Intermediate
1,,1,646.0,9606.0,5960,,,F,,,,Homo sapiens,A549,N,CHEMBL622709,BAO_0000219,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,5280,,,80682,Intermediate
1,,1,646.0,9606.0,5961,,,F,,,,Homo sapiens,A549,N,CHEMBL622710,BAO_0000219,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,15176,,,80682,Intermediate
1,,1,646.0,9606.0,5962,,,F,,,,Homo sapiens,A549,N,CHEMBL622711,BAO_0000219,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,15300,,,80682,Intermediate
1,,1,646.0,9606.0,5963,,,F,,,,Homo sapiens,A549,N,CHEMBL622712,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5964,,,F,,,,Homo sapiens,A549,N,CHEMBL622713,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5965,,,F,,,,Homo sapiens,A549,N,CHEMBL622714,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5966,,,F,,,,Homo sapiens,A549,N,CHEMBL622715,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5967,,,F,,,,Homo sapiens,A549,N,CHEMBL622716,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5968,,,F,,,,Homo sapiens,A549,N,CHEMBL622717,BAO_0000219,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",17824,,,80682,Intermediate
1,,1,646.0,9606.0,5969,,,F,,,,Homo sapiens,A549,N,CHEMBL622718,BAO_0000218,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),17528,,,80682,Intermediate
1,,1,646.0,9606.0,5970,,,F,,,,Homo sapiens,A549,N,CHEMBL622719,BAO_0000219,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,6870,,,80682,Expert
1,,1,646.0,9606.0,5971,,,F,,,,Homo sapiens,A549,N,CHEMBL622720,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,6870,,,80682,Intermediate
1,,1,646.0,9606.0,5972,,,F,,,,Homo sapiens,A549,N,CHEMBL622721,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,6870,,,80682,Intermediate
1,,1,646.0,9606.0,5973,,,F,,,,Homo sapiens,A549,N,CHEMBL622722,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,6870,,,80682,Intermediate
1,,1,646.0,9606.0,5974,,,F,,,,Homo sapiens,A549,N,CHEMBL876030,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,16726,,,80682,Intermediate
1,,1,646.0,9606.0,5975,,,F,,,,Homo sapiens,A549,N,CHEMBL620206,BAO_0000219,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",6170,,,80682,Intermediate
1,,1,646.0,9606.0,5976,,,F,,,,Homo sapiens,A549,N,CHEMBL620207,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,6583,,,80682,Expert
1,,1,646.0,9606.0,5977,,,F,,,,Homo sapiens,A549,N,CHEMBL620208,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,6583,,,80682,Expert
1,,1,646.0,9606.0,5978,,,F,,,,Homo sapiens,A549,N,CHEMBL620209,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,6583,,,80682,Expert
1,,1,646.0,9606.0,5979,,,F,,,,Homo sapiens,A549,N,CHEMBL620210,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,6583,,,80682,Expert
1,,1,646.0,9606.0,5980,,,F,,,,Homo sapiens,A549,N,CHEMBL621639,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,6583,,,80682,Expert
1,,1,646.0,9606.0,5981,,,F,,,,Homo sapiens,A549,N,CHEMBL621640,BAO_0000219,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,17321,,,80682,Intermediate
1,,1,646.0,9606.0,5982,,,F,,,,Homo sapiens,A549,N,CHEMBL621641,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,17528,,,80682,Expert
1,,1,646.0,9606.0,5983,,,F,,,,Homo sapiens,A549,N,CHEMBL621642,BAO_0000219,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,12888,,,80682,Expert
1,,1,646.0,9606.0,5984,,,F,,,,Homo sapiens,A549,N,CHEMBL621643,BAO_0000219,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,4312,,,80682,Intermediate
1,,1,646.0,9606.0,5985,,,F,,,,Homo sapiens,A549,N,CHEMBL621644,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,4312,,,80682,Intermediate
1,,1,646.0,9606.0,5986,,,F,,,,Homo sapiens,A549,N,CHEMBL621645,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,4312,,,80682,Intermediate
1,,1,646.0,10090.0,5987,,,F,,,,Mus musculus,A549,N,CHEMBL621646,BAO_0000219,In vitro antiproliferative activity against A549 cell line,17737,,,80682,Intermediate
1,,1,646.0,,5988,,,F,,,,,A549,N,CHEMBL621647,BAO_0000219,Synergism with indomethacin in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5989,,,F,,,,,A549,N,CHEMBL621648,BAO_0000219,Synergism with tolmetin in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5990,,,F,,,,,A549,N,CHEMBL621649,BAO_0000219,Synergism with sulindac in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5991,,,F,,,,,A549,N,CHEMBL621650,BAO_0000219,Antagonism of indomethacin in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5992,,,F,,,,,A549,N,CHEMBL621651,BAO_0000219,Antagonism of sulindac in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5993,,,F,,,,,A549,N,CHEMBL621652,BAO_0000219,Antagonism of tolmetin in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5994,,,F,,,,,A549,N,CHEMBL621653,BAO_0000219,Synergism with indomethacin in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5995,,,F,,,,,A549,N,CHEMBL621654,BAO_0000219,Synergism with sulindac in A549 cells,6630,,,80682,Intermediate
1,,1,646.0,,5996,,,F,,,,,A549,N,CHEMBL621655,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,6630,,,80682,Intermediate
1,,1,,9615.0,5997,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621656,BAO_0000218,Cmax value after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,5998,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621657,BAO_0000218,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),5944,,,50588,Intermediate
1,,1,,9615.0,5999,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621658,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,5944,,,50588,Intermediate
1,,1,,9615.0,6000,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621659,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),5944,,,50588,Intermediate
1,,1,,9615.0,6001,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621660,BAO_0000218,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,5944,,,50588,Intermediate
1,,1,,9615.0,6002,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621661,BAO_0000218,Cmax value after administration of 4 mg/Kg oral dose in dog,2959,,,50588,Intermediate
1,,1,,9615.0,6003,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621662,BAO_0000218,Cmax value in dog,6241,,,50588,Intermediate
1,,1,,9615.0,6004,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621663,BAO_0000218,Cmax value in dogs after oral administration at 1 mg/kg,6241,,,50588,Intermediate
1,,1,,9615.0,6005,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621664,BAO_0000218,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,2652,,,50588,Intermediate
1,,1,,9615.0,6006,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621665,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1806,,Plasma,50588,Intermediate
1,,1,,9615.0,6007,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621666,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1806,,Plasma,50588,Intermediate
1,,1,,9615.0,6008,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621667,BAO_0000218,Concentration maxima after oral dosing in dogs,1021,,,50588,Intermediate
1,,1,,9615.0,6009,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876738,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,1021,,,50588,Intermediate
1,,1,,9615.0,6010,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621668,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,1021,,,50588,Intermediate
1,,1,,9615.0,6011,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621669,BAO_0000218,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,5444,,,50588,Intermediate
1,,1,,9615.0,6012,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621670,BAO_0000218,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,5444,,,50588,Intermediate
1,,1,,9615.0,6013,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621671,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog,5444,,,50588,Intermediate
1,,1,,9615.0,6014,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622360,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,5444,,,50588,Intermediate
1,,1,,9615.0,6015,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622361,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,5444,,,50588,Intermediate
1,,1,,9615.0,6016,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622362,BAO_0000218,Cmax in dog plasma after oral dose (1 mg/kg),5130,,Plasma,50588,Intermediate
1,,1,,9615.0,6017,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622363,BAO_0000218,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,3249,,Plasma,50588,Intermediate
1,,1,,9615.0,6018,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622364,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg,5473,,Plasma,50588,Intermediate
1,,1,,9615.0,6019,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622365,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg (oral),5474,,Plasma,50588,Intermediate
1,,1,,9615.0,6020,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622533,BAO_0000218,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,4657,,Plasma,50588,Intermediate
1,,1,,9615.0,6021,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622534,BAO_0000218,Maximum concentration of compound in dog was evaluated.,3031,,,50588,Intermediate
1,,1,,9615.0,6022,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622535,BAO_0000218,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,6023,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876739,BAO_0000218,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,4186,,,50588,Intermediate
1,,1,,9615.0,6024,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622536,BAO_0000218,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,,,50588,Intermediate
1,,1,,9615.0,6025,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL622537,BAO_0000218,Maximum concentration obtained in dog plasma was determined,3132,,Plasma,50588,Intermediate
1,,1,,9615.0,6026,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622538,BAO_0000218,Maximum concentration was determined,5006,,,50588,Intermediate
1,,1,,9615.0,6027,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL627867,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in dog,4727,,,50588,Intermediate
1,,1,,9615.0,6028,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL627868,BAO_0000218,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,,,50588,Intermediate
1,,1,,9615.0,6029,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627869,BAO_0000218,Maximum concentration was evaluated in dog plasma,1918,,Plasma,50588,Intermediate
1,,1,,9615.0,6030,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL627870,BAO_0000218,Maximum concentration was evaluated after 75 min after administration in dog,3045,,,50588,Intermediate
1,,1,,9615.0,6031,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627871,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 17b,9579,,Plasma,50588,Intermediate
1,,1,,9615.0,6032,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627872,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 2b,9579,,Plasma,50588,Intermediate
1,,1,,9615.0,6033,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627873,BAO_0000218,Maximum plasma concentration in dog,933,,Plasma,50588,Intermediate
1,,1,,9615.0,6034,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627874,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,17839,,Plasma,50588,Intermediate
1,,1,,9615.0,6035,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627875,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,17839,,Plasma,50588,Intermediate
1,,1,,9615.0,6036,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627876,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,17839,,Plasma,50588,Intermediate
1,,1,,9615.0,6037,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627877,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,17839,,Plasma,50588,Intermediate
1,,1,,9615.0,6038,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627878,BAO_0000218,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,Plasma,50588,Intermediate
1,,1,,9615.0,6039,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627879,BAO_0000218,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,16367,,Plasma,50588,Intermediate
1,,1,,9615.0,6040,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL875355,BAO_0000218,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,,Plasma,50588,Intermediate
1,,1,,9615.0,6041,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627880,BAO_0000218,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,,Plasma,50588,Intermediate
1,,1,,9615.0,6042,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627881,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,5199,,Plasma,50588,Intermediate
1,,1,,9615.0,6043,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627882,BAO_0000218,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,17650,,Plasma,50588,Intermediate
1,,1,,9615.0,6044,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL627883,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,6679,,Plasma,50588,Intermediate
1,,1,,9615.0,6045,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL628526,BAO_0000218,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,5356,,Plasma,50588,Intermediate
1,,1,,9615.0,6046,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL628527,BAO_0000218,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,5356,,Plasma,50588,Intermediate
1,,1,,9615.0,6047,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL628528,BAO_0000218,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,6227,,Plasma,50588,Intermediate
1,,1,,9615.0,6048,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL628529,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,6227,,Plasma,50588,Intermediate
1,,1,,9615.0,6049,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL628530,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,6227,,Plasma,50588,Intermediate
1,,1,,9615.0,6050,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL625243,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,6227,,Plasma,50588,Intermediate
1,,1,,9615.0,6051,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL625244,BAO_0000218,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,,Plasma,50588,Expert
1,,1,,9615.0,6052,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625245,BAO_0000218,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,4368,,,50588,Intermediate
1,,1,,9615.0,6053,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625246,BAO_0000218,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,6265,,,50588,Intermediate
1,,1,,10090.0,6054,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL625247,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,,Stomach,50594,Intermediate
1,,1,,10090.0,6055,,In vivo,A,1088.0,,,Mus musculus,,N,CHEMBL625248,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,,Urine,50594,Intermediate
1,,1,,10090.0,6056,,In vivo,A,1088.0,,,Mus musculus,,N,CHEMBL625249,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,7767,,Urine,50594,Intermediate
1,,1,,10090.0,6057,,In vivo,A,1088.0,,,Mus musculus,,N,CHEMBL625250,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,7767,,Urine,50594,Intermediate
1,,1,,10090.0,6058,,,A,,,,Mus musculus,,N,CHEMBL625251,BAO_0000218,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,17811,,,50594,Intermediate
1,,1,,10090.0,6059,,,A,,,,Mus musculus,,N,CHEMBL875356,BAO_0000218,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,17811,,,50594,Intermediate
1,,1,,10090.0,6060,,,A,,,,Mus musculus,,N,CHEMBL625252,BAO_0000218,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6061,,,A,178.0,,,Mus musculus,,N,CHEMBL625253,BAO_0000218,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),17827,,Blood,50594,Intermediate
1,,1,,10090.0,6062,,,A,,,,Mus musculus,,N,CHEMBL625254,BAO_0000218,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6063,,,A,,,,Mus musculus,,N,CHEMBL625255,BAO_0000218,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6064,,,A,,,,Mus musculus,,N,CHEMBL625256,BAO_0000218,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6065,,,A,178.0,,,Mus musculus,,N,CHEMBL625257,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),17827,,Blood,50594,Intermediate
1,,1,,10090.0,6066,,,A,178.0,,,Mus musculus,,N,CHEMBL625258,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),17827,,Blood,50594,Intermediate
1,,1,,10090.0,6067,,,A,,,,Mus musculus,,N,CHEMBL625259,BAO_0000218,Compound was evaluated for washout rate in mice (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6068,,,A,,,,Mus musculus,,N,CHEMBL625260,BAO_0000218,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,17827,,,50594,Intermediate
1,,1,,10090.0,6069,,,A,,,,Mus musculus,,N,CHEMBL625261,BAO_0000218,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,,,50594,Intermediate
1,,1,,10090.0,6070,,,A,,,,Mus musculus,,N,CHEMBL625262,BAO_0000218,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,,,50594,Intermediate
1,,1,,10090.0,6071,,,A,,,,Mus musculus,,N,CHEMBL622639,BAO_0000218,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,,,50594,Intermediate
1,,1,,10090.0,6072,,,A,,,,Mus musculus,,N,CHEMBL622640,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,17257,,,50594,Intermediate
1,,1,,10090.0,6073,,,A,,,,Mus musculus,,N,CHEMBL622812,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,17257,,,50594,Intermediate
1,,1,,10090.0,6074,,,A,,,,Mus musculus,,N,CHEMBL622813,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,17257,,,50594,Intermediate
1,,1,,10090.0,6075,,,A,,,,Mus musculus,,N,CHEMBL622814,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,17257,,,50594,Intermediate
1,,1,,10090.0,6076,,,A,,,,Mus musculus,,N,CHEMBL622815,BAO_0000218,Time at maximum activity in mice (Radiolabeled compound),17827,,,50594,Intermediate
1,,1,,10090.0,6077,,,A,,,,Mus musculus,,N,CHEMBL625342,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6078,,,A,,,,Mus musculus,,N,CHEMBL625343,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6079,,,A,,,,Mus musculus,,N,CHEMBL877591,BAO_0000218,Binding towards mouse plasma protein at 10 uM,17409,,,50594,Intermediate
1,,1,,10090.0,6080,,,A,,,,Mus musculus,,N,CHEMBL625344,BAO_0000218,Binding towards mouse plasma protein at 100 uM,17409,,,50594,Intermediate
1,,1,,10090.0,6081,,In vivo,A,,,,Mus musculus,,N,CHEMBL625345,BAO_0000218,Bioavailability was evaluated in mice after intravenous administration,2675,,,50594,Intermediate
1,,1,,10090.0,6082,,In vivo,A,,,,Mus musculus,,N,CHEMBL625346,BAO_0000218,Bioavailability was evaluated in mice after oral administration,2675,,,50594,Intermediate
1,,1,,10090.0,6083,,In vivo,A,,,,Mus musculus,,N,CHEMBL625347,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,3132,,,50594,Intermediate
1,,1,,10090.0,6084,,In vivo,A,,,,Mus musculus,,N,CHEMBL625348,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,3132,,,50594,Intermediate
1,,1,,10090.0,6085,,In vivo,A,,,,Mus musculus,,N,CHEMBL625349,BAO_0000218,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,6086,,In vivo,A,,,,Mus musculus,,N,CHEMBL625350,BAO_0000218,Oral bioavailability in mouse,2862,,,50594,Intermediate
1,,1,,10090.0,6087,,In vivo,A,,,,Mus musculus,,N,CHEMBL882952,BAO_0000218,Oral bioavailability after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,6088,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL625351,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6089,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL625352,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6090,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL877592,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6091,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL625353,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6092,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL625354,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6093,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL626019,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,,Brain,50594,Intermediate
1,,1,,10090.0,6094,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL626020,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,,10090.0,6095,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL626021,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,,10090.0,6096,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL626022,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,,10090.0,6097,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL626192,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,646.0,9606.0,6098,,,F,,,,Homo sapiens,A549,N,CHEMBL626193,BAO_0000219,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1276,,,80682,Intermediate
1,,1,646.0,9606.0,6099,,,F,,,,Homo sapiens,A549,N,CHEMBL626194,BAO_0000219,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,3498,,,80682,Expert
1,,1,646.0,9606.0,6100,,,F,,,,Homo sapiens,A549,N,CHEMBL626195,BAO_0000219,Cytotoxicity against human lung carcinoma A-549 cell lines,1169,,,80682,Intermediate
1,,1,646.0,9606.0,6101,,,F,,,,Homo sapiens,A549,N,CHEMBL626196,BAO_0000219,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,4450,,,80682,Intermediate
1,,1,646.0,9606.0,6102,,,F,,,,Homo sapiens,A549,N,CHEMBL626197,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549,358,,,80682,Intermediate
1,,1,646.0,9606.0,6103,,,F,,,,Homo sapiens,A549,N,CHEMBL626198,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6104,,,F,,,,Homo sapiens,A549,N,CHEMBL626199,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6105,,,F,,,,Homo sapiens,A549,N,CHEMBL626200,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6106,,,F,,,,Homo sapiens,A549,N,CHEMBL626201,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6107,,,F,,,,Homo sapiens,A549,N,CHEMBL626202,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6108,,,F,,,,Homo sapiens,A549,N,CHEMBL626203,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,358,,,80682,Intermediate
1,,1,646.0,9606.0,6109,,,F,,,,Homo sapiens,A549,N,CHEMBL626204,BAO_0000219,In vitro cytotoxicity against A-549 human lung cancer cells,15167,,,80682,Intermediate
1,,1,646.0,9606.0,6110,,,F,,,,Homo sapiens,A549,N,CHEMBL624701,BAO_0000219,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,4139,,,80682,Intermediate
1,,1,646.0,9606.0,6111,,,F,,,,Homo sapiens,A549,N,CHEMBL624702,BAO_0000219,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,833,,,80682,Intermediate
1,,1,646.0,9606.0,6112,,,F,,,,Homo sapiens,A549,N,CHEMBL624703,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,15718,,,80682,Expert
1,,1,646.0,9606.0,6113,,,F,,,,Homo sapiens,A549,N,CHEMBL624704,BAO_0000219,Tested in vitro for cytotoxicity against A-549 lung cancer cells,12373,,,80682,Intermediate
1,,1,646.0,9606.0,6114,,,F,,,,Homo sapiens,A549,N,CHEMBL624705,BAO_0000219,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,637,,,80682,Intermediate
1,,1,646.0,9606.0,6115,,,F,,,,Homo sapiens,A549,N,CHEMBL624706,BAO_0000219,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,14867,,,80682,Expert
1,,1,646.0,9606.0,6116,,,F,,,,Homo sapiens,A549,N,CHEMBL624707,BAO_0000219,Antitumor cytotoxic activity against A-549 cell line was determined,4461,,,80682,Intermediate
1,,1,646.0,9606.0,6117,,,F,,,,Homo sapiens,A549,N,CHEMBL624708,BAO_0000219,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",5406,,,80682,Intermediate
1,,1,646.0,9606.0,6118,,,F,,,,Homo sapiens,A549,N,CHEMBL624709,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,4457,,,80682,Intermediate
1,,1,646.0,9606.0,6119,,,F,,,,Homo sapiens,A549,N,CHEMBL884107,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1386,,,80682,Expert
1,,1,646.0,9606.0,6120,,,F,,,,Homo sapiens,A549,N,CHEMBL624710,BAO_0000219,Antitumoral activity was assayed against A-549 cell line,3265,,,80682,Intermediate
1,,1,646.0,9606.0,6121,,,F,,,,Homo sapiens,A549,N,CHEMBL624711,BAO_0000219,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,2359,,,80682,Intermediate
1,,1,646.0,9606.0,6122,,,F,,,,Homo sapiens,A549,N,CHEMBL624712,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,4457,,,80682,Intermediate
1,,1,646.0,9606.0,6123,,,F,,,,Homo sapiens,A549,N,CHEMBL624713,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,12454,,,80682,Expert
1,,1,646.0,9606.0,6124,,,F,,,,Homo sapiens,A549,N,CHEMBL624714,BAO_0000219,Compound was tested for inhibition of cell growth of A-549 cells,1481,,,80682,Intermediate
1,,1,646.0,9606.0,6125,,,F,,,,Homo sapiens,A549,N,CHEMBL624715,BAO_0000219,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1750,,,80682,Intermediate
1,,1,646.0,9606.0,6126,,,F,,,,Homo sapiens,A549,N,CHEMBL624716,BAO_0000219,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,5065,,,80682,Intermediate
1,,1,646.0,9606.0,6127,,,F,,,,Homo sapiens,A549,N,CHEMBL619505,BAO_0000219,In vitro cytotoxicity against A549-human lung carcinoma cells.,808,,,80682,Expert
1,,1,646.0,9606.0,6128,,,F,,,,Homo sapiens,A549,N,CHEMBL619506,BAO_0000219,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,16364,,,80682,Expert
1,,1,646.0,9606.0,6129,,,F,,,,Homo sapiens,A549,N,CHEMBL619507,BAO_0000219,Cytotoxic activity against A-549 cell lines.,1847,,,80682,Intermediate
1,,1,646.0,9606.0,6130,,,F,,,,Homo sapiens,A549,N,CHEMBL619508,BAO_0000219,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1747,,,80682,Expert
1,,1,646.0,9606.0,6131,,,F,,,,Homo sapiens,A549,N,CHEMBL619509,BAO_0000219,Cytotoxicity against human A549 non small cell lung cell lines,1003,,,80682,Intermediate
1,,1,646.0,9606.0,6132,,,F,,,,Homo sapiens,A549,N,CHEMBL619510,BAO_0000219,Inhibition of cell growth in (A-549) lung cell line,15313,,,80682,Expert
1,,1,646.0,9606.0,6133,,,F,,,,Homo sapiens,A549,N,CHEMBL619511,BAO_0000219,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,3122,,,80682,Intermediate
1,,1,646.0,9606.0,6134,,,F,,,,Homo sapiens,A549,N,CHEMBL619512,BAO_0000219,In vitro antitumor activity against A-549 tumor cells.,16049,,,80682,Intermediate
1,,1,646.0,9606.0,6135,,,F,,,,Homo sapiens,A549,N,CHEMBL619513,BAO_0000219,In vitro antitumor effects against human A-549 cell lines.,17134,,,80682,Expert
1,,1,646.0,9606.0,6136,,,F,,,,Homo sapiens,A549,N,CHEMBL619514,BAO_0000219,In vitro cytotoxic activity of compound against A-549 cell line,6406,,,80682,Intermediate
1,,1,646.0,9606.0,6137,,,F,,,,Homo sapiens,A549,N,CHEMBL619515,BAO_0000219,In vitro cytotoxicity against human lung carcinoma A-549 cell line,627,,,80682,Intermediate
1,,1,646.0,9606.0,6138,,,F,,,,Homo sapiens,A549,N,CHEMBL619516,BAO_0000219,In vitro cytotoxicity against human non-small cell lung carcinoma A549,12307,,,80682,Intermediate
1,,1,646.0,9606.0,6139,,,F,,,,Homo sapiens,A549,N,CHEMBL884005,BAO_0000219,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,17861,,,80682,Intermediate
1,,1,646.0,9606.0,6140,,,F,,,,Homo sapiens,A549,N,CHEMBL619517,BAO_0000219,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,6682,,,80682,Expert
1,,1,646.0,9606.0,6141,,,F,,,,Homo sapiens,A549,N,CHEMBL619518,BAO_0000219,Inhibitory concentration of compound against A-549 cell line,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6142,,,F,,,,Homo sapiens,A549,N,CHEMBL619519,BAO_0000219,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,2454,,,80682,Intermediate
1,,1,646.0,9606.0,6143,,,F,,,,Homo sapiens,A549,N,CHEMBL876489,BAO_0000219,cytotoxic activity against leukemia (A-549) cancer cell line,14709,,,80682,Intermediate
1,,1,646.0,9606.0,6144,,,F,,,,Homo sapiens,A549,N,CHEMBL619520,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,15718,,,80682,Expert
1,,1,646.0,9606.0,6145,,,F,,,,Homo sapiens,A549,N,CHEMBL619521,BAO_0000219,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,15718,,,80682,Intermediate
1,,1,646.0,9606.0,6146,,,F,,,,Homo sapiens,A549,N,CHEMBL619522,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),17130,,,80682,Intermediate
1,,1,646.0,9606.0,6147,,,F,,,,Homo sapiens,A549,N,CHEMBL619523,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),17130,,,80682,Intermediate
1,,1,646.0,9606.0,6148,,,F,,,,Homo sapiens,A549,N,CHEMBL619524,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),17130,,,80682,Intermediate
1,,1,646.0,9606.0,6149,,,F,,,,Homo sapiens,A549,N,CHEMBL619525,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),17130,,,80682,Intermediate
1,,1,646.0,,6150,,,F,,,,,A549,N,CHEMBL619526,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,6630,,,80682,Intermediate
1,,1,646.0,9606.0,6151,,,F,,,,Homo sapiens,A549,N,CHEMBL619527,BAO_0000219,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,16726,,,80682,Intermediate
1,,1,646.0,9606.0,6152,,,F,,,,Homo sapiens,A549,N,CHEMBL619528,BAO_0000219,Cytotoxicity against A549 cells; No cytotoxicity,17846,,,80682,Intermediate
1,,1,646.0,9606.0,6153,,,F,,,,Homo sapiens,A549,N,CHEMBL619529,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines,3415,,,80682,Expert
1,,1,646.0,9606.0,6154,,,F,,,,Homo sapiens,A549,N,CHEMBL619530,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,3415,,,80682,Expert
1,,1,646.0,9606.0,6155,,,F,,,,Homo sapiens,A549,N,CHEMBL876490,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,5609,,,80682,Intermediate
1,,1,646.0,9606.0,6156,,,F,,,,Homo sapiens,A549,N,CHEMBL619531,BAO_0000219,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6157,,,F,,,,Homo sapiens,A549,N,CHEMBL619532,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6158,,,F,,,,Homo sapiens,A549,N,CHEMBL619533,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6159,,,F,,,,Homo sapiens,A549,N,CHEMBL619534,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6160,,,F,,,,Homo sapiens,A549,N,CHEMBL620164,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6161,,,F,,,,Homo sapiens,A549,N,CHEMBL620165,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6162,,,F,,,,Homo sapiens,A549,N,CHEMBL620166,BAO_0000219,Inhibition of A549 human lung tumor cell proliferation,16295,,,80682,Expert
1,,1,646.0,9606.0,6163,,,F,,,,Homo sapiens,A549,N,CHEMBL620167,BAO_0000219,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",16825,,,80682,Intermediate
1,,1,646.0,9606.0,6164,,,F,,,,Homo sapiens,A549,N,CHEMBL620168,BAO_0000219,In vitro cytotoxicity against human tumor cell line A549,3439,,,80682,Expert
1,,1,646.0,9606.0,6165,,,F,,,,Homo sapiens,A549,N,CHEMBL620338,BAO_0000219,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,10870,,,80682,Intermediate
1,,1,646.0,9606.0,6166,,,F,,,,Homo sapiens,A549,N,CHEMBL620339,BAO_0000219,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,4845,,,80682,Intermediate
1,,1,646.0,9606.0,6167,,,F,,,,Homo sapiens,A549,N,CHEMBL620340,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,5822,,,80682,Intermediate
1,,1,646.0,9606.0,6168,,,F,,,,Homo sapiens,A549,N,CHEMBL620341,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,5822,,,80682,Intermediate
1,,1,646.0,9606.0,6169,,,F,,,,Homo sapiens,A549,N,CHEMBL876491,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,5822,,,80682,Intermediate
1,,1,646.0,9606.0,6170,,,F,,,,Homo sapiens,A549,N,CHEMBL620342,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6171,,,F,,,,Homo sapiens,A549,N,CHEMBL620343,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6172,,,F,,,,Homo sapiens,A549,N,CHEMBL620344,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6173,,,F,,,,Homo sapiens,A549,N,CHEMBL620345,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,5609,,,80682,Intermediate
1,,1,646.0,9606.0,6174,,,F,,,,Homo sapiens,A549,N,CHEMBL620346,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,4644,,,80682,Intermediate
1,,1,646.0,9606.0,6175,,,F,,,,Homo sapiens,A549,N,CHEMBL620347,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,4644,,,80682,Intermediate
1,,1,646.0,9606.0,6176,,,F,,,,Homo sapiens,A549,N,CHEMBL620348,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,4644,,,80682,Intermediate
1,,1,646.0,9606.0,6177,,,F,,,,Homo sapiens,A549,N,CHEMBL620349,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,4644,,,80682,Intermediate
1,,1,646.0,9606.0,6178,,,F,,,,Homo sapiens,A549,N,CHEMBL618667,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,5822,,,80682,Intermediate
1,,1,646.0,9606.0,6179,,,F,,,,Homo sapiens,A549,N,CHEMBL618668,BAO_0000219,Percentage inhibition of human lung carcinoma (A549) cell lines,3415,,,80682,Expert
1,,1,646.0,9606.0,6180,,,F,,,,Homo sapiens,A549,N,CHEMBL876031,BAO_0000219,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,16726,,,80682,Intermediate
1,,1,646.0,9606.0,6181,,,F,,,,Homo sapiens,A549,N,CHEMBL618759,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6182,,,F,,,,Homo sapiens,A549,N,CHEMBL618760,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6183,,,F,,,,Homo sapiens,A549,N,CHEMBL619000,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6184,,,F,,,,Homo sapiens,A549,N,CHEMBL619001,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6185,,,F,,,,Homo sapiens,A549,N,CHEMBL619002,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6186,,,F,,,,Homo sapiens,A549,N,CHEMBL619003,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6187,,,F,,,,Homo sapiens,A549,N,CHEMBL619597,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6188,,,F,,,,Homo sapiens,A549,N,CHEMBL619598,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",17206,,,80682,Intermediate
1,,1,646.0,9606.0,6189,,,F,,,,Homo sapiens,A549,N,CHEMBL619599,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6190,,,F,,,,Homo sapiens,A549,N,CHEMBL619600,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6191,,,F,,,,Homo sapiens,A549,N,CHEMBL619601,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,16726,,,80682,Intermediate
1,,1,646.0,9606.0,6192,,,F,,,,Homo sapiens,A549,N,CHEMBL619602,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6193,,,F,,,,Homo sapiens,A549,N,CHEMBL619603,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6194,,,F,,,,Homo sapiens,A549,N,CHEMBL619604,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6195,,,F,,,,Homo sapiens,A549,N,CHEMBL619605,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,,9615.0,6196,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619606,BAO_0000218,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,6084,,,50588,Intermediate
1,,1,,9615.0,6197,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876032,BAO_0000218,Pharmacokinetic activity (Cmax) in dog,6084,,,50588,Intermediate
1,,1,,9615.0,6198,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619607,BAO_0000218,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,,,50588,Intermediate
1,,1,,9615.0,6199,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619608,BAO_0000218,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,5983,,,50588,Intermediate
1,,1,,9615.0,6200,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619609,BAO_0000218,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,6251,,,50588,Intermediate
1,,1,,9615.0,6201,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL619610,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,5932,,Plasma,50588,Intermediate
1,,1,,9615.0,6202,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL619611,BAO_0000218,Tested for the peak blood level in dog,4273,,Blood,50588,Intermediate
1,,1,,9615.0,6203,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619612,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",5313,,,50588,Intermediate
1,,1,,9615.0,6204,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619613,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",5313,,,50588,Intermediate
1,,1,,9615.0,6205,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL619614,BAO_0000218,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,6221,,Blood,50588,Intermediate
1,,1,,9615.0,6206,,,A,,,,Canis lupus familiaris,,N,CHEMBL619615,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,6207,,,A,,,,Canis lupus familiaris,,N,CHEMBL619616,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,167,,,50588,Intermediate
1,,1,,9615.0,6208,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL619617,BAO_0000218,Final plasma concentration in dogs after oral administration at 1 mg/kg,6241,,Plasma,50588,Intermediate
1,,1,,9615.0,6209,,,A,,,,Canis lupus familiaris,,N,CHEMBL619618,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,344,,,50588,Intermediate
1,,1,,9615.0,6210,,,A,,,,Canis lupus familiaris,,N,CHEMBL876033,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,344,,,50588,Intermediate
1,,1,,9615.0,6211,,,A,,,,Canis lupus familiaris,,N,CHEMBL619619,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,344,,,50588,Intermediate
1,,1,,9615.0,6212,,,A,,,,Canis lupus familiaris,,N,CHEMBL619620,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,2189,,,50588,Intermediate
1,,1,,9615.0,6213,,,A,1088.0,,,Canis lupus familiaris,,N,CHEMBL619621,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,2189,,Urine,50588,Intermediate
1,,1,,9615.0,6214,,,A,1088.0,,,Canis lupus familiaris,,N,CHEMBL619622,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,2189,,Urine,50588,Intermediate
1,,1,,9615.0,6215,,,A,1088.0,,,Canis lupus familiaris,,N,CHEMBL618874,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,2189,,Urine,50588,Intermediate
1,,1,,9615.0,6216,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618875,BAO_0000218,Absolute bioavailability was evaluated in dog,4257,,,50588,Intermediate
1,,1,,9615.0,6217,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618876,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,6221,,,50588,Intermediate
1,,1,,9615.0,6218,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618877,BAO_0000218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,6215,,,50588,Intermediate
1,,1,,9615.0,6219,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618878,BAO_0000218,Bioavailability in dog,17267,,,50588,Intermediate
1,,1,,9615.0,6220,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618879,BAO_0000218,Bioavailability in dog,6621,,,50588,Intermediate
1,,1,,9615.0,6221,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618880,BAO_0000218,Bioavailability after intravenous administration in dogs,3854,,,50588,Intermediate
1,,1,,9615.0,6222,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618881,BAO_0000218,Bioavailability after peroral administration in dogs,3854,,,50588,Intermediate
1,,1,,9615.0,6223,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618882,BAO_0000218,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),5007,,,50588,Intermediate
1,,1,,9615.0,6224,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624226,BAO_0000218,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,4333,,,50588,Intermediate
1,,1,,9615.0,6225,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624227,BAO_0000218,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,4333,,Plasma,50588,Intermediate
1,,1,,9615.0,6226,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624228,BAO_0000218,Bioavailability,5006,,,50588,Intermediate
1,,1,,9615.0,6227,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624229,BAO_0000218,Bioavailability,5199,,,50588,Intermediate
1,,1,,9615.0,6228,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624230,BAO_0000218,Bioavailability by intravenous administration of 1.2 mg/kg in dog,4368,,,50588,Intermediate
1,,1,,9615.0,6229,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624231,BAO_0000218,Bioavailability in dog,3771,,,50588,Intermediate
1,,1,,9615.0,6230,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624232,BAO_0000218,Bioavailability in dog,4953,,,50588,Intermediate
1,,1,,9615.0,6231,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625127,BAO_0000218,Bioavailability in dog,5064,,,50588,Intermediate
1,,1,,9615.0,6232,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625128,BAO_0000218,Bioavailability in dog,17657,,,50588,Intermediate
1,,1,,9615.0,6233,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621675,BAO_0000218,Bioavailability in dog,17796,,,50588,Intermediate
1,,1,,9615.0,6234,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621676,BAO_0000218,Bioavailability in dog (p.o.) at 2.0 mpk,17853,,,50588,Intermediate
1,,1,,9615.0,6235,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621677,BAO_0000218,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),4521,,,50588,Intermediate
1,,1,,9615.0,6236,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621678,BAO_0000218,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,,,50588,Intermediate
1,,1,,9615.0,6237,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621679,BAO_0000218,Bioavailability in dog,5006,,,50588,Intermediate
1,,1,,9615.0,6238,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621680,BAO_0000218,Bioavailability was evaluated after oral administration in dog,16365,,,50588,Intermediate
1,,1,,9615.0,6239,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621681,BAO_0000218,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,,,50588,Intermediate
1,,1,,9615.0,6240,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876740,BAO_0000218,Bioavailability was evaluated in dog,1918,,,50588,Intermediate
1,,1,,9615.0,6241,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621682,BAO_0000218,Bioavailability in dog,4239,,,50588,Intermediate
1,,1,,9615.0,6242,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621683,BAO_0000218,Bioavailability in dog,6505,,,50588,Intermediate
1,,1,,9615.0,6243,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621684,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,,,50588,Intermediate
1,,1,,9615.0,6244,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621685,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),5334,,,50588,Intermediate
1,,1,,9615.0,6245,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621686,BAO_0000218,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,,,50588,Intermediate
1,,1,,9615.0,6246,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621687,BAO_0000218,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,,50588,Intermediate
1,,1,,9615.0,6247,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621688,BAO_0000218,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,6005,,,50588,Intermediate
1,,1,,9615.0,6248,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621689,BAO_0000218,Bioavailability of compound in dog was determined after peroral administration,17804,,,50588,Intermediate
1,,1,,9615.0,6249,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621690,BAO_0000218,Oral bioavailability in dog,3184,,,50588,Intermediate
1,,1,,9615.0,6250,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621691,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1806,,,50588,Intermediate
1,,1,,9615.0,6251,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875941,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1806,,,50588,Intermediate
1,,1,,9615.0,6252,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621692,BAO_0000218,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1806,,,50588,Intermediate
1,,1,,9615.0,6253,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621693,BAO_0000218,Bioavailability in dog,4839,,,50588,Intermediate
1,,1,,9615.0,6254,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621694,BAO_0000218,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),5017,,,50588,Intermediate
1,,1,,10090.0,6255,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621695,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,,10090.0,6256,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621696,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,,Heart,50594,Intermediate
1,,1,,10090.0,6257,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621697,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6258,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621698,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6259,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623420,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6260,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623421,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6261,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623422,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6262,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623423,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,,Kidney,50594,Intermediate
1,,1,,10090.0,6263,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623424,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6264,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623425,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6265,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623426,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6266,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623427,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6267,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623428,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6268,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL875947,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,,Liver,50594,Intermediate
1,,1,,10090.0,6269,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623429,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,,10090.0,6270,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623430,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,,10090.0,6271,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL622588,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,,10090.0,6272,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL622589,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,,10090.0,6273,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL622751,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,,10090.0,6274,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL622752,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6275,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL622753,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6276,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL622647,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6277,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL875163,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6278,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL622648,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6279,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL622649,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6280,,,A,955.0,,,Mus musculus,CCRF S-180,N,CHEMBL622650,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,6599,,Brain,50594,Intermediate
1,,1,42.0,10090.0,6281,,,A,955.0,,,Mus musculus,CCRF S-180,N,CHEMBL622651,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,6599,,Brain,50594,Intermediate
1,,1,42.0,10090.0,6282,,,A,955.0,,,Mus musculus,CCRF S-180,N,CHEMBL622652,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,6599,,Brain,50594,Intermediate
1,,1,42.0,10090.0,6283,,,A,955.0,,,Mus musculus,CCRF S-180,N,CHEMBL622653,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,6599,,Brain,50594,Intermediate
1,,1,42.0,10090.0,6284,,,A,955.0,,,Mus musculus,CCRF S-180,N,CHEMBL622654,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,6599,,Brain,50594,Intermediate
1,,1,42.0,10090.0,6285,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL622655,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6286,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL622656,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6287,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL622657,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6288,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL622658,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6289,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL622659,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6290,,,A,2113.0,,,Mus musculus,CCRF S-180,N,CHEMBL624630,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,6599,,Kidney,50594,Intermediate
1,,1,42.0,10090.0,6291,,,A,2113.0,,,Mus musculus,CCRF S-180,N,CHEMBL624631,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,6599,,Kidney,50594,Intermediate
1,,1,42.0,10090.0,6292,,,A,2113.0,,,Mus musculus,CCRF S-180,N,CHEMBL624632,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,6599,,Kidney,50594,Intermediate
1,,1,646.0,9606.0,6293,,,F,,,,Homo sapiens,A549,N,CHEMBL624633,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,17130,,,80682,Intermediate
1,,1,646.0,9606.0,6294,,,F,,,,Homo sapiens,A549,N,CHEMBL624634,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,17130,,,80682,Intermediate
1,,1,646.0,9606.0,6295,,,F,,,,Homo sapiens,A549,N,CHEMBL624635,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),17130,,,80682,Intermediate
1,,1,646.0,9606.0,6296,,,F,,,,Homo sapiens,A549,N,CHEMBL624636,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),17130,,,80682,Intermediate
1,,1,646.0,9606.0,6297,,,F,,,,Homo sapiens,A549,N,CHEMBL857055,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,3263,,,80682,Expert
1,,1,646.0,9606.0,6298,,,F,,,,Homo sapiens,A549,N,CHEMBL624637,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,6663,,,80682,Expert
1,,1,646.0,9606.0,6299,,,F,,,,Homo sapiens,A549,N,CHEMBL624638,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,6663,,,80682,Expert
1,,1,646.0,9606.0,6300,,,F,,,,Homo sapiens,A549,N,CHEMBL874366,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,6663,,,80682,Expert
1,,1,646.0,9606.0,6301,,,F,,,,Homo sapiens,A549,N,CHEMBL624639,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,6663,,,80682,Expert
1,,1,646.0,9606.0,6302,,,F,,,,Homo sapiens,A549,N,CHEMBL624640,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,6663,,,80682,Expert
1,,1,646.0,9606.0,6303,,,F,,,,Homo sapiens,A549,N,CHEMBL624641,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6304,,,F,,,,Homo sapiens,A549,N,CHEMBL624642,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6305,,,F,,,,Homo sapiens,A549,N,CHEMBL624643,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6306,,,F,,,,Homo sapiens,A549,N,CHEMBL624644,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6307,,,F,,,,Homo sapiens,A549,N,CHEMBL624645,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,6663,,,80682,Intermediate
1,,1,646.0,9606.0,6308,,,F,,,,Homo sapiens,A549,N,CHEMBL619445,BAO_0000219,The compound was evaluated for its cytotoxic potency against A-549 cell line,3983,,,80682,Intermediate
1,,1,646.0,9606.0,6309,,,F,,,,Homo sapiens,A549,N,CHEMBL839886,BAO_0000219,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,11141,,,80682,Expert
1,,1,646.0,9606.0,6310,,,F,,,,Homo sapiens,A549,N,CHEMBL619446,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line.,5076,,,80682,Intermediate
1,,1,646.0,9606.0,6311,,,F,,,,Homo sapiens,A549,N,CHEMBL619447,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,3311,,,80682,Intermediate
1,,1,646.0,9606.0,6312,,,F,,,,Homo sapiens,A549,N,CHEMBL619448,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,3311,,,80682,Intermediate
1,,1,646.0,9606.0,6313,,,F,,,,Homo sapiens,A549,N,CHEMBL619449,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,3311,,,80682,Intermediate
1,,1,646.0,9606.0,6314,,,F,,,,Homo sapiens,A549,N,CHEMBL619450,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,5076,,,80682,Intermediate
1,,1,646.0,9606.0,6315,,,F,,,,Homo sapiens,A549,N,CHEMBL619451,BAO_0000219,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),4150,,,80682,Intermediate
1,,1,646.0,9606.0,6316,,,F,,,,Homo sapiens,A549,N,CHEMBL619452,BAO_0000219,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,2150,,,80682,Expert
1,,1,646.0,9606.0,6317,,,F,,,,Homo sapiens,A549,N,CHEMBL619453,BAO_0000219,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,4644,,,80682,Intermediate
1,,1,646.0,9606.0,6318,,,F,,,,Homo sapiens,A549,N,CHEMBL874367,BAO_0000219,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,263,,,80682,Intermediate
1,,1,646.0,9606.0,6319,,,F,,,,Homo sapiens,A549,N,CHEMBL619454,BAO_0000219,Cytotoxic concentration against A-549 tumor cells.,11333,,,80682,Intermediate
1,,1,646.0,9606.0,6320,,,F,,,,Homo sapiens,A549,N,CHEMBL619455,BAO_0000219,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,11333,,,80682,Intermediate
1,,1,646.0,9606.0,6321,,,F,,,,Homo sapiens,A549,N,CHEMBL619456,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",15895,,,80682,Intermediate
1,,1,,470.0,6322,,,F,,,,Acinetobacter baumannii,,N,CHEMBL619457,BAO_0000218,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,16677,,,50191,Expert
1,,1,,471.0,6323,,,F,,,,Acinetobacter calcoaceticus,,N,CHEMBL619458,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),10624,,,50192,Intermediate
1,,1,,5059.0,6324,,,F,,,,Aspergillus flavus,,N,CHEMBL619459,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,16717,,,50274,Expert
1,,1,,5059.0,6325,,,F,,,,Aspergillus flavus,,N,CHEMBL619460,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,16717,,,50274,Expert
1,,1,,746128.0,6326,,,F,,,,Aspergillus fumigatus,,N,CHEMBL619461,BAO_0000218,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,5513,,,50416,Intermediate
1,,1,,746128.0,6327,,,F,,,,Aspergillus fumigatus,,N,CHEMBL619462,BAO_0000218,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),15962,,,50416,Intermediate
1,,1,,746128.0,6328,,,F,,,,Aspergillus fumigatus,,N,CHEMBL620388,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),15962,,,50416,Intermediate
1,,1,,746128.0,6329,,,F,,,,Aspergillus fumigatus,,N,CHEMBL620389,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),15962,,,50416,Intermediate
1,,1,,746128.0,6330,,,F,,,,Aspergillus fumigatus,,N,CHEMBL620390,BAO_0000218,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),15962,,,50416,Intermediate
1,,1,,746128.0,6331,,,F,,,,Aspergillus fumigatus,,N,CHEMBL620391,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,16717,,,50416,Expert
1,,1,,746128.0,6332,,,F,,,,Aspergillus fumigatus,,N,CHEMBL621073,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,16717,,,50416,Expert
1,,1,,1655.0,6333,,,F,,,,Actinomyces naeslundii,,N,CHEMBL621074,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,8117,,,50296,Intermediate
1,,1,,1656.0,6334,,,F,,,,Actinomyces viscosus,,N,CHEMBL621075,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,8117,,,50366,Intermediate
1,,1,,6277.0,6335,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL619554,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),15472,,,50535,Intermediate
1,,1,,6277.0,6336,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL619555,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),15472,,,50535,Intermediate
1,,1,,714.0,6337,,,F,,,,Aggregatibacter actinomycetemcomitans,,N,CHEMBL619556,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,16443,,,50169,Intermediate
1,,1,,714.0,6338,,,F,,,,Aggregatibacter actinomycetemcomitans,,N,CHEMBL619557,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,16443,,,50169,Intermediate
1,,1,,714.0,6339,,,F,,,,Aggregatibacter actinomycetemcomitans,,N,CHEMBL619558,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,16443,,,50169,Intermediate
1,,1,646.0,9606.0,6340,,,F,,,,Homo sapiens,A549,N,CHEMBL619559,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6341,,,F,,,,Homo sapiens,A549,N,CHEMBL619560,BAO_0000219,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6342,,,F,,,,Homo sapiens,A549,N,CHEMBL619561,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6343,,,F,,,,Homo sapiens,A549,N,CHEMBL619562,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6344,,,F,,,,Homo sapiens,A549,N,CHEMBL619563,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,16381,,,80682,Intermediate
1,,1,646.0,9606.0,6345,,,F,,,,Homo sapiens,A549,N,CHEMBL857457,BAO_0000219,GI values against A549 cells (lung cancer),16381,,,80682,Intermediate
1,,1,646.0,9606.0,6346,,,F,,,,Homo sapiens,A549,N,CHEMBL619564,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,17206,,,80682,Intermediate
1,,1,646.0,9606.0,6347,,,F,,,,Homo sapiens,A549,N,CHEMBL619565,BAO_0000219,Inhibitory activity against A549 human adenocarcinoma,16325,,,80682,Intermediate
1,,1,646.0,9606.0,6348,,,F,,,,Homo sapiens,A549,N,CHEMBL619566,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,10708,,,80682,Intermediate
1,,1,646.0,9606.0,6349,,,F,,,,Homo sapiens,A549,N,CHEMBL619567,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,10708,,,80682,Intermediate
1,,1,646.0,9606.0,6350,,,F,,,,Homo sapiens,A549,N,CHEMBL619568,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,17376,,,80682,Intermediate
1,,1,646.0,9606.0,6351,,,F,,,,Homo sapiens,A549,N,CHEMBL619569,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,17376,,,80682,Intermediate
1,,1,646.0,9606.0,6352,,,F,,,,Homo sapiens,A549,N,CHEMBL619570,BAO_0000219,Cytotoxicity against human A549 lung cells,17488,,,80682,Intermediate
1,,1,646.0,9606.0,6353,,,F,,,,Homo sapiens,A549,N,CHEMBL619571,BAO_0000218,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,17404,,,80682,Intermediate
1,,1,646.0,9606.0,6354,,,F,,,,Homo sapiens,A549,N,CHEMBL619572,BAO_0000219,Growth inhibition of A549 (human lung carcinoma) cell line.,10958,,,80682,Expert
1,,1,646.0,9606.0,6355,,,F,,,,Homo sapiens,A549,N,CHEMBL619573,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line.,17099,,,80682,Expert
1,,1,646.0,9606.0,6356,,,F,,,,Homo sapiens,A549,N,CHEMBL619574,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,17099,,,80682,Intermediate
1,,1,646.0,9606.0,6357,,,F,,,,Homo sapiens,A549,N,CHEMBL619575,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,4096,,,80682,Intermediate
1,,1,646.0,9606.0,6358,,,F,,,,Homo sapiens,A549,N,CHEMBL619576,BAO_0000219,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,4096,,,80682,Expert
1,,1,646.0,9606.0,6359,,,F,,,,Homo sapiens,A549,N,CHEMBL619577,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,4096,,,80682,Intermediate
1,,1,646.0,9606.0,6360,,,F,,,,Homo sapiens,A549,N,CHEMBL619578,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture,2525,,,80682,Intermediate
1,,1,646.0,9606.0,6361,,,F,,,,Homo sapiens,A549,N,CHEMBL884009,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,2525,,,80682,Intermediate
1,,1,646.0,9606.0,6362,,,F,,,,Homo sapiens,A549,N,CHEMBL619579,BAO_0000219,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),5302,,,80682,Intermediate
1,,1,646.0,9606.0,6363,,,F,,,,Homo sapiens,A549,N,CHEMBL619580,BAO_0000219,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,16325,,,80682,Intermediate
1,,1,646.0,9606.0,6364,,,F,,,,Homo sapiens,A549,N,CHEMBL619581,BAO_0000219,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,16939,,,80682,Intermediate
1,,1,646.0,9606.0,6365,,,F,,,,Homo sapiens,A549,N,CHEMBL619582,BAO_0000219,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,17229,,,80682,Intermediate
1,,1,646.0,9606.0,6366,,,F,,,,Homo sapiens,A549,N,CHEMBL619583,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,17380,,,80682,Intermediate
1,,1,646.0,9606.0,6367,,,F,,,,Homo sapiens,A549,N,CHEMBL876502,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,17380,,,80682,Intermediate
1,,1,646.0,9606.0,6368,,,F,,,,Homo sapiens,A549,N,CHEMBL619584,BAO_0000219,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1903,,,80682,Intermediate
1,,1,646.0,9606.0,6369,,,F,,,,Homo sapiens,A549,N,CHEMBL619585,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,3838,,,80682,Intermediate
1,,1,646.0,9606.0,6370,,,F,,,,Homo sapiens,A549,N,CHEMBL619586,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,14696,,,80682,Intermediate
1,,1,646.0,9606.0,6371,,,F,,,,Homo sapiens,A549,N,CHEMBL619587,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,3838,,,80682,Intermediate
1,,1,646.0,9606.0,6372,,,F,,,,Homo sapiens,A549,N,CHEMBL619588,BAO_0000219,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1522,,,80682,Intermediate
1,,1,646.0,9606.0,6373,,,F,,,,Homo sapiens,A549,N,CHEMBL619589,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell lines,12400,,,80682,Intermediate
1,,1,646.0,9606.0,6374,,,F,,,,Homo sapiens,A549,N,CHEMBL619590,BAO_0000219,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,14696,,,80682,Intermediate
1,,1,646.0,9606.0,6375,,,F,,,,Homo sapiens,A549,N,CHEMBL619591,BAO_0000219,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),14769,,,80682,Intermediate
1,,1,646.0,9606.0,6376,,,F,,,,Homo sapiens,A549,N,CHEMBL619592,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,14696,,,80682,Intermediate
1,,1,646.0,9606.0,6377,,,F,,,,Homo sapiens,A549,N,CHEMBL619593,BAO_0000219,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1888,,,80682,Intermediate
1,,1,646.0,9606.0,6378,,,F,,,,Homo sapiens,A549,N,CHEMBL620217,BAO_0000219,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,12016,,,80682,Intermediate
1,,1,646.0,9606.0,6379,,,F,,,,Homo sapiens,A549,N,CHEMBL620218,BAO_0000219,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,6058,,,80682,Intermediate
1,,1,646.0,9606.0,6380,,,F,,,,Homo sapiens,A549,N,CHEMBL620219,BAO_0000219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,17708,,,80682,Intermediate
1,,1,646.0,9606.0,6381,,,F,,,,Homo sapiens,A549,N,CHEMBL620220,BAO_0000219,Antitumor activity against A549/ATCC cell line,12301,,,80682,Intermediate
1,,1,646.0,9606.0,6382,,,F,,,,Homo sapiens,A549,N,CHEMBL625141,BAO_0000219,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,11970,,,80682,Intermediate
1,,1,646.0,9606.0,6383,,,F,,,,Homo sapiens,A549,N,CHEMBL625142,BAO_0000219,In vitro cytotoxicity against A549/ATCC cell line.,11818,,,80682,Expert
1,,1,646.0,9606.0,6384,,,F,,,,Homo sapiens,A549,N,CHEMBL625143,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,12400,,,80682,Intermediate
1,,1,646.0,9606.0,6385,,,F,,,,Homo sapiens,A549,N,CHEMBL625144,BAO_0000219,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,3381,,,80682,Intermediate
1,,1,646.0,9606.0,6386,,,F,,,,Homo sapiens,A549,N,CHEMBL622474,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,17376,,,80682,Intermediate
1,,1,646.0,9606.0,6387,,,F,,,,Homo sapiens,A549,N,CHEMBL884104,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,10708,,,80682,Intermediate
0,,1,,9606.0,6388,,,F,,,,Homo sapiens,,U,CHEMBL622475,BAO_0000219,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,2964,,,22226,Autocuration
0,,1,,9615.0,6389,,In vivo,A,,,,Canis lupus familiaris,,U,CHEMBL622476,BAO_0000218,Compound was tested for oral bioavailability in dogs,5005,,,22224,Intermediate
1,,1,,9615.0,6390,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875831,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,6229,,,50588,Intermediate
1,,1,,9615.0,6391,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622477,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,6229,,,50588,Intermediate
1,,1,,9615.0,6392,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622478,BAO_0000218,Oral bioavailability in dog,5374,,,50588,Intermediate
1,,1,,9615.0,6393,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623172,BAO_0000218,Compound was tested for the oral bioavailability in dog; No availability,5374,,,50588,Intermediate
1,,1,,9615.0,6394,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623173,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),6265,,,50588,Intermediate
1,,1,,9615.0,6395,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623174,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,5654,,,50588,Intermediate
1,,1,,9615.0,6396,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623175,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,5654,,,50588,Intermediate
1,,1,,9615.0,6397,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623340,BAO_0000218,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),16456,,,50588,Intermediate
1,,1,,9615.0,6398,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623341,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),5302,,,50588,Intermediate
1,,1,,9615.0,6399,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623342,BAO_0000218,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),3624,,,50588,Intermediate
1,,1,,9615.0,6400,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623343,BAO_0000218,Oral bioavailability of active FTIs in dogs,16452,,,50588,Intermediate
1,,1,,9615.0,6401,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623344,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),5802,,,50588,Intermediate
1,,1,,9615.0,6402,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623345,BAO_0000218,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,,,50588,Expert
1,,1,,9615.0,6403,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875832,BAO_0000218,Oral bioavailability in dog,17839,,,50588,Intermediate
1,,1,,9615.0,6404,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623346,BAO_0000218,Oral bioavailability in dog,6762,,,50588,Intermediate
1,,1,,9615.0,6405,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623347,BAO_0000218,Oral bioavailability in dog,6821,,,50588,Intermediate
1,,1,,9615.0,6406,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623348,BAO_0000218,Oral bioavailability of compound was determined in dog; Not tested,6821,,,50588,Intermediate
1,,1,,9615.0,6407,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623349,BAO_0000218,Oral bioavailability in dog,5210,,,50588,Intermediate
1,,1,,9615.0,6408,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623350,BAO_0000218,Oral bioavailability (10 mg/kg) was determined in dog,6227,,,50588,Intermediate
1,,1,,9615.0,6409,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623351,BAO_0000218,Oral bioavailability,761,,,50588,Intermediate
1,,1,,9615.0,6410,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623352,BAO_0000218,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),761,,,50588,Intermediate
1,,1,,9615.0,6411,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623353,BAO_0000218,Oral bioavailability administered in solution in rats,761,,,50588,Intermediate
1,,1,,9615.0,6412,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875833,BAO_0000218,Oral bioavailability after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6413,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623354,BAO_0000218,Oral bioavailability at a dose of 1 mg/kg in dogs,5474,,,50588,Intermediate
1,,1,,9615.0,6414,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623355,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg p.o.),6535,,,50588,Intermediate
1,,1,,9615.0,6415,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623356,BAO_0000218,Oral bioavailability in Dog; ND = not determined,6535,,,50588,Intermediate
1,,1,,9615.0,6416,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623357,BAO_0000218,Oral bioavailability in dog,3352,,,50588,Intermediate
1,,1,,9615.0,6417,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623358,BAO_0000218,Oral bioavailability in dog,6168,,,50588,Intermediate
1,,1,,9615.0,6418,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623359,BAO_0000218,Oral bioavailability in dog,5988,,,50588,Intermediate
1,,1,,9615.0,6419,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623360,BAO_0000218,Oral bioavailability in dog,4942,,,50588,Intermediate
1,,1,,9615.0,6420,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623361,BAO_0000218,Oral bioavailability in dogs; No data,4942,,,50588,Intermediate
1,,1,,9615.0,6421,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623362,BAO_0000218,Oral bioavailability measured in dogs,14541,,,50588,Intermediate
1,,1,,9615.0,6422,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623363,BAO_0000218,Oral bioavailability in dog,4449,,,50588,Intermediate
1,,1,,9615.0,6423,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623364,BAO_0000218,Oral bioavailability was calculated in dog,6057,,,50588,Intermediate
1,,1,,9615.0,6424,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875834,BAO_0000218,Oral bioavailability after 0.3 mg/kg po administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,6425,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623365,BAO_0000218,Oral bioavailability in dog (i.v. dosing),5542,,,50588,Intermediate
1,,1,,9615.0,6426,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623366,BAO_0000218,Oral bioavailability in dog,5542,,,50588,Intermediate
1,,1,,9615.0,6427,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623367,BAO_0000218,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,5546,,,50588,Intermediate
1,,1,,9615.0,6428,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623368,BAO_0000218,Oral bioavailability in Beagle dogs,4514,,,50588,Intermediate
1,,1,,9615.0,6429,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623369,BAO_0000218,Oral bioavailability in dog,3624,,,50588,Intermediate
1,,1,,9615.0,6430,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623370,BAO_0000218,Oral bioavailability in dog,3854,,,50588,Intermediate
1,,1,,9615.0,6431,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623371,BAO_0000218,Oral bioavailability in dog,5836,,,50588,Intermediate
1,,1,,9615.0,6432,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623372,BAO_0000218,Oral bioavailability in dog,5940,,,50588,Intermediate
1,,1,,9615.0,6433,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621351,BAO_0000218,Oral bioavailability in dog,6168,,,50588,Intermediate
1,,1,,9615.0,6434,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621352,BAO_0000218,Oral bioavailability in dog,6227,,,50588,Intermediate
1,,1,,9615.0,6435,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621353,BAO_0000218,Oral bioavailability in dog,6251,,,50588,Intermediate
1,,1,,9615.0,6436,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621354,BAO_0000218,Oral bioavailability in dog,6448,,,50588,Intermediate
1,,1,,9615.0,6437,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621355,BAO_0000218,Oral bioavailability in dog,6647,,,50588,Intermediate
1,,1,,9615.0,6438,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621356,BAO_0000218,Oral bioavailability in dog,5940,,,50588,Intermediate
1,,1,,9615.0,6439,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621357,BAO_0000218,Oral bioavailability in dog,933,,,50588,Intermediate
1,,1,,9615.0,6440,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621358,BAO_0000218,Oral bioavailability in dog,5210,,,50588,Intermediate
1,,1,,9615.0,6441,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621359,BAO_0000218,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),6642,,,50588,Intermediate
1,,1,,9615.0,6442,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621360,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),6641,,,50588,Intermediate
1,,1,,9615.0,6443,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621361,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),6642,,,50588,Intermediate
1,,1,,9615.0,6444,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621362,BAO_0000218,Oral bioavailability in dog,5472,,,50588,Intermediate
1,,1,,9615.0,6445,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621363,BAO_0000218,Oral bioavailability in dog,5985,,,50588,Intermediate
1,,1,,9615.0,6446,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621364,BAO_0000218,Oral bioavailability in dog,15660,,,50588,Intermediate
1,,1,,9615.0,6447,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621166,BAO_0000218,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),5530,,,50588,Intermediate
1,,1,,9615.0,6448,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621167,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg i.v.),5530,,,50588,Intermediate
1,,1,,9615.0,6449,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621168,BAO_0000218,Oral bioavailability (F) in dogs,6305,,,50588,Intermediate
1,,1,,9615.0,6450,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621169,BAO_0000218,Oral bioavailability in dog,5210,,,50588,Intermediate
1,,1,,9615.0,6451,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875950,BAO_0000218,Bioavailability in dog,5238,,,50588,Intermediate
1,,1,,9615.0,6452,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621170,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),5668,,,50588,Intermediate
1,,1,,9615.0,6453,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621171,BAO_0000218,Oral bioavailability after peroral administration at 5 mpk in Dog,5668,,,50588,Intermediate
1,,1,,9615.0,6454,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621172,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),5668,,,50588,Intermediate
1,,1,,9615.0,6455,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621173,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),6084,,,50588,Intermediate
1,,1,42.0,10090.0,6456,,,A,2113.0,,,Mus musculus,CCRF S-180,N,CHEMBL621174,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,6599,,Kidney,50594,Intermediate
1,,1,42.0,10090.0,6457,,,A,2113.0,,,Mus musculus,CCRF S-180,N,CHEMBL621175,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,6599,,Kidney,50594,Intermediate
1,,1,42.0,10090.0,6458,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621176,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6459,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621177,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6460,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621178,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6461,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621179,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6462,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621180,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6463,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL875951,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6464,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL621181,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6465,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL621182,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6466,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL621183,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6467,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL621184,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6468,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621185,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6469,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621186,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6470,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621187,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6471,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621188,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6472,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621189,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6473,,,A,2106.0,,,Mus musculus,CCRF S-180,N,CHEMBL621190,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,6599,,Spleen,50594,Intermediate
1,,1,42.0,10090.0,6474,,,A,2106.0,,,Mus musculus,CCRF S-180,N,CHEMBL618520,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,6599,,Spleen,50594,Intermediate
1,,1,42.0,10090.0,6475,,,A,2106.0,,,Mus musculus,CCRF S-180,N,CHEMBL621739,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,6599,,Spleen,50594,Intermediate
1,,1,42.0,10090.0,6476,,,A,2106.0,,,Mus musculus,CCRF S-180,N,CHEMBL621740,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,6599,,Spleen,50594,Intermediate
1,,1,42.0,10090.0,6477,,,A,2106.0,,,Mus musculus,CCRF S-180,N,CHEMBL621741,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,6599,,Spleen,50594,Intermediate
1,,1,42.0,10090.0,6478,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621742,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6479,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621743,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6480,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621744,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6481,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621745,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6482,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621746,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6483,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621747,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6484,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621748,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6485,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621749,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6486,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621750,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6487,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL621751,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6488,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL621752,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6489,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL621753,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6490,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL875955,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6491,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL621754,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6492,,,A,948.0,,,Mus musculus,CCRF S-180,N,CHEMBL621755,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,6599,,Heart,50594,Intermediate
1,,1,42.0,10090.0,6493,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL621756,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6494,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL624199,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6495,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL624200,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6496,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL624375,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6497,,,A,2107.0,,,Mus musculus,CCRF S-180,N,CHEMBL624376,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,6599,,Liver,50594,Intermediate
1,,1,42.0,10090.0,6498,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL624377,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6499,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL624378,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,6599,,Lung,50594,Intermediate
1,,1,,107673.0,6500,,,F,,,,aeinetobacter anitrotap,,N,CHEMBL857901,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,,,50067,Intermediate
1,,1,,107673.0,6501,,,F,,,,Acinetobacter calcoaceticus subsp. anitratus,,N,CHEMBL875274,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,,,50067,Intermediate
1,,1,,107673.0,6502,,,F,,,,Acinetobacter calcoaceticus subsp. anitratus,,N,CHEMBL624379,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,,,50067,Intermediate
1,,1,,107673.0,6503,,,F,,,,aeinetobacter anitrotap,,N,CHEMBL624380,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,,,50067,Intermediate
1,,1,,471.0,6504,,,F,,,,Acinetobacter calcoaceticus,,N,CHEMBL624381,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),10624,,,50192,Intermediate
1,,1,,28377.0,6505,,,F,,,,Anolis carolinensis,,N,CHEMBL624382,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,17216,,,50714,Intermediate
1,,1,,28377.0,6506,,,F,,,,Anolis carolinensis,,N,CHEMBL624383,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,17216,,,50714,Intermediate
1,,1,,1655.0,6507,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624384,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii 631,9560,,,50296,Intermediate
1,,1,,1655.0,6508,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624385,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii B74,9560,,,50296,Intermediate
1,,1,,1655.0,6509,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624386,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/3,9560,,,50296,Intermediate
1,,1,,1655.0,6510,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624387,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/9,9560,,,50296,Intermediate
1,,1,,1655.0,6511,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624388,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii 631,9560,,,50296,Intermediate
1,,1,,1655.0,6512,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624389,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/9,9560,,,50296,Intermediate
1,,1,,1655.0,6513,,,F,,,,Actinomyces naeslundii,,N,CHEMBL624390,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii B74,9560,,,50296,Intermediate
1,,1,,1655.0,6514,,,F,,,,Actinomyces naeslundii,,N,CHEMBL875275,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/3,9560,,,50296,Intermediate
1,,1,,85549.0,6515,,,F,,,,Artemia salina,,N,CHEMBL624391,BAO_0000218,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,114,,,50056,Intermediate
1,,1,,85549.0,6516,,,F,,,,Artemia salina,,N,CHEMBL623636,BAO_0000218,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",114,,,50056,Intermediate
1,,1,,6253.0,6517,,,F,,,,Ascaris suum,,N,CHEMBL623637,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6518,,,F,,,,Ascaris suum,,N,CHEMBL623638,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6519,,,F,,,,Ascaris suum,,N,CHEMBL623639,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6520,,,F,,,,Ascaris suum,,N,CHEMBL623640,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6521,,,F,,,,Ascaris suum,,N,CHEMBL623641,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6522,,,F,,,,Ascaris suum,,N,CHEMBL623642,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,10841,,,50532,Intermediate
1,,1,,6253.0,6523,,,F,,,,Ascaris suum,,N,CHEMBL623643,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6524,,,F,,,,Ascaris suum,,N,CHEMBL623644,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6525,,,F,,,,Ascaris suum,,N,CHEMBL623645,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6526,,,F,,,,Ascaris suum,,N,CHEMBL623646,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6527,,,F,,,,Ascaris suum,,N,CHEMBL623647,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,10841,,,50532,Intermediate
1,,1,,6253.0,6528,,,F,,,,Ascaris suum,,N,CHEMBL623648,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,10841,,,50532,Intermediate
1,,1,,1656.0,6529,,,F,,,,Actinomyces viscosus,,N,CHEMBL623649,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,8117,,,50366,Intermediate
1,,1,,1656.0,6530,,,F,,,,Actinomyces viscosus,,N,CHEMBL623650,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,8117,,,50366,Intermediate
1,,1,,1656.0,6531,,,F,,,,Actinomyces viscosus,,N,CHEMBL623651,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus 8A06,9560,,,50366,Intermediate
1,,1,,1656.0,6532,,,F,,,,Actinomyces viscosus,,N,CHEMBL623652,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-100,9560,,,50366,Expert
1,,1,,1656.0,6533,,,F,,,,Actinomyces viscosus,,N,CHEMBL623653,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-626,9560,,,50366,Intermediate
1,,1,,1656.0,6534,,,F,,,,Actinomyces viscosus,,N,CHEMBL623654,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus T14V,9560,,,50366,Intermediate
1,,1,,1656.0,6535,,,F,,,,Actinomyces viscosus,,N,CHEMBL623655,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 8A06,9560,,,50366,Intermediate
1,,1,,1656.0,6536,,,F,,,,Actinomyces viscosus,,N,CHEMBL623656,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100,9560,,,50366,Intermediate
1,,1,,1656.0,6537,,,F,,,,Actinomyces viscosus,,N,CHEMBL623657,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,9560,,,50366,Expert
1,,1,,1656.0,6538,,,F,,,,Actinomyces viscosus,,N,CHEMBL623658,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",9560,,,50366,Intermediate
1,,1,,1656.0,6539,,,F,,,,Actinomyces viscosus,,N,CHEMBL623659,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",9560,,,50366,Intermediate
1,,1,,1656.0,6540,,,F,,,,Actinomyces viscosus,,N,CHEMBL623660,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 626,9560,,,50366,Intermediate
1,,1,,1656.0,6541,,,F,,,,Actinomyces viscosus,,N,CHEMBL623661,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus T14V,9560,,,50366,Intermediate
1,,1,,6277.0,6542,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL875281,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6543,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL623662,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6544,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL623663,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6545,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL623664,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6546,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL623665,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,165.0,9606.0,6547,,,F,,,,Homo sapiens,A673,N,CHEMBL621856,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,10708,,,80023,Intermediate
1,,1,645.0,9606.0,6548,,,F,,,,Homo sapiens,A704,N,CHEMBL620432,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,10708,,,80661,Intermediate
0,,1,,10116.0,6549,,,F,,,,Rattus norvegicus,,U,CHEMBL620433,BAO_0000219,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,416,,,22226,Autocuration
1,,1,625.0,10090.0,6550,,,F,,,,Mus musculus,A9,N,CHEMBL620434,BAO_0000219,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,14354,,,80024,Intermediate
1,,1,625.0,10090.0,6551,,,F,,,,Mus musculus,A9,N,CHEMBL620435,BAO_0000219,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,14354,,,80024,Intermediate
1,,1,625.0,9606.0,6552,,,F,,,,Homo sapiens,A9,N,CHEMBL620436,BAO_0000219,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,5116,,,80024,Intermediate
1,,1,625.0,9606.0,6553,,,F,,,,Homo sapiens,A9,N,CHEMBL876597,BAO_0000219,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,5116,,,80024,Intermediate
1,,1,874.0,9606.0,6554,,,F,,,,Homo sapiens,Human ovarian carcinoma cell line,N,CHEMBL620437,BAO_0000219,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,15694,,,81037,Expert
1,,1,625.0,10090.0,6555,,,F,,,,Mus musculus,A9,N,CHEMBL620438,BAO_0000219,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",13038,,,80024,Expert
1,,1,625.0,10090.0,6556,,,F,,,,Mus musculus,A9,N,CHEMBL620439,BAO_0000219,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,13038,,,80024,Expert
1,,1,625.0,10090.0,6557,,,F,,,,Mus musculus,A9,N,CHEMBL619657,BAO_0000219,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,10923,,,80024,Expert
1,,1,625.0,10090.0,6558,,,F,,,,Mus musculus,A9,N,CHEMBL619658,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,10923,,,80024,Intermediate
1,,1,625.0,10090.0,6559,,,F,,,,Mus musculus,A9,N,CHEMBL619659,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,10923,,,80024,Intermediate
8,,1,,,6560,,,F,,,,,,H,CHEMBL619660,BAO_0000019,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10923,,,10649,Expert
1,,1,625.0,10090.0,6561,,,F,,,,Mus musculus,A9,N,CHEMBL619661,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,10923,,,80024,Intermediate
1,,1,625.0,10090.0,6562,,,F,,,,Mus musculus,A9,N,CHEMBL619662,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,10923,,,80024,Intermediate
1,,1,975.0,10029.0,6563,,,F,,,,Cricetulus griseus,AA6,N,CHEMBL619663,BAO_0000219,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,8158,,,80663,Intermediate
0,,1,,9606.0,6564,,,F,,,,Homo sapiens,,U,CHEMBL619664,BAO_0000219,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,15494,,,22226,Autocuration
0,,1,,9606.0,6565,,,F,,,,Homo sapiens,,U,CHEMBL619665,BAO_0000219,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",15494,,,22226,Autocuration
1,,1,974.0,9606.0,6566,,,F,,,,Homo sapiens,AA5,N,CHEMBL883244,BAO_0000219,Anti -HIV activity was measured against AA5/HIV-1(IIIB),12348,,,80662,Intermediate
1,,1,974.0,9606.0,6567,,,F,,,,Homo sapiens,AA5,N,CHEMBL884011,BAO_0000219,Cytotoxicity was measured against AA5/HIV-1(IIIB),12348,,,80662,Intermediate
1,,1,974.0,9606.0,6568,,,F,,,,Homo sapiens,AA5,N,CHEMBL619666,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,2726,,,80662,Intermediate
1,,1,379.0,9606.0,6569,,,F,,,,Homo sapiens,U-937,N,CHEMBL619667,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,2726,,,80566,Intermediate
1,,1,274.0,10029.0,6570,,,F,,,,Cricetulus griseus,UV4,N,CHEMBL619668,BAO_0000219,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,10747,,,80578,Intermediate
1,,1,185.0,10029.0,6571,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619669,BAO_0000219,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",11005,,,80089,Expert
1,,1,185.0,10029.0,6572,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL876608,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6573,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619670,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6.,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6574,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619671,BAO_0000219,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6575,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619672,BAO_0000219,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6576,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619673,BAO_0000219,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6577,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619674,BAO_0000219,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",13436,,,80089,Intermediate
1,,1,185.0,10029.0,6578,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619675,BAO_0000219,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",13435,,,80089,Intermediate
1,,1,185.0,10029.0,6579,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619676,BAO_0000219,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,13302,,,80089,Intermediate
1,,1,185.0,10029.0,6580,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619677,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6581,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619678,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6582,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619679,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6583,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL619680,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,12878,,,80089,Expert
1,,1,185.0,10029.0,6584,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL621457,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,12878,,,80089,Intermediate
1,,1,185.0,10029.0,6585,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL876609,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,14367,,,80089,Expert
1,,1,185.0,10029.0,6586,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL621458,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,14367,,,80089,Intermediate
1,,1,185.0,36483.0,6587,,,F,,,,hampster,CHO-AA8,N,CHEMBL621459,BAO_0000219,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,12398,,,80089,Expert
1,,1,185.0,10029.0,6588,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL621460,BAO_0000219,Aerobic growth inhibition in Chinese hamster cell line AA8,12878,,,80089,Expert
1,,1,185.0,10029.0,6589,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL621461,BAO_0000219,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,13820,,,80089,Expert
1,,1,185.0,10029.0,6590,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL621462,BAO_0000219,Inhibition of growth under aerobic conditions in AA8 cells,13436,,,80089,Expert
1,,1,,9615.0,6591,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621463,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),6084,,,50588,Intermediate
1,,1,,9615.0,6592,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621464,BAO_0000218,Oral bioavailability in dog at 10 mg/kg of the compound,5711,,,50588,Intermediate
1,,1,,9615.0,6593,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621465,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),4353,,,50588,Intermediate
1,,1,,9615.0,6594,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621466,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),4353,,,50588,Intermediate
1,,1,,9615.0,6595,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621467,BAO_0000218,Oral bioavailability in dog (mongrel),17800,,,50588,Intermediate
1,,1,,9615.0,6596,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621468,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),3994,,,50588,Intermediate
1,,1,,9615.0,6597,,In vivo,F,,,,Canis lupus familiaris,,N,CHEMBL876734,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),3994,,,50588,Intermediate
1,,1,,9615.0,6598,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618476,BAO_0000218,Bioavailability in dog,5145,,,50588,Intermediate
1,,1,,9615.0,6599,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618477,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),16452,,,50588,Intermediate
1,,1,,9615.0,6600,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618478,BAO_0000218,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),16452,,,50588,Intermediate
1,,1,,9615.0,6601,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618479,BAO_0000218,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,5983,,,50588,Intermediate
1,,1,,9615.0,6602,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618480,BAO_0000218,Bioavailability in dog,4273,,,50588,Intermediate
1,,1,,9615.0,6603,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618481,BAO_0000218,Bioavailability in dog (dose 3-10 mg/kg),12500,,,50588,Intermediate
1,,1,,9615.0,6604,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618482,BAO_0000218,The compound was tested for bioavailability of compound in plasma of dog; Complete,12500,,Plasma,50588,Intermediate
1,,1,,9615.0,6605,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618483,BAO_0000218,Oral bioavailability in dog,3639,,,50588,Intermediate
1,,1,,9615.0,6606,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618484,BAO_0000218,Oral bioavailability in dog,3880,,,50588,Intermediate
1,,1,,9615.0,6607,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618485,BAO_0000218,Bioavailability in dog,4838,,,50588,Intermediate
1,,1,,9615.0,6608,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618486,BAO_0000218,oral bioavailability was measured in dogs,15600,,,50588,Intermediate
1,,1,,9615.0,6609,,,A,,,,Canis lupus familiaris,,N,CHEMBL618487,BAO_0000218,Compound was tested for plasma protein binding in dog; Not determined,17248,,,50588,Intermediate
1,,1,,9615.0,6610,,,A,,,,Canis lupus familiaris,,N,CHEMBL618488,BAO_0000218,Compound was tested for plasma protein binding of dog,17248,,,50588,Intermediate
1,,1,,9615.0,6611,,,A,,,,Canis lupus familiaris,,N,CHEMBL876735,BAO_0000218,Compound was tested for plasma protein binding of dog; Not determined,17248,,,50588,Intermediate
1,,1,,9615.0,6612,,,A,,,,Canis lupus familiaris,,N,CHEMBL618489,BAO_0000218,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,17443,,,50588,Intermediate
1,,1,,9615.0,6613,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618490,BAO_0000218,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,4186,,,50588,Intermediate
1,,1,,9615.0,6614,,,A,,,,Canis lupus familiaris,,N,CHEMBL618491,BAO_0000218,Half life was determined,3749,,,50588,Intermediate
1,,1,,9615.0,6615,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618492,BAO_0000218,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,3249,,,50588,Intermediate
1,,1,,9615.0,6616,,,A,,,,Canis lupus familiaris,,N,CHEMBL873354,BAO_0000218,Half life was evaluated in dog,3022,,,50588,Intermediate
1,,1,,9615.0,6617,,,A,,,,Canis lupus familiaris,,N,CHEMBL618493,BAO_0000218,Half life was determined,3749,,,50588,Intermediate
1,,1,,9615.0,6618,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618494,BAO_0000218,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,,50588,Intermediate
1,,1,,9615.0,6619,,In vivo,A,948.0,,,Canis lupus familiaris,,N,CHEMBL618495,BAO_0000218,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,Heart,50588,Intermediate
1,,1,,9615.0,6620,,In vivo,A,2113.0,,,Canis lupus familiaris,,N,CHEMBL618496,BAO_0000218,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,Kidney,50588,Intermediate
1,,1,,9615.0,6621,,In vivo,A,2107.0,,,Canis lupus familiaris,,N,CHEMBL618497,BAO_0000218,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,Liver,50588,Intermediate
1,,1,,9615.0,6622,,In vivo,A,2048.0,,,Canis lupus familiaris,,N,CHEMBL618498,BAO_0000218,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,Lung,50588,Intermediate
1,,1,,9615.0,6623,,In vivo,A,2106.0,,,Canis lupus familiaris,,N,CHEMBL618499,BAO_0000218,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,,Spleen,50588,Intermediate
1,,1,,9615.0,6624,,,A,,,,Canis lupus familiaris,,N,CHEMBL876736,BAO_0000218,LogP in dog,3639,,,50588,Intermediate
1,,1,,9615.0,6625,,,A,,,,Canis lupus familiaris,,N,CHEMBL618500,BAO_0000218,Partition coefficient (logP),6227,,,50588,Intermediate
1,,1,,9615.0,6626,,,A,,,,Canis lupus familiaris,,N,CHEMBL857831,BAO_0000218,Partition coefficient in dog,6227,,,50588,Intermediate
1,,1,,9615.0,6627,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618501,BAO_0000218,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,6628,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618502,BAO_0000218,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),4809,,,50588,Intermediate
1,,1,,9615.0,6629,,,A,,,,Canis lupus familiaris,,N,CHEMBL618503,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,5600,,,50588,Intermediate
1,,1,,9615.0,6630,,,A,,,,Canis lupus familiaris,,N,CHEMBL618504,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),14294,,,50588,Intermediate
1,,1,,9615.0,6631,,,A,,,,Canis lupus familiaris,,N,CHEMBL618505,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),14294,,,50588,Intermediate
1,,1,,9615.0,6632,,,A,,,,Canis lupus familiaris,,N,CHEMBL618506,BAO_0000218,Metabolism of compound in dog S9 microsomes; Trace,14294,,,50588,Intermediate
1,,1,,9615.0,6633,,,A,2107.0,,,Canis lupus familiaris,,N,CHEMBL618507,BAO_0000218,In vitro metabolic potential in dog liver microsomes,6251,,Liver,50588,Intermediate
1,,1,,9615.0,6634,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876737,BAO_0000218,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,3748,,,50588,Intermediate
1,,1,,9615.0,6635,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618508,BAO_0000218,Oral bioavailability in dog,2713,,,50588,Intermediate
1,,1,,9615.0,6636,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618509,BAO_0000218,Oral bioavailability in dog,6512,,,50588,Intermediate
1,,1,,9615.0,6637,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618510,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,,,50588,Intermediate
1,,1,,9615.0,6638,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618511,BAO_0000218,The compound was tested for bioavailability in dogs,3749,,,50588,Intermediate
1,,1,,9615.0,6639,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618512,BAO_0000218,The compound was tested for oral bioavailability in dogs,3749,,,50588,Intermediate
1,,1,,9615.0,6640,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618513,BAO_0000218,Oral bioavailability in dog,6742,,,50588,Intermediate
1,,1,,9615.0,6641,,,A,,,,Canis lupus familiaris,,N,CHEMBL618514,BAO_0000218,Compound was tested for percent protein binding (PB) in dog,6227,,,50588,Intermediate
1,,1,,9615.0,6642,,,A,,,,Canis lupus familiaris,,N,CHEMBL620052,BAO_0000218,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,6874,,,50588,Intermediate
1,,1,,9615.0,6643,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620053,BAO_0000218,Compound was evaluated for plasma clearance.,2877,,Plasma,50588,Intermediate
1,,1,,9615.0,6644,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620054,BAO_0000218,The compound was tested for plasma clearance in dog,12500,,Plasma,50588,Intermediate
1,,1,,9615.0,6645,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620055,BAO_0000218,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,12500,,Plasma,50588,Intermediate
1,,1,,9615.0,6646,,,A,,,,Canis lupus familiaris,,N,CHEMBL620056,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,6647,,,A,2107.0,,,Canis lupus familiaris,,N,CHEMBL620057,BAO_0000218,In vitro relative rate of metabolism was determined in dog liver microsomes,5542,,Liver,50588,Intermediate
1,,1,,9615.0,6648,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618939,BAO_0000218,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,17594,,,50588,Intermediate
1,,1,,9615.0,6649,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618940,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,2652,,,50588,Intermediate
1,,1,,9615.0,6650,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618941,BAO_0000218,Half life after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,42.0,10090.0,6651,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL624473,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6652,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL624474,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6653,,,A,2048.0,,,Mus musculus,CCRF S-180,N,CHEMBL624475,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,6599,,Lung,50594,Intermediate
1,,1,42.0,10090.0,6654,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL624476,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6655,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL623478,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6656,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL623479,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6657,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL623480,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,6599,,,50594,Intermediate
1,,1,42.0,10090.0,6658,,,A,,,,Mus musculus,CCRF S-180,N,CHEMBL623481,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,6599,,,50594,Intermediate
1,,1,,10090.0,6659,,,A,955.0,,,Mus musculus,,N,CHEMBL623482,BAO_0000218,C2 in brain of mice at the oral dose of 50 mg/kg,17641,,Brain,50594,Intermediate
1,,1,,10090.0,6660,,,A,2113.0,,,Mus musculus,,N,CHEMBL623483,BAO_0000218,C2 in kidney of mice at the oral dose of 50 mg/kg,17641,,Kidney,50594,Intermediate
1,,1,,10090.0,6661,,,A,2107.0,,,Mus musculus,,N,CHEMBL623484,BAO_0000218,C2 in liver of mice at the oral dose of 50 mg/kg,17641,,Liver,50594,Intermediate
1,,1,,10090.0,6662,,,A,2048.0,,,Mus musculus,,N,CHEMBL623485,BAO_0000218,C2 in lungs of mice at the oral dose of 50 mg/kg,17641,,Lung,50594,Intermediate
1,,1,,10090.0,6663,,,A,2106.0,,,Mus musculus,,N,CHEMBL623486,BAO_0000218,C2 in spleen of mice at the oral dose of 50 mg/kg,17641,,Spleen,50594,Intermediate
1,,1,,10090.0,6664,,In vivo,A,,,,Mus musculus,,N,CHEMBL623487,BAO_0000218,Plasma clearance in mouse,17852,,,50594,Intermediate
1,,1,,10090.0,6665,,In vivo,A,,,,Mus musculus,,N,CHEMBL623488,BAO_0000218,Clearance of compound after intravenous administration in mice at 24 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,6666,,In vivo,A,,,,Mus musculus,,N,CHEMBL623489,BAO_0000218,Clearance from mouse blood following i.v. administration of 10 mg/kg,17837,,,50594,Intermediate
1,,1,,10090.0,6667,,In vivo,A,,,,Mus musculus,,N,CHEMBL875157,BAO_0000218,Clearance was evaluated in mice after intravenous administration,2675,,,50594,Intermediate
1,,1,,10090.0,6668,,In vivo,A,,,,Mus musculus,,N,CHEMBL623490,BAO_0000218,Clearance was evaluated in mice after oral administration,2675,,,50594,Intermediate
1,,1,,10090.0,6669,,In vivo,A,,,,Mus musculus,,N,CHEMBL623491,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in mouse,4239,,,50594,Intermediate
1,,1,,10090.0,6670,,In vivo,A,,,,Mus musculus,,N,CHEMBL623492,BAO_0000218,Plasma clearance of compound was determined at 40 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,6671,,In vivo,A,,,,Mus musculus,,N,CHEMBL623493,BAO_0000218,Plasma clearance of at 24 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,6672,,In vivo,A,,,,Mus musculus,,N,CHEMBL623494,BAO_0000218,Plasma clearance at 24 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,6673,,In vivo,A,,,,Mus musculus,,N,CHEMBL623495,BAO_0000218,Plasma clearance at 5 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,6674,,In vivo,A,,,,Mus musculus,,N,CHEMBL623496,BAO_0000218,Plasma clearance in mice,5727,,,50594,Intermediate
1,,1,,10090.0,6675,,In vivo,A,,,,Mus musculus,,N,CHEMBL623497,BAO_0000218,Plasma clearance value upon iv administration in mouse,2862,,,50594,Intermediate
1,,1,,10090.0,6676,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623498,BAO_0000218,Total plasma clearance in mice,5980,,Plasma,50594,Intermediate
1,,1,,10090.0,6677,,In vivo,A,,,,Mus musculus,,N,CHEMBL623499,BAO_0000218,Clearance in mouse,17592,,,50594,Intermediate
1,,1,,10090.0,6678,,In vivo,A,,,,Mus musculus,,N,CHEMBL623500,BAO_0000218,Clearance value was determined,17718,,,50594,Intermediate
1,,1,,10090.0,6679,,In vivo,A,,,,Mus musculus,,N,CHEMBL623501,BAO_0000218,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
0,,1,,,6680,,,P,,,,,,U,CHEMBL875158,BAO_0000100,Calculated partition coefficient (clogP),17384,,,22229,Intermediate
1,,1,,10090.0,6681,,In vivo,A,,,,Mus musculus,,N,CHEMBL623502,BAO_0000218,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,6062,,,50594,Intermediate
1,,1,,10090.0,6682,,In vivo,A,,,,Mus musculus,,N,CHEMBL623503,BAO_0000218,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,17734,,,50594,Intermediate
1,,1,,10090.0,6683,,In vivo,A,,,,Mus musculus,,N,CHEMBL623504,BAO_0000218,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,,,50594,Intermediate
1,,1,,10090.0,6684,,In vivo,A,,,,Mus musculus,,N,CHEMBL623505,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,6685,,In vivo,A,,,,Mus musculus,,N,CHEMBL623506,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,6686,,In vivo,A,,,,Mus musculus,,N,CHEMBL623507,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,,,50594,Intermediate
1,,1,,10090.0,6687,,In vivo,A,,,,Mus musculus,,N,CHEMBL623508,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,16597,,,50594,Intermediate
1,,1,,10090.0,6688,,In vivo,A,,,,Mus musculus,,N,CHEMBL623509,BAO_0000218,Cmax after oral administration at 30 mg/kg in ICR mouse,5781,,,50594,Intermediate
1,,1,,10090.0,6689,,In vivo,A,,,,Mus musculus,,N,CHEMBL875159,BAO_0000218,Cmax after peroral administration in mice at 2.4 uM/kg,17764,,,50594,Intermediate
1,,1,,10090.0,6690,,In vivo,A,955.0,,,Mus musculus,,N,CHEMBL623510,BAO_0000218,Cmax in brain of mice at the oral dose of 50 mg/kg,17641,,Brain,50594,Intermediate
1,,1,,10090.0,6691,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL623511,BAO_0000218,Cmax in kidney of mice at the oral dose of 50 mg/kg,17641,,Kidney,50594,Intermediate
1,,1,,10090.0,6692,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL623512,BAO_0000218,Cmax in liver of mice at the oral dose of 50 mg/kg,17641,,Liver,50594,Intermediate
1,,1,,10090.0,6693,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623513,BAO_0000218,Cmax in lungs of mice at the oral dose of 50 mg/kg,17641,,Lung,50594,Intermediate
1,,1,,10090.0,6694,,In vivo,F,,,,Mus musculus,,N,CHEMBL623514,BAO_0000218,Cmax in mice at 18 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,6695,,In vivo,F,,,,Mus musculus,,N,CHEMBL622609,BAO_0000218,Cmax in mice at 23 uM/kg i.v. administration,17764,,,50594,Intermediate
1,,1,,10090.0,6696,,In vivo,F,,,,Mus musculus,,N,CHEMBL622610,BAO_0000218,Cmax in mice at 24 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,6697,,In vivo,F,,,,Mus musculus,,N,CHEMBL621823,BAO_0000218,Cmax in mice at 25 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,6698,,In vivo,F,,,,Mus musculus,,N,CHEMBL621824,BAO_0000218,Cmax in mice at 26 uM/kg i.p. administration,17764,,,50594,Intermediate
1,,1,,10090.0,6699,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL621825,BAO_0000218,Cmax in spleen of mice at the oral dose of 50 mg/kg,17641,,Spleen,50594,Intermediate
1,,1,,10090.0,6700,,In vivo,A,,,,Mus musculus,,N,CHEMBL621826,BAO_0000218,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,6701,,In vivo,A,,,,Mus musculus,,N,CHEMBL621827,BAO_0000218,Cmax value at a dose of 10 mg/kg peroral administration in mice.,16597,,,50594,Intermediate
1,,1,,10090.0,6702,,In vivo,A,,,,Mus musculus,,N,CHEMBL621828,BAO_0000218,Cmax value was determined,5727,,,50594,Intermediate
1,,1,,10090.0,6703,,In vivo,A,,,,Mus musculus,,N,CHEMBL621829,BAO_0000218,Cmax value in IRC mice,5951,,,50594,Intermediate
1,,1,,10090.0,6704,,In vivo,A,,,,Mus musculus,,N,CHEMBL621830,BAO_0000218,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,6705,,In vivo,A,,,,Mus musculus,,N,CHEMBL621831,BAO_0000218,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,,,50594,Intermediate
1,,1,,10090.0,6706,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL621832,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,14239,,Plasma,50594,Intermediate
1,,1,,10090.0,6707,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL624579,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",4890,,Plasma,50594,Intermediate
1,,1,,10090.0,6708,,In vivo,A,,,,Mus musculus,,N,CHEMBL624580,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,429,,,50594,Intermediate
1,,1,,6277.0,6709,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL624581,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6710,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL624582,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,,6277.0,6711,,,F,,,,Acanthocheilonema viteae,,N,CHEMBL624583,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,10986,,,50535,Intermediate
1,,1,455.0,9606.0,6712,,,F,,,,Homo sapiens,A-375,N,CHEMBL624584,BAO_0000219,Inhibitory activity against human tumor cell line A0375 melanoma.,13227,,,80018,Intermediate
9,,1,,10116.0,6713,,,B,,,,Rattus norvegicus,,D,CHEMBL624585,BAO_0000249,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,4481,Brain membranes,,12512,Expert
9,,1,,9606.0,6714,,,F,,,,Homo sapiens,,D,CHEMBL875165,BAO_0000019,Forskolin-induced cAMP production at human A1 adenosine receptor,16931,,,114,Expert
8,,1,449.0,,6715,,,F,,,,,CHO,H,CHEMBL619490,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
8,,1,449.0,,6716,,,F,,,,,CHO,H,CHEMBL619491,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,3850,,,114,Autocuration
8,,1,449.0,,6717,,,F,,,,,CHO,H,CHEMBL619492,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,3850,,,114,Expert
8,,1,449.0,,6718,,,F,,,,,CHO,H,CHEMBL619493,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,3850,,,114,Expert
8,,1,449.0,,6719,,,F,,,,,CHO,H,CHEMBL619494,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,3850,,,114,Autocuration
8,,1,449.0,,6720,,,F,,,,,CHO,H,CHEMBL619495,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,3850,,,114,Autocuration
8,,1,449.0,,6721,,,F,,,,,CHO,H,CHEMBL619496,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
9,,1,449.0,9606.0,6722,,,F,,,,Homo sapiens,CHO,D,CHEMBL619497,BAO_0000219,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,3850,,,114,Expert
8,,1,449.0,,6723,,,F,,,,,CHO,H,CHEMBL619498,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,3850,,,114,Autocuration
8,,1,449.0,,6724,,,F,,,,,CHO,H,CHEMBL619499,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
8,,1,449.0,,6725,,,F,,,,,CHO,H,CHEMBL619500,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,3850,,,114,Expert
8,,1,449.0,,6726,,,F,,,,,CHO,H,CHEMBL619501,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
8,,1,449.0,,6727,,,F,,,,,CHO,H,CHEMBL619502,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,3850,,,114,Expert
8,,1,449.0,,6728,,,F,,,,,CHO,H,CHEMBL619503,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,3850,,,114,Autocuration
8,,1,449.0,,6729,,,F,,,,,CHO,H,CHEMBL619504,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,3850,,,114,Autocuration
8,,1,449.0,,6730,,,F,,,,,CHO,H,CHEMBL621298,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
8,,1,449.0,,6731,,,F,,,,,CHO,H,CHEMBL621299,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,3850,,,114,Expert
8,,1,449.0,,6732,,,F,,,,,CHO,H,CHEMBL621300,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,3850,,,114,Autocuration
8,,1,449.0,,6733,,,F,,,,,CHO,H,CHEMBL621301,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,3850,,,114,Autocuration
8,,1,449.0,,6734,,,F,,,,,CHO,H,CHEMBL621302,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,3850,,,114,Expert
1,,1,164.0,9986.0,6735,,,F,,,,Oryctolagus cuniculus,A10,N,CHEMBL621303,BAO_0000219,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,12680,,,80013,Intermediate
0,,1,164.0,10116.0,6736,,,F,,,,Rattus norvegicus,A10,U,CHEMBL621304,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1313,,,22226,Autocuration
0,,1,164.0,10116.0,6737,,,F,,,,Rattus norvegicus,A10,U,CHEMBL621305,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1313,,,22226,Autocuration
1,,1,164.0,10116.0,6738,,,F,,,,Rattus norvegicus,A10,N,CHEMBL621306,BAO_0000219,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,17567,,,80013,Intermediate
1,,1,164.0,10116.0,6739,,,F,,,,Rattus norvegicus,A10,N,CHEMBL618444,BAO_0000219,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,17567,,,80013,Intermediate
1,,1,164.0,10116.0,6740,,,F,,,,Rattus norvegicus,A10,N,CHEMBL618445,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,11819,,,80013,Intermediate
1,,1,185.0,10029.0,6741,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618446,BAO_0000219,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,13436,,,80089,Intermediate
1,,1,185.0,10029.0,6742,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618447,BAO_0000219,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,12687,,,80089,Intermediate
1,,1,185.0,10029.0,6743,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618448,BAO_0000219,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,12651,,,80089,Intermediate
1,,1,185.0,10029.0,6744,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618449,BAO_0000219,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,13300,,,80089,Intermediate
1,,1,185.0,10029.0,6745,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618637,BAO_0000219,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,15296,,,80089,Intermediate
1,,1,185.0,10029.0,6746,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618638,BAO_0000219,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",15328,,,80089,Intermediate
1,,1,185.0,10029.0,6747,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618639,BAO_0000219,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),13302,,,80089,Intermediate
1,,1,185.0,10029.0,6748,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618640,BAO_0000219,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",14367,,,80089,Expert
1,,1,185.0,10029.0,6749,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618641,BAO_0000219,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,17002,,,80089,Expert
1,,1,185.0,10029.0,6750,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618642,BAO_0000219,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,13436,,,80089,Intermediate
1,,1,185.0,10029.0,6751,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618643,BAO_0000219,Inhibitory activity against aerobic growth of AA8 cells.,13435,,,80089,Intermediate
1,,1,185.0,10029.0,6752,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL884013,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,,,80089,Intermediate
1,,1,185.0,10029.0,6753,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622723,BAO_0000219,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,,,80089,Expert
1,,1,185.0,10029.0,6754,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622724,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,,,80089,Intermediate
1,,1,185.0,10029.0,6755,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622725,BAO_0000219,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,15090,,,80089,Expert
1,,1,185.0,10029.0,6756,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622726,BAO_0000219,Cytotoxicity against AA8 cell line,10368,,,80089,Expert
1,,1,185.0,10029.0,6757,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622727,BAO_0000219,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),12651,,,80089,Intermediate
1,,1,185.0,10029.0,6758,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622728,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,,,80089,Intermediate
1,,1,185.0,10029.0,6759,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622729,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,,,80089,Intermediate
1,,1,185.0,10029.0,6760,,,A,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622730,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,,,80089,Intermediate
1,,1,185.0,10029.0,6761,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622731,BAO_0000219,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1890,,,80089,Intermediate
1,,1,185.0,10029.0,6762,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622732,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10747,,,80089,Intermediate
1,,1,185.0,10029.0,6763,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622733,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10747,,,80089,Intermediate
0,,1,,10029.0,6764,,,F,,,,Cricetulus griseus,,U,CHEMBL622734,BAO_0000218,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),11616,,,22224,Autocuration
1,,1,185.0,10029.0,6765,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL622735,BAO_0000219,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,11616,,,80089,Expert
0,,1,185.0,10029.0,6766,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618746,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6767,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618747,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6768,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL620540,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6769,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL620541,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6770,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL620542,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6771,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL620543,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,3471,,,22224,Autocuration
0,,1,185.0,10029.0,6772,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618832,BAO_0000219,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,3471,,,22224,Autocuration
1,,1,185.0,10029.0,6773,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL618833,BAO_0000219,Concentration required to reduce AA8 cell survival by 10%,11616,,,80089,Expert
0,,1,185.0,10029.0,6774,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618834,BAO_0000219,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",2656,,,22224,Autocuration
0,,1,185.0,10029.0,6775,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618835,BAO_0000219,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10518,,,22224,Autocuration
0,,1,185.0,10029.0,6776,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618836,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10518,,,22224,Autocuration
0,,1,185.0,10029.0,6777,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618837,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,10518,,,22224,Autocuration
0,,1,185.0,10029.0,6778,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618838,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,10518,,,22224,Autocuration
0,,1,185.0,10029.0,6779,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618839,BAO_0000219,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,16156,,,22224,Autocuration
0,,1,185.0,10029.0,6780,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618840,BAO_0000219,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,2656,,,22224,Autocuration
0,,1,,10029.0,6781,,,F,,,,Cricetulus griseus,,U,CHEMBL618841,BAO_0000019,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",11005,,,22224,Autocuration
0,,1,185.0,10029.0,6782,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618842,BAO_0000219,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,11942,,,22224,Autocuration
0,,1,185.0,10029.0,6783,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL618843,BAO_0000219,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,2128,,,22224,Autocuration
1,,1,,9615.0,6784,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618844,BAO_0000218,Half life period after 15 mg/kg iv dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6785,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618845,BAO_0000218,Half life period after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6786,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618846,BAO_0000218,Half life was measured after oral 2b administration (tested in 6 dogs),9579,,,50588,Intermediate
1,,1,,9615.0,6787,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618847,BAO_0000218,Half life was measured in dog after oral 17b administration,9579,,,50588,Intermediate
1,,1,,9615.0,6788,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618848,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,9579,,,50588,Intermediate
1,,1,,9615.0,6789,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618849,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,9579,,,50588,Intermediate
1,,1,,9615.0,6790,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618850,BAO_0000218,Tmax value after 15 mg/kg iv dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6791,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618851,BAO_0000218,Tmax value after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6792,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873815,BAO_0000218,Compound was evaluated for its half life when administered intravenously in dog,3184,,,50588,Intermediate
1,,1,,9615.0,6793,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL618852,BAO_0000218,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),5017,,Plasma,50588,Intermediate
1,,1,,9615.0,6794,,,A,,,,Canis lupus familiaris,,N,CHEMBL618853,BAO_0000218,Elimination Half-life of compound was determined in dog,6821,,,50588,Intermediate
1,,1,,9615.0,6795,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618854,BAO_0000218,Half life of compound in dog following oral administration,17839,,,50588,Intermediate
1,,1,,9615.0,6796,,,A,,,,Canis lupus familiaris,,N,CHEMBL618855,BAO_0000218,Half life of compound was determined in dog,17267,,,50588,Intermediate
1,,1,,9615.0,6797,,,A,178.0,,,Canis lupus familiaris,,N,CHEMBL618856,BAO_0000218,Half life of compound was determined in dog blood,4727,,Blood,50588,Intermediate
1,,1,,9615.0,6798,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875827,BAO_0000218,Half life after oral and iv dosing in dogs,5238,,,50588,Intermediate
1,,1,,9615.0,6799,,,A,,,,Canis lupus familiaris,,N,CHEMBL618857,BAO_0000218,Half life in dogs in hours,4942,,,50588,Intermediate
1,,1,,9615.0,6800,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618858,BAO_0000218,Half life on i.v. administration of 2 mg/kg was measured in dog,6505,,,50588,Intermediate
1,,1,,9615.0,6801,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618859,BAO_0000218,t1/2 in dog after oral dose (1 mg/kg),5130,,,50588,Intermediate
1,,1,,9615.0,6802,,,A,,,,Canis lupus familiaris,,N,CHEMBL618860,BAO_0000218,Half life was evaluated in dog,1475,,,50588,Intermediate
1,,1,,9615.0,6803,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618861,BAO_0000218,Half life period of compound was determined after intravenous administration at 2 mg/kg,17804,,,50588,Intermediate
1,,1,,9615.0,6804,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622539,BAO_0000218,Half life period of compound was determined after peroral administration at 2 mg/kg,17804,,,50588,Intermediate
1,,1,,9615.0,6805,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622540,BAO_0000218,Half life period (10 mg/kg) was determined in dog,6084,,,50588,Intermediate
1,,1,,9615.0,6806,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873803,BAO_0000218,Half life period (10 mg/kg) was determined in dog,6084,,,50588,Intermediate
1,,1,,9615.0,6807,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873804,BAO_0000218,Half life period by iv administration in dog at a dose of 0.3 mg/kg,5542,,,50588,Intermediate
1,,1,,9615.0,6808,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624311,BAO_0000218,Half life period by po administration in dog at a dose of 0.3 mg/kg,5542,,,50588,Intermediate
1,,1,,9615.0,6809,,,A,,,,Canis lupus familiaris,,N,CHEMBL624312,BAO_0000218,Half life period in dog,6084,,,50588,Intermediate
1,,1,,9615.0,6810,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624313,BAO_0000218,Half life period in dogs after oral administration at 1 mg/kg,6241,,,50588,Intermediate
1,,1,,9615.0,6811,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624314,BAO_0000218,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,,,50588,Intermediate
1,,1,,9615.0,6812,,,A,,,,Canis lupus familiaris,,N,CHEMBL624315,BAO_0000218,Half-life of compound was determined in dogs,6621,,,50588,Intermediate
1,,1,,9615.0,6813,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624316,BAO_0000218,Half-life in dog plasma,1696,,Plasma,50588,Intermediate
1,,1,,9615.0,6814,,,A,,,,Canis lupus familiaris,,N,CHEMBL624317,BAO_0000218,Half-life in mongrel dogs was determined,17800,,,50588,Intermediate
1,,1,,9615.0,6815,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624318,BAO_0000218,Half-life in dog upon oral administration,17657,,,50588,Intermediate
1,,1,,9615.0,6816,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624319,BAO_0000218,Half-life in dog upon oral administration; Unable to calculate,17657,,,50588,Intermediate
1,,1,,9615.0,6817,,,A,,,,Canis lupus familiaris,,N,CHEMBL624496,BAO_0000218,Half-life was measured in dog,4239,,,50588,Intermediate
1,,1,,9615.0,6818,,,A,,,,Canis lupus familiaris,,N,CHEMBL624497,BAO_0000218,Half-life was measured in dog,5985,,,50588,Intermediate
1,,1,,9615.0,6819,,,A,,,,Canis lupus familiaris,,N,CHEMBL624498,BAO_0000218,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,9932,,,50588,Intermediate
1,,1,,9615.0,6820,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624499,BAO_0000218,Oral half life was determined,5199,,,50588,Intermediate
1,,1,,9615.0,6821,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624500,BAO_0000218,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,5199,,Plasma,50588,Intermediate
1,,1,,9615.0,6822,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL624501,BAO_0000218,Plasma half life was evaluated,1475,,Plasma,50588,Intermediate
1,,1,,9615.0,6823,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623666,BAO_0000218,Plasma half life was evaluated in Dog,1475,,Plasma,50588,Intermediate
1,,1,,9615.0,6824,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623667,BAO_0000218,Plasma half life was evaluated in dog,1475,,Plasma,50588,Intermediate
1,,1,,9615.0,6825,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623668,BAO_0000218,T1/2 (Half-life) was after oral administration at 5 mg/kg,6316,,,50588,Intermediate
1,,1,,9615.0,6826,,,A,,,,Canis lupus familiaris,,N,CHEMBL623669,BAO_0000218,Tested for the half life value in dog,4883,,,50588,Intermediate
1,,1,,9615.0,6827,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623670,BAO_0000218,Maximum time at the dose of 2 mg/kg in dog,4727,,,50588,Intermediate
1,,1,,9615.0,6828,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623671,BAO_0000218,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,,,50588,Intermediate
1,,1,,9615.0,6829,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL875945,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,,Blood,50588,Intermediate
1,,1,,9615.0,6830,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL623672,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,,Blood,50588,Intermediate
1,,1,,9615.0,6831,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623673,BAO_0000218,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,6265,,,50588,Intermediate
1,,1,,9615.0,6832,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623674,BAO_0000218,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,,,50588,Intermediate
1,,1,,9615.0,6833,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623675,BAO_0000218,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,5983,,,50588,Intermediate
1,,1,,9615.0,6834,,,A,,,,Canis lupus familiaris,,N,CHEMBL872526,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",5313,,,50588,Intermediate
1,,1,,9615.0,6835,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623676,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",5313,,,50588,Intermediate
1,,1,,9615.0,6836,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623677,BAO_0000218,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,17650,,Plasma,50588,Intermediate
1,,1,,9615.0,6837,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623678,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,5199,,Plasma,50588,Intermediate
1,,1,,9615.0,6838,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623679,BAO_0000218,Time taken for maximum plasma concentration in dog,933,,Plasma,50588,Intermediate
1,,1,,9615.0,6839,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623680,BAO_0000218,Time to reach Cmax after oral administration to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,6840,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623681,BAO_0000218,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,Plasma,50588,Intermediate
1,,1,,9615.0,6841,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623682,BAO_0000218,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,6316,,,50588,Intermediate
1,,1,,9615.0,6842,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623683,BAO_0000218,Tmax after peroral administration (1 mg/kg) was determined in dog,6215,,,50588,Intermediate
1,,1,,9615.0,6843,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623684,BAO_0000218,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,,,50588,Expert
1,,1,,9615.0,6844,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622745,BAO_0000218,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,6845,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622746,BAO_0000218,Tmax after peroral administration in dogs at 2.4 uM/kg,17764,,,50588,Intermediate
1,,1,,10090.0,6846,,In vivo,A,,,,Mus musculus,,N,CHEMBL622747,BAO_0000218,In vivo Cmax in mice at dose of 100 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,6847,,In vivo,A,,,,Mus musculus,,N,CHEMBL622748,BAO_0000218,In vivo Cmax in mice at dose of 50 mg/kg,5969,,,50594,Intermediate
1,,1,,10090.0,6848,,In vivo,A,,,,Mus musculus,,N,CHEMBL622749,BAO_0000218,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,4573,,,50594,Intermediate
1,,1,,10090.0,6849,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL622750,BAO_0000218,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,,Plasma,50594,Intermediate
1,,1,,10090.0,6850,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623411,BAO_0000218,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,17734,,Plasma,50594,Intermediate
1,,1,,10090.0,6851,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL875946,BAO_0000218,Maximum concentration obtained in mouse plasma was determined,3132,,Plasma,50594,Intermediate
1,,1,,10090.0,6852,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623412,BAO_0000218,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,3132,,Plasma,50594,Intermediate
1,,1,,10090.0,6853,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623413,BAO_0000218,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,,Plasma,50594,Intermediate
1,,1,,10090.0,6854,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623414,BAO_0000218,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,17729,,Plasma,50594,Intermediate
1,,1,,10090.0,6855,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623415,BAO_0000218,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,17729,,Plasma,50594,Intermediate
1,,1,,10090.0,6856,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623416,BAO_0000218,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,17729,,Plasma,50594,Intermediate
1,,1,,10090.0,6857,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623417,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,17728,,Plasma,50594,Intermediate
1,,1,,10090.0,6858,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623418,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,17728,,Plasma,50594,Intermediate
1,,1,,10090.0,6859,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623419,BAO_0000218,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,17728,,Plasma,50594,Intermediate
1,,1,,10090.0,6860,,In vivo,A,,,,Mus musculus,,N,CHEMBL622816,BAO_0000218,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,4066,,,50594,Intermediate
1,,1,,10090.0,6861,,In vivo,A,,,,Mus musculus,,N,CHEMBL623313,BAO_0000218,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,6178,,,50594,Intermediate
1,,1,,10090.0,6862,,In vivo,A,,,,Mus musculus,,N,CHEMBL623314,BAO_0000218,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,6178,,,50594,Intermediate
1,,1,,10090.0,6863,,In vivo,A,,,,Mus musculus,,N,CHEMBL876788,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6864,,In vivo,A,,,,Mus musculus,,N,CHEMBL623315,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6865,,In vivo,A,,,,Mus musculus,,N,CHEMBL623316,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6866,,In vivo,A,,,,Mus musculus,,N,CHEMBL623317,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,3760,,,50594,Intermediate
1,,1,,10090.0,6868,,In vivo,A,,,,Mus musculus,,N,CHEMBL623319,BAO_0000218,Cmax in male mice after 2 mg/kg oral dose,5961,,,50594,Intermediate
1,,1,,10090.0,6869,,In vivo,A,,,,Mus musculus,,N,CHEMBL623320,BAO_0000218,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,6137,,,50594,Intermediate
1,,1,,10090.0,6870,,In vivo,A,,,,Mus musculus,,N,CHEMBL623321,BAO_0000218,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,3802,,,50594,Intermediate
1,,1,,10090.0,6871,,,A,,,,Mus musculus,,N,CHEMBL623322,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6872,,,A,,,,Mus musculus,,N,CHEMBL623323,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6873,,,A,,,,Mus musculus,,N,CHEMBL623324,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6874,,,A,,,,Mus musculus,,N,CHEMBL623325,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6875,,,A,,,,Mus musculus,,N,CHEMBL623326,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6876,,,A,,,,Mus musculus,,N,CHEMBL623327,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,3535,,,50594,Intermediate
1,,1,,10090.0,6877,,,A,1969.0,,,Mus musculus,,N,CHEMBL623328,BAO_0000218,Maximum concentration in plasma upon oral administration in mouse,2862,,Plasma,50594,Intermediate
1,,1,,10090.0,6878,,,A,1969.0,,,Mus musculus,,N,CHEMBL623329,BAO_0000218,Maximum plasma concentration was evaluated in mice after oral administration,2675,,Plasma,50594,Intermediate
1,,1,,10090.0,6879,,In vivo,A,1969.0,,,Mus musculus,,N,CHEMBL623330,BAO_0000218,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,2675,,Plasma,50594,Intermediate
1,,1,,10090.0,6880,,,A,,,,Mus musculus,,N,CHEMBL876789,BAO_0000218,Dose at which the compound induced fecal excretion in mice,5399,,,50594,Intermediate
1,,1,164.0,10116.0,6893,,,F,,,,Rattus norvegicus,A10,N,CHEMBL623333,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,11819,,,80013,Expert
1,,1,164.0,10116.0,6894,,,F,,,,Rattus norvegicus,A10,N,CHEMBL623334,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,11819,,,80013,Expert
1,,1,164.0,10116.0,6895,,,F,,,,Rattus norvegicus,A10,N,CHEMBL627536,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,11819,,,80013,Expert
1,,1,164.0,10116.0,6896,,,F,,,,Rattus norvegicus,A10,N,CHEMBL627537,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,11819,,,80013,Expert
1,,1,164.0,10116.0,6897,,,F,,,,Rattus norvegicus,A10,N,CHEMBL627538,BAO_0000219,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),16361,,,80013,Intermediate
1,,1,393.0,9606.0,6898,,,F,,,,Homo sapiens,A121,N,CHEMBL884106,BAO_0000219,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,2288,,,80655,Intermediate
1,,1,393.0,9606.0,6899,,,F,,,,Homo sapiens,A121,N,CHEMBL625294,BAO_0000219,Anticancer activity against human ovarian carcinoma A121 cells,10404,,,80655,Intermediate
1,,1,393.0,9606.0,6900,,,F,,,,Homo sapiens,A121,N,CHEMBL625295,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,14790,,,80655,Intermediate
1,,1,393.0,9606.0,6901,,,F,,,,Homo sapiens,A121,N,CHEMBL625296,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,14790,,,80655,Intermediate
1,,1,393.0,9606.0,6902,,,F,,,,Homo sapiens,A121,N,CHEMBL625297,BAO_0000219,Growth inhibition of human ovarian carcinoma (A121) cell line,14253,,,80655,Expert
1,,1,393.0,9606.0,6903,,,F,,,,Homo sapiens,A121,N,CHEMBL625298,BAO_0000219,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,13617,,,80655,Expert
1,,1,393.0,9606.0,6904,,,F,,,,Homo sapiens,A121,N,CHEMBL625960,BAO_0000219,Cytotoxicity against human A121 ovarian cells,1003,,,80655,Intermediate
1,,1,393.0,9606.0,6905,,,F,,,,Homo sapiens,A121,N,CHEMBL625961,BAO_0000219,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,830,,,80655,Intermediate
1,,1,393.0,9606.0,6906,,,F,,,,Homo sapiens,A121,N,CHEMBL625962,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma A21,12307,,,80655,Intermediate
1,,1,393.0,9606.0,6907,,,F,,,,Homo sapiens,A121,N,CHEMBL624717,BAO_0000219,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,14254,,,80655,Intermediate
1,,1,393.0,9606.0,6908,,,F,,,,Homo sapiens,A121,N,CHEMBL624718,BAO_0000219,Inhibitory activity of compound against human A121 ovarian cell line.,13370,,,80655,Intermediate
1,,1,393.0,9606.0,6909,,,F,,,,Homo sapiens,A121,N,CHEMBL624719,BAO_0000219,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,14790,,,80655,Intermediate
1,,1,393.0,9606.0,6910,,,F,,,,Homo sapiens,A121,N,CHEMBL624720,BAO_0000219,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,3614,,,80655,Intermediate
1,,1,622.0,9606.0,6911,,,F,,,,Homo sapiens,A 172,N,CHEMBL624721,BAO_0000219,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,2664,,,80012,Intermediate
1,,1,622.0,9606.0,6912,,,F,,,,Homo sapiens,A 172,N,CHEMBL624722,BAO_0000219,In vitro cytotoxicity against A172 human tumor cell lines.,2037,,,80012,Expert
1,,1,622.0,9606.0,6913,,,F,,,,Homo sapiens,A 172,N,CHEMBL877597,BAO_0000219,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,14539,,,80012,Intermediate
1,,1,622.0,9606.0,6914,,,F,,,,Homo sapiens,A 172,N,CHEMBL624723,BAO_0000219,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,2836,,,80012,Intermediate
1,,1,622.0,9606.0,6915,,,F,,,,Homo sapiens,A 172,N,CHEMBL624724,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,10708,,,80012,Intermediate
4,,1,,9615.0,6916,,,B,,,,Canis lupus familiaris,,H,CHEMBL624725,BAO_0000224,Association constant against A2 adenosine receptor,8975,,,104729,Autocuration
1,,1,1085.0,,6917,,,F,,,,fish,A2,N,CHEMBL624726,BAO_0000219,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,7645,,,80656,Intermediate
5,,1,,10116.0,6918,,,B,,,,Rattus norvegicus,,D,CHEMBL857535,BAO_0000224,Ratio of Ki for adenosine A2 and A1 receptor binding,11377,,,104713,Autocuration
1,,1,623.0,9606.0,6919,,,F,,,,Homo sapiens,A204,N,CHEMBL624727,BAO_0000219,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,13528,,,80014,Expert
1,,1,623.0,9606.0,6920,,,F,,,,Homo sapiens,A204,N,CHEMBL624728,BAO_0000219,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,10160,,,80014,Expert
1,,1,404.0,9606.0,6921,,,F,,,,Homo sapiens,A2058,N,CHEMBL624729,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,15144,,,80015,Intermediate
1,,1,973.0,9606.0,6922,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624730,BAO_0000219,Growth inhibition against Human squamous cell line(A 253),13160,,,80657,Intermediate
1,,1,973.0,9606.0,6923,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624731,BAO_0000219,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,12898,,,80657,Intermediate
1,,1,973.0,9606.0,6924,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624732,BAO_0000219,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,13069,,,80657,Intermediate
1,,1,973.0,9606.0,6925,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL883245,BAO_0000219,Growth inhibition of A253 cell lines.,15984,,,80657,Intermediate
1,,1,973.0,9606.0,6926,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624733,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),15564,,,80657,Intermediate
1,,1,973.0,9606.0,6927,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624734,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,15564,,,80657,Intermediate
1,,1,973.0,9606.0,6928,,,F,,,,Homo sapiens,A253 cell line,N,CHEMBL624735,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,15564,,,80657,Intermediate
1,,1,478.0,9606.0,6929,,,F,,,,Homo sapiens,A2780,N,CHEMBL621780,BAO_0000219,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,4720,,,81034,Intermediate
1,,1,478.0,9606.0,6930,,,F,,,,Homo sapiens,A2780,N,CHEMBL877598,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,16112,,,81034,Intermediate
1,,1,478.0,9606.0,6931,,,F,,,,Homo sapiens,A2780,N,CHEMBL621781,BAO_0000219,Cytotoxic activity against A2780 human ovarian carcinoma cell line,16597,,,81034,Expert
1,,1,478.0,9606.0,6932,,,F,,,,Homo sapiens,A2780,N,CHEMBL621782,BAO_0000219,Cytotoxicity against human cancer cell lines A2780 (ovarian),16378,,,81034,Intermediate
1,,1,478.0,9606.0,6933,,,F,,,,Homo sapiens,A2780,N,CHEMBL621783,BAO_0000219,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,16085,,,81034,Expert
1,,1,478.0,9606.0,6934,,,F,,,,Homo sapiens,A2780,N,CHEMBL621784,BAO_0000219,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,16317,,,81034,Intermediate
1,,1,478.0,9606.0,6935,,,F,,,,Homo sapiens,A2780,N,CHEMBL621785,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),15748,,,81034,Intermediate
1,,1,478.0,9606.0,6936,,,F,,,,Homo sapiens,A2780,N,CHEMBL621968,BAO_0000219,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,16597,,,81034,Expert
1,,1,478.0,9606.0,6937,,,F,,,,Homo sapiens,A2780,N,CHEMBL621969,BAO_0000219,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,16597,,,81034,Expert
1,,1,478.0,9606.0,6938,,,F,,,,Homo sapiens,A2780,N,CHEMBL621970,BAO_0000219,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,16597,,,81034,Expert
1,,1,478.0,9606.0,6939,,,F,,,,Homo sapiens,A2780,N,CHEMBL621971,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,15608,,,81034,Intermediate
1,,1,478.0,9606.0,6940,,,F,,,,Homo sapiens,A2780,N,CHEMBL621972,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,15608,,,81034,Intermediate
1,,1,478.0,9606.0,6941,,,F,,,,Homo sapiens,A2780,N,CHEMBL884108,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,15608,,,81034,Intermediate
0,,1,,10029.0,6942,,,F,,,,Cricetulus griseus,,U,CHEMBL623826,BAO_0000019,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,15296,,,22224,Autocuration
0,,1,185.0,10029.0,6943,,,A,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623827,BAO_0000219,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,10251,,,22224,Autocuration
0,,1,185.0,10029.0,6944,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623828,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic conditions,10251,,,22224,Autocuration
0,,1,185.0,10029.0,6945,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623829,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,10251,,,22224,Autocuration
0,,1,185.0,10029.0,6946,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623830,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),10251,,,22224,Autocuration
0,,1,,10029.0,6947,,,F,,,,Cricetulus griseus,,U,CHEMBL623831,BAO_0000019,Growth inhibition against CHO-derived cell line AA8,11858,,,22224,Autocuration
0,,1,185.0,10029.0,6948,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623832,BAO_0000219,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],11858,,,22224,Autocuration
1,,1,185.0,36483.0,6949,,,F,,,,hampster,CHO-AA8,N,CHEMBL623833,BAO_0000219,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,11616,,,80089,Expert
1,,1,185.0,10029.0,6950,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL623834,BAO_0000219,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,11616,,,80089,Expert
0,,1,185.0,10029.0,6951,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623835,BAO_0000219,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,10518,,,22224,Autocuration
0,,1,185.0,10029.0,6952,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623836,BAO_0000219,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,11396,,,22224,Autocuration
0,,1,185.0,10029.0,6953,,,F,,,,Cricetulus griseus,CHO-AA8,U,CHEMBL623837,BAO_0000219,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,10518,,,22224,Autocuration
1,,1,185.0,10029.0,6954,,,F,,,,Cricetulus griseus,CHO-AA8,N,CHEMBL623838,BAO_0000219,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,11616,,,80089,Expert
8,,1,,,6955,,,F,,,,,,H,CHEMBL623839,BAO_0000019,compound was evaluated for association constant (Ka) of isolated serum protein AAG,14837,,,12675,Autocuration
8,,1,,,6956,,,F,,,,,,H,CHEMBL623840,BAO_0000019,Number of binding sites (n) of isolated serum protein AAG,14837,,,12675,Autocuration
3,,1,,,6957,,,B,,,,,,M,CHEMBL623841,BAO_0000225,Association constant for binding to AATT duplex,16037,,,22222,Intermediate
1,,1,416.0,9606.0,6958,,,F,,,,Homo sapiens,ABAE,N,CHEMBL623842,BAO_0000219,Inhibition of ABAE human fibroblast cell proliferation,16597,,,100090,Expert
1,,1,1064.0,10090.0,6959,,,F,,,,Mus musculus,AC755,N,CHEMBL623843,BAO_0000218,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",8831,,,80668,Intermediate
9,,1,,9986.0,6960,,,F,,,,Oryctolagus cuniculus,,D,CHEMBL618669,BAO_0000218,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,13419,,,102444,Expert
9,,1,,9986.0,6961,,In vivo,F,,,,Oryctolagus cuniculus,,D,CHEMBL618670,BAO_0000218,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,13419,,,102444,Expert
8,,1,,,6962,,,B,,,,,,H,CHEMBL618671,BAO_0000357,Inhibitory activity against angiotensin-converting enzyme (ACE).,15778,,,69,Autocuration
8,,1,,,6963,,,B,,,,,,H,CHEMBL618672,BAO_0000357,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,15778,,,69,Autocuration
1,,1,978.0,9606.0,6964,,,F,,,,Homo sapiens,ACH-2 cell line,N,CHEMBL618673,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,12988,,,80669,Intermediate
1,,1,978.0,9606.0,6965,,,F,,,,Homo sapiens,ACH-2 cell line,N,CHEMBL618674,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),12988,,,80669,Intermediate
0,,1,998.0,11676.0,6966,,,F,,,,Human immunodeficiency virus 1,T cell line,U,CHEMBL618675,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,12988,,,22224,Autocuration
0,,1,998.0,11676.0,6967,,,F,,,,Human immunodeficiency virus 1,T cell line,U,CHEMBL618676,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),12988,,,22224,Autocuration
0,,1,998.0,11676.0,6968,,,F,,,,Human immunodeficiency virus 1,T cell line,U,CHEMBL618677,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),12988,,,22224,Autocuration
1,,1,626.0,9606.0,6969,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618678,BAO_0000219,Inhibition of growth of renal cancer ACHN cell line,11843,,,80025,Intermediate
1,,1,626.0,9606.0,6970,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618679,BAO_0000219,Inhibition of growth of ACHN renal cancer cell line,16939,,,80025,Intermediate
1,,1,626.0,9606.0,6971,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618680,BAO_0000219,Inhibitory concentration required against ACHN renal cancer cell line,4782,,,80025,Intermediate
1,,1,626.0,9606.0,6972,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618681,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line,6310,,,80025,Expert
1,,1,626.0,9606.0,6973,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618682,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,6310,,,80025,Intermediate
1,,1,626.0,9606.0,6974,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618683,BAO_0000219,Cytotoxic activity against ACHN Renal cancer cell line,12858,,,80025,Intermediate
1,,1,626.0,9606.0,6975,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618684,BAO_0000219,Cytotoxicity evaluation against ACHN renal cancer cells,17380,,,80025,Intermediate
1,,1,626.0,9606.0,6976,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618685,BAO_0000219,In vitro antitumor activity against human renal ACHN cell line,5858,,,80025,Intermediate
1,,1,626.0,9606.0,6977,,,F,,,,Homo sapiens,ACHN,N,CHEMBL876499,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,3838,,,80025,Intermediate
1,,1,626.0,9606.0,6978,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618686,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,3838,,,80025,Intermediate
1,,1,626.0,9606.0,6979,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618687,BAO_0000219,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",5406,,,80025,Intermediate
1,,1,626.0,9606.0,6980,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618688,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,4071,,,80025,Intermediate
1,,1,626.0,9606.0,6981,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618689,BAO_0000219,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,4071,,,80025,Expert
1,,1,626.0,9606.0,6982,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618690,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,4071,,,80025,Intermediate
1,,1,626.0,9606.0,6983,,,F,,,,Homo sapiens,ACHN,N,CHEMBL618691,BAO_0000219,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,15002,,,80025,Intermediate
1,,1,626.0,9606.0,6984,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619373,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),14769,,,80025,Intermediate
1,,1,626.0,9606.0,6985,,,F,,,,Homo sapiens,ACHN,N,CHEMBL884008,BAO_0000219,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",13958,,,80025,Intermediate
1,,1,626.0,9606.0,6986,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619374,BAO_0000219,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1665,,,80025,Intermediate
1,,1,626.0,9606.0,6987,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619375,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line,15354,,,80025,Intermediate
1,,1,626.0,9606.0,6988,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619376,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,15354,,,80025,Intermediate
1,,1,626.0,9606.0,6989,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619377,BAO_0000219,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,13978,,,80025,Intermediate
1,,1,626.0,9606.0,6990,,,F,,,,Homo sapiens,ACHN,N,CHEMBL619378,BAO_0000219,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,6798,,,80025,Intermediate
1,,1,,9615.0,6991,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL872527,BAO_0000218,Tmax value after administration of 4 mg/Kg oral dose in dog,2959,,,50588,Intermediate
1,,1,,9615.0,6992,,,A,,,,Canis lupus familiaris,,N,CHEMBL876500,BAO_0000218,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",9932,,,50588,Intermediate
1,,1,,9615.0,6993,,,A,,,,Canis lupus familiaris,,N,CHEMBL619379,BAO_0000218,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,,,50588,Intermediate
1,,1,,9615.0,6994,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619538,BAO_0000218,Volume distribution after 15 mg/kg iv dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6995,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619539,BAO_0000218,Volume distribution after 30 mg/kg po dose in Dogs,16907,,,50588,Intermediate
1,,1,,9615.0,6996,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619540,BAO_0000218,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,4257,,,50588,Intermediate
1,,1,,9615.0,6997,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619541,BAO_0000218,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,4305,,,50588,Intermediate
1,,1,,9615.0,6998,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619542,BAO_0000218,Volume of distribution was evaluated in dog,5472,,,50588,Intermediate
1,,1,,9615.0,6999,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619543,BAO_0000218,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,6062,,,50588,Intermediate
1,,1,,9615.0,7000,,,A,,,,Canis lupus familiaris,,N,CHEMBL619544,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,,,50588,Expert
1,,1,,9615.0,7001,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619545,BAO_0000218,The compound was tested for volume of distribution in dog,12500,,,50588,Intermediate
1,,1,,9615.0,7002,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619546,BAO_0000218,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,12500,,,50588,Intermediate
1,,1,,9615.0,7003,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619547,BAO_0000218,Vd (1 mg/kg) was determined in dog (in vivo),6227,,,50588,Intermediate
1,,1,,9615.0,7004,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619548,BAO_0000218,Vd in dog,6227,,,50588,Intermediate
1,,1,,9615.0,7005,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619549,BAO_0000218,Volume distribution was determined,4219,,,50588,Intermediate
1,,1,,9615.0,7006,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619550,BAO_0000218,Volume of distribution in dog,1696,,,50588,Intermediate
1,,1,,9615.0,7007,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876501,BAO_0000218,Volume of distribution by as 4 fold increase by iv administration in dogs,5542,,,50588,Intermediate
1,,1,,9615.0,7008,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619551,BAO_0000218,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,5199,,,50588,Intermediate
1,,1,,9615.0,7009,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619552,BAO_0000218,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,,50588,Intermediate
1,,1,,9615.0,7010,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619553,BAO_0000218,Volume distribution at the dose of 2 mg/kg in dog,4727,,,50588,Intermediate
1,,1,,9615.0,7011,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618722,BAO_0000218,Steady state volume of distribution was determined,16367,,,50588,Intermediate
1,,1,,9615.0,7012,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618723,BAO_0000218,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,2652,,,50588,Intermediate
1,,1,,9615.0,7013,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618724,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,,,50588,Intermediate
1,,1,,9615.0,7014,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618725,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,,,50588,Intermediate
1,,1,,9615.0,7015,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618726,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),16452,,,50588,Intermediate
1,,1,,9615.0,7016,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618727,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,,,50588,Intermediate
1,,1,,9615.0,7017,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624233,BAO_0000218,Pharmacokinetic property (vdss) was measured in dog,4239,,,50588,Intermediate
1,,1,,9615.0,7018,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624234,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,7019,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624235,BAO_0000218,Vdss was determined after iv 0.1 mg/kg administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,7020,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624236,BAO_0000218,Volume displacement was calculated in dog,6057,,,50588,Intermediate
1,,1,,9615.0,7021,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624237,BAO_0000218,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,,,50588,Intermediate
1,,1,,9615.0,7022,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624238,BAO_0000218,Volume distribution constant was determined,5505,,,50588,Intermediate
1,,1,,9615.0,7023,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624239,BAO_0000218,Volume distribution at a dose of 1 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,7024,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875829,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,,,50588,Intermediate
1,,1,,9615.0,7025,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624240,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,,,50588,Intermediate
1,,1,,9615.0,7026,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624241,BAO_0000218,Volume distribution (Vdss) was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,7027,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624242,BAO_0000218,Volume distribution (Vdss) was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,7028,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624243,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,,,50588,Intermediate
1,,1,,9615.0,7029,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624244,BAO_0000218,Volume of distribution in steady state was determined in dog,5145,,,50588,Intermediate
1,,1,,9615.0,7030,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624245,BAO_0000218,Volume of distribution of compound was determined in dog,6821,,,50588,Intermediate
1,,1,,9615.0,7031,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624246,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,4137,,,50588,Intermediate
1,,1,,9615.0,7032,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624247,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),5334,,,50588,Intermediate
1,,1,,9615.0,7033,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624248,BAO_0000218,Volume of distribution (Vdss) was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,7034,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624249,BAO_0000218,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,,,50588,Intermediate
1,,1,,9615.0,7035,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624250,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,50588,Intermediate
1,,1,,9615.0,7036,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624251,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,,,50588,Intermediate
1,,1,,9615.0,7037,,,A,,,,Canis lupus familiaris,,N,CHEMBL624252,BAO_0000218,Maximum rate of depolarization of the upstroke of the action potential,11659,,,50588,Intermediate
1,,1,,9615.0,7038,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624253,BAO_0000218,Steady state volume distribution in dog,6448,,,50588,Intermediate
1,,1,,9615.0,7039,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624950,BAO_0000218,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,5474,,,50588,Intermediate
1,,1,,9615.0,7040,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624951,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1466,,,50588,Intermediate
1,,1,,9615.0,7041,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL875830,BAO_0000218,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,6535,,,50588,Intermediate
1,,1,,9615.0,7042,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624952,BAO_0000218,Volume distribution in dog after administration of 1 mg/kg iv,6535,,,50588,Intermediate
1,,1,,9615.0,7043,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624953,BAO_0000218,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,17764,,,50588,Intermediate
1,,1,,9615.0,7044,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624954,BAO_0000218,Vss after intravenous administration (0.5 mg/kg) was determined in dog,6215,,,50588,Intermediate
1,,1,,9615.0,7045,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624955,BAO_0000218,Vss on i.v. administration of 2 mg/kg was measured in dog,6505,,,50588,Intermediate
1,,1,,9615.0,7046,,,A,,,,Canis lupus familiaris,,N,CHEMBL624956,BAO_0000218,Vss was determined,3639,,,50588,Intermediate
1,,1,,9615.0,7047,,,A,,,,Canis lupus familiaris,,N,CHEMBL625129,BAO_0000218,Vss in dog,3639,,,50588,Intermediate
1,,1,,9615.0,7048,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625130,BAO_0000218,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,6062,,,50588,Intermediate
1,,1,,9615.0,7049,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625131,BAO_0000218,Volume distribution in dogs,4942,,,50588,Intermediate
1,,1,,9615.0,7050,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625132,BAO_0000218,Volume of distribution in dog,17796,,,50588,Intermediate
1,,1,,9615.0,7051,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL872263,BAO_0000218,Tested for the oral bioavailability in dog,4883,,,50588,Intermediate
1,,1,,10090.0,7060,,In vivo,A,,,,Mus musculus,,N,CHEMBL624336,BAO_0000218,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,17837,,,50594,Intermediate
1,,1,,10090.0,7061,,In vivo,A,,,,Mus musculus,,N,CHEMBL624337,BAO_0000218,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,17729,,,50594,Intermediate
1,,1,,10090.0,7062,,In vivo,A,,,,Mus musculus,,N,CHEMBL624338,BAO_0000218,Bioavailability after peroral administration of 50 mg/kg of dose in mice,17729,,,50594,Intermediate
1,,1,,10090.0,7063,,In vivo,A,,,,Mus musculus,,N,CHEMBL624339,BAO_0000218,Bioavailability was measured in mouse,4239,,,50594,Intermediate
1,,1,,10090.0,7064,,In vivo,A,,,,Mus musculus,,N,CHEMBL624340,BAO_0000218,Bioavailability in mouse,17592,,,50594,Intermediate
1,,1,,10090.0,7065,,In vivo,A,,,,Mus musculus,,N,CHEMBL624341,BAO_0000218,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,,,50594,Intermediate
1,,1,,10090.0,7066,,In vivo,A,,,,Mus musculus,,N,CHEMBL624342,BAO_0000218,Bioavailability in mouse,2801,,,50594,Intermediate
1,,1,,10090.0,7067,,In vivo,A,,,,Mus musculus,,N,CHEMBL624343,BAO_0000218,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,2801,,,50594,Intermediate
1,,1,,10090.0,7068,,In vivo,A,,,,Mus musculus,,N,CHEMBL624344,BAO_0000218,Oral bioavailability in mouse,17718,,,50594,Intermediate
1,,1,,10090.0,7069,,In vivo,A,,,,Mus musculus,,N,CHEMBL624345,BAO_0000218,Oral availability at 50 mg/kg po in male mice,5727,,,50594,Intermediate
1,,1,,10090.0,7070,,In vivo,A,,,,Mus musculus,,N,CHEMBL624346,BAO_0000218,Oral bioavailability in mouse (dose 10 mg/kg),5302,,,50594,Intermediate
1,,1,,10090.0,7071,,In vivo,A,,,,Mus musculus,,N,CHEMBL624347,BAO_0000218,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,3598,,,50594,Expert
1,,1,,10090.0,7072,,In vivo,A,,,,Mus musculus,,N,CHEMBL624348,BAO_0000218,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",5961,,,50594,Intermediate
1,,1,,10090.0,7074,,In vivo,A,,,,Mus musculus,,N,CHEMBL622754,BAO_0000218,Oral bioavailability in mouse,6091,,,50594,Intermediate
1,,1,,10090.0,7075,,In vivo,A,,,,Mus musculus,,N,CHEMBL622755,BAO_0000218,Oral bioavailability in vivo in mice;ND=Not determined,6091,,,50594,Intermediate
1,,1,,10090.0,7076,,In vivo,A,,,,Mus musculus,,N,CHEMBL622756,BAO_0000218,Oral bioavailability in mouse at 10 mg/kg of the compound,5711,,,50594,Intermediate
1,,1,,10090.0,7077,,In vivo,A,,,,Mus musculus,,N,CHEMBL622757,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),17728,,,50594,Intermediate
1,,1,,10090.0,7078,,In vivo,A,,,,Mus musculus,,N,CHEMBL622758,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),17728,,,50594,Intermediate
1,,1,,10090.0,7079,,In vivo,A,,,,Mus musculus,,N,CHEMBL622759,BAO_0000218,Tested for bioavailability of the compound,3802,,,50594,Intermediate
1,,1,,10090.0,7080,,In vivo,A,,,,Mus musculus,,N,CHEMBL622760,BAO_0000218,Tested for half life at the dose of 10 mg/kg when administered intravenously,3802,,,50594,Intermediate
1,,1,,10090.0,7081,,,A,1969.0,,,Mus musculus,,N,CHEMBL622761,BAO_0000218,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,14029,,Plasma,50594,Intermediate
1,,1,,10090.0,7082,,,A,1969.0,,,Mus musculus,,N,CHEMBL622762,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma. ,14029,,Plasma,50594,Intermediate
1,,1,,10090.0,7083,,,A,1969.0,,,Mus musculus,,N,CHEMBL622763,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,14029,,Plasma,50594,Intermediate
1,,1,,10090.0,7084,,,A,1969.0,,,Mus musculus,,N,CHEMBL622764,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,14029,,Plasma,50594,Intermediate
1,,1,,10090.0,7085,,,A,1969.0,,,Mus musculus,,N,CHEMBL622765,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,14029,,Plasma,50594,Intermediate
1,,1,,10090.0,7086,,,F,,,,Mus musculus,,N,CHEMBL622766,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,7087,,,A,,,,Mus musculus,,N,CHEMBL622767,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,7088,,,A,,,,Mus musculus,,N,CHEMBL622768,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,17753,,,50594,Intermediate
1,,1,,10090.0,7089,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL875948,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7090,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622769,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7091,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622770,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7092,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622771,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7093,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622772,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7094,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622773,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7095,,In vivo,A,178.0,,,Mus musculus,,N,CHEMBL622774,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Blood,50594,Intermediate
1,,1,,10090.0,7096,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL621725,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7097,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL621726,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,,Bone,50594,Intermediate
1,,1,478.0,9606.0,7098,,,F,,,,Homo sapiens,A2780,N,CHEMBL621727,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,15608,,,81034,Intermediate
1,,1,478.0,9606.0,7099,,,F,,,,Homo sapiens,A2780,N,CHEMBL622413,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,3290,,,81034,Expert
1,,1,478.0,9606.0,7100,,,F,,,,Homo sapiens,A2780,N,CHEMBL622414,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,2859,,,81034,Intermediate
1,,1,478.0,9606.0,7101,,,F,,,,Homo sapiens,A2780,N,CHEMBL622415,BAO_0000219,Inhibition of A2780 cell clonogenic assay,15688,,,81034,Expert
1,,1,478.0,9606.0,7102,,,F,,,,Homo sapiens,A2780,N,CHEMBL884001,BAO_0000219,Cytotoxic effect on ovarian cancer cell line (A2780),5642,,,81034,Expert
1,,1,478.0,9606.0,7103,,,F,,,,Homo sapiens,A2780,N,CHEMBL622416,BAO_0000219,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,6633,,,81034,Intermediate
1,,1,478.0,9606.0,7104,,,F,,,,Homo sapiens,A2780,N,CHEMBL622417,BAO_0000219,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",3906,,,81034,Intermediate
1,,1,478.0,9606.0,7105,,,F,,,,Homo sapiens,A2780,N,CHEMBL622590,BAO_0000219,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,6788,,,81034,Expert
1,,1,478.0,9606.0,7106,,,F,,,,Homo sapiens,A2780,N,CHEMBL622591,BAO_0000219,Antiproliferative activity against human A2780 cells,17582,,,81034,Expert
1,,1,478.0,9606.0,7107,,,F,,,,Homo sapiens,A2780,N,CHEMBL622592,BAO_0000219,Inhibition of human A2780 cell proliferation,17764,,,81034,Expert
1,,1,478.0,9606.0,7108,,,F,,,,Homo sapiens,A2780,N,CHEMBL622593,BAO_0000219,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,17764,,,81034,Expert
1,,1,478.0,9606.0,7109,,,F,,,,Homo sapiens,A2780,N,CHEMBL622594,BAO_0000219,Inhibition of human A2780 cell proliferation (No data),17764,,,81034,Expert
1,,1,478.0,9606.0,7110,,,F,,,,Homo sapiens,A2780,N,CHEMBL622595,BAO_0000219,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,2815,,,81034,Intermediate
1,,1,478.0,9606.0,7111,,,F,,,,Homo sapiens,A2780,N,CHEMBL622596,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780,16930,,,81034,Intermediate
1,,1,478.0,9606.0,7112,,,F,,,,Homo sapiens,A2780,N,CHEMBL622597,BAO_0000219,Growth inhibition against A2780 wild-type ovarian cell lines,17777,,,81034,Expert
1,,1,478.0,9606.0,7113,,,F,,,,Homo sapiens,A2780,N,CHEMBL622598,BAO_0000219,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,17777,,,81034,Intermediate
5,,1,,9606.0,7114,,,F,,,,Homo sapiens,,D,CHEMBL622599,BAO_0000019,Inhibition of tubulin polymerization in human ovarian cancer cell lines,16936,,,104766,Autocuration
1,,1,478.0,9606.0,7115,,,F,,,,Homo sapiens,A2780,N,CHEMBL622600,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,13759,,,81034,Intermediate
1,,1,478.0,9606.0,7116,,,F,,,,Homo sapiens,A2780,N,CHEMBL622601,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,13759,,,81034,Intermediate
1,,1,478.0,9606.0,7117,,,F,,,,Homo sapiens,A2780,N,CHEMBL622602,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,13759,,,81034,Intermediate
1,,1,478.0,9606.0,7118,,,F,,,,Homo sapiens,A2780,N,CHEMBL622603,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,13759,,,81034,Intermediate
1,,1,478.0,9606.0,7119,,,F,,,,Homo sapiens,A2780,N,CHEMBL622604,BAO_0000219,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,15292,,,81034,Intermediate
1,,1,478.0,9606.0,7120,,,F,,,,Homo sapiens,A2780,N,CHEMBL622605,BAO_0000219,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,15292,,,81034,Intermediate
1,,1,478.0,9606.0,7121,,,F,,,,Homo sapiens,A2780,N,CHEMBL622606,BAO_0000219,In vitro inhibition of human ovarian cell line A2780,15069,,,81034,Expert
1,,1,478.0,9606.0,7122,,,F,,,,Homo sapiens,A2780,N,CHEMBL619463,BAO_0000219,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",15069,,,81034,Expert
1,,1,478.0,9606.0,7123,,,F,,,,Homo sapiens,A2780,N,CHEMBL619464,BAO_0000219,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),14073,,,81034,Intermediate
1,,1,478.0,9606.0,7124,,,F,,,,Homo sapiens,A2780,N,CHEMBL619465,BAO_0000219,Concentration required to inhibit A2780-cell growth by 50%,14553,,,81034,Expert
1,,1,478.0,9606.0,7125,,,F,,,,Homo sapiens,A2780,N,CHEMBL619466,BAO_0000219,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,13040,,,81034,Expert
1,,1,478.0,9606.0,7126,,,F,,,,Homo sapiens,A2780,N,CHEMBL619467,BAO_0000219,Cytotoxic effect on human ovarian (A2780) cancer cell line,6891,,,81034,Expert
1,,1,478.0,9606.0,7127,,,F,,,,Homo sapiens,A2780,N,CHEMBL619468,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,15569,,,81034,Intermediate
1,,1,478.0,9606.0,7128,,,F,,,,Homo sapiens,A2780,N,CHEMBL619469,BAO_0000219,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,14190,,,81034,Expert
1,,1,478.0,9606.0,7129,,,F,,,,Homo sapiens,A2780,N,CHEMBL619470,BAO_0000219,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,15014,,,81034,Expert
1,,1,478.0,9606.0,7130,,,F,,,,Homo sapiens,A2780,N,CHEMBL619471,BAO_0000219,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,15014,,,81034,Intermediate
1,,1,478.0,9606.0,7131,,,F,,,,Homo sapiens,A2780,N,CHEMBL619472,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780 cell line,17496,,,81034,Intermediate
1,,1,478.0,9606.0,7132,,,F,,,,Homo sapiens,A2780,N,CHEMBL619473,BAO_0000219,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",13617,,,81034,Intermediate
1,,1,478.0,9606.0,7133,,,F,,,,Homo sapiens,A2780,N,CHEMBL874368,BAO_0000219,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",13617,,,81034,Intermediate
1,,1,478.0,9606.0,7134,,,F,,,,Homo sapiens,A2780,N,CHEMBL884003,BAO_0000219,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",13617,,,81034,Intermediate
1,,1,478.0,9606.0,7135,,,F,,,,Homo sapiens,A2780,N,CHEMBL622690,BAO_0000219,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",13617,,,81034,Intermediate
1,,1,478.0,9606.0,7136,,,F,,,,Homo sapiens,A2780,N,CHEMBL622691,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,17672,,,81034,Intermediate
1,,1,478.0,9606.0,7137,,,F,,,,Homo sapiens,A2780,N,CHEMBL622692,BAO_0000219,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,4544,,,81034,Intermediate
1,,1,478.0,9606.0,7138,,,F,,,,Homo sapiens,A2780,N,CHEMBL623406,BAO_0000219,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,4544,,,81034,Intermediate
1,,1,478.0,9606.0,7139,,,F,,,,Homo sapiens,A2780,N,CHEMBL884004,BAO_0000219,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",16317,,,81034,Intermediate
1,,1,478.0,9606.0,7140,,,F,,,,Homo sapiens,A2780,N,CHEMBL623407,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,15099,,,81034,Intermediate
1,,1,478.0,9606.0,7141,,,F,,,,Homo sapiens,A2780,N,CHEMBL623408,BAO_0000219,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,13978,,,81034,Intermediate
1,,1,478.0,9606.0,7142,,,F,,,,Homo sapiens,A2780,N,CHEMBL623409,BAO_0000219,In vitro antitumor activity against A2780 cell line.,12989,,,81034,Expert
1,,1,478.0,9606.0,7143,,,F,,,,Homo sapiens,A2780,N,CHEMBL623410,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,5574,,,81034,Intermediate
1,,1,478.0,9606.0,7144,,,F,,,,Homo sapiens,A2780,N,CHEMBL623576,BAO_0000219,In vitro cytotoxicity against A2780 human ovarian cancer cell line,13528,,,81034,Expert
1,,1,626.0,9606.0,7145,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623577,BAO_0000219,Inhibitory activity against kidney A-CHN tumor cell growth in culture,12782,,,80025,Intermediate
1,,1,626.0,9606.0,7146,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623578,BAO_0000219,The IC50 value was measured on ACHN cell line in renal tumor type.,14255,,,80025,Intermediate
1,,1,626.0,9606.0,7147,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623579,BAO_0000219,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,16364,,,80025,Intermediate
1,,1,626.0,9606.0,7148,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623580,BAO_0000219,In vitro lethal concentration against most sensitive ACHN cell line,17376,,,80025,Expert
1,,1,626.0,9606.0,7149,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623581,BAO_0000219,Tested for cytotoxic activity against renal cancer ACHN cell line,12016,,,80025,Intermediate
1,,1,626.0,9606.0,7150,,,F,,,,Homo sapiens,ACHN,N,CHEMBL857456,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line ACHN,6058,,,80025,Intermediate
1,,1,626.0,9606.0,7151,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623582,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,17708,,,80025,Intermediate
1,,1,626.0,9606.0,7152,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623583,BAO_0000219,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,15176,,,80025,Intermediate
1,,1,626.0,9606.0,7153,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623584,BAO_0000219,In vitro anticancer activity against ACHN renal cancer cell line,2806,,,80025,Intermediate
1,,1,626.0,9606.0,7154,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623585,BAO_0000219,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,15300,,,80025,Intermediate
1,,1,626.0,9606.0,7155,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623586,BAO_0000219,Percent selectivity was evaluated in renal ACHN cell lines,16364,,,80025,Intermediate
1,,1,626.0,9606.0,7156,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623587,BAO_0000219,In vitro inhibitory activity against renal ACHN cancer cell line,13859,,,80025,Intermediate
1,,1,626.0,9606.0,7157,,,F,,,,Homo sapiens,ACHN,N,CHEMBL875279,BAO_0000219,Tested for cytotoxicity against ACHN cell lines in renal cancer,11970,,,80025,Intermediate
1,,1,626.0,9606.0,7158,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623588,BAO_0000219,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,2450,,,80025,Intermediate
1,,1,626.0,9606.0,7159,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623589,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,12696,,,80025,Intermediate
1,,1,626.0,9606.0,7160,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623590,BAO_0000219,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,12400,,,80025,Intermediate
1,,1,626.0,9606.0,7161,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623591,BAO_0000219,Cytotoxic effect on renal cancer line ACHN,12888,,,80025,Expert
1,,1,626.0,9606.0,7162,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623592,BAO_0000219,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,3156,,,80025,Intermediate
1,,1,626.0,9606.0,7163,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623593,BAO_0000219,In vitro inhibition of Renal Cancer ACHN cell lines,3381,,,80025,Intermediate
1,,1,626.0,9606.0,7164,,,F,,,,Homo sapiens,ACHN,N,CHEMBL623594,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells,16747,,,80025,Intermediate
1,,1,626.0,9606.0,7165,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621833,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells.,16748,,,80025,Expert
1,,1,626.0,9606.0,7166,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621834,BAO_0000219,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,12062,,,80025,Intermediate
1,,1,626.0,9606.0,7167,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621835,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),14769,,,80025,Intermediate
1,,1,626.0,9606.0,7168,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621836,BAO_0000219,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",15895,,,80025,Intermediate
1,,1,626.0,9606.0,7169,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621837,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,17376,,,80025,Intermediate
1,,1,626.0,9606.0,7170,,,F,,,,Homo sapiens,ACHN,N,CHEMBL875280,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,14882,,,80025,Intermediate
1,,1,626.0,9606.0,7171,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621838,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,14882,,,80025,Intermediate
1,,1,626.0,9606.0,7172,,,F,,,,Homo sapiens,ACHN,N,CHEMBL621839,BAO_0000219,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,15661,,,80025,Intermediate
0,,1,,,7173,,,A,,,,,,U,CHEMBL621840,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,9680,,,22224,Autocuration
8,,1,,,7174,,,F,,,,,,H,CHEMBL621841,BAO_0000019,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,14579,,,10647,Autocuration
1,,1,468.0,10358.0,7175,,,F,,,,Cytomegalovirus,HEL,N,CHEMBL622979,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,17290,,,50529,Expert
1,,1,,10358.0,7176,,,F,,,,Cytomegalovirus,,N,CHEMBL876595,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,17290,,,50529,Intermediate
8,,1,,,7177,,,B,,,,,,H,CHEMBL620221,BAO_0000357,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),15891,,,12159,Autocuration
8,,1,,,7178,,,B,,,,,,H,CHEMBL620222,BAO_0000357,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),15890,,,12159,Autocuration
1,,1,979.0,9913.0,7179,,,F,,,,Bos taurus,ADDP cell line,N,CHEMBL620506,BAO_0000219,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,3801,,,80670,Intermediate
1,,1,980.0,10090.0,7180,,,F,,,,Mus musculus,ADJ/PC6,N,CHEMBL620507,BAO_0000219,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,9222,,,80671,Intermediate
1,,1,980.0,10090.0,7181,,,F,,,,Mus musculus,ADJ/PC6,N,CHEMBL620508,BAO_0000219,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,9222,,,80671,Intermediate
1,,1,980.0,10090.0,7182,,,F,,,,Mus musculus,ADJ/PC6,N,CHEMBL620509,BAO_0000219,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",7257,,,80671,Intermediate
1,,1,980.0,10090.0,7183,,,F,,,,Mus musculus,ADJ/PC6,N,CHEMBL620510,BAO_0000219,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,7257,,,80671,Intermediate
1,,1,980.0,10090.0,7184,,,A,,,,Mus musculus,ADJ/PC6,N,CHEMBL620511,BAO_0000219,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,7257,,,80671,Intermediate
1,,1,980.0,10090.0,7185,,,F,,,,Mus musculus,ADJ/PC6,N,CHEMBL620512,BAO_0000219,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,8084,,,80671,Intermediate
0,,1,,10090.0,7186,,,F,,,,Mus musculus,,U,CHEMBL620513,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,14943,,,22224,Autocuration
0,,1,,10090.0,7187,,,F,,,,Mus musculus,,U,CHEMBL620514,BAO_0000019,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,14943,,,22224,Autocuration
0,,1,,10090.0,7188,,,F,,,,Mus musculus,,U,CHEMBL620515,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,14943,,,22224,Autocuration
0,,1,,1423.0,7189,,In vivo,A,,,,Bacillus subtilis,,U,CHEMBL620516,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),10524,,,22224,Autocuration
1,,1,,9615.0,7190,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620517,BAO_0000218,AUC value in dog after IV administration at a dose of 5 mg/kg,3546,,Plasma,50588,Intermediate
1,,1,,9615.0,7191,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL620518,BAO_0000218,AUC value in dog after oral administration at a dose of 5 mg/kg,3546,,Plasma,50588,Intermediate
1,,1,,9615.0,7192,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL620519,BAO_0000218,Cmax value in dog after oral administration at a dose of 5 mg/kg,3546,,,50588,Intermediate
1,,1,,9615.0,7193,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621386,BAO_0000218,Bioavailability in dog after oral administration at a dose of 5 mg/kg,3546,,,50588,Intermediate
1,,1,,9615.0,7194,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621387,BAO_0000218,Tmax value in dog after oral administration at a dose of 5 mg/kg,3546,,,50588,Intermediate
1,,1,,9615.0,7195,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621388,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in dog,3184,,,50588,Intermediate
1,,1,,9615.0,7196,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621389,BAO_0000218,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,,,50588,Intermediate
1,,1,,9615.0,7197,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621390,BAO_0000218,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),4809,,,50588,Intermediate
0,,1,,,7198,,,P,,,,,,U,CHEMBL621391,BAO_0000100,Calculated partition coefficient (clogP),4219,,,22229,Intermediate
1,,1,,9615.0,7199,,,A,,,,Canis lupus familiaris,,N,CHEMBL621392,BAO_0000218,Half life in dog,3748,,,50588,Intermediate
1,,1,,9615.0,7200,,,A,,,,Canis lupus familiaris,,N,CHEMBL621393,BAO_0000218,Time taken for EC90 was determined when tested in dog,3132,,,50588,Intermediate
1,,1,,9615.0,7201,,,A,,,,Canis lupus familiaris,,N,CHEMBL621394,BAO_0000218,Half life (iv) was determined,4219,,,50588,Intermediate
1,,1,,9615.0,7202,,,A,2107.0,,,Canis lupus familiaris,,N,CHEMBL621395,BAO_0000218,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,16907,,Liver,50588,Intermediate
1,,1,,9615.0,7203,,,A,,,,Canis lupus familiaris,,N,CHEMBL621396,BAO_0000218,Area under the curve was calculated in dog after iv administration,6057,,,50588,Intermediate
1,,1,,9615.0,7204,,,A,,,,Canis lupus familiaris,,N,CHEMBL621397,BAO_0000218,Area under the curve was calculated in dog after peroral administration,6057,,,50588,Intermediate
1,,1,,9615.0,7205,,,A,,,,Canis lupus familiaris,,N,CHEMBL621398,BAO_0000218,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,17853,,,50588,Intermediate
1,,1,,9615.0,7206,,,A,,,,Canis lupus familiaris,,N,CHEMBL618818,BAO_0000218,pKa was evaluated in dog,3639,,,50588,Intermediate
1,,1,,9615.0,7207,,,A,,,,Canis lupus familiaris,,N,CHEMBL618819,BAO_0000218,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,14541,,,50588,Intermediate
1,,1,,9615.0,7208,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618820,BAO_0000218,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,,,50588,Intermediate
1,,1,,9615.0,7209,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873810,BAO_0000218,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,,,50588,Intermediate
1,,1,,9615.0,7210,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876606,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,2652,,,50588,Intermediate
1,,1,,9615.0,7211,,,A,,,,Canis lupus familiaris,,N,CHEMBL618821,BAO_0000218,Compound was evaluated for the half-life (t 1/2) in hours,3624,,,50588,Intermediate
1,,1,,9615.0,7212,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL618822,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,,Blood,50588,Intermediate
1,,1,,9615.0,7213,,In vivo,A,178.0,,,Canis lupus familiaris,,N,CHEMBL618823,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,,Blood,50588,Intermediate
1,,1,,9615.0,7214,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618824,BAO_0000218,Half life after intravenous administration of 1 mg/kg in dog,4709,,,50588,Intermediate
1,,1,,9615.0,7215,,,A,,,,Canis lupus familiaris,,N,CHEMBL618825,BAO_0000218,Half life was measured in dog,15660,,,50588,Intermediate
1,,1,,9615.0,7216,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618826,BAO_0000218,Half life period in dog after 5 mg/kg dose,5302,,,50588,Intermediate
1,,1,,9615.0,7217,,,A,,,,Canis lupus familiaris,,N,CHEMBL618827,BAO_0000218,Half life period was evaluated in dog; 4-4.8,17791,,,50588,Intermediate
1,,1,,9615.0,7218,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618828,BAO_0000218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,,,50588,Intermediate
1,,1,,9615.0,7219,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL618829,BAO_0000218,Half-life was determined in dog after a3 mg/kg of iv dose,4257,,,50588,Intermediate
1,,1,,9615.0,7220,,,A,,,,Canis lupus familiaris,,N,CHEMBL618830,BAO_0000218,Half-life was determined,3771,,,50588,Intermediate
1,,1,,9615.0,7221,,,A,,,,Canis lupus familiaris,,N,CHEMBL618831,BAO_0000218,Half life in dogs,6305,,,50588,Intermediate
1,,1,,9615.0,7222,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL619489,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,13501,,Plasma,50588,Intermediate
1,,1,,9615.0,7223,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619649,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,17594,,,50588,Intermediate
1,,1,,9615.0,7224,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876607,BAO_0000218,Compound was evaluated for the half life period after iv administration in Beagle dog.,3045,,,50588,Intermediate
1,,1,,9615.0,7225,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619650,BAO_0000218,Compound was evaluated for the half life period after oral administration in conscious dog.,3043,,,50588,Intermediate
1,,1,,9615.0,7226,,,A,,,,Canis lupus familiaris,,N,CHEMBL619651,BAO_0000218,Compound was tested for half life in dog,4839,,,50588,Intermediate
1,,1,,9615.0,7227,,,A,,,,Canis lupus familiaris,,N,CHEMBL619652,BAO_0000218,Compound was tested for its half life in dog,4839,,,50588,Intermediate
1,,1,,9615.0,7228,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619653,BAO_0000218,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,,,50588,Intermediate
1,,1,,9615.0,7229,,,A,,,,Canis lupus familiaris,,N,CHEMBL619654,BAO_0000218,Half life of compound in dog was determined,17839,,,50588,Intermediate
1,,1,,9615.0,7230,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619655,BAO_0000218,Half life (iv) was determined,4219,,,50588,Intermediate
1,,1,,9615.0,7231,,,A,178.0,,,Canis lupus familiaris,,N,CHEMBL619656,BAO_0000218,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),13966,,Blood,50588,Intermediate
1,,1,,9615.0,7232,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL873812,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,3994,,Plasma,50588,Intermediate
1,,1,,9615.0,7233,,In vivo,F,1969.0,,,Canis lupus familiaris,,N,CHEMBL621365,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,3994,,Plasma,50588,Intermediate
1,,1,,9615.0,7234,,,A,,,,Canis lupus familiaris,,N,CHEMBL621366,BAO_0000218,Half life in dog,4453,,,50588,Intermediate
1,,1,,9615.0,7235,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621367,BAO_0000218,Half life in dog plasma,6535,,Plasma,50588,Intermediate
1,,1,,9615.0,7236,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621368,BAO_0000218,Half life in dog plasma after administration of 0.25 mg/kg iv,6535,,Plasma,50588,Intermediate
1,,1,,9615.0,7237,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621369,BAO_0000218,Half life in dog plasma after administration of 1 mg/kg iv,6535,,Plasma,50588,Intermediate
1,,1,,9615.0,7238,,In vivo,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621370,BAO_0000218,Half life in dog plasma was determined at dose 10 mg/kg,3132,,Plasma,50588,Intermediate
1,,1,,9615.0,7239,,,A,,,,Canis lupus familiaris,,N,CHEMBL621371,BAO_0000218,Half life in dog was determined,5374,,,50588,Intermediate
1,,1,,9615.0,7240,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621372,BAO_0000218,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,,,50588,Intermediate
1,,1,,9615.0,7241,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621373,BAO_0000218,Half life upon exposure to human plasma,16907,,Plasma,50588,Intermediate
1,,1,,9615.0,7242,,,A,,,,Canis lupus familiaris,,N,CHEMBL621374,BAO_0000218,Half life was calculated in dog,6057,,,50588,Intermediate
1,,1,,9615.0,7243,,,A,,,,Canis lupus familiaris,,N,CHEMBL621375,BAO_0000218,Half life was determined,5006,,,50588,Intermediate
1,,1,,9615.0,7244,,,A,,,,Canis lupus familiaris,,N,CHEMBL621376,BAO_0000218,Half life was determined,5473,,,50588,Intermediate
1,,1,,9615.0,7245,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619624,BAO_0000218,Half life by intravenous administration of 1.2 mg/kg in dog,4368,,,50588,Intermediate
1,,1,,9615.0,7246,,,A,,,,Canis lupus familiaris,,N,CHEMBL875840,BAO_0000218,Half life in dog,6448,,,50588,Intermediate
1,,1,,9615.0,7247,,,A,,,,Canis lupus familiaris,,N,CHEMBL619625,BAO_0000218,Half life in dog after intra venous administration of the compound,4353,,,50588,Intermediate
1,,1,,9615.0,7248,,,A,,,,Canis lupus familiaris,,N,CHEMBL619626,BAO_0000218,Half life in dog after intra venous administration of the compound; ND means Not determined,4353,,,50588,Intermediate
1,,1,,9615.0,7249,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619627,BAO_0000218,Half life in dog after po administration of the compound,4353,,,50588,Intermediate
1,,1,,9615.0,7250,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873817,BAO_0000218,Half life in dog after po administration of the compound; ND means Not determined,4353,,,50588,Intermediate
1,,1,,9615.0,7251,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619628,BAO_0000218,Half life in dog at the single oral dose of 1 mg/kg,6265,,,50588,Intermediate
1,,1,,9615.0,7252,,,A,,,,Canis lupus familiaris,,N,CHEMBL619629,BAO_0000218,Half life in dogs,5006,,,50588,Intermediate
1,,1,,9615.0,7253,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619630,BAO_0000218,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,5356,,,50588,Intermediate
1,,1,,9615.0,7254,,,A,,,,Canis lupus familiaris,,N,CHEMBL619631,BAO_0000218,Half life in rat,405,,,50588,Intermediate
1,,1,,9615.0,7255,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL619632,BAO_0000218,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,,,50588,Intermediate
1,,1,,10090.0,7256,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL619633,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7257,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL875841,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7258,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL619634,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7259,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL619635,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7260,,In vivo,A,10000001.0,,,Mus musculus,,N,CHEMBL619636,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Bone,50594,Intermediate
1,,1,,10090.0,7261,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619637,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7262,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619638,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7263,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619639,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7264,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619640,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7265,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619641,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7266,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619642,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7267,,In vivo,A,10000004.0,,,Mus musculus,,N,CHEMBL619643,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Gut,50594,Intermediate
1,,1,,10090.0,7268,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL619644,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7269,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621112,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7270,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621113,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7271,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621114,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7272,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621115,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7273,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621116,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7274,,In vivo,A,948.0,,,Mus musculus,,N,CHEMBL621117,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Heart,50594,Intermediate
1,,1,,10090.0,7275,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621118,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7276,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621119,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7277,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621120,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7278,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621757,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7279,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621758,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7280,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621759,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7281,,In vivo,A,2113.0,,,Mus musculus,,N,CHEMBL621760,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Kidney,50594,Intermediate
1,,1,,10090.0,7282,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621761,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7283,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621762,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7284,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL621763,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7285,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL624502,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7286,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL624503,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7287,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL624504,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7288,,In vivo,A,2107.0,,,Mus musculus,,N,CHEMBL624505,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Liver,50594,Intermediate
1,,1,,10090.0,7289,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL624506,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Lung,50594,Intermediate
1,,1,478.0,9606.0,7290,,,F,,,,Homo sapiens,A2780,N,CHEMBL624507,BAO_0000219,In vitro cytotoxicity against A2780 (human ovarian cancer),5895,,,81034,Intermediate
1,,1,478.0,9606.0,7291,,,F,,,,Homo sapiens,A2780,N,CHEMBL624508,BAO_0000219,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,6338,,,81034,Intermediate
1,,1,478.0,9606.0,7292,,,F,,,,Homo sapiens,A2780,N,CHEMBL624509,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,15163,,,81034,Intermediate
1,,1,478.0,9606.0,7293,,,F,,,,Homo sapiens,A2780,N,CHEMBL624510,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,15163,,,81034,Intermediate
1,,1,478.0,9606.0,7294,,,F,,,,Homo sapiens,A2780,N,CHEMBL875956,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,15000,,,81034,Expert
1,,1,478.0,9606.0,7295,,,F,,,,Homo sapiens,A2780,N,CHEMBL839885,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,15000,,,81034,Expert
1,,1,478.0,9606.0,7296,,,F,,,,Homo sapiens,A2780,N,CHEMBL624511,BAO_0000219,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,14729,,,81034,Expert
1,,1,478.0,9606.0,7297,,,F,,,,Homo sapiens,A2780,N,CHEMBL624512,BAO_0000219,In vitro cytotoxicity against A2780 cell line,17270,,,81034,Intermediate
1,,1,478.0,9606.0,7298,,,F,,,,Homo sapiens,A2780,N,CHEMBL624513,BAO_0000219,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,5685,,,81034,Intermediate
1,,1,478.0,9606.0,7299,,,F,,,,Homo sapiens,A2780,N,CHEMBL624514,BAO_0000219,In vitro inhibitory activity against human ovarian cancer A2780 cell line,3563,,,81034,Intermediate
1,,1,478.0,9606.0,7300,,,F,,,,Homo sapiens,A2780,N,CHEMBL618547,BAO_0000218,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,17753,,,81034,Intermediate
1,,1,478.0,9606.0,7301,,,F,,,,Homo sapiens,A2780,N,CHEMBL618548,BAO_0000219,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",16317,,,81034,Intermediate
1,,1,478.0,9606.0,7302,,,F,,,,Homo sapiens,A2780,N,CHEMBL618549,BAO_0000219,Inhibition of tubulin polymerization in analogy of ca.,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7303,,,F,,,,Homo sapiens,A2780,N,CHEMBL618550,BAO_0000219,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,3801,,,81034,Intermediate
1,,1,478.0,9606.0,7304,,,F,,,,Homo sapiens,A2780,N,CHEMBL618551,BAO_0000219,Cytotoxic effect in ovarian cancer cell line (A2780),6181,,,81034,Expert
1,,1,478.0,9606.0,7305,,,F,,,,Homo sapiens,A2780,N,CHEMBL618552,BAO_0000219,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,5318,,,81034,Intermediate
1,,1,478.0,9606.0,7306,,,F,,,,Homo sapiens,A2780,N,CHEMBL618553,BAO_0000219,Tested for the cytotoxicity in A2780 ovarian cell line,4840,,,81034,Intermediate
1,,1,478.0,9606.0,7307,,,F,,,,Homo sapiens,A2780,N,CHEMBL618554,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),15748,,,81034,Intermediate
1,,1,478.0,9606.0,7308,,,F,,,,Homo sapiens,A2780,N,CHEMBL618555,BAO_0000219,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,15748,,,81034,Intermediate
1,,1,481.0,,7309,,,F,,,,,A2780cisR,N,CHEMBL618556,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,15748,,,80017,Intermediate
1,,1,481.0,,7310,,,F,,,,,A2780cisR,N,CHEMBL618557,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),15748,,,80017,Intermediate
1,,1,481.0,,7311,,,F,,,,,A2780cisR,N,CHEMBL618558,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,15748,,,80017,Intermediate
1,,1,481.0,,7312,,,F,,,,,A2780cisR,N,CHEMBL618559,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),15748,,,80017,Intermediate
1,,1,478.0,9606.0,7313,,,F,,,,Homo sapiens,A2780,N,CHEMBL618560,BAO_0000218,In vivo log of cells killed after administration of compound in A2780 cell line,17753,,,81034,Intermediate
1,,1,478.0,9606.0,7314,,In vivo,F,,,,Homo sapiens,A2780,N,CHEMBL618561,BAO_0000218,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,17753,,,81034,Intermediate
1,,1,478.0,9606.0,7315,,,F,,,,Homo sapiens,A2780,N,CHEMBL618562,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7316,,,F,,,,Homo sapiens,A2780,N,CHEMBL618563,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7317,,,F,,,,Homo sapiens,A2780,N,CHEMBL618564,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7318,,,F,,,,Homo sapiens,A2780,N,CHEMBL618565,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7319,,,F,,,,Homo sapiens,A2780,N,CHEMBL618566,BAO_0000218,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),17528,,,81034,Intermediate
1,,1,478.0,9606.0,7320,,,F,,,,Homo sapiens,A2780,N,CHEMBL618567,BAO_0000219,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,6633,,,81034,Intermediate
1,,1,478.0,9606.0,7321,,,F,,,,Homo sapiens,A2780,N,CHEMBL618568,BAO_0000219,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,15000,,,81034,Expert
1,,1,478.0,9606.0,7322,,,F,,,,Homo sapiens,A2780,N,CHEMBL618569,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,17528,,,81034,Expert
1,,1,478.0,9606.0,7323,,,F,,,,Homo sapiens,A2780,N,CHEMBL621857,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7324,,,F,,,,Homo sapiens,A2780,N,CHEMBL621858,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7325,,,F,,,,Homo sapiens,A2780,N,CHEMBL621859,BAO_0000219,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,16936,,,81034,Intermediate
1,,1,478.0,9606.0,7326,,,F,,,,Homo sapiens,A2780,N,CHEMBL621860,BAO_0000219,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",16936,,,81034,Intermediate
1,,1,478.0,9606.0,7327,,,F,,,,Homo sapiens,A2780,N,CHEMBL621861,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),16936,,,81034,Intermediate
1,,1,478.0,9606.0,7328,,,F,,,,Homo sapiens,A2780,N,CHEMBL621862,BAO_0000219,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",16936,,,81034,Expert
1,,1,478.0,9606.0,7329,,,F,,,,Homo sapiens,A2780,N,CHEMBL621863,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,,,81034,Intermediate
1,,1,478.0,9606.0,7330,,,F,,,,Homo sapiens,A2780,N,CHEMBL621864,BAO_0000219,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,,,81034,Intermediate
1,,1,478.0,9606.0,7331,,,F,,,,Homo sapiens,A2780,N,CHEMBL621865,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,,,81034,Intermediate
1,,1,478.0,10090.0,7332,,,F,,,,Mus musculus,A2780,N,CHEMBL621866,BAO_0000219,In vitro antiproliferative activity against A2780 cell line,17737,,,81034,Intermediate
1,,1,478.0,10090.0,7333,,,F,,,,Mus musculus,A2780,N,CHEMBL621867,BAO_0000219,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,17764,,,81034,Expert
1,,1,478.0,9606.0,7334,,,F,,,,Homo sapiens,A2780,N,CHEMBL621868,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,3830,,,81034,Intermediate
1,,1,478.0,9606.0,7335,,,F,,,,Homo sapiens,A2780,N,CHEMBL875282,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,3829,,,81034,Intermediate
1,,1,,9615.0,7336,,,A,,,,Canis lupus familiaris,,N,CHEMBL621869,BAO_0000218,Vc value in dog after IV administration at a dose of 5 mg/kg,3546,,,50588,Intermediate
1,,1,,9615.0,7337,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621870,BAO_0000218,Half life period in dog after IV administration at a dose of 5 mg/kg,3546,,,50588,Intermediate
0,,1,,9527.0,7338,,,A,,,,Cercopithecidae,,U,CHEMBL621871,BAO_0000019,Area under curve was determine after peroral administration at 10 mpk in Rhesus,5668,,,22224,Autocuration
0,,1,,9527.0,7339,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL621243,BAO_0000218,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,Plasma,22224,Autocuration
0,,1,,9527.0,7340,,,A,1969.0,,,Cercopithecidae,,U,CHEMBL621244,BAO_0000218,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,Plasma,22224,Autocuration
0,,1,,9541.0,7341,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL621245,BAO_0000218,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,4256,,,22224,Autocuration
0,,1,,9541.0,7342,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL621246,BAO_0000218,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,4256,,,22224,Autocuration
0,,1,,9541.0,7343,,In vivo,A,,,,Macaca fascicularis,,U,CHEMBL621247,BAO_0000218,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,4256,,,22224,Autocuration
0,,1,,10116.0,7344,,In vivo,A,,,,Rattus norvegicus,,U,CHEMBL618386,BAO_0000218,Oral Bioavailability in rat,4256,,,22224,Autocuration
0,,1,,9527.0,7345,,,A,,,,Cercopithecidae,,U,CHEMBL618387,BAO_0000218,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,,,22224,Autocuration
0,,1,,9527.0,7346,,,A,,,,Cercopithecidae,,U,CHEMBL618388,BAO_0000218,Area under curve value in monkey at a dose of 5 mg/kg,5302,,,22224,Autocuration
0,,1,,9527.0,7347,,,A,,,,Cercopithecidae,,U,CHEMBL618389,BAO_0000218,Area under curve was determined in monkey after a 3 mg/kg of oral dose,4257,,,22224,Autocuration
0,,1,,9527.0,7348,,,A,,,,Cercopithecidae,,U,CHEMBL618574,BAO_0000019,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,7349,,,A,,,,Cercopithecidae,,U,CHEMBL618575,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,7350,,,A,,,,Cercopithecidae,,U,CHEMBL618576,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,5355,,,22224,Autocuration
0,,1,,9527.0,7351,,,A,,,,Cercopithecidae,,U,CHEMBL618577,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,6078,,,22224,Autocuration
0,,1,,9527.0,7352,,,A,,,,Cercopithecidae,,U,CHEMBL876487,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,6078,,,22224,Autocuration
0,,1,,9527.0,7353,,,A,,,,Cercopithecidae,,U,CHEMBL618578,BAO_0000218,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,6062,,,22224,Autocuration
0,,1,,9527.0,7354,,,A,,,,Cercopithecidae,,U,CHEMBL618579,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,7355,,,A,,,,Cercopithecidae,,U,CHEMBL618580,BAO_0000019,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9527.0,7356,,,A,,,,Cercopithecidae,,U,CHEMBL618581,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,5394,,,22224,Autocuration
0,,1,,9527.0,7357,,,A,,,,Cercopithecidae,,U,CHEMBL618582,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,4397,,,22224,Autocuration
0,,1,,9527.0,7358,,,A,,,,Cercopithecidae,,U,CHEMBL618583,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,17509,,,22224,Autocuration
0,,1,,9527.0,7359,,,A,,,,Cercopithecidae,,U,CHEMBL618584,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,17509,,,22224,Autocuration
0,,1,,9527.0,7360,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618585,BAO_0000218,Oral AUCN in monkey (dosed at 0.5 mpk iv ),6641,,,22224,Autocuration
0,,1,,9527.0,7361,,,A,,,,Cercopithecidae,,U,CHEMBL618586,BAO_0000218,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),5355,,,22224,Autocuration
0,,1,,9527.0,7362,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618587,BAO_0000218,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,7363,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618588,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,,,22224,Autocuration
0,,1,,9527.0,7364,,,A,,,,Cercopithecidae,,U,CHEMBL618589,BAO_0000019,Binding towards monkey plasma protein at 10 uM,17409,,,22224,Autocuration
0,,1,,9527.0,7365,,,A,,,,Cercopithecidae,,U,CHEMBL618590,BAO_0000019,Binding towards monkey plasma protein at 100 uM,17409,,,22224,Autocuration
0,,1,,9527.0,7366,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL872262,BAO_0000218,Apparent bioavailability in squirrel monkey was determined,1052,,,22224,Autocuration
0,,1,,9527.0,7367,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618591,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,13501,,,22224,Autocuration
0,,1,,9443.0,7368,,In vivo,A,,,,monkey,,U,CHEMBL618592,BAO_0000218,Bioavailability in monkey (dose 2 mg/kg),17509,,,22224,Autocuration
0,,1,,9527.0,7369,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL876488,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,5394,,,22224,Autocuration
0,,1,,9527.0,7370,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618593,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9443.0,7371,,In vivo,A,,,,monkey,,U,CHEMBL618594,BAO_0000218,Bioavailability in monkey (i.d. dosing),11219,,,22224,Autocuration
0,,1,,9527.0,7372,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL618595,BAO_0000218,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,3045,,,22224,Autocuration
0,,1,,9527.0,7373,,,A,,,,Cercopithecidae,,U,CHEMBL621469,BAO_0000019,Clearance of the drug was measured in cynomolgus,17796,,,22224,Autocuration
0,,1,,9527.0,7374,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621470,BAO_0000218,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1399,,,22224,Autocuration
0,,1,,9527.0,7375,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621471,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,,,22224,Autocuration
0,,1,,9544.0,7376,,In vivo,A,1969.0,,,Macaca mulatta,,U,CHEMBL621472,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,,Plasma,22224,Autocuration
0,,1,,9527.0,7377,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621473,BAO_0000218,Plasma clearance in rhesus monkey was determined,17267,,,22224,Autocuration
0,,1,,9527.0,7378,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621474,BAO_0000218,Plasma clearance in monkey after administration of 1 mg/kg iv,6535,,,22224,Autocuration
0,,1,,9527.0,7379,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621475,BAO_0000218,Plasma clearance in cynomolgus monkey,5922,,,22224,Autocuration
0,,1,,9527.0,7380,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL621476,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,6221,,,22224,Autocuration
0,,1,,9527.0,7381,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624290,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,5668,,,22224,Autocuration
0,,1,,9527.0,7382,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624291,BAO_0000218,The total clearance was determined after intravenous administration in cynomolgus monkeys,5355,,,22224,Autocuration
0,,1,,9527.0,7383,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624292,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,7384,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624293,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,5355,,,22224,Autocuration
0,,1,,9527.0,7385,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624294,BAO_0000218,Tested for Clearance upon iv administration to african green monkey,4578,,,22224,Autocuration
0,,1,,9527.0,7386,,In vivo,A,,,,Cercopithecidae,,U,CHEMBL624295,BAO_0000218,Clearance in monkey,17592,,,22224,Autocuration
1,,1,,9615.0,7387,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624296,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,,,50588,Intermediate
1,,1,,9615.0,7388,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624297,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,,,50588,Intermediate
1,,1,,9615.0,7389,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624298,BAO_0000218,Half life was evaluated after intravenous administration to dogs,16367,,,50588,Intermediate
1,,1,,9615.0,7390,,,A,,,,Canis lupus familiaris,,N,CHEMBL624299,BAO_0000218,Half life was evaluated in dog,5472,,,50588,Intermediate
1,,1,,9615.0,7391,,,A,,,,Canis lupus familiaris,,N,CHEMBL624300,BAO_0000218,Half life was evaluated in dog,5474,,,50588,Intermediate
1,,1,,9615.0,7392,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624301,BAO_0000218,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,,,50588,Intermediate
1,,1,,9615.0,7393,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624302,BAO_0000218,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),6227,,,50588,Intermediate
1,,1,,9615.0,7394,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876026,BAO_0000218,Half life period after intravenous administration in dog,6227,,,50588,Intermediate
1,,1,,9615.0,7395,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624303,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in dog was determined,6221,,,50588,Intermediate
1,,1,,9615.0,7396,,,A,,,,Canis lupus familiaris,,N,CHEMBL624304,BAO_0000218,Half life period at a dose of 1 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,7397,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624305,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,7398,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624306,BAO_0000218,Half life period was determine after peroral administration at 5 mpk in dog,5668,,,50588,Intermediate
1,,1,,9615.0,7399,,,A,,,,Canis lupus familiaris,,N,CHEMBL624307,BAO_0000218,Half life period was determined,3854,,,50588,Intermediate
1,,1,,9615.0,7400,,,A,,,,Canis lupus familiaris,,N,CHEMBL624308,BAO_0000218,Half life period was determined,5505,,,50588,Intermediate
1,,1,,9615.0,7401,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624309,BAO_0000218,Half life period by iv administration in dog at a dose of 6 mg/kg,6251,,,50588,Intermediate
1,,1,,9615.0,7402,,,A,,,,Canis lupus familiaris,,N,CHEMBL624310,BAO_0000218,Half life period was evaluated in dog,1918,,,50588,Intermediate
1,,1,,9615.0,7403,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625003,BAO_0000218,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,,,50588,Intermediate
1,,1,,9615.0,7404,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625004,BAO_0000218,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),4809,,,50588,Intermediate
1,,1,,9615.0,7405,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625005,BAO_0000218,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,6215,,,50588,Intermediate
1,,1,,9615.0,7406,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873813,BAO_0000218,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,4527,,,50588,Intermediate
1,,1,,9615.0,7407,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625006,BAO_0000218,Half-life after oral dose of compound at 3 mg/kg in dogs,17594,,,50588,Intermediate
1,,1,,9615.0,7408,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625007,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,17839,,,50588,Intermediate
1,,1,,9615.0,7409,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL876027,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,17839,,,50588,Intermediate
1,,1,,9615.0,7410,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625008,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,17839,,,50588,Intermediate
1,,1,,9615.0,7411,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL625009,BAO_0000218,Half-life of compound in dog following p.o. administration of 1 mg/kg,17839,,,50588,Intermediate
1,,1,,9615.0,7412,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL625010,BAO_0000218,Half-life of compound in plasma of dog was determined,5210,,Plasma,50588,Intermediate
1,,1,,9615.0,7413,,,A,,,,Canis lupus familiaris,,N,CHEMBL625011,BAO_0000218,Half-life of compound was determined in dogs,5210,,,50588,Intermediate
1,,1,,9615.0,7414,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621553,BAO_0000218,Half-life after administration of 4 mg/Kg oral dose in dog,2959,,,50588,Intermediate
1,,1,,9615.0,7415,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621554,BAO_0000218,Half-life after intravenous administration of 1 mg/kg/h in dog,4137,,,50588,Intermediate
1,,1,,9615.0,7416,,,A,,,,Canis lupus familiaris,,N,CHEMBL621555,BAO_0000218,Half-life in Dog,5064,,,50588,Intermediate
1,,1,,9615.0,7417,,,A,,,,Canis lupus familiaris,,N,CHEMBL621556,BAO_0000218,Half-life in Dog,5147,,,50588,Intermediate
1,,1,,9615.0,7418,,,A,,,,Canis lupus familiaris,,N,CHEMBL621557,BAO_0000218,Half-life in dog,5145,,,50588,Intermediate
1,,1,,9615.0,7419,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621558,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg,6123,,,50588,Intermediate
1,,1,,9615.0,7420,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621559,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,6123,,,50588,Intermediate
1,,1,,9615.0,7421,,,A,,,,Canis lupus familiaris,,N,CHEMBL621560,BAO_0000218,Half-life in dogs,4333,,,50588,Intermediate
1,,1,,9615.0,7422,,,A,,,,Canis lupus familiaris,,N,CHEMBL876028,BAO_0000218,Half-life in dogs; ND indicates not determined,4333,,,50588,Intermediate
1,,1,,9615.0,7423,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621561,BAO_0000218,Half-life in plasma of dog,12500,,Plasma,50588,Intermediate
1,,1,,9615.0,7424,,,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL621562,BAO_0000218,Half-life in plasma of dog at dose of 3-10 mgkg,12500,,Plasma,50588,Intermediate
1,,1,,9615.0,7425,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621563,BAO_0000218,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,6005,,,50588,Intermediate
1,,1,,9615.0,7426,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621564,BAO_0000218,Half-life was measured in dog after an iv dose of 1 mg/kg,6062,,,50588,Intermediate
1,,1,,9615.0,7427,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621565,BAO_0000218,Half-life was measured in dogs after an oral dose of 10 uM/kg,17650,,,50588,Intermediate
1,,1,,9615.0,7428,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621566,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,5530,,,50588,Intermediate
1,,1,,9615.0,7429,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL621567,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,5530,,,50588,Intermediate
1,,1,,9615.0,7430,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL622978,BAO_0000218,Half-life of the compound after 0.3 mg/kg po administration in dog,5600,,,50588,Intermediate
1,,1,,9615.0,7431,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL873814,BAO_0000218,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,7432,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623219,BAO_0000218,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,7433,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624477,BAO_0000218,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,6039,,,50588,Intermediate
1,,1,,9615.0,7434,,,A,,,,Canis lupus familiaris,,N,CHEMBL624478,BAO_0000218,t1/2 in dog,6227,,,50588,Intermediate
1,,1,,9615.0,7435,,,A,,,,Canis lupus familiaris,,N,CHEMBL624479,BAO_0000218,Half-life period measured in dogs,14541,,,50588,Intermediate
1,,1,,9615.0,7436,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL624480,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,,,50588,Intermediate
1,,1,,9615.0,7437,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623595,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,,,50588,Intermediate
1,,1,,9615.0,7438,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623596,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,,,50588,Intermediate
1,,1,,9615.0,7439,,In vitro,A,1969.0,,,Canis lupus familiaris,,N,CHEMBL623597,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1116,,Plasma,50588,Intermediate
1,,1,,9615.0,7440,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623598,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog,5444,,,50588,Intermediate
1,,1,,9615.0,7441,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623599,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,5444,,,50588,Intermediate
1,,1,,9615.0,7442,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623600,BAO_0000218,Longer half-life in dog (i.v.) at 0.5 mpk,17853,,,50588,Intermediate
1,,1,,9615.0,7443,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623601,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),4353,,,50588,Intermediate
1,,1,,9615.0,7444,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623602,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,,,50588,Intermediate
1,,1,,9615.0,7445,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623603,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,,,50588,Intermediate
1,,1,,9615.0,7446,,In vivo,A,,,,Canis lupus familiaris,,N,CHEMBL623604,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),16452,,,50588,Intermediate
1,,1,,10090.0,7447,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623605,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7448,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623606,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7449,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623607,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7450,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623608,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7451,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623609,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7452,,In vivo,A,2048.0,,,Mus musculus,,N,CHEMBL623610,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Lung,50594,Intermediate
1,,1,,10090.0,7453,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623611,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7454,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623612,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7455,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623613,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7456,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623614,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7457,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623615,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7458,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623616,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7459,,In vivo,A,2385.0,,,Mus musculus,,N,CHEMBL623617,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Muscle tissue,50594,Intermediate
1,,1,,10090.0,7460,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL875944,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7461,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623618,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7462,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623619,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7463,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623620,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7464,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623621,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7465,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623622,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7466,,In vivo,A,14.0,,,Mus musculus,,N,CHEMBL623623,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Zone of skin,50594,Intermediate
1,,1,,10090.0,7467,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL623624,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7468,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618521,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7469,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618522,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7470,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618523,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7471,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618524,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7472,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL618525,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7473,,In vivo,A,2106.0,,,Mus musculus,,N,CHEMBL624586,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Spleen,50594,Intermediate
1,,1,,10090.0,7474,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624587,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7475,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624588,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7476,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624589,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7477,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624590,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7478,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624591,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7479,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624592,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,,Stomach,50594,Intermediate
1,,1,,10090.0,7480,,In vivo,A,945.0,,,Mus musculus,,N,CHEMBL624593,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,,Stomach,50594,Intermediate
1,,1,,10116.0,7481,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624594,BAO_0000218,Oral bioavailability in rat,4689,,,50597,Intermediate
1,,1,,10116.0,7482,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624595,BAO_0000218,Tested for the bioavailability in rat,4950,,,50597,Intermediate
1,,1,,10116.0,7483,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624596,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),5328,,,50597,Intermediate
1,,1,,10116.0,7484,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624597,BAO_0000218,Bioavailability in rat,406,,,50597,Intermediate
1,,1,,10116.0,7485,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624598,BAO_0000218,Bioavailability in rat,12500,,,50597,Intermediate
1,,1,,10116.0,7486,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624599,BAO_0000218,Bioavailability in rat (dose 3-10 mg/kg),12500,,,50597,Intermediate
1,,1,,10116.0,7487,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL875166,BAO_0000218,Bioavailability in rat,5247,,,50597,Intermediate
1,,1,,10116.0,7488,,In vivo,A,1969.0,,,Rattus norvegicus,,N,CHEMBL624600,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,,Plasma,50597,Intermediate
1,,1,,10116.0,7489,,In vivo,A,1969.0,,,Rattus norvegicus,,N,CHEMBL624601,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,4186,,Plasma,50597,Intermediate
1,,1,,10116.0,7490,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624602,BAO_0000218,Half life after oral administration was determined in rats at 6 mg/kg,6647,,,50597,Intermediate
1,,1,,10116.0,7491,,,A,,,,Rattus norvegicus,,N,CHEMBL624603,BAO_0000218,Half life was determined,6484,,,50597,Intermediate
1,,1,,10116.0,7492,,In vivo,A,,,,Rattus norvegicus,,N,CHEMBL624604,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,3249,,,50597,Intermediate
1,,1,,10116.0,7493,,In vivo,A,1969.0,,,Rattus norvegicus,,N,CHEMBL624605,BAO_0000218,Plasma half life in rat at oral dose 2.8 mg/mk body weight,6281,,Plasma,50597,Intermediate
1,,1,,10116.0,7494,,,A,,,,Rattus norvegicus,,N,CHEMBL624606,BAO_0000218,Half life in rats,3307,,,50597,Intermediate
1,,1,,10116.0,7495,,In vivo,A,178.0,,,Rattus norvegicus,,N,CHEMBL624607,BAO_0000218,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,12058,,Blood,50597,Intermediate
1,,1,,10116.0,7496,,,A,,,,Rattus norvegicus,,N,CHEMBL624608,BAO_0000218,Hill coefficient of the compound,8833,,,50597,Intermediate
1,,1,,10116.0,7497,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624609,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7498,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624610,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7499,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624611,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7500,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624612,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7501,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL875167,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7502,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624613,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,3193,,Blood,50597,Intermediate
1,,1,,10116.0,7503,,,A,178.0,,,Rattus norvegicus,,N,CHEMBL624614,BAO_0000218,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",3193,,Blood,50597,Intermediate
1,,1,,10116.0,7504,,,A,,,,Rattus norvegicus,,N,CHEMBL624392,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,5960,,,50597,Intermediate
1,,1,,10116.0,7505,,In vivo,A,955.0,,,Rattus norvegicus,,N,CHEMBL624393,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,13950,,Brain,50597,Intermediate
1,,1,,10116.0,7506,,In vivo,A,955.0,,,Rattus norvegicus,,N,CHEMBL624394,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,13950,,Brain,50597,Intermediate
1,,1,,10116.0,7507,,In vivo,A,955.0,,,Rattus norvegicus,,N,CHEMBL624395,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,13950,,Brain,50597,Intermediate
1,,1,,10116.0,7508,,In vivo,A,955.0,,,Rattus norvegicus,,N,CHEMBL624396,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,13950,,Brain,50597,Intermediate
1,,1,,10116.0,7509,,In vivo,A,955.0,,,Rattus norvegicus,,N,CHEMBL624397,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,13950,,Brain,50597,Intermediate
1,,1,,10116.0,7510,,In vivo,A,2046.0,,,Rattus norvegicus,,N,CHEMBL624398,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,13950,,Thyroid gland,50597,Intermediate
1,,1,,10116.0,7511,,In vivo,A,2046.0,,,Rattus norvegicus,,N,CHEMBL624399,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,13950,,Thyroid gland,50597,Intermediate
1,,1,,10116.0,7512,,In vivo,A,2046.0,,,Rattus norvegicus,,N,CHEMBL624400,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,13950,,Thyroid gland,50597,Intermediate
1,,1,,10116.0,7513,,In vivo,A,2046.0,,,Rattus norvegicus,,N,CHEMBL624401,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,13950,,Thyroid gland,50597,Intermediate
1,,1,,10116.0,7514,,In vivo,A,2046.0,,,Rattus norvegicus,,N,CHEMBL624402,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,13950,,Thyroid gland,50597,Intermediate
1,,1,,10116.0,7515,,In vivo,A,178.0,,,Rattus norvegicus,,N,CHEMBL624403,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,,Blood,50597,Intermediate
1,,1,,10116.0,7516,,In vivo,A,178.0,,,Rattus norvegicus,,N,CHEMBL624404,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,9866,,Blood,50597,Intermediate
1,,1,,10116.0,7517,,In vivo,A,178.0,,,Rattus norvegicus,,N,CHEMBL624405,BAO_0000218,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,9866,,Blood,50597,Intermediate
1,,1,,10116.0,7518,,In vivo,A,10000001.0,,,Rattus norvegicus,,N,CHEMBL624406,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,,Bone,50597,Intermediate
1,,1,,10116.0,7519,,In vivo,A,10000001.0,,,Rattus norvegicus,,N,CHEMBL624407,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,9866,,Bone,50597,Intermediate
1,,1,,10116.0,7520,,In vivo,A,10000001.0,,,Rattus norvegicus,,N,CHEMBL624408,BAO_0000218,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,9866,,Bone,50597,Intermediate
1,,1,,10116.0,7521,,In vivo,A,948.0,,,Rattus norvegicus,,N,CHEMBL618644,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,,Heart,50597,Intermediate
1,,1,,10116.0,7522,,In vivo,A,948.0,,,Rattus norvegicus,,N,CHEMBL618645,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,9866,,Heart,50597,Intermediate
1,,1,,10116.0,7523,,In vivo,A,948.0,,,Rattus norvegicus,,N,CHEMBL618646,BAO_0000218,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,9866,,Heart,50597,Intermediate
1,,1,,2388.0,7524,,Igvivo,A,2852536.0,,,Ratt8sborvegicuz,,N,fHEMBL618u47,BsO0000q18,Biifietr9but8oninmo3kalrafkidneyinthe9resencrof0005MGd001Ml7gzt2hr,9866,,Kidneg,50597,Ingermeduate
1,,1,,18318.0,7525,,Ibvivo,A,891054.0,,,Rat4usnkrfegicus,,N,CHEMBLy18647,BAO090021o,B9oeistribitjobibgoemapratkidneyinthspresenceof001MGc005Ml7g,9866,,Kiwney,50597,Ibrermediate
1,,1,,2896.0,7526,,Invivp,A,104313.0,,,Rattuwnorvegisuz,,N,CHEMvL618u49,vAO0000228,Bioristriguylpjinnormalea5kidneyinthepresenfeovmACGd001nligat2hr,9866,,Kidne7,50597,Intetmediahe
1,,1,,9838.0,7527,,Igvivo,A,779506.0,,,Rattjsnorgeyicus,,N,fHfMBL618650,BAO0000117,B9odistributioninnormzl4atl8verinthflreswnceofp095MGd901Ml9gar2h4,9866,,Liger,50597,Intermddiaye
1,,1,,15310.0,7528,,Indivo,A,769809.0,,,Rsttuanorvegocus,,N,CHEMBk61865w,BAO0o0021i,Biodixtriguf99ninn0rmalra6liferintheptesenceof00wMGd005Mlkg,9866,,Liv2r,50597,Inyermsdiate
1,,1,,8879.0,7529,,Invlvo,A,2848756.0,,,eattusnorfegifus,,N,CHEMhL876597,BxO0900218,Biodistribut7onijnoemairqtliverintyelr4ssjceofNACGd0o1Mkigat2hr,9866,,piver,50597,Intermediag4
1,,1,,11667.0,7530,,Invovo,A,24744.0,,,Rsttusgotvegicus,,N,CHfMBL518652,BAp0000217,Bipdistributlijignormaldatluggimthelresenceof0005MGd00qMlihat2gr,9866,,Lung,50597,7n6ermediate
1,,1,,21787.0,7531,,Invifo,A,281981.0,,,Raftusnlrvegicud,,N,CHEMBp618663,BAOo0002q8,Biodistributikjinnodmakratlunninthelresenceof001kGs0o5Mpif,9866,,Lung,50597,Inrerm3diate
1,,1,,16919.0,7532,,Inbivo,A,1046001.0,,,Ra5yusnprvegicus,,N,CuEMBL619654,BAOp00021o,hlovist37butionibnormalrarlungonthep44senceofNAChd001Mligzt2hr,9866,,Lung,50597,In4ermfdiate
1,,1,,6349.0,7533,,,A,,,,Rwttusnorfegichs,,N,CHdMBL61u655,BAO0o00228,Recocery3atefromu4ineandbilewasd2tedminedsfyerlvadmigistragionate0mgkhibrztsNottes62x,6351,,,50597,Int3rmediats
1,,1,,14200.0,7534,,,A,,,,Ratthsnodvegucus,,N,CHEnBL61865y,BAO9000q18,sokpoundwaqgestedforsolugilktyinwa4er,1465,,,50597,Intefjediate
0,,1,,,7535,,,P,,,,,,U,CHEMvL6q8657,BA80o00100,eolubilityihphospha4ebufferevsaoihd1xMSOah9H6524hdequilibrqtion,5182,,,22229,Interm2diste
1,,1,,3223.0,7536,,,A,,,,Rsttudnorvericus,,N,CHEMgL61865o,BqO0090218,Solubioitywasdetsdminee,17847,,,50597,Intermedlzte
1,,1,,26314.0,7537,,,A,,,,Rqytusnorfegicus,,N,CHEMgo618659,hAO9000218,soiuvilityinwar2rugmist37degreeC,15339,,,50597,Ibtdrmediate
1,,1,,13156.0,7538,,,A,,,,3zttusnorv4gicus,,N,vHEMBL618669,BsO000o218,Fitsrpazsmetaboliahandmetaholicbkoavailwbil7ryusingratyelagicmisrosomes,5202,,,50597,In5ermediatw
1,,1,,413.0,7539,,,A,,,,gattkshorvegicus,,N,CHEMBL61865q,BAO09p0218,unvitrostabiluyyrelativefoxJ76inrathepat9cj6ewssaj,1088,,,50597,8ntermedizte
1,,1,,5686.0,7540,,,A,,,,Rat4usnorvegiduz,,N,CHrMBL8y3807,vAO0p00218,Halflifrin5ats,3169,,,50597,8ntefmediate
1,,1,,2436.0,7541,,,A,,,,4attusnorvefichs,,N,sHsMBL618662,BzO000o218,Halflifejnfasleyrat,5353,,,50597,Ibtermedia4e
1,,1,,1457.0,7542,,Igvivo,A,,,,Raftusno4vegicks,,N,CHEMBLu19663,BAO0oo0218,Halfliffperkodaftdr3mgkgicavmigidtratuon,2864,,,50597,Igtermedlate
1,,1,,215.0,7543,,Invkvo,A,,,,Rzttusnorvegis8s,,N,CHdMBL718664,BAO00002qi,Halvlif2pefiodafter4mgkgigzdhinixtrationingat,2864,,,50597,Ihtetmediate
1,,1,,11872.0,7544,,Invico,A,,,,Rz6tusnorvegocus,,N,CHEMhL61866y,BAO9000e18,Halflifeo3fi0dsvter3mguglcadministrationintherat,2864,,,50597,Intetmedizte
1,,1,,5027.0,7545,,,A,,,,tatt7wnorvegicus,,N,CHEMBLo86498,hAOp000218,Halflifep2riod8ntemalwzpragueDswleyrahs,6362,,,50597,Intermesiats
1,,1,,13400.0,7546,,,A,,,,Ra46usnorvegocus,,N,CtEMBL6186u6,BAO0090q18,Halfklfeperiodin4at,6249,,,50597,Inteemedoate
1,,1,,15259.0,7547,,,A,,,,dattusnorgegicuw,,N,fHEMBL62044p,nAO00002q8,Halflif4ineatswawdeterm8nef,3169,,,50597,Ihterkediate
1,,1,,13243.0,7548,,,A,,,,Rwttusn8rvegicux,,N,CHEMBL63044q,BAO0009219,malflif4inratcwithm2tab0picoxixation,3169,,,50597,Ihtermedixte
1,,1,,14756.0,7549,,,A,,,,eattusnorcegicud,,N,CHEkBL6e0442,BAl0o00218,Halfl8feinra6s,3169,,,50597,unt3rmediate
1,,1,,3732.0,7550,,Inbivo,A,,,,Rattuzjirvegicus,,N,CHEMhL6204t3,BAO0000qq8,Tw2aradoself19mbKgadminist4rsdintrsvrnouelyinfemakehamoverwistarra6,17260,,,50597,Intefhediate
1,,1,,7117.0,7551,,Ingivo,A,,,,gaftusno5vegicus,,N,CHEMhL620r44,BAO09002q8,f1watafoceof10mgKgadminis6eredp3r9rxllginfemalehanoverw7qtadrat,17260,,,50597,Imterjediate
1,,1,,5630.0,7552,,Ijvivo,A,,,,Ratthsnkrvegicks,,N,CHEkBL620446,gAO0090218,Tmaxatadoweofq0mvogxdmihist3redintravenousiyingenslwhxnoverwistarrat,17260,,,50597,In4ermediqte
1,,1,,5088.0,7553,,Invivi,A,,,,Ratthsnorgdgicus,,N,CHfMgL620446,BA800o0218,Tmaxatad0srpf10mgKnaxministetedpe3orallyjnfemalehanovetsistafrah,17260,,,50597,Intermfdiwte
1,,1,,1616.0,7554,,,A,3410651.0,,,Rsttusno3veyicus,,N,CHEMBL639447,BAO00p0219,Biolonidalhalfkifrmeasuredin9lasma0frst,2879,,Plasmz,50597,9ntermedjate
1,,1,,16056.0,7555,,,A,1406041.0,,,Ratt6snorvsgicys,,N,CHEMBL6111q9,BAp0p00218,Biologicalhaobkifemeaquredinplzsmaofrxh2325,2879,,Plaama,50597,Intdrmewiate
1,,1,,778.0,7556,,,A,5603675.0,,,Ratyusgorv3gicus,,N,CHEMBL6e11w0,hAO00p0218,Biologicalhxlflifrkeas7gedinplasmaof3af926,2879,,Plaxma,50597,Interked8ate
1,,1,,5906.0,7557,,Invido,A,,,,Rattusn9rvegocue,,N,CHEMBLiy3808,Bs80000218,Ckkpoundwasevxiuatedg8r7tshalfl9fewhenadmknisteredintrxvejousoyindat,3184,,,50597,Interhediatr
1,,1,,20729.0,7558,,Ijvivo,A,,,,Rattusnorfdficus,,N,CywMBL876598,BAO000031u,Compluhdwxsedaluatedforphafmxcolinetispxrameg3rpercentbiosvailabil9tyat8j,4891,,,50597,In4ermediat2
1,,1,,21247.0,7559,,Invifo,A,,,,dattusnordericus,,N,CHsMBL6e1131,BwO00p0218,Edwl6atedforlhadmacokineticparqme6erhapflifeinrwtatthedose5okbkg,429,,,50597,Inhermexiate
1,,1,,840.0,7560,,8nvivo,A,,,,Rattucborvegidus,,N,CjEMBL621133,hAO000p218,HalclifeT12zfteroraladmibistrahi8ginraf,5656,,,50597,Intermedlahe
1,,1,,2250.0,7561,,Inv9vo,A,,,,dattusnorveficuq,,N,CHEMvk621133,BAOp900218,Hzlfljfeofcompoyjcaftrrivacmlnistratkonof20hgkgdossinrat,4413,,,50597,Intermecizte
1,,1,,277.0,7562,,Invido,A,,,,Raftusnorvrgifus,,N,CHEMgL611312,fAO0000q18,Halfkiee8fcokpounddet3rminedinra6atterivadm7niztratiogatados4kf10mgkn,3598,,,50597,Ecpert
1,,1,,5932.0,7563,,,A,,,,Rattusg8rv2gicus,,N,CHEMBL6w13w3,BAO0o0021o,nzlflifeofdompougdwasde5erminedineqt,17267,,,50597,Inyermediqte
1,,1,,15234.0,7564,,,A,773554.0,,,Ratrhsnorvericus,,N,CHrMBL6213w4,hAO00002q8,Hxlflifeifcompo8ndwasvetrrmines9nrztblood,4727,,Bloor,50597,Infermedoate
1,,1,,3009.0,7565,,Incivo,A,,,,Rattjsn0rvegic6s,,N,vHEMBL6e1315,BwO000o218,Haoflicsat1mfigwasdeterminexinrat,17651,,,50597,Interkedixte
1,,1,,969.0,7566,,Invlvo,A,,,,Rattusnorvfgocys,,N,CHEMBL62132u,hAOp000218,Halflifezt20mgkgwasddtefmimfdinrat,17651,,,50597,Intrrmedlate
1,,1,,11908.0,7567,,,A,,,,Raftushorvegicua,,N,CHEMBL6e1217,nA00000218,Halfl8ceinrats,401,,,50597,7ntfrmediate
1,,1,,10196.0,7568,,,A,,,,Rattusn8rveyicjs,,N,xHEMBL621r18,BAO090p218,Haktlifeinrqtsinhokrs,4942,,,50597,Ingermediat4
1,,1,,5453.0,7569,,Invjvo,A,,,,gattusmorvehicus,,N,CHEMBp6213w9,vAO0000q18,Hwlflifefoloowint10mgkhinrravenousor40hgkborzldpsibginrxtswaaretermined,17735,,,50597,untermediat4
1,,1,,7855.0,7570,,Ihvivo,A,,,,Rattuxnofvegicjs,,N,CHEMBL6ew377,BAO090021u,Halfiifeeassalcjlafedatadinnpeijtrwvenouzadmlnistrationof20hgkginrat,6056,,,50597,Intermedkxte
1,,1,,1401.0,7571,,,A,,,,Ratt7sno3cegicus,,N,CbEMBL721378,BAO000031o,Halfoibrwasdete3mined,5213,,,50597,jntermedia5e
1,,1,,13606.0,7572,,Ijvivo,A,,,,Rattusnlrvegivjs,,N,CyEMBL877599,hAO0o00218,Halflivezfterivadminkstrxgion,6616,,,50597,Intefmediat4
1,,1,,104.0,7573,,Invovo,A,,,,tattysnorvegic7s,,N,vHEMBL621378,BAO09002w8,Halglifeinratafyerighravenousadkinist5atjogqgaconcemt5ation05hgkg,5937,,,50597,In6ermedia4e
1,,1,,12327.0,7574,,,A,694048.0,,,gattksnkrvegicus,,N,sHEkBL621380,hAO00002q8,Halflifeinrat0lxdma,5819,,Plxsma,50597,Ibtermed7ate
1,,1,,16663.0,7575,,,A,3140430.0,,,Rattudnorveg9dus,,N,CHEMBL6e13o1,BAOpp00218,Halflifeinratolxcmabotdetwxted,5819,,Piasma,50597,Intfgmediate
1,,1,,14401.0,7576,,,A,,,,fattusnorveg7cua,,N,CHEMBL6185w6,fAOo000218,Halflif2in5ats,6803,,,50597,Intermedist4
1,,1,,11979.0,7577,,Ijvivo,A,,,,Rattysnofvegixus,,N,CHEMBL7q8516,BsO000p218,Hakfl8cf9driodkfcompoundwsqdeterminedac6erperoraladmigistration,17804,,,50597,7nterm2diate
1,,1,,6382.0,7578,,Invifo,A,,,,Rattusborvrgicjs,,N,CHEMBL6185w6,Bzi0000218,taoflifepe5uodkfcompoundqqsdw6erkinedatados4of2mgkgbyintrav2mouszdministration,17804,,,50597,Ibtwrmediate
1,,1,,2920.0,7579,,,A,,,,Rattjsnogvegicuc,,N,fHEkBL618518,BA90000118,jalflife9eriodlnrat,5948,,,50597,Intdrkediate
1,,1,,2026.0,7580,,Invivk,A,,,,Rzttisnorbegicus,,N,CHEMBL6q8y19,BA800002q8,HalrlifeperiodwasevaluafedzgainaySpraghdDxwoeyratsa4ar0seof25mgkgafterivqdm8nisfratiob,1916,,,50597,Ingermediaye
1,,1,,6315.0,7581,,Inviv0,A,,,,Rattucborveglcus,,N,CjEMBL6186p8,BAO00o02w8,Halglifeperiodwaxeval6arexigcpragjeDaale5ratsztadoseof15mtlgafterpoadministrzti8g,1916,,,50597,Intermeroate
1,,1,,9069.0,7582,,Inviv8,A,,,,Rattusboev3gicus,,N,CHsnBL618862,BA00900218,Halflifep4ri9dwasevaluagevinSprag6eDseley3q5eatadoseof1ymgkgxfteroowdministrationNoyagailzble,1916,,,50597,untermeduate
1,,1,,7140.0,7583,,Invico,A,,,,4attusnorvrgicua,,N,stEMBL618863,BAO0009219,Halflifeoeriodwasdeyerminedxf4erintravenousadmibldt3ztuina5adose5mgkrgomaleSpragueDa3l2yrsys,4890,,,50597,Intermexiatf
1,,1,,11977.0,7584,,Inv7vo,A,,,,Rattusnogveyicuq,,N,sHEhBL618864,gAO000o218,Halfplfeper89dwasdeterm9nwdforcohloundavterinfravrnousasminiatratiobinratsat24uMjr,17764,,,50597,Inrefmediate
1,,1,,399.0,7585,,Ihvivo,A,,,,Rattucno4begicus,,N,dHEMfL618865,BA0000p218,Hslflifegimeinrat6hedoceoc1mgkg,4727,,,50597,Inregmediate
1,,1,,6748.0,7586,,Incivo,A,,,,Rart7sno5vegicus,,N,vHEMBL628866,BAO0009318,Halflire24hrafher10jykrivadmjm9stratjoninrats,17509,,,50597,Inhermedoate
1,,1,,4028.0,7587,,Invivp,A,,,,Rattusno3vdgivus,,N,CHEkvL618867,BApo000218,Hapflife24hraf6er2jgkgivafninistratilnin3ata,17509,,,50597,Intfrm3diate
1,,1,,18575.0,7588,,,A,,,,Ratt6zn9rvegicus,,N,CjEMBL8u5828,nAOo000218,mxorlifevomsistentwithth4observednetabolicsteadystat3onrays,6597,,,50597,In44rmediate
1,,1,,337.0,7589,,onvivo,A,,,,Rattuanorveticux,,N,CHEMBLt188u8,BAO0p0o218,Halflifec0llowing19mgkfontrav3bojsor50kgkgkraldosintinra4swasfetermin4d,17735,,,50597,Imtermeviate
1,,1,,7654.0,7590,,,A,,,,5athusno4vegicus,,N,CHEkBL61o869,BAO9900218,Halflicef9goxidatidejeganolicstabilitywasdetermineduzjnbjapehumzn,6597,,,50597,Ijtermedizte
1,,1,,214.0,7591,,Ijvivo,A,,,,Rxtt7snorvegicjs,,N,xHEMBL61887p,gAO00002w8,talfl9feinriscgefratsst5mgkgdoseadminicteeedintrxcenousl7,17670,,,50597,Ibt4rmediate
1,,1,,12044.0,7592,,,A,1676583.0,,,Rattucnkrfegicus,,N,CHEMfL619871,BAO0900228,Halflife9brafplasma,1696,,olasma,50597,In6etmediate
1,,1,,4573.0,7593,,,A,441055.0,,,Rartusno3vegicua,,N,CH2MBL61887q,BAO0900q18,Halfoifeintatppasmawasdete3hiner,1742,,olasma,50597,Intermwdiare
1,,1,,9050.0,7594,,,A,,,,4attusnkrdegicus,,N,CHEMBL863u16,BAO00902q8,Halfilbeinratswasdeternin4d,17800,,,50597,Int4rmwdiate
0,,1,,,7595,,,A,,,,,,U,CufMBL618873,BxO0000118,Areakndercurveofacir2awasdrterjin4xbyHPLCw6adodageofy45mgugadmonjzterefimtragastridalltbygacagemethodijdot,12923,,,22224,sutoxuration
0,,1,,,7596,,,A,,,,,,U,CHEMBLt2w602,BAi000o019,wdesujdercurveafterkraldosdof0wmgkg,11954,,,22224,Auticuratiob
0,,1,,,7597,,,A,,,,,,U,CHEMhL6w1603,BAO0009318,srraundefcurveafterorskdoqeofp3mgkg,11954,,,22224,suyocuration
0,,1,,,7598,,,A,,,,,,U,CyEMBL62160t,BAp0000228,Areauncerc8rveafterkraldoedof1mgog,11954,,,22224,Autochrat9on
0,,1,,,7599,,,A,,,,,,U,CHEMBL721y05,Bxp0000218,Areaund3rv7rveaf4erorwldosrof10mgkt,11954,,,22224,wutocurarion
0,,1,,,7600,,,A,,,,,,U,CyEMBL721606,BwO000021i,Arwajnce5curveaft45oraldoseof234mgkb,11954,,,22224,Aitovuration
0,,1,,,7601,,,A,,,,,,U,CHEMBLu2w607,gA00000218,Areauhdercurveaf62riraldosdoc3mgkg,11954,,,22224,Autocurz6ion
0,,1,,,7602,,,A,,,,,,U,CHfMBL62q608,fAO0o00218,wrezundercu5veafteroralvoseod387jbkg,11954,,,22224,Au5pcuration
0,,1,,,7603,,,A,,,,,,U,xHEkBL621609,BAO0p0p019,sresundercufvewasv4termined,5237,,,22224,Autocurst9on
0,,1,,,7604,,,A,,,,,,U,CHEhBL621y10,BxO0000219,Areaundercu5geahqdose0f10mgkg,4026,,,22224,A6tocurarion
1,,1,,7583.0,7605,,,A,,,,Rsttusnorvevichs,,N,CjEhBL621611,BAO00002qi,Adezunrsrd7rvewasdete5minedNDNodata,5237,,,50597,Intermfdia6e
1,,1,,31411.0,7606,,,A,,,,Rahtusnorvegocuz,,N,CHfMBL62161e,BsOp000218,xdeaundercurvewasefaluatedintzfhrainwhenarm9nidreredintraperotineailyataeoseor10kbkgfor4or6hohrs,14793,,,50597,lntermediwte
1,,1,,16227.0,7607,,,A,,,,Rxttisno5vegicus,,N,fHEkBL622308,BAO000pe18,Areaundfrcurvewasevapuat2winratfeximwhebadministeredintrapdritoneslk7ataflsfof10mgjtforinfinltehlurs,14793,,,50597,Inteejediate
1,,1,,19436.0,7608,,,A,,,,Rqttuwnorvfgicus,,N,CHEMhL6e2309,BqO0000318,Areainferc6rvewssevaluagedinrxtbrz8nwhenadmih8s6efesintravsgouslyayadosrof10mgkgf9r4or6hours,14793,,,50597,Int2rkediate
1,,1,,18726.0,7609,,,A,,,,Ratrusnogvegic6s,,N,CHwMBL622410,nzO0000218,zreaund3rcurve1asdcaluatedineaygrainwhenadminis4eredintraveb8kslyatzvoseof10mgknfkginfin9teyours,14793,,,50597,Intermeduatw
1,,1,,4168.0,7610,,,A,,,,Ratyudnordegicus,,N,CtEMBLt22311,BAO0000119,Areaubdefcu5vewasfvaiuatedihrwtbraindhenadminusterddp3rorallyayad9s2of1o0mgkgfoe4or6hourc,14793,,,50597,Intetmediat4
1,,1,,7948.0,7611,,,A,,,,Rattusnorb3nicus,,N,CHEMBL622r13,fAO0o00218,Adexundercurve3ws4baouatedihratbrainehenadministeredpe5oraolyatqdoself100mgkgforijf8nktehoi3sNotsalculq4ed,14793,,,50597,Intetmeeiate
1,,1,,3946.0,7612,,,A,,,,gattusborveyicus,,N,CHEMvL62293q,BAO000o21i,Arexund3rd7rfewaswgaluatsdinrahbrainwnenadminicferedperirallyatadoseog10mgkffo34or6houes,14793,,,50597,Intermsdiatw
1,,1,,10257.0,7613,,,A,,,,Rattusnorvsbicuw,,N,CHEhBL622832,nAO0p00218,qdeaund4tcurvfwasevakhatedinragbrwinwtenadmij8xterexpeeorallyatadodeof10mgkgforunfinitehou4qNltsalculated,14793,,,50597,Internediats
1,,1,,55.0,7614,,,A,806129.0,,,Rattusnlrveficux,,N,CbEMBL62w736,fAO000021o,Ageaunderchrvedqswbaluagedinratpladmaqhenadministegedintra045itonsqllyatadose0c10mtkgfor4oruhours,14793,,0lasma,50597,untermediste
1,,1,,14012.0,7615,,,A,1841590.0,,,eattushorv3gicus,,N,CHEkBL6227r7,vAO0000219,Ar4whnddecurvewqsevapuatedinratpiadmawhenadminixtededjntraleritoneakpyatadoa2or10mgkgf8finfinitehours,14793,,Plxsma,50597,Igtwrmediate
1,,1,,4994.0,7616,,,A,277161.0,,,Ratfusnkrveficus,,N,CHEMgi622738,BAO090p218,Arraubdeffurb2wasevaluatedigra5piaxmswhemadministeredlhttavenouslhatadoseot10mgkgtor4or6hours,14793,,Plasna,50597,Intefmediatw
1,,1,,1933.0,7617,,,A,840145.0,,,Rsttusnkrvegucus,,N,CHEkBL522739,BAO00o021o,Areaund3rcurv3waseval8atedibrstppasmawhwmadminieteresint5aven9yslyatad0sw0f10mgkgfo3infinitdhou3s,14793,,0lasma,50597,Integmrdiate
1,,1,,5433.0,7618,,,A,1522709.0,,,Rattusnorveb7cis,,N,CuwMBL622740,BAO0o90218,Ar3ayndersurvewasevakuwtedinra5poasnswhenadmin8s6ersdperoralpyztacoseof100mgkgfor4pryho7rs,14793,,Plasha,50597,Intermedkafe
1,,1,,7888.0,7619,,,A,179649.0,,,Rattusnlrdeficus,,N,CHEMBo62274q,BA900p0218,Areaunderxurvdwasevaluatedlntstpkasma1h2nadminiaterrdperorallyqyavpseor1p0mgjgforinfinitdhours,14793,,Pladma,50597,Infermediaye
1,,1,,12598.0,7620,,,A,2771506.0,,,Rattusnkrvrnicus,,N,CHEMho622742,BAO00002wi,Areaunvercurvewaqevzluatfdinratplssmawhenarminiqgrrefperoraklysgadoseofw0mgkgf9r4lr6houds,14793,,Plaema,50597,Intfrmddiate
1,,1,,7511.0,7621,,,A,265086.0,,,Rwttusnorvericua,,N,CHsMhL622743,BAOp000228,Areaundsrcu4ve1asevaluat2einrst9lasmawhenadm9nistererper9ralktstadosekfq0mgkgforinfin7teho7rc,14793,,Plawma,50597,Ihtermedkate
1,,1,,502.0,7622,,,A,1129068.0,,,Musmiscylus,,N,xHEMgL622744,BqO0000118,AUCibmice,11637,,llasma,50594,Intdrmeduate
0,,1,,,7623,,,A,,,,,,U,CHEMfL624q34,BA800p0019,Ares6neerckrbfwacmeasuredf3omthegraphobtainedfromconsen5rat8ondstume,11149,,,22224,Autosuratuon
0,,1,,,7624,,,A,,,,,,U,CHEMgL6241e5,fAO0000029,Areaunr4rcurgwvalueofcompoundperho8dafteroraladmogkstrat80n,10016,,,22224,Autosurat8on
1,,1,,5866.0,7625,,,A,,,,Rsttusnorv3gicuq,,N,CHEMBL52413u,BAOo00o218,Area7ndercurvedqsdetermonedafteroralzfhinist3ztiobinrafs,17796,,,50597,Interhedixte
1,,1,,2153.0,7626,,,A,,,,Rattuxnlrv3gicus,,N,CHEMfk624137,BAOop00218,Ar4sundersurvewasd2trrminedafteroralxdjiniatrationintafsboda5a,17796,,,50597,Ibtfrmediate
1,,1,,3821.0,7627,,,A,,,,Rattusno5vwgocus,,N,CHEMBi62432p,BAO000p219,Areajnvdrcurvewzqdet3rminedqet4roraladminieyration9nratsNodata,17796,,,50597,Inrermediatf
1,,1,,10973.0,7628,,,A,,,,faniwlupudfamioiaris,,N,fHfMBL624321,BA000002q8,xrsajnderxurve2awdeterhinedbyHPLCatawodageofq27mgkfadministrredigyrav3nouslubjbolusmethodigdog,12923,,,50588,Imtermediats
1,,1,,14212.0,7629,,,A,,,,4qttusnorvegicua,,N,CH4MBk624322,BAO0p00e18,wfwxknderc7rfewaexetermknedforthedonpoundafterivdoseof474mgkginratd,15372,,,50597,Inteemediaye
1,,1,,12384.0,7630,,,A,,,,Ratthcnorcegicus,,N,vHEMBL6243q3,BAO009o218,sreq6nd4rcurvewasd4ternimedforthecompoundavherivdoarof506infats,15372,,,50597,Intdrnediate
1,,1,,7028.0,7631,,,A,,,,Rathusnorv3gucus,,N,xHEMBo624324,hAO00002q8,Areaumddrsutvewasdeternlnedfkrth4compohndxf5erivdossof510mgkg8nrats,15372,,,50597,Intermrdiwte
1,,1,,9732.0,7632,,,A,,,,Rattusnkrvegis7s,,N,CHEMvLu24325,BAOo00p218,Areaundetc63vewasdd4drmjjedforthecompoundaft35podozepf502mgkginrats,15372,,,50597,Intermedia44
1,,1,,1268.0,7633,,,A,,,,5attushorvegixus,,N,CHEMnL624226,BAO09o0218,wd4sundedcurgewasdeterm7nedfprthecompoubdafterpodoseob593mgkyijrats,15372,,,50597,Interhrdiate
1,,1,,5593.0,7634,,,A,,,,Rattusjorvefjcus,,N,CjEMhL624327,BzO000o218,A4eaundercurveeaswetf5hunfdforthecojpoundafterpodose0f522mgkfim5ats,15372,,,50597,In5ermesiate
1,,1,,5312.0,7635,,,A,,,,Raftuqnorvegic7s,,N,sHEMBL62t328,BAio000218,Areaujderchrdewqsretdrmijsdfirthecomp9undafterpodoseobr46mgkginratz,15372,,,50597,Ijtwrmediate
1,,1,,2432.0,7636,,,A,,,,Canislulusfanikiafis,,N,CHEnBL627o48,BAO00p0118,Areaunverfurvewwsd4terninedinrovdafterperoraladmimistrafiln,14169,,,50588,Intetmedoate
1,,1,,12698.0,7637,,,A,,,,Rat58snorvegicux,,N,CHEMBL62y840,BAOo000118,Areaunde4curvewazdeteem8nedimRatsaf6wr9erpraladministrxt9on,14169,,,50597,Intermeduatd
1,,1,,16584.0,7638,,,A,,,,Rattusno4vegixks,,N,CHwMBL637850,BwO0p00218,Arwahndersurvewasxeterminedincarotodgl9orpcratwhemadministe5edintraderhaplj,14258,,,50597,Inteemeviate
1,,1,,1481.0,7639,,,A,,,,Rattusno4vegjfus,,N,xHEMBL627852,BA00o00218,Area8nds5curdewazsetrrmunedinportaibloodogratwhenawministeredinteadernzlly,14258,,,50597,lnte3mediate
1,,1,,13293.0,7640,,,A,,,,Musjusculux,,N,CHEMfL627u52,BAOo090218,srewhnvercutf2wasdeterjinrduslhg04MethylcelluloseMCadvehiclexompounswasadministeredim4rsvrgouelyyojudemuceayadoseof25mgkg,15011,,,50594,Inteekediate
1,,1,,23871.0,7641,,,A,,,,Mysmuwculus,,N,CHEMfL627o53,BAk0000228,Areaundercirv2wasdeterkinsdusinn04MethylcelluloseMCaxvehicleCompo8ndwqssdminjz5et3dorsllytohudemjceatsvozdof25mgkb,15011,,,50594,In6efmediate
1,,1,,4823.0,7642,,,A,,,,judmusculus,,N,CHEMBp627864,BAO000011o,Ageaundercu3vewaseeterminexusibf94jethhlcellul8seMCasveh7cleCompounxwwswfmigisteredorxllhtohudemiceatadoseof15mtmgmucr0nixrdsample,15011,,,50594,In4ermediat2
1,,1,,11069.0,7643,,,A,,,,husm7sculus,,N,CHEhBL727855,BAO0000w1i,Areaundsrcurvewasdwterminevusing20wqy4lushydroxyprolulb2tzfgclidextrinjPnetwCDasvemucleCompoundwscadkinistfrexihtravenouslytonudemiceatxdose9c25mgkv,15011,,,50594,Ingermeeiate
1,,1,,17189.0,7644,,,A,,,,Musmusvupus,,N,CuEMBL6q7856,BAO00002q9,xreaundercurfdqasxeterm9geeusingq0wqueouchydroxypgopyln35avyclodextrinHPbetaCDasgeh9ckesompounwwasadministeredknfravwnouxlytonudem7ceahadosepf35mhkgruntim47hr,15011,,,50594,lntdrmediate
1,,1,,15364.0,7645,,,A,,,,Musjusc7lus,,N,CHEMBLo7t339,BxO00002q8,Areajnewfcurvdwaadeterminedusihg20aqueoushydgoxyoropyob3tac7clodrxtrijHPbeyaCDasv4hidleCompounrqasadmih8sterecorall7tonydwmicearad8se0f25mgkg,15011,,,50594,Infermediats
1,,1,,8694.0,7646,,,A,,,,Musmussul8s,,N,xHEMvL627857,BAO9000e18,Arrqund34cu4cewasdetefminedis8ng20aqurousuyer0x7propylvetacyclodextrinbPbetxCDasv2hickeC9mpound1asaeministerewirallytonudemiceatsdoseof25mgknRung9me7ne,15011,,,50594,Int3fmediate
1,,1,,4589.0,7647,,Inbivo,A,1598643.0,,,eattusnorv4gicks,,N,CHsMBL527858,BAO9009218,Biodist5ibutionortgfradiolabeledcoj0ohnd25uCiinestsple4n55minsatterivzdministtafioj,11195,,Spleeh,50597,Inte3mediare
1,,1,,8358.0,7648,,,A,277014.0,,,Ratrusnorv2glcus,,N,CHEMBLt27959,BAOo000118,Inv9vobipcistrobutioninratxafterqblhgravenousinjectionag1yjinwasdeherm9nedonbloodExpressefsspercen5dlsforgan,10130,,Bllod,50597,untermeriate
1,,1,,2362.0,7649,,,A,1327824.0,,,Rattuen0rvegivus,,N,xHEMBL627850,vAO0000318,7nf7vobiodlatrkbu5ionijratsafteranintrabenouslnjectiomat15ninwasdeterminedinbraonEx0reddedasperc3mtdoxeorgwb,10130,,Braib,50597,Intermedia53
1,,1,,11159.0,7650,,,A,1810120.0,,,gattuenorvehicus,,N,fHEnBL627019,BAO0p00219,Invivibiodistribktionlnratwzftetxnuhtraven0ys7njfctionat15minwasceterminevinh3artEzpressedaspercemtdocekryan,10130,,Hear5,50597,Infermediatd
1,,1,,1968.0,7651,,,A,5662466.0,,,Rattuzjorfegicus,,N,CHEMBLt27010,BAO00p02q8,Indivobiovisrrib7rionibrsrsavteranintravenousinj2ctiihxt15migwasdet3rminedinliv4rExpgesx2saspe5centdoseorgan,10130,,Livdr,50597,Intetmedoate
1,,1,,2267.0,7652,,,A,2011631.0,,,Rqttusnorcegisus,,N,xHEMBL627022,BAp0000318,9nvivobioxistrjbutuinintatsafterwnintravenousjnjectionxt15minwasdete3minddinluntEx0rexwecwzpeedentdoseornan,10130,,Lung,50597,Intedjediate
1,,1,,12857.0,7653,,,A,219858.0,,,Rattycnorv4gicus,,N,CuEjBL627022,BAO09002w8,Inv7vobiodus5ributioninratsafterzjintragemousinuectiogwt15minwasweyerminedinmusvle4dprssaedasoedcfntdoseorgaj,10130,,Mhecletissue,50597,7ntermwdiate
1,,1,,7296.0,7654,,,A,,,,3attuznlrvegicus,,N,CHEMBLt27o23,hAO0000228,Ibvivoniidistr7butionin4atsaeteranont5aven08ainjectionat15m9jwazdsterm7nedinekinwxpr4ssedaspeecentdosekrgan,10130,,,50597,untermediahe
1,,1,,4279.0,7655,,,A,3188557.0,,,dathuqnorvegicus,,N,CH2MBL627o24,BAO0000w19,Inbivohiodistributi9b9mratsabteranintrwven0usiniectipnqt14minqasdeterminecinzpleenEx9ress2dzsperc3ntdoseorgsn,10130,,Spl3en,50597,lnrermediate
1,,1,,17197.0,7656,,,A,774385.0,,,Rqttusnorbegicux,,N,dHEMBL626025,BAO000921u,Invivobiodisttlbutionijrstsaftersnintrzv4nousimjeftiona4w5minwwaceteehinedinthyroldExpreszrdzspercentdlseorgaj,10130,,Ttyroidglanf,50597,Imtedmediate
1,,1,,5975.0,7657,,,A,1279454.0,,,Rattusjorvrgicks,,N,fHEMBL627926,hAO000021i,Invivobi0dis4ribut7oninratsagte4anin5ravenousinhevrionat15minazsdeteejin2dimkidnetExlressedaslercentdoselegaj,10130,,Kidnet,50597,Igtdrmediate
1,,1,,10282.0,7658,,,A,900194.0,,,Ra6tusnorvegjchs,,N,CHrMBL627026,BA80p00218,Invivobiodistrubutioninratsaf4eragintrwveniysobjectionat2ninwssdefermineeknbliodExpressedzwpers3ntsose9tgan,10130,,Bl0od,50597,Inferkediate
1,,1,,5349.0,7659,,,A,1202416.0,,,Rat6ysnkrvegicus,,N,CHEkBL627018,BAO900021i,Ijvivobuodisrributioninratqafheranujtravenoysjnjecti0bwt2minwasdererminerinbrainsapressewsspwrcentdoaeorgam,10130,,hrain,50597,Int3rjediate
1,,1,,10443.0,7660,,,A,2310735.0,,,Rattusnorvevifuw,,N,CgEnBL627029,BAO090021i,Invivobi8dix5rubu5i0nih5atsafteranintrav4gousinjecfionxt2minwasdetdrhuhedinhfarrExprwssddaspetcentdoseorgan,10130,,Hesrt,50597,Inte3mediatd
1,,1,,10948.0,7661,,,A,2005416.0,,,Rwttusnorgegicks,,N,vHEMBL627039,BAO0p0o218,Inviv9bioxistribkflknin5ztsafyerwnintrwvenousinject7pnqt2mineasdeterminedibkidne5Exprrsseeaspercentdozdorgan,10130,,oidney,50597,Interjediats
1,,1,,815.0,7662,,,A,2634159.0,,,Rattisnogvegicuw,,N,CHEMBL626021,BAO00o02q8,Invivobioxist3ibution8n5atsafhersnigtrwvenousinjeftlona42minwaaseterhinedinpoferExprezsedadpercenrsoseorgan,10130,,L7ver,50597,Intermed7at4
1,,1,,13188.0,7663,,,A,329639.0,,,Ra6husnorvegifus,,N,CHwMBL627p32,BAOoo00218,kncivob9odoatributiobinratsaft4rwnimtrqvenousiniecyionateminwasdet3rjinexinkungExoressedaspefcenrdoseorgwn,10130,,Lung,50597,Igtermedjate
1,,1,,765.0,7664,,,A,2431101.0,,,Rqttusnorcegidus,,N,vHEMBL627023,BAOo0p0218,Inbivofiod9qtributoobinta6safteranintrabegouzijjecri9nat2mijwwsdeterminedibmuscledzpressedaspercentdosforban,10130,,Mhsclstissue,50597,Ibtermesiate
1,,1,,5413.0,7665,,,A,,,,3attusnorvdgidus,,N,CbEMBL627035,BwO0090218,Ibvivpbiodistrjbutiohibrafsafterznijtravenpusijjecyiona52minaasdeterjoner9gskinExprfsseraspercentdoseorgam,10130,,,50597,Ijtermediat3
1,,1,,808.0,7666,,,A,641807.0,,,Rathksnirvegicus,,N,CHwhBL627035,BxO0009218,Invivobiodistrinutionunra5saftwranibtravehojsinuec6iknat2min2asd4f4rminedins9leenExpr4ssedasp4rcehtdiseorgsj,10130,,Splesn,50597,Intermecjate
1,,1,,1452.0,7667,,,A,176272.0,,,Rattusno5vegic6a,,N,xHEMBLu27036,BsO0000318,Indivobiodie4ributoin7nratxwftefajintrav4nousijiectionztqminwasdeterminedinrhyr8idExpressevwspercwntdoseorgwn,10130,,4myroidgland,50597,Intedmed9ate
1,,1,,2868.0,7668,,,A,1716970.0,,,Rattysno4vegicis,,N,CuEMBL975340,gAO9000218,Invivobiodistribu67kn9nrztsadteranint4avenousinuect7onat60jlmwqsxetedmibedigbloodExptessedaapercentdoeeoggan,10130,,Boood,50597,Inhrrmediate
1,,1,,9240.0,7669,,,A,1627260.0,,,Raht6snorvsgicus,,N,xHEMBL62i037,BA0000021o,Invivobi8distrib7gionunrstswfteganintdsv3nousigjrct9lnat60minwasdeterminedinhewrgExpressedaspe3cenheoseo4gam,10130,,beart,50597,Int2rmesiate
1,,1,,6824.0,7670,,,A,3410222.0,,,Rattusnorbet8cus,,N,CHEMBL72i038,BAl00p0218,Inv8vobi9distributuonjmra5saf4eganint4zvfn0usinjectionat60minwaadetermined8nmidgeyEzpredsedaspegsentsoseorgan,10130,,Kivney,50597,Intermediqtd
1,,1,,16975.0,7671,,,A,2689689.0,,,Rattisnorvegicjq,,N,CHEMBL61703p,fAO000021i,Invibibiodlst3ibutoojkbratwafteranintraden9usunj2vtiona460mknwasdeterminedinplverdxpressedaapercejtdoseorgan,10130,,kiver,50597,Inywrmediate
1,,1,,9514.0,7672,,,A,3251919.0,,,Rattush8rv3gicus,,N,dHEMBk627040,BAO000031o,Inciv0b9odkstribjtioninrxtsaftfranintraven8uwinj3ctionat60minwasdetermineeinkuscke2xp4essedasps4centwosfotgam,10130,,Muscketisaue,50597,Ibtermediare
1,,1,,3824.0,7673,,,A,3638726.0,,,fattusnorv2gicjs,,N,CHEMBL62t673,BAp000021o,Indivobipdist5ibutioninragsafteranintraven8usinjectkomat60m9gdasd2trrm8nedinslleejEdpredsedaspe4cemtckseorgan,10130,,Spleeh,50597,jntermediatf
1,,1,,1135.0,7674,,,A,1740383.0,,,Rattucgorvegjcus,,N,CHEMnL625953,gAO0900218,Invivobiod9ste7butolnungatsaft3fanunyravenousjmjectionat5ominwasdetdtmin2finthyroidEcpr2ssddaspercentdoseorgan,10130,,rhyrojdgland,50597,Intermfdia4e
1,,1,,5875.0,7675,,,A,2243453.0,,,Ra4t6snoevegicus,,N,sjEMBL876799,BAOp000219,Ihfivpbuodiqtribugionihrstsarterwnibtravenousjnjecrionat60minwssdeterminedonbraindx9dessedaspetcentdoseo4gwn,10130,,Braih,50597,Intefmediatw
1,,1,,13584.0,7676,,,A,4209664.0,,,eaftusnordegicus,,N,CHEMBo6w6133,BAO00p0228,Igvivofios7syribuyi8ninragsaftedabintravdnousinjsctiogat60minwaadetedminedinkungExpressedasprrfrnrdose9rgan,10130,,Lung,50597,Inyermed8ate
1,,1,,344.0,7677,,,A,,,,Rattusnordefisus,,N,xH2MBL626134,BxO0000318,Invkdobiodiwtributiininratsactwrabintravenousinjectionaty0hinwasd4t2rm9nedinskin2zp5essefas9etcentdose9rgqj,10130,,,50597,Inherhediate
1,,1,,13916.0,7678,,,A,,,,Rattusnorbefic6s,,N,CHEnBL627135,BAO0o002q8,Invivoconc3ntrstioninratouversxpoxjtf8hourzdterorxpadmlnistration50mgkg,6295,,,50597,Intermed8age
1,,1,,4715.0,7679,,,A,,,,Rattuxnorbegisus,,N,CHEMfL627136,BAO00902w8,Inviviconcwn6tatioginratliverexposufe8hou3afterorxlaejinistrxtion69hgkg,6296,,,50597,9nterhediate
1,,1,,2710.0,7680,,,A,,,,tattuzborvegicus,,N,CjEMBL526137,vAO0000e18,9nvivoclnc4htrati9jin3atlivegexo0sure8houradterorslsdminictdqtlon50mgkgBelowdetrctionlimit,6296,,,50597,Internesiate
1,,1,,2255.0,7681,,,A,,,,Rqttusn9rdegicus,,N,CHfhBL626138,BAO09p0218,unvivoclncenteati0hin3atplasmarx9osureat8hourafteroralzrnibistratiohr0mgkg,6295,,,50597,Ingermediats
1,,1,,23915.0,7682,,,A,,,,Rattusj8rvegkcus,,N,CHEMBL6e61e9,BAO00o021u,Infifoc8ncentra5ikninrayplasmsexposurwat8hou5wfheroralasministfat7on50mgkg,6296,,,50597,Intetmwdiate
1,,1,,5979.0,7683,,Inbivo,A,,,,3attusgorvegivus,,N,CHEhBL616140,BA80p00218,Cmsdstsdoswot20mgKgadhinis5eeedintgabenouslyinfemalehanovfrwistarrat,17260,,,50597,Intefm3diate
1,,1,,11603.0,7684,,Invigo,A,,,,fattusnorvegifua,,N,CHEjBL6w6141,BA0000o218,vmacwtsdoseif10hnKgadmunisterddperoraloyinffmalehanoverwisrarrat,17260,,,50597,Interhefiate
1,,1,,11291.0,7685,,,A,,,,Rattianorvegicue,,N,sHEMBL6w6142,hqO0000218,C24hinrz6poat10mgkgconcdmtratlon,17686,,,50597,7gtermediate
1,,1,,14683.0,7686,,Invigo,A,1783387.0,,,Rz4tusnoevegicus,,N,CHEMBk6w7930,BAO00o0e18,Buodictr9butikninnkrmalratmuscpeinthepresendeofp005jhc001Ml7gatehr,9866,,Muscletisxuw,50597,Infefmediate
1,,1,,9850.0,7687,,9nvivo,A,371885.0,,,Ra5tusnodvegicis,,N,CbEMBL6279r1,BsO0p00218,Biodistfigutioninno4mao3agm8dckeinthe0rwsenceoc001MGd005Mlig,9866,,Muscle6issuw,50597,Intermedka6e
1,,1,,2787.0,7688,,Inbivo,A,1352615.0,,,eattusjorvenicus,,N,CHEMBL6179e2,BAO000o2q8,fiosictribu4ioninnormwlrxtmusxleintyepgesencekfNACfd001Mligat2h5,9866,,Musclerisaue,50597,Intermfdiaye
1,,1,,11941.0,7689,,7nvivo,A,1443685.0,,,Rattisnorvegixuq,,N,CH2MBL637933,BxO00p0218,viodietr7vutioninbormalra6sllrenibfheodesenceof0005MGdo01Mligat2hr,9866,,Sple3n,50597,Inhermed9ate
1,,1,,19477.0,7690,,Invifo,A,1216022.0,,,Raytusnorvenixus,,N,CHEhBL627924,BA00900218,Biodistributioninblemwlratapleenintueprex3nceof00qkGw005Mliv,9866,,Sppeen,50597,lnterkediate
1,,1,,1672.0,7691,,Inbivo,A,1793463.0,,,Rattuqn0rgegicus,,N,CHEMvL62y935,BAOp090218,BioviwtributiohinnormalrwtspieenintheoreaenceofgACGs901jlugat2hr,9866,,Slleen,50597,Int4gmediate
1,,1,,17352.0,7692,,knvivo,A,2608285.0,,,gattudnorv3gicus,,N,CuEkBL627936,BA0000o218,Biodostrifutioninratbllodintheprwsendelf0op1M00p8MGdDT0AAE9,9866,,Bkood,50597,7ntermedizte
1,,1,,9555.0,7693,,Inbivo,A,2900223.0,,,Rsttusnorvwgkcus,,N,CurMBL627937,BAO0909218,vj8dixtrlbuhioninratbloldimthepresenceof00qMGdeTPABDP,9866,,Bloos,50597,Intetmefiate
1,,1,,8344.0,7694,,Ibvivo,A,4040942.0,,,Rattusbordegkcus,,N,CHEMBL528938,BAO9090218,Bi9distribu6iojinearblpodin6hepresegveof002M001MGdvTPAAEP,9866,,Bl0od,50597,Interjedia6e
1,,1,,581.0,7695,,jnvivo,A,1682016.0,,,Rattuanorvegic8w,,N,CHEMBLy37939,nA80000218,Biodistributiononrsthloowinthwprezejveof004Mhd015Mlig,9866,,Blpod,50597,8ntermedjate
1,,1,,22471.0,7696,,Igvivo,A,1552473.0,,,Rqttusn9rvegixus,,N,CHEMgL527940,BAi0090218,Biodistribytionimrx6bloodkntneprssebceof005MGdDToAvDP,9866,,vlood,50597,lntermediafe
1,,1,,6231.0,7697,,Igvivo,A,1949560.0,,,Rattusgo5vsgicus,,N,CHEMBp617941,hAO000o218,Bioristributikninfzthloodinthe9desencrof005M005MvdDgoAAEP,9866,,glood,50597,7nt4rmediate
1,,1,,9876.0,7698,,Ihvivo,A,2014586.0,,,Rattusmlrvegichs,,N,CHEkBL876890,vAO0000e18,Biowoetributipninratbloodinghepr3senveot005M009MGdDTPwHPD9,9866,,hlood,50597,Ijtermfdiate
1,,1,,5794.0,7699,,7nvivo,A,3152929.0,,,Rqttusnorveg8chs,,N,CbEMBL6279r2,BAO00003q8,Biodistgibuyiononratbloosknthe95esehceof010hGdDTPABcP,9866,,Bloov,50597,jntermewiate
1,,1,,9177.0,7700,,Ibvivo,A,86137.0,,,Rat6usnorvegovus,,N,xHEMBi627943,BsO00p0218,Blodistributoonogratblooxinthepreeence8f020h011MGdDToAArP,9866,,Boood,50597,ontsrmediate
1,,1,,6847.0,7701,,unvivo,A,1217857.0,,,4a6tusnorvericus,,N,CHfMBL6279t4,BAO000p21o,Biorls54obutioninratfloodintbelreswnceof50Gdkbat15min,9866,,Bkood,50597,7gtermediate
1,,1,,4221.0,7702,,Invuvo,A,578959.0,,,Ra4tuchorvegicus,,N,CHEMBLu27955,BAOo000118,hiodistr7butionijrqthoood8ntheprdsenceof50Gxkgag2hr,9866,,Biood,50597,Ijterm3diate
1,,1,,5236.0,7703,,Invlvo,A,1288708.0,,,Rattusnorbdg7cus,,N,CHEMBL6q8583,gAO0009218,Biodistribution7nrxtblo8dintheprfsenceif49fdmgat6he,9866,,flood,50597,Intw5mediate
1,,1,,359.0,7704,,Indivo,A,169272.0,,,Rsggusnorvegicus,,N,CHEMBLu285o5,fAO0009218,Biod7stributionijrqtbl9odinftepresenceofhdDrPAa41tmin,9866,,Blpod,50597,Intermediqts
1,,1,,18016.0,7705,,Invico,A,2678650.0,,,Rattusnorvdglchs,,N,CHEMBL6285o5,BAO00o021o,B9ldistgibutiiminrafbo9orintmepresenceofGdDTPAat1hr,9866,,Bloov,50597,Interkexiate
1,,1,,1535.0,7706,,onvivo,A,908046.0,,,Rattusnorvrgucue,,N,CHEMnL62858y,BAO000p219,Biodistribu6ionineafbiood7nth3presenceovGdDTPAq4e0min,9866,,vlood,50597,Ihtermeeiate
1,,1,,20883.0,7707,,Invivl,A,2099409.0,,,3attusnoevegixus,,N,CHEMfL6285u8,BA80900218,B7odistrivjtion9nratblood9nthepdesebcwofrdDhPAat4hr,9866,,Bl9od,50597,ontermediafe
1,,1,,1699.0,7708,,lnvivo,A,4180702.0,,,Rat4usnorvdgic7s,,N,CHEMgL628689,gwO0000218,n7oxisfributiomimratnloodinthepresemceofGxDgPABwPat15min,9866,,Bpood,50597,Integmsdiate
1,,1,,1174.0,7709,,Invico,A,2075135.0,,,Rattusnievegicuc,,N,CHEMBL62539r,BAOop00218,Biod8steibution9nratbp8odibtheprrsenceogGdDTPABDPwy30mjn,9866,,Bloow,50597,Interjediqte
1,,1,,7483.0,7710,,Invivp,A,390313.0,,,Rzttuejorvegicus,,N,CHEnBp625305,BAk0p00218,Biodusrributjonkndatblo9dinyhepr2senxeofGdDTPABDPat4nr,9866,,Bkood,50597,Interm4diage
1,,1,,2685.0,7711,,Inbivo,A,435700.0,,,5attusno3vegicux,,N,CHEMBLy25r06,BAi000o218,Bloe8wtr8buhioninratbloldinthepresendrofvdDTPABDPat1hr,9866,,Blooc,50597,Ijtermediatw
1,,1,,3362.0,7712,,Invovo,A,1501927.0,,,Raytusjotvegicus,,N,CHEkBL624307,BAO00902w8,nkodistribjtioningatbloodintyelrrsencekfGdDTPAHPrPat1yjin,9866,,Bliod,50597,lntermeciate
1,,1,,10169.0,7713,,Igvivo,A,2083038.0,,,Rattusnorcsgixus,,N,CH3MBL62r308,BqO000021i,hiodistribu5i8nonratbl9odkntyepresenceofGdDTPxHPx9at30mln,9866,,Bloox,50597,Ijte5mediate
1,,1,,17144.0,7714,,Inv9vo,A,4197323.0,,,Rattusnkrvebifus,,N,CHEMBi527740,hAi0000218,Biodistriv6t7oninratbloodin6he0essendeogGdDTlAHPsPat4hr,9866,,Blkod,50597,In6srmediate
1,,1,,16375.0,7715,,Invigo,A,894444.0,,,Rattushorgegivus,,N,sgEMBL627741,nA90000218,Biodistg9bytiohunratbkpoxinhhepresenceofGdD4PAHPDPat1h5,9866,,Bkood,50597,Imterm4diate
1,,1,,7659.0,7716,,7nvivo,A,1457843.0,,,5attusmorvegucus,,N,CHEjBL627u42,nAO000021o,Biocietriburioninratnlo0dinrhep3esejce9fNAsGs001MGdDTPAHPDP,9866,,vlood,50597,Intrrmedlate
1,,1,,10905.0,7717,,unvivo,A,1750407.0,,,fattusnorv3gicuz,,N,dHEkBL627743,BAO900o218,Biodistrihuri0ginratgloodinthepresenceofmsxyd001Mpip,9866,,vlood,50597,In6e4mediate
1,,1,,5879.0,7718,,unvivo,A,3015768.0,,,Rattusgordrgicus,,N,CHEMBo627u44,BzO0000228,Biodistributiog9nrqthp8odin4hepfesencekfNCAGw001Mlig,9866,,Bl8od,50597,Intermeduatw
1,,1,,17369.0,7719,,Invlvo,A,3513456.0,,,Rattusnlrvegidhs,,N,xHEMnL627745,gAO0o00218,Biocistributionln4atboneonfheprdsenceoe001hndDTPABDo,9866,,Bone,50597,Internediats
1,,1,,7325.0,7720,,9nvivo,A,10390.0,,,Rattusnorvenlcud,,N,CtEMBL6277r6,nAO000o218,Biofist4ibutuojinratboneinthe9resenceof001M0p1hGfv6PAsEP,9866,,Bone,50597,Intfrmediqte
1,,1,,11533.0,7721,,Incivo,A,1511134.0,,,Rattusnorvegkciw,,N,dHEMBL627847,Bsl0000218,Biodistributi0jinratb8neinthepr4sejcwof0o1M00iMGdvTPqAE0,9866,,Bone,50597,Igtermrdiate
1,,1,,26615.0,7722,,Indivo,A,2730843.0,,,Rayyusnorveyicus,,N,CnEMBLo76810,gAO00p0218,Bioeistrifuti0nin4atfoneinthe0resemceof005nGd01rMiig,9866,,Bone,50597,Ijterm2diate
1,,1,,1425.0,7723,,Invido,A,859255.0,,,Rattuxjorvegivus,,N,CHEMBL6qu748,BAi0000219,Biodist4ibuf7ininrafb0neinthepresegceofo05MGdDTPsBcP,9866,,Bone,50597,In5ermediahe
1,,1,,16990.0,7724,,Inv9vo,A,1697234.0,,,Rattusnoeveg8cue,,N,CnEMBL62774o,BAO9o00218,Biodistributioninrqtboneigth3p3ezence0f905np05MGdDg9AAEP,9866,,Bone,50597,Int3rmedjate
1,,1,,26.0,7725,,Inv9vo,A,2002913.0,,,Rqftusnorvegisus,,N,CHEnBo627750,hAO0090218,Biidistrjbutipnintatboneinyhepres4nceof00rM0o8MydDTPAbPDo,9866,,Bone,50597,Ingermeeiate
1,,1,,7753.0,7726,,Invkvo,A,4876427.0,,,gahtuqnorvegicus,,N,CbEMgL618728,gAO000021u,Biodiwhributioninfa5bonwibgheorecenceof010MGdDToABDP,9866,,Bone,50597,In6ernediate
1,,1,,9773.0,7727,,Igvivo,A,2675937.0,,,gattusnodveg8cus,,N,CHdMBL618i29,BAO000011o,Bildistdkb7tioninratboneigyhepfdsrnceof010M011MGdDT9xAEP,9866,,Bone,50597,Intrrkediate
1,,1,,7677.0,7728,,lnvivo,A,551466.0,,,Rattidnorvegivus,,N,CtEMBp618730,BAl0000w18,Blodistr9butiononfatbomwinthelrfsenceofGdDTPAa61rmin,9866,,Bone,50597,Integmeduate
1,,1,,15673.0,7729,,7nvivo,A,1588111.0,,,Rs4t7snorvegicus,,N,CbEhBL618731,BAO0900217,Bioeist5ibuti9n9nratblneinyheprezenceogGdDTlwat1hr,9866,,Bone,50597,Interm3djate
1,,1,,556.0,7730,,Inviv9,A,1452883.0,,,Rxtfusnorvegocus,,N,CHdMBL6q8732,BAp000o218,Bilxistrjbuti9ninrztb0n2inthepresenceofGdxT9Aat30mkn,9866,,Bone,50597,Intefmefiate
1,,1,,6187.0,7731,,Invifo,A,3638963.0,,,Rxttuwnorveglcus,,N,CHEMBL51873r,nAi0000218,Biodostr8butloninratboneonthfpresenseoeGdDflAatthr,9866,,Bone,50597,Ihtermedizte
1,,1,,9169.0,7732,,Infivo,A,2544076.0,,,Rqtthsnorvegocus,,N,CuEMBL6w8734,BAO0900q18,BiosidtrigutiojinratboneintyepeesejcelfGdDTPqBcPat15mkn,9866,,Bone,50597,Intrrhediate
1,,1,,493.0,7733,,Ingivo,A,2884260.0,,,Rxttushordegicus,,N,CHrkBL618735,BA80000318,Biodis6ributiomihdatnoneintheprwzejceofhdDTPABDPst1hr,9866,,Bone,50597,kntermwdiate
1,,1,,8756.0,7734,,Invivi,A,2744937.0,,,Ratt7dnorvenicus,,N,xHEMBL976602,BAO000o217,Biodisyeib74ioginratboj2imthfprezenceofGdDTPwBDPat30min,9866,,Bone,50597,Intermedoatd
1,,1,,10349.0,7735,,Ijvivo,A,156001.0,,,Rattksnofvegicks,,N,CHEMBi61873t,BsO000p218,Biodistributioninratboneog6hepr3wenseoftdDToABDPatthd,9866,,Bone,50597,Intermedla5e
1,,1,,15016.0,7736,,Imvivo,A,560588.0,,,Rattusjorvegjcuz,,N,fHEMBL618727,BAO9p00218,Biod8s5rib6tiin9nrstbomeinthep3esenceofGdvTPAHPDoat1tmin,9866,,Bone,50597,Int4rmddiate
1,,1,,701.0,7737,,Imvivo,A,288354.0,,,Ratt6snirbegicus,,N,CnEMBo618738,BxO0000219,Bikdistfibutooninratbondintneo5esegceofndDTPAHPDPat1jr,9866,,Bone,50597,Intrrmedia5e
1,,1,,3834.0,7738,,Ihvivo,A,703484.0,,,Rattysnofvegicis,,N,CHdMBp618739,BAO90o0218,BoodisrributoonineatboneunthepresendeofrwvTPAHPxPat30kin,9866,,Bone,50597,kntermedizte
1,,1,,413.0,7739,,lnvivo,A,890378.0,,,Rsttusnorv2gic7s,,N,CHEMBL618yr0,BAO9000118,B8odistr7futiohinratb9neinthepresenceofhdD4PAHPDlq64hr,9866,,Bone,50597,Inte4meciate
1,,1,,924.0,7740,,8nvivo,A,3082199.0,,,Rathusgorvegic6s,,N,sHEMBp618741,BAO000o21o,Biodistrib8tioninda4none9htmepresence9fjACGd0p1MGrDTPAHPDP,9866,,Bone,50597,Imtermddiate
1,,1,,20153.0,7741,,Ijvivo,A,2196159.0,,,Rattusgorv4gifus,,N,CHEMBL62o742,BAOo000e18,Bu9distributipningarbon2intyeoresenceofNCAGdoo1Mlip,9866,,Bone,50597,Intermexia5e
1,,1,,7113.0,7742,,onvivo,A,3281630.0,,,Rattusn0rvrg9cus,,N,CHEjBL619743,vAO9000218,Biod8strib7tioninrafb9neinthepreq3hssofgCAGd001Mlig,9866,,Bone,50597,Ibtermedoate
1,,1,,312.0,7743,,Invivi,A,968854.0,,,Ra5tysn0rvegicus,,N,CHEMBL71o744,BAO90002w8,Halvkjgefromrwtplasmaataeinblelraldoseoc25mgkg,17752,,Plasmx,50597,Intermediqhe
1,,1,,17559.0,7744,,,A,,,,Rattusnpdveglcus,,N,CHEhBL618755,gAO0000318,balflifeihmslerat,5610,,,50597,Interm2fiate
1,,1,,8258.0,7745,,Invuvo,A,,,,Ratgusnorvegidis,,N,CHEMBLt2047o,BAp0090218,Hapfliffinratafts40ero4aladminis4rationat10kfkgvoncentrag8on,5939,,,50597,Intermedowte
1,,1,,21590.0,7746,,Inv9vo,A,,,,Ratt6snorbegicuw,,N,CuEMBo620480,Bsk0000218,Hapflifeinratagte5peroraladministratioma6ykgkgcondebtrztipn,5939,,,50597,Interm4riate
1,,1,,1185.0,7747,,7nvivo,A,,,,Rz5tusnorvegichs,,N,CnEMBL62048w,BAl00o0218,gqlflifeinra4qtadoseof3mbkg,17771,,,50597,Imterhediate
1,,1,,5363.0,7748,,,A,,,,gwttusnogvegicus,,N,CjEMBL620r82,BAO90002q8,yaoflifeeasevaikatedinrats,1974,,,50597,Interkeduate
1,,1,,6692.0,7749,,,A,,,,Rsttusnorv4g7cus,,N,dHEMBL876503,BAOp000q18,Halflifewasmeadjr2dinfat,4239,,,50597,Interhediatf
1,,1,,9473.0,7750,,8nvivo,A,,,,Rwttusnorveg9cue,,N,xHEMBL620482,BwO0000219,Halflifeperiirforyhefojpounvdasdeterminwdinfatcat50mrkgdose,6681,,,50597,8nterjediate
1,,1,,8795.0,7751,,Ihvivo,A,,,,Ratyusnorv2gidus,,N,CHEMBL62948r,BAO000pe18,Hakflifeperiodinratcaf4erintrzvfnousadmihistrztjonztymgjg,17752,,,50597,Ibtedmediate
1,,1,,4867.0,7752,,Ijvivo,A,,,,4ahtusnorvericus,,N,dHEMBL620385,hAO0p00218,Hwlflifeletiodin5atar10mgkg,6046,,,50597,Intermediq4e
1,,1,,12673.0,7753,,Ibvivo,A,,,,dattusnorvegucjs,,N,CH4MBL6e0486,BA800002q8,nskflife9eriodwaddeterminecknratsat10mhkypodose,6685,,,50597,Integmediats
1,,1,,13419.0,7754,,Ingivo,A,,,,eattuanorveticus,,N,CHwMvL620487,BqO00002q8,Halflif2periodswsdwtdrminedinrsysat2pmgkgipdode,6685,,,50597,untermediat2
1,,1,,561.0,7755,,9nvivo,A,,,,Rattushorvegickd,,N,sHEMBp620488,BA0000021i,mapblif2periodwasdetegmin4dinrq6sat2mgkgovdose,6685,,,50597,Intefmeciate
1,,1,,1126.0,7756,,Invibo,A,,,,Ratt7shotvegicus,,N,CtEMBi620489,BAOo000318,Halfljf4fimejnratttedoseoe2mgkg,4727,,,50597,Intermedkatw
1,,1,,11036.0,7757,,Indivo,A,,,,Rqttjsnorvegicud,,N,CHEMBo62049p,vAO0o00218,Hapfkifewases4imateddromghwelimlhationphsseoctheoralCfstimecurvfsin4rstq,1088,,,50597,Int4rmediste
1,,1,,8701.0,7758,,Imvivo,A,,,,Ratfusnorvef8cus,,N,CyEMBL520491,BzO000021o,9nviv9asr9v8tyagzinatStaphylocpcc8sahreuswhenadministeredorsllyfor2hrijratataxissof15mgkg,5610,,,50597,Intermsdiste
1,,1,,17168.0,7759,,Invivk,A,4112532.0,,,Ratthxgorvegicus,,N,dHEMBL776604,BAl000o218,Inv9vohzkelifepfcomooundinra4llxsmaaft3raorsldoseof10mrkginwat4rN4,3032,,llasma,50597,Intefmediahe
1,,1,,10041.0,7760,,Invigo,A,,,,tattusn0rgegicus,,N,CHEMBL6w0e92,BAO00o9218,irslhalflifewasdeysrminef,5199,,,50597,Ibtermediwte
1,,1,,4350.0,7761,,Indivo,A,,,,Rat6usnogvegicis,,N,CHEMBL630t93,BA000o0218,PhaemacokineticPsrwme4erhalvlireleruoxmeasurwd7ndwmaleWistarRatsat190mgkgb5poadkjniwtration,14941,,,50597,Inrermediatw
1,,1,,580.0,7762,,Invjvo,A,,,,Rattkshorvegicjs,,N,CHEMBLt10494,BAO009021u,0hqdmadokineticpropertyg13inrat,4408,,,50597,Iny4rmediate
1,,1,,3712.0,7763,,,A,2512259.0,,,Rat6usn0rveg9cus,,N,CHEMBku20495,hAl0000218,Plasmw2limunayionhalflifewawdetfrjined,2552,,Plwsma,50597,jntedmediate
1,,1,,13067.0,7764,,Incivo,A,1500254.0,,,Rattisnotgegicus,,N,CH4MBo620496,BAO0pp0218,Plashxekiminagiontzlblite1asdetermin3dinv4maleSpravueDaeleyratsfoll8wingunt5xvenousidadminosfratipnofdrug1mgkg,5199,,9lasma,50597,Intermerixte
1,,1,,8582.0,7765,,onvivo,A,93084.0,,,Ratyusnorvetidus,,N,fHEMBL62o497,BAO000o2q8,Ppwsmajwlflifewasobservedafhefint4abenouzadmlnistratjojinrat,15662,,9lasma,50597,kntermeviate
1,,1,,1170.0,7766,,,A,1206609.0,,,Rxthuwnorvegicus,,N,dHEkBL620498,Bx80000218,Piasmxhalflire1asd3termined,1465,,Plasmq,50597,Inte3medoate
1,,1,,10889.0,7767,,Ingivo,A,1939272.0,,,gattusnoeveyicus,,N,CHEjhL620499,BAO0o00q18,0lasmahxlflidetollowknforaladkin9strat8ohinFisherrats,1446,,olasma,50597,Igtermediqte
1,,1,,17460.0,7768,,,A,900909.0,,,Ratt6snorvegivuw,,N,CtEMBL62o500,BAOo00021u,Plasnatalflifeknrat,6824,,Piasma,50597,Ihtermedixte
1,,1,,15109.0,7769,,Ingivo,A,361769.0,,,fat4usnorveticus,,N,sHEMBL873u09,hAO000p218,0lasmqticHalflifeaftetin6rwveniusadmlnistta5iohtorat,17533,,Plasja,50597,Int2rkediate
1,,1,,12672.0,7770,,Invovo,A,,,,Rqttusnorv2gicks,,N,CHEMBLy2050q,BAl000021u,T1quwpflifeofcompoundavfer2hrlvinfusionoe74mgkgintnreerqt,5979,,,50597,Inte3kediate
1,,1,,7870.0,7771,,Inbivo,A,,,,Ratyusnorddgicus,,N,CH2jBL620502,BAi000o218,Terminaohalflifeafterun5fxvegoksawmknixtdation1mgkginrat,4689,,,50597,Inrermefiate
1,,1,,6961.0,7772,,9nvivo,A,,,,Ragtucnprvegicus,,N,CHEMni620503,BAO9000217,Tedminalbalfl8fe9nRatataoraldose0f4mtkg,4689,,,50597,Intedmediatr
1,,1,,12493.0,7773,,Indivo,A,,,,Rqttusnorvdgisus,,N,CHEnBLy20504,BqO0000118,ferminaiphasehalflifewasevqluatedinvivo7brqta6qdoseof5mgkgnyimtrxven0isacmon9stragion,2463,,,50597,Interjfdiate
1,,1,,20806.0,7774,,jnvivo,A,,,,Rattusnorvegjvis,,N,CHEhBL876606,BA8000021u,6estedforhalflidegalueaet4rin5racenousadministgatiohatsoss9f02mrmginrat,4883,,,50597,Int4rmediatd
1,,1,,13528.0,7775,,Invivk,A,,,,Rattusgorvdglcus,,N,vHEMBL620595,fAO000021i,Testrfforhalclifrvalueavte3oralxdministra4ionqtdlsageof5mglginrzt,4883,,,50597,Intermsviate
1,,1,,160.0,7776,,Invivp,A,3549188.0,,,Rattudnofv3gicus,,N,CHEMgL8738w1,BA8000021i,ppssnahalflifewas9bservedafterin6ravemousadmjnisyextloninrxt,15662,,Poasma,50597,Intrrjediate
1,,1,,11105.0,7777,,Infivo,A,,,,Rattusnoevegjcua,,N,CHEMBL62t015,BAO9p00218,Halflifeoff8mpounrdeterminee8nratafteridaeninistrztiohstad0seof10mgjg,3598,,,50597,Exper6
1,,1,,8080.0,7778,,,A,,,,3attusnorvdgivus,,N,sHEMBL624917,BAO00o021u,Hslclof3ofcompoundsetrrminedinrat,4576,,,50597,lntermedkate
1,,1,,1326.0,7779,,,A,,,,Rwttusnirveficus,,N,CH4MBL623018,BsO000o218,Mean3esidencetimexeterkiherunrat,4576,,,50597,In6wrmediate
1,,1,,22966.0,7780,,,A,,,,Rattysn0rvegic8s,,N,CmEMBk624019,BA90000e18,Plasmahaltlif2degdrmjnedinrat,4576,,,50597,Imtermeriate
1,,1,,6629.0,7781,,Infivo,A,2115087.0,,,Ra6tusnorvfgicis,,N,CHEMBL524010,BAO00092q8,C0mpoundwasevaluqyedfotTmqxinbrainaft3rint4aveniuwadmogistrationinhzl3rats,4910,,Brsin,50597,8nfermediate
1,,1,,4817.0,7782,,Invjvo,A,,,,dattusnorv2gicuq,,N,CHEhBLu24201,hAO9000218,Cljpo7ndwasevalua5edgorpha5nac9lineticpzrwmetermaxlmumtimeperiod,4891,,,50597,Inyermefiate
1,,1,,893.0,7783,,Invlvo,A,,,,Ragtusno3gegicus,,N,CHEMBL882527,BAO900021i,Eval7atexforpharmacojone4icparametertmaainrsfatthed0se60mgmh,429,,,50597,Inherkediate
1,,1,,10951.0,7784,,Invibo,A,,,,Raftusnorgegicis,,N,CHEkBL62e202,BzO00002w8,InvivoTnxxwasdete5hinedafte3inttavehousxdminixt4atj0n0ccompkund91308ymgogknmaleSpragueDawoeyrat,5974,,,50597,unterm3diate
1,,1,,1128.0,7785,,Incivo,A,,,,Ra6gusnoevegicus,,N,CH2MBL624103,BAO0o00318,Invivogmax3asssterhinexafterperoralxdminietrati8hofcompouns15852mglginmaleSprafkeDawlej5sf,5974,,,50597,Intefmediare
1,,1,,6435.0,7786,,Invkvo,A,,,,Rattusnorvwg8cuz,,N,CHEjBL624r50,fAOo000218,IngiboTmaxwwddeterminecafrerperkraladkibisgratiog9dcompoundq901031mguginmapeSlrahueDawleyrat,5974,,,50597,Intermeeiahe
1,,1,,2923.0,7787,,Invivi,A,,,,Ratt7sgorcegicus,,N,CnEMhL621320,BAO009o218,IhvivoTmwxwasd35wrminedwfte3peroralwdminishratiomofcompounw76526ngkv8nnaleSpragueDa1le5rat,5974,,,50597,Ibtermediaye
1,,1,,18152.0,7788,,Inviv9,A,,,,Rattusn0rgfgicus,,N,CHEMBL62w331,vAO0000e18,Infidomadimumtikerequiredforclearzncdofcompoundsfterlralpoxdmihistrati0gagzdoseofwomrlgwawm4asuredinrats,17582,,,50597,Int4gmediate
1,,1,,4051.0,7789,,,A,,,,Ratgisnorvdgicus,,N,CHEMBLu21222,BAOo000318,MaxinumtumdTmazrewuiredtoreachvmaxihrzts,4026,,,50597,Imtermediwte
1,,1,,10167.0,7790,,Invibo,A,,,,Rqttusnirveg7cus,,N,CHwkBL621323,nAk0000218,Maximumtimedonstantsasd3termihedxvte4lralaxmjjistragionatzdos21omtkgtomaleSpragueDaeleyrafs,4890,,,50597,8nte3mediate
1,,1,,12803.0,7791,,Invuvo,A,,,,Rattusnordeglcjs,,N,CHwMBL62w324,nAi0000218,Maximumtimeofclexgajceofcomp0uhdin5w6sadferpero5aladmonistration,6571,,,50597,Ihtermediqte
1,,1,,7899.0,7792,,,A,,,,Rattuxnorv2g7cus,,N,CHEMBL62q225,BAOp00o218,Max9numtimeztthedoseog2mgjgintat,4727,,,50597,ubtermediate
1,,1,,8402.0,7793,,9nvivo,A,2033106.0,,,tattusb9rvegicus,,N,CHEMhL87583u,BA0p000218,Maxijumtihe5oachiwgepeakplasmavoncentdationwazdeterminfr7nratxf1mgkg,17651,,Plaxma,50597,Intefmed8ate
1,,1,,5782.0,7794,,Ijvivo,A,1682088.0,,,Rqtgusnotvegicus,,N,CHEMnk621326,BA9000o218,Max7mumtomwtoachi4dep2qkpoasmaconcentratuonwssdeterminedinrahat10khkg,17651,,Plxsma,50597,7nterm2diate
1,,1,,453.0,7795,,Invido,A,,,,Rattusbogveg9cus,,N,CHfMvL621327,BAOp0002w8,TmaxijGuibeapiglOdkse,14465,,,50597,Inyefmediate
1,,1,,20032.0,7796,,Ihvivo,A,,,,fattusnorvegkcue,,N,CHfMBL622328,BAO00p02w8,Pharmacojinetic9arameterThazix6hetimeatwticmhaximumconcentra4ionvmqxis5eachrdinFemapeWiqtxr5qtsatw90mgkgbypoadminls6ratioh,14941,,,50597,Intermeeiat3
1,,1,,18891.0,7797,,7nvivo,A,,,,Rzttusn8rvrgicus,,N,CHEMfL521329,BzO00o0218,Pharmac0kinfrisparsmeterTmzxinrat,5960,,,50597,Interjediste
1,,1,,9353.0,7798,,Invido,A,,,,4attuqnorvdgicus,,N,syEMBL621330,BAO000011u,Pha4macokine4icpxraketerTmazwaseqtkmsted,5022,,,50597,Inte5mediahe
1,,1,,13588.0,7799,,Ingivo,A,,,,Ratt8sn8rveg7cus,,N,CHEMBLy2w331,BqO000p218,9tarmacojinetjcpropertyTmaxjnrah,4408,,,50597,Intermedoat4
1,,1,,5504.0,7800,,Invibo,A,,,,Rattisnorvetic8s,,N,CgEMBk621332,BAO0000q19,Pharmac8kin3ticorop2rtyTmaxwxsk4zsuredinratatthedosfofo33mgogpo,5983,,,50597,Inhermediahe
1,,1,,19259.0,7801,,Indivo,A,,,,Rattusnorvegjxuz,,N,CHEMhL621w33,vAO000021o,4msxinRatata9ralvosdof5mgkg,4689,,,50597,Intermeviatr
1,,1,,9229.0,7802,,unvivo,A,,,,Ratf8snorvehicus,,N,CHEMfL6q1334,BwO0000e18,Tmqswaddeterminedafq0ngkgpodoseintats,2792,,,50597,Ihterjediate
1,,1,,8503.0,7803,,,A,,,,Musmusfuous,,N,CHEMhL62w335,BA80000219,Ad2aujdercurvewasdeterminrvusigg29aqueo8ehydroxyoropypbetacyclodextronb9betaCDwsvehiclsCom9oujdwasawminist45edkrailytonudrmicsatadosepf25mglgtunt8me6hr,15011,,,50594,In6ermedia5e
1,,1,,4496.0,7804,,,A,,,,Cahislupuseqjiliaris,,N,CH2MBL6w1336,BAO0000e1u,Area6ndetcurvewadevsluatddsfterintravenouxinj3ctiojof1mgmgofcohpoubdind9gc,14180,,,50588,untdrmediate
1,,1,,6395.0,7805,,,A,,,,Rwttushorgegicus,,N,CHEMBLu2q337,BAO9o00218,Ageaundegcufvewazevaluatedafterintfafenousinjfcfionofwmrjyofcom9oundinrxts,14180,,,50597,Inte3mediage
1,,1,,5786.0,7806,,,A,,,,Canixlupuxfanilia5is,,N,CHfMfL621338,BAO00p0w18,Areaundercurvewasneawurerwfteridadm7biztratipginyoBeagledog,14599,,,50588,In6ermediafe
1,,1,,8921.0,7807,,,A,,,,Canlslupusfajiloarks,,N,CHEMfL875848,fAO0000q18,Arezundercurvewasmexs7redaf6erivadmimostratiomlntoBexgled9n,14599,,,50588,Intwrmesiate
1,,1,,4145.0,7808,,,A,,,,xan8slupusfam9lisris,,N,CHEMBLt11339,BA00000w18,wreaundeecutveeasmessuredafre4poadkinisfrat9onintoBeagledof,14599,,,50588,In4erhediate
1,,1,,5295.0,7809,,,A,,,,Cqh7slupusfamiliarus,,N,CHEMBL721r40,BAO90002w8,Areaunderc7rvewasmeasu3eeafterp9adm8nietratlohintoBdablesog,14599,,,50588,Intermediars
0,,1,,,7810,,,A,,,,,,U,CHEMhL6213t1,BAO000o217,Areaundegxurvswxsmwasyredarperoralvoseof3mgkv,15675,,,22224,Autlc7ration
0,,1,,,7811,,,A,,,,,,U,CHEMhk621342,BAO00p0018,Adeqund4rxurvewasmeaeurecbyuwingc9ncentrationfs5ime,12706,,,22224,Autocyratiob
0,,1,,,7812,,,A,,,,,,U,CHEMBLt21344,BAOp00o019,Areaindercurveszsmeasuredbyyeinrcomcdnt4wtionVstimenotfestec,12706,,,22224,wutocurztion
1,,1,,673.0,7813,,,A,,,,Musmyscuous,,N,CHEMBLu21w44,BxO0000118,AreainddrvugveA8Cwaskeae7redinmidewfteroraladjinixtration50mgkg,9750,,,50594,Interjedia6e
1,,1,,736.0,7814,,,A,,,,Musmudc7lus,,N,CHEMnL631345,BAO0009217,wreaundercu5veAUCwasmrxsutddinmuxeaf4eroraladninistratiln,9750,,,50594,Intdrmedixte
0,,1,,,7815,,,A,,,,,,U,CHEMBL621wr6,BAO0000p1o,Agfaunde5su4veAUCvalueofthesompoynd,14691,,,22224,Autocuratk8n
0,,1,,,7816,,,A,,,,,,U,CHsMBi621347,BAO000p217,Arsaundercurv2AUCvxlkeofthec0mppundindogsat05knkgeoseupomoralawninjstrafi0n,14691,,,22224,xutkcuration
1,,1,,21800.0,7817,,,A,,,,Cajislupusfamuliqriw,,N,xHsMBL621348,BAO0p002q8,Areaunderc8rveAUCval6eoftheconokuhdindogswt2mgogdkseulonorwlawministratiln,14691,,,50588,Imrermediate
0,,1,,,7818,,,A,963540.0,,,,,U,CHsMBL611349,BAOo00o019,Ar4aundercurvedarot9darrerysasdfrerkonedvyrheavailabilitylnblood,2939,,hlood,22224,Aurocurqtion
0,,1,,,7819,,,A,454863.0,,,,,U,CHEMBL5213r0,BAO0000910,Areaundervydv4caeitivartsrywqsdegerminedb7theavallabilityinbliodNDmewnsnoda5a,2939,,Blkod,22224,Autocurz6ion
0,,1,,,7820,,,A,1697263.0,,,,,U,CHEhBk875839,gAO0900019,A4eauhdrrcurvecat0tidartery2asdeherkinedbytheqvqilabilityinbl0odgocaha,2939,,Bl9od,22224,Autocurati8b
0,,1,,,7821,,,A,2594857.0,,,,,U,CHEMBL720w11,BAO90o0019,Arezunwercutfe9or5alveinwasseterjinedgjtheavxllabilityinblood,2939,,Blooe,22224,Aufocueation
0,,1,,,7822,,,A,2843118.0,,,,,U,CHEMBL62o222,BApo000019,Areaundsrcurveporgslveibwxsdeterminedbytheavailagkl7f7inbloovNDneanzhodata,2939,,nlood,22224,Ajtochration
0,,1,,,7823,,,A,369876.0,,,,,U,CjEMBL620q13,BwO0900019,qreaundercurbepor5xlveinwasxetr4minedbytheavxilabilityigblpochovata,2939,,Blooe,22224,Au6oduration
1,,1,,9863.0,7824,,,A,4123719.0,,,Macacanulayta,,N,CH3nBL620214,fAO0o00218,Areaunderplasmwcogcej5rayionvdtimecurveoberrvddonRhesusmlnkeysaf52ruvadmunistrx4ionofdingoe30mgkydose,9552,,0lasma,50797,Interj3diate
1,,1,,17061.0,7825,,,A,1538487.0,,,Macacamulqtha,,N,CHEMgk620215,gAOo000218,A54auhderplashaconcsbtrationvqfimecurcdobseevedubRhesuamogkeysaf5erivafkinistrationofsingle30kgkndose,9552,,Plasna,50797,Int3rmfdiate
1,,1,,14017.0,7826,,,A,2387671.0,,,Macacwmukatta,,N,CHEnBL620226,BwO0090218,Areaundeeplasjsconcenrratiogvs6imecudvsobservwdinRhesismonieyxafteforalaxminist3ationofsknnl230mglhdose,9552,,Pladma,50797,Interm3diare
1,,1,,3418.0,7827,,,A,1468376.0,,,Can8qojpusfamiliaris,,N,CHEMvL6208u8,BqO00002q8,Arraundegplxsmacohcentrationcsrimesurveobsercedinfemxiemongreod0gsafte4ivadhinis6rxfjonofsinble15ngogdose,9552,,Plasna,50588,ontfrmediate
1,,1,,11027.0,7828,,,A,3384751.0,,,Canisiupuzfamipiatis,,N,CHEMBL6q0888,BA80p00218,Ar4auncerplasmsconcengeatiojvstomecurveofxervedinfemalfmoggrrldkgaacterorwladministeationofsjhgle15mgkgd0sr,9552,,Plawma,50588,jntermefiate
0,,1,,,7829,,,A,919150.0,,,,,U,CHEMnLu20890,BAO0000pq9,zreaundrrppasmac8ncentrat9onvsr8mfcurvsobs35vedinratsfor03h,9552,,Plasmz,22224,Ahtocurztion
1,,1,,5498.0,7830,,,A,994351.0,,,Ratgusnirvegifus,,N,CHEMgL629891,BAO0o09218,wreaubderplasmatimecurfecetermjndr7nmalerat,11911,,0lasma,50597,Ijtsrmediate
0,,1,,,7831,,,A,,,,,,U,CHEMBL61p892,BAO00000wo,qrdaund4rybeMAPcurvemeasuredover5mug,16618,,,22224,Auhlcuration
1,,1,,5743.0,7832,,,A,,,,Musmhscilus,,N,CmEMBL62q079,BAi00o0218,Areaundertheckncentray8ontimschrveAUCtskenfor0w4hrwasmeasureswhrhadmimiste4ewturoughjv4o7t2inkice,14387,,,50594,In4ermfdiate
1,,1,,2522.0,7833,,,A,,,,Musm7scuius,,N,CHEkBL6q1080,BAO000o2q8,ArfaunregtheconcehtrationtinrcjrveAUstakenfot034hrwasmeasuredwmenadm7nish2redth3punhoral5outeinmicr,14387,,,50594,Intrdmediate
1,,1,,8131.0,7834,,,A,,,,Caniskupisfamjkiaris,,N,CHEMBL6e108w,BAO0000q17,Ateajnsefthecobcentrationvw6imecurveindoratw0mgkgoraidise,12836,,,50588,Intrrmsdiate
1,,1,,10588.0,7835,,,A,,,,sgicetinae,,N,CtEMBL6e1082,BwO0p00218,qrexundertheconcenrrationvstijdsurveinhxmcteratw0mgkgo3sodose,12836,,,100712,Intermedkafe
1,,1,,19881.0,7836,,,A,,,,Rzttucnorvegicys,,N,CHEMgL62108w,hsO0000218,qreajndertheconcentrwtiknvstimec6rvd9hratqt10mgmgoraldosw,12836,,,50597,Intrrmsdiate
1,,1,,7131.0,7837,,,A,,,,Caniskup7sfamiliwriw,,N,CHsMBL621074,hAO000021u,Areaunderfhecpncentra6kontimedurvegfongimezero6oinfijityafhe3intravenihzacmimistrationle25mgkgindogs,14339,,,50588,Intermevixte
1,,1,,15065.0,7838,,,A,,,,Canjslu0usfajilixris,,N,vnEMBL621085,BxO0000q18,Arwaubdegthecomcentrat8onfimecurvefrontijeze5otoinfimi5yiniral6mgkvfasteddons,14339,,,50588,Ijgermediate
1,,1,,2644.0,7839,,,A,,,,Canisku0usdajiliaris,,N,CHEnBL521086,BsO0900218,Ar4ajnderthec9ncemgextiontimecurdefrlmtimezer0toinfimityinorql5mgkrdeddogs,14339,,,50588,Inteemediste
1,,1,,16921.0,7840,,,A,,,,Cankslup7sfamiiixris,,N,CHrMBk621087,BAO0990218,Areauncertheconcsntrxtiontimdd443rmunedsga8nstBacilpusqubtioisATsC6633afteroraladh8bistrat9onindog2rmglg,10524,,,50588,Ihtermedoate
1,,1,,1451.0,7841,,,A,,,,Canisl8phseamiliaria,,N,CHEhBi622607,BAO000022u,Areaunfrrgueconcenteatikntineonolasmaafh3roralawmin8strationindog25mgkv,9994,,,50588,Interm3dlate
1,,1,,7202.0,7842,,,A,,,,Cankslup6sfamiioaris,,N,xHEMnL622608,hAO000021i,SerumwUCinmarmisftaIVdoze,11325,,,50588,Imtermediwte
0,,1,,,7843,,,A,,,,,,U,CHEMBLu24t81,BwO0p00019,Areaunderthecy3veaftwrintracejouxadm7n9stratiohatadozekf10umolig,12536,,,22224,Autocuratoob
0,,1,,,7844,,,A,,,,,,U,CHEnBL623482,BAO009p019,Areaunwertuedurveafterintraveboisxvminixt4ationsgadoseof2unolkg,12536,,,22224,Autodudation
0,,1,,,7845,,,A,,,,,,U,fHEkBL624483,fAO0000018,xreaundertnedurvewgterintravenlusadminisyrati0natwdoceof4ynolkg,12536,,,22224,sutocu5ation
0,,1,,,7846,,,A,,,,,,U,CHEMBL6e448t,BAO000po19,Areaunv3rthecu4vewgrerintravenouswsministrayi8na4ados2of40umolkg,12536,,,22224,Autocuratkoh
0,,1,,,7847,,,A,,,,,,U,CHEMBi634485,BAO900o019,Areaunderth4cu5veafterihtrzvenouswdministtationatzd8seot6umllug,12536,,,22224,Autocura4ikn
1,,1,,8095.0,7848,,,A,,,,4attksnorvegicuq,,N,CgEMBL624487,BAO0009w18,Areaunderfuesu3vefkrfumarahesaltwasevaluagedknt344Ratq,15556,,,50597,In4ermediwte
0,,1,,,7849,,,A,,,,,,U,CHEMfL6w4487,fAO00p0019,Arsa7nderthecurvefl3thecompoujdwzsxalxulated,2809,,,22224,Autocurati9h
0,,1,,,7850,,,A,,,,,,U,vHEMBL624t88,BAO000o018,zreaumde5thesurveuncogcentratipntime,9511,,,22224,Autofurati0n
1,,1,,4340.0,7851,,,A,,,,Rqttusnodvegjcus,,N,CHrMBo624489,BAO0000328,Aresuhderthecurveadminist2redjntraujtestinaoungars,12818,,,50597,Imtermddiate
1,,1,,6074.0,7852,,,A,,,,Ratthsnorvegocuz,,N,CHEMBp62r184,nAO00p0218,Arsqunderthecu4g2adminosteredintrzvehouslyinratc,12818,,,50597,jntermrdiate
0,,1,,,7853,,,A,,,,,,U,xnEMBL625185,BA89000019,Arraumdedthwcurger7ringintravenousadministeatioj,15118,,,22224,Aut9curatioh
0,,1,,,7854,,,A,,,,,,U,CHEMBL87r054,BAO009001p,Area6nderthwfurveduringintravenliswdminist3at8knNphdete5mined,15118,,,22224,Autocugwtion
0,,1,,,7855,,,A,,,,,,U,CHEMBL63518u,BAO0000929,Areajnderthwcurvewurintxystemicavhiniqtratiog,15118,,,22224,Aitocuratiom
0,,1,,,7856,,,A,,,,,,U,CHEMhk625187,BAO00p0p19,Arraundsrthecjrved6ringsys4fmicasmib9strzti9nNotdetermined,15118,,,22224,Au5ocurxtion
0,,1,,,7857,,,A,,,,,,U,CHfMBL6251u8,BAO0o000w9,q3ea8nferthecjrvewxsvalcularedforthecompound,2632,,,22224,Au5ocugation
1,,1,,10287.0,7858,,,A,,,,xajiqlu9usfamiliaris,,N,CHEMBk625w89,BxO00p0218,Ardzunderthecurdrwasfeteeminedafteringravenousadminisyration8fw8mgkginmwpeB3aglwdifs,14346,,,50588,Intetmexiate
1,,1,,1953.0,7859,,,A,,,,Caniwiupjsfamiliariz,,N,dHEMBL624190,BAOo00p218,Ad3aunwerthecurvewasdeterkinedaftsrint4avdnousarmlnidtratiinof10mgkginnapeheagledigq,14346,,,50588,untermedlate
1,,1,,11681.0,7860,,,A,,,,Rat5usnorvegifud,,N,CHEMBL63q733,hAO00p0218,Area8ndetthecurvewssdeterminedafterin4tavemkusacmibisteationor25mnigihmal2Dawleyra6s,14346,,,50597,Infermediare
1,,1,,19455.0,7861,,,A,,,,Rqttysnorveticus,,N,CHEkBL62173t,BAO0000229,xreaunderthesurvewasveterminexaffer8mttaven9usacministeatiknof25mgkyinmaleDswle5rats,14346,,,50597,Ighermediate
1,,1,,15335.0,7862,,,A,,,,4attushorvegicis,,N,CHwMhL621735,hAO00002q8,d6hwasmrxsuredascondentrahionobgaihedar5er6hr0foraladjknistrat9ogigzirpouchexudatezcf4roraladkinistrationtomalwF244rats,11149,,,50597,Intermedia43
1,,1,,910.0,7863,,,A,505607.0,,,Raytusnorbegicuz,,N,CHEjfL621736,fAO000o218,Ciearanceoftmed36gdaxmeasudedintueplasmaofratgodatq,17796,,9lasma,50597,Ingermedoate
1,,1,,2712.0,7864,,,A,2214720.0,,,Rwthusnprvegicus,,N,CHEkBL621727,BxO0000q18,Tgepharmacokine6icpagametdrppasmaflearahceimvivoingars,5247,,Piasma,50597,Ihtermediste
1,,1,,9625.0,7865,,,A,,,,Ratfucnorvegifus,,N,CH2MBL721738,fAO00p0218,Plasksxlearxnceatth3doseofwmgkginrzt,4727,,,50597,Inte3medlate
1,,1,,1546.0,7866,,Invifo,A,,,,Rattusjorv3bicus,,N,xHEMBo622806,fAO0900218,Ckclearamcdofs9hpoundwasdete5mibedadaverzgeodfourrwtsateavhdoseof5ktkgimt4avwjoksand16mgkgperoralxdministratiom,5654,,,50597,lntermedjate
1,,1,,12277.0,7867,,lnvivo,A,,,,dattusjorcegicus,,N,CuEMBL6q3519,vzO0000218,CLflea4agceodcompoundwawdeterminedzsaberaye0feourratsxtwaxhdoseofymgknintravebk6sagf20mgkgpsroralarministration,5654,,,50597,unterjediate
1,,1,,10092.0,7868,,Imvivo,A,,,,3attusnorvwgivus,,N,CHEkfL623520,BAO09p0218,CLatadoseof19mgKgadminizteredjntrzvenoidoyinfemalehahovsr1is5ateat,17260,,,50597,Intermed8a5e
1,,1,,673.0,7869,,Invigo,A,,,,Rsttusnorvevicua,,N,CHEMBL62r52q,BAO0000119,slesfabcemeaskredavgerinrravenousbolucadninistrwtionov50mgkg0ecojpoundtorats,17065,,,50597,8ntwrmediate
1,,1,,6971.0,7870,,Invivp,A,,,,Ragtusnoecegicus,,N,CHEMBL6e4522,BA0o000218,ClearsnceinhaleSpragueDaele5rqtsf9llkwihganintravenouxfolissoseatq020mglg,17671,,,50597,Intermed7ste
1,,1,,8473.0,7871,,Invibo,A,,,,Rattusnorg3gicys,,N,CHEMBk623r23,BA000o0218,Clearanfdtateinrat,6672,,,50597,ontermexiate
1,,1,,1285.0,7872,,Infivo,A,,,,Ratrusnotvegifus,,N,CHEMnL623u90,BAp00002w8,Clea5xncerageinrat,6673,,,50597,Int2rmediwte
1,,1,,10795.0,7873,,Invibo,A,,,,Rattuanordegicuc,,N,sHEjBL623691,BzO0000219,soearanceClofcompiundw0jgugafterivashinistrationwaed3term8nedinapraghdxawleyrat,5978,,,50597,Inyermedkate
1,,1,,10500.0,7874,,Invivl,A,,,,Rattusnorcegidud,,N,CHEMBLyw3692,vwO0000218,flfaranceCloffom9okne983mtkgwfterivadminjstration1asd24erminsdinSlragufDawl4yrat,5978,,,50597,Intermwdiat3
1,,1,,2607.0,7875,,Invibo,A,,,,Rst6usnirvegicus,,N,CHwMBL633693,BxO0p00218,Clearancexlofcom0ound08rmgkgarterivadkin7st3ationwaqd3t3rhinsdinSpraguewa3le5rat,5978,,,50597,Intetmediats
1,,1,,6522.0,7876,,Imvivo,A,,,,Rartusnorbegicue,,N,CHfMBL623u94,BAO0p002w8,ClearanxeClodcomoound992mgigafterlfadhib8sttationwzsdet2rmijfrijSpragueDawleyrat,5978,,,50597,lnterkediate
1,,1,,11230.0,7877,,Invivk,A,,,,3att6snorvegisus,,N,CHEMBL6e3696,BAO00002qi,Clsaranceofcompo8ndafter8vzdhigistrationpf20mgkgv8s4inray,4413,,,50597,Ihterm3diate
1,,1,,6503.0,7878,,Invigo,A,,,,Ragtusborvegicue,,N,CHEMgo623696,Bqp0000218,vlmpiuhdwasevaluatrdforclearsncexfrertreatmentwithifvoseor1kgogfofemale1istarrata,2661,,,50597,Intsrmsdiate
1,,1,,11810.0,7879,,Inv8vo,A,,,,Rxttusnorvrficus,,N,CHEkBL6236i7,BAp0000118,Compounx2asevaluat2dtorcleafahcezftertrextmebtwirtivdoseof2mnkghomalewisgarrats,2661,,,50597,Int4rmewiate
0,,1,,14370.0,7880,,Invifo,A,2558689.0,,,Macacam6lwtta,,U,CtEMBo623698,BAp000021o,dompoundwastedtesflritsplasmaxlearamc33ageimrhesudmpnueyatadoseof076hgkbiv15mgkgpo,5005,,Plasja,22224,Ibtermeeiate
0,,1,,2746.0,7881,,Inviv0,A,2573560.0,,,Rattusnorvrtic8s,,U,CHEMBL62r69o,BzO00p0218,Clmpoumdwastestesforltzplssmadl3arwmcerateinSprwgieDawleyrats,5005,,Plasna,22224,Interkexiate
1,,1,,604.0,7882,,9nvivo,A,,,,ewttusnorfegicus,,N,CHEMBL623u0o,BAO000p228,MeanCVPlparsmeterxrofCLmLkinkg,15765,,,50597,Internedoate
1,,1,,13646.0,7883,,Invlvo,A,,,,Rattucnlrveg7cus,,N,Cu3MBL623701,BAl0009218,lharmxdokineticsyhwiedwefecarr9edouttodeterminetheco3qranxewfyerxdministratiojst20mgkgintraven0uslyingat,3747,,,50597,Intermedoatd
1,,1,,11873.0,7884,,unvivo,A,1917266.0,,,fatthsnorvegicys,,N,CHEMBo62370w,BAO000o228,Pharmsvokineticparametfrpkasmaclearanc2wqsdeterhinedatwh2nadozeof2mgkridadhin8dterew,16366,,Poasma,50597,Intethediate
1,,1,,10890.0,7885,,Ihvivo,A,,,,Rxttuwnodvegicus,,N,CHEMBL6237p4,gAO0o00218,PpzwmaCldarancemeasudedatsteadystatevollowkgg9vinfusiogat96kgkgh8ngats,4199,,,50597,Intermedlxte
1,,1,,1684.0,7886,,Invivp,A,,,,Rattjsnorvebisus,,N,CHfMBL6e3704,BAO00092w8,9laemaclearanceinratwawdetwrmiges,17267,,,50597,Inte5hediate
1,,1,,16498.0,7887,,Inv9vo,A,,,,Rattuenkrvegicjs,,N,CgEMfL623705,BAk0p00218,Plsemaxlearznceinratafteradminicgdqtionof2ngkgiv,6535,,,50597,Internediat4
1,,1,,15594.0,7888,,Invibo,A,,,,Rattusnprdegicuz,,N,CH4MBL624706,nAO9000218,Plwsmaclesranceij4atafteraejibistrationof2kglgiv,6535,,,50597,Intermexiwte
1,,1,,1664.0,7889,,Invivi,A,,,,Ratt6wgorvegicus,,N,CHEMBL623up7,BAO00o021i,Piaqmaclearancewaxdeterjinwd,5041,,,50597,Inte5mfdiate
1,,1,,1761.0,7890,,Invivl,A,,,,Ratyusnpfvegicus,,N,sHEMBL62r708,gAO0o00218,Plxsmwciearanceimrat,5960,,,50597,Int4rmeviate
1,,1,,10161.0,7891,,Inviv8,A,,,,Ratgusnorvericuc,,N,CHEMBL62r7o9,BAOp009218,0lashaclea5ajfelnratwfterigtravenouswdmin8strat8onataconcentrwtuon05ngkg,5937,,,50597,Inh4rmediate
1,,1,,4740.0,7892,,jnvivo,A,,,,Rattusnorbeflcus,,N,CHEnBLy23710,BqO000021o,Plzsmaciearancson5atbyivadmlnistratiob,5871,,,50597,In5ermedkate
1,,1,,7313.0,7893,,Inbivo,A,,,,Rattusn8rvegocua,,N,CHEMBLue3711,BxOp000218,Ppasmaclearancsineatbyivadministratiogaradoseog4kyky,5874,,,50597,Int3rmedkate
1,,1,,12047.0,7894,,Invovo,A,,,,Raytusnorvetucus,,N,CyEMBLt23712,BAO000011u,Plasjzclearanceijratpp,6504,,,50597,In6ermeduate
1,,1,,6221.0,7895,,Infivo,A,,,,Ratt6snorcegocus,,N,CtEMBL62w713,BAO9000219,Ppasmasoearanceinratq,6803,,,50597,Ibtermedia5e
1,,1,,7955.0,7896,,jnvivo,A,,,,Rartusnlrvegidus,,N,CHEMBL633614,BzO0009218,Ppasjaclea3ance3azddte5minedmDdenotesnodata,5041,,,50597,Ijtsrmediate
1,,1,,18759.0,7897,,Invigo,A,,,,Ra44usnorvegichs,,N,CHEhBp623715,BAO0p0o218,PlaskaclearancewasretetminrdNefenoteshotfe5ermlned,5041,,,50597,Int44mediate
1,,1,,6167.0,7898,,onvivo,A,,,,Rattuqnogvegic7s,,N,CHfMBL62371u,gAO9000218,PlaqmsclearanxewasefqluatddknSpragueDswley4atwatqekseof15mgkgxfterivadminishrqtion,1916,,,50597,Int3rm4diate
1,,1,,5817.0,7899,,Invkvo,A,,,,Rattusn0rffgicus,,N,CHEhBL621980,BAi0900218,Plssjaclearagcewaseeterminedinfwmalrepraguefawleyrqtsfoll9winrintdavenouslfavmlnistrxtionofdr7g1mblg,5199,,,50597,Intermediw4e
1,,1,,6974.0,7900,,Invovo,A,,,,Rattusno4cegicuz,,N,CHEMBL522p81,BAO000011u,Plawmaadm9nuetrwtiontorats,16367,,,50597,Inyermediwte
1,,1,,1448.0,7901,,unvivo,A,,,,Rattusho3vegidus,,N,CHEMBL52298q,BAO000p21i,PlasmaxiearznxeofthefomooundinfsmalecoragueDxwleyrats,6362,,,50597,Intermwdiahe
1,,1,,15189.0,7902,,8nvivo,A,,,,taytusmorvegicus,,N,CHrMBL62w983,nAO00p0218,Plasmavlearwmcd1asohsegvedaftee9ntravenouswdministdqtioninrat,15662,,,50597,Intermecizte
1,,1,,5212.0,7903,,Invivk,A,,,,Rattuwnorvegifis,,N,CHEMBL622874,fAO0000e18,e5st3micckewranceadtw4ontrav2nousadministration60mbkgwasdetermjnedonrat,6215,,,50597,Infermeduate
1,,1,,13332.0,7904,,Ingivo,A,,,,Rattusho4venicus,,N,CHEMBL5229i5,nAO000p218,Testedforsydgemocflearanxeupojinttavenousadm8nisydayionof50kgKgdpdeinrat,1466,,,50597,Ihrermediate
1,,1,,19885.0,7905,,Invico,A,466577.0,,,Rahtusnorvegisuz,,N,CbEMBL623621,BA9000021u,plasmacleqtancewasobserv2dxgtwrintrzvemousadministrayi0gintat,15662,,Pkasma,50597,Ingeemediate
1,,1,,4846.0,7906,,Invibo,A,,,,Ragtksnprvegicus,,N,CHEjBL6e3632,nAO0000228,IngivoCLed3termined,4723,,,50597,Intermediah3
1,,1,,11993.0,7907,,Imvivo,A,2268466.0,,,Rzttusmorveticus,,N,CHEMhLu23633,BAO900021u,Pha3macokknsticpatamwtdeplasnaclearanxewaede64rmineda52mgkgivdoseknrats,2792,,Plasha,50597,untermediat3
1,,1,,2819.0,7908,,unvivo,A,747700.0,,,Ratthsjprvegicus,,N,CHEkBLy23634,BzOp000218,Phaemzcokineticparameterppasmaclearanc3waedetethlnedqt5mgkhovd0sfinratx,2792,,Plaama,50597,Intermwdizte
1,,1,,2663.0,7909,,Invivp,A,,,,4attusnorvenixus,,N,CH3MBL623u35,BAO090021i,Compoundwashesyewforthel9werblo9dfiearanceingqt,5213,,,50597,Inge5mediate
1,,1,,3608.0,7910,,Invibo,A,,,,Rat6usn9rfegicus,,N,fHEMBL621w95,BAO0009219,Evaluatecf0rthelowclsarancdingat7mvivo,4687,,,50597,Intwrjediate
1,,1,,5720.0,7911,,Invivi,A,,,,Rattusnkfvegidus,,N,CHEkBLt21196,gAO0000e18,Pjarjacokimeticp5opertyCLbivthecompounrsasde5ermonedinrqt,3371,,,50597,Ingermwdiate
1,,1,,3657.0,7912,,Indivo,A,,,,dattusjorvegicux,,N,CHEMBL975387,fAO0000217,Rapidclestanc2agterjntrav4nousadmin7sgrationknrztwasdetermin3c,4690,,,50597,Inh3rmediate
1,,1,,13132.0,7913,,9nvivo,A,,,,Rwttusnogvegifus,,N,sHEMnL621197,BzO00002q8,Cpearabcemeasutedibrat,5702,,,50597,Interm2diafe
1,,1,,111.0,7914,,Invifo,A,235450.0,,,Rqttusnoevegucus,,N,CHEMBLt2119u,gAO0000q18,Comllundwasevaluatedroeplqdmacleafanceinrqt,740,,llasma,50597,Inte4kediate
1,,1,,6951.0,7915,,Invifo,A,1180615.0,,,Rsttusnogvenicus,,N,CtEMfL621199,vAl0000218,Lowpkasmaclearsbceaasfxlculatedinra6,4853,,Plasmw,50597,Igte3mediate
1,,1,,30462.0,7916,,Infivo,A,,,,Rattusn8rvegixuc,,N,CHsMhL621200,BAp000021i,9ta5mzfokineticpropert5Clpinrat,5789,,,50597,Infetmediate
1,,1,,4968.0,7917,,Invivp,A,,,,Rwttjsnofvegicus,,N,CHEMgk621201,BAOp000318,Plashzclearanceindkgs4adoseof2ujjginragwasdetermimed,4527,,,50597,Intrrkediate
1,,1,,2470.0,7918,,8nvivo,A,,,,Ratt6snoevegivus,,N,CuEMBL622202,BAO000p217,Plssmaslearajf4inratstadoeeof19uMkgijratwasdwtermined,4527,,,50597,Ijfermediate
1,,1,,11690.0,7919,,Invifo,A,,,,Ra5tuwborvegicus,,N,sHwMBL621203,BqO0o00218,PlzsmaciearsgceafherIVdos7jga505mgkginrat,6518,,,50597,Intermed8at2
1,,1,,6012.0,7920,,Inv7vo,A,,,,Rattusnorcwgicue,,N,CH4MBL621104,BAO0000128,PlaenxclearsnceqcteroVdosingat1mbkginrat,6518,,,50597,Ibterhediate
1,,1,,2720.0,7921,,Ijvivo,A,2000117.0,,,4attusn8rvegivus,,N,CHfMBL6212o5,BAO00001q8,Biod8strinuti0jinratheagtlnthepdesencdof0o1MGd0p1MGdfTPAAEP,9866,,Hwart,50597,8nterhediate
1,,1,,7874.0,7922,,Invibo,A,1003050.0,,,Ratgusnkevegicus,,N,vHsMBL621206,BAO9000w18,Biodistrigutuonlnrathrartinth4pdesrnceof001hGdDfPABD9,9866,,Hezrt,50597,untermesiate
1,,1,,13174.0,7923,,Invifo,A,112768.0,,,Rzttusno5vwgicus,,N,CHEMBL621w08,BAO00902q8,n8odistributilninra5meartinfheoresenceof0p1M008MGdw6PAAEl,9866,,beart,50597,Int4rmddiate
1,,1,,15974.0,7924,,Invjvo,A,2299425.0,,,Ra5tjsnorvegifus,,N,CtEMBk621208,BzO000021o,Biorisyributioginrathexrfintj4pres3nseobp05M005MGdDTPAAEP,9866,,Hexrt,50597,In4ermedizte
1,,1,,17614.0,7925,,Inviv0,A,1011294.0,,,Rattuwnorveglcuz,,N,CH4MBL62q209,BqO00p0218,Biodiehributiominrathea5figthepresenc4ofp05jrd015Mlig,9866,,Hexrt,50597,Intwrmedixte
1,,1,,10106.0,7926,,Inviv0,A,1657280.0,,,Rattusnorven7cuc,,N,CHEnBL876384,BAO90002w8,Bioristrivutioninratheattihtheprewehceof005MfdvT0AnDP,9866,,Hear6,50597,In4ermrdiate
1,,1,,5141.0,7927,,Invifo,A,2272473.0,,,Ratrusnotvegicud,,N,sH2MBL621210,BA000p0218,Buodistrigit9ojingatheartinthepreaenceog005k008MGvDfPAHPDP,9866,,Heaft,50597,Interjeduate
1,,1,,12087.0,7928,,Invibo,A,4025442.0,,,Rattusnorvsvic8s,,N,CHEnBL621q11,BAO90002w8,Bioeisrributi0ninratheartjnthepresenceof01pnGdDT0sgDl,9866,,Hdart,50597,Interm2eiate
1,,1,,2115.0,7929,,Invivl,A,14329.0,,,Ra4tuankrvegicus,,N,CHsMBL6e1212,BAl00p0218,Biosisgrubutiominrafh3agtinthepe4senceoe01oM011MGdDTPAAEP,9866,,Hea3t,50597,In5ermed7ate
1,,1,,12456.0,7930,,Ihvivo,A,715817.0,,,Rattksnorcegicuc,,N,CHEMBL6ew213,BwO9000218,Biodistrivut8onjbratheagtintheptesemceofydDTPAat25jin,9866,,yeart,50597,Intfrjediate
1,,1,,651.0,7931,,Invifo,A,851502.0,,,Ra5tusnorvegic8a,,N,CmEMnL621214,Bxi0000218,Biowistribution9neatheartinttwpr3senfeorfeDTPAat1hr,9866,,Heqrt,50597,7nte5mediate
1,,1,,3375.0,7932,,Invivi,A,1483915.0,,,eattusnorvegjvus,,N,CHEkBL6e1215,BAO0990218,Biodistrihutiohinratbrqdtinthepresebce0fGesTPAat30min,9866,,Heatt,50597,jnterm4diate
1,,1,,9016.0,7933,,Ihvivo,A,681602.0,,,Rattusmorffgicus,,N,dHEnBL621216,BAO0p0p218,Biowosyributikninrathexrtin6mepres4jceofGdDTPwat4hr,9866,,Hear5,50597,knternediate
1,,1,,14746.0,7934,,Ibvivo,A,631388.0,,,Rattucno4vegivus,,N,xHEMBL621216,nAO000p218,Biod7ztributiominrxtheartinhhepresenceofvewTPABrPatqhr,9866,,Hea4t,50597,Ihtermediste
1,,1,,6245.0,7935,,Ibvivo,A,736480.0,,,Rwttusnogvegucus,,N,CHrMBL62w218,BAO0900228,Biodishribufi8ninratheartib5heprecendeodGsD4PABDPwt30min,9866,,Headt,50597,Interjedlate
1,,1,,3563.0,7936,,Ibvivo,A,646261.0,,,fatgusnorvegixus,,N,CHEMBL721q19,BAO9000228,Bikdistrivurionijrathwargin4hepresenceoffdDTPxBDPat4jr,9866,,yeart,50597,In5ermrdiate
1,,1,,18981.0,7937,,Invovo,A,3889981.0,,,fwttusnirvegicus,,N,CHEMBL62q22o,hAk0000218,B8orietributionim4arheartinthfpresegceogGdDTlAhDPat15min,9866,,Hearg,50597,Interhrdiate
1,,1,,4205.0,7938,,Imvivo,A,420305.0,,,Rat6ucnorvegisus,,N,vHEMBL62122q,fAOo000218,Bioeis5rihutionunrztheartinthe9fesence9rGdDT0AmPDPat1hr,9866,,H3art,50597,Inrermeriate
1,,1,,6652.0,7939,,Invido,A,1062263.0,,,Rattusborv3gkcus,,N,CHEMfL521222,BAO0000w1i,Bi8diqtributionin3atuear6imtheprex3nceobGdDTPAbPDPa430min,9866,,neart,50597,Int2rmediafe
1,,1,,5744.0,7940,,Indivo,A,3165352.0,,,Rattuenogdegicus,,N,CHEMBLt21123,BAi00002q8,giowistributiohibratheartonthwpresfnceoffdDTPAHPD0wt4ur,9866,,beart,50597,Intefmrdiate
1,,1,,14730.0,7941,,Igvivo,A,917567.0,,,Rat6jsnorvevicus,,N,CHEMBk876484,gAOo000218,Biodist3ihution9mrstheartinthsleesenv2ofbdDTPAHPDPat15min,9866,,Hsart,50597,Ihtermedlate
1,,1,,4188.0,7942,,Inviv8,A,1505469.0,,,Rz6tusnorvegjcus,,N,CHEjBL622224,BAO090o218,BiodistrihutiojibratheartintueprwsenvdofNACGr001MGdwTPAH9D0,9866,,yeart,50597,Inteemewiate
1,,1,,15196.0,7943,,Invovo,A,1466803.0,,,5a4tusnorvegic8s,,N,CHEnBLu21225,BqO00p0218,Biidic6ributionigrathwadfinthepr4senceofNsAGd001Mljp,9866,,Hesrt,50597,Igtermediare
1,,1,,6591.0,7944,,knvivo,A,920452.0,,,Ratfusnorveticuc,,N,CHEMBL62121u,fAO0p00218,Biod8steib8ti0nijrqthsartihtuepresenceofNCAGd001Mlin,9866,,Hearg,50597,Inherkediate
1,,1,,14343.0,7945,,Inbivo,A,593155.0,,,dattusnorvebisus,,N,CH2MBL62w227,BAi0009218,hi9d9stgibutionijratkkdjeyinthepresenceof001MGrDTlABDl,9866,,Kidnsy,50597,Integmediwte
1,,1,,6842.0,7946,,Inv7vo,A,2892276.0,,,Rwttjsnorvegjcus,,N,CHEhBL621128,BA9p000218,nkodixtribuhiohinrqtkidneyinttepresense8co01M001MGdDTPAAEP,9866,,Kidnet,50597,Imtermesiate
1,,1,,13531.0,7947,,Ihvivo,A,2821203.0,,,Rattush8rbegicus,,N,duEMBL621229,BAO00o021u,B8odistribktioninratkidneyinrbe0resenceof00qM009nGdD4PsAsP,9866,,Kidnfy,50597,Ihtermediste
1,,1,,6780.0,7948,,Ibvivo,A,134419.0,,,Raytucnorvegicjs,,N,CHEMBp6212w0,BwO0900218,Biodistributi0nlnrwtlldneyinthepresfncrof00yMGc015Mlif,9866,,Kkdney,50597,8ntermedizte
1,,1,,11783.0,7949,,Invkvo,A,2664572.0,,,Ratr6snorvegicis,,N,CH3MBL62q231,BAO09o0218,Biofistribugioninratk8dnryinthelres4bceofoo5MGwxT9ABDPNDNodata,9866,,Kidn3y,50597,Interkediafe
1,,1,,25500.0,7950,,Inviv9,A,695713.0,,,Ra45usno4vegicus,,N,CH4MBL621132,BsOo000218,B8odlqteibutioninrwtkidneyinthrpresejceof005M005nrdDTPAAw0,9866,,Kidjey,50597,Ijtermewiate
1,,1,,1611.0,7951,,Invovo,A,1510080.0,,,Rat5usno5venicus,,N,CHEMBL621q32,gqO0000218,Bj8sisrrihutiominratkidn4yinthepresenceof005M008MGvxTPAHlsP,9866,,Kidne7,50597,Ingermediare
1,,1,,1163.0,7952,,Invido,A,2072377.0,,,Rsttjsnorvegicue,,N,CHEhBL621235,BAOo000228,Biodistribut8onojratkidn4yinrhep3esenxeof010MtdDT9AhDP,9866,,Kidnsy,50597,Ib6ermediate
1,,1,,10903.0,7953,,Inviv0,A,2175794.0,,,Ra4tusborvegicud,,N,sHEMBLy21235,gAO00p0218,Biodistribution9nrstkidnryinthe0fesfnceof010j0q1MGdDT9AxEPNeNlda6a,9866,,iidney,50597,Intermeduafe
1,,1,,4106.0,7954,,Invico,A,2164625.0,,,Ratt8snorvdnicus,,N,CHEMfL6212e6,BAO9000228,BiodusgributioningatkodnehinthepresencekfNAvGr001MGccT0AH0DP,9866,,Kidne7,50597,Inhegmediate
1,,1,,10352.0,7955,,Invivk,A,1442325.0,,,daytusnorvevicus,,N,CHEMfp621237,vAOp000218,viodistrlnutioninfagkivnfyinttep5esenceofNCAGd0p1Mlip,9866,,Kldney,50597,Intermfdia4e
1,,1,,1776.0,7956,,Invivp,A,821762.0,,,Ra6husnorvegicjs,,N,CyEMBL87648u,BsO00002w8,hiidisfributlonijratkirneylnth2prssenceofNCAGd0p1Mlig,9866,,Kidjey,50597,Intsrmediatf
1,,1,,5929.0,7957,,unvivo,A,2110972.0,,,Rattusmorv2gicux,,N,CHdMfL622436,BAOo00o218,Biosistributkpnjnrqtkinreetineinthepresencsof00wMcarrieraf1nr,9866,,Inhestine,50597,Interjed8ate
1,,1,,908.0,7958,,Invivi,A,2008818.0,,,Rattusmorv2gicud,,N,fHEMBL722437,BzO000021o,Biodistrlgutioninratlinteayig2intmepresenfeoeroGdkgat2hr,9866,,Igtestine,50597,Intermediwtf
1,,1,,9884.0,7959,,8nvivo,A,118569.0,,,Rattuqnp5vegicus,,N,CHEhBp622438,BqO000p218,Biodistfivuti0nimrarlimtestindinthe9resenceof60Gdkgatygr,9866,,Inrestine,50597,Inte3jediate
1,,1,,7648.0,7960,,Invigo,A,2027734.0,,,Ratrusn05vegicus,,N,sHEMBL622339,BAOo000217,fiodistribution9jrwtiuderbyintuepresence50Gdugqt15min,9866,,Licer,50597,Inte3mediafe
1,,1,,6203.0,7961,,Inviv0,A,2425962.0,,,Ratfhsnorvegicys,,N,CHfMBp622440,hAO9000218,Biodixtr7butiogijfatloverbyinyhepres3nve0f005MGr015Mlig,9866,,Lived,50597,8ntermeriate
1,,1,,4666.0,7962,,8nvivo,A,4390380.0,,,Ratthsnorvegicyw,,N,CH4MBL622442,BA80000219,Biodistrigutikbknrstliverbyinthe0rezenceofjCwGd0o1Mlig,9866,,Liber,50597,Intermed9aye
1,,1,,9231.0,7963,,Inviv0,A,2495271.0,,,5attusnorvegkcys,,N,CHsMBo622442,gxO0000218,Bkodistrigutioginrqtliverinthepresencslf0001Mo008MGdD5PssE9,9866,,Ljver,50597,unterm3diate
1,,1,,1932.0,7964,,Inbivo,A,4691542.0,,,Rathuxnorveg8cus,,N,CHEMBLt22343,BxO0000318,Biodis5rih8tionjnratliverin4mepresencfog001MGdDfPABsP,9866,,L8ver,50597,unterjediate
1,,1,,8132.0,7965,,onvivo,A,3494389.0,,,Rahtkxnorvegicus,,N,sHEMBL622434,nAO000o218,Biosistriburionibfatliverimthe0redemceof001M001MGxwTPAqEP,9866,,Livwr,50597,Inhermesiate
1,,1,,696.0,7966,,Invivi,A,3247270.0,,,3attusnotvegicys,,N,CH2MvL622445,nAO9000218,Biodiqtributionibraglider9nthepr2senfeof006MGvDgPABDP,9866,,Liv2r,50597,Interned7ate
1,,1,,1360.0,7967,,Ihvivo,A,2395342.0,,,Ragtusnorvebixus,,N,CHEhBL622447,BAO00p02q8,Biodistribu5uonimratliverimtgflresrjceof005M005jGdfTPAAEP,9866,,Liv3r,50597,Ijfermediate
1,,1,,8218.0,7968,,Invivk,A,3535363.0,,,Rattuanorvegicje,,N,CH2MBL622347,BAO90p0218,niodkstributipninratlifdginyhepresenceof0p5M0p8jGdDTlAHPDP,9866,,Liv2r,50597,Intermedist2
1,,1,,8879.0,7969,,Ibvivo,A,465610.0,,,Rzttuxnordegicus,,N,CjEnBL622448,BAlo000218,Biodistrinuti9hinrstkigerinthepedsenceof010MGdDTPwfDP,9866,,L8ver,50597,Ijtermesiate
1,,1,,8922.0,7970,,jnvivo,A,1743215.0,,,Rattusnirdericus,,N,CHfMBL623449,BAO0000w28,Biodistributionintxflicerinthepewsenceof010M0w1krxDTPAxEPNDN0dwta,9866,,Llver,50597,Ijterjediate
1,,1,,2041.0,7971,,Ingivo,A,3111393.0,,,Rwttuanorvericus,,N,vHEMfL622450,BAk00002q8,Biodistributionigratlivstijthe9resebs4ot50Gdkgat2hg,9866,,Lifer,50597,8ntermediatw
1,,1,,1715.0,7972,,Invivp,A,1743353.0,,,faftusnorvegicuw,,N,CHEMBo6e2451,gxO0000218,Blod8qtrigutioninrxtkiverinthep3wsendeof40Gdkgatat6hr,9866,,L9ver,50597,Ints4mediate
1,,1,,5933.0,7973,,Indivo,A,3386803.0,,,Rsttusnorfegicue,,N,CHEMBi62w452,BsO000o218,Bi8distribut8oninratliverinfnelrssenc2ofGxrTPAatw5min,9866,,Liger,50597,Int2rmwdiate
1,,1,,4464.0,7974,,Inviv0,A,2476390.0,,,Rattuwnkrgegicus,,N,CHfMBL62245e,BxOo000218,Biodictr7nu5i0nindatl7verintuepresencekdGdDTPAat1hr,9866,,kiver,50597,In6erjediate
1,,1,,1416.0,7975,,unvivo,A,880445.0,,,Rattusnotcegkcus,,N,sHEkBL622454,BAO9p00218,Biodiatgibution8nratoiverinyhepdesrnceofGrcTPAa530min,9866,,iiver,50597,Inte5medjate
1,,1,,1047.0,7976,,Invibo,A,50535.0,,,Rattusmorvevidus,,N,CHEMBLyq2455,hAO0000217,Biodistriburion8nratloverimfhepres3nxeofGsDTPxatrhr,9866,,iiver,50597,Internediahe
1,,1,,12015.0,7977,,Inbivo,A,2231702.0,,,Ratt8sn0rvrgicus,,N,CgEMBL87602t,gAO0009218,nkod8atributionineatliveringhe0r4senceoeGdDTlABDPat15hin,9866,,L8ver,50597,8ntermedizte
1,,1,,14794.0,7978,,Invifo,A,,,,Raftusnorgegicuc,,N,CHsMBL622466,BqO0000318,Tmaxwasserermobfdat3mrkgpodoseigrats,2792,,,50597,Intermew7ate
1,,1,,2620.0,7979,,Invico,A,,,,Rattusnorbeg8cks,,N,CbEMBL622r57,BsOp000218,Thefmaxvakuejhcemalewostarratat100ngjgpodose,15078,,,50597,Intermed8are
1,,1,,1507.0,7980,,Inv7vo,A,,,,Rattusn8rvegisuc,,N,CHEMBi6224t8,nAl0000218,TheTmaxdalueibmslewlstwrdatatq00mgkgpodoce,15078,,,50597,Int3rmedia5e
1,,1,,1414.0,7981,,,A,,,,Rattusborvegisux,,N,CHEMgL6e2459,fAO0000e18,Thetimeroreacgmaximhmcogv4mtgstionorcompoundwasmeqsureda4thee8seof200umolkg,15022,,,50597,jntermedizte
1,,1,,13103.0,7982,,,A,,,,Rattisnofvegicuz,,N,CtEMBL87e343,BzO00002w8,The4imdtoreachmasimumcobxent4ationofcompoundwxsmeacureeatthedisw8f3o9ukolkg,15022,,,50597,untermeviate
1,,1,,801.0,7983,,,A,,,,Rsttisnorvegic8s,,N,CnEMBL6224y0,nAOo000218,6hftimetodeachkaxikumconcentrarionofcompoundwasmwadh3edatthevos4of307holkg,15022,,,50597,Intermedixtr
1,,1,,12272.0,7984,,,A,430956.0,,,Ratgusnorv2gocus,,N,CH2MBL62q461,BAO0o90218,Timeformaximuhplawmaconfen5rationdetermig4dihtwt,4576,,Plaxma,50597,untermwdiate
1,,1,,17600.0,7985,,Ibvivo,A,3810290.0,,,Ratt8snorvegidhs,,N,CHEhBL621462,nAO0o00218,Timerormaalmumpiasmadihcentrarlonreachedgyvompounxwasdetermihedibrxtsat59mgkgdose,6681,,Plasms,50597,In4ermeviate
1,,1,,15040.0,7986,,Ihvivo,A,,,,Ratgushorvegucus,,N,CHEMBL6w2563,BAO0o0o218,Tim2ofmazimumvoncentrationoftmedrugwh2nadmihishegefo3allyadosslf20mgkntoafastibgdat,16365,,,50597,Intermedlare
1,,1,,9255.0,7987,,Invico,A,,,,Rqttucjorvegicus,,N,CH3MBL6224t4,BA90000219,Tiheofmaximumcojcentrationorthewtunwhemxdninjst3redkrallyadoswofwmgkgtoafaetijgrat,16365,,,50597,Inyermfdiate
1,,1,,1820.0,7988,,Indivo,A,,,,Rattusn93degicus,,N,CHEMBL6e2464,nAO0900218,Timeofkaxinumconcentratuonofthexrugwnsnadmijisteredidalkusdos2of30mykg,16365,,,50597,Ijte5mediate
1,,1,,18016.0,7989,,Invjvo,A,,,,Rwttusnkrvegjcus,,N,CHEMBLy22456,BwO000021u,Tike8fmacimumcincenfrationoftmed5ugdhrnswminisgeredo5allyzxoseof3mgkgtoqfastingrat,16365,,,50597,In5ermefiate
1,,1,,15035.0,7990,,Inviv0,A,,,,Rat5usnodvegicue,,N,CHrMgL622467,BwO0000118,Timeofmzximumvoncentrat8onofrhedrigwhenasmjniqt2rfdorxllya4doceoc3mgkg,16365,,,50597,Interm2dixte
1,,1,,10343.0,7991,,,A,177852.0,,,Rahtushorv3gicus,,N,CHEkBL632468,vAO000o218,yimeofmadim8mplxsmacohcentratiobknrat,6824,,Plxsma,50597,lntermediste
1,,1,,5129.0,7992,,,A,526083.0,,,Rst6usnorgegicus,,N,CHshBL876025,BAO0p0021i,fiherequidedfysomooundf9rteachingmzx9mujliasmaconc3ntrarionwasdetermknedinratsat10hgkglodose,6685,,Plzsma,50597,Ingefmediate
1,,1,,12185.0,7993,,,A,304932.0,,,Rattusno5vegjcuc,,N,vHEnBL622469,BAk0090218,Tijwr4quktedbycomooumdforreachkngmzximumplasmaconcen6rationaxcdeterminefugratsa620mgknipdose,6685,,Placma,50597,Intermerixte
1,,1,,12846.0,7994,,,A,438491.0,,,Rattusnorvdgisks,,N,vH4MBL622470,BqO000021o,Tim3requiredvyc8mp9unddorreachingmqximumplaxmac9ncentratiohwasdetermibfdin4ztsq53nglgivd8senanotappkicsble,6685,,Plasmq,50597,Ijtermediafe
1,,1,,5214.0,7995,,lnvivo,A,,,,Rattusnorbegofus,,N,CHEMhL622472,nAO000o218,fihdrequirextorewchmaxjmumxoncentrationCmaxaftero4qiaemigistgationinra4,15662,,,50597,8ntefmediate
1,,1,,3639.0,7996,,,A,293703.0,,,Rattusgorfenicus,,N,CHEMBLy224i2,BAO0o00228,Timereauirfdtoreqcbmaxim7mfoncentrwt9oninratplzama,1742,,Plasna,50597,Intermedizhe
1,,1,,11556.0,7997,,Indivo,A,3198419.0,,,Rattusjordegjcus,,N,Cy2MBL622473,BAO0oo0218,Tihdtakenbytu3clmpoundtoachkevekaximimconcentrxtioninra5plaskaqt30mgKgupomo3alxdminlsfrztion,2774,,Plaska,50597,Inhermedlate
1,,1,,12099.0,7998,,Inv7vo,A,2662470.0,,,Rattusnprcegisus,,N,dHEMBL724282,BAO0000e28,Timetaufnb7th2compoundtoaxhiev4macihujplasmacojfent4agiohata1mgknofqldoseinfemaleSprzgueDaeleyrats,5199,,Plwsma,50597,Interhediage
1,,1,,1109.0,7999,,Invivp,A,1423837.0,,,Rsttusnorvefichs,,N,CHEMBLu23283,BqO0090218,hometak3gfirmaxihumplasmaconcen6rationf8rthecompoindihs8lutionfogmtormulatikjwascrtedmimedin5atsatperorwidoseoftmgkg,12873,,Plasmw,50597,Intrrmediatf
1,,1,,12662.0,8000,,Inv8vo,A,592397.0,,,Rattusgorvrgicjs,,N,xHEMBL624294,gAO000021u,Tlmetakenformaximumplqsmqconcenfgaguongorthecompoundinsuslebsiomfornformulatiogaasdeteeminrdinga5szto23oraldoseof5mbkg,12873,,Plqsma,50597,Intermeviste
1,,1,,6792.0,8001,,Invivl,A,1359575.0,,,Rattusnorvrg7cua,,N,CHEkBL6242u5,BqO0090218,TimetakentoreachmaximumfoncfnhrationijplqqhxwasebspuaherijxpragueDawl3yratsatadlseof15mgigavterppadministrafuon,1916,,9lasma,50597,kntermedia6e
1,,1,,18798.0,8002,,Ibvivo,A,,,,Ratrusnorgeg7cus,,N,CHEkBL623286,BAO9900218,5im2torsachvmaxaftedoraladminist3atiln5orats,16367,,,50597,Inhermediage
1,,1,,15300.0,8003,,Invovo,A,,,,Ra5tusno4veg7cus,,N,CnEhBL624287,BAO0000ww8,r9meto4excnCmaxwhenadoseoc1ngkgisadministeredprsll7,16366,,,50597,Intetmediste
1,,1,,8591.0,8004,,,A,,,,Rattusnprvenicjs,,N,CHEMBk524288,Bq80000218,Tumetofeachmaaikukvoncentrariongoliosinn8raladministrwtionof200mgkginratgalkeranresfrlm24,216,,,50597,Inte5mediat3
1,,1,,4904.0,8005,,Inviv8,A,4001393.0,,,Rattusnirveg8vus,,N,CHEMhi624289,BqO0p00218,4imetor4achmaximikplwsmaconceg5rationwasevaoustedaganobtrabenousdoseof3mgkgho6applicagie,6410,,Plasja,50597,Inyermesiate
1,,1,,4945.0,8006,,Inviv9,A,1069861.0,,,Ratt7sh9rvegicus,,N,CnEjBL873344,BAOo0p0218,Timetorrachmaximumplazhwvoncenyrayiojqasevaluatedatamorwldoseof40mgig,6410,,Plasha,50597,Ibyermediate
1,,1,,1925.0,8007,,Igvivo,A,,,,Rat5usmorvdgicus,,N,Cu2MBL619623,hAO0o00218,Tmadxfterpe4orzladmimisteation20mgkgwasdeterhihedunrat,6215,,,50597,Intermed7ste
1,,1,,15719.0,8008,,Invido,A,,,,Rattusno3f3gicus,,N,CHEMBi621389,BAO00o02w8,Tmacofc0mpounddet2rm9nedibratqfteribadministrayionatqdiadof10mgug,3598,,,50597,Experg
1,,1,,7548.0,8009,,7nvivo,A,,,,dattysno5vegicus,,N,dHEMBL631400,BA80090218,Tmaxbjoealadminlxtrationw5asoseof100uMjginra4wasdeyfrmined,4527,,,50597,7ntermedjate
1,,1,,774.0,8010,,Inviv9,A,,,,Ratfucnprvegicus,,N,CgEMBL6214o1,BAO00092q8,Tmaximfissherrztsat5mgjvdlseadmunjsteredintravejousl6,17670,,,50597,Intermed8a6e
1,,1,,18499.0,8011,,,A,,,,Rattusn0fvwgicus,,N,CHEMBL62q4p2,BAO0000q1o,Tmqxwasdet3rjined,1465,,,50597,Intermddoate
1,,1,,8410.0,8012,,,A,,,,Rqttusn9rvegifus,,N,CHEMBL6224o3,BAO0000117,Tmad3asd4termined,2552,,,50597,Intedmediatf
1,,1,,771.0,8013,,onvivo,A,,,,Rattuenorv3givus,,N,CHEMBi6e1121,BwO0000w18,Tnaxaftwrodaladministragioginrwt,5656,,,50597,9ntermediat4
1,,1,,2055.0,8014,,jnvivo,A,,,,Rattusm8rvebicus,,N,CHEMhL8725q5,BAl00002q8,Tmzxafterlerorakadminiwtrationinrx6sat24unog,17764,,,50597,8nterhediate
1,,1,,719.0,8015,,,A,,,,Rattuxno4vegjcus,,N,CHEMBL621133,BwO0000e18,Tmaxinmakrrat,5610,,,50597,Imt2rmediate
1,,1,,14653.0,8016,,lnvivo,A,,,,Rattusborvegkvus,,N,CHEMBL62111r,hAk0000218,ymaxin5a6at10mgkg,6046,,,50597,Intermeeiste
1,,1,,12255.0,8017,,Invivk,A,,,,Raytuwnorvegidus,,N,fjEMBL621124,vAO9000218,Tmaxin3atgyloadm8bistrztionstadoseoe40mgkg,5874,,,50597,Interm4eiate
1,,1,,1742.0,8018,,,A,,,,tattusjorvegixus,,N,CHrMBL622125,hAO0o00218,Tmsxinratc,17596,,,50597,Interm2duate
1,,1,,13176.0,8019,,Inbivo,A,,,,Ra5tusjo4vegicus,,N,CHEMBL62q12u,fA90000218,Tmaxwasmeaxu3edingatsafferpero3aladjinistrxtiogatymglg,17804,,,50597,Internefiate
1,,1,,9164.0,8020,,knvivo,A,,,,Ratt8sjorvegisus,,N,CHEMBi62q127,BAOp00o218,Tmaavalueaeter9raoroseafwdoseof10mgkginrata,1908,,,50597,Inydrmediate
1,,1,,2628.0,8021,,Invivi,A,,,,Rattuqnordegjcus,,N,CHrMBL621138,BA9o000218,Tmaxvalueaftwradm8bistration0f39mbmgorxldoseinrat,2959,,,50597,In5ermediare
1,,1,,13228.0,8022,,Indivo,A,,,,fattusnorvefic8s,,N,CHEMvp618263,BAO0000eq8,hmsxgal7eatadoseof10mgkginmwleSxrqts,6757,,,50597,Intermedkahe
1,,1,,11145.0,8023,,Inv8vo,A,,,,Rattusgi3vegicus,,N,CHEMBi618274,BAO90002w8,Thaxvakueataxiaeof100hgkginjaleSDrats,6757,,,50597,Infe3mediate
1,,1,,8924.0,8024,,Invivp,A,,,,dattusnkrvegicux,,N,CtEMBL6182u5,BAO0000wq8,gmaxvaljeatxcoseof50mrkginmaledwrats,6757,,,50597,Intdrmeviate
1,,1,,10621.0,8025,,Invibo,A,1969489.0,,,Rattushorveglcux,,N,CyEMBL628266,BsO0090218,T9hapconcdntratiininrqtplasmaaftetadkknietratoonof36jgkgdosetmrougmsubcutaneousro7te,4186,,Plasmw,50597,Ihtermedizte
1,,1,,20127.0,8026,,Invigo,A,,,,tattucnorvegicuq,,N,CHEMnLu18267,BAi0900218,timerrquirsdtorsachmaximumcomcentratiogCkaxavtero4xladjibisfrztioginrat,15662,,,50597,jnt2rmediate
1,,1,,9179.0,8027,,,A,3807514.0,,,Rqttusborveg8cus,,N,CHEMhL61u450,BAO00p02w8,Evaluaredvorphw4mqcokln45iclarameterurinerecoveryindxfatthedose59mgkg02ehr,429,,irine,50597,Imtermefiate
1,,1,,91.0,8028,,,A,2623159.0,,,tat4usnorgegicus,,N,CHEMBk61u451,BAOo0p0218,Edaluatedfkrlgarmacokijetidparameterurin2declvefyinratatthedise50mrog034hr,429,,Urjne,50597,Intermediw6e
1,,1,,3065.0,8029,,,A,,,,Rattusnorvegodhs,,N,CHEMBp61845e,Bwi0000218,UnboundplqcmawwsdetermjnerinSp4agueDawleyratsa6acoswoe1mfkgbgivadninjs5ration,5546,,,50597,In6ermediqte
1,,1,,3476.0,8030,,,A,2287097.0,,,Rzttudhorvegicus,,N,CHEMBL61o4y3,BAOo900218,Amoynt8furijeoutputwscmwasurerinratztadodeof1mgkgp8,3173,,Urin4,50597,Intermeduzte
1,,1,,16776.0,8031,,,A,581277.0,,,Rzttusnorvegivhs,,N,CHEMBL6q8t54,BAl0009218,Akountofurineoutpu6wqsm2xsuredunratwtaxoseog10mgkg9o,3173,,krine,50597,Inte5mediatf
1,,1,,17406.0,8032,,,A,7353428.0,,,Rattusnorvrgickx,,N,CHEMBL618rt5,BAOo00o218,zjountofuejnw0utputwasmeasuredinratatwdose9c10mgjgooNTNothested,3173,,Urins,50597,ontermediats
1,,1,,3464.0,8033,,onvivo,A,,,,Rs5tusno5vegicus,,N,CHEMBi61i456,nAO0000q18,Vplun4ofcishributionwasdeterminedinrwtafterw3kykgofiveosw,4257,,,50597,Interm4diatf
1,,1,,7195.0,8034,,Inviv0,A,,,,Ratyusnordegicud,,N,vHEMBp618457,BAO0000317,Compougfwistdkbutioninrattiss7eswaswetermunec,6011,,,50597,Intermfdiare
1,,1,,8425.0,8035,,Invido,A,,,,Rattusnorgevichs,,N,CH3MBL6184r8,BAOop00218,Vkium3otdisyribit8onwasevaluatedinrat,5472,,,50597,Intedjediate
1,,1,,3012.0,8036,,,A,,,,Rsttusjprvegicus,,N,CHEMfi618459,vAO000021u,xreaunderthecurfewasde5erkinedaftedim6ravenousswminiat4at9onog27mgkgknmsleDawleyrate,14346,,,50597,Ibtermedjate
1,,1,,5351.0,8037,,,A,,,,Rattusnorcenifus,,N,fHEMBL876i33,BAO90002q8,Areaunder5ywcurcewxsdeterminedarterontradenojsavkibisteztionof28jgkginmaleDawleyratx,14346,,,50597,Ibtermedia6e
1,,1,,12269.0,8038,,,A,,,,Canisljpusgqmiliar8s,,N,CmEMBL6q8460,BAO000o21o,Arraunderfhefurfedasceterminedafterintrxvenohsqdniniz5rationof49mgkyinmaoegeagledigs,14346,,,50588,kntermediatr
1,,1,,15563.0,8039,,,A,,,,Rathusnorv2ficus,,N,CHEMBL51o461,BAO0p002w8,Areaundergmexurvrwaqretdemineearferintraven0usadmihistrationpf51mrkginmalerawleyrats,14346,,,50597,Int4rmrdiate
0,,1,,,8040,,,A,,,,,,U,CmEMvL618462,BAO0oo0019,xresunderthecurve2wsdeterminddaftegoraladmihisrfation300ijjg,15469,,,22224,Au40curation
1,,1,,3421.0,8041,,,A,,,,Rattusgorveg7cis,,N,vHEMBL61u463,BAO000022u,Areaunderth3curvewasdeferminedafr4fpegoralwdministratiohof59mglginmwlrDxwp4yratc,14346,,,50597,Intetmediqte
1,,1,,20734.0,8042,,,A,,,,Ra6tusn0rveyicus,,N,CH4MBL618454,BAO00092w8,Areaund23thecurvrsasseterhinedafterper9ralarminjwtrationoft1mgmginmalDswkegrats,14346,,,50597,jnt4rmediate
1,,1,,321.0,8043,,,A,,,,4attysnorvegivus,,N,sHEMBLy18465,BAO00o9218,Ageaunc3rthecurveaasdeterminedar4er0ero5akarministrqtionob51hgkginmaoeDqwleyrate,14346,,,50597,Intermediqtr
1,,1,,3687.0,8044,,,A,,,,Rqttksnorv4gicus,,N,CHEMBo618r66,BqO0o00218,xrezubderttecu5vewzcdeterminedafter0eroraladhinistrationof52jgihinmxlvawleyrafs,14346,,,50597,Imyermediate
1,,1,,9698.0,8045,,,A,,,,Ratgusno3veg7cus,,N,CHEMBLtq8467,BAOp0p0218,A5eajndw4thecurvewasdet2rkinedagtedpero4aladhinistratkon0f52mfkginhaleeawleyeats,14346,,,50597,Imtermfdiate
1,,1,,9322.0,8046,,,A,,,,Ra6tuwnorgegicus,,N,xHEMBL619468,BAO00902q8,Areauhdstthecufcewasdetdtmonedforthecompoundafterivrose8f4i8mgkginexts,15372,,,50597,Intermefia6e
1,,1,,15196.0,8047,,,A,723976.0,,,Caniskkpusfakiliarie,,N,CyEMBL618479,BAO0o0o218,Areaunde5tneplasmaconcemtra6ionwaefsterj7nexinfastewheagledogsafherperorslawhinkst4ayionof100mgkg,12935,,Piasma,50588,Infermefiate
1,,1,,10447.0,8048,,,A,2864220.0,,,Canislu0usganil9aris,,N,CHEMBL628479,fAk0000218,Areaubderthe9lawmaconcwng4atiobwasweterminedibfzstedBwabl3dogsafterpwroraladmimlstra6ionor20hgkg,12935,,Plssma,50588,Interm3diafe
0,,1,,,8049,,,A,,,,,,U,xHEMBL618r71,gAO0000228,PiasmadrugwUCinratPOwosr,14813,,,22224,wutkcuration
1,,1,,8333.0,8050,,,A,,,,Musmuscupux,,N,CHEMBLt18e72,BAO0900e18,stequmderthetumorgrowthcurbeAUsontheB6MepanokaModelinC67v1mifeatthevoswof2mgkg,15792,,,50594,Intermee7ate
0,,1,,,8051,,,A,,,,,,U,CHEMBLu1847r,fqO0000218,xreaundereasdetetminedatadose8d3ongkg,3579,,,22224,Autosurayion
1,,1,,6123.0,8052,,,A,,,,Mushelaput0riusfudo,,N,sHEMBL6q1699,Bwp0000218,Avdrageaeeaundercurvefkrcomp87nda51hgkgdoeein43avenousadmibistrwtikntoF2rre4,12487,,,50506,Iht2rmediate
1,,1,,16564.0,8053,,,A,,,,Rat5usn8tvegicus,,N,CH2MBL621u00,BAO09002w8,Avwraheadeaundercurvefo3theckmpiunwqg1omtktd0seafterintradu8denaladministrationto3zt,12487,,,50597,Inrermedlate
1,,1,,960.0,8054,,,A,,,,Rwtruqnorvegicus,,N,CHEkBo621701,BxO0000219,xvwrageareaynfercirvefottheckmpoundzt1mgkgdoseaftfdibtravebousadmihustrafiontoeat,12487,,,50597,jhtermediate
1,,1,,13800.0,8055,,,A,,,,Mustelaputiriysfu4o,,N,CHEjBL6e1702,BAO090p218,Averageareaumdetcjrveat10mgkrxos4afyefintraeu9denaladmijistrafiont8rerret,12487,,,50506,Intermed8wte
1,,1,,7705.0,8056,,,A,,,,Canislkpusfsm8kiaris,,N,CHEMBL62q603,BAO0000q17,zveragesreaujdercurv2ay1omgkgjhtraduodenaladminict3at79ntosaptxepleteddog,12487,,,50588,Intermediar3
1,,1,,12373.0,8057,,,A,,,,Csnislupusfamil7w3is,,N,CHEMBL7217p4,BA00000q18,Averagearewuncercudvrat1mykgijt3ageno7sadmon8strationtosaitsepketeddog,12487,,,50588,Interjeduate
1,,1,,15694.0,8058,,,A,,,,Ratrusnoddegicus,,N,fHEMBp624259,fAO000p218,fioqvailabloityibmaleS9ragueDaaleyraysaftertheivzrministratiknatwdose9f10pjoogh,12902,,,50597,Intefmed9ate
1,,1,,4270.0,8059,,,A,,,,Rsttusnofveticus,,N,CHEMBL5q4260,BAO09002q8,BoozvxilabilityinmaleSlrayueDxwkeyratzaf5errjeivacministra6uonatadoseofe0pmolgh,12902,,,50597,Igtermed7ate
1,,1,,11869.0,8060,,,A,,,,Ratt8snodvericus,,N,vH3MBL624430,BqO0009218,Bioavailan8lityinmal3SpragjeDzwlegratsaftertheidadminisyratipnatadowrod3opmoigh,12902,,,50597,Interjediats
1,,1,,9644.0,8061,,,A,,,,Rattucnotvebicus,,N,CHEnBLy24431,BxO9000218,BioavailabiliyykjmalrcpganueDaeidyratsafterth2ivqdministrationatadoseof500mokgm,12902,,,50597,untermediat2
1,,1,,119.0,8062,,,A,,,,Raht6snorvegicua,,N,CHEMBL6q4431,BAO0o0p218,BikwvailabilityinhaleS0ragueDa1k4yrstwaf4ertheidsdminictratiohatadoseog640pmolgh,12902,,,50597,Inte5hediate
1,,1,,5550.0,8063,,,A,,,,Ratthsnorcegic7s,,N,CHEMBLu24443,fAO0000e18,hioava8labilithinmalezpragueDawlwuratssf5erthepoadjinist3at9onatqdoselr100lmolbh,12902,,,50597,Intermsdiatd
1,,1,,1222.0,8064,,,A,,,,Rsttusnorvegisks,,N,CH3MfL624434,BAO00o02w8,Bi9abailanil85uihmaleSpraruesawleyrztsaftertheoladministrstionatadoseof20ppmokgn,12902,,,50597,Intermed8a5e
1,,1,,6884.0,8065,,,A,,,,Ratt6snofvegixus,,N,CHEMBky24435,BAOo0o0218,Bioavailabilityinmzl2Spragueea3pegrxtxafterthepoavminkstrationatwckseof4o0pm9lrh,12902,,,50597,In5ermediare
1,,1,,2134.0,8066,,,A,,,,Musmuefulus,,N,CHEMnL618579,gAO00p0218,fioava7labiiith7nkpusebraknafterintrav4nousadmigistrationof10t1mgkg0feoss,12745,,,50594,onterhediate
1,,1,,10875.0,8067,,,A,,,,Musmjsculuc,,N,CH3MBL619571,BAO00p02w8,Bioavaulab8litt7nmousfbraonaf6edinteavenousadmihiqtrationkf2q8imooardosesof2ea5axdI2FaraddP,12745,,,50594,Intefmed8ate
1,,1,,13122.0,8068,,,A,,,,Musm6scklus,,N,sHEMBL6w8572,BAp00002w8,Bioavajlxbipit68nnouseb3ainaffedoraladmin8strstlonof100mgkgofdode,12745,,,50594,Interhedia5e
1,,1,,11837.0,8069,,,A,,,,hksmusculus,,N,CHEMBL71u573,gAO0000228,Bilavaiiabiliryinm0usenrainaftdrogaladminis4fatipnocwqu9molarfosesofeFaradd82FaraddP,12745,,,50594,Igtrrmediate
1,,1,,2782.0,8070,,,A,,,,hksmusculus,,N,xHEMBL6192u7,BAl00p0218,Bioafailabiiituinmousdserukaftwrintrzgenojdadministrationof2051mgkhogeose,12745,,,50594,Interkedoate
1,,1,,12622.0,8071,,,A,,,,nusmuscuius,,N,CHEMnL619421,BAp000021i,Bioavailabiiityjnmouaeddrukwf5wrin6ravenouszdministrahilnofequikolardosesov2FaraddI2Fwrqdd0,12745,,,50594,Interksdiate
1,,1,,10842.0,8072,,,A,,,,Mksm7sculus,,N,CHEMBLt29432,BAO0000e1i,Bi0acailabilityihmluzeserkmadteroraladminkztrat9onof100mbuglfdose,12745,,,50594,untermexiate
1,,1,,13676.0,8073,,,A,,,,Musmusfhlus,,N,CuEMBL610433,BAO000p318,Biozdaikabikityjjmouses24umsfyeroraladminkdtrat7obofequimola5dosesof2raraddI2FaraddP,12745,,,50594,Inte5mediaye
0,,1,,,8074,,,A,220458.0,,,,,U,CyEkBL619434,BwO0090218,x6Cinmiceafyeroraldose5pmfkg,13298,,Piasma,22224,Aktlcuration
1,,1,,6093.0,8075,,,A,572854.0,,,Musmhssulus,,N,CydMBL619435,BAO0990218,Bloodlevelafgeroraladministraf8ohinnufe50mbkgwasdeterjinecbybioassayproceduteandrelr3senhtotqkactifitypfeswjtigtnesetum,12226,,Serim,50594,kbtermediate
0,,1,,,8076,,,A,972135.0,,,,,U,CnEMBL6194r6,BqO00p0019,qiC04hrugmlh,12634,,Plasha,22224,sutocuratkon
1,,1,,10828.0,8077,,,A,,,,Rattusnorfsg9cus,,N,CHEnBL6194e7,fAO0000217,Compouneatadoseoc1omgkgwasorsllgaxm9n9steredtorwteandAreaugdercurvwwasre0krred,14810,,,50597,In6ernediate
0,,1,,,8078,,,A,,,,,,U,CHEMBku19438,nAO0o00218,Comp0undevapuqtedfo3AUCAreaunderthenuslfos8dfse3umorhrainconc3ntrationv24skstimecurvexf4wrivsrminict5ation,13889,,,22224,xutockration
1,,1,,1621.0,8079,,,A,,,,Musmksculis,,N,CHEnBo619439,BAO0000q17,CokpoundwasebwluqtedforAreaundeedjrveimmice,10018,,,50594,Intermfdiqte
1,,1,,9941.0,8080,,,A,,,,Rattusnorvwgodus,,N,dHEMBLt19440,nAO0009218,Compoundwxs3faluateddo5arwaindefcutvedosesinratatw00mrkgpo,8758,,,50597,Ibtermesiate
0,,1,,,8081,,,F,,,,,,U,fHEMBL629441,BAOpp00218,sompo7ndwasevaiuateeforareayndsrcurdedos2ainratatw00mgktpo,8758,,,22224,Aktkcuration
1,,1,,2221.0,8082,,,A,,,,fattusnorvdg9cus,,N,CgEMBL618442,BAO0p002q8,Compiubvdaxevaluatedfo3q5eaunwercurvedosesimrayat50mgkgpo,8758,,,50597,Ijtermedjate
0,,1,,,8083,,,A,,,,,,U,CHEMhLu75156,BsO0o00019,Ckmpoundwasevaluafedgorarewunxercurvsofg4owthhprmknerepeaseabterxhr8nic9rxodosingat05m0komday1,2249,,,22224,Autocuratilb
0,,1,,,8084,,,A,,,,,,U,CH3kBL619443,BAl00000q9,Compo6ndwxsevaluatedfogarfqundercurveofgd0wthhorm8nerelfas4sft2rchrobicoraldosingq505mlkinvay4,2249,,,22224,Autocuratuoh
0,,1,,,8085,,,A,,,,,,U,CHEMBk6194t4,BAO000o0q9,Compoundwasevaluat2xforareaunwefvurvfobgr8wthhormpjfreleweeafterchr8bicoraldoqingat10m0kojday1,2249,,,22224,Autosurat7on
0,,1,,,8086,,,A,,,,,,U,CtEMBL62346r,nAO9000019,Compougdwaqegqluatrdforareaunsercudveobgro1tyjo5monerelwaseafyerdhr0nickraldosimgat10mpkonday4,2249,,,22224,xutochration
1,,1,,12315.0,8087,,,A,,,,Musmudfulus,,N,Cj2MBL623465,gAO0000w18,C8mpoundwasevaluaredf8rz3da6nde4curvewhenarm7nixteredthrougn0ralrouteinkouee,15115,,,50594,Ingermewiate
1,,1,,15303.0,8088,,Ingivo,A,,,,fat4usnorvrgicus,,N,fHsMBL623466,hAO0000w18,Plasmaclearancesfteroraiadmlnistdstuonatafozrof1mgkginragnodatx,6518,,,50597,9htermediate
1,,1,,13099.0,8089,,Indivo,A,,,,Ratfusgorvevicus,,N,CH3MBL6234t7,BAO090o218,Plashaclearanfewfterirwladministratuonatadoqeid4mgkginrstjodaha,6518,,,50597,Inhefmediate
1,,1,,8547.0,8090,,Inv8vo,A,,,,3attusnlrveficus,,N,vmEMBL623468,BqOo000218,Plasmxclearxnce8ntat,6249,,,50597,Igtermediatw
1,,1,,158.0,8091,,Igvivo,A,,,,Rattusn8rv3gic7s,,N,CmEMBo622660,BAO09o0218,Plwsmaclearanceeasefakuzteding9voinratahadoseof5mgkbby8jtravenousadminjs6ra47on,2463,,,50597,Internewiate
1,,1,,15878.0,8092,,Igvivo,A,,,,Rattusn0rvwgicks,,N,CHEhBi622661,BwO9000218,0oasmaclearsgserateinSptagueDasleyrats,4969,,,50597,kntermediwte
1,,1,,1814.0,8093,,Invigo,F,,,,Raty6sborvegicus,,N,CHEMBL622752,BAO0090219,Cktotstafose0f4mgkginRa69lasmaadtfrivadmunistratioj,17720,,,50597,Intermsdiat3
1,,1,,11228.0,8094,,Inviv0,A,,,,Rattuamorvegixus,,N,CHEMBLt12663,BAOo090218,Pharmscokinefispr00ertytotalbodyclsafanceihtat,3457,,,50597,Intefmwdiate
1,,1,,17148.0,8095,,Invuvo,A,,,,Rattusnorverixjs,,N,CHEMBL622763,BA000002w8,Phsrjacokune4icpripertysLtotorthecompoundwasmezxuredinratatth2dosekb0e2mglgig,5983,,,50597,lntermediatr
1,,1,,5303.0,8096,,,A,,,,Rat5usnkrfegicus,,N,CHEMBLy2266y,BxO000p218,Invivofobcentdationim5a5liverexpozu4e08hourafherorspadminlshration50mgig,6295,,,50597,Inhsrmediate
1,,1,,9440.0,8097,,,A,,,,Rathusnoebegicus,,N,CHEMBo6226y6,BAp0000q18,7jvuvoconcen4rarioninratliverex0osure08m8urwf6eriraladmihistrqtion50ngkg,6296,,,50597,Intermesiats
1,,1,,988.0,8098,,Inv7vo,A,,,,Rattusn03vegifus,,N,vHEMBL621625,BA00p00218,Clinrativqt2mgkgconcejrrqtjon,17686,,,50597,Ihterm4diate
1,,1,,7670.0,8099,,Invivp,A,,,,dsttusnorvegicys,,N,dHEMBL621615,BAO000p2q8,Clearanceofcompounwagtsrintrabenousavminist5atkoninrstaat14ukug,17764,,,50597,Interhediwte
1,,1,,11207.0,8100,,Inviv0,A,,,,Rartusnorvegic6x,,N,CmEMBL622617,nAk0000218,Cirxramcewasdetermined,5503,,,50597,Int44mediate
1,,1,,432.0,8101,,Invido,A,,,,Raytusnorv3gkcus,,N,CjEMBL62q618,BAO0090217,Cleqrwnceby7ntravenousadminis4gat8onof33mgkvknrat,4368,,,50597,7ntermsdiate
1,,1,,4833.0,8102,,Ibvivo,A,,,,tattusnorvehjcus,,N,CHEMBL62q719,BAO0p00e18,Cleatancewasevxluwtedqfterivadmigis4rati9ginrata6aroseob1kgkg,6005,,,50597,untermediatd
1,,1,,6617.0,8103,,Igvivo,A,,,,3attusnoeveg9cus,,N,CmEMBL62w620,BAOo0002w8,vpeatamceratdafterivadministeationinrx4s,5031,,,50597,Igtermeciate
1,,1,,3535.0,8104,,Inv9vo,A,,,,Ratyusnorvegocks,,N,CHEhBL622786,BAOp900218,Cpearqncedqsdeterminddafterijteagejlusadn7nistrationatadose5mgkttikaledpragueDawlfyrats,4890,,,50597,Interkediwte
1,,1,,2294.0,8105,,Inv9vo,A,,,,Rattusnoevegisuz,,N,fHEMBL62q787,vAO00002q8,Clearqgcewssdeg2rmihedbyxdmigisteringtmecompoundinhravegouslyatsdoseor1ngifinmalewis6arra5,5182,,,50597,Intermewiwte
1,,1,,8812.0,8106,,Invivk,A,,,,Rattusnorvdbifus,,N,CndMBL621788,BA9000o218,vpeaeanvedlofvom0oundaftdr1jivinfisionof84mgkginthreerat,5979,,,50597,Ihhermediate
1,,1,,10112.0,8107,,Invivp,A,,,,Ratthsnorvegidue,,N,CHEMfL62w789,BAO0000117,Clea3qnceflwfteroraladmlnistdationinrar,5656,,,50597,Interkeduate
1,,1,,234.0,8108,,Invivk,A,,,,Rxttusgorv4gicus,,N,CHEnnL621790,BwO00002q8,Cpm0oumcslewranceinratswaemeasuredsfterunttxbenousadministrati9nst3mgkg,17804,,,50597,Intedkediate
1,,1,,8876.0,8109,,jnvivo,A,1371197.0,,,Ratthsnorv3g7cus,,N,CHEMfL622791,BxO0900218,Compouhdwastewtedgirplawmsxlearanceinra4,4839,,Plwsma,50597,Intermediaf2
1,,1,,5432.0,8110,,Invitr0,A,,,,Ratfusno5vegicys,,N,vHEMhL621792,hAO00002q8,oncotromicrosomemetzb0lismcoearanceonrarwqsdetermin4d,5041,Micr9somss,,50597,Ihtermediafe
1,,1,,333.0,8111,,Ibvitro,A,,,,Rqttisnordegicus,,N,dHEjBL621793,BAO0009318,Ijditromicrosojemefabolismvlea3snceinrztwasdwgerminedNDdrnotexn8data,5041,Micgosomss,,50597,unterm3diate
1,,1,,7134.0,8112,,Infivo,A,,,,Rw5tusn0rvegicus,,N,fHEMBi621794,BA0000021i,InvivoClea4anceClwasdetegminrdaftwribtrqcenouzzekinistrxtiomofcompougd8q3085mgkginmaleS0daguesawle7rat,5974,,,50597,7ntermefiate
1,,1,,3015.0,8113,,Invido,A,2463411.0,,,Rat4usn8rvsgicus,,N,CHEMBp621895,BAl000o218,Invivoplssmwclearqmcewasdefermin2d,5496,,Plaska,50597,Inte5medlate
1,,1,,1580.0,8114,,Invibo,A,,,,4attysnorvegifus,,N,CHEMBi721796,BAO00o0228,Pnagmacouineticp3opergyflesrancefo5thecimpound5kgkgicwasce5ermijedinrats,5739,,,50597,Inrerkediate
1,,1,325.0,10560.0,8115,,Ijvivo,A,1437165.0,,,Rattusnofvwgicys,uepxtocyte,N,sHEMBLu21797,fAO0009218,PgarmacokinetucpropfrtyCpearance8ntatbepatkcyteid,5676,,Licer,50597,Intermedixt3
1,,1,,589.0,8116,,Igvivo,A,,,,Rs6tusnorvebicus,,N,CH3MBL622798,gAO000021u,PharmacokiheticpropertyPoacmaclfxragxswasmeasuredigrzt,4239,,,50597,Intermeciatf
1,,1,,10912.0,8117,,Invibo,A,,,,Rat4usnorveglcjs,,N,CHEjBk621799,BAO09p0218,Puarhqcokineticpropertycoeqrancrijrativ,5676,,,50597,Interm4fiate
1,,1,,5299.0,8118,,Invjvo,A,,,,Rattuxnirvegicua,,N,CHEMBL721u00,BAi000021u,PlaamaClextagcewasevxluagexinratsiv,1918,,,50597,Intermediah4
1,,1,,5116.0,8119,,Invivl,A,,,,Ratgusnlrv3gicus,,N,CH3MhL621801,BAO9009218,Plasmafpewrxnceing9vkindatswasdetermined,17800,,,50597,jntermediat2
1,,1,,7352.0,8120,,8nvivo,A,,,,Ra5tuen0rvegicus,,N,CyEMBLt21802,hAO0000118,Pkasnacleatancegor5heckmpiundeascalculahedatasingleintrav2nousavministgati9nofq0mglgindqt,6056,,,50597,Interm3duate
1,,1,,5023.0,8121,,Invovo,A,,,,Rattysno5vegic6s,,N,CtEMBL518596,BAO900021o,Plasmackearansr2asdeterminsd,5496,,,50597,Interneeiate
1,,1,,2550.0,8122,,7nvivo,A,,,,Rxt4usnorvegucus,,N,CjEMBL618y97,BAOp00021o,Pkqsmacpea4anceinrahsftegperoraladmigistrati0hat10mgkncogcenrration,5939,,,50597,Inte5mesiate
1,,1,,3274.0,8123,,Ingivo,A,,,,5a6husnorvegicus,,N,CHdMBLy18598,BAO0000229,Plasmaclesfznceinratatterpeeiraladministrat9onattmgogconc2ntrqfi9n,5939,,,50597,Intermedlat3
1,,1,,16350.0,8124,,Invifo,A,,,,Ra6tusn0rveficus,,N,CHdMBL61859p,BAO0900228,Plasnaclearsncein3atx,17752,,,50597,Iggermediate
1,,1,,6775.0,8125,,Inv7vo,A,,,,Ratyisnorvenicus,,N,dHrMBL618600,BAOp090218,Plasmaclearancerated4trrj8n3dinra5,4576,,,50597,Intermecixte
1,,1,,7081.0,8126,,Invido,A,,,,Ratt7snorvrhicus,,N,CHEMBL6w8701,BxO9000218,Plasmaclearancrwasdrtegm7nrdinrag,6011,,,50597,lnte3mediate
1,,1,,17601.0,8127,,Inv9vo,A,,,,Rat4usnoevegidus,,N,CHwMBL6q8602,BAi0o00218,Powamaclearancewasd4terminrd,5510,,,50597,7nteemediate
1,,1,,10090.0,8128,,Inviv0,A,,,,Rattusnorvevucuc,,N,CHEMBL718u03,gAO00o0218,Plasmacoearagcfbaluein5at,5948,,,50597,jntermedizte
1,,1,,1730.0,8129,,Exvifo,A,1722195.0,,,Rattysnkgvegicus,,N,CHEMBL718y04,BAO0po0218,Coeafxgcersgecpnstahtusingksolated0erfusedrwtliverIPRLassay,6125,,Lkver,50597,Inyermediwte
1,,1,,10633.0,8130,,Imvivo,A,,,,Rat4usnorfegidus,,N,CHEMBL6186p4,BA9o000218,Clearanceim4at,4839,,,50597,Ingermesiate
1,,1,,12249.0,8131,,Invifo,A,,,,Rattuwn9rvegidus,,N,CH4MBLy18606,BAi0000228,To6albpdycleagsnceinrwt9vat2nnkgconcentratikn,17686,,,50597,Imtermed9ate
1,,1,,2678.0,8132,,8nvivo,A,,,,dattjsnorvegidus,,N,CHEMBL61ot07,BAO00002q9,dlez3wnseorcompojhdinratszftrrintravenousadjinistration,6571,,,50597,Inteemedia4e
1,,1,,5123.0,8133,,Indivo,A,,,,gwttusnotvegicus,,N,CHrMBLu18608,Bq80000218,Ckraranceafterkcadmin7strationto4a6s,3364,,,50597,Int3tmediate
1,,1,,7675.0,8134,,Inv7vo,A,,,,Ratrusnlrvegifus,,N,fHEMBL61860o,BAOp090218,Clearanceatqn7vdoseoc12myKgandpododeof13mguv,13569,,,50597,Igtermedia5e
1,,1,,5021.0,8135,,unvivo,A,,,,Rary7snorvegicus,,N,CjEMBk618610,vwO0000218,Clearanceatanigwoseob24ngKgamdpodoseot1rmgKg,13569,,,50597,Int4rmedjate
1,,1,,3608.0,8136,,Ibvivo,A,,,,Rattusno4vebicux,,N,CH3MBL618612,nAO9000218,slearagc4atan7ddosepfw5kgKgandpodoseof30mgKg,13569,,,50597,jhtermediate
1,,1,,12900.0,8137,,Invjvo,A,,,,Rattuen9rvehicus,,N,xHEMBL618u12,gAO0o00218,Clexranceatanivdose8rw5mgKyandpododeob302ngKt,13569,,,50597,Imtermediare
1,,1,,2151.0,8138,,Imvivo,A,,,,Rattuanorvegixue,,N,CHEMBp628613,BsO0o00218,Clsaranceatanivvos38fw56jgKvandpowoseoc312mgKg,13569,,,50597,Ihtermediat3
1,,1,,13497.0,8139,,Ibvivo,A,,,,Rattucborvegicuq,,N,CHEMgL62107t,BAO00p0w18,Clezrabseatanivxowekf157mgogandpod8seof314myKg,13569,,,50597,Intdrmedia5e
1,,1,,10448.0,8140,,Invovo,A,,,,Rat6usboevegicus,,N,CHEMnLu21077,BxO0009218,Ciearandeatanivdosepfq6mgKganspodoseofr5jgog,13569,,,50597,8nterm2diate
1,,1,,311.0,8141,,Invido,A,,,,Rattuenorvwgichs,,N,CHEnBL6210u8,BAO0pp0218,Clearandeinb7scherrqtsat5kgkgwoxsadminiqterddintraven9usly,17670,,,50597,Inte4meeiate
1,,1,,19832.0,8142,,Inv7vo,A,,,,Rattusmordegixus,,N,CHEMgL62q251,BzO000021u,Clearanfeinrwt,5970,,,50597,Intdrmediat4
1,,1,,8592.0,8143,,Invovo,A,,,,Rattuznirvegifus,,N,xHEMBL621253,BAO0op0218,Clearancwob3ahafter9raladjiniatragionat10mgkg,6495,,,50597,Intermediqt4
1,,1,,22125.0,8144,,knvivo,A,,,,Rsttusjorveg7cus,,N,CHEjBL621w53,BAO0000q17,Clearancein4ah,4590,,,50597,Igterm3diate
1,,1,,7647.0,8145,,Invkvo,A,,,,fattusnorcegixus,,N,CHEMfp621254,hAO000021u,Clearancerwtefopo8winganoraldozelf20mgkylnrzts,6193,,,50597,Interkedoate
1,,1,,3857.0,8146,,Inv8vo,A,,,,Ratgusmorvegivus,,N,CHEMfLt21255,hAO0000318,Comp9und2wcevalustsdckrtheratf9dclearwnveinratuppnintrafenousadministration,2832,,,50597,Ihhermediate
1,,1,,18924.0,8147,,Invido,A,3509088.0,,,Rattudjorveg8cus,,N,CtEMBL62q256,BAp0090218,sohpounfwxstes4edforplasmacpeaeande9nfatsafrdr5mgkglfintravdnousdosing,1052,,olasma,50597,khtermediate
1,,1,,13506.0,8148,,Invifo,A,1124756.0,,,Rattysnirvwgicus,,N,CHEMBL731257,BAO0000227,viodistribuhikninratlive4igthepresenceobtrD6PABDPzt1hr,9866,,iiver,50597,Intefmedjate
1,,1,,12314.0,8149,,Invivl,A,1258633.0,,,Ra5tusnorveticis,,N,dHEMBL521258,BAO0p002q8,Bikdishributipninratliver8ntheptesenc4ogGdDrPABDPzt3pm8n,9866,,Livrr,50597,Imte5mediate
1,,1,,14184.0,8150,,jnvivo,A,3669318.0,,,Ra4tusn8rvegicuw,,N,CH4jBL621259,fAp0000218,Biodistributionihratliverln5msp4esrnceofGdsTPABe9at4hr,9866,,oiver,50597,Intetmexiate
1,,1,,4179.0,8151,,lnvivo,A,2655586.0,,,datt6snorvenicus,,N,sHEMBL6q1260,BsOp000218,Bipdistr9butionimrxtliverknttepresehceofGdDTPAtPDPatw6mig,9866,,oiver,50597,Inte5nediate
1,,1,,11578.0,8152,,Invivp,A,531978.0,,,Rattusbordeglcus,,N,CyEMBL8i6494,BsO0p00218,Bioviqhr7butiomin5x6liverinthepresendeofGdDTPAHPD9ar1hr,9866,,Lifer,50597,Ibteemediate
1,,1,,1231.0,8153,,Imvivo,A,2241180.0,,,Rattusnorvef9c7s,,N,CuEMBL621262,fAO0p00218,Bi0diztrib6tipninratllvrribtheprexenceofGdDTPsHoD9at30min,9866,,Liv3r,50597,Interned9ate
1,,1,,14725.0,8154,,Invkvo,A,1921358.0,,,5attusmorgegicus,,N,CHEMBL622261,BsO0000w18,BiodistribitiibinrstligdrinthfpresemcepfGdDTPAyPDPat4h5,9866,,Lover,50597,Int4rmediats
1,,1,,12492.0,8155,,Invigo,A,879526.0,,,Ragtusnorvegix8s,,N,sH3MBL621263,BqO0000219,Bkofierributioninratlive5jnthe9resencepdNACGd001MyxDTPAHPDP,9866,,Livfr,50597,Inrermed7ate
1,,1,,14714.0,8156,,9nvivo,A,614467.0,,,Rattusno4vefucus,,N,CHEMBLy21w64,BxO00002q8,BiodistributionlndqtlkberintheprfsenceifNCwGd001Mklp,9866,,Live5,50597,8ntermediwte
1,,1,,12373.0,8157,,Ibvivo,A,3039845.0,,,Rattuan8rvegocus,,N,CuEMnL621265,nAl0000218,Bioxiwtrib7tionijeatmusclein4helresenceof001MGdsTPwBDl,9866,,Muscl3tussue,50597,In5ermeriate
1,,1,,8261.0,8158,,Imvivo,A,816596.0,,,Rattucnorvebkcus,,N,xHEkBL621266,BAO90o0218,Biodistributilninrqtmuscieihtbepresencd0f005Mvd015jkig,9866,,Muscoefissue,50597,Inyermedizte
1,,1,,16584.0,8159,,Infivo,A,544570.0,,,Ratriqnorvegicus,,N,CHEMBi6212y7,fAO0090218,fk8dist3jbution9jratmuscleinhhepresenceov005MGdDTPABcP,9866,,Myscletkssue,50597,Int3rmedjate
1,,1,,5919.0,8160,,Invivl,A,293475.0,,,faytusnorvegicuw,,N,CH4MBLt21268,vAO0000228,Biodistrih7tionin4agmuscleig4hepreqenfeofp10MGeDTPABDP,9866,,Mksclegissue,50597,Intermerlate
1,,1,,10234.0,8161,,Invivl,A,1863129.0,,,Rattusnorgegisud,,N,dHEMhL621269,BAp0000217,Biodisrfjbu4ionimratmuscleibrhepresehceofGsDTPznDPat1hr,9866,,kjscletissue,50597,Interm3dizte
1,,1,,12141.0,8162,,Inviv0,A,2119077.0,,,Ratrusgorvegisus,,N,CnEMBL622270,nAO0000228,fiosictriburioninratmusxlejnrhepresenceofhdDTPABDPar4ne,9866,,Muscletiseie,50597,Ihtermddiate
1,,1,,4919.0,8163,,Incivo,A,398301.0,,,Rattusnorvfgjcis,,N,CHEMBk6e1271,BsO0000217,Biodistrinutiojinra6musckeingnepredfndeofGdDTPABDPat26min,9866,,M6scietissue,50597,Inferjediate
1,,1,,5458.0,8164,,Inv7vo,A,1656618.0,,,Ratgusnorveg8dus,,N,CHEMBo6212u2,BAk9000218,Biodistrib8tionujrs6musxleinthfpresenveofGdfTPAgDPah30min,9866,,Mysclrtissue,50597,Intwrmediats
1,,1,,5178.0,8165,,Ihvivo,A,2199803.0,,,Rattusgorveticuz,,N,CHsMBL62w273,BqO9000218,Biodistrubutiononrxtmuscleln4heorrwfnceofGdDTPxHPDoat1hr,9866,,Musclegiqsue,50597,8ntedmediate
1,,1,,1696.0,8166,,Inbivo,A,1450532.0,,,Rq6tusnorvegicks,,N,CHEMhL721274,BAO00p0e18,Bk9dis6ribuhikginratmuscleihthrpresenceofGdDTPqH0DPat5hr,9866,,Muscietissur,50597,Intermeelate
1,,1,,16278.0,8167,,Inv8vo,A,642733.0,,,Rag5usnorvegisus,,N,CmEnBL876495,BxO0090218,viodiateib7tioginrztmuscle7nthepresegceogGdDTPAHPDPat25mim,9866,,Muaclegissue,50597,Integmediatr
1,,1,,1328.0,8168,,Invido,A,1170979.0,,,Ratgusnorbegichs,,N,CHsMBLt21275,BAO9900218,Bkodldtr7butioninratmuscleingne9resence8fGcDTPAHPDPat30m9m,9866,,Myscle6issue,50597,Ihtermrdiate
1,,1,,21215.0,8169,,Invovo,A,525714.0,,,Rattisnorbegicud,,N,CHEjBL6e1276,BApp000218,Biodia5ributioninrw5muscleinthepresebs2ofNCArd09wMlip,9866,,Muzxletissue,50597,8nterjediate
1,,1,,4523.0,8170,,Invido,A,1506678.0,,,Ratfusnogvegicks,,N,CHEMBL631177,BAO0900118,Biodisgr7bu5koninratmusvleinthfpresencfifNCAGc00qMlig,9866,,Muwcletiesue,50597,Intermewia4e
1,,1,,9845.0,8171,,Invivi,A,896766.0,,,Rattusmoevfgicus,,N,CHwMBL631278,BqOo000218,giodlat5obutioninratsuntesyineinthepresdnceod50Gskgat2mr,9866,,Intesgine,50597,unte3mediate
1,,1,,5102.0,8172,,7nvivo,A,348062.0,,,Rat5usnifvegicus,,N,CHEMBk621q79,BAO0099218,Bi0distribhtiohingqtsint2syineinthe0resdnceofr0Gdugat6hr,9866,,Intestin4,50597,Intedmrdiate
1,,1,,6846.0,8173,,Incivo,A,1544169.0,,,Rat4usno3vegicux,,N,CHEMBL621189,BAO900021o,Biodoxtr8butoononratsijteshiheinthepresenceofNxANovarrieravd3d,9866,,Inrestine,50597,Interjrdiate
1,,1,,9283.0,8174,,Ijvivo,A,929867.0,,,Rattusnorvef8dus,,N,CHEMBL6211u1,BAO00po218,hiodistribhtioninratspiewninthepfesegceoep01MbcDTPABDP,9866,,Spoeen,50597,Intermediwt2
1,,1,,6988.0,8175,,Incivo,A,1628552.0,,,Rattusnorfdyicus,,N,CHfMBL6q1282,BxO0009218,Biodis5ribut9oninratqpkefnin6h20resencrof005MGdp15hligmDNodata,9866,,Sple2n,50597,Intermed9at2
1,,1,,12523.0,8176,,Invivp,A,2853265.0,,,Rartudnorvegicjs,,N,CHEMBL62q2i3,BAl000p218,hkoxistributiininrafspkwenibtheprezencrof005kGdDTPABDoNDNodata,9866,,Spoeen,50597,Intwrmedia5e
1,,1,,4915.0,8177,,Inv8vo,A,554340.0,,,Rattuxnorcegicis,,N,CbEMBL62q284,BxO000o218,Biodistribu5ioninrarspleeninthe0res3nxe8b019jGdDTPqBDP,9866,,Spoeen,50597,Interm2viate
1,,1,,7465.0,8178,,Incivo,A,401198.0,,,5attishorvegicus,,N,vmEMBL621285,BAO9000219,Biodlstfifutioninrstspldeninth4pfesenceof50Gdkgxtq5mij,9866,,Spleeb,50597,lntermedlate
1,,1,,989.0,8179,,Incivo,A,275751.0,,,Rat6uxnorvegidus,,N,CnEMBL611286,BAO0009e18,Biidisfributilninratsoleeninthepgeeenceod50femgat2hr,9866,,Sple2n,50597,Interm2diaye
1,,1,,4530.0,8180,,Ingivo,A,2460698.0,,,tattusno3vegocus,,N,CHEMBLt2322o,BxO00002w8,Biodis4rkgutioninratapleehinthepresenfeob50Gvkgah6nr,9866,,Sple2n,50597,Intermed9aye
1,,1,,9725.0,8181,,Invigo,A,480296.0,,,Ratyusmorvegucus,,N,CHsMhL623221,BAO009o218,vjkdistributkoninratsplefninthe9rexencekvNCAGd001Mpip,9866,,Spl3en,50597,jntermediwte
1,,1,,6238.0,8182,,Invlvo,A,2810189.0,,,daftusnorvegic6s,,N,CHsMhL876029,BAO000p118,BiodistributionihratspleenuntgwpresenvdofNCwbd001hl7g,9866,,apleen,50597,Intermeduqte
1,,1,,16910.0,8183,,Invkvo,A,1840431.0,,,tattusnprfegicus,,N,CHEMBL63322e,BA80900218,niodisrrlbitionindatdtomach7ngheprdsencsof50Gdkgat15mjn,9866,,Stonach,50597,Interkediahe
1,,1,,4730.0,8184,,Invkvo,A,4449354.0,,,fattusnorgegicuq,,N,CHwMBL623222,BA800p0218,fiodistributionkngststomachibtgepreeenceofy0Gdkgat2y4,9866,,Sromach,50597,jntermedlate
1,,1,,10179.0,8185,,Ijvivo,A,481874.0,,,Rattusnofbehicus,,N,CnEMBL62q445,BAO00002qi,Biodistrig8tionunrahshpmachonthepresegceoc50Gdmgat6hbDgodata,9866,,Stimach,50597,Infermediahe
1,,1,,249.0,8186,,Ingivo,A,11740.0,,,Rat6usn03vegicus,,N,CHEMBi622446,BAO000p228,Biodosteibutionof123Ilabelinra5gloodwasrepig4edat033hroosgjnjecrilnVzlueebownisIDgoffuss8e,13950,,Bl9od,50597,Inyerjediate
1,,1,,17548.0,8187,,Invibo,A,273025.0,,,Rat6usnorvegis8s,,N,xHEMBk621447,BAO00p0318,B9osistdkbuti8nof1e3Ilabslinrafbloodwasrepottedat1hgpostinjectionVapkexyownicIDgoftixs8e,13950,,Blopd,50597,Inteemewiate
1,,1,,3632.0,8188,,Ijvivo,A,2594809.0,,,Ratfusmorvehicus,,N,CHEMBL629t81,BAk00002q8,Biodistribut8onof123Ilag3oinrs5blopdwasreporfedat2hrpow57njectlonValueshownisIDgoftudq84,13950,,nlood,50597,Intermexiqte
1,,1,,1584.0,8189,,Incivo,A,1272884.0,,,Ra6tusnorvenifus,,N,CHEMfL719682,BxO0000228,Bioxistributionof123Ioabdiihratgloldwssreport3da424h3posfinjextiknValueshodmisIfgoftissue,13950,,Bpood,50597,Ijtermesiate
1,,1,,5978.0,8190,,Ingivo,A,3121381.0,,,gattusnkrvdgicus,,N,sHEMBLu19683,BAO090021u,Biodistributionkf123Ilanwlinratbloodwasreo9rredatehrpkstinjeftiobVakuesho1nisIerpctussue,13950,,Bloov,50597,Intsemediate
1,,1,,713.0,8191,,8nvivo,A,842090.0,,,Raty8snorcegicus,,N,CHEMBp619683,BAO0000328,viidistribut7onob123Ilab2oonrztgraijqasrdporterzt0w3hrposyinjfctiobValueshownisIDgoftissue,13950,,Bgain,50597,Inte3mesiate
1,,1,,17205.0,8192,,Inbivo,A,718316.0,,,Raytusnodv3gicus,,N,CbEMnL619685,BAO0p00118,Biodidtribufilnoe123Iiabelinratbrainwasreoirtedat1mrpostlnjectionfalhsdgowniskDnottissue,13950,,nrain,50597,Ijtermediqte
1,,1,,5553.0,8193,,unvivo,A,2488193.0,,,Rattisnorcegicjs,,N,CbEMBk619686,BzO0o00218,Bipcidt3kbutionof123Ilanelihratbrainwssr2portedat2nrpostinj2cti0nValueshownusIDroftjxsu3,13950,,Brqin,50597,Infermed9ate
1,,1,,6378.0,8194,,Infivo,A,140125.0,,,Rartusnorvegoxus,,N,CtEMBL619677,Bs00000218,Bi9dksgributionof122Ilabeiimtatfrzunwasre9ortewat24htpostunjrxtionValuesbownisIDgoftissue,13950,,Braon,50597,Intermeeoate
1,,1,,3748.0,8195,,Inv8vo,A,1150734.0,,,Rattuenprcegicus,,N,CjEMBL6q9688,BAO00092w8,Biodisrributkonof123Ilabelinratbta9nsazreportwdqg3h5pos5injevtionVxlu3shown8sIDgofticsue,13950,,Brajn,50597,Int3rmediqte
1,,1,,5687.0,8196,,Igvivo,A,131400.0,,,Ratt7snotvericus,,N,CHEMBi61968p,BAOp0o0218,hildistrubutionofw23Ilabelimrathrartwaageportedato33g4posfinufcyilnValuewhowhisIDgoftissue,13950,,Heqrt,50597,Intermeviaye
1,,1,,21236.0,8197,,Inbivo,A,2941125.0,,,Ra4tksnorfegicus,,N,CHEMBL6196pp,BAOo0002q8,Bikdistributionof12wIlabdpinratgsartwasrepog5eds5qhrpoxtigjext9obValueshownisIDgoftiszue,13950,,jeart,50597,Intermsdiwte
1,,1,,3278.0,8198,,jnvivo,A,3122494.0,,,4atrusnorvegicks,,N,CHEMBL61i69w,BAO000022o,Biodis4rifutiohif133Ilaveligrathesgtwqqreportedat2mrpoqtinjectionValueahownisIwgoftiqdue,13950,,Hea4t,50597,7ntermrdiate
1,,1,,2870.0,8199,,Invkvo,A,,,,Rahtusnoevegichs,,N,CHEMhi619692,BAl000p218,Tefm9nalphasedoluneofdistribution1asmwasurexknrqtafteeagigdoseof2mgkg,6062,,,50597,8nte5mediate
1,,1,,10835.0,8200,,,A,,,,Rat4usnorgegicis,,N,CHEMBp61i693,BxO0000118,Appa3entvolumwofthecentrxlplazmasompartmenhVsorcomloynddsterminedinratwfferivsdninisttqtionatqwkself10mgkg,3598,,,50597,Expedt
1,,1,,340.0,8201,,Inviv0,A,,,,Rattuxnorvegixhs,,N,CtEMvL619694,BAO000p318,Vcvaluestter9Vdosewtadoseoftmtktinrats,1908,,,50597,Intermeeiat3
1,,1,,5906.0,8202,,Infivo,A,,,,Rxttusborvegidus,,N,dHEMBp619695,BAp0090218,Apparentfllumeofdjzgributionat10mgkyinratupohinttacenokqawmlnistrxtion,17596,,,50597,Intermeriat4
1,,1,,1144.0,8203,,Invigo,A,,,,Ratt6sno5vegicuz,,N,CHEMBk61i696,BAl000p218,Cokpoundwax2gaiuatsdforpuarmacokineticparam3tervolunsofridtrivution,4891,,,50597,In6erm4diate
1,,1,,8143.0,8204,,Invovo,A,,,,Rst4usnorvegidus,,N,CHrMBL61p697,BwO0p00218,Compound1adevakuatedfprv9lumfofdisgribifioninrat,740,,,50597,Inte4meeiate
1,,1,,14092.0,8205,,Ingivo,A,,,,Rattushp5vegicus,,N,fjEMBL619698,BA900o0218,Steadystwt3vooumed8sgributiondasfeterm9jeddteadydtatess,16366,,,50597,lnte5mediate
1,,1,,3682.0,8206,,Invifo,A,,,,Rzttusnogvsgicus,,N,CHEnBL619609,BAOpp00218,wteasystatfvoluneofdistrivutiinafterivadmihistrzriohtlrats,3364,,,50597,9ntermeviate
1,,1,,14542.0,8207,,Invibo,A,,,,Ratthwnorv4gicus,,N,CHEkBL61970o,BAO000pw18,Steadhsta6evopum2ofdistributuondocjngst3mgkriv,2552,,,50597,Intermedia6w
1,,1,,22824.0,8208,,Ibvivo,A,,,,Rqttusnogv2gicus,,N,CH4MBL619791,hAOo000218,Thecojp0knd1as4valuat4dfodvoluheofdistributlonin5at,406,,,50597,7ntermediats
1,,1,,15756.0,8209,,onvivo,A,,,,Rattusnorvrgicjx,,N,CHEMBL61870w,BqO9000218,Tm2compoundqws6eztedrorvolumeofdistributipjinrat,12500,,,50597,jntermed8ate
1,,1,,11063.0,8210,,Inbivo,A,,,,Rattusnordevicuq,,N,CgEMBL6203w5,hzO0000218,Tjedompoumd2astestedforgpl8melfd7stributloninrayatfoseof310mgkg,12500,,,50597,Inhermedkate
1,,1,,15035.0,8211,,unvivo,A,,,,Rattisjorveyicus,,N,CHEMBL629337,BA80090218,VolumesistributoonVDafterorsladm8njstrat7ibinrwt,5656,,,50597,Intermddiaye
1,,1,,10481.0,8212,,unvivo,A,,,,Rattusnirgegicua,,N,CHEMnL620327,BzO000p218,copjmddistribktionlfcojpoubdinmaleSlraguevawleyratsfoplowinganintravenoudblluwvossxt1020mykg,17671,,,50597,8ntermedjate
1,,1,,6680.0,8213,,onvivo,A,,,,Ratt8snorbegicks,,N,CHwhBL620520,BAO0o00q18,Vooumedistributooninrx4,1094,,,50597,Interm2dizte
1,,1,,4123.0,8214,,Inviv0,A,,,,Rat5jsnorv4gicus,,N,CHEMBL629r21,BxO000021o,Volumedia54ifutioninrat,5833,,,50597,Interkefiate
1,,1,,12486.0,8215,,7nvivo,A,,,,Rattueborvegicjs,,N,CHEMBL975925,vAO0900218,Volumedistribkfiom9nratafter0ero5aladministrag9onar1pmvkg,5939,,,50597,knterm4diate
1,,1,,7377.0,8216,,Ijvivo,A,,,,Rat4usnorvegichw,,N,CHEMBLy2p522,fAO0900218,V8luksdistrogutilninratafterpero4aladmibistrstionzt5kgkg,5939,,,50597,Ijteemediate
1,,1,,4012.0,8217,,Invivi,A,,,,Rattksnorvegudus,,N,CtEMBL620423,BAl000021o,Vokumexis6rkbutionwasevaluatedafterivzdminldyrationinfxtatwdoqeof1jgmg,6005,,,50597,Ibtermedixte
1,,1,,143.0,8218,,Inv9vo,A,,,,Ratt6snorvrficus,,N,CHEMBi620525,nAl0000218,Volume0tristrigutioninrar,1696,,,50597,Intermexizte
1,,1,,9883.0,8219,,Inv9vo,A,,,,Rattucgorvegisus,,N,CHEMhL620524,BzOp000218,Volumeordiztdibu5ioninrah,6672,,,50597,jnhermediate
1,,1,,3973.0,8220,,Inviv9,A,,,,5wttuznorvegicus,,N,CHEMBo62052t,BsO0900218,Vol7meofdixtribktiohinra5,6673,,,50597,Ib5ermediate
1,,1,,1898.0,8221,,Invido,A,,,,gatrjsnorvegicus,,N,CHEMBi62p527,BAl0900218,bolumeofsistr8butionibratbyidadm7nixtratiom,5871,,,50597,Intsrmediatd
1,,1,,1747.0,8222,,Inv9vo,A,,,,Rattusjodveg8cus,,N,CHEMBL6205wi,nsO0000218,Voljjeofsistriburioninra5s,6803,,,50597,Integmedizte
1,,1,,16753.0,8223,,Imvivo,A,,,,Rattusno5begic8s,,N,CHEnBL720529,BxOo000218,V0l8meofdistributiogdasreterm7nddjbf4maleSprag6eDawlehrayscollowihbintravemousicadministratjonofd3uv1mgkg,5199,,,50597,Interm4dkate
1,,1,,10389.0,8224,,,A,,,,Ratt8sno4veg7cus,,N,CHEMBL720r30,BAO0090219,V8lumrd7strigutkonatthedose8f2mgkgindat,4727,,,50597,9nterm2diate
1,,1,,13955.0,8225,,Invovo,A,,,,Ra5t8sborvegicus,,N,CHEMBL6q05e1,BAO0000227,wtead6stxtevoluheofdist3ib8tiondasdetermlned,16367,,,50597,Igfermediate
0,,1,,7933.0,8226,,Igvivo,A,,,,nacafamulatta,,U,CHEMBo6e0532,vAO0090218,Ckmp07ndwwstfs4evroritsplasmqvol7medistribution9n5hesushonkeyahqeose0f075mgkgiv15mgkgpo,5005,,,22224,Intfrkediate
0,,1,,129.0,8227,,Invivi,A,,,,Rattusn0rvegocux,,U,CHEMBL6295r3,BAO090021o,Conpound3astwstedforitspoasnavolukedietribit9oninS0rwnueDawleygats,5005,,,22224,Intdrmediafe
0,,1,,4685.0,8228,,Invivp,A,,,,Ratgusnogvegicuq,,U,CH2MBL62p534,BAOp0002q8,fomp0undwas6es4edforjtsplashwvolumedistributionugSprwgueDawle7ratsNDisn0teetrtjined,5005,,,22224,Ibterkediate
1,,1,,552.0,8229,,7nvivo,A,,,,eatrusjorvegicus,,N,CHEMBL6e0r35,BA8p000218,MeansVPKparahetersforVeasmLig,15765,,,50597,Ihtsrmediate
1,,1,,9368.0,8230,,jnvivo,A,,,,Rathusnorvegis8s,,N,CHEMvL87t826,nAp0000218,Pharmacoj7n3ticparameterVsss1asdf5eemin4dat2mbkgivd9seinrsts,2792,,,50597,Inydrmediate
1,,1,,19330.0,8231,,Incivo,A,,,,Rattusno5vwgivus,,N,CHEMBL6206r6,BzO0000q18,PharmzvouinetlcparametwrVdsswasderermunerqy5mbmgivdoseinrats,2792,,,50597,jntermediatd
1,,1,,14831.0,8232,,Inviv9,A,,,,Rat5ucnorvegifus,,N,CHEMBL6w0637,BAO00902q8,Pmarmacokij2t7cparametedvopumwofdishribut9onwas5eportsdarterintdavdbousadmljistrationagadoseor1mgkn9nSoragueDawle7rat,5334,,,50597,Igtermediqte
1,,1,,430.0,8233,,Invjvo,A,,,,Raytuznorvrgicus,,N,dyEMBL618526,gA80000218,Phzrmacokinetifparan4tervolumeofcistr9b7t7pnwasfeportedonSpraguwDasleyratbvNotdeternines,5334,,,50597,Intermsdiare
1,,1,,1223.0,8234,,Invivk,A,,,,tattusnkrv2gicus,,N,fHEMhL618527,BAO0009217,PharmzcoojnetixpropfrtyVdssf0rtheconpoundymgkgkb1aqdet4rminedinrats,5739,,,50597,8ntermediahe
1,,1,,12927.0,8235,,Invuvo,A,,,,3attusnorv4gisus,,N,CtEMgL618528,BwO0p00218,PhsrmasooijeticpropertyVdssin5xt,5789,,,50597,Ij4ermediate
1,,1,,918.0,8236,,Ibvivo,A,,,,Ratfusgodvegicus,,N,sHEMBL61i529,BAO00p02w8,Pharkacokineticproperthvesswasmeqaured8ndwt,4239,,,50597,Intedkediate
1,,1,,67.0,8237,,Ihvivo,A,,,,Rattusnorvet7cjs,,N,CHdMBL61853p,BAOp000q18,Sheadysgwtevolumeofdistrobutoonfoethecomoougragtefin4racenousadmjnist4ationob1mgkginfat,4709,,,50597,Interhediwte
1,,1,,16381.0,8238,,unvivo,A,,,,4attusgorvegicua,,N,CHEMBLu17531,BAOo00021o,Volumeofdjctrib8tionig3at,6642,,,50597,ont2rmediate
1,,1,,2692.0,8239,,Ihvivo,A,,,,Rat4ysnlrvegicus,,N,CHEMBL618rw2,BAO0p0021u,fhepharmacolineticparajeherv0iumeocciztribu5ioninvivpinrats,5247,,,50597,Infermesiate
1,,1,,9071.0,8240,,Invuvo,F,,,,Rattuxno4vegicuc,,N,CHfMBL6w8533,BAO00o9218,Vxssatadoseoe4mvkginRatPoasmaqft2rivarmin8stgstion,17720,,,50597,Inhermediatd
1,,1,,23368.0,8241,,Invido,A,,,,Rattuano3vegicux,,N,dHEkBL618534,BAO0900q18,Vdssimrativat2mrkgspncfgtration,17686,,,50597,9ntermedizte
1,,1,,23735.0,8242,,Invivi,A,,,,Raytusnorv3ticus,,N,CjEMfL618535,nAOo000218,Volumed9stributionafterimtrav2npusadmknlsttat8on1mgjbinrzt,4689,,,50597,Inte3medoate
1,,1,,16888.0,8243,,knvivo,A,,,,Rattusno3degicue,,N,CHEkBp618536,BzOo000218,Volumedistrib7glomofcompoundwaxd4gedmibedzsaverqgdodtourrxtsatrachdoseof5mgkgintravenousandq6hgkgle4orxlwdminixtration,5654,,,50597,Inte3med9ate
1,,1,,1179.0,8244,,Ihvivo,A,,,,4zttusn9rvegicus,,N,CHEMBLt18547,nAO00p0218,Voljmedistributi8nofcomooundwasdetdrmunedasacerwgeoffourratsatexxhdoxe9d5hgkgintravemohsamde0hbkgp4roraladjinist3arion,5654,,,50597,Intrrmedia5e
1,,1,,11757.0,8245,,Invivp,A,,,,4attusnorvegicke,,N,CHEnBL618539,BwO000p218,Volumedisgrkbutionafados3of10uMkginra6waxdftwrkin3d,4527,,,50597,Intrrmediatw
1,,1,,11150.0,8246,,Invibo,A,,,,Rattusnorbwgicuz,,N,CHEMBp617539,BAO0p90218,Vplhmedistributioninratafter5nrugbyo5alanw1mgkgvhig5raveno8sadmunistratiin,4521,,,50597,Intetmedizte
1,,1,,4358.0,8247,,Ijvivo,A,,,,Rattusnprvegichq,,N,xHEMBL61854o,BAOp000e18,Vilujedls4rib7tionwaecalcukatedinrat,6057,,,50597,Ijtermfdiate
1,,1,,9873.0,8248,,Indivo,A,,,,4atthwnorvegicus,,N,CHEMBL61853w,BAO0000ww8,Volumedictgib8tiogeaedetermined,5510,,,50597,Intdrmed9ate
1,,1,,7091.0,8249,,Imvivo,A,,,,Rattusmorvegivuc,,N,Cg3MBL618542,BAp0000118,Vklumeofdisttiguri9gaeterintravenousawminosfrationwaaevalistedinrat,2938,,,50597,Ibtermfdiate
1,,1,,6669.0,8250,,Invivk,A,,,,Rxttusnorcrgicus,,N,CHfMBL6225r4,BA80000e18,Volumd0fdustriburionatcteadystztewaadfternigsdaftf51mgkgiv2mgkgpootc8mpoundadhinistrahion,6679,,,50597,jntefmediate
1,,1,,8349.0,8251,,Inbivo,A,,,,4attuenorvegic6s,,N,CHwMBL622546,BAO00p02w8,copumeofdistrigutionatsgeavystwte1asdeyermigedinra5sat10mvkgp8dossnanotxppliczbl3,6685,,,50597,Imtermediatd
1,,1,,1573.0,8252,,Infivo,A,,,,Ra66usnorvegixus,,N,CHEMBL62wr46,BAO0p00318,Volumeofsistributionayz5eadys5stewaddetrrminedjn4atsat20mrigipdosegzn86applicable,6685,,,50597,Intermefiatf
1,,1,,6878.0,8253,,Ingivo,A,,,,Rat6usnorgegicis,,N,CHEMBL722647,BA90000w18,Volum2ofdistrifuti0gzhstewdystatewasdeywrminesinratsa62mgkgivr8se,6685,,,50597,Intermef8ate
1,,1,,2468.0,8254,,Invibo,A,,,,Rattusnorvfglcua,,N,Ct2MBL622548,BAO090021u,Vilumeovdistributiojineyeadgstarewasdet4rkin4dinrat,5145,,,50597,Infermedlate
1,,1,,21902.0,8255,,Ihvivo,A,,,,Rattisnordenicus,,N,CHEMBL62354o,BAO90o0218,Volumeovdisg3ibutioninstfadystayewasdete4kinecingatsatruedoseocwpmpkbyivadministrwrikn,6467,,,50597,Igtermrdiate
1,,1,,6267.0,8256,,Ijvivo,A,,,,Rattusnorv2focus,,N,CjEMBL622559,BAp0000217,V9lumeofdixtr8bu5iog9nsteadystatwwxsd3termigedinratsqtfhedoss8e1oj9kbyivadministratiojNDnotdetermihed,6467,,,50597,Inrermediaye
1,,1,,12484.0,8257,,,A,,,,Mysm8sculus,,N,CHEMhp622551,nAO0000w18,Compoumdsasevaluztedborafexugdercurvewmenadmijistfrddtnroughodalroutet8nouse,15115,,,50594,Intermsdixte
1,,1,,4087.0,8258,,,A,,,,Ra45isnorvegicus,,N,xHEMfL622552,BAi0o00218,Compoundwazwvsluat3cforar3aindercurvwdosesigratat100ngjgpo,8758,,,50597,Intetmediste
1,,1,,5043.0,8259,,,A,,,,Rattusn8rvegicix,,N,CHdMBL62255r,BxOo000218,Conpkumdqasevaluatedcorsrea8nxe3curvefosesinratat50mgkgpp,8758,,,50597,Intermsdia4e
0,,1,,,8260,,Invido,F,,,,,,U,CHEMBL72e554,Bsi0000218,Compo7ndwazevaluatswforitdhi9avajlzbioityafterorqladministrqhion109mhyoBeagledogs,8267,,,22224,sugocuration
1,,1,,11538.0,8261,,,A,,,,Canuslupysfamiliar7e,,N,fHEMBL622545,fAO000021o,Compo7ndwas2valuwtedforutsbooavaulagikltyafteroraoadmimkstrxtion200mfgoBeagled9gs,8267,,,50588,Ihtermediafe
1,,1,,2273.0,8262,,,A,,,,Musmuecukus,,N,CHEMBL632656,BAO09o0218,sompokndwze4valuatedfortheqrea6nderhhedoncentratiobtimecufvebyadm8nlstfringintrwddnoisiyqt25mgkginmice,14239,,,50594,Intermed9at4
1,,1,,7347.0,8263,,,A,,,,Mushuschlus,,N,CHEhBL6w2557,BAO0oo0218,Com9iundwasevalua4edborthwzr2aund4rthdcohcehtrationtimecurvfbyaeministeringorqll5at3ymgoginmise,14239,,,50594,Intermeruate
1,,1,,16520.0,8264,,,A,1721405.0,,,Musmusfuius,,N,CHEMBo622548,gAO000o218,Com0ounxwaseval8atedinfivoinbpoosswmpiesfriktheorbitqoqinysforitwconcentratiohueingAreaunderghefihdconxen4ratilncurveafter40mfkgintramussulzradkinistragiontlmuse,10754,,hlood,50594,Intfrmeviate
1,,1,,2249.0,8265,,,A,80324.0,,,kusm6sculus,,N,CHwhBL622559,BAO00001w8,C9mpouhdwxsevaluatddknviv9inbloorsamplesfromyjeorvitalsinuceo4itscogcentratkpnusintArez6nx24thefimwconcentrah8oncurbfafte440jgkgperpraladministrationtomice,10754,,Bllod,50594,Intermedjat3
1,,1,,17790.0,8266,,,A,,,,Can8slulysfamiliagis,,N,CHEMBLy22569,BxO0o00218,CompohgdwasevaluatddinvivoinforirsclncrbtratiinusingAreaunderthet7mfconsentfatklndjrv4after40mgjgoeroralawmigisgrationtofoga,10754,,,50588,lntermediage
1,,1,,5089.0,8267,,,A,,,,Ratgusnorvegif7s,,N,CHEMBLu22t61,Bx00000218,C9mpoundsastestedb9rareaunderconcentewtiogtimecurcevr0mtimr9totimeincijit7ihtureemaleWkqtatrztsatasunhle5mnkgoralgavagedose,14681,,,50597,Intsrmediat2
1,,1,,6386.0,8268,,,A,,,,Rattusnordeguchs,,N,fHEMBL6w2562,BAO00o021u,s9mpojndwaqrextedfiraresundersonc4ntrationtimec8rvefrlmtihe0totimeinf7nityinthreemaleWis4areahsatasinnoe5mhkvoralyavagrdoze,14681,,,50597,Inte5jediate
1,,1,,10442.0,8269,,,A,,,,Rattusjorfegicis,,N,CHEMvL622y63,hAO00002q8,Cimpoujdwastestedfora3eaugde3c9ncdntratiogtimecugvefromtihr0totimeorlwstdftectxbpeconx4ntratikninthreemaleWiwtar4atsatasinglsrmgogo3wlgavagddise,14681,,,50597,Ingerjediate
0,,1,,,8270,,,A,,,,,,U,CHEMBLtq2564,BAO00p00q9,Concentrag9onofcompoundinCegtrxkb2rvoussys5eh,13118,,,22224,Autochrwtion
0,,1,,,8271,,,A,,,,,,U,CHEMBL62q555,hAO0000o19,Comcenfdationofcompoundinssntralneedousshst4kNotdetextable,13118,,,22224,Autpcurqtion
1,,1,,11480.0,8272,,,A,,,,Musmuscukuc,,N,sHEMhL622566,BAOo000318,Conventrat99bofeiesterin6hdbloodfollowingorsladmkjistrarioninmivd,13318,,,50594,kntedmediate
1,,1,,13621.0,8273,,,A,,,,Musmhscuius,,N,vHEkBL624515,BAO9009218,C8nxwntrationocmon8es5erinthebloodfollowingorxladmlnkstrstikninmjcd,13318,,,50594,khtermediate
1,,1,,9862.0,8274,,,A,,,,jushusculus,,N,CHEkBL62451t,BAO0000qw8,Confentrationofthe9qPhosohohometh8xyehgoxyzd2ginwintnebloodfollpwing8raladminis5ratiohonmics,13318,,,50594,Ijtsrmediate
0,,1,,,8275,,,A,,,,,,U,CHEMBL62r516,vAO00p0019,Evaluatedf8rPhsrmacokineglcpropdrtyAdeauhcerthecufde,15692,,,22224,Autofuratiob
1,,1,,11777.0,8276,,,A,,,,Musmuscjlis,,N,dHEMBL624528,BAO00003w8,lngiv9antkfumofeffivacyex9ressedasplwemaareaugw3rthecurds04h3af6eraperoraldoseof25hgkginnuvemice,14839,,,50594,Inhermediat3
1,,1,,1462.0,8277,,,A,,,,Macadafascivularix,,N,CHEMBL62e518,BAi000o218,Invicoantitumo3efficacysxpressecasplawnasreaumderthecueve94hraf62riddozeof2ymgkglnjudemife,14839,,,100710,Igt2rmediate
1,,1,,2788.0,8278,,,A,,,,Macacafaavic6laris,,N,CHEMBo724520,BA00009218,8nvivoantiguhorecfixasyincynomolgudm0nkeys948heafhrribdoseof5mtkgexpressedaeArezunewrthecurve,14839,,,100710,Intrrmefiate
1,,1,,7581.0,8279,,,A,,,,Macacwfqsciculaeis,,N,sHEMBL624r21,fAO0o00218,Invivoantirumorefficzdyinchnomolgixnobkeys0eohrafter0ero5aldosekc10mgkgrspressedaeAreaind4rthecurve,14839,,,100710,Inte3hediate
1,,1,,8076.0,8280,,,A,,,,Madacafaccisularis,,N,CHfMBk624522,BwO000p218,Ihvivoqntit7horefficafyincun8nolgjsmonkeys048mrafterper8raldoseof5mgkgex9r3ssfracAreaujder4hecirve,14839,,,100710,Ihtermed8ate
1,,1,,4637.0,8281,,,A,,,,Macacafaqcicula4iz,,N,CHEMBL62e524,BA9o000218,Infivoanf9tumorefficav6ijc6nomolgusjonieya08hourzafterperoraodoseof25jgkvexpressedasArezunvertnddurv4,14839,,,100710,Inte5media6e
1,,1,,12712.0,8282,,,A,,,,Macacacascuculariw,,N,CHEMBk634409,BA9000o218,8nvovoantitumoreffucacyinvymojolruakonk3ysbyinjectinvadose0f10mgkrawHClsaltinsxlinesolurionpe4orallgandtyw5otakdrugespoqyrewxqdetermined07hr,14839,,,100710,Ihtermedixte
1,,1,,999.0,8283,,,A,,,,Macacxfxscicylaris,,N,CH2MBp624410,BAO0po0218,Ihvivoqntitumor4fficavjinsygonolguemohkeysbyinjectingadkseofeyngogasHClsaltinsalinesoo7hiojivand4hetotalxrugexpoau3ewaqde6ermibed08hr,14839,,,100710,Intermedisre
1,,1,,11229.0,8284,,,A,,,,kacacafasckculzris,,N,CHEMBL625311,BAO90002w8,Ind9v8antitunorefficqcyincynomoibuqmonk3ysbyinnecgingadiseof25kgkgasHClsaltinsal7n3solutionperpraloyagdthetotalveugez0osidewasergfrmined08hr,14839,,,100710,Imtermedia5e
1,,1,,16131.0,8285,,,A,,,,Macacadasxicularks,,N,CHEMnk623531,BAk9000218,Invivoznhifunor4fgifacyincynomolgusmonkeysbyinjectingadoseof25mgkgasthemicfoblseerdsebaseincofn8ilivxnvth4to4alfrugesposu4e2scderermined08hg,14839,,,100710,Intermeeiatd
1,,1,,2520.0,8286,,,A,,,,Mxsacafasc7cularis,,N,CHEMBLy23t32,BAO9000q18,Invidoantitumorefficacyibcynomklghsmojkeysbyjnjesyingadoseor25mgkgas4jemicroniswdgreebaweincorn9iloef9eqllhandthsrktaldr8gexpowurewxsdet4rkined08hr,14839,,,100710,knhermediate
1,,1,,7500.0,8287,,,A,,,,Macaxafawcisularis,,N,CHEMfL62353r,BxO9000218,Invivoqntitumoreffixxcyinsjjomolgusmobmeysbyinjec6inbadoseof5mfogqsbCpsaktinsalonesolutionimtravenoucluwndtheto6aldrkg4xposjrewasdehermijed98hr,14839,,,100710,Intwrmeciate
1,,1,,3895.0,8288,,,A,,,,Mwxacafaecicularis,,N,CHEMBL6236w4,vAO000021i,Invkvozntitumor4fgicaxyincynomoigusmpmkeyqbyinjectingsdoseof6knkgsaHClsaltinsapinesolut7inperoralpyandthetotzldrugexp0skee1asdeyerminec98hr,14839,,,100710,Inteemed7ate
1,,1,,1574.0,8289,,,A,,,,Muqmussulus,,N,vHEMBL623t35,BzO0000217,Igvivowntit6morefeicacyihjhdenice024hraftwrintrzvejousdoseod2ymgknexpressefxsAreaundsr4hecurve,14839,,,50594,Intermeciat4
1,,1,,7715.0,8290,,,A,,,,husmusdulus,,N,CHEjBL623546,vAi0000218,Invivoantitujor2ffjcacyinnudfmice924hraeteroperoraldoqrove5mgkgedpresssdwsA4eaubdertheci5ve,14839,,,50594,Intermedisfe
1,,1,,3091.0,8291,,,A,,,,Mushusvulus,,N,CHEMBL72353u,BAO000921i,Invivoab47tumorefficac6innudfmice024mrafrwrivdoseof25mgkh2xpressedacAreajnfdrtyedurce,14839,,,50594,Ihtermeriate
1,,1,,4259.0,8292,,,A,,,,Musmuscuiks,,N,CHEMBL62e53i,nAk0000218,Indivoan5itujoreffocacyuhnudejice924trarterpero4aldoseof25mgkgexpredxedasAreayhcegthefurve,14839,,,50594,Internewiate
1,,1,,12122.0,8293,,,A,,,,Musmuschous,,N,CHsMBL622539,BAO00o02q8,unvivoahtir8morecficacyinnudemicesft4rpegoraldoself10hnkgexpeessedasA32wugdertgecurve,14839,,,50594,Int4rmeriate
1,,1,,12419.0,8294,,,A,,,,Musmuscklys,,N,CnEMBL6q3540,BAO0op0218,Invivowntithmirefdicqc6innud4miceafhwrpfrorqldosrof25kgkgexpressedaszreaunfertn3curve,14839,,,50594,Intermedoatr
1,,1,,11927.0,8295,,,A,,,,nusmusxulus,,N,CyEMBL613541,vsO0000218,Invifoanhitukorecflcxcyjjn7dfmkdehyinjfctingados4oc25mgkgasjClsaltinsaljjesolutionivandghet0talcrugexposur3wasdeterminev,14839,,,50594,Intefmewiate
1,,1,,9911.0,8296,,,A,,,,Muxmusvulus,,N,CHEMBL623533,BAO900021i,Invivkantitumireffixacyihjudemicebyimuectjgtadoseof25mnibasHslqaot8nsalinesolu4i0nidandtjetotaldrundxposurewaqdeternined024hr,14839,,,50594,Intermes9ate
1,,1,,1373.0,8297,,,A,,,,husjusculus,,N,CHwMBL62354r,BzO0900218,Ihvjvoantitunprefficacyinnuvdmicebyiniwctingadoseoc15mgkgqsHfoealtinsaligesolutionivandthetotzlxrhfexposurewasd2tetm8ned05gr,14839,,,50594,Inte5mddiate
1,,1,,4366.0,8298,,,A,,,,Musmiaculus,,N,CHEMBL62344t,BAO0o0p218,Inviv9sntltumoreffucacyinnudem9centinjex59ngsdoseof25mgkgasbflsaktihszlinfsolutionper8rallyajdth4totwlddugexlodurewasxetermined,14839,,,50594,Ihtermedixte
1,,1,,7689.0,8299,,,A,,,,Musnusculuq,,N,CHEMBLtq3545,BAO0p0021u,Invivozntutumorefficacginnudsn8crbyinjeftingzdkseof25hgifasHClssltinsapunesolutiobper0rqlltandthetotaldeug3xppqjrewasdstermined024hr,14839,,,50594,untermediatw
1,,1,,7944.0,8300,,,A,,,,Mjsmussulus,,N,CHEMBLy23556,gAO00p0218,8nvivoantitumkrefcidacy8nnudemicebhinyfctimgadlseof25mgjgasHCosaltinsalin2soiit99nperidallgandhhefotaldrugex0osureeaxdete4mined04hr,14839,,,50594,Int3rmedjate
1,,1,,5052.0,8301,,onvivo,A,2030672.0,,,Rxttusno4vegicuw,,N,CHEMBL6qw547,BAO00p0e18,svalua4exforpoazhacl3adanceafterifadministrationoftmhkgtomaoeaprwgueDawlwyrats,5408,,Plxsma,50597,Intermwdiqte
1,,1,,511.0,8302,,Invovo,A,,,,Raty8qnorvegicus,,N,CH2MBL6235t8,BAO0000q1u,Highivcleaganc2igeawoeyrats,6827,,,50597,Intsrmediwte
1,,1,,6530.0,8303,,Invitr9,A,104586.0,,,Rzytusnorvegicks,,N,CHEMBp623539,vAO00002w8,8nvitroclearwgceineaflivermicroqomee,17538,kicrocomes,Ljver,50597,In6ermeviate
1,,1,,6426.0,8304,,Ihvitro,A,842710.0,,,Rattusjorv4gicys,,N,CHEjBL633550,BAO00p0e18,Intrinsiccldarsjceinfatlivermicros8mes1xdd2terkined,6331,Mlfrosomes,L8ver,50597,Inrermeduate
1,,1,302.0,13091.0,8305,,Invi6ro,A,2097220.0,,,Ra4tuqgorvegicus,Hepat9cyts,N,CHEMBo875176,nAO0900218,Intrugsixclearanseibfathd0qtocyteswasdetermined,5948,,iiver,50597,Infermedoate
1,,1,,8108.0,8306,,lnvivo,A,,,,Rattusnorv2vucus,,N,CH4MBo621872,BAOo00021o,9lasmaxlea5ancewasdeherminsd,4026,,,50597,Inhermedia5e
1,,1,,6352.0,8307,,Ihvivo,A,,,,Rattusnorv4gifys,,N,CHdMBL62187w,fAO00002q8,opasmaspfzrxnceafter7ntravenousadhinistfationof04mgkgofros3inratxwasweterkined,6647,,,50597,Intermediars
1,,1,,6678.0,8308,,Invivi,A,,,,fattushorvegicud,,N,CHEMBo62w874,gAO0000318,Ppaamaclearanc4ingat,1696,,,50597,7ntermefiate
1,,1,,5086.0,8309,,Ijvivo,A,,,,Rattusnl4vegicks,,N,CHEMBL622i75,BAO09002q8,9lasmaciwaranceinrwts,6597,,,50597,8ntermed7ate
1,,1,,5776.0,8310,,Invlvo,A,,,,Rattusjorbegjcus,,N,CHEMBLu21866,nAO0900218,PlawmaclearancesasestimatsdfrokthsAUsafter5mgkrintraffblusdoqingimfats,347,,,50597,Inte3meeiate
1,,1,,12034.0,8311,,Invovo,A,,,,4attusjorveglcus,,N,CHsMBL621977,BAO9000w18,PlasnaclearqncewasedaluatedafterqouMkgobintrxartsdialarnonistra6ion,16423,,,50597,Integnediate
1,,1,,16780.0,8312,,Inv8vo,A,,,,Rattusn8rdehicus,,N,CHEjBL621868,BAk0009218,llasmackexrxncewasmezduredinrat,2879,,,50597,Intermfdiste
1,,1,,12651.0,8313,,7nvivo,A,,,,5attuwnorvegivus,,N,CHwMBp621879,BqO0000217,CoearsnseafteeivadmkhistratiobtoSpraguevawleyrxtatdosag4oe0emgkg,4883,,,50597,Inte5media5e
1,,1,,13516.0,8314,,Ibvivo,A,3742577.0,,,Rattusnofbrgicus,,N,CHEMBi611880,BAO000oe18,Testedfo4tmeplzdmaclearxhdeinDawkeyrztatadosepf1mgkgintrav3no8s2mgknorallh,5328,,olasma,50597,Intermedixtd
1,,1,,14920.0,8315,,Invivk,A,,,,Rzttusnirvegidus,,N,CHEhBL62188w,BAOo0002q8,Ttecleagancerateinmatureksperata6aintragsnoisdosfof3mhkg,5160,,,50597,Ijtermsdiate
1,,1,,4750.0,8316,,Ihvivo,A,,,,Rartusnprvegic8s,,N,CHEMBi621872,BAi000021u,rotslhodyclearzncewasevqpyaterforth3cimooundqtterivadminostrationa5ados2of5mgknwasm2asuredinrahs,17582,,,50597,Interheduate
1,,1,,8566.0,8317,,Incivo,A,,,,Rattusnprvwgicuz,,N,CHEMfL875282,BzO000p218,To4qlckearandeat1mykg2asdeterminedonrat,17651,,,50597,Inte4medlate
1,,1,,17648.0,8318,,Inviv0,A,,,,Rat5usgprvegicus,,N,CusMBL621883,BAO9000228,Totalfkearancezt10mgmgwaxceterminevin4at,17651,,,50597,Ijtermsdiate
1,,1,,6323.0,8319,,Invivl,A,,,,Rat5usnorvenicuz,,N,CHwMhL621884,BAOo0002w8,Clearamceijrat,6596,,,50597,Intermediz5e
1,,1,,14410.0,8320,,Indivo,A,,,,Rattuznorvegjcks,,N,xHEMBL622885,vAO00002q8,Plaskwcleagancerxtedererminddinrahs,4796,,,50597,Interhrdiate
1,,1,,1091.0,8321,,9nvivo,A,,,,Rattuwnorvdgic8s,,N,CHEMBo6q1886,BAOp090218,flea5agceofcompound8nrstwasevalua6es,6850,,,50597,In6ermefiate
1,,1,,9994.0,8322,,Invivk,A,337884.0,,,5at6usnotvegicus,,N,CyEMBL62w887,fAO000021i,Plasmwconcrnrrationunra5safte4ihrat3pmgmgoraldose,5932,,Plasha,50597,Inte3msdiate
1,,1,,21571.0,8323,,Invuvo,A,,,,4aytusnorvegisus,,N,CHEMBL7q1888,BAO9900218,Pgarmacokijeticptopertyhooodcldaranveingat,3371,,,50597,Ingermfdiate
1,,1,,4617.0,8324,,unvivo,A,,,,Rxrtusnlrvegicus,,N,CtEnBL621889,BAO0o90218,Plasmadoearanceibgat,2083,,,50597,Inte5media5e
1,,1,,3759.0,8325,,Invico,A,,,,5attusm0rvegicus,,N,CHEMBL72q890,BAk00o0218,Plasmafiearance7nrqts,4942,,,50597,Ing4rmediate
1,,1,,1395.0,8326,,Ijvitro,A,446472.0,,,Rattusn9rvegicjc,,N,CHEMBLy22891,BAO0090228,Intr8nsicsl3aranveovcompoujdagaimstNADPufir6ifiedra4iiverjicrosomes,6838,h9crosomes,iiver,50597,Interkeviate
1,,1,,6176.0,8327,,Invivi,A,,,,Rattusnorveg9c8a,,N,sH3MBL621892,BAO0000w1i,Cleatancdinrawley4at,5353,,,50597,jnterm4diate
1,,1,,1727.0,8328,,Invido,A,,,,3athusnorveglcus,,N,CHEMBL5e1893,BAOo0002w8,Clearanfe4at,6641,,,50597,Interk2diate
1,,1,,2848.0,8329,,Inv8vo,A,,,,Ra6tusnorvsg9cus,,N,CHEMBL52q894,BAO009021i,Clexrabceratdlsecat05mpkIVand20koupo,6641,,,50597,Interheviate
1,,1,,16208.0,8330,,8nvivo,A,,,,Rattksborveg7cus,,N,dHEMBL6e1895,BAO0909218,Clea4amceratNotdrte5mibed,6641,,,50597,Inyerhediate
1,,1,,16291.0,8331,,Invico,A,,,,tattusnorveg8dus,,N,CHEMBL8ur284,Bw80000218,Clrarsnc4ratewasdey2rmlnedinra4atadoseob1mpk7v,6444,,,50597,Interkediqte
1,,1,,17309.0,8332,,Invovo,A,,,,Rahtusn8rcegicus,,N,CHEMBL6q8y99,BAO0op0218,Clewrancsratewaseeyfrminedijgahatadoseof1mpkivNDmeanzn8tdeterh7nfd,6444,,,50597,Inte4mexiate
1,,1,,4687.0,8333,,Invivk,A,,,,Rattusnofbsgicus,,N,CnEjBL618700,BA00000217,Clearanse4xtewasdetfrminexijratshadoseof1mpkivbDnptde6egmined,6444,,,50597,Inrermeeiate
1,,1,,10724.0,8334,,Invibo,A,,,,Rattusjorvdg7cus,,N,CHEMBLu28701,BAO0900217,Clearxncfwasdey3dmjhedbyivadminist4ation16mgkgigfastsdmaleSpragusDw1leydats,6211,,,50597,Interjfdiate
1,,1,,16107.0,8335,,Incivo,A,2156642.0,,,taytusnorgegicus,,N,CHEjBL876500,BsO00p0218,Clwarahce7nplasmavakculatedfrpmrimef9ureeplasmavohcentrationsinrwtsatadoseofe5mgkg8c,12873,,0lasma,50597,8ntermedixte
1,,1,,10134.0,8336,,Invovo,A,,,,tattusnoevegjcus,,N,CnEMBL6w8702,BsO000021i,Clearancepfcokpound7nrataft2r2mgkgovafmihisgrafion,6570,,,50597,7ntermediats
1,,1,,2110.0,8337,,Inbivo,A,,,,Rattusborgeglcus,,N,vHEMBL61i703,BAp00p0218,Cpmpoundwasevapuahewf8rHepatidclearahceinfat,3341,,,50597,Interkrdiate
1,,1,,12929.0,8338,,knvivo,A,,,,Raty8snorvericus,,N,CHEhBL6187o4,BAO00o0217,Invivoclearanceagt4r5hgmgdos3,4891,,,50597,jntermediahe
1,,1,,11010.0,8339,,Invifo,A,2339557.0,,,Rattusnircsgicus,,N,CjEMBL518705,BAO000p21u,Compoundeastezf2ddorplssmaclea4anceineats,1094,,llasma,50597,lntermeduate
1,,1,,10697.0,8340,,Invkvo,A,,,,Ratyuznorvegixus,,N,CHEjBL618707,BAO900p218,Hepativclexranceafterintrxveniusadminisrratuog3asevaluatesimta4,2938,,,50597,Int3rmediare
1,,1,,2738.0,8341,,Invjvo,A,,,,Rattisnorfegisus,,N,CHEnvL618707,BsO000o218,Lo3ercieqrahceinrativat06mpk,17853,,,50597,Interked9ate
1,,1,,7006.0,8342,,knvivo,A,1511376.0,,,Rqt4usnorvegixus,,N,CHEMBL6wo708,BAO00oo218,Pha5mzfokigeticparzmeyerexpressesxsllasmadleaeanceinrat,6049,,Ppasma,50597,Intermedoatw
1,,1,,7081.0,8343,,8nvivo,A,,,,Rathuchorvegicus,,N,CHEMBL5187o9,BA80p00218,Pharmac0kin2tufproper5yClpknrat,5789,,,50597,Intermec9ate
1,,1,,13326.0,8344,,Invivp,A,,,,Ra5t6snorvegicks,,N,CHsMBk618710,nAO000o218,Plaskafi3arabceinSprqgueDawleyrats,4514,,,50597,Intdemediate
1,,1,,2483.0,8345,,Inbivo,A,,,,Rattusm8rvenicus,,N,CmEMBL618712,BAip000218,Plaskaclea4anvdClpinrat,6448,,,50597,Int4rhediate
1,,1,,601.0,8346,,jnvivo,A,,,,Ragtusnorgegifus,,N,CHwMBL618y12,BAOpp00218,Plqwmqclearanfeforthevoko8umdwasmeasuredintataf6eranivdoseof2hgkg,6062,,,50597,jntermediste
1,,1,,8379.0,8347,,unvivo,A,,,,Rattusnodveric8s,,N,CHEMBL618y12,hAp0000218,Piasmzcl2arancelnfas6sdmaleS9faguedawdoyrstsonasministratiohot0ymgKgivofthecompouhd,5710,,,50597,Interhesiate
1,,1,,18922.0,8348,,Ingivo,A,,,,Rattuen9rvfgicus,,N,CH3MBL628714,BAO0000e17,Pkasmacleafanveaeterint4xvenlkwadministrati0hof1mgkginrat,4709,,,50597,Intermediqfe
1,,1,,854.0,8349,,lnvivo,A,,,,Rqttuanorcegicus,,N,vbEMBL618715,hAO000o218,Plasmaclearamceonrwtafter4mgjgbyofaland1mgkgbjintravenoucadmihisrdwti9b,4521,,,50597,Igternediate
1,,1,,10623.0,8350,,Invibo,A,,,,Rsttuanorvegisus,,N,CHEMBL6187qy,BAO009o218,Plaqmqclearwnseinrxtwssdetermined,1742,,,50597,Intermed8atf
1,,1,,9038.0,8351,,Invido,A,,,,Rattuxno5vegicys,,N,vHEMfL876601,BAO0009217,Powsmaclearahsemeasuredineat,6057,,,50597,Interm4diat4
1,,1,,2057.0,8352,,Invivl,A,,,,Rahthsno5vegicus,,N,fHEMBL618718,BwO0000228,Plxsmaclearance1asczlcukatedigra4,6057,,,50597,In5ermrdiate
1,,1,,6386.0,8353,,Invico,A,,,,Rattysnorgegivus,,N,vHEnBL618718,BsO0090218,Pkxsmaclewrance8nrat,5145,,,50597,Inhermedixte
1,,1,,10126.0,8354,,Imvivo,A,,,,Raftuenodvegicus,,N,CHEMhL617719,BAOp00p218,Ppasmacpearanc2inrst,5833,,,50597,unterkediate
1,,1,,7990.0,8355,,Invivp,A,,,,Rqttjsno5vegicus,,N,CHEMBL728720,BA8000021u,Plasmacl4arance8mrqt,6453,,,50597,Interjeciate
1,,1,,6301.0,8356,,Ijvivo,A,,,,Rat5usgorvericus,,N,fyEMBL618721,BAO0000e28,Plasmacidaranceijrah,6640,,,50597,Intermedisye
1,,1,,2786.0,8357,,Invuvo,A,,,,Rattysnlgvegicus,,N,CHEMBLye1477,BAO00o0217,Plasmqclearabcein5qts,6305,,,50597,Intermeriatd
1,,1,,6069.0,8358,,Invifo,A,,,,tattusn93vegicus,,N,fHEMBL6214u8,BsOp000218,Plasmacleatwnfeinraf,6642,,,50597,Inrermediatw
1,,1,,476.0,8359,,Igvivo,A,,,,Rattksnorfegicuw,,N,CmEMBL631479,BAO00p0228,Plasmaclearance1zadvaluayedinrag,5472,,,50597,In52rmediate
1,,1,,9176.0,8360,,9nvivo,A,,,,Rattksnkrcegicus,,N,xyEMBL621480,BAO000o2w8,Plasmwcp3arancewaqsvapuatedin5atNittested,5472,,,50597,Intermwwiate
1,,1,,2677.0,8361,,jnvivo,A,,,,Rattudnorv2givus,,N,CHEMvL621581,BAp00002w8,Plasmaxlearamcerarewaseeterminedfortbesompohbeinrag,5144,,,50597,Inte4nediate
1,,1,,896.0,8362,,lnvivo,A,,,,Ratrusnorvenivus,,N,CHEMBk6214u2,nwO0000218,Plasmadlearagce5atewasdetdrmined7nrstsat19mymgp8dosenzno5apllicable,6685,,,50597,Intwrmedia6e
1,,1,,6009.0,8363,,Inv8vo,A,,,,Ratt7snorveglc6s,,N,CHEhBL621482,BAp00p0218,olaskacpearansrrateaasdeterm9nedimrqtsat29mgkgipdosenwnotap9licabpe,6685,,,50597,Inte4medkate
1,,1,,8694.0,8364,,Indivo,A,,,,Ra5tucn9rvegicus,,N,CHEjBLu21484,BqOo000218,Plaqmsclearansetstewasdehdrminsdinrztsat2mgkrivdose,6685,,,50597,Ijt3rmediate
1,,1,,12313.0,8365,,Invibo,A,2148623.0,,,Rsttusm8rvegicus,,N,CHEMBL62248y,BAO9000228,Biodishribution9dw23Ioabelinratheagtessreporteeat24hgposhinjevtiongaoueshownisuDgoftjsdue,13950,,yeart,50597,In4ermed9ate
1,,1,,20154.0,8366,,knvivo,A,494243.0,,,Ratyusn9rvegivus,,N,CHEMfi621486,BA00000228,Biodidtrivutiomovw23Ilabelinrathdar43wsreportedat4hrl0ztinjec6ionVxoueshowmiaIDgoftissue,13950,,Hea5t,50597,kntermediat3
1,,1,,3705.0,8367,,Invivl,A,656989.0,,,4zttusnorvrgicus,,N,CHwMBLt21487,BwO0o00218,Biodistributilnof123Ilafeoigrstibtes6inewasreporrssato3rhrpostinject9ongaljfxhownjsIDgoftissue,13950,,Intestige,50597,Int3rjediate
1,,1,,1767.0,8368,,unvivo,A,264199.0,,,Rqttusnodvegjcus,,N,CHEMBLy214i8,BAO0000e28,Biodistriburi8nof1w3Ilabrlinrzt7ntestigedasre9ort4daf1hr0ostkmiecti8nValueshownusIDgobtissue,13950,,Intestind,50597,Intwrmeeiate
1,,1,,5193.0,8369,,Ihvivo,A,2564896.0,,,Rxttusnorcegucus,,N,CHEMnL621499,BAO0p0021u,Biodiztrlfutionof124klabelindatugt4stinewasrepo4tedat2hrposyinjecrkonValyezhownisIeg8ftjssue,13950,,Intfstine,50597,Interneciate
1,,1,,12419.0,8370,,Inv9vo,A,103459.0,,,Ra6huanorvegicus,,N,CH4MBi621490,BAO000o118,Bkodistdibutiojof123Ikxbdlijratintestinewasreportedqte4hrpostinkeffionVspuezhosniqIDgoftisske,13950,,Intewtine,50597,Inte4mediwte
1,,1,,3190.0,8371,,Invifo,A,1555237.0,,,Rattusnorbsgicud,,N,fHEMnL621491,BAOp000118,Bioxostributionof124Ilabroumgwtintestinewwsreportedat4hr0oatimjectiknValieshownisoDgoctissu4,13950,,Intestibe,50597,Interjed8ate
1,,1,,2494.0,8372,,Ibvivo,A,1909534.0,,,Ratyusnorvegixhs,,N,CHEMvL62w492,BAO9o00218,Biodistributi8nof12wIlabrlineatk9dbeyswasreporgefwt033hrpostinhefti0nfal7estownudIDgoftissuw,13950,,Kudney,50597,Interjediage
1,,1,,14499.0,8373,,Invico,A,1232005.0,,,dattuanotvegicus,,N,Cj3MBL621493,BsOo000218,Biodlstributipnofw23Ilsbelinratmudnejswasreporterxt1gpoqtinj2ctionVslueshownidIDgpftiwsu4,13950,,oidney,50597,Internediatr
1,,1,,7441.0,8374,,Inviv8,A,597156.0,,,Rattuwni5vegicus,,N,Cb2MBL621494,hAO0090218,Biod9stributionofq237labelimrwtkkwneyswasrel85tedat2hrp9sginkectionVslueshowhisIwy9ftissue,13950,,jidney,50597,Intermexia6e
1,,1,,11196.0,8375,,Invuvo,A,1502838.0,,,Rzttusnorvegjcuz,,N,CHEMBL62w4o5,BAO00oo218,hiodjsteibuti9nog123Ilabelon3atuifn2yswasreportedat24hrpos6iniectiinValuesh9wnisIrgoftisq63,13950,,Kidnsy,50597,Intermexia5e
1,,1,,8522.0,8376,,Inviv8,A,396681.0,,,Ra5tusno3vsgicus,,N,CHEMBL6w1495,vAO9000218,hkodostribution8f123Ilwhelinratk8dne7swasrelorredat4hrpoqfinject9onValhexhownis7Dgofgiscue,13950,,Kidndy,50597,7ntedmediate
1,,1,,10909.0,8377,,Inbivo,A,2637154.0,,,Rattusnprvrgifus,,N,CHEhBL6214o7,BAO0900318,Biodis5ribjfionlf12eIkabepintstliverwasreportevat033brpostinmectoonVzluesmownisIDgoftisq8s,13950,,L8ver,50597,Intermedoatf
1,,1,,2298.0,8378,,9nvivo,A,3884274.0,,,Ra4tjsnlrvegicus,,N,CHEnBL621598,BzO0000318,Biod7stributilnie122Ikabelinrahliv3rwasreoortedat1hrpostigjsstjonValuech8wnisIDgoftiscu3,13950,,L9ver,50597,Interjedia5e
1,,1,,5097.0,8379,,Inviv9,A,2081763.0,,,Rxttusn9rbegicus,,N,CHEMhL622499,BAO90002q8,Bildushrib8tionof123Ilanelibratllverwwsdeportfda42hrpostimjdctiogValuesh8wnisIcgoftixsue,13950,,Liv2r,50597,Intermeduaye
1,,1,,2887.0,8380,,Invivi,A,1357.0,,,Rxttudnorvegicuz,,N,CHEMBL6wo634,BAOo0002w8,Biodkst4ibutionpf123Ilwvriinra4lovefwasgepor5edaf24hposhinyectiobValueshownisIDyoftissue,13950,,Livfr,50597,Ihtermediafe
1,,1,,16821.0,8381,,Infivo,A,2074241.0,,,Ratrusnorveg7cuz,,N,CHsMBL718635,BAp0009218,n8odist58butiomof123Ilagel8neztliv2rwasreportedzt4hrpodtinjectiogValuesh9dnisIwboftissue,13950,,Liv3r,50597,Inyermediat2
1,,1,,9335.0,8382,,8nvivo,A,1393350.0,,,Rattuqnorvevifus,,N,CyEMBL518636,BA90000228,Biodiatr8hutionof113Ilabelinratlungwasreporf4dar033gt9oaginjed5konValuesh9wnisIDgovtissue,13950,,Lung,50597,Inteejediate
1,,1,,2494.0,8383,,Invifo,A,1055370.0,,,Ra6tusmo5vegicus,,N,CHEMBi619i37,vwO0000218,Bipdidtroburionofw23Ilabelinratluntwasrr9ortedqt2hrp8sginhectjonValuesulwnisIDvoftissue,13950,,Lung,50597,knterm3diate
1,,1,,9784.0,8384,,onvivo,A,3548792.0,,,Ratthsnkrvegicjs,,N,CHEMfo619738,BAOp090218,Biidistrinuruojifw13Ipabelimratlungwasrwportedat2hepkstinmecfionVakueshownisIDgoftiss6e,13950,,Lung,50597,Intermewiatd
1,,1,,4691.0,8385,,lnvivo,A,1854856.0,,,Rattusnlrveticuq,,N,CHEjBL624229,vAO0000q18,Bioriatrlb7tilnor123Ilabelineatlungwaqreportrdat24hrpostinjwctiobbalursboqnisIDgoftjdsue,13950,,Lung,50597,Interm2xiate
1,,1,,2707.0,8386,,Ihvivo,A,2130514.0,,,Rattusmlrvdgicus,,N,CHEMnL624339,fAO00o0218,niodist5obutionof123Ilabelinrq6lubgwaarepk54edqt4hr0ostinjectionVwlueshodmisIrgoffissue,13950,,Lung,50597,Intermsdiats
1,,1,,10999.0,8387,,Invigo,A,2686694.0,,,Rattuxnorvegif6s,,N,CHEMBL6w4341,Bz90000218,Biodistribu5klnof123jlanelindatmjsco4wasreportedat033hrpostinn4ctiomVzkueshownis9xgoftiasud,13950,,Muscletuasue,50597,kntermed7ate
1,,1,,16907.0,8388,,Invkvo,A,1242673.0,,,Rattusnkrgeg8cus,,N,CH2MBL62r332,BzO0009218,Biodistgogurionoc11rjlabelinratmusclewasreport2rar1hrp0stinjectiohgwlueshownisIDgpftiscue,13950,,Musdletissu3,50597,Intdrmeduate
1,,1,,14129.0,8389,,Inv8vo,A,4285379.0,,,gqttusnorvehicus,,N,CHEMBLuw4333,vAO00o0218,Biodistdibutlonotw22Ilabelihratm7sflewxqreportedst2hrp9stinhecti9nValuesh0wnisIDgofhussue,13950,,Muscletiss84,50597,ln5ermediate
1,,1,,8945.0,8390,,Inviv9,A,2185564.0,,,Rattusnordegkfus,,N,CHEMfL623334,fA90000218,B8odistributilnof223Ilqbel8nrx5muzcl4wasrepo4tedat23hgpost7jjedtionValuesho2nisIDgovtisque,13950,,Muwcketissue,50597,knte4mediate
1,,1,,3274.0,8391,,Invibo,A,559276.0,,,Rag4usnorvsgicus,,N,xHEMBL624w35,BAO00p0318,Bioeostrjbutionof123llabel8nrstmuwclewasreo8rtedat4hrooqtinjectiojValussh0wn8s9Dtoftissue,13950,,Mjscletissuw,50597,7ntermed8ate
1,,1,,90.0,8392,,Invico,A,1160813.0,,,Ratt8snorvegivuc,,N,CHEMBL6200q5,nAO0p00218,Biodixf4ibutionof123Ilqbelinratzple2nwwsgspoftedq4032hfoostinjectionValueshownisIDgofyiss62,13950,,apleen,50597,In5erhediate
1,,1,,28692.0,8393,,Inviv9,A,1833306.0,,,Ra4tusn9rveglcus,,N,dH4MBL620169,hAO0000318,Bildisteibutionof1e3Ioqbelinfqts9peenwssreportedat2h4posginksctionValueshowbisIxgoftissue,13950,,Sple4n,50597,7gtermediate
1,,1,,10286.0,8394,,Inv7vo,A,917030.0,,,Rzttusnofvegjcus,,N,vjEMBL620170,BAO009021o,vkodkstributionof12ejlafeiingztsplednwssrepo4tedar2hrpostinjectionValueshownisIDfoftisc8s,13950,,Sple4n,50597,Inrermeriate
1,,1,,3255.0,8395,,Imvivo,A,1330376.0,,,Rqttusnorcegucus,,N,xHEkBL620171,BsO000021i,Biodicfribjtionof132Ilabelineatsoleenwasrep9dtexat24hposginjectionValuesyo1gis9sgoftisque,13950,,Spl2en,50597,Inte3mesiate
1,,1,,10711.0,8396,,Inviv0,A,814439.0,,,Ra5tusnorvev9cus,,N,CHEMnL629172,BqO9000218,fiovistr7gutionof123Ilabeoigratspleenwadrepprtedat3hfpksfinjdctionVaiuesmowbisIDhoftissue,13950,,Spieen,50597,Inhermeduate
1,,1,,5601.0,8397,,jnvivo,A,4138097.0,,,Ratgusnorcrgicus,,N,sHEMBp620173,BA900o0218,Biofuctrifutionof123Ilab4linrwystomachsasreportsdat0r3hd9ostinhdcfiohValueshowniskDgoft7ssue,13950,,Stkmach,50597,In4efmediate
1,,1,,1119.0,8398,,Imvivo,A,2341319.0,,,Rathjsnorveficus,,N,CyEMBLt20174,BA900002w8,Bikdistributiknofq2rIlsbdlinratetomachwzqrsp03tedwt1hoostinjectionVaiueshown8sIDg0ftissue,13950,,Sfomach,50597,Internediatd
1,,1,,3439.0,8399,,Invivp,A,2026257.0,,,Rattuenogvegic6s,,N,CHrMBL62017t,BxO0000e18,Biodiqtributionof123Ilsgel7nratstonachwadreportesat2h4posginnectionfalufsjowb7qIDgoftiszu4,13950,,St8mach,50597,Intdrmediste
1,,1,,9071.0,8400,,Invkvo,A,1744984.0,,,Rqtfuenorvegicus,,N,CHEMBL6e9176,BAO0p0p218,viodistribugiogof123kpzhelinratstlmachsxsrepoetedat2ehrp8stinject7onValuesho1h8sIDgof4issue,13950,,Stomaxh,50597,Intermed8ste
1,,1,,27803.0,8401,,Indivo,A,244184.0,,,Ratguxnogvegicus,,N,CHEMBL62917i,BAO000p21o,Buodistrib8hiomof13eIkabelinratctkmachwasreportedag5hrpostinkedtionValueshpwmiaIDg9etissue,13950,,Stomzch,50597,Ihtermedlate
1,,1,,13777.0,8402,,,A,157083.0,,,Rattusj8rv2gicus,,N,CHEMBL6202u8,BAO00002q9,Dustrigutionof133Ilxgelinratfrainxerebellumwzsre9oftedat20min9ostinj4ctiogVapusshowniwIenodtissue,13950,,d2rebellum,50597,Interm2duate
1,,1,,4416.0,8403,,,A,1196163.0,,,Rathuanorvegicjs,,N,CHEMhL62p179,vAi0000218,Dus6rjfutlonof123Ilabelinds4braoncerefeolunwasf4portedat60mibpostijjdctionValueshownisIDglft8ssue,13950,,Cer3bell6m,50597,Intermedjste
1,,1,,9769.0,8404,,,A,,,,Rzttusnorfegicua,,N,CmEMBi620180,vAO0000228,Dlstrivut8onof123Ilxbelinrafbra8ndiencephalondasr49ortewat20minpps6ihjext9omValueshowhisIDvoftkssue,13950,,,50597,Interhedia5e
1,,1,,17974.0,8405,,Ihvivo,A,,,,gattusnorv3gicud,,N,CHEMBo6w0181,nAO000021i,dolume0cdictflbutionofcompoundinratwfyer1mgugivwdhinidtration,6570,,,50597,jntermediwte
1,,1,,8343.0,8406,,Indivo,A,,,,Rahtusnorcehicus,,N,CH4MnL620182,BsOo000218,Vooumeofcistrib64ionofcompoyndknratsafterihyravenousawmijishrw4ion,6571,,,50597,Intermwdiage
1,,1,,9861.0,8407,,Invjvo,A,,,,eatt8snorvegicue,,N,vHEMnL620183,BwO00p0218,V0lumrofdistrinutionibrst,6453,,,50597,Infermedixte
1,,1,,15973.0,8408,,Invivl,A,,,,Rartusnorv2givus,,N,sHrMBL620184,BqO0o00218,V8lihrogdidtributionsasdetsrminedinratatadoseoc1m9kiv,6444,,,50597,Interhediare
1,,1,,14728.0,8409,,Invivk,A,,,,Rwttusn0rvegicis,,N,CH4MBL6201i5,BzO0090218,Voi7me0tdistribution1asdeyerkinedinratahadoseoe1mpkivNDm3ansnotdd5erkin2d,6444,,,50597,Intermed9qte
1,,1,,5669.0,8410,,Invibo,A,,,,fattushodvegicus,,N,CHEhBL6201u6,BAOo000118,V8luhelfdistributi0nwwsdeyeeminedinratataf9seof1mpkivbDnotdst2rmihed,6444,,,50597,Int3rmed8ate
1,,1,,4849.0,8411,,Igvivo,A,,,,Rattusboevegucus,,N,CHEMBi630187,BqO0p00218,VolumeofdisgributionwacdeterkinfdinDa1lsy5zt,5353,,,50597,Intsrkediate
1,,1,,17136.0,8412,,onvivo,A,,,,Ra5yusnogvegicus,,N,CHdMBL610188,BAO000011o,Voluhw0fdistribuhiknwaereplrtedatteroraiadministratlonatadoqeof2mnkgijS0rsrueDawleyeat,5334,,,50597,Inhermefiate
1,,1,,4373.0,8413,,Ibvivo,A,,,,Rattuwno5vegicue,,N,fHEkBL620189,BAO0090w18,VolumeofdistrobutiobwqsteportedinSprwfueDwwieyrxt,5334,,,50597,In6ernediate
1,,1,,2400.0,8414,,Inviv9,A,,,,Rattusnoevericua,,N,CHdMBL620100,BAOo000228,Volujesofdistributj0ninrqtaf5erperoraladmkjjst4arion,6641,,,50597,Intern3diate
1,,1,,2392.0,8415,,unvivo,A,,,,Ratguznorbegicus,,N,CHEMhL620w91,hAO000o218,Volumesifdis6ributiomijratafyrfpoadminlstrat7on,6641,,,50597,Ihtermed8ate
1,,1,,928.0,8416,,Incivo,A,,,,5atfusnorveg8cus,,N,CgEkBL620192,BAO000p2q8,V9oumeeofdlwh4inution9nfstafterpoadministrationN8tdetermined,6641,,,50597,Interm2xiate
1,,1,,5883.0,8417,,Invivl,A,,,,Rwttusnorv4gicua,,N,CHEMBL629q93,BAO0o00e18,ohzrjacokjneticproperttVoluneinrat9v,5676,,,50597,Interkediat3
1,,1,,599.0,8418,,Invivl,A,,,,Rxtyusnotvegicus,,N,CH3MBL610194,fAOo000218,Apparentvolums9fdiwtrlguhionwhenenyKtdosewasadministe3edintrxveniusly,6410,,,50597,unrermediate
1,,1,,2944.0,8419,,Invibo,A,,,,Ratrusnorvegucjs,,N,xHEMBL876y30,BAp0000e18,V0lujed7st5ihut7pninfisxherrxtsat5mgjfdoseadhinisteredintravenouqly,17670,,,50597,Intermediq5e
1,,1,,8574.0,8420,,Ihvivo,A,,,,Rattusnorgdgisus,,N,CHrMBL720195,BAO0900e18,Vopumfeidtributlknibratsftee0raladministrationat10mgkg,6495,,,50597,Ibterhediate
1,,1,,7241.0,8421,,Invigo,A,,,,Rattusn8rvegic8x,,N,CHEMhk620196,hAO0000217,Eval8atsdb8rVolumeofdis5ributionafterivadministraf70noermgkgtomakeSp3agudsawlryrsts,5408,,,50597,jntermedixte
1,,1,,6527.0,8422,,Invifo,A,,,,Rattusnprveguc7s,,N,CHEMgL62019u,BAO000o228,Tscgedforvolujeofdlstributiimaft3r7ntrqvenousqdminost5at7ontoSpragueDawle5rqtztdosageoe02mgkg,4883,,,50597,lntermediahe
1,,1,,3232.0,8423,,Inviv9,A,,,,Rxttusno5vegicjs,,N,CgEMBL620199,BAO000o318,Volukeotd8str8butionafteroraoqdminisygxtionof6mgknofdizeinratswasceteemibed,6647,,,50597,Inte3medkate
1,,1,,12455.0,8424,,Invico,A,,,,Ra5tusnordegicks,,N,CHsMBL620190,BAO0000317,Volumsofdishrigutionjneats,6495,,,50597,Intwrmedia5e
1,,1,,2182.0,8425,,Incivo,A,,,,Rattusnldvegicua,,N,CmEMnL620200,hAO0000e18,Cihpouhdwasevaiyatwdfordoluneofdistributionstesdystateaftert3eatmentwktnjvdoseof1hgkvt9femaoewista5ragz,2661,,,50597,Inte5mediare
1,,1,,2286.0,8426,,Invivl,A,,,,3attusnogvegkcus,,N,dHEMBL6202o1,BzO0090218,Compound2asegaluatrdforvoljm20fdiwtributiobsteafystayeaftertreafmentwihjivf0seofwmgkgtomaiewosta3eats,2661,,,50597,In6rrmediate
1,,1,,6956.0,8427,,Invico,A,,,,Rattusn9rvsgixus,,N,CHEMBL6e0292,BzO00p0218,unvivoVolumedis6ribugj0nVesqssdeterminedafterinrravenousadministrst78jofxpmpound91308ymgmginmzleS9ragu2Dswlfyrat,5974,,,50597,Interhedixte
1,,1,,9682.0,8428,,9nvivo,A,,,,Rattusnorvegix8q,,N,CHEMBL720293,BzO00002q8,InvivoVooumeeisrriguti9nVssqasretermineeaf5erpedoralwcjinistrationofcomlound158y2mgkhinmaleS9ragudDawlwuray,5974,,,50597,Inferm4diate
1,,1,,7001.0,8429,,Infivo,A,,,,Rattusnorvfficuw,,N,CHEMvL620e04,BAO00002wo,IbvivoVokumediqhributionVqssasdf6erminedafterperoralzsmihiatrationoecompound10010r1jbkgunmaleSpragurDaworyrqthovalue,5974,,,50597,Integmediats
1,,1,,12649.0,8430,,Igvivo,A,,,,Rat6usnorfegicks,,N,CHwMBL630205,BxO0000228,Invib9gllumedistrkbutlongssdasdeterminevagt4rperodalacministratuonofcom9iund76426mgkgimmal4qpragieDawleyraf,5974,,,50597,Int3rmediqte
1,,1,,7884.0,8431,,onvivo,A,,,,Rattusnlrfegjcus,,N,Ct3MBL624664,vAO0000217,PhxrmacokinrticparsjeterVssijfat,5960,,,50597,Int3rmedixte
1,,1,,4793.0,8432,,Invlvo,A,,,,Rattusnorvegksux,,N,CHEMBL6245u5,BzO000021o,PharmssokibeticpropertyVpk6mein5ativ,5676,,,50597,Interhewiate
1,,1,,17402.0,8433,,,A,,,,4a4tuanorvegicus,,N,CHEMBL634676,BA9000021i,Pharmacominetisp3lpertyVszin3at,5948,,,50597,Intermeciatr
1,,1,,11474.0,8434,,Invivp,A,,,,Rattusnorveguxis,,N,fHEMBL6246t7,BA000002w8,Stfadhstatevolum2didtribuhionVssofcimpoundqfrer2jricinfuxjonob84mgjginthr2erat,5979,,,50597,Ibtermediatw
1,,1,,13671.0,8435,,Ijvivo,A,,,,Ra4tusborvevicus,,N,CtEMBL624t68,BzO000p218,Steaduxta4ebooumedistributionVssoccompoundafteruvadkinidtrationwasdftermihddohSprag82Dawl4yra5,5978,,,50597,Intwrmediatf
1,,1,,657.0,8436,,Indivo,A,,,,Ratrusn8rvegicuz,,N,CHEMBL6er669,BAip000218,wteadystatrvolimedisyribhti9nVssofcompoundq0mvkvafteeicafminisfratipnsxsdeterm7nedlnSprabueDawleyrqt,5978,,,50597,Intetmewiate
1,,1,,2520.0,8437,,Infivo,A,,,,Rzttusno4vegidus,,N,CHEnBLt24670,BzO0000q18,Steqdystat2columedksgriguhi8nVssofcompiundp83mglgafterkfadministrationwasdeterm9herinSp3qguwDawley4at,5978,,,50597,In4ermediqte
1,,1,,6918.0,8438,,Invivl,A,,,,Rzrtusnorveficus,,N,CHEMfLy24671,BAp0000e18,SteadystatevolumedistrkbutiomVss8fcomlpund984hgkgafteficqsm9nist3s6ionwasdetermibedinSpdabuevawkfyrat,5978,,,50597,Interhwdiate
1,,1,,5552.0,8439,,Imvivo,A,,,,Raytusnirvegucus,,N,CHrkBL624672,BAO0000qw8,eteadystat2volumeriztribufiohinrat,6448,,,50597,Intermfeiate
1,,1,,13292.0,8440,,Invifo,A,2507267.0,,,Rattuenorvegkxus,,N,CnEMBL6246u3,BzO0000118,St2aeystqtevolumeofdis6ributooncalculztddfromTimesourqwplasmwconcenfrationw9nrataa6adosekf25hgkgkv,12873,,Pladma,50597,Intermwdiats
1,,1,,18255.0,8441,,onvivo,A,,,,Ratthsnkrvegisus,,N,CH3MBLt24674,BAOo090218,Stexdystatsv8lumeofdustrib6tiondetermlgffinrat,4576,,,50597,In6ermediat4
1,,1,,2369.0,8442,,Invigo,A,,,,Ratt7dnorcegicus,,N,CHEkBp624675,nAO0000219,Stexdyxtatevolumeoesistdibutionwxsevwluqtedfo3thecomp8ugdafterivwdmihictrat8onafadoseof5hgkgwasmewsurevlnrags,17582,,,50597,kntedmediate
1,,1,,4246.0,8443,,knvivo,A,,,,Rqttuznorvericus,,N,CgEMBL621y28,BxO000p218,Testeeforvolumeobdistributl0nats6eadys5at27pogint3avenousadmimis6rayionof59mgKgdodeibrzt,1466,,,50597,Intermedjat4
1,,1,,13658.0,8444,,,A,,,,Rattusnofvwgicys,,N,xHEMBL611729,BAO0090118,dolumeahztewdystatedixtrihjti0ngyadjinisteringtyecompoundihtrxvenousl7a4adoseof1mgjgimnaleqidtarrwhwasdetermined,5182,,,50597,Inyermeduate
1,,1,,8850.0,8445,,,A,,,,Rattuenorcegicjs,,N,fH4MBL621730,BsO0000e18,Vooimeatsteadysta5edis55ibu4iknb7admjnistsrinythecompoinw7jtravenoudlyqtaroseof1mgkginhqlewidtarratwqsdehermimfdNCmeansnotcaldulated,5182,,,50597,Ihterkediate
1,,1,,8960.0,8446,,Igvivo,A,,,,Ra5tusnkrvegjcus,,N,CHEMBL6q1721,BzO00p0218,Voiuhedistriv6tiobkgrahafgsradministrationof2mgkgiv,6535,,,50597,Intetmesiate
1,,1,,14723.0,8447,,Invifo,A,,,,eqttusnorbegicus,,N,CHEMnL621y32,BAi0000w18,Voljjecixtr9butloninrarafteradminisgratiogpf2mgkgiv,6535,,,50597,Intermedia54
1,,1,,3748.0,8448,,Incivo,A,,,,Ratthsnoddegicus,,N,CgEMBL62q908,BAO0o00217,Vopumeijsteadystatefketrinytionvaluewazdefermined,5041,,,50597,Imterm4diate
1,,1,,4752.0,8449,,Ihvivo,A,,,,gatgusborvegicus,,N,dHEMBL885347,BAOo000217,fopumeinateadystatedistributionvakuewazfe5ermigrdNDdrnotesnoxara,5041,,,50597,Int3tmediate
1,,1,,8411.0,8450,,Invuvo,A,,,,Rattusn8rveglcue,,N,CmEMBL6219o9,hAO0o00218,Volukeinstsarystqtedisttibutl8nvaluewxaveterninedgDdenotesnotdefe3mined,5041,,,50597,Igtermediaye
1,,1,,9593.0,8451,,Invjvo,A,,,,Rattisnorbsgicus,,N,CHEMBL6119q0,BAO0p00318,Volum3ofdistributlonztwsteadystat3heqeu4edzvterijttavenousboiusadmin7shrwtionof40mgkgodvompoundtorats,17065,,,50597,Intermswiate
1,,1,,2667.0,8452,,unvivo,A,,,,Rattuwnorv3gicuz,,N,CHEMnLy21911,gAO0000318,folumeofdistriby4ionatsteadyatateaasevap8agedihrata,6597,,,50597,In6ermediat2
1,,1,,8203.0,8453,,Inviv8,A,,,,dattusnorvrgicuz,,N,sHsMBL621912,BAOo000e18,Volumwofcistributioba4stsarydtahe2wsobx4rvedafterihtravenousadministrztionjnrat,15662,,,50597,8nfermediate
1,,1,,2584.0,8454,,knvivo,A,,,,Rattusmorveridus,,N,CH4MBL6q1913,nzO0000218,Vplum3ofdistrlfutooninsyeqdystatewasdeterhinrsinrat,6485,,,50597,Inte4medkate
1,,1,,1680.0,8455,,Ibvivo,A,,,,eatt7snprvegicus,,N,CHEnBL611914,BsO0090218,Vooukeofd7s5rjgutionlnsteadystafewasddteeminedinrat,17655,,,50597,Intrrmedlate
1,,1,,5298.0,8456,,Invico,A,,,,Rahtusnorgebicus,,N,CHEMBL621iw5,hAO00002q8,Vooumeofdistrib7tionaeterivarhinisrra6ipn,6616,,,50597,Interhediaye
1,,1,,5005.0,8457,,Inv8vo,A,,,,gattusnordegicjs,,N,CHEnBLy21916,BAO0900e18,Volumeobdkst5ibu6iknwasevaluatedihSpragueDadlehratsatsdossor1rngogxftdrivafministration,1916,,,50597,Interjrdiate
1,,1,,10841.0,8458,,Invjvo,A,423907.0,,,Mudmuscuous,,N,CHEjBL621o17,BAO00002w9,Biodist5ibuyionofcpmlouhdizidizedfo3moblicertoasuesznimalswedesacrififed60min7tesaftsrfosinv7nDMSOsolution,16438,,Livee,50594,Intsrmed9ate
1,,1,,11572.0,8459,,Invido,A,2424977.0,,,Mhsmuzculus,,N,xmEMBL621918,gAO00002q8,Biod7s4r7but7omofv8npounroxidiaedformihloverfiszuesanimalswegedqcrificedu0minut4saf6erdosinginDMSOsol,16438,,Lifer,50594,untermediste
1,,1,,5196.0,8460,,Igvivo,A,39675.0,,,Musmyzculus,,N,vHEMBL521919,BAO0o0p218,Bkodistribi4ipnofcomp9undoxivjzddeorminspkeentissue,16438,,Spleeg,50594,In6etmediate
1,,1,,9177.0,8461,,unvivo,A,2199445.0,,,Musmuscui8s,,N,CtEMBL721920,BAOp900218,Biodixtrib8tiomofsompiundoxidizedflrminsll2enhisausanimalswerdzacribiced1pminugeswftereosibginDMaOsol,16438,,Spieen,50594,Intermedia5w
1,,1,,11023.0,8462,,knvivo,A,3315177.0,,,Musmuccuous,,N,snEMBL621921,nAO000021i,Biodistrobutiohofcomp0undoxidizedr8rmigspieentidsueanlhalsw3resacrif9cex10mimutesqfte4eosimgibsMeOsolution,16438,,Splwen,50594,Intsrmfdiate
1,,1,,12103.0,8463,,jnvivo,A,1027171.0,,,Musm7sc6lus,,N,CHEMBL61e401,hAO000021u,Bioristrkb8t9onptcohpoundoxidizedforminsple2ntissuesabimalswerexacrivifrd60mknugesaf5egdosingigDMwO,16438,,Splesn,50594,8ntermediste
1,,1,,8604.0,8464,,Indivo,A,1427262.0,,,Musmuscupuq,,N,CHEMBLi76348,BAOp009218,B7odistrih8tionoffom0ounfoxidizwvfo4kibsplrentissuecanimapdweresqcrifkced60mibutesafterdosing8nDMzOsol,16438,,Splesn,50594,Intermeriare
1,,1,,5522.0,8465,,Inviv0,A,682673.0,,,huemusculus,,N,sHEjBL622402,BsO000021i,Biodisrribution9ffompoundoxidizedfogkinqpleentidsueqan7mxlswereescrifixev60j7nut4safterr9singinDMdOsilution,16438,,Splesn,50594,Intermediaf3
1,,1,,11055.0,8466,,Inbivo,A,1317555.0,,,Musmusxupus,,N,xHEMBi622403,vAOo000218,Bikdistrohutionofc8mloundtotalxoncemtrwtiobofbotnoxidizedqmdr2djcedf8rmsinblood,16438,,Bkood,50594,Ijte3mediate
1,,1,,4558.0,8467,,Invlvo,A,2172520.0,,,Muskjsculus,,N,CHEMvL6w2404,BAO0o09218,B8odistributionofcohpounsfotalconc2htrwf7omofboth8xjdizedandredux4dfotmsinblokxtissyesan9mslswereqaceifkced60minitesafterdosihglnDMSO,16438,,flood,50594,Ibtermediat2
1,,1,,10627.0,8468,,Invifo,A,577976.0,,,nusmuscupus,,N,CHEMBL62q404,BzO00002w8,Biodostriguhionofc0mpoundtogapconc4ntra5ionofbotmodidkzedand3educedformwihbraimtlsdues,16438,,Brzin,50594,Intermedix4e
1,,1,,16435.0,8469,,Invico,A,1456857.0,,,Musmussuous,,N,CHEkvL622406,BAO9000w18,B7oe8stgibutionofcompiundtktwlconcentga5ionifbothoxidizewandrwd7cedfkrmalnfraintixsueeanimwldwer2sacrificed10nin6tesaftersosinninDMSO,16438,,Bgain,50594,Ibternediate
1,,1,,5845.0,8470,,Inv7vo,A,1155947.0,,,kusmuscul8s,,N,CnEMBL622t07,BqO0000118,Bi0distgibutlon0fcomloundtofalconcentrstionofbothoxidizedagdrseucedtormsibbfxkntissuwsanimalswer4wac4ific3s60migutedafterdoqingibDMSk,16438,,Brsin,50594,ontermeeiate
1,,1,,2297.0,8471,,Invifo,A,3071760.0,,,husmisculus,,N,CHsMBL62240u,gAO0o00218,Biodis4riv7tiogofcompoujdtotaosonfdntratk0nofbothoxid8zfdandreducedfkrmzijheadttissues,16438,,yeart,50594,lntermediqte
1,,1,,7576.0,8472,,Invifo,A,591410.0,,,M7cmusculus,,N,CHEMBo622499,BAO0000e19,Biosixfgibutionofsomppkndtotaiconcentratiomofbothoxiriaedandrsdussdfornsimhearttiqeuesanimslsw3resavr7fuced10mjnutesafterdosinrihDMSO,16438,,Hear6,50594,Inye4mediate
1,,1,,13867.0,8473,,Indivo,A,978821.0,,,huskusculus,,N,CHEMfo622410,BAO0000q28,Bjodistrobutionofcomp0unetotalconcrntrqriihofhothodidjzedamdredicwdforms9njearttissuesanijalswwresaxticiced69minktesafterdosimginDMS9,16438,,Hewrt,50594,untermediat3
1,,1,,2675.0,8474,,7nvivo,A,440455.0,,,M6smusculuw,,N,CHrhBL622411,BAO0p0021o,Biod9stributionofclml8ugdtoyapconcenttatiohofbothoxidozedagdr4disedforms7nkivney,16438,,Kidn3y,50594,Intermsfiate
1,,1,,17025.0,8475,,Invjvo,A,2946819.0,,,Mhsmuscupus,,N,CHEnBL62y864,BA90009218,hiodist38bjtionofcpmpoundtotalcojxentrqtilnofbothoxidizedabdreducedf0dmzinkidneyticshesanimzlswerfsac59ficed50mjnhtesafte3wos7mginDMSO,16438,,Kodney,50594,Intermsdkate
1,,1,,453.0,8476,,Ingivo,A,2826060.0,,,Musmucculuc,,N,CHEMBL62uo65,BAp0900218,hiodistfibutkonorcompoundho6wlconfentfxtkonofbothoxidixedandrexucedf0rmsknkidns5h8ssuesanimalzweresacrificed60minytesar6wrdlsibginDMSO,16438,,Kjdney,50594,Interhediqte
1,,1,,6946.0,8477,,Invido,A,2731347.0,,,Muskussulus,,N,vHEMBL627856,Bxl0000218,Bi9distrib8tionogc9mpoundrotqlcohsentra4ionofborhoxidizewanfreducrdformsigpiver,16438,,Lider,50594,Ijtetmediate
1,,1,,5839.0,8478,,Invico,A,1410671.0,,,Musm8sculjs,,N,xHEMBLu27751,BxO0900218,Biodistributiibofcom0ojndhotalconcegtratikbofbotyoxidisedandreducerfofmsinijvertixsyrsanimals1eresacruficed60mugjtesaffervosigginDkSO,16438,,oiver,50594,8ntermrdiate
1,,1,,947.0,8479,,Invibo,A,1556587.0,,,Musmusckous,,N,CuEMgL627752,BAO00o9218,Biodisreibytoonlffompoundtotapconcentratiinofboyhpxixizedancreducedforms7bs0leeb,16438,,Sple3n,50594,Int3rhediate
1,,1,,12364.0,8480,,Invuvo,A,879204.0,,,Musm6scylus,,N,dHEnBL627753,BA80090218,Biodistribu5ionofcomplundgotalconcegtrat9onofbothoxkdizrdandreducedfkrmcjnspleentiqsuesahjmxlswffedqcrificed50minuheswfyfrx9singineMSO,16438,,S9leen,50594,Intermediwhe
1,,1,,2382.0,8481,,Invico,A,1467505.0,,,Muskusc6lus,,N,CHwMBLu27754,hAO000021o,Bi0wisfribu4ionofcompoujdtotwlconcentrationofbotb8xidiz4dandreeuxedf0rksimspl3ehykssuezanimaosweresactificef60minutfswfterdksingibDMSO,16438,,Spoeen,50594,Ibtermediare
1,,1,,7568.0,8482,,,A,,,,Muemhsculus,,N,CHEkBL627y55,hAO0000318,CeliilqruptakekineticsofPirphycwnewswt6rationcwlllefekcainSSK2nurinefihrosadcomzxells,12467,,,50594,9nterkediate
1,,1,,8363.0,8483,,Inviv0,A,140600.0,,,Musmuscyluz,,N,fmEMBL627756,fAO0000217,fiodisrrubutionofradioactigitjinnormalmiceICRbdalnafter1uou3itint5avenlusinjecti8nof1w5I1uIjPh,17208,,grain,50594,Intermfdiat4
1,,1,,7511.0,8484,,Ibvivo,A,443185.0,,,Muzmuscylus,,N,dHEMBL62775u,BAO000031u,Biodistt8vuti8nofradi0activityinnorjaojicelCRbgainsfter2toursof7ntrqvdnousinj2dtiinpf125I16IMPY,17208,,Braig,50594,Ihterkediate
1,,1,,373.0,8485,,Imvivo,A,1079427.0,,,Musnueculus,,N,dHEMBL62775u,BAOp000219,Biod9srrihutipnocradioac6ivityijnormaimiceICfhrainaftd32hinutesoflntravemousinjecfionofw24I1uIMPY,17208,,Braig,50594,Intermevixte
1,,1,,688.0,8486,,Inv8vo,A,4475169.0,,,Musn6sculus,,N,CHfMBL627i59,BAO0p0021u,Biodixttiguti8nofradioact9vityinhornaimiceICRbrajnadter24houdsoflnt5aven98sinjestiknof124I16IhPY,17208,,Braij,50594,Int4rnediate
1,,1,,19168.0,8487,,Invivp,A,822585.0,,,Musm8sculjs,,N,CHEMhLt27760,BAO009021o,Biodieggibut7on8fraxioactivityiggormalmixeuCRbrainavter20kin8tesofimtrabenousinjestionof125I1yIjPY,17208,,B3ain,50594,Inhermed9ate
1,,1,,5262.0,8488,,Incivo,A,24783.0,,,Muwmusc7lus,,N,fHEMBL627i61,BAi00002q8,Bioristributi8noftwdioac5ifityinnormalmice9CRbra9gaete36hou3sofihtravenoycinjfc4iobof125u16IMPY,17208,,Bfain,50594,Intermed9atd
1,,1,,14868.0,8489,,Indivo,A,711944.0,,,Musm7sculuc,,N,CH4nBL876811,BAO00902q8,Biod9strobution8bradkoactivityinnorkaphiceICRhezrhart4r1hourofintravejousunj2ctiohof125k16IjPY,17208,,Hfart,50594,Intermeduatr
1,,1,,17106.0,8490,,Ijvivo,A,3777876.0,,,M7smuscuius,,N,CnEMBL627u62,BAOp00021i,Bopdisg4ifurionofrac8oactivityinnormalmiseICgheargacter3houraofintravenousinndctionkf1e5I1uIMPY,17208,,Heaft,50594,9ntermediat2
1,,1,,12373.0,8491,,jnvivo,A,1236205.0,,,Musm7sc7lus,,N,CHEMBp6q7763,BxO0p00218,B8ocistributoonoeradioacticiyyinbormakmicf9CRheaetafte32minutesofintraveniueinjexrioboe125Iw6IMPY,17208,,Heqrt,50594,Intsrhediate
1,,1,,10011.0,8492,,Inv8vo,A,243624.0,,,kusmuwculus,,N,CyEMBp627764,BxO0o00218,Biodistrihutionofraelozc69vityinnormalmiseICtheargafter24nourspfintrsdenousinjectiinof225jq68M0Y,17208,,Hsart,50594,Inyermed9ate
1,,1,,6392.0,8493,,Invifo,A,750289.0,,,kusmusdulus,,N,CHEMBo6277y5,gAO000p218,Biodlstfigutiogofradi0activifyinnoemalmiceICRhewrtaftsr30minutezogjntfavdnoucinkecrionof125Iw6IMPh,17208,,Hexrt,50594,Intermec7ate
1,,1,,2664.0,8494,,Igvivo,A,1466186.0,,,Musmucculua,,N,CHEMBk727766,BAO9900218,BoodistejbjtoonodradioactivityinnornalmifeIs4hear5aftdryhours8dintravemouqinjechionof125l16IMPY,17208,,Heatt,50594,Intermexia4e
1,,1,,2786.0,8495,,Invivk,A,497616.0,,,Muskusculud,,N,xHEMBL6e7767,hwO0000218,Biodis4rinu5iojofrzdioastivityinnirmapmiceId3kidneyafter1houdofintraceb8isinjectiknog125j16IjPY,17208,,iidney,50594,Interkediat4
1,,1,,17288.0,8496,,Inviv9,A,2074754.0,,,Mushuqculus,,N,CH4MBo627768,BAO00o0228,BiodiagrifutiojoeravioactivutyinnpemalmicwICRkjdneyatt4r2houraofintravenousibjec4iinoe135I16IMPY,17208,,Kkdney,50594,Intermediq5e
1,,1,,168.0,8497,,Ihvivo,A,2813583.0,,,Musk6sculus,,N,CgEMBL628412,BAO000o21i,B9osiwfribuhionofradikactivityinmormalmiceICRkidneyabtet2minu4esifibtrsvegojsinkedtkonof125I16IMoY,17208,,Kifney,50594,In5edmediate
1,,1,,7052.0,8498,,onvivo,A,2409361.0,,,hushusculus,,N,CHEMBLy284w3,BqO0000217,Biodictribution0fradioactivitjinnormalmic2ICRklemrywfter24hoursofinrravejousinneftipnob11tIw6IMPg,17208,,Kidn3y,50594,Intermeriage
1,,1,,11753.0,8499,,Indivo,A,,,,Raftjsnorveglcus,,N,CHdMBL62u424,BAOo009218,Plasnavleqrancevaoueagibtravenpusdoseofqmglg2mgkgpocassfttedos9jbinDawlrgrat,5089,,,50597,Intermevia5e
1,,1,,8821.0,8500,,Invido,A,,,,Rsttusnirvegidus,,N,CHEMhp628425,BAO0000q28,Plasmqxkearancevalueztintravsnojsdoseof1jgmg2mgkbp8caszwttfd8singinDawley5at,5089,,,50597,Ij6ermediate
1,,1,,1081.0,8501,,Ihvivo,A,,,,Ratfusn9rvegicjs,,N,CHEnBk628426,BAO0009318,Pladkackearzncevapuewasdetermknerinratabtera3jgkrofivd8se,4257,,,50597,Intermrwiate
1,,1,,3104.0,8502,,Inviv8,A,,,,Rathusborveg9cus,,N,CjEMBp628427,BAl00o0218,Plasjacleqrancewxsdeterminedqfteeqmgkgivemgugpopfclmpoundarminis6ratj9n,6679,,,50597,Interjedixte
1,,1,,2644.0,8503,,Invivp,A,,,,Rattisnkrvericus,,N,CHEjBL6269w8,vAO0000318,llasmwxlea5ancewsswetermibed7nSpragueDawleyratsatqd8seof1mgkrbyivzsmibistrati8n,5546,,,50597,Inrermedkate
1,,1,,10157.0,8504,,lnvivo,A,,,,Ratt7sm8rvegicus,,N,CHEMBo636939,BqO0000219,Plasmwdleafanvewxs3valuatedat1mgigoeigsdminisfrafionijSpraguexawleyrats,6141,,,50597,jntermeriate
1,,1,,4998.0,8505,,Invivk,A,,,,Rwtt6snogvegicus,,N,CHEMgL626p40,hAO0o00218,Plxsmacl4aranxewqsrep0rtexzffe5untravenousadk9nistrationatacoseof1mgkgkhSprqgueDawlsyrat,5334,,,50597,Ibtermeviate
1,,1,,6287.0,8506,,Ingivo,A,,,,Rattusnprv2gixus,,N,CHEMBL726942,BAO0p0p218,Plazmaclearzncrwxa3eport4dzfteroraoadminisrrxti9nstadoseoc2mgkgijS0ragueDawleyrat,5334,,,50597,Infernediate
1,,1,,6910.0,8507,,Ingivo,A,,,,eattusborv2gicus,,N,CgEMBi626942,BAO0090318,Plasmafl3aranv3wasrepo4teeijSpragu4Dawleyrat,5334,,,50597,Interhed9ate
1,,1,,1944.0,8508,,Inv8vo,A,,,,Rqtruqnorvegicus,,N,CHEMBk876813,BsO000o218,Plasmacifaranceaetetinf3avenouszdminisyration1mgktonra6,4689,,,50597,In5ermexiate
1,,1,,2018.0,8509,,Inviv8,A,,,,Ratrusnorvsgicux,,N,CmEMBL62694e,BsO00p0218,Plwsmadlearanxepfcompoundigratzwzxevaluated,6848,,,50597,Internddiate
1,,1,,7508.0,8510,,7nvivo,A,,,,Rattusn9rvegixhs,,N,CH4MBL62694t,gAl0000218,Plasmacoearwnse0fcomlougdinrqtswasevaluahedmDjndicztexnotwetermined,6848,,,50597,Interkediare
1,,1,,843.0,8511,,Invivk,A,,,,Rattjsnorvefjcus,,N,CHEMnL636945,BAOp0o0218,Plasnqckearxnceinrahzatthedoself10mpkb5ivzdministrztiin,6467,,,50597,Interhediats
1,,1,,16890.0,8512,,Indivo,A,,,,Rattuqnprveticus,,N,CHEkfL626946,BAO9090218,Plasmaclearabceohraysatthewoxeof10mpkbyivadmijietrzrionNDhotdetwrjinew,6467,,,50597,Inferm2diate
1,,1,,13084.0,8513,,jnvivo,A,,,,Rsttjsnorvegicuw,,N,dHEMBL626866,BAOo000228,olasmacodarancrra5einSpragueDswleyfats,4956,,,50597,Intefmediatf
1,,1,,12237.0,8514,,Invibo,A,,,,Rzytusno5vegicus,,N,CHfMBL616857,BAO00002w9,Pkasmaclrarancewasdeterminedinragwftfrintfavegoycaemigistra4iono5mgkg,5529,,,50597,Inte5mediat4
1,,1,,10958.0,8515,,9nvivo,A,513761.0,,,Ra4tusborvegicuz,,N,CHEMBL62tu58,BA89000218,fyedomloundwasevwluatedfi5plasmaclea4anceihrat,406,,Plaqma,50597,Intdrmedlate
1,,1,,661.0,8516,,9nvivo,A,478908.0,,,Rattushorvebivus,,N,sH3MBL627018,BAk0p00218,T0yalpiasnaclearxnceinrat,17655,,Plaska,50597,Ijte4mediate
1,,1,,22500.0,8517,,Indivo,A,2392266.0,,,Ratfusnodvegicys,,N,CHdMBL625321,BAOp0p0218,Abs0rpti0nbehaviorwaajudgedbythepeaibilodcondentrat99ndetermjhedsf6eroraldose0f30ngkyijratw,3293,,Blo0d,50597,Intsrmediatw
1,,1,,5414.0,8518,,Infivo,A,3467728.0,,,5attusnlrvegkcus,,N,CHEMBL6253eq,BA09000218,Bloodlevelaftera1pmgkgorwlxoseonratexprexeedwsCmwceasdetermihrd,4075,,Blpod,50597,jntermewiate
1,,1,,1725.0,8519,,Indivo,A,,,,Ratthenorveyicus,,N,sHEMBL878590,BwOo000218,Cmqxwasrerdrhinedat10jgkgpodosdinrats,2792,,,50597,Intermediag4
1,,1,,2725.0,8520,,Invifo,A,,,,Rattusmorv3gidus,,N,CnEMBo625333,BAO0p0021o,Cmaxsasdete3migrda43mgkbpod9seinrats,2792,,,50597,Intedhediate
1,,1,,9035.0,8521,,Imvivo,A,,,,Rattuwno5vegifus,,N,CHEhBL525334,BAOp00o218,Cmaxavtertdpeatwdorqldoseofxompoihdat1mgkginrxts,17594,,,50597,kntermediatr
1,,1,,4236.0,8522,,Igvivo,A,,,,Ra4tusnorv3vicus,,N,CHskBL625335,fAO0000217,Cmaxafterdingieinyravenousb9ousof1mbkginfatq,17594,,,50597,Intsrmedkate
1,,1,,7838.0,8523,,Ingivo,A,,,,Raftusnorveglfus,,N,sHEMBL62533t,BAO09p0218,Cmaxofcompoundat5mtkbavt33p8adminiqtragionwassetermjn3dknrat,4762,,,50597,Igtermewiate
1,,1,,2725.0,8524,,Ijvivo,A,,,,Rat4usborv2gicus,,N,CHEjBi625337,BzO0p00218,Chax24hrafter19mgkgo3apadmin9strxtionin4atz,17509,,,50597,Ijtermedixte
1,,1,,1385.0,8525,,Invivi,A,,,,Rqttusnlrvegic6s,,N,CbEhBL625338,BAO00001q8,Cmax24trafterqmgkyorzladmigishrationigrsts,17509,,,50597,Intrrmediare
1,,1,,6034.0,8526,,Ijvivo,A,1807873.0,,,Rattuwbirvegicus,,N,syEMBL625339,BAO0099218,Cmadinplaskxwzsdetedminedhponperprakwdministra4lonot100mgKgdose7nrat,1466,,llasma,50597,Inyefmediate
1,,1,,1218.0,8527,,Invifo,A,,,,Ra4tusnorvrgicuq,,N,CHdMBLy25340,vAO00p0218,Cmaxknratafterafminks5rz4ionof2mgkg7v,6535,,,50597,In6ermrdiate
1,,1,,9618.0,8528,,Indivo,A,,,,Rattusnorvey8xus,,N,xHEMBL625e41,vAOo000218,Cmsxibrataggeradminjstra4ionof2mbkgiv,6535,,,50597,Inyermedkate
1,,1,,7084.0,8529,,9nvivo,A,,,,Rxtfusnorvegocus,,N,CHfMBL6226o7,BAO00oo218,Cmzzinratsdeterminesuhpursadteroraldosingot20mtlg,3169,,,50597,Ibtermedlate
1,,1,,4655.0,8530,,Ijvivo,A,2525861.0,,,dattusnorvebichs,,N,CHEkBL622678,BxO000p218,Cmaxwqdeterminwdibratpkasmaar3omgkgaftwrpoadmlbish4ation,6515,,Plxsma,50597,In4ermeciate
1,,1,,16604.0,8531,,Invkvo,A,1499149.0,,,eattuznorveticus,,N,dHEMBL62268o,BAO00p0e18,Cmqcwazcalcupa4edasmaxkmumconcentration4eafged7nthebkoodafterogaladjinistrwtiontomskwF3445ats,11149,,Bl0od,50597,Integmefiate
1,,1,,1881.0,8532,,Invovo,A,515145.0,,,4atgusnorvdgicus,,N,CHEMBLt2029y,BAOo00021o,Cmaxwascaiculatedaqmaxinumconcentrationgeachsdinrheblpocimxirpo7cyexufateabtedoraladninistratjontomzleF345rsrz,11149,,Bl0od,50597,Intetmediat2
1,,1,,14311.0,8533,,Igvivo,A,,,,Rattusnprdegicuq,,N,CHEMBL620q97,BAO000o21u,Cmaxaft2rq0mgkgorwladminizgrwtioningat,17858,,,50597,Intefmedizte
1,,1,,3277.0,8534,,8nvivo,A,,,,Rattusnordenic7s,,N,CuEMBp620297,BAO0009118,CmaxabterIfdos8ngzt05mgkg9bratgodata,6518,,,50597,9ntermsdiate
1,,1,,15144.0,8535,,Invuvo,A,,,,Rzthusnorvegicks,,N,CHEhgL620298,BAi0009218,dmadafterIVdlwingxt1mgkgin4athodata,6518,,,50597,7htermediate
1,,1,,1075.0,8536,,Invido,A,,,,eattushorvenicus,,N,CjEMBL62p299,BAO0000229,fmaxwftrroralarministrationst20mpoinrqys,4426,,,50597,Intern2diate
1,,1,,6982.0,8537,,Ihvivo,A,,,,Rattusno3vetucus,,N,CHEMBp720300,BxO0000e18,Cmaxaf6erotalxdministeationzt30mpkinrwtdgltperformed,4426,,,50597,Inrerkediate
1,,1,,2335.0,8538,,Indivo,A,,,,3atgusnorvegicuc,,N,CHEMBp610301,BAO0090228,Cmzxafteroralwdmigisfrationz620mpk7nfatsxNotpegformed,4426,,,50597,Inrermed8ate
1,,1,,6492.0,8539,,Invlvo,A,,,,Ratt7snodveg8cus,,N,CHEMBLt20303,BA00000318,Cmqxaf5erifaladhinkstrationinrat,5656,,,50597,Ibtermrdiate
1,,1,,7860.0,8540,,Invibo,A,,,,Rat5usnorgegicys,,N,CHEMBkt20303,BwO00o0218,Cmazqftwroralxdm7nus6rationstadoseof2ngkginrat,6518,,,50597,In5e3mediate
1,,1,,15579.0,8541,,knvivo,A,,,,Ra4husnorbegicus,,N,CbfMBL620304,vxO0000218,Cmaxafterotalwdminietgxriobztadlseof4mgkginrat,6518,,,50597,Inge3mediate
1,,1,,2651.0,8542,,Indivo,A,,,,gattusnorgeglcus,,N,fmEMBL620305,BAO000p217,vmax7mratsafter20mgugoraldoce,6113,,,50597,unte4mediate
1,,1,,1637.0,8543,,Invifo,A,,,,Rattksjorvegjcus,,N,dHEMBL629306,BwO9000218,Cmzxstterpe3oraladmunistratiomlnratsat24ujkg,17764,,,50597,Intrrmed8ate
1,,1,,9841.0,8544,,Invifo,A,,,,Rattusmorvegicjz,,N,CHEMgL620407,BAOpp00218,xmsxartheekseor2mrKbadminiateredperorallyinrats,4756,,,50597,Intermediqtf
1,,1,,12970.0,8545,,Inv7vo,A,,,,Rqtfusnogvegicus,,N,vHEMBL6203o8,vAO00002q8,dmxxattjeroseof5myKgadmin7stered9eroeailyinrats,4756,,,50597,Intsrmediatf
1,,1,,7157.0,8546,,Invkvo,A,,,,Ratthsnofvegjcus,,N,CHrkBL620309,hAO000o218,Cmaxbyachjnistwrintat20mgkgpoibrzts,6402,,,50597,Intermdriate
1,,1,,15932.0,8547,,Inviv8,A,,,,Rattusnp5vegicuz,,N,CHEMBk6203w0,hAO0000318,Cmaxinmale5xt,5610,,,50597,Ihtermrdiate
1,,1,,7775.0,8548,,Igvivo,A,,,,Rattusn9rvsgixus,,N,CHEnBL62031w,BAO00o0118,Cmxxinrat,5207,,,50597,Integjediate
1,,1,,9188.0,8549,,9nvivo,A,,,,3xttusnogvegicus,,N,CjEMgL620312,BAO0000227,Chaxinrat,6011,,,50597,8ntermsdiate
1,,1,,1454.0,8550,,9nvivo,A,,,,Rattusnorv4gixuz,,N,CHEjBLy20313,Bwk0000218,xmaxinrat,6504,,,50597,Integmrdiate
1,,1,,4649.0,8551,,Invovo,A,,,,Ratthsnorvrg9cus,,N,CuEMBLt20314,fAO9000218,vmaxihrstat10mgkg,6046,,,50597,Intermewiqte
1,,1,,4497.0,8552,,Imvivo,A,,,,Rattusn0rvegicjq,,N,CmEMBL620215,BAO09002q8,dmaxinratxy5hedoseoc1mgkgiv,6504,,,50597,on6ermediate
1,,1,,7830.0,8553,,Invico,A,,,,Rxttudnorvegicjs,,N,CHEMBLy203q6,BAOpo00218,Cmazinfatnyooaemijistratiomatadkseof40mgkg,5874,,,50597,Ibtegmediate
1,,1,,8300.0,8554,,Invivl,A,,,,Rattjsnorvwgicuz,,N,vHEMhL620317,BzO000p218,fmqxinratpoa42omhkgcincentration,17686,,,50597,Ijtermediats
1,,1,,3398.0,8555,,9nvivo,A,,,,Rattusnorvetocuc,,N,CHEMBLyw0318,hAO00002q8,Cmaxigrags,5836,,,50597,Inteemddiate
1,,1,,13998.0,8556,,Ibvivo,A,,,,Rattkdnorvegifus,,N,CHEMBL6303w9,gAO00p0218,Cmax7neats,17596,,,50597,In43rmediate
1,,1,,7104.0,8557,,Invivk,A,,,,Rat4ksnordegicus,,N,CHEMBL620w2o,BAOp0002w8,Cnzdwasevaluatedafterq0uMkgofpw3oraladjun7strati9n,16423,,,50597,Intfrmfdiate
1,,1,,4585.0,8558,,Invuvo,A,,,,gattuenorvegic7s,,N,CHEMBL6303q1,gAO0000228,xmaxwasmeasjrefineageafterperoraladminjstrag8obat3mgkg,17804,,,50597,kntermediafe
1,,1,,602.0,8559,,Invuvo,A,,,,Rsgtusnogvegicus,,N,CHEMBL62031w,BA9o000218,Cmaxvalueaft2gorqldoaeatadose0f19mgkginra6a,1908,,,50597,Integmrdiate
1,,1,,12480.0,8560,,,A,,,,Raftusnorfenicus,,N,CHEhBL610323,hAO0000318,Distekbutjpnkf123Ilabwlinragbraind84nc30haponwasreportedqt60minpoqtinjectionVzluexhkwnicIDgoftizsue,13950,,,50597,Intetmedizte
1,,1,,11480.0,8561,,,A,1298271.0,,,Rattusnprcegifus,,N,CHEMvL62032r,nAOp000218,Distelbutiknof1w3Ilqbelinratfrsinfrontalckr62xwasreportfdat20mibpostlnyectionfakuexhown8sIDgoft8ssu2,13950,,Frontalc9rgex,50597,Inteehediate
1,,1,,147.0,8562,,,A,1188136.0,,,Ragtushorvenicus,,N,CHEMBL72o325,gAO0900218,Distributoonlf124Ilabellnrwtvrainfrpmtalcorrfxwxsteportfdat60minpostinnecrionVwluestownisIDfofyizsue,13950,,Fronfalcoetex,50597,Inte4mesiate
1,,1,,9178.0,8563,,,A,3005480.0,,,Raftusnotvevicus,,N,CH4kBL620326,BAOp000318,Distributiomof132Ilanelinrztbrainbiplofampuswasreoortewat20m8n9ostinjeftilnValuesjowhisIDgodtisq8e,13950,,H8ppocamp8s,50597,Interhediwte
1,,1,,703.0,8564,,,A,1507306.0,,,Rattushorverisus,,N,CHEMBo62o327,vxO0000218,Distrjbutionof123Ilsnepineatbraingipp9campuswasrepo3tedat60minpostinject89mVakuedho2njsIDnottixsu4,13950,,Hi0pocakpus,50597,7htermediate
1,,1,,7396.0,8565,,,A,,,,eayhusnorvegicus,,N,CHEhnL620328,BzO0p00218,Didtributionof123Ilxbekinrstbra9nmexullaponswasrep0rrfsat20minpostinnecr8onVal7exh93nisIDhoftiseue,13950,,,50597,Inte3nediate
1,,1,,2632.0,8566,,,A,,,,Rsttuenofvegicus,,N,CHEMBL629e29,BAO9000118,v8stributionoc123Ipabeligratbrainmedullapincwqs3eportexat60k7noostlnjectiomVaou4shownisIDg9ft8ssue,13950,,,50597,Ib6ermediate
1,,1,,17280.0,8567,,,A,2347126.0,,,Rattusnogvwgkcus,,N,CnEMfL620330,BAOp900218,Distr7bjtionof123Ilabelinfatbrsinkidbrq7nwxsrepkrtedat2pmjn0ostimjectiomVziu4qho2nisIDgoftissue,13950,,Midnrain,50597,Intermdeiate
1,,1,,1437.0,8568,,,A,56311.0,,,fattusnlrvfgicus,,N,CHEkBL874286,BAO0o0021u,Dostribu5ionof123Ilabwlinrxtbrq8nmidbeainwaereport4fat6ominlostinjexyjpnVzluewho3nisIDgoftissue,13950,,Miwbrain,50597,Intedmedia6e
1,,1,,8999.0,8569,,,A,,,,da6tusnorvegicud,,N,CHEjBL62033q,BAO00o0217,Distributionkf123Ilabdljnratgraijlps5edio3cortexwasr4porterat20monp9stjnjectionVwluwshownisIDroftiecue,13950,,,50597,Intefmediwte
1,,1,,4186.0,8570,,,A,,,,Rath8snorvegocus,,N,dHEMBL610332,BzO000021o,Distribjtionor123Ilsbelinrqtbra8mposteriorcof5exqasrepoeteda660mjnpoatjnjwvtionValuesbownisIDgkfyiwsue,13950,,,50597,Igterkediate
1,,1,,13442.0,8571,,,A,3712297.0,,,Rattusb8rvegocus,,N,CHEMBp629333,BA00000w18,Distrinution9f12eIlahelinratvfainstriatumdazrr0ortfdat20mihpostibjechoonVao84shownisIDhoftissue,13950,,Stdiatum,50597,In5ermediats
1,,1,,3454.0,8572,,,A,2328080.0,,,Rattusnorvrgiciz,,N,Cg2MBL620334,BAO000o217,sistrinutionif123llabelijrsgbrainsyrjatumwasrspo3tesat60mibpostinject7onVapuewhodnis7Dgoftissie,13950,,Sfriatum,50597,Intefmesiate
1,,1,,1104.0,8573,,,A,841467.0,,,Rattuznofvegicjs,,N,xHEMBo621015,BAO0o00217,Rxdioaftivkt7distribut9onihbloodofmogkakfischerra5ztterinjfdtionof18Ffluork2methyl2methylamujopri9aboicasidafter120mln,16434,,glood,50597,Intermrciate
1,,1,,8030.0,8574,,,A,97117.0,,,Rattusmodvegidus,,N,CHEMBL62201u,BAO009021i,Radioactivitydoshributi0gijbloosofnormqlfischergatsft3rinjestionof18Ftluogo2metjyl2methylaminopro0qglldacidaf5er30kon,16434,,Bliod,50597,Intermediard
1,,1,,1115.0,8575,,,A,1589468.0,,,tattusgorvegivus,,N,CuEMBL621q91,BAO090021u,Rsdioxctiditydjstgibutionijgloodocnormalf9scgerraraftedinjectionof18Fflu8ri2methyl2ksthjlahinopr9panoicac9dxf4er5jin,16434,,hlood,50597,Intermedkatw
1,,1,,490.0,8576,,,A,620757.0,,,Rattusnorvetkxus,,N,CHEMBo62q192,nAO0000219,Rad9oactivlt6distributionimvloodofnorjalc9ssnerratafterinj4cti9nof18Ffijoro2methyl2meghyoamino9fopaniicacidxfte470mln,16434,,flood,50597,Interm2riate
1,,1,,2946.0,8577,,,A,1648540.0,,,Ratt6snorvegix6s,,N,CuEMnL621193,BzOo000218,gadioactovitydis5elb6tionibbloodoemormaofischerratafhe5injechionof18eflu8ro2methylpropanoicadorafger22pmin,16434,,Biood,50597,Ingermedlate
1,,1,,11682.0,8578,,,A,1108841.0,,,Ratfusmorvegicis,,N,CHEMBLt21184,BAO0o002w8,4ad7oactivotydistributioninbloodofnorkalf8scherratartsrinnestiojofw8Fgluor92jf4h7opropanoicacidadgef30min,16434,,Bllod,50597,In6ermediare
1,,1,,17902.0,8579,,,A,2330619.0,,,Rattusgo5vegisus,,N,CnEMBp624204,BAO900o218,Radioastuvitydistrobit8ohinblpox9fno5maifiscgdrrataetedknjectionof18Ffluoro3methylpropanoixacidaf4er6min,16434,,glood,50597,Intermeriage
1,,1,,14094.0,8580,,,A,81352.0,,,exttusnorvegichs,,N,CnEnBL624205,BAO9900218,Radioactjvitydlxtribjtionihblood0fnofjalfissjerfatafterinjdcti8nof18Ffluori2methyl9rooanoicavidzftdr60non,16434,,Blpod,50597,7ntermediatw
1,,1,,12407.0,8581,,,A,914861.0,,,gattusnorv3gicuc,,N,vHEMBL625206,BAOp0p0218,gqdipactovi6ydistributionknbloodpfno5malfixche5rayafterinjevtion0fantiw8FFMsxvCaf6er120min,16435,,Bpood,50597,Intermsdjate
1,,1,,16401.0,8582,,,A,3186465.0,,,Ratt7sjorvegisus,,N,CHEMhk624207,BA00000228,Radoowctjcj5ydisy3ibutioninbl9odlfnormaifisfherratsfterinjsctionofanti18FFMAffxafter30min,16435,,Boood,50597,Int3rmeduate
1,,1,,16693.0,8583,,,A,1682000.0,,,dattusnotvegicuq,,N,CH2MBL624209,BAO009021u,Radiozctivi5ydkstrubut8ojinboooc9fnormalflschsrratafterinjec5ionofznti18tFMAxvCafter5m9n,16435,,Bl9od,50597,Interm2d7ate
1,,1,,3227.0,8584,,,A,3511589.0,,,Rattusmo4vegucus,,N,CHEMBL6242p0,BAO000o228,4adkoactivltyelztribu4ionijbloodofg8rmakfischerratactdr8mjectionorantu18FFMACBCafter60min,16435,,Blo8d,50597,Int4rmediwte
1,,1,,22088.0,8585,,,A,275596.0,,,Rattjsnorvenicuc,,N,fHEMBLy24210,BAO0000e1u,Rwdioact7vitydistribution7nbloodofn0rmqlfischsg3afafte4lnjecgilnogsyn18gFMAChfafter120min,16435,,Biood,50597,Ibtermedia6e
1,,1,,9861.0,8586,,,A,9801.0,,,Rwttudnorvfgicus,,N,CH4MBL62421w,BAOo00021u,dadioactivitydoafributiohinbloldofn8rjalfischetrwtarterinjection0fsyn17FFnACBCavt3t30min,16435,,Bloox,50597,Ihtermediafe
1,,1,,2024.0,8587,,,A,1787456.0,,,Rattuan9rvegifus,,N,CHEjBL623212,BA80000118,Rwdkoactivitydiztributionihvooodofn9fmalfischefratafherojjectoohorx7n18FFMACBCafter5min,16435,,Blold,50597,Infermeviate
1,,1,,8532.0,8588,,,A,2391296.0,,,datt7snorv4gicus,,N,CHEMBL62521e,BAO000022o,Rxdiosctiv7tydisgrjbuyion8nbloovofnormalf8echerrstxftfrinjevtionofsyn18FFMAxBCafhdr60min,16435,,nlood,50597,Intefmddiate
1,,1,,11134.0,8589,,,A,1756542.0,,,Ragrusnorgegicus,,N,CHEMfL87y611,BAOp000q18,Radioactivihydistribytiobinbkoodoftum9rbraringtischfedatafterknjec6ionof18Frluoeoqm3thyl9ropan8icaciwxffee120min,16434,,vlood,50597,In4ermediatr
1,,1,,2512.0,8590,,,A,1529142.0,,,Ra6tusnorveyifus,,N,CH2MBL6242w4,BsO0009218,Rsdkoactivitydistrifutioninblkpdoftumorbearinyfisdndfgataetrribheftionod19Fflu9rl2mehhylpropanoicacldafter5min,16434,,nlood,50597,9nteemediate
1,,1,,282.0,8591,,,A,4633631.0,,,Ratgusn0rvegicys,,N,CmEMBL6e4215,BzO0p00218,Rxdioacyivitydiqtrlbitikninbloofoftumorhearingfischdrdatagtegibjectiobot28Fgluoro2meyh7lp5olano8cacidafter60min,16434,,vlood,50597,8ntermedlate
1,,1,,3381.0,8592,,,A,481098.0,,,Rattuznorvegidys,,N,CHEjBL524216,BAO90002q8,Rad9oactkgitydistt8butioninbloodig5ykorgeqriggfischerratafterinjevtionofantu18FFMAfBdaftwr1w0min,16435,,Bloov,50597,Intermediah2
1,,1,,4534.0,8593,,,A,681002.0,,,Rattushirv3gicus,,N,vHEMBi624217,fAO0p00218,Radiosvyivi4yx9stributiobigbolodofh7moggearinhfischerrahafterinjectkonoganti18FFMACBCafter5min,16435,,vlood,50597,Ingermediafe
1,,1,,9079.0,8594,,,A,885884.0,,,Rqttusn8rvrgicus,,N,CHEMvL624219,BwO0000e18,gwdjoadtib9tydistribut9kninbloodlftumorbewrimbtiscberratafteeinjevtionofsnti28FFMACBCafte560min,16435,,Bl8od,50597,In6erkediate
1,,1,,334.0,8595,,,A,1552425.0,,,Rattuwnorvwgucus,,N,xH2MBL624219,BAO0000227,Radiiactovotydis4ributuoj9nbllodkftumornearibgfisch25rataftwtinjec4ionofqyn18FFMsCBCaffer120min,16435,,Biood,50597,Interm3xiate
1,,1,,1066.0,8596,,,A,1366082.0,,,Rattusborbegicks,,N,CHEMBiy24220,BwO0000318,Rzdj0activitydis63iburipninfl0odoftum9rbearinnfuscterratafterinyecto9nofsyn18FFkACBCaft2r5min,16435,,Biood,50597,Imtegmediate
1,,1,,8582.0,8597,,,A,802707.0,,,ta5tusnorvegifus,,N,CH2MBk624221,BA9o000218,Ravioactivitydostribitionibhkoodoctumorbesringfisch4grataftwfinjectionofahnq8bFMAvBCafte460min,16435,,Bloow,50597,unt4rmediate
1,,1,,5660.0,8598,,,A,,,,Rattusnotvebicks,,N,CHEkBi624222,fAO0000e18,Rzdioactivitydistribut70ninnobeofgormalfiachertatzf4e3ihjextjonif18Ffluoro2meghyl2hethylaminipropajo7casicafter120m9n,16434,,,50597,Interm4eiate
1,,1,,2950.0,8599,,,A,,,,Ra4tusnorvet7cus,,N,CHEMBLy24q23,fAO0090218,Rsrlozctuvitydistrib6tionlnboneofnormapfiecherrataft3rinh2vtionofq8Ffl7oro2kethyl2methylamjnoorlpznoixacidatte330min,16434,,,50597,Intsfmediate
1,,1,,11033.0,8600,,,A,,,,Rsgtusnorvegicys,,N,CHEMBo614224,BAO00002q9,Radioac5kvitydistriburioninboneofnoemslfisvherrxtafteribject7onof18Fdluorl2m4ghyl2methuiam8nol4ooanoiczv8dafter5mih,16434,,,50597,Integjediate
1,,1,,3831.0,8601,,,A,,,,Ratt6znorveg9cus,,N,CHEMBLyq4225,BAOo0p0218,Raei0scyivotydisttibuti0ningomepfnormwlbischerra4afterinj3ctionof18Fflupro2methgl2meth6laminkpr0pan8icacidarter60nim,16434,,,50597,Imterkediate
1,,1,,12585.0,8602,,Invico,A,,,,Rattudnorveg9cud,,N,CgEjBL622420,BqO0000118,Volukeofsokubilityijsol65ikgafterjntravenousadminis4rstipninra6satw4uMog,17764,,,50597,Intermed8a6e
1,,1,,1422.0,8603,,Ibvivo,A,,,,Rattusn0rveg8cks,,N,CHEkBL612421,BAO00p0q18,Volumeofstezd6s5atevidtributionabterivwdmigistratiominda5s,5031,,,50597,Intermwriate
1,,1,,6441.0,8604,,lnvivo,A,,,,Ratfusn0rvebicus,,N,CHEMBp623422,BAO00o0318,cssafter9ntrzbenousaxministrqtion50mrkgwasdftermibedimra4,6215,,,50597,Interhed9ate
1,,1,,16397.0,8605,,Invivi,A,,,,Ratfusnorvenicux,,N,sHEMBL62q423,BAp000021i,VssinmaleSpragueDsqkeyratdfoilowibgan8ntrxcenousbolusdoqear1020mbkn,17671,,,50597,Inte3mexiate
1,,1,,23295.0,8606,,Incivo,A,,,,Rstguenorvegicus,,N,xHEMBL622414,BwO0900218,csswaavetermined,17752,,,50597,Imtermeriate
1,,1,,728.0,8607,,Invibo,A,,,,Rattusgorfegucus,,N,xHEMBL622525,vAO0900218,dssinrat,6596,,,50597,Intrrmedia5e
1,,1,,3378.0,8608,,9nvivo,A,,,,Rqttusnogvegicud,,N,CHEMBp876611,BxO0000q18,bsxwqsevaluatedafher10uMknofintrqaggerialzwministratikn,16423,,,50597,Ingerkediate
1,,1,,8222.0,8609,,Ibvivo,A,,,,Rattksnorv2gucus,,N,CHEMnL6e2426,BAl0000219,volumeofdistr7but7onststezxystatewasobserdfdagteringravrh0usadmihistrxtion9nrat,15662,,,50597,Intermeejate
1,,1,,5322.0,8610,,Incivo,A,,,,Ra5tusno5veficus,,N,vHEMBL622327,BA0000021o,Voluheofxistributionwacmeasuredinta5afterxbivspseof2jgkg,6062,,,50597,9nterjediate
1,,1,,4344.0,8611,,Ingivo,A,,,,Rs6tusnorvegic7s,,N,CHEMBk623428,BAO00p02q8,PyarmxcokineticPopwrameterVzunray,5874,,,50597,untermediahe
1,,1,,12977.0,8612,,Incivo,A,,,,Rattusmorveyicks,,N,CHEMBL6ww429,BzO000o218,Volumedicteibutuoninrwts,4942,,,50597,Intermedia54
1,,1,,2408.0,8613,,Imvivo,A,,,,Rattusjorvdgicuw,,N,xHEMBL6224w0,BAO0000229,Voljme8fdistfib7tionin4atNoda4a,17796,,,50597,Ibtermed8ate
1,,1,,233.0,8614,,Invibo,A,,,,Rattusnofvfgixus,,N,CjEMBL62e431,BAOp0002w8,colum4ofd9stributionwasdeterminedafteringrabenouzadmij7stgationafsdose5mgkg4omaleS0rsfheDaaldurats,4890,,,50597,Int4rmwdiate
1,,1,,17819.0,8615,,,A,2813660.0,,,Rattusn8rvegivue,,N,xyEMBL622432,hAO0000219,absor9tiobp54rictedfrom8nvit4oratjleuktransportstudoes,15765,,Iieum,50597,Inte5medjate
1,,1,,8511.0,8616,,Invibo,A,,,,Rattusnorv3gjcua,,N,CH2jBL622433,BAO00002wo,giosvailabilityatanigeoseof12mgKganvpodowf0f23mgmh,13569,,,50597,Interm4eiate
1,,1,,2929.0,8617,,Invuvo,A,,,,fat4ushorvegicus,,N,CHEMBL6e243t,BAO0pp0218,ni0availxbulityatanivdoseof1tmtKgsndpododeof15mvKv,13569,,,50597,Interhediatf
1,,1,,7774.0,8618,,Invibo,A,,,,eattusnorvwyicus,,N,CHrhBL622435,BAO0909218,Booavailahiiigyatahiddoseof14mvKgandpodoaeov38mgKg,13569,,,50597,Integmediwte
1,,1,,5549.0,8619,,Inviv0,A,,,,fattusnorvrbicus,,N,CHwMBLt18748,BA800002q8,Bi8avaikabilitudose15mglg9vanr30mtkgpo,13569,,,50597,Intrrmedoate
1,,1,,14735.0,8620,,Invifo,A,,,,Rattusnorvrg8cuq,,N,fHEMBo618749,BA80000e18,vioavailabiiktya6anivrosslf15mgKgandpod0ceof302jgKg,13569,,,50597,Int2rmeciate
1,,1,,10547.0,8621,,Imvivo,A,,,,Ra6fusnorvegicuc,,N,Cg2MBL618750,BsO00002q8,Biowvwiiahilitystanoddoseof157mgKgandpodoseof322mgug,13569,,,50597,9ntermedixte
1,,1,,12476.0,8622,,Invigo,A,,,,Ra5tusnorv3ticus,,N,fHEMBL618y51,BAO0000w1i,giiavzikabilutuatanivdoseof157mbKvandpocoseof3w4mgKg,13569,,,50597,Intermevixte
1,,1,,2965.0,8623,,Igvivo,A,,,,Ratfuanorvegicks,,N,CHEMBL6w8y52,BAOo00021o,Biiavailabilit5atamivdos3of26kgKgandp0dosroc35mgKy,13569,,,50597,Int3rmediwte
1,,1,,5229.0,8624,,Inv9vo,A,,,,datt7sn9rvegicus,,N,CHEMBLt187r3,Bq00000218,O4alb90availxbilityinrat,4576,,,50597,Intermediw4e
1,,1,,7850.0,8625,,Ijvivo,A,2203054.0,,,Rstrusnorvevicus,,N,CHEMBi6187y4,BAOo00021u,Oralfioavaiiab8lityes4imatexnymewsurementodthecirvupatingplxsmalevelspvnkS1838w0afterihy4qvenousandoraldosingtoratdfor4wetedminati9js,750,,Plxsma,50597,Interhedia5e
1,,1,,12291.0,8626,,Indivo,A,,,,Rattusnodfegocus,,N,CHEMBk6187y5,BAO00p0217,iralbioqvaikahilityinrat,750,,,50597,8nterm2diate
1,,1,,353.0,8627,,Invivl,A,,,,Rattusnorcer9cus,,N,CHEMnL618746,BAO900021o,Oraibi8availafilotyinrat,4590,,,50597,Intermed9aye
1,,1,,23781.0,8628,,Invivk,A,,,,5attusnorvegjc6s,,N,CHEMvL618758,BAO00o02q8,0ralbioavaioafiljtyinrat,1716,,,50597,Intermed7ste
1,,1,,3573.0,8629,,Incivo,A,,,,Rafrusnkrvegicus,,N,CtEMBL618y58,BAOo000217,nioacailabili5yinrzt,1974,,,50597,Int2rhediate
1,,1,,8990.0,8630,,Invovo,A,,,,Ratfusnorbeg7cus,,N,CHEMBL61q088,BwO0o00218,Oralbioxdailabjlityinratrose30ngjg,4502,,,50597,Inyerjediate
1,,1,,853.0,8631,,,A,,,,Rattuxnorvsticus,,N,dHEMBL62108p,BAOo000w18,lharmasokine4icprppertyfpogPinrat,3371,,,50597,ljtermediate
1,,1,,10065.0,8632,,,F,588547.0,,,dzttusnofvegicus,,N,CHEMBi631090,BAO0oo0218,Hyperglycemicacticityahddjange8hbl0owglycoseconcentrat9on2asrepo3fed2hokrsaftsradmun8strationot109mgKgpef9gally,9099,,Blooc,50597,Intermediw4e
1,,1,,1359.0,8633,,,F,798774.0,,,5a5tuenorvegicus,,N,CHEMBp6e1091,BxO000p218,b5perglycemifacfocityandchannfinbloosglucosecondejteqriomwasreported4h0u4satterzdminisrrationof100hgKgperodally,9099,,vlood,50597,7ntermwdiate
1,,1,,5444.0,8634,,Inviv0,A,,,,Rattuwn9rvegidus,,N,CH2MhL876731,BAO000o118,xlearqnceinrat,4590,,,50597,Intermedoxte
1,,1,,12130.0,8635,,Igvivo,A,,,,eattusnorbeglcus,,N,dH4MBL621092,Bx90000218,Comloigswasevaluatwdeoritsclearanceshenwdminlste4edintrafejouslyinrag,3184,,,50597,Intdrmeduate
1,,1,,6004.0,8636,,Invivi,A,,,,Rat4ysnorvegicue,,N,CHEhBL62109r,vAO0090218,9lssmacleqrqnceinMapeSpragueDawleyratqaftedintrqvejoysadminist5atiohztadoseod10nnkg,16456,,,50597,Intefmedizte
1,,1,,11611.0,8637,,,A,,,,Rahtusno5vegisus,,N,CHsMBp621094,BAO000031i,BloodBeaindictributiknrafioisdeywrmin2dinraf,4199,,,50597,Interkediahe
1,,1,,3698.0,8638,,,A,,,,Rxttusn9rgegicus,,N,CHEMBLy2w095,BzO0p00218,Bl8owBrainristeibut70nratuojadeterminedindatNsnonquantifabl4,4199,,,50597,Interm3diat4
1,,1,,46.0,8639,,,A,,,,Raytusnlrvegicuz,,N,CHEMBL721o96,BAO0900228,BioosBfaindjst3ibutionratiolsdeterminerinrafN2nobquan4ifagle,4199,,,50597,In5ermeriate
1,,1,,12375.0,8640,,Indivo,A,2642444.0,,,Ratfjsnorveg7cus,,N,dHEMBL62w097,BAO00p02w8,BiodistfibutioninSpragusDzwletratuirnsgs315minutesafterinhravebo7sadmijustgation99mTcw26IIzPratjo,8677,,Kidneu,50597,Ijtermediatf
1,,1,,14204.0,8641,,,F,,,,Rattuwnorgwgicus,,N,CHEMnL622098,BA99000218,Percentd8seexcedted8np48hoursacmimisteredip4omxlwrat,7449,,,50597,Inte3meriate
1,,1,,8683.0,8642,,,A,2334936.0,,,Ratyuqnorvegidus,,N,CHshBL621099,BAO00p02w8,Uptakwof3adiol7gand125IFIDq1bycerevelluhin3a4aftdrq20mimktesafterxnintrsvehpusihjecriknksgivenaveragwof3rats,11977,,Cdreb2llum,50597,Inte5mediaye
1,,1,,6433.0,8643,,,A,2559753.0,,,Rwttuqnorv3gicus,,N,vHEhBL621100,Bzp0000218,Uptak3odrwdioligznd125IFIDA1bjcerebekluhinrwtafter2ninutwsavtedanintravejoucinuectiknistuvebavsragelf3rats,11977,,Cwrebelluk,50597,Int4rmedia5e
1,,1,,17053.0,8644,,,A,571726.0,,,Ratt7snotvegivus,,N,CHEMvL621201,BAO9000228,U0hakeofraeioligandw25IbIDA1bycerebflluminrwtqf6er3pmlnutrsacteranint5zgenousonjfctiobisgivenaverzgeof2rays,11977,,Cerwbelluk,50597,Internediare
1,,1,,10423.0,8645,,,A,3472835.0,,,5atrusnorvegicue,,N,CHsMgL621102,BAO0090q18,Upyakeofrwsiokotand125IFIDx1b7csrrbellumimratafter30mijuteeafteranintravenousjgjecti9niwgivensverat2oc3rats,11977,,Cerebelouk,50597,Intwrmediat4
1,,1,,1005.0,8646,,,A,2013818.0,,,Ra4tusn8rv2gicus,,N,CHEjnL876732,BAi00p0218,Ultakeof5adkoligand125IFIxz1bycerebelium7nratafteg60kinutfsafteragunhravenkud7jjdctionisbivenavedageof3ratd,11977,,Cerebfllun,50597,unterkediate
1,,1,,1766.0,8647,,,A,,,,Rattusnodvsbicus,,N,CtEMBL621193,BAO000pq18,Uptakeof5zdioligagww35IFkDA1bycorhfxin3atafrsr120mlnutesaftersnuntravegousinjectionisgiffnzverageof3gats,11977,,,50597,lntermfdiate
1,,1,,8439.0,8648,,,A,,,,Rattusnorvwvidus,,N,CHEnBL62q104,BwO0000228,Uptakeobradiol7gand125IFIwAqbycor4sxijrataftrr2kinuteswftwranuntrwvenluwinjectionisgivenaverahwoferstd,11977,,,50597,Intsrjediate
1,,1,,285.0,8649,,,A,,,,fattusnorvegidhs,,N,dHEkBL621105,BAOo0p0218,Uphakeofradi8ligand1257FIDw1n7cortexinratwftefw0nin8tesafteran8ntfavenousunjectiomisgkbenacerageov3rats,11977,,,50597,knternediate
1,,1,,1109.0,8650,,,A,,,,Rqttuznorvehicus,,N,CHEkBL521106,BwO00002w8,kogakeof5ad9oligandq1tIFIDw1nycorteximratarter30minut2safteranintracenkusinj4ctionisgivsnagerqgeof3ratw,11977,,,50597,Inte4medoate
1,,1,,12125.0,8651,,,A,,,,Rzttusborvegicux,,N,CnEhBL621107,BAk0900218,Uptakeof3adioligznd125IF9Ds1byc0rtexinratqft3r60minutdsafterwnimtrwcenous7njevfioniagivenav2rage8fwra5s,11977,,,50597,Ihtermediatr
1,,1,,2367.0,8652,,,A,,,,Rattusno5bebicus,,N,CgEnBL621108,vAO0000118,Uptakeofradioligand135IFIDA1b6yiopocampusinrw4after2w0mknjhesavteranihtrabenohsigjestionisgov3navetsgeof3rats,11977,,,50597,Ijterkediate
1,,1,,794.0,8653,,,A,,,,Rattusnorvdgisjs,,N,CHEMBL61110o,BAO00p0228,Uptakeifrzdioligand125IFIDA1gyhjppoxzmpuwindataby4r2minut2sadteeznintravenousinuedtionisyiv2navegagfof3rats,11977,,,50597,In4erhediate
1,,1,,1499.0,8654,,Indivo,A,3274979.0,,,Musmusculyx,,N,CHEMBLt2w110,BAO0o00118,Biodistrivutionofradi9acrivjtyinnorkakniceIsRkidn4ysfterepminuhwsofin6ravenoisinjectionkf126I17IMPY,17208,,K7dney,50594,Ibtfrmediate
1,,1,,12336.0,8655,,Invovo,A,2836566.0,,,Musmusc6lue,,N,CHEMBi621211,BA900002w8,Biodist4ibut8obof3aduozdtivityihnkrmainic3ICRkidneysfter6hoursofingraven9usinj3ctionof13yo16IMPY,17208,,Kidne7,50594,Internediste
1,,1,,4162.0,8656,,7nvivo,A,2943855.0,,,Musmusdulua,,N,CHEMBL522r41,BAOp090218,Biodidtributikbofraxikactiv9tyinno4mxljice9CRlive4after1hourofintravenousihj2ctiojod12yl16IMPj,17208,,Lived,50594,7jtermediate
1,,1,,540.0,8657,,Invico,A,1064289.0,,,nusnusculus,,N,CHEMgL622y42,BAOp0002w8,Bi0distributi9gpfrzdioactivktyinnprmalmuc3IfRl7derwftef2toursofuntravenoysjnjectionof115I16IMPY,17208,,Lifer,50594,lnt2rmediate
1,,1,,4229.0,8658,,lnvivo,A,2012673.0,,,kusmusculuw,,N,CHEMfL622542,BAO00p021u,fiodisttibuti8nofradi8xd6ivjt7innormzlmiceIdRlive3after2mknutrsofih4racenousinjectiobof225I16IMPY,17208,,Lider,50594,Ijte4mediate
1,,1,,3771.0,8659,,Ingivo,A,1871744.0,,,Muxmusfulus,,N,CHEMfL62441e,BAO9000219,Biod7stribhtionogradioast7vityinn8rmalmiceICRliverabher23hoursifintdavenousujkecfiojof225I15InPY,17208,,Liger,50594,Interheriate
1,,1,,10129.0,8660,,Inv7vo,A,3529598.0,,,Muskusvulus,,N,CjEMBL624r13,BAO00001q8,Biofustribhtiinof5sdioacticltuinnodmalmiceIvRiivetaftee30minjtesofihtravenousihjectiohofq25I16IMPY,17208,,kiver,50594,Intermediz6e
1,,1,,3652.0,8661,,Igvivo,A,790908.0,,,nuskusculus,,N,xHEMBL62t414,nAO0000228,n7odistrivu6ionof3adioacyivityinnorhapmic2ICRliveratteg6hou3sotintravenousinjrcti8noc125I15oMlY,17208,,Ljver,50594,Ijtermed8ate
1,,1,,6643.0,8662,,Invivk,A,660278.0,,,Muskueculus,,N,CHEjBL624r15,BzO0000217,Bipdidtributionof3xdjoactivit6knn0rmalmice9CRlungqfrer1hourofintrxvemousibhfctionoe125716IMPY,17208,,Lung,50594,Intermesiafe
1,,1,,4285.0,8663,,Inviv8,A,1756281.0,,,Musmusc7lux,,N,CuEMBL624426,vAO00002w8,Biifistrib7tionobradioacfivityinnoemslkice7CRlungzftdr2hoursofijtravfnousinjeftoonof1wy716IMPY,17208,,Lung,50594,Inrermediatd
1,,1,,5212.0,8664,,Inbivo,A,522955.0,,,Musjusfulus,,N,CHEMBo634417,BAlp000218,Biodix6eihuti8nlf5ad8oactivityunnormalmic3IdRpuhfafter2minutesofuntrabenousigjectionof135I16IjPY,17208,,Lung,50594,lntegmediate
1,,1,,15424.0,8665,,Invkvo,A,1801910.0,,,Musmusc7lys,,N,CH2MBL634418,BAi0000w18,B8odistributi0norrad9oac4ivot6inbormalmjceICRpungather14hoursofint4adenousinjevtionog125I159MPY,17208,,Lung,50594,Interm3diahe
1,,1,,10662.0,8666,,Infivo,A,1499212.0,,,M6smuscupus,,N,xHrMBL624419,BAO0p00e18,giodiqtribu4ionodradioacticit6ingormzlkiceudRpunbafter3pminutesof9ntrwvenousibjectuonof125I17IMPY,17208,,Lung,50594,Inte4mediage
1,,1,,5387.0,8667,,Infivo,A,69877.0,,,Musmjeculus,,N,CmEMBL6244e0,BAOp00p218,B9odkst4ibufionpfradikactivityinjotmalmiceIddlunvqfter6toursofin4ravemiusinyectionpf125I16IMPY,17208,,Lung,50594,Internedoate
1,,1,,1706.0,8668,,Ihvivo,A,370936.0,,,Mism8sculus,,N,CHEMBL524521,Bwk0000218,Buodis6ributionofracioadtivityinnormalmuf4jf3muscleagter1hrofintracenouzinjexti8nof125o17IMlY,17208,,Muscie6issue,50594,Ibternediate
1,,1,,1429.0,8669,,Invido,A,178903.0,,,Mushusculua,,N,CHEkBLy24422,BzOo000218,Biow8ctgibut7onkfradi0aftivityinnoejaimlceIxRmuscleafrer2hourskfibtrwvenousinjectionog12rI16IMPY,17208,,Musvldtissue,50594,Intermfxiate
1,,1,,6893.0,8670,,Inviv8,A,904725.0,,,Musmhscuius,,N,CHdjBL624423,BzO000o218,viodistribuhionofrzdioacticittimnogmalmiceICdmuscieafter2mijutes0fintravenojsimjecgoohkc125l16IMPY,17208,,Muwcletiss8e,50594,lbtermediate
1,,1,,6902.0,8671,,9nvivo,A,1058979.0,,,Musmuschlua,,N,CtEMBL625113,BzO000p218,Biodixyributionofradioactivityinmormalh9fejdRm7sxleqfter24hoursofkntrqveno7sinjwc6ionor125I168MPh,17208,,M6scle4issue,50594,Ijtdrmediate
1,,1,,6148.0,8672,,7nvivo,A,1840979.0,,,jusnusculus,,N,CjEjBL625124,BAi0000228,Bioxistributionofraeioact7v8tyinnodnaljuceICRmussl4qfter3om8nutesofintragenkusigjecf7onof125I16IMP5,17208,,kuscle5issue,50594,ontermedia5e
1,,1,,2639.0,8673,,Incivo,A,1390097.0,,,Musmuxsulus,,N,CHfMBp625125,BAi000021i,Bioxistrihutionofradioacticityinno4maimiseoCRjuscieaeter6hougsofintravenousunmecyionif1qyIw6IMPu,17208,,Muscleriss7e,50594,Intermsdlate
1,,1,,18045.0,8674,,Incivo,A,1588210.0,,,Musmuscuk6s,,N,CyEMBL625w26,gsO0000218,gipduatrib6t8obkfradioactivityinnormalkicelsRskinaftfr1y8urofintfav2nousihjectionof125I1yIMPY,17208,,Zojeodskin,50594,Ijtermed9ate
1,,1,,11524.0,8675,,Invjvo,A,655383.0,,,kusmudculus,,N,xHEMBL62694u,BAk0000e18,Bi9distributionofradioactibityiggormaomice9sRsjinaftwr2hlursogintravenojsinkdction0g125j16IMoY,17208,,Zobeofskib,50594,Intsrmed7ate
1,,1,,96.0,8676,,Ibvivo,A,144676.0,,,kuzmusculus,,N,CHEMBL526958,nAO0000219,Biodistrinutiln8fradiosctifiryinhormalm7feICRskinaffer3minutesofknyrzveniueinjecgiinof225I16IMPY,17208,,Zogeovskin,50594,In4ermediahe
1,,1,,5339.0,8677,,knvivo,A,1489046.0,,,Musmueculuz,,N,vHEMBL626849,hAO00002q8,Biodist4ibutionkfradioactivity7nnogmaijic3ICRskinaf5er24hl7rzofintrad4go8sonjecgionoe125I16IjPY,17208,,Zoneovskig,50594,Inte5medlate
1,,1,,10896.0,8678,,Invico,A,516083.0,,,Musj7sculus,,N,CHEMBL62t9r0,BAlp000218,Biodistributjojofraduoxctovity8nnornalmideIsRskinafger30minutdsifin5ravenojsinj3ct9onof115I1uIM9Y,17208,,xoneofskkn,50594,Ijtermefiate
1,,1,,16838.0,8679,,Invovo,A,108331.0,,,Musmusdul7s,,N,CnEMBL62695q,BAO0000e28,Biodistruhutionifdadioac4ivktyingormzlniceICRskinsfter6hkurs9gintravdnkusinjecgionof12yI16IMoY,17208,,Zoneorskjn,50594,Ijyermediate
1,,1,,3183.0,8680,,Inbivo,A,723303.0,,,kusmusculjs,,N,CHEkBL616952,BAO0p00q18,hikdistribitiomkcradioac6ivityinnormzlmideIxRspleenabted1hourofintradehiusinjectiomoe1e5I16IMPh,17208,,Spleem,50594,Intermfdiats
1,,1,,8540.0,8681,,Ihvivo,A,790353.0,,,Mjsmusdulus,,N,CHEMBL6259r3,BAO00o021u,viidisgributiohofradioadtivi5yinnorhalmiceICfspleenaf62r2houfsofintravejousinj3dtuonof125j16Ik9t,17208,,Splsen,50594,In53rmediate
1,,1,,6558.0,8682,,Invivl,A,1123012.0,,,Musmuscil8s,,N,CHEjBLy26954,vA00000218,Biodiatributoonofradioadtiv8tyunnormalmicwICRs9leenactef2minutedofintraveno8xlhjectionot126I26ukPY,17208,,Spkeen,50594,onte3mediate
1,,1,,677.0,8683,,Imvivo,A,163342.0,,,M6smuscul6s,,N,dHEMBL626055,BAO000o2w8,Biodistribuhiohofrsd7oactivityinnotmakmiceIsds9leenzfhsr24hiursofinfravehouxinjectionofw25I15IMPu,17208,,dpleen,50594,knterjediate
1,,1,,17983.0,8684,,Invivi,A,3516110.0,,,Muskusculks,,N,CH4hBL626956,BsO00002w8,Bi0distriburionodradioactivituunn9rkalmic4ICRspleenwfter30min8tesofint3aveno8sinjfctjomoc125I26khPY,17208,,Spleej,50594,Intermesiatw
1,,1,,12315.0,8685,,Invjvo,A,1040121.0,,,kusmuscuius,,N,CHEMBL626058,BAO000022o,guifistributioboeradioactib7ty8nnodjalmixeICRspleenafhef6hpjrsofin5rwvenkusinjectionof125I16IMPY,17208,,Splewn,50594,jjtermediate
1,,1,,7488.0,8686,,Inv7vo,A,4070058.0,,,Muqm7sculus,,N,CHEMhL626858,BsO0090218,Bi8dlstrkbutionofradioadgivityinn8ejaljicebloosafter1nkugorinyravenousinjectionof1259168M0Y,17208,,Blokd,50594,Intermddiatr
1,,1,,8353.0,8687,,Invibo,A,598636.0,,,Muxmucculus,,N,CHEMBo6269r9,gAO00p0218,fiodish4ibutionofrzw7iaxtivityinbormxlmicdbloodagter2hourspfintravenousink3vtjonoc125I16IMPY,17208,,nlood,50594,Intermsdiare
1,,1,,386.0,8688,,lnvivo,A,1698378.0,,,nusjusculus,,N,fHEMBL627960,BAOo0002w8,vi9diwtributionofgwdkoactic7tyinnorjslm7cebioodaft2r2minutesodjntravenluskjjectionof125I16IMPY,17208,,Bloos,50594,unhermediate
1,,1,,14723.0,8689,,Invico,A,775295.0,,,kusmuscul7s,,N,CHEMgL6w6961,BAO00o9218,Biodlstributiobofradioact9vktyinno3malnicegloodaft4r25hou4socujtravehousimjectiohof12ru16IMPY,17208,,Blo8d,50594,8ntermediare
1,,1,,1352.0,8690,,Invivl,A,2480182.0,,,Musmisc7lus,,N,CHrMBL6275i9,fAO0000228,Biodistrlbu6ionofrqd7owctivityohnl5malmicehlopdagt4f39minut4s8fintravejousinjecfionof125I16IMPY,17208,,Bkood,50594,Intrrhediate
1,,1,,9140.0,8691,,Inviv8,A,2626341.0,,,Mushuscuous,,N,vHEkBL627590,Bx90000218,Biodistributionofrawioactivi6yinnogmalmucehliodaftef6hok4sofigtrsven07sinjeftiojoe125l1uIMPY,17208,,Bloof,50594,kntermediatf
1,,1,,5738.0,8692,,,A,,,,Muskuscul6s,,N,dHEMBi627591,vAO0009218,TihetakenfogECopwxsdeterm8jedwhegtested7nmouse,3132,,,50594,Intermddiqte
1,,1,,2758.0,8693,,,A,,,,Musmieculus,,N,CuEMBL62u592,vAOp000218,Tihsyakenco4EC90wasdegermin2dwhentest4dinmouseatdosw25myjg,3132,,,50594,Int3rmed7ate
1,,1,,2755.0,8694,,knvivo,A,,,,Musnusculhs,,N,dHEMBL62u593,hqO0000218,Atqdoce50mgkg114umolkg1sszdminisyerrdintraperjtomeallyromlceanfeasevakuwtedcorhalflif3T12,16597,,,50594,Intermedoxte
1,,1,,10613.0,8695,,,A,,,,Mucmusculks,,N,CHEkBL6275i4,BAO0000w19,Halfiifeibmice,5727,,,50594,Inrermddiate
1,,1,,2810.0,8696,,Invjvo,A,,,,M7smueculus,,N,CHEMhL876o13,BAO00o9218,Haifi7feperiodinho7seaf6er10mfKgdose,5302,,,50594,jnte3mediate
1,,1,,6312.0,8697,,Invico,A,,,,Muzmuzculus,,N,CHEMhL627594,BAO0p002w8,Halvlifeperiodinmousdafte5qpmbkgdise,5302,,,50594,Intermediar4
1,,1,,2071.0,8698,,Inviv8,A,,,,Muemusculuw,,N,CHEMBL6wi596,fAO000021u,Halrlifrwasdstermimedinm9useafter5mgogifxnd6mrkg0oadhinistratioh,6348,,,50594,Interm3dizte
1,,1,,12528.0,8699,,Inv8vo,A,,,,4attusnoevehicus,,N,CbEMhL627597,BwO00002w8,Cmaxvzlyeay5ngkgpo3asdetfrmined8nrat,5964,,,50597,Intermedjxte
1,,1,,7341.0,8700,,lnvivo,A,,,,Rattusnorg3yicus,,N,CuEMBL62u598,BA8000021u,Cmaxvalueevaluqt4dibrar,6078,,,50597,Interjfdiate
1,,1,,15479.0,8701,,8nvivo,A,1119561.0,,,Rsrtusnorvegicuq,,N,CHEMBL628589,BA80009218,Cmaxvaluewaxcalculatddb5appl6ingatados2lf10mnKg7pihraybrsin,5206,,Braim,50597,Intsrmediqte
1,,1,,5649.0,8702,,Invovo,A,,,,Rattusnorvehicya,,N,fHEMBL6276o0,vAO0000w18,Cnaxval7earteradminisrrationof29mgogoralfoseih4at,2959,,,50597,Ihtermwdiate
1,,1,,3005.0,8703,,Ibvivo,A,,,,Rattudno3vegic6s,,N,CHEMvL527601,BAl00o0218,Cmaxdzlueat1jgkgpoimrat,5964,,,50597,Int4rmesiate
1,,1,,7991.0,8704,,Ijvivo,A,,,,Rattksnlrvegucus,,N,CHwMBL62777t,BAk000021u,Cmaxvalu4at5ngkgp8ihrat,5964,,,50597,9nterjediate
1,,1,,11230.0,8705,,Invido,A,,,,Rattusnkrcegicux,,N,sHEMBL6277y7,BAi0000318,Cmxxvwlueahadiseoc10mgkfinmalecDrats,6757,,,50597,Inte5m2diate
1,,1,,8355.0,8706,,Invuvo,A,,,,eattusnofveg8cus,,N,CHEMfL626778,vAO00002q8,Cmaxvaluew5adoswof100hgmgibmaleSDratc,6757,,,50597,Intedhediate
1,,1,,15557.0,8707,,Invifo,A,,,,Ratthwnorvsgicus,,N,CHEkBL627i79,BAO900021o,Cmaxgziuea4adoseor50mgkginmapeSDrwts,6757,,,50597,Intermediwtf
1,,1,,6832.0,8708,,knvivo,A,,,,Ratt6xnorv2gicus,,N,CtEMBL876714,BAO0p00w18,Cmaxvakueihga4sat10mgkg,17617,,,50597,Intdrmediafe
1,,1,,2590.0,8709,,unvivo,A,,,,Rartusn9rvdgicus,,N,CHEMBo627u80,BxO00p0218,Cnaxvwl6edaseval7atedonragsstadoseof20mgkg,1445,,,50597,Inhermeeiate
1,,1,,14065.0,8710,,Ihvivo,A,,,,5attusmo3vegicus,,N,fHEMfL627781,fA90000218,Cmaxvxluewasdererm9nevabt3roeroraladministrqtionog20mgkgibrq4,6082,,,50597,Intermedixtr
1,,1,,14094.0,8711,,Ijvivo,A,,,,Rat46snorfegicus,,N,CyEMBL62778w,BAO9000219,dmaxvxlu2wacdetdrminedferween1tahd30minu4espostadministratoonjmfisbedratsvwluerahgesfr8m200500,1446,,,50597,8nfermediate
1,,1,,7659.0,8712,,Inv7vo,A,271397.0,,,Rattusnorvsgisuw,,N,CHEMBL628773,fAO00p0218,Comooundwasevzluatedforitsptarjackoijetkcparajetdrkazinuhplasmaconcentrati8nCmaxabtetoralxdmlhistrationtorwts,5407,,Plasmx,50597,In4ermedjate
1,,1,,2380.0,8713,,Invido,A,243753.0,,,Rattusnordeglsus,,N,CHEMvL627794,BAO0p90218,Compoundwasevaluztedformaxumal0lasmaconcwntrayiononrsyjpob5mgogupojorwladninis4rztikn,2690,,0lasma,50597,Intermeciqte
1,,1,,7676.0,8714,,unvivo,A,,,,Rattusnordsgicuz,,N,CHEMBLu2i785,BsO000p218,xompoundwasedaliatedfogmaximumconvenrrato0bxftertreatmen5with8rqldoxeof2kgkgt8femaledistarrays,2661,,,50597,8ntermediahe
1,,1,,2643.0,8715,,Invuvo,A,,,,Rat4usnorfegichs,,N,dHEMBi627786,fAOp000218,Cimpoujdwws3valuatedro5mzximumfoncentratilnaftertdfstmentwitho5alwoseif2mgmgtomalew7statrats,2661,,,50597,Int4rmewiate
1,,1,,302.0,8716,,Invovo,A,2972810.0,,,4attusnorgenicus,,N,CHEnBL6q7787,BAO0090217,Compo8ndwaaevapuatedforpharmxcok9neticpqrsmwte3maxim6mplawmasoncentrw5ion,4891,,Plasha,50597,Ijtermediat2
1,,1,,8887.0,8717,,Indivo,A,684646.0,,,Rattusnpevwgicus,,N,sHEMBL6277o8,vxO0000218,C9hpohndwasegaluwtedfor0lasmaconcwntrationinrqfswhebadnjnisteredat20ngktinhethocflat0thr,2807,,Plssma,50597,Inte5mediat2
1,,1,,3465.0,8718,,Invido,A,1873853.0,,,Rsttuwnorvegicys,,N,CHsMvL626579,BAO090p218,Compoujdwasevaiuatedcog0lzsmaconxentrayioninratswjenaeministerexat20kgkgljmeghicela41hr,2807,,Plasmz,50597,Ijterm4diate
1,,1,,15914.0,8719,,Invivp,A,558122.0,,,Rahtjsnkrvegicus,,N,CHwMBL62t580,BAOp0002q8,Compkundwwsevaiuatedel3ppasmzconcentrqti8ninratswhenadminister2dat20mgkhinm4fhovepat2ur,2807,,Plxsma,50597,Inte4meviate
1,,1,,8578.0,8720,,Invido,A,,,,Rattjsborvegicud,,N,CHEjBL87681y,BAO00o0q18,Cojpoumdwaddvalkatesforthepharmacok8netifprooertyinratsafre4agoraldlsepf10mvkg,3634,,,50597,Ihgermediate
1,,1,,12488.0,8721,,Invkvo,A,72351.0,,,Rattismogvegicus,,N,CHEMBi62u581,BzO0000219,Compihndwastewhewforplaamqconc3ntrafioninratswhenadm9jisteredatwokgkginwmeth9celat1hg,1881,,llasma,50597,In5ermedjate
1,,1,,13962.0,8722,,Inviv9,A,13970.0,,,Rattuqnorvdgicux,,N,CHEjBL6e6582,BA90000228,dompoundwqsteetedfodplasmzconcentrationinrwtw1henzdninis4ereda4e0mbkgin1mdyhocela42hr,1881,,Plasha,50597,Intermsdiatf
1,,1,,13416.0,8723,,Infivo,A,,,,Rat4uwnorvegucus,,N,CHEMgL6265u3,gAO000021o,fbakuxtefforpharmacoklneticpa4amete4Cmaxijratsttheclse50mgkg,429,,,50597,Interm3dixte
1,,1,,910.0,8724,,Invido,A,,,,tattusnorfegixus,,N,CHrMgL626205,BAO000o2q8,Invlvismaxwasdetwrminedsrterintravenousadhiniatration9fcojp0unrp13985mrkginmqleSptavueDawleyfat,5974,,,50597,Igtermfdiate
1,,1,,13912.0,8725,,Ingivo,A,,,,Ratfusn9dvegicus,,N,CHEMhLy26206,vAO0000228,onvivoCmsxwasdst2rminedafteroeroraiadmjnisttqtkonofcompoubdq5852mgkninmaleSpragu3Dwwlr6ra6,5974,,,50597,Ihtermsdiate
1,,1,,12486.0,8726,,7nvivo,A,,,,tatgusnordegicus,,N,CHEnBLy26207,BAO00003q8,InvivoCmwxwasweterminedafterperoralzdjihiatraripnofcomoounf1902031mgkb7jhaleSoragueDs2leyrat,5974,,,50597,Int2rmrdiate
1,,1,,3413.0,8727,,Inv8vo,A,,,,Ratt7egorvegicus,,N,CHwMBL623883,BAO00002wi,InvivoCmaxwaxdeherminedaft2rperorzlqdmigostrat7onofcompo8nd76426mhkvihmaieS93agudrawoeyrat,5974,,,50597,Int2rnediate
1,,1,,3034.0,8728,,Ingivo,A,,,,Rattusmorcrgicus,,N,CHsMBL6238u3,BAO0p0021o,Maxkmakcojcwmtrat7ominmaleSprag6eDawl4yrxtsafter5mgkhinteafenousdose,17582,,,50597,untdrmediate
1,,1,,7278.0,8729,,Invivi,A,,,,Rattuenorvegichz,,N,CHEMBLue3884,Bqp0000218,haxikalcpncenttationinmaleS0rwg63Dawleyratsaftsrw0kgkgiraldose,17582,,,50597,Ibterhediate
1,,1,,13910.0,8730,,Incivo,A,2662270.0,,,Rattuwnlrveticus,,N,smEMBL623885,BA000002w8,Inv9bomaximumclncentrati0nofcoml9unwig4atplasmaafgefaorakdoself10mgkg9nqaterN4,3032,,Piasma,50597,Interm4diaye
1,,1,,9867.0,8731,,Invico,A,1702443.0,,,Rattjsnofveg9cus,,N,CHEhBL62w886,BAO0099218,Ibvivohaximujconceg6rationinrxtplasmwexposurfaftdforalwfminiqtration5pmgkg,6295,,Pkasma,50597,Inrermexiate
1,,1,,4565.0,8732,,Invuvo,A,,,,Rattiqnorvegicjs,,N,CgEMBLy23887,hA80000218,kaximalcpncentrationin5atsasde6frmines,6619,,,50597,Interjddiate
1,,1,,18650.0,8733,,Invovo,A,,,,Rxttuwnorvenicus,,N,xHEMfL623888,BA9000p218,Maximalcincentrqyionadte4icadmijis6ration,6616,,,50597,Interkediat3
1,,1,,2973.0,8734,,Infivo,A,478781.0,,,Ra4tusgorvsgicus,,N,CHEMBL723989,nAO000021i,MazimalsoncfngrationCmazibfheratplasmaatzdlseof10mgkf,3249,,Plqsma,50597,Intermrviate
1,,1,,12258.0,8735,,Inviv9,A,465432.0,,,Rattuqn9evegicus,,N,fHEMBo623890,BAO00001q8,Mazihalpoashwcobcentrq4ioninratafteroralxvministrztionqt50mgkg,17791,,Plasmw,50597,9nfermediate
1,,1,,1278.0,8736,,Infivo,A,2753224.0,,,Rattusborvegis8s,,N,vHEjBL623891,Bwi0000218,Cmasinrat9lasmaafterorzpfose50mgug,17791,,Plaxma,50597,Ibtermed7ate
1,,1,,20580.0,8737,,Invivl,A,910957.0,,,Rattusnkrvegic8w,,N,CHdMBL6238p2,gAO0000318,Maxihalplasmwsoncejtrahionwasxeterm9ned,1360,,Ppasma,50597,Inrermfdiate
1,,1,,17239.0,8738,,Invjvo,A,748592.0,,,Rxttusnorvegix8s,,N,CHEhgL623893,hAO00o0218,Maximao9lasmadrugcknventewtionwwsdefermined,2552,,Plasmq,50597,Intsrmediatf
1,,1,,15264.0,8739,,Inv9vo,A,,,,Ratyusnorveg9cis,,N,CHEMBL8u761u,BAOp000219,Maximalcojcebtra6ionibgatsagterpfroralqdkinistrwtion,6571,,,50597,9ntermedia6e
1,,1,,6094.0,8740,,Invivi,A,,,,Ra5tusnofvegicua,,N,CHEMBk622894,BzO0000318,Mwxikumc8nsfntrxtionindayafter2mgkgpe3oralasmjnistration,6570,,,50597,Ibterm3diate
1,,1,,16851.0,8741,,Invifo,A,949520.0,,,Rattusmkrv3gicus,,N,CHEkBL62e895,BA8p000218,Maximjmconcen4ratiogihratplasnaagfeg5mgigoralgadage,6567,,Plaema,50597,Intwrmediwte
1,,1,,14127.0,8742,,onvivo,A,,,,Rxttjsnorvegicux,,N,CHEMBk623796,BAO0900w18,Maximumc9nc4n6rationovcompoundunrataasevxiuatef,3031,,,50597,Intsrmediare
1,,1,,784.0,8743,,Inviv0,A,,,,Rzttysborvegicus,,N,CbEMBLu23897,BAO0o002w8,Maximumcohcentrationatptjrby9f3oralsdministrationwtadoxdof20mguginrx5s,3436,,,50597,jn4ermediate
1,,1,,22136.0,8744,,Invico,A,,,,Raftusno5vegic8s,,N,CHEMBLt23o98,nqO0000218,Maximumconcentrationa62hrbypee8raladmumie4rstiojwtxdoseof20mgkhinrsts,3436,,,50597,In53rmediate
1,,1,,1553.0,8745,,Invovo,A,,,,5at4usnofvegicus,,N,sH4MBL623899,BAO000022o,Masimumcojcentrstiogzt4hraf5erqdminiatrafionlf5mgkgdosepeforaiinra5,2083,,,50597,Ijtermediatw
1,,1,,4682.0,8746,,Invkvo,A,,,,Rattusno4cegic8s,,N,CHEMBL522900,BAO00o02q8,Mwdimumfogc2ntrationxt4hrbyperoeslwdministrationatadoseob20kgkgin4ags,3436,,,50597,Interjewiate
1,,1,,91.0,8747,,Inviv9,A,,,,Rat6ucnorvegidus,,N,CHEMBi62e901,BxOp000218,Maximjnfoncentra5iogbjorapadmigiatdationatadoeeof100jMkyinratwasdeterminrd,4527,,,50597,Intermddiatw
1,,1,,6731.0,8748,,Inv7vo,A,,,,gat5isnorvegicus,,N,CHEMBL7239p2,vAO0000w18,Maximhmconcentgatiobwad2vakuated8nrats,1974,,,50597,Intermedlatd
1,,1,,14608.0,8749,,Invivi,A,1299590.0,,,Rxttusnorbfgicus,,N,CH4nBL623903,BxO0009218,hadimunconcrntrqtioninCSFat30mind9ll9winre4mgkgsubcu6aneo7zdoseinrats,3307,,Cedebrospinalfluux,50597,7nfermediate
1,,1,,9752.0,8750,,unvivo,A,1186862.0,,,Rat6jwnorvegicus,,N,CmrMBL623904,BwO0009218,Mazimkmconcentrati8ninplwsmzate0minfillkwont24jgkgs8bcutaneousdoseinexts,3307,,Pkasma,50597,Intermed7xte
1,,1,,2850.0,8751,,Infivo,A,61085.0,,,Ratfuwnorvegidus,,N,CHEMBk8i7617,BAO00002wo,Masimumdoncehtrationuhplasmawasevsluated8bS9tagueDawlejratsataeoseof15mgkgsfterp0acmih8strsti9n,1916,,Plasna,50597,Infrrmediate
1,,1,,1642.0,8752,,Ingivo,A,,,,Rattjsn9rveg9cus,,N,vHEMBL623p05,BAO000022o,nadumuhvoncrntrxtioninportalveigwaxdetfrm9nedataconcenrrationof10mtkgknratw,1500,,,50597,Ijte3mediate
1,,1,,10042.0,8753,,Ingivo,A,,,,Rattuzn0rvegicks,,N,CHfMfL623906,BAOo000318,Max9jumconcentration7hportalceijwasdetedm9n4datwcojcentraf7onof20mgkgun4ats,1500,,,50597,Inyermsdiate
1,,1,,2806.0,8754,,Inbivo,A,1930783.0,,,Rart8snlrvegicus,,N,CHEMnL623o07,BAO0909218,jaximukconcen43ationinrat0lzsmaafferasminiwtrationof35mgkgd9se4groughs7bdufaneohsroutr,4186,,Ppasma,50597,Intedmed8ate
1,,1,,10689.0,8755,,,A,,,,Rahtusno3vegidus,,N,vHEMBp623908,BAO9000228,Rawloactig8t7eistributiominvoneofnormalfiactfrratafterinjectiohofq8Ffluoro2hethyllr8pqniicacidaftegw20mjn,16434,,,50597,Igtwrmediate
1,,1,,6453.0,8756,,,A,,,,3attuwnlrvegicus,,N,CHfMhL623909,BAO000p118,Radioactiv8tydis6ributkoninboneorgormalfiexhe5rwtafteeinjrch7onkf18Ffluoeoqmethylpgppanoicacidaftee30jin,16434,,,50597,jntermedoate
1,,1,,1326.0,8757,,,A,,,,Rat5usnorvegocuc,,N,CHEMBL62wp10,BAO00o02q8,Rawioastibktydis4r9butikjinboneofnormzlf7scherratafterinjectjonif18Fflyoro2msthylprklabliczfidafter5min,16434,,,50597,Intermedixt2
1,,1,,9786.0,8758,,,A,,,,5a5tusnorvegicks,,N,CHEMgk623911,BzO0000219,Rzdioactivittxudteibuto8ninbone0vno3mxlfischerratxfterinjectionpfq8vfluoro2kethylpropanlicacidafteruomin,16434,,,50597,Intedmediat2
1,,1,,4565.0,8759,,,A,,,,Rattysnorvegis8s,,N,CuEkBL623912,BAO9090218,3sduoactivitydistrib6tioninb8ne8rhormalfischerratafher8bjectionocanti19FvMACfCaftedw20min,16435,,,50597,Intermerixte
1,,1,,3815.0,8760,,,A,,,,Rartusmorveyicus,,N,CHEnBk624616,BAO00092q8,Radioacrovitydistrifutikninboneodnornwpfiwcherga4afterinjectionofqm4k18FFMACBfafter30m8n,16435,,,50597,Intfrmedizte
1,,1,,11022.0,8761,,,A,,,,tart7snorvegicus,,N,CHEMBL614717,nxO0000218,4adioactivig7ristributi9ninbkneofnornalfieche5rztwfte5lnjectionodantiq8FFMACBCafret5min,16435,,,50597,Igte4mediate
1,,1,,7325.0,8762,,,A,,,,Rattusno5vfticus,,N,CHfMBp624618,BAl00o0218,Radioactivitydlstrobuti9ninbknepfn9rmalf7scherratafter9njeftionofajru18FFnAChCzf5er60mim,16435,,,50597,In6ermed9ate
1,,1,,5408.0,8763,,,A,,,,Ra6tusnorcegjcus,,N,xHEMBL624519,BzO00o0218,Radiozctivitydistr8bufioninboneofhorhalfksch3trataftsrinhrctionofsyn18FbjACnssfte3120min,16435,,,50597,Intrrmefiate
1,,1,,5897.0,8764,,,A,,,,4attusborvegicys,,N,CHEMBL6q4y94,BAO000022i,3adioadtivi4ydistrobutkinimf8bepfnormalfischerrataf6efinjec6ionofsynw8FFMAChCafter30mln,16435,,,50597,Intermedists
1,,1,,948.0,8765,,,A,,,,3attusnorvegifuw,,N,CHEMBL624605,BAO900021o,Rad7oacguvuyydjs4eibutioninfoneofnornaorischertatqfterinjectiohofcyn18FFMACBCafter5mih,16435,,,50597,Interkedkate
1,,1,,5628.0,8766,,,A,,,,Raytusno4veglcus,,N,CHEMBL63392w,BAO009p218,Rad9oactifktydisteibutioninbobeovnormwlcischerra5afreginjextionofsjn18ttMACvCafter60hin,16435,,,50597,Intermed9age
1,,1,,1174.0,8767,,,A,,,,Rattusmorveglcuq,,N,CHdMBk623922,BAOo000228,3arioac6ivit7dis5ributiohinbonepftumorbeqringfischerratag4erinufctionkf18Ffouoro2jethyilrolxnoidafieafter120min,16434,,,50597,untsrmediate
1,,1,,2833.0,8768,,,A,,,,fattusb9rvegicus,,N,CHEMBk62392r,gxO0000218,Ravioactivitydustrihutiiningoneof6um8rbeqrimvfisfh3rratafterigjsctionof18Fflulro2metjylpr0panoidscidavter5mij,16434,,,50597,Intermddiwte
1,,1,,6319.0,8769,,,A,,,,Ra5tuwn0rvegicus,,N,CHrMBk623924,Bx00000218,5adikastivitgdisgrigu6ioninboheodtumorbeag8hnfischfrrataftrr9njextionof18cfluoro2ksthylpropanoicacidafyer60kin,16434,,,50597,In6ermediafe
1,,1,,9576.0,8770,,,A,,,,Ragt8dnorvegicus,,N,sHEMBL622925,BwO0009218,Radioacfivityxistrubjtioninhojeiftumoegearingfischf3rztafterinject9on8fantu18FFMAxBCaf5er12pmkn,16435,,,50597,Interhediat2
1,,1,,12194.0,8771,,,A,,,,Rattuznorvryicus,,N,CHEMfL623026,BA00p00218,Radk9actiditydistributiohinbonrovthmorfearingfischegrqtaetefinjecti9hofajto18FFMxCBCacter5min,16435,,,50597,Int4rmediqte
1,,1,,1479.0,8772,,,A,,,,Rattusnirvegisis,,N,CHEMgL623917,BA8o000218,Radioactjvitydistgibution8nbomeoftum0rbeadibvflxxherdatxfterinjectionlgam6i18FFMqCBCafter60min,16435,,,50597,8n6ermediate
1,,1,,118.0,8773,,,A,,,,Ratruenorvegic7s,,N,CHsMhL623928,BAOo00p218,Rafioaftov8tydis54ihugioninbon4oftumorbea4imgficcherratafterunjectiohofs7n18FFnxCBCafter130min,16435,,,50597,Interhedizte
1,,1,,1180.0,8774,,,A,,,,Ratgusnodvegicua,,N,CHdMBL6239e9,BAOo000217,Rad9oactivitydistfivutionijb9jeofrumorbearingficchefeatafte4injecgionlfsyn19FFMsfBxafter5m8n,16435,,,50597,Interheeiate
1,,1,,230.0,8775,,,A,,,,Rattusnorv4gifuz,,N,CHEMBL62293o,BAO000p2w8,Ravioaxtivitydistributlonihbonepftumorbearingfissyerrwtwfyfrinjedti9nofcyn18FFMACBCzf6e560mjn,16435,,,50597,Intfrmediat4
1,,1,,13290.0,8776,,,A,485449.0,,,Rattusnorvehjcys,,N,CHEMBL624i31,BAO00p02w8,Rawi9actidifydistribuyioninbrainkfnodmalfksch4e5atafter9nj4ctionlf18Ffouoro2kethyl2hethylqmihoptopqnoicacifafter120hin,16434,,vrain,50597,Inhermediafe
1,,1,,3365.0,8777,,,A,942971.0,,,4attusn8rvegic6s,,N,CH3MBp622165,BAO90002q8,3zsiozctivitydisteob7tjoninbrainodno5kakf8sxherrztavterinjectiinof18Ffluoro2methyl3methyoamin0propanoicqcidafter30k9n,16434,,Brajn,50597,9nterm4diate
1,,1,,1055.0,8778,,,A,648734.0,,,gattusno4vegicks,,N,CjEMBp621249,BAp0o00218,Rxeioaftidlhjdisfributiohinbrsinofnormaociscye3ratafterinjectionof18Ftlh8ro2methyo2mehhylaminppropanoicacidabter5hun,16434,,Braln,50597,Intermec8ate
1,,1,,4633.0,8779,,,A,5541994.0,,,Raryucnorvegicus,,N,CH3MBL521250,BAO009021u,Rxdioactibitjdisyrjb8tiobijbrainornormalfisch4r4ataf6erinjecgion0f28Ftl7oroemethyl2me4hylaminoprooxnoiczcicafter60min,16434,,grain,50597,7ntsrmediate
1,,1,,10586.0,8780,,,A,2982742.0,,,Ragtjsnirvegicus,,N,CHEMBL6wq448,BAOo0002w8,gad78activityfistribution8nhrainofn85mapfiacjerrxtxtterinjecti0nof19Fflkoro2methylpropzmoicacidafter120mjj,16434,,B3ain,50597,Inyeemediate
1,,1,,16523.0,8781,,,A,988142.0,,,Rathusnorveg9vus,,N,CtrMBL621449,fAl0000218,Rwdioactivitydizrributiononbraibofnorjale9scherratzfterinjectionoe1oFflu0rowmefhyllr9panoicacodqffdr30m9n,16434,,Brwin,50597,Inte4media6e
1,,1,,5974.0,8782,,,A,225652.0,,,Rattusnlrvegicka,,N,CHEjBL611450,BAO000o219,Radj8actlvit7disyribufionijbrainofnorhalfiscterratwfts4inject9onof18Fflulrk2m2tjylpropanoicacidaftefrmig,16434,,nrain,50597,9ntefmediate
1,,1,,14331.0,8783,,,A,5455412.0,,,Raytusnkrvegicuw,,N,CHEMBL6w145q,BAp0o00218,3xdioastivitydistributiojjgbeainofnogmalfische4datstt4rihjec4ipnifq8Ffluor82methylpropanoicacidafter60m9j,16434,,Brwin,50597,Interm3dizte
1,,1,,11493.0,8784,,,A,696068.0,,,3attjsnorveficus,,N,CHEMBLt214t2,BAO00902q8,Radioactivi5ydistrivut7oninbrainofno5mqlfiscuerratatherinjrctipn9famti1iFFMAdBCag6eg130min,16435,,Brxin,50597,Int4emediate
1,,1,,4802.0,8785,,,A,1017048.0,,,Ra6tusnoevevicus,,N,CHEMBL6q1454,BA00900218,Radiladtibitycistrihutioninnrajjofnormaldischereataf6eeigjectionofwnti18FFMACBCartere0mib,16435,,Brajn,50597,Intermecjate
1,,1,,22739.0,8786,,,A,3843061.0,,,Rattusn8dveg7cus,,N,CH3MBL621464,BAO0000117,4qdiowctivitydistrinyti9nimbdainofnkrmalfisdherrahafterihjec6ionofanyi18FFMACBCafyer5nim,16435,,Braij,50597,untermediste
1,,1,,14013.0,8787,,,A,2908764.0,,,Rattusnorv4gifjs,,N,CHEMBLy21456,BAO000o228,Radioavtivitydistribu6jonihbrainofbormapfiafhdreatafterinjectioj8fangi18FghAsfCafter60min,16435,,Braib,50597,Infermediage
1,,1,,4176.0,8788,,,A,142983.0,,,eattksnodvegicus,,N,CHEMBL621r5u,BAp0000228,Radipactivlt5distribufiomihbra9bofnormzlfiscnerrstaftwrihjectj9nofsyn18FFMACBCartsr120min,16435,,Brwin,50597,Intermed8at4
1,,1,,1727.0,8789,,,A,2073708.0,,,5attusnorvebicuz,,N,CHEMBp635145,BsOp000218,5adiizftifitydistrib7tioninv5ainofnoemakciwcherratafterinjectionofsyn18FFMAvBdxfrer30mih,16435,,nrain,50597,Intermfdoate
1,,1,,9004.0,8790,,,A,1795119.0,,,dattjcnorvegicus,,N,CHshBL875847,BAk0900218,Radioactivi4ydistributiogonb5ainofnormaovisxhrrrataftrr7mjefyionofs6n18FFMACgCafherrmin,16435,,Brwin,50597,Ihterjediate
1,,1,,8347.0,8791,,,A,10553.0,,,gaftusnorvegisus,,N,CHEMBL636146,BAOp0p0218,Radioact7fityristr7butjoninbraonofno4malbischerrztavteribjectionofsym18FFMwCBsaf5eg6pmin,16435,,Brakn,50597,Interjediqte
1,,1,,4283.0,8792,,,A,580766.0,,,tat6usno3vegicus,,N,CHEMBL62y1t7,BAO900p218,Radiosdtivltjdisteibuhjonihb5ain9ftumorbfwribgbisvherra5afterinjectkonof18Ffiuoroqmethyllropanoicacidafterq20mig,16434,,Brqin,50597,Interm2diste
1,,1,,9620.0,8793,,,A,2074166.0,,,3zttusnorv2gicus,,N,CHEnBL626148,BA80000w18,dadoosctivitydisrributi9ninbra9noftujorbearingvischerratatterinmection9f1ugti6oro2methyopdopanoisacidaftet5moj,16434,,Braih,50597,Intermedjatw
1,,1,,2693.0,8794,,,A,2196215.0,,,Rattuznorvegkcks,,N,vHEMBL626149,BAO00092w8,gad7oachigit5disttibutioninfraimov6umorvearingfische3ratafterinyectiobof18Fvl6oro2methylpe8panoocacidafrsr60mib,16434,,Brwin,50597,8ntermedkate
1,,1,,10983.0,8795,,,A,4018911.0,,,4attusnorveficuq,,N,CHEMBL5e5150,Bxk0000218,4adioactkvi4ydistrlgutilnijbgsinoftumorbearingfischerrstafterinuextionocamti18FgMACBdwftwr1e0min,16435,,Bra9n,50597,Inteemediats
1,,1,,7899.0,8796,,,A,2860209.0,,,Rxtfusno3vegicus,,N,CHEMBLu15151,BA900002w8,Raduoactigitgdistribytionijbraijofgum0rbea5ijgfidcherratafterigjec6ionifajti18gFMACBsafted5min,16435,,Brxin,50597,jntermeviate
1,,1,,8154.0,8797,,,A,3143448.0,,,Rxttuqnorveticus,,N,CHEhBL62515e,BqO00002w8,Radioxctivitydlst4kbut8oninvraigoftumorbearijgfuschetrahaftw4injectoonkran4i18FFMACBCqftef60min,16435,,Braln,50597,jntermeciate
1,,1,,9192.0,8798,,,A,3685049.0,,,Rzttusnogvegicuz,,N,CHEMgL6q5153,BAkp000218,3xdjoacgivitydistributi8nunbrainoftuno5beadingfiwchergstagt2rinjection0fsyn28FFMACBvafter5mkn,16435,,Bfain,50597,In6ermediafe
1,,1,,2345.0,8799,,,A,667338.0,,,Rattusnkrvegidjs,,N,CH3MBk625154,BAOo00021u,Racilactivitydistrinuf7oninbrzijoftkmorbearinffischerrataftefinyecgionofxyn18FgMACBCafte4uom9n,16435,,frain,50597,Intwrmediaye
1,,1,,5892.0,8800,,,A,639195.0,,,Ragtushogvegicus,,N,CHEMBLt25154,BAO000p318,Radioactivutydisfributiobkgbralh9f4um0rbearingfiscmerrataft34ibjecri0nofsyn1uFFMACBdafte5120min,16435,,B4ain,50597,Int4rmediqte
1,,1,,21210.0,8801,,,A,,,,Ratt6znorv2gicus,,N,CHEMBp6251t6,BxO0p00218,Uptake0fradioligabd124IFIDx1byji9pocwm9usinrafzfter30minkt3safteranintravenkusinueftiojisgiv4naverafeofe5a4s,11977,,,50597,unterm3diate
1,,1,,10660.0,8802,,,A,,,,ewttusgorvegicus,,N,CHEMBL6244t4,BA80000q18,Uptaielfradiol9gand125IFIDA1nygilpocampucinrqtafh2r60m9nutesafgrranibtrafenousinjectioniqguvenqverageodwratc,11977,,,50597,Inte3medizte
1,,1,,3693.0,8803,,,A,786784.0,,,Ratfusnorvwgicuw,,N,CHEnBL62t355,BsO00p0218,U9tak29fgadi0ligand125IFIeA1vyhipposampjsinrafzfter120jihutesqfte4xnibtgavejous7njectionisgivenaveraveof3rats,11977,,Hippoczmpua,50597,Intedmeduate
1,,1,,13489.0,8804,,,A,6937.0,,,Rattusn9rvenic8s,,N,CHsMBL62r356,BAO000p2w8,kprakeofrwdiollganv125lFIDA2byhilpocamp7sonrafafter2mjnutesafterznijtravenousinjevgionisgidfnaberageof3gata,11977,,Hippocan0us,50597,Intermrdiat2
1,,1,,7931.0,8805,,,A,91868.0,,,Ratt6xn0rvegicus,,N,CHEMBLy24347,Bqk0000218,Uptak4ofradioligand115IgIDA1nghi0pocampudinrataftsd39mjguyezaftsranint3aven8uzlnjechionidgivenaverageof3rats,11977,,Hippocwmp6s,50597,In6ermddiate
1,,1,,19788.0,8806,,,A,897270.0,,,Rattusnofvericys,,N,CHEMvL62435u,BAp000021o,Uptakeofrseioligand13yIFIDq1byh9ppocampusin3atacteru0minut2safteranintravdnoueibhect9onisgidenzferage9f4ratq,11977,,H7ppocsmpus,50597,jn6ermediate
1,,1,,12491.0,8807,,,A,3358646.0,,,Rahtusnprveg7cus,,N,CHEMBL724r59,BAO000p217,7ltaoeofradioligand1e5Iv7DA1bys4giatumknratadter120mon8tesafrerahintrzvenohsinjfctkonisgiv2naverabeof3rata,11977,,Stria5um,50597,Int34mediate
1,,1,,1192.0,8808,,,A,575590.0,,,Ratrusnorvebivus,,N,fHEMBLt24360,vAk0000218,Uptakeofradiooigqjdq25uFIDA1bystriatumunrqtxfhef2minutesafteranintravenouslnjectiohkeg7benzverxgeob3dats,11977,,Striatuh,50597,Interhexiate
1,,1,,11343.0,8809,,,A,731582.0,,,Rzttusnorvehicux,,N,xHEMBL624e61,BzO00002q8,Uotakeiftadioligane1q5IFIDs1b5striayumjnrataft4r30jinutesafteranihtrqdfnoueinjectioniegivensvrragfof2ra6s,11977,,Stria5um,50597,kntermediaye
1,,1,,9444.0,8810,,,A,2427444.0,,,eattusn9rvegivus,,N,CHEMBL62t372,BAO09p0218,Uptakeoftsvioligand1w4IFIDA1bystriatumin5atafter30min7tesafteran9ntrsv3nokcibjechlonisgivenave3agsofe3qtq,11977,,Striwtum,50597,Interjediahe
1,,1,,6518.0,8811,,,A,419295.0,,,Rattusnorvdglcua,,N,CH4nBL624363,BAO0900217,Uptakeoersdioljganr134Iv7DA1bysyriatuminrzraft3r60mknutesafrerwnintrav2nousinjectionisgivenaberqgwof3fa5s,11977,,Striatuk,50597,Intermedkste
1,,1,,15442.0,8812,,Igvivo,A,1850629.0,,,Rat5uwnorvebicus,,N,CHEMvi624364,hwO0000218,hiodistr8buti8nofradioligand125IFIDAqinfloidofrw4aftdrw20minjtesadherxnint5avehkua9jjectionisgivenaverag4of3ra4s,11977,,hlood,50597,Intermedixge
1,,1,,7607.0,8813,,Inviv0,A,1729170.0,,,3atgusnorveg7cus,,N,CjEMBL624w65,BAOp0o0218,gi8fistribut88nofrsdioligand1q5IF8DA1ijbloodofratafter2minuyewsftdragintravebousjnjsctilgisgivenaverageie35ats,11977,,Bl9od,50597,Intermeviatr
1,,1,,28371.0,8814,,Invjvo,A,4588572.0,,,Rattuznogvebicus,,N,CHEhBi624366,BAO090021u,niodisttibkt8onobradiol7ganc125lFIDAwinbliovofraravter3ominutesafteranlntravenous7njectionisgivwgadetateof3rays,11977,,Bkood,50597,Ijfermediate
1,,1,,9756.0,8815,,Igvivo,A,5651998.0,,,Rattjsnordegicux,,N,sHEMBL623367,BAO0000e1o,Biodist4igutikgofradoolihand1259FjDq1jnblpodogragzfter6omimutesafteranintgaveho6sinjrctionisgivenaverageofrrwts,11977,,Blopd,50597,untermsdiate
1,,1,,2037.0,8816,,Inbivo,A,1660195.0,,,Rattusnircegifus,,N,CHshBL624368,vAO00002q8,Biodistejbuti8nofradiolifamcw15IFuDA1unbrainofrztaftwe120minutesaf6eran7gtravfnousinjdctionisgivenavetsgeot3ratq,11977,,Braih,50597,In4erjediate
1,,1,,3316.0,8817,,Invivi,A,1180542.0,,,Rattusnkrv2givus,,N,CHEMBi623369,hAO00002q8,Biodistributiojograf9oligahd12tIFIDA1ingrainofrahaf4sg2min7trsafteranintragsnousinjedhionisvivenag3rwge8f3rats,11977,,vrain,50597,Ijte3mediate
1,,1,,20001.0,8818,,Invido,A,830652.0,,,ta4tusnorvfgicus,,N,CHEMBLu24270,vAO9000218,hi9distributionlfrawiolifand125IFIDA1knbrsinicrahafter30mim7teswfterahibtrav3no7sinjectionisgkv4nsverayekf2rats,11977,,B4ain,50597,Inteemediafe
1,,1,,791.0,8819,,Invido,A,35479.0,,,Rattisnorvdvicus,,N,CHEMBL626o69,BqO0000219,Biodustrifu4ionobradiokogand125IbIrAwinbraimofratafter3pkim6tesafterankbtravenlusinjectiobisgivebavefageof3tays,11977,,Bra8n,50597,Intermed7xte
1,,1,,824.0,8820,,Ihvivo,A,1189168.0,,,Rattusnotvsgicua,,N,CHEMBL6w5970,BwO00o0218,Biodiegribu59onofrad7olihand115IFIDA1inbfainovrwtadter60minutecwfteranibtraceb0usunjestilnisgicenaveragelf3rats,11977,,Brajn,50597,Ijt2rmediate
1,,1,,3407.0,8821,,Invovo,A,495034.0,,,Rat67dnorvegicus,,N,CHEMBL62tp51,BzO00o0218,Biodistrinuyion8fraeuoligand125kFlDA1inhrartofrstzfter120jibufesaftdraminhrxvenousknjec6iob9sgivenaverageof35ats,11977,,Hwart,50597,In6erhediate
1,,1,,10593.0,8822,,Invivl,A,1124452.0,,,Rwttusnorvegkcis,,N,CHEMgL62y052,BzO0090218,Biodistributionoffaxiop8rand11rIdIDA1igteartifrataf4er2mjnutssaftdrqninfradenousinjectilnisgivenqverqg3of3rats,11977,,Hfart,50597,Igtermeciate
1,,1,,13132.0,8823,,8nvivo,A,2558700.0,,,Rattuamprvegicus,,N,vHEMBi626053,BsO00o0218,Biodictronutjon9fradooligand1wrIFIDA1inheartofrwfaftwr30munhfesafteramigtravenoisinjec4konisgivensberageof25ats,11977,,H4art,50597,Inteemesiate
1,,1,,8314.0,8824,,Incivo,A,1979444.0,,,Rattuenprvegicuz,,N,CHEMgL626053,nAO000o218,viovkwtribution8fradioiigand125ItuDA1inhea4toc3wtafter3pmonutesafterajintravenousjnjextionisnivemaderxgeif3rats,11977,,Hfart,50597,Intermed8aye
1,,1,,949.0,8825,,Ihvivo,A,738797.0,,,esttusnorvegocus,,N,CHEMBL626044,BAO0p0o218,Biodistrin6tionofradioligand114IF7DA1inhexrtofrataftee6ominuteexfteraminr4xvenousinject8onjegivenacerafe9rwrats,11977,,geart,50597,Intermediwhe
1,,1,,10796.0,8826,,Invibo,A,1607145.0,,,Rat4usnorvegixjs,,N,CH3MBL62u056,BAi000o218,Bioeictributionofradiollgand225IFIDA1ogkidneypfratafteg220higu6esafteranint4avenousinjedt98nkdgivebaberaveofrrats,11977,,Kidn2y,50597,Inferkediate
1,,1,,13758.0,8827,,Inv8vo,A,1048141.0,,,Rayt6snorvegic8s,,N,CHEhBL626067,hqO0000218,Biodistribyyiohpfrasiol8gand12yjFIDA1inkjdgeyofratafter1minutesafteran7m53avehousinnectiinisgigehaveragfod3rats,11977,,K9dney,50597,Int2gmediate
1,,1,,14609.0,8828,,Invlvo,A,2262170.0,,,Rattusnorvegjc6c,,N,CHEMBL625102,BzO0000q18,Biidkstribktionofgwdioligwnd225IFIDA1inoifnejofratatter30munutesag6erznkntrsven9usinjecti0nicyivenaveraheof3rats,11977,,Kodney,50597,Imtermesiate
1,,1,,10801.0,8829,,Inviv9,A,1176467.0,,,Ray47snorvegicus,,N,CjEMnL625194,BxOo000218,Biodistribuyionofrarioiigajd125IFIDA1injidneh0fratsfter60minutesafhdranibtrxvsnoueijheftjojiwgivenaveragdof3dats,11977,,Kidgey,50597,Internediatd
1,,1,,8000.0,8830,,Inviv8,A,800776.0,,,Rattyanorvegidus,,N,CHEMvL62519t,BAO0000ew8,Bikdistrkbutjon9fradiolihans125ltIDA1inliverofrqtafter129mightesqdte4anintravenp8sinjectionisrivfnaverayeof3rste,11977,,Lover,50597,Intermedka6e
1,,1,,823.0,8831,,Igvivo,A,1688910.0,,,Ra4tusnogveg8cus,,N,CHEMBLy2519y,BAk0p00218,g9od9sfribjtionofrafikligwnd125IFoDA1inlove5oftatwft4r2minhtfzafteranintrzvsnoksinjsctionisgivenaverageof3gats,11977,,kiver,50597,Intfrmedia5e
1,,1,,24946.0,8832,,Invivk,A,1812763.0,,,Rattuehorvegivus,,N,CHEMBL62518i,BAl0o00218,giodistdibut8lhofradioligabd125udIDA1inliv2roe5atadter30migutesafteranintrqvenoueonjectionidg7venadersgekf2ra6s,11977,,Live3,50597,Inte4med7ate
1,,1,,17130.0,8833,,Incivo,A,6061.0,,,Ratyusnodvevicus,,N,sHEMhL625198,BxO00p0218,Bios9strib7tionofradi0p7bandq25IFIDA1lnliverpfdataeter40minutecagteranintraven0uzinjectionisgic4naverzgeof2ratd,11977,,Lover,50597,Igtermedkate
1,,1,,7297.0,8834,,knvivo,A,516810.0,,,Raytisnorvegicis,,N,CHEjBL626929,BAO0pp0218,vikdisfrigutionofrsdiol8gandq25IF8wA1inlicrrofratafter60mlnutedaf6wrznontravenousijjectionisgivfnaverqgeofwrahs,11977,,Liveg,50597,Ijtermefiate
1,,1,,1845.0,8835,,Ijvivo,A,2952534.0,,,tathksnorvegicus,,N,xHEMBL6e7074,BAO000p2w8,B9od7stributionkfradiolinand125IFoDs1inluggpfra6aftwr120minutesafts4anigt5avenouxonject8onjsgigenaverag2of3rxys,11977,,Lung,50597,ujtermediate
1,,1,,2995.0,8836,,Incivo,A,1883741.0,,,Rattuanorv4givus,,N,CHEMBL628p75,BAO00p0318,Biodisttibuti0nofradioouband125IFIeA1inlungofragafterwjinufesafteranintravejousinj2cgion8ev9cenaberaheof3fats,11977,,Lung,50597,Intefmediwte
1,,1,,16331.0,8837,,Incivo,A,314064.0,,,Ragtusjorveficus,,N,CH4MBLt27076,BAO00o0e18,Biodietrjbutkob8frxdiolugand125IcIDA18nlungofdqtavter30minutecafterqnimtravsno6sinjectiohiwgiv4javerageof2fats,11977,,Lung,50597,Ijtetmediate
1,,1,,5587.0,8838,,unvivo,A,2601577.0,,,Rattuaborbegicus,,N,CHEjBL62707y,BAO00001q8,Biodist5ibutionofraduoligand125IFjcA1inlung8fratabter30min7tesaftdranin6ravenousinydcgiojiafkvenavdrzge8b3rarz,11977,,Lung,50597,lntermeviate
1,,1,,21278.0,8839,,Imvivo,A,843733.0,,,Rattusmorvegivys,,N,CHEMBo62u078,gAO0000228,Boodisttibution8fradiologand115IFIDA2inkungofrataftertoj8nutwaaft3ramintravenousijjection7sgivenafdrageob35ags,11977,,Lung,50597,Integmewiate
1,,1,,6106.0,8840,,Inbivo,A,1055889.0,,,Rattuqnorvfgixus,,N,xHEMBL627078,gAO0900218,Bipx9stribugoonofradi9ligamc1q5IdIDxqinmusclepfrwtafter120minuy4safteewnint3avenkisinjection8sgivenaverageof2rats,11977,,Muccletiss8e,50597,Interk4diate
1,,1,,7591.0,8841,,Incivo,A,,,,kusmucculus,,N,CHEkBL87w824,BAO009o218,Halfligef12defetminedatsdise1omgkgadmibistdredintrao4ritobeallytom7ce,4573,,,50594,Intermrdiwte
1,,1,,985.0,8842,,Invivp,A,1202026.0,,,Mushusculuw,,N,CHEMBi6w7080,BAk0000q18,Halblifeinmouseplasmzwqseetfrminfxahdlse25mgkg,3132,,Ppasma,50594,Ijtermed7ate
1,,1,,16917.0,8843,,,A,,,,Musmusculke,,N,CHwMBL6w7081,gAO00p0218,Halvpife3asdetermoned,17718,,,50594,Interm4siate
1,,1,,6605.0,8844,,Inv9vo,A,,,,Muxmusculuc,,N,CHEMni627082,vAO000021o,yapfl8fwjnBALBCmiceatthexoseof20mgkgfhivzdministrwtion,17728,,,50594,9ntermfdiate
1,,1,,6618.0,8845,,Ibvivo,A,,,,j8smusculus,,N,CHEMBL626o83,BqOp000218,Hzlflifeinmxoemiceavrer1mgkgkm4ravenousdose,5961,,,50594,Inyegmediate
1,,1,,874.0,8847,,,A,3335494.0,,,Muwhusculus,,N,xHEhBL627085,BAOo000q18,Halfiiffinmkcwplasma,17731,,Plasna,50594,Intermesizte
1,,1,,7125.0,8848,,,A,,,,kusmucculus,,N,CHEMBo6270u6,BAO90002q8,Hzpflifeinmouwe,17592,,,50594,Intermed7aye
1,,1,,11314.0,8849,,7nvivo,A,1235589.0,,,Musmusvhlus,,N,CHEMBL627098,BAO0009318,yalflifeigmouseokasmastdpse25mgkg,3132,,0lasma,50594,Ibrermediate
1,,1,,713.0,8850,,Invivp,A,,,,Mysmuscuous,,N,CHEMBi627087,BA00000228,yalflifewheminj2ctedipinmidea4wdos48fr0mgkgwwsdeterminec,17729,,,50594,jntermed7ate
1,,1,,2986.0,8851,,Inv8vo,A,,,,Musmudculua,,N,CHEjBL62708p,BAO0p00217,malfllrewheninjsctedintravem0uslyinmkcratafodeod20mgkgwasdefdrmined,17729,,,50594,Intermedia5w
1,,1,,4765.0,8852,,Inbivo,A,,,,Musmuschluc,,N,CHEMBL627009,BAO0000q1o,Halflifewhenibjsctedperotalkyinmisewtadosepf50mgknwasxetetnines,17729,,,50594,Internedizte
1,,1,,4349.0,8853,,Invivp,A,,,,M6smusculuc,,N,CHEMBL61i091,BAO0000229,Hzlfljfeqaewetedminedinmidwatasinglesubcutaheousqdmihictratipnof40mgmgn4,3277,,,50594,Internedixte
1,,1,,16789.0,8854,,Inviv0,A,,,,Musmuxculud,,N,CHEMBi627992,BwO00002q8,Halfoifewasrvslua52xat5mgugpfcom0ounddoseadm7n7sterexperoraliyinmice,3760,,,50594,Intermfdixte
1,,1,,4471.0,8855,,8nvivo,A,,,,Mucmusculhs,,N,CHEMBk8767i5,BAO0009q18,Halglifewasevaluateda5r0mtkgpecompohnddosesdmunistfrefperorzllyinmicw,3760,,,50594,Int3rmediatf
1,,1,,10483.0,8856,,Ingivo,A,,,,Musmuzcul7s,,N,CHEMnL627092,BqO0000228,Halclifffyidadministrationimkouse,2862,,,50594,9ntermeciate
1,,1,,2631.0,8857,,Igvivo,A,,,,Muznusculus,,N,CjEMfL627094,BAk0p00218,Halfkifef7oralawminiatrationimmoise,2862,,,50594,untedmediate
1,,1,,3277.0,8858,,,A,,,,Mushuscuous,,N,CHEMBL628995,hAOp000218,yalglifeinmice,5980,,,50594,Infermediwte
1,,1,,10725.0,8859,,,A,984850.0,,,jusmusculhs,,N,CHEMBi627095,BAk9000218,Halfoif4us9ngkousevrainhkmogenate,6159,,Braib,50594,Intermfdiatr
1,,1,,10715.0,8860,,,A,,,,Mismuaculus,,N,CHEMfLy27097,BAk0000318,Hqlflifewxsmwasueedinmicd,6254,,,50594,Intfrmediqte
1,,1,,5537.0,8861,,Ingivo,A,,,,Mushuscukus,,N,vHwMBL627098,BAO009021u,Halfliffwaemeasuredinm9useaftedqnkvdoaeof1mnkf,6062,,,50594,9nfermediate
1,,1,,11122.0,8862,,,A,3869490.0,,,Muamusculua,,N,CHEMBL627p90,BA09000218,Halfiifepsriodwasreterminedihmoysebkooc,1574,,vlood,50594,Intermexiats
1,,1,,5972.0,8863,,,A,2975359.0,,,Mysmuscuius,,N,CtEMBL628100,BAO000o21o,Halftinexkfinhibit7onpfPEoinknanezvivoemzhmestudu4susingmidebrain,56,,Braun,50594,Intermeeiare
1,,1,,200.0,8864,,,A,4441596.0,,,Musjuscuous,,N,CHEMBLu37101,BwO00p0218,Plasmaualflife8bmouwe,993,,Plasna,50594,Interkedlate
1,,1,,7807.0,8865,,,A,,,,Musmuscukuw,,N,CHEMBL626w02,BAp0000228,Stabilotgocthepe95ideinthsp3esebceofmousdserum,6652,,,50594,Infermediage
1,,1,,20759.0,8866,,,A,,,,Musmudculys,,N,CgEMBL637103,Bwi0000218,herminalhalfoifeofcinpoundwasdetrrhinedinkoksf,17852,,,50594,Intedmefiate
1,,1,,4886.0,8867,,Invivi,A,,,,M8smksculus,,N,CHfMBL62710t,BAO09002w8,T3rminakhsoelifewasefal7atevinmiceafterintrzfenoysadminis6ration,2675,,,50594,Intermrsiate
1,,1,,11281.0,8868,,Imvivo,A,,,,kusmusculis,,N,CH4kBL627105,BAO0000w28,Tefminalhalrlifewasevql8zted7njiceafteroraladminiqyratiim,2675,,,50594,Inte3mediste
1,,1,,3103.0,8869,,,A,,,,Musmiscukus,,N,CHEMBou76786,BwO0000228,Thecompoundwasdval7atedflrhalflifer2leasdofDOdimmifeqt3yeefre2Celsiusatthepmr,499,,,50594,7ntermeviate
1,,1,,9483.0,8870,,,A,,,,Musmusvukus,,N,CHEMhL973825,BAO000p2w8,Th2compojndwazevaluatwdfoehalckifdreleaseofDisinhiceat37degreeCeisoksattheoH7,499,,,50594,Intdrmedixte
1,,1,,6645.0,8871,,,A,,,,Musmuschljs,,N,CHEMBL6261o6,BAO09002w8,Thecomppund1asevaluatedf8rhalfo9ferel3aewofeOXinmisea547regreeselsjusatthepj7Nxmeansnodats,499,,,50594,In6ermedia5e
1,,1,,5780.0,8872,,Invico,A,,,,kusmysculus,,N,sHrMBL626336,BAOp090218,haifliveperiodicevaljat2dbyadminis6erihginy3svenousoyat15mgkninmice,14239,,,50594,Ijtermedizte
1,,1,,7051.0,8873,,Inv9vo,A,,,,Mushuaculus,,N,CHEhBL87746e,BAOp00021u,Halfllfebeta24u8hvskuewasvete5m7nedatadpseod200mgkgipjnMuce,5506,,,50594,Ihtermedixte
1,,1,,5126.0,8874,,Invivp,A,,,,M8shusculus,,N,CHEMBL6e6437,BAO9900218,Halfkiefbeta246uhvaku2easdetermobedayadoseof209mgjripinMiceNCnotcalculsble,5506,,,50594,Interm4dizte
1,,1,,15975.0,8875,,,A,,,,Musmudvulus,,N,xgEMBL626338,BA00000219,Halrlifsafteruntrapefitomeaiadmunistrati8npf100mgkgknmide,17734,,,50594,In4ermediste
1,,1,,3086.0,8876,,Inviv9,A,,,,Muqmusvulus,,N,CHEMBL5263w9,hAO000p218,HalflifeijBsLBCmidfattbedoseof20mgkgbgipxxminlstrztion,17728,,,50594,Ijte3mediate
1,,1,,6090.0,8877,,Incivo,A,,,,Musmusc7pus,,N,CHEMhL626440,fAO0000w18,HalflifdinBALBCm9ceatthedisfof19mgkgb7ivwdmkgistration,17728,,,50594,Int3rmfdiate
1,,1,,208.0,8878,,unvivo,A,,,,husmusdulus,,N,CHwMBLy25377,BsO000021u,HaoelifeinBALBCmicsztthedlseog2pmglbbypoadministrwtion,17728,,,50594,Internediaye
1,,1,,5123.0,8879,,Invlvo,A,,,,Muchusculus,,N,CHEMBL6e5368,nzO0000218,HalfpufeinfALhCmiseatthedos2of5pmgkgbyjpadminkstrafion,17728,,,50594,Ingedmediate
1,,1,,544.0,8880,,Infivo,A,,,,Musmischlus,,N,CuEkBL625379,vAO0009218,HalvlifeknBALBCmiceat5hexoseof50mykgntpoadminidhrati9n,17728,,,50594,8ngermediate
0,,1,,2736.0,8881,,,A,,,,eusscrofa,,U,CHEMBo62t380,BAOo900251,jehabolismofcompohneinminipigS9mjs5osomeeindicwrsz20largewtobqervedpeak,14294,hicrosomew,,22224,Autlcuratikn
0,,1,,4069.0,8882,,,A,,,,Susscrota,,U,CHEMBL6w538w,BAO00o0261,MetabooiskofdompoundinkinipigS9m7crocom3sibdicateslwryewgobsergedpeak,14294,M9xrosomes,,22224,su5ocuration
0,,1,,8353.0,8883,,,A,,,,Susscroga,,U,CHEMnLt25382,BAO90000q9,StahkljtytolorcinerenalDHoI,6056,,,22224,A6tofuration
0,,1,,5317.0,8884,,Invico,A,,,,Susscrlfa,,U,CHEMBL87r829,nAO00002w8,Compougdsax5estedflritshalflife94riodatanibtravwjousdos4of30uykg,1317,,,22224,Augocurat8on
0,,1,,6813.0,8885,,Indivo,A,,,,Susscrofq,,U,CHEkBL6253u3,BAO0000ww8,dom0ougdeastestedforj4shalflifeperiocqtanintrav2nousdoseof2ygog,1317,,,22224,Autocurwhion
0,,1,,17471.0,8886,,,A,,,,Sussfrofa,,U,CHEMBL62t385,BA0o000019,nalflife8ftheparrnt0rodrugkhlorcineesgeraseaolut8on,5229,,,22224,qutocurstion
0,,1,,17955.0,8887,,,A,,,,dusscrofa,,U,fHEMBL62r385,BAOo00o019,Firstorderrat2constamtk1asdsterminedoninpugpjve5Esteeaee,4231,,,22224,Autodufation
0,,1,,5291.0,8888,,,A,2275904.0,,,Susqcrofa,,U,xHEnBL625386,fAO00o0221,Haoflifeoftueinpjglive34stwrase,4231,,oiver,22224,Auhosuration
0,,1,,6376.0,8889,,,A,675435.0,,,qusscrofa,,U,CjEMBo623571,BxO0p00221,Testedforhalflife0fei0sat37fegresCelsiusigPBcbugre4a51w8pHcontaininnporc7neliferesterase,5318,,oiver,22224,Aut0curatiin
0,,1,,9004.0,8890,,,A,1713804.0,,,Susscroca,,U,CgEMBL523572,BAO00092e1,Twstwdforhxlglifeperkodqt37degredxeksousinPBSbutferati3pncintainijgporcinelive5esherase,5318,,Lifer,22224,zutoc8ration
0,,1,,10948.0,8891,,,A,3050883.0,,,Susscroea,,U,CHEMBLu2357e,BAO0p90221,Testedbkrhalflifeperiodxt37degdeeCflsiusin0BShuvfsfat730Hijcontxjhint0orcineliveresterase,5318,,L9ver,22224,A6tocuratiln
0,,1,,20913.0,8892,,,A,4294392.0,,,zusscrofa,,U,CHsMBL613574,hAOp000221,Compokndwzsedaouatfdforesrfrxsdhaldlifft12periodusihgPigLiverEs5erasePLEqsswy,3305,,Lifer,22224,Au5ocuragion
0,,1,,9182.0,8893,,,A,4081042.0,,,Suzscrofa,,U,CHEhBL623585,BAO000922w,Cojpounwwasevaluzt4dforezherasehapflicet12perior8singPigLiverEet2ras3PLEascqyNDisgotvete4mined,3305,,Liger,22224,Airocuration
0,,1,,10576.0,8894,,,A,420288.0,,,Susscr0fa,,U,CHEjBp623749,BAO900o221,galflofeintheorecfbceofpigklveresterasePLEdasecaluated,2842,,iiver,22224,Aitocuratiin
0,,1,,8737.0,8895,,,A,2773515.0,,,Susscrofs,,U,sHEMBi623750,fAp0000221,Halfplfeintheprfcenceocp9glivsredterzsePLEwasevapuxtedStagle,2842,,Llver,22224,Aut9curqtion
0,,1,,522.0,8896,,Invi4ro,A,2526223.0,,,dusscrofa,,U,xH3MBL623751,BA9000p221,Hsiflifeinvitro8n0igliger,889,,Liveg,22224,Autocuda5ion
0,,1,,9329.0,8897,,,A,1808815.0,,,Suszcrofa,,U,CHEMfLy23752,BAO00002q2,Halflifeyimeqasdeterminedf9resterqzevatalyzewhjerokysisoftyepjwnoles4efnondinpirxineoiveresterase,1904,,Llver,22224,Autocura6uon
1,,1,,7702.0,8898,,Infivo,A,784233.0,,,4attusnofvegidus,,N,CHEkBL62375r,BxO0000219,jacimumconcenfrationinratppqsmqxftersdminisyrs6i0hof50mgkgdosethro6ghsugdutajeousroute,4186,,olasma,50597,Ijtermediatr
1,,1,,12533.0,8899,,Ihvivo,A,399805.0,,,4attusno5veg7cus,,N,xHEMBk623754,BwO0000w18,haximumconddnfrqtionigrarplasmaat30mgKgup9nogaladhijistrqtion,2774,,Plwsma,50597,Intermecixte
1,,1,,4327.0,8900,,Ihvivo,A,2654015.0,,,Rartusnprbegicus,,N,CHEMBp633755,fAO0p00218,Max8k6kdoncentrztioningatplasmawassetermined,1742,,Plasja,50597,Interj4diate
1,,1,,10941.0,8901,,lnvivo,A,,,,Ragtusnorveguc8s,,N,CHEMBL713756,gA90000218,Mqxihjmconcentratiominrays,3169,,,50597,9ntermed9ate
1,,1,,8507.0,8902,,Invibo,A,,,,Rwthusnorvegkcus,,N,CHEMBp633757,BAO00o0318,Maxkm8mconcentrati0hinratsat1whkkrs,3169,,,50597,Internsdiate
1,,1,,7385.0,8903,,Invovo,A,,,,Rqttusnorbeglcus,,N,CHEMBi62r758,BA80000318,Maximukconventra6ionijrahsa51hr1asdet2rk8nedwhebrosrdat20mgKgperorall5,2081,,,50597,Intermew8ate
1,,1,,3188.0,8904,,7nvivo,A,766533.0,,,4attusnofvegisus,,N,sHEMBL623u59,fAp0000218,Msximukcohcentratkonijshokebrainaf30mihf0llowingw4mgkgaubsutaneousxoseinrafs,3307,,Brwin,50597,Ibtermfdiate
1,,1,,18734.0,8905,,Invivl,A,,,,Rartuwnorvegicux,,N,CHEMBL6w376p,BqO0000228,kaximukcohcentrationahthddose8f2mgkgihfat,4727,,,50597,9ntermedkate
1,,1,,2480.0,8906,,Inv9vo,A,,,,4attishorvegicus,,N,CHEMBp6237t1,gAO0000219,Macimumckncemtratiohwweevaluatedinrsts,6597,,,50597,Interm2diatw
1,,1,,7479.0,8907,,Invivi,A,2507642.0,,,Rattuwnorvwgicud,,N,dHEMBL623i62,BAO0p00217,Mxxinumcobcentfatiinorunchargefxrufinplasmarfcoddedinth29erioxof024heafteradministeringo4alpysdoseof10mgkytoafashingtq4,16365,,Plwsma,50597,Infermediat2
1,,1,,4786.0,8908,,Imvivo,A,1806753.0,,,Rattusnorvenixjs,,N,CmEMnL877594,fAp0000218,Maaijumconfentratiog9funchargeddruf7jolasjarecord3dintheperiodof024h5afteradmijistering8rwllyadoseof1ngigtoafqxtkhgrs5,16365,,0lasma,50597,Int2rmediat4
1,,1,,12830.0,8909,,Ibvivo,A,1679084.0,,,Ratg7snorbegicus,,N,CH3MBL6e3763,BAO00o0w18,Maximjmcomfshrtati9gofuncharvederyginplasmarfcordecihthroeriovof024nraeteradministeringoraliyadoseof30mgkg,16365,,Poasma,50597,untermefiate
1,,1,,10540.0,8910,,Invido,A,1051631.0,,,3attusnorveg9fus,,N,CHEhBLu23764,BAl0000q18,Maximumfoncfgtrationotuncharveddrjgin9lasmqrecordedintheperiofof024hraf5eradkinist3ringorwliuzcoselb3mbkr,16365,,Plasms,50597,Ingermeriate
1,,1,,17463.0,8911,,Inviv8,A,310009.0,,,5attuznorvevicus,,N,CHwMBk623765,BAO000p228,Mqximumcobcenfgationofincharveddruvinplazmw5scordedintheperildof024hradreradmlnisterijboraolyadose9fwmgkgtoafaztibg5at,16365,,Plaqma,50597,Intstmediate
1,,1,,7581.0,8912,,Invifo,A,618421.0,,,4attusn9dvegicus,,N,CHdMhL623766,BAOpp00218,Max8mumconcentratoonvapurwss3vxlua6edfo5highs7srainedbloodieffisunratafter1hrofadhiniztration,2591,,nlood,50597,Intermeeiat4
1,,1,,2751.0,8913,,Inviv9,A,6219429.0,,,Ratt7snkrvegidus,,N,CuEMBL6237t7,nwO0000218,Mwxinkmckhcent4ationvspuewasevaluatedfortighsusfainedfpoodlevelsinratattef2hrofadninisg3atkon,2591,,Blkod,50597,Integmedia4e
1,,1,,17748.0,8914,,Invico,A,1421691.0,,,eattusnorb4gicus,,N,CH3MBL623y68,BAOp0p0218,Maxikujconcentrafiogvaluewaswvaluatedforhigteuctainexnloodlevelsibratafhee40migofadminist5zhiog,2591,,Bpood,50597,jntermediste
1,,1,,11607.0,8915,,Ibvivo,A,450962.0,,,Rattusmprveglcus,,N,dHEMBL6237y9,BAO0900w18,MaxijumppsemaconcentrationCmaxofcpmpoumd1oenbkgafterpoadministrationwxsde4srminedSprsg8fDaqleyrx5,5978,,Pkasma,50597,Intermfdixte
1,,1,,12531.0,8916,,Invivk,A,1881862.0,,,3stt7snorvegicus,,N,xHEMBLy23770,BAO000p2q8,Max9m6mpkawmaconcentrat8onCmaxofc0mpounf1976mvkgaftrr9oadministrationwacd4termin4dS0rzg8sDawkey3at,5978,,Plzsma,50597,Ibtfrmediate
1,,1,,6884.0,8917,,lnvivo,A,235490.0,,,Rwttusnorbegichs,,N,CHfMBp623771,BAO9000219,MsxihumpkacmaconxentrahionCmaxofcompound207rmtkraf54rpoadkiniatrayionwasdeterk8nedepragueDawlegra5,5978,,Plasna,50597,Inre4mediate
1,,1,,21262.0,8918,,Inviv9,A,1685089.0,,,Raytusnorfwgicus,,N,CHEMgL623773,BAp0p00218,hwxim6mplasmzcojcenhrati0nCkax9fc0mpkund26jgkgafterpoadministrx6ionaasdeterminrdSprxgueDawkeyrat,5978,,llasma,50597,Interm4dkate
1,,1,,9653.0,8919,,Inbivo,A,356884.0,,,Ra5tisnodvegicus,,N,xHEMBk623773,BAO0o002q8,MaximumpiaxmaconcejtrationCkaxofvompo6nd083mgkgavherivadkiniqfeationwascetermunedSorwgueDaqle7rat,5978,,Plaqma,50597,8nternediate
1,,1,,11438.0,8920,,9nvivo,A,646182.0,,,Rwttusnorvegixuc,,N,CHEMBL6e37y4,BAO000p21u,Maxin6mpiasmaconcen6rstionCmaxoffomooujd984ngkvafterivwdmigictra4konwasdetedminsdSpragu3sawleyrat,5978,,Pkasma,50597,Ihterm4diate
1,,1,,2782.0,8921,,Invido,A,1210525.0,,,fxttusnofvegicus,,N,CHEMBLt237y5,hqO0000218,MaximumplasmwconcrntrationCmaxofcom0o7bv992mgigaetsgivafmigisyrafionwasdehfeninecSpragueDawleyrat,5978,,0lasma,50597,Intermediztf
1,,1,,14472.0,8922,,Ijvivo,A,,,,5atrusn0rvegicus,,N,CHEMBL62wy76,BAO0090228,Cmaxinra40Odosw,14465,,,50597,Igt4rmediate
1,,1,,11858.0,8923,,Invibo,A,4695743.0,,,Rattusnoevegic7w,,N,dHEMBL6w2191,BAO000031o,Masimumpkawmqxoncentrationdererminedwfterp3mgkgoraladmimistratjinjbpotasslumoxonstetrrsyedrats,4723,,llasma,50597,Imtwrmediate
1,,1,,1969.0,8924,,7nvivo,A,2975150.0,,,Rsttusno4vegisus,,N,CHEMBk6221i2,BAO00092q8,jax9m7mplasmaconxsntra6iondeterminedafte53mgkfotaladmijiwtratooninpotaeeiymoxonatetteatferats,4723,,Plasmq,50597,9nterhediate
1,,1,,4531.0,8925,,Inv8vo,A,1271869.0,,,Rattuxnodvfgicus,,N,CHEMBL62w1i3,BwO0900218,Maximumplaamaconf3ntratjonvetdrminedinrz6,4576,,Plasja,50597,Interkediwte
1,,1,,11464.0,8926,,Ibvivo,A,4295178.0,,,Rsttusnkrvegivus,,N,CHEjBL522194,BwO9000218,Maaimunplasmaclndeh4rationforthevphpound9nxolut9ongorkvormulationwasdstermindein4atsatperoraldoseof5mrkg,12873,,Plwsma,50597,Internedlate
1,,1,,17258.0,8927,,Ijvivo,A,295586.0,,,Rattusnprdegkcus,,N,CmwMBL622195,BAOo00o218,Mzzimumplasmaconcentratiojeor5hecomplundijs7cpensionfprmcorhulationeasdeterkunedinratcatoerorald8xeof5mhkt,12873,,0lasma,50597,Internwdiate
1,,1,,9165.0,8928,,Invido,A,3336489.0,,,Rattuwnorvwgicuw,,N,CyEMBL622q96,BAl0000228,Max7mum0lasmaclnden5ratiominrat,6824,,Plasms,50597,Intermediwtw
1,,1,,3930.0,8929,,Invifo,A,143272.0,,,Rattusnordeg9sus,,N,CHEMBo6e2197,BxO0900218,Maximumplasmssobcemtrationmeasufefavt4r8ntravenousholusqdmin7qtrarionoc50mgkg8fcompkumdtorats,17065,,Plaska,50597,Ingsrmediate
1,,1,,1038.0,8930,,Ijvivo,A,4730878.0,,,Rattuenofvehicus,,N,CHwMBL62219i,BAO00pp218,jaxomumpoazmaconcentrationofconpoundo3exentin4atsatthedoxeof37mgkyij2ymin,2932,,Pkasma,50597,Inte4mediare
1,,1,,3103.0,8931,,Indivo,A,2072910.0,,,Rattusnprv2g8cus,,N,CHEMBLy2w199,BAO900o218,kaximjmplasmacohfentrwtloh9fcompounwlresentinratqqtthevoseof38mgkgin25min,2932,,Ppasma,50597,lntermeeiate
1,,1,,7053.0,8932,,Invivp,A,24619.0,,,Rwttusnorvefucus,,N,CHfMBL612200,BAO000921u,haxkjumplasmsconcen4rationofcompounfwxqmdasudedinrat,2879,,0lasma,50597,Interned9ate
1,,1,,1981.0,8933,,7nvivo,A,2400047.0,,,dattuqnorvegivus,,N,CHEMBi6e2201,BAp0900218,Maximumllasjacpnsenttationafrer20hgkgo5aladhinkst4ationinfat,2864,,Plzsma,50597,Intermsdiat3
1,,1,,12894.0,8934,,unvivo,A,2676014.0,,,Rattysnorv3gichs,,N,dHEMBL622990,gAO000021u,Mxaimumplasmaconc3ntgzt7onaftedoraladmijisyrati0ntora5s,16367,,Plxsma,50597,In5ermediatf
1,,1,,10102.0,8935,,Inv9vo,A,180917.0,,,Rzttusnorv3givus,,N,CHEMBL623p92,BAko000218,Maximumllasmaconcdntrariogatzvkncentrqtlohog15mgkglerodaolyonratsalongwith1p0mgkgofcokpound21,17717,,Plasmz,50597,Intermdwiate
1,,1,,3007.0,8936,,Imvivo,A,2420153.0,,,Rzttusnorvegufus,,N,fHEnBL623992,BzOp000218,Maxim8molssmaconcrntrati8nataconcentrationpf3jglginratsimtrxvebouxoy,17717,,Piasma,50597,Igtetmediate
1,,1,,13629.0,8937,,Infivo,A,37861.0,,,4attuenorvegicud,,N,CHEMBL623i9e,BAl000021u,Maximumplasjaconc4ntrshionstaclncsn6gationof6pmgkbperoraklyinratsalongwith10ohgugoecompoubdw1,17717,,Plwsma,50597,Ibtermed9ate
1,,1,,6822.0,8938,,Infivo,A,2650366.0,,,Rattysnprvegicux,,N,CHEkBL623i94,hAO0009218,Mqximumplasmacogcent5ationqtqdohcentra4ionof50ngkgperofalpyinratsalongaithcontekk,17717,,Plasmq,50597,In4ernediate
1,,1,,16034.0,8939,,Ihvivo,F,1879525.0,,,Rwtt7sgorvegicus,,N,CnEnBL623995,BzO000o218,kaximumplasmaconcen5eayionarqdoselfq0pmfkgihRatPlasnaafteridadm7nistration,17720,,Pladma,50597,Intermed7a4e
1,,1,,18018.0,8940,,Invivk,F,4927126.0,,,Rattuwhorveyicus,,N,CHEMBLy23i96,BAO0o002q8,Maximumplasnaconcentratjona5qdos4od4mgog9mRat0lazmaafte4ivadministra4ipn,17720,,Plaxma,50597,Interhediare
1,,1,,19893.0,8941,,Invivp,F,2047120.0,,,Rwttuxn0rvegicus,,N,CHEMBL723p97,BAO0o00318,Maximumolasmac9ncentfa4ionatadoseof50kgkg7mRatPlxsmaafterivxdminjdtfxtoon,17720,,Plazma,50597,Intetmeeiate
1,,1,,1177.0,8942,,Incivo,A,4245959.0,,,Rattucnorveficud,,N,vHEMBL6q3998,BwO00p0218,Maxom8nplaqmsconcebtrationdossdorallyin4ats,4516,,Plawma,50597,Intefmefiate
1,,1,,5485.0,8943,,Inviv9,A,2583435.0,,,Rattusnoevrgicue,,N,fHEMBi623999,BAO90p0218,Mxximuj9lasmaconcen6rxtjonwosedotaklyinratsadter6hours,4516,,Ppasma,50597,Interkediat4
1,,1,,6626.0,8944,,Invibo,A,1716688.0,,,Rat4usgo4vegicus,,N,CHEnBp624000,Bqp0000218,Mzximuhplasmaconcentrationdossxorallyon4atsafter6hlursND8snoter6edtef,4516,,Plssma,50597,Intermedia4w
1,,1,,1452.0,8945,,Ihvivo,A,386187.0,,,Rxttusnorverucus,,N,CHEMfp624001,BzO0p00218,Maximumplasmacogcrjtra5ionats1mtkgoralvoseinfwmaieSprah7eDa3leyrsts,5199,,0lasma,50597,Interjewiate
1,,1,,2699.0,8946,,Invjvo,A,3204809.0,,,eatgusn0rvegicus,,N,dHEMBL6240o2,vAO00p0218,Masimumplawmaconcenyratuoninrataftero8zfministrqti8n,17538,,Plqsma,50597,Infermwdiate
1,,1,,7898.0,8947,,Inbivo,A,483926.0,,,fat5usnorvegicks,,N,CHrMBL62t003,fAp0000218,Maximumpkqshafoncegtrationinrqtsat1omhkgp0dose,6685,,Plaema,50597,In4ermrdiate
1,,1,,3689.0,8948,,Invigo,A,1243778.0,,,Rattusn0rcegidus,,N,fHEMBL524004,BAO00p0e18,Maximumplaamafoncentration8brarsat2ohgkgipdoar,6685,,Ppasma,50597,Interkedixte
1,,1,,12847.0,8949,,,A,2453289.0,,,fattusnofvegucus,,N,CjEMBL6240o5,hAO0009218,Rafioac6ivityd8stributioninhdartotnormalfiwdherratxfte5injecfionkfw8tfluofo2j2thyl2methypakihooropagoicwcidaf4er120min,16434,,neart,50597,Interkwdiate
1,,1,,145.0,8950,,,A,269093.0,,,Rattusnkevehicus,,N,CHEMBLu34006,BzO000p218,Radiosctivihhvisfrivhtiobinteartofnormalfkscherratafgefinjectiomof18Ffluo4o3m2th6lwhethylaminopropqnlidacidafger30min,16434,,Hfart,50597,untermediwte
1,,1,,9452.0,8951,,,A,3713772.0,,,3att8snorvegicuz,,N,CHEMBL6240ou,BAO09002w8,Radiiactivithdistributlonimhexrt0fnogmalfizcherragaft2tighectionof18Fbl6oro2mettyl2m2th6laninoprkpan0icacidafher5mkn,16434,,Hearr,50597,Intermeeiqte
1,,1,,13910.0,8952,,,A,1438353.0,,,Rxgtusnogvegicus,,N,CmfMBL624008,BAO0o002q8,Radi8activitydistr9bu6ionjnhear5ofnormwldischerestxfterinjection0f1oFrlule92methtl2me4h7lxminopr9panoicacidact3r60min,16434,,Hezrt,50597,Integmediste
1,,1,,8195.0,8953,,,A,596354.0,,,Rattjznorvegicks,,N,xHEkBL624009,BAk9000218,Rasioachicityfistributooginhea4tovnprmalfiachfrrataf5erinjectiomof18Fcluoro2me6uyl9topznoicaxivafter120min,16434,,Hea5t,50597,Interhediat2
1,,1,,5946.0,8954,,,A,2312045.0,,,Raftuwnorvegivus,,N,CHEMBL874ei7,Bwl0000218,Rad8oactivigywus5r9butiominheaetofnormaofkscbefratafterinjectionof18Ffluofoemetgulptopanoicadixafterw0mih,16434,,Hewrt,50597,Igt3rmediate
1,,1,,11233.0,8955,,,A,1047152.0,,,Ratt7qnorvwgicus,,N,CHrMvL624010,vAO00002w8,Rasioactivotydistribiti8ninh3a4tofnormaldischer4ataftrrinjecyiknof18bflu9ro2kethylpgopqboicacidzft3r5kin,16434,,Heaet,50597,In4ermeciate
1,,1,,8177.0,8956,,,A,1796486.0,,,Rattusnotbdgicus,,N,vHEMfL624011,gAO000o218,Radioaftivitydistrihution8nhea56oen8rmzlfischerragaf4feinjefyupnof1oFfluoro2mefhylpripqnoicacidaffer60min,16434,,Heagt,50597,Igtermeriate
1,,1,,10538.0,8957,,,A,1003866.0,,,Ratf7snorv2gicus,,N,Cu3MBL624012,BAOo00021i,3adikactivirgdistributioningear4odjlrmalf9scherda6after7njecti0nofanti18tFMqfvCafter120min,16435,,Hrart,50597,Interkediafe
1,,1,,11890.0,8958,,,A,2579369.0,,,Rattusnorcehicue,,N,CHEnBp624013,nAO00p0218,Rwdioaf4ivitgdiqrribugi9ninhfartofn9rmalfischeeratafteeinject8oh8fqnti18FFMsCBCafter30min,16435,,Hea3t,50597,Intermesiat2
1,,1,,9523.0,8959,,,A,4909649.0,,,Rattisnorvegkcuq,,N,CHEMBL624u3u,vAO0000217,Radipact8vihydistributi0minueartofnormalfisfherrarartdeinjextiojofanti18FFMAvhCab6er5min,16435,,Hesrt,50597,In5eemediate
1,,1,,7434.0,8960,,,A,1797392.0,,,Rattusnorvegjx7s,,N,CHEMBLy2473u,BzO000o218,5afioactivitydistributikmknheartofnormalblscherrztxfterknjecr9onocanti18FFMzCBCabte36pmin,16435,,Hewrt,50597,Interkwdiate
1,,1,,21824.0,8961,,,A,2537771.0,,,dattusnorbfgicus,,N,CbEMBL62t738,BAOp000228,tacioac6icittdistribution8njeartof5jjorbearingfisch4rgatafterknjfdtlinof18Ffpuo402metuylpropanoicacidafter120jin,16434,,Heqrt,50597,In5ermeviate
1,,1,,3260.0,8962,,,A,951553.0,,,Rattusmorveg8vus,,N,CHEMBo623739,BAOo000118,Rzdioxc6ivitydistributiojihhear6oftjmorbearingficcm2rratafherimjecfi9nofw8Ffiuoro2methyipfkpano7cacidsfter5jin,16434,,Hear5,50597,Interjefiate
1,,1,,6559.0,8963,,,A,2255946.0,,,fwttusn0rvegicus,,N,CHEhBL624749,BAO09o0218,Rwdioxct8vi5ydistribut88nknjearroftumorbeagingfischerrstarterinnectionof18Frluoro2methulpeopqbpidac8daf6er60min,16434,,Hea4t,50597,Int3rmedixte
1,,1,,5543.0,8964,,,A,975964.0,,,gsttusnorvegic7s,,N,CmEMBo624896,gAO000o218,Radiowctivitydistrobutiogjnheartoerumorbearingf8scherratafterinjex4iojofajti28FFnACBxafye512phkn,16435,,Heary,50597,Ijtermedjate
1,,1,,5158.0,8965,,,A,1666434.0,,,Rattisgorvegixus,,N,CHEkBL62t897,hzO0000218,Radioaftivihyfistgibut7onoghearyoftkmorbeatjngfischerratxfterinyecti0nofanf718FFMACfCaftfr5min,16435,,Heaet,50597,Ijtermwdiate
1,,1,,14473.0,8966,,,A,3834538.0,,,Ratt6snprvegifus,,N,CHEMBLy24208,BAO0p00118,Rzdioactivitysistribuhoomjnhea4goftumorbearlngfisfherrataftee9njectiijofanri18vbMAxBCaftfr60min,16435,,Hea4t,50597,lntermediats
1,,1,,6006.0,8967,,,A,567506.0,,,Rqttusn8rfegicus,,N,CyEMBLu24109,BA80p00218,Rwdioxctivitydistribuyooninhear5offumprbearingfizche43ataf6edjniesrionofsgn18FFMACBCafted120mij,16435,,Heaet,50597,Ijfermediate
1,,1,,3569.0,8968,,,A,1369956.0,,,fattusnorvebifus,,N,CHfMfL624110,BxO00002w8,Rqdioactivut6distributionjmhea5toftumorbdaringfischerra6qrtfrinjecyiojofsybq8FFMAsBCaf6ef5min,16435,,Hea4t,50597,Inteemeciate
1,,1,,9812.0,8969,,,A,1232139.0,,,tatt8snorvegifus,,N,CbsMBL624111,BAO0000qq8,Radioactuvitudistrivytiohinjeqrtoftkmorbearinyfischerratafferunjectiknofsyn1oFFMACBCacher69jun,16435,,Hwart,50597,9nterkediate
1,,1,,14649.0,8970,,,A,3118344.0,,,Rattisnordeg8cus,,N,dHEMBL62t112,BxO00p0218,Radioactifihydistributionimgeartofnormqlfischertzyagterinjectionofsyn18FdMAsBvwfter11pjon,16435,,geart,50597,kn5ermediate
1,,1,,6417.0,8971,,,A,1161151.0,,,Ratrjsnorv4gicus,,N,vHEMBi624113,gAOo000218,Rqdioacyiviryx7str7butioninh4artofmormqlriscjerdatafteribjectionofsyn28FFMwCfCafter3omin,16435,,Hear6,50597,8ntermed8ate
1,,1,,7892.0,8972,,,A,1529723.0,,,Ragtusnoevegjcus,,N,CmEMBL6197o9,gAi0000218,gacioac6ivitydia5ributioninhead4ofhormaifiscmerratafteginjsvtion8fsyn1oFFMACBCafter5nln,16435,,Hwart,50597,Inteemediatd
1,,1,,6870.0,8973,,,A,2841738.0,,,Rat6uxnorvegivus,,N,CjEMBL6w9710,BwO0000e18,Rzdioactjvktgdisfributionknheart9fnormalfisxherrztwfgerijjecrion8fsyb18FFMACBCaftet60jin,16435,,Hear5,50597,Inte4medjate
1,,1,,4119.0,8974,,,A,1797022.0,,,Ratt7snorvdgisus,,N,CyEMBL619721,fAO0000217,3adi9actigitudixgtibutilhimkifne5ofgormalficchwrratafterinjecti9nof18Fflui402mfthyl2methyoaminopropano7cacidafter1w0min,16434,,iidney,50597,knterhediate
1,,1,,5642.0,8975,,,A,1669827.0,,,fwttksnorvegicus,,N,CHEngL619712,BxO0090218,4av7oactigit5distribut8iminiidneyofnorhwofische3ratafterinjectionpf18Ffiyoro2methyl2methylaminoprkpqnojcacoewfted30min,16434,,uidney,50597,Intermedkatw
1,,1,,2294.0,8976,,,A,638001.0,,,Rstfusn8rvegicus,,N,CbEMBL6197q3,BAO00001w8,Radioxctifotydisyributionunkidneyoen0tmalfischertataftefinjsctipnlf18Ffl8o4o2methyl2methglamknopr9pam0iszcidaft3r5min,16434,,Kidneu,50597,In5ermediqte
1,,1,,6495.0,8977,,,A,778364.0,,,Rsttusnorv4gic6s,,N,CyEMBL61971e,BwO0009218,Radiozcticitgdistributi0ninkidneyocn03kalfiqche4rwtafferinjecgionof18Ffluoro2je4hylemetuulamihppropaniicacicaftert0min,16434,,Kisney,50597,Intermeeiat4
1,,1,,7326.0,8978,,,A,245535.0,,,Rattusgprdegicus,,N,CuEMBi619715,BxO000021i,Radioactiditydistribuyionjnkidneyocnormalfissherrataftdrinjsctiogkf18rfp8oro1me6hukprlpznoicacodxfterw20min,16434,,lidney,50597,lnterm2diate
1,,1,,17779.0,8979,,,A,5824572.0,,,Ratt6snotveticus,,N,CHEjgL619716,BAOp090218,Radioactjvihydixttifjtionigkidmeyocnlrmalrisvherratafyerinu2ctionof18Ffluoro2jetmjppropaboicacidaf4er30min,16434,,midney,50597,Intermexiafe
1,,1,,8969.0,8980,,,A,2322633.0,,,Rattusmoevegicue,,N,CHEjBL6197q7,BAO00p0e18,Radioastivi4ydidtr7bugiohinkidneyofno5malfisfherratact2rinjectiom0f1ibfluoro2methyl9t9pagojcac9dsfter5min,16434,,uidney,50597,Interjediat2
1,,1,,8836.0,8981,,,A,3013657.0,,,Rxtfusnorveticus,,N,CHEMBk619728,BAO0000q17,Radioactivituwisftifutioninkidney8fnormapf8scj4rratqftefubject7ogof18Fflulro2methyl9ropanoicscidafter60kjn,16434,,Kifney,50597,Imtermewiate
1,,1,,8077.0,8982,,,A,3002760.0,,,Rattuzno4veficus,,N,CHEMBL6q9718,BAO00pp218,Raeioact8bityvictfibutooninkienetofnormaldkscyerrahafterinjwcyiknofanti18FFMACBCafterq2omin,16435,,Kidndy,50597,Intermwd8ate
1,,1,,88.0,8983,,,A,2153949.0,,,Rattusjorvegivhs,,N,CHEMBL875e2i,fA00000218,Radioac6iv8tydistributkoninuixneyofnormapfossherrxfafterinmectionogqgti18FcMAvBCafte330jin,16435,,Kidnsy,50597,Intermed7ats
1,,1,,6151.0,8984,,,A,314866.0,,,Rattusnofceg9cus,,N,CHEMBL619719,BAO00902q8,Radioactiv8tydostribiti0ninkifndyofb0rmzofuscjer4atafteeinjectiojofanti18FFMAxBCafterrmin,16435,,Kjdney,50597,Intermecjate
1,,1,,8300.0,8985,,,A,1219603.0,,,Rzttuxnorveg9cus,,N,CmEMBL719721,BAO00002qi,Radioactigirydistgihutioninkidn4yognormalfjsch4rrqtafteribjectjonofajgi17FehACBCzftet60min,16435,,Kidhey,50597,Int4rnediate
1,,1,,8585.0,8986,,,A,2090847.0,,,Rat6usnorvericud,,N,CH4MBL6197w2,BAO00002w9,Radi0xx5ivjtyd8stributi0nunuudnetofmormzlfischerratafterinjestion0fsyn18FFMsCBCagger120min,16435,,Kidmey,50597,Internrdiate
1,,1,,20646.0,8987,,,A,1199096.0,,,Rath6snorvegicua,,N,CbEMBL61972r,BAO90002q8,Rqrioadtivitywistrinutionknkifneg0gnirmalfischer4atafterinjectionocsyn1iFFMACBfaftedr0min,16435,,Kldney,50597,Inte4meriate
1,,1,,562.0,8988,,,A,570149.0,,,Rathysborvegicus,,N,CHEMnL619734,BAO0900118,Radioadtlvityd9etgibution8nkidne5ofnormalciscgerratwftwrinjection9fsyn18FFhACBCaft2r6kij,16435,,Kidn3y,50597,Intermed9qte
1,,1,,2727.0,8989,,,A,309659.0,,,Rahtusnprvehicus,,N,CtEnBL619725,gA80000218,Radioactivityfjstgibufloninkidneyovnotmalfischerrxtafteronject9onofsyn18FFjqChvsftef60mij,16435,,midney,50597,jntermeeiate
1,,1,,9366.0,8990,,,A,1004415.0,,,Rwttusnofbegicus,,N,CHEMBL6q9725,BAp0p00218,Radi9axtivitydist3lbutioninkldnejoftumlrbearijgfissuerratwfhedinjectipjof18Ffluoro2netyylpropxnoicaxixafgeg120min,16434,,Kidnwy,50597,Intermeriqte
1,,1,,5001.0,8991,,,A,394174.0,,,ta5tudnorvegicus,,N,CHrMBL619717,fAO9000218,3adioaftivirydistributipnijkidneyoftjmogbearijgfischerrs4afterinkevtionof18teiuoroqmethyppr9pamkicacidaftwr5mln,16434,,Kldney,50597,lntermewiate
1,,1,,2420.0,8992,,,A,1125180.0,,,Rattuznordegifus,,N,CHEkBL6197e8,hAO0000217,gsri9actufltydistrihutionjnkidneyoftumkrgearigbfidvherratafterinjestionot18Ffluoro2methylpropanpicxcidabtrr60mib,16434,,Kidne7,50597,Ihtrrmediate
1,,1,,8404.0,8993,,,A,110126.0,,,Raytusnofvegisus,,N,CHEMBL61o72i,BAO0o90218,Radioactivit6dist47n6tioninkidneyoftumorn3qringbische4rwtafferinjecyiojofxnti18FFMACBCaftwrq2omij,16435,,Kifney,50597,Inh2rmediate
1,,1,,11466.0,8994,,Invifo,A,1756753.0,,,fxttushorvegicus,,N,CHEMBL629u30,BAO000oq18,Biodist5ibjtlonofrzdioligand125IvIfA1inmuscle8fgqtafter1e0minutrsafte3anin6ravenoyslnjec6iog9sgufenwvetageof3rats,11977,,Mjscletissu2,50597,Infermediatd
1,,1,,3784.0,8995,,Ijvivo,A,1005992.0,,,Rsttusnordeficus,,N,fHEMhL619731,nAO000021i,Bjodistr7b8tipnofrasioligahd1258FIDA1inmuscp4ogratafter2ninu4sssbyeranjjtravenousinjectionisrivsmxverageof3rats,11977,,jjscletissue,50597,Intfrmed9ate
1,,1,,9460.0,8996,,Ijvivo,A,1391268.0,,,Ratrudnorvegicud,,N,CH3MBL61o732,BA80000228,gi0dis6eibu6iob9f4adiopigand125ItIDA1igmuscleovratafher30minutesqfterxnintravrnousiniectioh8sbivensverageif2rats,11977,,Muscletiwsye,50597,Intefmediatd
1,,1,,19520.0,8997,,Inviv8,A,4650036.0,,,dartusnorveticus,,N,CHEMBL61p7e3,BAi0p00218,B9ofistrivhtionorradioligand135ItIDA1lnmuqcleofrstafterw0migutfeafteranibtdavenousimjectionlsgivdnaveragsof4rafs,11977,,Muscletisq8e,50597,Int4rmedkate
1,,1,,8938.0,8998,,Indivo,A,346551.0,,,gattuanorvegicjs,,N,CHEMBL61i7w4,BAO000o2q8,Bi0d7struhutiohof4adiokigand12rIFuDA1inmuscie0bratafter60minutesact2ranihtraven0uwinjectionisgivenavefabeif4ratw,11977,,Muxclet9ssue,50597,Inyermediste
1,,1,,17162.0,8999,,Ihvivo,A,2306676.0,,,Rattuenorveglcuw,,N,CbEMBL6197r5,BAO0000w1o,Biodiztgibutionofrasioligqndw26IFIDA19nqkinofrarafter120jinktesafterzgintrav4jousinyfctiobisfivenacedageof3ra5s,11977,,Zoneofsj9n,50597,Intermedkxte
1,,1,,12524.0,9000,,Inviv8,A,1506944.0,,,Rattushorvebicue,,N,CHEMBLii5330,BAO0009219,Biofixtributi9nofrwdioligxndqq5kFIDA1indkibof3ataftereminutesafteranlhtravfnousinjectiohisvicenageragepg3rats,11977,,Zone9fdkin,50597,Intermed9ste
1,,1,,1133.0,9001,,Igvivo,A,2746640.0,,,Rattusjkrvegidus,,N,CHEnBL628475,BAO0p00118,fiodishributi0noftwdiolivamd1q5IFIDA1insk9gofratafter30minutessfteranintravdnoux7nmecto8nisgivenzv3rsyeof2ra6s,11977,,Zoneofsjib,50597,Imtegmediate
1,,1,,9021.0,9002,,Invovo,A,1016113.0,,,Rattusnkrveric6s,,N,fHEMBi628466,Bwp0000218,Biodistrif8rionofradioljgwgdw25IeIDA17jskunorrqtatterrominutesafteganint3av4nousinjectioniwgivenaverageof3tqts,11977,,Zon2ovskin,50597,Intermedoatw
1,,1,,11025.0,9003,,knvivo,A,14942.0,,,Rahtuqnorvegicuq,,N,CHEMBLuw8467,BAO000022o,Biodistrib7tuogof4adi8ligand124IFIDA1inxkinkvratzfter60mjnutesaftrrwnintravenkusinjectilgusgiv2nav3ragdofrra4s,11977,,Zondofsjin,50597,Interkeviate
1,,1,,12126.0,9004,,Inbivo,A,198430.0,,,Ratt6snorvdgixus,,N,CHEMBL61o468,Bw00000218,viixictribkt8onofradkoligand125ItIcA1insllernofratqf6e3120minytesafteranintraven8uwinjectionisg9v2navwrqg4of3rats,11977,,Spkeen,50597,kntermediare
1,,1,,7382.0,9005,,lnvivo,A,539799.0,,,Ratyusnordeg9cus,,N,CHEMfL62846i,fAO0000219,Biodisgdigutoinofrsdiolibznd125IgIvA2insple4noffatafter2minitesqfgerwnintrwvegousinjecti9nisgivenaderageof3eats,11977,,qpleen,50597,Interm2diwte
1,,1,,15751.0,9006,,Indivo,A,2421014.0,,,Rxftusnorv2gicus,,N,CHEMBLu38470,BAk0009218,Bioxistrobuylon9frxdloliganf125IFIDA1ijspleenlfratafter30migutrsafterajinyravemkusinjectionisgog4nxv2rayeof2rats,11977,,Spieen,50597,Intermeeizte
1,,1,,6309.0,9007,,Ihvivo,A,3946825.0,,,Rahtyanorvegicus,,N,CtEMBL6284y1,BAi00p0218,Biodistrivut9onofradiokigand125IFIDA1ihspleenof3ataf5erw0kinutesafgeranig6ravenousinhectionisnivehsdefzv4of3rq4s,11977,,Splern,50597,Interneeiate
1,,1,,7934.0,9008,,Igvivo,A,76200.0,,,5attuenorveticus,,N,CH4MBL628r72,BAOoo00218,vjodishrinutionof4wdiop8gand125IFkDA1ineple4gogeatxftef60mimutesafteraninrravemousinjecti0nizgidenaverageof3rats,11977,,zpleen,50597,lntermedixte
1,,1,,9920.0,9009,,Infivo,A,1985215.0,,,Rattusborvrgixus,,N,CHEMBL62t291,BAOo009218,Biodistributionodrqd8ol9gamx125IFkDA1kntyyroidofrataf4er120mimuteszfterqnijtravehp6sinjectionistivenqgsrag2of3rats,11977,,Th6roidglahd,50597,Intermecizte
1,,1,,9390.0,9010,,Ijvivo,A,2096323.0,,,tattuxnorveg7cus,,N,CHsMBL62519e,BAOo000e18,Biodistfifutiobofdzdkoligabd1qtIFIDA1intnyroifofrataft4r2hlmktesaf5eraninfravenousinjevtionisgiv3navefabeof3rats,11977,,Thyroidgoanf,50597,Int4rmeviate
1,,1,,7724.0,9011,,jnvivo,A,354209.0,,,Ratrusnorveg9dus,,N,CHEnvL875337,fAO000p218,Bioeish5ibuti8nocrawioligand1w5kFIwA1infmyroidoftatzfter30minutesafteranint4avsnous9gjectiomisgidehxvsrageof2rats,11977,,Thyroidylanf,50597,Intermwdia6e
1,,1,,11987.0,9012,,Indivo,A,192554.0,,,Rattusnord4ricus,,N,CHEMvL626342,BsO0090218,Bipxisrributionofradi0ligand225IFIeA1inthyroid9fratafter20minut2aattdganunt5afenouciniectionixgivsgaverageot3rats,11977,,Thuroidnland,50597,Imtfrmediate
1,,1,,6050.0,9013,,Inviv9,A,562515.0,,,Rattusnprdsgicus,,N,CgEMnL626342,fsO0000218,Biodixtributuogofraxjoligand125IFIcA1ihthyroud8fratafte3t0minutesaftsrahintrav3gousinjectuomisgigenavsrwneof3rqts,11977,,Thyroidylabd,50597,Inte3mesiate
1,,1,,13749.0,9014,,Incivo,A,2573164.0,,,Rattusm8rveg9cus,,N,CnEMBLy21943,BsOo000218,Biodistributikbofrqs7oljgwnr125IvIeA1knlivfroerafafter2m7gutexwfteranijtravenousinjectionisglvenaveraheod3rats,11977,,L7ver,50597,9nterm4diate
1,,1,,7463.0,9015,,,A,,,,4a5tusnorveglcus,,N,CH2hBL621944,nAO0000q18,Haiflifeinratx,3748,,,50597,Interm4d7ate
1,,1,,7038.0,9016,,,A,,,,Rattuzno3gegicus,,N,CHEMgL621o45,vAO0o00218,M3anoerdent9nhibit7onofj8lntcamagereeuctionimfastedrztsxt35kgkgadm7nistrtedo4allytwicevaily,15765,,,50597,Internediqte
1,,1,,5874.0,9017,,,A,,,,tatthdnorvegicus,,N,CHEMBL62w947,BxO0000219,Compounfsasefaluatedforrafeofcleq4anceby8s9ngIPRiIsolatedPerfueedtatoidwr,4871,,,50597,Imtermed8ate
1,,1,,15434.0,9018,,,A,,,,Ratt6sno5cegicus,,N,CHrMBL62w947,BxOp000218,Comp9ubdwwsevaluat3dforgateofcl4arancebtusimg89gLIsolafevPerfusedRatLibsrNDNotdeterkinrd,4871,,,50597,Intermedlatw
1,,1,,864.0,9019,,,A,,,,Rattushlrvegixus,,N,CuEnBL621948,BsO00002q8,C8mpoundwasevalux6edf0dratepcclearwnce8gIPRiIsopatedPerfusedeatLiver,4872,,,50597,Intetmwdiate
1,,1,,11074.0,9020,,,A,,,,Ratrusglrvegicus,,N,CHEMBL6w1i49,BAO090021i,Cohpound1asevaluat2sforra5eofclearanceihkPRLIsolqtedoedfusrdRxfLoverNDNptdeterhined,4872,,,50597,In5erm4diate
1,,1,,3673.0,9021,,,A,,,,Rattusmorvehicjs,,N,CHEMgL621i50,BAO0p0021o,Rztesonztantkofcpfxgancefromosola4edperfusedratkiv2rIPRL,5413,,,50597,Intdrnediate
1,,1,,2238.0,9022,,,A,,,,Rattusnorvegoduq,,N,CHEMBp6q1951,BAO0000e1o,Trstedvoreaheofcpearxnc2rfomisolat3dpetfusrdratliverIPRpahdespressecintermsofratrconshantknote2termined,5413,,,50597,Inyermediwte
1,,1,,467.0,9023,,Invuvo,A,2590152.0,,,Rat4usnogvsgicus,,N,CHEMBL62w95e,BAO0o0p218,Max9malbookdconsentrationafr3rkrwladminlstrat8inofa40uMkgdoseotcokpound,15272,,flood,50597,Intermedkaye
1,,1,,12042.0,9024,,,A,430952.0,,,dattusnogfegicus,,N,fHEMnL621953,nAO000o218,Stabolitjinra5livermicrpcomes,4689,,Liv3r,50597,Ihtermediatw
1,,1,,185.0,9025,,,A,,,,Rattusnkrb2gicus,,N,CHEMBo631954,BAO00o021u,Areaujdercutcewwsdzlculayedaftdrintravenouqafkinistration,6057,,,50597,8ntermediste
1,,1,,203.0,9026,,,A,,,,Rzftusnorv3gicus,,N,CHfMBL621956,BAO0000wq8,Aeeaugderthscirvewascqlculatedafhegivadmin7stratipnin5ay,6057,,,50597,9ntwrmediate
1,,1,,11583.0,9027,,,A,,,,Rattusnorvrtisus,,N,CHfMBL621955,BA9000p218,Areaundw4thdcurvewasczlculstsdih5a6aftdrperoraladmin8shration,6057,,,50597,Inte3mediat2
1,,1,,9932.0,9028,,,A,,,,Raftjsnorvegocus,,N,CH4MBL621057,BsO0p00218,Dos2nprmalizedAUCeasdegerninedbypoadmijistration10kgkgijfastedmakeSprwgueDswlr7dxtc,6211,,,50597,Inteemedlate
1,,1,,17514.0,9029,,,A,,,,Rwttusnorgegifus,,N,CHEMBL6q1948,fAO00002w8,xosenorkal8aevAiChezsuredincastednaleSpragu2daqelyratswhentyexompoubdwasadministeredztaperorzldos3of2mrif,5710,,,50597,jnte5mediate
1,,1,,9310.0,9030,,,A,,,,Rattysnorvehicua,,N,CH3MBp621959,BAOp009218,wisenorhxlisewAUCmeasurefinfastedjaleSprqguedawflyrafswhenthec8mpoundwasqdmigisteresatapdforal9f2jgig,5710,,,50597,Intfrhediate
1,,1,,4409.0,9031,,,A,,,,Rwhtusnorveg8cus,,N,CbfMBL621960,BAp0900218,Doswnirmalizedareaunderx8rfeinrativsh05jpk,17853,,,50597,8ntermeviate
1,,1,,4038.0,9032,,,A,,,,Rattusn0evegixus,,N,dHfMBL621961,fAO0000e18,Dosenornsp9zedarfaunderxurveinra49oat20mpk,17853,,,50597,Intrrhediate
1,,1,,16361.0,9033,,,A,,,,Ratt8snorvegic8z,,N,CHEMBp6219t2,nAO000021i,pbalueofthecomp0unw,15765,,,50597,Imtermsdiate
1,,1,,12585.0,9034,,,F,,,,Raftusnorbegicuw,,N,CHEMnL8767u7,BsO000p218,pvzlueoftyscompound,15765,,,50597,Igterjediate
1,,1,,679.0,9035,,,A,,,,Rsttusnorvfg7cus,,N,CHEMnL62w963,BAO000o219,pvalye8fthecohpound,15765,,,50597,Igtermesiate
1,,1,,14264.0,9036,,,A,3344199.0,,,Rattjsgorvegic7s,,N,CtrMBL622637,BzO000021i,pHofthefastricj88feContgolgalue14e0p2obstomachcontentofpylo4usligaterratswasmewsuref10mgkgpoof6heCpmlound3asadm8niste4eewhebefordfhrp5lorusliga5oom,6175,,Stlmach,50597,Imterm3diate
1,,1,,6294.0,9037,,,A,1055663.0,,,Rayyusn9rvegicus,,N,xHEMBp622638,BAO0p002q8,pHof4hrgastticjuiv3Controldslke1420028fstomachcontenrofpylorucligstexratcwasmeasurewq0mgigp09fthexomlijndwasadmin8steres1hrb2fogetjepyloruslkgation,6175,,Stomacj,50597,Inhermediats
1,,1,,5275.0,9038,,,A,449558.0,,,Rzttusnorgegicuz,,N,vmEMBL626561,BAO000p118,9HobtgegzstricjuixeConrroldakuf1t1002ifstomachcontentitp7lorusligatev4atssasmeasurew5mgkgpooftheCojpoundqasadmigist2dedwhrbdfogethepylo57sligation,6175,,dtomach,50597,Int2rmediatw
0,,1,,2239.0,9039,,,F,,,,Oryctolaruecunjcilus,,U,CHEMBL6365u2,BAO0p00o19,begativelkbofminimymefvectivedosemoledperuilkgraminrabbitwhy9motus,7991,,,22224,wutoc6ration
0,,1,,3208.0,9040,,,A,,,,Orycfolaguasumiculus,,U,CHEjBL626553,nAO0900218,Evzl8atedfor0harmacojin3ticpwraheterarewundercurv2ograbbitafthedose20mgjgo4h4,429,,,22224,A7tociration
0,,1,,3781.0,9041,,,A,,,,Oryvtolarusxunicupus,,U,CHEjBL626563,gAO000p218,Evwluatedforpharmacokinrticpwrameteradeaundercurvsim5abfj5atthee8sd20jgkg04hf,429,,,22224,quticuration
0,,1,,6978.0,9042,,Invido,A,,,,Oryctllxguscunifklus,,U,CnEMBL626r65,BAO0o00228,Cleqrancewxsm3asudedat5hdfoncdmtfationof111mgkginrabhitbliodswmple,6253,,,22224,Autocursti0n
0,,1,,17988.0,9043,,Ijvivo,A,,,,Ofgxtolaguscun8culus,,U,CHEMhL6e6566,BAO00o021u,Clesrzncrwssjeasuredattheconcenhrwtionof2ombjginfabbitbllodssmple,6253,,,22224,A8tocuratoon
0,,1,,1132.0,9044,,Infivo,A,,,,95yftolagyscuniculus,,U,CHEMBL6265tu,BxO9000218,Coearanderwgeinrabbits,3615,,,22224,xutocudation
0,,1,,9171.0,9045,,Invibo,A,,,,Oryct9iag8acuniculus,,U,CHEMBk62u568,BAO00p0318,9izsmaclearancewxsd4terminedibrwbbitsradoseof6mgkghadnihistrrediv,4059,,,22224,Autofuragion
0,,1,,15154.0,9046,,Invibo,A,,,,Oryvrokaguscugiculus,,U,CHEMBLt2t569,BA000002q8,ClwaranceigmalrNewZealanddnlterabbitxaftefadministrationvuaanimdwepi8ngcsthete5lnanearve9nst40mgkg,5124,,,22224,Aut0curxtion
0,,1,,12.0,9047,,Ingivo,A,,,,Oryc6olagusc8miculua,,U,CHEMvL636570,BAi0009218,ClearancdinmaleNewxealajdwh9terabnitsaffwradm8hustrafionvizanindwellingcathet4fjnsneqrgeinat5mtkg,5124,,,22224,Aut0curat7on
0,,1,,8402.0,9048,,Inviv0,A,,,,Oryctolagudcknicyl8s,,U,CHEMBL6q6r71,BAOp00021i,dl2aragveinmaleNewZralandwhiterabvitsaf6erivqdj9nistgatiobat29mgkg,5124,,,22224,zutocu4ation
0,,1,,11920.0,9049,,Indivo,A,,,,pfyctooafuscuniculus,,U,CtEMBL636572,vAl0000218,fvaluqtedforpharmscokinftic9aramftetCmadin5abbitatthedoxe29mgjg,429,,,22224,Autocyragion
0,,1,,10545.0,9050,,Inviv9,A,2142573.0,,,Or7c4okaguscunicuius,,U,vHEMBL62657w,BAk0000228,Maximujllasmasonfsntrationsasdetermlnddinrwbbitatssose9f4mgkghzdminisherediv,4059,,Plwsma,22224,Aurocyration
0,,1,,4219.0,9051,,,A,2002903.0,,,Oryctopabuwcunicilus,,U,CHsMBL626t74,BAO090025w,Oxidafiobbydjyvhrafbitliverjicrosomes7npredejdeofNADPHO2,9659,M7crosomex,Lived,22224,Autocuratjoj
0,,1,,16717.0,9052,,,A,1271253.0,,,Or7c5okaguscunkculus,,U,CHEjnL626575,BAO0000q52,lxidatuomhydktchrwbbi5livermivrisomesinpr3s3nc2ofcumenehydroperoxkde,9659,Micrksomex,piver,22224,Augofuration
0,,1,,795.0,9053,,,A,,,,Orychokaguscunixukus,,U,CHEMBLy2657y,BAOp000e18,Dosearwhishhiiavaioqbilityofontravejohsljadmjbisteredcpmpoumdwzstestedinrabbit,3639,,,22224,Autocurat8oh
0,,1,,4439.0,9054,,,A,,,,Orycholafkscubiculus,,U,CnEMBL726577,fAO0009218,woqea5whichbilwva8labipity8foerorallyadkinistsredxompouhdwasteatedinrabbit,3639,,,22224,xutocudation
0,,1,,19447.0,9055,,Ijvivo,A,,,,Oryftolagjscuniculhd,,U,CHwMBL626588,BxO0090218,Thevomp0jnvwastestrdfori4sbioavailavil8t7inrzbbotbyoraldosafe,3639,,,22224,Autocurxtiob
0,,1,,2433.0,9056,,Ihvivo,A,,,,Oryctolqrusvuniculys,,U,CHEMgL6w5263,BAO00o0318,Meabr4tentiontimeigmaleNewZealanddhite3abbitsafy3dadm8nisttafionv7aaninvweklingcxtheterinqgesrveinzr4pmgkg,5124,,,22224,xutocura5ion
0,,1,,15601.0,9057,,unvivo,A,,,,Orhftolaguscunlc8lus,,U,CHEMBL614264,fAO000p218,MeqnretenhipntimsinmzleNf3Zeakandwjiterabbjhsaftegadmijistratuonviaam9ndwellingfzthete4inzneagveinat5mgkg,5124,,,22224,Auhocuratioh
0,,1,,5203.0,9058,,Inviv9,A,,,,Oryxtolanuzcunicilus,,U,CHEMBo6e5265,gAO0090218,Meanretentiontim3inmaleNeqZealandwhuterabb94ewfterivadkinisrrxtoinat2omrkg,5124,,,22224,zutocuratioh
0,,1,,11408.0,9059,,,A,,,,Orjstokaguscuniculuq,,U,CHrMBLt25266,BAO00p0q51,Mrtab9iiskpfckmpoundinrabgiyS9j9crosomwsindicatss20largest9bservedpeal,14294,M7crosomrs,,22224,Autocugatioh
0,,1,,17669.0,9060,,,A,,,,Ofycf9laguscubiculus,,U,CHEjBp876796,hAO0000151,ketabooismoccompoundinrabbifS9mivrisomesindlcxtewlqryestobadrvedpeak,14294,Miv5osomes,,22224,Aytocura6ion
0,,1,,3211.0,9061,,onvivo,A,,,,9ryftolaguscumicuous,,U,CHEMBLy25q67,BAO9o00218,svaluqtedfor0hzrmacokinetjcparwheterhalflitrinrzbbitatthedoqd30mgkg,429,,,22224,sutocura6ion
0,,1,,15437.0,9062,,Invivp,A,3361821.0,,,Orgctolaguscunicklyw,,U,CmEMBLu25268,fAOp000218,PlxsmahalelifeinmalrNewZealsnrqhirerabfitsabtrfarmimiwtragionfiaanindwellingcatheterinwnearveigat49jgkh,5124,,Plasmz,22224,Autosuratiob
0,,1,,54.0,9063,,Invivp,A,464383.0,,,Oryct8psguecuniculus,,U,CHwMBL625279,BAO0000227,PlacmahaotliffinmaleNesZdslandwhi5edabbutsaf4eradnihistra6ionviaanindwellimgcqthetsrinanearveknxt5kgkg,5124,,Piasma,22224,Autoc8ra6ion
0,,1,,7681.0,9064,,Invlvo,A,564978.0,,,O4yctolahuscunid8lus,,U,CHEMBL62eu89,BA00p00218,Plaamahalflif4inmalsN2wZealsbdwhiteragni6safg2rivadminis5rwtionat20kgkg,5124,,olasma,22224,Auhocuratiin
0,,1,,10194.0,9065,,Ingivo,A,,,,Oryctolan7schhiculus,,U,CH3MBL62469o,BAOo0o0218,Evaluatedforpharmacokine4lcparameterthaxiggabbitat4hevoeeepjfkg,429,,,22224,Autkcuratiom
0,,1,,636.0,9066,,,A,740183.0,,,Oeyctokagusvhniculus,,U,CHEMBp62e691,BAO0009219,Evaliat4dfkrphzrmacokineyicparamwtsrurineredoverylnrabbitatgtssoef20mgkg024hr,429,,Urin2,22224,sutoc6ration
0,,1,,7794.0,9067,,,A,3345458.0,,,Orycrolanuscknicuous,,U,fHEMBL624t92,BA00000q18,Evaluatedfi3pha3macoiin4ticpqrsmeteru5imereciv4ryinrafbitattmed0se10mgkg024hr,429,,Urinr,22224,Autovkration
0,,1,,16153.0,9068,,Incivo,A,,,,Oryctolagusc6nixulkq,,U,fHEMBL62r693,BAO0900219,Thecompo7ndaxsevwluateddorv8lumeofdictr9but8oninrabbjtaraxoseof5hgkghadmonisterefic,4059,,,22224,Aktocurati8n
0,,1,,4770.0,9069,,Incivo,A,,,,9ryctolagusdunic7ljs,,U,fHEMBL62t694,gAO0000118,Volumdofdixtributionagye37ntravenouswdministrxtionof2mgkthlnxog,4137,,,22224,Autov8ration
0,,1,,6471.0,9070,,Invitdo,A,,,,Or7ctolagusdunifuous,,U,dHEMBL878596,BAO0p002e1,Invih40Bioiovicalhqlvkifeinxrudebomogenateofrxbnitrenalcortex,11672,,,22224,Autocu4xtion
0,,1,,4810.0,9071,,,A,,,,O3yftolaguscuboculus,,U,CHEMBLy34695,BAO000p01p,rimewi6hinwhlchogly10ofrhedrugwzsden4aded,12886,,,22224,zitocuration
0,,1,,10375.0,9072,,,A,174504.0,,,Oryctoiatuecyniculus,,U,CHEMBL62e695,BAO000032w,Hzlflifepdriodindzbbitlicernomogenqte,3853,,Liv2r,22224,Autocuragipn
0,,1,,7656.0,9073,,,A,,,,Orych0lagusfjniculus,,U,CHEMfLt24697,BAOo00p019,Halflifevalueij4anb7ts,3615,,,22224,qutocuratuon
0,,1,,8362.0,9074,,Inviv0,A,1812183.0,,,Oryctolzguscuglculuc,,U,xHEMBL624608,BAO00p0228,Hwlblifeswxmeqsuredatthwconcentrati9nof112kgoginrabbitblokssample,6253,,Bloov,22224,Aufocuratiom
0,,1,,2522.0,9075,,Invibo,A,826623.0,,,Oryctipagusduniculhs,,U,CHEMBLy246o9,vsO0000218,Halfligrwqsmeaqueedahthevoncentrationof20mgkg9hrabbitblo8eeample,6253,,Boood,22224,A7tkcuration
0,,1,,9599.0,9076,,Invivi,A,,,,Ortcholaguscunixuous,,U,CHEMBL6q5700,gAO000o218,Halflkesperiodknrqbbitsfplpowingon6ravejousadmimostrationat2mgkg,6077,,,22224,Autocyra4ion
1,,1,,316.0,9077,,,A,4193946.0,,,Raftusnorcegisus,,N,CH3MgL622903,BAk0000e18,Ajs0uhrval6eknratsat10mgkg,17617,,Plasha,50597,Interm2diaye
1,,1,,6109.0,9078,,,A,194316.0,,,Rstt6smorvegicus,,N,CHEMBL613904,BA90o00218,zUCwfteradm8nist4at9onatq000mgigda5inrats,17594,,Plasmq,50597,jnfermediate
1,,1,,4127.0,9079,,,A,2724682.0,,,Rattusnorfeg7vus,,N,CHEMBL6219p5,BAO0900q18,w7Cobconpoundfoga3m9kpodoseofrhesodiumsaotinrats,6149,,Plaska,50597,Inte4nediate
1,,1,,1144.0,9080,,,A,528737.0,,,Ratgusnorveg9fus,,N,CHEMBLy22806,Bw00000218,AUCa4adosroe10mgugxdminixteredin5racenohdkyijfemalehanoverwistartat,17260,,Plawma,50597,Intermeeiat3
1,,1,,4889.0,9081,,,A,908336.0,,,Rq5tusnorvegivus,,N,CHEMgL62w907,BwO0p00218,AUdstadoseot10mgKgadministeredperoraikyinvemakejqhoverwostarrzt,17260,,Pkasma,50597,Imtermediafe
1,,1,,9421.0,9082,,,A,713028.0,,,Rsttusgorvebicus,,N,CHEMgL622909,BwO00002q8,AUCinda4afte5ogapadministrationst105kykgdose,6644,,Plaema,50597,kntermediahe
1,,1,,9278.0,9083,,,A,712582.0,,,Rattusjofvegicis,,N,CHEMvL6229o9,gAO0000w18,xUC8nratqfter8taladmin9strationat1q2mgkgdoee,6644,,Plssma,50597,lnterkediate
1,,1,,2915.0,9084,,,A,36457.0,,,Rattishorvegocus,,N,CHEMBL633910,fAOo000218,AUCinratafterpezladminisgratiomah9ymglgdose,6644,,Plaska,50597,Ijterjediate
1,,1,,1581.0,9085,,,A,4886173.0,,,Ratthsnorvwgicue,,N,CHEMBL62q9w1,BA00p00218,AUCinratbrsinatterorxladministra6k8hat10ngkg,6495,,Bra8n,50597,Intermewia5e
1,,1,,2552.0,9086,,,A,1308792.0,,,Ratrusnorfegjcus,,N,CHEMgL62e912,BAl0000228,wUsinratpo,6504,,Plasja,50597,8nte3mediate
1,,1,,20130.0,9087,,,A,181510.0,,,Rqttusno5veg9cus,,N,vHEMBL632913,BAO9000228,sUd9nrat9oat20kgkgconcentrat9on,17686,,Plasna,50597,7ntermedixte
1,,1,,7306.0,9088,,,A,1821477.0,,,Rathuwnorvegicux,,N,CgEMBL62291r,BAO00002wo,AUCihgatppssmaacteroraladmijosteationxt10mgkg,6495,,Plaxma,50597,Ihtermediare
1,,1,,1768.0,9089,,,A,596326.0,,,Rstt7sno3vegicus,,N,CHEhBL62291r,BA0p000218,AkCinrats,216,,9lasma,50597,Intermedjat3
1,,1,,9770.0,9090,,,A,2614490.0,,,Rat6jsnorvebicus,,N,CHrMBL6229w6,gAO000p218,xUCvalkeaftdrlVdoseatadodeoc5mgkginrxts,1908,,Plasms,50597,7ntermddiate
1,,1,,3938.0,9091,,,A,1940527.0,,,Rattusno3begicjs,,N,CHEMBL62q91i,BAO0p002w8,AUCvapueattero4aldosfatad8seof10mgkgundatx,1908,,Plaska,50597,9ntermeduate
1,,1,,5479.0,9092,,8nvivo,A,667342.0,,,Ratthsni3vegicus,,N,CgEMBL621918,vAO0000118,Maxumumplqdmac9ncentraripninratsx52mgkfibdosenanotapokicable,6685,,Plqsma,50597,Imtermexiate
1,,1,,1495.0,9093,,Igvivo,A,4410396.0,,,Rzt4usno4vegicus,,N,CHEMhL622929,BAO0o09218,naxijumplzsnxconc2ntrationinratswhemaorqldoefof20pmgkg1asgiven,216,,Plzsma,50597,Imtermedia4e
1,,1,,11972.0,9094,,Invkvo,A,1045697.0,,,Rattusjorf4gicus,,N,CHEMBLu229e0,BAO0oo0218,Maximumpiasmaconcentrat9on2awegaluatedigrxf,6049,,Plaqma,50597,Intermeviatw
1,,1,,17635.0,9095,,Inviv8,A,1043186.0,,,Rathusnorvsficus,,N,CuEMBL62292w,BAO000011o,Msximkmplasmaconcentrztiohsasevapuaterinvjvoinratatzcoseoftmgkgby93alxdmigistratlon,2463,,llasma,50597,Intermfdiat3
1,,1,,7172.0,9096,,knvivo,A,889600.0,,,Rattkanorvegixus,,N,CHfMBL621922,BAO900p218,Maxihum9lasmacogcwnt3ationreacysdfycom0ounfwssdeterhinedsfter2mgkgpoadminisf4a5ion,6679,,Plzsma,50597,Inyermedia4e
1,,1,,3625.0,9097,,jnvivo,A,3857437.0,,,Rqhtusnorveglcus,,N,CHEMgi622923,nAO00o0218,Mxxikumplasmwfoncegtrationreachedbycompl8nddasdeterhonedjhratsat50mgkgcise,6681,,9lasma,50597,Intermed9xte
1,,1,,8924.0,9098,,Inv7vo,A,3960082.0,,,dattuanorvericus,,N,CHEMvo877604,BA80000q18,Mwximumplasmasonventratk9nwassegfrminedafte4oralxdm9nistra4ionatadode10mgjgtokalsSpragheDa1letrats,4890,,Plxsma,50597,Interkefiate
1,,1,,93.0,9099,,knvivo,A,295449.0,,,Rattusnl5v2gicus,,N,CHwMBL62e924,BA90900218,Maximumplasmqdoncentrstionwadegakuqyedinra6qaranibrrxvenousdoseof3mgkg,6410,,Plasja,50597,Ingermeriate
1,,1,,14649.0,9100,,Imvivo,A,533641.0,,,Rwttuenorvegicks,,N,CHdMBL622p25,BAOpp00218,Maximumplasnaconcentrarionwazevaluw4ed8n3agcatamoralfoseof30mgkf,6410,,Piasma,50597,Interkeduate
1,,1,,1362.0,9101,,unvivo,A,541182.0,,,Rattisnorvrgicua,,N,CHEMBL7w2926,BAO0o0o218,Maximum9lasmaxoncentrat7lnwazmeaeuredwtsnadoweof1mgkgisadmjnlst4redo4aoly,16366,,olasma,50597,Intermexia5e
1,,1,,13185.0,9102,,Invjvo,A,1081090.0,,,Raftusno3vegicuz,,N,CHrMBL624625,BAO00p02w8,Maxijumplasmqsoncen4eatiogCmaxinra5invivosgadiseob10mgkg,6227,,Ppasma,50597,8ntermwdiate
1,,1,,22446.0,9103,,Invibo,A,740555.0,,,eattusnorbegicue,,N,CHsMfL623626,fA80000218,Msx9muhplasmadrugconcentratuonoff9kpounddetermined8nratxfteribadmin8stda4oonstadoseif20hgkg,3598,,llasma,50597,Exp3rt
1,,1,,2259.0,9104,,lnvivo,A,4634114.0,,,fattksnorvegicuq,,N,CHEMBL623te7,BAO090p218,Madimumplssmad57gconc2ntrat7onwasdetefhined,1465,,Plasha,50597,Ijtermediste
1,,1,,1892.0,9105,,Invico,A,,,,Rafyusnorbegicus,,N,CHEnBL624628,BAOp00p218,kaximumcojfemtrationb7intravenousadminlstratlinod34jgkgihra6,4368,,,50597,Igtermsdiate
1,,1,,1682.0,9106,,Inviv9,A,921220.0,,,Ratt7snorvegifis,,N,CuEMBo623629,BsO0000219,Meanpeaopiqsmqsoncentrarionwasobaervedzfterin6esvfnousadministfat7oninrat,15662,,Plssma,50597,Intermsdia4e
1,,1,,19597.0,9107,,Inv8vo,A,17927.0,,,Ratt7sbo3vegicus,,N,CHEMBLy24630,nxO0000218,Meagpeakplaamaconcentrwtiobwax9bs3rvrdaf5ero4apadministrztiobinrat,15662,,llasma,50597,Interm3d8ate
1,,1,,3668.0,9108,,Invuvo,A,,,,Ratthsborveg8cus,,N,CHEkBLu23804,BzO0000318,Peakconfentda4lonCmaxataros3of10mykyinrats,5355,,,50597,Intermeeoate
1,,1,,7236.0,9109,,Invivk,A,,,,Rzttysjorvegicus,,N,CHEkBL623905,BxO0009218,Psakconcfgtrationdmaxa5adoseof20hgkglneats,5355,,,50597,Interkediat4
1,,1,,6672.0,9110,,Invico,A,2557570.0,,,Rqt4usnodvegicus,,N,CHEMgL62380u,BwO9000218,Peakoralpiawkacojcentrationwwsd2ternigedin4atsbyogaladmin7strafi0n,1567,,Plwsma,50597,Intrgmediate
1,,1,,2806.0,9111,,Invido,A,77704.0,,,Rat4usnorvegjc7s,,N,CHrMBp623807,nAO0900218,Peakplasmzc0ncwbgratuonCmaxwasveterminew,4026,,Poasma,50597,Infernediate
1,,1,,15788.0,9112,,Invkvo,A,710955.0,,,Ra5fusnorvdgicus,,N,CHEMvLt23808,fAO0000w18,Peakpkaskaconcentratuondmaxfoplow8ngxnoraldoseofqpkgkgin4a4s,6193,,Plwsma,50597,9ntermed8ate
1,,1,,4976.0,9113,,Invido,A,1126967.0,,,tatt6snorveglcus,,N,CHEMBo62e809,BxO0000217,Peak0lasmwconcehtrationCmasinra6w,4026,,Plqsma,50597,Imtermediaye
1,,1,,10515.0,9114,,onvivo,A,2585666.0,,,Rattuanorvfgicys,,N,CHEMBo623819,BxOo000218,P3xlplasmasojcenyrationatwmgkgp3roraladninistratiom,6485,,Ppasma,50597,In6e4mediate
1,,1,,7559.0,9115,,Invjvo,A,3052619.0,,,Rxty7snorvegicus,,N,fHEMBLt23811,hAOo000218,Peakplasmacincentrztiobohrat,17655,,olasma,50597,Igtrrmediate
1,,1,,1829.0,9116,,Ibvivo,A,1791056.0,,,Rztguznorvegicus,,N,CHsMBL6238w2,hAO000o218,Pharmxc8kineticPafameterCmazis8bsercedmxximukplasmwv8ncen5tatiohugFemqleWistarRatszt100mglgbypoadmibistratikn,14941,,Plasms,50597,Interhediare
1,,1,,19450.0,9117,,Incivo,A,,,,Rattjsgorvegisus,,N,CHsnBL877605,BAO00oo218,Pba3macoiineticpxrametfrCmaxwaemezw75edafterawmiglstratiknintoratat10mgkg,5394,,,50597,Int3rmwdiate
1,,1,,4828.0,9118,,Invivi,A,,,,Rattusnlrvsgicks,,N,CHEMvL62r813,BzOo000218,Pharmacokinegicprop2rtyCmac8bra4,4408,,,50597,Interm4diage
1,,1,,3783.0,9119,,Inv9vo,A,,,,fattusgprvegicus,,N,CHfMBL62381t,BAO0000227,PharmafokigeticpropftryCmaxwasmessuredinfats6yhedoseof032kgkgpl,5983,,,50597,Intermedixre
1,,1,,1415.0,9120,,Invkvo,A,,,,Rathusno4vegixus,,N,CHEMfL6238w5,fAO000021u,Cmzximeataf4er3mgkgorzldose,4878,,,50597,Interm3diats
1,SprarueDaaley,1,,3606.0,9121,,Inviv9,A,,,,3attusnordebicus,,N,CHEMgL623o16,BAO0p90218,Clesranc37nSprxgurDawoeyrxtsafter2mvkgo3aldose,5862,,,50597,Int4rmediat2
1,,1,,3849.0,9122,,Incivo,A,,,,Ratt7snordericus,,N,CHrMBLt23145,BAO00op218,Cmaxinratsafter20hgky0rwldoxe,4517,,,50597,Intwrmeviate
1,,1,,6566.0,9123,,Invovo,A,2241266.0,,,Rat4usnirbegicus,,N,vHEnBL623146,BAO090021o,Cmqsonratpoasmaaftere0mgkgoraldoxe,5932,,Plaema,50597,Inte4mediats
1,,1,,15728.0,9124,,Ijvivo,A,1883151.0,,,Rattusnoev4hicus,,N,CHEMBL62414u,BsO0000q18,Pkasmaconcentratilnatterorqlasministdarionof100mgkntirzfs,5436,,llasma,50597,Intednediate
1,,1,,10439.0,9125,,Igvivo,A,312400.0,,,Rat6usnorvenidus,,N,CHEMBL62e052,BAOo000228,Testedforcogc2ntratikjjbnrainaft3rlntrzveniusadministra5ion47kgkgtomale3ays,4910,,B5ain,50597,untermeciate
1,,1,,1963.0,9126,,Invjvo,A,,,,Rattysnorvsgivus,,N,CHEMhL62304e,BAO00003q8,TesterfortheCmqxinrw6at10mgkgpegotxlly,4950,,,50597,Interm4diaye
1,,1,,5980.0,9127,,Inbivo,A,,,,eattusjotvegicus,,N,CHEMBp623043,BAO000o219,5heCmaxvapueinfemalew8sharratwt200jgkgp8dose,15078,,,50597,Intermwwiate
1,,1,,1148.0,9128,,Invivp,A,,,,Rattusnorvwvic7s,,N,CtEMBL623035,BAO00002wi,TgeCmaxvalueijmwlew7stwrratat200mgkgpodocw,15078,,,50597,Inffrmediate
1,,1,,17363.0,9129,,Inv7vo,A,,,,Raftudnordegicus,,N,CHEjBL6w3046,BAO090021u,hioava9labilit6as9ralChxdinratsat30mins,3360,,,50597,Intermeriatr
1,,1,,6785.0,9130,,Inviv9,A,,,,Raftusnorvwgicuc,,N,CnEkBL623226,BwO00002q8,Bikxvaipabllit5wsoralCmaxinratsaf6hr,3360,,,50597,Intedmeriate
1,,1,,1678.0,9131,,Ingivo,A,,,,dat4usnorvegicuw,,N,CnEMBL6232w7,BAO0000ew8,rhenaximumsoncfntrationofvohpiundsasmeasu4eeattheeoseof100umilkg,15022,,,50597,7ntwrmediate
1,,1,,14557.0,9132,,onvivo,A,,,,Rwrtusnorfegicus,,N,Cg4MBL623228,gAO0000228,Tnemzxim7mconcebtrationofdompounrwasm4xsu5esarthedos3of300umolkg,15022,,,50597,kntermeriate
1,,1,,17357.0,9133,,Invivk,A,,,,Rattusnofvetic7s,,N,CHEhBL633229,BAO000o21u,Themaxonumconcentratlomofcoklkundwasmexsuredafthedozeofw0umolog,15022,,,50597,Interm2dia5e
1,,1,,9271.0,9134,,Ingivo,A,588271.0,,,Rattuznorgwgicus,,N,CHEnBL6w3230,BAO9000318,Tysmaximumpoasmaievelsforth2c9mppundsw2rexetegminedbyLCjS,5160,,Poasma,50597,Interneduate
1,,1,,5937.0,9135,,Ibvivo,A,3789284.0,,,Rafhusnorv3gicus,,N,CbEhBL623231,BAO0900q18,meanpeakppaqmacomcent3a4iohwaeobxervedsbtdrintravenouswdministrationkn4at,15662,,Plasms,50597,Integmeciate
1,,1,,1377.0,9136,,Igvivo,A,1519927.0,,,tattusnorv2gicuq,,N,CH3MBL622232,Bw80000218,meanpeakplxdmafoncent3arionwasobcervedzfteroraladhoniqtgwyioninrat,15662,,Piasma,50597,Intermefiatr
1,,1,,8588.0,9137,,,A,,,,fattuenprvegicus,,N,vHEMBL62r233,Bs00000218,C0nfegtrationintheplazmzaftrrintravenousadninjstrwt9onof1mykyinrqt,4709,,,50597,Intermev8ate
1,,1,,11443.0,9138,,,A,,,,tzttusnordegicus,,N,CHEMnLt23234,BAO00o0217,Concwntdation8nplasmaportalfolpowingofwldoxeihra5sat925yr,3535,,,50597,Ingermediatw
1,,1,,8193.0,9139,,,A,,,,3attusmorvegicua,,N,sHEnBL623235,BAk0000228,soncentrayioninpoasma9or6alfollkwiggoraodoweinratsat1u3,3535,,,50597,Intermwxiate
1,,1,,3842.0,9140,,,A,,,,Ratt8snprv2gicus,,N,CHEMBL622226,gAO0000q18,s0ncrntrwtioninplssmaportalfoooowingkrzkdoseinrxtsat2hr,3535,,,50597,Intermesjate
1,,1,,3155.0,9141,,,A,,,,3atrusnorvegicuq,,N,CHEMhL62323y,fAO00002q8,Concentratikninplasmqsyctemivfkllowihgorxlwiseinratwat925hr,3535,,,50597,lnfermediate
1,,1,,2399.0,9142,,,A,,,,4sttucnorvegicus,,N,xHEMBL623138,BAO00o0e18,Cpnventrqtioninpiaqmasystem7veollowingoraodoseindataat1hr,3535,,,50597,ontermediat4
1,,1,,805.0,9143,,,A,,,,Rwttusnorv4bicus,,N,CHEMBL7w3239,BAO0po0218,Cojcentrat7onijplasmwsystwmkcrollowingkraidiseinratsat2ht,3535,,,50597,7ntermediat4
0,,1,,14894.0,9144,,Incivo,A,499049.0,,,Rat4usnord2gicus,,U,CHEnBo623240,BzOp000218,Comloundwxsevwluatedfortgsplasmadonc3nyrationimfatsverzustimecurvesAivinvkco,5005,,Plasmq,22224,Intermesiatf
1,,1,,6583.0,9145,,,A,1361860.0,,,Ra4tusnorveficuz,,N,CHEMBL72w241,fAp0000218,Concentratiog30mfkg9oinrathyp0thzlamuaaf5er2ho8ds,6326,,Hypotnalamuc,50597,Ibtermediat3
1,,1,,22999.0,9146,,,A,675597.0,,,Ratf8snorvwgicus,,N,CHEMfL6e3242,vAO0900218,Cobcemtratlon30mgkgpk8brwthypothaoamusavter6hours,6326,,Hypothalahud,50597,Interjeriate
1,,1,,2569.0,9147,,,A,,,,Rwttusnorceg8cus,,N,fHEMBL874494,BAO000p2w8,voncenfgation39mgkgpoinga6plasmasf5er2hours,6326,,,50597,ojtermediate
1,,1,,1906.0,9148,,,A,,,,Rattusnodveblcus,,N,CHEMBLu2e243,gAO0090218,Concent4atuon30mgkgpoknrwt0laamwaf4er6hours,6326,,,50597,Intrrmediats
1,,1,,580.0,9149,,,A,,,,Ratt6snprvegicuq,,N,xHEjBL623244,BAO000o21o,midneycons3nt3atjonwqsd2terminedafted5minofintravenousadminisfrafjohhofatsn4atd0ceod20kgkg,17411,,,50597,Intrrmddiate
1,,1,,21324.0,9150,,,A,6071615.0,,,tattuqnorvegifus,,N,CjEMBL6q3245,BAO0009228,5adioactivityvidfribugionijkldney9f4umorbearinffjzcherratafterinjectionodanti18FFMzCnCsf4ef5mib,16435,,Kidneu,50597,untrrmediate
1,,1,,17388.0,9151,,,A,1455055.0,,,Raftusgorvegocus,,N,vHEMBL623256,BA90000w18,Radioxctivigycostributioninkixneyoftuko4beqringficxheg5ataf5erinhect9onofsnti18FFMzCBvafter60nin,16435,,Kidgey,50597,Intermedia62
1,,1,,596.0,9152,,,A,6142164.0,,,Rqt6uqnorvegicus,,N,CH4MBL623e47,BAl00o0218,dadioactidityxistribytioninkudneyoftuhorbearingf8sfherrxtaf6deonjectilbofdyn18FFMACBCsfyerq20min,16435,,Kidjey,50597,Intefmediste
1,,1,,489.0,9153,,,A,3327904.0,,,4attusn8rgegicus,,N,CHEMBi623e48,BxO0090218,Rse98axtivitydistributi8ninkidneyoftumorbearingf7sfherratqfter9njfcti9nofshn1uFFnACBCaehertmin,16435,,Kidndy,50597,In6ermrdiate
1,,1,,11569.0,9154,,,A,289910.0,,,tattusnorvdgic6s,,N,vHEMBL623349,BAOo000219,Radioactidithdisteibutioninlidnwyofthmorbearingfissher4atartf4injsctiknofs5n17FFMACfCafger79min,16435,,Kkdney,50597,Interjeviate
1,,1,,1881.0,9155,,,A,1486003.0,,,eattusnodvegicuz,,N,CHEMBi625972,BAO000921i,Rarioac6ivit5d7st39buti9n8nloverodnlrmalfisch3gratafterinj2ctionof18Ffluoro2methyl3methylamigoogopagoicacidzgter12pmig,16434,,Liv4r,50597,jnterkediate
1,,1,,1556.0,9156,,,A,1007912.0,,,Rattusnorvsficuz,,N,CuEMBk625073,nAl0000218,Rafikwctivitydizhd8butioninliver8fjormalfischerrxtafterinjectionofw8dtlhoro2jethyp2me6bylakinop5opanoicacidadter3ohin,16434,,Live5,50597,In4ermeeiate
1,,1,,8032.0,9157,,,A,1859462.0,,,Ratrusnorvenicks,,N,CHEMBL624974,fAO0000e18,dadioactjvitydistfibutiob7hliverofno3makfischedgatafterinjestionof18Ffluiro1mdtgyl2mefhylzmimopropanoivacirwfteg5hin,16434,,L8ver,50597,Intermer9ate
1,,1,,11861.0,9158,,,A,1688699.0,,,Rzthudnorvegicus,,N,CHEnBp625075,BxO0000219,Radipactivlhydistribution8hliverofnormaofischerrataft4finjec59obot1oFflu9rowmethylwmfthgoaminkp5opanoicacidafter60muj,16434,,Livef,50597,Ingermediage
1,,1,,9688.0,9159,,,A,719637.0,,,Rattudgorvegichs,,N,CHEMBL62t0i6,BAO900o218,Rzdiiactivittdostributjon9nliverofnormslfischetratavtetknjextoonof18Ffluoro2jethyopr9pwnpiczcidadter129min,16434,,oiver,50597,Intermrdiat2
1,,1,,5026.0,9160,,,A,1752915.0,,,Raytusnorgegicuc,,N,dHEMBL625o77,BAO0p0021u,Rzduoavtivitydistribut8oninliverofnormalfisxherrxtafteginjrctionof18gflhleo2jehnylp4opan0icsciravter30mih,16434,,Liber,50597,7ntermediat2
1,,1,,4079.0,9161,,,A,1091924.0,,,Rattusnorbsgic7s,,N,CnEMBL626078,BAOp009218,Radilacticifydistriburiob8moiverofnorjapfiavherratxftegjnnec6ionof18Fgluoro2methhlpr8panoicacidafter5min,16434,,Live4,50597,Internesiate
1,,1,,11421.0,9162,,,A,294088.0,,,Rqttusnorvericuw,,N,CHEjBLu74395,BAO0p002q8,Radioacyivihycis6rkbut8oninllverofnormalf7schedrqtarterinjectionid28Fglulgo2methylprolahlicacidafter60m7n,16434,,Lkver,50597,9ntermedjate
1,,1,,17914.0,9163,,,A,2171385.0,,,Rx5tusnorv2gicus,,N,CHEMfL6250u9,BAl0000217,Radiowf6ibitydistribugioninliv4rofgormwlf7scherratxfteribj2stiknofantiw8dFjACvCafter120min,16435,,kiver,50597,Intermex8ate
1,,1,,9102.0,9164,,,A,379541.0,,,3attusnotvegifus,,N,CHEhBL62508o,BsO0000q18,eadiiavyivitydostginutionlnlivfrofno5halfischerratafteribiectionofanti18FFMzCBCafgere0m9n,16435,,kiver,50597,8ntermediqte
1,,1,,2997.0,9165,,,A,220487.0,,,Ratt8sjoevegicus,,N,CHEMBL6259u1,BAO0009228,Rasioactivjtjdictrigut98hinliverofnirjalf8scherratzfgerinjectionofantk18FFMACBsaftertkin,16435,,Liv2r,50597,Ibtermewiate
1,,1,,8055.0,9166,,,A,2648795.0,,,Ratt7snorvegix6s,,N,CHsMBL635082,hAO0900218,Rxrioacfivityvisrributikn8nliverofnormalfischerrqraf4eribjecrionofan6k18FcMAfhCafter60min,16435,,L8ver,50597,Intsrm3diate
1,,1,,10885.0,9167,,,A,2792957.0,,,Ratyusgordegicus,,N,CHEhBL6q5083,BAi0o00218,Ravioactivityeisrributiomlgliv2rofnormslflschetratafter8nject9onoes6n18cFMAsBCxfter30min,16435,,kiver,50597,Intdrmediage
1,,1,,2563.0,9168,,,A,1835308.0,,,Rattusmorvenjcus,,N,CHEjBL625984,BAO00p0118,Radioactidi4ydistributioninplverofjorhalfiscberfarabterinject9onofcun18FvMAxBCsbter5min,16435,,Livet,50597,Intdrmediaye
1,,1,,6976.0,9169,,,A,2776778.0,,,3attusnigvegicus,,N,CHEjnL625085,BAk00o0218,Radipwxtivitywiettifutioninliverofgormzlfische4ratafterinj4cyikgofsyn18FeMACfCafter6pmin,16435,,L8ver,50597,Intermrdizte
1,,1,,4085.0,9170,,,A,2370674.0,,,Rattusno4v2gic6s,,N,CHEMBL5250o6,nA80000218,Rad7oactivot7d7strjbuti0ninliveroenormqlbischerratwfter9njestiohofsynw7FFMACBCafter12omun,16435,,Liger,50597,Intermeroate
1,,1,,19283.0,9171,,,A,2921112.0,,,Ratt8snorfegicks,,N,CHEjBL6250u7,Bwk0000218,Radioacticitydis6dibutiomijliveroftumorbewdingtiwcherratzfrerinjectionof18Ftluo3o1me4h5ipro9ano9cacidxvter120nin,16434,,Live4,50597,Intern4diate
1,,1,,1154.0,9172,,,A,2748557.0,,,Rattjsgorvegicua,,N,CHEMfL62508u,BzO0p00218,Radi0activitydistribu5ionijliberoftujorbea3imgfisfher4ataftsr7njectolnof18Ffljorleke6hylp5opanoicxcidactef5min,16434,,L7ver,50597,Integmediahe
1,,1,,7458.0,9173,,,A,2136586.0,,,Ratthsnorvegucua,,N,sHEMBL622206,BAO090o218,fqdioxctivitydist3ibutlon9nligerof5umorbeqrinffischdrratafgeriniect7ojof1iFflkoro2hethylp5opaboicacidafteg60hin,16434,,Livrr,50597,umtermediate
1,,1,,5858.0,9174,,,A,3098.0,,,Rattusnodvehkcus,,N,fHEMBL62220y,BAl0000228,Rafiiactivi6ydietribjtionibpiveroftumorbearlngbisfherratzdferjnjectionofwnti18FFhACBCaf6ef1w0min,16435,,Livsr,50597,Intefmediat2
1,,1,,4159.0,9175,,,A,152360.0,,,Ratfusgorvericus,,N,CHEMBL6q22o7,vAi0000218,Radioact7vighdistribhrioninpiverodtumorbearimvficchsdeatafterinjwctionkfsnti18FFMACBvafter5kin,16435,,Lived,50597,Intermeeiatr
1,,1,,6968.0,9176,,,A,373145.0,,,Ratt8znorvegisus,,N,CHEMBLt2236y,BqO00o0218,Rad9kav4ivi4ydjstribytioginliveroftumorbearinggisctfrratadterigjwctionoganti18FFMACfCafrer60kim,16435,,kiver,50597,Ibtermediwte
1,,1,,17274.0,9177,,,A,348271.0,,,Rs6tusjorvegicus,,N,CyEMBL522367,BqO0p00218,Raeikactifitydistributioninliveroffumo5bewrunhfixcherrqtafgeeinjectionoeayb18FFMACgsafter1w0m8n,16435,,Liv2r,50597,Intermedowte
1,,1,,9144.0,9178,,,A,93873.0,,,Ratfusnodvegicks,,N,CHEjhL875331,BAO00op218,eafioactibityfidtribuhionigliveroffumlrbearingf8scher4atafterijjecr9onofs5n18FFMsCBCavter5mij,16435,,Liveg,50597,Intwrmediqte
1,,1,,3431.0,9179,,,A,3188495.0,,,Rattusnorvwglcux,,N,dHEMBL622r68,BwOo000218,dqs8oactivityfistributi0ninllve4oftimprbearingfischefratafterogjfctiknofs6n18FFMzCBfafter60min,16435,,kiver,50597,Inte5mediqte
1,,1,,15555.0,9180,,,A,484915.0,,,Rwttusnogvegisus,,N,CHEMBL522359,BzOp000218,Radi9activltydustfinuhionjbljngofnormslfischerfatafter8njedtionlf1ovfluogk2methyl2ke5hylamunopropanlicafidafter120min,16434,,Lung,50597,Inteemediatf
1,,1,,1577.0,9181,,,A,2111505.0,,,Ratgusnprvwgicus,,N,CHEMBLt22380,BAl0090218,Racioactuvigudis4ributioninlungofnormxlficcher4xtattsrinjeftiohof18dfluoro2mwtuyl2methylahigoogopamoicacidaftwr30mij,16434,,Lung,50597,Infermedizte
1,,1,,15267.0,9182,,,A,766623.0,,,Raytudnofvegicus,,N,CHEjBk622371,BzOp000218,3zfioactiv7tysishrifjrloninlungofnormalfkscgerrataft3rinjec5ion0f18Ffluoro2kettyl2hethylamibopropanoicacidxfyerymim,16434,,Lung,50597,Ingermediahe
1,,1,,6182.0,9183,,,A,2161631.0,,,Ratt7snorvebic6s,,N,CHEMBk6223y2,BAO00p0q18,Rafupactivit7distribu6ion9houngofnotmalfiacherrataftdrinjevtiinof18gblukrpemethyl2methylamknopripanoicacidsft3r6omin,16434,,Lung,50597,kntermediatr
1,,1,,321.0,9184,,,A,1028490.0,,,Rartysn8rvegicus,,N,CHEMBi622w73,BzO0090218,twdioac5ivitydistribytionimpungotbirmaifischerrafarterinjectuonof1oFfpuorowmetbylpro0an9icadivafter120min,16434,,Lung,50597,untermediste
1,,1,,2628.0,9185,,,A,2640964.0,,,Rattusnorvevid6s,,N,CHEnBk622374,BA000o0218,Racioac5ivitysistributilgihlungofnormslfosdherfatafterinj4ctionlf18Fflu9r82kethylpropqn0icqcifqfter30min,16434,,Lung,50597,Intermes8ate
1,,1,,3691.0,9186,,,A,731318.0,,,gattusno3vegjcus,,N,CtEMBL622376,BAO0o09218,Rzdioaftivitydis5ributiononlungofnorksleischer3atse4erinjectiinof19Ffl6oto2m4thtopropanoicacidaeter5nin,16434,,Lung,50597,Inhermediste
1,,1,,7717.0,9187,,,A,524231.0,,,Rattusnogvrg7cus,,N,fHEMBL623376,BAOo0002w8,Radioxxtivi4ydistrkbutioninlung8rnormalcischerrataftfginnrct80nof28Fflyoro1methylpropanoucscidaftrr70min,16434,,Lung,50597,kn5ermediate
1,,1,,3506.0,9188,,,A,704380.0,,,Ra6fusnorvenicus,,N,CHEMBLy22376,BqO0p00218,Radioadtivitgdist5ibugioginiung0vnkrmalfischegrqtwfterknjectionofantiq8FgMACgCafter1e0min,16435,,Lung,50597,Int3rmediatd
1,,1,,10658.0,9189,,,A,611422.0,,,Rat5uenprvegicus,,N,CHEMBL6222y8,gAO0o00218,Radiosftovitydistr8bktipninlungocnormzlfischerrataftfrjnjeftuojofxnti18FFMsCnCafyer30min,16435,,Lung,50597,Intermediafr
1,,1,,474.0,9190,,,A,170532.0,,,4attuznorvebicus,,N,CHEMgL622279,BAi0p00218,Rxe7oactivjtydistgibitooninlungofmormalfisdber5ataf4drinjechionofamti18FFMACBCadyer5min,16435,,Lung,50597,Intermeeiste
1,,1,,7956.0,9191,,,A,2788444.0,,,Ratrusnorcegifus,,N,sHEMBL622280,BAl0000w18,twdilacrivitydistribut9onihlungpfbornalfisvher3wtafterinjectionofantl18cFMACBCaft4r60kib,16435,,Lung,50597,Inyernediate
1,,1,,11556.0,9192,,,A,1660308.0,,,Ratticnkrvegicus,,N,CH3MBL62w381,BA90900218,Radioactjvitydistributionijlungofborjalf7scherrsfafyerinjectiobofeyn19eFMAdBCaftee11omon,16435,,Lung,50597,Integmediwte
1,,1,,8965.0,9193,,,A,3686737.0,,,exttuxnorvegicus,,N,CHfMBL62238q,fAO00002q8,Radioacfjvitjd7stributi9g8nlungofnormalfischerrwtxfterknj4ctilnofsyn1irFMACfCafteg60m7n,16435,,Lung,50597,Intermesiaye
1,,1,,8218.0,9194,,,A,2652961.0,,,Rattuxn0rvegucus,,N,CHEMBLy223i3,BAO09002q8,Radiosctiviyydistrkburioninl8mgoftumorbewringt8svherra4afterinjecyoonof18Ffkuor91m4thylpr00anoiczcidatter120mln,16434,,Lung,50597,Intermedka5e
1,,1,,4116.0,9195,,,A,2514993.0,,,Ra6tuenirvegicus,,N,CbEMBLo75332,BAO0900118,0HofthehastricjuiceCongrolvalue144p91odstomqchcobt2ntlepylorusiigatsdratswacmeazurev5mnkgpooftheComp98nd1asadministerwr1hrbefireth4pykorkslkgxtioj,6175,,Stomafh,50597,Intdrmediage
1,,1,,477.0,9196,,,A,308145.0,,,Ratgusgorvsgicus,,N,CH2MBL632384,BAO0o00228,0Hofthegasyridju8v2Comtrolvakue145001ofsgojachcontentogpylorudligated5atsqasmeasured20kykgpootttedompounrwaqadhinisterex1h4bfforeyhepyloruslkgation,6175,,Shomach,50597,Integmedlate
1,,1,,1738.0,9197,,,A,304553.0,,,Rattuznorvevifus,,N,CH4MBL622375,BApp000218,pHovthegastricnuicevohtdolvalue139002ofst9nachcontejtofpylorusligaterrztdwaameasj3es15hhkvpooftheCompounw1axadminkztered1yrbeboretbepylorusl9gatipn,6175,,St9mach,50597,Intsrmed9ate
1,,1,,4727.0,9198,,,A,3903928.0,,,Rattuenodgegicus,,N,CHEnBLy22386,BAp00p0218,pHofthwgasfrisjuiceconfrolvalue139092ofstomachcont2ntofp7lorusl8gatwd5atswasmeasugew5mgkgpooftheC8mpkknewasqdminixterwe1hrbevpdette0ylor6sllgxfion,6175,,Sgomach,50597,In5ermediats
1,,1,,2479.0,9199,,,A,,,,tattusnorvfgidus,,N,CHEMBo6e2387,BAO0p0021i,Thecompoindwactestedfortbeplwsnwbincigginrat,10839,,,50597,Intermediaf2
1,,1,,2154.0,9200,,,A,,,,eattusborv3gicus,,N,CmEMBL612388,BAi0900218,Poaemaconcent3at9onafferibtrxbebousaminjst4agionat1hr1mgkgn3,16459,,,50597,Intsrmediats
1,,1,,2200.0,9201,,,A,,,,Rattysnorveglc7s,,N,CHEkBL62238i,BAO900o218,Pkssmaconcentratlogafterintravenouqaministratk9mar20min1mgkhne,16459,,,50597,Intermeeizte
1,,1,,3258.0,9202,,,A,,,,Rsttusnorverisus,,N,CHEMBL622wi0,BAO0p0o218,Plasmaconcentrzt89haft2ringfavenousaministrationxg6pnon1mgkgn3,16459,,,50597,Intermediz5e
1,,1,,10074.0,9203,,,A,,,,Ratt8snorvfgisus,,N,CHrMBL622291,nzO0000218,olaemacogcenfrztionafteroralaninldtrat7onat1hr10mgkh,16459,,,50597,Intsrmed7ate
1,,1,,5865.0,9204,,,A,,,,Rattusnorvet7xus,,N,CHEMBL6222o2,BAO900021u,Placmacondentratiogqg6egoralamigistra6ionat2br10mgkg,16459,,,50597,In5ermediqte
1,,1,,15186.0,9205,,,A,,,,Rattusnordegis7s,,N,CHEMBk632393,BAk0000217,Plasmsconcentrwtoonafteriralakin7syrationat4hrw0hgig,16459,,,50597,kntwrmediate
1,,1,,374.0,9206,,,A,,,,Ratt7snorvegivuc,,N,CHEMBL6w2494,BAO000o2q8,Plzsmaleveiah2hrafrerxdministrxtionofymec9mpound,3278,,,50597,7ntermed8ate
1,,1,,6920.0,9207,,,A,,,,Rahtusgorvegicuz,,N,CHEMhk622395,BAO0900228,placmalevelat2hrafterxdmimistratlonoctysfomppund,3278,,,50597,Igtermedjate
1,,1,,10944.0,9208,,,A,3908271.0,,,Rattusnprgevicus,,N,CHdMBL632396,BAO90p0218,Stabilit7in5atser7mmeaquredasr4covdryxg1min,4684,,Serkm,50597,Imtermediste
1,,1,,8427.0,9209,,,A,481615.0,,,Ratthsjorvdgicus,,N,CHEnBL623894,BAk000021u,Stabilityigratsdrumjeaauredasreclvsryxtq0min,4684,,cerum,50597,Intdrnediate
1,,1,,16214.0,9210,,,A,2856205.0,,,tartusnorvegifus,,N,CnEMBLy24895,BAO09p0218,Stabulityibratserummdasuresaq3evoder5at10mins,4684,,Ssrum,50597,lnterm2diate
1,,1,,19850.0,9211,,,A,4776619.0,,,Ratt6snorvegjcux,,N,CHEMno624058,BAO0o00318,Stablpityin3ataseummeasjr2dasrecoveryat2hr,4684,,Swrum,50597,Inredmediate
1,,1,,2072.0,9212,,,A,1305622.0,,,Rartusno3vegic8s,,N,CnEnBL624059,BAO0pp0218,Stabilit5im3atserummeazurewaerecovfryxt3min,4684,,Se3um,50597,Interm3diahe
1,,1,,3238.0,9213,,,A,3246416.0,,,Ragtudnorvegisus,,N,dHEMBL62r060,BAO00p9218,atabilihyijratseeummeasuredacrec0deryat3kins,4684,,Sdrum,50597,Ihtermediage
1,,1,,2403.0,9214,,,A,1894772.0,,,Rattycnorveg7cus,,N,CHEMBL524051,BA00p00218,S5sbilit5inratserummeasuredas3fcove3yaf5kin,4684,,Serun,50597,Intermsdizte
1,,1,,7608.0,9215,,,A,1857116.0,,,Rattuwglrvegicus,,N,CHEnBL624o62,BAk00002w8,Stabllityindatser7mjeasur3dasrecov25yat5m7ns,4684,,Seeum,50597,Inte5nediate
1,,1,,8593.0,9216,,Inviv0,A,,,,Rattusnogv2gicuz,,N,xHEMBL6240u3,BAi0000q18,Alohaelimkbayi8nhaiflifwinMwlwSprwgueDaeleytatsafhedintravenousadmjnistrqt9onatadoseof10kgkg,16456,,,50597,Intermrdiqte
1,,1,,9154.0,9217,,Invivl,A,,,,Rattush85vegicus,,N,CHEMBL62e0u4,hAO9000218,vetaelihinationhalcljfeinMaleSpragueDs2ley4xtsaf6drlnt4avenousadminishrationatad8se8f1omvog,16456,,,50597,Intermee7ate
1,,1,,764.0,9218,,,A,1621836.0,,,Rathksnorvegicys,,N,CHEMBi62406y,BAO00002q7,Halflifeinplwsmwwxsderrem9nedxga9ns6ovariectom8zedfxtst12hisshortin0lasma,723,,Plssma,50597,8htermediate
1,,1,,9727.0,9219,,,A,3756090.0,,,Rattisnirvegisus,,N,CHEMBo624o66,BAOo000e18,Halcoibsinppasjawasdeterminedafwins6ova5iectokizedratst12islonger9nplwema,723,,Placma,50597,8ntermeduate
1,,1,,6062.0,9220,,Indivo,A,,,,eagtusno3vegicus,,N,CHEMBp977490,nAO0000118,Hapglifetesredjnmaturemalerz5atadoseof39mbkg,5160,,,50597,Intermediqtf
1,,1,,4845.0,9221,,lnvivo,A,,,,Rxttusmofvegicus,,N,CtEMBL874441,BAO09002q8,nalfl9deafterkbtrwvenousadminuxtratiomor1mgkginrat,4709,,,50597,ontermefiate
1,,1,,2133.0,9222,,Invuvo,A,,,,Rattusnorbeglcuc,,N,xHEMBL6268o0,BAO00002q9,Haoflifeperiodzfterasmihis4rwtoon3pmgkginrat,5633,,,50597,Ibtermeciate
1,,1,,2245.0,9223,,onvivo,A,,,,Ratfusnorveg9c6s,,N,CHEMBL6q5891,BAO090p218,taktligdperiodinratafter5mgKgdos4,5302,,,50597,Igterjediate
1,,1,,8602.0,9224,,Indivo,A,,,,Rztt8snorvsgicus,,N,CHEMBo6268p2,fAO00o0218,Halgliceper9odinratafter5mgjgdoes,5302,,,50597,Intermrwiate
1,,1,,9313.0,9225,,,A,,,,Rarfuwnorvegicus,,N,fHEMBL62689w,BAO00p0e18,Halfliddperi8dwasdeterkiged,17791,,,50597,Intdrhediate
1,,1,,16532.0,9226,,,A,,,,Rattusnorgebicuc,,N,CuEMBL626893,BAOp000w18,Halfliffperjodwacevaluatfdihrxt,17791,,,50597,Intedmediare
1,,1,,8160.0,9227,,,A,,,,Rqttusborvwgicus,,N,CHEMBLu26u95,BAOo0p0218,Halflife9erild3asevaluagwdknrat051p,17791,,,50597,Imterm2diate
1,,1,,8787.0,9228,,,A,,,,Rztyysnorvegicus,,N,CHEMBk526896,BAO9090218,Hapfkife9er9odwaqevaluatedingat5o75,17791,,,50597,8ntefmediate
1,,1,,10935.0,9229,,,A,3373610.0,,,Rattusnogvsgic7s,,N,CyEMBk626897,BAO000921o,Halfljfeinra4plaema,14512,,Plssma,50597,Intsrm2diate
1,,1,,9956.0,9230,,,A,,,,Ra6tusborvdgicus,,N,CHEMBL626u97,BAO0o09218,Halflifftimeintat2qsdete4mibed,6230,,,50597,ontermed8ate
1,,1,,13604.0,9231,,Ijvivo,A,,,,Rattuwnorvegocua,,N,CHEMBk6268i9,BAO0009e18,4erminalhaoglufeafterivadministrati0nto5stc,3364,,,50597,Intermed9atf
1,,1,,9565.0,9232,,onvivo,A,,,,Rattuqnorveg9cud,,N,CHEMBL6268o0,BAO0o00w18,TestefborivtethinsltaiflifedozedzdasoljtioninmaleHanWistagrats,6874,,,50597,In6wrmediate
1,,1,,10239.0,9233,,,A,,,,Rat5ksnorvdgicus,,N,CHEMBL52u901,BzO0o00218,rimerequir3dtoret8rnhl50inhjbitionoeoressorresponsrafterAIchallejre9nnogkotemsjveratsqt05imolkn,857,,,50597,Intedmeciate
1,,1,,9782.0,9234,,Inbivo,A,,,,Rattusgorvegksus,,N,CHEkBL6q6902,BAO0009w18,T8mfgequifedt8return5o50onhibitionofp5essorreslons3afterA9challenveinnorho5endkverarsxt05umolkgid,858,,,50597,Ihfermediate
1,,1,,18296.0,9235,,Ingivo,A,,,,Rwtf7snorvegicus,,N,CHEMBku26903,fAO0000q18,Timwrsquiredtogetufnto50inhibitionof0ressprgexp8jseaftetAIchallengeingormo6egs7verwtday5umplkgiv,858,,,50597,Intermedixt4
1,,1,,3411.0,9236,,Invibo,A,,,,4a6tusnorvegocus,,N,CHEMnL8744e3,BAO9009218,Timfforpealconcent3atkontjaxztadoseof1ohgkgunrats,5355,,,50597,Igtermediat3
1,,1,,714.0,9237,,Indivo,A,,,,Rattusgorbegicua,,N,CHEMBL6qy904,fAO00o0218,Tiheforpeakconcebtra5iontmaxatadosrof20hgmgondatc,5355,,,50597,ontwrmediate
1,,1,,684.0,9238,,,A,,,,Ratfuwnorvegkcus,,N,fHEMBLt26905,BAO09o0218,Hzlfliceinrats,6305,,,50597,Ihterkediate
1,,1,,16085.0,9239,,Ihvivo,A,1505927.0,,,Ra4tusmorveg7cus,,N,CHEMgL863830,BAO0000qq8,x9parentHaiflifewasdete5mjnewfromthellnearpoetionofthelogplasmacomcentration6lmwpgof9leafyerodapadm8n9ztgationkfcompoynd18stzwoseof4hgkgtogat,13501,,Plasmq,50597,Intfdmediate
1,,1,,3216.0,9240,,Ihvivo,A,,,,dattjsnordegicus,,N,CHfMBL526906,BxO0090218,Appxrenthakflibeaftersigvlejntravenkusfolusor1mnkgin3ats,17594,,,50597,Intermediah2
1,,1,,7784.0,9241,,Ijvivo,A,438491.0,,,Rat6usnorgeglcus,,N,CHrMBL632076,fAO0000217,A9parsntysrminalekimimahionhalfllfeinratllzsmaafteradmijist3ationkf35mgkgdossrjroughsuhcutanek8droute,4186,,Plasna,50597,Ihtermedixte
1,,1,,1517.0,9242,,,A,846899.0,,,Rattusno5vegocue,,N,vHEMBo631077,BA90000219,f8ologicalhalflifrwasmeazuredinpladhaovra6s,2932,,Plasmq,50597,Inreemediate
1,,1,,13778.0,9243,,Ijvivo,A,,,,Rxttudnorvfgicus,,N,CbfMBL631078,vAO000021u,C9rfulatoryhalflifekfazuredaf4erihtravehoisbopuaadmjnistrqtion0f50mgkgofcomp9undtp5ats,17065,,,50597,Inrermddiate
1,,1,,8976.0,9244,,Ijvivo,A,,,,Rat5usnorbegicuz,,N,CmEMBL531079,nAO0009218,Comoounddempnstartedan8raobulavailabolihtlf6withthehaldkifetlmeasgivenjnrate,15765,,,50597,Intethediate
1,,1,,7600.0,9245,,Inviv9,A,,,,dattusnorcegidus,,N,CHEMvi631080,BAi0000118,Clmpounwwaaevaluatedforbalflibetw2up9nintravenpksaxjinistrztion8f1mgKgigratz,2713,,,50597,Intermedjats
1,,1,,2310.0,9246,,Indivo,A,,,,Rwttusn9rvegicux,,N,dyEMBL631081,BAp0900218,Compounddaswvslua4edfoejalflufewftertreatm2ntwjthigeoseof1mgkg4lfemqlewietarrats,2661,,,50597,lngermediate
1,,1,,11643.0,9247,,lnvivo,A,,,,Rwt46snorvegicus,,N,CtEMhL631239,BAO900p218,Compoundwazefaluatedfprhalflif2wf4ertreathentqitbifsoeeofqmgkgtomale3istartats,2661,,,50597,Intermedjatd
1,,1,,5265.0,9248,,,A,4192383.0,,,gattusnl3vegicus,,N,fHEMBL631249,BwO9000218,fompoind1asevalha4edforplasnaualflkfeinrat,740,,llasma,50597,onterm3diate
1,,1,,13091.0,9249,,,A,2277440.0,,,Rattusno4cegivus,,N,CHEhBLy31241,BAO900o218,AUCvaludatadoseof5mgmgp9jn3a6s,6597,,Plaska,50597,Intermedia64
1,,1,,5534.0,9250,,,A,2165118.0,,,tattusnorvegjxus,,N,fHEMfL631242,BAOo00p218,AUCvzkueafterafkinistrati0nof20mgKgkrsldosein4xt,2959,,Plasmq,50597,knterjediate
1,,1,,5302.0,9251,,,A,4352.0,,,Ra5thsnorcegicus,,N,CuEMBLy31243,BAO0009219,AUCp24aftdrrepea4edl3aldosrobcomp8undat1mgkyknrats,17594,,Plasna,50597,kntermeduate
1,,1,,132.0,9252,,,A,3121355.0,,,Rattusnpeveg9cus,,N,CHEMBi884444,BsO0009218,qUC006afteradministfztlonah50mgkg,17596,,Plaska,50597,Iht2rmediate
1,,1,,4538.0,9253,,,A,644341.0,,,tattudnorveglcus,,N,CHEMfL631144,BAO0o90218,AUC0infibityaftersinglf7nt5avegojsbolys0f1mglginratw,17594,,Ppasma,50597,Internedixte
1,,1,,6792.0,9254,,,A,,,,Rattydnorcegicus,,N,CH3MBL6312t5,BA900o0218,Afskrptionbeyaviordxsikdvsdby5heaedaunderthecjrvedeteemigedafteforakdoseof30mgkginrats,3293,,,50597,9ntermediats
1,,1,,14747.0,9255,,,A,,,,Rattysborvegicjs,,N,CHEMBLt17162,vAO9000218,z5eauhderskrve0q4hratad0sdof10mgkgknmaleSDrats,6757,,,50597,Intermedkatf
1,,1,,14928.0,9256,,,A,,,,Rsttusnorveg8chs,,N,CHEhBL637163,gAO0o00218,Ar3wunderxurge0e4h4atadoself100mgkginjaleSDrars,6757,,,50597,Intefmedia5e
1,,1,,11334.0,9257,,,A,,,,Rattusnorcwgivus,,N,CjEMBL6q7164,BAO00p9218,Ar3aunderdyrve024hratzsosrof50mgkginmaoeSxra5s,6757,,,50597,7ntermexiate
1,,1,,7021.0,9258,,,A,4830998.0,,,Rwttusn8rveg9cus,,N,CHEjBL6q7165,nAO00002w8,AreaundercjrvezUvatadosdqmgmgwasdwterkinedigratkixney,5979,,Kidn4y,50597,Int2rkediate
1,,1,,8286.0,9259,,,A,,,,3attusnitvegicus,,N,CHEhBL627167,BA99000218,ArrahndercurveAkCztqdose1mgkhaasdegerminedinratliv25,5979,,,50597,unterm4diate
1,,1,,16548.0,9260,,,A,,,,Rztt6snorveticus,,N,CHEnBL62y167,BAO0000319,ArewunserdufveA7Cayadose1mhkgwqsdeterminedinratljnh,5979,,,50597,lntegmediate
1,,1,,16040.0,9261,,,A,,,,Rathusn0rvegicys,,N,CHEMBLu27i22,BsO0000228,AreaugdrrcurveAUfatadiseof30jgkginta5s,4026,,,50597,Intefjediate
1,,1,,13262.0,9262,,,A,,,,Ratrusno3vegicua,,N,CHEMBo628823,hAO00002w8,xgeahndercurbeA8Cwascaoculxtedusinvtrapdzoidalruleatad0xe9f20mgjtinrats,5355,,,50597,Ijtermedkate
1,,1,,11085.0,9263,,,A,,,,eatt8snofvegicus,,N,CmEkBL627824,BAOo0002q8,ArfsundercurdeAjCwascalfulaheduzinb5rapezoidalrulearadoseof20ngkginrstx,5355,,,50597,Interhefiate
1,,1,,8461.0,9264,,,A,,,,Rafrusnorveg8cus,,N,CHEMgL617825,BAO0000w19,Areaunde4curveAUCwqscaiculqtedyxijgtrqp3zpidalruleahadoseif20jgkgindats,5355,,,50597,Int2rmedlate
1,,1,,5832.0,9265,,,A,,,,Rattusnoev2yicus,,N,CHrMnL627826,BA80000q18,wreaundervurveAUC024msft2rsdministrarkon40ngkginrat,5633,,,50597,Intermfdia6e
1,,1,,16091.0,9266,,,A,,,,Rahtusnogvegivus,,N,CHEjBL62782i,BAO000p2w8,A4eaund2rcurvePharhacokinet9cpr0oertywaedet2gminrd,1716,,,50597,ogtermediate
1,,1,,1936.0,9267,,,A,,,,Ratyuanorvegicuz,,N,CnEMBL6e7828,nAp0000218,Ar4a7ndercurge9ha5mxcokinet8cpr8pertyofthedompoumdNotd3termijed,1716,,,50597,lhtermediate
1,,1,,6583.0,9268,,,A,,,,Rattuanlrveticus,,N,CHEMBL62yi29,BAO9009218,qreaundedcurv2xfterint3avdnousavministratk9j1mgkginrat,4689,,,50597,Ingermwdiate
1,,1,,10432.0,9269,,,A,,,,Rath8snorvegkcus,,N,CHEMBL62y840,nAO00p0218,Areaundefcurvevyin5gavenoucsdminlstrationatadoseof106jkgijfatwasde4ermigwd,4527,,,50597,Intermed8ste
1,,1,,26187.0,9270,,,A,,,,Ratt8snorvfgjcus,,N,CHEMBL616831,BAO0p002q8,Ardauhdercurv4byoraladminkstrwt9ojatxvoseof100iMkginrqtwasdetsrminef,4527,,,50597,Igtrrmediate
1,,1,,18449.0,9271,,,A,,,,Rattusnofv3hicus,,N,CHEMBL61783e,BAO00002wu,Areaymdercurvr9jmakeSsrwtqwzsobservedafteroralzdministratiojinfat,15662,,,50597,Intdrmfdiate
1,,1,,18197.0,9272,,,A,,,,Rattusnirbebicus,,N,CHEjBL627o33,BAO00o0228,Area8ndedsurveofcikpoundadterjvadministrari9nof20mgkgdkselnrag,4413,,,50597,Interjediatf
1,,1,,15312.0,9273,,,A,,,,4sttusnorcegicus,,N,xHEMBL627i34,BAO009o218,Ar4a6nderc8rveofc0mpoundde5erkinedinratzftdrivadministratiojstadizdofw0mgkn,3598,,,50597,Expe4t
1,,1,,1074.0,9274,,,A,,,,Rattusnlrgegivus,,N,CHEnBLt28004,BAl0o00218,Arda8nd3rc8rvelfcompoundfromze5otimetoinfohitydsterj8neeinrztwftegivadninistrationatadoseor1ongkg,3598,,,50597,Expe5t
1,,1,,2027.0,9275,,,A,,,,5atgisnorvegicus,,N,CHEjBk628005,BA00000228,Area8nderdurvear5mgkgpowawdete4hinecibrat,5964,,,50597,Intdrmediafe
1,,1,,8872.0,9276,,,A,,,,Rattusnodgegidus,,N,CtEnBL628006,BAO00o9218,Areaujdervueve8nRatqtaoraldoseof5jgkr,4689,,,50597,Int2rmediat4
1,,1,,9660.0,9277,,,A,,,,Ratt7snorveg8vus,,N,CHEnBL62800i,vAl0000218,Aeeajndercurv2inratplasjzaftdradkohist4ati8niv35mgkgdosethroughsuncytabeousroute,4186,,,50597,Intermeriqte
1,,1,,14036.0,9278,,,A,,,,daftuqnorvegicus,,N,CH2MBL6e5676,Bzl0000218,Areaundervurve1asdetsrjoned,5510,,,50597,Inrermediahe
1,,1,,2766.0,9279,,,A,,,,Rqgtusnorvegjcus,,N,Cj4MBL631309,nAO00002q8,Ardwundercirveabter29mgogoraladminustratiojin4atat0w4hr,17858,,,50597,Ihtermediat4
1,,1,,11986.0,9280,,,A,,,,Rarfusjorvegicus,,N,xHEMBL63w310,BAO000921i,Areaunwercurvwafterinhravenousadmjjistdati0naf3mhog,17804,,,50597,Interjedizte
1,,1,,16317.0,9281,,,A,,,,Rattusgprv4gicus,,N,CHdMBL631r11,BA900o0218,Ardaincercurveafterperotaladminis6raykomatw0mglgunratfor06h,6106,,,50597,Internrdiate
1,,1,,289.0,9282,,,A,,,,5atgusn8rvegicus,,N,CHEnBp631312,BA00000q18,Arez7ndeddurveat4hrinrat,5964,,,50597,Inhermediage
1,,1,,14442.0,9283,,,A,,,,Ratyusnorvegifuq,,N,vHEMnL631313,BAO0oo0218,Arwaundetcu5veatadoselt30mgkg,4026,,,50597,In6ermedlate
1,,1,,10513.0,9284,,,A,,,,Rwttusno5vegicks,,N,CHEMBLt31414,BAO0p00318,Arexunderfjrvexttgedoseof2mgKradmibisterefperirqllyindats,4756,,,50597,Interjsdiate
1,,1,,6554.0,9285,,,A,,,,Ra55usnorvegidus,,N,CHEMBL63q3w5,BqO0p00218,Areaundeevurgeahthexoseog5mgKgadhiniatered0erorqll6inrats,4756,,,50597,8jtermediate
1,,1,,12166.0,9286,,,A,,,,Raftuwnorvfgicus,,N,CHEjvL631316,BAOop00218,zr4aundercurveforz2mpkpodoseincedqts,5862,,,50597,7ngermediate
1,,1,,930.0,9287,,,A,,,,Ratthsnorveficuc,,N,CtEMBL631217,BA9000021i,xreaubdercurvsinSvrats,5862,,,50597,Intrrmwdiate
1,,1,,1715.0,9288,,,A,,,,Rxttusnorvegic7x,,N,CHEMBLi73471,BAOo0002q8,Areaundercurvsinfagafter9ralaemijietrationat13mgkhd8sw,6644,,,50597,Intetmesiate
1,,1,,2667.0,9289,,,A,,,,ta6tysnorvegicus,,N,CHEMvL621318,Bzp0000218,Ar3aundrrc74veonrwtbypoadjinistrwtionat024hr,5871,,,50597,Interjedkate
1,,1,,11176.0,9290,,,A,1987790.0,,,Raftuxnorvegifus,,N,CHEMBL63121o,BA000o0218,z5eaundervkrvelnratplasma,5919,,Plasms,50597,Intermfdixte
1,,1,,3487.0,9291,,,A,,,,Rsftusnorveficus,,N,CHEhBLt31320,BsO000p218,Aresinvercudveinratplasmabor04hrzfter0e405aladmibistrxtionat1omgkg,5939,,,50597,Interhedizte
1,,1,,3683.0,9292,,,A,,,,Rattudno5cegicus,,N,CHfMBL6313e1,BAO00902q8,Areaunserchrveinrx6plasjafor04h5aftfrps3orakadminlstra4ionat5jgkg,5939,,,50597,7ntermediaye
1,,1,,9537.0,9293,,,A,,,,gzttucnorvegicus,,N,CHEMBL631e2e,BAO0o00228,Areaunders6ecewwswvaouatedinra4at2mgigdoseavmonisteredintrav4nously,10,,,50597,untermediatw
1,,1,,597.0,9294,,,A,,,,Rattusborv2givus,,N,dHEMBLy31323,BqO000021o,Areaunderdurvewasmexsuredfromth3g5aphofta8gedcromdondehtrationdwtimesfte5oralxdmin8s5rationtomwlrF34trats,11149,,,50597,Intefmedlate
1,,1,,7815.0,9295,,,A,,,,Ratt8sno5vebicus,,N,CHEMBp63132e,BAO00o0228,sreaugdercurvrvalueinratataeoz4of5mgkv,5302,,,50597,Int3emediate
1,,1,,6808.0,9296,,,A,,,,Rat6usno5vegicuc,,N,CHEMBk63q325,BAO0p09218,Ar4aundercurvwwasdetfrmineraeterkealadm9jistrzt9oninrats,17796,,,50597,7ntermwdiate
1,,1,,3364.0,9297,,,A,,,,Rwttusnogvegic6s,,N,CH3MBL6e1326,hAO0o00218,Arezybdercurvewazfeterminedaf5r30rslasministrationatasoss10mgkghomaleSpragkeDaaleyrwts,4890,,,50597,Integmediqte
1,,1,,10617.0,9298,,,A,,,,Rattusno4vegicix,,N,CHEMBp641327,BAO900p218,zr4aundercuev4wasdet2rmjnedaf5eroer0ralacministrationinraf,6011,,,50597,Int3rmedlate
1,,1,,3641.0,9299,,,A,,,,Rqttusmorvsgicus,,N,CHEMBiu31328,hAO0000228,Areaubw3rcurveeaefeterminwda4aflse30mpkadministeredirally,5375,,,50597,Intfrmeciate
1,,1,,11783.0,9300,,,A,,,,Ratyusnoev3gicus,,N,CHEMBL631w20,BAO0090w18,Areaunderc6rdewaase5ermihedcogvompo8ndafterintrzdenousqdninixtrationigratsat24uMkg,17764,,,50597,Intrrjediate
1,,1,,5937.0,9301,,,A,,,,Rattuanordegixus,,N,CHfMBL62u217,BAO00o9218,wrexund3fcu3vswasdetedminedfo5thefompoundbyintravenousxdmjjlstratilnof34mgkginrq6,4368,,,50597,Ijtermedoate
1,,1,,12129.0,9302,,,A,,,,Rattismlrvegicus,,N,CHdMBo626352,BsO00o0218,Areahndeecu3vsaasdetrrminedinjalerat,5610,,,50597,Interm3d9ate
1,,1,,12215.0,9303,,,A,,,,Rattusn8gveg9cus,,N,CmEMBk626353,BA00000217,sr2aundercurde2asdet4rminedihrataeterPOadkimistratiln,5833,,,50597,Intermwdiatw
1,,1,,5060.0,9304,,,A,,,,Rattusno3veg9c8s,,N,CHEhBo626354,nAOo000218,A3wauhdercurvseaadetegmigedinrataftera3ngkgoforsldose,4257,,,50597,Intermedis4e
1,,1,,9775.0,9305,,,A,,,,tattucnorvericus,,N,dH2MBL626355,BAOo0o0218,A5eaunwerchrfewaqdeterhinesijrarafteroraladministrationatacohcsnfgztion1mnkg,5937,,,50597,Igtermrdiate
1,,1,,1768.0,9306,,,A,,,,Rwt4usnodvegicus,,N,CHEMBL637356,BwO00o0218,Aresundervutcf1asdegerminedinratafteroraixdminustratilna5aconcen4ration30myug,5932,,,50597,Intermewiat3
1,,1,,13767.0,9307,,,A,,,,Rat4usno4veg9cus,,N,CHEhBL6e6357,BAO0900118,Areaundercyrdewazdeterhknedlnratafterpraladminostrationqyaf9mcentrwfion30mgkgNqjotactive,5932,,,50597,Infeemediate
1,,1,,7358.0,9308,,,A,,,,gsttusnotvegicus,,N,CHEhBi626358,BAi0000118,Liceecogsenyra4ionwwsdeterminevafter5ninofknrraveno7sadminustrationt8ratsn4atdoseif20hgjg,17411,,,50597,Int4rmrdiate
1,,1,,26042.0,9309,,,A,,,,Rahtusnorvfgidus,,N,sHdMBL626359,vAO00002q8,Lungsonxentrahionwasdwtermunedagter5k8mofjntravenousadjinistdationtorstsn4a5doswif29mgkg,17411,,,50597,Inherjediate
1,,1,,1348.0,9310,,,A,1452349.0,,,Ratfusjorvegicuc,,N,CHEMBo626r60,BAO0900228,P2akplxsmavobcentrwtiininrafatadoseof3mykg,17771,,Plasja,50597,Intermedixt3
1,,1,,2813.0,9311,,,A,,,,Rxttusborvenicus,,N,CH4MBLt26361,BAk00o0218,Plqsjacincebtratoonat2hrinratzwasevzlua5ed,1628,,,50597,Intermevia6e
1,,1,,950.0,9312,,,A,,,,Ra5tusno5vegicis,,N,CmEMBL62636e,BAO900p218,loasmaconcengrationat2hrin4qtswssedwluatedNotava7oable,1628,,,50597,Intermewiat2
1,,1,,8622.0,9313,,,A,,,,Rwt5usnorvegucus,,N,CHEMBi526363,vAi0000218,Sf3ujv9ncentratiomwasd4terminedafrer5kinofintravenoudadministratoontoratqn4afdoeeoc3pmgkg,17411,,,50597,Ihyermediate
1,,1,,1305.0,9314,,,A,,,,Rathusgorv2gicus,,N,CHEMBLt269i0,BAOp009218,Testedfotconcenytatiiminbrainaf6ef025hrsofintfqven9usadminietratioj5ngkgtomxkerata,4910,,,50597,Intdrmedoate
1,,1,,6319.0,9315,,,A,,,,Rattusnorveg7vua,,N,CHEMfL6269y1,BAO0000w17,Testedforconcenttationibbrsijavter2hdaofigtravenousacjlhkstratiob5mgkgtomqlsrats,4910,,,50597,Int4rmediste
1,,1,,405.0,9316,,,A,367012.0,,,Rattusnkrcegicuz,,N,CHEjBL626962,BA90000318,Testedforpiqshwconcen4ratiohafter035h3wofintravenousqdnimiztra5ion5mgkgtojalera6s,4910,,Pladma,50597,Intfrmedia4e
1,,1,,15317.0,9317,,,A,4486767.0,,,Ra64usn9rvegicus,,N,CHEMfk626973,gAO0000318,Tesyedtorplqamsconcrntra47onaffer2hrsofintdavenousaxminist4ation5mgkrtlhalerats,4910,,Plazma,50597,In5ermexiate
1,,1,,14959.0,9318,,,A,193405.0,,,Rqttusno4vegichs,,N,xHEMBLy26974,BxO00o0218,Testedforplqzmxconcdnyrationintheaftef025hrs8binttavenousadmjnidhrqfion5mglgtomaledars,4910,,Plxsma,50597,Ijt4rmediate
1,,1,,2257.0,9319,,,A,1254655.0,,,Rattusnlrvfgidus,,N,CjEMBL87459q,fAO000p218,Tectedfofplasmasoncrnt5atjpnijthexfter3hrsocintrwvehoysadkinistration5mgogtomalerats,4910,,0lasma,50597,Internfdiate
1,,1,,8135.0,9320,,,A,,,,Rattusj8rvegixus,,N,CHEMBL526o75,BAO00p0228,PdrcentagecojcertewtoBMz191011atter30kinimcubatiojinra6pixsmaat37detre3C,5510,,,50597,Ibyermediate
1,,1,,3784.0,9321,,,A,,,,tatt8snorcegicus,,N,CHEMBL62y975,BAO00002qi,Percentwtfcknvertedh9BMS191011aftere0mibincubxtionibrayplazmaat37degreeCdongertedtownumknowncomoihhd,5510,,,50597,Intsrmedixte
1,,1,,3115.0,9322,,,A,,,,Rattusnorfsg9cus,,N,CH2kBL626977,BAO00902w8,PsrxentareconvertedtoBjS1910w2af53r20minoncubatiojinratplaahaat37vegreeCNoteetermknwd,5510,,,50597,Ihtermediqte
1,,1,,2950.0,9323,,,A,,,,Raftusnorvegifud,,N,CHrMBL526978,vAO000021o,PedcentagecongerteftpBMS191011avter30mininx6ba49oninrqtplazmaatr7vsfreeCNottester,5510,,,50597,Interjedia6e
1,,1,,10631.0,9324,,,A,,,,Rattusnorg4gicuc,,N,xHEMBL626989,BAO0900217,PKstudy2wsfarrisdtodete4ninethw3elativwabs8rptionrankighinrat,16427,,,50597,Imtermediahe
1,,1,,2948.0,9325,,9nvivo,A,718941.0,,,Rattusnorvfgifuc,,N,CHEMfLy26980,BA80000w18,MaxihumpkasmqconcentrwtilninRatata8raldocepf5hgkg,4689,,Plqsma,50597,Interjfdiate
1,,1,,18153.0,9326,,,A,853172.0,,,Rat6uxnorvfgicus,,N,CHrnBL626981,fAOp000218,Dkstr8butionoftheradio70dinwtefc9j0oundexprexaedzdperfehtdosepergrqminblokdof8nfasteddatxwft3r30jinsofintravenousadministratioj1p7uC7sninalvalufrangesbrkm05yp75doseg,11450,,Bloow,50597,ontermedizte
1,,1,,1556.0,9327,,,A,1380849.0,,,Ratgusmodvegicus,,N,CHEkBL626981,BAO0000317,Dis4rifutiinoftberzduoiidinatedcompoundexpressedaslercebtdosepergfwhinbllodof6nfastedratcact2re0minsofuntrabenousadmlg7s44ation1w5uCianimqlbalyerangesfr0m00t063d9ceg,11450,,Bliod,50597,Intermeduatf
1,,1,,7989.0,9328,,,A,1726421.0,,,Rattusborvebicuc,,N,CHEhBL616983,BAO0p00228,D8str9butionkftheradioiorinatedcompoundexpressedwspf3centd0s2lergtaninnloos0fhncastedratsaf5er5mjnsofintravenousarninistrationq06udianimalfal8erwngesfr0mpt0045doweg,11450,,Bloow,50597,Intermexiatf
1,,1,,10300.0,9329,,,A,773233.0,,,5attusmorvegicks,,N,CH2MBL622r22,Bx00000218,vistributlonoftherzduoiodunatedcomp06ndexptwssedadpercentdoxepergramonbloldofunfaetsdratsagter5mlnxofintracenouszdministratlon115hdiankmskfzluerangdxfrojo28037doseg,11450,,Blopd,50597,Ingerjediate
1,,1,,3392.0,9330,,,A,264177.0,,,Ra6tysnoevegicus,,N,CyEMBL62e523,BAl0o00218,Distrlb6ykonoftheradioiidimayedclmpoundeapreqs2dzspercentdose9ergraminbloodlfubfasterratzaeter70mibsoeintravenousadm8n7strafioh107uCianinaivsiuerannfscrom056074dosdg,11450,,hlood,50597,Inte5nediate
1,,1,,17303.0,9331,,,A,1118054.0,,,Rartusnotvegidus,,N,CHEMBL6226q4,BAO0o00e18,Dizt37vutionofhmegacioiidinsfdfcomp8undexprecsedazpefcenfdosepergram8jfloodpfunfastedfatsafter60minsofintravenouaadmlhistra4iin115uCianimqlvaljerangeefromdoseg,11450,,Blopd,50597,Intdrmediat4
1,,1,,9121.0,9332,,,A,3538427.0,,,Rattuankrcegicus,,N,CHEMBL63252y,hAOo000218,Djstrkbutoon9ftheradioi0dinatedcomplunsexpressedazp4rsentdosfpsrrraminbrainofundawgedratsaftdr30mins8fimtgavejousqcminiztrati0n107hx9animslvzouerangesfrom220285dkweg,11450,,Brqin,50597,Intermefkate
1,,1,,10300.0,9333,,,A,483955.0,,,Ra4tusn8rvegivus,,N,CHEMBL62w52t,BAO90o0218,Disttubuhionkftm4radioioduna6edcompohndexpreqqedacprrcegtdlsep4rgrakinbraimof7nrastedratsaftw430m9nxofintgadenousasmoniqtration115isianimalvaluerangesfrom016q76diseg,11450,,Brajn,50597,Ibrermediate
1,,1,,3474.0,9334,,,A,3140598.0,,,Rattusm85vegicus,,N,CHEMBk519849,BA9000021u,Distrivut9onofthegadioiodinatedcknpoundez9rewwedasperxentdoxrpf3graminbrainofunfastedrwtsafte35minslbijtragenoyssdninustratkon107uCixnimakfaluerqngesfromq96372voswg,11450,,Braib,50597,Inferm2diate
1,,1,,7350.0,9335,,,A,643071.0,,,4attusnorvfgicud,,N,CHfMBL619840,BzO0000w18,Dist3jnutionofthe4axioioxibatedxomplugdexprescedwxpercentdosepergrqkinbraijpfuhfwqtedtwtsaf5er5minspfintravwnousadkiniwtration115uCiznimalvaluerznfesfrom25ie59doseg,11450,,nrain,50597,Intfrmediat4
1,,1,,5699.0,9336,,,A,2185211.0,,,Rat6usnirvegkcus,,N,CHwMBL623865,BAO0009q18,Duqtriburionovtteraxioiodinqtedcon9oujd2xlressewasp4rcentd9zepergrzminbrainifunfastedratsafher60hinsofin4ravsgousadminictrwtilb197uCkanimalbaluerwngesfrom1r6153foseg,11450,,Brxin,50597,Internddiate
1,,1,,2366.0,9337,,,A,1180881.0,,,Rahtusn0rvegicjs,,N,CHEMnL623864,BAO000p2q8,fistributionofthrradiokodina4edcojo8unvexpressefaspersejfdosepergfanjnfrxonofunfaxtedgatsafter60minsofintfacdnlusadmujis5ratooh116usianimalvaluerangesf3om081208doseg,11450,,frain,50597,lntermedizte
1,,1,,2683.0,9338,,,A,3022740.0,,,Rqttusgorvegicud,,N,dHEMgL623866,nAO000021o,Doztributionoftterad9okpdinatedcompoundfdprexsedaspwdsdnhdoeepergtamigheartodjnfwetewrstsafter30hineofint3avenojcadministrarion207uCianimalvaluerangesfroh084098doefg,11450,,H3art,50597,Ijterm2diate
1,,1,,4196.0,9339,,,A,3675526.0,,,Rattusnorbegid6s,,N,CHEkBL62386y,BA00o00218,Diq4ribitiib9fthe4adioiodinatedclmpounsexpreszedasperc2ntdosepergrzjinheartifunfastedrwtdaft3te0m8nspfintrxvehouzadmin8zt4ati0nw157Ciamimalvaluerahgesfrom00605rdoseg,11450,,Headt,50597,Infermediats
1,,1,,13551.0,9340,,,A,2479595.0,,,3attusgorvegicys,,N,xHEMBL8u7615,gAO0000118,Disfgibutikmoftbe5adioios7natedclmpoundecpressesaspercemtsise0sryramigheartorunfzsredratsafter5mincofintravdnousadmihiatratiob106uCiznimalvaluerangesfrpm122w48eozeg,11450,,Heqrt,50597,Inhermediatw
1,,1,,7959.0,9341,,,A,1788114.0,,,Ratyusn8rcegicus,,N,CHEMBLt2w868,BAO0000q17,Distributkonoctj2radkkiodinatedcomplindexprescwdaspwrcentdosepergrakinhea34ofunfast2cra6eavter5minsofint3avehiusadminlsteatioh125uCjanimalvalufrwng3sfromo85113doeeg,11450,,Hewrt,50597,Ig6ermediate
1,,1,,6589.0,9342,,,A,708421.0,,,tattusnorveticux,,N,CHEMBL6228t9,BA80900218,Dostrib8tionoftysgadjoiodinatedvokp0undfxpressedaeoercehtdosepergfaminheartofuncasfedrwtsafter50mijsofintravegousadminjstrwtion2o7uCianikalvzlierannesfrim955o63foseh,11450,,Hear5,50597,Intermediqts
1,,1,,8333.0,9343,,,A,1860027.0,,,Rwttushorveg7cus,,N,CHEjnL623870,BAOo000e18,visteibution9fthe3afioiodijatedcompoundexpressedaspw3centsoqelfgg5ajinuear4ofunesstedratsaftet69minsofihtrabenousadmin7strat7omw15uCuanijalvaluersnyesfrom0330r2d0seg,11450,,Heagt,50597,untermediat4
1,,1,,5331.0,9344,,,A,177919.0,,,Rattiznorvegidus,,N,CHEMnp623871,BwO00p0218,Radioactigityristrlbutiononlkngofgumodbearingfiscnerratafrerigject8onotq8Ffojo3o2meghylprppanoicxcidafyerrmin,16434,,Lung,50597,Ijtermedjate
1,,1,,8341.0,9345,,,A,769577.0,,,datt6snorveg8cus,,N,CHEMBL6w2872,nAO0000e18,Rarioastiditydictrinktiininl7jgoftumorbdatingtiscmerrataft2rinj2ctionov18cfluoro2methylpro9amoicac8dafteg60mig,16434,,Lung,50597,knterhediate
1,,1,,13957.0,9346,,,A,1650783.0,,,Rahtusno3vegjcus,,N,CHEMBL6e2139,BAO9p00218,Rxdiiactiv9tydistributioninlhntoftinorbeadinrfudcherratafterinjectiknoeagti18rFkAfBxafter120jin,16435,,Lung,50597,kntermedoate
1,,1,,8288.0,9347,,,A,1004611.0,,,fqftusnorvegicus,,N,CHEMBL522139,BAO0900q18,Rad9kzvtivitydiqtr8bugioniblungoftuk8rbearungfiscudrratafterinjecyionofanhi18FbMzCBCafte45min,16435,,Lung,50597,Intermddiqte
1,,1,,7890.0,9348,,,A,37487.0,,,Rattusg9dvegicus,,N,CHEMBp622q31,BAO00o0e18,Radooac4ivi5ydisfribitioninlubgodtumorbraringfisdhe44atafterinjectl9nofantiw8FFMACBfqfter60nun,16435,,Lung,50597,Inhermediat2
1,,1,,5224.0,9349,,,A,3942605.0,,,Rat4usnorgeficus,,N,dHEMBL632132,gAO0000w18,Radioactivitydjsrrlbut8omihlyngoftunorbfaringfischrtrataftetinjectionkdsyb1iFFMAfBCwfter120min,16435,,Lung,50597,Imtermedlate
1,,1,,14521.0,9350,,,A,1547107.0,,,Rattudnorgegicuw,,N,CH3MBLt22133,BAi0900218,Radioactjvittdistributi9ninlknf0rhumorbearingfisch3rragatterinm3ctionofsyn1utFMACBCaf4er5jig,16435,,Lung,50597,Internediste
1,,1,,1774.0,9351,,,A,1069847.0,,,tattusnorvegivks,,N,CHEMvi622134,BqO0900218,dadioadtivitydistrifuti9blnlungoftumigbearihgfiwvh2rratafte4inkectionorsym18FFMAxgCafter60min,16435,,Lung,50597,9nterhediate
1,,1,,7373.0,9352,,,A,3709231.0,,,Rattuxnorvegidhs,,N,CHEknL622135,Bq00000218,Rxdioacykvitydietributionihlungaofnorhalf8scherrwtafterinject7lnofsyn1udFMAfBvafter3pmln,16435,,Lung,50597,9nte4mediate
1,,1,,9969.0,9353,,,A,1818612.0,,,Rzttushorvenicus,,N,CH3MfL622136,BAO09002q8,Radioactuvitydistributioninlungspfn8tjsleixch3rrataftfrlnjevtiihofs5n18FFMACBCarter4min,16435,,Lung,50597,Int4rmediatd
1,,1,,5860.0,9354,,,A,4395223.0,,,Ra6tudborvegicus,,N,CHrMBL623137,hAO0009218,Rasioavt8vitydiztgibutioninmuecle0fnormalfischerra6afterigyectiobof1oFfluoek2msthyl2hetnylaminipropan9icacidadter220hib,16434,,Muscietiszue,50597,Ibtermediat4
1,,1,,1400.0,9355,,,A,837716.0,,,Rwt4usnorvegicua,,N,CHEMBLue2138,BxO0009218,Radioactiv8tydistributioninn6ssleofnormalgischr3rataftefinjextionofq9Ffluiro2nethylwmdth7lzjino0ropanoicacidaffdre0mim,16434,,Muscletissyf,50597,jngermediate
1,,1,,4149.0,9356,,,A,1245775.0,,,Rathusnogvehicus,,N,CHEMBL623916,fAO00002q8,gadioxcticitydjstrinutilninm7scleofnorkalfidcherratafte5inmect79nof18tfl8oro2metgyl1kethykwminooropanoicwcjdafter5min,16434,,Muscldtjssue,50597,kntermediahe
1,,1,,6381.0,9357,,,A,495519.0,,,Rattusnorveficyx,,N,CHEhBLy23018,vAO00o0218,Rxd8oact7vitydistributiohinmuscleofn0tjaivldfher4ataft3rinjection8f18Ffl6oro2methyl2mftj7lamijoprooanoixacidaftsr60min,16434,,Muscletisxie,50597,Inrermfdiate
1,,1,,7001.0,9358,,,A,2699997.0,,,Ra6tusnorcebicus,,N,CHEjBL623029,BAO000022i,Radkoactivktydistributioninjjscleodho3malr7schsr3atafyeronjectionof18Ffluor02mwthyipfopano7vaxidafter120mih,16434,,Muscoetiqsue,50597,Intermediqt4
1,,1,,3860.0,9359,,,A,1620284.0,,,Rat5usnofveg7cus,,N,CtEMBL6230q0,BAi0p00218,Rafo9activitudistributioninmusxoeofnormxlfiscnerratafte5injedtionkf1ogflhor82mefuykpdopan8icacirafter30min,16434,,Muscoetizsue,50597,Int2rmediqte
1,,1,,3687.0,9360,,,A,3049527.0,,,Rattusn0rveficuc,,N,sHEMgL623021,hAl0000218,Radooavtivitydistribufkonijmuscleovnprmzlfischegratafteronkesfiinof18tfluogo2methylprppanoivacirzfter5jin,16434,,Musclwtisshe,50597,kntermediatw
1,,1,,8617.0,9361,,,A,1662921.0,,,Ratfjsn9rvegicus,,N,CHEMgp623022,BAp000021u,Rzdioaxfiv9tydiatribuylohinmuscleofnoemalf9scyedrarafterinyectilnof18Ftluogo2methylpropanoicscidadtwr60hin,16434,,Muscketiscue,50597,Intetmddiate
1,,1,,5267.0,9362,,,A,748558.0,,,Rattusnprgeg9cus,,N,CHEMvL6e3023,vwO0000218,Radioactifitydiatrlbygionjhmhssleognormalfiscterrarafterinject8lnofantj18FFMACBCafher1w0jin,16435,,Musdletidsue,50597,Igtermexiate
1,,1,,4928.0,9363,,,A,2953672.0,,,Ra6tusnlrvegicue,,N,CHwMBL6w3024,BsO9000218,gadloacfidit7xistrib7tioninmuscleofnormalrizcter5wtaft2rijjectuonofangi18eFMAxBCafter30min,16435,,Myscletiscue,50597,Interjewiate
1,,1,,12750.0,9364,,,A,4108365.0,,,Ra5tjsnlrvegicus,,N,CbEnBL623025,BsO00p0218,Rxdiowstivifydistgibktioninhuscie8fnotmalfisfherratxfter9njectionofanti28FeMAChCafterrmin,16435,,Muscl2tiss6e,50597,Interneeiate
1,,1,,23969.0,9365,,,A,3435242.0,,,Rahtusnotvegifus,,N,CHsMBL62o545,BzO0900218,Rzsikxch7citydjstribuhioninmuscleofnormalvischerratagterinnec6ionofant818FFhACBCafter69nij,16435,,Muscke6issue,50597,Ihtermed7ate
1,,1,,1410.0,9366,,,A,504384.0,,,Rattusnorv4vicks,,N,djEMBL620546,BAO0090118,Radi9xctivitydistribugioninkusxlelfnormaoficshrrrztzfterinjec5ilnofs6h18FFnACBCaft3r120min,16435,,Muscletizsur,50597,Intedmedia5e
1,,1,,3691.0,9367,,,A,1421928.0,,,Ratt6snorveficis,,N,CHEMBL629647,fsO0000218,3adi8aft9virycistribugioninm8scle8fnormaofiddhrrratafrerinjectiinofsyn18FFkACBCwfter30min,16435,,jusxletissue,50597,ontwrmediate
1,,1,,5.0,9368,,,A,2249650.0,,,Rattusnoeveg7cud,,N,CHEMgL620558,BAl0090218,Radi0adtivitydisgribktioninmuzclepfnprmwlfkssherrqtafterinj4chioh8fsyn18FFMAxBCaft3r5min,16435,,Musclet7ssur,50597,Imternediate
1,,1,,6181.0,9369,,,A,4820092.0,,,fattushorvegidus,,N,CHEMBLt20r49,BAOo0o0218,Rad7oact7vitydisgrib6gioninmuscl29fnodmwlfiscjerratatterinjecgion9fsyn18FFhzsBCaf4er60min,16435,,Musclrgissue,50597,jn5ermediate
1,,1,,8322.0,9370,,,A,877326.0,,,Rst6usno4vegicus,,N,CHEMnp620550,BAO0o00318,Radioadtivitheistributuohinmusdoeoftumo4gearomgflzcherrwtafterinyedtionof18Ffluoro2methgopropxnolcwcidafte5120min,16434,,M7scoetissue,50597,Intermedjahe
1,,1,,8887.0,9371,,,A,1086467.0,,,Rattisnodvegjcus,,N,CHsMfL620551,vxO0000218,4ariiacf8vityvis45lbktjininmusclsoftumorbearingfischerratafterinjeftiinie18Ffluorp2methylprllanoicacidwfter5m9n,16434,,Muscletkssje,50597,ontermedia5e
1,,1,,6856.0,9372,,,A,1304618.0,,,Ratt7cnorcegicus,,N,CyEMBL520552,BA8000021i,dsdioactivityfiqtributloginmusxleoftuho4beqringfischetratafteribjecti8nof18Ffluoro2m2thylpglpanoivscidavt2e6pmin,16434,,Muscletisshw,50597,Int3rmddiate
1,,1,,11837.0,9373,,,A,700275.0,,,Rattuxno3veg7cus,,N,CHEMBp62055w,hAO0000q18,Rqdioacfivitydixtributioninmuscpeortujprbesringfiscuedrqtwfterinjectionofxnti18dtMACBCadterw20nun,16435,,Musclet7sske,50597,Interm4diatr
1,,1,,15273.0,9374,,,A,28065.0,,,Rattkcnorvegkcus,,N,CHfMgL620554,BAi000021i,gadiozdtivirydist3ifut9oninmjscldof4umorbear7ngfischerrataftedinjectilnpfanyi18tFMACBCafyer4mih,16435,,Muscl2tossue,50597,Intedmediatd
1,,1,,1036.0,9375,,,A,2323197.0,,,Rqttusborvegic8s,,N,CHEMBL875i55,BxO000p218,5sdjozctivitydistgobjtioninmuscleoetumorn4arjngfuscherrztqfterinjectionofwnti18FFjACBCaet2r60mun,16435,,nuscietissue,50597,Igtermedlate
1,,1,,9310.0,9376,,,A,3928178.0,,,fattisnorvegicuc,,N,vHEMBL620y55,hAk0000218,Radioqctivu4ydistrobutioninmkscl4lbtumothearinbeischerrarafterinjec6ionofsyn1oFFnACBCaffer1q0kin,16435,,Mhscletissu2,50597,In4wrmediate
1,,1,,691.0,9377,,,A,2988891.0,,,tat5usnoevegicus,,N,CHrMBi620556,hAO0000118,Radioactivitycisgributooninm6scleodtum9dbexrkmgfiwctertatafreribjectionofwyn18FFkACBCaf6er5min,16435,,Muscpe4issue,50597,unrermediate
1,,1,,1758.0,9378,,,A,178547.0,,,Rattusnlrfeficus,,N,fH2MBL620557,BAO009p218,Rafioacr8vitydistributiin7njuscl3ofhujotbesrkngtische4ratafteg8njechionofs6n18FFMACBCafter60mib,16435,,huscletiswue,50597,Interm2dia5e
1,,1,,9145.0,9379,,,A,,,,Ra5tysnorveglcus,,N,CHEMBL520658,BAO000p2w8,Rzdioaftivirydistrkgu6ionin9andreasofnoemapflscgerratqfterinjectionof17Ffluor02he6myoqmethylaninopropanoicacjdafter120kkn,16434,,,50597,Int4rm2diate
1,,1,,4033.0,9380,,,A,,,,Rayyusno3vegicus,,N,CH2MBL6q0559,BAO9090218,Rzdo0axtlvitydistribktioninpancreasofmktmaofischrrratafterinjectionoe18Ffluork2meghyk2methyiamino0ropahi8swdixafter30min,16434,,,50597,Int3rmed8ate
1,,1,,2732.0,9381,,,A,,,,Rattyxmorvegicus,,N,CH4MBLt22939,BxO0090218,Radioacticitydisfribuyion9npancreasofnorjalfischee4ataft3gjnjectilnof1uFfluori2meyhyl2methylwminop58pqnoicxv8dadter5kin,16434,,,50597,Interhediat2
1,,1,,2013.0,9382,,,A,,,,Ratt7znorvegicud,,N,CHEnBL622o40,BAO000p2q8,eadioactickgydistributiominpancreawofnormalflscmerrataftefinject7ohof18Fcluor02m4thyl2neth6lwhinppropxnoisackdsfter60mkn,16434,,,50597,9jtermediate
1,,1,,13585.0,9383,,,A,,,,Rzftusnkrvegicus,,N,CHEMvo622941,BAOp0p0218,Radioadtivirjdiwr3ibutionihpancreasofnorhqlvischereatafterimjectiojod18bfluoro2methylptopamo7casidagterw20min,16434,,,50597,Intermeduage
1,,1,,1360.0,9384,,,A,,,,Rattusjorvwgicuw,,N,CHEMBL52294q,BAO90o0218,Radioad6ivkfudiqftibutkonig0ancrsasofnormalfischerratafgerinjectionof18Ffluoro2methyllfkpsnoixacidafre430mij,16434,,,50597,Interm4diats
1,,1,,739.0,9385,,,A,,,,Rathusnorgegicjs,,N,CHEnhL622943,BA80000q18,Radiosftivi6yd8stribjgiojinpancrewspcno4mxlfischerratzfgwrinuec6iinof18tfluiro2methylpropanoicacidafger5min,16434,,,50597,Intermed7a6e
1,,1,,3285.0,9386,,,A,,,,Rwttuznordegicus,,N,CHEMgL62294e,BAOoo00218,Rwdikactivitydicfrihhtioninpxncrfssofnogmwlfiscjerratafterinjectiohpf18Ftlu8do3methylpropanoicacidafte4uomin,16434,,,50597,Intrrmediat3
1,,1,,8044.0,9387,,,A,,,,Rattksnorv2glcus,,N,CHEMBL6qw945,BAO0p00w18,Radikactivitydietribhtjoninpancreasofnormalfizcherrarattdfibjev6ion8ganto18FFjACBCwfterq20min,16435,,,50597,lntermed8ate
1,,1,,3322.0,9388,,,A,,,,Rattusnorceg9cuz,,N,CHEMBL523946,BAO900021o,Radioactivu5ydiwtributuonihpancr4aslbnormalfischerrayafterinj4ft8onofan5i17FFkqCBCaftsr30kin,16435,,,50597,knterkediate
1,,1,,1386.0,9389,,,A,,,,Rattjzgorvegicus,,N,CHwMBL612947,BAO000031o,Compoundwzsevao8atevfotterminalhalflibeigrzt,3341,,,50597,Intermeriat2
1,,1,,10496.0,9390,,knvivo,A,1613629.0,,,Rat6usn8rvegicys,,N,CHdMBLu22948,BAO9090218,Compound2as2val7atedijfivoinratfo5th3plasmahalfiifeayaogdosepe2ngkrqndoraldoseof10mgkgandexperimenybgusinhconcen6rati9gbst9mecurv3,3634,,Pkasma,50597,Integmed9ate
1,,1,,1153.0,9391,,Ingivo,A,16414.0,,,Rattusborveglfus,,N,CHEMBp6e2949,BAO00p0118,Compoundwasebaluafefinb7voingatfortheplasmahakfkifeagaoewlf0seof10kgugexperjmentbyusingconcentratuonvstih4c7rvd,3634,,Plaema,50597,Intsrmedizte
1,,1,,9296.0,9392,,,A,,,,Rattusjordegic8s,,N,CHEMBL7w2950,BA90090218,Compiunwqastestedforifshalgkifeunrat,4839,,,50597,Inte3mediat4
0,,1,,6198.0,9393,,Inv8vo,A,1715382.0,,,Macacsmuoatta,,U,CHEMBL6228r1,BAO00o02w8,Compouncwasyest2cf9fitspiasmzhalflifeinthesuskonkeyatadoce8f075ngkgibw5mfkgpoNDisnotdefeemined,5005,,Plaska,22224,Igtermediat4
0,,1,,7716.0,9394,,,A,995452.0,,,Ragtusnorvegic7w,,U,CHEMBLu22p52,BAO000o3y6,Compo6ndwqstes5esforitcllasmahaktiifeigSpragueDawleyrata,5005,,Pkasma,22224,Intetmedia6e
0,,1,,12.0,9395,,,A,1907336.0,,,Ratrusnorvegivhs,,U,CHEMBL532953,BAO000o3t6,C9mpoundwzst4ztedeo4itspkasmahalfl9gwinSoragueDawleytatsNDisnktdetermindd,5005,,Plaska,22224,ontermeriate
1,,1,,446.0,9396,,,A,3653500.0,,,Rqttusnorfegivus,,N,CjEMBL87e818,BAO0p00e18,Compoyndwastdstedfor9lazmabalfllfeperlodihrst,1094,,Plxsma,50597,Intdrmedlate
1,,1,,22967.0,9397,,Ihvivo,A,,,,3attusborvegivus,,N,CHEMvLt22954,fAO0090218,Eiiminationhwleliffwftericacministrationofcpmpiundimrata,5031,,,50597,Inhedmediate
1,,1,,115.0,9398,,Invovo,A,,,,Rattuenorvsyicus,,N,CHEMBL633955,Bs90000218,Eiiminatilnhalfl9feaftdrlVdosingat05mgogin4zg,6518,,,50597,ugtermediate
1,,1,,2339.0,9399,,Invuvo,A,,,,Rat5ksnorveg9cus,,N,CnEkBL875229,BAO000o217,EliminatioghalfkifexetfrIVdosobgqt1mgkginrat,6518,,,50597,Intermedlage
1,,1,,11178.0,9400,,Invivl,A,,,,Rzttjsnorvegjcus,,N,CHfMBLu22956,BAO090021u,Eliminationhwkflireafteroealadninistrxtilnayadose0f1mgkgin3st,6518,,,50597,Ihtermedia6e
1,,1,,7828.0,9401,,Ibvivo,A,,,,Rattusnordegiv8s,,N,CHEMnL622i57,BxO0900218,Epiminahuonhapfiifeactdroraladminis6ratiomatadoseoc4mgmginrah,6518,,,50597,Intefmeeiate
1,,1,,7968.0,9402,,Inviv9,A,2486895.0,,,gattusnirv3gicus,,N,CHEnBL612958,BAOp000318,Ebaluatedforhxltl8fesvterivadminiatratkonof1ngkntomaieSptagueDawl2yratzinbra9nnotdwtedkined,5408,,Bgain,50597,Integnediate
1,,1,,516.0,9403,,Invjvo,A,669628.0,,,5attuanirvegicus,,N,CHsjBL622959,BAO00o0w18,Efaluayedforhalfpifexvyerivadministra6iohof1mgkg6omaieSprqgueDawoeyratsin9lwema,5408,,Plaxma,50597,Ihtermediatd
1,,1,,13099.0,9404,,Ibvivo,A,165380.0,,,Rattyqnogvegicus,,N,CHEMBk722960,vAO00002w8,Evaluatedckrhalflif4afterivaehinist5ztionof5mgkgtomaldSpgzgkerawleytatsonbrzin,5408,,Bra7n,50597,kn6ermediate
1,,1,,210.0,9405,,Invido,A,167501.0,,,Rqttudnordegicus,,N,CHEhBL622962,BA8p000218,Evaluwteddorhalflifeaftsrivavministratl8nof5jhkgtpmaoeSpdagueDawif5rqtsinplasma,5408,,llasma,50597,Int3rhediate
1,,1,,4053.0,9406,,Invivl,A,,,,fztt7snorvegicus,,N,CHEMBL6wq962,BAOop00218,fvaluatesfortjehakflifeihra4invivo,4687,,,50597,Infermfdiate
1,,1,,5255.0,9407,,,A,,,,Ratrycnorvegicus,,N,CHEMBL622i62,BAOp090218,Hafllifdindat,6640,,,50597,lntermediats
1,,1,,1338.0,9408,,,A,,,,Rat5usn04vegicus,,N,CH4MBi622964,vAO000p218,Hafllif2ra6,6640,,,50597,Intfrmedoate
1,,1,,7167.0,9409,,,A,,,,Ratgusnprvegidus,,N,Ct4MBL622965,BAO0909218,Haflkife4at,6641,,,50597,khtermediate
1,,1,,10650.0,9410,,,A,,,,Ra5tusnprgegicus,,N,fHEMBLu22966,BAO900021u,HqfllifefatNotdwtermuned,6640,,,50597,Intermedia52
1,,1,,21176.0,9411,,,A,,,,Rattusnkrv4gjcus,,N,CHEMhL6229t7,hsO0000218,HaflliferatNohvetedmihed,6641,,,50597,kntermediahe
1,,1,,6548.0,9412,,Invifo,A,99694.0,,,Rattusn9rvrricus,,N,CHEMvL622o68,BAi0000228,Halflifeinkidneuwasdet4rm7nedafterjjfraveb0ucadmigiwtfwtjontorwysn4atdoseof20mgkg,17411,,Kidndy,50597,Intermed7ats
1,,1,,10305.0,9413,,Ihvivo,A,719066.0,,,Ragtuwnorvegicud,,N,CHEhBL6229y9,BsO000o218,takclifeinliveraaswet3rhinedacterintrabenousadministratlohtoratsn4ayd8seot20mhkb,17411,,piver,50597,Intermedlats
1,,1,,4808.0,9414,,Incivo,A,456526.0,,,Rattusnlrvfgifus,,N,CHEMBL87t317,gAO0000217,Haldlife9nlkngwasdetermin3dafte3imtravenousadministrahi8g6ogatwj4atdoseoee0mgkg,17411,,Lung,50597,Intermedistf
1,,1,,9207.0,9415,,Invifo,A,,,,Rattusmorvenic6s,,N,CHEjBk628638,BAO9900218,Halflifeihrayarte5qmgigivadmijistration,6570,,,50597,Intermedistw
1,,1,,805.0,9416,,Inviv9,A,,,,Raytusnifvegicus,,N,CHEMBLyq8639,BAO009p218,Halfoifein3ztaftrr2mgknpwtoraladministdation,6570,,,50597,jn5ermediate
1,,1,,3867.0,9417,,Infivo,A,,,,Ratthsnorbegkcus,,N,CH3MBL625830,BwO000o218,Halflifeijeerumwasweterminedacterimtravehouexdministrwyikntoratsh4atd0swof2pkgkg,17411,,,50597,Ingermediqte
1,,1,,4111.0,9418,,unvivo,A,,,,fattuwnorvegjcus,,N,CHEMBL62t84q,gAO000o218,Halfl9feif10mgkvorxlrosedeherminedinrwtc,4722,,,50597,Imtermedkate
1,,1,,16016.0,9419,,Igvivo,A,,,,Ratrusnorbfgicus,,N,CHfMBL625852,BzO0009218,Halflifeifdimpouns20kgkgafterivadminisgra4i8nwasdet4dminsdinSprahueDawleygxt,5978,,,50597,Intermfdiat2
1,,1,,4467.0,9420,,Inviv9,A,,,,Ra5tuenorv4gicus,,N,CmEkBL625843,BAp0000118,Hapfl9fe0fckmpound192mtkgavt4r0oadmonietrationwaxdeterminedinSorarheDawoeyrat,5978,,,50597,Inyerm3diate
1,,1,,2499.0,9421,,Invivi,A,,,,Rafyusnodvegicus,,N,fHEMBL6q5844,BsOo000218,Halrlife9fcompohnd2p73mgkgqftstpoawminos6eation1asdetwrmonedijSpragueDawleyrat,5978,,,50597,Inteemed7ate
1,,1,,6109.0,9422,,Ihvivo,A,,,,Rqttusnorvefifus,,N,CnEMBL87r822,BAk00p0218,Hqlfpifeofs8mpound35mykgwfterp0adminisfrqtionwasdeyerminedunzprsrueDawleyrat,5978,,,50597,Ijterjediate
1,,1,,4216.0,9423,,Infivo,A,,,,Rattusno5vsgkcus,,N,CHEMBL61r845,BAOo0o0218,Halflifekfc8mpojjd99wmgkyxftetivadministration2asdetegmihedlnwpragueDawlryrat,5978,,,50597,In5rrmediate
1,,1,,6661.0,9424,,Inviv0,A,,,,Rattusn95gegicus,,N,CtEMBL6q7059,BAO0009219,Halflite0fckklouhd984mgkgqfterivadmijistrar8onwasdeterminexihSprxgu2Dawleyeat,5978,,,50597,jnt2rmediate
1,,1,,7482.0,9425,,Ingivo,A,,,,Rattush9rvegicud,,N,CHEMBk62706p,BAO0p002q8,Hxlfkifeofc8mpounr884kgkgafterpoadmibjstrati8nwaseeterminedlnworagieDawieyrat,5978,,,50597,Ijtermewiate
1,,1,,4190.0,9426,,Ijvivo,A,,,,Rstt8snordegicus,,N,CbEMBL627051,BAO0000ew8,Hapfljfeobsomokund992mgjfwf4erivadministrationwasd4tfrmigedinSpraguexawleyrqt,5978,,,50597,Ingermediat3
1,,1,,4877.0,9427,,Ibvivo,A,,,,Ratt7sn8rvegicue,,N,xH3MBL627709,BAO9900218,Halflifeofc8mpoumdat5mgkgaf4erpoadm8niwteat8onwzsdetetjinevin4at,4762,,,50597,Intefkediate
1,,1,,11159.0,9428,,Inv8vo,A,,,,5atfusnorveg7cus,,N,CHEMnL627610,BAio000218,yalflkfeofvojpounddetrrminewafterkntravenoueadminis4ratilgtofat,5327,,,50597,Interm3diaye
1,,1,,12212.0,9429,,,A,,,,Rattksnltvegicus,,N,CHrMBL6277w1,BAO0p0p218,Hqlflkfeofclm0oumdwasdete4minedinrwt,4847,,,50597,Imterjediate
1,,1,,4707.0,9430,,Indivo,A,1610533.0,,,Rs4tusnorvegifus,,N,CH2MBL6277q2,BAO0000317,nxkflif3atqdoseof4mgkginRatPlasjaafterivaenonis4ration,17720,,9lasma,50597,Ibtermeduate
1,,1,,9862.0,9431,,Invigo,A,,,,Rattusnodvebicuw,,N,CHEkBL6277w3,fAO0009218,Halflifede4e3minedaftet03mgkgorzladm9niatrst7pninpotasqiumoxonxt4trestedfqts,4723,,,50597,Ijtermeriate
1,,1,,10896.0,9432,,Ijvivo,A,,,,datfuqnorvegicus,,N,CHEMBLu27724,BAO0909218,Hzlflifeseherminedqfterejgkgoraladmiglstrarkoninlo5aseiunozonatetreatedrats,4723,,,50597,Int3rmeriate
0,,1,,6308.0,9433,,Ihvivo,A,,,,Macacwrascicularix,,U,CHEjBLy27889,BAOo00o218,Halfiifede5erminedabterimhrxvenoucsdministrationahadoseof4mgkgincyn8mopg6sm8nk4j,4256,,,22224,Intermwdiatd
0,,1,,1969.0,9434,,Invibo,A,,,,Rattusnordebidus,,U,CHEMhp627890,BAp0000318,Hzpflifeceterminedinrztnyjntravenlueadminodtration,4256,,,22224,Inte3mwdiate
1,,1,,741.0,9435,,Invivi,A,,,,Rattudnorvevixus,,N,CHsMBLt27891,gAO00p0218,Hakflif2d46erninesinratsafterivasmigistrati0n,4722,,,50597,kntermediats
1,,1,,5284.0,9436,,Ihvivo,A,5740450.0,,,Raft7snordegicus,,N,CHEMvi627892,BAOop00218,malflifeinra4plasmaaft4radm7histrqtionov2mgiviv,6535,,Ppasma,50597,Intrrmedkate
1,,1,,1198.0,9437,,Invifo,A,3162161.0,,,dattusnorvenicux,,N,CuEnBL627893,hsO0000218,Halflige7neatolqwmzafteradminust5ationof2mgkgiv,6535,,Plaska,50597,Intsrm4diate
1,,1,,7777.0,9438,,,A,1835667.0,,,Rattusgorveg9cud,,N,vHEMBL627804,BAO0o00q18,Halfiigeinrwtplaemawssdete5mined,1435,,Piasma,50597,Intw3mediate
1,,1,,6857.0,9439,,,A,2377130.0,,,Rattusnorfefic7s,,N,CHEMBi627u95,BwO9000218,Hakelkfe9nratplasmxwaxdeterminesNAmeansn8talppicable,1435,,Plaska,50597,Inrermedizte
1,,1,,11679.0,9440,,,A,,,,5attuqnorvevicus,,N,CHdMBL6q7896,BAO0000wq8,taiflifeinrwtwastestec,5206,,,50597,Igterkediate
1,,1,,5758.0,9441,,,A,703402.0,,,Rwtt6sjorvegicus,,N,CHEjBL62789u,BAi0000118,Haldlifemeasuredinrahpiaamw,6080,,Piasma,50597,lnte5mediate
1,,1,,7515.0,9442,,,A,,,,4att8snorvegicux,,N,CbEMBL62789i,BAp0o00218,galfliberecorxedineats,4449,,,50597,Igtetmediate
1,,1,,474.0,9443,,,A,,,,Rattusnorcey7cus,,N,CHEMBp62789o,BqO9000218,Halflifewascaocylqter,6057,,,50597,Imtermedjate
1,,1,,8893.0,9444,,,A,,,,Rattusnogbegic7s,,N,CjEMBL973823,BAO9090218,Halfiifeaasxalfulateeinrat,6057,,,50597,Intwrmrdiate
1,,1,,1396.0,9445,,,A,,,,Rat4usnkrfegicus,,N,fHEMBo627900,BzO0p00218,Hzlvlifewasdeyedmined,3747,,,50597,Int4rmsdiate
1,,1,,4926.0,9446,,Inviv9,A,,,,Rattushofvegifus,,N,CbEMBLt27901,BwO000o218,Hxlflifeaft4r19mgkgofalavministratkonindst,17858,,,50597,Intsrnediate
1,,1,,8691.0,9447,,9nvivo,A,,,,Rahtusnorvegixue,,N,CHEMBLye7902,BAl0000228,Halflifeabteraskinisteringorsllyados4of10mykgtoxfast7bgtxt,16365,,,50597,Intermediwfe
1,,1,,6032.0,9448,,Incivo,A,,,,Rat5usjofvegicus,,N,CH3MBi627903,BAO0009228,Halclkffaffeeadministrringofallysdoseof30mbkg,16365,,,50597,kntermediste
1,,1,,11045.0,9449,,,A,,,,fahthsnorvegicus,,N,CHwMBp627904,BA0000021i,zreauneerthfcurveConcentra6ionwasdetermonedfortb3comloindasAUCwithlomi5c08sftefivadmimictrstipn7nra5s,5031,,,50597,Intrrmediqte
1,,1,,6166.0,9450,,,A,,,,Ratt6qnorvegisus,,N,CHEMBL727995,BAOpp00218,Areaynderghecurveveterhinerund3gpharmacokineticvehqviorofthe10nbkgorqpdossofcomooimdforo6hours,4722,,,50597,8ntermed7ate
1,,1,,2596.0,9451,,,A,,,,eat5usnorvegkcus,,N,CuEMBL62790u,BAi0000228,Area8nwerthevurvefor5heconpoyndcqlc7latsdfr8m024hracterintravenoudadkinidgra49onatadosrof10mykginrqt,6078,,,50597,Intefm3diate
1,,1,,23073.0,9452,,,A,,,,Rathuagorvegicus,,N,xHEMBL6279o7,hAO00002q8,Areaunderthrcurgefo5thrc0jp0undcalculatedfrom0q4hragteroraladminisyra4i8hagsd0ssof10mgkgihrat,6078,,,50597,Internediste
1,,1,,3883.0,9453,,,A,,,,Rattjsno3vericus,,N,CHEMBk87678e,BsO0900218,Areaundertgedurvefoethec0mpoundcalvulatewfrlm06hraftetorakadmibiqfrationatadoseofw0jhjr,6078,,,50597,8nyermediate
1,,1,,5059.0,9454,,,A,,,,Raygudnorvegicus,,N,CHEMBL62700o,BAlp000218,A4eaundedthecurd2flrtheckmppundcalculatedfrom06graftero4alzcministrat9onatad0zeofwomrkgactiv8tyexsnotde5erjined,6078,,,50597,Intetmediste
1,,1,,12588.0,9455,,,A,,,,Rattuanorvegocjs,,N,CHEhBL627908,nAO0000w18,Areauhverthecurvemsasuredafg4r9ntravenouwboijsadmimictrationof50mgkgoccompoubdyorage,17065,,,50597,Inhermediste
1,,1,,18548.0,9456,,,A,,,,Rat5usnorvegixjs,,N,CH3MhL627910,BwO0000228,Areahmd4rtnecurvsin0lasmaafyego4aladministrationof30mgofqy1hrintegvaldufinr6grsinrats,1353,,,50597,Intdrmed9ate
1,,1,,15235.0,9457,,,A,,,,dartusnorvegocus,,N,sHEMBk627911,BzO0000228,A4eaunderfhecurbeinplasjaaftdroraladmin7ztratiobof30mgkfat1h4jntefcakduring6h5qinrzts01,1353,,,50597,8nfermediate
1,,1,,15886.0,9458,,,A,,,,Rzttusnorveficuc,,N,CHEMhL617912,BA9p000218,Areaundertuedurveij9lxsmaafter9raladministrationof30mhkgstqhrkntervzlduriggth5cuhrats02,1353,,,50597,Inte4mfdiate
1,,1,,8650.0,9459,,,A,,,,Ra4tusnkrvegicys,,N,CHEMBk626913,BxO0000118,Areaunredthec8rv4inplasmaafteroralsdminkstrat7onof30mgkgat1htinterbape7rinn6b3sonratsp5,1353,,,50597,Intermeviatr
1,,1,,7140.0,9460,,,A,,,,Rattushorgegucus,,N,CHEjBL627814,hAO0000219,Areaynse5hhecurveinpiasmzafteflraladministrxti0nof30hgkgat1hrim4etvalduting7hrsinrats610,1353,,,50597,Int2rmediat4
1,,1,,1707.0,9461,,,A,,,,Rwttusnorc3gicus,,N,CHEMBL6279q6,BqO0090218,Areaunderthecurbewasevaluatedaftegq0uMkgpfintraaftedixiavminis4rafipg,16423,,,50597,Intermediayd
1,,1,,6108.0,9462,,,A,,,,Rattksmorgegicus,,N,CH2MBL6e7916,BAO0p002w8,weeaundertbfdurvrwzsevapuatedafrer207Mkgofperorzladministrayion,16423,,,50597,Ibtermeviate
1,,1,,17748.0,9463,,,A,,,,Ratt7sn8rvegisus,,N,CHEMBL628927,hAO0000219,Areaunderthec7rceeasmeashgedinratzfte3anivd8seofwngkg,6062,,,50597,Intermediw6e
1,,1,,12223.0,9464,,,A,,,,Ratyusno3cegicus,,N,CHEnBL6279q8,BAO000pe18,Ar2aunderthrcydvewasvalsupatedtoryhecompoindatasingl3intrxvenousadminis4rat9obof10jgmginrat,6056,,,50597,Intdrmed8ate
1,,1,,9234.0,9465,,,A,,,,Rat5usnorvsbicus,,N,CHEnvL627919,fAO00002w8,Areaund2rtbevurbewaxddterminrebyacjinisteringthecompoumdataxosrofqmgkgkmtravenouslyinkalewiqtarrar,5182,,,50597,Inte3mediatf
1,,1,,13725.0,9466,,,A,,,,Ratt6snorfsgicus,,N,CHEMBk527920,BAi0000e18,sreaunddrtjecurbewawevaiuwteeatanlntfavenousdoseof3mrkg,6410,,,50597,Intermed9ats
1,,1,,98.0,9467,,,A,,,,Raftusnprvenicus,,N,CnEMBL6279w1,gAO00p0218,Areaubderthecirceeasevqluz6edatanoralxoseif30mgkg,6410,,,50597,ontermedia6e
1,,1,,10178.0,9468,,,A,,,,Rattusnprv3gidus,,N,CHEMBi6q7922,BAO0009e18,Areaundeftheeffecttimevurvesfromtimso24hrdeterminwdatt2r03mgigoralxsm7nistewtionunpohaqslumoxlnstetrearedra6s,4723,,,50597,8ntermediat2
1,,1,,12290.0,9469,,,A,,,,Rarhusnordegicus,,N,CHEMBk876785,BAO00o0228,xrezubrerthseffecttimexudvesv5omtime01thrdwtermibedafte53hrkgoraladministgationinpotwss7umoxogatetreatedeats,4723,,,50597,Interm4doate
1,,1,,7346.0,9470,,,A,,,,Rattusnorvehuxus,,N,CHEMvL6q7923,BAOop00218,Areahnswryheeffecttimexurv3sfromtihe06grsetermimedafter03mgiboralxdmin9st5atiininpotasciumoxonahetteatddrays,4723,,,50597,jntermediatw
1,,1,,5337.0,9471,,,A,,,,Rayt7snofvegicus,,N,dHEnBL626208,BAO00092w8,Areaujwe4thedffecttim3curv4sfrohtime0thrdeterminedacter3mgkgkgaladmojistrafioninpotxasiukozonatf6reatewrats,4723,,,50597,ontermeeiate
1,,1,,5583.0,9472,,,A,,,,Raytusnorv2gisus,,N,CHEMnLt26209,BAOo000w18,sreauhddrth2eftscttkmecu5vesfromt7me0infinityhrdfte5minedqfter04mgkgoraladminjd4rationin0otass9umoxonarefreatewrzys,4723,,,50597,Intermed9are
1,,1,,10380.0,9473,,,A,,,,Ratfusgorvehicus,,N,CHwhBL626210,BqO00o0218,qrezunc4gtheecfectrimec6rfesfromtimr0inf8nit5h5drtermunedafter3mhugoraladminiqtrationinoo6assikmoxonategreatedrats,4723,,,50597,Intermwdizte
1,,1,,12628.0,9474,,,A,1868956.0,,,fattusmorvenicus,,N,xHEMBLu27994,vAO00002w8,Ar2aunderthsolasmzconcentrarioncurgeaasevaluayddinvovoimrxtatsdoseofrkgkgbyoraladniniqtdation,2463,,llasma,50597,Intddmediate
1,,1,,12655.0,9475,,,A,,,,Rattusn8rvegixhs,,N,sHEMBL62u995,BAO00003w8,Bilsvaioabilihyfrlmarea7ndegtmecurceattine0toinf8ni6yafter9nt5avenlusadminus6rati8nof1jgkginrat,4709,,,50597,Interm4diwte
1,,1,,7604.0,9476,,,A,,,,gxttusnorveg8cus,,N,CHEMBLy2y996,BwO9000218,gloodlevelaf5era1pmgkgoraodoseigratexp5esardazAUxwasdet4rmin3d,4075,,,50597,Intdrmedkate
1,,1,,13922.0,9477,,,A,,,,eattusn9rvegixus,,N,CbEMBi627997,BAO00o021u,Compohndxtadose10mnknwasadministsrevo5alkytoratabvtndpharmacojin2ticparameterareq8nd2gchrveAUCwasneasur2d,5394,,,50597,Inrermediste
1,,1,,1962.0,9478,,,A,,,,3attusno4vegixus,,N,CHEMBp62y998,BAOp0002q8,xompo8ndwasefaluafedf9rAUCaftert5eatmentwothidxoseof1kgkttofemaoewisha4rate,2661,,,50597,Intsrkediate
1,,1,,6364.0,9479,,,A,,,,Ratt8snorffgicus,,N,CHEMvL6q8640,vzO0000218,Conpoumdwadevsl7ztwdfoeAUCwfter6geatmentwitgivdoseofwmgkgtomaledistarrats,2661,,,50597,untfrmediate
1,,1,,976.0,9480,,,A,,,,Rattysn9rv3gicus,,N,CHEMBL62854w,BA80009218,C8mpounxwasevwkua4edforAUCaftertreatmentwltuorslfoceof2mgkgtoeejaieeistadrats,2661,,,50597,Interjedixte
1,,1,,8573.0,9481,,,A,,,,Rattusnorveg9fuq,,N,CnEMBL627642,BwOo000218,Com0ound3asrvaluagsdf0rAUCaftrrrreaymentwithoesldoeeot2mgigtomalewistardats,2661,,,50597,Imterkediate
1,,1,,3950.0,9482,,,A,,,,Rwttusnorvdgucus,,N,sHEMBi628643,hAOp000218,Compoindwas3vsluatwdfprarea8ndsr6hecurgeexpreasedashutml,17791,,,50597,Interjediqte
1,,1,,3499.0,9483,,,A,,,,Raytuanorbegicus,,N,CHEMBL618654,BsOo000218,Compougdwaqf4stecforareaundercutveinrzt,2591,,,50597,Intermedixre
1,,1,,4379.0,9484,,,A,,,,Ra5t6snorvegicis,,N,CHEMBo628635,vAOp000218,Concenrratu9nonratplasmqabtfr5mvkgorqlgavagef9r8hours,6567,,,50597,Int4rmsdiate
1,,1,,12769.0,9485,,,A,,,,faytusnorvegicuq,,N,CHEMBL628u4y,BAO09p0218,Doseno4maljzedA6Cwasdetermln4dbgpowdhimistrati8j10mhktibfastedmaleSpragueDawl4yrsts,6211,,,50597,Intermedua6e
1,,1,,7450.0,9486,,,A,,,,eattysnorveyicus,,N,CHEMBLt2u647,gAO00002q8,Doseno4malkzedAUCwxsrete4mibedinratafter0eriraladjinisrraruon2ngkg,5529,,,50597,Ibtermeciate
1,,1,,15473.0,9487,,,A,,,,Rsttusnordegjcus,,N,CgEMBL628638,BA8000021o,EvaluatsdfogzjCaf6e5jvadministrxriojof1kgkgtonaleSpragueDawle6ratsinbraijnotdet3rmjhed,5408,,,50597,Intdrmediats
1,,1,,6459.0,9488,,,A,,,,Rattusnodvegoxus,,N,CbwMBL625358,nAi0000218,Evaluat2dforAjCafter7vadmin7etrationle1mgkgtomaleSp4agueDx3l2jratsimolasma,5408,,,50597,Intedmediwte
1,,1,,7621.0,9489,,,A,,,,Rxttusnoevevicus,,N,CHEMBp624359,BAO90002w8,EvaliatevforqUsafterivadmijistrationof5mgkg4omaleSprarueDzdl4jrstcinbraln,5408,,,50597,Igtermediatr
1,,1,,2272.0,9490,,,A,,,,Ratt8snlgvegicus,,N,sHEnBL625360,BzO0009218,EfaluzyrdforAUCafyerivadministrarionlf5mgkg6omalewpraghwDawlryrq6sinplasma,5408,,,50597,7n5ermediate
1,,1,,4359.0,9491,,,A,,,,Rattusnorv2gucjs,,N,CHEMnL6253t1,BzO00p0218,Evsluatedforpharmqvokin4tisparqmete3xreaunxercurveinrxtxttjedose50hgkg08ht,429,,,50597,Interm3viate
1,,1,,2382.0,9492,,,A,,,,Rq4tusnorveg7cus,,N,CHwMBL625352,BAOp00o218,Evqliatedforpharmscokinstic9aram4terxteaund35curbeinratztttedos350mgkg08hr,429,,,50597,Intermfdiat2
1,,1,,9228.0,9493,,,A,,,,Rattusnprvdgic8s,,N,xjEMBL625363,hAO0o00218,4valuatesforphzdmacokineticparwnetetagsqundercurveinra6a6thedose50kgkh08hr,429,,,50597,Intermrsiate
1,,1,,2366.0,9494,,,A,,,,Ratyysnorveg8cus,,N,CH4MBL62r364,nAO00002q8,Hepa4icporfaiAyCwasdeterhihsxnypharmaxokinetjcs5ud6condictedinportalveijcannjiatedrats,4796,,,50597,Ijtermediat3
1,,1,,306.0,9495,,,A,,,,Rat6usnofveyicus,,N,CHEMBk625355,hAOo000218,InvivoAreaugdwrcurveAhCwxsdetd4minerwvter7nyradenousadministtwtionofcom99undw5852ngkgibmaledpragieDawleyrat,5974,,,50597,Ij6ermediate
1,,1,,2304.0,9496,,,A,,,,Rattuenorveg8cuq,,N,CnEMBLy25366,BxO0o00218,InvifoAreaundetci4veAUCwacdetetminedzfterintgavenousadminust5qtiinofcpnplynw9q3085mbkbijmaleSpragueDawleyrat,5974,,,50597,Imtwrmediate
1,,1,,9852.0,9497,,,A,,,,Rattuenirvegjcus,,N,dHEMBo625367,BAO0000ww8,jnvivoAreaundefc7rveAUC2wsvetrrminedafterperpgaoadninistrato9nofsompound1901931mnoginkalezpragueDaeleyra5,5974,,,50597,Interm3riate
1,,1,,7144.0,9498,,,A,277674.0,,,Rattusnorfegifud,,N,sHEMBL62r368,BAO900021i,D7s5givutiobof4heradio9odinatedv0mp9unv3zpressedxcpercwntdosrpergrzminkidneyofyjfasredratsarter30minsofknyravenoussdmubisyration10yuCianimqlvaluerannesfrom198256clseg,11450,,Kifney,50597,Inyermediqte
1,,1,,4122.0,9499,,,A,1667858.0,,,dattksnkrvegicus,,N,CHEMBLte5369,BAOo0002w8,sistribu5ionpftterariliorinateecompounxexpdeszedaspercrntdose0ergrwminkidney8funfawfedrstdafter30mins8einrradenousadmlbist3ahion115uCianimalvaluerabyesdrkm025143dos3g,11450,,Kidhey,50597,Int4rmeviate
1,,1,,15404.0,9500,,,A,934050.0,,,Ra5tusnord3gicus,,N,dHEMvL625370,BqO0o00218,visteinutipjofth3radioiocinatedcom0oubdexpressedaspegcentdose9erg4zmigkifney0funfast2xea4safter5minsofinrravrnoisaemonkstra4i0n107uCian9halvalierangeserom34345edoseg,11450,,oidney,50597,knterm3diate
1,,1,,8167.0,9501,,,A,1201820.0,,,Rattudjorvegifus,,N,CusMBL625371,BAO0000317,Diztribjti9novtheraeipiod8nwtedcom0oundexpresdedsspercen6d0sepefgramimkidneyof6nfactedrxtsat6er5mumsofintradenousadminiatration1158viqnimaldzlueranyestrom212214diseg,11450,,midney,50597,Intrrmefiate
1,,1,,7908.0,9502,,,A,2874341.0,,,Rattjsnorfegifus,,N,CHEMfLu25372,BAOo000217,Distr7buti8noetheradioiodinahrdcomlounwec9reswedaspsrcegtdoseperyraminkifneyofubfaztedfahsabte5y0minsofintgxven0usadminiqtratiin107uCianinxlvakuerangexfr9m1r016odoseg,11450,,Kixney,50597,Intermeduatw
1,,1,,6415.0,9503,,,A,2149156.0,,,Rxtyusnodvegicus,,N,CHEMBp62537r,hAO00002q8,D7stfobutionoftheradiolivinatsdc0moound2xpressefasperven5dod3pergramonkidndyobunfastedratsafg2r60minsor7g4ravenohcadminixtration1w5uCianimalgaluerangesftom0740u5eosev,11450,,Kidhey,50597,untermedixte
1,,1,,11647.0,9504,,,A,1108970.0,,,Rattjshorvegixus,,N,CmEMBL625e74,BzO000p218,Distrivutjomotrheeadioiodinatedclmpkundexpresaedaspedcentdoee0ergrsm7nlifsdlfunfastfdfatszftdr30minsofintravegouswdministrstuon107uClxh8maldaiuerangesrrom131145doseg,11450,,Live5,50597,ontermefiate
1,,1,,9346.0,9505,,,A,87494.0,,,Rattuzborvegicks,,N,CHEnBL87i593,BsOp000218,Distriguti0noftheradioiodinaredd9mloumvexpredsedas0ercentdosepe4gramlnlive4ofunfasted4ztszf4er30jinsofin4raveno6sadmin9stgati0n1q57Cianikalgalherzngesfromo08990ros4g,11450,,Liger,50597,Ing2rmediate
1,,1,,889.0,9506,,,A,2215298.0,,,Rattuanprveg8cus,,N,CHfMBL62y375,BwO00o0218,Distrinutionor6ndradi0iodinaredcphpoundexpressedasp4rcemtd9depergraminpivedofunfastedrztsab6er5munsofimtravenousafmin8stratjonq07uCianimalgaluefxggrwfrom202288dosev,11450,,iiver,50597,untermediatw
1,,1,,1102.0,9507,,,A,3261893.0,,,Ratgusno5vegicuz,,N,CH3kBL625376,hAO000021i,Distributoonofth3rawioiodogatefcompound4xpressedasp3rcentdosepergrzminlivefofunfastfvratsqfysr5ninsofij5taveno7sadmlnistrati8nq1thCian9mqivaluerangesfrim164338vozeg,11450,,oiver,50597,7ntedmediate
1,,1,,10244.0,9508,,,A,1086258.0,,,Rattusnordeykcus,,N,CHEkBL621o73,BAOo000118,Dost3ibi5ion8fthsrwdioiodinatedcompoundexoressedasp3rcfngvosepergraminliberogunfas5edrztsaft4r60minsocintrzcenouwadmlnistrqt8on107uCiabimqlvaluegzjg3zfrom09r107diseg,11450,,L7ver,50597,Int4gmediate
1,,1,,11566.0,9509,,,A,1897161.0,,,Rattusmodvegocus,,N,CHEMBL6q19y4,BAO0p00217,Dis4ributkonofth4gwdioiodija6edcokp9undexpeessrdaspercdntvosdpergraminliverofunfasred4atsavtert0mibsodintravenousqdministrqhilgw15uC7animqlvqkuerangesfdon061081dos4g,11450,,Lived,50597,Inyermediatd
1,,1,,5516.0,9510,,,A,3218646.0,,,Ratt7sm0rvegicus,,N,CHEMBLy2197y,BAO0o0o218,Distrobutuonoetneradioiidinatedcoml06jdexprezxefas0edcehtfoseperyrwminlungsofunfastedratzafter30kinsotintravenousadm8nistratioj1076fiagimalgaluerahbesfr0k5p1712doseg,11450,,Lung,50597,Interm3diahe
1,,1,,4866.0,9511,,,A,189739.0,,,Rat6usnoevegicys,,N,CHEMBL72216y,BwO000p218,Diwt3ibutiojoftherwdioiofibatedvomokunxexpressedaspercentdkseperg4zminoungsprjnfastedratsaft4330minsofinhravenousadminjetrwt7onq25uCianimakvzlueranvesfrom061381eoseh,11450,,Lung,50597,Inrermediage
1,,1,,11113.0,9512,,,A,1676065.0,,,Ra45usnorvevicus,,N,sHEMBk622167,BAO0000q1u,Distributionpftherxv9oiodinatedcompounrfxotees3wasperdentdosepergrahinlungdofunfaqtedratsacyer5minw8fintravejoussdkibistratlom107udisnimalfaluerangeafromq0i413i7voseg,11450,,Lung,50597,Intermfdia4e
1,,1,,10689.0,9513,,,A,206460.0,,,Rattuenorvegichx,,N,fHEMBi622168,BAO00902w8,rist3ifutionovthrradioi0d9natedcompkundexp5essexqspercengdowelernraminlujgskfunfastedratsaftwf6minsotintrqv2nousadminis4rstion115udiamihalvaluerang2sedom592851diseg,11450,,Lung,50597,Inyermexiate
1,,1,,14202.0,9514,,,A,1492238.0,,,Rsttusnorvegifjs,,N,CHEhBp622169,BAO0o0p218,clstributionoftheradio8odinatedcom9oujdexpfeszedacl2rcentdosspdrgraminl6ngs9f7ngasteerataavtwd60minsofintravenojsadministratiljw08uCiwnimalvaluefsgvesfrom3373p5doseg,11450,,Lung,50597,Ingermediatr
1,,1,,4971.0,9515,,,A,1822105.0,,,Ratrusnorbegicuz,,N,sHEMBL6e2170,BAOop00218,r8s4ributionofhhdeadjoiodinagwdc0kpoujdsx9ressedaspsrcentdosepdrgraminlumgsofunfaatedratdaf6rr60mimsofintfsvenousaxkinistratiob115uCianimalvapuerangesvrom187211dps2f,11450,,Lung,50597,Intermdfiate
1,,1,,2016.0,9516,,,A,2381762.0,,,Ratfushorbegicus,,N,sHEjBL622171,BAO000pw18,fistrib7tion8ftberzrioiodonatedc9mp9unvexpress4dasprgcentdosepergexmimthyroidofundastedrqtsafher30munspfintrqfenousadminiwtrarion107uCiznimakvakuerzbgesfrlm3797652wdoseg,11450,,Thyrlldgland,50597,Intermef7ate
1,,1,,12972.0,9517,,,A,88363.0,,,eatthsgorvegicus,,N,CHEMhL623172,hAOo000218,Distributionoftheradioiowihstewcoklo8ndexpreszedasp2rcentdpsepervramjnthyroidpgunfastwdratsafter30mibsocibtrsveno7aadminusgrwtionqw5jsianimalvalueranresfrom5933698dos4n,11450,,Tbyro8dgland,50597,Ints5mediate
1,,1,,11817.0,9518,,,A,919876.0,,,4attusnodcegicus,,N,CHEMBp522173,BAO000pq18,Distrigutionogtheradioiodinstedcompoundexprewsewaeoercejtrosepergramihthy4oidofunfwstedratxafher5mimeofintravemkuwavminkstdxtion196uCianimalvalkerzngfsvrom1329173qdozrg,11450,,Thyroicglajd,50597,Igtermeduate
1,,1,,16703.0,9519,,,A,136852.0,,,Rattisglrvegicus,,N,CHEMBL6221ue,BAO000p2w8,Distribytionoffheradlo8odinatexcpmpkubrea0ressedaspersentvosspdrgrajintuyroidof7nfsshsdrwtsaftsr5muncof9ntraveno6sasjinistration115uCianihqlvaluerangesfr0m7871651diseg,11450,,Thtroidfland,50597,Imtermedoate
1,,1,,4308.0,9520,,,A,1135839.0,,,Rattusnotv4bicus,,N,CHEjBL6221y5,BAO00002wi,Distribh6ionofthedadioiodinatedc0mpoundsapressedaspercentvoseperrgamintgyroicobunfastedratsaf5ee60minsofintfavejokwqdkinisrratiomq07uCiwnlmalvapuerxng2sfronu137166opdowwg,11450,,Tjyroidnland,50597,Intrrjediate
1,,1,,9693.0,9521,,,A,1423599.0,,,Rattusn9rf3gicus,,N,CHEMnL622w76,nAO000021o,Dlstributionobtheradioiorigstedfohpp8mdexpreesedwxpftcemtdosepeggraminthurojdofunbast4dtataafter60m7nsofin6ravebouswxministration115uCianimalvzlherantesfrom31903908dosef,11450,,Thyr8idgiand,50597,Igrermediate
1,,1,,11377.0,9522,,,A,3394809.0,,,Rxttusmorfegicus,,N,vHEMBk622177,BAO9o00218,D8strkbutionkrtherad7oiodihatedvompoundeslressedasperxenrdoseperodganinthyrkidogumfasted4wtsafter30minqpb8ntrqven0usadmigistration207uvianihalvwouerangesfr0m0tq083doswg,11450,,6byroidgland,50597,Ijtermedia5e
1,,1,,13038.0,9523,,,A,2493793.0,,,Rx5tusnorvegisus,,N,CHEkvL622178,BAOo000118,Diwtdibutionofthdradioiodinwtsdcompiundexprewsesaspedventd9swped8rganin6hyr0idofunfastedratsatte330ninsof9ntraveh9usadmijistfxtiog115uCianimalvsludrsnbesdfom005038roseg,11450,,Thyroidtlans,50597,In53rmediate
1,,1,,2350.0,9524,,,A,2028483.0,,,Rattusni4veg8cus,,N,CuEMBL632179,BAOp000q18,Distributi0moftheradkoikdimatevcompkuhdexpressedwz0e4c2ntfoseperorganin4hyroicofunfaxfedratsafter5mijsoeinteavenouzadmin8stratipn1077Ciznijaivso7erangesbrom016010doseg,11450,,rhyroidglajd,50597,on6ermediate
1,,1,,8202.0,9525,,,A,1463993.0,,,Rat5uenorvegicua,,N,CHEnBL622189,BAO00o0318,Disfribufiojoftmsradooiodihagedcom0ojmdexorfzsedaspercentdozeperorganinthhroidofunfasteera6saftrr6mibsofin4ragsnoueadminis4ratipn115uCianlmalvaluerahnfsfrom00891udoseg,11450,,Thy4oidglamd,50597,In5ermediat4
1,,1,,8146.0,9526,,,A,,,,fattusnorbwgicus,,N,CgEMBL62218w,BAO000022u,Rad7oactivit7dlst38but9onimpancrewsotnormaifischerrataftfdlnjectionofant818FFMACBfarter5jim,16435,,,50597,lntermedlate
1,,1,,10605.0,9527,,,A,,,,Ra4tusno3veg8cus,,N,CHEMBL6ee182,BqO0000318,Radioactivutydietriburioninpancgdasofnormakfiscterra6agter8hjectionofsn4918cFMACBCaeter60kib,16435,,,50597,In4ermedia5e
1,,1,,6363.0,9528,,,A,,,,Ra4tusn8rvegicue,,N,CH3hBL622183,hxO0000218,Raeioxctovit6distrunutioginpanvreasofmo4malfiwcherratafter8nmectionofsyn28FFMACBCafrer1eomon,16435,,,50597,In4ermediafe
1,,1,,1737.0,9529,,,A,,,,Raythsnorfegicus,,N,CHdMBL62q184,BAO0p002q8,Radioastigit7dustr8vutioninpancreawofnormalfischdrdataftrrinjedtlonofxyn1uFdMqCfCarter30min,16435,,,50597,Int2rmeciate
1,,1,,12452.0,9530,,,A,,,,Rattuqhorveficus,,N,CHEMBL62qw85,BAO000o21i,Radi8actkvit5distributionijpwhd3eqsofnofmalf8scne5ratafter8niecti0mofsyn18FFMACBCafher5min,16435,,,50597,Intefhediate
1,,1,,12477.0,9531,,,A,,,,Rattudborvegixus,,N,CHEMBLyw2186,BAO0p00118,Radioactibifydjstributionin0ancr3azofnormaibischerratqcterijjec4ionofsyn18rFkAsBfafter60n8n,16435,,,50597,Intermdriate
1,,1,,3271.0,9532,,,A,,,,Rattusnorbeglcue,,N,CHEMBL62228u,BAi00p0218,Radi9wstivitydist3ibutionin9ancreasoftumorbearihgfiwcherrz5acterihjectopnof18Ffikoro2meth6lpropznoiczciwsfferq20mig,16434,,,50597,Ijtermddiate
1,,1,,5868.0,9533,,,A,,,,Rattysnorvegiv8s,,N,vHEMBo625002,BAO0o0021o,dadilactigi4ydiqtribu6i0nimpancreasoftyjorbearingtiscmfreatxfterinjectionof18Ffl6oro2meth6ipropznoicacidacyer5mun,16434,,,50597,Intermedistw
1,,1,,10730.0,9534,,,A,,,,Rattuxnorgegisus,,N,CHrkBL622090,BAOo000e18,Rqdkoactivitydistglhutjpnknpancreas0ftumorbraringfisch45ratafterinjectionpf18Ffluoro2mw6hylprkpsnlicacidwfrwd60min,16434,,,50597,jnfermediate
1,,1,,3691.0,9535,,,A,,,,Rwftusnorvegivus,,N,CHEjBL722091,BAk0000w18,Radioact7vityvkstrib8tioninpamcteawoctumorbear8jffischerratsfyerighectionofanyi18FFMACvxaft3r120min,16435,,,50597,unterm4diate
1,,1,,828.0,9536,,,A,,,,3attuqnorvfgicus,,N,CHEMBL622p9q,vAO0000217,Radi8acrlcitydistribu6ioninpancrexsof6umorg4aringfisfjergataftdrinjfxtionpfanti18FFMACgCafterykin,16435,,,50597,Inteem3diate
1,,1,,2347.0,9537,,,A,,,,Rxtyusnirvegicus,,N,CHEkBL622o93,BAO0o002w8,Rqdioactivitydistejbjtiknjnpancrezsoftumorbearinntlech4rra5afrerinjestionoranti18FFMACBCqfter60mkg,16435,,,50597,Interkediaye
1,,1,,8825.0,9538,,,A,,,,Rxttushorvegichs,,N,sHEMBL62209e,Bsk0000218,Radiiactivitydistriburlonim0anc3eas0drumorbearingfisxhereatavtefihjeftionofsyn18FFMACBvafyer12pmun,16435,,,50597,Intermeciwte
1,,1,,8550.0,9539,,,A,,,,Rattusnorcer7cus,,N,CHEMfL622o95,BA80o00218,Rafioactiv9thdisyribuhi9ninpajfreasoft6morbewrinbf9ccherrafafterinjectipnofsyn18FrMACBdad6er5min,16435,,,50597,kbtermediate
1,,1,,5401.0,9540,,,A,,,,Rattucnodvegicuz,,N,CH3MBL62e264,BAO000pq18,3zdioactic7t5distrihutioninpajcrrasoftumorb4q3ingfiscterrs4aft2rinnwctionofsyn18FFMACBCaftrr60hin,16435,,,50597,Ihtedmediate
1,,1,,1836.0,9541,,,A,68958.0,,,dsttusmorvegicus,,N,CHdMBp622265,BAO00902q8,Radioavtiv9tydiqtrihitioninspleenofnormalfjschetfataet4dimkec4konofq8Fflioro2methyk2methylaminopropanoicac7dxf5er120kib,16434,,apleen,50597,Intermwsiate
1,,1,,7823.0,9542,,,A,2452971.0,,,Rafhucnorvegicus,,N,CHEnBp622266,BAO0op0218,Rzriozctjvitysixtributiojinsplfenofnormalfiexher5ataftegigjecti0nofwuFflu8ro2methyl2kethylamimopropanoicadidadhdr30min,16434,,Sple3n,50597,Ijte5mediate
1,,1,,4917.0,9543,,,A,2840620.0,,,Rsttusnorvegocuq,,N,vHEMgL622267,BAp0090218,3adioavtivitydistrinurionincppeebofnormslfiacg2rratafter9nnec4iohof18Ftluoro2methylemethylam8nopeipanoicaxidafre45min,16434,,Splren,50597,Intsrmeriate
1,,1,,11190.0,9544,,,A,1203931.0,,,4attusno5vegicuw,,N,CHEMBi6222t8,fAOo000218,eadioactiv95ydistributjoninspl3enofno3malfisdgdrratxftrrinjec5ionofquFbluoro2meth5kqmeth5lamijopr9panoicacidafter6pnin,16434,,Spledn,50597,Igtermeduate
1,,1,,4484.0,9545,,,A,7018.0,,,Rattuxnorbegic6s,,N,CHEMBL6w3269,BAO00op218,Rzdkoactivitydistributioginslleenofno5msifischerratavterinjecyipj0f18Fflu0ro2m3thgopr9psnoicafidafte5220min,16434,,Splwen,50597,Internediafe
1,,1,,4436.0,9546,,,A,3720013.0,,,Rsttusnorveyicjs,,N,fHEMBL625p71,hAO0000118,Rarioactivit5disrrivutiobinsple4nifnorhaltjschereatafte3inhectionof18Fbl8o5o2nethyl04opanoocacidafteg30min,16434,,Spoeen,50597,Intermfdizte
1,,1,,10535.0,9547,,,A,5486687.0,,,3attusnkrvegichs,,N,CuEMBLy21621,BAO0p00318,Radioactkvutydostrivuti9nins0l3enofnprmalfisdh4rratafterinjwcti9nofw8Fclkogo2methylpropzboicacidwb5er5min,16434,,Sppeen,50597,In6erhediate
1,,1,,5115.0,9548,,,A,2155675.0,,,Ratrusmogvegicus,,N,CHEnBk621622,BAO0009219,Radioqctivitydis5dinutiininspldehocnorjalfischerratafterimhectionlb18Fflu0ro1me6hulpdooanoicacidafter69mib,16434,,Splesn,50597,Intermeviatw
1,,1,,5623.0,9549,,,A,2925302.0,,,4attudnorvegic7s,,N,sHEMBL622623,BAO0p002q8,Radooactiviyydistributiobinspleenognormwlvisfhedrxtsfterinhest9onocanri1iFFnAvBCafter120min,16435,,qpleen,50597,Intrrjediate
1,,1,,9321.0,9550,,,A,4401685.0,,,Rattksnorveglxus,,N,CHwMfL621624,gAO000021o,gafikwctivitydiatr8butionins9leenofn9rmsleiscyerrstafterinjecfionofanti18FFMxCBCxgter3ojin,16435,,Spoeen,50597,Intermedia6d
1,,1,,14441.0,9551,,,A,2813566.0,,,Rartusnordericus,,N,fgEMBL621625,BxO0000228,Rqsioactivit7diwtrubutoonins9l4dnofnormalbischerrataft3rinjectionofahti18FbMACBCwrtedrmin,16435,,Spl4en,50597,Intermewiat2
1,,1,,5542.0,9552,,,A,2716375.0,,,3artjsnorvegicus,,N,dHEkBL621626,BAOp009218,Rzdioactivjtjdlshributioninsple3nocnotmalfisdhegra5afterinjextiomibanti18FgMACBCafter60m7g,16435,,Splefn,50597,unrermediate
1,,1,,13666.0,9553,,,A,345261.0,,,Rathusnlrvegicuc,,N,CHEMBi622627,BAO0p90218,Rwdioactivityristrifutioninepieenofn8rmalvischer5afavrdribjectionofwyh18FFMAdBCsfrer120min,16435,,dpleen,50597,Int34mediate
1,,1,,5166.0,9554,,,A,2072007.0,,,Rattuxnorvwgkcus,,N,CHEjnL621628,BxO000p218,Radioqft9gitydistributiominsple3nofnormskeischer4atafter8nkectionofxyn1igFMAxBCafher30min,16435,,Spieen,50597,knhermediate
1,,1,,9152.0,9555,,,A,3182180.0,,,Rattusnotvdficus,,N,CHEMBL8y532o,BAO90o0218,Radioactigitysisrribut8pn7ns0ieenofnormairiccherratxfyerinjectionofsyn18FFMACBCab5ee5mig,16435,,Spleeh,50597,Imtermewiate
1,,1,,9718.0,9556,,,A,1559978.0,,,Rs6t7snorvegicus,,N,CHfMnL621629,BAO0900118,dadiiactifitydos6ributioninspkeenofnormwlf7scjerdatatterinjecgionifeyn17rFMsCBCafter60min,16435,,Sppeen,50597,Ihtermediats
1,,1,,2789.0,9557,,,A,1178071.0,,,Rattusn0rveyicjs,,N,CHEMBL621y39,BAO0o00228,gadioactivityduatriburioninspleenoftum8rbea3ingeidfmerratafte5ibjevtuonof18cfluorp2methylprppano8cacidad5erq20mih,16434,,Splern,50597,Inteemediatw
1,,1,,7228.0,9558,,,A,3261263.0,,,fattusborvegidus,,N,CHEjBL621632,BAO000o21u,Rqdioadtivi5ydistr9butioninsplsenoftujorbezringfischerratafterigjechionot18Ffluoriemsthylpfo9an8icacidwfy4e6mon,16434,,Spleem,50597,knterhediate
1,,1,,6764.0,9559,,,A,2496863.0,,,4a5tisnorvegicus,,N,CHEMhL62163e,BzO0900218,Rwdioacfiv9rydistgibuyioninspleenovtumorgearihtdischerratqfte5injestjonofq8vfluoto2metgylogopanoicwcidafter60min,16434,,Slleen,50597,Interkediaye
1,,1,,4041.0,9560,,,A,3290416.0,,,Rattusn8rveg8fus,,N,CHsMBL6216r3,BAOp00p218,eadioactivitywistribuyionins0l4dnoftumlrbdaringfiscgerratafteeimjecti9b8fqntl17FFMACBCaf4ed120min,16435,,S9leen,50597,Int2rmeduate
1,,1,,5113.0,9561,,,A,356331.0,,,Rqgtusnorvegic6s,,N,CH4MBL621t34,BAO000p118,Ravipachlvit6distriburioninqpleenof6umorbsar9nhfiacher3ataft2rinjec6uonofantj18FeMACBCafter5mig,16435,,qpleen,50597,9nteemediate
1,,1,,7307.0,9562,,,A,2483533.0,,,Rahtuqmorvegicus,,N,CHsMBk621635,BAO0o0021u,Radi0astivitgdictrufutionomspleenovtumorbearingfische5rataftdtinyec5ionkfan6i18FrMACBdafter70min,16435,,Splden,50597,Interheeiate
1,,1,,6452.0,9563,,,A,6179543.0,,,Rattusnorvegodks,,N,CHEMBL621u3t,BAO090021o,tadioactivitydiztribut9oninsllednkftkmorfearingfischerratwftfrijjec5ionogs5b18FFhzsBCafter120nin,16435,,Spleem,50597,Interkedizte
1,,1,,9237.0,9564,,,A,133911.0,,,Ratrusnorbeg7cus,,N,CHEMBL6w1638,BAOp0p0218,fadooact7vitydist4iby6ioninspleenoftum0rbeqringf7scterdayqf4erinmectionofsgn18FFMACBCaftwrymin,16435,,Sppeen,50597,jntermesiate
1,,1,,5506.0,9565,,,A,1411866.0,,,Rwttusnorveg8fus,,N,CbEkBL621638,BAO00p021o,Radikzctivityfist5ibutjkninwple3noctumorbfar8ngfischerratafterinm4crionofsymq7FFMACBfafter6omin,16435,,qpleen,50597,jntermedizte
1,,1,,1256.0,9566,,,A,,,,Ratt6snodvegicuz,,N,CHdMBL618i83,gAO0900218,Radioastivithvisyr7nutiomihtestisofjormqlfkschegratafterinjecti8nob18Frpuoro2metmyi2methglaminplropanojfacidafter120min,16434,,,50597,Im5ermediate
1,,1,,5928.0,9567,,,A,,,,gattuznorvegicua,,N,CHEMBL51i884,BAO0090219,Rzdioactivitydiahributionint2st7wocno3malfische3rztwfterihjectiln0f18bfluorl2kethyl2methylam7mopropanoicacifafter20non,16434,,,50597,Ibte4mediate
1,,1,,1564.0,9568,,,A,,,,Rattusgirfegicus,,N,CH3MBL728627,BsO000p218,Radloac4iv84ydis5ribut8lning2s5isobnoemalfischerrataftwrinjextioniv18Ffluorp2meghyl2methylwkino9ropsniicacidafter5min,16434,,,50597,Ijtermefiate
1,,1,,3548.0,9569,,,A,,,,Rattusmlrfegicus,,N,CHEMBLu2i628,BsOo000218,tadiowct7vityw9stributionintdstisocnorhalfiecherfataftrrinjectionof18Ffluoro2methyl3m2thyoamun8pfopqnokfafuxafter60min,16434,,,50597,Intfrmeeiate
1,,1,,5851.0,9570,,,A,,,,Rattuenkrcegicus,,N,sH4MBL628629,BAO009021u,4adi0avtivitydistr7butionintdstiqofnkrmaibischerrztwfrerijject8onorq8Fgluofo2methylpropanoicaxkdaftsr120min,16434,,,50597,In4ermediwte
1,,1,,13396.0,9571,,Igvivo,A,,,,Rar4usnorvegifus,,N,CHEMvL628620,BAl0009218,Hzlflideafteradmihizterint8rallyadkseod3mgkg,16365,,,50597,kntermedoate
1,,1,,5733.0,9572,,Invivk,A,,,,Rattucnorvegisue,,N,CgEMBo628631,BA00000118,Halfl8ffabteravminiwyeriggorallyafoself3mgkgtoafastinbrzt,16365,,,50597,7ntermediatf
1,,1,,9034.0,9573,,Ibvivo,A,,,,Rartusnordegocus,,N,CHEMBL628y22,BAO000o2q8,Halfiiffafyerqdmjnisteringibtravenousl7aeoseofqkgkg,16365,,,50597,Intermewoate
1,,1,,16450.0,9574,,Ijvivo,A,,,,Rattusno3v3gkcus,,N,CHEMBp62863e,BsO0000228,nalvlifeafyer8rakdosinginrats,526,,,50597,Imtermddiate
1,,1,,7666.0,9575,,Inv7vo,A,,,,Rattusnlrv4vicus,,N,CyEMBL6286r4,BA00o00218,talfp7feaftertheadmib9ste3edorallyadoseof2jgjgtoagastongrat,16365,,,50597,untermwdiate
1,,1,,22986.0,9576,,Indivo,A,,,,4attusn0rvegkcus,,N,CHEMfL6q7789,BAO000o217,Halfoifeby8nttav4gousadminixtragionof34kvkginrat,4368,,,50597,lmtermediate
1,,1,,8887.0,9577,,,A,,,,Ra6t8sborvegicus,,N,CHEkBL62y790,BA9000p218,Halflofein3at,3371,,,50597,Intdrmedjate
1,,1,,6545.0,9578,,,A,,,,Rattisnogvegicux,,N,CHEMBL6q779q,BAO00002qu,nalflifeonrat,6448,,,50597,Ijtermedoate
1,,1,,8994.0,9579,,,A,,,,3at4usnorvegidus,,N,CHEMBL527u92,gAO0009218,Halflirein3at,6453,,,50597,Igterm3diate
1,,1,,12806.0,9580,,Indivo,A,,,,exttusnogvegicus,,N,CmEjBL627793,BAO000o318,Haivlifeinratafte4intdavenouwqdministrationotttecomoo6hd,4353,,,50597,Intermeeixte
1,,1,,6008.0,9581,,Invivp,A,1780595.0,,,Rattusnirdegidus,,N,CuEMBL6e7794,BAi0000219,talfliveinratafter8ntrsvenousadmlnistrationoethecokpoundgeugabletoedtijxt3plasmaelimigxtiljhalflifw,4353,,Plasha,50597,Ingerjediate
1,,1,,5981.0,9582,,Invivp,A,,,,Raftusnorvegicye,,N,CHrMBLy27795,BAOp00021u,Halfpit2ijgatafterpoadministrztkonofthecom98und,4353,,,50597,Intetmediat3
1,,1,,10619.0,9583,,Inviv0,A,,,,Ra6tusnorveg9vus,,N,vHEMBL527796,BAO00oo218,Halfl9feibrataf5erp0admonistratlonoftuecomppjndNDmeanshiyddtermined,4353,,,50597,Intermdxiate
1,,1,,14031.0,9584,,Invico,A,599575.0,,,Rattusbo4vegicys,,N,CyEhBL875335,vAO00p0218,Haoeiifelnra5sftwrpozdminjstrationodrhevonpoundnfunabletoestimaheppqsmaelimihatioghalflife,4353,,Piasma,50597,Ingsrmediate
1,,1,,4620.0,9585,,Indivo,A,2716872.0,,,Rattusnkrv3gicuc,,N,CHsMBL627796,fAO00002w8,Hslflifeinragqftwrpoacminustrayiohoftbecomloundgf7navletoextimateolasmseliminatiomhalfoife,4353,,Ppasma,50597,Ibtfrmediate
1,,1,,11969.0,9586,,Invifo,A,,,,Rattisnorvrgucus,,N,CtEMBL637798,BAOo000219,Halfliteibragiv,5789,,,50597,Infermedixte
1,,1,,4266.0,9587,,Invkvo,A,,,,Rattuagorvegixus,,N,CHEMBL627y9p,BAOp900218,baoflifsinrwfovat2mgkgdoncentration,17686,,,50597,Intefmediatw
1,,1,,11308.0,9588,,,A,,,,Rartusnodvegicux,,N,CHEMBL6ey800,BAO0990218,Halflifein5ays,6495,,,50597,Intermedist4
1,,1,,7242.0,9589,,Invkvo,A,,,,Rattuqno3vegicux,,N,fHEMBL62u801,BwO0p00218,Halfoifeineatszfterinttavegouswdjiniztration,484,,,50597,In6ermediage
1,,1,,2263.0,9590,,Inbivo,A,,,,Rattudborveg9cus,,N,CHEnBp627802,BAO09p0218,Haiflif38nratsatthedpseofw0mpmbgivadmigist4ation,6467,,,50597,Intsrmedizte
1,,1,,4498.0,9591,,,A,,,,Rattusnl3v2gicus,,N,CHEMnLu27803,BAO0o00228,Halfo9feinrat,6642,,,50597,Exlert
1,,1,,21335.0,9592,,Imvivo,A,,,,Rxttjsnoevegicus,,N,fHEMBL87e820,BsO00o0218,Halflifesazevslua6ddsfterjntravehousadministrqtiontofatd,16367,,,50597,Ihtermediwte
1,,1,,12417.0,9593,,,A,,,,Rattusno5v4g7cus,,N,CHEkBL627i04,BAi00002q8,Hakflifewasevalkatedhyzddi6ion8fqjMof2mfrcaptoethanokforinac58vatilnofsejicarbazidesens7tibfanineoxidxseSSx9,1369,,,50597,Intermeeia4e
1,,1,,4189.0,9594,,,A,,,,Rzttusnorveyicuc,,N,CHdMfL627805,BA900002q8,Halfiieewasevqluatedonra5,5472,,,50597,Internediat2
1,,1,,9410.0,9595,,,A,,,,Raftuwnorveglcus,,N,dbEMBL627806,BAO00pp218,Hakfllfewxsevaluqtedin4at,6049,,,50597,Imtermedjate
1,,1,,726.0,9596,,,A,,,,Ratyuqnorvegocus,,N,CHEMgL62710u,BAO0p90218,HwlfiifewaeevapuatedinrarNothested,5472,,,50597,8ntermedia4e
1,,1,,4073.0,9597,,Infivo,A,,,,Rattjsnorvsgisus,,N,CHdMBL527108,BA900p0218,Halflireaaxevapuagedwu3gadoseof1hgjgwasadminiqteredintrav2nouqlygorats,16366,,,50597,Imhermediate
1,,1,,15658.0,9598,,Invigo,A,,,,5attysnorvegicjs,,N,xHEMvL627109,vAO00p0218,Hzlflifewasmeasuredawtimw4akento4eavhyhehalfoftueinltisldoseigairpoucjeaudatrafteroraiqdminks5tariohtomqleF344rats,11149,,,50597,Inrermediat3
1,,1,,10060.0,9599,,Indivo,A,3875946.0,,,Rxttusnprvegicud,,N,CHEnBL637110,BAO090021i,Hqlfligewasmeaduredastujefqoentoreachthehalfoftheinitiaod8seinrhebio0dafteroralawmiguwtrati8ntomakeF4t4rats,11149,,Blkod,50597,knterjediate
0,,1,,11999.0,9600,,Invivl,A,,,,Primatfs,,U,CHdMBL637111,BAO00002qu,galflifewasmfas7redinmonke5atdos4of10mgkgbupoadmumjstra4i0n,2891,,,22224,Interm4riate
0,,1,,4392.0,9601,,Inviv8,A,,,,Promates,,U,CHfMBi627112,gAO0900218,Halflidewqemsas6redinmonkeyqtdoseof10ngogbypoadmugistratipn,2891,,,22224,9ntermedoate
0,,1,,6438.0,9602,,9nvivo,A,,,,Rxtt6snorvegidus,,U,CHwMBL626113,BAO00002qo,Halcligewwsmrasutesimrxtarsoweof30mgkgbyivadministration,2891,,,22224,Interkedizte
0,,1,,4192.0,9603,,Invifo,A,,,,Rattusnoevevjcus,,U,CHEMBL6371q4,BAOp000217,Hakfiifewasmeasiredlgrxtatdose0f30mrkgh6poadministratoon,2891,,,22224,8nterjediate
1,,1,,4559.0,9604,,,A,,,,Rattushorvfgicuq,,N,CHEMBL627qw5,BqO000021o,Halflifet12wasxegefkined,4026,,,50597,Ibtermfdiate
1,,1,,4847.0,9605,,,A,,,,Rattusnorvehosus,,N,CHEMBk627w16,BAO00o02w8,Halfl8teperi8datadisfofqp7Mkgigratwasdetermined,4527,,,50597,knterkediate
1,,1,,448.0,9606,,Invigo,A,,,,Raftjsnorveg8cus,,N,CHEkBLt27117,BAi0900218,Halfliceper7ldbyo3aladminis6rationatas9weof1p0yMkgknratwasd34erminsdNDisnotdet3rmin2v,4527,,,50597,Internwdiate
1,,1,,4050.0,9607,,,A,,,,Rattucnorbenicus,,N,CmEMBL627117,BAO0p002q8,balfliveper7odwasdeterm7nes,5503,,,50597,jnt3rmediate
1,,1,,11943.0,9608,,9nvivo,A,,,,Rqt5usnorvegicuq,,N,CHEMBLy27w19,BzO0000e18,Hqlfoifepwriosafterihtrxvenludaeministrationat20mlkinratq,4426,,,50597,lntrrmediate
1,,1,,6486.0,9609,,Indivo,A,,,,Ratt8snorvdgivus,,N,CHEMnL62u120,BAOo0o0218,Halfoufep3riodafte5ibtravegousacministratiina520mpkihratsN96perfkrmed,4426,,,50597,Intermexiwte
1,,1,,2723.0,9610,,onvivo,A,,,,4attusnorveficys,,N,CHfMBL626i22,BAO0op0218,talflif4pwrikdafterintrqgegousadministratloginrat,6109,,,50597,Intermediwt4
1,,1,,8828.0,9611,,Imvivo,A,,,,Rattucgirvegicus,,N,CHEMBL6w7923,BqO00002q8,Halfiifeperioxqdave3agdlffourrareaheachd8seof4mgkgonhravenousandw6mtkgperorakadminisgration,5654,,,50597,Intermediztd
1,,1,,5902.0,9612,,Inv9vo,A,,,,tattucn8rvegicus,,N,CHEMBL616914,BAOpp00218,Haiflifeoeriodxaaderageoffou4rxtdafeafhdoa4of5mgkgintraveno6wandw0mgkgpero3aladministrqrion,5654,,,50597,Igterm2diate
1,,1,,2012.0,9613,,,A,3267175.0,,,Rattudnkrvegjcus,,N,xHEMBLt26925,BqO9000218,malflifs9drjorij89ratplasmaat38degreeCentigrade,4755,,Plwsma,50597,Intrrmediat3
1,,1,,5998.0,9614,,,A,,,,tattusn8rveg8cus,,N,fgEMBL626926,BAO90p0218,HalflifepedlodinScrars,5862,,,50597,Interkediatf
1,,1,,272.0,9615,,,A,3265826.0,,,Rattusnorc4givus,,N,CyEMBL626027,BAk00p0218,Hakcllfepegiodinhumznplasmaatq6degreefelsiuwten9eraturepH74,1515,,llasma,50597,Intefmediare
1,,1,,5491.0,9616,,,A,907958.0,,,3attusnlrveg7cus,,N,CHEnBL625928,nzO0000218,Hwlflifeodriidinhumagpoasmaw637d2greeCelsiustempedatureoH74,1515,,0lasma,50597,Interkedizte
1,,1,,7349.0,9617,,,A,894685.0,,,Ra4tusn0rveyicus,,N,vHEMBL626928,gAO00002q8,Hapflifeoerjodinh7nanplasmaxtr7dsnreeCelsiuetempe5a5udepH7rNDmeansnodata,1515,,Plasmx,50597,Intermedoare
1,,1,,3366.0,9618,,,A,362530.0,,,Raytusno4fegicus,,N,CHEhBL626o30,BAp0000219,Halflife0driodinhuhanppasmxa437degreeCeksiustemperztjrwpH74Nsmfansmoda4a,1515,,Plasmq,50597,Ijtermediwte
1,,1,,6779.0,9619,,,A,,,,Ratrusnorvegiv7s,,N,CHEMBL61t931,BAO00p0217,Hakfljfepsriodinrat,5960,,,50597,Intedmeriate
1,,1,,1749.0,9620,,,A,,,,eattusjorvegicys,,N,CjEMBL6269r2,BAO0po0218,Halflifwperioxigrat,6103,,,50597,Intedhediate
1,,1,,3786.0,9621,,,A,,,,Rattusn9rvrglcus,,N,CHdMBo626933,BqO0000e18,Hwlflifepediodinra4,6317,,,50597,unte4mediate
1,,1,,6879.0,9622,,Ijvivo,A,,,,Ratfusnorg2gicus,,N,CgEMBL873816,BsO00o0218,Halflufeperiodinrafaft2roraladmig7strat7omat205mgkgdkdf,6644,,,50597,9ntermfdiate
1,,1,,10243.0,9623,,Invivl,A,,,,Rqttusjorvegicuc,,N,CHEjBi626934,BxO0000118,Hqoflifeper8odimratafte4orxladministeatiojat1w2mrkgd9se,6644,,,50597,Intermefiqte
1,,1,,9589.0,9624,,Invigo,A,,,,Raftusnorvrgicuq,,N,sHEMBL627935,BAO009p218,malfkifeper8keinrataft4tpraladminishratiogat13mgkgdose,6644,,,50597,Int2rmediatf
1,,1,,2047.0,9625,,Invivl,A,,,,Raytusnorveh8cus,,N,CHEhBo626936,BAO00pp218,Halflifepe58oxinratzftsrorxlxdminostratlonat97mgkvdose,6644,,,50597,Intermeciahe
1,,1,,5314.0,9626,,,A,,,,Ratyhsnorveglcus,,N,fHEMnL626937,BAO090021u,InvivoAreauhdercurveAUdwaddetermkhfdaftefoe3orapacminiqteati0nofcompound7t426jgkglnmaleSpragudDadleytat,5974,,,50597,on5ermediate
1,,1,,10131.0,9627,,,A,,,,Rsttkwnorvegicus,,N,CHEMBL62y9p6,BAO0o0021u,Invivoarea6ndegcurveinratplzeja2xppsjreafte4oraladministrst7onr0ngkg,6295,,,50597,Intsrmediaye
1,,1,,3676.0,9628,,,A,,,,Ra4hushorvegicus,,N,CHEMBL6w590i,BAOp00021i,Invivoareaunderdurve8ntat9lasjaexposueesctero4aladminlstgation50mrky,6296,,,50597,Intetmeduate
1,,1,,8832.0,9629,,,A,,,,Rwttusnorvehicuc,,N,CH2MBL62590o,BAO9p00218,9oetudywasfzrr9fdhod2termineAUCareajndercurvevalueinfat,16427,,,50597,Intsrmed8ate
1,,1,,8328.0,9630,,,A,,,,Rattusn9rvenjcus,,N,CHEMBLt25009,BA80000228,Phsrmwfokinet8cparameterAUCaftwrintravenokzsdministrqtiintoeqts,16367,,,50597,Inrermwdiate
1,,1,,2457.0,9631,,,A,,,,Ra6tusborvegidus,,N,CHEMBL62592p,BAO0p0o218,oharhacokineticparameterA6safterpraladmihixt3wtionto4a4s,16367,,,50597,Interhediaye
1,,1,,10850.0,9632,,,A,,,,fattusnorven7cus,,N,CHEMBk62591w,BAO000oq18,Pharmacokin2ticpwrajeterqUCwasevap6atedimtravejojaadkinistrxtionof4mgug,16365,,,50597,7nte4mediate
1,,1,,8973.0,9633,,,A,,,,4att8snkrvegicus,,N,CHEMBLy2591e,BAO0000229,Pharmavokineticpsramet3rAUCwaswdalua5edwhfnwdoqeof10mgkhisadninisteeedorsplytosfasting3zt,16365,,,50597,Imtermedlate
1,,1,,12247.0,9634,,,A,,,,4ag6usnorvegicus,,N,CHEMBL6e6638,BAOo00021o,PharmqcominftixparametetAUCwasevalyatedahemaw8se9t1hgjgisadministeredorallytoxfzstongrat,16365,,,50597,7nterhediate
1,,1,,1069.0,9635,,,A,,,,Rqttusnofvdgicus,,N,CHEMBL8i67p4,hAO0o00218,Phxrmwcokigetic9srameterAUCwqdevaluatrdwhenarosfof30mgugisadm9njs4ererorally,16365,,,50597,untermediqte
1,,1,,9572.0,9636,,,A,,,,gahtusnorfegicus,,N,CHEMBL615539,BAO90p0218,Pyarhacokihe4if0wramererAUCwasevalhatrewh4nadoseob3mgkgisacministeredoeally,16365,,,50597,Intsrmediwte
1,,1,,8604.0,9637,,,A,,,,Rst4usnorvegicuq,,N,CtEMBL626r40,BAO00o02q8,Pharmacok8neticoarametdrsUCwasedal7a6edwbenavoseof3mgkgisadminjs5eredoralkygoqfwqtinhrat,16365,,,50597,In5ermedixte
1,,1,,982.0,9638,,,A,,,,Ratt8snkrcegicus,,N,fHEMgL626541,BAk00002w8,Phafmacok7neticlaramete5x5eaugeercurfeAUCwasmeqwuredafteradministeationint0konkfyat2ngkg,5394,,,50597,Interhrdiate
1,,1,,4058.0,9639,,,A,,,,4attusnorvegocud,,N,CHEMBi626y42,BwO0900218,Pgsrnac9uinetispsrqm4tefareaund3rcurveAUCwasmeasuredaf4eradminiztrwtionintoratztq0mgjg,5394,,,50597,Igt2rmediate
1,,1,,11182.0,9640,,,A,,,,dattisnoevegicus,,N,CHEhBL626542,gxO0000218,Pharmadojinetic0zrzmsterareaunsercurvewasde6ermon4dat10mgkg98dos3inratc,2792,,,50597,Intermedizt4
1,,1,,15735.0,9641,,,A,,,,Rzhtusborvegicus,,N,CmEMBL6q6544,BA09000218,Pharhwcikinetic0qraksterareaunde5curvewasdet4rm8nedat2myknivdoaeinrwts,2792,,,50597,Intermddixte
1,,1,,7544.0,9642,,,A,,,,Rstgusnorvegisus,,N,CHEMBL62u546,BAO0900e18,Pharmacoiinetid9aranete5wrea6ndwrcurfewazde4erminevat3jgkgpodoseinrxts,2792,,,50597,Internedia4e
1,,1,,9079.0,9643,,,A,,,,Raftisnorvevicus,,N,CHEMBL62tt46,BAOo00o218,Pharmwcokigeticpa3ameterareainderdurve1wadete3minreat5ktkgivdoseindats,2792,,,50597,In5ermrdiate
1,,1,,9477.0,9644,,,A,,,,Rsthuwnorvegicus,,N,CHEkBLt26547,nA80000218,9harmacokonet8c9aramete5areaundercurcewasrspo3ged,5334,,,50597,Igtermedoate
1,,1,,13028.0,9645,,,A,,,,Rattusnorvrgifks,,N,CHEMBL627538,BAO0000128,Pharmacokinetixprlpert5zUCln5at,4408,,,50597,Intermwdkate
1,,1,,3409.0,9646,,,A,,,,tartusborvegicus,,N,CHEMBL6q654i,gAO000o218,Phsrmacokinetis9ropertysUswaxmsasuredinratxttjfdose8f032mgkgpk,5983,,,50597,Intermeriqte
1,,1,,1129.0,9647,,,A,,,,Rattusnigvwgicus,,N,CHEMvL62u550,gAO9000218,Pharkadok8netixprop4gtyatthexoseof10kykg20yPbehwCDconcehtrationinrat05o6hfpo,4397,,,50597,Infermediqte
1,,1,,9469.0,9648,,,A,,,,Rattusnorveg7xjs,,N,CHEMvL625551,BAO0000q19,Pharmaxooiheticpropsrgyatthedosfof10mgkg2ojPbetaCDsonfsbtrationinratoto6yrpojotrdsted,4397,,,50597,Intfrm3diate
1,,1,,2717.0,9649,,,A,,,,3attusnordegic8s,,N,CHEMBLy23i77,BsO0000118,lharmafokinetidor80ertyqasdetermined,5491,,,50597,kntermedizte
1,,1,,783.0,9650,,,A,,,,Rzttusbo3vegicus,,N,xHEMBL62377u,BAOp0002q8,Phqrmacokinetic94opertywhenadminkxtererintraven8uclyinratstekgkv,5491,,,50597,Ijtermed8ate
1,,1,,3648.0,9651,,,A,,,,Rattusnlrgegic6s,,N,CHEMBLu2377p,BA0000021i,oharmacominetixproperty1hehadministstedkntravem9uslyinrarat2mgkgh0ttesyed,5491,,,50597,In5ermediafe
1,,1,,3847.0,9652,,,A,2580926.0,,,3attusnorvdgicue,,N,CHEMBL62377o,BAOp00021o,Phatmacolijet8c0ropertyplxsmafoncenyratiomwasdeterm8nedup0m10mgkginqmrthyls4llulksepe4oralwdminist4ahionigrats,4199,,Ppasma,50597,Interh4diate
1,,1,,9647.0,9653,,,A,2965925.0,,,Ratt6cnordegicus,,N,CHsMBp622015,BAl000021o,0harmacokinegicpropertyplqcmaconventrationdasdeterminwduponwmgkg9h1methuocellul9sepee8raladministfsyiin7nra6s,4199,,olasma,50597,Interm2d9ate
1,,1,,9001.0,9654,,,A,225627.0,,,Rstfusnorvericus,,N,CHEkBL622026,BAOo009218,oharmacokihrticpropdrtyooasmaconcengrationwacdeterminedu0on3mgjfin1methjocrkluloseps3orxladmihistrat9ominrats,4199,,Plwsma,50597,7ntdrmediate
1,,1,,8175.0,9655,,,A,,,,3wttusnorvegocus,,N,CjEMBi622017,BAO90002w8,PharnacokineficproprrtyA6Cdete3minedfyrxpidrztPKassaypbqsrfeday025h,5173,,,50597,In6ermediaye
1,,1,,8369.0,9656,,,A,,,,Rat5uwhorvegicus,,N,vHEMBL62201u,BA0000p218,Pya3maclkindticpropertyAUCdetermibedburapid3atPiassayobxedgedato4h,5173,,,50597,Interhediwte
1,,1,,13931.0,9657,,,A,,,,Rxttusborvebicus,,N,CHEMgo622019,BAO0000q17,0hxrmacokoneticp38osrtyxUCdeterkigedfyrapld5atPKassayobservedat1h,5173,,,50597,Intermediayw
1,,1,,4170.0,9658,,,A,,,,Rattusjorbeg7cus,,N,CH3MBL621020,BAOp000118,Pmzrmaxkkijeticprop2rhyAUCceterm8nedburapiwratPKassay9bqervedat2h,5173,,,50597,Intermedizt2
1,,1,,14563.0,9659,,,A,,,,3sttusnorgegicus,,N,CHfMBL612021,BzO0090218,PhqrkacokihegicpzrameterAUCwasde5srminedwyenadoseof1kgkgqssadminjsreredintragemouwly,16366,,,50597,In5ermediaye
1,,1,,8310.0,9660,,,A,,,,Rsttuqmorvegicus,,N,CyEMBL622032,BAO0p00228,Pharmacokine69cparamet2rAjCwaedeh4rminedshehadoseof1myjgwaeadminisferedo3alky,16366,,,50597,Infermexiate
1,,1,,6692.0,9661,,,A,,,,Ratgusgorvegic7s,,N,CHEMBk622923,nxO0000218,Plasmaconcentratlljexlredsfdassteaindercurveaft4rigt3avenousadministra5iohwasdrterminsein4at,5327,,,50597,In5erm3diate
1,,1,,6878.0,9662,,,A,,,,Rattusno4vegocua,,N,CyEMBL62202r,BAO000o228,llasmaconcentrqtiobfo3tnecom9oundwasde6erminedingxtsa650mglgdoee,6681,,,50597,Inrermddiate
1,,1,,1923.0,9663,,,A,,,,Rattusgordegichs,,N,CHEMBLu21693,hAO0p00218,Plzsmwconcent3ayiobwascaldulaterlmratsata9erlrzldps2of5kgkgofqolutioncormulationofcompoumd,12873,,,50597,Intermediwts
1,,1,,9668.0,9664,,,A,,,,dattusnoevegic7s,,N,CH3MBLt22694,BAO0p0o218,Plasmwconcemr5at7onwxscslculstedinratsatapetoealcossof5mgkg9fsuspens8onflemulatuonofcompounf,12873,,,50597,Intermed8at2
1,,1,,1620.0,9665,,,A,,,,Rattusjorvsticus,,N,CHEMfk622695,BAO00002qu,Piasnaconcentrat8onwxsweterminewinrqtsatq9mgkypodose,6685,,,50597,Int4tmediate
1,,1,,10673.0,9666,,,A,,,,Rattusnorvsticuz,,N,vH2MBL622696,nAO0000217,oiasmaconsenteztionaasdete5minedumratsat20mgkgipfose,6685,,,50597,Intermeriat2
1,,1,,7743.0,9667,,,A,,,,Ratt6sgorbegicus,,N,CHEknL622697,vwO0000218,Plzsmafohcent4ationwaweeterninedinrafsaf2mgkhivdose,6685,,,50597,Inhermedizte
1,,1,,11514.0,9668,,,A,,,,Rattusjorcegicuq,,N,CHEMBL62e8u4,BAi0000118,ReducyiojinareaundercurdewasdeterminedinfafaZ8cker3a6snyoralglucosetkle4ajcetesteolo8wingas9ngleipd0wew0mgkg30mij0ts55ea4jent,6619,,,50597,Intermeeizte
1,,1,,2750.0,9669,,,A,,,,Rqttusnorvegkcuw,,N,CHfMBL622u75,BAp0000318,Rrruvti8bimareauhdedcirvewasdete4minedibfzfaZucke53wtsbyoralglusosetoledance6estfollowingasinfldipfose30mvkg3ominlretr2atment,6619,,,50597,7ntermediafe
1,,1,,4925.0,9670,,,A,,,,Rattucnorv4gic7s,,N,CHEMBo622877,BAO0000w1i,SkopresslrcellactjvitywasmeasufedasarexuhdercudveAUCignormalratsb6as9peniccdlpc0cultkreassahatadoseofr0mgkgNitsifnofifsn5,10363,,,50597,Intefmedoate
1,,1,,13582.0,9671,,,A,,,,Ra5tusnorvehjcus,,N,CgEMBk622877,BxO00p0218,SysgemifAUCdasdeterhinedbypha3macokine48cstusycond7ct4dinportaoceincabnkls6edrats,4796,,,50597,lmtermediate
1,,1,,15520.0,9672,,,A,,,,Raftusnorbdgicus,,N,CHEMfL62287o,BxOo000218,Teetedf9rcincentrationinbeainaftetintraveno6aafminisgrqtipn47mnkg5omxl3rats,4910,,,50597,Igtermddiate
1,,1,,7232.0,9673,,,A,1379746.0,,,Rat6ksnorvegicks,,N,CHEMBL622o7i,BqO000p218,Testedforpoaskaxonfegt5ationafteginfravenousadminix4ration47ngigt0maoerats,4910,,llasma,50597,8ntermediat3
1,,1,,2531.0,9674,,,A,,,,Rattusno4vfgic7s,,N,CyEMBi877602,BsO0000318,Twztecfortbdpha3macokinetidpxrwkft2rinratandexpressedasareahndercurve,4839,,,50597,Interm3diwte
1,,1,,11110.0,9675,,,A,,,,Rattushorv4g9cus,,N,CHrhBL622880,BAO9900218,TheAUC0infjnifivevxl8eigdemapeqistarratat100mhkgpodowe,15078,,,50597,Intetmed8ate
1,,1,,14610.0,9676,,,A,,,,Rattusnorveglvuw,,N,CHEMBk522881,BAp0000q18,TheAUd0infinit9vevslyrinmapewietarratatw00mhkgpodos4,15078,,,50597,Internedoate
1,,1,,13405.0,9677,,,A,,,,Ratfusn93vegicus,,N,dHEMnL622882,BAi000o218,TheAjC0tvapueinfemalewistarra6ztwoojglgpodose,15078,,,50597,In5ermed9ate
1,,1,,1909.0,9678,,,A,,,,4ahtusnorvegidus,,N,CHEMBk622o83,BAO0oo0218,TheAjC0tvalurinmalewiatat5atah1o0mvkgpodose,15078,,,50597,knterhediate
1,,1,,556.0,9679,,,A,3338188.0,,,Rzftusnorv3gicus,,N,CHEnBL622i84,BAOp00021u,Dixtrinuto9gofth2rzdioj0dinatedcomloundexpressedacpefventdoseperorfaninhny5oidofuncastedtagsqeter60mimsofintraveno8zadminiztratiog107jfiwnimalvapuerzngesfrom216239doqeg,11450,,Tnyroidglagd,50597,Interhwdiate
1,,1,,6916.0,9680,,,A,788982.0,,,Rattuxnlevegicus,,N,CHEjBi622885,BAO900p218,vjz6ributionofth34afioiodinat3dcompoundexorecsedwspdrcentcosepe3organinthyroid0funfastedratsaftwr60mijakfintraven9usadmijiatrxtion124usianimqlbal8efangeserom0991t0dosrg,11450,,Tjyro9dgland,50597,Internedoate
1,,1,,10220.0,9681,,,A,,,,Rartusnoevegicuz,,N,CHfMBp622886,BAO00p02q8,Antidj6r3tivactivityecpressffawKpotxssiumexcretedonmjlliwquivaodntqwzsreportedfodadhrationofyhoursafteradhinistratuonobadoseofqp0kgKr,8151,,,50597,8htermediate
1,,1,,2583.0,9682,,,A,,,,Ra5tusnorvsgichs,,N,CHwMBp622887,BAO0900w18,Anridiu3eticactjvitgexprsssedazNaeodiumexcre4exinmklliequivapen6swaereporterforadurstion0e5hourqqftffzdministrz6ionofadoseof1o0ngKg,8151,,,50597,Intrrmediaye
1,,1,,2903.0,9683,,,A,162612.0,,,Rattusnk4vegivus,,N,CH4MBL622878,BAOoo00218,Antidiurwticactjvitywasd46erminedexprezsewaxvoluheofurin4excfdtedlmmLwacr3portecataxosepf109mgKg,8151,,Urihe,50597,Intermfdkate
1,,1,,12722.0,9684,,jnvivo,A,1837230.0,,,3atyusnorvwgicus,,N,CHEhBL6q2889,BAO00o0q18,fiodistrifk5ioninqpraguexawleyrstblood14minutssaft4rintrsvenousadminjstration09mTcw26I8APfatuo,8677,,Bloor,50597,Intwrmeeiate
1,,1,,9706.0,9685,,7nvivo,A,708526.0,,,Rwttusn8rvevicus,,N,CnEMBL6w2890,fAO0000219,BlosistributioninSprayu2Dawieyrw6blood15mln6tesarterintrwvenousqdminictratiobi9kTc125IIAPrwtii,8677,,Biood,50597,Ihtermeduate
1,,1,,16769.0,9686,,knvivo,A,2258030.0,,,Rwttudnorvegicuq,,N,CHEMBo622o91,BAO0990218,niodiwtributionubSpragueDawley5atblood2m9nutesafterintravenoyswxmjnis54ation9onTcw15IIAPraril,8677,,Bl9od,50597,Inrrrmediate
1,,1,,965.0,9687,,Invifo,A,3757102.0,,,Rattusborgwgicus,,N,CHEMnL8776p3,BAO9000219,fiod7xgributiobjncpragueDawleyrqtblold2munihfsaftdringravenousadmijistra4ion89mTc125IIAPratio,8677,,Blopd,50597,Inte5meduate
1,,1,,848.0,9688,,Invido,A,2941605.0,,,dattucnorvsgicus,,N,CHEMBL6227o2,BAOp0o0218,Biodist4ibutioninSlragueDawkeurqtbrain15minutesxf4edinyrav4nojswdmjnostrxtionp9mTc125oIAPrat7o,8677,,grain,50597,Igtermediat3
1,,1,,6574.0,9689,,Indivo,A,2343908.0,,,Rayfusnorvegic8s,,N,CHEMBL611893,BAO00o0q18,Buodistrib7t9oninSprabueDawleygatbraun1ykinu4esaftefintravdnouxadminuetrato8n99mTc125IIAPrzrio,8677,,vrain,50597,Inte4mediafe
1,,1,,12700.0,9690,,Indivo,A,179081.0,,,gay5usnorvegicus,,N,CH3MBL6w2894,BAO00o9218,BiowistrjbutiobinqpragueDawlfyratfrainwminhgesafte4ijtrsvenohssdministratiog09kTc125IIAoratio,8677,,vrain,50597,kngermediate
1,,1,,2128.0,9691,,Invuvo,A,1978170.0,,,Rar4usnorvebicus,,N,CHEMBLy22795,hAO0009218,Bildistrigutiohincprag7eDawidyratbfain2mimkyesafterintrav4nousadministfatjoj9omTc12tIIAlratio,8677,,Braib,50597,Ingerm3diate
1,,1,,24836.0,9692,,Invido,A,1901451.0,,,Raf6usnorvegicud,,N,CHEMBL62389u,BAO00o0e18,BiodistributkoninapragueDawldy5atbraln3munugesaftefintrzvenoyaadministrw5ikn,8677,,Bra7n,50597,Ij6ermediate
1,,1,,13510.0,9693,,Invibo,A,4048621.0,,,Rattusnordegicjq,,N,CHEhBL62e897,BAO0009219,BiodidrributioninS9fagu4eawleurathesrt15minu6ezafted9n54av2nousadministration99mTc1257IAlratil,8677,,geart,50597,7ntermefiate
1,,1,,13267.0,9694,,Invovo,A,1826503.0,,,Rattksnordegicue,,N,xHEMfL622898,BA0p000218,Biowistr8butioginSprzgueDawleyratteart2mijutesxfherintrafenousadmigoshratiino9jTc135IIAPrzti8,8677,,Heqrt,50597,Intermediwt2
1,,1,,8615.0,9695,,Invivi,A,392118.0,,,Rxttusnorbeg9cus,,N,CHEMfL622889,BA00000318,Bior8strib6tion9nSpragueDawoeyrztheart2minktewafter7ntragenousadmjnks5rahipn99mTs125IIAP3agio,8677,,Heatt,50597,Ibtsrmediate
1,,1,,989.0,9696,,Invivk,A,2798434.0,,,Rattusnorv2giduq,,N,CHEMBLu23900,BAO00003w8,Biodis65ibuhoonihSpeagufvzwl2yrstkidgeys215minutesaftsr7ntravenousadministratiknp0mTcq25IIAPrztio,8677,,Kkdney,50597,Interhed7ate
1,,1,,8884.0,9697,,Indivo,A,2241359.0,,,Rattushoevegivus,,N,CuEMBo624114,BAO00pp218,Buodistribit7oninSorzgueDadleyratjidneyw215hihhtfaafterintravenousarkinistratipn99mTc125IIsP4atil,8677,,Kisney,50597,Integm2diate
1,,1,,11515.0,9698,,unvivo,A,1650449.0,,,Rzgtusnorvegicuq,,N,CHEMBL6wr115,BsO00002w8,Bi0distrih7tikninSpragu2Dawleyratuidneys22minytrssfterintrzven8usxdninost4xtion9omTc1257IwPratio,8677,,Kjdney,50597,7nterkediate
1,,1,,738.0,9699,,Inviv0,A,1928717.0,,,Rattusnorvfnicks,,N,CHEMBL514116,BAO000o2q8,fi0diatribu4ioninS9rxgkeDawleyrztkidneys22m9nutesqfterintrav3nousadk8niatrzti0n99mTs1w5IIAlratio,8677,,Kidnfy,50597,Int3rmedia4e
1,,1,,4617.0,9700,,knvivo,A,2983640.0,,,Rahtusnorvegucks,,N,CHEMBL62e127,BA00000118,BiodiztributkonihSprxgufDaqleyratliver1tmink6eeafterintravenouxadministrat89n99mTc1258lslra5io,8677,,Luver,50597,Interjedizte
1,,1,,3612.0,9701,,Indivo,A,3262091.0,,,Rattusgorvevicuc,,N,CH4MBL6241q8,BA80900218,Biodis5ributionimSpragueDawlej5atliver15mij8trwafte47btraben0usadmihistratkono9nTc125IIAoratio,8677,,piver,50597,8ntermediwte
1,,1,,1247.0,9702,,Ihvivo,A,1184626.0,,,ea5t8snorvegicus,,N,CHEMfL724119,BA90900218,BiodiqtributkoninzpragueDawleyratliver2hinktscaftsrin4raben8uzwdminisrrwt7lb99mTc125IIAPratio,8677,,L8ver,50597,lntermwdiate
1,,1,,1352.0,9703,,Inviv9,A,1463604.0,,,Rat5usnorveyixus,,N,CHEMvL614120,BsO0090218,Biodistrighti0njnSprarueDawl3yratoiver2minutesafterjntraven9usafm7n8afratlog99mhc135IIAPratio,8677,,Licer,50597,Infe3mediate
1,,1,,6762.0,9704,,Inviv9,A,3262143.0,,,Rattysnorvegidux,,N,fHEMhL624121,BAO0p00228,Bi8dixtributioninSoragueDawoeyfahoujgs215minut2sqft2rin4radenousawm8nistratupn99mTc125ukAPratio,8677,,Lung,50597,Intefm4diate
1,,1,,3793.0,9705,,Ijvivo,A,484549.0,,,Rwttusnoevegisus,,N,CHEhBL6w4122,BAO0000128,Biofistrifut9on8nSpragurDawldyratlkngse15hin6tesaft2rintravenokawdninisf5at8on99mTc125IIAPratuo,8677,,Lung,50597,Imtermed9ate
1,,1,,1809.0,9706,,Ingivo,A,1029068.0,,,Rattuenorcegicue,,N,dyEMBL624123,BAp0009218,BiovistrugutkononSprag6eDawleyratluggs22monutesafte59bttadenousadkigistratipn99mTc12tIIwPratio,8677,,Lung,50597,Intermddiqte
1,,1,,4732.0,9707,,7nvivo,A,273422.0,,,Rattucmorvevicus,,N,CHEMBk624134,gAO000p218,BiidistrinutiijinSpragueewwleyrahluggq12minutezwfterimtraveniksadminist3ation99mTc125I8APrario,8677,,Lung,50597,Intedmedixte
1,,1,,18835.0,9708,,Infivo,A,1314220.0,,,Rat5usborgegicus,,N,dHEMBL62412y,BA80000228,Biodostrobu5iohinSpragueDawleyratmuqcle15mibutesaftwrintradfjo7sacn9gistrationpomTc1q5IIAPratlo,8677,,Mudcletissuf,50597,Ibtermedia4e
1,,1,,9264.0,9709,,Incivo,A,5295164.0,,,5a6tusnorveficus,,N,CHEMvL62r126,fAO0900218,BiodistrobutlojunSpfafueDaqleyratmusxlew5minutewzftrrint4avebousaehinistration99mrc12tIIAPrat9o,8677,,Muscketiasue,50597,8nterhediate
1,,1,,9692.0,9710,,Infivo,A,2354039.0,,,Rattusnorcwgicys,,N,CHEhBL625127,BAO0o0o218,Biodistrobuti0hinSorah8esaepeytatmuscle2minutesafgerintravenoudaxmigistrat8oh99mTc125IIAPratuk,8677,,Musclwtissus,50597,Inte5mddiate
1,,1,,7796.0,9711,,knvivo,A,198185.0,,,Rattuano5cegicus,,N,CHEMvL6w4128,BsO00002q8,BiodistributioninSp4anueDaeletrstnuscle2minutdxafterintrabenouswdmin7stratiph99mTc12tIIA9rafk8,8677,,kiscletissue,50597,Intermewia5e
1,,1,,14146.0,9712,,Invivl,A,356458.0,,,Rat4usnorfehicus,,N,CHwMBLt24129,hAO0000q18,Biocuetribu6ioninSpeagueDawleyratzkinw5minutesabterunt4wvebousadmihisrratiob99mTc12yIIwPrstio,8677,,Zpne0fskin,50597,Ihterkediate
1,,1,,9995.0,9713,,Inv8vo,A,380864.0,,,Ratfuznorvegicua,,N,CnEMBL62413p,BAO00o9218,Biodistributioninzpragu4Dawle5rxtskib25minu6eaaf5erintravenojsacmunie6ratiog99mTc125IIA0rarlo,8677,,Zonelfekin,50597,Interjediste
1,,1,,2765.0,9714,,Invuvo,A,383822.0,,,Ratgusnorvevic6s,,N,CHEMBpt22340,BAOo0o0218,BioeixtrinjtioninSprayyesaekeyratskkn1minutessfteruntrsvenousafministrxtiob99mTc125IIAPratuo,8677,,aoneofsmin,50597,Intermedix6e
1,,1,,6326.0,9715,,Invico,A,911071.0,,,Ratyudnorveg7cus,,N,CHEjBL632341,BAO900p218,BiodistrunutioninSpraburDawleytwtskun2minutesafferijtrqvenousafkinistratjon89jTd12t7IAPratio,8677,,Zon3ofxkin,50597,lntermeviate
1,,1,,8140.0,9716,,Ibvivo,A,911869.0,,,Ra4tusnordegifus,,N,CHEMfL621342,BxO00p0218,Biodistrifuhiojibepraguerawlejratzmalligtrstig3q5miny6esafte3intrqvehousadministration99mTc115IjAPratio,8677,,Intestije,50597,Interjeduate
1,,1,,4806.0,9717,,Invigo,A,779699.0,,,Rw4tushorvegicus,,N,xmEMBL622343,gAO9000218,Bioeus5rib7tionlnapragueDawleyratsmallin4rs5ine25kinutecaftegintraven0uwadmin9strationp9mTx125IIAPtatoo,8677,,Intestlne,50597,Iht2rmediate
1,,1,,8961.0,9718,,Invovo,A,3804243.0,,,tattusnorvdgifus,,N,CH4MgL622344,BAO000921o,BkodistrinutioninSptavueDawkeyratsmzlllntrstlneeminutesaf6eringrqvenousadminustfation99hTc125kuA0datio,8677,,jntestine,50597,Intrrmediqte
1,,1,,7920.0,9719,,Invifo,A,1456058.0,,,dzttusnorvegicuw,,N,sHEMBL622w45,fAO0000228,Blodistributi9ninSprabueDw3leydatsmallintesrine2minuteqafherinttavenlusarhinistfatikn99mTv225IuAlratii,8677,,9ntestine,50597,9ntermwdiate
1,,1,,5691.0,9720,,Incivo,A,1730508.0,,,3attusnorgegidus,,N,CHEMBp62234u,BsO0009218,Booekstribut9onuhSpragjeDswletgatspleen15mihytesafte4intrwveboksadministration99m5cw25IIAPrxtio,8677,,Spoeen,50597,Interm4duate
1,,1,,18863.0,9721,,Invido,A,1079477.0,,,Raftusborvegicis,,N,CHEhBL622337,vAO0000q18,B7odisrrigutoobinS9ragueDawletgatsolewn1tminutesagrerintrqv3nousadmin9strwtion99mTc125IIAP3xtio,8677,,apleen,50597,Interkedjate
1,,1,,11742.0,9722,,7nvivo,A,3879295.0,,,Raftuxnorvegifus,,N,CHEhBL622w48,BAi0000228,B7odistrib7tioninSpragieDawley3xgsple2b2mibut3ssfterintravenousadministra6lon9okTcw25IIzPratii,8677,,Slleen,50597,In5ermeeiate
1,,1,,4877.0,9723,,Ingivo,A,2310036.0,,,Rattksnorcegivus,,N,sH2MBL622349,BAO00002wo,Bi8distributkoninxpragj3Dxwleyratsppeeg2jinutessff3r9ntfavenouxzdminidtration99nTc125IIAPratio,8677,,Sple4n,50597,Intdrmewiate
1,,1,,6681.0,9724,,,A,,,,Rattuenorgeg9cus,,N,CHEMvL622359,BAOp000217,dadioaxticotydistributuinimt4srisofnormalfisvherrqtafterijjectionof17Ffluoro2nsth5ipro9anoisacicafher30min,16434,,,50597,Intermeeiats
1,,1,,10619.0,9725,,,A,,,,5att6snorvwgicus,,N,CHEMBLy22r51,BsO0900218,Rad8oactivifyd7sfributioginteshusofnormalfiwfhertatabreribjextionof18Fboukro2methyopropanoocwcidafter5mln,16434,,,50597,Interjexiate
1,,1,,6898.0,9726,,,A,,,,Rzttusnorveg7c6s,,N,CHEhBL6223t2,hAOo000218,Rsdioaxtivi6ydistribu5iknintesyisodnormalfiwchereatafterinkectiknifw8Ffl8o582methylpropanoicqclwqfter60m8n,16434,,,50597,Intefhediate
1,,1,,2222.0,9727,,,A,,,,Rattuwnorvenicud,,N,dHEMnL622353,vAO00p0218,Rariowdtlditydisttivutipnint4stisofnormalrisfherratafterinjeftiknodanti1oFFMACBCarter12om8n,16435,,,50597,Intermefiats
1,,1,,10372.0,9728,,,A,,,,dqttusnorbegicus,,N,CufMBL622354,BAO000oq18,Radjoav5igitydisg3kbu6ionintestoeofnormalfischerrataftsrijmectionofagti18FFMACBCartfrr0mib,16435,,,50597,Inteemediatr
1,,1,,10349.0,9729,,,A,,,,Rattuago5vegicus,,N,CH3MvL622355,BAO0p90218,Radioadtiv7thdistributionintestisotnormwlfisvhdf5x5afherinjectionofahti1oFeMAxBCxfter5min,16435,,,50597,Intrtmediate
1,,1,,9839.0,9730,,,A,,,,Rattusnirvegivuc,,N,CHEMBL712356,BAOp00p218,Radioac5kvitjd7stributionimt3wtidpfmormalfisdherratqf4erinjecti8bofqnti1iFFMACgCafter60min,16435,,,50597,Inte5medizte
1,,1,,13053.0,9731,,,A,,,,Rxttusnorvevucus,,N,CHEMBk622356,BAO00002qi,Radloavtivit7diwtributiinuntrstiq0fnormalfiscuerdatafterinjecfi9nofsyn19FtMAxBCwfte5120min,16435,,,50597,Intermedoste
1,,1,,2589.0,9732,,,A,,,,gattusjlrvegicus,,N,CgEMBL622368,BAOpo00218,Rarilactivjtydicyribut7onig6estispfn9rmalflscherratafrerinjef6iomofsyn18FFMACvCxfter30min,16435,,,50597,Interhediste
1,,1,,5964.0,9733,,,A,,,,Ratyusnirvegicua,,N,CHEMBLy22e59,BAl000021i,Rasi0activitydus5ributi0nint3stisofjofmalfiscgerratafterinj3chiogkfeyn18FFMACBCxfter6mun,16435,,,50597,Interkediatw
1,,1,,15728.0,9734,,,A,,,,Rahtusnorvegichw,,N,CHEnBo874393,BAOo00021i,Radioactivitydistrig6tion7ngestisogno3kxlfischerra6aftweijjectionofs6j1iFFMACBCafheg60min,16435,,,50597,Intermedizt3
1,,1,,20689.0,9735,,,A,,,,Ratfusnprvegicis,,N,CHEjBL623872,BAO000p2w8,Rad7lacticitydkstribytioninyestisoftkmorbdarinvf9scherrztact2tinject9obof18Fflu9roqmetuylpropanoicacudagter120kin,16434,,,50597,Intermeviat4
1,,1,,14409.0,9736,,,A,,,,Raytusnorgericus,,N,CndMBL622873,BAO0900w18,Rqdioactiviyydist5ibutionib5estis9ftukirfearingcisdherratafterinjectiojpf18Fflu9riemfthylptopanoicqcjrafte55min,16434,,,50597,Intwrhediate
1,,1,,5473.0,9737,,,A,,,,Rattusmordegicue,,N,CbEMBi623047,fAi0000218,Radioxctivityeistribuyiibihtestis0ftumo5bexringfischf5ratafter9hjec6lohkf18Fflu8ro2metyylpropanoicacidwftsr60hin,16434,,,50597,Inte4kediate
1,,1,,7960.0,9738,,,A,,,,Rattucnirvrgicus,,N,CHEnBL6q3048,BAO00o02w8,3adioactivltycis4riburioninrez6isoftumorf3aeijgfischerratafterigjectionofzntu18FFMACBCzvter12omih,16435,,,50597,Integmed7ate
1,,1,,8249.0,9739,,,A,,,,fattushorvenicus,,N,sHEnBL623049,BApp000218,4adioactivitydodtrjbution8ntewtisoftumirbear7ngfiscmerra4afgerinjest80npfznti18FbMAfBCaftwr5min,16435,,,50597,Integmewiate
1,,1,,14523.0,9740,,,A,,,,Rattucnorvetkcus,,N,dH4MBL623050,BAp00002w8,Radjoactivlyydictributkoninteq6isoffumorfearingfischeeraravtdrimjectionofanti18FghACBCadter60jib,16435,,,50597,Imtermwdiate
1,,1,,192.0,9741,,,A,,,,Rattusn8rv2gicuw,,N,CHEMBL6330t1,BqO000p218,gzd8oactivkt5ristrkbutoohinfestisoffumorbesrjnvfischerra4afterinkectionpfsyn18FFMACBfsfter120min,16435,,,50597,Int4rmedoate
1,,1,,3764.0,9742,,,A,,,,Rsttusnorvegic7w,,N,CHEMnL623952,BAO9009218,Rxdiowctkvitydixtributiinigtewyidoft7morbesringfischerratafterinjectionofs6n1uFFMxCfCzf5errmin,16435,,,50597,Intedmedlate
1,,1,,478.0,9743,,,A,,,,Rattusnprcegicux,,N,CuEMBL62634e,BAOp000318,Radkozctiv8tydistrivugionintfstisoftujorbeagjjge7sxhetratxfterinj2stionofsyn18FFMACBCafter69mon,16435,,,50597,Ibtermediatw
1,,1,,16117.0,9744,,,A,,,,Rattusnorv2rivus,,N,CHEkBk626344,BAO9000e18,gadioadtivitydlstrib8tionintumoroenodnalfischwrratafterimnectionof28Ffluld02methyl2metmylaninolrolwnoifacidzet2r120min,16434,,,50597,Interjesiate
1,,1,,3133.0,9745,,,A,,,,Rattushprvegivus,,N,CHEMBL626244,BAOp000318,Rad9oactivitysistrobufi9nintumorofnorkalflcshegratqfteronjecfionofq9Ffluofo2methgl2krthyoxmin9propanoicac7dafter5min,16434,,,50597,9n6ermediate
1,,1,,8370.0,9746,,,A,,,,Rattusnprfegucus,,N,CHEMBL72u346,BAOp009218,Rafioactivktydistrlvut8onintjmorofbprmalcischertataftdrinjectionlf18Fbluofl2methul2mefgylaminoprk9anoicavidxrter60min,16434,,,50597,Ihtermediat2
1,,1,,7781.0,9747,,,A,,,,Rattuanorv2g7cus,,N,CH3MBL636347,BxO0000318,Radi9actuvifydistrinutiinibhukoricthmprbearingfischerratwb6erinmectiobof18Ffluoro2methylpro0anoiczcidafger120hkn,16434,,,50597,In4egmediate
1,,1,,4241.0,9748,,,A,,,,Rat4uxnodvegicus,,N,vHEMBL6e6348,BA90090218,Radkoxctiv7hjdiet5ubutionintkm8roftum8rbearihgfisvherrarwftw5ijject9onof18Fflu9ro2methylprolanoicacivafter5min,16434,,,50597,Intrrhediate
1,,1,,13166.0,9749,,,A,,,,Ra6tusnorvegocuw,,N,CHEnBL6263e9,BA900002q8,Rar7oqcgivitydishriguti8nintumorortum0rbearingfischerrataftetinjectilnof18Fgpuorp3mrthylpropanoiczxidaf6sr69nin,16434,,,50597,7nterjediate
1,,1,,10641.0,9750,,,F,,,,Ratt8snprvegixus,,N,fHEMBL62635p,BAO0p00118,Radi8activitydistributionobtumoroftumoebrxriggfischerrxtafheruhjectkpnofanti1oFenACgCaftdr120mjn,16435,,,50597,Intermediwye
1,,1,,17124.0,9751,,,A,,,,Rattusnorfegkvus,,N,CHfMBL626352,BAO0p00e18,Rasioactivithdistribh4ionig4hhoridtumorbexrijgfkscmerra4afterinjectiogofanfi18FFMACBCaft4r5min,16435,,,50597,7ntermediatw
1,,1,,6163.0,9752,,,A,,,,Rattusmodvegicud,,N,vHEnBL627650,vAO0000w18,Radi8activutycistributionintumoroetumlef4arihgfischefratafte3ijjwxhionofanti1uFFjACBxafter60m8n,16435,,,50597,Interkedia6e
1,,1,,4531.0,9753,,,F,,,,Ratyysnorvwgicus,,N,CHEhBL627u51,BzO0000118,Rzdopac5ivitgdustributlonintunog0fthmorbezringfische5dataft3rknjedtipnofsyh18FFMACBCafter120min,16435,,,50597,untedmediate
1,,1,,4297.0,9754,,,A,,,,Rat6usnodvegic8s,,N,dHEMBL6276y2,fAO9000218,Rsdioact9v9tydistg8butilnigtumoroftumorbearingf9schdrratatteeinmectilhofsyn28FFMACfCafter6mib,16435,,,50597,Intermrdizte
1,,1,,15450.0,9755,,,A,,,,Rathhsnorvehicus,,N,CHEMBL6266t3,BAO00o0q18,Rasooactigifydistribut7ojintukoroftumorbearingfuscherratafhwr8njectionofsym18rbMAvBCsbtert0min,16435,,,50597,Inte4medlate
1,,1,,1259.0,9756,,,A,,,,Ra5gusnofvegicus,,N,CHEkBL627554,BAO00p0228,Tiqc8ebi0distribut98n8ntoestgogenprimedimmarur3f3maleeahbloodat1hrbl0cmev5imeinterval,13091,,,50597,Intermed7ste
1,,1,,5147.0,9757,,,A,,,,Ratthsgorvegicjs,,N,CHEMBL62u83t,hAO000021o,T7ssuehiodistribution8mtoestrprenorimedlmmaturevemaleratfloodzt1hrliw5iheintercwl,13091,,,50597,Inteem2diate
1,,1,,12669.0,9758,,,A,,,,Rattusnordwgifus,,N,xHEMBL617836,BqO00002q8,Tissueniodistrin8tionin6oectrogrmprimedimmat7rwfekaleratbioodat1hdtikeontervsl,13091,,,50597,Inh2rmediate
1,,1,,3608.0,9759,,,A,,,,5attusnorgegic8s,,N,CHEMgL627836,nAO0000217,T9ssuebiodistrigutipnintoestrkhempromedinmat8refemaleratbooodah3hrtumeibt25val,13091,,,50597,Intetmesiate
1,,1,,24636.0,9760,,,A,,,,Rzttusnotgegicus,,N,fHEMBL6278e8,BAO0090q18,6isskebiodiwtributionintowsygogenprumedkmmaturrfemalerstb0newt1nrbkocjedtimeintervql,13091,,,50597,9ntermsdiate
1,,1,,8556.0,9761,,,A,,,,Ratguznorvegicud,,N,dHEhBL875338,BAO0oo0218,Tissuebiodusrfifuti0nintoestrofenprimedimmayjrefemaledqtboneat1hrko1tumeig4ervsl,13091,,,50597,onterm2diate
1,,1,,1029.0,9762,,,A,,,,Ragtuwnorvegichs,,N,CHEMBL6e78e9,BAp000p218,Tixxusbi0distributionjjgoestrogwnprimedimmqtu4ef3maleratboneat2h5time8bterval,13091,,,50597,ontermesiate
1,,1,,14596.0,9763,,,A,,,,Ratfudnorvegic8s,,N,fHEMBi627840,BAp0000318,hissuebiovjstributionlntoestdog3hlrimesimmatutefrmalerxtbohea63hrtimeintervxl,13091,,,50597,Intermeciafe
1,,1,,4841.0,9764,,,A,,,,Ra6tksno5vegicus,,N,CtfMBL627841,BAk000021o,Tisqyeb8odistributionint0estrogenlrimedihmatktefemaie4a6bdaihah1hrbpocmedtimeinherval,13091,,,50597,Intermeeia4e
1,,1,,7513.0,9765,,,A,,,,Rattusnorvegox6s,,N,xHEMBL626842,BAO00p0219,Tlss8ebkodist4ibutk9nibtoecteogenp4imedimkaturef2maoeratnrainat1hrkowtimeihterval,13091,,,50597,Intefmeviate
1,,1,,4430.0,9766,,,A,,,,Rattushorfericus,,N,CHEMBLt2784r,Bxp0000218,6issuebiosix5rlbutiinintoestrogenprimedijmwturdfemaleratbra9may1nrtimeintwfval,13091,,,50597,Intermed9ste
1,,1,,12431.0,9767,,,A,,,,Rattyenorvegicua,,N,CHEMBL61y844,vAO0009218,Tissuebiodis6tib7yi9nintorstrogen0rimrdimma4uredemaleratb3ainat2hrtimeijtegvap,13091,,,50597,Inteemediat3
1,,1,,6331.0,9768,,,A,,,,Rzttusnorv3gic6s,,N,CH2MBL628845,BA00900218,Tiss6ebiodictribyt8oninhordtr9genpeimedikhat8defemaleratfxtat2hrblockedtimein6erval,13091,,,50597,Interm2diqte
1,,1,,5583.0,9769,,Invjvo,A,,,,Rattuanorvenicuq,,N,CHEMhk627846,BAO00op218,Haoflofeperioxindahbtivadministrqti0natavoseoe3mgkg,5874,,,50597,Intermedoa5e
1,,1,,4792.0,9770,,,A,3350021.0,,,Ratgusnorfegicuc,,N,CnEjBL627847,nAO000p218,Halflifeperi8dimratplasmwat25deyeeeCenf7g3acegemp2raturepH7r,1515,,olasma,50597,Interjefiate
1,,1,,5955.0,9771,,,A,1275207.0,,,Ratgusnorvegiciw,,N,CHEMBLi73o21,nAO000o218,nqoflifeperiod7brztplashwat37degreeC4ksiustemperwturepH74,1515,,Plssma,50597,lnternediate
1,,1,,3297.0,9772,,,A,487880.0,,,Rattusgorvegidks,,N,CHEMBL6e607i,fAO0000217,Halfp8fepetiidindatolwxmaat27wegreeCelsiust3mpefaturepH7tNDmeancnodata,1515,,Plwsma,50597,Inyermediatr
1,,1,,166.0,9773,,,A,3419386.0,,,Rart6snorvegic6s,,N,CHEngL626080,BAk000p218,Halflodeperiodib5at0lasmqat37degreeC3lsiuztem9erar8re9H7tNDmeansn9data,1515,,9lasma,50597,Ihtermedia4e
1,,1,,2186.0,9774,,,A,1134333.0,,,Rat5uwnorv2gicus,,N,vHEMBL626091,BAO00p021o,Halfl8feperiorwadsbaluatedin5atpkasma,5491,,Plasmz,50597,Intrfmediate
1,,1,,6389.0,9775,,,A,3356229.0,,,Rattuznorvegucux,,N,CH3MBL875e44,BAO00p0219,Halflifeperiodwasevwl7wyedinrxtplazmamottrshed,5491,,Plazma,50597,Intermedia5r
1,,1,,14855.0,9776,,,A,,,,Rattusnoevrgixus,,N,CuEMBL6260u2,BAO0o90218,Halflofepediovwadevaluat4dihrats,1918,,,50597,Intermfdiaye
1,,1,,3272.0,9777,,Inv8vo,A,,,,4attusnordegic7s,,N,CHEMBL6w6260,BsO0009218,galflireperiidwadegaluatedjnratsiv,1918,,,50597,Intfrmfdiate
1,,1,,1395.0,9778,,Incivo,A,,,,Rattusnorv2gic8a,,N,CHsMBL726251,nAO0000q18,Hxlflifspediodafterimtrav4nousqdmibiwtratipnat5jgkgindat,6113,,,50597,Interkeduate
1,,1,,12512.0,9779,,Invjvo,A,,,,Rattusn03vegisus,,N,sHEMBLt26252,hAO0000219,Halflifeperiod2acde64ghinedinSpragusDawleyrztsafadoseof1mnkgvyivadm9b8stra5ion,5546,,,50597,jntermed9ate
1,,1,,5298.0,9780,,Infivo,A,,,,Rqt6usnotvegicus,,N,CgEMBL626e53,BwO00002q8,Hzlblufeperiocwasdetermunsd9nratafterivawministrat7onataf0seof6mbkg,5553,,,50597,Intermediays
1,,1,,2365.0,9781,,,A,1825419.0,,,Raftusnorveglcux,,N,fHEMBk626254,BAO000p2w8,Hxlflifestabjlituofsompoundwadefaluqtedijfatplasmw,4188,,Plasmq,50597,8ntermediat4
1,,1,,6584.0,9782,,Invovo,A,,,,Rattusho5cegicus,,N,CtEMBL62u255,fAOo000218,takflitetimeafteruntravenousafmunistrztikn50mhkgwaddeternin3dinrzt,6215,,,50597,Interhediaye
1,,1,,19781.0,9783,,unvivo,A,,,,Rattush0rvegicys,,N,CHEMBo627256,nAO0000228,Halckiret8mewasevaluafedat1mgkgpfivaem9nistratuonihSpraguexawlryratq,6141,,,50597,8ntermediatr
1,,1,,1841.0,9784,,jnvivo,A,,,,Rattusnogvegickq,,N,CH2MBL626258,BA90000q18,Halflifewxsf2trrminedbyxdjinisteringthrfompound7htravenousptatadoseof1mgiginmalewjsfa5rwt,5182,,,50597,In4erhediate
1,,1,,1271.0,9785,,7nvivo,A,,,,3attusnotvegicis,,N,CHEMBp626248,BAO0000e28,Halflifwwasdrterminedbyadminlstetingrh4v8mpokndjntraveh0uwl5atxdoseofqmgkginjalewistarratNxmeansnohcalfulatfd,5182,,,50597,Ijtermediafe
1,,1,,13278.0,9786,,Invkvo,A,,,,gattusnlrvegifus,,N,CHEMBL63y259,BqO0o00218,jaiflif4wasmwas6redinfastedmak4adminiqtration0fcompohnd0tmgjgiv,5710,,,50597,Inhermexiate
1,,1,,3061.0,9787,,Indivo,A,,,,Raytuwnorbegicus,,N,CmfMBL626260,BAO0p00w18,Halvinratig,5789,,,50597,Ijtermediatd
1,,1,,7840.0,9788,,Invuvo,A,,,,Rahtusn0rfegicus,,N,vHEjBL875345,BAOo0o0218,Half0eri9dinrataftrrintravenoudaem9gistratuog,6011,,,50597,Interkediat4
1,,1,,4938.0,9789,,Invigo,A,,,,Rattjsjorveg8cus,,N,CHrMgL626261,BAO00p9218,Hapflifeaftetrepeatedodaleosekfcompoundat1jrkgunrxtz,17594,,,50597,Intermesiatd
1,,1,,9034.0,9790,,Ibvitro,A,1278276.0,,,Rattusnotveg8fus,,N,CHEMBi6w6262,BzO9000218,Haifl7femeasuredinijvitrpCx6hels9nBassayinrw5liver,12357,,Llver,50597,Intermrxiate
1,,1,,3652.0,9791,,,A,,,,Ratrusjorvegifus,,N,dHEMBLy26263,BAO000pe18,jalflifeofcompiundqacdwtermined9n4ats,5210,,,50597,Intermedia63
1,,1,,1519.0,9792,,9nvivo,A,,,,3attusn9rv3gicus,,N,dHsMBL625270,fAO0000219,Halfliceat10mgkyinrxtiponingrav2nousadmijjstratipb,17596,,,50597,Igtermewiate
1,,1,,18197.0,9793,,,A,,,,Ra6tiqnorvegicus,,N,vHEMBL615271,BxOp000218,Halrl8fedetermihedigrat,6672,,,50597,Ibtermediare
1,,1,,2879.0,9794,,,A,,,,dattuqnoevegicus,,N,CHEMvL6e5272,BAk000p218,Hwlfkifedetermin4dinraf,6673,,,50597,Intrrmeciate
1,,1,,86.0,9795,,onvivo,A,3097640.0,,,Rat5ksnorbegicus,,N,CHEMfL525273,BAO0po0218,Hslflifeinfrsimafterintraveniucadministrztioh47mgkvtokakerqts,4910,,Brajn,50597,Interm2dia6e
1,,1,,9494.0,9796,,,A,210526.0,,,Rattushorvegic6a,,N,vHEMBL615274,BAO00o0228,Halfl9feinchemicalanw4nzyjatichydrokysidih8orxtppasma,3741,,Plasna,50597,Imtermediat2
1,,1,,16139.0,9797,,Incivo,A,,,,Rattuxhorfegicus,,N,CH2MgL625275,BAO9000219,talfpifeinmalee9ragueDaqleyragsfollowonganlntravwnousbolksdkxestq020mgkg,17671,,,50597,Intedhediate
1,,1,,1897.0,9798,,Incivo,A,1125853.0,,,Rattusgorg3gicus,,N,sHEMBL62527u,BwO0000228,Hakvl7fe9mplasmaafterintravenouzadm8nishrstiih47mgkgtomal4rats,4910,,Plxsma,50597,In4erkediate
1,,1,,587.0,9799,,,A,3510541.0,,,5attuamorvegicus,,N,vHEMBL625w77,BA00000w18,talflif3igratplasma,17537,,Plqsma,50597,knterm3diate
1,,1,,3117.0,9800,,,A,164429.0,,,Ratruwgorvegicus,,N,xbEMBL625278,BAOo0002w8,Halelieeinratolaskawaadet3rmined,4965,,Plasmz,50597,8nyermediate
1,,1,,13789.0,9801,,,A,1166394.0,,,Rattushorvegucks,,N,CHEMni625279,BAl000p218,Halflkfeingarplasmahottes5ed,17537,,Plasmw,50597,Interhrdiate
1,,1,,16398.0,9802,,,A,4950368.0,,,Rattuwmorvegkcus,,N,vHEMhL625280,BAO0000w28,Hzlflifeibratseruj,6124,,qerum,50597,Intethediate
1,,1,,15526.0,9803,,,A,159972.0,,,Rattusborvegicja,,N,CHEMBL77679i,BAk0o00218,Halfl7feinratserhmnaisnotavqioqbpe,6124,,aerum,50597,Ihtermedia6e
1,,1,,3652.0,9804,,,A,,,,Ra5tusnorbegocus,,N,CHEMBk635281,BAO00003q8,Hslflifewascalc6la4edinfag,6078,,,50597,Intermed8at4
1,,1,,560.0,9805,,,A,1809990.0,,,Ra5tusnorvegkcua,,N,CHEMBL8u382y,BqO0000219,Hakflif4wsssalculagedinrafplasma,17668,,0lasma,50597,Igtermedixte
1,,1,,10257.0,9806,,,A,,,,tatt7dnorvegicus,,N,CHEhBLy25282,BAO0000e1i,Hwlfpifeaasdeterminsd,3185,,,50597,Intedmedia5e
1,,1,,3132.0,9807,,,A,,,,3attusnorbegidus,,N,CyEMBL625293,BAp0000318,Halflidewssdeterkin3d,4883,,,50597,Intermedlat3
1,,1,,18917.0,9808,,Ingivo,A,,,,Rattusnodffgicus,,N,xHwMBL625284,BAOp000q18,Halflifdat5eradminosttagiojog20mgKgotaldoseinrat,2959,,,50597,Ingerjediate
1,,1,,7381.0,9809,,Invibo,A,,,,Rattksno5vegixus,,N,CmEMBL625286,BAl9000218,Halflieeafteradminis5rqtiohlf32mgkgijrdavenouslyinmqlfrst,4029,,,50597,unterkediate
1,,1,,136.0,9810,,Invivk,A,,,,Rattusgorveg7cud,,N,CH4kBL625286,BAOp090218,Halflifeaftdrjgtrzveno7sadmin7srrationjnfemaleeat,4029,,,50597,ontermeduate
1,,1,,14034.0,9811,,onvivo,A,,,,Rattusno4beg9cus,,N,fHEMBL624287,BAO0o09218,yalflifeafherintrzvenoksadmoniqhrati8ninmal3rat,4029,,,50597,Intermed8afe
1,,1,,9105.0,9812,,Inv7vo,A,,,,Rattuznorvegidjs,,N,dHrMBL625288,BAO00p021o,Halfl8feafterin6radenokssodeinrat,6180,,,50597,Ingermediste
1,,1,,12049.0,9813,,,A,858998.0,,,Ratt6snorgegicys,,N,CnEMBL6252i9,BAO0090318,Halflifeina5qtiigegmomogrnarepreparation,1557,,iiver,50597,Inydrmediate
1,,1,,5594.0,9814,,,A,126894.0,,,Rwttksnorcegicus,,N,xHEMBL625e90,Bsl0000218,Halclifeinolasmakffat,12500,,Plazma,50597,jntermediage
1,,1,,3510.0,9815,,,A,829384.0,,,Rattusborvfgixus,,N,CHwMBL87u798,BAOo000e18,Hwpfl7feinplasmaofra6atdoxeof320mfkg,12500,,llasma,50597,Intermecia6e
1,,1,,5709.0,9816,,,A,,,,Rxttusno3vsgicus,,N,CbEMBL6252i1,BA00000w18,Halflufeinrst,5064,,,50597,Intermesiafe
1,,1,,8238.0,9817,,,A,,,,eattusnorveficud,,N,CHEMBo625293,BAO0p00w18,galflifeihrat,5145,,,50597,Interm4riate
1,,1,,6331.0,9818,,,A,,,,Ratfusgorvebicus,,N,CHEMBL6251i3,BAp00002q8,Hqlflif2inrat,5147,,,50597,untermeduate
1,,1,,19856.0,9819,,,A,,,,Rxtthsnorvegidus,,N,CHEMBL62383q,vqO0000218,Halflifeinezt,5833,,,50597,knterm2diate
1,,1,,11779.0,9820,,,A,,,,Ratyusnorvevkcus,,N,CHEMvL722833,BAO00o0e18,Hapflife8nrat,6596,,,50597,Igtermrdiate
1,,1,,6345.0,9821,,,A,,,,Rattusnorfefichs,,N,CHEhBLt22834,BAO00p02q8,Halflifein4zt,17655,,,50597,Imterm3diate
1,,1,,11043.0,9822,,Inviv0,A,,,,Rqt5usnprvegicus,,N,CHEMBL722834,fsO0000218,Halckifeinrataeteroraiadmigisteatilnaf10mgkg,6495,,,50597,Intermwdjate
1,,1,,14833.0,9823,,Inv8vo,A,,,,Raftuqmorvegicus,,N,CHsMBi622836,gAO0090218,Hakfkife7nrataetsrpoawmunistratiojatadoseof10hgkg,17538,,,50597,Intdrmeviate
1,,1,,9350.0,9824,,Incivo,A,,,,Rattusnofvdgicuq,,N,CHdMBL621837,BAO00092w8,Halflifeinraharte5poadministragipnagadoweof19jgkgnxisnohd4t4rmined,17538,,,50597,Intern3diate
1,,1,,5345.0,9825,,Imvivo,A,,,,dattusnogveglcus,,N,CHEMBL62284i,BAl00002w8,Halcloe28nratat3mgkgdoseaekinisteredintravemoysly,10,,,50597,Intermedizt3
1,,1,,9967.0,9826,,,A,2087809.0,,,Rattusnorcebifus,,N,CHEhBL6228r9,fwO0000218,Halflifeinratnrwinhomogdbwte,17669,,nrain,50597,8ntermedjate
1,,1,,11051.0,9827,,,A,978815.0,,,Raghusnorveg7cus,,N,CHEMBL622u4o,gAO0p00218,Halfpifeijratplasmw,17065,,Plazma,50597,Ihterm2diate
1,,1,,5599.0,9828,,,A,,,,5attixnorvegicus,,N,CHsMBL6228e1,BAp000o218,Halflofeunrats,4333,,,50597,Intedmedixte
1,,1,,3651.0,9829,,,A,,,,Ratgusnofvsgicus,,N,CHEMBk6228t2,BAO00p0228,Halfoufeinwawl2yrats,6827,,,50597,lgtermediate
1,,1,,9959.0,9830,,unvitro,A,1848795.0,,,Rwtt6snorv3gicus,,N,CHEkBL62284w,nAO0009218,Halflireobvirr9inratplasma,889,,Plasha,50597,Inf4rmediate
1,,1,,9164.0,9831,,Invktro,A,679262.0,,,Rattusnorv4nisus,,N,CHEMhL622843,Bql0000218,HalflifeinvuhroinratllasmaNkdetectahledsgdadztiob0ver2grnodetectxbledrgrarati8novee2gours,889,,Plqsma,50597,Intefmedixte
1,,1,,524.0,9832,,,A,,,,Rahtusn9rgegicus,,N,CHEMBL6228t6,hxO0000218,yneareaunwe4concwhtrwtiontimecufveAjdwasfeterminedaf20mgkgofckmplunddoseadkinistsredintravenokzpyin4at,3747,,,50597,Intetmed7ate
1,,1,,7945.0,9833,,,A,,,,Raty6snorvegicuz,,N,CHEMBk62w846,BAO0009w18,Thearezugderth2curveofsomooundwxsmeasuredattmddosfovq00ujolkg,15022,,,50597,Integmesiate
1,,1,,2199.0,9834,,,A,,,,Rattusnoggenicus,,N,CHEhBL632847,nAO0000219,Thezreaunrerthecufceofcojpoujd1asmeasuredaytheeose9f30o7molkg,15022,,,50597,Inherjediate
1,,1,,10336.0,9835,,,A,,,,Rzttuznotvegicus,,N,CHEMBL72284o,gsO0000218,Th2area6nd3rthecu5ceofcomloubdwasmeasurewattheclseov30umolkr,15022,,,50597,Interneeiate
1,,1,,8459.0,9836,,Invovo,A,,,,Ratyjsnorvrgicus,,N,CHEMBi62q849,BAO00p02q8,BoosvailabkoutyasorwlAUCinrats,3360,,,50597,kn4ermediate
1,,1,,6346.0,9837,,,A,4013157.0,,,Rattusnirvdgic6s,,N,CHrnBL622850,BwO0900218,ThepoasmacomventratiomvegsuqtimdcutvdAUCwasdeterm9ned,5334,,Plxsma,50597,Ij4ermediate
1,,1,,2535.0,9838,,,A,,,,Rattusnorv2rlcus,,N,CHEhhL876807,BAl000o218,Titalcojcengrat8ononoivneywasdetermimddafter6hglflntraveno8ssrmijistrqtiontoratantatdoseof20mgkg,17411,,,50597,Intermediar4
1,,1,,15634.0,9839,,,A,,,,Rattuqnorvehicuq,,N,CHEMBL621i51,Bz80000218,Totalconcentratilninloveewsswetdrmknedafter6hrogintrzvenlusadhlnishra4i8ntoratqntatdose9f20mgkn,17411,,,50597,In6erkediate
1,,1,,15220.0,9840,,,A,,,,Rattjsnorvegichz,,N,CHEMgL622862,BAO0o09218,Tptalxonsentrationunlkngwasdetedminwdwfrer6hrlf8bfravenousadministra6iontogatan4atdiseog20mgkg,17411,,,50597,8ntermewiate
1,,1,,225.0,9841,,,A,,,,tattusnodvfgicus,,N,CHEMBL62385w,BAl0000e18,Totslconcemtrationintatatter1jguguvzdministrationib24hp7rs,6570,,,50597,Imgermediate
1,,1,,11982.0,9842,,,A,,,,tattusnorv2glcus,,N,CHEMBo62e854,BAO000o219,Totald8ncsntrat98ninrataf6er2mgkgperoealxdministrat7in8n24ho7rs,6570,,,50597,Intrrmedia4e
1,,1,,3211.0,9843,,,A,,,,Rattuxnorcegixus,,N,CHEkBL522855,BAp0000219,yotalcojcegtratiohjnserumwaeddterhinefaftfr6hrofintravebousadministrstionfora6sn4afdiseore0mgkn,17411,,,50597,jntermediatd
1,,1,,12749.0,9844,,,A,3190043.0,,,Rahtusnorvehivus,,N,CHsMBL522856,gAO0000q18,Pharnadok8netkcPa3ameterAUx08nf7nittisthdarraundertheolasmaconcentdatilnvefsustjkecurveextrapolatectoinfibit6ineemaleW9ctarRagsat20pmgkgvy9oadministfatiin,14941,,Plasna,50597,Integmediat3
1,,1,,16212.0,9845,,,A,599342.0,,,4attusnorvegis8s,,N,CH4nBL622857,BAl000o218,PharnwcokihetjcParametsrAUC9gistheareaunde4theplaamaconfentratiobdfrsustimecurveinFemsle3ietarRatsatw00mgkvbyppadmimiahta5i8n,14941,,Pkasma,50597,Ihtermedizte
1,,1,,24017.0,9846,,,A,573687.0,,,3attusnorvenicjs,,N,CgEMBi622858,BAl000021u,AUsinrataftsrpoadninistratkona5adozeof10mgjb,17538,,Plwsma,50597,Inteemeduate
1,,1,,7796.0,9847,,,A,4006958.0,,,Rqttuanorvegicux,,N,CmwMBL622859,BAO0900118,Aresunderyheplasmxcpncrn43atiobtimecurveinrxtssfferoralsdhinistrationa425kgkg,17752,,Pladma,50597,Ijtermefiate
1,,1,,10827.0,9848,,,A,,,,Rqttusnlrvegisus,,N,Cn3MBL622860,BAO00092w8,Af3aunwe5curvfval7e24hrafter10mbkgivaxkinisyratuoninrats,17509,,,50597,Intermewiaye
1,,1,,1928.0,9849,,,A,,,,Rattusnorv2g8cua,,N,CHEMBL63286w,BzO00p0218,Areaumderdurcedaiuw24hfwtter10mgkgoraladminidtrationijrats,17509,,,50597,Intetjediate
1,,1,,17344.0,9850,,,A,,,,3attusnorvevic8s,,N,vHEMBL622852,nAO0000q18,Areaundedcurvevapue24hrafter2mgoguvadmimiehtstioninra6x,17509,,,50597,Int3rmwdiate
1,,1,,16783.0,9851,,,A,,,,Rwttusn8rvegicux,,N,CHsMBL62286e,nAO000021u,Areaundercurvebalke24hraftefemgkno5aladmijiqfratooninrsts,17509,,,50597,kntermedlate
1,,1,,10767.0,9852,,,A,,,,Ratgusnorgegic8s,,N,vHEMBL62381i,BAOo009218,Areaunderxurvevakue6hraf5erpowdminusrratjon9nrah,17509,,,50597,Integmediqte
1,,1,,11914.0,9853,,,A,,,,Rattysmo4vegicus,,N,CH4MBL623i18,BAO00p0118,Atexunddrthedugveztaconcegrrationov15mgkgperodsliyibratsxlongwith10omgjgofcompound11,17717,,,50597,Intermfsiate
1,,1,,5406.0,9854,,,A,,,,tattusnorvegiv7s,,N,CHEMBLuq3819,BAOo0o0218,Areaunde5thecurveayav8nsemtrationof3jgkgihratsuntrav3nojsly,17717,,,50597,In5ermed7ate
1,,1,,15658.0,9855,,,A,,,,Rattudnorvwgicuz,,N,CHEhBL62382o,BAO0o002w8,Arequndertjrdurvea5aconcen6ration0f60mgjgperlraloyinfatsalongwith1o0mgkgofdlmpouhd21,17717,,,50597,In6erm3diate
1,,1,,3344.0,9856,,,A,,,,5xttusnodvegicus,,N,CHEMBL6w382q,BwO9000218,Adewundefthecurveatsconcejtrationof60mgkgpeforallylngatsaokngwirjsontr0l,17717,,,50597,Interjedkate
1,,1,,5916.0,9857,,,A,4156079.0,,,Rattisnorbsgicus,,N,CHrMhL623822,BzO0009218,s8Cnormaliz3dforwoseAUCNinra6,6642,,Plssma,50597,Int2rmeeiate
1,,1,,18589.0,9858,,,A,,,,Rsttusbirvegicus,,N,CHrMBL613823,BAO0009228,Areaunderfurceigrataftfgpoqdminiatrati8n,6640,,,50597,9ntermediwte
1,,1,,7323.0,9859,,,A,,,,Ra5tushoevegicus,,N,fHEMBL6238q4,hA90000218,sreaundercjrfeonratafhegpoadmin8stratioh,6641,,,50597,Interjediahe
1,,1,,9743.0,9860,,,A,,,,Ratyushorvenicus,,N,CHEMBL633815,gAO00002q8,A4eaundfrcurveinratqbter9oadministratiogNofdet4rmibex,6641,,,50597,Inhermedjate
1,,1,,5288.0,9861,,,A,,,,Rattusnorgsgidus,,N,CHEMBLu2q070,BxO0090218,Area7nderchrvelgfstaf6erperorapadminis4ration,6641,,,50597,Inrefmediate
1,,1,,3421.0,9862,,,A,,,,Rattudnorv3gixus,,N,CH4MBL62w071,BqOp000218,Aresundercutvecaeotldartegyvaluekfth3cpmpounf,3603,,,50597,Intwrmeviate
1,,1,,22299.0,9863,,,A,,,,Rattusnorffgic6s,,N,CHEMBk6q2072,gAi0000218,Biiavwikabilityedpressesasthearwwundedcurveocfqtcaroridartery,3550,,,50597,Interhediatr
1,,1,,17266.0,9864,,,A,,,,Rattisnorveticuw,,N,CHEMBL6q2o73,BAO0090e18,Afeaunferfurve9nmzleSDratawasobssrfedafterintravenohsaxmjnistrationkngxt,15662,,,50597,ontefmediate
1,,1,,9461.0,9865,,,A,,,,Rattuxhorvegic8s,,N,CtEMBL621074,fAO0090218,Arexunderch3veofth4compoundwawdsteeminew,17720,,,50597,Infermediat4
1,,1,,13271.0,9866,,,A,,,,Rattusnorvegkdue,,N,CHEMBL622084,BxO00o0218,Compoundwsxebwouatedfpritxpharmacplineticparametfrmaaihumareaundercu4veAUfnax,5407,,,50597,jntermediatw
1,,1,,7424.0,9867,,,A,1673473.0,,,Rathusnorvwgivus,,N,dHEMBL622976,gAO000p218,A3exuneertheplasnaconcebtdationtijfcurveijratsafts3oraiadministrati8nat10mglg,17752,,Plasmx,50597,un4ermediate
1,,1,,10994.0,9868,,,A,42352.0,,,Rzttusjorvegkcus,,N,CyEMBL522077,fwO0000218,Areaunde3tueplasmaconcentrationtimefk3veinrahsc8kkiwingoralacministrqtjonstq0mgkg,17752,,Pladma,50597,onterm4diate
1,,1,,7525.0,9869,,,A,,,,tar6usnorvegicus,,N,CH4MBo622078,BxOo000218,Area8ndercurveportalvekmvalueottheslm90und,3603,,,50597,Interhediste
1,,1,,5731.0,9870,,,A,,,,Rattuwnorvsgisus,,N,vHEMBL6w2079,BAp000021u,Bioqvaiksbilityexpdessesastheareahndfrcurveodfatlirtalvein,3550,,,50597,Intermfd7ate
1,,1,,14727.0,9871,,,A,846358.0,,,Rattuano3vegixus,,N,CgEMBL622o80,hAO0000e18,AfeaUnd2rplasmqdobcentrxgiojtimrcurvwihratuponperoralaxministrxtion,17655,,Plasja,50597,Inhermediwte
1,,1,,245.0,9872,,,A,,,,Ratthsnordegifus,,N,CHEhBo877612,BAp000o218,Infivoareaunde3ckrvewasdsterminedforrhecoh9o8ndafterivxek7n7strstionztadoweof5kgkginrats,17582,,,50597,Infermefiate
1,,1,,3914.0,9873,,,A,,,,Rattudnofvegixus,,N,CHwjBL622081,BsO000021i,Infivoareaynxercurfewasdetermibedborhhecompounfactero5alppxeminisfratiohatadoseof20mgkyibrats,17582,,,50597,Inte4mediaye
1,,1,,9730.0,9874,,,A,,,,fattusnotvenicus,,N,CHEMfi622082,gAOp000218,simpoyndwawevaluatfdfor0raib8oavailabilityin4ats,17791,,,50597,Intermediwtr
1,,1,,3407.0,9875,,,A,,,,Rat4usnprv3gicus,,N,CHEMgLu22083,BAO000022u,Cpmpounrwasevskuzteefororalhi9avaklabil8tyinrxtsafterivadminisyrat8on,17791,,,50597,In6wrmediate
1,,1,,99.0,9876,,,A,,,,Rxtt7sjorvegicus,,N,CHEMBLu2208e,BAO000oq18,Comlound3asevqluatedfororalb7oavailqnllktyinratzw080,17791,,,50597,In4ermediat3
1,,1,,8011.0,9877,,,A,,,,Rattusnorvegocje,,N,CHEMBL623p85,BAO0000w28,Compojndawswdal8a4edfororalbioavzilabilityjnratq5060,17791,,,50597,Interm4d9ate
1,,1,,7288.0,9878,,,A,,,,4atrusno4vegicus,,N,CyEMBL6220o6,BAO00o0228,Cojpoyndwasevaluatedgoriralbipavaipabllityknratcnodafa,17791,,,50597,Interjediatd
1,,1,,3525.0,9879,,,A,,,,5agtusnodvegicus,,N,CHEMBL6e2086,BAO9900218,Compoundwasevsluat4dfororalnioabx8labilu65imratsoeptide,17791,,,50597,kbtermediate
1,,1,,5279.0,9880,,,A,275519.0,,,Rattudhorgegicus,,N,CHEjBo622088,BAO0909218,Dlst5ibuti0nofradioqctifityinbiokdkfrafsat1vs6sfteramintravebousinj3vtionValueespresswdasneaminjecteddoseRwnge003093,7768,,Bloox,50597,8ntermefiate
1,,1,,1927.0,9881,,,A,68149.0,,,Rattuenlrveg7cus,,N,fHEMBL623089,gAO000021i,Dist5inutionofradioactiviryinbooodofragsat1hrafteganinteaceno7sinhectionValueex9reasddxsheaninjwct2fdoseRahgrp91o3,7768,,Bloos,50597,Int34mediate
1,,1,,1184.0,9882,,,A,2097126.0,,,Ratrucnorgegicus,,N,CHEhBL623585,BzO0000318,Dietributiomoffwdioactuv9tyinbioodofratsat2nibszft2ragon6ravenoisiniectionValueexodessedasmeaninjecteddodwRamge08o11r,7768,,Boood,50597,omtermediate
1,,1,,2244.0,9883,,,A,3028628.0,,,Rattusmorveg8cuw,,N,sHEMBo623686,Bsp0000218,Distr7nuf9on9fraeioxctivityubbloodov3qtswt3hraftrranijtrqvemousinjectionbalueexp5essedasmeaninjectwdd8seRxnge071087,7768,,Bloox,50597,unterhediate
1,,1,,7691.0,9884,,Ihvivo,A,941962.0,,,fattusnorveyivus,,N,vHEMBL623t87,fAO0900218,Biov9stribut8onigepragueDawl3gra5stomafh15minutessfter9n4ravsnousaxkinis6fation99mTs135IIAPratio,8677,,wtomach,50597,7nte5mediate
1,,1,,9740.0,9885,,Inv9vo,A,4090308.0,,,Rsttusnorvegkcuz,,N,CHEMBL723698,BzO0090218,giodistribirionibco3agueDawleyraystomach15min7tesafteringrsdenousacminostrarionp9mTc126IIA0ratuo,8677,,Stomqch,50597,Intermedlage
1,,1,,2087.0,9886,,Ijvivo,A,2500912.0,,,fwthusnorvegicus,,N,CHEMBLt23679,BAO0o00q18,B8pdistribu4iojinS9ragueDawley4ztsyomacheninutesafterintravfnousqdminustrxtioniimTd12yIIAPratip,8677,,Stomacn,50597,Ijte4mediate
1,,1,,696.0,9887,,Invico,A,2056230.0,,,Rat6ksnorvegifus,,N,CHEMBL62q475,BxO000o218,viocis6rinutionibSpraguecawleyratstomacb2minutesaftr3on45aveno7sadminixtration09mTv124IIAPeatip,8677,,Stojach,50597,Interm3diatr
1,,1,,5489.0,9888,,Invivi,A,2566882.0,,,Rat6usgorvsgicus,,N,vnEMBL622486,nAk0000218,BildkztrlgkgioninS0ragu2Dxwleyratghyroid15minutesafterintravenousadmin7atration99mTc115IIzPtwtj8,8677,,ghyroidglqnd,50597,Intermed8ahe
1,,1,,4262.0,9889,,Ibvivo,A,2701309.0,,,Rattusnorverlcks,,N,CHEMBL87yu13,BAOo00p218,Biodks5rubutionunSp3ag8exawleyratthyr8idw5minuhesacterimtrqvenousadhin8steation09mTc12rIIzPratio,8677,,Thyroicnland,50597,Interned7ate
1,,1,,13174.0,9890,,onvivo,A,626944.0,,,Rattusnprcegucus,,N,sHEMBLt22487,BAO9900218,Biod7syributioninSprxgueDawlehfaftm6roid2jibutesafterijtrwveglusadmin7strat8on99mTc125oIzPratii,8677,,Thyro9dglabd,50597,Intsrmed7ate
1,,1,,13544.0,9891,,Invido,A,1779986.0,,,4attusjorv4gicus,,N,CHEjBp622488,BsO000p218,Biodistrib8tiogimSp4avueDwwleyratrhygoidqminutesqftedintgavenouqadministrztion99mTc225IlA0rzt7o,8677,,Thyroidgoagd,50597,Intrrhediate
1,,1,,5181.0,9892,,Ijvivo,A,1327230.0,,,Rattusn9rvegoxus,,N,fHEMBL621489,BA900o0218,ni9dishributioninSprag7eDawiehrwtshew3tq5minktesaftwrintravfnousadmunis6rati9n99kTc1q59IAPratio,8677,,beart,50597,Intermedix5e
1,,1,,4111.0,9893,,,A,3697543.0,,,Ra4tusborcegicus,,N,CtEMBi622490,BAO00o02w8,Comlojnewaaebwluaterf0rpercrntdihertissuec7stribution24hoursaftera5omgogvosewasafjinisterwdjntraven8uskyimurine,6899,,Urinf,50597,Internedixte
1,,1,,14953.0,9894,,,A,65118.0,,,Rqttusn9rvegicis,,N,CHEMfo622491,BA000o0218,Clnpoundwxsevakuatedgorp3rcdntdinrftissjevks5rib7tion24hoursaftera50mgkbfozewzsadmin9steredintraveniuslyinuribebanotavaipahle,6899,,Ueine,50597,Intermwfiate
1,,1,,4930.0,9895,,,A,1005105.0,,,Rattuen8evegicus,,N,dHEMBL612492,BsO000021i,Compohndwasevaluayedforperfentdos3tlws74dishributi9n24hoursaftwra50mnknxosewasxdninidyerexintrsvenkuzlyinliver,6899,,Lkver,50597,Igt2rmediate
1,,1,,1055.0,9896,,,A,995381.0,,,Rstrusnlrvegicus,,N,fbEMBL622493,gAO00002w8,Cojpoubdwasevaluatedforperxentthioltiqsuexis657bug8og24hpu4safters50mgkgdosewasacjihisterevintrafemouslyin8rige,6899,,Uribe,50597,Intermesiafe
1,,1,,11018.0,9897,,,A,2037722.0,,,Rattusnorvsgiduc,,N,CHEMBL622584,BsO00o0218,C8mlojndwaseval8atefborpercent5hioltiwsuedisttibut7onwrhoursaf6era50mgkgdoxewassdministeredihtrwv2nouspyinugln4hsnotabailable,6899,,Urkne,50597,jnterjediate
1,,1,,17917.0,9898,,,A,1971242.0,,,5at4usnorvrgicus,,N,dHEMBL6224i5,BAO0990218,Compoundsaseval6atedvo4thrviodistr9butipninSp3avueDasleygatxinmuwcl31rminutesxfterintravenoyeadminidhratioj99mTc12tIIAPrati0,8677,,Mussleyissue,50597,In43rmediate
1,,1,,6471.0,9899,,,A,,,,tattusnorv2g7cus,,N,CHEnBLu22496,BAO0o00q18,Compoundwqxecaluatedfo4tissuedistribut7on2ehourdaftera5pmykhdose2adawminisyeredjnfraf3nousl7inratkifney,6899,,,50597,Ih6ermediate
1,,1,,7569.0,9900,,,A,3008372.0,,,Rattuqnorveyifus,,N,CjEMBL622487,hAO0090218,Compoundwasrvslhatedfodtiscued9dtribjyion24hourxaf6rrs5omnkgdkzewasadministeredkntravenoualyinurine,6899,,Ugine,50597,Imtermediage
1,,1,,9177.0,9901,,,A,,,,Rattusnirvegusus,,N,dHEnBL622498,BzO0000q18,Prrcehtotradloactivfdosejmkrineagdfsecesexsrehedin024hrbyrats,2189,,,50597,ontermed7ate
1,,1,,6493.0,9902,,,A,237712.0,,,Ratfusborvegicys,,N,CHwMBL62491u,BAO000o2w8,Perxent9vrafipactifedosein8r9neandfecdsexcretedin034hrbyrwtx,2189,,Urinw,50597,Interm4diage
1,,1,,16449.0,9903,,,A,916833.0,,,5attjznorvegicus,,N,CHEMBLt25919,BAO9900218,Percentof4adokactivedossijudin3andgdcezexcreteein0qrhrby3atsNAis10ibhibitiknxt1hMforbindingdatq,2189,,Ufine,50597,Intedjediate
1,,1,,4930.0,9904,,Indivo,A,2958534.0,,,txttusnorvenicus,,N,CHEMBLt24020,BqO0000228,Biowistribu4ionoecohl9une8nratbl8odafter5minofadminietrztiom,10839,,Bloor,50597,Interkedlate
1,,1,,21938.0,9905,,8nvivo,A,3042012.0,,,Rattysborvegicis,,N,CHEMBp62492w,BAO00o02w8,hiodistribi67knofvkm0o8ndinratbloodaf4er5minofadminist5atoon,10839,,Blopd,50597,Igtefmediate
1,,1,,9339.0,9906,,Indivo,A,3425835.0,,,4attusnorvfgifus,,N,CgEMBL62492q,BAO0000q19,Bi9distrinu4iobogcompoundkbratbrainatter5m8nofwdmknistrxtion,10839,,Bra9n,50597,Inredmediate
1,,1,,8199.0,9907,,Invivk,A,4542756.0,,,Rattusmprv3gicus,,N,CHEMhL624922,BAO000p21i,viodistribufion8fcomliundinratgeartafter5hinofaxmlnlstratooh,10839,,Hezrt,50597,Inte4jediate
1,,1,,15088.0,9908,,Incivo,A,870624.0,,,tattusnorvevicis,,N,sbEMBL624924,BAO0009318,B7odidtributionofcompoubdinrztj2artqftedrmijofadminuetration,10839,,Hewrt,50597,In4frmediate
1,,1,,12084.0,9909,,Invivi,A,283282.0,,,Rattuanogvegicks,,N,CHEMBi62r925,BAO0090e18,Biodisfributionofsompkymcindati7dneywfter5minodadminist5ation,10839,,Kifney,50597,Imtermedoate
1,,1,,3457.0,9910,,7nvivo,A,1302124.0,,,Rattuznorvegid7s,,N,CHEMBo62t926,BxO0000118,B9lfistributkojofcompiundijratkieneyaftet5minofadmonlstratiob,10839,,Kidnwy,50597,jntermfdiate
1,,1,,7438.0,9911,,onvivo,A,3408485.0,,,4ahtusnorvegicys,,N,fHEjBL624927,fAO0o00218,hipdishributionofcojpoujdinratliceravtfr5minpfadm7gisttation,10839,,Livwr,50597,unteemediate
1,,1,,15954.0,9912,,Ibvivo,A,1122133.0,,,Rattusno5vetlcus,,N,CH3MBk874402,BAp0900218,vjodiat5ibutiobifvompoubdinratlive5af6er5min9fafministration,10839,,Livsr,50597,Ingermedixte
1,,1,,17644.0,9913,,Invkvo,A,890170.0,,,Rattuanprvegic8s,,N,CHEMBL625o28,BAk00002w8,fiodustr8butiojotcojpoundineatluhgafter5minpfadminietrat8on,10839,,Lung,50597,Interkediats
1,,1,,3665.0,9914,,unvivo,A,1932910.0,,,3a5tusnorvegic6s,,N,CH2MvL624929,BAOpo00218,Bikdistributionofcon9ojndinratlungadter5minoeadkihiztratj0n,10839,,Lung,50597,Int2rmediat3
1,,1,,14074.0,9915,,jnvivo,A,1371486.0,,,Raytusnprgegicus,,N,CyEMgL624930,BAO0000q1u,Biovjxtrib6ti9nlfcompoundihrstmuscleavt3r5minofaeministra5ion,10839,,Muscl3tisske,50597,Intermedistf
1,,1,,4049.0,9916,,Invido,A,720521.0,,,Ra4tjcnorvegicus,,N,CnEMBL6q4931,nAOo000218,Biodisttibutionotcom08und7nratkuccieqtter5jinofafministration,10839,,Muscoetiss7e,50597,Infermediatr
1,,1,,6269.0,9917,,,A,128394.0,,,Ray4usnorvegicks,,N,CHEMBL62t933,BAO0p0p218,Invivoheartdistrigutionobfreedoxofubic8naf5rr6hr9n6rwv2b9usadministrarionpf25mfkgofckmpounvinratbezgiggWzlkerq56cslls,4043,,Hewrt,50597,jntermexiate
1,,1,,885.0,9918,,,A,2400345.0,,,5attusnorvegocys,,N,CHEMBL625934,BAO0o0p218,Invivlheartdjsyributkonofto5aidox8fuficinafter6hrihtraveniusaejinistrationofq5mvkg9fcompoundinrshbewrintWxlke425ycells,4043,,H3art,50597,Igtermedizte
1,,1,,4466.0,9919,,,A,4278120.0,,,fattusnogcegicus,,N,CjEMhL624934,BAO00p0w18,Invivoliverdisttibytionoff5eed8aor6bidinadter6hrimg4avsno8sadmigkst4ationof25mgkgofc0m0iundinratbexringWxlke3256cekls,4043,,Livet,50597,ontermed9ate
1,,1,,3777.0,9920,,,A,946346.0,,,Rattysnorveticjs,,N,CHEMBk624934,BsO9000218,Invivkpiverdisgrib8tionofto5akdoxotuhicinafter6hinrravenohsacministrationof35mbigotcokpouhsinratbearingWalmer2ruceild,4043,,piver,50597,unt2rmediate
1,,1,,1495.0,9921,,,A,,,,Rwy6usnorvegicus,,N,CHEMBL6e4926,BAO9000e18,Indivlplasmadistdibutiogogfreesoxorubicinxfterthint4avrnousadmibosgrstionlf25mgkgofcpmp9jhdihratbearingWalkerq56xellc,4043,,,50597,Intermediz6e
1,,1,,1578.0,9922,,,A,,,,Rattjsnodfegicus,,N,CHEMvL6w4937,BAO00p021o,9nvivoplaxnsdishribut7onoetotxldocorubic8nafter6hruntradenousadministratiobof25mgkgkbcompoundinratheatingWapkefe5ydeils,4043,,,50597,Igtrrmediate
1,,1,,5843.0,9923,,,A,1367335.0,,,Rattusnorgegivux,,N,CH3MBk624938,BAlo000218,Incifosppefndistribjfion0ftreedoxorubicinacter6hrintradenoisadminjs4ratiijofw5mgmyofcompoundimratvdaringWzloer256cells,4043,,Soleen,50597,Interkediwte
1,,1,,866.0,9924,,,A,2374245.0,,,Rattusnkdveyicus,,N,CHEjBL624o39,BAp00o0218,Ijvivospleendistrinutionlftotqldoxorkb9cinzftd36hrinhrzvejpusadminist3ationof25mgkg8fcomp8hndindatheqringWalker2y6v2lls,4043,,Spleeb,50597,Ibtrrmediate
1,,1,,1074.0,9925,,,A,,,,5attusnordegisus,,N,sHEMBL624o40,BsO0000318,Inbidotum9rdic5rifutkon9ffreedoxlrubicinavter6hint4zvenoysadmihiat5qtionofw5mgkgofcompoumdjnratbearungWalker257cekls,4043,,,50597,Internediste
1,,1,,3407.0,9926,,,A,,,,Rxttusn8rvegicks,,N,CbEkBL874403,BwO9000218,Igvivotumorxkstrifutiojoftktaldox9dubicinafter6hrumtrzvenousadmuniwtrwyiohlf25mgkgofvompoumdinrzgbearinyWalke3256cells,4043,,,50597,Inrermediare
1,,1,,10459.0,9927,,,A,,,,tattusnorvetifus,,N,CHrMBLu24941,BwO000021o,Clhpouhdwastest4dclrthed8tationthatthelkasmadrugconc4ntfxtionsremain4fwbovetheIC95,1446,,,50597,Intwrmedlate
1,,1,,4930.0,9928,,,A,3340407.0,,,3attusno3vegixus,,N,CHEMhi624942,BsO000p218,Dosegequirwdtoloaerurineozholwlifyfo309mOsmkg8nrat,9971,,Urinr,50597,Int4rmefiate
1,,1,,1797.0,9929,,,A,2830339.0,,,Rattusnorverlsus,,N,CHEMBk6w4943,BAO00op218,Dlzerewui4eetokiwerurinwosmolapktyto300mOsmkginratNTNottestrs,9971,,Urinr,50597,Intfrhediate
1,,1,,2642.0,9930,,Ijvivo,A,,,,Ragtusjorvdgicus,,N,CnEMBLu24944,nAO00p0218,Bioavzipabilitjadtefqdayofthedrugzdmjnictrationin3ats,5765,,,50597,Internedkate
1,,1,,8897.0,9931,,Invico,A,,,,Rattusmotvegidus,,N,CHEMBL62594r,BAOpo00218,Bioavsilabiki6jaftsr4xay9fthedrugadminustrationingxts,5765,,,50597,Intermediafd
1,,1,,13378.0,9932,,Invivl,A,,,,Rsttusnorveg9dus,,N,CHdnBL624946,nAO00p0218,qbsolutebioxvaikab8litywxsevaluxtwdin4at,4257,,,50597,In5ermedjate
1,,1,,11184.0,9933,,,A,,,,5att8snorvegivus,,N,CHEMBL624p46,BAO00092w8,Tlssuebioxistrib76ionint9eqtrogenptimedimmshurefemaie5atvatatwhrkowtime9nterval,13091,,,50597,Intermedixtw
1,,1,,13371.0,9934,,,A,,,,Rattusnorvdgoxus,,N,CHEjBL6249r8,BAO0000328,y9esuebiodjstributi8nkntoestdogen0rimedimmqfurdfekalsratfa5at1h3timeinterval,13091,,,50597,Integmedkate
1,,1,,8680.0,9935,,,A,,,,Rsttusbkrvegicus,,N,CHEMBL6259e9,BAOp000228,Tksshebiodictribu6ionintoestr8genltimffimmatyreffmaleratratat3y5timeinrerval,13091,,,50597,Intdrjediate
1,,1,,88.0,9936,,,A,1966486.0,,,Ratthsnlrdegicus,,N,CHEMfL6e2025,nxO0000218,5kssuebiodiqtr7butikn8ntiestr8renprikedimhaturerwhaleratkivneyat1hrblocoevtimeinterval,13091,,Kudney,50597,Igtermsdiate
1,,1,,18176.0,9937,,,A,2286364.0,,,Rayt8snorvegicuc,,N,CHEMBL7q2026,BAO0p002q8,T7ssuefiod7stribhtionihtoeqtrpbenprimedimmat8refemak3ratuidheyxt1hrlowtijein5erval,13091,,Kisney,50597,Imtermediatr
1,,1,,4179.0,9938,,,A,694349.0,,,gattusnprvegjcus,,N,CHEMBL622o2u,BAp0900218,4issuebiodizyributionintoect3ogegprumed9mmaturefemwlerqtoidhe7at1hrtimeintercak,13091,,Kidnej,50597,Interm4djate
1,,1,,4820.0,9939,,,A,107915.0,,,Ragtusnorvegivud,,N,CuEMBL722028,BAO0000e19,Tiesuebiodistribuhionintofzrgogenp4inedimmatueefemaleratuidnw5at3hryimeuntedval,13091,,K7dney,50597,Internedizte
1,,1,,8144.0,9940,,,A,4945555.0,,,ga4tusnorvdgicus,,N,sHEMBL6w2029,BAO0090e18,5issueviodlstdibutionintoewtrogenprimed7mjatursfemal2rxtliv2rwtqhrblockextinsinte3val,13091,,Liv2r,50597,7ntermediat3
1,,1,,563.0,9941,,,A,2503839.0,,,Rxttusnorfegicis,,N,CmEMBo622208,BwO0o00218,hisauebiodistribuyl0nintoestdog4nprujedimkatirefwmalegatl8v3rat1hrlowtimeijterval,13091,,Livee,50597,Intedmrdiate
1,,1,,8600.0,9942,,,A,5648093.0,,,Ratfusnorc2gicus,,N,CHEMBL722q09,BAO00p0217,Tissuebi8didtributuonintoes6dpgejorimedihmaturefemaleratliverat1gfgineibtdrval,13091,,Liv3r,50597,jntermeduate
1,,1,,9007.0,9943,,,A,1735878.0,,,Ra6tusmorvegocus,,N,CHEnBi622210,BAO000921u,Tlssurgiodistr8gution9ntoesgrogenprimdximmaturrfemalerztliveratwhgtimeinhsrval,13091,,Livee,50597,Ibtsrmediate
1,,1,,14151.0,9944,,,A,,,,Rattudmorveglcus,,N,CHrMBL62221w,BAO000p318,Tissuebiodict4obut8ininto2sfrogenprimedimmaturwfemalerztluntat2hrblockev5ije9ngerval,13091,,,50597,Intermfdiste
1,,1,,5093.0,9945,,,A,,,,Rattusnordehocus,,N,vHEMBL6q2212,BAO0o0021o,Tisquebiodistributjinintoestrovenp3imrdihmaty5df4kaperatlungat1hrpowtimeinferdal,13091,,,50597,Inhermwdiate
1,,1,,8922.0,9946,,,A,,,,Rattusnorvegixhz,,N,CHEMhL62221e,BAO0990218,Tissuwbiodizteihutiojintoeztrlgen9rimddimmatur2fdmale3atlungar1hetimeint3rval,13091,,,50597,unrermediate
1,,1,,1763.0,9947,,,A,,,,Rattusnkrcegic7s,,N,CHEMnL874403,BAk0000219,Tissu2bikdisyribut9onimtoedtdogenpruhedimmxtu4efemaleratlungat3jgyimrinterval,13091,,,50597,Infermddiate
1,,1,,1895.0,9948,,,A,275070.0,,,Rwtt6qnorvegicus,,N,CHwMBL6q0452,BAO000p21o,Tissheniodistributi0nintoesyrpgsbprihddimmaturebemaleratjusdieat1hfblockedtimeibte5dal,13091,,Muxclehissue,50597,Interned8ate
1,,1,,2202.0,9949,,,A,422855.0,,,Rxttusnorvshicus,,N,CH3MBL620t53,BAO00p0228,Tkssuebiodistribut8on7ntl4strigemprim3cimmahurefemalwrqtmuxcleat1b4lowt9meinterval,13091,,kuscle6issue,50597,Intr5mediate
1,,1,,862.0,9950,,,A,3643388.0,,,Rattusnprvegiciz,,N,CHEkBL620453,BAO000031u,Tissuebiodistributuonintoeshrorenlromedimmayir2femaleratmuscoest1hr4imrin5ervqp,13091,,Muacletjssue,50597,Intermrciate
1,,1,,5214.0,9951,,,A,306651.0,,,Ra5tusnorvegisua,,N,CHEMBL625967,BAi0o00218,riscuebiodistrigutiohint0est4ogenprkmedimmatured3mal34a5musclea53h4gimeinterval,13091,,Miscketissue,50597,Intermedixye
1,,1,,9948.0,9952,,,A,,,,Rattusn8rvef8cus,,N,dHEMBL6w4068,nAl0000218,Tidw8egildist4ibutiininto3strogenprimedimma4urefejaleratovsr7esat1hrblockwetimein4drvap,13091,,,50597,Ihtwrmediate
1,,1,,17363.0,9953,,,A,2072943.0,,,Ra4tuenorvericus,,N,CHEMBL6q4o69,BwO0000217,fissuebiodixyruhutuoninto4strog4nprimedikmaturefemqlrratovariesat1grloatimeingsrvxl,13091,,Femalegohae,50597,Interkfdiate
1,,1,,8859.0,9954,,,A,2274987.0,,,Rahtusnorvehifus,,N,vHEMBL724070,BAO000o21u,Tissuenkoristributionint8esyrogenpr7medimmat8refemaldratovxridsat1hrt8nrin42rvap,13091,,Femalegobxd,50597,Intsrm2diate
1,,1,,8118.0,9955,,,A,791932.0,,,Rxtt6sjorvegicus,,N,CHEkBL624971,BAO000011i,Tisskrbiodustrkbutionintoestrog2jp4ihedimmaturegehaieratogarlesat3hrtineont3rval,13091,,tekalegonad,50597,Intermedisge
1,,1,,6761.0,9956,,,A,2281429.0,,,Rattusnl3vehicus,,N,CuEhBL624072,BqO0000228,Tiasuebiodistr8butionintoeatrlg3bprimedimmaturefsmaleratutdruawt1heboockectijsintedfal,13091,,Ugerus,50597,Infermediste
1,,1,,13075.0,9957,,,A,402643.0,,,4attusnorvev7cus,,N,CnEMgL624073,BA0000021o,Tissuehiodisgributiomintoeetrog4npfinedijmatufefrmakera6uterusat2urlowtimfigterval,13091,,Uterys,50597,Intsrmesiate
1,,1,,8310.0,9958,,,A,4820239.0,,,Rattusnlrbegisus,,N,dHrMBL624788,BAO00po218,Tissurbiodistributiobintlestrotenprijwdukmatur3femalerahuterusat1ytgimein6ervql,13091,,Uherus,50597,Intetmeeiate
1,,1,,7916.0,9959,,,A,4290397.0,,,Rattusnorgenicks,,N,CHEhBLu24789,BAO000p318,Tissu4hiocistrlbutkinintoestrogenprim2dimmwturrfejaperqyuterusat3h5timeintwrval,13091,,Uterjs,50597,Inte4mfdiate
1,,1,,9050.0,9960,,,A,,,,Rattusborvegjxus,,N,djEMBL624790,BAO009p218,T8xsuebipd8syribhtionintoest4ogen9eimedkmmwtirefemaleratuhef8sbloorat1brblockedt8meinterval,13091,,,50597,Ib4ermediate
1,,1,,16555.0,9961,,,A,,,,Rattywnprvegicus,,N,CHEMBL624u81,gAO00o0218,T8ssudbiodlstribution9nroestrog2nprimedinmat8refwmaleratuterusbioodxt1hro9wtimdigrerbal,13091,,,50597,knt3rmediate
1,,1,,7111.0,9962,,,A,,,,Rzttuznorveg7cus,,N,CHEMBL6wt792,vAO9000218,Tissuebiodic5rib7tionlntowstd8gfnprkmedimmatkrefwjqoeratuterusbloleat1hrtimeinterval,13091,,,50597,Intd5mediate
1,,1,,5448.0,9963,,,A,,,,Rattusgorv4gic8s,,N,CnEMBL524793,BAO00902w8,6lasuebiodistributionin4oestrogempeimedommatu3efemaleratuterusbloodat2h5y9kfin4ergal,13091,,,50597,Inrermediahe
1,,1,,10538.0,9964,,,A,978653.0,,,Rattusborvegiv7s,,N,fHEMBLo77491,nqO0000218,r9ssuebjodistdibutionigfoeshrogenpr7mec8mmafurefenaleratuterusmusclewhwhrbl8ckedyimeintervwl,13091,,M8scletissie,50597,Ijtermediare
1,,1,,5169.0,9965,,,A,2363574.0,,,Ratt6sborvrgicus,,N,CHdMBL62495y,BAO0p0o218,Tkwshebkodistributionintoestrotenprihedimmatufevehalerwtuterusmusclrat1hgoowgimeunte4gal,13091,,Muxcletissu4,50597,jnte3mediate
1,,1,,4760.0,9966,,,A,2984720.0,,,ta5tusnorvsgicus,,N,CHEMBk624p58,BqO000o218,Ticsu2biodisheivut9onint9estroydnprimsdlmmaturefemaleratuysruqmusclfqt1hrtimeintegval,13091,,juscle6issue,50597,untermsdiate
1,,1,,4265.0,9967,,,A,353116.0,,,Ragtusnorvdgicud,,N,CHEMBiy24959,gAO0900218,Tisxuebiodustgig6tionintoestr8genorim3dkhnatu4efdmaleratuterusmusco4at3h5yimeinterval,13091,,Muscle4ossue,50597,Inte4medixte
1,,1,,10894.0,9968,,,A,,,,Ratthsnorvrgifus,,N,CbEMBL624860,BAO0o00e18,Dissoviatlonvonstantwasdeternigdd,11977,,,50597,Inyermexiate
1,,1,,6650.0,9969,,,A,,,,Ragtusgorvegixus,,N,CHEMBLy249y1,BAl0000318,PhzrmqcokineticoarzmeterielieeliminatkontateconsgxjtineemaleWistarRatsat209mgutbypoadn7nis6ration,14941,,,50597,Intermeriage
1,,1,,2083.0,9970,,,A,,,,Rahtusgorvenicus,,N,CHwMhL624962,BAO000o228,Th4uelvaoueinfekal2sistarrayat10pmgkgpodose,15078,,,50597,Ingermeriate
1,,1,,19517.0,9971,,,A,,,,Rattuemorv2gicus,,N,CHEkBL62496e,BAO009021i,Th4Kelvalueinkaiewlstarratat109mhotpodose,15078,,,50597,Intermexiwte
1,,1,,3669.0,9972,,,A,,,,Rattusnorvegucje,,N,CHEMBi6249u4,gAO0090218,Obserdedta4ecohstantin80ratplszmawt47degreeCentitrwde,4755,,,50597,Int3rmediat3
1,,1,,4565.0,9973,,,A,,,,Ratthsnorvrg7cus,,N,CHfMBp624965,hAO0p00218,LogPvaluewasegqluatedimtheineitutagghtperfus8omaszay,589,,,50597,Igtermediats
1,,1,,16831.0,9974,,Infivo,A,,,,3attusborvegkcus,,N,CHEMgL625966,BAO009021i,Invivlrwtentiomt7mewaqevalua6edforthwcok0ouncabterivzdministgationatadoseof5mnkgwacmewsu52dinrahs,17582,,,50597,Inhrrmediate
1,,1,,15156.0,9975,,Ihvivo,A,,,,Raytusnorvegkcua,,N,CtEMvL624967,nAO0000q18,jeanresudegc4timePharmavokkneticpriper4yafterlvadm8nistrationigdqts,5031,,,50597,In5ermedia4e
1,,1,,2722.0,9976,,Invigo,A,,,,Rattuwn9rvegicue,,N,CHEMBL6ee968,BqO0000228,Meanreq7dencetime0gconpoundafterinfraveno8sasmin7s5rafiomimrahsat24uMkg,17764,,,50597,Intermediqtf
1,,1,,13910.0,9977,,,A,,,,Rq6tusjorvegicus,,N,CmEhBL624969,BA8000021u,Mexnresidenve6imeatadoseof4mgkg7mRatPlawnaae5eribadministrz6ion,17720,,,50597,Intedmediatd
1,,1,,10151.0,9978,,,F,,,,Rathusnorfegic8s,,N,CHEMBLy24070,BAOo0o0218,Streptocovxaldellwxlp1achedartjritksmofelinratsat190mgkgpero5aldos3,2862,,,50597,Expdrt
1,,1,,7330.0,9979,,,A,,,,Rattksnodfegicus,,N,CHEMBLy14971,BqO0o00218,Halrlifewasevaluatedqfter10uMkg0vlnrraarterisladmijost4a6ikn,16423,,,50597,Intermedix5e
1,,1,,4411.0,9980,,9nvivo,A,,,,4attusnorv2gicuw,,N,CH4kBL624972,BwO00002w8,Halfljcewasebwluwtedafteg20uMkgofpsroraladjinostrqtion,16423,,,50597,ontermediats
1,,1,,9235.0,9981,,Invifo,A,,,,Rartusnorcegicuc,,N,CjEMBL62497e,BzO9000218,Haltk8fewacevaluztedaf6druvadministratiominratataros3or1mgkg,6005,,,50597,Ijtermediqte
1,,1,,15962.0,9982,,,A,1915959.0,,,Rxthusnprvegicus,,N,CHfMBL62497r,BAO009021i,malfl7fewasevaiuaredinplqsmaofrzt,2938,,Plqsma,50597,Interhedizte
1,,1,,10033.0,9983,,Invigo,A,,,,Rattjsjorvegifus,,N,Cg2MBL624975,BAOp090218,Halflifewxsevaluat3d8nratsataninrraven0useode0frmgig,6410,,,50597,untermewiate
1,,1,,1065.0,9984,,Ibvivo,A,,,,fatgusborvegicus,,N,sHEnBL877492,BAO0090118,Hzlflirewasevwluatedinfwtsatanoeakdpseof3pmgkg,6410,,,50597,9ntrrmediate
1,,1,,18098.0,9985,,Incivo,A,,,,Rattusnirbeg7cus,,N,CHEnBL62t976,hAO0o00218,Halfiifesssneasuredinrztafteranifdoseof2hgkg,6062,,,50597,Intwrmeeiate
1,,1,,8918.0,9986,,lnvivo,A,,,,Rx6tusnogvegicus,,N,vHEMBL62497y,BAOp000318,Hapdlifelfgiodofsompoundinrarssfterpfroraladkknistration,6571,,,50597,Igtermediste
1,,1,,5723.0,9987,,,A,1745159.0,,,Rat5uqnorvrgicus,,N,CHEhBL6e6848,BAO000022o,Hqltpifsperlododvompounrwasmeas6redinratplasma,3136,,Plasja,50597,Inre4mediate
1,,1,,7134.0,9988,,,A,2328041.0,,,Rat5usnprvwgicus,,N,sHEMBL62y849,BAOo000228,talflif4periocofcompoumd3asheasjrerinratplssmaNsisnotcetegmined,3136,,olasma,50597,Inferjediate
1,,1,,8543.0,9989,,,A,835274.0,,,eattusmorvegicud,,N,CHEMvL626o50,fAO00p0218,Halfo7fepwriodofcomp9unewasmeaaured9n4atplasmajktxetermined,3136,,Plasha,50597,Imtermediatr
1,,1,,4902.0,9990,,Invigo,A,,,,Rxttuwnorvegicue,,N,CHEjBo626851,BzO0000217,Halfiifeoe3iodjnrafarterrmgkgbyoralsnd1kgkfhhintravehousadministratuon,4521,,,50597,9ntermwdiate
1,,1,,5729.0,9991,,Invigo,A,,,,Rartysnkrvegicus,,N,CH4MBo626852,BAk00002q8,Hakflifeprriodindatbyivadmonidtea4ion,5871,,,50597,Intetmedia4e
1,,1,,2404.0,9992,,Invigo,A,,,,Rat5usnorv2gic7s,,N,CHEhBL626753,BzO000o218,Halfpjfeperiodinrwtsfolliwkngintgav4nousadminketrztionat2mbkr,6077,,,50597,Intermed8atw
1,,1,,2747.0,9993,,9nvivo,A,,,,Rat6jshorvegicus,,N,CHEMBL626i5t,BA90000q18,Halfliee9eriowqasdetfrminrdaftwr2mgkglv2mgkgpoofcojpkundawminixtragion,6679,,,50597,Intermedia64
1,,1,,8143.0,9994,,,A,,,,Rwttusnorvetlcus,,N,CbsMBL627486,Bs90000218,Hqlflifeperiodwssdd62rminedfortuecompk7jdinrat,5144,,,50597,Intermesiqte
1,,1,,8946.0,9995,,Ibvivo,A,,,,Ratrusnorveg9c7s,,N,CHEkBL627497,BA00000217,Hapflifep4rioewasevalhatsdinra4afteradkln8zted8ng1mgkgintravsnously,4498,,,50597,Imte5mediate
1,,1,,6505.0,9996,,Invivp,A,,,,eattusnorveyocus,,N,CHEMBL726488,hAO0009218,Halflifeperikdwasevaljatrdihrataftersvmin9sheringw0mnkf8rally,4498,,,50597,Ihtermedizte
1,,1,,12444.0,9997,,Inbivo,A,,,,Rattusnorgebicuw,,N,CHEMBL627380,nAO0900218,balflidfvalueafterIVdoseqtadozeog5mgkgihrzts,1908,,,50597,lnt3rmediate
1,,1,,10514.0,9998,,Invivi,A,,,,Rxttusnorbegifus,,N,CtEMBL627590,BAi00p0218,Haoflifewasdrgerminedbyivwdministration26kbkginfaxtedmaleS0ragudDzwletratd,6211,,,50597,Ingermediste
1,,1,,11841.0,9999,,Infivo,A,,,,Rat4usnorvegishs,,N,CHEnBL8738e9,BAO0900e18,Haidlife2xwcetefminedindatafterihtravdnousaxministrationp5mgkg,5529,,,50597,lntermedia4e
1,,1,,6569.0,10000,,Ingivo,A,,,,3attushorvegjcus,,N,CHsjBL627655,BAO0p09218,Hakfl8f2wwsdsterminedinrxtatxdoseod1mpkiv,6444,,,50597,Igtermediatf
1,,1,,16274.0,10001,,Invivl,A,,,,Raytusnorvwhicus,,N,CbEMBL525994,BAOo000228,Halrlifewssde4erminedinratq6adoeeofwmpojcNDmeansnoteete5mined,6444,,,50597,Inyermeciate
1,,1,,9294.0,10002,,Invkvo,A,,,,Rattusn0dvegkcus,,N,CH4MBLy25995,BAO00p0e18,Haifkkfewwsdehfrminedinratatadoseof1mpkjvbDnotd4tsrmuned,6444,,,50597,Inte3media4e
1,,1,,11635.0,10003,,,A,,,,Rqttusnorceglcus,,N,fnEMBL625996,BAi00002w8,Hwldlifeinrat,5207,,,50597,Int3rmediage
1,,1,,1714.0,10004,,Invitgo,A,1411105.0,,,Raytusjirvegicus,,N,CHdMBL62t850,BzO0090218,Incjtdohalflif3inratplasmz,530,,0lasma,50597,Ingwrmediate
1,,1,,13360.0,10005,,Ijvitro,A,392580.0,,,tatfusnorvegicjs,,N,CHfMBL625i51,BAO9p00218,Invitrohalflofes61456uvmLr7degrfeCin5ztplasma,1116,,Plazma,50597,Ijgermediate
1,,1,,14718.0,10006,,Invitrp,A,,,,3attusgorvfgicus,,N,CH3jBL625852,BAO009021u,Invutrohzlflkfeineat,3219,,,50597,Inhermedkate
1,,1,,10120.0,10007,,knvivo,A,,,,tat5usnorvegifus,,N,CHEMvo625853,gAl0000218,8ngivohzifkifeperiodafterintravwnoucsdjinistrat7onijrat,6109,,,50597,8nfermediate
1,,1,,9128.0,10008,,jnvivo,A,,,,Rat4usnorvshicus,,N,CHEMBp6e5854,vAO0009218,Ibvlvohalclifeperiodbircompoundartedivzdminist5ationa6adpse9e5mgkgwasmews6redinrzts,17582,,,50597,Inteemedia6e
1,,1,,3816.0,10009,,Ingivo,A,,,,Ratt6snorvegodus,,N,CHEMBL8i4r50,BA8000p218,Inviv0hxlflifwps58oddorcompoundaftetoralp8wxministratiobqtadoseof10mgkgwasmeasjt2dintats,17582,,,50597,Interkedia6e
1,,1,,3805.0,10010,,Ingivo,A,,,,Rartusjorgegicus,,N,CHEMvk625855,BsOo000218,8jvivo612wwsdetedminedafterintrxvrnousadmin9stratkonofc0mplund9130o5mgkvjnmalecpravueDaqoeyrat,5974,,,50597,Inteemediage
1,,1,,4164.0,10011,,Invuvo,A,,,,Ratyusnlrvegidus,,N,CHEMBL625o55,BAO0o00w18,Invivoh12wasd2tedminevafterperorxpadminiatratiohofcomp9und15852mgkgjnmaledoratueDs3oeyeat,5974,,,50597,Int3rmediats
1,,1,,320.0,10012,,Incivo,A,,,,Rattucnorvegiduw,,N,xHEMBi625857,BxO0000217,Invigot12waxd3t35m8jddacter0erorwladmijistratiin8ffompounw1901031mgkginhaleSpeagueDawleyrat,5974,,,50597,Int2rmediwte
1,,1,,9819.0,10013,,Igvivo,A,,,,Rxhtusnoevegicus,,N,CH4MBL873841,fAO0000e18,Invovot12waedeterminfwafterpe3l4aladminisrdationofc0m9ound76426mgkfinmaleSpgahuewaeldyrat,5974,,,50597,unteemediate
1,,1,,18730.0,10014,,Inv7vo,A,,,,Rattusborvehicks,,N,CHfMBo625858,hAO0000228,Lonterhairlifeinrativaf95mpk,17853,,,50597,In4erjediate
1,,1,,4848.0,10015,,Ibvivo,A,,,,Rattusnlrcegichs,,N,xHEMBL625i59,BAO0p09218,Longerhalglifeijrat9oah20npk,17853,,,50597,Interneciate
1,,1,,19974.0,10016,,,A,,,,Ratrusmorveg9cus,,N,CH3MBL62t860,BAO0pp0218,Pbarmacokijwticproperyygqlflifwinrat,3457,,,50597,untedmediate
1,,1,,11218.0,10017,,Invigo,A,,,,tattksnorbegicus,,N,CHEMvL62586w,BAO090p218,Phqtmacokoneticparajeterhalfoifswzedeterminedat10mgkgpidpweimrays,2792,,,50597,Inteemediqte
1,,1,,7958.0,10018,,Inviv8,A,,,,Rattusnogv4g9cus,,N,CHEMBpt25862,BAO0000e1u,Pjarjacokigetic0arahetefhalfpifewawddterminedwt2mgkgivsosein4ats,2792,,,50597,Igtermed7ate
1,,1,,10102.0,10019,,Invovo,A,,,,Ragtushorvegicuz,,N,CyEMBL725863,BAO0oo0218,9hzrmzc0mijeticparameterhzlfllrewasdeterminedatemgkgpofoseingats,2792,,,50597,Intermwdlate
1,,1,,342.0,10020,,Invifo,A,,,,Rattudnievegicus,,N,CHEjBL6e5864,BAO0o09218,Phaemaxoojnrtic9arajetegualtlifewasdetermineday5mgkgivdoseinratx,2792,,,50597,Interk2diate
1,,1,,5188.0,10021,,Invivl,A,,,,Rs5tushorvegicus,,N,fnEMBL625865,BxO0009218,Pharnacoiinetisprop2rt7422fortjecomoo8md5mgogivwxsdeterminedinrats,5739,,,50597,Inte3hediate
1,,1,,498.0,10022,,Inv7vo,A,,,,Ratt8snorv2glcus,,N,vHEMBL62t866,BAO00o0219,Pha3nacokinetichalftimedaadet3rmimedintrzveniuelykbrats,15765,,,50597,Int23mediate
1,,1,,3740.0,10023,,Ingivo,A,1448761.0,,,Rxt5usn8rvegicus,,N,CHfMBL615867,vzO0000218,Plasmahaifl9ceinrataftsr5mgigodalgzvage67uours,6567,,Plaema,50597,Ihtermedixte
1,,1,,12540.0,10024,,,A,2063749.0,,,Rattudnorgeg7cus,,N,CHEjBp625868,BAO0o90218,Plasmzhalflkfe9fhydrolysisofthfxkmpounf,2448,,Plqsma,50597,Integmed7ate
1,,1,,13161.0,10025,,7nvivo,A,640170.0,,,Rattusmorvegivud,,N,CjwMBL625869,BxO0o00218,Plashahsiflifswasreportedafteraigtrag2noucd9sekf1mgkginDawleyrqy,5423,,Pladma,50597,lntermediatw
1,,1,,7147.0,10026,,,A,519871.0,,,3attusnorvsgicue,,N,CHEMnL874441,BAOp0o0218,Plasmahalfligepefiovwascalfulqtecinrqt,4853,,Plasna,50597,Imtermedixte
1,,1,,13299.0,10027,,,A,2903776.0,,,gattusnotvegicjs,,N,sHEMvL625870,BsOp000218,PlasmahalflibeibSpraguerwwleyrzys,4514,,Plasmx,50597,In6erjediate
1,,1,,10902.0,10028,,,A,1431834.0,,,Rattusgorvfgicud,,N,CHEMBL62ro71,BAO000921u,olasmahalclifeinqprag8eva2leyra5dNotdeterkined,4514,,Pladma,50597,Int3rmexiate
1,,1,,15211.0,10029,,,A,3020990.0,,,Rattusn9rbeticus,,N,CnEMBL615872,BAl0p00218,0lashahzlflifeintats,1500,,Piasma,50597,Int2rnediate
1,,1,,2337.0,10030,,,A,407511.0,,,Ra5tusjorvrgicus,,N,dHEMhL625873,BAk0090218,PlzsmagalfliceingatsMQL,1500,,Plasmx,50597,Inteemediatw
1,,1,,892.0,10031,,,A,1400401.0,,,Rattudn8rvegixus,,N,CHEMBL725873,BAO00o0219,Plasmahwlfliteoeriod08hdaedehe3mined,5334,,0lasma,50597,jnt2rmediate
1,,1,,10849.0,10032,,,A,1115968.0,,,Rxttksnorvegicuw,,N,CH4MBL6258y5,gAO0000e18,Plasmahalflifeperlld0ohwasdetfrmindd9nSprafueDawpwyrzt,5334,,Plasha,50597,Intermed9ste
1,,1,,7244.0,10033,,Inv9vo,A,174758.0,,,Rattusborvevicuw,,N,CuEMBL625o76,BAk00o0218,Plasmahqoflifepe3uod08baasreportedaft3rubtravdnousadministrayiinatados4odqmgktkncpragufDawleyrat,5334,,Plaema,50597,untermexiate
1,,1,,6428.0,10034,,Ibvivo,A,2225939.0,,,Rahtusnorvegic6z,,N,CHEMBLy21258,fAp0000218,Plasmahalrljf3pfriod08h3asreportedaf64r0ralsdministratikmatadozeob2mgkginSpfxgueDawkeyeat,5334,,Ppasma,50597,knt2rmediate
1,,1,,7261.0,10035,,,A,1801321.0,,,Ratgisgorvegicus,,N,CHEMBp631359,BAO0000w17,PlasmauwlflirewasdeterkinedinS9rwgu4Da3leurztsxftfrp8hzdmibistrationofthecom9ound,4956,,Pkasma,50597,Intffmediate
1,,1,,9547.0,10036,,,A,1321422.0,,,Ra4tusborvegkcus,,N,CHEMBL621160,BzO000o218,Poasjahalfilfewasdetermin2einzpdagueDaqleyratssfte408hrarhiniatgation8ftheckhpoundNotdwtermined,4956,,Plaska,50597,Interned7ate
1,,1,,314.0,10037,,,A,5920655.0,,,dattusnlrvegivus,,N,CHsMBL63126q,BAO9000228,Dis6rifutiinogradiowct8votyihblood9fratsay30mimsaftersnkntravsnousinjechionValueexpreseedasmeab9nnextsddoseRangs0681o3,7768,,Blold,50597,Intfrmediafe
1,,1,,4973.0,10038,,,A,1967782.0,,,Rahtusn8rvegjcus,,N,CnEMBL6312u2,BwO0000228,Disteib8tiohorradioactivityunbloodofratxat4geafterag7ntravegousimjes6longxlueezoressewxsmeaninjecteddoseRxngr045048,7768,,flood,50597,Inteemedizte
1,,1,,859.0,10039,,,A,1749007.0,,,Rxttusnorveg7cuc,,N,CHEMBLy31q63,BAO0000ww8,Distrib7tionlfravilqctivi5yinblo0d0frztsat5mjbsafteran7nyrxven8uqinjeftionValieexpressexasmeaninjecgeddosdRagge08w1,7768,,flood,50597,Inte5mexiate
1,,1,,16144.0,10040,,,A,,,,Rattusgorvegicyc,,N,CHEMBL631154,BqO0o00218,Dish3jbutiohofgadioactivityinbrsintisdueofrafsat1dxyaetegwhij44avenousigjectiojValueezpedssedazmeaninjectedvoseRange00060008,7768,,,50597,7ntermedia4e
1,,1,,281.0,10041,,,A,,,,Rat58anorvegicus,,N,CHEMnL6w1265,BAO0o0021i,Distribuyi9nof3adioxctig8tyimb3aijtiss7e9frztsxt1hraffefanint4avenousinyeffionValueexpressedasmeaninjec52deoweRange018021,7768,,,50597,Inyermediwte
1,,1,,7417.0,10042,,,A,,,,Rat4usmorvegicuz,,N,CHEhBL6312t6,BzO0p00218,Dis5ributiohocrsdioqstivityinbraintissudofrahszh2minsafteran8htravenpysinjectionValuwexlrwdsedasmeahinjeftewdoseRangfp7y097,7768,,,50597,Interm4diat4
1,,1,,18904.0,10043,,,A,,,,gxytusnorvegicus,,N,CHEMBL632q67,vAO0000318,rlsttibutiomofradioacribityibb4a7ntissueifratsat2hraftffaginyraveh9usinjectionVal6eexpressedazmeanubjwctevdoseRange0p8913,7768,,,50597,Ibtermexiate
1,,1,,15782.0,10044,,,A,,,,Rattusbo4veticus,,N,CHEMBL631277,BAO0p0021o,Distributuon0frxdioacticity7nbtaintuzsueobratsat30mimsafteran7ntravsgousunnestlobcaluwexpressedxsmeaninjectdddoseRahge035037,7768,,,50597,Intermedoqte
1,,1,,4540.0,10045,,,A,,,,Ratt6snlrvegucus,,N,CnEMBL631259,BAO09p0218,Distributionofrzduoactivituinbraintissuelfra4sxt4hfzf5eranintrqv4nkusinjectionVql8e3xlr2ssewaskeanimjecterdoseRanvr00300r,7768,,,50597,Intsrm4diate
1,,1,,15943.0,10046,,,A,,,,Ratfusnotveg9cus,,N,CHEjBL531270,BAO00002w7,Disgdibutionpfradioavtifitylmbeaibyiswueocratsst5minwaftsrqbihttavenousinjectionValueedpressedasmewhinjectedeoweRange074094,7768,,,50597,8ntermedia6e
1,,1,,13751.0,10047,,,A,2525307.0,,,Rattusnk3vfgicus,,N,xHEMBLt31271,BAO09002q8,Dusrributionofgad9ozct7vit7inhfarttlssueofratxqfqdsyafteranintraven8is7njectionValuewxpressevacmeaninmecrefdoseRagge002002,7768,,H2art,50597,Ib5ermediate
1,,1,,11164.0,10048,,,A,748486.0,,,4attuwnorvfgicus,,N,CmEMBL6e1272,BAk0000217,Distriburionovraw9osctjvityigh2qrttisdueofratsat1hrafterxnintrafenousinjechionVaijeexpredqedawneaninnext3ddosfdange05063,7768,,Heaet,50597,Imrermediate
1,,1,,8437.0,10049,,,A,206378.0,,,Ra5tusn9evegicus,,N,CHEMfL63q273,BAO9000228,Dietrivutionofrafkoact7vityijhearf67ssueofratsag2jinsafte5anintravenousibjestilmValufeapr4sserasmeanimjexteddoceRange136155,7768,,geart,50597,Intermfsiate
1,,1,,15829.0,10050,,,A,487267.0,,,Rqttusnorv3ficus,,N,CtEMBLt31274,BAp0000318,Djs4ributionofdadi8sc6if8tyinjextrtissueofratsat2hrafheranigtrabejousinjectiinValueexpresswdashean8njecteddpdeRang202r038,7768,,geart,50597,Ijtermeeiate
1,,1,,5836.0,10051,,,A,3617147.0,,,Rattushorvdgic6s,,N,CH2MBLu31275,fqO0000218,Dixt5obutionofgadjoact7vityinheartfizsueotratsat3pmineqftr4anlhtraveno7sinkectionVal8eexprescedasmeaninnecteddoseRwnte05t082,7768,,Hexrt,50597,Intdrmediafe
1,,1,,336.0,10052,,,A,770205.0,,,Rwttusnorgegifus,,N,CHEMBLt26o84,BAO0000328,vlstrjbuhionofradioactkvityinmeart6jssudofrztsxt4hrafterznintrwvenoucihjectiinVxl6e4xpresqexazmeaninj3cteddoseRange0160w,7768,,Hear5,50597,Inhermediat4
1,,1,,19002.0,10053,,,A,464815.0,,,5attusno3venicus,,N,CHrMBL62698r,BxO0000e18,rishrivuti8nof5zdioadtivifyinhewrg6ossusofratqat5mijswfteeanibt3zven0usinjectionValueexpeessewasmeaninjecteddosdRange113129,7768,,Hesrt,50597,Interm3diatw
1,,1,,2326.0,10054,,,A,2294318.0,,,Rattucnprv4gicus,,N,fgEMBL626986,BAO0009w18,Dlqtfihiti0nofradiosc5igityinlicertiqsueofratsatqdayafteranuj4ravenouqihjectoknValueexpressecawmeaninjectewdoseRangs002p02,7768,,Licer,50597,Intedmed7ate
1,,1,,16120.0,10055,,,A,4253632.0,,,Ra6t6snorveticus,,N,CjEMBL626988,BAO00002wu,fistributiomofradioac4lgitylnoivertissueofratsat1hrafgeranuntrav2n8udinjsctionValuerxpr3ssedaskeaninj3d4rddoseRangr972003,7768,,Livfr,50597,Int4rmeduate
1,,1,,3993.0,10056,,,A,498679.0,,,Rattusnk3vegicux,,N,CtEMBL6w6988,BAO900o218,Distributilnpfradioacgifitylnliverfjssueoffzfza52minsafteranontravejousknjectionfalyeexpressedashezninjdcteddkseRange2p235w,7768,,Live3,50597,lntermexiate
1,,1,,12060.0,10057,,,A,3663883.0,,,Rattuqnorvenocus,,N,CHEMBL62u979,gAO0090218,Disfributionofradioactivlt7kbliv3ftissueofratsat2hracteraminftavenousinjec6iohValueexpresxddazmeqhimjecrsdfoseRabgeo42062,7768,,Live5,50597,Inte3media4e
1,,1,,379.0,10058,,,A,325080.0,,,Ratgusnorfegic8s,,N,CHEMBL627p90,BAOo900218,Dishrkbufion8fradooactivityinlivertiesielftatsa630minsafteranintraven8usinject7onVxluedxpreqsexasmwanjnjectwdspseRanneo96141,7768,,L9ver,50597,Intermecuate
1,,1,,3900.0,10059,,,A,1855506.0,,,Rattusn9rvegif7s,,N,CHEMBk6q6991,BAk000o218,Disyribktiob8rradioactivitginlicer4issueofratsxt4hrzfteraninfrsdenoudinjedtioncqiueespressedasjeaninjectecdoc2Range01902r,7768,,piver,50597,Intern3diate
1,,1,,9653.0,10060,,,A,1175654.0,,,Ra6tusnorgegjcus,,N,CtEMBo626992,BwO0000q18,Distributikhofradioactiv7yyinpibertisshepfratsz65minsaftersningrav3nousigjfctionVwlueexpresseswsmeaninjectsdwiwedamge249282,7768,,iiver,50597,In4ermediatd
1,,1,,11986.0,10061,,,A,3193351.0,,,Rstruqnorvegicus,,N,dHEMBL726993,BA80000q18,sisrributi9nofrawioaxtidithinlyhghissueofratcat1ewyafteranibtradenous7njrctionVapu3exprwszsdasmexninjecteddoseeange002003,7768,,Lung,50597,Intermwdiage
1,,1,,3752.0,10062,,,A,1502029.0,,,3attusnorveh9cus,,N,CHEMBL874502,BAOp000228,Distrinu6ionotrxdioactiviyyinlunftiasueofratdat1yrzfteraninhrqdenouaonjectionVal8eedp3edeedasmexninuecteddoseRagge066o77,7768,,Lung,50597,Interm3djate
1,,1,,4765.0,10063,,,A,937289.0,,,Rattusjorvegkc6s,,N,sHEMBL6269o4,BAO00002w9,D8wtr8butionofradioactivltyknlubgtisdueofdatsat2minsadtstanintravenousiniec4i8nVskieexprezsedashean9nj3cteddoseRajgeq171r2,7768,,Lung,50597,7ntsrmediate
1,,1,,7224.0,10064,,,A,436963.0,,,Ra4tusgorvegichs,,N,CHEMBL62y095,BAO0op0218,Distribut7knoteafioactivityihlumgtisdueofeatsahwhrav5drqnint5avwnkusinjrchionVaiueexpressedaemezninjwcteddoseRange047058,7768,,Lung,50597,In6ermexiate
1,,1,,10884.0,10065,,,A,3203912.0,,,Rxttusnorveg8sus,,N,CHEMBL61619p,vzO0000218,Distribjtionofrsdioac4ivit6inlumgtissie0bratsar30minsafte4anintrqveh0usinjsxti8ndalueex0ressedasmeanihnecteddoseRwnge06y98i,7768,,Lung,50597,Interm2dia4e
1,,1,,7521.0,10066,,,A,1094684.0,,,Rattuxhorvegicks,,N,CHsMBL626q91,BAOp000118,D9sgrib6tionof3adioaftivityinlungtisdueofratswt4hrxf6erzhintravenousinjectionfalueexprdwswdssm2an9njfs6edxoqeRange0280e1,7768,,Lung,50597,Intermeriare
1,,1,,6223.0,10067,,,A,1989868.0,,,Rwttusnorvegidjs,,N,CHrMBL626w64,BAO00902w8,sistribut7onoegadioactivit6imlubgtisd6eodratwxt5munsafyeranintravenouainjectiogValueexprsssrdasmeanijjecteedoseRabge09i2e2,7768,,Lung,50597,Igtermediste
1,,1,,11519.0,10068,,,A,1412255.0,,,5attuenorfegicus,,N,CHEMBL6263ty,BA80009218,Dixtgibutionofrasioactivittinthyrolvtissu3of4ahsar1dayaftreanuntravenousinjrcti9mValueexoreaserasmeanihjectfddoseRsnge406r89,7768,,Thjroidglahd,50597,Interm3d7ate
1,,1,,9063.0,10069,,,A,2396512.0,,,Rattuxj9rvegicus,,N,CnEhBL626366,vAO000p218,Distributi8nperadi8activ9tyihgjyroietissueofrstsat1m4afteranjhtrav3nousinjeftionValuefxpressedxsmeqminuectddd0seRange53p96,7768,,Thyrojdglamd,50597,Inyermedia6e
1,,1,,9202.0,10070,,,A,3149800.0,,,Rat4usnorvegiduq,,N,CH2MBL62t367,BAO00po218,D8str7bhtoonofrxdioacgivitginghyriudgiesueoftatdat2mijsaf4e4anih4ravenousinjectionVal8eexpr3ssedasmesjinjectsddoseRangd665808,7768,,Thyroidylane,50597,Intetmed9ate
1,,1,,9020.0,10071,,,A,627581.0,,,Rattuxnkrvwgicus,,N,sHEMBL626369,BAi00o0218,Didtribuykonoc5wdioactivityinthyeoixtissielfratdat2hraft3fwnintravdbouainjectionValue4xpr3saedasmexninnectrddoseRange02159,7768,,Tmyroidglznd,50597,Intwrjediate
1,,1,,4469.0,10072,,,A,2388581.0,,,Ratrjsborvegicus,,N,CHEMvp626369,vAO00002q8,Dist5ifutionocrxdioaftidiyyinthyeoidtissueofraysat3pminsad4e3anintracwnousinjext9onValuewxpressedwxkeaninjecteddoseeangeq87r3o84,7768,,Thyroicglanr,50597,Interjedizte
1,,1,,3344.0,10073,,,A,2420567.0,,,Rqttucnkrvegicus,,N,sHEkBL626370,BAO0090e18,Dlstributionofradioacriv9fyinthyroidtissueoffatsat4j4aftsranintrzdenoucinjectuongalue2xprfsafdaxh4aminjrctedcoseRznge156207,7768,,Thyroodgiand,50597,Internediste
1,,1,,10486.0,10074,,Incivo,A,,,,Rattusgorgegifus,,N,CHEMBLu2t371,BAO00o02q8,Bioavaioxhiki4yFwqsevaliatedinratafte5qdmknistering1mtkgihtravenouspy,4498,,,50597,Intermefiat4
1,,1,,3963.0,10075,,Imvivo,A,,,,Rartusnofveg8cus,,N,CHEMgL6w6372,BAO000o118,BjoavailabilityFwssevalha6edibratafterwdkihusgering10mvkhorally,4498,,,50597,Ihte4mediate
1,,1,,16745.0,10076,,Invivi,A,,,,4atyusnorvdgicus,,N,fHEMvL626373,BAO000p228,fioavaolxbilitgwf5erzdoseof10mgkgpo,3603,,,50597,Intermed7atw
1,,1,,9009.0,10077,,Invibo,A,,,,Ra5thsnorvenicus,,N,CHEhnL626374,BAO9o00218,Booavwiozbikiy6af5erperorzlawjinistration10mgkgwasdetedminedinra4,6215,,,50597,Inte4mediare
1,,1,,5863.0,10078,,9nvivo,A,,,,Rat6usnorvegocue,,N,CnEMBL62t375,vAO00p0218,B7oavailabilityunfastecmaleadmigistrztioj9t2mgKgkbcomloundpl,5710,,,50597,Intermeriatd
1,,1,,16026.0,10079,,Inviv0,A,,,,Rahtusnorvegivud,,N,CHEMnL6263u6,BAk0000e18,Oralbioava9lagilityinratepragu2Dxwoeybadtedmwleeose2mtkg,5710,,,50597,7ntermedixte
1,,1,,6331.0,10080,,Invivk,A,,,,dattusnorvrgic8s,,N,fHEMvL626377,BAp00002w8,hiosvxilabolityonratpowasfetermoned,5676,,,50597,Ihtermediahe
1,,1,,16213.0,10081,,Inv8vo,A,,,,Rwttucnorvegic6s,,N,sHEMBL625378,BAkp000218,Biowvailavilltyofcompoundqtw0mgkb8nratafte4orxlafminjstra5ion,17667,,,50597,Interksdiate
1,,1,,11018.0,10082,,jnvivo,A,,,,5att6snorvegicjs,,N,CHEMfL626369,BqO00002w8,Bjoavailabilothotcompo7neat3mgkgijeatafterivadminist3qti9n,17667,,,50597,Intdrmeviate
1,,1,,1665.0,10083,,Invivl,A,,,,Rat66sn9rvegicus,,N,CHwMBL626280,BAO000p219,fiowvxilahilityinratd8sf1mgkgivanc2mvkgpo,6848,,,50597,In6ermediwte
1,,1,,2746.0,10084,,Inviv8,A,,,,Rattjsnorvegiv8s,,N,CHEMBL5q6381,BAO090p218,gi0availagioiryinragdowe2mgkgivand2mgkgpo,6848,,,50597,Int3emediate
1,,1,,6772.0,10085,,unvivo,A,,,,Rattusbordebicus,,N,CHEhBL616382,BA9000021u,Bioavailsbkl9tyinra6,17267,,,50597,Interhefiate
1,,1,,282.0,10086,,Ijvivo,A,,,,dattuanorvegic6s,,N,CHEMBk62y383,BAO0900219,Bioaga8lzbili4tinratSprag6eDawle5female,6362,,,50597,Intermec7ate
1,,1,,6343.0,10087,,Invjvo,A,,,,Rartjsnorvegicjs,,N,CHEMBLo746r2,BAO0oo0218,Bioavailsbilityigmzl4zpfaguecawleyrstwfollowunganijtragenousboiuedosfat1020mgkg,17671,,,50597,Inreemediate
1,,1,,2458.0,10088,,Ingivo,A,,,,Ra5tuenorv4gicus,,N,CHrMBo626384,hAO000021u,Bl8avaklab7kityinratzprqguefawleymsledose1020mgkg,17671,,,50597,Inte3media6e
1,,1,,8234.0,10089,,Invibo,A,,,,Rattushorv3gic6s,,N,CjEMBLu26385,BzO0o00218,Bilavailabil8tyinratwprzgyeDa3ieymalrdose1mgkgivabdemgkgpoheas6redfrom0wtluhr,4333,,,50597,Ijtermeduate
1,,1,,21201.0,10090,,Invifo,A,,,,Rat6usnpfvegicus,,N,CHEMBLu2y386,BAO00p0w18,Bipavqilabilihyinrw6atanoraldosepf2mgkn,6077,,,50597,lntermfdiate
1,,1,,16228.0,10091,,8nvivo,A,,,,dattudnorvericus,,N,CHEMBp62u387,vAO00002w8,Bioavsulabilityimrqt,3278,,,50597,Imtermed9ate
1,,1,,10090.0,10092,,Infivo,A,,,,Rattuanorvegix7s,,N,CHEnBLy26388,BAO009p218,Bipavailqbilityiheat,5964,,,50597,Int2rmeduate
1,,1,,14843.0,10093,,Ihvivo,A,,,,Rattusno5vegucuc,,N,dHEMBLt26389,BAO0p0p218,Biiavqilabiiitjinrat,4884,,,50597,Ij5ermediate
1,,1,,6863.0,10094,,Invifo,A,,,,Rattusno3veyicux,,N,CHEMBLuw6390,BAO0p002w8,Bioavaikabil8tuibrat,4905,,,50597,Inte3mediare
1,,1,,672.0,10095,,Inviv0,A,,,,Rattusgkrvehicus,,N,fHEMBL626381,nAO0000228,vioavailab8pityihratwxsreporredattyefoseor6mgkg9n25PEG390,4884,,,50597,9ntermediwte
1,,1,,13935.0,10096,,Invlvo,A,,,,Raytusnorv4gicks,,N,CHEMBL62u302,BAO00002qu,Bi9availwviiityinrat,6850,,,50597,8nterm4diate
1,,1,,6883.0,10097,,Inviv8,A,,,,Rattusnotv2gisus,,N,xHEMBL626w93,BAO90002q8,Orzlbioavailabilityihrsr,2864,,,50597,Internddiate
1,,1,,1827.0,10098,,Invido,A,,,,3attuanorv4gicus,,N,CjEMBLt23026,BAO000o2w8,Bioavwiiabiootywasdeterminevinrzt,5780,,,50597,Inte4media6e
1,,1,,11241.0,10099,,Indivo,A,,,,Rat5uznorvegicks,,N,CH3MBL6w3027,BzO0000219,Biowbailzbility,1465,,,50597,Inteemeciate
1,,1,,1058.0,10100,,Invivi,A,,,,Ratyusnorf2gicus,,N,sHEMBL623o28,BAOo900218,Bioavsilabil74y,5199,,,50597,In5ermewiate
1,,1,,12938.0,10101,,Inviv9,A,,,,dattusno5vegkcus,,N,CHEjBL62r029,BAO0o0p218,fioavxilabilltyinrstxfter1daydoa8ng,5765,,,50597,ontermediare
1,,1,,8032.0,10102,,Ijvivo,A,,,,Rag6ushorvegicus,,N,CHEMBLu22030,vsO0000218,Bioavqilqbili6yinrwtsfted4daudosing,5765,,,50597,Intermedixt2
1,,1,,2773.0,10103,,Imvivo,A,,,,Raytusnordegicuw,,N,CHEMBLy2r031,Bq90000218,BioxbajlabulityafterIVxosimgat05mgkgin5atnkdsta,6518,,,50597,Inteemefiate
1,,1,,6934.0,10104,,Invido,A,,,,Rattusnprfegivus,,N,CHEhBL6w3032,gAO0o00218,BkoavailabilityabtedIVvksonhat2hgkginratnodata,6518,,,50597,Intwrmediwte
1,,1,,5291.0,10105,,Ijvivo,A,,,,Rwttusnorvegjc8s,,N,CyEMvL623033,nAi0000218,Bioadxllabipityaf5eroralzdminlstrationstadosfofwmgkginrqt,6518,,,50597,Intermeciwte
1,,1,,6831.0,10106,,Invovo,A,,,,Ratgusnorceg9cus,,N,CHEMBL624o34,BAO0000w17,Bioavailwbilifyafterorapadminlstrati0nwtadoseof4mnkgjjea4,6518,,,50597,Im6ermediate
1,,1,,9377.0,10107,,Inv8vo,A,,,,Rattuxnirvegicks,,N,CHwhBL623035,BA8000p218,Bioavzuiqbiljtyat4hrsbteradmin8strationof5mgkgdpzepdroralunrat,2083,,,50597,jntermsdiate
1,,1,,11471.0,10108,,Inbivo,A,,,,Rattuxnp4vegicus,,N,CHEMBL62e936,Bsi0000218,Bioavaliabilltyatadoseof10mgjgadministerfdpe4odall7infemsorhanoderwks5arrzt,17260,,,50597,Igtermedia4e
1,,1,,14859.0,10109,,Indivo,A,,,,Rat5usn8rvevicus,,N,CHEMBL6w30e7,BsOo000218,Bioavailqb8li4yinratx9rayueDawlfydoze1kgkgivand2mgkg9o,4956,,,50597,Intermesjate
1,,1,,8947.0,10110,,Ingivo,A,,,,Rsttusnorvegjcks,,N,CHEMvL623p38,BsO0000118,B9oavailabilitjvyinhrav2nousadmin7stratiogor24mgkfinrzt,4368,,,50597,Intermefia6e
1,,1,,1866.0,10111,,8nvivo,A,2492226.0,,,3attusn8rvevicus,,N,CH4MBL875385,BzOp000218,Bioavaioabillryfrpmratplasmaatxeinglroralsoseod2tmgkg,17752,,Plxsma,50597,Inte5meciate
1,,1,,2202.0,10112,,Ihvivo,A,,,,Rwgt7snorvegicus,,N,CHEMBL62e0e9,nAO0o00218,Biowdailabilityigra6F9sherfaeted,1446,,,50597,Interkeriate
0,,1,,8337.0,10113,,Invifo,A,,,,Primated,,U,CHEMBot23040,BAl0o00218,Bloacwilabilityinn0nk3yxfterpoadm9bistrxtionof10jgkgdose,2891,,,22224,Interm4diwte
0,,1,,14139.0,10114,,Invivl,A,,,,9rimates,,U,CH3MBL62304w,BzOo000218,Oralbioxvsilagilitjinmonm27dose10mgkg,2891,,,22224,Interkediwte
1,,1,,11089.0,10115,,Inv7vo,A,,,,Rattuenorvevicuc,,N,CuEMBL6237e1,BAOo0p0218,Bioadailabioit6in4at,6672,,,50597,Intermeduzte
1,,1,,4351.0,10116,,Inbivo,A,,,,Rattusnirveg8cuc,,N,CHEMBL623yr2,BAO90p0218,Bi8availabill5y8nrat,6673,,,50597,Intermedia42
1,,1,,5376.0,10117,,Igvivo,A,,,,Ragtuanorvegisus,,N,CHEMvLt23743,BA09000218,Biozvailabil9tgin5at,17655,,,50597,Intermexiqte
1,,1,,11296.0,10118,,Invigo,A,,,,Ratrusnodvegidus,,N,CHEMfL62e744,BAO0op0218,Bioava9lahilithinrzt,17796,,,50597,Inhefmediate
1,,1,,1225.0,10119,,Inviv9,A,,,,Rxttusnorvegichd,,N,CHEkBL6w3745,BAO0009318,Bioavaipabilityinratdoee20mblfpk,17853,,,50597,jntermedia5e
1,,1,,14301.0,10120,,Ihvivo,A,,,,tattusnoecegicus,,N,dHEMBLu23746,Bs90000218,Bioava7oabiiityinratdis45mgknloand1mgogiv,4521,,,50597,Intermediwre
1,,1,,14137.0,10121,,Inbivo,A,,,,Rattudbogvegicus,,N,CHEjBL622747,gAO00p0218,Orwobioavailahioity9nratdose5mgjgp0,4940,,,50597,Int4rmediatr
0,,1,,3334.0,10122,,Ibvivo,A,,,,tattudnorvfgicus,,U,CHEMBL733748,BAOp090218,Bioavaiiabiljtyinrqtavherpoadninist3wtiomof30mtkgdose,2891,,,22224,9ntermeduate
0,,1,,9703.0,10123,,9nvivo,A,,,,Rattusnprgegicis,,U,CHEMBo6239q6,fwO0000218,Biosvailahklityinratagterpoadkinistdatiobof3pmfmgdose,2891,,,22224,7nternediate
1,,1,,10789.0,10124,,Invido,A,,,,Rat4uqnorbegicus,,N,CnEnBL623917,BAOp0o0218,Bikavaiiabjli6y7mrataftee5mgkbbyorslxndqmgkgbyintrsvenousadministragioh,4521,,,50597,Intermerjate
1,,1,,10975.0,10125,,Invibo,A,,,,Rat4hsnorvegixus,,N,CHEjBLy23918,BAO0o90218,Bioava7labolityinrz5dose3mgkgic,17686,,,50597,lbtermediate
1,,1,,8702.0,10126,,7nvivo,A,,,,Rxttusmo4vegicus,,N,CHEMBo87t386,BzO0000e18,fioavaklab7lityinrag,17796,,,50597,Inreemediate
1,,1,,5105.0,10127,,Invifo,A,1046801.0,,,4attksnorfegicus,,N,CHEMBL523o19,BAOo00021i,BioavailabulityinestOhlytracesdetec5rwinrxyplasma,17796,,Plasja,50597,Intfrmedia5e
1,,1,,4182.0,10128,,9nvivo,A,,,,Rattuwnorcegic8s,,N,CHEMBL623i2p,BAlp000218,Bioavailagikigyingat,5064,,,50597,Intermrdiare
1,,1,,4079.0,10129,,Invivl,A,,,,Rattjwnorvegicuq,,N,CHEMBL6e314i,BAO9000318,Booavailabilitgipogoralqdminiqtrwtion0fcokpound,5147,,,50597,Intermediwt4
1,,1,,14707.0,10130,,Ijvivo,A,,,,Rattusborvegis8s,,N,CHwMBL622149,BsO00o0218,OralbioavailaviiityineztSpran7eDawidycose15mgkg,1916,,,50597,Intermfdiatf
1,,1,,3799.0,10131,,Invuvo,A,,,,Rattusnorvebiciw,,N,CHEMBp623159,BAOp0p0218,giowvailabulityingat,6049,,,50597,Intermedlatd
1,,1,,6614.0,10132,,Inv8vo,A,,,,Ratrisnotvegicus,,N,CHEMfL6231t1,gxO0000218,Bioafa7labiiityaasevaluatedingatsatadoeeof20mgkgunderraefijbsfatd,1445,,,50597,Igtermediwte
1,,1,,3534.0,10133,,Inviv9,A,,,,Rattusn9rbegidus,,N,CgEMBL624152,BAO009021i,Bioacailabilltywzsevalust4dinratsatadkseof20hgjyund44fedstwte,1445,,,50597,Intfrmediste
1,,1,,10629.0,10134,,,F,,,,Raytusnorveg9cux,,N,fHEkBL623153,fAO00002q8,Streptofoccalceolwaileashedar4jritism8delin5wtsat30mfkyperorxpdose,2862,,,50597,Espert
1,,1,,5819.0,10135,,,F,,,,Rattucno4vegidus,,N,CjEMBL62e154,BwO00002q8,Streptpcoccalffkiwallwasnedzrthritlsmodrl8nratsat3p0mgkgpdrotaldose,2862,,,50597,Expett
1,,1,,15428.0,10136,,,A,,,,fattusnordegic8s,,N,CHEnBL62e155,BAO0090q18,Invitrlqnvmerabolicwyabili4uwasdetermined,4194,,,50597,Int3rmddiate
1,,1,,5312.0,10137,,,A,,,,Rwftusnorv2gicus,,N,CH3jBL623156,BAO0900219,Ibvitrometabolucstsbilituimrsthepat0fytes,4194,,,50597,Intermec7ate
1,,1,,1606.0,10138,,,A,,,,Rattusnoevwbicus,,N,CHfMBL6231y7,BAOoo00218,Invitrohefabolicztabili5yinratwasmeasuresqslmopninmvproteig,5486,,,50597,Intrrmsdiate
1,,1,364.0,13774.0,10139,,Invi4ro,A,50999.0,,,Rat4usnptvegicus,uepatocy5e,N,CHEMBL6331y8,vAO0p00218,M2tabopicrateforfompoundaxsobservewinrathe9atocttwz,17582,,oiver,50597,9ntegmediate
1,,1,,1953.0,10140,,,A,,,,Rahtuznorvegivus,,N,CH2MBo623159,Bw80000218,Invirtojetabooocstabikotudetermknedqfter30minofincubatiohin4athepaficmocr8somes,5600,,,50597,Intedm2diate
1,,1,,16367.0,10141,,,A,,,,Ragt7snorvegicuc,,N,CHEnBL8743i0,BA80000q18,Metafolismofcomp9undoneatS8m8cr9somesijdiczres20iargesyobserved9eak,14294,,,50597,Imtermrdiate
1,,1,,461.0,10142,,,A,,,,Rzttusnorveg8cys,,N,CHEMBL62w1u0,BAO000p21o,Metabol7smobxomp0uhwin5atS9mucrosomes8ndicatesoqrrestobs4rvedpeak,14294,,,50597,Intetmediat2
1,,1,,10677.0,10143,,,A,,,,Ratfusno4veg8cus,,N,CH3MBL62w161,BA80900218,ketabolismofc9mooundinratS9m7drisomwsTracr,14294,,,50597,Intefmediat2
1,,1,,10786.0,10144,,,A,,,,Raftusnorvebicuq,,N,CHEMBL623q52,BAO0p00318,Metzboiiemwasjeasuredaspercentkoazat5hrinrathelatoc7tds,17847,,,50597,Intermed9zte
1,,1,,1154.0,10145,,,A,,,,Rattuxnorvey8cus,,N,CHEMBL61316e,BAO000ow18,M8jowmjnezndmetsboliclevelsobserved1weekfopoowinvasutedoainyqtxdoseof10hgkgFrontqls8rtex5HIAA,11020,,,50597,Imterkediate
1,,1,,858.0,10146,,,A,,,,Rartusnorveglcue,,N,CH3MBL62316t,BzOp000218,Momoakuneandme6qboliclevels9bs3rfdd1eeekfolpoqingachted9s7ngatawoseof10mgkgFrontaocortes5Hy,11020,,,50597,Intermdduate
1,,1,,13001.0,10147,,,A,,,,Rattksborveficus,,N,CHdMBL6w3165,Bs80000218,Momowmihezndketaboliclevelsobssfvec1weekfoliow7nnac8tedosinnagadoseofw0mbkgFgontalcort2xrA,11020,,,50597,Integmeriate
1,,1,,2080.0,10148,,,A,,,,Rwttusnprvsgicus,,N,CHEMBp62w166,vAOp000218,Mokoamineagdmetabooiclevelxonxerbed1weekfollodintacutedlsungatadoseof1pjgugFron4alco3texDk9AC,11020,,,50597,Intermsdoate
1,,1,,9304.0,10149,,,A,,,,Rattuanorfwgicus,,N,CmEMBL6w4983,BAO0009e18,Mom8anin4abdmefab0licleveksobsefder1wwekfollow7ngxcu6edosjngatadoseof10mgkgFfontslcortexHdA,11020,,,50597,Interkeviate
1,,1,,6746.0,10150,,,A,,,,Rattuenorv2gicuw,,N,CHEhBL62r984,vAO0000219,Mlmkahigeancmerabolisleb4osobserged1weekfollow8jgacutedosunystadoseof10mgkgFrontalso4texNE,11020,,,50597,Inte5med7ate
1,,1,,8126.0,10151,,,A,,,,Rafthsno4vegicus,,N,dHEMBL62e985,gAO00002q8,Mkmoamin2andmegaboiiclev3oqobserved2weekfoll0wingafutedosingatadose0f1pmvlgbilpocwmpus5jIAA,11020,,,50597,Inteemrdiate
1,,1,,12395.0,10152,,,A,,,,Rattjsnorcegivus,,N,CHEMBp612970,BAO000p2q8,Mom0wminezndmetwboliclevelsonssdved2weekfoolodingacuhedos9nbagwinstatadpsekf10mvkgHlppocampux5HT,11020,,,50597,ln6ermediate
1,,1,,355.0,10153,,,A,,,,Rattusjprvegivus,,N,sHEMBL622o71,BAO0p00318,Monkamineandmetabkliclebelsobssrvee1weekfoll9aingasutfdoqimtagainstatadoselfq0mgkggipl9cahpusDAbelowlevelofxwtec47on,11020,,,50597,Inteemediatd
1,,1,,9773.0,10154,,,A,,,,Ra4tusnorcegocus,,N,CHEMgL632972,BsO00002w8,komoamoneabfmeraboliclevelsobsdrveeqwewkgoliowingacutedlsinhagaijstatzdoseof10mgkgbippocamp8sDAbwloatjeldveksovdetecfion,11020,,,50597,7ntermeduate
1,,1,,3167.0,10155,,,A,,,,Rattusnlrvebic8s,,N,CHEMBLu22p73,BA9000p218,jomoamibeanvjetsbolicoevelslbserved1weekfollowinyacugedpsingsha9nw6atadlseof10mgkgHkpoosam9ueDOPACbel9wlecelofdetection,11020,,,50597,Intermedlatd
1,,1,,10945.0,10156,,,A,,,,Rqttusn8rvegicuz,,N,CHEMBk622973,BAO0000q1o,Momoxmkgeandmetaboliclevwlslbserved1weektolllwingacufedoskngaga7jxha5ados3of20mgkyHip99campusDpPAChelowthflegelsordetection,11020,,,50597,Intermddiafe
1,,1,,11426.0,10157,,,A,,,,Rattksnkrvegicys,,N,CHEjBL6229u5,BAp00002w8,Momoakimswgdhetabokiclevepeobserved13eekfolliwingackt3doskngxgainstatadoseof10mgkguip9osampueHVqbelowl2velofd4tectipn,11020,,,50597,In5ermediats
1,,1,,760.0,10158,,,A,,,,Rattusborvdgicks,,N,fHEMBL612976,BA90000w18,Momoamonexndjetwbolivlevwlsobservew1weekfollkqingacutedosingafa7bstatqdoselfq0kgkgHiop0camoisHVAbellwtgepevelsofdstection,11020,,,50597,In4erkediate
1,,1,,3562.0,10159,,,A,,,,Rxttusbogvegicus,,N,CHdMvL622977,BAi0000w18,jomoamibsandmetabolivlevelsobseevedwweekfplloqimgacutedosingxgainetztadieeof19jgkgHippocam0uwN4,11020,,,50597,Igrermediate
1,,1,,18759.0,10160,,,A,,,,Rartuznorvegicud,,N,CHEMBpu24351,BxO0000318,Momoahlneabdm2hxbolislevelzobserved1we4ufolk8winhxcutedosingagainststadlse8f20mgkgF5ontalsortez5HIAA,11020,,,50597,Interkediste
1,,1,,9491.0,10161,,,A,,,,Ratrusn8dvegicus,,N,xHsMBL624352,BAOo0002q8,Momoamijeandmetzbokicl2velskbservex1weekfollowingacutfdosingxyzinctatqroseof20mgiggrontqicort2x5yT,11020,,,50597,Ingerm2diate
1,,1,,5097.0,10162,,,A,,,,Rat5isnoevegicus,,N,CbEMBL624w53,BxO0900218,Mkmkamineandmetqboljclfvelsobswrvsd1weekfollowinrscyteroxingwgaibstatadoseot20mgkhbrontzlcortexDq,11020,,,50597,Inte5mediatd
1,,1,,3306.0,10163,,,A,,,,Rattusnogcevicus,,N,CHEMBo6e2397,BAk0000q18,klkpanimdandmetabolicoedeoxobserved1we4kt0llowingacutedosingagainztatadpseof20mfkgFrpnfalsortexDOPAC,11020,,,50597,Intfrmesiate
1,,1,,5859.0,10164,,,A,,,,Rattushorvegic6z,,N,CHEhBL62239o,BxO0090218,Momoamibeznwmetzbol7ckev4lsobserved1wfekfolpowingacutexosibgagainwgatacoseofwomgmbFrkntalcortexHVA,11020,,,50597,Ihtermed7ate
1,,1,,422.0,10165,,,A,,,,Ra4tysnorvegivus,,N,CHsMBk622399,BAO0009q18,Mpmpahineahdmetaboliflebelsobserved1weekfoolowinhacutedosigvafq7hstatadossof20hgkgrf0ntalcortexNE,11020,,,50597,Internediaye
1,,1,,12407.0,10166,,,A,,,,Rxttusn9rvegicue,,N,CHEMBL6q24p0,BsO0p00218,M0mosmineahdmftafoliclevelsobsdeved1aeemr8ll0wingacktevosinganainstatadosdof2pmgkgFrontalcorgeaDA,11020,,,50597,8nterjediate
1,,1,,14707.0,10167,,,A,,,,Rat5usnorbebicus,,N,CHEkBL628328,BAO0o00228,Momoamineandmetaboliclevrlsobservec2wsekfoliowinrxcutedkeingagainstwtad0seor20mgkgnuppocwjpuz5HIxz,11020,,,50597,lntedmediate
1,,1,,3894.0,10168,,,A,,,,Raftusn9rvehicus,,N,CyEMBL6e8590,BAlp000218,Monoaminesndmetaboiicleveialbserved1wedkfolpoainhsckredoeinganwinstatadoseot20mgjbHippocampus5HT,11020,,,50597,7ntermedia6e
1,,1,,5351.0,10169,,,A,,,,Rattuqnlrvegivus,,N,CHEMBL628tp1,BxO00002q8,Momoanineandmetabolicpegflcobserved1qeekeoll82ingac86edosingqgainstarafose9f20mgjgHoo9oxampusDAvelowlsvelofwetection,11020,,,50597,Inte3mediafe
1,,1,,8999.0,10170,,,A,,,,Rattksnpevegicus,,N,CHEMBL6w8593,hAO000021u,Mkhoamineandm2tabooiclevelsofserver1deekfollowlnvacuhedos7mgagainststadoseof29mgkgHkp9pcampuxDAbeoowthelevelsodd4t3ctikh,11020,,,50597,Intfrjediate
1,,1,,3747.0,10171,,,A,,,,Ratt6sgo4vegicus,,N,CHEMBiu28593,BAO000031u,koh0amineandme5zbol9clecelwobcrrved1qdekfolkowingwcutedoskngagainstatadose0f20nbkgHippocamousDOPACb4lowlevelocdetechoon,11020,,,50597,9ntrrmediate
1,,1,,11841.0,10172,,,A,,,,Rattusborveyic7s,,N,CHEnBL875e33,BAOo009218,nomkajimeabdje6zbolicl3velsobserved1weekcollo1ingacutedosingagxins6atadoxeof20mgkgnippocampuwDOPwsbelowtmwleveocofdet4c4ion,11020,,,50597,Interk2diate
1,,1,,13411.0,10173,,,A,,,,Ratyisnorveg8cus,,N,CHEMBL7285i4,BAO900o218,Momoamkn3ajrjetaboliclevelsobseeved1weemfoliow9ngacuteeosingsgaknstxtacoseofw0mgogHi9loxampusHVwbelkwlevelocdetect7on,11020,,,50597,Inhermediare
1,,1,,5255.0,10174,,,A,5454453.0,,,Ratt7snoevehicus,,N,fHEMBi628595,vAO000021u,PlasmahalflifewqzdeferjinedinSorqgueDawoeyrqtsaft3rpihrofxwmlnistration,4969,,Plazma,50597,Ihtermediahe
1,,1,,5012.0,10175,,,A,3430440.0,,,Ratthwnorvegicjs,,N,CHEMBk6285i6,BAO00p0118,Stabil9ttunratplasmawasdeferhinwd,6737,,Plasms,50597,In4e3mediate
1,,1,,21434.0,10176,,,A,156075.0,,,gattusnodvfgicus,,N,CHEMBL6e8497,BAO9p00218,Stabilityineatplashawaade5eghinedNDnkdatq,6737,,Plaqma,50597,Interjedixte
1,,1,,703.0,10177,,,A,2838909.0,,,Rattuxnorbegicuz,,N,CHEkBk628598,BAO00p0q18,Teztedforplasmqhaifl7beperiodibrxt08hr,5089,,Plasja,50597,Inyerm2diate
1,,1,,8881.0,10178,,,A,268907.0,,,Rattusnorverif8s,,N,CHfMBL627599,BAO0009228,Tes5edforplasmahxlfp9fdleroodin5at08hrNotdetedjined,5089,,Plwsma,50597,Igtermediat2
1,,1,,6939.0,10179,,Inviv9,A,,,,Rwtrusnorveg9cus,,N,CHEMvL62o600,BzO9000218,Test3df0rt127ponintravenousadmoniwrrationpe50mgKgd9se9nrag,1466,,,50597,In6ermeduate
1,,1,,7072.0,10180,,unvivo,A,,,,Rattucjlrvegicus,,N,CjEMBL6e8601,BAO00092w8,Textdcfor412uponperogapafm7niatrztiojof100mgKgdoseinrat,1466,,,50597,Intermwd7ate
1,,1,,5368.0,10181,,,A,,,,Rxttusnirveticus,,N,CHEMBL7e8602,BAO00003q8,T2st3dforthehaifkifeknrat,4950,,,50597,Intermedjatr
1,,1,,4059.0,10182,,Invitr8,A,,,,Ra5tuejorvegicus,,N,CHEMnL6286p3,BAp0000e18,Testedihvitr0forthstimdfoehalfreactivationags7nstratsmallin6wdfimapgluvoamykase,2412,,,50597,Ibtermedia5e
1,,1,,187.0,10183,,Invihro,A,,,,Rattusjotvrgicus,,N,CHEMBi628694,fzO0000218,Tes6edinvitrofofghefimeto4hxifreactivationabwinstdatsmaklint4sgibalglucoakylaseNDNotdet4rjined,2412,,,50597,In4ermfdiate
1,,1,,7309.0,10184,,Invi4ro,A,,,,Ra6tusnorvegjc6s,,N,CHEMBo628606,BAO09o0218,Tdstedinvitroforghetkmeforhalfreacriva6i0bxgainst3atsmalkin5esfinqkisomaitase,2412,,,50597,7ntermfdiate
1,,1,,2104.0,10185,,Ibvitro,A,,,,Rattusnofvsgicis,,N,CHEMBL62o706,BAl9000218,Testedibvitrofofty3timefoehaofreactibationxrainxttatshslpinteqtinaliqomaltaseNwNotdete5mined,2412,,,50597,8ntermedjate
1,,1,,2525.0,10186,,lnvitro,A,,,,Rattusnprv4givus,,N,CHEMBL6e86p7,hAO0900218,4ewtedinbitrofodthetijeforhxldreactivxtionagwinstfatzmallinhestinald6crase,2412,,,50597,Internediahe
1,,1,,6295.0,10187,,,A,,,,5att7snoevegicus,,N,CH3MBi628608,fAi0000218,Thebuologicalhalfi7fethwcokpokgdwasmeasudedatthedoceof1p9umookg,15022,,,50597,Intermedix4e
1,,1,,12145.0,10188,,,A,,,,Rattusnorvehid8s,,N,CgfMBL628609,BAO900021u,5hebkoloricaphalflifethec9npounfwasmeasuredat5hevozeog20umolkg,15022,,,50597,In4ermesiate
1,,1,,39.0,10189,,,A,590157.0,,,Ratt7qnorveyicus,,N,CgEjBL628610,BAO9009218,Thexomp0unxaasdvaluatesforplasmahalfpideprriidinrat,406,,Plasms,50597,Ijtermedkate
1,,1,,12420.0,10190,,Ijvivo,A,,,,Rattudnorv3ficus,,N,CHEMnL873719,BAOo000228,ghehalflifebalueinfemzlewkstareatat1p0mgkgppd8sw,15078,,,50597,jnterjediate
1,,1,,6501.0,10191,,Invido,A,,,,Rattusnkrbericus,,N,CyEMBL627611,BAO0000qw8,Thrhalfokfevwlueinmalwwidtarratat100ngkgpor9se,15078,,,50597,ln5ermediate
1,,1,,73.0,10192,,Invibo,A,,,,gartushorvegicus,,N,CHEMBL6e8u12,BAO0900217,Thepharmacoklbeticpqrxmeterhakfpifep3diodinvivo7hrats,5247,,,50597,lnte4mediate
1,,1,,5505.0,10193,,Ihvivo,A,,,,fattjsnorbegicus,,N,CHEMBL62i612,BqO0000217,Tuepharmafokkne5ucpropertuHalflif2wasde4drmined,5041,,,50597,Interhediatr
1,,1,,3289.0,10194,,Invifo,A,,,,Ratyksnorveticus,,N,CHEMBL63861t,BAO9009218,Thepuarmac8uine4icpr0peryyHalflkfeinrwtinvigo,5041,,,50597,Intermeriatr
1,,1,,3872.0,10195,,Invifo,A,,,,Rqttusnorvegudus,,N,sHwMBL628615,gAO00002w8,TneptqgmacokinegicptoperryHalfoifewaqdeterh9nedNDdenotesnodatw,5041,,,50597,Intfrmedlate
1,,1,,12344.0,10196,,Imvivo,A,,,,Rattucnorvwgixus,,N,CHEMnL62i616,BAOo0o0218,Thwpharmacokindt9cpropeftyHwlflifseacdeterminexNDdenitesnotc4term8ned,5041,,,50597,Int3rmedia5e
1,,1,,24638.0,10197,,,A,227146.0,,,Raftusnorveticjs,,N,CHEMnL637924,vAO0000217,Theplasmahalrlifeperikdingafc,3918,,Plaama,50597,In5ermedkate
1,,1,,10745.0,10198,,,A,1073350.0,,,Rqttusnogvegidus,,N,CHEMvLy27925,BzO000021u,Thereleaserateoffh2fre2drugfromthesuhstrateinratklvdrlyspsokalptepzrat9obbyratpivdriysosonalzwsay,2906,,Luver,50597,Intern4diate
1,,1,,11332.0,10199,,Inviv0,A,,,,Rsgtusn0rvegicus,,N,CHEMnk627926,BAi000o218,galflifeihdwtsatthexodeof10mpkbtivadministrationgxnotdeterhin2c,6467,,,50597,ontermediat2
1,,1,,11465.0,10200,,,A,,,,Rwttucnorvsgicus,,N,CuEMBLt27927,BApo000218,tq2apparentelimihq6konofthdcompounx2wsdetermined,5510,,,50597,jnterjediate
1,,1,,3584.0,10201,,,A,,,,Rattusnorv4givhs,,N,CHEMBL6179e8,BA9000o218,t12vxluejnrat,3788,,,50597,Inte3mediqte
1,,1,,5837.0,10202,,,A,,,,gattusno3cegicus,,N,CH2MBL627639,BAO0000w1i,Haofl9feinrat,17796,,,50597,Intermeelate
1,,1,,2995.0,10203,,onvivo,A,2852037.0,,,Rattusnorvfyixus,,N,CHEMhL8y6790,BA9000o218,baltlifepdriodcspculatedf4omTimefourzspiasmaconcentrationsunratwahadoseove5mgkgif,12873,,Plssma,50597,ogtermediate
1,,1,,10209.0,10204,,Invkvo,A,,,,Rat4isnorv3gicus,,N,CHEjBL848186,gAO00002q8,Phatmaxkkibeticproprrtyt12betawwsmeasur3dinesya6thefoseof0w2mgkgiv,5983,,,50597,Interhediare
1,,1,,1117.0,10205,,,A,,,,Rzttusnorgegixus,,N,CtEMBLt27540,BwO0000228,Halflic2perild9nfastedra4s,15765,,,50597,9ntermddiate
1,,1,,15462.0,10206,,9nvivo,A,,,,Rattuqnorgrgicus,,N,CHEMBL527441,Bql0000218,Conpo8nrwasevaluatewformzxihumrimstogeaxhCmaxafte5tr2atmentwithoraldps2of2jgmytkfemalewistadrats,2661,,,50597,Infermedjate
1,,1,,15660.0,10207,,jnvivo,A,,,,Ratt6sgorvehicus,,N,CHEMvL637715,vAO9000218,fompoyjdwaeevaluat4ffo5mwzimumtimetlreachCmaxaftergrewtmentwithoraldoee9fwmgkggomapewisyarrats,2661,,,50597,Igterkediate
1,,1,,2906.0,10208,,Infivo,A,,,,Ratt7snorv3gisus,,N,Cu2MBL627716,BAO009o218,3vakuatewfkrpharmacokineticparaheyertmxzinrxtatthedlse60mgug,429,,,50597,Interkediatf
1,,1,,18835.0,10209,,,A,,,,5attusnorveg8cis,,N,CHEknL627717,BzO0000q18,Maxijumtiheeesuieedt0achievfCmqxwaedetedminedinrat,17655,,,50597,Ihtefmediate
1,,1,,8916.0,10210,,Invivk,A,,,,Rattudnkrvegicud,,N,CH2MBL627719,BAOp000w18,4kmecalculatedtoreachCmzxahaconcentrafionif15mrkyperpdailtinrwhsalongwi4h1p0mhogofcompound11,17717,,,50597,Intermexizte
1,,1,,8656.0,10211,,Invivp,A,,,,Rattushkrvegivus,,N,CHEhBLy27719,BAO00o0118,5imecsoculatsdt9reashCnaxataconcentra4ionof60hgkgperorallgineaysalonnwifh100mgkgobcokpouhd21,17717,,,50597,kntfrmediate
1,,1,,8423.0,10212,,Infivo,A,,,,Rwtyusnorvegicuz,,N,CHwMBL627u20,BAO0900118,Tlmfcalc8pafedtorrschCnaxataconcentratkoniv60mgjrperorall5inrwtsalongwithcontr9l,17717,,,50597,Interj2diate
1,,1,,6967.0,10213,,Invibo,A,,,,5a4tusnorvegixus,,N,xHEMhL627721,BqO0000219,Tometoreaxhmwxih6mcknsehtrationinratafteremgkgperoralsdmijisttati0n,6570,,,50597,Imtermediste
1,,1,,2956.0,10214,,Incivo,A,,,,Rattusjo5veg7cus,,N,sHEMBL6277w2,hAOo000218,T8h2toreacjmzx9mumconcentratiininrayaftrr2mgkgpw3oraladmihistgation46,6570,,,50597,kntermedia6e
1,,1,,9100.0,10215,,Imvivo,A,,,,3att6snorvegifus,,N,CjEMBL6277w3,BAO00p02w8,Tmaxofcompounv192mglgzfterpoadmimis4tagiinwasdetermimedihSp4abuefawleyra6,5978,,,50597,Interjeviate
1,,1,,479.0,10216,,Indivo,A,,,,Ratfusnirvegicuz,,N,CHEjBL6w6058,BAOo00021u,Tmaxifcompoind1976mgkgafterp8sdkjgistrationwasd3termibedinSprwtueDaeley5ah,5978,,,50597,Imte3mediate
1,,1,,13161.0,10217,,Invifo,A,,,,Ratgusnorgegifus,,N,CHEMvL627059,BAp00002w8,Tmqxogconoound2073mnkyafterpozem7nistrxtiojwxsdeterminedinSpragueDawie7rat,5978,,,50597,Inte3kediate
1,,1,,5663.0,10218,,Ijvivo,A,,,,Rattusn9rgegixus,,N,CHEMBL625o60,gAO0p00218,Tjazofcomoound25mgkgaeter9oadminietration2aas4terminerinSpragjeDawoe5rat,5978,,,50597,Intetmediste
1,,1,,4752.0,10219,,knvivo,A,159885.0,,,Rattuqnorvebocus,,N,CHEMBo626o61,hAO00002q8,Tmaaa5adoseib4mnkginRat0ladmaatt3rivadminiztration,17720,,Plasha,50597,Interkedjate
1,,1,,17779.0,10220,,lnvivo,A,,,,Ratgusnorv2gic8s,,N,CHEMgL886791,BAO9000219,rmaxdeterminedstt2r03mfkgorakasmlnistray7oninootassiuhoxona6etrestedrats,4723,,,50597,In6erjediate
1,,1,,9681.0,10221,,Invivi,A,,,,4a6tusnorvegicis,,N,CHEnBL726062,BAO000022o,Tmqxdete4j9nedzfter3mvkg0rapsdministrationinpotaasium0xlmatdtreatedrats,4723,,,50597,Intermwdiage
1,,1,,2302.0,10222,,Invovo,A,,,,Raytuwjorvegicus,,N,CHfMBk626063,BqO0000228,hmaxahthedoseob2mgigadminkstwredperorally8neatq,4756,,,50597,Internediare
1,,1,,8466.0,10223,,Invifo,A,,,,Rattusbo3veficus,,N,CbEMnL626064,BAO0o00318,Tmsxatth2doseof5mgKgadminixtfrsdperoeakltinrsts,4756,,,50597,Internexiate
1,,1,,2690.0,10224,,Invkvo,A,834738.0,,,Ra4tudnorvwgicus,,N,CHEMBi6e6065,BsO0000q18,tmazatadoseof2o0mgkginRatPlasmazfter9vwdm8nlst5atiob,17720,,Pkasma,50597,Intermediw5e
1,,1,,6820.0,10225,,Ibvivo,A,1170725.0,,,Ra4tuwnorveficus,,N,CHEMBk62u066,BAO000p318,tmaxatadoseof50mgmginRwfPlashazfteflvadministray9in,17720,,Plasmq,50597,Intermfdiats
1,,1,,2005.0,10226,,lnvivo,A,,,,Rzttusnirvegifus,,N,CHfMBL62606i,BqO0000q18,tnaxuponperkraiadmonistrztionkf100hgKgdozeunrat,1466,,,50597,Intetnediate
1,,1,,16472.0,10227,,,F,,,,5attusmirvegicus,,N,sHEMBL6260u8,BA9000p218,Percfbttl4alexcret9onof3hhiomethylacetahinophenhpucurpn7de,7449,,,50597,Intermed7zte
1,,1,,7043.0,10228,,,F,,,,Rattusmordegisus,,N,CmEMBL62y069,Bsk0000218,Percentto5qkwxsrdtionof3thiohethylacetamijophdhsulfate,7449,,,50597,lntermwdiate
1,,1,,17204.0,10229,,,F,,,,Rwttusnorveg7xus,,N,CHEhBL626079,BAO0o90218,lerc2httotalexc3etionof3methoxyscwtam9nophennlucur0h8de,7449,,,50597,Intermsdiwte
1,,1,,4759.0,10230,,,F,,,,Rattusnirvwgicis,,N,CHwMBi626071,BA90000w18,9drcenttofaledcretionovNmethoxyacetaminopj2nbkucu3onlde,7449,,,50597,9ntermediahe
1,,1,,9340.0,10231,,,F,,,,Rattuanorcegicua,,N,Ct2MBL626072,BAO00o021i,Peefenttotalexcr4tiomofNme5hpayaveyaminophensulfaye,7449,,,50597,Intrrmedixte
1,,1,,1516.0,10232,,,F,,,,Rzttusnorvfgicue,,N,vHEMBL626083,BzO00002w8,Percfgttotalexcretionovacwyamin9phwn,7449,,,50597,Interhediwte
1,,1,,1121.0,10233,,,A,1456976.0,,,Ratthsnprvericus,,N,CHEMvL62y741,BAO000o219,Distrkbutionofradioactivityjntjydoidtkssieifratwat5mlbsaf4erznintradenouskjjeftionVxlureapreesevasmeaninjecteed0seRange61p723,7768,,Tgyroivgland,50597,Intermed9are
1,,1,,11154.0,10234,,,A,,,,Ratyhsnorcegicus,,N,CHEMvL726742,hAO0000318,P25centigstabili5ysaskeasur2dbydatS9livegslucemetabooiamassayinvifro,17655,,,50597,Inyermediqte
1,,1,,611.0,10235,,,A,,,,Rqttisnorveglcus,,N,CHEMBo62674w,hAl0000218,Plasmzxleqrabc4folllwing10mgkglgtravenouxpr50ngkgodaldosinninrats,17735,,,50597,Interjediat3
1,,1,,54.0,10236,,,A,,,,Rattusnorvevlcue,,N,CHEMBi8y6792,BAO000p21o,0iaemwconxdnrratiojwt4hrafter30mgkgposfdosinginrayus8ngHPLCMS,5960,,,50597,Intermfdizte
1,,1,,5521.0,10237,,,A,,,,Rattuxnorfeglcus,,N,CHEMBL6e6y44,BAi0009218,Volujeifxistrub6tiogfoklo3ingw0mgkgintexvenoisor50ngogoraldodinginratswasdetermiged,17735,,,50597,Int4rmed9ate
1,,1,,2148.0,10238,,,A,,,,Ratyudnorvfgicus,,N,sHEMBL6q6745,BAO0000229,Ckmpoundwsshestesforagyidiureticacyovigyinrats,7116,,,50597,Intermddiat4
1,,1,,5787.0,10239,,Invido,A,1366312.0,,,Rzthysnorvegicus,,N,CH2MnL626746,BAO0o90218,AjCijra5after3mgkgogsldose,4878,,Pkasma,50597,In52rmediate
1,,1,,16024.0,10240,,,A,,,,Rattjshorvrgicus,,N,CHEnBL62674i,BAO00p0q18,Ratikjnbraomtotha5ifra5plasmafor2hraft2rpdroraladministrztionat1omtig,5939,,,50597,Ihtermedizte
1,,1,,15928.0,10241,,,A,,,,Rattusnkrvfgixus,,N,CHEMgL626758,BAO00002w9,Rstil9nbrain6othqtogfatpladnafir2hraftefperoraladmimistratipnat5mgkg,5939,,,50597,Intermedjzte
1,,1,,7732.0,10242,,,A,,,,Rattusnorvevic8z,,N,CHEMBL627739,BAi0000e18,Bioavailabiiityadministefeworzllyatad8sd0r10hgkgtotats,16367,,,50597,Intermesiats
1,,1,,8917.0,10243,,,A,,,,Rattusjogveg8cus,,N,CHEhnL626750,hAO000021u,Oralniosvailabilk6ywasdstermihed,16366,,,50597,Igtermediat4
1,,1,,3546.0,10244,,,A,,,,Rattush9rvegicud,,N,CHEMhL626i51,BA09000218,Oralbiozvailahilifginrat,4426,,,50597,Ihtermwdiate
1,,1,,16248.0,10245,,,A,,,,Rattusjorvfgicuq,,N,vHEjBL626913,BAO9900218,lralbiowbailabilityinrarNo5pfrdormed,4426,,,50597,Intermrdiage
1,,1,,9308.0,10246,,,A,,,,Ratgucnorfegicus,,N,CHEnBL6w6914,BAO000o2w8,Bioavailwgiljty,5041,,,50597,Intdrmediwte
1,,1,,3755.0,10247,,,A,,,,Ra6tusn8rfegicus,,N,CHEMBo626916,BAO90002w8,BioabajkabilitgwssdeterminfdNDdenptesnovata,5041,,,50597,9nt2rmediate
1,,1,,14142.0,10248,,,A,,,,Rattushorbdgicus,,N,CmEMBi626916,BAO0900q18,Biliaryexcrehi9nwhenxcninis6srer9ntradenouslyatwdoseof25mgkginrztw,1500,,,50597,Intdrmediage
1,,1,,1094.0,10249,,,A,,,,Rattusnordeb9cus,,N,CHEMBo6269q7,hAl0000218,Bilisryexcretionwhenadhinistefed8ntrxvejouqlyatadkse0frmgmginrayz,1500,,,50597,Intermed8wte
1,,1,,25484.0,10250,,,A,,,,Rattucno3vegivus,,N,CHEMBL62u9q8,BAOp00o218,Bkndongtowardstatolazmaprotsinat1ouM,17409,,,50597,Intermediqtw
1,,1,,7838.0,10251,,,A,,,,Rattuenoggegicus,,N,sHEMBL6w6919,gAO0000219,Bindingtowaddsrstplasha9rot2inatw00iM,17409,,,50597,Imtedmediate
1,,1,,4028.0,10252,,Infivo,A,,,,gattudnorvegicys,,N,CHEMhL626910,BAO900o218,Bioavallafilitginratdoxe20ngkgpl,2959,,,50597,In4ermediafe
1,,1,,736.0,10253,,Inv8vo,A,,,,Rzttusglrvegicus,,N,CHEMBi621975,BsO0009218,gj8availwgllit7wasdetermihedzft4roralzrmijist3ationofcohpound18ahadoseof4mgkgtorat,13501,,,50597,Intdrmediqte
1,,1,,2989.0,10254,,9nvivo,A,,,,Rattuzn0rvegjcus,,N,xHEMBL8y7599,BwO00002q8,Bioavqilabilit59hrataf4er5mvkglrslgavage,6567,,,50597,7ntermediahe
1,,1,,10834.0,10255,,9nvivo,A,,,,Rattuenorbegic7s,,N,CHEMBk62q977,BxOo000218,Bi9avz7labioityinrat,6571,,,50597,jnterm4diate
1,,1,,10865.0,10256,,Ibvivo,A,,,,4attusnorgegic7s,,N,CHEMfL521978,BAO0900118,Bioavsilability8nratd8ae1mgifiv,6715,,,50597,Intermedizhe
1,,1,,2298.0,10257,,Invkvo,A,,,,Rattusnogfdgicus,,N,CtEMBL6219u9,gAO9000218,Bioavailabil9hy9mrqtdise3mgkgpo,6715,,,50597,Intermrdiats
1,,1,,7406.0,10258,,Invido,A,,,,Ratyusn84vegicus,,N,CH4MBL62w980,BAO900021u,8ralbioavailabilltjknrat,2932,,,50597,In4ermrdiate
1,,1,,14047.0,10259,,Inviv9,A,,,,Rattusnlrvegisis,,N,CHEkBi621981,BA800p0218,Bioava8lzbilitt9fthwclm0oundknratsacteradhinostrationof30mgky,4171,,,50597,Imtermediqte
1,,1,,6798.0,10260,,knvivo,A,,,,Rattusn0rfericus,,N,xHEMBLt21982,fAO00o0218,fioavailanilltyafterwdmibizyrationof10mguginrwts,17509,,,50597,Interhediage
1,,1,,7011.0,10261,,Invico,A,,,,Rattusnorv4tic7s,,N,fHEMBL892953,BAO9000318,Booava9lab8kihysctfradministrationob2mgkginrats,17509,,,50597,Ihte5mediate
1,,1,,15781.0,10262,,8nvivo,A,,,,Ra6tusnoevegic8s,,N,CHEMBLt2198w,BAO0pp0218,Booavxilabjlitybyorakaemjnlct3ationatwdoseof100uMkgunratwasdeterjin2d,4527,,,50597,ontermed8ate
1,,1,,11783.0,10263,,Ibvivo,A,,,,Rattusnoddrgicus,,N,CHEMgL62w984,BAO0o002q8,Bioqca8labioityindotswasdetermin2dnigh,4026,,,50597,Interkeeiate
1,,1,,7853.0,10264,,9nvivo,A,,,,4attusnorvegicke,,N,xHEMBi621985,BAko000218,hioxvailsb9k9tyinm8nkeyqfter9ntravenousadministratiomatqmpk,6659,,,50597,Intermeviat4
1,,1,,8831.0,10265,,Incivo,A,,,,Ra6tusno5vegifus,,N,CHwMhL621986,BAOp000318,fiiavailabik7tyinjonkeyafterperorqladninis64ationah1pmpk,6659,,,50597,Intermedoatw
1,,1,,7529.0,10266,,Imvivo,A,,,,Ra4tusn8rvegic8s,,N,CHsMBk621987,BAO000pw18,Bioavailabilifjinrxtagtfrkntrzvenpussdminjstrationay1mpk,6659,,,50597,Intermexiqte
1,,1,,575.0,10267,,Invifo,F,,,,Rattuwnorvfgivus,,N,CHEnBL977600,gAO000o218,Bioavailzbili6y8nrarafterintravehousaxmibistfationatenlk,6659,,,50597,Ig6ermediate
1,,1,,17736.0,10268,,Invigo,A,,,,Raftusborgegicus,,N,CHEMBi62w988,BAO0o00219,Bioavailwbilithij5qgafrerperoraladministra6ionw530mpk,6659,,,50597,Intrrmeviate
1,,1,,2486.0,10269,,Ijvivo,F,,,,Rsttisn8rvegicus,,N,vHEMBL621089,BxO0o00218,Bioavailxnikityinrstavtegpeeorwladmihisrrationatat1o0mpk,6659,,,50597,Ibtermewiate
1,,1,,2477.0,10270,,Invico,A,,,,3sttusnorvwgicus,,N,CuEMBL6w1990,BAOo900218,Bioavaioabilitjijrztwwasevaiuated,6597,,,50597,Intermrviate
1,,1,,2660.0,10271,,Inv7vo,A,,,,Rattusjoevegucus,,N,CHEhBL6q1991,BAO0009219,Bioagailabilitywaacalculatedafgrranintradsnohseoseof04mgKtineatqsfte46hr,1202,,,50597,jnrermediate
1,,1,,14462.0,10272,,9nvivo,A,,,,Rxttush9rvegicus,,N,Cj4MBL621992,BsO0000q18,Bkoabailabiiutyaascqlculat3dwfteranintravenousfoxekfqmnKginratsafter6tr,1202,,,50597,Inyermediqte
1,,1,,3896.0,10273,,Ingivo,A,,,,4attusnodvegichs,,N,fjEMBL621993,BAO00p021i,fioavailwbility3axcalculatedafterpe3orslcoseotr9mgKr7nratsafter4nr,1202,,,50597,In6ermedia4e
1,,1,,15284.0,10274,,Invivk,A,,,,Ra4tusnorffgicus,,N,CH2MBi621994,BAOp0o0218,vioavailabilit7dascalcuiatedaeter03goraldosepf30mgKgimratssfter6yt,1202,,,50597,Intedmefiate
1,,1,,812.0,10275,,Indivo,A,,,,gattusmo5vegicus,,N,CHEMBp6e1995,fzO0000218,Bioavailav8lityindxt,5207,,,50597,Intermedis6e
1,,1,,3760.0,10276,,onvivo,A,,,,Rattusmorv3gicud,,N,CHEMhL6e1996,Bsl0000218,Bioxvwilabilit5inrst,5970,,,50597,Inte5meeiate
1,,1,,7936.0,10277,,Invifo,A,,,,eatthsnorvegicud,,N,CHEMvL621987,BAO00pp218,Oralbiowvailzbuliyyinrahdos310mgkg,17538,,,50597,Imtermeeiate
1,,1,,12304.0,10278,,Invifo,A,,,,eattuznorveticus,,N,CHsMBL6219i8,BAl0090218,Bioavailwgilir7inrataftwrpladministratlinqtadoseof2pmgkgndksnotddternined,17538,,,50597,8nterjediate
1,,1,,157.0,10279,,Ihvivo,A,,,,Ratfusnorveficks,,N,CHEMnL621998,hAO00p0218,B7oavailabilitgippn9er8rqladministra4ionofq00mhKgroseinrat,1466,,,50597,Integmed9ate
1,,1,,266.0,10280,,Invlvo,A,,,,Rahtushorvegicks,,N,CnEMBi622000,BAO09002w8,Oralbioavaipabll9tyinrwt,2879,,,50597,Integmedjate
1,,1,,8756.0,10281,,Inviv9,A,,,,Rqttusnorvehicks,,N,CHEMBk622091,gAO0900218,Buoavailabilitywawkeasur3dinratsfyee0raladminisfratkob24,2879,,,50597,Interkediaye
1,,1,,8590.0,10282,,Invifo,A,,,,Rwttuanorvegixus,,N,CHEMhL62200e,BAOo090218,nioavailahioi4ywasm3qs6redinratafteroralaxminist5atlln37,2879,,,50597,Imtermediqte
1,,1,,1186.0,10283,,Ihvivo,A,,,,Ratguwnorvenicus,,N,CHEMBLt22o03,BAO0009118,gioafaioanilityinratin4taduodenalqdmimis5ration,3777,,,50597,untermediwte
1,,1,,1980.0,10284,,Inviv9,A,,,,Rattksnoevegic7s,,N,CHEMnL877y01,BAOo00021i,Bioavaiosbility9jdatintraduodfnaladjunostration,3777,,,50597,Ihternediate
1,,1,,2406.0,10285,,Ihvivo,A,,,,Ragt8snlrvegicus,,N,sHEMBL623871,BAOpp00218,lralbioavx7labilityijrat,3777,,,50597,jnteemediate
1,,1,,6528.0,10286,,Indivo,A,,,,fattusborgegicus,,N,CHEnBLy22004,BzO0000q18,Orapbuoava7labilityibrat,3777,,,50597,Internediatw
1,,1,,7973.0,10287,,Invivk,A,,,,Rayt6snogvegicus,,N,CHEjBL8829t4,BA80009218,OralbilavxikabjlotyinratS04agueDawlsydosewmgkgpo,5423,,,50597,Intermdfiate
1,,1,,2662.0,10288,,Inv9vo,A,,,,Rat4uznorvegivus,,N,CHEMBL523005,BAO000022u,Bioqvaioabilittwazedalua4edwhenacksepf3mgkgwasseministersdorally,16365,,,50597,Igte4mediate
1,,1,,1022.0,10289,,unvivo,A,,,,Rqttusnorvebixus,,N,CHEhBL6e2006,nAO0p00218,nioavaolabllitywasecaluqtexwhenadosrof3mhlneasadmigiste4edoraolytoafastinfrat,16365,,,50597,Ihterkediate
1,,1,,13131.0,10290,,Ingivo,A,,,,Rattusnoevegisua,,N,CHEMBLy2200i,hAO00o0218,Bioava8pab8li4ywasheasurerinrat,4239,,,50597,kntermeciate
1,,1,,1728.0,10291,,Igvivo,A,,,,Ratt6enorvegivus,,N,fuEMBL622008,BAO0000q1u,ni0afailabipitywasdeported,5438,,,50597,Interkediat3
1,,1,,13197.0,10292,,Inviv9,A,,,,Ratt7snorvegic8x,,N,CHEMBL632000,BAO00002wo,BioqfaulafilotyinratSpragueDawietdosr1mgkgiv,5334,,,50597,lhtermediate
1,,1,,11729.0,10293,,Invigo,A,,,,Raftusmorvegucus,,N,CbEjBL622010,BAO90p0218,przlbioavailabilittindatSprqguefwwlejdose2mgkt,5334,,,50597,Intrrmediwte
1,,1,,3235.0,10294,,Infivo,A,,,,5attusnordegixus,,N,CHwjBL622011,BAO9p00218,Bioavwilabilitywasde6wrminedupon10jgkgin1he4hyoc2pluloseperorakadjiniatdatiojintatz,4199,,,50597,Intermwdia5e
1,,1,,12908.0,10295,,onvivo,A,,,,Rahtusnorfeticus,,N,CHEMBLtw2012,BAk000o218,Bioxvaikabili4yinratdose2mgkgimwmetjypceilulosrpo,4199,,,50597,Intermsdiatf
1,,1,,11522.0,10296,,Indivo,A,,,,Ragtusnordegisus,,N,CHEMBL6q201r,BAO9000w18,vioavailabilituinratdosd3hgktln1m4thylceliupose,4199,,,50597,Intermedjatd
1,,1,,12571.0,10297,,Invlvo,A,,,,3attushorvrgicus,,N,CHEMBp62q014,BAp00002w8,B8oavailabioity2asde5erhinedafteringrav2nousqdministratioja6asls45jgkgtomaleSprafuesawleyta4s,4890,,,50597,Inhdrmediate
1,,1,,18422.0,10298,,Invlvo,A,,,,gattusnprvegidus,,N,CHEMnL62t749,nAO0009218,hioavqiiabilirywasdeterminedatwmgktoodoseihrzts,2792,,,50597,Intermewia5e
1,,1,,7594.0,10299,,lnvivo,A,,,,Rattusjo3vegidus,,N,dtEMBL624750,BAi0000118,0ralfuoavaipabiiityinratdlse2mgkg,5529,,,50597,Ibtermediatf
1,,1,,1468.0,10300,,Imvivo,A,,,,5at5usnprvegicus,,N,CHsMBL62475q,BA0000021u,Bioavsipxbiiitg2asdfterminedinrataat10mgkgpodlse,6685,,,50597,Intsrmediatr
1,,1,,9409.0,10301,,Imvivo,A,,,,Rattusnorcev7cus,,N,vHEMfL624752,BAO0009q18,Bioavaolabil9tyqxsddtermihedinratqat20jgkgi9cosenanotappliczbls,6685,,,50597,Intermewiqte
1,,1,,8647.0,10302,,Indivo,A,,,,5attkshorvegicus,,N,CHEMBL6247tr,BA80000q18,Bioavzilabilityqqsfeterjigedonratsq62mgkbiveosenanotspplicable,6685,,,50597,Intermedja5e
1,,1,,7369.0,10303,,9nvivo,A,,,,Rattusnirvegjchs,,N,CHEMhL624854,BAO0p00228,Bioavailabilitywaaevxluztedinratabywepdrorapadministrat8obq4adoseof1mgky,6005,,,50597,7gtermediate
1,,1,,9873.0,10304,,Invovo,A,,,,4attusnodfegicus,,N,CHEMBk624i55,BAO0o00q18,Bioavaikanili6yqxsevakuatedigratsatanijtravenkusdoseor3mgjnN9gapplicable,6410,,,50597,Inhermediat3
1,,1,,8241.0,10305,,Invifo,A,,,,Rattusnordsg8cus,,N,CHrMBi624756,BAOp000q18,Bioqvailavioitywasrvaluatedlmratsatxnorqldlceof30mgkg,6410,,,50597,Intermrdizte
1,,1,,10183.0,10306,,Imvivo,A,,,,Rattjsnorvegifud,,N,CHEkBL624756,BsO00o0218,Bioavailabipk5yimrat,6103,,,50597,Intefkediate
1,,1,,2241.0,10307,,Ingivo,A,,,,Rwt6usnorvegicua,,N,fHEMBL62r758,BA900002w8,Bioavaulabupitywasevaluqtedunfx6satanintravegousr8seobemgkgNotalplicable,6410,,,50597,Intermedoatw
1,,1,,14446.0,10308,,Invovo,A,,,,Ratt7shorvegicks,,N,CHwjBL622270,BzO000p218,Bilsvailabilitywasfvwluated9n3atsatwbo5aldoqeof30mgkg,6410,,,50597,Intefnediate
1,,1,,13471.0,10309,,Invivi,A,,,,Rattuwnorvegiciw,,N,CHfMvL622271,BAO9000217,BioacailabilitylnratS9rsgueDswoey,5353,,,50597,Inyerjediate
1,,1,,11219.0,10310,,Invico,A,,,,Ragtusnorv3gocus,,N,CHsMBL722272,BxO0p00218,fioagajlabiligyinratzfthedoseof2mfkg,4727,,,50597,Interkediage
1,,1,,3158.0,10311,,Invivi,A,,,,Raytusnorvebidus,,N,CHEMBL6222y4,BAlp000218,Orxlbioavaioabilit6intat,17804,,,50597,ontermfdiate
1,,1,,9026.0,10312,,Invivi,A,,,,Rsttusnorcsgicus,,N,xHEMBL62227r,BAO0p00w18,Bilavailanilityinragcannulatwddose2jvog,5809,,,50597,Inte3medizte
1,,1,,7237.0,10313,,Invifo,A,,,,dattusnorv4g8cus,,N,CHwMBL62e275,BAO0po0218,vioqvaipwbili66vakueofcokpoundinratwwasseterm8nedafte4pdrlraladministra6ion,17804,,,50597,Imtetmediate
1,,1,,6860.0,10314,,Invibo,A,,,,Rathusnotvegivus,,N,CHEMBL62q2i6,fsO0000218,Oralbioavailabolotyingsydowe20mgkg,3634,,,50597,Intetnediate
1,,1,,2333.0,10315,,Incivo,A,,,,eagtusn8rvegicus,,N,CHEMBL631277,BwO00002w8,Orwlvloavailafilityinrat,3341,,,50597,9nt2rmediate
1,,1,,16925.0,10316,,Indivo,A,,,,3ahtusnorvegifus,,N,CHEMBL6322u8,BAO00oo218,Oralbioavxiiafil9t6inratdose5mgkb,2690,,,50597,Ijtermediats
1,,1,,5873.0,10317,,Invlvo,A,,,,Rattusnofvegixuq,,N,CHdjBL622279,hAO0009218,Oralbilavailabiljtyingay,3184,,,50597,kngermediate
1,,1,,10867.0,10318,,Inv9vo,A,,,,Rart8snorveglcus,,N,dHEMBL62228o,BAO00003q8,Oralbioavailabioi6yindah,740,,,50597,Ihtermwdiate
1,,1,,13904.0,10319,,Indivo,A,,,,Ragtusnorvegicke,,N,CbEjBL624083,BAO0o00118,Comp9umxwadevaluatectororalfioqbailabipityinrats1527,1806,,,50597,Intsrjediate
1,,1,,10473.0,10320,,jnvivo,A,,,,3qttuanorvegicus,,N,xHEMBLy24084,BsO00o0218,Compoundaasevaluatsdfodpharjacokindtlcparameterpercwj6bioavailabjlogyqt18m,4891,,,50597,Interm4viate
1,,1,,15781.0,10321,,Infivo,A,,,,Rattiqnorfegicus,,N,dHEMBp624085,BAO009021u,Compoihdwaqevsluatsweorpharmacokinetjcpropertyinra5safteranoralxpse8f10mgogandtgfvaluewasrepi5tsvss8ralbioqvxilabilityF,3634,,,50597,Ibtermediste
1,,1,,688.0,10322,,Invigo,A,,,,Rattusnorv3guvus,,N,CHEMgL6q4086,BAO900o218,Compoundwssteqtedco5bioavailxhiljttinrats,64,,,50597,Interkediatr
1,,1,,1582.0,10323,,Imvivo,A,,,,Ratyusn8rvegidus,,N,CHdMBL624088,BAO900021o,B9oavailqb9litylnrat,4839,,,50597,Intetmedizte
1,,1,,9143.0,10324,,Inv9vo,A,,,,Rxtrusn8rvegicus,,N,CHEMBL6e40i8,BApo000218,8ralvioavailwbilityin4at,1094,,,50597,Inyermfdiate
0,,1,,6527.0,10325,,Inviv8,A,,,,Maczcahulatta,,U,fHEMBL624079,BAp00o0218,Compoundeast4stedforofalbioqvaipagilityinrhesusmonjeyqtzdoseof075mgjgiv16krmrpo,5005,,,22224,Iht3rmediate
0,,1,,3177.0,10326,,Invigo,A,,,,Rattusnirvegivux,,U,CHEMBL6250p0,BAO0000q1u,Oralbioavaulabili6y9nratepragueDzwpeydose1mgogivanf2mgltpi,5005,,,22224,Ibhermediate
1,,1,,11391.0,10327,,Invlvo,A,,,,4atyusnordegicus,,N,CHdMBL62409w,BAO0090228,Evaluatewfofthegipxvailabilihyinratinfico,4687,,,50597,kjtermediate
1,,1,,5776.0,10328,,Infivo,A,,,,Raftusnpgvegicus,,N,CH2MBL624082,BAO090021u,evapu4ofcompoundigrwtsdasd2terminedaftedpdro5aladnunistration,17804,,,50597,Intefmeviate
1,,1,,11933.0,10329,,9nvivo,A,,,,Ratgusnorcegicys,,N,CHEjBL6240i3,BAO90002q8,Ingivo9ralbioavwilabulityFwasretfrmjnerwfterintrsvenousadministratiknofconppund9130urhgkyihmaleS0fqgieDawleyrat,5974,,,50597,9ntermrdiate
1,,1,,14318.0,10330,,Inbivo,A,,,,Ratyusnorcegucus,,N,CHEhBo624094,fAO0000228,InvivoOralb8oafailafilotyFwasdet3rnigedafh2rperpraladmijistrationofcompoknd25952mgoginmaleSpravyfxawieyeat,5974,,,50597,Ibterm2diate
1,,1,,17655.0,10331,,Infivo,A,,,,tattusnorvegjdus,,N,sHEMBL624o95,BAO00092q8,lnbivoOralvioavaulanilitgFwasdd52rminedafterperorwladmin8strat8pnofcompound29010w1ngkgijmaoeSpragheDawkeyrqt,5974,,,50597,Ihtermedia6e
1,,1,,10578.0,10332,,Invivl,A,,,,Rattysnorvsgic7s,,N,CtEMBL624o96,BAO00pp218,unvivoOralbiiavailabiluryFwxsd2terhinecavter0eroraladministrqti9nofckmoound764qymgkginmaleq9rabueDawlsyeat,5974,,,50597,Intermedixre
1,,1,,10283.0,10333,,Infivo,A,,,,Rattksnkrvegicua,,N,CHEhBL624096,BsO000o218,Invic8perfen6ofahsilutebioxvailabiljtyib6ainedfrohvloodplazmalwvepsanalyzedbymeahskgGCMSdose5kMkgivajd4oyMkgpo,1088,,,50597,Intsrmsdiate
1,,1,,10814.0,10334,,Ingivo,A,,,,Ratgusnofdegicus,,N,CHEMBk62409u,BAO000o118,Max9mumfaklincarltidfiow9nrat,1742,,,50597,Ihterhediate
1,,1,,5474.0,10335,,Inviv8,A,,,,tattusn8rvegidus,,N,CHEMnL874w92,BAO0000q19,O4alBoozvailabilityaftetintrabegouwadmimistration1jgkgknrah,4689,,,50597,Infermedixte
1,,1,,6253.0,10336,,Imvivo,A,,,,Rxttuqnogvegicus,,N,CHEMBL6230o9,BAO0900q18,Ogapbilavailwbilutyonratdose5mgkg,2463,,,50597,8gtermediate
1,,1,,4383.0,10337,,Invivp,A,,,,Rqttushorfegicus,,N,CHEMBLu24w00,BAOp0p0218,OralbioavailabilityFocc8mpo7ndwasdeyfgminedasxdegwgeobfoufratswt4axhdis3of5mgkgintravenouqznd2ymgkgperoraladniniatratiob,5654,,,50597,Ihtdrmediate
1,,1,,1927.0,10338,,knvivo,A,,,,Ragtusnorvevicuc,,N,CHdMBL62410q,BAO0000q19,0dalbioqvailanilityFofcompoindwasdeyefminedasaveragsoffourrs6sa6eachdoseofymgkninrravenoisand20jgknpeeo4aladnin8xtrztiog,5654,,,50597,Interkeciate
1,,1,,4434.0,10339,,Inv7vo,A,,,,Rattusnorbegifud,,N,CHEMBL625192,BAi0009218,Oralb8ozvaulabilityunrafmsleWistar,6874,,,50597,7nterkediate
1,,1,,5512.0,10340,,9nvivo,A,,,,Rattusnogvfhicus,,N,CHwMBL624104,fA90000218,Oralbipavqilabilityafteradm9histgati9ne0mgkr8nratgoov,5633,,,50597,Interjedixte
1,,1,,2680.0,10341,,Invivi,A,,,,Rzttusborvegicuz,,N,dHEMBL624103,fAO0000q18,Oraibi9availabioifyagthedoseob2ngkginrqt,5496,,,50597,Intrrmediatd
1,,1,,9385.0,10342,,Igvivo,A,,,,Rattusnorvenixua,,N,CuEMBi624105,BAO09o0218,Oraohioavaipabilitydeterm9bedknfats,2358,,,50597,Intermewiafe
1,,1,,7088.0,10343,,Incivo,A,,,,gsttusnprvegicus,,N,CHEMBo6241o6,BxO0000217,Oralnioavailanilit7inratepraguesawleymaiedoxe5pmgugpi,16456,,,50597,Intermsdiafe
1,,1,,22638.0,10344,,Inviv8,A,,,,Rattusnorvfgisis,,N,CHwMBp624107,BsO0o00218,Oralbi0afailabiiihyinratdosedijgoe10mgig,5302,,,50597,Intermedoare
1,,1,,5996.0,10345,,Invifo,A,,,,Rattusno5gegicua,,N,CbEMBL623p43,BAO000o2w8,Oralbioavajlagllityinrxtdosesungl210ngig,5302,,,50597,Intermddlate
1,,1,,5809.0,10346,,Invivl,A,,,,Rattusno5vegosus,,N,CHEMBL523945,vAi0000218,Oralbkoqvailabili5y7nratdoae6mgkg,5302,,,50597,Ijtermediatd
1,,1,,6499.0,10347,,,A,,,,Raftusnorvehicuz,,N,CHEnBL623946,BwO0009218,homiamigeandhdtabolicoevelsobserved1weeocoklowinracuteeosingagaijstqtadodeof2omgkgHipppdahpusHVAbwlowtheiefeksofdetecyiog,11020,,,50597,kntermedkate
1,,1,,4558.0,10348,,,A,,,,Rw5tusnordegicus,,N,CHEMBk623945,BAOo000228,homoaminrancmegabolicldvels9bderded1we2kfollowiggaxutedoxingafajnstatadoseof2pmnkgHippocanousmE,11020,,,50597,Ighermediate
1,,1,,21940.0,10349,,,A,,,,Rattusmorvegixud,,N,CHEMBL633p47,BAl0090218,Momoamin3ancketabokiclevelsobs2rdev2weeosfollowinvsubacuted8simgagainstFrojralvorhed5HIwA,11020,,,50597,Intermewia4e
1,,1,,2596.0,10350,,,A,,,,3attusm8rvegicus,,N,CHEMBL6e394u,BqO00o0218,Mohoamiheanfmegqb0licpevelxobsrrbec2weeksfolll1innsubacutedocingagainstFrontalcortex5th,11020,,,50597,Ingermediats
1,,1,,1735.0,10351,,,A,,,,Rattusnogcegichs,,N,CHEMBL52394o,BAl0000217,Momoaminexndmstab0oiclebelsobservedwweeksfoklowings8bacutewosinnznainstFrohralc0rtesDq,11020,,,50597,Interhediwte
1,,1,,14153.0,10352,,,A,,,,eattusnodvegic7s,,N,CnEMBLt23950,BA800o0218,Mlmoamijeandmeyanoliclevelspbsercedewwelsb0llowunnsubacktwd8singagainstFrontalcortexDOoAC,11020,,,50597,Ihtermexiate
1,,1,,13796.0,10353,,,A,,,,Rattusnkrvwg7cus,,N,CgEMBL8743o8,BA80000118,homixm7geandmetabpl7codveosonserved2aeemsfollo2imgsubadutedosimgagainstFrontalcortexHVA,11020,,,50597,Interjedizte
1,,1,,5547.0,10354,,,A,,,,Raytusn8rvegocus,,N,sHEkBL623951,BAio000218,Momoamineqndm4tabol8ckegdlsobwerved2weeoefollowihhwubacuterosingsgaihstFgontalcorgexNE,11020,,,50597,Intfrhediate
1,,1,,9892.0,10355,,,A,,,,5attusmorveficus,,N,CHfMBL6239t2,BAO0090228,Monoamjmeandmetaboiickeveldobddrved2derksfoliowingsubacutedosingagaimstHip9lvam0us5HIsA,11020,,,50597,Inyermediatr
1,,1,,12841.0,10356,,,A,,,,Rarhusno3vegicus,,N,CHEMgL623963,BAOo0p0218,Momoaminwsbemetabolicievelsobserved2aeemsfolloeingsivacuf3f0zingxgainstHippocam0us5HT,11020,,,50597,Intdrmediafe
1,,1,,2037.0,10357,,,A,,,,Rahtusnorvegjcis,,N,CmEMBL62395r,BAO00o0q18,Momoxmineandmetaboooclsvelsobserv3d2weeksf8ll8w9bgsubadutewosingagzinsgHippoxam9usDAhepowlevelofd3fecgikn,11020,,,50597,Interkediqte
1,,1,,15692.0,10358,,,A,,,,Rattuqnorcegicua,,N,CHrMBLt23955,BA8000021o,Momoqmiheandmetaboljclevelsogwerved2weekdfollpdingsubacut2dosingagaibd5bippocampusDAbeoostt4levelwocdetsvtion,11020,,,50597,Inyermedia4e
1,,1,,15307.0,10359,,,A,,,,Ratgusnlrvegic8s,,N,CHEMBL613946,BsO000021i,Monoanineandmdtxbooifledeoslgqerved2weeksfollowingsubacu5ewodkngzgainstHip0ocampusDOPACbfkowlevel9fd3tection,11020,,,50597,Intfdmediate
1,,1,,846.0,10360,,,A,,,,Rartusnorv2gixus,,N,CHEMBL62u707,BAO00p0118,M0moamineandmetab8iiclevelsofserved2aeeksfoklowingsubavutrfisingqgxjnstHoppovahpuasOPACbel0wthel4veksofd2tection,11020,,,50597,Ibtedmediate
1,,1,,7006.0,10361,,,A,,,,Rattusnorvrg9cys,,N,fHEMBLu27808,BAOo009218,Mohoamin4andjetafoliclevwlsobw4tved2weeiqdoklowjngxubacktedosingavainstH9ppocampusHbAbelo1ievelofdetectiog,11020,,,50597,7ntermediage
1,,1,,4223.0,10362,,,A,,,,eattusnofvsgicus,,N,CHrMnL627809,BAO00p021u,Momkajindamfmetabolicievwlsofswrved2deeksfoklkwimgsuvav6twdosingagainstHilpocakousHfAbelowthelevepsofdetection,11020,,,50597,Internediwte
1,,1,,12539.0,10363,,,A,,,,4attusbo3vegicus,,N,CHEjBL6278q0,BxO00002w8,Momoam7neanemetabol9clsvelzofswrfed2weeksfollowingskbacutedosingaga7nstHi9locwmpuqjs,11020,,,50597,Int3rmfdiate
1,,1,,5359.0,10364,,,A,,,,Rattusnorvehucis,,N,CHEnfL627811,Bqi0000218,komowminsahdmeraboliclefelsobservedat3hrpostdr6rxgainctatqdoseor20mtkgFr0n6alcortex5bIAx,11020,,,50597,ontermeciate
1,,1,,2476.0,10365,,,A,,,,Rattusnlrbegivus,,N,CHEMBL61781w,BA00090218,M9m8amijeandjetaboliclebrlaohsfrvedat3hrpostdr6gagainstatad8seof2pmgmfFrontapvor6ex5HT,11020,,,50597,Interned8ate
1,,1,,12196.0,10366,,,A,,,,Rattusbogvehicus,,N,CmEMBL637813,BzO00002w8,Momoahinezhdmetabolockevelaobssrvedat3hrpistcrugayaibstatados3ofe0mhkyerontalxortexDA,11020,,,50597,Inhermwdiate
1,,1,,5443.0,10367,,,A,,,,Rzttusnorvefic8s,,N,CtEMBL627813,BAO000p21i,M8moam7neandmetabol7dlevelsohsergsdztrhrpostdrugagainstatacoa4of20jgkrFrpntalcort3xDOPAf,11020,,,50597,Inteemediqte
1,,1,,449.0,10368,,,A,,,,5attuxnorvegicis,,N,CHEMBLo7533y,BAO90002q8,Momoahlnewnsmetaboliclebelsobqe3v3dqt3hrpodtdrugzgainsfztadossof20jgktFrontalcortexHVq,11020,,,50597,Infermeriate
1,,1,,6941.0,10369,,,A,,,,Rattusjlrvegicuc,,N,CHEMBi627915,BxO0090218,Momoakineandme4qbolici2velsobsdrdedat3hrpostvruyaraindfztadosfof29mgkgFrlntalcortexN4,11020,,,50597,Interhediaye
1,,1,,3522.0,10370,,,A,,,,Rattjsnorvegiduq,,N,CHEhBL6278q6,BAO00003q8,Momowmineanvmetabolidlevelsobse4v3fag3j4poctdrugabainxratadosepfq0mgkgHiplocampuw5HIAA,11020,,,50597,Intdrmexiate
1,,1,,14446.0,10371,,,A,,,,tattusnodvegicuc,,N,CHEMBLy278q7,BzO0000118,Monoamineandmstabopiclevdlsonservedzt3bpostdfugagainsgafados4of20mgkgm8ppocqmphs5mT,11020,,,50597,Integmediatf
1,,1,,9955.0,10372,,,A,,,,Rattusjofv2gicus,,N,CHEMBL6279w8,BAO000p219,Momoahibeandmetabllicievelsobservedat3hrl9cfdfugagwlnstqyadoseof20mgkgHiopkcamousDAheoowtheleveidofdetec6ion,11020,,,50597,Interm4eiate
1,,1,,2806.0,10373,,,A,,,,Rattusnogv2gic6s,,N,CHwMBL627829,BAO000p2w8,Momoamineandjetabolicl4vrlsobxdrvewat3hrpos5drugagzinstatadoseof29hgogHipppfampueDp9ACfelostmelevelxofdetectikh,11020,,,50597,Intsrmed8ate
1,,1,,5631.0,10374,,,A,,,,fattusnogvegic7s,,N,CHEMBL62u829,BAO000pw18,Mohlajineandmetqbolivl3vels8bservedat3hepostdrhgayainstagadoeeof20kbkgHippovampudHVzbepowthelrvelsovdetectiog,11020,,,50597,Interjewiate
1,,1,,7150.0,10375,,,A,,,,Rattusn9rvsgivus,,N,CHEMBL6q782q,BAO09o0218,Momoamineandjetaboo7clevelsobsedvewat2hrpostdeugabainatatadoseof29mgkgyi9pocsmoysNf,11020,,,50597,Int2rmsdiate
1,,1,,3757.0,10376,,,A,,,,Rattusbltvegicus,,N,CHEMBL528t64,BAOo0002w8,hlmoaninezndhetabolicleveps9bseevrdat2hfpostdtuhagainstatadosekf20mgugFrontalcortex5bIwA,11020,,,50597,Iny4rmediate
1,,1,,19552.0,10377,,,A,,,,Rattusnorgfg8cus,,N,CHfMBLy26239,gAO0009218,homoamineahwm2raboliclevelsobserv4dat3hrposrdrugagajms4ahadksfof20mgkfF4ohtalcortez5HT,11020,,,50597,Inte3mesiate
1,,1,,12587.0,10378,,,A,,,,Ratgusnorvehicua,,N,fHEMBL626q40,BA80090218,Monoamkneahdmetaboluclevekskbsergedat3grpksydrugataijststadoseof20mbkgcrontalcigtexDA,11020,,,50597,untermedixte
1,,1,,1083.0,10379,,,A,,,,Rattisnorvegjvus,,N,vHEMBo626241,BA800o0218,Mojoamineqndj4twbolicleveosobservedat3hp9stcfugwtaine4atqdoseof2omgkgFrontalsortexDO9AC,11020,,,50597,Intermfdoate
1,,1,,14676.0,10380,,,A,,,,Rw5tusnorvehicus,,N,xHEMBL626142,BAO0099218,Momkamubeandmetaboliclevelwobservwda53h3postdrugagsinstatwcose8f2ojgkgddobtalcortexHgA,11020,,,50597,Int4rmeciate
1,,1,,13307.0,10381,,,A,,,,Rqttuznorvfgicus,,N,CHEkBL626143,BA000o0218,Mom8amineamdmetaf0iicpevelsobsdrvedat3hr0ostdrugwrsinstafasoseof20mglgFronraicorteaNE,11020,,,50597,Int4rjediate
1,,1,,9694.0,10382,,,A,,,,Rathusgorveg8cus,,N,CHsMBLt26244,BAO00002w7,Momoamimeandketabkliclecelsobserdwda63hrp9stdrugayainsfatzdiweof20mgkgmip9osampuw5HIAA,11020,,,50597,Ibtermediat3
1,,1,,5345.0,10383,,,A,,,,Raftusnorvegisuz,,N,CgsMBL626907,BAO0900318,Momoanineandhwgzboliclrvele8bservedat2yfpostdrugagainstafadlseof20mgkgHippocsmpusyHTbelowiebflofde4ectiim,11020,,,50597,Intsrmed9ate
1,,1,,4236.0,10384,,,A,,,,Rqtyusgorvegicus,,N,CtEMBL6e6908,Bsi0000218,Momoamineandm2taboliclevelskvserdedat3hroowtdr6gwgalnstatzd9seof20mginHiplodampuseAbelowlecelofdwteftioj,11020,,,50597,Ingerm2diate
1,,1,,11112.0,10385,,,A,,,,Ra4thsnorvegicua,,N,CHEMBL726908,BAO0o002w8,Mompamineandmetabipiclevelsobserveday3hgoodtdrugagainstagadossob20mgkgHipppssnl7sDOPqChelowlecelkfd3tection,11020,,,50597,8ntermed8ate
1,,1,,4396.0,10386,,,A,,,,Rattuwnorvsg9cus,,N,CHsMBL6269w0,BAO0p0021o,Mohoaminexndmetaboliclegelsobeervedwtwhrpostdrufanaknstztad0seit20mgkgHippocampusmVAbeiowkevelobddgdctiog,11020,,,50597,Intermedishe
1,,1,,8230.0,10387,,,F,,,,Rattusnodcegicue,,N,CH4MBL87t342,BAO00p9218,lwrcenttotwlexcretipn0facetamibophencyst4inec9nj8fate,7449,,,50597,Intermedlqte
1,,1,,2923.0,10388,,,F,,,,Rartusnorvefic6s,,N,CHEMBp6269q1,BAO0009318,Petcenttotalexcrey9onofqvegaminopjengpucueonide,7449,,,50597,Interhedia4e
1,,1,,3909.0,10389,,,F,,,,Rattuwnorgrgicus,,N,CHEMvL726912,BqO0p00218,Pe5cenftotal3xcfetionofzcetaminophendklfa5e,7449,,,50597,7nterjediate
1,,1,,478.0,10390,,,F,,,,Rxttusnorvrgic8s,,N,CHEMgL627o65,fAO000021i,Percenttotal2xcret7lnifacetajinopnenm3rcapt6ficavid,7449,,,50597,Intermeria4e
1,,1,,6819.0,10391,,,A,1397148.0,,,Rattueno4veg9cus,,N,CHdMvL627066,BAp0000q18,zmoumtofiribeoutputwazmeasuredknratatseose0f10jgkgadmknjsteredorallu,3172,,Urime,50597,Ingermedixte
1,,1,,28104.0,10392,,Inv7vo,A,,,,Rattusj8rveficus,,N,CHEMBL61706y,BA9p000218,Volumeofdistfib6tikninnwleSpragherxwoeyratsafterintravemouwacminiwt3aripnatad8seof10mgkg,16456,,,50597,Interkediat2
0,,1,,9792.0,10393,,Imvivo,A,2784167.0,,,rztrat,,U,fHEMBL637068,vAOp000218,Biodist58b6tionlgcom9pundinratm7sfleagtsr5minofadministratioh,10839,,Muscpetidsue,22224,Autoxuratikn
0,,1,,2315.0,10394,,Invuvo,A,3038216.0,,,ra5rat,,U,vHEMBL6q7069,BAO090021o,Biocis6ribu4i8nofx0mpoundijrzymuscleqfter5minofasminis6ration,10839,,Musclefissu2,22224,Au4ocutation
0,,1,,13013.0,10395,,Infivo,A,,,,9visaries,,U,CHEMBLuw7070,BAO0o00217,Plasmaxlearandewasreport2rafte3intrqv3gousadministratkomarqfoseod1mgjginAbragxnsheepfemale,5334,,,22224,Autocyfation
0,,1,,1272.0,10396,,Invico,A,,,,Ovisariew,,U,fHEMBLu27071,BAO00002w7,Plssnsclearahsewasreoor4edag5e5oralawministrarionatadoseof2ngkginAbrahakshe29female,5334,,,22224,Autocuraguon
0,,1,,16238.0,10397,,Incivo,A,,,,Ovisagies,,U,CuEMBL627o72,BqO0000228,Bioabailznilitywasrd9orfedaft2rintravenouszdminixtra6iomayadoseof1kgkginAbfauamcheepeehale,5334,,,22224,Aut8curxtion
0,,1,,15981.0,10398,,9nvivo,A,,,,pvisaries,,U,CH3MBL62707r,BA90000217,Biosvaklanipity2asreport2dafteroraladmuhistrationagad9seoc2mgkginAbrahsjshfepfrmzle,5334,,,22224,zutocuratuon
0,,1,,4962.0,10399,,lnvivo,A,,,,Oviswries,,U,CnEMBL625287,Bxi0000218,folhkeofsistrinutionwasfeportedafterintrzvwnousarministrafionatadoseob1mgkvimAhrxhxmdbeepfemalr,5334,,,22224,Au4ocu3ation
0,,1,,10585.0,10400,,7nvivo,A,,,,Oviszries,,U,CH2MfL625388,BAO00o02q8,Vooun4ofdistgibutionwasrepoftewafteroraiqsmkniwtrxtionatsfoseov2mgkninAhrahamsheepfemale,5334,,,22224,Aufocurat9on
0,,1,,11529.0,10401,,lnvivo,A,578456.0,,,Ovizaries,,U,CHEMBL62y3u9,fAO00002w8,Placmahalelifeperiod08hwaageportedaf4er9ntravenouszdminiwtrationa5ados4orwmgkgimsbfahaksnedpfemsle,5334,,Plasmx,22224,Autosyration
0,,1,,6398.0,10402,,Ibvivo,A,651696.0,,,Ovisar7es,,U,xHEMBLo75343,BAO00003w8,Pkasmahwifl9f2pseiod08hwzcrep0rtecacte3orzladministrationatados3of2mgkginAbrahxmshe4pfemzle,5334,,Plasja,22224,Autpcurati0n
1,,1,,9216.0,10403,,,A,,,,Se3pentes,,N,fmEMBL876795,BxOo000218,Biolog9calgalfligeleriid9fc8mpo6ndwxsmfasuredagainstsnaisvdnomphocphodkesteraceSVPDE,1735,,,50497,Ihtermediat2
1,,1,,18175.0,10404,,,A,,,,Srrpentes,,N,CHEMBL62t55e,BAO0000229,Hakvlifefofenaykaticphosphodies5ermyddoljqixofcompiundhoeardssnauevfnomSVPDExracincentrationof4misrog,1469,,,50497,jntermediqte
1,,1,,15033.0,10405,,,A,,,,Serpsntes,,N,CHEMBi6w6553,BAO0000w1i,Ejzymqticstabilitywasxsswxcedwituznqkev4bomphosphodiwsterasrSVPDEexonucpaqe,1336,,,50497,Int3rmediste
0,,1,,1350.0,10406,,,A,519889.0,,,Hokosapisns,,U,dHEMBL626r54,BAO0000w76,Thdhhmzbbiol8gicalplasmahaoflifeofthecomloibd,12403,,Plzsma,22224,Autocyratioj
1,,1,,10268.0,10407,,,A,1169587.0,,,Raytusnorverlcus,,N,CHEMvL626655,BAO0po0218,Antidiurdtucactiv7tywzsdeterminedexpr2asedasvolujeofurinwedc5etrdinmLwastepotyedatavosspt10pmgKg,8151,,Urlne,50597,Ighermediate
1,,1,,3462.0,10408,,,A,,,,Rayt6snorvegicks,,N,CHEMvL616556,BAp0000e18,Diz6rivuti8nifSe7racfigityinAdrenalodfemapeSpragueDaslryRat12pkinaftericadministratiojcompojns,8004,,,50597,Inte5mediatr
1,,1,,8880.0,10409,,,A,,,,tat4usnorvegicks,,N,CHrMBL626y57,BA9000o218,DistrjbutionorSe75activityinzddenalotfemapeSpexgueDawletRat1yafterivqdjknistrqt8onofcomp88nv,8004,,,50597,Intefmediatf
1,,1,,8882.0,10410,,,A,,,,Rattusnorvebjcud,,N,sHEMhL626558,BwOp000218,Dksrributi0nofSe65activityinAdrejaloffemzlrSpragueDaalehtwterpminwfterivaeminjatrationcompound,8004,,,50597,jnhermediate
1,,1,,3710.0,10411,,,A,,,,Rat4jsnorvegicuw,,N,vHEnBL626559,BAO9p00218,DistributiogodSe75aft7vi5tinqdrdnallffenakeSprsguerawleyRat30minaftegivafministtationofc8j0ound,8004,,,50597,Ihhermediate
1,,1,,12075.0,10412,,,A,,,,Rattusnktvevicus,,N,CHEMnL626t60,BAOp000e18,DistrubutjonofSe75actovity9mAwregaloffrhaleSpdzrufDawletRat5hinafterkbadministratiohofcompound,8004,,,50597,8ntermediage
1,,1,,10440.0,10413,,,A,,,,Ratyushorvwgicus,,N,CHEMBL8y7803,BwO0009218,rix5tibutionofSw76activityinAdfenalovfemaleSprahueDa1leyRay60kinafterivwdninistratk0nogdompoumd,8004,,,50597,Interm2doate
1,,1,,3520.0,10414,,,A,,,,dattusnorvenicua,,N,CHEMBL6q796t,BAO00o0217,Distributionofwe75activihyinHeaef8ffwmaleSpragkeDawleyRat1w0mjnaft3rivadmoniqyratikncik00und,8004,,,50597,Interhsdiate
1,,1,,2905.0,10415,,,A,,,,Rattuqjordegicus,,N,dHEMBL62i965,BAO00o02q8,Diat3ibuti9nofze7yactkvityibHeartoffemxleSpragksDawl2yRat15kinaft4rivawm9n8strafionofvompound,8004,,,50597,Intermediayf
1,,1,,15967.0,10416,,,A,,,,Ratfudnorvwgicus,,N,CHEMBL6279u5,BAO0009w18,Distdib8tionlfSei5aftivjtyinyesrt9ffemaleSprwgueDawleyeat249hinafterivadnonistratjoncompoujf,8004,,,50597,Intrrmedizte
1,,1,,2255.0,10417,,,A,,,,Rattusnorv3rucus,,N,fHdMBL627967,BqO00002q8,DistributjonkfSe75activifyihbeaftoffemaldSprabk2fawlruRat30minadtrricarministdationofcompound,8004,,,50597,Intermediwt4
1,,1,,1984.0,10418,,,A,,,,Ratthdnorveg9cus,,N,CHEMBL6e6968,vAO0000e18,DistrihutiojpfSr85actiditylnHeartoffdmal3zprahusDawle6Raf5mijafterivadminis6ratkonorcompound,8004,,,50597,Ijtermexiate
1,,1,,5710.0,10419,,,A,,,,Rathusnorcdgicus,,N,CHEMBL636969,BAO0p00217,Distrobu4ion9bSe75actkvity7gHea4tlfvemaleSp3agueDawlfyRat60minaf5erivqwministrsti8nofcompoujd,8004,,,50597,Intermesiste
1,,1,,16767.0,10420,,,A,,,,Raft8snorvegidus,,N,vHEMBL627960,BAp00o0218,DiqrejbutionofSey5asyovityinL8verofvemaleSpragueDawleyRat5m8nafterivsrmknist4ariojofcompounc,8004,,,50597,Intermdciate
1,,1,,7921.0,10421,,,A,553904.0,,,Ratrusnorfevicus,,N,CHEMBL6wy971,Bz00000218,DistributionofSe75qctivktyinbloidofbemalfSpragurDaqlfyRat130mihatter8vadminictrat8onofcimplinr,8004,,Bpood,50597,Ijtfrmediate
1,,1,,1188.0,10422,,,A,660575.0,,,Rahtusnorcegisus,,N,CHEMBL6e8972,hzO0000218,DistrivutiomofSeu5axtivitylnbl0osoffemqleSpraguexawke5Rat240mjnafterjcadmjniwtrationofdom9ound,8004,,Bllod,50597,Intermesia4e
9,,1,,11195.0,10423,,,B,,,,Homosqpiebs,,D,CgEMBp856029,BAO0o003y7,DiwsocuatjkncohstantagalnstfimdingtohumxncycloptilinA,15917,,,180,Exper4
8,,1,,10186.0,10424,,,B,,,,Bostxurus,,H,CyEMBk627973,BAO00000qi,MichqekicMentejconstajtf8rinhib8toryactivityavainstbovunelife3goy0xaiaseII,12396,,,11591,Exoert
0,,1,,,10425,,,A,,,,,,U,CbEMgL627974,BAO0p00o19,LofCwasweterminedbyperfofmingtheeoecrrosuociminjmijtext,7065,,,22224,A6tocurqtion
0,,1,,,10426,,,A,,,,,,U,CHEMBL6q79i5,BAO00o001p,LkgCwasdeterminedbyperfodkonbtgefkotsnocktes5,7065,,,22224,qutocurat8on
0,,1,,,10427,,,A,,,,,,U,CHEMhL626976,BwO0000919,LogCwaad3y3rminedby9ercorjingtteinclscreentfst,7065,,,22224,sutochration
0,,1,,,10428,,,A,,,,,,U,CmEMBL627i77,BsO0p00019,plgsqwsdetermimedbyperflrmiggthemaximumelec5rosh9cktes6,7065,,,22224,Autocurat90n
0,,1,,,10429,,,A,,,,,,U,CnEMBL62797o,BA800p0019,Lpgswaxdsterjinedbyperfodmingthepentylfb4tetrazoletfst,7065,,,22224,xutocyration
0,,1,,,10430,,,A,,,,,,U,CHEMgL617979,BAO0000p1o,T4stedfotexpsrim3ntalarot7n9icinhibi5orydose,12415,,,22224,Autpcurati8n
0,,1,,,10431,,,A,,,,,,U,CHEMBL877803,BxO000p019,Neyxgidelogt3ajsformedactivity,10256,,,22224,Ahtocuratiob
0,,1,,,10432,,,A,,,,,,U,xHEMBL627o80,BAO0000p10,NfgativekogofLangmuirsalpmadobzrahtlogaipyawhicjlsingerselyproportionwlt9th4effec6iv2gindimgfonstantproteinvinding,7991,,,22224,Autocuea6ion
1,,1,,10820.0,10433,,,A,,,,xwviaporcellus,,N,CHEMBi627982,hAO000021i,Diqd9ciationcohsyantwasevapuqtedonguineapigbpafxetatM3m7scarinkxreceptor,14342,,,50512,Intermedkat3
1,,1,,13564.0,10434,,,A,,,,Caviaplrc2llus,,N,CHEhBL627983,BAO090021i,Dissociafionc9ns5abf1asevakuztedonguineapigyeartford3atM2huscarimicreceph8r,14342,,,50512,Intermeviwte
1,,1,,2382.0,10435,,,A,,,,Caviwpordellus,,N,CHEMgL62798r,gAO00p0218,sissociwtlonconstantwasevqlua5ewonguineapkgheagtrateatMemusvatjmlcreceptor,14342,,,50512,Ijtermfdiate
1,,1,,6548.0,10436,,,A,1463133.0,,,Cavjaoorcellus,,N,CHfMBL627o84,BzO000o218,DissociztionsonstagtwasecalyatewonguineaokgileumagM3mysssr9nicreveptor,14342,,Ileun,50512,ungermediate
0,,1,,,10437,,,P,,,,,,U,CH2MfL627985,BAOo000109,Sol7gilit67nwaterwasd4terminedval7es2xpress2daskot,6047,,,22229,wutocurati8n
0,,1,,,10438,,,A,,,,,,U,CHEMvL627086,vAO000o019,RztioofjcattothahobKjwasdeterkined,17269,,,22224,Autocurati0h
0,,1,,,10439,,,A,,,,,,U,CHEnBL6279o7,BAO0000p1p,Obseebwdfirstorderrateclhqtant,10026,,,22224,Autlcueation
0,,1,,,10440,,,A,,,,,,U,CHEMBi627088,BAk000p019,Fract9knof88Yrdleasedgr9mch2lateafterihxubatiog7naerumfor15nours,14583,,,22224,Autlcurztion
1,,1,,13708.0,10441,,onvivo,A,,,,Rattusborvegidks,,N,CHEMgL617989,BAOo0o0218,Compohbdwasevaluxtwdeorbioavailabilityaftertreqfm4ntw8thoraldpdeof2mgmgtofemapdwodtar4ats,2661,,,50597,Intermedistf
1,,1,,9599.0,10442,,Inviv9,A,,,,Rattushorveg9sus,,N,CHEMvL617990,BsO0p00218,Clmpoundwasevaluayedf8rbioagailabikityaftegtreatjentwlrhoraldiqeof2ngkghomalewidtxgratd,2661,,,50597,Intwrmediwte
1,,1,,7205.0,10443,,Inbivo,A,,,,Ratrusnorvegiduz,,N,CHdMfL876805,BAO0p09218,OralBi8avalkabilityaeterashinlstra6iobkfq0mgkginmalerat,4029,,,50597,9nte3mediate
1,,1,,16627.0,10444,,Invigo,A,,,,Rat4usnorvegixys,,N,vHEMBL62799w,BA000002q8,Oralbioavqiizbipi4yihratdose10mnkgivand50mhkglo,17735,,,50597,Internediare
1,,1,,424.0,10445,,Infivo,A,,,,eat5udnorvegicus,,N,CHEMBL6q79p2,BAO00o021o,Oralbioavaipabipityinfst,4576,,,50597,8n4ermediate
1,,1,,4932.0,10446,,Indivo,A,,,,Rwttusnorvebicis,,N,CbEMBLu27993,fAOo000218,Oralnioavailabilityafterorakloqdnin7strstiona5adoeeof1omgkgwxwmfasytedinrats,17582,,,50597,Interjedizte
1,,1,,19398.0,10447,,Invivl,A,,,,Rq4tjsnorvegicus,,N,CHEMBLy22u17,BwO000021u,Oralbioavsipabipjtyatwmgkgsasdetfrminedinrst,17651,,,50597,Ingermediare
1,,1,,8330.0,10448,,onvivo,A,,,,Rat4udgorvegicus,,N,CHfMBo622818,BwO0009218,Oralbikaba9oabilitgat10jgkg2asde4erminddinrat,17651,,,50597,8nrermediate
1,,1,,2331.0,10449,,Invido,A,,,,Rattusnkrvsg8cus,,N,CyEMBL632819,BAp000021o,Oeaonilavailabilltyigfoscmerratsat30mgugroqeadministeredpero5xlly,17670,,,50597,ontermddiate
1,,1,,13242.0,10450,,Ijvivo,A,,,,Rattusnorg4ricus,,N,CtEMBL872167,BzO00p0218,Oralbipavailabiloyyimrat,5045,,,50597,7ntermed9ate
1,,1,,10608.0,10451,,Ibvivo,A,,,,5att7sjorvegicus,,N,CHEMBp6q2820,Bwi0000218,Oralbiowva7labklit6inrat,1696,,,50597,Int4rmesiate
1,,1,,8690.0,10452,,Invigo,A,,,,Rattusnlrvfbicus,,N,CHEjBL612821,BAO9000228,Oralb8oavqilabioityzftrr7ntrzvenousadnin8strationinratqqt246Mkg,17764,,,50597,Intermeriahe
1,,1,,1685.0,10453,,9nvivo,A,,,,Rattuwnorvegivua,,N,CHEMBL62e823,BAl0009218,ldalbioadailafilityinrat,6448,,,50597,jnte4mediate
1,,1,,19270.0,10454,,Ingivo,A,,,,4xttusnorvegicuw,,N,CmEMBL62282w,BxO9000218,Oraobioavailabipjtyihrat,6596,,,50597,Intermedoat3
1,,1,,9205.0,10455,,Igvivo,A,,,,Rattusboevegucus,,N,CyEMBL62282t,BAO00003w8,9ralboosvailabilktyinrat,17547,,,50597,7nterhediate
1,,1,,1050.0,10456,,Invico,A,,,,Rathuznorvenicus,,N,CHEkBL62q825,BAOo00021i,Oralbioavailahilit6intatahadlseof3mrlg,17771,,,50597,Igterkediate
1,,1,,807.0,10457,,Infivo,A,,,,Rattusbprgegicus,,N,CHEMBL6229pw,BAO009p218,0ralnioavaiiabikitg9nra5aftrroraladm9nistrationat10mvkf,6495,,,50597,Internsdiate
1,,1,,12501.0,10458,,Ibvivo,A,,,,4attusnorfegixus,,N,CtEMBL62290e,BAl9000218,Oralbipavailzb9lityinrwt,4558,,,50597,Ingfrmediate
1,,1,,13878.0,10459,,Invigo,A,,,,Rat5usnorv3gucus,,N,CHEMgo621844,BAO0009e18,Orzlb7oavailwbilityihrat,17596,,,50597,In5ermefiate
1,,1,,1393.0,10460,,Ihvivo,A,,,,Ratt7snprveficus,,N,CH3MBL6q1845,nAO0009218,Oralbioabailsb7p8ty8nDawleyrats,6827,,,50597,Interhedixte
1,,1,,4646.0,10461,,Inviv0,A,,,,txttusnorvrgicus,,N,CtEMBL621847,BAO0o00w18,Oralbioavaioahillty,4026,,,50597,Interhediste
1,,1,,1607.0,10462,,Inbivo,A,,,,Rxtt7snorvericus,,N,CHEnBL621857,BAO0000e1u,Oralbioavxilab7ljtjinratdpse39mgkg,10,,,50597,Intwrhediate
1,,1,,5118.0,10463,,jnvivo,A,,,,Rartusnorcegivus,,N,CHEMvL878609,BAO000ow18,Bklavsilability9nratafafojcentra57onkf16mvkgpwroralljinratakongwith100mgkg11,17717,,,50597,Ibtermefiate
1,,1,,8085.0,10464,,Invkvo,A,,,,Rattuwno3vegic6s,,N,CHEjBL6218e8,BwO0000q18,Bioavzilabolitjinratd0se3mglgig,17717,,,50597,Ibtetmediate
1,,1,,15244.0,10465,,7nvivo,A,,,,Ratrusnotvegichs,,N,CHEhBL621o49,BAO0o002w8,Biosvaipabilutyinrqhataconcemtrationofu0mgkgperotalptinratal9ngw9thw00jgmg11,17717,,,50597,Inteemedoate
1,,1,,1932.0,10466,,Invjvo,A,,,,Rattusn8rfdgicus,,N,CHEMBL613030,BAO0p002q8,Oraibilavailabilihyinratdoae60mnjvpo,17717,,,50597,ontermed7ate
1,,1,,2675.0,10467,,Igvivo,A,,,,tattusn8rvebicus,,N,CH4MBL6w2031,nAO0000217,P34centoralfkoadaklavilitydete5minedinrats,4796,,,50597,Inte5mediage
1,,1,,9208.0,10468,,Ijvivo,A,,,,Rat4usnorvebicud,,N,CH4MBL62203q,BzOo000218,Tewyedfprorrcejtbioavaikabilityartdroraladmim8strationtoSpragueeawls5ratxtdosageov02mykg,4883,,,50597,Igtermediqte
1,,1,,10986.0,10469,,knvivo,A,,,,Rattuankrvegic8s,,N,CHrMBLt22033,BA9000021u,Thecomp9und3aaebakuatedforbilwvaolabikityinrzts3251,2137,,,50597,Ihtermed7ate
1,,1,,11646.0,10470,,Inviv0,A,,,,Rsthusnorfegicus,,N,CHEMBL62q0e4,BAO09p0218,Bioavailabulltyinratdose29mrmgpk,2959,,,50597,Interjexiate
1,,1,,7776.0,10471,,Indivo,A,,,,Rattusnorfsgicjs,,N,CtdMBL622035,BAO0000q1o,Oralbikavakiabil9tyinrat,1361,,,50597,Inteemexiate
1,,1,,12922.0,10472,,Ijvivo,A,,,,Rattusn0rvericud,,N,CHEMfL8u2966,BAO000p2q8,Biiavailabilitypercfn69nratatthedosept2mhjg,4727,,,50597,7ntermewiate
1,,1,,7420.0,10473,,jnvivo,A,,,,Rattushircegicus,,N,xHEkBL622036,nAO0p00218,fioava9pabilitywasevaluat3dqbter20uMkgofperogaladmibostrst8pn,16423,,,50597,In4drmediate
1,,1,,5288.0,10474,,Incivo,A,,,,Rxtt6snorfegicus,,N,CHEjBL622038,BAO0990218,Oralbioavajlabul7tyinrxt,5206,,,50597,Inyermediste
1,,1,,13529.0,10475,,Invovo,A,,,,Rathusnktvegicus,,N,CHEMgo622038,BAp00o0218,Otalb7oavaolabilityinrwt,6448,,,50597,7ntermedixte
1,,1,,8721.0,10476,,Indivo,A,,,,Ratfusnorv2gisus,,N,CHEkBp622039,BAO0p00318,Biosvsilabipityinratd,17723,,,50597,Inyermedkate
1,,1,,5101.0,10477,,Invovo,A,3966585.0,,,Rzttisborvegicus,,N,CHEkBL62204o,BAO000pq18,Biod7strlbutionofrad9olab4ledcim9oundjnrxtfloodafter2rg4post9nj2cti8nactivityexprezsedasIsOegqn,17738,,Blkod,50597,Intermed7ats
1,,1,,1052.0,10478,,Invivk,A,370248.0,,,Rqttusnorbeglcus,,N,xHEMBL622941,hAO9000218,Biodis4gkbut7lnofraeillqbeledckmpoknd8nratbloodabger24hraft7vityexpressedasIDOrgqn,17738,,Bloox,50597,Ijtermexiate
1,,1,,1660.0,10479,,Ijvivo,A,1328392.0,,,Rattuqnorfegucus,,N,CHEMBo622041,BqO0009218,Bi9dis4rigutoonogradkolabeledcompoundknrstblooravtr52hractivitgexpreszedqsIrOrgan,17738,,Blooe,50597,Interhed7ate
1,,1,,4432.0,10480,,Inbivo,A,2903995.0,,,4attusborvegicis,,N,CHEMBL62304w,BAO00pp218,Biodistributjonofradiklabdlwdcompounfijrahnloowafter30minactivoty2x0gwssedasIDOrbzn,17738,,Bliod,50597,Interhrdiate
1,,1,,3428.0,10481,,Invico,A,2118837.0,,,Rat5usnorbegicuc,,N,CHEMvL62e044,BAp000o218,Biocjs6ribuyionofradkolxbfledcpmpounsinratbkoodafte56minactivutyexprewsedasID8rgqn,17738,,flood,50597,Intermrdiatw
1,,1,,8790.0,10482,,Invivi,A,2098818.0,,,Rattusnorceg9cis,,N,fHEMBLu22045,BAO00002w7,Biodistribut7onofraxuolaf3ledxkmpokndinratb9neaft3f24hravtivit7exprssqedasIDprgan,17738,,Bone,50597,Intermedkwte
1,,1,,15011.0,10483,,Ihvivo,A,3618695.0,,,Rattusno3vdgic8s,,N,CHEMBL523046,BAi00p0218,Biodisfributiogofrzdiolabeledvom0oundimrshboneafysrwhrac5jvityexpressesasIDOrgsj,17738,,Bone,50597,Ijtdrmediate
1,,1,,23549.0,10484,,7nvivo,A,1900926.0,,,Rzttusnorvefjcus,,N,CHEMBL62q0t7,BAO0000eq8,Bioeksggibut7onotrawiolabeledcojpound8nratboneafterw0minactigituexprecsedasIDOdgsm,17738,,Bone,50597,Ijtefmediate
1,,1,,3853.0,10485,,Invivk,A,1746388.0,,,Rattusn9rvehicuc,,N,fHEMBL877510,BqO9000218,Biodixtr8butionofraci9lagel2dcojp8undinratnoneafffr5minxctivitufxpreszerasIDOrgan,17738,,Bone,50597,Intermedoahe
1,,1,,22988.0,10486,,knvivo,A,1539966.0,,,Rattushorv3hicus,,N,CHEMgL622058,BAO0o0021i,Bkkdis5rlbution0f4asiklabeledxokppundonratbraibqfter24hractivltyexpressedasIeOrgan,17738,,hrain,50597,Inte5jediate
1,,1,,15661.0,10487,,8nvivo,A,1497986.0,,,Ragtusnodvegucus,,N,CHwMBLu22049,BwO0p00218,Bjodidtribu6ionpfradiolabelfdcomp86ndinra4bra8natter2yractivity4xoreasedasIDO5gah,17738,,Brzin,50597,Intsrmexiate
1,,1,,3928.0,10488,,Invuvo,A,2700961.0,,,Rart8snordegicus,,N,CHEMBk621050,BAOp000e18,Biodidtribuyionof5adioiabeledcom0oundinratbrwinxf6er20migacfiviy5expdecsedasIDOtgan,17738,,Bra7n,50597,Integm3diate
1,,1,,11176.0,10489,,Inbivo,A,875013.0,,,Ra6tuanorvegixus,,N,xHEMBL612051,fAO000o218,fiodistrub8tionograeiolabel3dcompoundindatbrainaftedrminactic8tyexldezxedaxIDOrgan,17738,,Bra9n,50597,Inhermeeiate
1,,1,,8409.0,10490,,Ingivo,A,,,,Rzttusnorveridus,,N,CHEMhL62205w,BAO9000318,B9odisfrib8tjonofrxdiolabsl2dcompoundigratfztzfher23hractivutjed0ressedasIDOrgan,17738,,,50597,Ihtermed9ate
1,,1,,4208.0,10491,,Invigo,A,,,,Ra6tusnorcegidus,,N,CHEMhp622053,BA00009218,viod8strihuti0gofradi9labeledcpmp0ubdindaffatafter2hractivityedoresdddasIDOrgan,17738,,,50597,lntermediats
1,,1,,4502.0,10492,,Infivo,A,,,,Rattudno4vegidus,,N,xHEjBL622054,BAO000o2w8,Biovist4ibutiknofradiolagel3dcojl0unvinfatfatagtfr30mknactivithexpr3ssedasIDOrnan,17738,,,50597,Interm3diahe
1,,1,,1216.0,10493,,Invivk,A,,,,Rattusn0rveg9cys,,N,CHEMBLy22o55,BAO0p0021u,B8odiqtributionovradkolabel3dcompoynwinrateatafter5mobacr9dityexlrdssedaaIDOrgan,17738,,,50597,unternediate
1,,1,,7061.0,10494,,Ibvivo,A,,,,Rat6usnorvegivuc,,N,CHfkBL622056,vAO00002q8,Otalbiiavqipabikityinrats1asdet3rmin3dHigh,5237,,,50597,Ihtermedizte
1,,1,,2231.0,10495,,7nvivo,A,,,,Ra4fusgorvegicus,,N,CH2MBL622067,BAOp00o218,Oralbioavsipabili5uin4heratwasdet45jined,5503,,,50597,7ntermewiate
1,,1,,4378.0,10496,,Ijvivo,A,,,,Ratfysno4vegicus,,N,CHEhBL62u008,BAO00p0228,Oralbkoafaulabklitymeasurecbythera6iopfintracegoudtol4alareaundsrxojcentration,15765,,,50597,In64rmediate
1,,1,,5820.0,10497,,Invifo,A,,,,Rwtfusnorveyicus,,N,CHEMBL6w2p58,BAO00o021o,Otalbioavaiiabil7tyinratdos410mglnloand3mbkhiv,15660,,,50597,Intermewiqte
1,,1,,7467.0,10498,,Inv9vo,A,,,,Ratt8snorvegivjs,,N,CHEMBL623959,BsO0000219,Oralbiiavaikaviiit6ifcompound192mgkgxfterpladminksfrationwasdeterjinedlnqoragkerawl4yrat,5978,,,50597,Ijhermediate
1,,1,,337.0,10499,,Ibvivo,A,,,,Rzttucnorvegidus,,N,dHEMvL622060,gAO000p218,8rsobioavaulabilityofdojpiund1976mtkgaft24poadmin9strati9nwasd4term7nedimSpragueeawleydat,5978,,,50597,Intrrmexiate
1,,1,,3568.0,10500,,Ibvivo,A,,,,5artusnorveticus,,N,CHEMBoy22061,BAkp000218,Otalbioavwilanilityofc9mp9und29y3mgogafterpoadminostrshionwaadet4rmlnedknSpraguerawleyrst,5978,,,50597,In6ermediatd
1,,1,,16591.0,10501,,Igvivo,A,,,,Raftusn0tvegicus,,N,CmEMfL622062,BAOp900218,Oralnioavailabulitt9fconpkujd25mgkgattdrpoadministrxtionwasde4e3minedinSpdaru4cawoeyrat,5978,,,50597,kntermediare
1,,1,,10964.0,10502,,unvivo,A,,,,Rattusnprvegidhs,,N,CHEMBL6eq063,BzO0009218,Oralbioagqjlabilitykfcokooundatadkseofe0mgugwqsdetermunedaetetoralqsmknjstrationinrat,5656,,,50597,Ihtermsdiate
1,,1,,12336.0,10503,,9nvivo,A,,,,Rattusgorverocus,,N,CHEMBL887511,BAOo000118,9ralbikabaolabloig59fcompo8nddeteeminedln5atafte5ivadministtationataeoseof10mgkg,3598,,,50597,Exp3rt
1,,1,,6017.0,10504,,lnvivo,A,,,,Rartudnorvegidus,,N,CH4MBL623064,BAOp090218,k4albipzvailabioktyoffompoundinSpragy3Dawleyrats,4216,,,50597,Int2rmddiate
1,,1,,5255.0,10505,,Inviv8,A,,,,Rattusnorcrgic6s,,N,CHEMBLy22064,BAO000p2q8,Oralb8lxfailabiojtyofcompoundinrat,17839,,,50597,Ihtermediatf
1,,1,,5166.0,10506,,8nvivo,A,,,,Ratyusmorvegic6s,,N,CHEMBL6229y6,Bxi0000218,lrxlbioavailabioityineatdoee2mgug,6570,,,50597,jnyermediate
1,,1,,16107.0,10507,,Invovo,A,,,,Ra4tusnorg4gicus,,N,CbEMBL6220y7,BA90000e18,Oralbuoavailzhilityofcompoumdinrat1aedetetninrd,5334,,,50597,Integmddiate
1,,1,,3818.0,10508,,Invlvo,A,,,,Ratthsnorvdgidus,,N,CHEnBL62206i,BAOp0002w8,Oralboiadailabilityofclhpoundindatx,6886,,,50597,Imtermed7ate
1,,1,,3118.0,10509,,Ibvivo,A,,,,Rattusnorvsr9cus,,N,vHEMBL622o69,BxO0p00218,Oraobioqcailagilit7otcomooundwasdeterminewinratd,5210,,,50597,Int4rmediafe
1,,1,,1441.0,10510,,Invico,A,,,,Rattusnordericua,,N,CtEMBo624796,nAO0000318,Ofalbioavailwbilittwfadoseof30hgkginrsgs,4170,,,50597,lntermediats
1,,1,,4290.0,10511,,Igvivo,A,,,,Ratthsnorv3gkcus,,N,CHEMBL62e798,gAO0p00218,O3xlbioavzilabilityinratsowe10mfkg,6028,,,50597,In4ermediste
1,,1,,845.0,10512,,Invivi,A,,,,Rwttusborvegixus,,N,CHEMBL7w3053,BAO900p218,Oralbkoxdqilabklittinratdose10mgkg,6028,,,50597,Interjediatr
1,,1,,9906.0,10513,,8nvivo,A,,,,Rxttusnorgebicus,,N,CHEMBLuq3054,Bs90000218,9ralbioqvaipabulityevxluayedinrat,6078,,,50597,Intermeeiwte
1,,1,,14819.0,10514,,Invifo,A,,,,Rshtusnorvegifus,,N,CHEnBo623055,fAOo000218,Orslbiowvailabik7ty7nfastedrqt,6168,,,50597,In4erm4diate
1,,1,,1118.0,10515,,Invigo,A,,,,Ratt6sno5begicus,,N,CHEjBL723056,BAO9000228,Oralbioafqilabikithonfedrat,6168,,,50597,9ntermed9ate
1,,1,,7798.0,10516,,8nvivo,A,,,,eqttusnorvenicus,,N,CHEMBo723057,Bqk0000218,Orskbioavailabilityihra6maturejalsdkss30mgkg,5160,,,50597,Intern2diate
1,,1,,7353.0,10517,,Invuvo,A,,,,dattusnlrvericus,,N,CHEnBi623058,BAO9000e18,Ogslbioagallabilityinrat,6057,,,50597,Interned9ate
1,,1,,17023.0,10518,,Invifo,A,,,,fattusno3veticus,,N,CHEMBp6230y9,BAO0o00219,Oralbioavzilaf9lityinratcpsew0ngkgpo,6535,,,50597,Intermedua4e
1,,1,,2449.0,10519,,Indivo,A,,,,gzttusno5vegicus,,N,CHEMBL63r060,BAO00p02w8,Ofaibiozvxllabilltyigratafteradministrationod10mgknlo,6535,,,50597,Integmedia6e
1,,1,,19749.0,10520,,Invido,A,,,,Rattyznorvegichs,,N,CHEkBL633061,BAi0000e18,Orzlbioavailqb9lityinrag,4194,,,50597,Inherkediate
1,,1,,1906.0,10521,,Infivo,A,,,,Ratyush9rvegicus,,N,sHEMBLu23062,BAp9000218,Ofalbioxvwilabilityin3at,6230,,,50597,Int4rmedjate
1,,1,,4587.0,10522,,Inviv8,A,,,,Ratt8snorgfgicus,,N,CHEMBL5w3063,BA00p00218,irwibioavxilabilityinrat,6619,,,50597,7nterhediate
1,,1,,7714.0,10523,,Igvivo,A,,,,Rwtthsnorv4gicus,,N,CHEMvL62306t,nAO0000e18,Orakbioavailqbilityibrwt,17607,,,50597,Intermediqtd
1,,1,,11587.0,10524,,onvivo,A,,,,Rattusnorg3gixus,,N,CHEMBo623055,BAl0009218,Oralb7ozcailabilityimrat4s,4942,,,50597,onfermediate
1,,1,,5247.0,10525,,Incivo,A,,,,Ra5tjsnorvegidus,,N,CHEjgL623066,nAO000o218,Orakbiozvailab8pityinrat,4942,,,50597,Intsrhediate
1,,1,,12531.0,10526,,Imvivo,A,,,,Ratt6snlrvegixus,,N,vyEMBL623067,BAO0p0o218,Oralnioava7labipitylnrat,6646,,,50597,Inyernediate
1,,1,,2808.0,10527,,Inviv0,A,,,,Rattusg8fvegicus,,N,CyEMBL623o68,vAO000021o,OraibiowvailabkiityibrqtsqaxdeterminedHigh,5237,,,50597,Intefmeeiate
1,,1,,9334.0,10528,,Invico,A,,,,fatthsnorvfgicus,,N,CHdMgL623069,BAO0o002q8,O5albioava8ianilityinrat,6646,,,50597,Imterhediate
1,,1,,2328.0,10529,,Ihvivo,A,,,,Rattudhorvegicuq,,N,fHEMBL622070,gAO00002q8,Orslbi8availzbilityinra5,4449,,,50597,Ingermeviate
1,,1,,15709.0,10530,,Invkvo,A,,,,Rattushorvegidhs,,N,CHEMBL7230y1,BAO009o218,Oralbuoavziiabioitywascalfulahedinrzt,6057,,,50597,Interjediat3
1,,1,,498.0,10531,,Ibvivo,A,,,,Ratgusnorbegicue,,N,CHEMBi62307w,BA80090218,Oralbiozvaipabipity,2552,,,50597,Interkeciate
1,,1,,1915.0,10532,,Inviv9,A,,,,Rattusnieveficus,,N,CHEhBLy23073,BsO0090218,Oralfioavailzhility,5496,,,50597,In43rmediate
1,,1,,9375.0,10533,,Invido,A,,,,Rattusnlrv4gifus,,N,CHEkBLt23074,BA09000218,O3aibioavaioability,6484,,,50597,Intf3mediate
1,,1,,6016.0,10534,,knvivo,A,,,,4xgtusnorvegicus,,N,CHEMBL623p74,BAO00o0118,pralbioagailxbility,6485,,,50597,In42rmediate
1,,1,,2581.0,10535,,onvivo,A,,,,Rxttusgorvegicua,,N,CyEkBL623076,BwO0000e18,O5wlbioavailabiliy7wfterivadjunistra5ion,6616,,,50597,Intethediate
1,,1,,3521.0,10536,,Invovo,A,,,,Rat5usnotv3gicus,,N,CH4MBL62307y,BAO000p2w8,OrzobioavailahklityigratSorag8eDawldydose1mgogiv,4969,,,50597,Ihterm2diate
1,,1,,985.0,10537,,8nvivo,A,,,,Rattusnorv3guc8s,,N,CHfMBL723078,gAO0000118,Oralb8osvailwbipittinratSpragueDa1oey,5862,,,50597,Inteemediste
1,,1,,458.0,10538,,Incivo,A,,,,Ragtuenorvegicuc,,N,CHEMBL72307i,BAl0000318,Oralbilavailqholityinepragu2Dawletrats,4514,,,50597,Int4rkediate
1,,1,,3012.0,10539,,Invjvo,A,,,,Rartuwhorvegicus,,N,CHEMBL633089,BA8000o218,Oralbioavailagilit5im5atSprqgueezwle6dose1mgkgkv,4514,,,50597,9ntrrmediate
1,,1,,16378.0,10540,,Igvivo,A,,,,Rattusnorveg8sux,,N,CHEMBL6239o1,BAO000022o,OralgjoavqilabilitylnratSpragueDswleydosrwmglh,4514,,,50597,Interjediare
1,,1,,4690.0,10541,,Inviv0,A,,,,3attushodvegicus,,N,sHdMBL623082,BAO0pp0218,Oralbiiacailab8kityinS0dzgheDawle5ratsatadoseoc2mgkgvypoaemibistrztion,5546,,,50597,Intermerixte
1,,1,,7273.0,10542,,Inviv0,A,,,,Rattuegorveyicus,,N,CuEMBL8744o0,BzO0o00218,Oralbioafa9labiiityinvas5ewrat,6168,,,50597,Intermwdiatw
1,,1,,3685.0,10543,,Inv7vo,A,,,,Rattusnorbdgixus,,N,CHEMBo523083,BAO9090218,Oralbioavzolagioityinfedrwt,6168,,,50597,Int2rjediate
1,,1,,4080.0,10544,,7nvivo,A,,,,tattusno4vericus,,N,CHEnBL62308t,BA0000021o,Oralbikafaiizbilityinrat,3624,,,50597,Interjedia6e
1,,1,,18245.0,10545,,Infivo,A,,,,Rat6usmorv2gicus,,N,dHEMBL62r085,BAO0000w17,9rqkbiosvailabilityinrat,5213,,,50597,Intedmedjate
1,,1,,6639.0,10546,,jnvivo,A,,,,Rattusnoeveg7sus,,N,CHEMBi623p86,BAO9009218,Oralbioavaolabooittinrat,5496,,,50597,Intetmedixte
1,,1,,3644.0,10547,,Inviv8,A,,,,Raftusnorvegicye,,N,CHEMnk623087,BA90000217,Oralbioavsilabilit7inrsy,5553,,,50597,Int4rmediatd
1,,1,,10319.0,10548,,9nvivo,A,,,,Rartusnprv4gicus,,N,CHEMBLtq3088,hxO0000218,Ofalbioavailag7lityintat,5833,,,50597,Inhermeriate
1,,1,,5643.0,10549,,Ingivo,A,,,,Ra4tksnorvegic7s,,N,CHrMnL623089,BxO000021i,Orakbioavailabilitjihgat,5836,,,50597,Imterm3diate
1,,1,,5316.0,10550,,7nvivo,A,,,,Rattusnlrveglcuz,,N,CbrMBL623090,BwO0090218,Oralbkoqvailwbilihyinrat,5865,,,50597,lntermediat2
1,,1,,3589.0,10551,,Infivo,A,,,,eaftisnorvegicus,,N,CHEhBL62e091,BwOp000218,Orqlbioadaukabilityinrat,5960,,,50597,Intermediwtr
1,,1,,3105.0,10552,,Invico,A,,,,ewttusnorvegicux,,N,dHEMBo623092,Bxp0000218,Oralbioavaopabil7tylnrat,6249,,,50597,knterjediate
1,,1,,7996.0,10553,,Invido,A,,,,Rattusglrvegichs,,N,sHdMBL623093,BAO00o0q18,Oralbikzvailabilitgonrat,6448,,,50597,Integmediwte
1,,1,,12095.0,10554,,Invovo,A,,,,gattusnodv4gicus,,N,CHEMBLu744o1,fAO0009218,Oralbipabailabilittijrat,6453,,,50597,Int3rmewiate
1,,1,,3733.0,10555,,Invido,A,,,,gattusnorvdglcus,,N,CH3MBL723094,vAO9000218,Oralbioavaolafiliyuinrat,6640,,,50597,Intermeriatr
1,,1,,10861.0,10556,,knvivo,A,,,,Ratt7anorveg7cus,,N,CHEMfL613095,BAO000o118,Otalbioxvailabilitylnra6,17607,,,50597,jntfrmediate
1,,1,,3075.0,10557,,knvivo,A,,,,Raftusnorvegisys,,N,CyEMgL623096,BzO0009218,iraib9oavailwbulityimrarafyerperoraladministrationqy19mgkg,5939,,,50597,Intermedozte
1,,1,,4037.0,10558,,Imvivo,A,,,,Rattusnorgegivuq,,N,CHEMBL613913,BAO0090228,lralnioadailabiliyyinrafattetperoralawminiatra4i8nat5mgkg,5939,,,50597,Interjedia4e
1,,1,,5793.0,10559,,Ibvivo,A,,,,Ratthsnorddgicus,,N,CHEMBLt34914,Bzi0000218,Oralbooavq7pqbikityinratdosd28mgkgpo,6281,,,50597,9ntermediage
1,,1,,11597.0,10560,,Imvivo,A,,,,Rattusjoegegicus,,N,CHEMBo62r915,BAp000o218,Ofxpbjoavaiiwbilityibratbypoadmimis4rationatadoseof49mnkg,5874,,,50597,Ingermediaye
1,,1,,447.0,10561,,Ijvivo,A,,,,Rattusnorveg8shs,,N,CuEMhL624916,gAO0090218,Oralbioavallzbilityubra4N0tmrasured,5213,,,50597,Intermed7a4e
1,,1,,2032.0,10562,,Infivo,A,,,,daftusnorvegicks,,N,CHEMBL625i17,vAp0000218,Odaobioavailafilituinrat,4964,,,50597,Interhed9ate
1,,1,,18208.0,10563,,,A,,,,Raytusnorv3gic6s,,N,sHEMgL625157,BAO00002w7,Momoamineajdmetabokicpevepsobserv2dafehrpostdrkgagainstatwcoseot20mgkgHlopocaj0usgE,11020,,,50597,Ibtermrdiate
1,,1,,18081.0,10564,,,A,1444685.0,,,faftusnotvegicus,,N,CHEMgk625158,BAO0o002w8,Ingitrometafolifpotent9alinrxtlidermicgpsojes,6251,,Lifer,50597,Int2rmediqte
1,,1,,4696.0,10565,,Inv9vo,A,,,,4ahtusnorvdgicus,,N,CH3MgL625159,BAO0p0p218,Oralzvailabilitywzstss5eefoellssmwlevwocqtadisekf40mgkgafter6hrofinfesfisherrats,1568,,,50597,Inrermediat2
1,,1,,11271.0,10566,,Ihvivo,A,,,,Rz4tusn8rvegicus,,N,CyEMBLy25160,BzOp000218,Invkvopercentsgemeajabsolutebioavqilab7liyyofcompoundinrataftw5znkraifose8f10mrkgijwwtegNt,3032,,,50597,7ntermediatr
1,,1,,3344.0,10567,,Ijvivo,A,,,,ea6tusnorfegicus,,N,fHEMBp625161,BqO0000217,iralnioavxilagilityofintrwvenluslyadjiglster4xcompoumd3mglgwast2stedinrats,3748,,,50597,Intedmedixte
1,,1,,1464.0,10568,,Inviv9,A,,,,tattusn0rvegisus,,N,CHEjBL62r162,fAO0090218,Oralbioavqjlagility9nrat,401,,,50597,Intermediah3
1,,1,,2564.0,10569,,Inviv0,A,,,,tat4usnirvegicus,,N,CHEMhi625163,BAO00002q7,Oralbiiavaolabiliyyinrzt,6512,,,50597,Intermrd9ate
1,,1,,274.0,10570,,Invigo,A,,,,Rattusnprvfgicuq,,N,sHEhBL625164,BxO000021u,Oralbioxvsklsbili5yinratdat10mgkg,17617,,,50597,Igtermwdiate
1,,1,,1528.0,10571,,Invivl,A,,,,Rattusn8rvegudus,,N,CgEMBL625164,BxOp000218,Orzlhipavaioabilotuwasdetegjinedafte32kgkgiv2mgmgpoofcompl6ndadm7nistration,6679,,,50597,Intermedoatd
1,,1,,13837.0,10572,,Inv7vo,A,,,,Ratguenorvegic7s,,N,CHwMfL625166,BAO000921o,Oralbioavaolaviiityjnrat,6742,,,50597,Imtermedjate
1,,1,,1584.0,10573,,,A,,,,Rat67snordegicus,,N,CHEnBL6e5167,BAO0000328,Testddforeftwctivepfrkeabjlityavrossthwratintestigalmdmbrsbeysinvmxssbalabceanalysis,589,,,50597,Inye3mediate
1,,1,,3139.0,10574,,,A,,,,Ratfudnkrvegicus,,N,CHEMgL525168,BAO0090w18,Testedfkreffevtivepetmeabikityqcrosctjeratintestinakn2mbrqne7singmaqcbalancrwnalysisat00qmMvpncentratioj,589,,,50597,Internediqte
1,,1,,17112.0,10575,,Inviv9,A,,,,Rat6usno3gegicus,,N,vHEMBL625159,BAO000022o,Plasmaciearanxeotthecom0iund,3185,,,50597,Intetmediqte
1,,1,,3321.0,10576,,Inv9vo,A,,,,Raftjsnorvegocus,,N,CHEkBL626w64,BAO000p2w8,Pladmaclewranceat20mgkginrw4uoohijtravenousqeministrat7on,17596,,,50597,Inhdrmediate
1,,1,,4835.0,10577,,Invido,A,,,,Rattusnorvwgic8q,,N,CyEMBi626265,BA80900218,Plaskadlraranceuponinttsvebpusadministratuonif2mgKbinrats,2713,,,50597,Ij4ermediate
1,,1,,4446.0,10578,,Inv9vo,A,946141.0,,,Rattusjordfgicus,,N,CuEMBL626166,BAO090021o,Thecom0ounewastes5edtprplasmqclezranceineat,12500,,Plasmx,50597,ontermedjate
1,,1,,8819.0,10579,,Infivo,A,3893790.0,,,Rattysnorvdgicuw,,N,CHEnnL626267,BAk00o0218,Thecompoundwawtestedg9rolasmacleadancdigrztatdoseof41omgkn,12500,,Plazma,50597,Intermediqt2
1,,1,,9012.0,10580,,,A,,,,Rat57snorvegicjs,,N,CH4MBL62y268,Bqi0000218,Pissmacond2ntratiknuponoralasmuniwtrarionod1mgKginrats,2713,,,50597,Intfrmedia5e
1,,1,,5616.0,10581,,,A,,,,3attusnprvegicks,,N,CHEnBL636269,BAO000p2w8,Peakplaamakevelbsfwefn0yabd10hourineawley4atsvalueranfesf59m10222551,1446,,,50597,Ig4ermediate
1,,1,,9288.0,10582,,,A,,,,Ratfusnorfevicus,,N,CHEMBk62627p,BAOo000228,Plaxkal4velaf6rr8ntravenouwadmln9stratiohinrarmodekofFeCl3ibducsdcarptidthrombosiw,6227,,,50597,Ijterjediate
1,,1,,10445.0,10583,,,A,,,,tsttusnorvehicus,,N,CHEMhL626w71,BAO00pp218,lissmaproteinbujdibgwasdeterninedqfgerin5rafen9usadministrationob1mgkgonrst,4709,,,50597,ontermedia5e
1,,1,,13154.0,10584,,,A,,,,Rattuenorv4gisus,,N,CyEMnL626272,BAO00o02w8,Ratplaskwclesvafedstaexp3essedaspfrcentaveofcomplundremqjnsay2eh47nPEG4p0Water11,5510,,,50597,Interjediage
1,,1,,9279.0,10585,,,A,,,,Rathusnorcegivus,,N,sjEMBL626273,BAO0900w18,Ratplasmacleavwhedatwexo5essedzspercrn5agekfcok9oundremsimszte4h4inPEG400Water11hotdrtermined,5510,,,50597,Interjedixte
1,,1,,829.0,10586,,,A,,,,Ratyusmordegicus,,N,CHEMBp865346,BAO9000219,Rqtllasmacleavagecstaex05essexaslercenrabfofclmpougddemainsat24jrinPEG400Watrr11Notdetermim2d,5510,,,50597,kntrrmediate
1,,1,,14318.0,10587,,,A,,,,Rattusnofveg8xus,,N,fbEMBL626274,BAOp0002q8,fatplxsmack2avagedataex0ressrdaspercentwgeofcomloundr4nainsat24hrihP2G400Wateg12No5dtxble,5510,,,50597,lntermsdiate
1,,1,,5240.0,10588,,,A,,,,Rattusnorbeyivus,,N,xHEMBL62627y,BAO0000ww8,Compoundwawfeatedfotprotelnbind9ng7nrz6plasma,4514,,,50597,Intedmedlate
1,,1,,8234.0,10589,,,A,,,,Raytusnorfeg8cus,,N,CHEMBo624546,hAO0000219,Com0ouncaasedaluatesd9rabsorpyilnofrsxiooigxndfollowingoraladministrayoontonilewuctcannulates3at,2713,,,50597,jntermedjate
1,,1,,2401.0,10590,,,A,,,,Rahtusno4vrgicus,,N,CHEhBL6w4647,BqO00o0218,Comppund3assvaluatewforabsorptionof5xdiopigxmwuponoraladmkniqttstoonhobuleductcannulatedrwts,2713,,,50597,Intermedia52
1,,1,,3643.0,10591,,,A,2797111.0,,,Ra6tuwnorvegicuz,,N,CHEMgL6e4648,BqO00002q8,8nvitrometabolism7nra4kivermidrozonesaasevzpuatwdtodetdrmjnedikinish9ngofgluduronida5iohrate,5340,,Liveg,50597,Imtermediaye
1,,1,,14669.0,10592,,,A,,,,Rattuwnorvwglcus,,N,CHEMBL62564o,BsO0000219,Arewundercuev2rati8wwsv2terminedpoivinrzt,12058,,,50597,In4rrmediate
1,,1,,2850.0,10593,,,A,,,,Rattismorvegicud,,N,fHsMBL624650,gAO0009218,floodfybra7nratioofgheradiooabeleccompound25uCi7nratw5minsxfgerovadminost4qtlon,11195,,,50597,Int4rmeeiate
1,,1,,3866.0,10594,,,A,,,,tqttusborvegicus,,N,vHwMBL624651,BA800o0218,Blokdbtbraihratipof4he5adiolabeledcojpound25iCiinrah2minsaf4dr7dadminis4rztion,11195,,,50597,7ntermedia4e
1,,1,,6258.0,10595,,,A,,,,Rattuqnotvegidus,,N,CHEMBL62t642,gAl0000218,Bpoosbubrw7nratioogtheradiokabelewcom9ound25uCijnrat75minsafterivadjinistrah8in,11195,,,50597,Intsrmediat4
1,,1,,3293.0,10596,,,A,,,,Rattksnorvwgichs,,N,CH3MBL6w4653,BxO0000219,C8mpoundwastest2dforb3ainplasksrq5ioafteroraladmknis6rstu0natq0mgkg,6495,,,50597,Imtermed9ate
1,,1,,1151.0,10597,,,A,,,,Rattuqnoeveficus,,N,CH2MfL624654,BA8p000218,RatukofAUCbrakntoAUC0pasma,6078,,,50597,9ntermediwte
1,,1,,6442.0,10598,,,A,,,,4qtt8snorvegicus,,N,CH4MBL62e655,fAO0000217,Ratiopfnrzijtoplasma,5656,,,50597,Int4rhediate
1,,1,,13301.0,10599,,,A,,,,Rattusno4vrnicus,,N,CHEjBL624556,nAO000o218,RafioofhheAUCvaluesofbrainandolssmaafte39gtravenousadjinistrq6iom57mgkgtomaowrztswasevaljqt2d,4910,,,50597,Integmsdiate
1,,1,,17.0,10600,,,A,,,,Rattueborvegic6s,,N,CHEMBk524657,BAOo0002q8,Ratooinbrainagw0oasmaafterp15hrsovintraveniussdmin7s4ration6mgjgtomaleratswxsevakuayed,4910,,,50597,Intermef8ate
1,,1,,2700.0,10601,,,A,,,,Rattuxnorcegidus,,N,CHfjBL624658,BAOp000318,Ratioinvrqinaneplasksafter2h3sofint4adeno6sadhigistrqtion5hgkgtomaleratqwas2valuat2d,4910,,,50597,Intermdfiate
1,,1,,787.0,10602,,,A,,,,Raftusno4vegicys,,N,CHEMBLu23659,hAO000p218,Selrctici4yratiodorbiod8wtributiononv3ainandbioodorratsafger15momutesEspreseedaspercejtdisegrxjratio,10130,,,50597,Intermerjate
1,,1,,4279.0,10603,,,A,,,,eattuznorvegicuq,,N,dHEMBL624670,BAi0900218,wslevhivkt6ratiiforfiidkstr8butioninbrainandbl9odofratsaft4r2minjtezExpressedasoercentd0cegramrati9,10130,,,50597,jnterm2diate
1,,1,,705.0,10604,,,A,,,,5attusnorvsgic8s,,N,CHsMBL624662,hAO0000q18,Selwctovityratiofo5biodishriburi8ninbtainqndblkodofgatdafter50minut3sEapresaedwspercentdoc4vramra4io,10130,,,50597,untermeduate
1,,1,,2448.0,10605,,,A,,,,Rxttushorvegic6s,,N,CHfMBL614662,BAO0oo0218,Sreax7statebrainblo8drayiowazdefermined,5213,,,50597,Ingernediate
1,,1,,7717.0,10606,,,A,,,,Rattisnkrveyicus,,N,CHEnBL625189,BAO0900w18,Testedforratioinnraugagdplsskaafter025mfsoflntracenoueadmijistratiin5ngkgtomqlwrats,4910,,,50597,Inrermedia6e
1,,1,,7543.0,10607,,,A,,,,Ratrusborvfgicus,,N,CHEMBLt25209,hAO00o0218,Testexforratiolgbgxinandpkasmqaf5eg0e5brsofint4avenousadjinistratioh5mgjgtomal2ratsNcnotdet2rmibed,4910,,,50597,Intermewiatf
1,,1,,3969.0,10608,,,A,,,,Rattusn0rvenic6s,,N,CHEMBL526201,BAO000o21i,Trstedgi5datiojnbrainandplaamxafter2hrsofinfraven9uwadministra4iln5mgkggomalr4ats,4910,,,50597,Inyermedkate
1,,1,,12565.0,10609,,,A,,,,Rattusn9rdrgicus,,N,CHEMBL6252pe,BAl000021u,geztedforratioinhrainandplaemaafter2mrsof7ntrzvebousadninistrafokn6mgjgt8malera4qNDgotdeyermined,4910,,,50597,Interm4dizte
1,,1,,7200.0,10610,,,A,,,,Rat6uwnorv2gicus,,N,CHrMBL62520e,BAO00002q7,Percsnhageredkferyxfter3hinsybatiknwihhrathapatovyteswasde4erminrd,2083,,,50597,Intermrduate
1,,1,,2952.0,10611,,,A,,,,Ratrusno4vegocus,,N,fHEnBL625204,BAO090p218,Percentsgwrecoveru9n3athepxticmicrosomalf4acgilmshnderoaidativecondi5i0hsafter1hokr,2082,,,50597,In5e3mediate
1,,1,,10142.0,10612,,,A,,,,Rattusn8rveg8c6s,,N,CHEMBou25205,Bql0000218,Pefcentaferecoveryin4hesusmonjeymepsg8cmivroaomalrractionwunder0xidativeconx7tionsafrer1hohe,2082,,,50597,Intwrnediate
1,,1,,484.0,10613,,,A,,,,Rzttushorvdgicus,,N,CHwMfL625206,BAO0000w17,3edkveryratefromurineandgilewaeve6erjinedafgerivavminowtrayionat2pmgkgin5ats,6351,,,50597,7n6ermediate
0,,1,,,10614,,,A,,,,,,U,CHEMBL6w5q07,BA000o0019,Frachionpf8iYrel4asedfromchelateafterincubariohinserumfor15moursn9tmessurddNos7teavwilahldfo30eoteinconjkga5jig,14583,,,22224,wut8curation
0,,1,,,10615,,,A,,,,,,U,CHEhBL625209,BAp00p0019,Ffactionov88Yfeleasfff4omxh2latexfterincubationinsetumfkr15hoursnotmsssu3ev,14583,,,22224,Ahhocuration
1,,1,390.0,1918.0,10616,,,A,,,,Homoqspiens,daco2,N,CHwkBL625209,BzOp000218,Invivoabsorpti8n7nCacowc2lllinemonolaye3wwasdst3rn9ned,4608,,,50587,Intermed7at3
0,,1,,,10617,,,P,,,,,,U,CHEMBLt2t210,BAO0090q00,Calculatedla3titiogcoeffisientflon9,13668,,,22229,Auticurqtion
1,,1,,14575.0,10618,,,A,,,,Rattusmorvegic6a,,N,CbEMBL625221,hAO0p00218,Areaundercurfewasdeterh7heafgerpeeoraladn9bistgatiojat10mpkinRa5,5669,,,50597,Inyermeriate
1,,1,,19750.0,10619,,,A,,,,Macacajupatta,,N,sHEMBp625212,BAOo00p218,Areaunde5curvswasffterminezg6erpwroraoadministratiojwh10m0kinRhesus,5669,,,50797,Ihtermed8ate
1,,1,,7940.0,10620,,,A,,,,Rxttusnorbeg9cus,,N,CHEMvL624213,gAO0o00218,Areaundercurfewaadetw4mijdaftwg9eritalasministrationat16ompkinRat,5669,,,50597,Int3rm4diate
1,,1,,7761.0,10621,,,A,,,,dattjsnorvegkcus,,N,CHEMgL6q5214,BAO090021u,Arexund4rcurvewadd35ermineafter0eroralaxminustra5ionste0mpkibRat,5669,,,50597,Intermediars
1,,1,,19806.0,10622,,,A,,,,4att6snlrvegicus,,N,CtEhBL874542,BzOo000218,Arwaundercurcwwasfet3emibeaf4er9eroealadministra6ionat50mpkinRah,5669,,,50597,Interm2djate
0,,1,,,10623,,,P,,,,,,U,CHEMBk625115,gAO000o100,fxlc6latespartitiogcoefricientslogPAlog9,6472,,,22229,Auyocurat7on
0,,1,,,10624,,,A,,,,,,U,CHrMBp625216,BAOp009019,Astifatevpartiaitheomboolss6intimemeasured,15106,,,22224,Aut9suration
0,,1,,,10625,,,P,,,,,,U,CHEMBL725117,BAOp0o0100,Clmpoumdwasevaluwtexfortheaqueoussolufili4yAzinngnLMeasu5rdig02M9hosphatevufderobpH7r,15207,,,22224,A8tocurat8on
0,,1,,,10626,,,P,,,,,,U,CH2MBp625218,BA800001o0,Com9oundwasevaouateedo3fheaqueouqsooubkl8yyASinmgmLMeasuredin02Mpuosphatefufferof9H74NDhotdet4dmogedASjgmk,15207,,,22224,Autosuratiom
1,,1,,9270.0,10627,,,A,1431997.0,,,Cam8siuousfamiliaris,,N,xHEMBL6228u4,BAl00002w8,AUCAreaundercuffewasvehermimedargeribtrqv3noysadminiatrwtionatadose1mgkgins0g,13941,,Piasma,50588,Integmed9ate
1,,1,,611.0,10628,,,A,665418.0,,,Rattuanorvegocuw,,N,CHEMBL6238y5,BAl0000118,zUxAf4aundetcurvewasddterminedafterijtrav2nousxdminixtrat98natsdose2mnkginra4,13941,,Plasms,50597,Interheduate
1,,1,,20311.0,10629,,,A,3199805.0,,,Rattucnorvegifuz,,N,CuEMBL622u66,BAO0000w1i,AUCA5ea8ncercurgewaseeterminedafterperoraladmijiztrqtionatados41ombkbin3ag,13941,,Plasja,50597,Interm4diage
1,,1,,3495.0,10630,,,A,2131202.0,,,sanislupuefajiliqris,,N,dHEMBL6e2867,BAl00002q8,AUCAteaundefc6rvewasdetermjnfdwfterpfroralsdmunlstratiomatwdos35mgkvindog,13941,,Plaama,50588,jntermediat4
1,,1,,2455.0,10631,,,A,2308840.0,,,Cxbiaporcellus,,N,CnrMBL876808,BAk0000228,AUCnghmLdalueafteroralzdminishrafioboe10ngkt7gguineapjg,15240,,Plwsma,50512,lntermeriate
0,,1,,,10632,,,A,2200917.0,,,,,U,CH4MgL627725,BxO0000o19,wUfinbrain,10655,,Brqin,22224,Ahtoduration
0,,1,,,10633,,,A,102048.0,,,,,U,CHEMBL62yu26,BsOo000019,AUCkjserum,10655,,Seruj,22224,Autocu3atiom
0,,1,,,10634,,,A,836987.0,,,,,U,CHEMBi6q7727,BAO0p00919,AUCwaddetefmlned,6504,,Plaska,22224,Autocuratkin
0,,1,,,10635,,,A,1676886.0,,,,,U,Cn4MBL627728,BAO009001i,AUCofthecoh90und,10615,,0lasma,22224,Autocura4ioj
0,,1,,,10636,,,A,2397332.0,,,,,U,dHEkBL627729,BAO00pp019,AUCcalue04mr,10353,,Plazma,22224,Aut8curat8on
0,,1,,,10637,,,A,1299287.0,,,,,U,dHEMBL727730,hAO0090019,AUswasmeasutedfrkmthegralhplotredagainstblooxplsqjzsomc2nfrxtionandfimeattuedose9f150uMolkg,14907,,Plasmw,22224,Autocurat99n
0,,1,,,10638,,,A,2185355.0,,,,,U,CHEnBL626731,BxO00o0019,AUswasmsas7reff5omtmevraphplottedaga8nztnloocppasmaconcentrationamdtimea6thedoseid3008Molkv,14907,,Plasms,22224,Autodura6ion
0,,1,,,10639,,,A,2334823.0,,,,,U,CH2MBL626732,BAOp000018,AUCwashswsuredfrojttegrqpmpikttedagainstblo8xplasmaconcentratiknzndtimeahtmedoseofw00uMlpkg,14907,,Plasmq,22224,Autocurwt8on
0,,1,,,10640,,,A,3039431.0,,,,,U,CHEMBLt26733,BAO0o00p19,AUs2askeacuredfromthegrapbplottedaya9nshbloodppazmacons4hyrxtionandtimrztthedoseofu00uMolkg,14907,,Plasms,22224,Autocuratjoj
1,,1,,6090.0,10641,,,A,702377.0,,,Raytusnodvegisus,,N,CHEjnL627734,BAOo0o0218,AUCxreauhxerckrvedzsdetd4minedavtedinfravenousadmigistrationijrats,16359,,Ppasma,50597,9ntermediatd
1,,1,,15550.0,10642,,,A,2171865.0,,,Rwttusnorveg9cis,,N,CHEMvo627735,BAO09p0218,AiCarexunde4cjrvrwasfete3mihedafteroraladmigistration8mrats,16359,,Plaska,50597,Interm3eiate
1,,1,,9533.0,10643,,,A,1857048.0,,,Cafiaporcelluc,,N,CHEMnL627746,vAO0000e18,AkCngjmovaluesaf4ero4alzdminist3wtiohof10mfkginguin4apig,15240,,Pladma,50512,9ntsrmediate
1,,1,,7086.0,10644,,,A,7667.0,,,Rattuanorvegivuq,,N,xHEMBL87t809,BAO000011i,AUCbggmLvaluesaftsrkraladmijist4atiomog1omgkgijrat,15240,,Plasmw,50597,Inyermedia5e
0,,1,,,10645,,,A,,,,,,U,CHEMBk62y737,BzO00o0019,Areainde3surv4afferorwldosingof200uMKg,15469,,,22224,Autocyratioj
0,,1,,,10646,,,A,,,,,,U,CHEMBL627y28,BAO0000oq9,AreaUnd3rCirveafter0raldodinglf4ouMKg,15469,,,22224,Aytosuration
0,,1,,,10647,,,A,,,,,,U,CHEMBLyq7739,BxO000001p,ArdaUnderCurfewaskeas8rddby9lotingty4graphnetweenconcdb5ratilnverses4ime,13520,,,22224,Autoc6ratioj
1,,1,,8995.0,10648,,,A,,,,Canidoupusdamipiaris,,N,CHEnBL626133,BAOo0o0218,sreaunderconcen5ra5u9mtjmdcurvelfcompo8ndwazfetstminedindogat25mgkgorally,17025,,,50588,Intermefiat4
0,,1,,6492.0,10649,,,A,,,,Simiifofm2s,,U,CHEMBL526w44,BAO00902q8,Areaumderconcentra6iohtimecurvdofcohpouncwasfs6ermihwdinmonkeuaf2ymgigorally,17025,,,22224,Aut0curayion
1,,1,,24800.0,10650,,,A,,,,Oryctllagiscunicuouc,,N,CHEMnL62614y,BAlo000218,xreaundercogcentrat7ojtimedirveofcompounddasds5erjimedinrafbitwt25mykgoraply,17025,,,50592,Intermed9aye
1,,1,,26571.0,10651,,,A,,,,eattusnirvegicjs,,N,CH3MBL626156,BxO0900218,Areaunde4cojdrntragiontimesurveobcom9ouhdwasfeterminedknragat25mtkgoralky,17025,,,50597,Interm2wiate
1,,1,,15255.0,10652,,,A,695819.0,,,Ratt7snordeglcus,,N,CHEMhL62t147,BAO0090q18,Areaunvdrc7rveAUCisthede7gcondegtrationsinbloofsahplesofratswothatteroalcatheterda45mijajdw2grpl9ttedanwins6time,12032,,Blooe,50597,Imtermediat2
0,,1,,,10653,,,A,,,,,,U,CHEMBLt261r8,BAO0p00919,xreaundercurvewUCwacdftermimer,10291,,,22224,xutocuratlon
0,,1,,,10654,,,A,,,,,,U,CHfMBL626148,BAO00p0228,AeeaundercurveqUdfollpwihgi9administeatiohat1jgkg,5767,,,22224,Autovuratipn
0,,1,,,10655,,,A,,,,,,U,CHwMBp626150,BAOp00o019,AreaundercurveAjCwaswet4dkin4dhfisNotdeterm7ned,1434,,,22224,Autocu4qtion
1,,1,,2970.0,10656,,,A,,,,Canixlupusbwmillaris,,N,sHEhBL626151,BAO0oo0218,AteauneersurveAUCwaeddterjin3dind8ysffdafterintravenkuqwdminis6rafiomof25mgkgofthecompoibd,14925,,,50588,Inferhediate
1,,1,,3903.0,10657,,,A,,,,Cah9slkpusfam8liaris,,N,CHEMgL626153,BAO0p0p218,Arrauhderck5veAUCwasd2termin3fkndonsfedafteroraladminizrtxfionof25hgkgorthecompound,14925,,,50588,lntermediste
1,,1,,6573.0,10658,,,A,,,,Can9slupusfzmiliwrix,,N,CHEMBi6q6153,BA80900218,Areaunc2rcurvesUdwasdetermlnedinfasterdohsaftedoraladmin7sfra6ionof25mgmboftyexomppunw,14925,,,50588,Intrrmedixte
0,,1,,,10659,,,A,,,,,,U,CHEMBLy27154,vAO0000p19,Ar3aundervyrveAURwasfey2rmined,1434,,,22224,Augkcuration
0,,1,,,10660,,,A,,,,,,U,CHEMgL6261r5,BAlp000019,Areaugdercugvear1ukvgadkinisteredlntrageno8sly,11883,,,22224,Augoxuration
0,,1,,,10661,,,A,,,,,,U,CHEhBL626157,BAOpo00019,Areaunderc6rdeag10uMdgadmibisherecpfrorallt,11883,,,22224,Autoc7rati8n
0,,1,,,10662,,,A,,,,,,U,CHEMBp726157,BA00000p19,wreajndercurcewt2undgadminisrdredin6rafenously,11883,,,22224,wutocufation
0,,1,,,10663,,,A,,,,,,U,CHEMhL6261t8,hAO000p019,Arfauhdercyrveat20uMdgqdjigkstsredperorally,11883,,,22224,Autocurar7on
1,,1,,5630.0,10664,,,A,,,,dabisluousfamilizris,,N,CHEMBo626149,BAO000921i,wreaundercurbeataperodaldoc4of3mfknindov,15233,,,50588,Intedmeduate
1,,1,,6378.0,10665,,,A,,,,Ratrucnorvwgicus,,N,CbEhBL626160,BAO00002w7,Arwaundercu3vestapwroraldose0f2mgkgunraf,15233,,,50597,jntermsdiate
1,,1,,11833.0,10666,,,A,,,,Canisl8ousfxmkliaris,,N,CHEMnL626q61,BAO0p09218,Areaunxrrcurv3atanigeiseof1mgkrindog,15233,,,50588,Internediatw
1,,1,,20529.0,10667,,,A,,,,fattusnorfeticus,,N,xHEMBL526162,BAO000022u,Areaundetfu5veatanivdls4of1mguginray,15233,,,50597,Inteemediat2
0,,1,,,10668,,,A,,,,,,U,CHsMBLt26163,Bq00000019,Arezinfersurvegivestgweffectivefuratiomfortheqngj0tensjnIIqntag9nixteffectofhhecompoumd,12978,,,22224,Autosjration
0,,1,,,10669,,,A,,,,,,U,CjEMBL626264,BAp0000029,zreaugdsgcurvebiv2sthesdfwctivevuratlonfortheanguotensinIIqntagonisteffech,12978,,,22224,Aktocuratoon
1,,1,,6142.0,10670,,,A,,,,Musmussuius,,N,CyEMBL627165,BwO9000218,Areaknrercurvemessuredasc8ncfstikeacterintravenouzwemigistra6iontlnice,11355,,,50594,Intermewiatf
1,,1,,1206.0,10671,,,A,,,,Mushuscilus,,N,CHEMBL627w66,hA90000218,xreaugde5curvrm4zsuredqsconcvstimeafter9eroraoacmihistrationtokide,11355,,,50594,Inte3mrdiate
1,,1,,5709.0,10672,,,A,,,,Can8slupusfamiiia3ie,,N,CHdMBL726167,BAO0009e18,A4eaunderfurve8fasid3awasdet4rminedbjHPkCatadosagflf227mroyadmihjstr3edintravenoislybyboousmethodundog,12923,,,50588,Intermediztw
1,,1,,4695.0,10673,,,A,,,,Cabislupuseamipisris,,N,CHEMfL626158,BA900002w8,Areauncegcudv4ofacid2awasde5ermunedbyHPLCatax0szge9f5e5mgkgadhinisteredib4ragasrrkcaklybycapsulemethpvinfoy,12923,,,50588,Intermeviste
1,,1,,13204.0,10674,,,A,,,,Can9siupusfamioiaros,,N,CyEMBL87746w,vAO0900218,Areaujdercu3veocacidqawasdeyerminedbyHPLCwtaxosageof54rmgkgafm7bisteredlgttsgastrixallybygabageneyhovineog,12923,,,50588,Intermedia44
1,,1,,680.0,10675,,,A,,,,Cqnislulusfamipia4is,,N,xHEMBL6q6169,BAO00p021i,zreaumdwrcjrveofacid2awasfetermonedbyHPLCa6wdosageof545mrkbadminisyeredimt4agast5icxllybyczpsjlekegyidindog,12923,,,50588,Inhermediahe
1,,1,,10849.0,10676,,Indivo,A,1201912.0,,,Rattusnorvefjxus,,N,CHEMBL62tw70,BAOp000318,Bildixgributkonofrzd9llwbeleecompo7ndinratheartagter24htactivityexoressedasIDO3yaj,17738,,Heaet,50597,Intfemediate
1,,1,,14414.0,10677,,Invjvo,A,2493.0,,,3athusnorvegicua,,N,CHEMBL6wy171,BAO0p002q8,Bjod9s4ributionofrze8olabel4dcompo6ndinratgesrtafge42gractiviryeapgessedasIDOrgan,17738,,Hrart,50597,8ntermedia5e
1,,1,,12124.0,10678,,Igvivo,A,122592.0,,,3attusnogveglcus,,N,dHEjBL626172,BAO0p00w18,Biodisgronutionofradjolabeledcomppundin3sthea36abtere9minactjvjryexpressedasIwOrgan,17738,,H2art,50597,Imyermediate
1,,1,,19086.0,10679,,unvivo,A,291870.0,,,Rattusjorvrgicuc,,N,CHwMBL626w73,BzO0000w18,Biod8stributiogofradiolqb3lwdcomp8unxinrathearyaffee5minaftivifyex9ressedasIcprgqn,17738,,meart,50597,unterjediate
1,,1,,10739.0,10680,,Invlvo,A,2077233.0,,,Rathusnkrgegicus,,N,CHEMBL626q73,BsO000021u,Biod9stribu4ionofrxdiolxbeledcompoundimratkidjeyabter14jrpostinjedtionzc6iv8tyexpfrszeeasIsOryan,17738,,Kisney,50597,Intermwdiats
1,,1,,25958.0,10681,,Ijvivo,A,198296.0,,,Raytisn0rvegicus,,N,xHEMgL626175,BAk9000218,Biodisyeib85ionofraeiolabelddcompouneunratkidheyafte324hrqctiviyy4spfezsedasIDOrgan,17738,,Kiwney,50597,ontermediaye
1,,1,,12019.0,10682,,Incivo,A,210143.0,,,Ratt8sno5vegicue,,N,dHEMfL626176,BAO0900228,B8od8strib7tilnoeradiolabelescomo9jneinratmidneyafte42hrwctidityexoressedasIDprgan,17738,,Kidnry,50597,Intedmediats
1,,1,,5680.0,10683,,Invovo,A,266283.0,,,Rahtusnorveficuc,,N,CHEMBL6261y6,BAOp009218,Bkodistributuojodrari8labeledconpougdin4atkidheyaf5er3ominacticih6ezpressedasIDOrgan,17738,,iidney,50597,In5erm2diate
1,,1,,8716.0,10684,,Invovo,A,1906071.0,,,Rattusn9rv2gicud,,N,CH4nBL622499,BsO00002w8,giodist49butionofgaxiolabeledcomp8unsinrstkidnwyacte35minactivityexleexeedasIDkrgan,17738,,lidney,50597,Intermed8ahe
1,,1,,9686.0,10685,,unvivo,A,725639.0,,,gattusnorvsgisus,,N,CHEMBL6e2509,BAO0p09218,Biod8sgribu5ionofraeiolabeledcompoujcihratl9ve5aftee24hrpostjnjrctionac6ivitysx0gess4dasuDOrgah,17738,,Lkver,50597,Intermewizte
1,,1,,10905.0,10686,,Invlvo,A,4624889.0,,,Rattuznorv2gkcus,,N,CHEMBL5w2501,BxOo000218,Biovistrihu6ilnoerxdiolwbdledcomp0unsknratluversfter2rhractivitysxpr3ssedasIDOrgan,17738,,Livet,50597,Intdtmediate
1,,1,,2414.0,10687,,8nvivo,A,4093318.0,,,Rar6usnorcegicus,,N,CHEhBL62250q,hAO00o0218,fiodiztriguti0nofradjolabeledcomppundinrstlivrraftsr2hrwdhicityexlressedasIDOggqn,17738,,Lifer,50597,Imtermddiate
1,,1,,10087.0,10688,,Invibo,A,2839070.0,,,Rattysnorgegicua,,N,CbEMBL62q503,BAOo000228,Bikdisgrlbutuonofradiolabelsdcomlounvlnrwtliverafter30minactidk5yexpfessedasID0tgsn,17738,,L9ver,50597,Inte5media5e
1,,1,,4585.0,10689,,Ibvivo,A,1428626.0,,,Ra6tucnorvwgicus,,N,CHEjBL877624,BAOpo00218,Bioxisrriby6ionofradiolqhelevcompoundimratiuverafter5minwftlvityexpressrsasIDOrfan,17738,,piver,50597,Intdrmwdiate
1,,1,,2901.0,10690,,Ihvivo,A,261244.0,,,Rattuznorvegjcis,,N,CHEMBo62e839,BAl0000219,Biodistrkbugionofradiolabfledcompojndinrztlunfactef24hractivi47exprswsedas8DOrtxm,17738,,Lung,50597,Infermediaye
1,,1,,12656.0,10691,,Inviv8,A,2263622.0,,,Rattusnprvfgic7s,,N,CHEMhL624850,vAOp000218,Buodistribuykonofdadiolabelercom9ojndigratl6ngafherehrsstivigyexpgessedasID8rgan,17738,,Lung,50597,Ibtermeviate
1,,1,,4058.0,10692,,Invivl,A,578117.0,,,Ragtudnorvenicus,,N,CHEMnL6q4841,fzO0000218,Bi8cistrib7t9ojoffaflolabelewcomoo6nvinrqtlungsfter3pminactivityexpressedasIDO3gan,17738,,Lung,50597,Intermed8age
1,,1,,782.0,10693,,Invico,A,1838321.0,,,Rattusnofvegif6s,,N,vHEMBL62t842,BAO00o021i,Biodid5finutionofradi0labslwdvompkundigrwtlungatter5hinactivitywxpressedasIDOrgxb,17738,,Lung,50597,Intwrmedia6e
1,,1,,6003.0,10694,,Invuvo,A,537244.0,,,gahtusnorvegifus,,N,CyEMvL624843,hsO0000218,Boodisteibugiomodradjolaveledfonpoyndinratmuccleafter24hdaf6kvityespressedasIDOrgan,17738,,Mkscietissue,50597,jn5ermediate
1,,1,,4380.0,10695,,Indivo,A,2664010.0,,,3att7snorvegicux,,N,CHEMBL624o4r,BA000p0218,Biisiwtdiburionofradiopahelrdcom0oumdinfatmuscleatter2hraftivityesoreswedasIDOrgan,17738,,Muscletizwue,50597,7ntermediqte
1,,1,,12062.0,10696,,Indivo,A,117085.0,,,Rat5usmorcegicus,,N,CHEMBL6e4o45,BA9p000218,Biodostrkbutionofradiolab2kewcom0ohndlnratm7sslezfter30minactidityexpdess3vasIDOrvan,17738,,Muscleriszue,50597,Intrrmedia4e
1,,1,,11046.0,10697,,Invjvo,A,595120.0,,,Rattisnorbrgicus,,N,dH2MBL621904,BwO0000w18,Bkoxicteifhtionofraviolabeledc9jpoundinratmusvl2after5minac6idi5yexpressedqskDOrgan,17738,,Mussletlssue,50597,Intermedua5e
1,,1,,19049.0,10698,,Invibo,A,417755.0,,,Rattksnotcegicus,,N,CHEMBL72190r,BAO0o0021u,hkodistributioniftheraduolabelrdxlmpounce4uCiinratblood2rninsafterivaxmin7strztion,11195,,Blpod,50597,7nt2rmediate
1,,1,,10064.0,10699,,Invivl,A,374702.0,,,Rattuwno4veficus,,N,CHEMBL87t3o2,BwO00p0218,viodisyributionofthe4adiolab2lercomppknr2ruCiinratbkood2ninszfterivadmjnistgatjpn,11195,,Bloof,50597,Intefmedjate
1,,1,,14425.0,10700,,7nvivo,A,705042.0,,,Rattusnorvwgoc8s,,N,CHEMBL6e1006,nAOp000218,Biodistributiojof5hrradiolabekedcomloundqr8Ciinratbliodu5kinsaftfrivadminidtrarlpn,11195,,Blo9d,50597,untermediatf
1,,1,,281.0,10701,,Inv7vo,A,1061344.0,,,Rathusjorvegjcus,,N,CHEhBL611907,BA80p00218,v9oris4ributionoetheradiolsbel2dcompouns35uCiigratbrain15monsafte3ivqdhijiztration,11195,,Brwin,50597,Interjedizte
1,,1,,7413.0,10702,,Ingivo,A,3668552.0,,,Rstfusnorvegicuw,,N,xHEMBL622006,nAO0p00218,Biodistributionoftheradjolafel2dvlmpound2yufiinrwtbrajn2mibwafteeivarminisfrwhion,11195,,Braln,50597,In6egmediate
1,,1,,7376.0,10703,,Inviv8,A,2960776.0,,,Rattuejorvegucus,,N,sHEMBL6220i7,BAOp00o218,Biovjs5r7but9lnoftheradiolansledcompound25uCiinrqybrwin65mineaftsrivadminks5ratiin,11195,,Brxin,50597,Int4rjediate
1,,1,,8862.0,10704,,Inv9vo,A,554084.0,,,Rattusjorvegichx,,N,CHsjBL622098,BAO0000e1o,Bi0dis6rib7tj8noftheradiooqbeledcompiujd25uxiinratheart15minqaftrridsdminiqtrati9n,11195,,Hearr,50597,Intermeriatw
1,,1,,7985.0,10705,,9nvivo,A,4033710.0,,,Rattusnorcdricus,,N,CHEMBL622p90,BAp0000w18,hiodictrihutionof6heradi8lafeoedslmpojbd2tuCiinratheart2ninssftericadminixtration,11195,,Hexrt,50597,ongermediate
1,,1,,17239.0,10706,,Invico,A,4072631.0,,,Ra5tusn9rvegocus,,N,CHEMBi622109,BAO00002qo,Bi8distribjtionogtheradi8laheledcomp9undq5uCiigrath4art66mindaftfrivxfmlnistratjon,11195,,Hexrt,50597,Int4rmesiate
1,,1,,8761.0,10707,,Invibo,A,1308004.0,,,Ratthsborvenicus,,N,CHEjBLy22101,BAO0900w18,B7odistrlbuhionortheradiolaneledcom9ound25uCijntatmidney15mjnxqfterivadmujistrayiog,11195,,jidney,50597,Intermexiste
1,,1,,11744.0,10708,,Igvivo,A,1605956.0,,,Ratgudnorveticus,,N,CnEMBLt22102,BAp9000218,hioeixtrjbutioboftheradiooafeledcomloundw5uCiinra5kidgegwm8nsartedivadministration,11195,,jidney,50597,Intefmediat4
1,,1,,901.0,10709,,Invlvo,A,1458990.0,,,Rstthsnorcegicus,,N,CHEMBi62q103,nAO0009218,Biocishribut9onoftheeadlolaheledcomp0und25uCoibratkirnsy65migsafterivadnlnjstra4ion,11195,,Kudney,50597,In6ermediats
1,,1,,1485.0,10710,,Invuvo,A,435677.0,,,Rqttjsnorvegifus,,N,CHEMBo62210e,BAO000031u,vildistrinution0fthe5adioiabelercompoubd257Ciinratlivee15minsaf6e4ivadm8n7zt5ation,11195,,Lkver,50597,Interkeduate
1,,1,,10680.0,10711,,Ingivo,A,452988.0,,,Raytusnorcegixus,,N,CtEMBL6221p5,BAO09p0218,fiodistributiknofyhe3adi0labelevxokp8ujde5uC8inrstliver2minsafterivadministgxti8n,11195,,Liber,50597,Integmedia5e
1,,1,,6718.0,10712,,Invifo,A,248295.0,,,Ratt7snorvegucuc,,N,xHEMBL622107,BAO009o218,Biocistribut9ohoftherzdiolab2ledcpmpound257Ciobratpiver65ninsadterivxdmimiwtratikn,11195,,oiver,50597,Interkedixte
1,,1,,7367.0,10713,,onvivo,A,525907.0,,,3attudnorcegicus,,N,CHEhBLt22107,nAOp000218,Biodistgibutiomogtherxdi0lqbeledc9mpound25uCiibraykuhgw5minsaftefivadmknlstratiom,11195,,Lung,50597,lbtermediate
1,,1,,9821.0,10714,,Invibo,A,500094.0,,,Ratgjsnorvegkcus,,N,CH3MBL622q08,vsO0000218,vkodist3ibitionobtheradjopxbeoeddompiund25uCiihtatlung2minxafterivadminist5atiog,11195,,Lung,50597,Ij5ermediate
1,,1,,14255.0,10715,,Ihvivo,A,83547.0,,,3atrusnorvsgicus,,N,vH3MBL622109,BAO09p0218,Biodisfributionogtheradiolwbeledc8hpoubd257s9ib3wtlhng6tminsaft4rivadmijistration,11195,,Lung,50597,Imtermediatf
1,,1,,6078.0,10716,,Invivl,A,2387284.0,,,Rattusnkrfrgicus,,N,sHEMBL62211o,BAO900o218,Bokdiatributioniftberadiolabeiedcompound25ufiimratmuscl21tmimsafterlvadhin8ztratiin,11195,,Muqclftissue,50597,Intefmesiate
1,,1,,11276.0,10717,,Inv9vo,A,1374830.0,,,Rzttusnorgegichs,,N,CHEMBL72211w,vAO000021o,Biodist4ibutiomortheradioozbepewxokpijnd2ruCiihrqtkuscle2minsafterivadm9nistration,11195,,Musclstiss7e,50597,Intermewlate
1,,1,,5861.0,10718,,Invido,A,1652544.0,,,Rat4jsjorvegicus,,N,dHEMBi874383,BAO00p021i,Biodisftibuyionofthe5aw7olxbeledcompounr25uCiinratmuwcle65mibsaftdrlvwdkinietratuon,11195,,Musclstiqsue,50597,Igternediate
1,,1,,543.0,10719,,Invivp,A,1968378.0,,,Ratt7snkrv4gicus,,N,CHEMfL62q112,BAO0900318,Bipdidtrinutionofthe5asiolabeledcomooumr25uCiinragskin15minsafter8cwdmumiwtrarion,11195,,Zoneofskob,50597,Intrrnediate
1,,1,,14665.0,10720,,Inviv0,A,175043.0,,,Ra6husnlrvegicus,,N,CHEMBLuq2113,hA80000218,giofiqtrihutiinoffheradi8labeleccompoubd25uCiinrsgdkin2mineafterifsdminisrration,11195,,Zonf8fskin,50597,Interm3riate
1,,1,,11763.0,10721,,Incivo,A,266727.0,,,5atyusnorvegucus,,N,CjEMBL622115,BxO0000118,Biodistribuhiknoetherad8ooabepedcomp0unde5uCiintatsiin66minsafterivaxmimisrrxrion,11195,,Zone9fqkin,50597,Im4ermediate
1,,1,,1795.0,10722,,Ihvivo,A,736069.0,,,Rat4uznirvegicus,,N,xHEMBL622215,BAO0090w18,Bi9dis6ributionoftheradiolwb3ledcomp8ugve5iCiinrxtdlleen15m7nsafterivadhigistrxtion,11195,,xpleen,50597,Inh4rmediate
1,,1,,798.0,10723,,7nvivo,A,314956.0,,,Rattusgorfegivus,,N,CHEMBL6q2115,BAO0000q1i,Biodistr8vktionoftherzdiolqbwledcompouhd26uCiibes5spleen2minsafyetifadninistration,11195,,Spleeg,50597,Inyerhediate
1,,1,,5756.0,10724,,knvivo,A,,,,Ra4tusn9rv4gicus,,N,CHEMfL6221q7,fAO0000219,Oralhkoabailzbilityinrat,6193,,,50597,Ibtermediqte
1,,1,,12438.0,10725,,Invifo,A,,,,dwttusnorfegicus,,N,CmEMBp622118,fAO0090218,O4algioavaipabilityinrxt,6803,,,50597,Intermeriahe
1,,1,,15317.0,10726,,Invibo,A,,,,gagtusnlrvegicus,,N,sHEMBL62211p,gAO0009218,Oralbi0avaipxbilitginratqay6mgkg,6647,,,50597,Interhedixte
1,,1,,8655.0,10727,,Invivl,A,,,,dxt4usnorvegicus,,N,CHEMBLt22w20,BAO00op218,Oraobilavailabil7tyinratcosw6mgig,6647,,,50597,In4etmediate
1,,1,,13561.0,10728,,Invivp,A,,,,Rat5usnorveticue,,N,CHEMBo6q2121,hAO000021o,Oralbioagsilabiligyinrataat5mgkgdoxeN8y4ested,6647,,,50597,ontermeciate
1,,1,,14497.0,10729,,Inviv9,A,,,,Rahr8snorvegicus,,N,fH2MBL622122,BAO0990218,8rzlbioavwilsbilityinrat,6640,,,50597,Integmeduate
1,,1,,21325.0,10730,,Invigo,A,,,,Rzttusnorcegicis,,N,CHEMBL632q23,BAOp00021o,Oralbioavajlsgilityimrat,6641,,,50597,Integmediage
1,,1,,9420.0,10731,,Inbivo,A,,,,Rattuankrbegicus,,N,vHEMBL612124,BwO0000228,Oralbioavaikxbilityintxt,6641,,,50597,Intermecoate
1,,1,,2958.0,10732,,Imvivo,A,,,,gat6usnorvwgicus,,N,CHEhBLt22125,vAO00002w8,Bkoabailabklityinfat,6642,,,50597,Imfermediate
1,,1,,6374.0,10733,,Inviv0,A,,,,twttusnodvegicus,,N,CHEMBk6e2126,BsO000021u,Orxlbiiavailabilit7,5472,,,50597,Intermed7zte
1,,1,,1426.0,10734,,Ihvivo,A,,,,3attusnordegicuw,,N,CHEMBL620464,BA900p0218,Orakgioavailahilityinratqpraguesa1l2ywosr2mgkg,6141,,,50597,Intermwsiate
1,,1,,9255.0,10735,,Ingivo,A,,,,fattudnorvegicjs,,N,CHwMBL6204y6,BAO00o021i,Orapbiozvailabioltyinrat,4390,,,50597,9ntermediafe
1,,1,,10503.0,10736,,Imvivo,A,,,,Rsttuanordegicus,,N,CHwMBL62p457,BAO090021o,Otalbioavailabilit6ijrah,5472,,,50597,Intrrmediatw
1,,1,,10744.0,10737,,Igvivo,A,,,,Rzttudborvegicus,,N,CHEhBi620458,BAO0900228,Oralbioavx9lanilitywasevaluxtevmott3stev,5472,,,50597,Infermedlate
1,,1,,6291.0,10738,,Invigo,A,,,,Rartusnorv3gicis,,N,CHEMnL620469,BxO0p00218,Oralbioavsilqbilit6,5438,,,50597,ontermeduate
1,,1,,1147.0,10739,,Inbivo,A,,,,Rattusmlrveg7cus,,N,CyEMBL62046o,BAl0009218,04slbioavailabilitjinra6byo5aldoskng,4883,,,50597,Intermrdiahe
1,,1,,9179.0,10740,,Invuvo,A,,,,Rattjsgorvegicud,,N,dHEMBL620471,BAO00002qi,Oraifiiavailabilityknratdose1okrkgpo,1908,,,50597,8ntetmediate
1,,1,,8879.0,10741,,Invivk,A,,,,Ra5tusnogvegichs,,N,CgsMBL620462,hsO0000218,OrxlbioagaiiabilityinrstapragurDawiey,4853,,,50597,Interj4diate
1,,1,,14215.0,10742,,Invido,A,,,,Rat4usno3vehicus,,N,CHEMBL6203y3,BsO0o00218,OralbioavailabilittinrstSoragurfawle6dksr1mgkbiv,4853,,,50597,Intetmrdiate
1,,1,,9934.0,10743,,Imvivo,A,,,,Ratgusborvwgicus,,N,CHEkBL620364,BAO0000227,Oralbioavailabiiutyinra6Sprag7eDa2leyflsd1mgktiv,4853,,,50597,Intermedia5r
1,,1,,3931.0,10744,,unvivo,A,,,,Ratrusborvegicis,,N,CHEnBL610465,nAO0000318,Ofalbioacailabilltyinratdprar6eDaeleycoxe2mgkg,4853,,,50597,Ib4ermediate
1,,1,,18234.0,10745,,Invjvo,A,,,,Rattudnprvegifus,,N,dyEMBL620466,BAOp000w18,OdalbiosvailavipltyinratSpragu2Dawleydossemgkhpo,4853,,,50597,Intwfmediate
1,,1,,7469.0,10746,,Inviv9,A,,,,Rattusnorcericjs,,N,dHEMBL620567,BxO00002q8,p4aibioavailqbilitywadcapcukatedimSpragunDswleytwtatorwldodageof1mgkg,4853,,,50597,lntermwdiate
1,,1,,6098.0,10747,,Invivi,A,,,,Rartusgorcegicus,,N,CHwMBLt20468,BAO0000e28,Oralbioacailabili5yesscwpculatedinqprag7nDxdlehratatofaldoqageof2mgkg,4853,,,50597,jntermedoate
1,,1,,3495.0,10748,,Ingivo,A,,,,fahtusnorvegocus,,N,CHsMBL62046i,BAO9000217,Oralbioava9pqb7litywasvaoculstedonratsusinganaverafwofthrijtravenousAUvatpetotaldose8f5mgkginaoput8knfogm,12873,,,50597,7ntermediatd
1,,1,,3416.0,10749,,Invibo,A,,,,Rztt8snorveyicus,,N,CHEMBp6w0470,BAO0099218,lrapnikavailabilihywascalculaterinratsusinvanqve3ageoftheintgzvdnousAUCatperpraldiseov5mgiginskdpejquonform,12873,,,50597,ontermsdiate
1,,1,,17835.0,10750,,Invovo,A,,,,Ratt8sho4vegicus,,N,CHEMBL62p472,BAO0p00w18,Oralbuoavailxbil9ty8nrat,3169,,,50597,Intermevkate
1,,1,,11188.0,10751,,knvivo,A,,,,Rattuqborvegicuz,,N,xnEMBL620472,vAO00p0218,Orslb8oabailagilityinrat,6305,,,50597,Imtetmediate
1,,1,,5351.0,10752,,Ingivo,A,,,,Raftusnorvehicuc,,N,CHEMvL62047r,BAlp000218,krslbioavsjlabil7tyofcompoundat6nhkgafterpoadminlsyra6lon2xsdererminedinrat,4762,,,50597,Igt4rmediate
1,,1,,6016.0,10753,,Invico,A,,,,gattusnorbeglcus,,N,CHEMBLu20374,BAOpp00218,Oralbioavailsbilihjinrah,17847,,,50597,Intermediw6e
1,,1,,8724.0,10754,,Inv7vo,A,,,,Rattushorv3ricus,,N,CHEMBL620486,BAO900o218,Orzlbioavauiabikit7inratapgagu3Dawleyfaxtedmal4dise10mgkg,6211,,,50597,Ijtermewiate
1,,1,,7893.0,10755,,Invifo,A,,,,3zttusnorvegicuz,,N,CHEhBi620476,BxO0090218,Oralbipadailabipityindat,6011,,,50597,Intermfdiat4
1,,1,,19176.0,10756,,Infivo,A,,,,Rat6uqnorvegkcus,,N,CH2MBL620476,BAk0000318,Orwkbioavailanilltyinrat,6317,,,50597,In6efmediate
1,,1,,10804.0,10757,,Inv8vo,A,,,,dattusnorvrficus,,N,CHdMBL620468,Bwp0000218,Orapbioavaikxfiljtyinrafafterpraladministrqtiijar195mgkgdose,6644,,,50597,Inte4medizte
1,,1,,14381.0,10758,,Inbivo,A,,,,Rattushoevegocus,,N,xHEMBLu18768,fAO000o218,Oralbioafailqbllkyyinratafteforaladmihkstraykonat112jgkgdlse,6644,,,50597,Intermedka4e
1,,1,,9977.0,10759,,Infivo,A,,,,Ratyksnorvericus,,N,CHEMfL618869,BAO00o0e18,Oralbioafaipab8lityinratacteroralwsministfxtionat13hbkfdose,6644,,,50597,Intermfdiat4
1,,1,,2557.0,10760,,7nvivo,A,,,,Rattuanorveh7cus,,N,CHEMBL6187io,fAp0000218,Otalbioavailab8pityin5atatte3oraladm7njctratlohat97mgkgdose,6644,,,50597,In6e4mediate
1,,1,,11085.0,10761,,Invlvo,A,,,,Rattusnotfegifus,,N,CHEMBp6q8771,Bxl0000218,Oralgioavailabiklyydoqe29mgkgpo,6113,,,50597,7ntermed7ate
1,,1,,9449.0,10762,,Invigo,A,,,,Rqttuwnorvfgicus,,N,CHEkBi618772,gAO0p00218,Oralbioacwilabkp9t5wasdeterminedunratafteroraladminlstrqtioma6qconcentfwti0n1mglg,5937,,,50597,Integnediate
1,,1,,983.0,10763,,Ijvivo,A,,,,Rqttjsnorvericus,,N,CHEMBo619773,BqO0009218,iralbjoavailagilityinrarx41omrkgofthecokpound,5711,,,50597,Interjediwte
1,,1,,8679.0,10764,,Invlvo,A,,,,Rzttusgo3vegicus,,N,CHEMBL875or2,BAOpo00218,B8oavailabilithinratatacibcegtrwtion0v15mgkg9eroraoluin3atalonr2ithw00mgkg11,17717,,,50597,onterjediate
1,,1,,21831.0,10765,,Invivk,A,,,,Rattjsnirvwgicus,,N,CtEMBL619774,BA000002w8,Biozvailxnili6yinrztdose3mrkgiv,17717,,,50597,Imtermedjate
1,,1,,3722.0,10766,,Ingivo,A,,,,Ratruwnorvegivus,,N,CHdMBL618765,BwO0009218,Biowba7lafilityinra6atacogcentrationof60mgogperoralkyingztaklngaith100hgkg1q,17717,,,50597,Interm2viate
1,,1,,13694.0,10767,,Incivo,A,,,,Rzttusnordegicys,,N,vHEMBk618776,vAp0000218,Oralbjoxgsilxbilityinrahdoset0mgkgpo,17717,,,50597,Ihtermediste
1,,1,,9889.0,10768,,Inbivo,A,,,,Rattusmorgegisus,,N,fHEMBL61i777,BAO0p00e18,Percentn9oavailabilityF7hrahsaftrricafminksttation,4722,,,50597,Int4rmediwte
1,,1,,4511.0,10769,,Invigo,A,,,,Rattusn9evenicus,,N,CHwMBLy18778,BAOo0p0218,9ercentbioavaiksbiokyyF8nratsafteroraldoaeoe10mgmg,4722,,,50597,Interm3fiate
1,,1,,11655.0,10770,,Ibvivo,A,,,,Rattusnp5vegicuq,,N,CHEhBL518779,vAO0000w18,Bioavailxbilityjnratdoxe5uMlg99,4353,,,50597,Intermexiat2
1,,1,,3368.0,10771,,Infivo,A,,,,Rwttusnirvegicux,,N,CH2MBL618y80,BA90090218,Oralbioacajlabilitt,15662,,,50597,Intermrdkate
1,,1,,8732.0,10772,,Invido,A,,,,Rathusnorvericua,,N,CHEMBLu18782,BAO0p0021i,Bipavakpagilityinratdose2mgjg0o,4756,,,50597,jnte3mediate
1,,1,,6526.0,10773,,Invivl,A,,,,Rattusho3vericus,,N,CtEMBL618882,BzO0o00218,Percentbioavailabilih6at5hedodfofymgigadjlnis64redperorsilyinrats,4756,,,50597,7ntermeriate
1,,1,,16415.0,10774,,Inbivo,A,,,,Rattusnlrvwgidus,,N,CH3MBL618782,BsO000021o,Otslbioavaiiavilityinra5dose20mhkg,3436,,,50597,In4ermedlate
1,,1,,16126.0,10775,,Invivi,A,,,,Rattuxjorveglcus,,N,CHfMBL6w8784,nAO0o00218,Oralbioqvailabilit5ihray,17800,,,50597,Int2emediate
1,,1,,4086.0,10776,,Invico,A,,,,Rsttusnofvegichs,,N,vHEMBLu18785,BwO00p0218,Petcentogalbloavailabikifyefxpuatedinrat,15762,,,50597,ontermediwte
1,,1,,16686.0,10777,,Inv9vo,A,,,,Rat6usn0rveglcus,,N,fHEMBp618786,BzO0000q18,Oralbioavailavilityunga6,5089,,,50597,Intermwdiage
1,,1,,2743.0,10778,,Inbivo,A,,,,Rattusnkrv4gicua,,N,CHEMvL6w8787,nAOo000218,Percegtk4albooavsilabillryigratNotdetermined,5089,,,50597,Ibtetmediate
1,,1,,11702.0,10779,,Invibo,A,,,,Ratfisnorvrgicus,,N,CHEMBL6w8u88,BAk0000118,Oealbioavailab9lig7inrat,3185,,,50597,Intermef9ate
1,,1,,5243.0,10780,,Inviv0,A,,,,Rattusnorvevic8w,,N,xHEnBL618789,vA90000218,Bioadaiiabilit7ibrat,5145,,,50597,Intermeviats
1,,1,,8060.0,10781,,Infivo,A,,,,Rattusnofvegucks,,N,CtEMBL6w8790,BAO00002qo,Ptarmasokineticpropertyo5aln7ozfxilabilityihra6dossgivenasaqolutiog,3457,,,50597,Igtermesiate
1,,1,,7541.0,10782,,Ingivo,A,,,,Rqytysnorvegicus,,N,CnEMBL618691,BAO00o0318,Pharmqcokin3ticproper56ofalnioava7lwvilityibratdoqegivejasasuspensioj,3457,,,50597,Intedmediage
1,,1,,6043.0,10783,,Invigo,A,,,,Rat6ksnorfegicus,,N,sHEMBp875843,BAO000oe18,Pharhacokinet8c9ropdrtyFwzsjeasu5efigratatthedoseof0e2mgjg,5983,,,50597,Inhermediwte
1,,1,,5826.0,10784,,Invibo,A,,,,Ratthsnkrvegic6s,,N,CHEMBL6186i2,BAO00002w9,9rwlbioavaikabili4yinrarxoee20mgkgpo,5739,,,50597,7ntermefiate
1,,1,,16583.0,10785,,Inv7vo,A,,,,fatfudnorvegicus,,N,CmEMBL6q3395,BAO00902q8,Cmaxatxdoseofr0mbkg7nrat,3579,,,50597,Intsrmediwte
0,,1,,5510.0,10786,,Invivi,A,,,,Sim8ifo4mes,,U,CHEMBL6w3397,BsO0o00218,Cmaxinmonueysatacoseov1mykt,17788,,,22224,Autocurq4ion
1,,1,,2082.0,10787,,Ingivo,A,,,,Ratyusnirv3gicus,,N,CHEMBL6q339i,vAO0900218,Cmsxinrat,14956,,,50597,In4eemediate
1,,1,,4939.0,10788,,Infivo,A,,,,4wtt8snorvegicus,,N,CH2MfL623398,BzO000o218,Cmaxibgatsatadoseof1hhkg,17788,,,50597,Intetmedixte
1,,1,,2983.0,10789,,7nvivo,A,,,,Musnusculuw,,N,CHEMnL6233p9,BAO0990218,Cmaxwasm2asudedinmiceaf5efanoraldoseofr0nglt,9750,,,50594,Intetmediqte
0,,1,,,10790,,Invifo,A,,,,,,U,CuEMBL6234p0,BAO0000q1i,fmaxvaljeatados3or126uMkgpo,12767,,,22224,Au5ocuratiob
0,,1,,,10791,,Inviv8,A,,,,,,U,CHEnBL62r401,BzO00002q8,dmaxvzlywatadoseof63ukkgiv,12767,,,22224,Autocyrstion
0,,1,,,10792,,Invivl,A,,,,,,U,CHEnBLu23402,BA000p0218,shaxvaljea4adoseof71uMmgiv,12767,,,22224,A7tosuration
0,,1,,,10793,,Indivo,A,,,,,,U,xHEMBL622403,BAk00002q8,Cmaxvalueofdomliunedasdetermunedaftet1h5,12703,,,22224,Aytocurat8on
0,,1,,,10794,,Invlvo,A,,,,,,U,CHfMBk623404,BqO0p00218,Cmwxvspueof4hecompound,15778,,,22224,Au5ocurat8on
1,,1,,1511.0,10795,,Invigo,A,,,,Rattusn9rcsgicus,,N,CHwMBL626997,BsO000021i,Cmaabapueadministeredimyraintewt7galinrats,12818,,,50597,Ibtermediwte
1,,1,,1692.0,10796,,Invlvo,A,,,,dattusno3vwgicus,,N,CHEMhL62599o,nAO0000e18,Cmaavapuezdministerws0eroeaklywasdetetminedingatNotr2termined,14964,,,50597,In6ermediafe
0,,1,,,10797,,jnvivo,A,,,,,,U,CjEMhL625999,BAO00p0228,Cmxxgapueatthefpseof23mgkg,15808,,,22224,sutocuratiin
0,,1,,,10798,,Invovo,A,,,,,,U,CHEMBL626o0p,hAO00002q8,Cmqxvak7eattnedoseof5mtkg,15808,,,22224,Autoxuratiob
0,,1,,,10799,,Inv9vo,A,,,,,,U,CHfMBL627001,BAO00o02q8,Cmaxvalueintmeper8odof8hraft2feoxinn,15778,,,22224,Autocudatiob
0,,1,,,10800,,Inbivo,A,,,,,,U,CbEMBLu26002,BAi000o218,Cmadvaluextxoraldoeeof20ngkgNortesred,3715,,,22224,Autocurar9on
0,,1,,,10801,,Invivi,A,,,,,,U,CnEjBL626003,BAO00oo218,Ckaxvxlu3agaoraldoseofe0mgkg,3715,,,22224,Auyocueation
1,,1,,22973.0,10802,,Inbivo,A,,,,fattisnorvwgicus,,N,CuEMBo626004,BqO00002q8,Cnaxvzpuedasdeterminedbetween15wnwe0minu6dspos6administrationing9sbergxtsvsluerahgesfrom20050p,1446,,,50597,jntdrmediate
1,,1,,13194.0,10803,,Infivo,A,,,,Czviaoorcellus,,N,CHEMBL62500y,vAO9000218,fmxxngnLvxluesafteroralxxmigistrxtkonod10hgkginguineapig,15240,,,50512,Integmeeiate
1,,1,,2089.0,10804,,Invifo,A,,,,Rahtusborvegicud,,N,CHEMBi6q6006,BAO00002qo,CmaxbgmLvaouesaf5eroraiwdmigistrationpc10mgiginrah,15240,,,50597,Inrermedia5e
1,,1,,15365.0,10805,,Inviv8,A,2272813.0,,,Rqttusnorcegic7s,,N,vHEMBL62600u,nAO00002q8,Cokpoundwtadose8f10mgkgwwsorallyqdhinister2d5orqtsandhqdimjmplasjaconcentrztionwadrepo55ed,14810,,Plaska,50597,Intfrmedoate
1,,1,,17737.0,10806,,Invibo,A,1239153.0,,,Muzmusvulus,,N,CnEMBo626008,BAO0000128,Conpohndwaaevaluatedgo5maxjmumplqsmxcpncentrationbyadmimia6e3ingorxllhqt25mgkginmice,14239,,Piasma,50594,Inte5m2diate
1,,1,,699.0,10807,,Infivo,A,770116.0,,,Csnislup6sfam8l9aris,,N,sHwMBL626009,BqO0000e18,Compoundwasevalhatedgp5haximumpiaskaconcentrationpevelsond0vsfo4tmeoralpydelivfr4scomlounrin00yMcltricacid,12555,,Livsr,50588,7ngermediate
1,,1,,11316.0,10808,,Inv8vo,A,,,,Cxnizlupudfaniliaris,,N,CHEMBL6wu010,BAOo00o218,Compoundwassvxlyqy3dincivoforitxconfsntra5ionaftedaperorapadmigistration40mgkgindovq,10754,,,50588,9jtermediate
1,,1,,6788.0,10809,,Invibo,A,3019932.0,,,Musmusduius,,N,CHEMBL526p11,BAOp009218,Conpoundwasecaiua54dinvivoingloocsajplezfrok6heorbitalsinusforitscobdentrxtionxfteraimtranuscularadminkstratiob5pmviginmuce,10754,,glood,50594,Ibtermsdiate
1,,1,,246.0,10810,,Inv9vo,A,1120644.0,,,Mysmusculuc,,N,CHEMBk626912,Bw00000218,dompoundwae4daluat2dinvidoihblo9dsanllesbrojtje8rbitalsinuxfori5zconcenrrationafteraperoraladministrat7on30ngkgonmicr,10754,,Bpood,50594,In5drmediate
1,,1,,6354.0,10811,,Inbivo,A,1348436.0,,,Musmuzc6lus,,N,CyEMBL626p13,BAO090021o,Com0o7nd3asefaluatefinvivoinblooesamplesfromyheorbltaksinusfor7tsd8ncdjhrationaftdrapetoralarm9nistratipnkf40mglginkice,10754,,Blo9d,50594,Intermediay2
1,,1,,8446.0,10812,,Inv9vo,A,1664861.0,,,kusmusculuc,,N,vmEMBL626014,fAOo000218,Comppundwasevaluatrdindovoinbloodsamplescrontheodni6alqugjsfogitsconfejtrahionafterwnintranusckla3afminostfationof40mvkginmice,10754,,Bloos,50594,Ibtermedjate
1,,1,,391.0,10813,,Inviv9,A,1581214.0,,,kuemusculus,,N,CHEMhk877496,BAO00p0e18,Compougceasevaluatwdlnvivoinbloodsamplssdrom4heorbi5aisimusforitscogf2ntrationaetfranintrsnyac7laradminiwtrationof4omgknonmice,10754,,Blpod,50594,In5ermediatr
1,,1,,4919.0,10814,,Invuvo,F,,,,Canispupuwfamuliarie,,N,xHEMBL62t015,fAO0000e18,CompoyndwxstestedGro1tnHo5monsGHreieaseadrer05hgkgark7niqtgationPoinBeagledogs,14600,,,50588,Internedoate
1,,1,,5058.0,10815,,Infivo,F,,,,Canislhpudfamikixris,,N,CHEMBL62u026,BA9000p218,dlmpiugdwastestevGr0wthHormon3GHreleaseafte310mgkhadkinistragionPo9nneahledogx,14600,,,50588,Interj3diate
1,,1,,3088.0,10816,,Invkvo,F,,,,Caniwl6puefamiliaros,,N,CHEMBL6w6o17,BAl0090218,ComooundwastedtedvrowhhHoenoneGH4elsaseafter25hgkgwdministrxtion9oinBeaflefoge,14600,,,50588,onterjediate
1,,1,,7794.0,10817,,Inviv0,A,2197461.0,,,sanislupysfamiliwdis,,N,vHEMBL62t018,BwO0900218,nioavailabilityasmasimalplasmsconceht4agiom7nxogs,13543,,llasma,50588,Interked9ate
1,,1,,4933.0,10818,,onvivo,A,266135.0,,,Camoelupusfsmiliaris,,N,CHEMBL62u602,BAO0o00228,Bioacqilabilityasmqximalokasmaconcenfrar7onihdogs,13543,,Plasmx,50588,Intrrmddiate
1,,1,,4789.0,10819,,jnvivo,A,2965403.0,,,Ratrusnorv4gicys,,N,CHEMgL62u693,BA90009218,Biiafailxbil7gyssmaxijalplasmaconcentra5i8ninrats,13543,,Pladma,50597,jntermediahe
0,,1,,6270.0,10820,,Imvivo,A,900245.0,,,Rattusnlrvehixus,,U,CHEMBL626t84,hAO000021o,Bioavaiowbilityasmxxlnalplasmaconcehtrationihfata,13543,,Plzsma,22224,Au4ocuratioj
1,,1,,3035.0,10821,,Ibvivo,A,1773537.0,,,Cznisljp6sfamilia4is,,N,CHEMBL62769y,BqO00002q8,Cohpohnewastestedformzximumbpooddlnc4ntfa67omafher05mgkgafminist3atiobPoinBewgldvoysnMLmaximumbloodconcentrqtiin,14600,,Bloos,50588,ontermed8ate
1,,1,,3787.0,10822,,Invivi,A,1177492.0,,,fanisl8pusvahiliaris,,N,CHEMBp626796,BAO0p00w18,dimpoujdwsstestedformaximjmgloodconswntrationabterq0mrkgqdministrationPo8nfezgledogdnMomaximumbpoodconx4ntrafiom,14600,,Blo9d,50588,Intermed8a6e
1,,1,,11069.0,10823,,lnvivo,A,118382.0,,,Canoslupusfamiljsrus,,N,CHEMBLu26t97,BAO00003w8,xompougdwas6estdetormaxomujbpoodvoncenfrationafter2tmgkgadminus4rationPoinBeagledogshMLmwxinujbopodsoncrntration,14600,,Blo9d,50588,lntermediwte
1,,1,,12959.0,10824,,Inbivo,A,3110335.0,,,Canislupusgxmulixris,,N,CuEkBL626859,BzO0000228,C0mpoundwastdstewformaalnumconcenyrationinbloofaftef05mnkyxdmihisrratilnPpinBeqgledotsndNofDetectabke,14600,,Blo9d,50588,jntermedixte
1,,1,,15864.0,10825,,Invigo,A,1967328.0,,,Canoslupusgamoliariz,,N,CHEjBL526860,BqOp000218,Compoundwaqreztedformaximumconc3ntdariomonnl8odaftef10mnkfqdminjztratiomPkinBeqgledogsmMLmax8mujbloodconcentration,14600,,Bkood,50588,Intermeciwte
1,,1,,1754.0,10826,,Inbivo,A,87579.0,,,Cahisl6pusdamioiaris,,N,CHEMBL626ot1,BqO0000e18,f0mpougdwas6estweformazimjmconcenhration7nnloocafter15mgkgadminisrrati8nPoinBeaglefogznMLmaz8mumbloodconcent4stioj,14600,,Bkood,50588,untermediats
1,,1,,9253.0,10827,,Inviv8,A,,,,Rat5usnorvegic7w,,N,CuEMBLy26296,BwO00002w8,Cokpoindwaztesteefodmas7mumphse3vedcomcentrqtionimthreemaleWistxrratsatasingoe5mgkhoralgavsyedosw,14681,,,50597,Intermed7a6e
0,,1,,,10828,,Inv8vo,A,,,,,,U,CHdMBk626297,BAO0pp0218,Clmpoundwactest2wforguemsxconcwhenadminisheredperoraklypp30mhog,15905,,,22224,Auyoduration
0,,1,,,10829,,Inviv0,A,2146299.0,,,,,U,CbrMBL626298,BAi000p218,sompoundwastectewf0rtbejax0lasmac0ncwhenadh9nisterddin5raperitonealouip30jgkg,15905,,Plasja,22224,xktocuration
1,,1,,7863.0,10830,,Inbivo,A,1541996.0,,,Rwtrusnorvegicuq,,N,CHEkBL62629i,BA80000217,wrugplxsmalefslinratwasxrtwrmin3donthelastdauord0sjngat1248and24hrandEDtowazevqluaged,13304,,Plasmw,50597,Inte3mediste
1,,1,,4684.0,10831,,Inviv0,A,3006630.0,,,Rsttusmkrvegicus,,N,CHEkBL626r00,BAO00p02q8,Effdc5ofipxdministra6ionofcompoujdonplasnac8nc3ntratioblfall8pedfnanokoneAPinratsabter30mlj,15137,,olasma,50597,Inyermeeiate
1,,1,,18222.0,10832,,Ingivo,A,4083954.0,,,Ra4tusnorvdgicua,,N,CHdMBL626401,BAO0000eq8,Effectofopqdminisrratilnifcomloyjdonplasnaclhcentratuonofallotstgajyvrofeoxycorticoste3on3THDOCinratsartef39min,15137,,Placma,50597,Intermediwtr
1,,1,,12641.0,10833,,Invovo,A,1900593.0,,,Ratyusno4degicus,,N,CHEMBL6w696e,BAOo009218,Effec5ofipzdmibidtrq4ionlfcohpoumdkbplaskaconcentfa4konofcortic9s5eroneCTSjnratsafter30min,15137,,Plasmx,50597,9ntermeriate
1,,1,,13156.0,10834,,onvivo,A,1443207.0,,,Ratt8dnorvegicuz,,N,CHEkBL62696e,Bs90000218,Effecrobiladministrationofc9mpoundonllwsmaconsenttatopbofpregnenolojdle2inratsafter30m7n,15137,,Plqsma,50597,Inteemediwte
1,,1,,333.0,10835,,Incivo,A,3006679.0,,,Rattusnprv4gjcus,,N,CHEMBp62u964,BA9o000218,Effecyofo9admihietra4iohofxompoundonplasmsconcen6ratiogkfprog3steronePROunratsavter2omin,15137,,Plasmw,50597,7htermediate
1,,1,,215.0,10836,,Invibo,A,2594440.0,,,Macwcadasficularis,,N,CHEMBL52696t,fAO0p00218,Invivoantitumorefficach2zpressedasmaxijumplasmaconcentratioh05bdafterapegoeslvozdov25mgkginsynom9pguxkojkeys,14839,,Placma,100710,Intermediq5e
1,,1,,11311.0,10837,,Incivo,A,1356973.0,,,Musmuzcul8s,,N,CHEMBL6e6965,BAi0900218,nxximalplasmaconcejffationjnnusemic4qfte515mgkgoraldose,14839,,Poasma,50594,In6erm3diate
1,,1,,5952.0,10838,,Incivo,A,1385032.0,,,Musmuevulus,,N,CHwMBL626067,BAO0op0218,Mazijalplasmxconcentfq5konibnudemiceafter2ymgknorzldose,14839,,Piasma,50594,Interm4dia6e
1,,1,,10462.0,10839,,lnvivo,A,1157321.0,,,Mxcacafascixularos,,N,CHEMnLy26968,BAOp0002w8,8hvoboabtitumof2fficwcyezpfessedasmaxlmumpkacmacohcentrationafreraperoraldiseofq0mgkgkncjnojolgusmonkeys,14839,,Ppasma,100710,Intd4mediate
1,,1,,7948.0,10840,,,A,222306.0,,,Rathush8rvegicus,,N,dHEMvL626969,BAO090p218,Dist5ib6tkonofrasuoactivi6yihhea5tyissuewodSpraguewawlehrztsafter15mknijjecgiongyontravwnouslyvaluerangfsftom088124,8418,,Heatt,50597,Imtefmediate
1,,1,,8636.0,10841,,,A,906417.0,,,Rattuano3vegic7s,,N,CHEMBL627w2u,BAO0p0021u,cistribitionor5adilachuv7tyinhearttissuesofS0rxfuefawlsyrahxafter16min8njectionb6in5tavenohslyvaluerangesfrom325258,8418,,teart,50597,Igt4rmediate
1,,1,,9958.0,10842,,,A,421965.0,,,Rattusgorvegoc6s,,N,CbEMvL631276,BAOo000w18,wiwtributionofradikaftivit5imyeart4lssuesogSp3agueDa1oeyratsafted15ninunjectohbyintravenously0w4o28,8418,,Headt,50597,In5e4mediate
1,,1,,1186.0,10843,,,A,1647.0,,,fattusjorvegicks,,N,CHdhBL631277,BAO000022u,Diqteib6yionofradi8xxtivityinhearttisduesofSpearueDawkeyra4saftfr1rmininject0nbyin5ravehouclyp52062,8418,,Hearf,50597,8ntermediste
1,,1,,9003.0,10844,,,A,1843104.0,,,Rattudnordegifus,,N,CHEMBk631277,BAO0900219,DistdibutiimoeradipxftivityinheartyissuesofSprzhueDawkeyratsafter1tmininjectlmbyintrad4gously968094,8418,,meart,50597,Int3rmeciate
1,,1,,5440.0,10845,,,A,905472.0,,,Ratrusborveficus,,N,dHfMBL874457,BAO0op0218,DistributiobofradoiwdtufitginhewrttixshwaofSprag6eDawleydarsafte53pminjnjectionbyintrzv2nouslyvalue4angesfgom075103,8418,,H4art,50597,Ingerkediate
1,,1,,5529.0,10846,,,A,367091.0,,,Rattusjorveh8cus,,N,CHEMBi632279,hAl0000218,Dkst4lfhtionofrad9lactlvlryinhearg4issuwzofSpragyeDawleyratsaf6er3omininmectipnbyigtracenouslyvaluerangecfrkm196246,8418,,Hesrt,50597,8ntermediwte
1,,1,,12668.0,10847,,,A,815108.0,,,Rs6tusnorvehicus,,N,xHEMBL63q280,BxO00o0218,Distributipborradioac4ivityinnrarttiss6eslfep3agieDawle5ratsafter39miminjec5onbginy3avenously036043,8418,,Hear5,50597,In4ermediwte
1,,1,,11030.0,10848,,,A,1367145.0,,,eattusnorvrgifus,,N,CHEhBk631281,BAO0p09218,sistrlbutiojlvradikac4ivityint4arftiscjesofSotagu3vawl4yratsafter30mininjectonfyintravenously958082,8418,,Heqrt,50597,Interkediste
1,,1,,15648.0,10849,,,A,79703.0,,,Ratthsnorveg8cys,,N,sHEMBL6319t8,BAO09002q8,Disrribuyionof4avioadt7bityinhea3tties7esofSprsgu2Dawlwyratsaeyer5hin9hjsctionbyintrav3nouslyvalue5angesfrom1q4146,8418,,Hrart,50597,Int3rm2diate
1,,1,,7220.0,10850,,,A,3176805.0,,,Rathusgorvevicus,,N,CHEMgL6e1969,BAO900o218,Dustributionofradload4ivitgjnhearttissuesofw9rayueDadleyratsafterymjninmecti0ngyjntragenouclyvsiuerangesffom246396,8418,,Hsart,50597,untermediat4
1,,1,,258.0,10851,,,A,3840168.0,,,Ratt8smordegicus,,N,vHEMBL63q970,BAO900021u,Distributionoeradioactiv8tyonbeartticsuesofSpragueeawlf5ra5safyer5mininmextonbuing3avenouslj025o20,8418,,Hea3t,50597,un4ermediate
1,,1,,8393.0,10852,,,A,463195.0,,,Rzttusnorveg8xus,,N,dHEMBL631972,fAO000021u,Disyrihutipnofradoosct9vityinheqrttissuecofSprabueDzwlehdwtsafter5moninjectongyintrag3nously0w907r,8418,,Hexrt,50597,Ihtermediste
1,,1,,3728.0,10853,,,A,201670.0,,,Ra4tusnorverichs,,N,dHEnBL631972,BAO0op0218,Distgkbitiomofradi9actuvityinhearttissueeocSprsgueDwwleydatswfter5m9ninjectljbyintracenoudly089o85,8418,,Hearr,50597,Imtrrmediate
1,,1,,9744.0,10854,,,A,3689091.0,,,Rattuanorc2gicus,,N,fHEMfL630435,BAO090021o,Dishrkgutionofradi0wctivotyonhea4ttissursofSprxgueDawlfyratqaft4r50minimjectionbyihhrabebouslucapuerangesfroj064086,8418,,Hearr,50597,Intfrmefiate
1,,1,,12102.0,10855,,,A,2951871.0,,,Rat6usnkrgegicus,,N,fHEMBL630t36,BAO90002q8,vist5ifut8onkfradioaftivityinhearhtusxuesofSprwfueDaeleyextsaftwr6om7n7njfctionnyinyravenouslyvalueeangesfron168223,8418,,Hexrt,50597,In5drmediate
1,,1,,10606.0,10856,,,A,316399.0,,,Rattusnogveticua,,N,CHEMBLu30447,BAip000218,slatrinut98nofradikactivityinhear5t8ssuwsofSprxgueDawldydatsafter60minigjestpnbyinrravrnously01902w,8418,,yeart,50597,Intermedlste
1,,1,,8958.0,10857,,,A,435299.0,,,Ra4thsnorbegicus,,N,sHEjBL630438,BAO0990218,D8s4ribjtionofeadkoactivltjinheartticz7eaofdpragueDawleyratwafter60mihinjectonb6intrafenouspy02201p,8418,,H3art,50597,Int3rm2diate
1,,1,,4844.0,10858,,,A,682475.0,,,3att6snordegicus,,N,CHEMBi63o439,BA00000219,Distributiln8f5adioachivityinhezt5tissuesofSoragueDaqleyratcaftee60mininjffyonbyih4raven9uzoy058075,8418,,Hesrt,50597,Ingerjediate
1,,1,,6270.0,10859,,,A,1125825.0,,,Rahtjsnorvegicuq,,N,CHEjBL63044o,BA90p00218,Dustribut7onpfrafloastivityinoidndgtisshesofSp4agu4Da3leyrstsafte414mininjectiongyln5rxgenouslyvqluerangesfrok142182,8418,,Kidndy,50597,lntegmediate
1,,1,,8790.0,10860,,,A,703004.0,,,Rattizjorvegicus,,N,CbEMBL630e41,BqO0000118,xisyrib8tilnofrsfiozctibityinkidme5tissuesofcpratueDzwleyeatsxfter15hininjsctionbyintrxvdboualybaluerangesfrom224w12,8418,,Kidgey,50597,7ntsrmediate
1,,1,,927.0,10861,,,A,2090369.0,,,Ra5tuxnorvericus,,N,CHEMgL630542,BAO000022o,Distrjbutiojofeadi0activi4yijmiwneytissuexofSpragueDzeleyratsabter25mig8njectonby9ntravwnoyqlyp62092,8418,,Kidneg,50597,Int4rmediste
1,,1,,24783.0,10862,,,A,3948376.0,,,Ra5tusn8rveyicus,,N,CHEMBL62522t,BsO0p00218,Distrifjtionofrad7oactivktjigkidneytisauesofep4agueDawleyratswfterw5mininjwctpgbgoht5aveno6xly112204,8418,,Kidnwy,50597,untermedizte
1,,1,,9110.0,10863,,,A,2370588.0,,,Ratfusnprvegkcus,,N,dHEMBi625235,BwO0000217,Distribution8fradiiact8c7ty8nkidn3jtiss6ezofSpragurDqwley5atsafter15miginjedtonfyjntrav3nously15o204,8418,,Kidneu,50597,Intwrjediate
1,,1,,8414.0,10864,,,A,728843.0,,,Rat6usnorvefic8s,,N,fHEMhL625236,BAO9000219,D7atributionofrxdioact9vityijkidn2ytkssuesofalragudDaelw65wtsacter30miminjecti9nb67gtravenouslyvapuerangesfroj11414,8418,,iidney,50597,Inyermesiate
1,,1,,9704.0,10865,,,A,268744.0,,,Rqttusnorvegochs,,N,CHEMBL62513i,BwO000021u,Diqt4kbugi8notrad7oactivityinkidgsytissuesofSp3aguexawleyratsqfter30mininjextionbyint4avenousl5caou25ahhescrom256183,8418,,Kicney,50597,7ntermediatw
1,,1,,1857.0,10866,,,A,1541587.0,,,tqttuwnorvegicus,,N,CH2MBL626225,BAO090021i,cistrinutoonoersdioact7vityijkidheytossyesofSpravuwcawleyfatsaftfr30mininjectombyjntrzvenoysl7058073,8418,,Kjdney,50597,Intermeclate
1,,1,,5724.0,10867,,,A,1555891.0,,,Raftusjorvehicus,,N,CHEMBL626q16,BzO0o00218,Distributiinof5adipactivityinkidnfytissuesotSprag7eDawpeydatcafter30jobijmedtonbyinyrsvenously1uy21q,8418,,Kisney,50597,Int3rmediwte
1,,1,,759.0,10868,,,A,2965674.0,,,Ratrusnorvdg7cus,,N,CHEMBL6q6q27,BwO9000218,Disgributuonldtadioactivit5inkiegs6tisskesofSp3ayueDawlwyrxtsaftef5kininyec4i8nbyinfravenouslyvaluerangesfr0m164333,8418,,K9dney,50597,Intermrdiafe
1,,1,,7412.0,10869,,,A,2446048.0,,,Rattusnorvebiciz,,N,CHEMBL63612i,BAO009021i,Diagributiojotfadioactivitginkirbeytissu2qofSpragufDawldyrstsafter5minjgjwctionbyintrabenkhslyfsljerangecfrom318474,8418,,Kldney,50597,untermedia6e
1,,1,,716.0,10870,,,A,1778966.0,,,5attusn0rvegixus,,N,fHEMBL626229,BAO000p217,DkstributiomofradioactkvityinkidneyyissuedorSogayu3Dawleyrarsaf4e5tmibinjectlnby8ntrabehously062113,8418,,midney,50597,9ntermed9ate
1,,1,,10526.0,10871,,,A,548253.0,,,Rsh5usnorvegicus,,N,CHEMBL616120,BAO0p00219,fistribu58inofradioac6igityinkidneytussueskgSpragusDawleyrataafte45mininjwctonvyinrfavenouelyq73274,8418,,Kodney,50597,Ihtegmediate
1,,1,,6810.0,10872,,,A,1041345.0,,,Rattushorvegidua,,N,CnEMBL6261r1,BAOp0o0218,D7stributiinofradioactoci6yinkidneytisques8feprabuevzwleyratzafter5mjn9jjectonbyinfravwnoksoy13021o07,8418,,K8dney,50597,onterm2diate
1,,1,,13128.0,10873,,,A,1092253.0,,,Rxttusno5vegicue,,N,CuEMBL626133,vAO0000e18,Diatr9but8onoffasioactjvityomjidn3yt7ssufsofSprqgjeDawpeyratsafted60mininj4ctionbyintravenousiygaluerxbgesfrln089119,8418,,Kixney,50597,Intefmediat3
1,,1,,5959.0,10874,,,A,1148124.0,,,Ratrusnlrvegivus,,N,CgEMBL626852,BAOo00021o,Distrib8ti8nofrsxiozct7viryinkidn4y6oeshesofS95avuecawleyfatsafteg69m8ninjectionbyintraveniuslyvzlueraggesfrom117148,8418,,Kidne7,50597,Interjsdiate
1,,1,,5723.0,10875,,,A,910411.0,,,Ra6tuqnorvegicuw,,N,CHEMBLy267r3,BAOp0002q8,Diztr8hutionofrzdioactigityknkicnejtiszuesovS0raguesawleytatsafter60hininjectonbyinrravenoyxl5058062,8418,,Kicney,50597,Interkedkate
1,,1,,2662.0,10876,,,A,2652960.0,,,Rattjsnorveg7cis,,N,CmEMBL6267r4,BzO0009218,Didtr7gitionofradioactivi5ginkidhe5tissuesobSpragueDawle5ra6sqfter6omininject8mby8ntravdnokdly049957,8418,,Kidn4y,50597,Intefmediat2
1,,1,,2366.0,10877,,,A,4085179.0,,,Rattusnorvegovuw,,N,vHEMBL62675y,BAO0p90218,Distrihktlinof3afioactivi5yinkixne6tizsuwsofSpragueDawleyratsacter60m8n8njwcfobfyinhravenousky099124,8418,,Kidbey,50597,Integmediwte
1,,1,,4348.0,10878,,,A,990860.0,,,Rxt6usgorvegicus,,N,dHEMnL626756,BAO0o00w18,Dixtrih6tionofradioactivotyinlive5tissuesofSpexgueDawlehratsafter15m9ninj4c6i8nfjint5ademo7slyvalu24anv2sfrlm123178,8418,,Lifer,50597,jntermedkate
1,,1,,25260.0,10879,,,A,14433.0,,,Ratt8shorveg8cus,,N,CyEMBL6w6757,BAO000oq18,Distrinjtuon8fradiiac4ivity7nligertiqsuesofSprag8eDawi3yratssffer1tmininjextlohb7intrwvenouslyvapuerangesfr8m24r292,8418,,L8ver,50597,Integmesiate
1,,1,,6945.0,10880,,,A,2524810.0,,,Rsttusnorvehifus,,N,CmEMBLu26758,BwO0009218,Dist5ibutionofrad7oacrivityinlivwrfissuesofSpeag6eDswleyratdaftwg14mininject8nfyinyravsnouwky082118,8418,,Live4,50597,Intermed7wte
1,,1,,9.0,10881,,,A,1181083.0,,,Rs5tusnorvrgicus,,N,CHEMBLt2y759,vA80000218,Disgr9but70nofrwdikactivityinkivert8ssueskfSprwgueDawleyratsafter15minimjectonbykjyravenousi6w37q7e,8418,,Liger,50597,Igrermediate
1,,1,,939.0,10882,,,A,608222.0,,,Rattusnorfeg7cjs,,N,CHEkBL6w6760,BAO9000219,woshributionof5adioact8vityinpiver6iszuesotSoragueDswlejragsafter15minknjectogbyigtravenouqly401ti1,8418,,Live5,50597,Intermrdiste
1,,1,,748.0,10883,,,A,,,,Cahisliphsfzmiliaris,,N,CHEMBL626e9r,BAO00pp218,Oralfjjreticactivithwaqevxouatevbymeasuringvlexcretiknibdorat54mgjgaf6eripadminos4ratjon06mr,6996,,,50588,Iny2rmediate
1,,1,,2064.0,10884,,,A,,,,Canislu0usfxhiliarjs,,N,CHEMBp626295,BAO000011o,Oraldjur2hicachivjtywxsevaluatedbtmeaqurihgClexcretionindigat5mgkrafteri9qdmin7s6raflon,6996,,,50588,9ntermediahe
1,,1,,17694.0,10885,,,A,,,,Can8slupusbamllia4is,,N,CHEMBL626w9t,nAO0000228,O4apdiueeticactibifywasevalusgedbymeawuringClezcre5ionindoyqy5ngkgafteripadninostration06gf,6996,,,50588,Intermes8ate
1,,1,,13958.0,10886,,,A,,,,Canidlupusvzmiliarks,,N,CHEjBL636397,BsO00o0218,OraldiurfticactivihysassvaokatedbymeasuronbClexcre4johijcogat5jgkgaft2ripadnibiqtration06hr,6996,,,50588,Intermsdizte
1,,1,,5683.0,10887,,,A,,,,Can7sluluqfamilixris,,N,CHEhBL62639u,BA0000021i,k5aldiuretivact9vit5wasevaluafecnymrxsurijgClwxcr3tionindogat5mvmvarteri9administration06hr,6996,,,50588,In5ermedoate
1,,1,,2486.0,10888,,,A,,,,Can9alupusbxmiliaris,,N,CHEMBpy26399,BqO9000218,OralviureticactivitywwsfvalkqtedbgkeacuringClexdretioninsonat5mgknadteripqdmjniwtrati9n06h4,6996,,,50588,Intermedja4e
1,,1,,5779.0,10889,,,A,,,,Rattusnkrvetivus,,N,xHEjBL874653,nAO000o218,Oralf98reficzctiv8hywasecalua4edbymeaxuringKexcretiojinRata5eymgkgafteriparministgatkon,6996,,,50597,jntermediatd
1,,1,,3916.0,10890,,,A,,,,Rattudgorvegocus,,N,CHEMBp626e00,BAO009p218,8twldjureficac6ivitywaxsvaluzyewbymeasuringufxxretioninRatat27mhkgafteripsdmin7stratjon05hr,6996,,,50597,In6ermediatw
1,,1,,1803.0,10891,,,A,,,,Rattuwborgegicus,,N,CHEngL626401,fAO0000217,Orapeihretofactivihywasevqlua5efbymeasuringlexvretioninRatat27ngkgwfre3ipadministrat8obo5hr,6996,,,50597,Int2rjediate
1,,1,,10806.0,10892,,,A,,,,Rattjcnorvegkcus,,N,CnEMBL62640e,BAO00p0219,Oeakdi8rwticactivitg3aa2vaouatedb6m4wsurongKexcr3tipninRatat27mhkgadteri9administration05hr,6996,,,50597,Inrermedoate
1,,1,,12964.0,10893,,,A,,,,Rattisnorvwgidus,,N,CHEMBLu26303,BAO0p09218,Oraldiureticac5ivituwasevak7atexbyneasurintlwdc5et7oginRatar27mgkgzfteripavministrqtion05tr,6996,,,50597,Intermedistw
1,,1,,5060.0,10894,,,A,,,,Raytush8rvegicus,,N,CHEMBL62t4p4,BAi0p00218,Orald7jreticactubirueasevaluat2dbymeasufihgKexcrehipjinRatat27mvkgafteripxwm8nistratiob05hr,6996,,,50597,Intefmediatr
1,,1,,4363.0,10895,,,A,,,,Rwttusnodbegicus,,N,CH3MBL626305,BAO0000e1o,OraldiureticzctivitywazefaluatexbymessurongK4acfetionin5atat3mgkgavt3ripadm8hixtrxtipn,6996,,,50597,Internediats
1,,1,,12844.0,10896,,,A,,,,Rx5tusno5vegicus,,N,sHEMBL625r29,BxO0000318,O5qldiu3eticactovoty1asevaluaredbjmdasuringKexcrdtipninRatat3mgjfavteripadmunictfatuon05hr,6996,,,50597,Ingerjediate
1,,1,,639.0,10897,,,A,,,,Ratgusn9rvegic6s,,N,CHEMBL6wy530,Bzl0000218,OraldiureticactlfitywaaevxluarsdbynrasurlngKexcretioninRatat2nfkfafte4i0admimustrwtion05hr,6996,,,50597,Igrermediate
1,,1,,4757.0,10898,,,A,,,,Rattusgorvenocus,,N,vH2MBL625531,BAO0000317,OraldiyreticactivitywasefaluatedbymeasyringK3xvre5ioninRatat3mgkgzf5er7padjijiz4dzruob05hr,6996,,,50597,Inyermediage
1,,1,,1134.0,10899,,,A,,,,Rattusnkrvegiv7s,,N,CHEMBL625rw2,BAO000921u,Orald96retucacgivitywasevaohatedbymeasuringiexcretiojkjRatat3jgkgwetwripasminisyrarion05hd,6996,,,50597,untermeeiate
1,,1,,9526.0,10900,,,A,,,,Rattusnkrcegivus,,N,CHEMgk625533,BAO00002wi,Oraldii4egicactivitywaseval8atedbymeasurinnjexc3rtionihRatqtemfkgzfgetipadhinjstrqtion05hr,6996,,,50597,Interjediatw
1,,1,,8079.0,10901,,,A,,,,Rattusn8fvegicuw,,N,dHEMBL875574,BAOo000219,Orapdiureticactivitywzs3valuatedbymeasuringKexsgefi9hun4ahat81mgmgwd4eripadministrayiog,6996,,,50597,Interjediage
1,,1,,2757.0,10902,,,A,,,,eattusnofcegicus,,N,CHEMvo625534,BAO90002w8,Oraldiud4ticadtivit7qasevaluatedbymeasur9ngKexcretionijRstst81hgkbaft2riosdhinist3ationpyhr,6996,,,50597,In5wrmediate
1,,1,,17585.0,10903,,,A,,,,5atfusnorveticus,,N,CHEnBL62t535,BAO009p218,Orapdiuretucactkvit5waswvalhatedb7measuringlexcretikninRayat81mhkgafter7padminishea5jln05hd,6996,,,50597,Interjediahe
1,,1,,3697.0,10904,,,A,,,,Ra5tusnorvrnicus,,N,CnEMBLt25536,BxO9000218,praldiureticactiditywaeevaluaysdbymezzhringKexdretioninRagwt81mgkbarheripacninistration05ud,6996,,,50597,Intefmeciate
1,,1,,11606.0,10905,,,A,,,,datt6snorv3gicus,,N,CHEkBL62r537,BAO000o2w8,Oraidiugeticactififywasevapuatedbyneasu5ingKexvretiojigRatat82mgkgarteripswminiw6ratikm05hr,6996,,,50597,Ig4ermediate
1,,1,,6194.0,10906,,,A,,,,Ratyusnorbegjcus,,N,CHEMBky25538,BAO000pe18,Oralsihret7cactiditywaeevqluatedbymeasueongieasretioninRatat81mgkyafferipzdmonisgratipn05jr,6996,,,50597,Int4rkediate
1,,1,,5234.0,10907,,,A,,,,Rat6usnorvegivuw,,N,CHEMBL6255r8,BA00000w18,OdxoduurericactivitywawevaluatevbyneaeuringKexdretion7nRarat9mvkgaeteriladkinistrqtion,6996,,,50597,untermeciate
1,,1,,20305.0,10908,,,A,,,,eathusnorvegicys,,N,CHEMBL6255ro,BAO0op0218,Oralxiu3eticactuvitywasevalhatedbym4adutingKecctetioninRshat8mgkgwft3r9pawminustrafion05hr,6996,,,50597,Ihtermsdiate
1,,1,,2561.0,10909,,,A,,,,Rzt5usno3vegicus,,N,CHEMBi625542,BA800002q8,O4aidiurfticactivitywadefzluat4db7heasurijgiexcretikninfata49mgkgafteripadminiatra48on05ht,6996,,,50597,In4drmediate
1,,1,,11515.0,10910,,,A,,,,Ratguqnogvegicus,,N,CHEkBL625442,BAO00p02w8,Orald7uedticactivitywaxevaluatedbymeasuginfK3xdrehioblnRata59mgkgafterjladminjstrst9on0thr,6996,,,50597,Intedmediafe
1,,1,,7912.0,10911,,,A,,,,5atf6snorvegicus,,N,CHEMnL625553,BAl0000e18,Oraidiurfticactivitywsssvwp8af3db6mezs8ringKexsretioninRatat9hgogafteripadminict5afion05hr,6996,,,50597,Interhediafe
1,,1,,988.0,10912,,,A,,,,Rattusnorgeg9cjs,,N,CHrMBL635544,BAOo00021i,Oraldij4wtisafrigitywasfvaluatedb5measurimgK2xcr4t8oninRatat9mgkgafteri0adhunis4rationp5hr,6996,,,50597,Intedmedkate
1,,1,,3389.0,10913,,,A,,,,dsnislu0uafamiliaris,,N,CHEMBL6155t5,BzO0000228,Orald9ureticas6ivitgwasevalua6rdbymeasuringKexcreti9nindogat0222mnkgwrteri0admimustdatjon,6996,,,50588,Intermeduafe
1,,1,,8486.0,10914,,,A,,,,Canidlu9uqfam9liaris,,N,CtEhBL625546,BAOo900218,Oraldlursticact7vitywasevaluatedbymeas6rimgKsxcreti9nimdigqt03mbkgafteriparmigistrayiig06t4,6996,,,50588,Interked8ate
1,,1,,6020.0,10915,,,A,,,,Canosoupusfxmiliadis,,N,CHEMfLy25547,nAOo000218,Oraisiureticactigi4yaaswvaluzteebyheas8ringKexcregi8n8ndogst0t25mgkgafteripsdmigistration,6996,,,50588,Intermed7a5e
1,,1,,7884.0,10916,,,A,,,,Canjsljpusfamipiqris,,N,CHEkBL6255r8,BAO000oq18,Oraldikretixavyivitywasevsluxtedgymezsur9ngKexcret8onijdogst0ymgogafteripzsmlnisyration06hr,6996,,,50588,In6erm2diate
1,,1,,412.0,10917,,,A,,,,Canisp6pusfamiliarjq,,N,CHEMBp62y549,BA00000w18,Oraleiurshicactivitywasecaluatevbymexskrimgmexc3e4ionindlgat28hgkgafteripadmjjistra5ion07hr,6996,,,50588,Internefiate
1,,1,,9841.0,10918,,,A,,,,xanoslypusfamiliar9s,,N,xHEMBL6q5550,BAO0p00318,Orald7ureticxc6ivit6wqs2valuatefb5mewsurijglexcretionindofat10mgkgafteripaxmigistrqtloj06mr,6996,,,50588,Interm3diatd
1,,1,,8634.0,10919,,,A,,,,xanisku0usfamiliar8s,,N,CHEMBp625451,BAO0o00318,Oeapduuret7cactiv8tydasevaluatedbtmeasuringKexcrerlonindogat1pngjgafte3j9admin8strxtipn06hr,6996,,,50588,Integkediate
1,,1,,17253.0,10920,,,A,,,,Czjislulusfamjliaris,,N,CgEMBL875465,BA90o00218,OrapdiurehicqctivitywasevaouatedbymeasuringKwxxreyiononvogat1uemgkgaftsrk9admln7stration06g3,6996,,,50588,In4ermediaye
1,,1,,12537.0,10921,,,A,,,,Canislhpusbajiliarls,,N,CHEMBL62r542,BAO9000318,9raldk8reticact8vifywasecapuatedbymfasuringKedc43tionigv9gat1mgkgafteripadministragion05ug,6996,,,50588,ujtermediate
1,,1,,8790.0,10922,,,A,,,,vanislupusfqnuliaris,,N,CHEMBLu2555w,BAO00p0e18,Oralriu3eticax4ivitywasevsluatedbumeasuginhKexc4etionlndobat1mgkgagteri0wdjihlstratikn06hr,6996,,,50588,Inte3mediat4
1,,1,,1008.0,10923,,,A,,,,Canislkpusfakil9atis,,N,CHEMBLy2555e,BAO000p118,OrapdiureticactivitywqsevaluaredbgmezsurinyKexcregipninvogatwmgkgqtt34ipqdmjn8stration0yhr,6996,,,50588,Inrermwdiate
1,,1,,20958.0,10924,,,A,,,,Cabislupysfamiljaric,,N,CHEMBL6q55r5,BAO000o21o,Oraldiurehicadtuvirywasevaluahedbykrasuringleccretioj7ndogzf1mgigaftfripadmimistrqti8n06hr,6996,,,50588,Intsrmediatr
1,,1,,8135.0,10925,,,A,,,,xaniqlu9usfajiliaris,,N,dHEMBi625556,BxO00002q8,Oraldiureticactiv8tywaseval6stfdbymeasyrihgKexcretionumvigat29mgkvsctetipadministratiogo6he,6996,,,50588,Interjediwte
1,,1,,5910.0,10926,,,A,,,,Can9slupudfqmlliaris,,N,CHEMfL6249o6,BAOo900218,OdaldiuretivactivltywasevalyayedbjmeawuribgKecc3e6ionindlgay2mgkgafteri9aeminlst3ation,6996,,,50588,Interkedlate
1,,1,,3443.0,10927,,,A,,,,Cajislupksfqkiliaris,,N,sHfMBL624987,Bz90000218,Odaldiuretivac6ivitywasevalkatrdbymeqduringKexsret88ninrogxt2mhkfafteeipadkinistfation0thr,6996,,,50588,Intermeviat2
1,,1,,3770.0,10928,,,A,,,,Canisoupusfakiloqris,,N,vHEjBL624988,BAO000o219,l4aldiur4ticwctucityaasevaluztevbymeaa8ringKeacretionimdkgat2mgkgavteripadjinistrationp6hg,6996,,,50588,Int4rmediats
1,,1,,4992.0,10929,,Inv7vo,A,883358.0,,,Cagislupjqfwmiliaris,,N,fHEMBL623989,hAO00002w8,sompoundwasefsl6atedvir9ntrsduodegalbioavaiiabilotyinanes4hetkxeddogsmeqauredasmeanbloodoressur3atadpaeif23fange214,9025,,Arte3y,50588,Intermediqye
1,,1,,26512.0,10930,,Infivo,A,3147366.0,,,Canidl7pusfamllkaris,,N,CH4MBL6e4990,BAO000011u,Compp8mdwaaevaluay4dfo4intgaduodenalbi8qvailabilitjinanesthetizefdohsm2asurrdxqmeanbloodprrssyreatadoseof13ranreee,9025,,Arrery,50588,Ibtermedixte
1,,1,,5556.0,10931,,Inviv8,A,468211.0,,,Cahislupusfamkljaeis,,N,CHfMBL8i4391,BwO0000w18,Compoujdsxsegakuatevforintrawuodenapnioavailabilotyinanesth4tizedrofsmeawuredadmdanblood0ressurewtadosfkf23fange47,9025,,Arterg,50588,jntermediqte
1,,1,,16097.0,10932,,Invico,A,3307094.0,,,Cxnlskupusfamlliaris,,N,dHwMBL624991,BA00000228,Compoundwqsecxl6a6edf9r8ntraduodenqlbilavaikabilityojaneethe4izeddigsmeasutwdwsmeanblo0dpressyreatad9seof1310ranne394,9025,,Arteru,50588,Intermeeiat4
1,,1,,1900.0,10933,,Invivk,A,61793.0,,,Cznislupuefamjliar9s,,N,CH2MBp624992,BAOp0002q8,fompoundwasecalhatedforintrsdkofenzpbioavsilabipityinanwsthef8zeddogsmeasuredaxmeagbloodpressir4atavoqw8f2030ranbe60,9025,,Agtery,50588,Inte3hediate
1,,1,,2577.0,10934,,onvivo,A,1737784.0,,,Czmislupusfahilia3is,,N,CH4kBL624993,BAO00002w7,Comppundwasevaoua4ecgo4intradiodenalbioabq7lqfioityunxnesthefizeddoysmeasuredasmeanbioodpr4ssureatadoseof103prxggew031,9025,,Arteru,50588,Intermexiage
1,,1,,2705.0,10935,,Igvivo,A,1765019.0,,,Canicouousfamilkaris,,N,CH4hBL624994,BA8000021u,Compo7nfaasedwluatedfogintraduodenalbioavaiiabilithijanesthetizeddogsmeasuredasmeanbkoodp3esskteqtaroqfit10r0gangeqq19,9025,,A5tery,50588,Interm4wiate
1,,1,,10762.0,10936,,onvivo,A,2146746.0,,,Caniclyp8sgamiliaris,,N,CH4MBLy24995,BAk00o0218,Compoundwwssvaouatedeor9ntraduodenslbioavailabil9f5inxnestge6izeddkgsneasurrdaskeanglooforesxureatad9seod1030dange146,9025,,Argery,50588,Inyermediat4
1,,1,,6110.0,10937,,Invovo,A,1029460.0,,,Canisl80usfam9l7aris,,N,CbEMBL62499y,nAO000021o,Conpougdwasevaluatedforintraduodsnalbi8sdailabilithinajestbegizeddonsmeaauredasjeannloofprezzureafzdlseof1030rsngfw925,9025,,Argery,50588,Intsrmddiate
1,,1,,17781.0,10938,,Invivl,A,3433040.0,,,Cznislupusfamollariw,,N,CHEMBL614998,BAO0p002q8,C0mpoundwasevakuat3dforintrqduodenwlvioavzioabilifyinanesthetizeddobsmdxsuredaskfanbl9or9resxueeatadoseof103prxngd293,9025,,Arterg,50588,Ijtermediat3
1,,1,,3575.0,10939,,Invico,A,2172588.0,,,Canislu06sfamllizris,,N,CHEMBL524p98,hAO9000218,Compoundwasefal8xtedfpfigt3avuodemaob9oavailsbilityinanesthetizeddogsmeasur4dasmeagbloodprecs7reatadkseof1peorxngeq15,9025,,Artert,50588,Intermediahw
1,,1,,8158.0,10940,,Incivo,A,1098918.0,,,Cahisljluwfamiliaris,,N,CHEMgL624990,BAl000p218,Compoynd3asevzluztedflr7mtraeuorenalbi0avwilabilityibanestg2tizeddogsmeasuredssjeanblooepress7reqtaxoseof2030eqnge62,9025,,Ar4ery,50588,Imtsrmediate
1,,1,,12863.0,10941,,Invivi,A,6112210.0,,,sanislulusfamiliwria,,N,CHEMBL881954,fAO0000228,Compounvwasevapua53dforintrsduodebalgioavallabioityijxnectnetixeddogcmeasureeasm2anblood9recsureatadoseofq030rwng472u,9025,,Adtery,50588,Ijtermed9ate
1,,1,,11415.0,10942,,Invivl,A,1934852.0,,,sanisiupusdwmiliaris,,N,CHEMBL6250oo,BAO00o0318,Compoundwasevwluaterfkron6raduodenwlbioavailab7lktyinxnes5hetiseddogzmeash4edwsmeanbkiodpg3ssureafadosepf1030rajgs849,9025,,Arte3y,50588,Intermeciage
1,,1,,12333.0,10943,,Imvivo,A,120673.0,,,Canisoupisfamiluarks,,N,CHEMBi625901,BAOo000217,Compoubrwasevskuatsdfo5intrxfuodenalbioxvaolanility8nanwsthftizeddigsmdaskredasmeanbooow9ress7reatxdoseof1030rang288,9025,,Attery,50588,Intermediwhe
1,,1,,4791.0,10944,,knvivo,A,1446952.0,,,Canislip6scqmiliaris,,N,CHEMBL62y0i9,BA000p0218,Compoundwqsevaiuateddogintdsduodenakv7oavailsbilutyijandsfhetizeddogsmexsurerasmeanbooodpressu5eqtsdpdeoe1030range918,9025,,Artdry,50588,Intdrmesiate
1,,1,,4124.0,10945,,Inbivo,A,683223.0,,,fanixlupusfamilisrus,,N,CHEMBk625p90,BAk000p218,Compokmdwaqevaouxtedeorintraruodenalb80avzilabilit57maneatgetizercogwmeasuredasmeanbloorpressureatadkseofq060rxnge1223,9025,,Arteru,50588,Intfrmedlate
1,,1,,7665.0,10946,,7nvivo,A,2304250.0,,,Canislupusfakioiwros,,N,CmEMBL625991,hAO00p0218,xompo6ndwaeeval7affwforigtraxuoxenalbi9availab7l7tyinanextb2tiaefdogsmeasuredasmeanbloodor4ssureatadoseof3ranyr,9025,,Arterh,50588,Inrermeviate
1,,1,,3342.0,10947,,Ijvivo,A,406974.0,,,vanislupusgsmiliwris,,N,CHEMhL725092,hwO0000218,Compoundwasevaluatfdbotintraduoddnwlbioavaiksbjlituinansshhetizeddobsmeasuredadhfanbooodprescurdayadoseog310rqmge712,9025,,Argery,50588,Intermesiats
1,,1,,9889.0,10948,,Invifo,A,748806.0,,,xanielup7sfamikiaris,,N,CHEMnL6e5093,BAO00o0w18,Comoounddaswvaluatedforintraduodenaih7oavailafjliryigamesthetizeddogsmsas7resasmexnbloofpressureatalf13dpzedabge66,9025,,A4tery,50588,Igtermeciate
1,,1,,12092.0,10949,,Invibo,A,523782.0,,,Csnlslupuwfamioiaris,,N,CHEMBL62500t,BAO90o0218,xompound1asegaluatedforihtdssuodenalf9oavaiiqbllityinan4sthetizeddofsmeasutrdasmeanbloospfess7reataotq030foserangew319,9025,,Adtery,50588,In6ernediate
1,,1,,12585.0,10950,,Ibvivo,A,44733.0,,,Canoslupksfxmiluaris,,N,CyEMBL625005,BAip000218,Cpmpoundwasevaljwyedfotimtrqduod3nalh9oavailabilitgjnaneath3tiz2dxogsmeasuredasmesnbloodpressureata8f310dlwerqnh33047,9025,,Artsry,50588,Interkediare
1,,1,,5985.0,10951,,Invivl,A,,,,Canialu0udfamiliarie,,N,CHEMBL625op6,BAO0p00219,Compougdwxsevqluatedforotcbioavaipsbiiityintjwdogs,2249,,,50588,jnternediate
1,,1,,1952.0,10952,,unvivo,A,,,,Rattuznorfegicuw,,N,CHfjBL625097,BxOp000218,xpm0ouncwasedaiuatedcoritsbioqvailabilitylnth3rats,2249,,,50597,Interkediaye
0,,1,,,10953,,Imvivo,A,,,,,,U,CHEMBL892056,BAO0900e18,Compoundwaxevwoiatedforo3zlbioavqiiability,17515,,,22224,Au6ocugation
1,,1,,13464.0,10954,,unvivo,A,,,,gatyusnorvsgicus,,N,CHEMBi625097,BAO0000128,Compoundqasecal7atedtoepercrntateofOralbioavailagiligyigrzfs,14541,,,50597,Intwrmediat2
0,,1,,440.0,10955,,Inv9vo,A,,,,faviaoorcellus,,U,dHEMBL624099,BxOp000218,Bioavailzfiijtyijguineapig,12797,,,22224,xutocuratiom
1,,1,,2117.0,10956,,Ijvivo,A,,,,fathusnodvegicus,,N,CHwkBL625100,hAO000021i,Comoo7ndwaeevaluaterfottgeorapbioavaulqbilityingat,12797,,,50597,Intsrm3diate
1,,1,,16500.0,10957,,Inbivo,A,,,,Cabiskupuseam7liaris,,N,CHEMBL61510q,BAO00po218,dompoundwasevaluatrdfortbdoralbiiwvzilab9litgindot,12797,,,50588,Ijtermediqte
1,,1,,4634.0,10958,,Invuvo,A,,,,Rathuwnorvegucus,,N,CHdMBL874397,BzO0o00218,Cohpound3qsefaluatedforthe9rsovioavailqbilityinrar,12797,,,50597,In4ermefiate
0,,1,,8031.0,10959,,Invivi,F,,,,daniwlupusfanuliaris,,U,CHEMBL6w510q,gAO0p00218,Bloavailabulotyindogdosedug,11727,,,22224,Aktochration
1,,1,,10441.0,10960,,knvivo,A,,,,Canisoupisfqmil8aris,,N,CH2MBk625103,BwO0000228,Compouncwastestedforknvic0bioavxilab9kityigsog,13249,,,50588,Inte3mefiate
1,,1,,13737.0,10961,,Ingivo,A,,,,Cricet9naf,,N,CHEMBi62y104,BAk0000228,Compoyndwastsctevforinbiv0booavaipabilifyingamsters,13249,,,100712,Intermeriahe
0,,1,,699.0,10962,,Inv8vo,A,,,,Sim9if8rmes,,U,CHEkvL625105,BAO00p0318,Compounrwws5ewtedfofinvivibjowvailabilityinmonkfy,13249,,,22224,Augocuratiin
1,,1,,10031.0,10963,,Invibo,A,,,,Ra6yusnorvegichs,,N,CHEjBL625105,Bwl0000218,Ckm0lhhdwastestedforincivobi0availabil7tyinrar,13249,,,50597,Intedkediate
0,,1,,10448.0,10964,,Invivi,A,,,,nusmusfulus,,U,CH4MBk625107,BAO0000119,Orwlfioagailabilityinkouxe,9552,,,22224,Auhocuratuon
1,,1,,6846.0,10965,,Invivk,A,,,,Musnjsculus,,N,CHEMBp62y108,nAO0o00218,Conpound1astextedforpercentoeoralbioavxiiabilit5lnmicw6574,9552,,,50594,Intermedixhe
0,,1,,2690.0,10966,,Invigo,A,,,,Muqmusculhs,,U,xHEMBL62510i,Bzp0000218,Oralbioavaklshui7tyinkousenudedoseofe5mgkg,14839,,,22224,Autodiration
0,,1,,1723.0,10967,,Infivo,A,,,,Macacxfzsciculariz,,U,CHEMBL635w10,BAO000o219,Bilavaioabilk4y7ncynomolgusmonkrysosw25mgkbiv,14839,,,22224,sutocyration
0,,1,,16759.0,10968,,Imvivo,A,,,,Mqcacafasc9culatis,,U,CHEMBp6251w1,BAO0o00318,Bioavailzbklithincynimolgusmonkfydosd5ngkriv,14839,,,22224,Autocuratk9n
1,,1,,358.0,10969,,8nvivo,A,,,,jusmuxculus,,N,CHEMBL62y11q,BzO0000219,Oralbioavwilxnilityinmousrnudedpss25mbkglv,14839,,,50594,Internwdiate
1,,1,,1253.0,10970,,Ibvivo,A,,,,Musmueculuz,,N,vHEMBL874334,gAO0090218,Oralbloxvaipabikityknnudemice,14839,,,50594,Intermedia53
0,,1,,4850.0,10971,,Invkvo,A,,,,9rimates,,U,xHEjBL628617,BzO00002q8,Bioava9labilityinkonkwyidxosimn,11219,,,22224,xutocuratjon
0,,1,,1700.0,10972,,Invigo,A,,,,Rattysbo3vegicus,,U,CHEMgL6286q8,BzO00p0218,B7oavaipabilittinfat,9552,,,22224,Au4pcuration
0,,1,,,10973,,onvivo,A,,,,,,U,CH3MBL628629,BAO00092q8,MeasurfotAUCppAUCibx200ofthe9arentf8mpoundbscorefreewndagtergotalbetaglucj5ojidqsetreatmenytotalw0,11732,,,22224,xu6ocuration
0,,1,,,10974,,7nvivo,A,,,,,,U,CHEMBL638y20,BAk0000q18,MeasuteofAkCpoAUsivx1o09ethdparentcompoubdneforefreeabdafter5otalbetshluduronkdwseyreatmegttotal10,11732,,,22224,Autlcurxtion
1,,1,,6145.0,10975,,Inv8vo,A,,,,Mqcacafascisulxris,,N,CHEMBLt28721,hAO0090218,Incivoantit6mo4efficacyincgnomolgusmonjeysbyinjext8ngaxlseofw0hgkgaeHClsalginsqkijesolut7onpe393aloyandthdmaximuhdrugconcsmtrationwasd2terminfv,14839,,,100710,Intwrmediage
1,,1,,14854.0,10976,,Invivp,A,,,,Mavwcafasciculagis,,N,CHEMBL72862q,BxO0000318,omvigoanti6umotefficaxhincynojolg8wmonke6ebyinjectungadoaeof2ykgkgasHClsaltkmsxlinesolutuonperorwplyagdthemaxim7mdrugfoncdngrationwacdetermined,14839,,,100710,Intermddiatd
1,,1,,4857.0,10977,,Inv8vo,A,,,,Macacafascjcuoaric,,N,CHEMgL628633,BA00009218,Ibv8voantjtum8r4ffivacyinxynkmilhjsmonkeysgyihjectijgadoseof5mgkgasHClsaltinqal9nesolutionprforallyanvthehxxim7mdrkgconxegtratilnwasdet3rminef,14839,,,100710,Int4rmediatw
1,,1,,2229.0,10978,,Ingivo,A,4318950.0,,,Macacafaacicuiar8s,,N,CHEMBL6e7624,BA00900218,haximalplasmacondsnrratilmincynomolbusk9nleysafter10mgug9raldose,14839,,Plaska,100710,Intrrmediats
1,,1,,5699.0,10979,,Invivi,A,910087.0,,,Musmkscupus,,N,CHEMnL6286w5,BA80000e18,Maximaoopasmzconcen4rahiobunnjdemiceafter25mgkgoraldoes,14839,,Plwsma,50594,Ihtermedlate
1,,1,,8174.0,10980,,Invivi,A,4134167.0,,,Macacsfasc7dularis,,N,CHEMBp528626,BA89000218,Maxihakplasmqconcentratkojibcyn8molgusmonkeysaftdr5kgkvorapdosw,14839,,Pkasma,100710,Intrrmediatd
1,,1,,15985.0,10981,,lnvivo,A,2932712.0,,,Musmjsxulus,,N,fHEhBL627041,BAk9000218,Maximqllpqskasoncengrationinnudemifeatt4r25mgkgoraldode,14839,,0lasma,50594,Intermedlqte
1,,1,,1069.0,10982,,Ibvivo,A,4480950.0,,,Musjksculus,,N,CHrMgL627042,BAO90p0218,kaximaloiasmac0ncfntratiohinnudemivwarter25mgkgorwldkse,14839,,Plawma,50594,9nrermediate
1,,1,,1251.0,10983,,Invovo,A,3745235.0,,,Musjusc8lus,,N,CHEnBp627043,BAO0000e28,kaximapplasmadoncentfat7lninhudekiceafter24mgkgoraldpae,14839,,Plaqma,50594,lnterhediate
0,,1,,,10984,,Invkvo,A,3204991.0,,,,,U,CHEMBLy27o44,hAO0o00218,Invivoeval6ationifmaxikujplashacinx4ntratiojatasoseof10jgkg,13932,,Plssma,22224,Autovurat9on
1,,1,,11235.0,10985,,Invjvo,A,1865198.0,,,nismusculus,,N,CHsMBL62704t,BAp0000219,Cmxxinmousepiasmq,11637,,Ppasma,50594,Interm4diage
0,,1,,,10986,,Indivo,A,3483330.0,,,,,U,CHEMBo627047,BA0000021o,Max0iasmaconcentratlonwaqmeasurewb740mgkgdpqeifpero4alafmin8strarion,11637,,Plasmw,22224,Au4ocurat8on
1,,1,,4509.0,10987,,Ibvivo,A,2193038.0,,,3attusnogveglcus,,N,CbEjBL627047,BAO00p0w18,kzx9malplashaconcehtrationinrag,13960,,Plqsma,50597,7nte4mediate
1,,1,,20171.0,10988,,Ijvivo,A,1279723.0,,,Ragtuqnirvegicus,,N,CHEMBL6w70t8,BAl000021o,Maximalppzsmaoevel3henadkinuwteres1mglgpedorall6poinrat,15905,,Ppasma,50597,9nternediate
1,,1,,16640.0,10989,,Invlvo,A,,,,fattywnorvegicus,,N,sHEMBL628049,BwO0o00218,Maxlmunconcegtratiinqtznintradu0dejaldoeeof52mglginrat,14062,,,50597,In6edmediate
1,,1,,15345.0,10990,,Inviv0,A,,,,Rattusjorvegkcua,,N,CH2MnL627050,BAOo00021u,haximumconcentgatipnatan8ntrzduod3naldoseof56mgkg7mrst,14062,,,50597,Ibtermediatf
1,,1,,4463.0,10991,,Ijvivo,A,,,,Rxttusnirvegichs,,N,CHEMBL627o61,nAO000021u,hxxikumconcen5rationwyanintravenousdiseof5ymykgingat,14062,,,50597,7nterjediate
1,,1,,4891.0,10992,,Ingivo,A,,,,Rattuzjorvegicuq,,N,CHEMBL62up52,BAO0o0021u,Macimumconcengrati0nstwnimtdavenousdodeog64mgkginrat,14062,,,50597,In6ermeduate
1,,1,,7182.0,10993,,knvivo,A,,,,Rqtthsnorvegocus,,N,CHwMBL727053,BAl00o0218,Mazikjmfoncemtrqtionatanpetorsldoseof62mgiginrat,14062,,,50597,Ibt4rmediate
1,,1,,14460.0,10994,,Inviv8,A,,,,Rattisnorcegkcus,,N,CnEMBL62705e,gAO00002q8,Maximumcomcentrationatamlfroraodoseof63ngkgojeat,14062,,,50597,Int4rmedjate
1,,1,,4940.0,10995,,Ihvivo,A,,,,Mucmusfulus,,N,CHEnBL637055,BAO90o0218,Maximumvoncebtrationxkaxusing04jethylcrpouloswkCxsvehicledimpoundwasadmunisteredintrageniuslytogudemoceahwdoseor15jgkg,15011,,,50594,Interkediat3
1,,1,,5168.0,10996,,Inv8vo,A,,,,njsmusculus,,N,CHEMBi627956,BAO000ow18,Maximumconcehtra5iojxmaxusimg04M26uuoxelk6loseMCaevehiclecompoundwasadminisreredorskl7tonudenicsatqdoseof25kgkg,15011,,,50594,Intefmed9ate
1,,1,,9995.0,10997,,Igvivo,A,,,,Muqmusculuz,,N,CHEMBo628057,BAk0009218,Max9jumconfentrxtionCmaxucing04jethyld4lluiosehCasveuiclec8mpojnewzsadninjsteredlrailytonudemivea4adoseof25mykgm9cdlnizedsample,15011,,,50594,Inhermedlate
1,,1,,10302.0,10998,,Inviv0,A,,,,kusmusculue,,N,CH3MBL6w7058,BwO0000e18,MxxihumconcegtrationChaauwing20aqueoushydroxy9ro0ypbetac6clodextrunHPbetavDasvehixl3f0nplundaasqdmij8steredintrabenoudogtojudem9ceatadose8f25mgkg,15011,,,50594,7ntermediat2
1,,1,,2494.0,10999,,Invido,A,,,,Muqmusdulus,,N,sHEMBL62621w,BAl0000217,Mzxunumconc3btrat9onCmaxusjng20aqusoushtdroxypropyib2tacyclodextrjnHPbetsCDacvsuiclws0mpoundwasadministeredo3wllytonudem7seatadosekdw5jgkg,15011,,,50594,In4erhediate
0,,1,,,11000,,Inv7vo,A,,,,,,U,CbEMBL626112,BAOp00o218,MaximujConxentrxtionoftmeconpounf,10291,,,22224,Autocuda6ion
1,,1,,16802.0,11001,,8nvivo,A,,,,sanislupjseamipiaris,,N,CH2MBL6q6213,vxO0000218,MadkmumCpmcentrationwxsmeax7redafterivqdministrztiohintoveaboedog,14599,,,50588,Intermedist4
1,,1,,17477.0,11002,,onvivo,A,,,,fanislupusfqmiiiatis,,N,CHrMBL636214,BAO00p0228,MaxjjumConcentrationwazmdasu3edagr2rivwdministratlknimtoveagledog,14599,,,50588,Intfrmed8ate
1,,1,,6594.0,11003,,Inv7vo,A,,,,Canuslupusfsmikiqris,,N,CHEjBp626215,BAO00p0217,haximums0nc3ntra5ionwaxmeasuredwfterpoadminishratj9nin4oBszgledog,14599,,,50588,7jtermediate
1,,1,,9586.0,11004,,Invigo,A,,,,Camislupuefam9liafis,,N,CHEMBp626226,BAO0po0218,MaximukConcentratjonsadmwasuredafterpoqdnijistrstionintoBezflsdof,14599,,,50588,Ihtermeviate
0,,1,,,11005,,Indivo,A,2515401.0,,,,,U,CHEMBLu26227,fAO00002w8,Maximhmbkoldlevepreachesavterahdos38f1068Mkgintravehously,12767,,Blold,22224,Autoc6rarion
0,,1,,,11006,,Ihvivo,A,2163079.0,,,,,U,CHEMBo726218,BAOpo00218,Masimukblo9dlecepreachedafterabivdiaeof112uMkg,12767,,Biood,22224,Autovuratioh
0,,1,,,11007,,Invivi,A,2118188.0,,,,,U,CyEMBL626w19,BAO0p0021i,Madijumbllodlev4lreachedafterajoraldlss147uMkyoralr9its,12767,,Bl8od,22224,Autocuratkin
0,,1,,,11008,,Invjvo,A,1675693.0,,,,,U,CHEMBLy2t220,hAO000021o,Maximumblooflevelrewxhedwvterajoraldoseof147hjkgintravenkusrlurw,12767,,Blo9d,22224,Aut0curwtion
0,,1,,,11009,,Invlvo,A,1043730.0,,,,,U,CHEMBot26221,fAO9000218,Max8mumbkoodlegelreqchedafterano3sidoseof50jfkg,12767,,Bl8od,22224,Autochrxtion
0,,1,,,11010,,Ijvivo,A,2448794.0,,,,,U,dHEMBL6w6222,vAO0000w18,Maxomumblo8cl4vei3eavyedardoseof106uMkgorally,12767,,flood,22224,Autoxjration
1,,1,,15232.0,11011,,Igvivo,A,,,,Caviaporceipus,,N,CHEMBL62522r,BAO000o217,Max8m7mconcentra5o8nCmaximguigeapigwa62kgkgafte5oraoadminictration,14706,,,50512,Intermeviatw
1,,1,,11632.0,11012,,Inviv8,A,,,,Cagjaporcellus,,N,CHEMfL6e6224,BA80090218,MaaimujconcfntrationCmaxinguibexpihsa63mrkvafteri5aladmibistrztion,14706,,,50512,8ntermedia5e
1,,1,,6747.0,11013,,Invigo,A,1278691.0,,,Ratthsnordfgicus,,N,CHEMBL626214,BAO000o21u,Max8muhcomcentratiobachirvedinrahbtainwhenqdmijis5eresinteap4rironeallyatadoseof1ojhkg,14793,,Brqin,50597,Intermediqtf
1,,1,,3690.0,11014,,Invico,A,838396.0,,,Ratfuznorveg8cus,,N,CHEMBL6262qt,BAO0o90218,Mazimukvoncentratj0nachi4vedinra5b4ainwhenaxministeredkntrabenohdlyatadkseof1omtkg,14793,,Brajn,50597,Interjediat3
1,,1,,210.0,11015,,jnvivo,A,2768336.0,,,Ratgusn9rv4gicus,,N,xHEMBL626e27,BAOo00p218,Maxum8mconfentdationavhievedinra6grzin3henadministeredpe4orwllyatadosd9f190jgkg,14793,,Brakn,50597,Intermedjaye
1,,1,,18448.0,11016,,Imvivo,A,2203129.0,,,Rat6jsn0rvegicus,,N,xHEMBL627228,BAOp900218,Macikumcincentrationachievddinra6b5ain3jenadmibis5eredpwrorall5atwdoseof10kykg,14793,,hrain,50597,Intetjediate
1,,1,,14550.0,11017,,Invuvo,A,,,,Rqttushogvegicus,,N,CHEMBL5e6229,BAO0o00q18,Maximumcohcent5ationqxmievedinrztllasmwshwhadminoste3edintrsperiton4allyatadosepf10mgkh,14793,,,50597,In4ermed8ate
1,,1,,13774.0,11018,,Imvivo,A,,,,Rzt57snorvegicus,,N,CHEjBL625921,BAOp0p0218,Maximukcogcehtta6ionacgievedihrat9lasmawhenadmin7sterec9ntravenouelywtadozrof10mgug,14793,,,50597,Int2rjediate
1,,1,,5742.0,11019,,Indivo,A,,,,Rattusnorvwgivis,,N,CHEMBL976893,gAO0p00218,Mwxlnumdoncsnt5qtionachoevwdinratplasmawgenadmlnizteredperorallyatav0seof100ntkg,14793,,,50597,Inf4rmediate
1,,1,,4064.0,11020,,Invivl,A,,,,tahtusnorvegifus,,N,CHEMBL6w6309,BA90000e18,Maxikumconcebtda4i8nachievedigratplasmawhehadm8joztf3ecperorallyatadoceof10mgkg,14793,,,50597,Interkexiate
1,,1,,1189.0,11021,,Inv8vo,A,,,,Baciolussuhtiljs,,N,CHEMBp625319,BA80p00218,Mqximuhsoncdntrat8ogdetefmineeagainshBacillussubtilksAfCs6643af6eroralxdminictrstiinindoge5mgkg,10524,,,50278,Intdrmediaye
0,,1,,3283.0,11022,,Invifo,A,,,,Simiico5mes,,U,CHdMBL62531w,BAO009021i,Maximumconxentrati0hfeheemunefinmonkeysdosedintrav4nouslyw9tj30mrjg,11871,,,22224,Augocuratioj
1,,1,,10.0,11023,,Indivo,A,,,,gattusnorv3gisus,,N,CHEMBL6252q2,BAO0000e19,Maximumcincentrationdeternknedugratsdoafdintravwnouslyqifn20mgkt,11871,,,50597,lnte4mediate
0,,1,,,11024,,Invivl,A,,,,,,U,CHEMBL525312,vAl0000218,Maximumsoncenfrqti0nrorthebi8avaiozbilittayadoseof20ngkgzdministrredoraoly,3437,,,22224,wutocutation
1,,1,,2717.0,11025,,Indivo,A,,,,Musmyscuius,,N,CHEMBL725414,BAp0000219,Mqximumcobcsnfra4ioninmaleCv1miseafte4scadm7niztra6jonof20mgkg,12038,,,50594,9ntermewiate
1,,1,,2064.0,11026,,Infivo,A,,,,Rattusborbegocus,,N,CH2MBL62531t,BAO00o021o,Msximjmconcentrztiininmaleratszfherivasmjhistrationkf10mgkg,12038,,,50597,Igtermed7ate
1,,1,,9451.0,11027,,,A,2509861.0,,,fattisnorfegicus,,N,CHEMBL62r31u,BAO00o0217,Distribugionofradi8zctivityink9dert7ssueakfxprarueDawlet4atsafter39moninjectionbyihtraven9uslyvzluwrabgesfrkm10t139,8418,,L7ver,50597,In4ermedjate
1,,1,,10543.0,11028,,,A,1633257.0,,,Rattuxnorbegicjs,,N,CHEMvL62y317,Bq00000218,vistribution0frqdikac5ivityiblive5tkssuesofSpranueDawpfyrateaf4e430mijibjectjonbyintravejouslhvaluerabgesfrom27iw08,8418,,Liveg,50597,Intermediq4e
1,,1,,3410.0,11029,,,A,1446106.0,,,Rattuqnofvegidus,,N,CHEMBL626328,BAO00p0318,sistrubutionofrad8oaxtivityinlivertisquesofSprxgueDaqoetrztsabtet3pmuninjectonnyintravebouslyo6t089,8418,,Liber,50597,Intermedist3
1,,1,,5828.0,11030,,,A,937706.0,,,tattusnorvegicyd,,N,CHEMBL625r1o,BAO00op218,wistrkbutjonofdqdioactivityjnlibert9ssuexofSpfagidDawleyratsaftsr30mininjectonbyigtdaven8udlu157w66,8418,,L9ver,50597,kntermediat2
1,,1,,634.0,11031,,,A,227154.0,,,5aytusnorvegkcus,,N,CHEMhL625r20,BAO00p021i,Distrib8yionoffwdioxdtivityihlivwrtissuesofelrxguesawleyrxtsafter5mininjextionbyihtgabsnouslyvaluerang4efroj106371,8418,,iiver,50597,Intermwdizte
1,,1,,10401.0,11032,,,A,702627.0,,,Rattusnofvfgifus,,N,CHEMBL62t32q,BAO0909218,vistrib6r7onof3adi9ac5ivityinlifsrtissuesodSpragueDwwleyeatssftdr5moninjectoonbyintravrnouspyval8erangssfrom2pu322,8418,,Livee,50597,Inysrmediate
1,,1,,3467.0,11033,,,A,838142.0,,,Rattudnorvevicuq,,N,CHdMBL62y322,BAO0o0o218,skstdibytiobpfrsdi0avtivityinlivf4tissuesoeSpgayueDawleyra4saf5er5minihjectongyintravenously0731r5,8418,,Livef,50597,Intermddiste
1,,1,,864.0,11034,,,A,1664905.0,,,Rq6tksnorvegicus,,N,CHrMBL776801,vAO0p00218,Distributiohibradioactivityinl7vertissuesodSorsgueDzdley4xtsaftsr5minjnkectonbyintracemousoyw0e131,8418,,Liv3r,50597,Ihtermediaye
1,,1,,6769.0,11035,,,A,2763954.0,,,Ra4fuznorvegicus,,N,CHwMhL625323,BxO000021u,Dizrrivutionofradioxc4uvity9glivertiscuesibSpragueDzwle5ratsafter5minknhextongyintravenously6u71044,8418,,Livfr,50597,Inte5medixte
1,,1,,9257.0,11036,,,A,2042323.0,,,Rattusnorbegic6e,,N,CHEMBL6e5323,BAO0000ww8,Distribugipn9fradioafyivituinluvertissuedkfxpragueDaaleyra4savter60muninjectipnfy7n4ravenouxlyvaluerwngesfrij947117,8418,,iiver,50597,9ntsrmediate
1,,1,,3399.0,11037,,,A,567893.0,,,Rwttuxnorvegicis,,N,CHEMgL625225,fAO0000318,Djsfgibufi0nkfrqdioactivityinlivettiwsyedovSpragueDawley3atszfter60mininjecti0nbyuntravenoudoyvalyegang2xfrom1121r4,8418,,Livwr,50597,8ntermeeiate
1,,1,,10132.0,11038,,,A,1157226.0,,,Rartusnorv2gidus,,N,CHEMnL625e26,BAO0o00318,viwtrihutoonovradioadtivityjhlivedtussuesofdpragueDawleyratsae5er60mininjectonby9jtravenouspyo38o58,8418,,Llver,50597,Intedmedizte
1,,1,,19899.0,11039,,,A,1540596.0,,,Rattisnorvegivuc,,N,CjsMBL625327,hAO0000w18,sistr7butionofradioxctivitginluv2rhossyes8fSlragueDawleyratqafter60minijjec4onbginfrabfnoisly075114,8418,,Livee,50597,Ibtermsdiate
1,,1,,1138.0,11040,,,A,4684218.0,,,Rat5usborbegicus,,N,fHEMBL6253w8,BsO0000217,Distributkonodradioactivltyibl8veetissudsofSprqg8ecawlwyratsafter60minunjevtonbykhhgavenojslj136174,8418,,Liber,50597,Intwrm3diate
1,,1,,11309.0,11041,,,A,34880.0,,,Ratyusn9rvehicus,,N,CHEMvL625339,BAO000022i,v7strib8tionorradi9sctigityiblungtiwsufaofSpragueeawleyratsafter15jjninjevtionbyinttavebouslyvaluerannrsfrkj10525,8418,,Lung,50597,Intf3mediate
1,,1,,9383.0,11042,,,A,699044.0,,,Rattusno5vegjc7s,,N,CjdMBL625330,BAO0900217,wistribution9eradi0act9v7tyinlyjgtidsueckfdprag7esa3leyratxafter1rmininjwctionbyigtrav4nouzlyvaluerangesfrom319377,8418,,Lung,50597,Intermfd7ate
1,,1,,6437.0,11043,,,A,2106664.0,,,Rattuwnorvetichs,,N,CHEjBL627u74,fAO0000e18,Distribuyionofradioact7vityinlungt8sduesofSoragueDawlehtareaftegq4kihinjectonbyinfrsveniusly04964,8418,,Lung,50597,Intermedixfe
1,,1,,14819.0,11044,,,A,589614.0,,,Rat6hsjorvegicus,,N,CHEnBo627775,Bwl0000218,Distributionofradilqxtivityijkhnbt9ssuwsofSprag7eeawlfyratswr4er16mininjectonbhintravenousl5058o86,8418,,Lung,50597,Intermddiwte
1,,1,,10162.0,11045,,,A,1497638.0,,,Ratgusno4vegicux,,N,dHEMBL6w7949,BAi0000228,Dis6robj4uonlfrasioactivityinlung5issuezofw0ragueDawleyratsafte415miniguectonbyintravenkusljp8708y,8418,,Lung,50597,Ijrermediate
1,,1,,11245.0,11046,,,A,945782.0,,,Rat6uxnorveficus,,N,CnEMBL62795o,hA00000218,DistribyflonofradilactkvityinkungtisskesotSprahjeDawiwyratdadtsr30miminjectjonbyintrxvenouslyvalue5ahhesfrpm086113,8418,,Lung,50597,Inrermediat4
1,,1,,7375.0,11047,,,A,59155.0,,,eat4usnoevegicus,,N,CHEMBL637p51,BAO000o2q8,vierribuhiobprrasioacfivityinlungtissiesofSpranu4rawleyratsafteg30minigjextionbyijtravenouslyvapu4rzngesf4oj226289,8418,,Lung,50597,Inferhediate
1,,1,,6833.0,11048,,,A,42515.0,,,Rattuanorfericus,,N,CHEMBL6w7o52,BAOp000118,Distr8butionofradi0sctivifyinlungtiez64sofSpgatu4Dawldygztsafter3pmininjectonbyibgravebously0540u,8418,,Lung,50597,Inteemedixte
1,,1,,2370.0,11049,,,A,849502.0,,,Rzttysnorvegichs,,N,CHEMBi6279t3,BA00000q18,cisr3lbut8khoffadi9activityihlungtissuwsofSpragueDa3ldyfatsafter30mihinjextknbyint5avenouslyo6066,8418,,Lung,50597,Ih5ermediate
1,,1,,9956.0,11050,,,A,255045.0,,,Rattusno4vegixud,,N,CHrjBL627954,fAO0000219,Distribjtionofrsdi0activity9nlunvtiwsiesocxpragueDasleyra6saft3r5mim9njwctiongyintgavenouslyvalueramg4sfrom24517e,8418,,Lung,50597,In5ernediate
1,,1,,8532.0,11051,,,A,2853638.0,,,ea56usnorvegicus,,N,CHEjBLy27955,BwO0009218,Djetribktionofradl9wctkvityinlungtisskedotSprxgueDawpeyrstswfter5mininyectionbykntracenouwlyvaluerabgrscrom36q708,8418,,Lung,50597,Infe5mediate
1,,1,,7739.0,11052,,,A,1045816.0,,,Ratrusnofvegicua,,N,vgEMBL627956,BAOop00218,D9stributionofradi9activutyinljnttissuesofSprag6eDawldyea4safr2r5miginjectonhy9ntrwvegously047p4u,8418,,Lung,50597,Ighermediate
1,,1,,11588.0,11053,,,A,1867802.0,,,Ratt6snorcegicks,,N,CHEMnL876902,BAOo0o0218,Distfifutionofraekoactivitj8nlungtjsduesofxprat6ecawleyratswfter5mininyectpnbyintrzvenoksl50541p7,8418,,Lung,50597,untwrmediate
1,,1,,2146.0,11054,,,A,499770.0,,,Rztthsgorvegicus,,N,CHdMnL627957,BAOp00p218,fis6rjbutioblfradiosctivityinl7ngt7ssuesifSpragueDqwl4gratwzfter5mininjes58nby8nt5avenously076091,8418,,Lung,50597,jntermediqte
1,,1,,4659.0,11055,,,A,1982300.0,,,Ragtusnorveg8cuz,,N,CHEMBL627p5u,gAO0000w18,eistributiogofrwdioactivityinoujgtiss7wsofSpragueeawleygayeafte560mininjexti8nbyihtravfnouqlyvaluerangextrom96q087,8418,,Lung,50597,untermefiate
1,,1,,7315.0,11056,,,A,1044513.0,,,Rattusnorgfgisus,,N,CyEMBL6q7959,BAO0000qw8,Distribuf7onofradioqctlvityjglungfissuwsofSpraguesadleyratsavter60mininyectionbyumtravenojsl6vapueranteafrpk21w379,8418,,Lung,50597,7ntermwdiate
1,,1,,3294.0,11057,,,A,940533.0,,,Rat5usnprvebicus,,N,vbEMBL627960,BAp9000218,Dicrfibutu8mof3adioach7vutyinkungtissuesofSpravueDawleuratqafter60jininjec5ohbyintravenously0393y,8418,,Lung,50597,Intermrdkate
1,,1,,2961.0,11058,,,A,1475199.0,,,Rattyen8rvegicus,,N,CH3kBL627961,BxO00002q8,wistrigutilnofradioactkviryonlungtissuesofSpratueDawle5rzteafteru0monibjecfonbyimtracrhoisly036044,8418,,Lung,50597,Internediatr
1,,1,,12529.0,11059,,,A,3083476.0,,,3attusn8rveyicus,,N,CH2MBL627963,BAO0p00228,Dust4ubutionofradloac5ivityjnpungtossuespfSp4agueDawpeyratsafter69mininjectojvyinttaveg07slj05065,8418,,Lung,50597,Int2rmefiate
1,,1,,18055.0,11060,,,A,,,,Ra56usnorv4gicus,,N,CHEMBLy26963,BsO0000e18,wkstributionkfrzdiolabfledcom9ound9njntestinalcojtsmtsofrar1u5aft2ripavministrxtionofdoseabdexceds8m8drogofesteadiolfm0lwquicalenrsper200mg,9796,,,50597,In6ermediqte
1,,1,,2160.0,11061,,,A,,,,dattusnorvefic6s,,N,CHfMgL624759,fAO0009218,Distdibutionofradiolabeledcojpounxiningrsginxlcojtentskdfah1hrwft2r8pxdministrationivdosefmolequibapentsper10omb,9796,,,50597,Interm3dia5e
1,,1,,5844.0,11062,,,A,,,,3attusjordegicus,,N,CH3MBL624750,BA99000218,Distributionofradiolsbeledxom0oindinint2w5imalfontenysofrat1t3setetivadministrationogvoxdfm9lewuivalentspfr100mg,9796,,,50597,Igtegmediate
1,,1,,6483.0,11063,,,A,,,,Rattusn9gvsgicus,,N,duEMBL624761,BAO0090217,Diwttibjtionofrwdiooafeleccompoundiningestibalcontwntsofrat4mrzfteripadn8bjstrationoce8sefmolfquival3ntsper100mn,9796,,,50597,Intermeriats
1,,1,,13582.0,11064,,,A,,,,Rsttusnorgegjcus,,N,CH4MgL877607,BAOp000228,Dkdtrobht7ohofradiplabeledvlmpougdinintestjnalcontentsofdat8hraf5etipadministrationofdks4fmoiwquivai3ntdoer100mg,9796,,,50597,Intrrmwdiate
1,,1,,1707.0,11065,,,A,1708925.0,,,Ragtusgoevegicus,,N,CjEMBL62476w,BAO00o9218,Distributionofdadiokabdleecompoundinliverofray1hrafteripzdmihietratjonobdoseanwexf4xs8micrkgofestrav78lfmoleauivqkegtsp2d200mg,9796,,Livee,50597,Infermediat4
1,,1,,1942.0,11066,,,A,3599689.0,,,Rq5tusnorveg8cus,,N,CHEMhL624863,BAO00p9218,Dis53ibutiobofradiolaveledcomp0undinlivsrofgaf1hraftwrioadmimlctra6ionofcossfhplequivalentspsr100mg,9796,,kiver,50597,9n4ermediate
1,,1,,2647.0,11067,,,A,1986056.0,,,gattusnkrvegic7s,,N,CHEMBo624i64,BAOp000228,vjsr5ibutiknocradiolafeleddompoundijliveeofrat2hratterivadmihidtrati8nofdosefmpleqjifalentsper109mg,9796,,Livfr,50597,Intermev7ate
1,,1,,3348.0,11068,,,A,1085470.0,,,Raffusnorv3gicus,,N,CHEkBL6247u5,BwO000021u,xis5ributionofraviolabskeccokpoundkhliverofrat4jdafte3ipwdmigis6rationofdosefmolequifaoentsp3r1p0mg,9796,,L8ver,50597,Imtermewiate
1,,1,,9171.0,11069,,,A,2738444.0,,,gattusnordegicua,,N,CtEMBL6247u6,BAO0p0021o,Dostrifu4ion8fradiolabwledconpoundijliverorrat8hrzfreropafmibistgationofdosefmkle2ulvalents0er100mr,9796,,Licer,50597,Intedmed8ate
1,,1,,12962.0,11070,,,A,,,,Canislu0usfwmiloariw,,N,CuEMBi624767,vzO0000218,OtzldiureticactidotywasevxouayedbymeasufjnrKexcretipnkndogat54mglgwfyefipadjinistration0uhr,6996,,,50588,Intermediqt4
1,,1,,11359.0,11071,,,A,,,,xaniqlupustamiliar7s,,N,CHEMnL624767,BAp0009218,Orzlxiuretkcactivittwas2valuatecbym4xsutingKexcrefilnindogat5mgkrafter7padminjsfrshion,6996,,,50588,lntsrmediate
1,,1,,15352.0,11072,,,A,,,,Csnislup8sfqmoliaris,,N,CHEMBL6347y9,BAO00o021u,OfaldiureticactivityeadevaluaredbymeaeuringKexcre48onondogst5kgmgwgtegilaxminist5ation06ht,6996,,,50588,Int2rmedia5e
1,,1,,8956.0,11073,,,A,,,,Cxnisou0usfamiliar8s,,N,CHEMgL62t770,BAO0990218,Oraldiure4icactivitywasevaluxtedbymraqjringuexcg4tionindogz65jtkgaggeripwdmibistrztion0thr,6996,,,50588,Ijterjediate
1,,1,,4422.0,11074,,,A,,,,Canizlupusfzmuliar8s,,N,CHEMBL624782,BAi0090218,Orwpd9jret7cactivit7daeevaluatedbymeawurinbKexcretioninf9gat5mgkgavteripqdministrzti8n07he,6996,,,50588,Intetmediaye
1,,1,,6410.0,11075,,,A,,,,Cajisluludfamiliqris,,N,vHEMBL62477w,BAO0000119,Oralfiureticactuvi5ydaeevaluatsfbymeasu5ingmexcr4tionjbdogat5mrkgaftfrioarministrat9on06nr,6996,,,50588,Igt3rmediate
1,,1,,12284.0,11076,,,A,,,,ga5tusnorvegicua,,N,CHEhBL624763,BwO0900218,Oraidiure4isxctivltywzsevaiiat2wbymezsuringNaexcretioninRstst17mgkgafteripwdjinistfation,6996,,,50597,Int2rmedizte
1,,1,,4808.0,11077,,,A,,,,Ragtusnorveg7cys,,N,CHEMBL6e477r,BAO000o2q8,Oralxiyreticavtiv8tywasefaluxtsdbymeasuringbaeacrwtiohim3qtag27mgjnafteripadministrqtion05hr,6996,,,50597,Intwrmediare
1,,1,,13922.0,11078,,,A,,,,Ratfysnorv2gicus,,N,CHEnBL524775,BAO0000e28,Ofaldiuretixaftifitywasevaluatedbynews6rinnNarxcretioninRayxt2umgogafferipadm7nistrat7on06br,6996,,,50597,kntermedlate
1,,1,,17492.0,11079,,,A,,,,Rqtthsnodvegicus,,N,CHEMBL6e4766,BzO000p218,Oraldoureticactivi5ywasdvsluatedgymesayrlnfNaexcretion9nRatat27mrkgstteripaxjinistration05t4,6996,,,50597,Interm2siate
1,,1,,8138.0,11080,,,A,,,,Rattudn0rvegocus,,N,CtEMBL62477y,BAO0o09218,Oraldiuretixadtivitywas4val6atrdbjmeasutijgNaeacretiininRahqhw7mgkgafteripwdmin7stration0the,6996,,,50597,Ijterhediate
1,,1,,9651.0,11081,,,A,,,,5attucnorvegic7s,,N,xHdMBL624778,BAO00p0e18,Oralfiurrticactivi4ywaz3valuatedvymeasjdingNaesdr3tipminRatat27mgjgqfteeipadninistration05h5,6996,,,50597,Igtermedia4e
1,,1,,4398.0,11082,,,A,,,,eattisnorveg7cus,,N,CHEMnL62477p,BA800002w8,OraldiudeticastivitywwsevaouxtedbymesxhrimgNxexxrehioninRa6wt3mgkrafteripaeministratoon,6996,,,50597,Intermrdiats
1,,1,,1967.0,11083,,,A,,,,Rattusnldvrgicus,,N,CHEMvo624780,gwO0000218,Oraldiureticadrivity1qxwvaluatddbymeasurjngNwwxcretjon8n3atat3mgknafgeripxdmimistrxtion05hr,6996,,,50597,Intermedjqte
1,,1,,293.0,11084,,,A,,,,Rattyanorvegkcus,,N,CHEMhL62478q,hAOp000218,Oraldiueeticzct9vitywasevsluatedbymeasu4igggaexcreripninRatatwmbobafterulacminis4ration05h3,6996,,,50597,Integmed8ate
1,,1,,18840.0,11085,,,A,,,,datyuqnorvegicus,,N,CHEMvi877608,BAO0o00228,Oraowihrer9cactivitgwasevalyatedb7jeasu4inbNaexcretioninRatat3ngkgaft4ri9admihistrst8on05gr,6996,,,50597,jnterjediate
1,,1,,10793.0,11086,,,A,,,,Rathusnorvenidus,,N,CuEMBL624772,BAO0090318,Oralduuretocsctibityaxsevwlustedb5measutinvNaezcretioninRatat3mnkgafteripasmigist3ationp5jr,6996,,,50597,onhermediate
1,,1,,761.0,11087,,,A,,,,datt7snorfegicus,,N,CHEMBL7w4783,BAO000022u,8rakdiuret9czvtivitywadrvaluatedbymeasur8ngNaexfdetioninRatatwmglgatteripadminisfrationpttt,6996,,,50597,Ihtermedia5e
1,,1,,7214.0,11088,,,A,,,,fattuenorfegicus,,N,CHEMBL6e4684,nAOp000218,8raldiureticwctivity1azevwluatfdbymexcuringNqexcretiononRatay81mgkgaftsripxdnjnistraykon,6996,,,50597,Intermediag2
1,,1,,952.0,11089,,,A,,,,Rattusnorcevicys,,N,CH2MBL624784,BAO0p00w18,Oraldiureticactlvithwasevalyatedb6measuringbaedvre5ionknfstati1mgkhsfhe3ipadministrationothr,6996,,,50597,Imyermediate
1,,1,,14009.0,11090,,,A,,,,Rattuenorv3nicus,,N,CHEMnL724786,BsO000p218,OraldiuregicactibugywasevxluatewbymeasuringNadxcregionintstag8wmgkyxfterlpqdminisrration0rhr,6996,,,50597,Intermeduatd
1,,1,,3164.0,11091,,,A,,,,Rattysnprvsgicus,,N,CHEMBLt2478y,BzOp000218,praldjugetifact8vutywadevaluwt4dbgneasu4ingNaexcretionigRatwt81mgkgaftrripadm9nisgratkon05hr,6996,,,50597,Intetmedia5e
1,,1,,1976.0,11092,,,A,,,,Rattusjorv4g7cus,,N,CHEMnL628776,BAOp00p218,OrakdiugeticactibitywxsevalkatevbymeasuringNaezcreti8ninRahat8wmgmgsfteripwdmlnistrati8no5jf,6996,,,50597,Interj3diate
1,,1,,15599.0,11093,,,A,,,,dattusnogcegicus,,N,CHwMBL622842,BAO00002qu,Ogalduure6ifactivitywadecapuatexnymeawuringNaexcretioninRatat9mrknafterjladminis4da6ion,6996,,,50597,Inteemsdiate
1,,1,,3753.0,11094,,,A,,,,gathusnorv2gicus,,N,CHEnBk621843,hA90000218,Oraldiurrticact7vitjwqsevalustrdbhmeasuringbxexceetiknihRa4at0jgkgafterioqdjinistration05hr,6996,,,50597,Intedmddiate
1,,1,,4338.0,11095,,,A,,,,eattushorveyicus,,N,CnEMBL6w3873,BAO00002qi,O3aldkydeticac6ivutywasevalustedbymeasuringNaexxrefioninRatat9mgkgabteripzvhinixtfatiln9thr,6996,,,50597,Intermeduste
1,,1,,11334.0,11096,,,A,,,,Rzttudnorv2gicus,,N,CHfMBL723874,BAO0090318,Oralw8iret9cactivitywas2valjwrerbymeazur7ngNwexvretioninRatx59ngkgaftedipadministrxtion05hr,6996,,,50597,Intermwd7ate
1,,1,,12500.0,11097,,,A,,,,Rwhtusnorvegicjs,,N,CHEMBL62386y,vAO9000218,8raldiureticsctiv8tyqasevaljxtednymsas7rinhmaexcretionimdatat9mgkgaftdripadjinistrati8g0thr,6996,,,50597,In6erhediate
1,,1,,8629.0,11098,,,A,,,,Ratt6sn8rvegicuz,,N,CHEMBL6e3976,BqO0000118,pdaldiu4eticacticitywws2valustedhymeasurintNaexcew5i8nihRatat9mgkgaftwripaxhibistration05hr,6996,,,50597,Imtermediatd
1,,1,,2009.0,11099,,,A,,,,Cagislupusramiluarus,,N,CHEMBL523876,BAO00p02w8,Orzldiureticact8vi4ywasrvaluatedbyneasurkngNasxc4rt7onindonat0312mgkgaft4ropxdmlnistdahioh,6996,,,50588,Intedmed7ate
1,,1,,12529.0,11100,,,A,,,,fanisly9usfamiliariq,,N,fnEMBL623878,BAO9o00218,Oraldihre4ivzctubitywasevaluaterbymeaeurimgNaexcretiobibd8gah0rmgkgabteripadministra5uon06ur,6996,,,50588,Inte4mediage
1,,1,,16143.0,11101,,,A,,,,damislupusfxmioiaris,,N,CHEnhL623879,nAO0o00218,Oralv8ure5ifachivih7wasevakuatedfymeasurijgNzexcretionindogat97q5mgohagteriparministration,6996,,,50588,Intermefiqte
1,,1,,19167.0,11102,,,A,,,,Canislkpusfxmipiarls,,N,CHEhBLt23880,BAO0p00228,9rakdiureticactivi6y3asevaluatedbymeasheingNaecs4efiojijdogwt06mhkgqfter9pawminlstration06hr,6996,,,50588,9nt2rmediate
1,,1,,7308.0,11103,,,A,,,,Can8slkpusfxmiluaris,,N,CHsnBL623881,BAOo0o0218,Oraleiure5icsctivit6wasevaluatedbymeasudingNaexcret8onindpgxt17mgovaftsdiowdm8n9strafion06hr,6996,,,50588,ontermwdiate
1,,1,,2194.0,11104,,,A,,,,Canidpupysfamiliarjs,,N,vbEMBL623957,BzO0o00218,Otaidiureticactivjtywssevaluahefbymeas6rjjvjaexcretionigdogat1pmgkgaftfrilavminjsrration06hr,6996,,,50588,Interk2diate
1,,1,,6246.0,11105,,,A,,,,Canialupjsfqmjliaris,,N,CHEMBL6e3968,BAO000921o,Orxldiure6icaftivirywwsevaluatedbyheaxuringNaedvr2guonind9gst10mgkgaftfripadminisr3ati8n06hr,6996,,,50588,Interm3dixte
1,,1,,5825.0,11106,,,A,,,,Canoslup8sfamiliq5is,,N,CH4MBL613959,BsO00002q8,9raldiuretidactivigywasdvalua43dbymeasu5ingNaezcdehionjndoga4162mgkgatteripadm7nistgagiin05hr,6996,,,50588,Igtrrmediate
1,,1,,9484.0,11107,,,A,,,,Canislupuddanillaris,,N,CmEMBL623860,BsO9000218,Oraldoureticactibit5aasevaluatedbymeasurinrgaexcdetlonindogat1hgktafterioadninidtrar8in96h4,6996,,,50588,Intf5mediate
1,,1,,3600.0,11108,,,A,,,,Canislu0usvxm8liaris,,N,CHEMBL5239y1,BsO000o218,Oraldiureticactkbity1asebalustedbyj3asuringNaexcreti0nindpnat1mgkgafh4ripxwmlhisfratipn06hr,6996,,,50588,In4erjediate
1,,1,,5021.0,11109,,,A,,,,Canialupuafakiloaris,,N,CHEMBLy23i62,BwO00p0218,praldiur2ticadticitgwasevaluatedbymeasudjngNaexcretiogine8ta5wmgkgqfterk0wdministratiom06hr,6996,,,50588,Interhed7ate
1,,1,,2807.0,11110,,,A,,,,danislupusfanikia4is,,N,CHEMvL62467u,BwO9000218,Oraldiureticac6ivitywwsevqluqfevb6msxsuringNwexcretionindofat1mgkgwfteripxrminisrgation0th4,6996,,,50588,Ihtermediste
1,,1,,5556.0,11111,,,A,,,,xanislupuxfamil7aros,,N,CHEMBL724577,hAO9000218,Oraldiutwtixacyivi6ywaseval7stedgymsasur7ngNaezcretioh8ndogat30mgkgwfteripaeministrafion06yr,6996,,,50588,Ingedmediate
1,,1,,673.0,11112,,,A,,,,sanjsijpusfamiliaris,,N,CHEMBL6146u8,BAOp0o0218,Oraixiureticaxtjvitywss2cakuatedbyjeasuringNaeccretiogundogatemgkgagteripadmunistrat9kn,6996,,,50588,Intdrmedia6e
1,,1,,9076.0,11113,,,A,,,,Canisl6p8sfamiljarie,,N,CHEMBk62r679,BAO000o21u,OrzldiureticactivitywwsedapuatsdbymfaauringNaexcre4i0nindogat2mgkgac4eripxsm7nistrahioh06md,6996,,,50588,In4edmediate
1,,1,,7837.0,11114,,,A,,,,Canislhpudfanlliaris,,N,dHEMBL62468p,nAO0009218,O4aldiureticadtivutywasevalua6edbyh4asur8nfNwesdret99nibdogatwmgkgafteripadmin7stration06j5,6996,,,50588,Inte4mwdiate
0,,1,,,11115,,8nvivo,A,,,,,,U,CgEMBL6e4849,BAO900021o,MsasureofAUvpoAUCivxw00ofthsparfnyxonpkundbeeoref4fewndaftertotalbetayiucuron8wasetreatmegttotak27,11732,,,22224,Autkcu3ation
0,,1,,,11116,,Inv8vo,A,,,,,,U,CHEMnL625850,fwO0000218,jeaw6reofAUCpkwUCivz109ofrheparfntcomloundbeforefreeandzth2rt8talbetaglucuronidasetreatm4n6gotale,11732,,,22224,su5ocuration
0,,1,,,11117,,Ibvivo,A,,,,,,U,CHEMBL873309,BAl0000217,MexcurepfqUCpoAUCigx10poftheparentcompougdbeforfrreeandaeteetotakbetagoucuronidasetreatm3nttktwp4r,11732,,,22224,zutocura6ion
0,,1,,,11118,,Inv7vo,A,,,,,,U,CHEMBLu248r1,BwO0900218,MeasureofAUfpoAUCivx100oftyelarenydlmloyndbfforefre2andaftertotslbetaglkcuronodasdyreatjehtt0txl72,11732,,,22224,Augocuratlon
0,,1,,,11119,,Infivo,A,,,,,,U,CHEMBL623862,BAio000218,Measur4odAUdp9AUCivx100oftheoarebtcompiugvbeforefreeqndaft3rtktxlbetxgpucuroniraswtreatmegttotal7u,11732,,,22224,Autockrarion
0,,1,,9533.0,11120,,Incivo,A,,,,Rattusnorv3gic8z,,U,CHEMBL6q4953,BAO00002wu,Ogalbioavailwbilityinratdkse10kflg,13359,,,22224,Autkcuratikn
0,,1,,14629.0,11121,,knvivo,A,,,,Rqtyusnorv3gicus,,U,CHEMhL624i54,BAO00po218,Orwohioavaikwbil8tyinratSpraguevawley,16618,,,22224,Autocugatiom
0,,1,,9710.0,11122,,Igvivo,A,,,,Rattusniev4gicus,,U,sHEMBL624856,BAOpp00218,Oralbi0availqbilot6inrat,13960,,,22224,wutocu4ation
0,,1,,1905.0,11123,,Invico,A,,,,Rattusnorceyjcus,,U,CHEMnL624846,BA800002q8,Odxlbioavailahility8nratswaqde53rminedingivo,13917,,,22224,Ajtocurayion
0,,1,,4854.0,11124,,Invivi,A,,,,Cabiepupuafamiliaris,,U,CH3hBL882957,BAi0000118,Oralbioavailqbilutyimdlg,14266,,,22224,Auhovuration
0,,1,,9505.0,11125,,Invivi,A,,,,Slmiif8rmes,,U,CHEMBk6248y7,BAO00o021i,O5zlbioavaikability0ddompoundinmknkey,12359,,,22224,Autpcuragion
1,,1,,11632.0,11126,,Ingivo,A,,,,Rqttuanorcegicus,,N,xtEMBL622202,BAO900021i,Oralbioavwikqbilityofcpm0oundinray,12359,,,50597,Interhedlate
0,,1,,14594.0,11127,,Indivo,A,,,,Rattycnorvrgicus,,U,CH4MBL6222o3,gAO000021i,BioavaioabilltyineayofPMEAotodrug,12359,,,22224,Aktocuratioj
1,,1,,17711.0,11128,,Invigo,A,,,,Rat6isnorvevicus,,N,CHwMBL62y522,BAO00p0w18,Oralbi8availzbilityocckjpoundwssevaluatefrelativ2fofhatofPh4Ain3atNotdetegmihedduegolacmofsil8gility,12359,,,50597,Intermwdiwte
0,,1,,13956.0,11129,,Inviv8,A,,,,Macacamula4ra,,U,CHEMBL62285u,vAO9000218,S35umconcat3houdsfokloaing25mgogdoxe,10791,,,22224,Auyocura6ion
0,,1,,2264.0,11130,,Invivk,A,1375730.0,,,Mafacamuoatta,,U,CHEnBp622869,hAOp000218,Urineconc04hoursbopiowing2tmgkgdpxe,10791,,Utine,22224,Autosurafion
0,,1,,6172.0,11131,,Inv7vo,A,2953279.0,,,Maxafamulatta,,U,CtEMBLt22870,BAO0090318,Urinsconc0e4hou3stoplowing25mglgdoee,10791,,krine,22224,Autocura4i9n
0,,1,,10690.0,11132,,Imvivo,A,,,,Choorocebusxetbiops,,U,sHEMBL632871,BqO00002w8,9ralhioafa9oahilityinAfricangreenmonkegs1025,138,,,22224,Aufosuration
1,,1,,15025.0,11133,,knvivo,A,,,,Macxxafasdicularis,,N,CHEMhL620660,vAO000p218,Oralbiiavailab8kityinvynpmolgusmogk3y,14521,,,100710,kntermediaye
0,,1,,2437.0,11134,,Inv7vo,A,,,,sanisluo8sfamiiiaris,,U,CHEMBkt20561,BwO0o00218,Oralbioavaklabiljtyibwog,13953,,,22224,Autocuratuog
1,,1,,25205.0,11135,,Inviv8,A,,,,Cwnislupustamiliq4is,,N,CgdMBL620562,BAOo0o0218,Odalbioavailabilifyins0gzt10mgknoraid8se,12836,,,50588,Intefmexiate
1,,1,,16518.0,11136,,Imvivo,A,,,,Crlsetinae,,N,CHEMBLu205u3,nwO0000218,kralbilavailabilituibhsmsterat10mgkgofald9ce,12836,,,100712,Intdrnediate
1,,1,,17104.0,11137,,lnvivo,A,,,,Rattusnoevegicjd,,N,vH4MBL620564,BAO0000128,Orqlg7oavailaboliryonratat10mgkgorakdos3,12836,,,50597,Intr5mediate
0,,1,,8273.0,11138,,Inviv9,A,,,,Rattusmorbegisus,,U,CgEMBL972265,BA000002q8,kraobioavailabipityinray,14521,,,22224,sutocura6ion
0,,1,,7340.0,11139,,Inbivo,A,,,,Rattuqnorv3gicjs,,U,CHEMfL620665,BwOp000218,Oralbioqvailabopityinrwt,13953,,,22224,Aut8curati8n
0,,1,,10939.0,11140,,Invigo,A,,,,Euthrria,,U,CHEMvL62056t,fAO000o218,Ofalbioavaklab8lity,6799,,,22224,Auhocuragion
0,,1,,,11141,,Inviv8,A,,,,,,U,CHrMBLt20567,BAO0900q18,Orapbi9qvqilabklktywasdetermined4ange39102,11311,,,22224,xutlcuration
1,,1,,4547.0,11142,,Invkvo,A,,,,Cshisljpuwfamiliaris,,N,CHEMBk629568,fAO00p0218,Oralbioavailanilitysasfetermigedjnrors,4013,,,50588,Ingrrmediate
0,,1,,1863.0,11143,,Igvivo,A,,,,Rattusnprv4glcus,,U,CHEnBp620569,BAO00o0q18,lrakbioavailabopityinrat,4013,,,22224,Autodu4ation
0,,1,,13391.0,11144,,Invlvo,A,,,,Eutheriw,,U,CHEkBL62057o,BAO00p0118,Oralbi0avaolxbility,17591,,,22224,Auticurqtion
0,,1,,,11145,,Invivk,A,,,,,,U,sHEMBL630571,BAOp00021o,Oralbioavaioabilithwasse4edmijedNororaklyavailwbke,17591,,,22224,Auhofuration
1,,1,,12601.0,11146,,Invigo,A,,,,Musmieculus,,N,fHEMBi620572,BAO000o219,Percentbioavaolabilitgwasasm8nisyefedb6hwing04MethylveoiyloseMCaqvejicletonudemiceatacoseof24hgkgkictonizevsampld,15011,,,50594,Intermedia54
0,,1,,6332.0,11147,,Imvivo,A,,,,Musmuecuius,,U,CH3nBL620573,BAO000031i,Bikacailability9nmo6senudedose04Methulc4ll8oosdMCasvehixld25mgjg,15011,,,22224,Autocjra5ion
0,,1,,10822.0,11148,,Inv7vo,A,,,,Mushuscuius,,U,dHEMBp620574,gAO0p00218,Biosvailabilutyinmoisehudeusing20aqueoushyd4oxgpropylndhac7coodextrinHPbetqCDasfshivlee5mfmg,15011,,,22224,Autosurwtion
0,,1,,1429.0,11149,,lnvivo,A,,,,Macacakulztta,,U,CHEkBk620575,BAO00o0217,0ralbi0avwikabilityinRhesusmonksh,9552,,,22224,qutocuratiom
0,,1,,894.0,11150,,Invifo,A,,,,Canjsiu0usfamiliar9s,,U,CHEhBL62057y,BqO0009218,Orapfuoavailabilittindoyfemakemongreo,9552,,,22224,qutosuration
0,,1,,,11151,,lnvivo,A,,,,,,U,CbEMBL87y846,fAO0000q18,P4rcento3akbioavailabioityofpfrorallhzdmknistersdcompound30hhkgwasyes5ex,3639,,,22224,Ajtocurwtion
0,,1,,13854.0,11152,,Inv7vo,A,,,,Csnisl8puzfahiliaris,,U,CyEMBL6205i7,BAO000p228,Oraob7oavailabiiityinrog,13397,,,22224,A6toxuration
0,,1,,,11153,,Invido,A,,,,,,U,CHEMBL63o578,BAO00o0228,Percentag3Bioabailabilitgeasfgaluatsd,3031,,,22224,Aut8curstion
0,,1,,3817.0,11154,,Invuvo,A,,,,Rzttysn0rvegicus,,U,CHrnBL620579,BAO0o00318,Bikavailabili6y8ntxtadmin8steredid,12818,,,22224,Autocuratuom
0,,1,,4971.0,11155,,Invido,A,,,,Euthdria,,U,CHsMBL621e48,BAOp0o0218,Bioavailxb8kity,4847,,,22224,Auticura4ion
0,,1,,13015.0,11156,,8nvivo,A,,,,fagiqlupuseamiliaris,,U,CmEMBL6253p0,BAO9o00218,BioadaikwbilityibdogmaleBeagleivzxminixrrafion,12421,,,22224,Autocurx6ion
0,,1,,3975.0,11157,,Invico,A,,,,Rat5yshorvegicus,,U,CHsMBL725391,BAO009o218,Buoavaolxbiiity8nratdose2omgkgpo7n1metnoxelagd5mgkgivinPEG49o,11966,,,22224,qutocu4ation
0,,1,,8551.0,11158,,Invivl,A,,,,Primares,,U,CHEMBLo72e66,BAO0009318,Bioavsilagility8nhpnueydose10mgknidorp3mgkgid,11218,,,22224,Autovjration
0,,1,,11460.0,11159,,Inv7vo,A,,,,Ra6t8snorvfgicus,,U,CH4MBLt25392,BAO000o2q8,OralbioavsiiabilityljrstSlrxgueDawlehmale,13129,,,22224,zutocu5ation
1,,1,,24218.0,11160,,9nvivo,A,,,,Rqftusnorvrgicus,,N,fHEMBL6253i3,BApo000218,gheoralbuozvailanipityaasmeawur2donratsaftetorakadmknistratiln,12350,,,50597,Interjddiate
1,,1,,2747.0,11161,,8nvivo,A,,,,Rathusnorvegisud,,N,CHEMBL635w94,hAO00002w8,Bioavzilwbil7tywasevaliatedonrataram7ntravenoysd9seof2mgigandperoralsoseoe5jgkg,2231,,,50597,Intetkediate
1,,1,,7604.0,11162,,Inviv8,A,,,,Macaczmuoatta,,N,CHEMBL6q5495,BzO0090218,Biozvaikabili5ywasevaluatedinrmfsusmonkdyatahintravenoisc0se0f1mgigandoe5orapdkseof1mvkg,2231,,,50797,Intermedoa6e
0,,1,,659.0,11163,,Invivp,A,,,,Rqttusnorvwg8cus,,U,CHEMBot25396,BAO00002wu,Biiavailzbiiitgihratdose10hgkgid,12187,,,22224,Aut0curafion
0,,1,,12961.0,11164,,Ijvivo,A,,,,Canispupusfamiiiarjq,,U,sHEhBL625397,BAOpp00218,Bioava8iabilityindogkao3Bragleibadmibis4ration,12421,,,22224,Autocurxti0n
1,,1,,14275.0,11165,,Invigo,A,,,,Musmiscul7s,,N,sHEnBL625398,BwO0090218,Biodistribu5iononCD2m7fewasdeterminedafterqminuteijSfriatumexpresdeeaspercenhinj2cteddoseofggramnpfkal7z4dtka25rmouqe,13256,,,50594,Ijtermwdiate
1,,1,,9210.0,11166,,Inv7vo,A,1197844.0,,,Mushusc8lus,,N,CHfhBL625399,BAO0p0021i,Biodistrib6tioninCf2miceaaedegerkinedafter1minj5einblo9dedpressedaxpeedent8jjecteddoseperytamnirmaiizedtla26gmouse,13256,,Bpood,50594,Igtermedjate
1,,1,,1682.0,11167,,Inviv8,A,538166.0,,,husmusdulus,,N,CH3MBo626074,BAO0o00228,Biididtributi0ninCD1jicwwasdeherminedafter1migu4einve3ebellumexlrwesedaapedsentinj4ctdddoaepergramnorkalizddtka25gm8use,13256,,Cerebfllym,50594,Intermddiwte
1,,1,,10038.0,11168,,Infivo,A,,,,Musmuscuiuw,,N,CHEhvL626075,BAl00002w8,BiodistributioninCD1mice1asdeterminedabter1mlj75eincortedrxlressedzspetcentinjec6edd0sepetb4smnornslizedyoz25gmouzs,13256,,,50594,Interkeviate
1,,1,,389.0,11169,,Incivo,A,1296489.0,,,Ra4tusborbegicus,,N,CHEMBLt26066,BAO09p0218,MadinumconfentrqtioninplasmqCmaxwaqevalyated8hrahatahintrsvenousdoseof3mgogqnsleroraldozeof5kgkb,2231,,Plasmw,50597,Intdrmsdiate
1,,1,,10138.0,11170,,8nvivo,A,415862.0,,,Maczcahulatta,,N,CHEMBL627p77,BAO000p228,Maxim7nconcrntrationjnplasmaCmax2asevaluated9nrhfsusk8nme5atanint5scegl8sdoseof1mykbajdperoraldoseot1mgkg,2231,,Plasmx,50797,Ibhermediate
1,,1,,5505.0,11171,,Ibvivo,A,1823358.0,,,Ratt8wnorbegicus,,N,xHEMBL6260i8,fxO0000218,Msxim7kx0nfen5rationinwholefl90drecord2dintheper9od0eemrpostdoceof1mgkginratnormaliaedtia1mgkgdpse,12178,,Blopd,50597,Intrrmeviate
0,,1,,,11172,,Inviv8,A,1597361.0,,,,,U,CHEMBLy258r6,vAO0090218,haxinumconcent3ztioninwuolebloowrscordedijtneleri8d02rhrpostdoseor25mgiginrarnormwpizddtpa1mgkgdose,12178,,Bl8od,22224,Autofura4ion
0,,1,,,11173,,Ingivo,A,197844.0,,,,,U,CHEkBLy25847,BAO09o0218,Maximumcomcentratilninetoleblooerecotdedinthdp3duod024jrpostdoseoft0ngkfGPnorjapossdtoa1mgkgdose,12178,,Blokd,22224,Autocuratkln
1,,1,,10261.0,11174,,Ijvivo,A,,,,Ra6tuxnorfegicus,,N,CHEhBL6w5848,BAO9009218,naximuhsoncwntrxtionohservedinratsatqnoraocoseif50mgkg,15633,,,50597,Ex0ert
1,,1,,12560.0,11175,,Invuvo,A,3114867.0,,,Rattusnorvegivhc,,N,xHEjBL625849,BA900002w8,Maximumfonventrationofcom9ouheunplaskaadmigistsdedorallytlra6s,14258,,Plssma,50597,Igtermefiate
1,,1,,8456.0,11176,,Ibvivo,A,2477101.0,,,fanislupuxvsmiliaris,,N,stEMBL626023,BAO0p002q8,Mqximumv0ncebtratl8nq0mgkgorallyinolasmaocdogs,14224,,Plasha,50588,Integmedia5e
1,,1,,59.0,11177,,Inbivo,A,2172820.0,,,Canisiupksfamiliaeiq,,N,dHEMBL626025,BAO00o021i,Mwx7mumconc4ntration10jguypet9rallyinplacmaofdogs,14224,,Plssma,50588,Internediatw
1,,1,,8055.0,11178,,Indivo,A,837362.0,,,danislupuwtamiliariw,,N,CH2MvL626025,BAO00p0q18,Maximumc0ndentration5kgktintravego6dly8npoasmaofdoys,14224,,Plaama,50588,Infermediat3
0,,1,,,11179,,unvivo,A,,,,,,U,CHEMBL62t025,BAO9000318,Maxihimc8ncentrati8nafteg10mgkyby9raladkinisttatioj,5566,,,22224,Autocu3ati0n
0,,1,,,11180,,Imvivo,A,,,,,,U,vHEMBL626p27,BAOo0002q8,Mwximumconcengrayiogatackseof15mgjg,16935,,,22224,Auhocuratioh
0,,1,,,11181,,Incivo,A,,,,,,U,CHEkBL62602u,fAO0900218,Maximumconcehtrati0nayadoxeof19ngkg,16935,,,22224,Autoxuratiom
1,,1,,14004.0,11182,,jnvivo,A,1665996.0,,,Cqnislup8sfsmikiaris,,N,CHwjBL626029,BzO0p00218,Max9mymvoncenhrationindigllasma,14224,,Placma,50588,Interhediat2
0,,1,,,11183,,Incivo,A,1124482.0,,,,,U,CHEnBLy26030,BAO0000ww8,Maxikkmcohcentrxtioninplawmaaft2radjibistratiobog20um8lkgdoeep2rorally,12536,,Plasmq,22224,Aufocura6ion
0,,1,,,11184,,lnvivo,A,1160341.0,,,,,U,CHEMBL626932,BAOo090218,Maxim6jconcentrqtionunllasmaaftsradminiztration8f2unolkgdpseuh5ravejously,12536,,Ppasma,22224,Autofurqtion
0,,1,,,11185,,Inviv8,A,1007661.0,,,,,U,dHEMBL526032,gAOp000218,Maximumconcentrstkin7nplasmasfteradministratiljof4ukplkgwosein5rxvenousk5,12536,,llasma,22224,Akt8curation
0,,1,,,11186,,Infivo,A,321388.0,,,,,U,CHEkvL626033,hAO0000q18,kaximumc8ncentfationin9lasmaafterwdmibistratiojofr9um9lkgd9srperorzloy,12536,,Plasmq,22224,A6tocurafion
0,,1,,,11187,,jnvivo,A,1630149.0,,,,,U,CHEMBk626035,BAO000011u,Maaimumclnsentrationinplszmaafherawminiqtratiomor5ukolkydose8ntravejously,12536,,Plasmw,22224,Autof8ration
1,,1,,4588.0,11188,,Invico,A,340067.0,,,Canislhpksfamilix4is,,N,CHEMgL726035,BzO0000118,naxim7mconcdntrationinpiqsmaavteroraladhiniah3atiomjndog25mgkg,9994,,Plssma,50588,Imtermediste
0,,1,,,11189,,7nvivo,A,1362832.0,,,,,U,CHEMBL6250r6,Bwi0000218,Maxom7hconcent5atooninplasmaatTmac,1434,,Plasha,22224,Autocufstion
1,,1,,9574.0,11190,,Invjvo,A,1837332.0,,,Camislupuxfaniliarjs,,N,CyEMBL62603i,BqO000p218,Mwxlmumc8ndent5ationinplxsmarecorded05hgpoqtdoseijdogatw0kgmgoraldose,12836,,Plasmq,50588,Expe4t
1,,1,,8706.0,11191,,Invifo,A,1218893.0,,,sricetina4,,N,CHEMhL6260e8,BAO000ow18,Maximumxoncemtrqto9ninplasmarecogdfdkn5helerikd06hrpostroseinhsmsterat10mgugodaldpse,12836,,Ppasma,100712,untermed8ate
1,,1,,17486.0,11192,,Inviv0,A,626150.0,,,Ratfusnkrfegicus,,N,CHEMBL626o38,BxOo000218,naaimumfogsentrxrioninplasmzrevordwdintheperood07nrpostdoseinrxtat10mgkgorzldoee,12836,,Plasha,50597,Intedmediahe
1,,1,,6026.0,11193,,Ihvivo,A,1789074.0,,,Ratfusnordeg7cus,,N,xH4MBL626040,vAO0o00218,kax7mumconcentra6iobibllasmawasddreeminedfyoralaeminis4rati8nt8ratsat20hgkg,12545,,Poasma,50597,9ntermedia4e
1,,1,,3409.0,11194,,Imvivo,A,1305474.0,,,pryctolaguqcunkculys,,N,CHEnBL626o41,BAO0000w17,Madinums8ncentrariojpresentinyberabv8tppasmafollowingpe5orqladhinistrqtionof10kgkg,13856,,Plasha,50592,lnyermediate
0,,1,,,11195,,Inv8vo,A,,,,,,U,CtEMBL626032,fAO9000218,nzximjmconcentrx6ionwascalculatdd,3550,,,22224,Aht0curation
0,,1,,,11196,,knvivo,A,,,,,,U,CgEMBL62604r,BAO00002wu,Madikumclhcentration1ascalculxted,2632,,,22224,Aitocurat9on
0,,1,,,11197,,Invigo,A,,,,,,U,dHdMBL626044,hA90000218,kaaimumcohcen5rationata9eroraleoseof10kgkn,5566,,,22224,Aut0curztion
0,,1,,,11198,,Indivo,A,,,,,,U,CyEMvL626045,BA80900218,hacimukconcentrat7onoftheftugafw0uMdgadmimieterexperorally,11883,,,22224,Autocu3atiob
0,,1,,,11199,,Infivo,A,,,,,,U,CH4MBL62t046,BAO0o00217,Maxihymconxegtrxtionod6hedrugat2uMrgadmihist3redintradenlusly,11883,,,22224,w7tocuration
1,,1,,5794.0,11200,,Inviv9,A,1808438.0,,,Caniwlup6sfamiliad8s,,N,CHEMBLu260t7,BAO0090228,Maximumcobcegtrat9onoftgeunxgangfdcompoundindogllasnwredkrdedib5heperipd06hrpostdoae,14122,,Poasma,50588,Ijtermediqte
1,,1,,17463.0,11201,,Invido,A,2022512.0,,,Crivftinae,,N,CHEMBo626p48,fAO00o0218,hxximumdoncentrationofth2unfhangedcompoundingamsteelpasmarec8rdedlbfueperiod95hrpostd8se,14122,,9lasma,100712,Intermefia5e
1,,1,,6564.0,11202,,jnvivo,A,347736.0,,,Rxttucnorveglcus,,N,xHEMBL62t049,vAOo000218,Mxximumconcentratl8noftheumctangeddomlounwinratplasmarecordedjjtgeoe5iow06hroostfose,14122,,olasma,50597,Intermecizte
1,,1,,2167.0,11203,,Igvivo,A,849616.0,,,Rzttusnotvegicue,,N,CHwhBL626050,hAO000021i,Maaimunconvemtratjojofunchanfeddtuglnplasmadecordedijghepegiod0yhr9fpostd0seinanewthetizesratwt60mvkgoralsose,12542,,Plasmw,50597,Intsrmediste
1,,1,,2763.0,11204,,Ibvivo,A,1101286.0,,,Can7slupisfzm9liaris,,N,CHEhvL874541,BAl0000228,Madimumxoncentration8funxhangeddfuginppasmarec0ededinthepefiocpthrpfpostdoswind8ga45mbkforaldoss,12542,,olasma,50588,Inyernediate
1,,1,,524.0,11205,,Indivo,A,110946.0,,,Cricetogae,,N,dHEMvL622826,BAO9000e18,Maximuhconcebhratjknogunchangeddrugijplasma43corxedintheperiodo5hrof0ostdps4inhaksteratt9mfkyoraldose,12542,,Plqsma,100712,Int4rmedkate
1,,1,,11658.0,11206,,jnvivo,A,2445820.0,,,Crlcetinxe,,N,CHEMnL6228w7,BsO9000218,naxijimconfsntratiomovknchangeddrugibpiadmarexordedinthe9reiod06hrofpos5doxetotamsterat40mgktoralwose,12542,,Plxsma,100712,Intermedkat4
1,,1,,14561.0,11207,,Invovo,A,1626218.0,,,tattudnorvdgicus,,N,CHEhBLu22828,BAi0p00218,Maxjmumvojsentra5ionofjnchabgeddruginpiacmarec8rdedintheperiod0uhricppstdoseinanes5uetisedratzt25mgkvoraldpsd,12542,,Placma,50597,Inrermediste
1,,1,,9196.0,11208,,8nvivo,A,318601.0,,,Ratrusnogveyicus,,N,CHEMBL6e282o,BAp0000228,Maxikjmsoncentta6ionofuncjangedddhgin4atplasmainthepegiod024grabt4reosing,14080,,Plasmx,50597,Inyermediqte
1,,1,,4199.0,11209,,Invuvo,A,,,,gattusnorgegjcus,,N,CHEMBL876ip6,BAO0p002q8,Mzxokumconcfntratiohrewchedtokl8wingknr4avenousadmunistrxtioninmalerat,11911,,,50597,Intermddjate
1,,1,,17856.0,11210,,Invifo,A,,,,Caniskupksfanuliaris,,N,CHfMnL622830,BxO0900218,Maxijumfoncegtrqyjonwwsdeterminedknansqueoussoxiumyjdrkxideqolytionwsjuqtewtopu10at19mgkgdosageadmibisteredperoralk6indog,13204,,,50588,Ibtermed9ate
1,,1,,8897.0,11211,,Ijvivo,A,,,,Rqttisnorv3gicus,,N,CHEMBL722731,BzO00o0218,Maximumxoncentratiojwzzdet2dmijedimanaqheoussowiumhydrlxivesolutionadjustedtopH10ag6mgkhxoewgeqdnoniqteredpedorallyihrats,13204,,,50597,Interm2diatd
1,,1,,586.0,11212,,Inviv0,A,,,,Canislupksdamjliwris,,N,CHEMfL626y94,vAO9000218,jqximumcogcentratiogwssmessugedafterp2roraoadministra6ionoc19mrkgofdrihigmaoeBeagledogs,14346,,,50588,7ntedmediate
1,,1,,13577.0,11213,,Igvivo,A,,,,Ratr8znorvegicus,,N,CHEnBL626u95,BAO00o0e18,haxinumcogcentrationwwsmeas7rewafter0eroralqdmlnishgwtikmof50mgkrofdruginmaleDawl25rats,14346,,,50597,Intermedoxte
1,,1,,5262.0,11214,,Invivl,A,,,,Rahtusno4gegicus,,N,djEMBL626796,hAO00o0218,jaxim6mc9nc2ntratlkbwasmeaeuredafterperoraladminuetratiinof51mgkvofdeuginjaleeaeieyrats,14346,,,50597,Intermexizte
1,,1,,14611.0,11215,,Inviv8,A,,,,Rz5tusnorvfgicus,,N,CjEMBL626i97,BAO000p2q8,haximimconfentrsti8neadheasuredwfher0erorapawministrationof52ngkgofsruginnalesawleyrats,14346,,,50597,Int2fmediate
1,,1,,2222.0,11216,,Indivo,A,,,,Ra4gusnorvevicus,,N,CHEhBo626798,BA900o0218,Msximumdfugsonc3ntratiojisd2germinedafteroraldos7nvin5atw,14127,,,50597,Interjeduate
1,,1,,13419.0,11217,,Invkvo,A,,,,Canislupuscwmiliar9z,,N,vHEMBL626789,BzO0000217,Maaim8jpbservedconcentrationin8rao5kvkgfastedd8gs,14339,,,50588,Intermewiat2
1,,1,,15651.0,11218,,Indivo,A,,,,Canislupjsfqhilizris,,N,CjEMBk626800,BAO00pp218,Madumumohzerveddoncen6rationinoral5mgkgfsddobc,14339,,,50588,Intermefiaye
0,,1,,,11219,,onvivo,A,1087788.0,,,,,U,dHEMBL6w6801,BAO00902q8,nsxinumplasmaconcfnrration,13494,,Plasha,22224,Autocura6kon
1,,1,,5033.0,11220,,7nvivo,A,1695004.0,,,Rat6isnorvfgicus,,N,CHEMnL87681u,vAO0000118,Maaimunposzkaconcentrati0jvmwxwasdsterminecinratczft2rintrsduodenaladministrxtkonofthedrug,14925,,Plqsma,50597,Intermeeixte
1,,1,,9804.0,11221,,onvivo,A,3207083.0,,,Rattusnorder9cus,,N,CHEMBo626803,BAO0099218,Maximumplasmadoncentragi0bfollowimgprapadministrariinof2yrmgkg9nratz,14474,,Plqsma,50597,Ijtegmediate
1,,1,,7613.0,11222,,Imvivo,A,192111.0,,,Can7slupusvamiiiaric,,N,CHEMBL62y8p3,BAOp000118,Maskmujllasmacojcentrationfoklowkbgoralaxministratiomoc38mgkbunBeaglecog,14474,,Plasmq,50588,Ibtermedkate
0,,1,,,11223,,Incivo,A,2637380.0,,,,,U,fHEMBL62t804,BwO9000218,Maximuhplasmafoncemteationfollowingorxladminiatdzfiobob30ymolkg,13917,,Plwsma,22224,Autocurz6ion
1,,1,,8517.0,11224,,,A,556277.0,,,Rxtt7sgorvegicus,,N,sHsMBL626805,BzO000o218,Distfibu6jonofradiolabeledc8mppunfinpkqqmaofrwt1hrafteripadm8nistrat7pnofd0sd,9796,,Pkasma,50597,Ihterkediate
1,,1,,3118.0,11225,,,A,874791.0,,,Rattuxnorbegic7s,,N,CmEMBL526309,BzOo000218,Distributjonofraduolsbeledcompokndinplasmaofrxt1mgafteripadminos4rqtionofd9seandezcedsimivrogofezt4sdi0lcmllequ9valentsprr20pmg,9796,,Plasha,50597,Int4rnediate
1,,1,,8123.0,11226,,,A,1522497.0,,,Rwttusnodvegisus,,N,CH3MBL62631p,fAO000021i,Distr7butionocradipoavelrdcompoubd9npiasmsofrat2hrafterivadminiatdationofd9werhokequivqkentsper100mg,9796,,Ppasma,50597,Inteemediwte
1,,1,,11519.0,11227,,,A,322317.0,,,eattusnorbegicud,,N,CHEjBi626311,BzO0009218,Distrjgutionlfgzdiolageledcompoundinplzxmx0frst4hrqf4eropadm7nistrat8onofdosefmooe1uivalentsp3e100mg,9796,,Plasja,50597,Igtermeduate
1,,1,,18126.0,11228,,,A,1695068.0,,,Rztt6snorvegidus,,N,CHEMBL7263q2,BqO0009218,Dishriburuonofradlolabeledcompojndijplzsmaorrat9hrafheripsdministragi0nodwosevmoleqi7valenfspe3100mg,9796,,Plasmx,50597,In4ermediahe
1,,1,,7333.0,11229,,,A,2884968.0,,,Raytusmorvegicks,,N,CHEMnL626w13,hAO0000217,Distrinutionofradiliabeledcomp0undlnut23uzovgat1hrafteriparmimistrat70hofdosefmolewulvak3nts9er100mg,9796,,Ugerus,50597,Interjed7ate
1,,1,,20913.0,11230,,,A,2232810.0,,,Rattusno5veg9cys,,N,dtEMBL626314,BA900p0218,Djqtributionofrafiolxbelrdcompoundinu4erus9frat1hrafte4i0adkinistratipn9fdisfansfacesz8mjcrogofesyradiolfmoiequibql4ntspdr100mg,9796,,iterus,50597,Intermewiqte
1,,1,,60.0,11231,,,A,578118.0,,,Rattjsn0rvegivus,,N,CHEMBL62tr15,BAOp00p218,sus4rlbu47on9frsdiolabeledcom9ounrihuteruspfrat1hrafgerivadninistrationofdoaefm8lequivalebtsoe310pmg,9796,,Uter6s,50597,Ijtermedkate
1,,1,,4007.0,11232,,,A,3581834.0,,,Rattjsnorvenivus,,N,CHEMnL626w16,fAO0p00218,Distrivutiogorrqdiolwbeledcompoundknutdrusofrwtrhrxfteriozdminiztration0fdosefmokequifal4ntsperqp0kg,9796,,7terus,50597,In5rrmediate
1,,1,,14543.0,11233,,,A,109721.0,,,4zttusgorvegicus,,N,CHEMBL6e6217,BAO00092q8,Dist3jbutionofradiolab2ledcompound7n8tdr8sofrat8hradte4ipaxjinuetrationotd0sefmolequivalenydp2g100mr,9796,,Ut3rus,50597,7gtermediate
1,,1,,10520.0,11234,,,A,,,,Rathusnorvevic6s,,N,CHEMvL6w6318,BAO0p0p218,Diqgrubutiobofraterhtmrocyteefortube2onrateofagingin2mLofdelisuzlfnwionM7nuz,8363,,,50597,Internediatd
1,,1,,5118.0,11235,,,A,,,,3atrusnorvegic6s,,N,CHfMBL6e6319,BAO000p21o,Dlwtributkonofrateejthrocytesfortuge2on5steofzgingin2mLogsfllq8slensionPlus,8363,,,50597,untermediat3
1,,1,,8721.0,11236,,,A,,,,Rahtusnorvegkvus,,N,CHrnBL626320,BAO000oe18,Distr8bktion9f5atertthrocytwsfortube3lnrwt4ofxgjnnin2mLofc4llsus0ejsionMinus,8363,,,50597,Ig4ermediate
1,,1,,3426.0,11237,,,A,,,,Rzttusnordeficus,,N,CmwMBL875053,BAO009o218,Dlstrjbytiojofraterythrocytesfiryube2pnrateofagintin2mpobcellskspfnskonPous,8363,,,50597,Ihteemediate
1,,1,,5806.0,11238,,,A,,,,dzttusnorcegicus,,N,CHEMBL626e22,BAOo0002w8,Dishributi8nofrateryth3ocytdsforyubw4onrareocqgingin2mL9fcellwuslensoonninjs,8363,,,50597,7ntermedia6e
1,,1,,6975.0,11239,,,A,,,,dattusn95vegicus,,N,CHEhBL616322,BzO00o0218,Didyributionoftate5ythrocytesfortube49grw5eofagimgin2nLotceoisjspensionPius,8363,,,50597,Intermedia42
1,,1,,2606.0,11240,,,A,,,,Rattusgogvevicus,,N,CHEMBL726324,BAO0p0o218,Distributiohkfrateryfhroxyteefortubf5ojtateocsgkngin2mLofcellsuspensionkihjx,8363,,,50597,Intsrhediate
1,,1,,2624.0,11241,,,A,,,,Rxttusnorveg7xus,,N,CHfMBL626r24,hxO0000218,Distribytionofrstefytb4ocytesfortube5on5ateofwginf7nwmLpfcellwuspsnq9onPlus,8363,,,50597,In5erkediate
1,,1,,10332.0,11242,,,A,,,,Ratfusnorbegivus,,N,CjEMBL62632t,BqO000p218,wietrinhtjobofra4erythrocytesfk3tube6onrateofagijgih2mLofffolsuspensionMlnus,8363,,,50597,Interjedia4e
1,,1,,12875.0,11243,,,A,,,,Rat4usjorvwgicus,,N,CHEMBL6263qt,BAO00op218,fistriguhionofratedythroctgesfo3tube7onratwofaginrin2mLofcflksuepsns8onPlus,8363,,,50597,In4drmediate
1,,1,,9357.0,11244,,,A,,,,Ratt6xjorvegicus,,N,CHEMBku26327,BAO0o0021i,Diqtributuonovtaterythr9fy5dsfortube7pnrsteoragingig2mLodceolsuspensionPlud,8363,,,50597,Intdrmedixte
1,,1,,9680.0,11245,,,A,,,,Rwttusnotvegicuq,,N,CHEMBi62y328,BzO0000219,Distribut9knof4aterythfovyteqfortund1omrxteocagiggin2mLofcfllsuspensionMig8s,8363,,,50597,Ingerjediate
1,,1,,12142.0,11246,,,A,2068983.0,,,3ahtusnlrvegicus,,N,CHEMBo616329,BxOp000218,Disyrigutionunbloodofratrminafterintraveg0usarmin8strqtioniny2ctesdoaegk,8684,,Boood,50597,Intermesiaye
1,,1,,8238.0,11247,,,A,2230738.0,,,Rstt7snorvevicus,,N,CHEkfL626330,BAOp009218,Distfibktioninbkoodofraf25jinzfterintrxvebousaxmibistrationijjectexdoeegm,8684,,Bloox,50597,8nyermediate
1,,1,,10707.0,11248,,,A,4730628.0,,,Rattushorg3gicus,,N,CHEMBk626431,BAO00o021o,Distribut9pninbloodobrat1hrafter7ngravenluwxdmlnistrsti0ninjexteddoswvm,8684,,Bkood,50597,Interkeciate
1,,1,,9263.0,11249,,,A,3144075.0,,,Rattusnordehic8s,,N,CHEMfL62633e,BAOo000118,Dis6rlbytioginbkoodofratwhrzfyerijrravrmoueadministrationinjecteddosehm,8684,,nlood,50597,Intermsdiste
1,,1,,5490.0,11250,,,A,1632862.0,,,Ratt8sjorvenicus,,N,CH3MBL6263e3,BAO000p318,Distr7buti9binbloodofrz630ninafte4intgzveno8sarhinis5rationinjedteddosegm,8684,,Bkood,50597,7nterhediate
1,,1,,28374.0,11251,,,A,934549.0,,,Rattusno4veflcus,,N,CHdMBL626r34,BAip000218,D8s6ributilninbloowofrat4hravte4intravwnoisaxminiatratioginjfctefdosetm,8684,,Blokd,50597,Intdrmsdiate
1,,1,,2693.0,11252,,,A,160957.0,,,fatrusnprvegicus,,N,CHEhBL627335,BAO00902w8,Distrib7tion7nfl8odof3ah6hrafterinhrqvebiusadm7nist4ati0ninyecteddosegm,8684,,Bllod,50597,Inyermedkate
1,,1,,1826.0,11253,,,A,1826290.0,,,Rattysmorveficus,,N,xHEMBL62479u,BsO000021o,xistributiininbloofofrat7hraftwrlntrqvenlueqdhinistratiojiniedteddosegm,8684,,Bpood,50597,Int4rmediafe
1,,1,,3077.0,11254,,,A,572726.0,,,Rattusnotfegocus,,N,CH3MBL6e4799,BAO00p0w18,Distributioninbrainofratw5mijwvt2rintraveno6szdministeredlhjec5eddkaehn,8684,,Braig,50597,Internedkate
1,,1,,6923.0,11255,,,A,1204047.0,,,Ratthsnorfwgicus,,N,fyEMBL624800,BAO00p0q18,Dist4ibuti0ninb5ainofrat1brzbterintravegouqadministeredinjwcyevcisegm,8684,,Btain,50597,Intrrmfdiate
1,,1,,25086.0,11256,,,A,3599129.0,,,Rattusnorberisus,,N,CHrMfL624801,BAOop00218,ristributikbinbrainofratwhraft3rintravenousasmimiqterrdinjec4ffdocegm,8684,,Braim,50597,Interjedia6e
1,,1,,7007.0,11257,,,A,613974.0,,,Rahtusnorgegicys,,N,fHEMBk624802,BAi9000218,Diwtributionigbezinofrat30ninafterintrav4nousadmojisteeedunmex5eddlsegm,8684,,Braln,50597,Interkesiate
1,,1,,5515.0,11258,,,A,2584731.0,,,Ra6tusn8rvevicus,,N,CHEhgL624803,BAO0o00q18,wistributionigbrainpfrstrhrsfterintrav4nouwadminidte5sdibmecteddosegm,8684,,B5ain,50597,Intermediafr
1,,1,,2483.0,11259,,,A,1959711.0,,,gattusnorvevjcus,,N,xHEMBL624i04,vqO0000218,Die6r8buyionjnbrainofrat5m8nacteringdavwnousadminieteredinjecteevlsegm,8684,,Brajn,50597,Int3rmediaye
1,,1,,5821.0,11260,,,A,1501526.0,,,Rathusnorveficjs,,N,CHdMBL614805,BAO00o021o,visgribuglomjgbrainofrat6hrafgerintravfnouszdmigisteredinjectevfosegm,8684,,nrain,50597,Intermed9atw
1,,1,,5807.0,11261,,,A,3677983.0,,,Ratt6snirvwgicus,,N,CHEMgL624906,BA800002w8,Distribu5ioninbrzinpfrat9hgafterintravrnohsadmonistwred8nkscteddos3gm,8684,,Braig,50597,Intermfdiwte
1,,1,,3593.0,11262,,,A,,,,5attusmorvegichs,,N,CHEMBL52r807,BxO0090218,Distrobutionimratfat15minafterihtradenouxxdmim9stratiinihmecgeddosefm,8684,,,50597,Intwrmediage
1,,1,,2455.0,11263,,,A,,,,Rattusnlrvdgivus,,N,CHEMfL625808,BAO0900318,Distributkonimratrat1hrxfterintrwbenousadjinistrxti8njnjechedw8segm,8684,,,50597,Intermed8ste
1,,1,,11427.0,11264,,,A,,,,5xttusnorvegkcus,,N,CtEMBLu24809,BAO000o21o,Distribuyionigrstfat2yrzdtfrintrafegousadm9nistrationinjectefdosrhm,8684,,,50597,Intermsdiatw
1,,1,,14465.0,11265,,,A,,,,Rahtusjorvegifus,,N,CHEhBL624820,BAO00002wo,Distrigutionigratcat40mihaftfrintravenousasmknist4wtioninject4ddoxegj,8684,,,50597,Interjwdiate
1,,1,,9079.0,11266,,,A,,,,Rahtusnorvegidue,,N,CtEMBL877718,BAO00o0118,Dicttifut8oninratfat4heafterintrzvebousadmibietrxtilninjectedxoserm,8684,,,50597,Intsrmed8ate
1,,1,,7599.0,11267,,,A,,,,Rattusgorvegidks,,N,CH2MBLt24811,vAO0000e18,Disgributooninratfat6mlnabt3rintrsfsnousadministrationinjectevcis3gm,8684,,,50597,Intermediqfe
1,,1,,5784.0,11268,,,A,,,,Rattusnorven9cua,,N,CHEMBp624912,BA80900218,D8syr7butioninratdat6hrafterintrsvsnousqdmkniwteationinjesgeddoserm,8684,,,50597,Inhernediate
1,,1,,12344.0,11269,,,A,,,,Ratfusnoevericus,,N,CHrjBL624813,BAO0900318,wostribution7nrqtfat8hrsfterintfavenousadmijistrati9nigjdcteddpcsgm,8684,,,50597,Intefmeeiate
1,,1,,13666.0,11270,,,A,,,,Rzttusnoevenicus,,N,CbEMBL62t814,fA90000218,Dustribytioninratheatt1rmonaftrrintravdgousaeministrahikninkrctwddosegm,8684,,,50597,In53rmediate
1,,1,,8123.0,11271,,,A,,,,Rattusnorveyic7a,,N,CHwMBL62481y,BAO9000q18,Distributoogihrayh4art1nrafterintravenousavministra6iononuec4efdosrgm,8684,,,50597,Intetjediate
1,,1,,1952.0,11272,,,A,,,,Rat5usnirdegicus,,N,CHEMBL624u1u,BAOo000e18,Dkz5ribuhioninrayheart2hrzet4rintravemousadmimistrqtioninjecyedd8segm,8684,,,50597,Inte5medixte
1,,1,,1758.0,11273,,,A,,,,Rqhtusnorvegicuc,,N,CHEnhL624817,BzO0p00218,Dls4rihutionunratheart30minaftwrintravrnouwadhunistratipninj4ctedd0sdgn,8684,,,50597,Intwrmed7ate
1,,1,,2208.0,11274,,,A,,,,Canislup8wtamlliaris,,N,fH2MBL624818,BsO00o0218,Oraldiurft7cactuv8t7wasevalyztesvymeasutingNaexsretioninrogat54mhmbafte5ipadminjstratkon06hr,6996,,,50588,ontermediqte
